1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	5	amod
4	drug2	drug2	NN	_	5	compound
5	administration	administration	NN	_	6	nsubj
6	decreased	decrease	VBD	_	1	dep
7	the	the	DT	_	9	det
8	mean	mean	NN	_	9	compound
9	AUC	auc	NN	_	6	dobj
10	of	of	IN	_	12	case
11	total	total	JJ	_	12	amod
12	drug3	drug3	NN	_	9	nmod
13	approximately	approximately	RB	_	14	advmod
14	55	55	CD	_	15	nummod
15	%	%	NN	_	6	nmod:npmod
16	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	incremental	incremental	JJ	_	4	amod
3	LDL-C	ldl-c	NN	_	4	compound
4	reduction	reduction	NN	_	13	nsubjpass
5	due	due	JJ	_	4	amod
6	to	to	TO	_	7	mark
7	adding	add	VBG	_	5	advcl
8	drug1	drug1	NN	_	7	dobj
9	to	to	TO	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	reduced	reduce	VBN	_	0	ROOT
14	by	by	IN	_	16	case
15	this	this	DT	_	16	det
16	interaction	interaction	NN	_	13	nmod
17	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	safety	safety	NN	_	15	nsubjpass
5	and	and	CC	_	4	cc
6	effectiveness	effectiveness	NN	_	4	conj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	administered	administer	VBN	_	8	acl
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	established	establish	VBN	_	1	appos
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	cholesterol	cholesterol	NN	_	5	compound
5	excretion	excretion	NN	_	3	dobj
6	into	into	IN	_	8	case
7	the	the	DT	_	8	det
8	bile	bile	NN	_	3	nmod
9	,	,	,	_	3	punct
10	leading	lead	VBG	_	3	advcl
11	to	to	TO	_	12	case
12	cholelithiasis	cholelithiasis	NN	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	preclinical	preclinical	JJ	_	4	amod
4	study	study	NN	_	9	nmod
5	in	in	IN	_	6	case
6	dogs	dog	NNS	_	4	nmod
7	,	,	,	_	9	punct
8	drug1	drug1	NN	_	9	nsubj
9	increased	increase	VBD	_	0	ROOT
10	cholesterol	cholesterol	NN	_	9	dobj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	gallbladder	gallbladder	NN	_	14	compound
14	bile	bile	NN	_	9	nmod
15	.	.	.	_	9	punct

1	Co-administration	co-administration	NN	_	8	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	14	csubjpass
9	until	until	IN	_	10	case
10	use	use	NN	_	8	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	is	be	VBZ	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	11	nmod
7	,	,	,	_	11	punct
8	concomitant	concomitant	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	administration	administration	NN	_	11	nsubj
11	increased	increase	VBD	_	1	dep
12	total	total	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	1.5-fold	1.5-fold	RB	_	11	advmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	11	nmod
7	,	,	,	_	11	punct
8	concomitant	concomitant	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	administration	administration	NN	_	11	nsubj
11	increased	increase	VBD	_	1	dep
12	total	total	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	1.7-fold	1.7-fold	RB	_	11	advmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	7	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	7	amod
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	interactions	interaction	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	seen	see	VBN	_	1	appos
10	when	when	WRB	_	13	advmod
11	drug2	drug2	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	co-administered	co-administer	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug4	drug4	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug5	drug5	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug6	drug6	NN	_	15	conj
22	,	,	,	_	15	punct
23	or	or	CC	_	15	cc
24	drug7	drug7	NN	_	15	conj
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	6	det
4	total	total	JJ	_	6	amod
5	drug2	drug2	NN	_	6	compound
6	level	level	NN	_	7	nsubj
7	increased	increase	VBD	_	1	appos
8	12-fold	12-fold	RB	_	7	advmod
9	in	in	IN	_	13	case
10	one	one	CD	_	13	nummod
11	renal	renal	JJ	_	13	amod
12	transplant	transplant	NN	_	13	compound
13	patient	patient	NN	_	7	nmod
14	receiving	receive	VBG	_	13	acl
15	multiple	multiple	JJ	_	16	amod
16	medications	medication	NNS	_	14	dobj
17	,	,	,	_	16	punct
18	including	include	VBG	_	19	case
19	drug3	drug3	NN	_	16	nmod
20	.	.	.	_	1	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	who	who	WP	_	3	nsubj
3	take	take	VBP	_	1	acl:relcl
4	both	both	DT	_	5	cc:preconj
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	should	should	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	carefully	carefully	RB	_	11	advmod
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Carcinogenesis	carcinogenesis	NN	_	16	nsubjpass
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	,	,	,	_	1	punct
5	Impairment	impairment	NN	_	1	appos
6	of	of	IN	_	12	case
7	Fertility	fertility	NN	_	12	compound
8	A	a	NN	_	12	compound
9	104-week	104-week	JJ	_	12	amod
10	dietary	dietary	JJ	_	12	amod
11	carcinogenicity	carcinogenicity	NN	_	12	compound
12	study	study	NN	_	5	nmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	5	nmod
15	was	be	VBD	_	16	auxpass
16	conducted	conduct	VBN	_	0	ROOT
17	in	in	IN	_	18	case
18	rats	rat	NNS	_	16	nmod
19	at	at	IN	_	20	case
20	doses	dose	NNS	_	18	nmod
21	up	up	RB	_	23	advmod
22	to	to	TO	_	23	dep
23	1500	1500	CD	_	24	nummod
24	mg/kg/day	mg/kg/day	NN	_	20	dep
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	males	male	NNS	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	and	and	CC	_	20	cc
29	500	500	CD	_	30	nummod
30	mg/kg/day	mg/kg/day	NN	_	20	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	females	female	NNS	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	-LRB-	-lrb-	-LRB-	_	40	punct
35	~	~	RB	_	37	advmod
36	20	20	CD	_	37	compound
37	times	time	NNS	_	40	nummod
38	the	the	DT	_	40	det
39	human	human	JJ	_	40	amod
40	exposure	exposure	NN	_	18	appos
41	at	at	IN	_	43	case
42	10	10	CD	_	43	nummod
43	mg	mg	NN	_	40	nmod
44	daily	daily	JJ	_	40	amod
45	based	base	VBN	_	47	case
46	on	on	IN	_	47	case
47	AUC0-24hr	auc0-24hr	NN	_	44	advcl
48	for	for	IN	_	50	case
49	total	total	JJ	_	50	amod
50	drug2	drug2	NN	_	47	nmod
51	-RRB-	-rrb-	-RRB-	_	40	punct
52	.	.	.	_	16	punct

1	A	a	DT	_	5	det
2	104-week	104-week	JJ	_	5	amod
3	dietary	dietary	JJ	_	5	amod
4	carcinogenicity	carcinogenicity	NN	_	5	compound
5	study	study	NN	_	10	nsubjpass
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	10	auxpass
9	also	also	RB	_	10	advmod
10	conducted	conduct	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	mice	mouse	NNS	_	10	nmod
13	at	at	IN	_	14	case
14	doses	dose	NNS	_	10	nmod
15	up	up	RB	_	17	advmod
16	to	to	TO	_	17	dep
17	500	500	CD	_	18	nummod
18	mg/kg/day	mg/kg/day	NN	_	14	dep
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	>	>	JJR	_	22	dep
21	150	150	CD	_	22	compound
22	times	time	NNS	_	18	dep
23	the	the	DT	_	25	det
24	human	human	JJ	_	25	amod
25	exposure	exposure	NN	_	22	dep
26	at	at	IN	_	28	case
27	10	10	CD	_	28	nummod
28	mg	mg	NN	_	25	nmod
29	daily	daily	JJ	_	25	amod
30	based	base	VBN	_	32	case
31	on	on	IN	_	32	case
32	AUC0-24hr	auc0-24hr	NN	_	29	advcl
33	for	for	IN	_	35	case
34	total	total	JJ	_	35	amod
35	drug2	drug2	NN	_	32	nmod
36	-RRB-	-rrb-	-RRB-	_	22	punct
37	.	.	.	_	10	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	nsubj
7	in	in	IN	_	9	case
8	tumor	tumor	NN	_	9	compound
9	incidences	incidence	NNS	_	6	nmod
10	in	in	IN	_	12	case
11	drug-treated	drug-treated	JJ	_	12	amod
12	rats	rat	NNS	_	9	nmod
13	or	or	CC	_	12	cc
14	mice	mouse	NNS	_	12	conj
15	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	mutagenicity	mutagenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	6	advmod
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	microbial	microbial	JJ	_	12	amod
12	mutagenicity	mutagenicity	NN	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	Ames	Ames	NNP	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	test	test	NN	_	12	amod
17	with	with	IN	_	19	case
18	Salmonella	salmonella	FW	_	19	compound
19	typhimurium	typhimurium	FW	_	16	nmod
20	and	and	CC	_	19	cc
21	Escherichia	escherichia	FW	_	22	compound
22	coli	coli	FW	_	19	conj
23	with	with	IN	_	27	nmod
24	or	or	CC	_	23	cc
25	without	without	IN	_	23	conj
26	metabolic	metabolic	JJ	_	27	amod
27	activation	activation	NN	_	16	nmod
28	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	clastogenicity	clastogenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	6	advmod
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	chromosomal	chromosomal	JJ	_	13	amod
12	aberration	aberration	NN	_	13	compound
13	assay	assay	NN	_	6	nmod
14	in	in	IN	_	18	case
15	human	human	JJ	_	18	amod
16	peripheral	peripheral	JJ	_	18	amod
17	blood	blood	NN	_	18	compound
18	lymphocytes	lymphocyte	NNS	_	13	nmod
19	with	with	IN	_	23	nmod
20	or	or	CC	_	19	cc
21	without	without	IN	_	19	conj
22	metabolic	metabolic	JJ	_	23	amod
23	activation	activation	NN	_	18	nmod
24	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	was	be	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	evidence	evidence	NN	_	5	nsubj
8	of	of	IN	_	9	case
9	genotoxicity	genotoxicity	NN	_	7	nmod
10	in	in	IN	_	16	case
11	the	the	DT	_	16	det
12	in	in	FW	_	16	amod
13	vivo	vivo	FW	_	12	dep
14	mouse	mouse	NN	_	16	compound
15	micronucleus	micronucleus	NN	_	16	compound
16	test	test	NN	_	7	nmod
17	.	.	.	_	5	punct

1	In	in	IN	_	7	case
2	oral	oral	JJ	_	7	amod
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	gavage	gavage	NN	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	fertility	fertility	NN	_	7	compound
7	studies	study	NNS	_	15	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	conducted	conduct	VBN	_	9	acl
11	in	in	IN	_	12	case
12	rats	rat	NNS	_	10	nmod
13	,	,	,	_	15	punct
14	there	there	EX	_	15	expl
15	was	be	VBD	_	0	ROOT
16	no	no	DT	_	17	neg
17	evidence	evidence	NN	_	15	nsubj
18	of	of	IN	_	20	case
19	reproductive	reproductive	JJ	_	20	amod
20	toxicity	toxicity	NN	_	17	nmod
21	at	at	IN	_	22	case
22	doses	dose	NNS	_	20	nmod
23	up	up	RB	_	25	advmod
24	to	to	TO	_	25	dep
25	1000	1000	CD	_	26	nummod
26	mg/kg/day	mg/kg/day	NN	_	22	dep
27	in	in	IN	_	31	case
28	male	male	JJ	_	31	amod
29	or	or	CC	_	28	cc
30	female	female	JJ	_	28	conj
31	rats	rat	NNS	_	26	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	~	~	NN	_	31	dep
34	7	7	CD	_	35	compound
35	times	time	NNS	_	38	nummod
36	the	the	DT	_	38	det
37	human	human	JJ	_	38	amod
38	exposure	exposure	NN	_	33	dep
39	at	at	IN	_	41	case
40	10	10	CD	_	41	nummod
41	mg	mg	NN	_	38	nmod
42	daily	daily	JJ	_	41	advmod
43	based	base	VBN	_	45	case
44	on	on	IN	_	45	case
45	AUC0-24hr	auc0-24hr	NN	_	38	nmod
46	for	for	IN	_	48	case
47	total	total	JJ	_	48	amod
48	drug2	drug2	NN	_	45	nmod
49	-RRB-	-rrb-	-RRB-	_	33	punct
50	.	.	.	_	15	punct

1	Pregnancy	Pregnancy	NNP	_	3	compound
2	Pregnancy	Pregnancy	NNP	_	3	compound
3	Category	Category	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	C	c	NN	_	3	dep
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	12	neg
9	adequate	adequate	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	well-controlled	well-controlled	JJ	_	9	conj
12	studies	study	NNS	_	7	nsubj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	in	in	IN	_	17	case
16	pregnant	pregnant	JJ	_	17	amod
17	women	woman	NNS	_	12	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	during	during	IN	_	6	case
6	pregnancy	pregnancy	NN	_	4	nmod
7	only	only	RB	_	12	advmod
8	if	if	IN	_	12	mark
9	the	the	DT	_	11	det
10	potential	potential	JJ	_	11	amod
11	benefit	benefit	NN	_	12	nsubj
12	justifies	justify	VBZ	_	4	advcl
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	fetus	fetus	NN	_	12	nmod
18	.	.	.	_	4	punct

1	In	in	IN	_	8	case
2	oral	oral	JJ	_	8	amod
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	gavage	gavage	NN	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	embryo-fetal	embryo-fetal	JJ	_	8	amod
7	development	development	NN	_	8	compound
8	studies	study	NNS	_	20	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	conducted	conduct	VBN	_	10	acl
12	in	in	IN	_	13	case
13	rats	rat	NNS	_	11	nmod
14	and	and	CC	_	13	cc
15	rabbits	rabbit	NNS	_	13	conj
16	during	during	IN	_	17	case
17	organogenesis	organogenesis	NN	_	11	nmod
18	,	,	,	_	20	punct
19	there	there	EX	_	20	expl
20	was	be	VBD	_	0	ROOT
21	no	no	DT	_	22	neg
22	evidence	evidence	NN	_	20	nsubj
23	of	of	IN	_	25	case
24	embryolethal	embryolethal	JJ	_	25	amod
25	effects	effect	NNS	_	22	nmod
26	at	at	IN	_	28	case
27	the	the	DT	_	28	det
28	doses	dose	NNS	_	25	nmod
29	tested	test	VBN	_	28	acl
30	-LRB-	-lrb-	-LRB-	_	36	punct
31	250	250	CD	_	36	nummod
32	,	,	,	_	36	punct
33	500	500	CD	_	36	nummod
34	,	,	,	_	36	punct
35	1000	1000	CD	_	36	nummod
36	mg/kg/day	mg/kg/day	NN	_	28	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	.	.	.	_	20	punct

1	In	in	IN	_	2	case
2	rats	rat	NNS	_	27	nmod
3	,	,	,	_	27	punct
4	increased	increase	VBD	_	5	amod
5	incidences	incidence	NNS	_	27	nsubjpass
6	of	of	IN	_	10	case
7	common	common	JJ	_	10	amod
8	fetal	fetal	JJ	_	10	amod
9	skeletal	skeletal	JJ	_	10	amod
10	findings	finding	NNS	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	extra	extra	JJ	_	13	amod
13	pair	pair	NN	_	10	dep
14	of	of	IN	_	16	case
15	thoracic	thoracic	JJ	_	16	amod
16	ribs	rib	NNS	_	13	nmod
17	,	,	,	_	13	punct
18	unossified	unossified	JJ	_	21	amod
19	cervical	cervical	JJ	_	21	amod
20	vertebral	vertebral	JJ	_	21	amod
21	centra	centra	NNS	_	13	appos
22	,	,	,	_	13	punct
23	shortened	shorten	VBD	_	24	amod
24	ribs	rib	NNS	_	13	appos
25	-RRB-	-rrb-	-RRB-	_	13	punct
26	were	be	VBD	_	27	auxpass
27	observed	observe	VBN	_	0	ROOT
28	at	at	IN	_	30	case
29	1000	1000	CD	_	30	nummod
30	mg/kg/day	mg/kg/day	NN	_	27	nmod
31	-LRB-	-lrb-	-LRB-	_	37	punct
32	~	~	CD	_	34	compound
33	10	10	CD	_	34	compound
34	times	time	NNS	_	37	nummod
35	the	the	DT	_	37	det
36	human	human	JJ	_	37	amod
37	exposure	exposure	NN	_	30	appos
38	at	at	IN	_	40	case
39	10	10	CD	_	40	nummod
40	mg	mg	NN	_	37	nmod
41	daily	daily	JJ	_	37	amod
42	based	base	VBN	_	44	case
43	on	on	IN	_	44	case
44	AUC0-24hr	auc0-24hr	NN	_	41	advcl
45	for	for	IN	_	47	case
46	total	total	JJ	_	47	amod
47	drug1	drug1	NN	_	44	nmod
48	-RRB-	-rrb-	-RRB-	_	37	punct
49	.	.	.	_	27	punct

1	In	in	IN	_	2	case
2	rabbits	rabbit	NNS	_	15	nmod
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	15	punct
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	incidence	incidence	NN	_	15	nsubjpass
10	of	of	IN	_	13	case
11	extra	extra	JJ	_	13	amod
12	thoracic	thoracic	JJ	_	13	amod
13	ribs	rib	NNS	_	9	nmod
14	was	be	VBD	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	at	at	IN	_	18	case
17	1000	1000	CD	_	18	nummod
18	mg/kg/day	mg/kg/day	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	24	punct
20	150	150	CD	_	21	compound
21	times	time	NNS	_	24	nummod
22	the	the	DT	_	24	det
23	human	human	JJ	_	24	amod
24	exposure	exposure	NN	_	18	appos
25	at	at	IN	_	27	case
26	10	10	CD	_	27	nummod
27	mg	mg	NN	_	24	nmod
28	daily	daily	JJ	_	24	amod
29	based	base	VBN	_	31	case
30	on	on	IN	_	31	case
31	AUC0-24hr	auc0-24hr	NN	_	28	advcl
32	for	for	IN	_	34	case
33	total	total	JJ	_	34	amod
34	drug2	drug2	NN	_	31	nmod
35	-RRB-	-rrb-	-RRB-	_	24	punct
36	.	.	.	_	15	punct

1	drug1	drug1	NN	_	2	nsubj
2	crossed	cross	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	placenta	placenta	NN	_	2	dobj
5	when	when	WRB	_	11	advmod
6	pregnant	pregnant	JJ	_	7	amod
7	rats	rat	NNS	_	11	nsubjpass
8	and	and	CC	_	7	cc
9	rabbits	rabbit	NNS	_	7	conj
10	were	be	VBD	_	11	auxpass
11	given	give	VBN	_	2	advcl
12	multiple	multiple	JJ	_	14	amod
13	oral	oral	JJ	_	14	amod
14	doses	dose	NNS	_	11	dobj
15	.	.	.	_	2	punct

1	Multiple	multiple	JJ	_	3	amod
2	dose	dose	NN	_	3	compound
3	studies	study	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	given	give	VBN	_	5	acl
7	in	in	IN	_	8	case
8	combination	combination	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug3	drug3	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	in	in	IN	_	15	case
15	rats	rat	NNS	_	10	nmod
16	and	and	CC	_	15	cc
17	rabbits	rabbit	NNS	_	15	conj
18	during	during	IN	_	20	case
19	organogenesis	organogenesis	NN	_	20	compound
20	result	result	NN	_	3	nmod
21	in	in	IN	_	23	case
22	higher	higher	JJR	_	23	amod
23	drug4	drug4	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	statin	statin	NN	_	26	compound
26	exposures	exposure	NNS	_	23	conj
27	.	.	.	_	3	punct

1	Reproductive	Reproductive	NNP	_	2	compound
2	findings	finding	NNS	_	3	nsubj
3	occur	occur	VBP	_	0	ROOT
4	at	at	IN	_	6	case
5	lower	lower	JJR	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	in	in	IN	_	9	case
8	combination	combination	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	compared	compare	VBN	_	12	case
11	to	to	TO	_	12	case
12	monotherapy	monotherapy	NN	_	3	advcl
13	.	.	.	_	3	punct

1	All	all	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	contraindicated	contraindicate	VBN	_	0	ROOT
5	in	in	IN	_	9	case
6	pregnant	pregnant	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	nursing	nursing	NN	_	6	conj
9	women	woman	NNS	_	4	nmod
10	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	15	advcl
5	with	with	IN	_	7	case
6	an	a	DT	_	7	det
7	drug2	drug2	NN	_	4	nmod
8	in	in	IN	_	10	case
9	a	a	DT	_	10	det
10	woman	woman	NN	_	7	nmod
11	of	of	IN	_	13	case
12	childbearing	childbearing	JJ	_	13	amod
13	potential	potential	NN	_	10	nmod
14	,	,	,	_	15	punct
15	refer	refer	VBP	_	0	ROOT
16	to	to	TO	_	19	case
17	the	the	DT	_	19	det
18	pregnancy	pregnancy	NN	_	19	compound
19	category	category	NN	_	15	nmod
20	and	and	CC	_	19	cc
21	package	package	NN	_	22	compound
22	labeling	labeling	NN	_	19	conj
23	for	for	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	15	nmod
26	.	.	.	_	15	punct

1	Labor	labor	NN	_	16	nsubj
2	and	and	CC	_	1	cc
3	Delivery	delivery	NN	_	1	conj
4	The	the	DT	_	5	det
5	effects	effect	NNS	_	1	dep
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	on	on	IN	_	9	case
9	labor	labor	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	delivery	delivery	NN	_	9	conj
12	in	in	IN	_	14	case
13	pregnant	pregnant	JJ	_	14	amod
14	women	woman	NNS	_	9	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	0	ROOT
17	.	.	.	_	16	punct

1	Nursing	Nursing	NNP	_	2	compound
2	Mothers	Mothers	NNP	_	17	nsubj
3	In	in	IN	_	5	case
4	rat	rat	NN	_	5	compound
5	studies	study	NNS	_	2	nmod
6	,	,	,	_	2	punct
7	exposure	exposure	NN	_	2	appos
8	to	to	TO	_	10	case
9	total	total	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	in	in	IN	_	13	case
12	nursing	nursing	NN	_	13	compound
13	pups	pup	NNS	_	10	nmod
14	was	be	VBD	_	17	cop
15	up	up	RB	_	17	advmod
16	to	to	TO	_	17	case
17	half	half	NN	_	0	ROOT
18	of	of	IN	_	19	case
19	that	that	DT	_	17	nmod
20	observed	observe	VBN	_	19	acl
21	in	in	IN	_	23	case
22	maternal	maternal	JJ	_	23	amod
23	plasma	plasma	NN	_	20	nmod
24	.	.	.	_	17	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	excreted	excrete	VBN	_	4	ccomp
9	into	into	IN	_	12	case
10	human	human	JJ	_	12	amod
11	breast	breast	NN	_	12	compound
12	milk	milk	NN	_	8	nmod
13	;	;	:	_	4	punct

1	therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	nursing	nursing	NN	_	10	compound
10	mothers	mother	NNS	_	7	nmod
11	unless	unless	IN	_	15	mark
12	the	the	DT	_	14	det
13	potential	potential	JJ	_	14	amod
14	benefit	benefit	NN	_	15	nsubj
15	justifies	justify	VBZ	_	7	advcl
16	the	the	DT	_	18	det
17	potential	potential	JJ	_	18	amod
18	risk	risk	NN	_	15	dobj
19	to	to	TO	_	21	case
20	the	the	DT	_	21	det
21	infant	infant	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Pediatric	Pediatric	NNP	_	4	compound
2	Use	Use	NNP	_	4	compound
3	The	The	NNP	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	17	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	in	in	IN	_	8	case
8	adolescents	adolescent	NNS	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	13	punct
10	10	10	CD	_	12	compound
11	to	to	TO	_	12	dep
12	18	18	CD	_	13	nummod
13	years	year	NNS	_	4	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	shown	show	VBN	_	0	ROOT
18	to	to	TO	_	20	mark
19	be	be	VB	_	20	cop
20	similar	similar	JJ	_	17	xcomp
21	to	to	TO	_	22	case
22	that	that	DT	_	20	nmod
23	in	in	IN	_	24	case
24	adults	adult	NNS	_	22	nmod
25	.	.	.	_	17	punct

1	Treatment	treatment	NN	_	2	compound
2	experience	experience	NN	_	10	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	pediatric	pediatric	JJ	_	8	amod
8	population	population	NN	_	2	nmod
9	is	be	VBZ	_	10	auxpass
10	limited	limit	VBN	_	0	ROOT
11	to	to	TO	_	13	case
12	4	4	CD	_	13	nummod
13	patients	patient	NNS	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	18	punct
15	9	9	CD	_	17	compound
16	to	to	TO	_	17	dep
17	17	17	CD	_	18	nummod
18	years	year	NNS	_	13	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	sitosterolemia	sitosterolemia	NN	_	23	compound
23	study	study	NN	_	13	nmod
24	and	and	CC	_	13	cc
25	5	5	CD	_	26	nummod
26	patients	patient	NNS	_	13	conj
27	-LRB-	-lrb-	-LRB-	_	31	punct
28	11	11	CD	_	30	compound
29	to	to	TO	_	30	dep
30	17	17	CD	_	31	nummod
31	years	year	NNS	_	26	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	in	in	IN	_	36	case
34	the	the	DT	_	36	det
35	HoFH	hofh	NN	_	36	compound
36	study	study	NN	_	26	nmod
37	.	.	.	_	10	punct

1	Treatment	treatment	NN	_	13	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	children	child	NNS	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	<	<	JJR	_	9	dep
8	10	10	CD	_	9	nummod
9	years	year	NNS	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	is	be	VBZ	_	13	auxpass
12	not	not	RB	_	13	neg
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Geriatric	Geriatric	NNP	_	2	compound
2	Use	Use	NNP	_	0	ROOT
3	Of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	patients	patient	NNS	_	2	nmod
6	who	who	WP	_	7	nsubj
7	received	receive	VBD	_	5	acl:relcl
8	drug1	drug1	NN	_	7	dobj
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	studies	study	NNS	_	7	nmod
12	,	,	,	_	2	punct
13	948	948	CD	_	15	nsubj
14	were	be	VBD	_	15	cop
15	65	65	CD	_	2	acl:relcl
16	and	and	CC	_	15	cc
17	older	older	JJR	_	15	conj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	this	this	DT	_	20	nsubj
20	included	include	VBD	_	15	dep
21	206	206	CD	_	20	dobj
22	who	who	WP	_	24	nsubj
23	were	be	VBD	_	24	cop
24	75	75	CD	_	21	acl:relcl
25	and	and	CC	_	24	cc
26	older	older	JJR	_	24	conj
27	-RRB-	-rrb-	-RRB-	_	20	punct
28	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effectiveness	effectiveness	NN	_	8	nsubj
3	and	and	CC	_	2	cc
4	safety	safety	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	were	be	VBD	_	8	cop
8	similar	similar	JJ	_	0	ROOT
9	between	between	IN	_	11	case
10	these	these	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	and	and	CC	_	11	cc
13	younger	younger	JJR	_	14	amod
14	subjects	subject	NNS	_	11	conj
15	.	.	.	_	8	punct

1	Greater	Greater	NNP	_	2	compound
2	sensitivity	sensitivity	NN	_	10	nsubjpass
3	of	of	IN	_	6	case
4	some	some	DT	_	6	det
5	older	older	JJR	_	6	amod
6	individuals	individual	NNS	_	2	nmod
7	can	can	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	ruled	rule	VBN	_	0	ROOT
11	out	out	RP	_	10	compound:prt
12	.	.	.	_	10	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Although	although	IN	_	10	mark
6	drug2	drug2	NN	_	10	nsubj
7	does	do	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	itself	itself	PRP	_	10	nsubj
10	cause	cause	VB	_	19	advcl
11	orthostatic	orthostatic	JJ	_	12	amod
12	hypotension	hypotension	NN	_	10	dobj
13	,	,	,	_	19	punct
14	its	its	PRP$	_	15	nmod:poss
15	administration	administration	NN	_	19	nsubj
16	to	to	TO	_	17	case
17	patients	patient	NNS	_	15	nmod
18	already	already	RB	_	19	advmod
19	receiving	receive	VBG	_	1	dep
20	drug3	drug3	NN	_	19	dobj
21	can	can	MD	_	22	aux
22	result	result	VB	_	19	dep
23	in	in	IN	_	26	case
24	profound	profound	JJ	_	26	amod
25	orthostatic	orthostatic	JJ	_	26	amod
26	effects	effect	NNS	_	22	nmod
27	.	.	.	_	1	punct

1	If	if	IN	_	8	mark
2	at	at	IN	_	5	case
3	all	all	DT	_	5	det
4	possible	possible	JJ	_	5	amod
5	drug1	drug1	NN	_	8	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	discontinued	discontinue	VBN	_	0	ROOT
9	well	well	RB	_	8	advmod
10	before	before	IN	_	13	mark
11	drug2	drug2	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	begun	begin	VBN	_	8	advcl
14	.	.	.	_	8	punct

1	Where	where	WRB	_	5	advmod
2	this	this	DT	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	possible	possible	JJ	_	11	advcl
6	,	,	,	_	11	punct
7	drug1	drug1	NN	_	8	compound
8	therapy	therapy	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	started	start	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	hospital	hospital	NN	_	11	nmod
15	and	and	CC	_	11	cc
16	the	the	DT	_	17	det
17	patient	patient	NN	_	19	nsubj
18	should	should	MD	_	19	aux
19	remain	remain	VB	_	11	conj
20	institutionalized	institutionalized	JJ	_	19	xcomp
21	until	until	IN	_	28	mark
22	severe	severe	JJ	_	24	amod
23	orthostatic	orthostatic	JJ	_	24	amod
24	effects	effect	NNS	_	28	nsubj
25	are	be	VBP	_	28	cop
26	no	no	RB	_	27	neg
27	longer	longer	RB	_	28	advmod
28	present	present	JJ	_	19	advcl
29	or	or	CC	_	28	cc
30	the	the	DT	_	31	det
31	patient	patient	NN	_	33	nsubj
32	has	have	VBZ	_	33	aux
33	learned	learn	VBN	_	28	conj
34	to	to	TO	_	35	mark
35	avoid	avoid	VB	_	33	xcomp
36	activities	activity	NNS	_	35	dobj
37	that	that	WDT	_	38	nsubj
38	provoke	provoke	VBP	_	36	acl:relcl
39	them	they	PRP	_	38	dobj
40	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	21	nmod
4	in	in	IN	_	5	case
5	which	which	WDT	_	10	nmod
6	34	34	CD	_	8	nummod
7	different	different	JJ	_	8	amod
8	drugs	drug	NNS	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	tested	test	VBN	_	3	acl:relcl
11	,	,	,	_	21	punct
12	therapeutically	therapeutically	RB	_	13	advmod
13	relevant	relevant	JJ	_	14	amod
14	concentrations	concentration	NNS	_	21	nsubj
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug2	drug2	NN	_	16	conj
19	and	and	CC	_	16	cc
20	drug3	drug3	NN	_	16	conj
21	displaced	displace	VBD	_	0	ROOT
22	protein-bound	protein-bound	JJ	_	23	amod
23	drug4	drug4	NN	_	21	dobj
24	in	in	IN	_	27	case
25	fresh	fresh	JJ	_	27	amod
26	human	human	JJ	_	27	amod
27	serum	serum	NN	_	21	nmod
28	to	to	TO	_	33	case
29	a	a	DT	_	33	det
30	small	small	JJ	_	33	amod
31	but	but	CC	_	30	cc
32	significant	significant	JJ	_	30	conj
33	extent	extent	NN	_	21	nmod
34	.	.	.	_	21	punct

1	Because	because	IN	_	6	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	6	det
4	extremely	extremely	RB	_	5	advmod
5	high	high	JJ	_	6	amod
6	binding	binding	NN	_	19	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	to	to	TO	_	11	case
10	plasma	plasma	NN	_	11	compound
11	proteins	protein	NNS	_	6	nmod
12	,	,	,	_	19	punct
13	these	these	DT	_	15	det
14	small	small	JJ	_	15	amod
15	decreases	decrease	NNS	_	19	nsubj
16	in	in	IN	_	17	case
17	binding	binding	NN	_	15	nmod
18	could	could	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	substantial	substantial	JJ	_	21	amod
21	increases	increase	NNS	_	19	dobj
22	in	in	IN	_	25	case
23	free	free	JJ	_	25	amod
24	drug	drug	NN	_	25	compound
25	levels	level	NNS	_	21	nmod
26	in	in	IN	_	27	case
27	plasma	plasma	NN	_	25	nmod
28	which	which	WDT	_	30	nsubj
29	could	could	MD	_	30	aux
30	result	result	VB	_	21	acl:relcl
31	in	in	IN	_	32	case
32	potentiation	potentiation	NN	_	30	nmod
33	of	of	IN	_	35	case
34	drug	drug	NN	_	35	compound
35	toxicity	toxicity	NN	_	32	nmod
36	.	.	.	_	19	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	mark
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug2	drug2	NN	_	12	compound
12	injection	injection	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	to	to	TO	_	15	case
15	patients	patient	NNS	_	8	nmod
16	receiving	receive	VBG	_	15	acl
17	these	these	DT	_	19	det
18	other	other	JJ	_	19	amod
19	agents	agent	NNS	_	16	dobj
20	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	change	change	NN	_	2	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	plasma	plasma	NN	_	8	compound
8	kinetics	kinetics	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	coadministered	coadminister	VBN	_	2	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	2	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	5	det
4	plasma	plasma	NN	_	5	compound
5	clearance	clearance	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	10	auxpass
9	slightly	slightly	RB	_	10	advmod
10	increased	increase	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	An	a	DT	_	2	det
2	increase	increase	NN	_	9	nsubjpass
3	in	in	IN	_	5	case
4	intracellular	intracellular	JJ	_	5	amod
5	levels	level	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	9	advmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	presence	presence	NN	_	9	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	drug1	drug1	NN	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	5	det
4	uricosuric	uricosuric	JJ	_	5	amod
5	action	action	NN	_	2	dobj
6	of	of	IN	_	8	case
7	.	.	.	_	8	punct
8	drugs	drug	NNS	_	5	nmod
9	used	use	VBN	_	8	acl
10	to	to	TO	_	11	mark
11	treat	treat	VB	_	9	xcomp
12	gout	gout	NN	_	11	dobj
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	compound
2	AND	and	CC	_	1	cc
3	OTHER	other	NN	_	1	conj
4	drug2	drug2	NN	_	6	nsubj
5	WILL	will	MD	_	6	aux
6	BE	be	VB	_	0	ROOT
7	ADDITIVE	ADDITIVE	NNP	_	6	dobj
8	TO	to	TO	_	9	mark
9	drug3	drug3	VB	_	7	acl
10	AND	and	CC	_	9	cc
11	MAY	MAY	NNP	_	14	compound
12	INCREASE	INCREASE	NNP	_	14	compound
13	PLASMA	PLASMA	NNP	_	14	compound
14	CONCENTRATIONS	CONCENTRATIONS	NNPS	_	9	conj
15	OF	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	TO	to	TO	_	19	case
18	TOXIC	TOXIC	NNP	_	19	compound
19	LEVELS	LEVELS	NNP	_	16	nmod
20	.	.	.	_	6	punct

1	Drugs	drug	NNS	_	9	nsubj
2	and	and	CC	_	1	cc
3	foods	food	NNS	_	1	conj
4	that	that	WDT	_	5	nsubj
5	raise	raise	VBP	_	1	acl:relcl
6	urine	urine	NN	_	7	compound
7	pH	ph	NN	_	5	dobj
8	will	will	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	renal	renal	JJ	_	11	amod
11	clearance	clearance	NN	_	9	dobj
12	and	and	CC	_	11	cc
13	urinary	urinary	JJ	_	14	amod
14	excretion	excretion	NN	_	11	conj
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	11	nmod
17	,	,	,	_	9	punct
18	thus	thus	RB	_	19	advmod
19	lowering	lower	VBG	_	9	advcl
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	19	dobj
22	;	;	:	_	9	punct

1	acidifying	acidify	VBG	_	2	amod
2	drugs	drug	NNS	_	6	nsubj
3	or	or	CC	_	2	cc
4	foods	food	NNS	_	2	conj
5	will	will	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	urinary	urinary	JJ	_	8	amod
8	excretion	excretion	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	increase	increase	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	8	conj
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	7	nsubj
2	given	give	VBN	_	1	acl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	may	may	MD	_	7	aux
7	predispose	predispose	VB	_	0	ROOT
8	to	to	TO	_	10	case
9	systemic	systemic	JJ	_	10	amod
10	bleeding	bleeding	NN	_	7	nmod
11	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypoglycemic	hypoglycemic	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	9	case
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	sulfonylurea	sulfonylurea	NN	_	13	compound
13	class	class	NN	_	9	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	competes	compete	VBZ	_	0	ROOT
3	with	with	IN	_	5	case
4	a	a	DT	_	5	det
5	number	number	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	for	for	IN	_	11	case
9	protein	protein	NN	_	11	compound
10	binding	binding	NN	_	11	compound
11	sites	site	NNS	_	7	nmod
12	,	,	,	_	5	punct
13	notably	notably	RB	_	14	advmod
14	drug2	drug2	NN	_	5	appos
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug7	drug7	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug8	drug8	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug9	drug9	NN	_	14	conj
29	,	,	,	_	14	punct
30	drug10	drug10	NN	_	14	conj
31	,	,	,	_	14	punct
32	and	and	CC	_	14	cc
33	possibly	possibly	RB	_	34	advmod
34	drug11	drug11	NN	_	14	conj
35	.	.	.	_	2	punct

1	Drug	drug	NN	_	6	compound
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	6	compound
4	Test	Test	NNP	_	6	compound
5	Interactions	interaction	NNS	_	6	compound
6	drug1	drug1	NN	_	7	nsubj
7	competes	compete	VBZ	_	0	ROOT
8	with	with	IN	_	10	case
9	thyroid	thyroid	NN	_	10	compound
10	hormone	hormone	NN	_	7	nmod
11	for	for	IN	_	12	case
12	binding	bind	VBG	_	7	nmod
13	to	to	TO	_	15	case
14	plasma	plasma	NN	_	15	compound
15	proteins	protein	NNS	_	12	nmod
16	,	,	,	_	15	punct
17	which	which	WDT	_	20	nsubjpass
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	reflected	reflect	VBN	_	15	acl:relcl
21	in	in	IN	_	26	case
22	a	a	DT	_	26	det
23	depressed	depressed	JJ	_	26	amod
24	plasma	plasma	NN	_	26	compound
25	T4	t4	NN	_	26	compound
26	value	value	NN	_	20	nmod
27	in	in	IN	_	29	case
28	some	some	DT	_	29	det
29	patients	patient	NNS	_	26	nmod
30	;	;	:	_	7	punct

1	thyroid	thyroid	NN	_	2	compound
2	function	function	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	basal	basal	JJ	_	5	amod
5	metabolism	metabolism	NN	_	2	conj
6	are	be	VBP	_	7	cop
7	unaffected	unaffected	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	elderly	elderly	JJ	_	3	amod
3	patients	patient	NNS	_	21	nmod
4	concurrently	concurrently	RB	_	5	advmod
5	receiving	receive	VBG	_	3	acl
6	certain	certain	JJ	_	7	amod
7	drug1	drug1	NN	_	5	dobj
8	,	,	,	_	21	punct
9	primarily	primarily	RB	_	10	advmod
10	drug2	drug2	NN	_	21	nsubjpass
11	,	,	,	_	10	punct
12	an	a	DT	_	14	det
13	increased	increase	VBN	_	14	amod
14	incidence	incidence	NN	_	10	appos
15	of	of	IN	_	16	case
16	thrombopenia	thrombopenia	NN	_	14	nmod
17	with	with	IN	_	18	case
18	purpura	purpura	NN	_	14	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	prolong	prolong	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	8	dobj
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	who	who	WP	_	16	nsubj
15	are	be	VBP	_	16	aux
16	receiving	receive	VBG	_	13	acl:relcl
17	the	the	DT	_	19	det
18	drug2	drug2	NN	_	19	compound
19	drug3	drug3	NN	_	16	dobj
20	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	given	give	VBN	_	5	advcl
12	to	to	TO	_	13	case
13	patients	patient	NNS	_	11	nmod
14	already	already	RB	_	17	advmod
15	on	on	IN	_	17	case
16	anticoagulant	anticoagulant	JJ	_	17	amod
17	therapy	therapy	NN	_	11	nmod
18	,	,	,	_	5	punct
19	and	and	CC	_	5	cc
20	the	the	DT	_	22	det
21	coagulation	coagulation	NN	_	22	compound
22	time	time	NN	_	25	nsubjpass
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	reassessed	reassess	VBN	_	5	conj
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	At	at	IN	_	4	case
2	a	a	DT	_	4	det
3	1.6-g	1.6-g	JJ	_	4	amod
4	dose	dose	NN	_	7	nmod
5	,	,	,	_	7	punct
6	drug1	drug1	NN	_	7	nsubj
7	produced	produce	VBD	_	0	ROOT
8	a	a	DT	_	12	det
9	slight	slight	JJ	_	12	amod
10	but	but	CC	_	9	cc
11	significant	significant	JJ	_	9	conj
12	increase	increase	NN	_	7	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	half-life	half-life	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	but	but	CC	_	7	cc
19	did	do	VBD	_	21	aux
20	not	not	RB	_	21	neg
21	produce	produce	VB	_	7	conj
22	a	a	DT	_	24	det
23	corresponding	corresponding	JJ	_	24	amod
24	decrease	decrease	NN	_	21	dobj
25	in	in	IN	_	29	case
26	the	the	DT	_	29	det
27	metabolic	metabolic	JJ	_	29	amod
28	clearance	clearance	NN	_	29	compound
29	rate	rate	NN	_	24	nmod
30	.	.	.	_	7	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	10	advcl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	,	,	,	_	10	punct
7	one	one	CD	_	10	nsubj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	cop
10	alert	alert	JJ	_	0	ROOT
11	for	for	IN	_	15	case
12	possible	possible	JJ	_	15	amod
13	excessive	excessive	JJ	_	15	amod
14	drug1	drug1	NN	_	15	compound
15	effect	effect	NN	_	10	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	can	can	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	displace	displace	VB	_	0	ROOT
5	drug2	drug2	NN	_	4	dobj
6	from	from	IN	_	9	case
7	plasma	plasma	NN	_	9	compound
8	protein-binding	protein-binding	JJ	_	9	amod
9	sites	site	NNS	_	4	nmod
10	,	,	,	_	4	punct
11	thus	thus	RB	_	12	advmod
12	increasing	increase	VBG	_	4	advcl
13	free	free	JJ	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	concentrations	concentration	NNS	_	12	dobj
16	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	13	case
8	the	the	DT	_	13	det
9	Jaff	Jaff	NNP	_	13	compound
10	alkaline	alkaline	NN	_	13	compound
11	picrate	picrate	NN	_	13	compound
12	reaction	reaction	NN	_	13	compound
13	assay	assay	NN	_	6	nmod
14	for	for	IN	_	15	case
15	creatinine	creatinine	NN	_	13	nmod
16	,	,	,	_	6	punct
17	resulting	result	VBG	_	6	advcl
18	in	in	IN	_	19	case
19	overestimations	overestimation	NNS	_	17	nmod
20	of	of	IN	_	23	case
21	about	about	IN	_	22	advmod
22	10	10	CD	_	23	nummod
23	%	%	NN	_	19	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	range	range	NN	_	17	nmod
27	of	of	IN	_	29	case
28	normal	normal	JJ	_	29	amod
29	values	value	NNS	_	26	nmod
30	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Mutual	mutual	JJ	_	2	amod
2	inhibition	inhibition	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	metabolism	metabolism	NN	_	2	nmod
5	occurs	occur	VBZ	_	0	ROOT
6	with	with	IN	_	8	case
7	concurrent	concurrent	JJ	_	8	amod
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	;	;	:	_	5	punct

1	therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	possible	possible	JJ	_	0	ROOT
6	that	that	IN	_	20	mark
7	adverse	adverse	JJ	_	8	amod
8	events	event	NNS	_	20	nsubj
9	associated	associate	VBN	_	8	acl
10	with	with	IN	_	13	case
11	the	the	DT	_	13	det
12	individual	individual	JJ	_	13	amod
13	use	use	NN	_	9	nmod
14	of	of	IN	_	16	case
15	either	either	CC	_	16	det
16	drug	drug	NN	_	13	nmod
17	may	may	MD	_	20	aux
18	be	be	VB	_	20	cop
19	more	more	RBR	_	20	advmod
20	apt	apt	JJ	_	5	ccomp
21	to	to	TO	_	22	mark
22	occur	occur	VB	_	20	xcomp
23	.	.	.	_	5	punct

1	convulsions	convulsion	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	concurrent	concurrent	JJ	_	7	amod
7	use	use	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	15	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	drug3	drug3	NN	_	8	conj
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	clearance	clearance	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	and	and	CC	_	15	cc
21	may	may	MD	_	22	aux
22	require	require	VB	_	15	conj
23	increased	increase	VBN	_	22	ccomp
24	in	in	IN	_	26	case
25	drug5	drug5	NN	_	26	compound
26	dose	dose	NN	_	23	nmod
27	to	to	TO	_	28	mark
28	achieve	achieve	VB	_	23	xcomp
29	the	the	DT	_	31	det
30	desired	desire	VBN	_	31	amod
31	response	response	NN	_	28	dobj
32	.	.	.	_	15	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	its	its	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	drug2	drug2	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	drug1	drug1	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	drug3	drug3	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	generally	generally	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	action	action	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	potentiated	potentiate	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	anesthesia	anesthesia	NN	_	7	nmod
10	,	,	,	_	9	punct
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	conj
13	and	and	CC	_	9	cc
14	drug3	drug3	NN	_	9	conj
15	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	24	nmod
4	,	,	,	_	24	punct
5	the	the	DT	_	7	det
6	concurrent	concurrent	JJ	_	7	amod
7	administration	administration	NN	_	24	nsubjpass
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	drug1	drug1	NN	_	11	compound
11	inhaler	inhaler	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	commonly	commonly	RB	_	16	advmod
16	used	use	VBN	_	11	acl
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	treatment	treatment	NN	_	16	nmod
20	of	of	IN	_	21	case
21	asthma	asthma	NN	_	19	nmod
22	was	be	VBD	_	24	auxpass
23	not	not	RB	_	24	neg
24	associated	associate	VBN	_	0	ROOT
25	with	with	IN	_	29	case
26	any	any	DT	_	29	det
27	unusual	unusual	JJ	_	29	amod
28	adverse	adverse	JJ	_	29	amod
29	events	event	NNS	_	24	nmod
30	.	.	.	_	24	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	drug1	drug1	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	potent	potent	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	3A4	3a4	NN	_	7	nmod
12	,	,	,	_	3	punct
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	plasma	plasma	NN	_	16	compound
16	levels	level	NNS	_	14	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	during	during	IN	_	21	case
20	concomitant	concomitant	JJ	_	21	amod
21	dosing	dosing	NN	_	14	nmod
22	.	.	.	_	14	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	13	nsubjpass
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	performed	perform	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	6	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	release	release	NN	_	6	dobj
9	of	of	IN	_	10	case
10	neutrophils	neutrophil	NNS	_	8	nmod
11	;	;	:	_	6	punct

1	patients	patient	NNS	_	7	nsubj
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	7	aux
7	have	have	VB	_	0	ROOT
8	more	more	RBR	_	9	advmod
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	dobj
11	of	of	IN	_	13	case
12	neutrophil	neutrophil	NN	_	13	compound
13	counts	count	NNS	_	10	nmod
14	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	sensitivity	sensitivity	NN	_	4	dobj
6	to	to	TO	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug3	drug3	NN	_	5	nmod
9	.	.	.	_	4	punct

1	Dosage	dosage	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	auxpass
9	decreased	decrease	VBN	_	6	xcomp
10	in	in	IN	_	13	mark
11	order	order	NN	_	10	mwe
12	to	to	TO	_	13	mark
13	maintain	maintain	VB	_	9	advcl
14	desired	desire	VBN	_	16	amod
15	prothrombin	prothrombin	NN	_	16	compound
16	time	time	NN	_	13	dobj
17	.	.	.	_	6	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	oral	oral	JJ	_	5	amod
4	anticoagulant	anticoagulant	JJ	_	5	amod
5	therapy	therapy	NN	_	2	dobj
6	require	require	VBP	_	0	ROOT
7	close	close	JJ	_	8	amod
8	monitoring	monitoring	NN	_	6	dobj
9	,	,	,	_	8	punct
10	especially	especially	RB	_	11	advmod
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	started	start	VBN	_	8	acl:relcl
15	or	or	CC	_	14	cc
16	stopped	stop	VBN	_	14	conj
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	5	det
4	multidose	multidose	JJ	_	5	amod
5	study	study	NN	_	25	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	given	give	VBN	_	5	acl
10	as	as	IN	_	15	case
11	5	5	CD	_	14	compound
12	or	or	CC	_	11	cc
13	10	10	CD	_	11	conj
14	mg	mg	NN	_	15	amod
15	BID	BID	NNP	_	9	nmod
16	in	in	IN	_	19	case
17	15	15	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	subjects	subject	NNS	_	9	nmod
20	concurrently	concurrently	RB	_	21	advmod
21	treated	treat	VBN	_	19	acl
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	,	,	,	_	5	punct
25	resulted	result	VBD	_	1	dep
26	in	in	IN	_	29	case
27	a	a	DT	_	29	det
28	mean	mean	JJ	_	29	amod
29	increase	increase	NN	_	25	nmod
30	in	in	IN	_	32	case
31	drug4	drug4	NN	_	32	compound
32	half-life	half-life	NN	_	29	nmod
33	from	from	IN	_	37	case
34	26	26	CD	_	36	compound
35	to	to	TO	_	36	dep
36	48	48	CD	_	37	nummod
37	hours	hour	NNS	_	29	nmod
38	and	and	CC	_	37	cc
39	AUC	auc	NN	_	37	conj
40	from	from	IN	_	41	case
41	4.55	4.55	CD	_	29	nmod
42	to	to	TO	_	43	dep
43	12.08	12.08	CD	_	41	nmod
44	ng	ng	NN	_	46	compound
45	*	*	SYM	_	46	dep
46	hr/mL	hr/ml	NN	_	43	dep
47	:	:	:	_	25	punct
48	similar	similar	JJ	_	49	amod
49	increases	increase	NNS	_	57	nsubjpass
50	in	in	IN	_	52	case
51	drug5	drug5	NN	_	52	compound
52	half-life	half-life	NN	_	49	nmod
53	and	and	CC	_	52	cc
54	AUC	auc	NN	_	52	conj
55	were	be	VBD	_	57	auxpass
56	also	also	RB	_	57	advmod
57	detected	detect	VBN	_	25	parataxis
58	.	.	.	_	57	punct

1	Microscopic	microscopic	JJ	_	2	amod
2	hematuria	hematuria	NN	_	14	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	9/15	9/15	CD	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	and	and	CC	_	2	cc
7	gingival	gingival	JJ	_	8	amod
8	bleeding	bleeding	NN	_	2	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	1/15	1/15	CD	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	were	be	VBD	_	14	auxpass
13	also	also	RB	_	14	advmod
14	observed	observe	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	A	a	DT	_	3	nsubj
2	5.5-fold	5.5-fold	RB	_	3	advmod
3	decrease	decrease	VB	_	0	ROOT
4	in	in	IN	_	8	case
5	the	the	DT	_	8	det
6	mean	mean	NN	_	8	compound
7	drug1	drug1	NN	_	8	compound
8	dose	dose	NN	_	3	nmod
9	from	from	IN	_	11	case
10	6.13	6.13	CD	_	11	nummod
11	mg/day	mg/day	NN	_	3	nmod
12	to	to	TO	_	14	case
13	1.13	1.13	CD	_	14	nummod
14	mg/day	mg/day	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	19	punct
16	approximately	approximately	RB	_	17	advmod
17	80-85	80-85	CD	_	18	dep
18	%	%	NN	_	19	dep
19	reduction	reduction	NN	_	11	dep
20	of	of	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	dose	dose	NN	_	19	nmod
23	-RRB-	-rrb-	-RRB-	_	19	punct
24	,	,	,	_	3	punct
25	was	be	VBD	_	26	cop
26	necessary	necessary	JJ	_	3	dep
27	to	to	TO	_	28	mark
28	maintain	maintain	VB	_	26	xcomp
29	a	a	DT	_	31	det
30	target	target	NN	_	31	compound
31	INR	inr	NN	_	28	dobj
32	of	of	IN	_	33	case
33	1.5	1.5	CD	_	31	nmod
34	.	.	.	_	3	punct

1	When	when	WRB	_	5	advmod
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	25	advcl
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	already	already	RB	_	10	advmod
10	receiving	receive	VBG	_	8	acl
11	treatment	treatment	NN	_	10	dobj
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	10	nmod
14	,	,	,	_	25	punct
15	the	the	DT	_	16	det
16	INR	inr	NN	_	25	nsubjpass
17	or	or	CC	_	16	cc
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	16	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	PT	pt	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	monitored	monitor	VBN	_	0	ROOT
26	closely	closely	RB	_	25	advmod
27	and	and	CC	_	25	cc
28	the	the	DT	_	29	det
29	dose	dose	NN	_	44	nsubjpass
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	adjusted	adjust	VBN	_	29	acl
33	as	as	RB	_	34	advmod
34	necessary	necessary	JJ	_	32	xcomp
35	until	until	IN	_	39	case
36	a	a	DT	_	39	det
37	stable	stable	JJ	_	39	amod
38	target	target	NN	_	39	compound
39	INR	inr	NN	_	34	nmod
40	or	or	CC	_	39	cc
41	PT	pt	NN	_	39	conj
42	has	have	VBZ	_	44	aux
43	been	be	VBN	_	44	auxpass
44	achieved	achieve	VBN	_	25	conj
45	.	.	.	_	25	punct

1	Furthermore	furthermore	RB	_	26	advmod
2	,	,	,	_	26	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	26	nmod
5	receiving	receive	VBG	_	4	acl
6	both	both	CC	_	7	cc:preconj
7	drugs	drug	NNS	_	5	dobj
8	,	,	,	_	26	punct
9	careful	careful	JJ	_	10	amod
10	monitoring	monitoring	NN	_	26	nsubjpass
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	INR	inr	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	PT	pt	NN	_	13	conj
16	,	,	,	_	10	punct
17	and	and	CC	_	10	cc
18	adjustment	adjustment	NN	_	10	conj
19	of	of	IN	_	22	case
20	the	the	DT	_	22	det
21	drug1	drug1	NN	_	22	compound
22	dosage	dosage	NN	_	18	nmod
23	if	if	IN	_	24	mark
24	indicated	indicate	VBN	_	10	dep
25	are	be	VBP	_	26	auxpass
26	recommended	recommend	VBN	_	0	ROOT
27	when	when	WRB	_	32	advmod
28	the	the	DT	_	30	det
29	drug2	drug2	NN	_	30	compound
30	dose	dose	NN	_	32	nsubjpass
31	is	be	VBZ	_	32	auxpass
32	changed	change	VBN	_	26	advcl
33	or	or	CC	_	32	cc
34	discontinued	discontinue	VBN	_	32	conj
35	.	.	.	_	26	punct

1	Patients	patient	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	be	be	VB	_	5	auxpass
4	closely	closely	RB	_	5	advmod
5	monitored	monitor	VBN	_	0	ROOT
6	for	for	IN	_	7	case
7	signs	sign	NNS	_	5	nmod
8	and	and	CC	_	7	cc
9	symptoms	symptom	NNS	_	7	conj
10	of	of	IN	_	12	case
11	occult	occult	NN	_	12	compound
12	bleeding	bleeding	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Oral	oral	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	drug3	drug3	NN	_	7	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	16	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	In	in	IN	_	5	case
5	patients	patient	NNS	_	1	nmod
6	with	with	IN	_	7	case
7	edema	edema	NN	_	5	nmod
8	,	,	,	_	1	punct
9	concomitant	concomitant	JJ	_	10	amod
10	administration	administration	NN	_	1	appos
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	0	ROOT
17	the	the	DT	_	18	det
18	edema	edema	NN	_	16	dobj
19	.	.	.	_	16	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	test	test	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubj
4	drug1	drug1	NN	_	3	dep
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	levels	level	NNS	_	6	dobj
8	of	of	IN	_	10	case
9	thyroxine-binding	thyroxine-binding	JJ	_	10	amod
10	globulin	globulin	NN	_	7	nmod
11	,	,	,	_	6	punct
12	resulting	result	VBG	_	6	conj
13	in	in	IN	_	18	case
14	decreased	decrease	VBN	_	18	amod
15	total	total	JJ	_	18	amod
16	T4	t4	NN	_	18	compound
17	serum	serum	NN	_	18	compound
18	levels	level	NNS	_	12	nmod
19	and	and	CC	_	6	cc
20	increased	increase	VBD	_	22	amod
21	resin	resin	NN	_	22	compound
22	uptake	uptake	NN	_	6	conj
23	of	of	IN	_	24	case
24	T3	t3	NN	_	22	nmod
25	and	and	CC	_	24	cc
26	T4	t4	NN	_	24	conj
27	.	.	.	_	6	punct

1	Free	Free	NNP	_	4	compound
2	thyroid	thyroid	NN	_	4	compound
3	hormone	hormone	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	remain	remain	VBP	_	0	ROOT
6	unchanged	unchanged	JJ	_	5	xcomp
7	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	,	,	,	_	13	punct
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	13	nsubj
6	in	in	IN	_	7	case
7	PBI	pbi	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	radioactive	radioactive	JJ	_	11	amod
10	iodine	iodine	NN	_	11	compound
11	uptake	uptake	NN	_	7	conj
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	agents	agent	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	certain	certain	JJ	_	7	amod
7	actions	action	NNS	_	5	dobj
8	or	or	CC	_	7	cc
9	side	side	JJ	_	10	amod
10	effects	effect	NNS	_	7	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	:	:	:	_	5	punct
14	drug2	drug2	NN	_	5	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug4	drug4	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	14	punct
23	drug5	drug5	NN	_	14	conj
24	,	,	,	_	14	punct
25	drug6	drug6	NN	_	14	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug7	drug7	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	14	punct
32	drug8	drug8	NN	_	14	conj
33	,	,	,	_	14	punct
34	drug9	drug9	NN	_	14	conj
35	,	,	,	_	14	punct
36	drug10	drug10	NN	_	14	conj
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	e.g.	e.g.	FW	_	40	dep
39	,	,	,	_	40	punct
40	drug11	drug11	NN	_	36	dep
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	,	,	,	_	14	punct
43	drug12	drug12	NN	_	14	conj
44	and	and	CC	_	14	cc
45	drug13	drug13	NN	_	14	conj
46	,	,	,	_	14	punct
47	drug14	drug14	NN	_	14	conj
48	,	,	,	_	14	punct
49	drug15	drug15	NN	_	14	conj
50	,	,	,	_	14	punct
51	and	and	CC	_	14	cc
52	other	other	JJ	_	53	amod
53	drugs	drug	NNS	_	54	nsubj
54	having	have	VBG	_	14	conj
55	anticholinergic	anticholinergic	JJ	_	56	amod
56	activity	activity	NN	_	54	dobj
57	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	11	nsubj
2	in	in	IN	_	4	case
3	the	the	DT	_	4	det
4	presence	presence	NN	_	1	nmod
5	of	of	IN	_	8	case
6	increased	increase	VBN	_	8	amod
7	intraocular	intraocular	JJ	_	8	amod
8	pressure	pressure	NN	_	4	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	hazardous	hazardous	JJ	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	taken	take	VBN	_	11	advcl
14	concurrently	concurrently	RB	_	13	advmod
15	with	with	IN	_	16	case
16	agents	agent	NNS	_	13	nmod
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug2	drug2	NN	_	16	nmod
20	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	affect	affect	VB	_	0	ROOT
4	gastrointestinal	gastrointestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	8	case
7	various	various	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	13	mark
11	as	as	IN	_	10	mwe
12	slowly	slowly	RB	_	13	advmod
13	dissolving	dissolve	VBG	_	8	acl
14	dosage	dosage	JJ	_	15	amod
15	forms	form	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	;	;	:	_	3	punct

1	increased	increase	VBN	_	4	amod
2	serum	serum	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	that	that	WDT	_	9	nsubj
9	alter	alter	VBP	_	7	acl:relcl
10	gastrointestinal	gastrointestinal	JJ	_	11	amod
11	motility	motility	NN	_	9	dobj
12	,	,	,	_	11	punct
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug2	drug2	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interfere	interfere	VB	_	18	advcl
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	18	punct
11	simultaneous	simultaneous	JJ	_	12	amod
12	use	use	NN	_	18	nsubjpass
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	drugs	drug	NNS	_	12	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	inhibiting	inhibiting	JJ	_	3	amod
3	effects	effect	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	10	case
7	gastric	gastric	JJ	_	10	amod
8	hydrochloric	hydrochloric	JJ	_	10	amod
9	acid	acid	NN	_	10	compound
10	secretion	secretion	NN	_	3	nmod
11	are	be	VBP	_	12	auxpass
12	antagonized	antagonize	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	agents	agent	NNS	_	12	nmod
15	used	use	VBN	_	14	acl
16	to	to	TO	_	17	mark
17	treat	treat	VB	_	15	xcomp
18	achlorhydria	achlorhydria	NN	_	17	dobj
19	and	and	CC	_	18	cc
20	those	those	DT	_	18	conj
21	used	use	VBN	_	20	acl
22	to	to	TO	_	23	mark
23	test	test	VB	_	21	xcomp
24	gastric	gastric	JJ	_	25	amod
25	secretion	secretion	NN	_	23	dobj
26	.	.	.	_	12	punct

1	Since	since	IN	_	7	mark
2	drug1	drug1	NN	_	7	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	may	may	MD	_	7	aux
7	interact	interact	VB	_	22	advcl
8	with	with	IN	_	11	case
9	concurrently	concurrently	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drug3	drug3	NN	_	7	nmod
12	,	,	,	_	22	punct
13	periodic	periodic	JJ	_	16	amod
14	serum	serum	NN	_	16	compound
15	level	level	NN	_	16	compound
16	determinations	determination	NNS	_	22	nsubj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	drugs	drug	NNS	_	16	nmod
20	may	may	MD	_	22	aux
21	be	be	VB	_	22	cop
22	necessary	necessary	JJ	_	0	ROOT
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	eg	eg	FW	_	25	compound
25	drug4	drug4	NN	_	27	nsubj
26	may	may	MD	_	27	aux
27	increase	increase	VB	_	22	ccomp
28	the	the	DT	_	30	det
29	plasma	plasma	NN	_	30	compound
30	concentrations	concentration	NNS	_	27	dobj
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	and	and	CC	_	32	cc
34	drug6	drug6	NN	_	32	conj
35	-RRB-	-rrb-	-RRB-	_	27	punct
36	.	.	.	_	22	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	13	nsubj
4	and	and	CC	_	3	cc
5	probably	probably	RB	_	7	advmod
6	other	other	JJ	_	7	amod
7	drug3	drug3	NN	_	3	conj
8	given	give	VBN	_	3	acl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug4	drug4	NN	_	8	nmod
12	can	can	MD	_	13	aux
13	cause	cause	VB	_	1	appos
14	unusually	unusually	RB	_	15	advmod
15	large	large	JJ	_	18	amod
16	or	or	CC	_	15	cc
17	prolonged	prolonged	JJ	_	15	conj
18	losses	loss	NNS	_	13	dobj
19	of	of	IN	_	20	case
20	fluid	fluid	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	electrolytes	electrolyte	NNS	_	20	conj
23	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	When	when	WRB	_	8	advmod
5	drug2	drug2	NN	_	6	compound
6	Tablets	tablet	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	16	advcl
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug3	drug3	NN	_	8	nmod
12	,	,	,	_	16	punct
13	care	care	NN	_	16	nsubjpass
14	must	must	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	taken	take	VBN	_	2	dep
17	,	,	,	_	16	punct
18	especially	especially	RB	_	21	advmod
19	during	during	IN	_	21	case
20	initial	initial	JJ	_	21	amod
21	therapy	therapy	NN	_	16	nmod
22	.	.	.	_	2	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	8	nsubj
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	necessary	necessary	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	:	:	:	_	1	punct
8	The	the	DT	_	10	det
9	hypotensive	hypotensive	JJ	_	10	amod
10	effects	effect	NNS	_	16	nsubjpass
11	of	of	IN	_	13	case
12	these	these	DT	_	13	det
13	drugs	drug	NNS	_	10	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	potentiated	potentiate	VBN	_	1	dep
17	by	by	IN	_	20	case
18	the	the	DT	_	20	det
19	volume	volume	NN	_	20	compound
20	contraction	contraction	NN	_	16	nmod
21	that	that	WDT	_	24	nsubjpass
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	associated	associate	VBN	_	20	acl:relcl
25	with	with	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	therapy	therapy	NN	_	24	nmod
28	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	dep
4	-	-	:	_	8	punct
5	induced	induce	VBN	_	6	amod
6	hypokalemia	hypokalemia	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	increase	increase	VB	_	1	dep
9	the	the	DT	_	10	det
10	sensitivity	sensitivity	NN	_	8	dobj
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	myocardium	myocardium	NN	_	10	nmod
14	to	to	TO	_	15	case
15	drug3	drug3	NN	_	10	nmod
16	.	.	.	_	1	punct

1	Serious	serious	JJ	_	2	amod
2	arrhythmias	arrhythmia	NNS	_	4	nsubj
3	can	can	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	May	May	NNP	_	6	nsubj
6	increase	increase	VB	_	1	dep
7	the	the	DT	_	8	det
8	risk	risk	NN	_	6	dobj
9	of	of	IN	_	10	case
10	hypokalemia	hypokalemia	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	increase	increase	NN	_	13	compound
13	salt	salt	NN	_	10	conj
14	and	and	CC	_	10	cc
15	water	water	NN	_	16	compound
16	retention	retention	NN	_	10	conj
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serum	serum	NN	_	5	compound
4	drug2	drug2	NN	_	5	compound
5	levels	level	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	1	parataxis
8	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	-	-	:	_	6	punct
5	induced	induce	VBN	_	6	amod
6	hypokalemia	hypokalemia	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	enhance	enhance	VB	_	1	dep
9	neuromuscular	neuromuscular	JJ	_	11	amod
10	blocking	blocking	NN	_	11	compound
11	effects	effect	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug4	drug4	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	the	the	DT	_	22	det
20	most	most	RBS	_	21	advmod
21	serious	serious	JJ	_	22	amod
22	effect	effect	NN	_	26	nsubj
23	would	would	MD	_	26	aux
24	be	be	VB	_	26	cop
25	respiratory	respiratory	JJ	_	26	amod
26	depression	depression	NN	_	8	ccomp
27	which	which	WDT	_	29	nsubj
28	could	could	MD	_	29	aux
29	proceed	proceed	VB	_	26	acl:relcl
30	to	to	TO	_	31	case
31	apnea	apnea	NN	_	29	nmod
32	.	.	.	_	1	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	cop
6	advisable	advisable	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	discontinue	discontinue	VB	_	6	xcomp
9	drug1	drug1	NN	_	10	compound
10	Tablets	tablet	NNS	_	8	dobj
11	three	three	CD	_	12	nummod
12	days	day	NNS	_	8	nmod
13	before	before	IN	_	12	case
14	elective	elective	JJ	_	15	amod
15	surgery	surgery	NN	_	12	dep
16	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	:	:	:	_	1	punct
6	May	May	NNP	_	7	nsubj
7	decrease	decrease	VB	_	1	dep
8	the	the	DT	_	10	det
9	antihypertensive	antihypertensive	JJ	_	10	amod
10	effects	effect	NNS	_	7	dobj
11	of	of	IN	_	13	case
12	drug3	drug3	NN	_	13	compound
13	Tablets	tablet	NNS	_	10	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	1	dep
6	arterial	arterial	JJ	_	7	amod
7	responsiveness	responsiveness	NN	_	5	dobj
8	to	to	TO	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	5	punct
11	but	but	CC	_	5	cc
12	this	this	DT	_	13	det
13	diminution	diminution	NN	_	16	nsubj
14	is	be	VBZ	_	16	cop
15	not	not	RB	_	16	neg
16	sufficient	sufficient	JJ	_	5	conj
17	to	to	TO	_	18	mark
18	preclude	preclude	VB	_	16	xcomp
19	effectiveness	effectiveness	NN	_	18	dobj
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	pressor	pressor	NN	_	23	compound
23	agent	agent	NN	_	19	nmod
24	for	for	IN	_	26	case
25	therapeutic	therapeutic	JJ	_	26	amod
26	use	use	NN	_	18	nmod
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Efficacy	efficacy	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	decreased	decrease	VBN	_	1	appos
7	due	due	JJ	_	11	case
8	to	to	TO	_	11	case
9	urinary	urinary	JJ	_	11	amod
10	alkalizing	alkalize	VBG	_	11	amod
11	effect	effect	NN	_	6	advcl
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	12	nsubj
4	,	,	,	_	3	punct
5	as	as	RB	_	3	cc
6	well	well	RB	_	5	mwe
7	as	as	IN	_	5	mwe
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	3	conj
10	,	,	,	_	3	punct
11	may	may	MD	_	12	aux
12	affect	affect	VB	_	1	dep
13	the	the	DT	_	15	det
14	hypoprothrombinemic	hypoprothrombinemic	JJ	_	15	amod
15	response	response	NN	_	12	dobj
16	to	to	TO	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	;	;	:	_	12	punct

1	dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	11	case
8	increased	increase	VBN	_	11	amod
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	concentrations	concentration	NNS	_	6	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	57	57	CD	_	14	nummod
14	%	%	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	11	punct
17	increased	increase	VBN	_	21	amod
18	plasma	plasma	NN	_	21	compound
19	bismuth	bismuth	NN	_	21	compound
20	trough	trough	NN	_	21	compound
21	concentrations	concentration	NNS	_	11	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	48	48	CD	_	24	nummod
24	%	%	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	11	punct
27	and	and	CC	_	11	cc
28	increased	increase	VBD	_	31	amod
29	drug4	drug4	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	11	conj
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	31	31	CD	_	34	nummod
34	%	%	NN	_	31	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	results	result	VBZ	_	0	ROOT
5	in	in	IN	_	8	case
6	a	a	DT	_	8	det
7	slight	slight	JJ	_	8	amod
8	decrease	decrease	NN	_	4	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	rate	rate	NN	_	8	nmod
12	of	of	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	absorption	absorption	NN	_	11	nmod
15	that	that	WDT	_	18	nsubj
16	is	be	VBZ	_	18	cop
17	clinically	clinically	RB	_	18	advmod
18	unimportant	unimportant	JJ	_	11	acl:relcl
19	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	12	nsubj
2	with	with	IN	_	5	case
3	a	a	DT	_	5	det
4	high	high	JJ	_	5	amod
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	170	170	CD	_	10	nummod
10	mEq	meq	NN	_	5	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	results	result	VBZ	_	0	ROOT
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	28	28	CD	_	16	compound
16	%	%	NN	_	17	amod
17	decrease	decrease	NN	_	12	nmod
18	in	in	IN	_	20	case
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	and	and	CC	_	12	cc
24	may	may	MD	_	25	aux
25	decrease	decrease	VB	_	12	conj
26	plasma	plasma	NN	_	27	compound
27	concentrations	concentration	NNS	_	25	dobj
28	of	of	IN	_	29	case
29	bismuth	bismuth	NN	_	27	nmod
30	from	from	IN	_	31	case
31	drug3	drug3	NN	_	25	nmod
32	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	clinically	clinically	RB	_	5	advmod
5	insignificant	insignificant	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	For	for	IN	_	2	case
2	information	information	NN	_	10	nmod
3	on	on	IN	_	5	case
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	2	nmod
6	associated	associate	VBN	_	5	acl
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	,	,	,	_	10	punct
10	refer	refer	VBP	_	0	ROOT
11	to	to	TO	_	15	case
12	the	the	DT	_	15	det
13	drug2	drug2	NN	_	15	compound
14	package	package	NN	_	15	compound
15	insert	insert	NN	_	10	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	other	other	JJ	_	12	amod
11	local	local	JJ	_	12	amod
12	drug2	drug2	NN	_	9	dobj
13	or	or	CC	_	12	cc
14	agents	agent	NNS	_	12	conj
15	structurally	structurally	RB	_	16	advmod
16	related	related	JJ	_	8	amod
17	to	to	TO	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	,	,	,	_	4	punct
20	since	since	IN	_	28	mark
21	the	the	DT	_	23	det
22	toxic	toxic	JJ	_	23	amod
23	effects	effect	NNS	_	28	nsubj
24	of	of	IN	_	26	case
25	these	these	DT	_	26	det
26	drugs	drug	NNS	_	23	nmod
27	are	be	VBP	_	28	cop
28	additive	additive	JJ	_	4	advcl
29	.	.	.	_	4	punct

1	Cytochrome	cytochrome	NN	_	2	compound
2	P4501A2	p4501a2	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	involved	involve	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	formation	formation	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	4	punct
11	the	the	DT	_	13	det
12	major	major	JJ	_	13	amod
13	metabolite	metabolite	NN	_	4	dobj
14	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vivo	vivo	FW	_	10	advmod
3	,	,	,	_	10	punct
4	the	the	DT	_	6	det
5	plasma	plasma	NN	_	6	compound
6	clearance	clearance	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	by	by	IN	_	13	case
12	70	70	CD	_	13	nummod
13	%	%	NN	_	10	nmod
14	during	during	IN	_	15	case
15	coadministration	coadministration	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	25	25	CD	_	20	compound
20	mg	mg	NN	_	21	amod
21	bid	bid	NN	_	17	dep
22	for	for	IN	_	24	case
23	2	2	CD	_	24	nummod
24	days	day	NNS	_	21	nmod
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	,	,	,	_	17	punct
27	a	a	DT	_	32	det
28	selective	selective	JJ	_	32	amod
29	and	and	CC	_	28	cc
30	potent	potent	JJ	_	28	conj
31	CYP1A2	cyp1a2	NN	_	32	compound
32	inhibitor	inhibitor	NN	_	17	appos
33	.	.	.	_	10	punct

1	Thus	thus	RB	_	20	advmod
2	strong	strong	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	20	nsubj
4	of	of	IN	_	6	case
5	cytochrome	cytochrome	NN	_	6	compound
6	P4501A2	p4501a2	NN	_	3	nmod
7	,	,	,	_	3	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug1	drug1	NN	_	3	nmod
11	,	,	,	_	3	punct
12	given	give	VBN	_	3	acl
13	concomitantly	concomitantly	RB	_	12	advmod
14	during	during	IN	_	15	case
15	administration	administration	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	3	punct
19	can	can	MD	_	20	aux
20	interact	interact	VB	_	0	ROOT
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	leading	lead	VBG	_	22	acl
24	to	to	TO	_	28	case
25	increased	increase	VBN	_	28	amod
26	drug4	drug4	NN	_	28	compound
27	plasma	plasma	NN	_	28	compound
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	20	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	CYP1A2	cyp1a2	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	coadministered	coadminister	VBN	_	4	advcl
10	.	.	.	_	4	punct

1	Possible	possible	JJ	_	2	amod
2	interactions	interaction	NNS	_	21	nsubj
3	with	with	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	known	know	VBN	_	4	acl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	metabolized	metabolize	VBN	_	5	xcomp
9	by	by	IN	_	10	case
10	CYP1A2	cyp1a2	NN	_	8	nmod
11	via	via	IN	_	13	case
12	competitive	competitive	JJ	_	13	amod
13	inhibition	inhibition	NN	_	8	nmod
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug1	drug1	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	may	may	MD	_	21	aux
20	also	also	RB	_	21	advmod
21	occur	occur	VB	_	0	ROOT
22	.	.	.	_	21	punct

1	Coadministration	coadministration	NN	_	28	nsubj
2	of	of	IN	_	7	case
3	a	a	DT	_	7	det
4	selective	selective	JJ	_	7	amod
5	and	and	CC	_	4	cc
6	potent	potent	JJ	_	4	conj
7	inhibitor	inhibitor	NN	_	1	nmod
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	9	punct
11	drug1	drug1	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	100	100	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	bid	bid	NN	_	9	appos
16	for	for	IN	_	18	case
17	2	2	CD	_	18	nummod
18	days	day	NNS	_	15	nmod
19	with	with	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	infusion	infusion	NN	_	18	nmod
22	administered	administer	VBN	_	21	acl
23	1	1	CD	_	24	nummod
24	hour	hour	NN	_	22	nmod
25	after	after	IN	_	24	case
26	drug3	drug3	NN	_	24	dep
27	-RRB-	-rrb-	-RRB-	_	1	punct
28	caused	cause	VBD	_	0	ROOT
29	a	a	DT	_	32	det
30	15	15	CD	_	31	compound
31	%	%	NN	_	32	amod
32	reduction	reduction	NN	_	28	dobj
33	in	in	IN	_	36	case
34	in-vivo	in-vivo	JJ	_	36	amod
35	plasma	plasma	NN	_	36	compound
36	clearance	clearance	NN	_	32	nmod
37	of	of	IN	_	38	case
38	drug4	drug4	NN	_	36	nmod
39	.	.	.	_	28	punct

1	Additives	additive	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	;	;	:	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	are	be	VBP	_	5	cop
5	incompatible	incompatible	JJ	_	0	ROOT
6	with	with	IN	_	8	case
7	drug3	drug3	NN	_	8	compound
8	solution	solution	NN	_	5	nmod
9	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	7	case
6	parenteral	parenteral	JJ	_	7	amod
7	solutions	solution	NNS	_	2	nmod
8	containing	contain	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	0	ROOT
13	,	,	,	_	12	punct
14	except	except	IN	_	20	mark
15	where	where	WRB	_	20	advmod
16	compatibility	compatibility	NN	_	20	nsubjpass
17	has	have	VBZ	_	20	aux
18	been	be	VBN	_	20	auxpass
19	previously	previously	RB	_	20	advmod
20	established	establish	VBN	_	12	advcl
21	.	.	.	_	12	punct

1	Precipitation	precipitation	NN	_	5	nsubj
2	or	or	CC	_	1	cc
3	haze	haze	NN	_	1	conj
4	may	may	MD	_	5	aux
5	result	result	VB	_	0	ROOT
6	from	from	IN	_	9	case
7	sodium	sodium	NN	_	9	compound
8	bicarbonate-calcium	bicarbonate-calcium	NN	_	9	compound
9	admixtures	admixture	NNS	_	5	nmod
10	.	.	.	_	5	punct

1	NOTE	note	VB	_	0	ROOT
2	:	:	:	_	1	punct
3	Do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	use	use	VB	_	1	dep
6	the	the	DT	_	7	det
7	injection	injection	NN	_	5	dobj
8	if	if	IN	_	10	mark
9	it	it	PRP	_	10	nsubj
10	contains	contain	VBZ	_	5	advcl
11	precipitate	precipitate	NN	_	10	dobj
12	.	.	.	_	1	punct

1	Additives	additive	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	.	.	.	_	4	punct

1	Consult	consult	VB	_	6	dep
2	with	with	IN	_	3	case
3	pharmacist	pharmacist	NN	_	1	nmod
4	,	,	,	_	6	punct
5	if	if	IN	_	6	mark
6	available	available	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	When	when	WRB	_	5	advmod
2	introducing	introduce	VBG	_	5	advcl
3	additives	additive	NNS	_	2	dobj
4	,	,	,	_	5	punct
5	use	use	VBP	_	0	ROOT
6	aseptic	aseptic	JJ	_	7	amod
7	technique	technique	NN	_	5	dobj
8	,	,	,	_	5	punct
9	mix	mix	NN	_	8	root
10	thoroughly	thoroughly	RB	_	9	advmod
11	and	and	CC	_	9	cc
12	do	do	VB	_	14	aux
13	not	not	RB	_	14	neg
14	store	store	NN	_	9	conj
15	.	.	.	_	9	punct

1	Drug-Drug	Drug-Drug	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	Effect	effect	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	Metabolism	metabolism	NN	_	3	nmod
12	of	of	IN	_	14	case
13	Other	other	JJ	_	14	amod
14	Drugs	drug	NNS	_	11	nmod
15	:	:	:	_	3	punct
16	drug3	drug3	NN	_	19	nsubjpass
17	is	be	VBZ	_	19	auxpass
18	primarily	primarily	RB	_	19	advmod
19	metabolized	metabolize	VBN	_	3	dep
20	through	through	IN	_	21	case
21	hydrolysis	hydrolysis	NN	_	19	nmod
22	by	by	IN	_	23	case
23	esterases	esterase	NNS	_	19	nmod
24	.	.	.	_	3	punct

1	Minimal	minimal	JJ	_	2	amod
2	metabolism	metabolism	NN	_	3	nsubj
3	occurs	occur	VBZ	_	0	ROOT
4	via	via	IN	_	9	case
5	the	the	DT	_	9	det
6	major	major	JJ	_	9	amod
7	cytochrome	cytochrome	NN	_	9	compound
8	P450	p450	NN	_	9	compound
9	isoenzymes	isoenzyme	NNS	_	3	nmod
10	.	.	.	_	3	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	20	advcl
6	,	,	,	_	20	punct
7	no	no	DT	_	10	neg
8	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	20	nsubjpass
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	metabolized	metabolize	VBN	_	12	acl
14	by	by	IN	_	18	case
15	the	the	DT	_	18	det
16	following	follow	VBG	_	18	amod
17	isoenzyme	isoenzyme	NN	_	18	compound
18	systems	system	NNS	_	13	nmod
19	are	be	VBP	_	20	auxpass
20	expected	expect	VBN	_	0	ROOT
21	:	:	:	_	20	punct
22	CYP1A2	cyp1a2	NN	_	20	dep
23	,	,	,	_	22	punct
24	CYP2D6	cyp2d6	NN	_	22	conj
25	,	,	,	_	22	punct
26	CYP3A4/5	cyp3a4/5	NN	_	22	conj
27	,	,	,	_	22	punct
28	CYP2E1	cyp2e1	NN	_	22	conj
29	,	,	,	_	22	punct
30	CYP2C9	cyp2c9	NN	_	22	conj
31	,	,	,	_	22	punct
32	CYP2C8	cyp2c8	NN	_	22	conj
33	,	,	,	_	22	punct
34	or	or	CC	_	22	cc
35	CYP2C19	cyp2c19	NN	_	22	conj
36	.	.	.	_	20	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug4	drug4	NN	_	7	conj
14	,	,	,	_	7	punct
15	or	or	CC	_	7	cc
16	drug5	drug5	NN	_	7	conj
17	in	in	IN	_	18	case
18	studies	study	NNS	_	5	nmod
19	in	in	IN	_	21	case
20	healthy	healthy	JJ	_	21	amod
21	volunteers	volunteer	NNS	_	18	nmod
22	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	elevation	elevation	NN	_	11	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	induced	induce	VBN	_	5	acl
7	by	by	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	affected	affect	VBN	_	0	ROOT
12	by	by	IN	_	13	case
13	administration	administration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	11	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	Metabolism	metabolism	NN	_	1	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	:	:	:	_	1	punct
11	Drugs	drug	NNS	_	20	nsubjpass
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	CYP450	cyp450	NN	_	17	compound
17	metabolism	metabolism	NN	_	13	dobj
18	are	be	VBP	_	20	auxpass
19	not	not	RB	_	20	neg
20	expected	expect	VBN	_	1	dep
21	to	to	TO	_	22	mark
22	alter	alter	VB	_	20	xcomp
23	the	the	DT	_	24	det
24	metabolism	metabolism	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	20	punct

1	Single	single	JJ	_	4	amod
2	dose	dose	NN	_	4	compound
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	studies	study	NNS	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	that	that	IN	_	14	mark
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	14	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	is	be	VBZ	_	14	auxpass
12	not	not	RB	_	14	neg
13	significantly	significantly	RB	_	14	advmod
14	affected	affect	VBN	_	5	ccomp
15	by	by	IN	_	17	case
16	concurrent	concurrent	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	drug4	drug4	NN	_	19	conj
24	,	,	,	_	19	punct
25	or	or	CC	_	19	cc
26	drug5	drug5	NN	_	19	conj
27	.	.	.	_	5	punct

1	Population	Population	NNP	_	3	compound
2	PK	pk	NN	_	3	compound
3	analysis	analysis	NN	_	10	nsubj
4	with	with	IN	_	6	case
5	a	a	DT	_	6	det
6	database	database	NN	_	3	nmod
7	of	of	IN	_	9	case
8	625	625	CD	_	9	nummod
9	patients	patient	NNS	_	6	nmod
10	showed	show	VBD	_	0	ROOT
11	that	that	IN	_	18	mark
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	18	nsubjpass
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	were	be	VBD	_	18	auxpass
17	not	not	RB	_	18	neg
18	influenced	influence	VBN	_	10	ccomp
19	by	by	IN	_	22	case
20	commonly	commonly	RB	_	21	advmod
21	prescribed	prescribe	VBN	_	22	amod
22	medications	medication	NNS	_	18	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug2	drug2	NN	_	22	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	n	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	77	77	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	,	,	,	_	25	punct
32	drug3	drug3	NN	_	25	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	n	n	NN	_	32	dep
35	=	=	JJ	_	34	amod
36	72	72	CD	_	35	dep
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	,	,	,	_	25	punct
39	drug4	drug4	NN	_	25	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	n	n	NN	_	39	dep
42	=	=	JJ	_	41	amod
43	75	75	CD	_	42	dep
44	-RRB-	-rrb-	-RRB-	_	41	punct
45	,	,	,	_	25	punct
46	drug5	drug5	NN	_	25	conj
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	n	n	NN	_	46	dep
49	=	=	JJ	_	48	amod
50	21	21	CD	_	49	dep
51	-RRB-	-rrb-	-RRB-	_	48	punct
52	,	,	,	_	25	punct
53	drug6	drug6	NN	_	25	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	n	n	NN	_	53	dep
56	=	=	JJ	_	55	amod
57	79	79	CD	_	56	dep
58	-RRB-	-rrb-	-RRB-	_	55	punct
59	,	,	,	_	25	punct
60	drug7	drug7	NN	_	25	conj
61	-LRB-	-lrb-	-LRB-	_	62	punct
62	n	n	NN	_	60	dep
63	=	=	JJ	_	62	amod
64	70	70	CD	_	63	dep
65	-RRB-	-rrb-	-RRB-	_	62	punct
66	,	,	,	_	25	punct
67	drug8	drug8	NN	_	25	conj
68	-LRB-	-lrb-	-LRB-	_	69	punct
69	n	n	NN	_	67	dep
70	=	=	JJ	_	69	amod
71	177	177	CD	_	70	dep
72	-RRB-	-rrb-	-RRB-	_	69	punct
73	,	,	,	_	25	punct
74	drug9	drug9	NN	_	25	conj
75	-LRB-	-lrb-	-LRB-	_	76	punct
76	n	n	NN	_	74	dep
77	=	=	JJ	_	76	amod
78	35	35	CD	_	77	dep
79	-RRB-	-rrb-	-RRB-	_	76	punct
80	,	,	,	_	25	punct
81	and	and	CC	_	25	cc
82	drug10	drug10	NN	_	25	conj
83	-LRB-	-lrb-	-LRB-	_	84	punct
84	n	n	NN	_	82	dep
85	=	=	JJ	_	84	amod
86	15	15	CD	_	85	dep
87	-RRB-	-rrb-	-RRB-	_	84	punct
88	.	.	.	_	10	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Because	because	IN	_	8	case
6	of	of	IN	_	5	mwe
7	their	they	PRP$	_	8	nmod:poss
8	mechanism	mechanism	NN	_	13	nmod
9	of	of	IN	_	10	case
10	action	action	NN	_	8	nmod
11	,	,	,	_	13	punct
12	drug2	drug2	NN	_	13	nsubj
13	have	have	VBP	_	1	dep
14	the	the	DT	_	15	det
15	potential	potential	JJ	_	13	dobj
16	to	to	TO	_	17	mark
17	interfere	interfere	VB	_	15	acl
18	with	with	IN	_	20	case
19	the	the	DT	_	20	det
20	activity	activity	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	Other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	3	conj
7	:	:	:	_	1	punct
8	A	a	DT	_	10	det
9	synergistic	synergistic	JJ	_	10	amod
10	effect	effect	NN	_	13	nsubjpass
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	expected	expect	VBN	_	1	parataxis
14	when	when	WRB	_	17	advmod
15	drug3	drug3	NN	_	17	nsubjpass
16	are	be	VBP	_	17	auxpass
17	given	give	VBN	_	13	advcl
18	concurrently	concurrently	RB	_	17	advmod
19	with	with	IN	_	20	case
20	drug4	drug4	NN	_	17	nmod
21	,	,	,	_	20	punct
22	similar	similar	JJ	_	23	amod
23	drug5	drug5	NN	_	20	conj
24	or	or	CC	_	20	cc
25	drug6	drug6	NN	_	20	conj
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug7	drug7	NN	_	25	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	Reports	report	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug2	drug2	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	diminish	diminish	VB	_	3	ccomp
8	the	the	DT	_	10	det
9	antihypertensive	antihypertensive	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	15	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	1000	1000	CD	_	10	nummod
9	mg	mg	NN	_	10	compound
10	TID	tid	NN	_	6	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	to	to	TO	_	14	case
13	healthy	healthy	JJ	_	14	amod
14	volunteers	volunteer	NNS	_	4	nmod
15	tended	tend	VBD	_	1	dep
16	to	to	TO	_	17	mark
17	increase	increase	VB	_	15	xcomp
18	the	the	DT	_	19	det
19	AUC	auc	NN	_	17	dobj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	10	10	CD	_	22	nummod
22	%	%	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	and	and	CC	_	19	cc
25	Cmax	cmax	NN	_	19	conj
26	-LRB-	-lrb-	-LRB-	_	28	punct
27	24	24	CD	_	28	nummod
28	%	%	NN	_	25	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	19	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	;	;	:	_	9	punct

1	however	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	as	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	17	nmod
7	,	,	,	_	17	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	is	be	VBZ	_	17	auxpass
15	not	not	RB	_	17	neg
16	generally	generally	RB	_	17	advmod
17	recommended	recommend	VBN	_	0	ROOT
18	because	because	IN	_	21	case
19	of	of	IN	_	18	mwe
20	the	the	DT	_	21	det
21	potential	potential	NN	_	17	nmod
22	for	for	IN	_	25	case
23	increased	increase	VBN	_	25	amod
24	adverse	adverse	JJ	_	25	amod
25	effects	effect	NNS	_	21	nmod
26	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	low-dose	low-dose	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	result	result	VB	_	0	ROOT
10	in	in	IN	_	13	case
11	an	a	DT	_	13	det
12	increased	increase	VBN	_	13	amod
13	rate	rate	NN	_	9	nmod
14	of	of	IN	_	16	case
15	GI	gi	NN	_	16	compound
16	ulceration	ulceration	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	other	other	JJ	_	19	amod
19	complications	complication	NNS	_	16	conj
20	,	,	,	_	13	punct
21	compared	compare	VBN	_	23	case
22	to	to	TO	_	23	case
23	use	use	VB	_	13	acl
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	alone	alone	RB	_	25	advmod
27	.	.	.	_	9	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	a	a	DT	_	5	det
5	substitute	substitute	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	for	for	IN	_	10	case
9	cardiovascular	cardiovascular	JJ	_	10	amod
10	prophylaxis	prophylaxis	NN	_	7	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Pretreatment	pretreatment	NN	_	10	nsubj
4	for	for	IN	_	6	case
5	four	four	CD	_	6	nummod
6	days	day	NNS	_	3	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	3	nmod
9	significantly	significantly	RB	_	10	advmod
10	increased	increase	VBD	_	1	dep
11	the	the	DT	_	12	det
12	clearance	clearance	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	by	by	IN	_	17	case
16	50	50	CD	_	17	nummod
17	%	%	NN	_	10	nmod
18	.	.	.	_	1	punct

1	This	this	DT	_	2	nsubj
2	resulted	result	VBD	_	0	ROOT
3	in	in	IN	_	5	case
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	2	nmod
6	in	in	IN	_	7	case
7	t1/2	t1/2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	from	from	IN	_	11	case
10	19.2	19.2	CD	_	11	nummod
11	hours	hour	NNS	_	5	nmod
12	to	to	TO	_	14	case
13	12.5	12.5	CD	_	14	nummod
14	hours	hour	NNS	_	11	nmod
15	,	,	,	_	5	punct
16	and	and	CC	_	5	cc
17	a	a	DT	_	20	det
18	35	35	CD	_	19	compound
19	%	%	NN	_	20	amod
20	reduction	reduction	NN	_	5	conj
21	in	in	IN	_	22	case
22	AUC	auc	NN	_	20	nmod
23	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	existence	existence	NN	_	2	dobj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	recirculation	recirculation	NN	_	8	compound
8	pathway	pathway	NN	_	4	nmod
9	for	for	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	gastrointestinal	gastrointestinal	JJ	_	14	amod
14	tract	tract	NN	_	8	nmod
15	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	established	establish	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	12	nsubj
5	of	of	IN	_	9	case
6	200	200	CD	_	7	compound
7	mg	mg	NN	_	9	amod
8	drug2	drug2	NN	_	9	compound
9	QID	qid	NN	_	4	nmod
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	alter	alter	VB	_	1	dep
13	the	the	DT	_	15	det
14	single-dose	single-dose	JJ	_	15	amod
15	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
16	of	of	IN	_	19	case
17	30	30	CD	_	19	nummod
18	mg	mg	NN	_	19	compound
19	drug3	drug3	NN	_	15	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	15	15	CD	_	5	nummod
5	mg	mg	NN	_	13	nsubj
6	once	once	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	for	for	IN	_	10	case
9	7	7	CD	_	10	nummod
10	days	day	NNS	_	5	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	alter	alter	VB	_	1	dep
14	the	the	DT	_	17	det
15	plasma	plasma	NN	_	17	compound
16	concentration	concentration	NN	_	17	compound
17	profile	profile	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	after	after	IN	_	22	case
21	b-acetyldigoxin	b-acetyldigoxin	NN	_	22	compound
22	administration	administration	NN	_	13	nmod
23	for	for	IN	_	25	case
24	7	7	CD	_	25	nummod
25	days	day	NNS	_	13	nmod
26	at	at	IN	_	28	case
27	clinical	clinical	JJ	_	28	amod
28	doses	dose	NNS	_	13	nmod
29	.	.	.	_	1	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	testing	testing	NN	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	no	no	DT	_	9	neg
6	protein	protein	NN	_	9	compound
7	binding	binding	NN	_	9	compound
8	drug	drug	NN	_	9	compound
9	interaction	interaction	NN	_	4	dobj
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	13	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post-marketing	post-marketing	JJ	_	10	amod
10	observations	observation	NNS	_	4	conj
11	,	,	,	_	4	punct
12	have	have	VBP	_	13	aux
13	shown	show	VBN	_	1	appos
14	that	that	IN	_	17	mark
15	drug2	drug2	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	reduce	reduce	VB	_	13	ccomp
18	the	the	DT	_	20	det
19	natriuretic	natriuretic	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	in	in	IN	_	27	case
26	some	some	DT	_	27	det
27	patients	patient	NNS	_	20	nmod
28	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	Studies	study	NNS	_	9	nsubj
2	with	with	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	agents	agent	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	not	not	RB	_	9	neg
9	demonstrated	demonstrate	VBN	_	0	ROOT
10	a	a	DT	_	11	det
11	reduction	reduction	NN	_	9	dobj
12	in	in	IN	_	14	case
13	natriuretic	natriuretic	JJ	_	14	amod
14	effect	effect	NN	_	11	nmod
15	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	single	single	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	multiple	multiple	JJ	_	3	conj
6	dose	dose	NN	_	7	compound
7	pharmacodynamics	pharmacodynamic	NNS	_	12	nsubjpass
8	and	and	CC	_	7	cc
9	pharmacokinetics	pharmacokinetic	NNS	_	7	conj
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	1	dep
13	by	by	IN	_	15	case
14	multiple	multiple	JJ	_	15	amod
15	doses	dose	NNS	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	1	punct

1	Nevertheless	nevertheless	RB	_	14	advmod
2	,	,	,	_	14	punct
3	during	during	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	therapy	therapy	NN	_	14	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	14	punct
11	patients	patient	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	closely	closely	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	21	case
19	declining	decline	VBG	_	21	amod
20	renal	renal	JJ	_	21	amod
21	function	function	NN	_	17	nmod
22	,	,	,	_	14	punct
23	as	as	RB	_	14	cc
24	well	well	RB	_	23	mwe
25	as	as	IN	_	23	mwe
26	to	to	TO	_	27	mark
27	assure	assure	VB	_	14	conj
28	diuretic	diuretic	JJ	_	29	amod
29	efficacy	efficacy	NN	_	27	dobj
30	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	9	nmod
6	,	,	,	_	9	punct
7	drug2	drug2	NN	_	9	nsubj
8	have	have	VBP	_	9	aux
9	produced	produce	VBN	_	1	appos
10	an	a	DT	_	11	det
11	elevation	elevation	NN	_	9	dobj
12	of	of	IN	_	15	case
13	plasma	plasma	NN	_	15	compound
14	drug3	drug3	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	and	and	CC	_	11	cc
17	a	a	DT	_	18	det
18	reduction	reduction	NN	_	11	conj
19	in	in	IN	_	22	case
20	renal	renal	JJ	_	22	amod
21	drug4	drug4	NN	_	22	compound
22	clearance	clearance	NN	_	18	nmod
23	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	9	nmod
4	conducted	conduct	VBN	_	3	acl
5	in	in	IN	_	7	case
6	healthy	healthy	JJ	_	7	amod
7	subjects	subject	NNS	_	4	nmod
8	,	,	,	_	9	punct
9	mean	mean	VB	_	0	ROOT
10	pre-dose	pre-dose	JJ	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	concentration	concentration	NN	_	16	nsubjpass
13	and	and	CC	_	12	cc
14	AUC	auc	NN	_	12	conj
15	were	be	VBD	_	16	auxpass
16	increased	increase	VBN	_	9	ccomp
17	by	by	IN	_	19	case
18	21	21	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	in	in	IN	_	21	case
21	subjects	subject	NNS	_	16	nmod
22	receiving	receive	VBG	_	21	acl
23	drug2	drug2	NN	_	24	compound
24	doses	dose	NNS	_	22	dobj
25	ranging	range	VBG	_	24	acl
26	from	from	IN	_	27	case
27	804	804	CD	_	25	nmod
28	to	to	TO	_	29	dep
29	1072	1072	CD	_	27	nmod
30	mg	mg	NN	_	31	compound
31	BID	BID	NNP	_	29	dobj
32	with	with	IN	_	36	case
33	drug3	drug3	NN	_	36	compound
34	15	15	CD	_	35	compound
35	mg	mg	NN	_	36	amod
36	QD	qd	NN	_	31	nmod
37	as	as	IN	_	38	mark
38	compared	compare	VBN	_	16	advcl
39	to	to	TO	_	40	case
40	subjects	subject	NNS	_	38	nmod
41	receiving	receive	VBG	_	40	acl
42	drug4	drug4	NN	_	41	dobj
43	alone	alone	RB	_	41	advmod
44	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	by	by	IN	_	13	case
13	drug1	drug1	NN	_	7	nmod
14	.	.	.	_	5	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	on	on	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	treatment	treatment	NN	_	1	nmod
5	should	should	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	closely	closely	RB	_	8	advmod
8	monitored	monitor	VBN	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	drug2	drug2	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	introduced	introduce	VBN	_	8	advcl
13	or	or	CC	_	12	cc
14	withdrawn	withdraw	VBN	_	12	conj
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	study	study	NN	_	13	nmod:tmod
5	in	in	IN	_	8	case
6	13	13	CD	_	8	nummod
7	rheumatoid	rheumatoid	JJ	_	8	amod
8	arthritis	arthritis	NN	_	13	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	RA	ra	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	patients	patient	NNS	_	13	nsubj
13	evaluated	evaluate	VBD	_	1	appos
14	the	the	DT	_	15	det
15	effects	effect	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	multiple	multiple	JJ	_	18	amod
18	doses	dose	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	pharmacokinetics	pharmacokinetic	NNS	_	15	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	taken	take	VBN	_	23	acl
27	once	once	RB	_	28	advmod
28	weekly	weekly	RB	_	26	advmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	have	have	VB	_	0	ROOT
5	a	a	DT	_	7	det
6	significant	significant	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	single	single	JJ	_	13	amod
13	doses	dose	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	displace	displace	VB	_	0	ROOT
8	drug2	drug2	NN	_	7	dobj
9	from	from	IN	_	14	case
10	its	its	PRP$	_	14	nmod:poss
11	human	human	JJ	_	14	amod
12	serum	serum	NN	_	14	compound
13	binding	binding	NN	_	14	compound
14	sites	site	NNS	_	7	nmod
15	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Anticoagulant	anticoagulant	JJ	_	4	amod
4	activity	activity	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	1	dep
8	,	,	,	_	7	punct
9	particularly	particularly	RB	_	14	advmod
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	first	first	JJ	_	14	amod
13	few	few	JJ	_	14	amod
14	days	day	NNS	_	7	nmod
15	after	after	IN	_	16	mark
16	initiating	initiate	VBG	_	14	acl
17	or	or	CC	_	16	cc
18	changing	change	VBG	_	16	conj
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	16	dobj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	receiving	receive	VBG	_	22	acl
24	drug3	drug3	NN	_	23	dobj
25	or	or	CC	_	24	cc
26	similar	similar	JJ	_	24	conj
27	agents	agent	NNS	_	24	dep
28	,	,	,	_	7	punct
29	since	since	IN	_	36	mark
30	these	these	DT	_	31	det
31	patients	patient	NNS	_	36	nsubj
32	are	be	VBP	_	36	cop
33	at	at	IN	_	36	case
34	an	a	DT	_	36	det
35	increased	increase	VBN	_	36	amod
36	risk	risk	NN	_	7	advcl
37	of	of	IN	_	38	case
38	bleeding	bleeding	NN	_	36	nmod
39	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	anticoagulant	anticoagulant	JJ	_	8	amod
8	effect	effect	NN	_	2	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	was	be	VBD	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	group	group	NN	_	12	nmod
16	of	of	IN	_	18	case
17	healthy	healthy	JJ	_	18	amod
18	subjects	subject	NNS	_	15	nmod
19	receiving	receive	VBG	_	18	acl
20	daily	daily	JJ	_	21	amod
21	doses	dose	NNS	_	19	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	that	that	WDT	_	25	nsubj
25	produced	produce	VBD	_	21	acl:relcl
26	an	a	DT	_	27	det
27	INR	inr	NN	_	25	dobj
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	International	International	NNP	_	31	compound
30	Normalized	Normalized	NNP	_	31	compound
31	Ratio	Ratio	NNP	_	27	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	between	between	IN	_	34	case
34	1.2	1.2	CD	_	27	nmod
35	and	and	CC	_	34	cc
36	1.8	1.8	CD	_	34	conj
37	.	.	.	_	12	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	subjects	subject	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	alter	alter	VB	_	0	ROOT
9	drug2	drug2	NN	_	10	compound
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	and	and	CC	_	10	cc
12	the	the	DT	_	15	det
13	average	average	JJ	_	15	amod
14	anticoagulant	anticoagulant	JJ	_	15	amod
15	effect	effect	NN	_	10	conj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	as	as	IN	_	19	mark
19	determined	determine	VBN	_	8	advcl
20	by	by	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	.	.	.	_	8	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	one	one	CD	_	4	nummod
4	subject	subject	NN	_	5	nsubj
5	showed	show	VBD	_	0	ROOT
6	an	a	DT	_	7	det
7	increase	increase	NN	_	5	dobj
8	in	in	IN	_	9	case
9	INR	inr	NN	_	7	nmod
10	from	from	IN	_	11	case
11	1.5	1.5	CD	_	7	nmod
12	to	to	TO	_	13	case
13	2.1	2.1	CD	_	11	nmod
14	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	since	since	IN	_	15	mark
11	patients	patient	NNS	_	15	nsubj
12	on	on	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	may	may	MD	_	15	aux
15	experience	experience	VB	_	6	advcl
16	changes	change	NNS	_	15	dobj
17	in	in	IN	_	18	case
18	INR	inr	NN	_	16	nmod
19	and	and	CC	_	16	cc
20	an	a	DT	_	22	det
21	increased	increase	VBN	_	22	amod
22	risk	risk	NN	_	16	conj
23	of	of	IN	_	24	mark
24	bleeding	bleed	VBG	_	22	acl
25	complications	complication	NNS	_	24	dobj
26	when	when	WRB	_	31	advmod
27	a	a	DT	_	29	det
28	new	new	JJ	_	29	amod
29	medication	medication	NN	_	31	nsubjpass
30	is	be	VBZ	_	31	auxpass
31	introduced	introduce	VBN	_	24	advcl
32	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	10	nsubj
2	,	,	,	_	1	punct
3	given	give	VBN	_	1	acl
4	at	at	IN	_	8	case
5	a	a	DT	_	8	det
6	common	common	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	dosage	dosage	NN	_	3	nmod
9	,	,	,	_	1	punct
10	increased	increase	VBD	_	0	ROOT
11	the	the	DT	_	13	det
12	drug2	drug2	NN	_	13	compound
13	half-life	half-life	NN	_	10	dobj
14	by	by	IN	_	16	case
15	51	51	CD	_	16	nummod
16	%	%	NN	_	10	nmod
17	and	and	CC	_	10	cc
18	decreased	decrease	VBD	_	10	conj
19	the	the	DT	_	23	det
20	drug3	drug3	NN	_	23	compound
21	metabolic	metabolic	JJ	_	23	amod
22	clearance	clearance	NN	_	23	compound
23	rate	rate	NN	_	18	dobj
24	by	by	IN	_	26	case
25	30	30	CD	_	26	nummod
26	%	%	NN	_	18	nmod
27	.	.	.	_	10	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	10	advcl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	,	,	,	_	10	punct
7	one	one	CD	_	10	nsubj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	cop
10	alert	alert	JJ	_	0	ROOT
11	for	for	IN	_	15	case
12	possible	possible	JJ	_	15	amod
13	excessive	excessive	JJ	_	15	amod
14	drug1	drug1	NN	_	15	compound
15	effect	effect	NN	_	10	nmod
16	.	.	.	_	10	punct

1	Excessive	excessive	JJ	_	3	amod
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubj
4	will	will	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	growth-promoting	growth-promoting	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	5	punct

1	Patients	patient	NNS	_	6	nsubj
2	with	with	IN	_	4	case
3	ACTH	acth	NN	_	4	compound
4	deficiency	deficiency	NN	_	1	nmod
5	should	should	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	their	they	PRP$	_	8	nmod:poss
8	drug1	drug1	NN	_	6	dobj
9	-	-	:	_	8	punct
10	replacement	replacement	NN	_	11	compound
11	dose	dose	NN	_	8	dep
12	carefully	carefully	RB	_	13	advmod
13	adjusted	adjust	VBN	_	11	acl
14	to	to	TO	_	15	mark
15	avoid	avoid	VB	_	13	xcomp
16	an	a	DT	_	18	det
17	inhibitory	inhibitory	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	20	case
20	growth	growth	NN	_	18	nmod
21	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	with	with	IN	_	10	case
8	chronic	chronic	JJ	_	10	amod
9	renal	renal	JJ	_	10	amod
10	insufficiency	insufficiency	NN	_	6	nmod
11	receiving	receive	VBG	_	10	acl
12	glucocorticoid	glucocorticoid	NN	_	13	compound
13	therapy	therapy	NN	_	11	dobj
14	has	have	VBZ	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	evaluated	evaluate	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	3	amod
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	growth-promoting	growth-promoting	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	replacement	replacement	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	13	advcl
6	,	,	,	_	13	punct
7	the	the	DT	_	9	det
8	drug2	drug2	NN	_	9	compound
9	dose	dose	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	carefully	carefully	RB	_	13	advmod
13	adjusted	adjust	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	controlled	controlled	JJ	_	8	amod
8	studies	study	NNS	_	4	nmod
9	of	of	IN	_	12	case
10	drug1	drug1	NN	_	12	compound
11	s	s	NNS	_	12	compound
12	interaction	interaction	NN	_	8	nmod
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	12	nmod
15	commonly	commonly	RB	_	16	advmod
16	used	use	VBN	_	14	acl
17	in	in	IN	_	21	case
18	chronic	chronic	JJ	_	21	amod
19	renal	renal	JJ	_	21	amod
20	insufficiency	insufficiency	NN	_	21	compound
21	patients	patient	NNS	_	16	nmod
22	.	.	.	_	2	punct

1	Limited	limited	JJ	_	3	amod
2	published	publish	VBN	_	3	amod
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	7	compound
7	treatment	treatment	NN	_	8	nsubj
8	increases	increase	VBZ	_	4	ccomp
9	cytochrome	cytochrome	NN	_	10	compound
10	P450	p450	NN	_	14	nsubj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	CP450	cp450	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	mediated	mediate	VBD	_	8	ccomp
15	drug2	drug2	JJ	_	16	amod
16	clearance	clearance	NN	_	14	dobj
17	in	in	IN	_	18	case
18	man	man	NN	_	14	nmod
19	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	6	compound
6	administration	administration	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	alter	alter	VB	_	3	ccomp
9	the	the	DT	_	10	det
10	clearance	clearance	NN	_	8	dobj
11	of	of	IN	_	12	case
12	compounds	compound	NNS	_	10	nmod
13	known	know	VBN	_	12	acl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	metabolized	metabolize	VBN	_	13	xcomp
17	by	by	IN	_	20	case
18	CP450	cp450	NN	_	20	compound
19	liver	liver	NN	_	20	compound
20	enzymes	enzyme	NNS	_	16	nmod
21	-LRB-	-lrb-	-LRB-	_	24	punct
22	e.g.	e.g.	FW	_	24	dep
23	,	,	,	_	24	punct
24	drug2	drug2	NN	_	20	dep
25	,	,	,	_	24	punct
26	drug3	drug3	NN	_	24	conj
27	,	,	,	_	24	punct
28	drug4	drug4	NN	_	24	conj
29	,	,	,	_	24	punct
30	drug5	drug5	NN	_	24	appos
31	-RRB-	-rrb-	-RRB-	_	24	punct
32	.	.	.	_	3	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	advisable	advisable	JJ	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	known	know	VBN	_	13	acl
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	auxpass
17	metabolized	metabolize	VBN	_	14	xcomp
18	by	by	IN	_	21	case
19	CP450	cp450	NN	_	21	compound
20	liver	liver	NN	_	21	compound
21	enzymes	enzyme	NNS	_	17	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	other	other	JJ	_	7	amod
6	addictive	addictive	JJ	_	7	amod
7	medications	medication	NNS	_	3	nmod
8	,	,	,	_	3	punct
9	in	in	IN	_	13	mark
10	that	that	IN	_	13	mark
11	it	it	PRP	_	13	nsubj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	3	advcl
14	the	the	DT	_	15	det
15	likelyhood	likelyhood	NN	_	13	dobj
16	of	of	IN	_	17	case
17	addiction	addiction	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	abuse	abuse	NN	_	17	conj
20	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	conj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	the	the	DT	_	13	det
11	CNS	cns	NN	_	13	compound
12	depressant	depressant	NN	_	13	compound
13	effects	effect	NNS	_	9	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	these	these	DT	_	19	det
18	other	other	JJ	_	19	amod
19	medications	medication	NNS	_	15	conj
20	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effectiveness	effectiveness	NN	_	3	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	,	,	,	_	8	punct
10	certain	certain	JJ	_	11	amod
11	drug3	drug3	NN	_	8	conj
12	,	,	,	_	8	punct
13	drug4	drug4	NN	_	8	conj
14	,	,	,	_	8	punct
15	drug5	drug5	NN	_	8	conj
16	,	,	,	_	8	punct
17	drug6	drug6	NN	_	8	conj
18	,	,	,	_	8	punct
19	drug7	drug7	NN	_	8	conj
20	,	,	,	_	8	punct
21	and	and	CC	_	8	cc
22	drug8	drug8	NN	_	8	conj
23	.	.	.	_	3	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	8	case
8	compounds	compound	NNS	_	5	nmod
9	that	that	WDT	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	metabolized/eliminated	metabolized/eliminated	VBN	_	8	acl:relcl
12	predominantly	predominantly	RB	_	11	advmod
13	by	by	IN	_	16	case
14	the	the	DT	_	16	det
15	UGT1A1	ugt1a1	NN	_	16	compound
16	pathway	pathway	NN	_	11	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	e.g.	e.g.	FW	_	19	dep
19	drug2	drug2	NN	_	16	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	5	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	resulted	result	VBD	_	0	ROOT
6	in	in	IN	_	10	case
7	a	a	DT	_	10	det
8	21	21	CD	_	9	compound
9	%	%	NN	_	10	amod
10	increase	increase	NN	_	5	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	5	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	CYP2B6	cyp2b6	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	CYP2C8	cyp2c8	NN	_	3	conj
6	in	in	FW	_	7	compound
7	vitro	vitro	FW	_	2	advmod
8	with	with	IN	_	10	case
9	Ki	ki	NN	_	10	compound
10	values	value	NNS	_	2	nmod
11	of	of	IN	_	12	case
12	6	6	CD	_	10	nmod
13	and	and	CC	_	12	cc
14	1-2	1-2	CD	_	12	conj
15	?	?	.	_	2	punct
16	M	m	NN	_	2	dep
17	,	,	,	_	16	punct
18	respectively	respectively	RB	_	16	advmod
19	.	.	.	_	2	punct

1	Systemic	systemic	JJ	_	2	amod
2	exposure	exposure	NN	_	10	nsubjpass
3	to	to	TO	_	4	case
4	substrates	substrate	NNS	_	2	nmod
5	of	of	IN	_	6	case
6	CYP2B6	cyp2b6	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	CYP2C8	cyp2c8	NN	_	6	conj
9	is	be	VBZ	_	10	auxpass
10	expected	expect	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	increase	increase	VB	_	10	xcomp
13	when	when	WRB	_	14	advmod
14	co-administered	co-administer	VBN	_	12	advcl
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	10	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	substrates	substrate	NNS	_	5	dobj
7	of	of	IN	_	8	case
8	CYP2B6	cyp2b6	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	CYP2C8	cyp2c8	NN	_	8	conj
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	5	nmod
13	.	.	.	_	3	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	9	punct
7	drug2	drug2	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	enhance	enhance	VB	_	0	ROOT
10	or	or	CC	_	9	cc
11	precipitate	precipitate	VB	_	9	conj
12	bradycardia	bradycardia	NN	_	9	dobj
13	,	,	,	_	12	punct
14	A.V.	A.V.	NNP	_	12	appos

1	block	block	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	arrhythmia	arrhythmia	NN	_	1	conj
4	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	23	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	that	that	WDT	_	6	nsubj
6	stimulate	stimulate	VBP	_	4	acl:relcl
7	alpha-adrenergic	alpha-adrenergic	JJ	_	8	amod
8	receptors	receptor	NNS	_	6	dobj
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug1	drug1	NN	_	2	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug3	drug3	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug4	drug4	NN	_	12	conj
19	or	or	CC	_	12	cc
20	drug5	drug5	NN	_	12	conj
21	-RRB-	-rrb-	-RRB-	_	12	punct
22	may	may	MD	_	23	aux
23	enhance	enhance	VB	_	0	ROOT
24	or	or	CC	_	23	cc
25	potentiate	potentiate	VB	_	23	conj
26	the	the	DT	_	28	det
27	pressor	pressor	JJ	_	28	amod
28	effects	effect	NNS	_	23	dobj
29	of	of	IN	_	30	case
30	drug6	drug6	NN	_	28	nmod
31	.	.	.	_	23	punct
32	Therefore	therefore	RB	_	37	advmod
33	,	,	,	_	37	punct
34	caution	caution	NN	_	37	nsubjpass
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	used	use	VBN	_	23	parataxis
38	when	when	WRB	_	41	advmod
39	drug7	drug7	NN	_	41	nsubjpass
40	is	be	VBZ	_	41	auxpass
41	administered	administer	VBN	_	37	advcl
42	concomitantly	concomitantly	RB	_	41	advmod
43	with	with	IN	_	44	case
44	agents	agent	NNS	_	41	nmod
45	that	that	WDT	_	46	nsubj
46	cause	cause	VBP	_	44	acl:relcl
47	vasoconstriction	vasoconstriction	NN	_	46	dobj
48	.	.	.	_	23	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	concomitantly	concomitantly	RB	_	8	advmod
8	treated	treat	VBN	_	6	acl
9	with	with	IN	_	12	case
10	salt-retaining	salt-retaining	JJ	_	12	amod
11	steroid	steroid	NN	_	12	compound
12	therapy	therapy	NN	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	i.e.	i.e.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	12	dep
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	4	punct
19	with	with	IN	_	23	nmod
20	or	or	CC	_	23	cc
21	without	without	IN	_	23	conj
22	salt	salt	NN	_	23	compound
23	supplementation	supplementation	NN	_	4	nmod
24	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	9	nsubjpass
3	for	for	IN	_	5	case
4	supine	supine	NN	_	5	compound
5	hypertension	hypertension	NN	_	2	nmod
6	should	should	MD	_	9	aux
7	be	be	VB	_	9	auxpass
8	carefully	carefully	RB	_	9	advmod
9	monitored	monitor	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	these	these	DT	_	12	det
12	patients	patient	NNS	_	9	nmod
13	and	and	CC	_	9	cc
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	minimized	minimize	VBN	_	9	conj
17	by	by	IN	_	19	mark
18	either	either	CC	_	19	cc:preconj
19	reducing	reduce	VBG	_	16	advcl
20	the	the	DT	_	21	det
21	dose	dose	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	or	or	CC	_	19	cc
25	decreasing	decrease	VBG	_	19	conj
26	the	the	DT	_	28	det
27	salt	salt	NN	_	28	compound
28	intake	intake	NN	_	25	dobj
29	prior	prior	RB	_	25	advmod
30	to	to	TO	_	31	case
31	initiation	initiation	NN	_	29	nmod
32	of	of	IN	_	33	case
33	treatment	treatment	NN	_	31	nmod
34	with	with	IN	_	31	nmod
35	.	.	.	_	9	punct

1	drug1	drug1	NN	_	15	dep
2	.	.	.	_	1	punct
3	drug2	drug2	NN	_	15	nsubj
4	,	,	,	_	3	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug3	drug3	NN	_	3	nmod
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug5	drug5	NN	_	7	conj
13	,	,	,	_	3	punct
14	can	can	MD	_	15	aux
15	antagonize	antagonize	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	effects	effect	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	drug6	drug6	NN	_	17	nmod
20	.	.	.	_	15	punct
21	Potential	potential	JJ	_	15	dep
22	for	for	IN	_	24	case
23	Drug	drug	NN	_	24	compound
24	Interactions	interaction	NNS	_	21	nmod
25	:	:	:	_	15	punct
26	It	it	PRP	_	27	nsubj
27	appears	appear	VBZ	_	15	parataxis
28	possible	possible	JJ	_	27	xcomp
29	,	,	,	_	27	punct
30	although	although	IN	_	32	mark
31	there	there	EX	_	32	expl
32	is	be	VBZ	_	27	advcl
33	no	no	DT	_	36	neg
34	supporting	support	VBG	_	36	amod
35	experimental	experimental	JJ	_	36	amod
36	evidence	evidence	NN	_	32	nsubj
37	,	,	,	_	32	punct
38	that	that	IN	_	50	mark
39	the	the	DT	_	42	det
40	high	high	JJ	_	42	amod
41	renal	renal	JJ	_	42	amod
42	clearance	clearance	NN	_	50	nsubj
43	of	of	IN	_	44	case
44	drug7	drug7	NN	_	42	nmod
45	-LRB-	-lrb-	-LRB-	_	47	punct
46	a	a	DT	_	47	det
47	base	base	NN	_	44	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	is	be	VBZ	_	50	cop
50	due	due	JJ	_	32	ccomp
51	to	to	TO	_	54	case
52	active	active	JJ	_	54	amod
53	tubular	tubular	JJ	_	54	amod
54	secretion	secretion	NN	_	50	nmod
55	by	by	IN	_	58	case
56	the	the	DT	_	58	det
57	base-secreting	base-secreting	JJ	_	58	amod
58	system	system	NN	_	54	nmod
59	also	also	RB	_	60	advmod
60	responsible	responsible	JJ	_	54	amod
61	for	for	IN	_	63	case
62	the	the	DT	_	63	det
63	secretion	secretion	NN	_	60	nmod
64	of	of	IN	_	66	case
65	such	such	JJ	_	66	amod
66	drugs	drug	NNS	_	63	nmod
67	as	as	IN	_	68	case
68	drug8	drug8	NN	_	66	nmod
69	,	,	,	_	68	punct
70	drug9	drug9	NN	_	68	conj
71	,	,	,	_	68	punct
72	drug10	drug10	NN	_	68	conj
73	,	,	,	_	68	punct
74	drug11	drug11	NN	_	68	conj
75	,	,	,	_	68	punct
76	drug12	drug12	NN	_	68	conj
77	,	,	,	_	68	punct
78	drug13	drug13	NN	_	68	conj
79	,	,	,	_	68	punct
80	and	and	CC	_	68	cc
81	drug14	drug14	NN	_	68	conj
82	.	.	.	_	15	punct

1	Thus	thus	RB	_	6	advmod
2	there	there	EX	_	6	expl
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	a	a	DT	_	6	det
6	potential	potential	NN	_	0	ROOT
7	for	for	IN	_	9	case
8	drug-drug	drug-drug	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	nmod
10	with	with	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	9	nmod
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	enhance	enhance	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	sedative	sedative	NN	_	9	compound
9	activity	activity	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	and	and	CC	_	11	cc
18	drug5	drug5	NN	_	11	conj
19	.	.	.	_	4	punct

1	Peripheral	peripheral	JJ	_	2	amod
2	Neuropathy	neuropathy	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Medications	medication	NNS	_	14	nsubjpass
5	known	know	VBN	_	4	acl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	5	xcomp
9	with	with	IN	_	11	case
10	peripheral	peripheral	JJ	_	11	amod
11	neuropathy	neuropathy	NN	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	used	use	VBN	_	2	appos
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	drug1	drug1	NN	_	19	dobj
21	.	.	.	_	2	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	7	case
5	10	10	CD	_	7	nummod
6	healthy	healthy	JJ	_	7	amod
7	women	woman	NNS	_	2	nmod
8	,	,	,	_	7	punct
9	the	the	DT	_	11	det
10	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
11	profiles	profile	NNS	_	33	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	following	follow	VBG	_	17	case
17	administration	administration	NN	_	11	nmod
18	of	of	IN	_	21	case
19	a	a	DT	_	21	det
20	single	single	JJ	_	21	amod
21	dose	dose	NN	_	17	nmod
22	containing	contain	VBG	_	21	acl
23	1.0	1.0	CD	_	24	nummod
24	mg	mg	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	and	and	CC	_	24	cc
28	75	75	CD	_	29	nummod
29	g	g	NN	_	24	conj
30	of	of	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	were	be	VBD	_	33	auxpass
33	studied	study	VBN	_	7	acl:relcl
34	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	were	be	VBD	_	4	cop
4	similar	similar	JJ	_	0	ROOT
5	with	with	IN	_	4	dep
6	and	and	CC	_	5	dep
7	without	without	IN	_	8	case
8	coadministration	coadministration	NN	_	6	conj
9	of	of	IN	_	12	case
10	drug1	drug1	NN	_	12	compound
11	200	200	CD	_	12	nummod
12	mg/day	mg/day	NN	_	8	nmod
13	to	to	TO	_	15	case
14	steady-state	steady-state	JJ	_	15	amod
15	levels	level	NNS	_	8	nmod
16	.	.	.	_	4	punct

1	Important	important	JJ	_	2	amod
2	Non	non	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	drug1	drug1	NN	_	7	compound
5	Drug	drug	NN	_	7	compound
6	Interactions	interaction	NNS	_	7	compound
7	Drugs	drug	NNS	_	2	dep
8	That	that	WDT	_	9	nsubj
9	Interfere	interfere	VBP	_	7	acl:relcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	:	:	:	_	2	punct
13	Concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	2	dep
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug5	drug5	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug6	drug6	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug7	drug7	NN	_	16	conj
25	,	,	,	_	16	punct
26	drug8	drug8	NN	_	16	conj
27	,	,	,	_	16	punct
28	drug9	drug9	NN	_	16	conj
29	,	,	,	_	16	punct
30	drug10	drug10	NN	_	16	conj
31	,	,	,	_	16	punct
32	or	or	CC	_	16	cc
33	certain	certain	JJ	_	35	amod
34	herbal	herbal	JJ	_	35	amod
35	supplements	supplement	NNS	_	16	conj
36	such	such	JJ	_	38	case
37	as	as	IN	_	36	mwe
38	St.	St.	NNP	_	35	nmod

1	drug1	drug1	NN	_	5	nsubj
2	with	with	IN	_	3	case
3	drug2	drug2	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	reduce	reduce	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	effectiveness	effectiveness	NN	_	5	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	contraception	contraception	NN	_	7	nmod
11	and	and	CC	_	7	cc
12	up	up	RB	_	14	advmod
13	to	to	TO	_	14	dep
14	one	one	CD	_	15	nummod
15	month	month	NN	_	7	conj
16	after	after	IN	_	15	case
17	discontinuation	discontinuation	NN	_	15	dep
18	of	of	IN	_	21	case
19	these	these	DT	_	21	det
20	concomitant	concomitant	JJ	_	21	amod
21	therapies	therapy	NNS	_	17	nmod
22	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	women	woman	NNS	_	14	nsubj
4	requiring	require	VBG	_	3	acl
5	treatment	treatment	NN	_	4	dobj
6	with	with	IN	_	7	case
7	one	one	CD	_	5	nmod
8	or	or	CC	_	7	cc
9	more	more	JJR	_	7	conj
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	7	nmod
13	must	must	MD	_	14	aux
14	use	use	VB	_	0	ROOT
15	two	two	CD	_	21	nummod
16	OTHER	other	JJ	_	21	amod
17	effective	effective	JJ	_	21	amod
18	or	or	CC	_	17	cc
19	highly	highly	RB	_	20	advmod
20	effective	effective	JJ	_	17	conj
21	methods	method	NNS	_	14	dobj
22	of	of	IN	_	23	case
23	contraception	contraception	NN	_	21	nmod
24	or	or	CC	_	23	cc
25	abstain	abstain	NN	_	23	conj
26	from	from	IN	_	29	case
27	heterosexual	heterosexual	JJ	_	29	amod
28	sexual	sexual	JJ	_	29	amod
29	contact	contact	NN	_	14	nmod
30	while	while	IN	_	31	mark
31	taking	take	VBG	_	14	advcl
32	drug1	drug1	NN	_	31	dobj
33	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	and	and	CC	_	7	cc
11	other	other	JJ	_	12	amod
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	increase	increase	VBP	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	and	and	CC	_	8	cc
14	drug5	drug5	NN	_	8	conj
15	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Drugs	drug	NNS	_	19	nsubjpass
2	which	which	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	potentiate	potentiate	VB	_	1	acl:relcl
5	the	the	DT	_	7	det
6	myeloproliferative	myeloproliferative	JJ	_	7	amod
7	effects	effect	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	9	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug2	drug2	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	1	punct
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	caution	caution	NN	_	19	nmod
22	.	.	.	_	19	punct

1	The	the	DT	_	4	det
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	binding	binding	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	to	to	TO	_	10	case
8	human	human	JJ	_	10	amod
9	plasma	plasma	NN	_	10	compound
10	proteins	protein	NNS	_	4	nmod
11	is	be	VBZ	_	12	aux
12	unaffected	unaffected	JJ	_	0	ROOT
13	by	by	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug3	drug3	NN	_	20	nsubj
18	does	do	VBZ	_	20	aux
19	not	not	RB	_	20	neg
20	alter	alter	VB	_	12	conj
21	the	the	DT	_	23	det
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	20	dobj
24	of	of	IN	_	26	case
25	normal	normal	JJ	_	26	amod
26	volunteers	volunteer	NNS	_	23	nmod
27	.	.	.	_	12	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	increased	increase	VBD	_	5	amod
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	bleeding	bleeding	NN	_	5	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug1	drug1	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	18	compound
18	therapy	therapy	NN	_	15	conj
19	.	.	.	_	10	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	8	nmod
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	adult	adult	JJ	_	4	amod
3	diabetic	diabetic	JJ	_	4	amod
4	patients	patient	NNS	_	13	nmod
5	under	under	IN	_	6	case
6	treatment	treatment	NN	_	4	nmod
7	with	with	IN	_	9	case
8	either	either	CC	_	9	cc:preconj
9	drug1	drug1	NN	_	6	nmod
10	or	or	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	there	there	EX	_	13	expl
13	is	be	VBZ	_	0	ROOT
14	no	no	DT	_	15	neg
15	change	change	NN	_	13	nsubj
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	clinical	clinical	JJ	_	19	amod
19	effects	effect	NNS	_	13	nmod
20	of	of	IN	_	22	case
21	either	either	CC	_	22	cc:preconj
22	drug3	drug3	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	the	the	DT	_	25	det
25	drug4	drug4	NN	_	22	conj
26	.	.	.	_	13	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	reduce	reduce	VB	_	7	xcomp
10	the	the	DT	_	12	det
11	tubular	tubular	JJ	_	12	amod
12	secretion	secretion	NN	_	9	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	18	case
16	an	a	DT	_	18	det
17	animal	animal	NN	_	18	compound
18	model	model	NN	_	9	nmod
19	,	,	,	_	9	punct
20	possibly	possibly	RB	_	21	advmod
21	enhancing	enhance	VBG	_	9	advcl
22	the	the	DT	_	23	det
23	toxicity	toxicity	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	7	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Tests	Tests	NNP	_	0	ROOT
3	Because	because	IN	_	11	mark
4	serious	serious	JJ	_	7	amod
5	GI	gi	NN	_	7	compound
6	tract	tract	NN	_	7	compound
7	ulceration	ulceration	NN	_	11	nsubj
8	and	and	CC	_	7	cc
9	bleeding	bleeding	NN	_	7	conj
10	can	can	MD	_	11	aux
11	occur	occur	VB	_	2	acl
12	without	without	IN	_	13	mark
13	warning	warn	VBG	_	11	advcl
14	symptoms	symptom	NNS	_	13	dobj
15	,	,	,	_	2	punct
16	physicians	physician	NNS	_	18	nsubj
17	should	should	MD	_	18	aux
18	follow	follow	VB	_	2	acl:relcl
19	chronically	chronically	RB	_	20	advmod
20	treated	treat	VBN	_	21	amod
21	patients	patient	NNS	_	18	dobj
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	signs	sign	NNS	_	21	nmod
25	and	and	CC	_	24	cc
26	symptoms	symptom	NNS	_	24	conj
27	of	of	IN	_	28	case
28	ulceration	ulceration	NN	_	24	nmod
29	and	and	CC	_	28	cc
30	bleeding	bleeding	NN	_	28	conj
31	and	and	CC	_	18	cc
32	should	should	MD	_	33	aux
33	inform	inform	VB	_	18	conj
34	them	they	PRP	_	33	dobj
35	of	of	IN	_	37	case
36	the	the	DT	_	37	det
37	importance	importance	NN	_	33	nmod
38	of	of	IN	_	40	case
39	this	this	DT	_	40	det
40	follow-up	follow-up	NN	_	37	nmod
41	.	.	.	_	2	punct

1	An	a	DT	_	2	det
2	inhibitor	inhibitor	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	CYP2C8	cyp2c8	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	4	nmod
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	an	a	DT	_	18	det
18	inducer	inducer	NN	_	13	conj
19	of	of	IN	_	20	case
20	CYP2C8	cyp2c8	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	24	punct
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug3	drug3	NN	_	20	nmod
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	may	may	MD	_	27	aux
27	decrease	decrease	VB	_	11	dep
28	the	the	DT	_	29	det
29	AUC	auc	NN	_	27	dobj
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	if	if	IN	_	5	mark
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	12	nsubjpass
6	or	or	CC	_	5	cc
7	an	a	DT	_	8	det
8	inducer	inducer	NN	_	5	conj
9	of	of	IN	_	10	case
10	CYP2C8	cyp2c8	NN	_	5	nmod
11	is	be	VBZ	_	12	auxpass
12	started	start	VBN	_	0	ROOT
13	or	or	CC	_	12	cc
14	stopped	stop	VBN	_	12	conj
15	during	during	IN	_	16	case
16	treatment	treatment	NN	_	12	nmod
17	with	with	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	12	punct
20	changes	change	NNS	_	26	nsubjpass
21	in	in	IN	_	23	case
22	diabetes	diabetes	NN	_	23	compound
23	treatment	treatment	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	needed	need	VBN	_	12	parataxis
27	based	base	VBN	_	26	dep
28	upon	upon	IN	_	30	case
29	clinical	clinical	JJ	_	30	amod
30	response	response	NN	_	27	nmod
31	.	.	.	_	12	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	properties	property	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	the	the	DT	_	10	det
10	addition	addition	NN	_	7	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	drug2	drug2	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	or	or	CC	_	13	cc
17	the	the	DT	_	18	det
18	combination	combination	NN	_	13	conj
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug5	drug5	NN	_	20	conj
23	.	.	.	_	7	punct

1	No	no	DT	_	4	neg
2	clinically	clinically	RB	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	changes	change	NNS	_	11	nsubjpass
5	to	to	TO	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	following	follow	VBG	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	11	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	properties	property	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	elimination	elimination	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	causing	cause	VBG	_	4	acl
8	an	a	DT	_	9	det
9	increase	increase	NN	_	7	dobj
10	in	in	IN	_	12	case
11	overall	overall	JJ	_	12	amod
12	exposure	exposure	NN	_	9	nmod
13	.	.	.	_	2	punct
14	The	the	DT	_	15	det
15	addition	addition	NN	_	18	nsubj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	has	have	VBZ	_	2	parataxis
19	no	no	DT	_	22	neg
20	clinically	clinically	RB	_	21	advmod
21	significant	significant	JJ	_	22	amod
22	effect	effect	NN	_	18	dobj
23	on	on	IN	_	26	case
24	the	the	DT	_	26	det
25	pharmacokinetic	pharmacokinetic	JJ	_	26	amod
26	properties	property	NNS	_	18	nmod
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	0	ROOT
4	of	of	IN	_	7	case
5	11	11	CD	_	7	nummod
6	HIV-infected	hiv-infected	JJ	_	7	amod
7	patients	patient	NNS	_	3	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	-	-	:	_	12	punct
11	maintenance	maintenance	NN	_	12	compound
12	therapy	therapy	NN	_	3	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	40	40	CD	_	15	nummod
15	mg	mg	NN	_	12	appos
16	and	and	CC	_	15	cc
17	90	90	CD	_	18	nummod
18	mg	mg	NN	_	15	conj
19	daily	daily	JJ	_	15	amod
20	-RRB-	-rrb-	-RRB-	_	15	punct
21	with	with	IN	_	23	case
22	600	600	CD	_	23	nummod
23	mg	mg	NN	_	12	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	twice	twice	RB	_	27	advmod
27	daily	daily	RB	_	12	advmod
28	-LRB-	-lrb-	-LRB-	_	33	punct
29	twice	twice	RB	_	33	dep
30	the	the	DT	_	33	det
31	currently	currently	RB	_	32	advmod
32	recommended	recommend	VBN	_	33	amod
33	dose	dose	NN	_	12	dep
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	,	,	,	_	12	punct
36	oral	oral	JJ	_	38	amod
37	drug3	drug3	NN	_	38	compound
38	clearance	clearance	NN	_	39	nsubj
39	increased	increase	VBD	_	12	acl:relcl
40	22	22	CD	_	41	nummod
41	%	%	NN	_	39	dobj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	90	90	CD	_	44	compound
44	%	%	NN	_	45	amod
45	CI	ci	NN	_	41	dep
46	6	6	CD	_	45	amod
47	%	%	NN	_	46	dep
48	to	to	TO	_	50	case
49	42	42	CD	_	50	nummod
50	%	%	NN	_	47	nmod
51	-RRB-	-rrb-	-RRB-	_	45	punct
52	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	alteration	alteration	NN	_	5	nsubj
3	will	will	MD	_	5	aux
4	not	not	RB	_	5	neg
5	result	result	VB	_	0	ROOT
6	in	in	IN	_	10	case
7	a	a	DT	_	10	det
8	drug1	drug1	NN	_	10	compound
9	dose	dose	NN	_	10	compound
10	modification	modification	NN	_	5	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	majority	majority	NN	_	10	nmod
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	;	;	:	_	5	punct

1	however	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	an	a	DT	_	6	det
4	increased	increase	VBN	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	dose	dose	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	small	small	JJ	_	13	amod
13	number	number	NN	_	9	nmod
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug3	drug3	NN	_	12	compound
12	USP	usp	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	because	because	IN	_	17	mark
15	they	they	PRP	_	17	nsubj
16	may	may	MD	_	17	aux
17	have	have	VB	_	6	advcl
18	additive	additive	JJ	_	19	amod
19	effects	effect	NNS	_	17	dobj
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	27	csubjpass
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	being	be	VBG	_	10	auxpass
10	treated	treat	VBN	_	8	acl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	4	punct
16	since	since	IN	_	18	case
17	the	the	DT	_	18	det
18	action	action	NN	_	4	nmod
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	on	on	IN	_	24	case
22	the	the	DT	_	24	det
23	vascular	vascular	JJ	_	24	amod
24	system	system	NN	_	18	nmod
25	may	may	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	potentiated	potentiate	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	6	nsubj
3	published	publish	VBN	_	2	acl
4	in	in	IN	_	5	case
5	2002	2002	CD	_	3	nmod
6	found	find	VBD	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	causes	cause	VBZ	_	6	ccomp
10	a	a	DT	_	13	det
11	statistically	statistically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	increase	increase	NN	_	9	dobj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	clearance	clearance	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	1984	1984	CD	_	13	nmod
3	,	,	,	_	13	punct
4	Drs	Drs	NNP	_	5	compound
5	Rimmer	Rimmer	NNP	_	13	nsubj
6	and	and	CC	_	5	cc
7	Richens	Richens	NNP	_	5	conj
8	at	at	IN	_	10	case
9	the	the	DT	_	10	det
10	University	University	NNP	_	5	nmod
11	of	of	IN	_	12	case
12	Wales	Wales	NNP	_	10	nmod
13	reported	report	VBD	_	0	ROOT
14	that	that	IN	_	19	mark
15	administering	administer	VBG	_	19	csubj
16	drug1	drug1	NN	_	15	dobj
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	lowered	lower	VBD	_	13	ccomp
20	the	the	DT	_	23	det
21	serum	serum	NN	_	23	compound
22	drug3	drug3	NN	_	23	compound
23	concentration	concentration	NN	_	19	dobj
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	with	with	IN	_	28	case
27	treatment-resistant	treatment-resistant	JJ	_	28	amod
28	epilepsy	epilepsy	NN	_	25	nmod
29	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	concentration	concentration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	falls	fall	VBZ	_	0	ROOT
6	to	to	TO	_	8	case
7	23	23	CD	_	8	nummod
8	%	%	NN	_	5	nmod
9	within	within	IN	_	11	case
10	five	five	CD	_	11	nummod
11	weeks	week	NNS	_	5	nmod
12	,	,	,	_	5	punct
13	according	accord	VBG	_	16	case
14	to	to	TO	_	13	mwe
15	an	a	DT	_	16	det
16	experiment	experiment	NN	_	5	nmod
17	published	publish	VBN	_	16	acl
18	in	in	IN	_	19	case
19	1989	1989	CD	_	17	nmod
20	by	by	IN	_	24	case
21	the	the	DT	_	24	det
22	same	same	JJ	_	24	amod
23	two	two	CD	_	24	nummod
24	scientists	scientist	NNS	_	17	nmod
25	that	that	WDT	_	26	nsubj
26	tried	try	VBD	_	24	acl:relcl
27	and	and	CC	_	26	cc
28	failed	fail	VBD	_	26	conj
29	to	to	TO	_	30	mark
30	elucidate	elucidate	VB	_	28	xcomp
31	the	the	DT	_	32	det
32	mechanism	mechanism	NN	_	30	dobj
33	behind	behind	IN	_	35	case
34	this	this	DT	_	35	det
35	interaction	interaction	NN	_	32	nmod
36	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	sedative	sedative	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	including	include	VBG	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug7	drug7	NN	_	10	conj
19	,	,	,	_	10	punct
20	and	and	CC	_	10	cc
21	drug8	drug8	NN	_	10	conj
22	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug2	drug2	NN	_	4	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	enhanced	enhance	VBN	_	0	ROOT
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	.	.	.	_	13	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	effect	effect	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	metabolism	metabolism	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	liver	liver	NN	_	3	nmod
11	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	8	compound
8	therapy	therapy	NN	_	6	dobj
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	mixed	mix	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	any	any	DT	_	9	det
8	other	other	JJ	_	9	amod
9	drug	drug	NN	_	5	nmod
10	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	cardioactive	cardioactive	JJ	_	8	amod
8	drugs	drug	NNS	_	2	nmod
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	27	nmod
3	to	to	TO	_	4	case
4	bleeding	bleeding	NN	_	2	nmod
5	associated	associate	VBN	_	4	acl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drugs	drug	NNS	_	7	conj
12	that	that	WDT	_	13	nsubj
13	alter	alter	VBP	_	11	acl:relcl
14	platelet	platelet	NN	_	15	compound
15	function	function	NN	_	13	dobj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug3	drug3	NN	_	11	nmod
20	,	,	,	_	19	punct
21	drug4	drug4	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug5	drug5	NN	_	19	conj
25	-RRB-	-rrb-	-RRB-	_	19	punct
26	may	may	MD	_	27	aux
27	increase	increase	VB	_	0	ROOT
28	the	the	DT	_	29	det
29	risk	risk	NN	_	27	dobj
30	of	of	IN	_	31	case
31	bleeding	bleed	VBG	_	29	nmod
32	if	if	IN	_	33	mark
33	administered	administer	VBN	_	27	advcl
34	prior	prior	RB	_	39	advmod
35	to	to	TO	_	39	nmod
36	or	or	CC	_	35	cc
37	after	after	IN	_	35	conj
38	drug6	drug6	NN	_	39	compound
39	therapy	therapy	NN	_	33	nmod
40	.	.	.	_	27	punct

1	The	the	DT	_	2	det
2	occurrence	occurrence	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	stupor	stupor	NN	_	2	nmod
5	,	,	,	_	4	punct
6	muscular	muscular	JJ	_	7	amod
7	rigidity	rigidity	NN	_	4	conj
8	,	,	,	_	4	punct
9	severe	severe	JJ	_	10	amod
10	agitation	agitation	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	elevated	elevated	JJ	_	14	amod
14	temperature	temperature	NN	_	4	conj
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	0	ROOT
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	patients	patient	NNS	_	17	nmod
21	receiving	receive	VBG	_	20	acl
22	the	the	DT	_	23	det
23	combination	combination	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug2	drug2	NN	_	25	conj
28	.	.	.	_	17	punct

1	Symptoms	symptom	NNS	_	3	nsubj
2	usually	usually	RB	_	3	advmod
3	resolve	resolve	VBP	_	0	ROOT
4	over	over	IN	_	5	case
5	days	day	NNS	_	3	nmod
6	when	when	WRB	_	10	advmod
7	the	the	DT	_	8	det
8	combination	combination	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	discontinued	discontinue	VBN	_	5	acl:relcl
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	typical	typical	JJ	_	0	ROOT
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	.	.	.	_	3	punct

1	Other	other	JJ	_	3	amod
2	serious	serious	JJ	_	3	amod
3	reactions	reaction	NNS	_	16	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	including	include	VBG	_	7	case
6	severe	severe	JJ	_	7	amod
7	agitation	agitation	NN	_	3	nmod
8	,	,	,	_	7	punct
9	hallucinations	hallucination	NNS	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	death	death	NN	_	7	conj
13	-RRB-	-rrb-	-RRB-	_	7	punct
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	0	ROOT
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	this	this	DT	_	21	det
21	combination	combination	NN	_	19	dobj
22	.	.	.	_	16	punct

1	Severe	severe	JJ	_	2	amod
2	toxicity	toxicity	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	the	the	DT	_	11	det
11	combination	combination	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	and	and	CC	_	13	cc
17	drug3	drug3	NN	_	13	conj
18	and	and	CC	_	17	cc
19	drug4	drug4	NN	_	17	conj
20	.	.	.	_	6	punct

1	One	one	CD	_	2	nummod
2	case	case	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypertensive	hypertensive	JJ	_	5	amod
5	crisis	crisis	NN	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	taking	take	VBG	_	11	acl
13	the	the	DT	_	15	det
14	recommended	recommend	VBN	_	15	amod
15	doses	dose	NNS	_	12	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	a	a	DT	_	17	conj
20	drug2	drug2	NN	_	19	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug3	drug3	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	.	.	.	_	8	punct

1	When	when	WRB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	used	use	VBN	_	28	advcl
7	together	together	RB	_	6	advmod
8	,	,	,	_	28	punct
9	the	the	DT	_	10	det
10	signs	sign	NNS	_	28	nsubj
11	of	of	IN	_	12	case
12	atropinization	atropinization	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	flushing	flushing	NN	_	12	dep
15	,	,	,	_	14	punct
16	mydriasis	mydriasis	NN	_	14	conj
17	,	,	,	_	14	punct
18	tachycardia	tachycardia	NN	_	14	conj
19	,	,	,	_	14	punct
20	dryness	dryness	NN	_	14	appos
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	mouth	mouth	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	nose	nose	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	14	punct
27	may	may	MD	_	28	aux
28	occur	occur	VB	_	0	ROOT
29	earlier	earlier	JJR	_	28	advmod
30	than	than	IN	_	33	mark
31	might	might	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	expected	expect	VBN	_	29	advcl
34	when	when	WRB	_	37	advmod
35	drug3	drug3	NN	_	37	nsubjpass
36	is	be	VBZ	_	37	auxpass
37	used	use	VBN	_	33	advcl
38	alone	alone	RB	_	37	advmod
39	.	.	.	_	28	punct

1	This	this	DT	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	especially	especially	RB	_	4	advmod
4	true	true	JJ	_	0	ROOT
5	if	if	IN	_	13	mark
6	the	the	DT	_	8	det
7	total	total	JJ	_	8	amod
8	dose	dose	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	cop
13	large	large	JJ	_	4	advcl
14	and	and	CC	_	13	cc
15	the	the	DT	_	16	det
16	administration	administration	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	delayed	delay	VBN	_	13	conj
22	.	.	.	_	4	punct

1	2	2	LS	_	0	ROOT
2	-	-	:	_	1	punct
3	4	4	CD	_	6	nummod
4	The	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	precautions	precaution	NNS	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	kept	keep	VBN	_	1	dep
10	in	in	IN	_	11	case
11	mind	mind	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	treatment	treatment	NN	_	9	nmod
15	of	of	IN	_	17	case
16	anticholinesterase	anticholinesterase	JJ	_	17	amod
17	poisoning	poisoning	NN	_	14	nmod
18	,	,	,	_	9	punct
19	although	although	IN	_	23	mark
20	they	they	PRP	_	23	nsubj
21	do	do	VBP	_	23	aux
22	not	not	RB	_	23	neg
23	bear	bear	VB	_	9	advcl
24	directly	directly	RB	_	23	advmod
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	use	use	NN	_	23	nmod
28	of	of	IN	_	29	case
29	drug1	drug1	NN	_	27	nmod
30	:	:	:	_	9	punct
31	since	since	IN	_	34	mark
32	drug2	drug2	NN	_	34	nsubjpass
33	are	be	VBP	_	34	auxpass
34	potentiated	potentiate	VBN	_	42	advcl
35	by	by	IN	_	37	case
36	the	the	DT	_	37	det
37	drug3	drug3	NN	_	34	nmod
38	,	,	,	_	42	punct
39	they	they	PRP	_	42	nsubjpass
40	should	should	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	9	parataxis
43	cautiously	cautiously	RB	_	42	advmod
44	in	in	IN	_	46	case
45	the	the	DT	_	46	det
46	treatment	treatment	NN	_	42	nmod
47	of	of	IN	_	48	case
48	convulsions	convulsion	NNS	_	46	nmod
49	;	;	:	_	1	punct

1	drug1	drug1	NN	_	15	nsubjpass
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug5	drug5	NN	_	1	conj
10	,	,	,	_	1	punct
11	and	and	CC	_	1	cc
12	drug6	drug6	NN	_	1	conj
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	avoided	avoid	VBN	_	0	ROOT
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	with	with	IN	_	20	case
19	organophosphate	organophosphate	NN	_	20	compound
20	poisoning	poisoning	NN	_	17	nmod
21	.	.	.	_	15	punct

1	No	no	DT	_	4	neg
2	drug-drug	drug-drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	administered	administer	VBN	_	8	csubj
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	significantly	significantly	RB	_	8	advmod
8	decrease	decrease	VB	_	0	ROOT
9	the	the	DT	_	11	det
10	serum	serum	NN	_	11	compound
11	concentrations	concentration	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	8	punct

1	Laboratory	laboratory	NN	_	2	compound
2	Tests	test	NNS	_	0	ROOT
3	The	the	DT	_	4	det
4	pathologist	pathologist	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	advised	advise	VBN	_	2	acl:relcl
8	of	of	IN	_	10	case
9	progestin	progestin	NN	_	10	compound
10	therapy	therapy	NN	_	7	nmod
11	when	when	WRB	_	15	advmod
12	relevant	relevant	JJ	_	13	amod
13	specimens	specimen	NNS	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	submitted	submit	VBN	_	7	advcl
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	informed	inform	VBN	_	0	ROOT
6	that	that	IN	_	19	mark
7	certain	certain	JJ	_	12	amod
8	endocrine	endocrine	JJ	_	12	amod
9	and	and	CC	_	8	cc
10	liver	liver	NN	_	8	conj
11	function	function	NN	_	12	compound
12	tests	test	NNS	_	19	nsubjpass
13	,	,	,	_	12	punct
14	and	and	CC	_	12	cc
15	blood	blood	NN	_	16	compound
16	components	component	NNS	_	12	conj
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	affected	affect	VBN	_	5	ccomp
20	by	by	IN	_	22	case
21	progestin	progestin	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	:	:	:	_	5	punct
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	a	a	LS	_	33	dep
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	Plasma	plasma	NN	_	31	amod
28	and	and	CC	_	27	cc
29	urinary	urinary	JJ	_	27	conj
30	steroid	steroid	NN	_	31	compound
31	levels	level	NNS	_	33	nsubjpass
32	are	be	VBP	_	33	auxpass
33	decreased	decrease	VBN	_	5	parataxis
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	progesterone	progesterone	NN	_	33	dep
38	,	,	,	_	37	punct
39	estradiol	estradiol	NN	_	37	conj
40	,	,	,	_	37	punct
41	pregnanediol	pregnanediol	NN	_	37	conj
42	,	,	,	_	37	punct
43	testosterone	testosterone	NN	_	37	conj
44	,	,	,	_	37	punct
45	cortisol	cortisol	NN	_	37	appos
46	-RRB-	-rrb-	-RRB-	_	37	punct
47	.	.	.	_	5	punct

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	b	b	NN	_	4	compound
3	-RRB-	-rrb-	-RRB-	_	4	punct
4	Plasma	plasma	NN	_	10	nsubjpass
5	and	and	CC	_	4	cc
6	urinary	urinary	JJ	_	8	amod
7	gonadotropin	gonadotropin	NN	_	8	compound
8	levels	level	NNS	_	4	conj
9	are	be	VBP	_	10	auxpass
10	decreased	decrease	VBN	_	0	ROOT
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	LH	lh	NN	_	10	dep
15	,	,	,	_	14	punct
16	FSH	fsh	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	.	.	.	_	10	punct

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	c	c	NN	_	5	compound
3	-RRB-	-rrb-	-RRB-	_	5	punct
4	SHBG	shbg	NN	_	5	compound
5	concentrations	concentration	NNS	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	decreased	decrease	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	d	d	NN	_	5	compound
3	-RRB-	-rrb-	-RRB-	_	5	punct
4	T3-uptake	t3-uptake	NN	_	5	compound
5	values	value	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	decrease	decrease	VB	_	0	ROOT
8	.	.	.	_	7	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	e	e	LS	_	8	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	There	there	EX	_	8	expl
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	cop
7	small	small	JJ	_	8	amod
8	changes	change	NNS	_	0	ROOT
9	in	in	IN	_	11	case
10	coagulation	coagulation	NN	_	11	compound
11	factors	factor	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	f	f	LS	_	13	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	Sulfobromophthalein	sulfobromophthalein	NN	_	13	nsubjpass
5	and	and	CC	_	4	cc
6	other	other	JJ	_	10	amod
7	liver	liver	NN	_	10	compound
8	function	function	NN	_	10	compound
9	test	test	NN	_	10	compound
10	values	value	NNS	_	4	conj
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	increased	increase	VBN	_	0	ROOT
14	slightly	slightly	RB	_	13	advmod
15	.	.	.	_	13	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	g	g	NN	_	8	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	There	there	EX	_	8	expl
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	cop
7	small	small	JJ	_	8	amod
8	changes	change	NNS	_	0	ROOT
9	in	in	IN	_	11	case
10	lipid	lipid	NN	_	11	compound
11	profiles	profile	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	21	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	21	punct
7	patients	patient	NNS	_	21	nsubj
8	taking	take	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	concomitantly	concomitantly	RB	_	8	advmod
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug4	drug4	NN	_	12	dep
15	,	,	,	_	14	punct
16	Genentech	Genentech	NNP	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	,	,	,	_	12	punct
19	drug5	drug5	NN	_	12	appos
20	,	,	,	_	21	punct
21	inhaled	inhale	VBD	_	0	ROOT
22	drug6	drug6	NN	_	30	nsubj
23	,	,	,	_	22	punct
24	other	other	JJ	_	25	amod
25	drug7	drug7	NN	_	22	conj
26	,	,	,	_	22	punct
27	or	or	CC	_	22	cc
28	parenteral	parenteral	JJ	_	29	amod
29	drug8	drug8	NN	_	22	conj
30	demonstrated	demonstrate	VBD	_	21	ccomp
31	adverse	adverse	JJ	_	33	amod
32	experience	experience	NN	_	33	compound
33	profiles	profile	NNS	_	30	dobj
34	similar	similar	JJ	_	33	amod
35	to	to	TO	_	38	case
36	the	the	DT	_	38	det
37	study	study	NN	_	38	compound
38	population	population	NN	_	34	nmod
39	as	as	IN	_	41	case
40	a	a	DT	_	41	det
41	whole	whole	NN	_	38	nmod
42	.	.	.	_	21	punct

1	Concurrent	concurrent	JJ	_	4	amod
2	and/or	and/or	CC	_	1	cc
3	sequential	sequential	JJ	_	1	conj
4	use	use	NN	_	17	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	with	with	IN	_	14	case
11	neurotoxic	neurotoxic	JJ	_	14	amod
12	or	or	CC	_	11	cc
13	ototoxic	ototoxic	JJ	_	11	conj
14	potential	potential	NN	_	9	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	avoided	avoid	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubj
3	can	can	MD	_	4	aux
4	enhance	enhance	VB	_	0	ROOT
5	drug2	drug2	NN	_	6	compound
6	toxicity	toxicity	NN	_	4	dobj
7	by	by	IN	_	8	mark
8	altering	alter	VBG	_	4	advcl
9	drug3	drug3	NN	_	10	compound
10	concentrations	concentration	NNS	_	8	dobj
11	in	in	IN	_	12	case
12	serum	serum	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	tissue	tissue	NN	_	12	conj
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	or	or	CC	_	8	cc
15	drug5	drug5	NN	_	8	conj
16	.	.	.	_	5	punct

1	DRUG	drug	NN	_	2	compound
2	INTERACTIONS	interaction	NNS	_	0	ROOT
3	There	there	EX	_	4	expl
4	are	be	VBP	_	2	acl:relcl
5	no	no	DT	_	8	neg
6	known	known	JJ	_	8	amod
7	drug/drug	drug/drug	NN	_	8	compound
8	interactions	interaction	NNS	_	17	nsubjpass
9	with	with	IN	_	12	case
10	oral	oral	JJ	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	Vaccinations	vaccination	NNS	_	8	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	8	nmod
15	are	be	VBP	_	17	auxpass
16	not	not	RB	_	17	neg
17	recommended	recommend	VBN	_	4	ccomp
18	in	in	IN	_	20	case
19	immunocompromised	immunocompromised	JJ	_	20	amod
20	individuals	individual	NNS	_	17	nmod
21	drug3	drug3	VBN	_	20	acl
22	together	together	RB	_	21	advmod
23	with	with	IN	_	26	case
24	high-dose	high-dose	JJ	_	26	amod
25	intravenous	intravenous	JJ	_	26	amod
26	drug4	drug4	NN	_	21	nmod
27	has	have	VBZ	_	28	aux
28	caused	cause	VBN	_	17	dep
29	deaths	death	NNS	_	28	dobj
30	in	in	IN	_	31	case
31	children	child	NNS	_	29	nmod
32	due	due	JJ	_	28	advmod
33	to	to	TO	_	35	case
34	haemorrhagic	haemorrhagic	JJ	_	35	amod
35	enterocolitis	enterocolitis	NN	_	32	nmod
36	.	.	.	_	2	punct

1	Impaired	impaired	JJ	_	3	amod
2	renal	renal	JJ	_	3	amod
3	function	function	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	described	describe	VBN	_	0	ROOT
7	in	in	IN	_	11	case
8	bone	bone	NN	_	11	compound
9	marrow	marrow	NN	_	11	compound
10	transplant	transplant	NN	_	11	compound
11	patients	patient	NNS	_	6	nmod
12	who	who	WP	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	conditioned	condition	VBN	_	11	acl:relcl
15	with	with	IN	_	18	case
16	high-dose	high-dose	JJ	_	18	amod
17	intravenous	intravenous	JJ	_	18	amod
18	drug1	drug1	NN	_	14	nmod
19	and	and	CC	_	14	cc
20	who	who	WP	_	22	nsubj
21	subsequently	subsequently	RB	_	22	advmod
22	received	receive	VBD	_	14	conj
23	drug2	drug2	NN	_	22	dobj
24	to	to	TO	_	25	mark
25	prevent	prevent	VB	_	22	advcl
26	graft-versus-host	graft-versus-host	JJ	_	27	amod
27	disease	disease	NN	_	25	dobj

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	the	the	DT	_	14	det
14	possibility	possibility	NN	_	4	nmod
15	of	of	IN	_	17	case
16	conduction	conduction	NN	_	17	compound
17	disturbances	disturbance	NNS	_	14	nmod
18	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	parasympathomimetic	parasympathomimetic	JJ	_	4	amod
4	effects	effect	NNS	_	1	nmod
5	administered	administer	VBN	_	4	acl
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	5	nmod
9	would	would	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	result	result	VB	_	11	xcomp
14	in	in	IN	_	17	case
15	additive	additive	JJ	_	17	amod
16	pharmacologic	pharmacologic	JJ	_	17	amod
17	effects	effect	NNS	_	13	nmod
18	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	might	might	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	anticholinergic	anticholinergic	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	used	use	VBN	_	8	acl
10	concomitantly	concomitantly	RB	_	9	advmod
11	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	when	when	WRB	_	11	advmod
7	anticholinergic	anticholinergic	JJ	_	8	amod
8	properties	property	NNS	_	11	nsubj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	aux
11	contributing	contribute	VBG	_	5	advcl
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	therapeutic	therapeutic	JJ	_	15	amod
15	effect	effect	NN	_	11	nmod
16	of	of	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	medication	medication	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug1	drug1	NN	_	18	dep
23	,	,	,	_	22	punct
24	inhaled	inhale	VBD	_	25	amod
25	drug2	drug2	NN	_	22	appos
26	-RRB-	-rrb-	-RRB-	_	22	punct
27	.	.	.	_	5	punct

1	While	while	IN	_	9	mark
2	no	no	DT	_	6	neg
3	formal	formal	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	performed	perform	VBN	_	16	advcl
10	,	,	,	_	16	punct
11	the	the	DT	_	14	det
12	following	follow	VBG	_	14	amod
13	concomitant	concomitant	JJ	_	14	amod
14	drugs	drug	NNS	_	16	nsubjpass
15	were	be	VBD	_	16	auxpass
16	used	use	VBN	_	0	ROOT
17	in	in	IN	_	21	case
18	at	at	IN	_	19	case
19	least	least	JJS	_	20	nmod:npmod
20	10	10	CD	_	21	nummod
21	%	%	NN	_	16	nmod
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	in	in	IN	_	25	case
25	either	either	CC	_	23	nmod
26	or	or	CC	_	25	cc
27	both	both	DT	_	28	det
28	Sj	sj	NN	_	25	conj
29	grens	gren	VBZ	_	16	dep
30	efficacy	efficacy	NN	_	31	compound
31	studies	study	NNS	_	29	dobj
32	:	:	:	_	29	punct
33	drug1	drug1	NN	_	29	dep
34	,	,	,	_	33	punct
35	artificial	artificial	JJ	_	36	amod
36	tears	tear	NNS	_	33	conj
37	,	,	,	_	33	punct
38	drug2	drug2	NN	_	33	conj
39	,	,	,	_	33	punct
40	drug3	drug3	NN	_	33	conj
41	,	,	,	_	33	punct
42	drug4	drug4	NN	_	33	conj
43	,	,	,	_	33	punct
44	drug5	drug5	NN	_	33	conj
45	,	,	,	_	33	punct
46	drug6	drug6	NN	_	33	conj
47	,	,	,	_	33	punct
48	drug7	drug7	NN	_	33	conj
49	,	,	,	_	33	punct
50	drug8	drug8	NN	_	33	conj
51	,	,	,	_	33	punct
52	drug9	drug9	NN	_	33	conj
53	,	,	,	_	33	punct
54	drug10	drug10	NN	_	33	conj
55	,	,	,	_	33	punct
56	drug11	drug11	NN	_	33	conj
57	,	,	,	_	33	punct
58	drug12	drug12	NN	_	33	conj
59	,	,	,	_	33	punct
60	and	and	CC	_	33	cc
61	drug13	drug13	NN	_	33	conj
62	.	.	.	_	16	punct

1	The	the	DT	_	4	det
2	induction	induction	NN	_	4	compound
3	dose	dose	NN	_	4	compound
4	requirements	requirement	NNS	_	11	nsubjpass
5	of	of	IN	_	8	case
6	drug1	drug1	NN	_	8	compound
7	Injectable	injectable	JJ	_	8	amod
8	Emulsion	emulsion	NN	_	4	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reduced	reduce	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	with	with	IN	_	15	case
15	intramuscular	intramuscular	JJ	_	13	nmod
16	or	or	CC	_	15	cc
17	intravenous	intravenous	JJ	_	15	conj
18	premedication	premedication	NN	_	15	dep
19	,	,	,	_	11	punct
20	particularly	particularly	RB	_	22	advmod
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	11	nmod
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	eg	eg	FW	_	26	compound
25	,	,	,	_	26	punct
26	drug3	drug3	NN	_	22	appos
27	,	,	,	_	26	punct
28	drug4	drug4	NN	_	26	conj
29	,	,	,	_	26	punct
30	and	and	CC	_	26	cc
31	drug5	drug5	NN	_	26	conj
32	,	,	,	_	26	punct
33	etc.	etc.	FW	_	26	dep
34	-RRB-	-rrb-	-RRB-	_	26	punct

1	and	and	CC	_	0	ROOT
2	combinations	combination	NNS	_	1	dep
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	eg	eg	FW	_	10	compound
9	,	,	,	_	10	punct
10	drug3	drug3	NN	_	2	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	etc.	etc.	FW	_	10	dep
19	-RRB-	-rrb-	-RRB-	_	10	punct
20	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	9	det
6	anesthetic	anesthetic	NN	_	9	amod
7	or	or	CC	_	6	cc
8	sedative	sedative	JJ	_	6	conj
9	effects	effect	NNS	_	4	dobj
10	of	of	IN	_	13	case
11	drug1	drug1	NN	_	13	compound
12	Injectable	injectable	JJ	_	13	amod
13	Emulsion	emulsion	NN	_	9	nmod
14	and	and	CC	_	4	cc
15	may	may	MD	_	17	aux
16	also	also	RB	_	17	advmod
17	result	result	VB	_	4	conj
18	in	in	IN	_	21	case
19	more	more	RBR	_	20	advmod
20	pronounced	pronounced	JJ	_	21	amod
21	decreases	decrease	NNS	_	17	nmod
22	in	in	IN	_	21	amod
23	systolic	systolic	JJ	_	22	dep
24	,	,	,	_	23	punct
25	diastolic	diastolic	JJ	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	mean	mean	VB	_	23	conj
29	arterial	arterial	JJ	_	30	amod
30	pressures	pressure	NNS	_	28	dobj
31	and	and	CC	_	30	cc
32	cardiac	cardiac	JJ	_	33	amod
33	output	output	NN	_	30	conj
34	.	.	.	_	4	punct

1	During	during	IN	_	2	case
2	maintenance	maintenance	NN	_	17	nmod
3	of	of	IN	_	4	case
4	anesthesia	anesthesia	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	sedation	sedation	NN	_	4	conj
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	rate	rate	NN	_	17	nsubjpass
10	of	of	IN	_	14	case
11	drug1	drug1	NN	_	14	compound
12	Injectable	injectable	JJ	_	14	amod
13	Emulsion	emulsion	NN	_	14	compound
14	administration	administration	NN	_	9	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	adjusted	adjust	VBN	_	0	ROOT
18	according	accord	VBG	_	22	case
19	to	to	TO	_	18	mwe
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	level	level	NN	_	17	nmod
23	of	of	IN	_	24	case
24	anesthesia	anesthesia	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	sedation	sedation	NN	_	24	conj
27	and	and	CC	_	17	cc
28	may	may	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	reduced	reduce	VBN	_	17	conj
31	in	in	IN	_	36	case
32	the	the	DT	_	36	dep
33	presence	presence	NN	_	36	dep
34	of	of	IN	_	36	case
35	supplemental	supplemental	JJ	_	36	amod
36	drug2	drug2	NN	_	30	nmod
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	eg	eg	FW	_	40	dep
39	,	,	,	_	40	punct
40	drug3	drug3	NN	_	36	dep
41	or	or	CC	_	40	cc
42	drug4	drug4	NN	_	40	conj
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	administration	administration	NN	_	28	nsubjpass
4	of	of	IN	_	7	case
5	potent	potent	JJ	_	7	amod
6	inhalational	inhalational	JJ	_	7	amod
7	agents	agent	NNS	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	eg	eg	FW	_	11	compound
10	,	,	,	_	11	punct
11	drug1	drug1	NN	_	7	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug3	drug3	NN	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	11	punct
18	during	during	IN	_	19	case
19	maintenance	maintenance	NN	_	3	nmod
20	with	with	IN	_	23	case
21	drug4	drug4	NN	_	23	compound
22	Injectable	injectable	JJ	_	23	amod
23	Emulsion	emulsion	NN	_	19	nmod
24	has	have	VBZ	_	28	aux
25	not	not	RB	_	28	neg
26	been	be	VBN	_	28	auxpass
27	extensively	extensively	RB	_	28	advmod
28	evaluated	evaluate	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	These	these	DT	_	3	det
2	inhalational	inhalational	JJ	_	3	amod
3	agents	agent	NNS	_	7	nsubjpass
4	can	can	MD	_	7	aux
5	also	also	RB	_	7	advmod
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	anesthetic	anesthetic	NN	_	9	dobj
12	or	or	CC	_	11	cc
13	sedative	sedative	NN	_	11	conj
14	and	and	CC	_	11	cc
15	cardiorespiratory	cardiorespiratory	JJ	_	16	amod
16	effects	effect	NNS	_	11	conj
17	of	of	IN	_	20	case
18	drug1	drug1	NN	_	20	compound
19	Injectable	injectable	JJ	_	20	amod
20	Emulsion	emulsion	NN	_	11	nmod
21	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	compound
2	Injectable	injectable	JJ	_	3	amod
3	Emulsion	emulsion	NN	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	cause	cause	VB	_	0	ROOT
7	a	a	DT	_	10	det
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	change	change	NN	_	6	dobj
11	in	in	IN	_	12	case
12	onset	onset	NN	_	10	nmod
13	,	,	,	_	12	punct
14	intensity	intensity	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	duration	duration	NN	_	12	conj
18	of	of	IN	_	19	case
19	action	action	NN	_	17	nmod
20	of	of	IN	_	24	case
21	the	the	DT	_	24	det
22	commonly	commonly	RB	_	23	advmod
23	used	use	VBN	_	24	amod
24	drug2	drug2	NN	_	19	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	eg	eg	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug3	drug3	NN	_	24	dep
29	and	and	CC	_	28	cc
30	drug4	drug4	NN	_	28	conj
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	.	.	.	_	6	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	interactions	interaction	NNS	_	34	nsubjpass
5	with	with	IN	_	8	case
6	commonly	commonly	RB	_	7	advmod
7	used	use	VBN	_	8	amod
8	premedications	premedication	NNS	_	4	nmod
9	or	or	CC	_	8	cc
10	drugs	drug	NNS	_	8	conj
11	used	use	VBN	_	4	acl
12	during	during	IN	_	13	case
13	anesthesia	anesthesia	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	sedation	sedation	NN	_	13	conj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	including	include	VBG	_	19	case
18	a	a	DT	_	19	det
19	range	range	NN	_	13	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	,	,	,	_	19	punct
23	inhalational	inhalational	JJ	_	24	amod
24	agents	agent	NNS	_	19	conj
25	,	,	,	_	19	punct
26	drug2	drug2	NN	_	19	conj
27	,	,	,	_	19	punct
28	and	and	CC	_	19	cc
29	local	local	JJ	_	30	amod
30	drug3	drug3	NN	_	19	conj
31	-RRB-	-rrb-	-RRB-	_	19	punct
32	have	have	VBP	_	34	aux
33	been	be	VBN	_	34	auxpass
34	observed	observe	VBN	_	0	ROOT
35	.	.	.	_	34	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	potentiate	potentiate	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	7	punct
16	resulting	result	VBG	_	7	advcl
17	in	in	IN	_	19	case
18	a	a	DT	_	19	det
19	prolongation	prolongation	NN	_	16	nmod
20	of	of	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	.	.	.	_	5	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	5	dep
9	drug1	drug1	NN	_	8	dep
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug2	drug2	NN	_	12	compound
12	gel	gel	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	,	,	,	_	9	punct
15	1	1	CD	_	16	nummod
16	%	%	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	prescribed	prescribe	VBN	_	9	acl:relcl
19	for	for	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	who	who	WP	_	23	nsubj
22	are	be	VBP	_	23	aux
23	receiving	receive	VBG	_	20	acl:relcl
24	anticoagulant	anticoagulant	JJ	_	25	amod
25	treatment	treatment	NN	_	23	dobj
26	,	,	,	_	18	punct
27	although	although	IN	_	31	mark
28	they	they	PRP	_	31	nsubj
29	are	be	VBP	_	31	cop
30	less	less	RBR	_	31	advmod
31	likely	likely	JJ	_	18	advcl
32	to	to	TO	_	33	mark
33	occur	occur	VB	_	31	xcomp
34	with	with	IN	_	37	case
35	topical	topical	JJ	_	37	amod
36	drug3	drug3	NN	_	37	compound
37	administration	administration	NN	_	33	nmod
38	because	because	IN	_	41	case
39	of	of	IN	_	38	mwe
40	low	low	JJ	_	41	amod
41	absorption	absorption	NN	_	31	nmod
42	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	on	on	IN	_	11	case
10	steroid	steroid	NN	_	11	compound
11	therapy	therapy	NN	_	8	nmod
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	the	the	DT	_	15	det
15	potential	potential	NN	_	4	nmod
16	for	for	IN	_	17	mark
17	developing	develop	VBG	_	15	acl
18	hypokalemia	hypokalemia	NN	_	17	dobj
19	.	.	.	_	4	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	for	for	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	receiving	receive	VBG	_	5	acl
7	high-dose	high-dose	JJ	_	8	amod
8	drug1	drug1	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	concomitantly	concomitantly	RB	_	5	advmod
12	,	,	,	_	3	punct
13	as	as	IN	_	14	case
14	anorexia	anorexia	NN	_	3	nmod
15	,	,	,	_	14	punct
16	tachypnea	tachypnea	NN	_	14	conj
17	,	,	,	_	14	punct
18	lethargy	lethargy	NN	_	14	conj
19	,	,	,	_	14	punct
20	coma	coma	NN	_	14	conj
21	and	and	CC	_	14	cc
22	death	death	NN	_	14	conj
23	have	have	VBP	_	25	aux
24	been	be	VBN	_	25	auxpass
25	reported	report	VBN	_	3	dep
26	with	with	IN	_	28	case
27	concomitant	concomitant	JJ	_	28	amod
28	use	use	NN	_	25	nmod
29	of	of	IN	_	31	case
30	high-dose	high-dose	JJ	_	31	amod
31	drug3	drug3	NN	_	28	nmod
32	and	and	CC	_	31	cc
33	drug4	drug4	NN	_	31	conj
34	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	and	and	CC	_	6	cc
10	other	other	JJ	_	11	amod
11	drug4	drug4	NN	_	6	conj
12	,	,	,	_	4	punct
13	and	and	CC	_	4	cc
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drug5	drug5	NN	_	4	conj
17	.	.	.	_	4	punct

1	If	if	IN	_	6	mark
2	signs	sign	NNS	_	6	nsubj
3	of	of	IN	_	5	case
4	folate	folate	NN	_	5	compound
5	deficiency	deficiency	NN	_	2	nmod
6	develop	develop	VB	_	11	advcl
7	,	,	,	_	11	punct
8	drug1	drug1	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	discontinued	discontinue	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	until	until	IN	_	12	mark
9	normal	normal	JJ	_	10	amod
10	hematopoiesis	hematopoiesis	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	restored	restore	VBN	_	7	advcl
13	.	.	.	_	7	punct

1	Mild	mild	JJ	_	2	amod
2	hepatotoxicity	hepatotoxicity	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	some	some	DT	_	8	det
8	patients	patient	NNS	_	5	nmod
9	when	when	WRB	_	14	advmod
10	drug1	drug1	NN	_	14	nsubjpass
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	were	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	5	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	5	punct

1	Due	due	JJ	_	4	case
2	to	to	TO	_	4	case
3	its	its	PRP$	_	4	nmod:poss
4	effects	effect	NNS	_	0	ROOT
5	on	on	IN	_	7	case
6	gastric	gastric	JJ	_	7	amod
7	emptying	emptying	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug1	drug1	NN	_	10	compound
10	therapy	therapy	NN	_	7	appos
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	considered	consider	VBN	_	4	dep
15	for	for	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	taking	take	VBG	_	16	acl
18	drugs	drug	NNS	_	17	dobj
19	that	that	WDT	_	20	nsubj
20	alter	alter	VBP	_	18	acl:relcl
21	gastrointestinal	gastrointestinal	JJ	_	22	amod
22	motility	motility	NN	_	20	dobj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	e.g.	e.g.	FW	_	26	advmod
25	,	,	,	_	26	punct
26	drug2	drug2	NN	_	14	dep
27	such	such	JJ	_	29	case
28	as	as	IN	_	27	mwe
29	drug3	drug3	NN	_	26	nmod
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	and	and	CC	_	14	cc
32	agents	agent	NNS	_	14	conj
33	that	that	WDT	_	34	nsubj
34	slow	slow	VBP	_	32	acl:relcl
35	the	the	DT	_	37	det
36	intestinal	intestinal	JJ	_	37	amod
37	absorption	absorption	NN	_	34	dobj
38	of	of	IN	_	39	case
39	nutrients	nutrient	NNS	_	37	nmod
40	-LRB-	-lrb-	-LRB-	_	43	punct
41	e.g.	e.g.	FW	_	43	dep
42	,	,	,	_	43	punct
43	drug4	drug4	NN	_	32	dep
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	.	.	.	_	4	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	using	use	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	studied	study	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	trials	trial	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	2	dobj
5	to	to	TO	_	6	mark
6	delay	delay	VB	_	4	acl
7	the	the	DT	_	8	det
8	absorption	absorption	NN	_	6	dobj
9	of	of	IN	_	13	case
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	13	amod
12	oral	oral	JJ	_	13	amod
13	medications	medication	NNS	_	8	nmod
14	.	.	.	_	2	punct

1	When	when	WRB	_	14	advmod
2	the	the	DT	_	4	det
3	rapid	rapid	JJ	_	4	amod
4	onset	onset	NN	_	14	nsubj
5	of	of	IN	_	10	case
6	a	a	DT	_	10	det
7	concomitant	concomitant	JJ	_	10	amod
8	orally	orally	RB	_	9	advmod
9	administered	administer	VBN	_	10	amod
10	agent	agent	NN	_	4	nmod
11	is	be	VBZ	_	14	cop
12	a	a	DT	_	14	det
13	critical	critical	JJ	_	14	amod
14	determinant	determinant	NN	_	27	advcl
15	of	of	IN	_	16	case
16	effectiveness	effectiveness	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug1	drug1	NN	_	16	nmod
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	27	punct
23	the	the	DT	_	24	det
24	agent	agent	NN	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	administered	administer	VBN	_	0	ROOT
28	at	at	IN	_	29	case
29	least	least	JJS	_	30	nmod:npmod
30	1	1	CD	_	31	nummod
31	hour	hour	NN	_	27	dobj
32	prior	prior	RB	_	36	advmod
33	to	to	TO	_	36	case
34	or	or	CC	_	33	cc
35	2	2	CD	_	33	conj
36	hours	hour	NNS	_	27	nmod
37	after	after	IN	_	39	case
38	drug2	drug2	NN	_	39	compound
39	injection	injection	NN	_	36	nmod
40	.	.	.	_	27	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	the	the	DT	_	7	det
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	14	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	alter	alter	VB	_	0	ROOT
15	the	the	DT	_	18	det
16	adverse	adverse	JJ	_	18	amod
17	event	event	NN	_	18	compound
18	profile	profile	NN	_	14	dobj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	.	.	.	_	14	punct

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	assess	assess	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	effect	effect	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	kinetics	kinetics	NNS	_	11	nmod
17	of	of	IN	_	19	case
18	oral	oral	JJ	_	19	amod
19	drug2	drug2	NN	_	16	nmod
20	.	.	.	_	7	punct

1	Mixing	mix	VBG	_	11	csubjpass
2	drug1	drug1	NN	_	1	dobj
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	The	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	parameters	parameter	NNS	_	2	dep
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	were	be	VBD	_	11	auxpass
11	altered	alter	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	mixed	mix	VBN	_	11	advcl
14	with	with	IN	_	13	nmod
15	regular	regular	JJ	_	14	dep
16	,	,	,	_	15	punct
17	NPH	nph	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	70/30	70/30	CD	_	22	nummod
21	premixed	premixed	JJ	_	22	amod
22	formulations	formulation	NNS	_	15	conj
23	of	of	IN	_	25	case
24	recombinant	recombinant	JJ	_	25	amod
25	drug4	drug4	NN	_	22	nmod
26	immediately	immediately	RB	_	27	advmod
27	prior	prior	RB	_	15	advmod
28	to	to	TO	_	29	case
29	injection	injection	NN	_	27	nmod
30	.	.	.	_	11	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	drug1	drug1	NN	_	9	nsubj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	cop
9	mixed	mixed	JJ	_	0	ROOT
10	and	and	CC	_	9	cc
11	must	must	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	9	conj
14	separately	separately	RB	_	13	advmod
15	.	.	.	_	9	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	26	advcl
6	for	for	IN	_	9	case
7	the	the	DT	_	9	det
8	metabolic	metabolic	JJ	_	9	amod
9	pathways	pathway	NNS	_	5	nmod
10	involving	involve	VBG	_	9	acl
11	CYP2D6	cyp2d6	NN	_	14	compound
12	and	and	CC	_	11	cc
13	CYP1A2	cyp1a2	NN	_	11	conj
14	enzymes	enzyme	NNS	_	10	dobj
15	,	,	,	_	14	punct
16	inhibition	inhibition	NN	_	14	conj
17	or	or	CC	_	14	cc
18	induction	induction	NN	_	14	conj
19	of	of	IN	_	20	case
20	either	either	DT	_	18	nmod
21	of	of	IN	_	23	case
22	these	these	DT	_	23	det
23	enzymes	enzyme	NNS	_	20	nmod
24	would	would	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	expected	expect	VBN	_	0	ROOT
27	to	to	TO	_	28	mark
28	alter	alter	VB	_	26	xcomp
29	drug2	drug2	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	.	.	.	_	26	punct

1	In	in	IN	_	7	case
2	a	a	DT	_	7	det
3	formal	formal	JJ	_	7	amod
4	,	,	,	_	7	punct
5	single-dose	single-dose	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	study	study	NN	_	19	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	n	n	NN	_	10	nsubj
10	=	=	JJ	_	7	dep
11	6	6	CD	_	12	nummod
12	males	male	NNS	_	10	dobj
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	the	the	DT	_	15	det
15	clearance	clearance	NN	_	19	nsubjpass
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	was	be	VBD	_	19	auxpass
19	decreased	decrease	VBN	_	0	ROOT
20	by	by	IN	_	22	case
21	38	38	CD	_	22	nummod
22	%	%	NN	_	19	nmod
23	following	follow	VBG	_	25	case
24	the	the	DT	_	25	det
25	coadministration	coadministration	NN	_	19	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	,	,	,	_	27	punct
29	an	a	DT	_	30	det
30	inhibitor	inhibitor	NN	_	27	appos
31	of	of	IN	_	32	case
32	CYP1A2	cyp1a2	NN	_	30	nmod
33	.	.	.	_	19	punct

1	In	in	IN	_	4	case
2	another	another	DT	_	4	det
3	formal	formal	JJ	_	4	amod
4	study	study	NN	_	25	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	n	n	NN	_	7	nsubj
7	=	=	JJ	_	4	dep
8	8	8	CD	_	9	nummod
9	extensive	extensive	JJ	_	7	dobj
10	and	and	CC	_	9	cc
11	n	n	NN	_	9	conj
12	=	=	JJ	_	9	dep
13	7	7	CD	_	15	nummod
14	poor	poor	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	12	dep
16	of	of	IN	_	17	case
17	CYP2D6	cyp2d6	NN	_	15	nmod
18	-RRB-	-rrb-	-RRB-	_	7	punct
19	,	,	,	_	25	punct
20	coadministration	coadministration	NN	_	25	nsubj
21	of	of	IN	_	22	case
22	drug1	drug1	NN	_	20	nmod
23	did	do	VBD	_	25	aux
24	not	not	RB	_	25	neg
25	alter	alter	VB	_	0	ROOT
26	the	the	DT	_	27	det
27	kinetics	kinetics	NNS	_	25	dobj
28	of	of	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	in	in	IN	_	35	case
31	the	the	DT	_	35	det
32	poor	poor	JJ	_	35	amod
33	CYP2D6	cyp2d6	NN	_	35	compound
34	metabolizer	metabolizer	NN	_	35	compound
35	group	group	NN	_	25	nmod
36	.	.	.	_	25	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	5	det
4	metabolic	metabolic	JJ	_	5	amod
5	clearance	clearance	NN	_	2	root
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	12	case
9	the	the	DT	_	12	det
10	extensive	extensive	JJ	_	12	amod
11	metabolizer	metabolizer	NN	_	12	compound
12	phenotype	phenotype	NN	_	5	nmod
13	decreased	decrease	VBN	_	12	acl
14	by	by	IN	_	17	case
15	about	about	RB	_	16	advmod
16	70	70	CD	_	17	nummod
17	%	%	NN	_	13	nmod
18	making	make	VBG	_	12	acl
19	the	the	DT	_	24	det
20	poor	poor	JJ	_	24	amod
21	and	and	CC	_	20	cc
22	extensive	extensive	JJ	_	20	conj
23	metabolizer	metabolizer	NN	_	24	compound
24	groups	group	NNS	_	25	nsubj
25	indistinguishable	indistinguishable	JJ	_	18	xcomp
26	.	.	.	_	5	punct

1	In	in	IN	_	6	case
2	this	this	DT	_	6	det
3	crossover	crossover	NN	_	6	compound
4	steady	steady	JJ	_	6	amod
5	state	state	NN	_	6	compound
6	study	study	NN	_	13	nmod
7	,	,	,	_	13	punct
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	13	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	were	be	VBD	_	13	cop
13	unaffected	unaffected	JJ	_	0	ROOT
14	in	in	IN	_	16	case
15	either	either	CC	_	16	det
16	phenotype	phenotype	NN	_	13	nmod
17	by	by	IN	_	19	case
18	the	the	DT	_	19	det
19	coadministration	coadministration	NN	_	13	nmod
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	13	punct

1	Addition	addition	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	13	case
10	further	further	JJ	_	13	amod
11	electrocardiographic	electrocardiographic	JJ	_	13	amod
12	parameters	parameter	NNS	_	13	compound
13	changes	change	NNS	_	8	nmod
14	of	of	IN	_	15	case
15	QRS	QRS	NNP	_	13	nmod
16	,	,	,	_	15	punct
17	QTc	QTc	NNP	_	15	conj
18	,	,	,	_	15	punct
19	RR	RR	NNP	_	15	conj
20	,	,	,	_	15	punct
21	and	and	CC	_	15	cc
22	PR	pr	NN	_	23	compound
23	intervals	interval	NNS	_	15	conj
24	than	than	IN	_	25	case
25	drug3	drug3	NN	_	13	nmod
26	alone	alone	RB	_	25	advmod
27	.	.	.	_	8	punct

1	When	when	WRB	_	13	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	13	nsubjpass
4	of	of	IN	_	5	case
5	either	either	DT	_	3	nmod
6	of	of	IN	_	9	case
7	these	these	DT	_	9	det
8	two	two	CD	_	9	nummod
9	drugs	drug	NNS	_	5	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	3	nmod
12	is	be	VBZ	_	13	auxpass
13	initiated	initiate	VBN	_	22	advcl
14	,	,	,	_	22	punct
15	the	the	DT	_	16	det
16	dose	dose	NN	_	22	nsubjpass
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	should	should	MD	_	22	aux
20	be	be	VB	_	22	auxpass
21	slowly	slowly	RB	_	22	advmod
22	titrated	titrate	VBN	_	0	ROOT
23	to	to	TO	_	25	case
24	desired	desire	VBN	_	25	amod
25	effect	effect	NN	_	22	nmod
26	.	.	.	_	22	punct

1	In	in	IN	_	7	case
2	a	a	DT	_	7	det
3	large	large	JJ	_	7	amod
4	compassionate	compassionate	JJ	_	7	amod
5	use	use	NN	_	7	compound
6	program	program	NN	_	7	compound
7	drug1	drug1	NN	_	10	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	concurrently	concurrently	RB	_	10	advmod
12	with	with	IN	_	15	case
13	commonly	commonly	RB	_	14	advmod
14	employed	employ	VBN	_	15	amod
15	antianginal	antianginal	JJ	_	10	nmod
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug3	drug3	NN	_	15	conj
21	without	without	IN	_	23	case
22	observed	observe	VBN	_	23	amod
23	interactions	interaction	NNS	_	10	nmod
24	.	.	.	_	10	punct

1	A	a	DT	_	2	det
2	variety	variety	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug2	drug2	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	were	be	VBD	_	12	auxpass
11	also	also	RB	_	12	advmod
12	added	add	VBN	_	0	ROOT
13	,	,	,	_	12	punct
14	sometimes	sometimes	RB	_	12	advmod
15	with	with	IN	_	17	case
16	improved	improve	VBN	_	17	amod
17	control	control	NN	_	14	nmod
18	of	of	IN	_	20	case
19	ventricular	ventricular	JJ	_	20	amod
20	ectopy	ectopy	NN	_	17	nmod
21	.	.	.	_	12	punct

1	When	when	WRB	_	15	advmod
2	drug1	drug1	NN	_	15	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	hepatic	hepatic	JJ	_	7	amod
6	enzyme	enzyme	NN	_	7	compound
7	inducers	inducer	NNS	_	2	conj
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug2	drug2	NN	_	2	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	taken	take	VBN	_	20	advcl
16	concurrently	concurrently	RB	_	15	advmod
17	with	with	IN	_	18	case
18	drug4	drug4	NN	_	15	nmod
19	,	,	,	_	20	punct
20	lowered	lower	VBD	_	26	csubjpass
21	drug5	drug5	NN	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	levels	level	NNS	_	20	dobj
24	have	have	VBP	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	0	ROOT
27	.	.	.	_	26	punct

1	Monitoring	monitoring	NN	_	7	nsubjpass
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	levels	level	NNS	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	during	during	IN	_	11	case
9	such	such	JJ	_	11	amod
10	concurrent	concurrent	JJ	_	11	amod
11	use	use	NN	_	7	nmod
12	to	to	TO	_	13	mark
13	avoid	avoid	VB	_	11	acl
14	ineffective	ineffective	JJ	_	15	amod
15	therapy	therapy	NN	_	13	dobj
16	.	.	.	_	7	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	formal	formal	JJ	_	4	amod
4	study	study	NN	_	8	nmod
5	,	,	,	_	8	punct
6	drug1	drug1	NN	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	shown	show	VBN	_	0	ROOT
9	not	not	RB	_	11	neg
10	to	to	TO	_	11	mark
11	affect	affect	VB	_	8	xcomp
12	drug2	drug2	NN	_	14	compound
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	.	.	.	_	8	punct

1	ECG	ecg	NN	_	2	compound
2	intervals	interval	NNS	_	13	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	PR	pr	NN	_	2	dep
5	,	,	,	_	4	punct
6	QRS	QRS	NNP	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	QT	qt	NN	_	4	conj
10	-RRB-	-rrb-	-RRB-	_	4	punct
11	were	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	affected	affect	VBN	_	0	ROOT
14	by	by	IN	_	16	case
15	concurrent	concurrent	JJ	_	16	amod
16	drug1	drug1	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug3	drug3	NN	_	16	conj
21	,	,	,	_	16	punct
22	or	or	CC	_	16	cc
23	drug4	drug4	NN	_	16	conj
24	.	.	.	_	13	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	increase	increase	VB	_	9	ccomp
12	,	,	,	_	11	punct
13	decrease	decrease	VB	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	leave	leave	VB	_	11	conj
17	unchanged	unchanged	JJ	_	20	amod
18	drug3	drug3	NN	_	20	compound
19	plasma	plasma	NN	_	20	compound
20	levels	level	NNS	_	16	dobj
21	;	;	:	_	9	punct

1	therefore	therefore	RB	_	5	advmod
2	patients	patient	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	followed	follow	VBN	_	0	ROOT
6	carefully	carefully	RB	_	5	advmod
7	during	during	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	therapy	therapy	NN	_	5	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	serum	serum	NN	_	7	compound
6	drug2	drug2	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	but	but	CC	_	4	cc
9	drug3	drug3	NN	_	23	nsubjpass
10	,	,	,	_	9	punct
11	when	when	WRB	_	12	advmod
12	used	use	VBN	_	9	acl:relcl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	gastrointestinal	gastrointestinal	JJ	_	16	amod
16	symptoms	symptom	NNS	_	14	dobj
17	due	due	JJ	_	14	advmod
18	to	to	TO	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	,	,	,	_	9	punct
21	has	have	VBZ	_	23	aux
22	been	be	VBN	_	23	auxpass
23	reported	report	VBN	_	4	conj
24	to	to	TO	_	28	case
25	lower	lower	JJR	_	28	amod
26	serum	serum	NN	_	28	compound
27	drug5	drug5	NN	_	28	compound
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	13	case
10	increased	increase	VBN	_	13	amod
11	plasma	plasma	NN	_	13	compound
12	drug3	drug3	NN	_	13	compound
13	levels	level	NNS	_	8	nmod
14	.	.	.	_	8	punct

1	One	one	CD	_	3	nummod
2	controlled	controlled	JJ	_	3	amod
3	study	study	NN	_	8	nsubj
4	in	in	IN	_	7	case
5	eight	eight	CD	_	7	nummod
6	normal	normal	JJ	_	7	amod
7	subjects	subject	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	a	a	DT	_	13	det
10	72	72	CD	_	11	compound
11	%	%	NN	_	13	amod
12	mean	mean	JJ	_	13	amod
13	increase	increase	NN	_	8	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	range	range	NN	_	13	dep
16	35-136	35-136	CD	_	17	nummod
17	%	%	NN	_	15	dep
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	in	in	IN	_	22	case
20	plasma	plasma	NN	_	22	compound
21	drug1	drug1	NN	_	22	compound
22	levels	level	NNS	_	13	nmod
23	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	at	at	IN	_	9	case
6	the	the	DT	_	9	det
7	first	first	JJ	_	9	amod
8	test	test	NN	_	9	compound
9	point	point	NN	_	4	nmod
10	which	which	WDT	_	14	nsubj
11	was	be	VBD	_	14	cop
12	the	the	DT	_	14	det
13	second	second	JJ	_	14	amod
14	day	day	NN	_	9	acl:relcl
15	after	after	IN	_	16	mark
16	starting	start	VBG	_	14	acl
17	drug1	drug1	NN	_	16	dobj
18	.	.	.	_	4	punct
19	drug2	drug2	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	22	nsubj
22	returned	return	VBD	_	4	parataxis
23	to	to	TO	_	24	case
24	pre	pre	JJ	_	22	nmod
25	-	-	:	_	22	punct
26	drug3	drug3	NN	_	27	compound
27	values	value	NNS	_	22	dobj
28	within	within	IN	_	30	case
29	48	48	CD	_	30	nummod
30	hours	hour	NNS	_	27	nmod
31	after	after	IN	_	32	mark
32	discontinuing	discontinue	VBG	_	27	acl
33	drug4	drug4	NN	_	32	dobj
34	.	.	.	_	4	punct
35	If	if	IN	_	39	mark
36	drug5	drug5	NN	_	39	nsubj
37	and	and	CC	_	36	cc
38	drug6	drug6	NN	_	36	conj
39	are	be	VBP	_	50	advcl
40	to	to	TO	_	42	mark
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	39	xcomp
43	concurrently	concurrently	RB	_	42	advmod
44	,	,	,	_	50	punct
45	drug7	drug7	NN	_	47	compound
46	blood	blood	NN	_	47	compound
47	levels	level	NNS	_	50	nsubjpass
48	should	should	MD	_	50	aux
49	be	be	VB	_	50	auxpass
50	monitored	monitor	VBN	_	4	parataxis
51	,	,	,	_	50	punct
52	particularly	particularly	RB	_	58	advmod
53	when	when	WRB	_	58	advmod
54	the	the	DT	_	56	det
55	drug8	drug8	NN	_	56	compound
56	dose	dose	NN	_	58	nsubjpass
57	is	be	VBZ	_	58	auxpass
58	changed	change	VBN	_	50	advcl
59	.	.	.	_	4	punct

1	An	a	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	adjustment	adjustment	NN	_	9	nsubjpass
4	in	in	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	dose	dose	NN	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Additionally	additionally	RB	_	20	advmod
2	,	,	,	_	20	punct
3	in	in	IN	_	6	case
4	one	one	CD	_	6	nummod
5	controlled	controlled	JJ	_	6	amod
6	study	study	NN	_	20	nmod
7	in	in	IN	_	10	case
8	five	five	CD	_	10	nummod
9	normal	normal	JJ	_	10	amod
10	subjects	subject	NNS	_	6	nmod
11	and	and	CC	_	10	cc
12	seven	seven	CD	_	13	nummod
13	patients	patient	NNS	_	10	conj
14	,	,	,	_	20	punct
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	20	nsubjpass
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	was	be	VBD	_	20	auxpass
20	decreased	decrease	VBN	_	0	ROOT
21	50	50	CD	_	22	nummod
22	%	%	NN	_	20	dobj
23	following	follow	VBG	_	25	case
24	the	the	DT	_	25	det
25	administration	administration	NN	_	20	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	20	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	oral	oral	JJ	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	The	the	DT	_	7	det
7	activity	activity	NN	_	13	nsubjpass
8	of	of	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	potentiated	potentiate	VBN	_	1	dep
14	by	by	IN	_	16	case
15	anti-vitamin-K	anti-vitamin-k	JJ	_	16	amod
16	activity	activity	NN	_	13	nmod
17	attributed	attribute	VBN	_	16	acl
18	to	to	TO	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	1	punct

1	-	-	:	_	6	punct
2	drug1	drug1	NN	_	6	dep
3	:	:	:	_	6	punct
4	Hyperthyroidism	hyperthyroidism	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	cause	cause	VB	_	0	ROOT
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	clearance	clearance	NN	_	6	dobj
10	of	of	IN	_	12	case
11	beta	beta	NN	_	12	compound
12	ratio	ratio	NN	_	9	nmod
13	.	.	.	_	6	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	reduction	reduction	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	needed	need	VBN	_	0	ROOT
9	when	when	WRB	_	13	advmod
10	a	a	DT	_	12	det
11	hyperthyroid	hyperthyroid	JJ	_	12	amod
12	patient	patient	NN	_	13	nsubj
13	becomes	become	VBZ	_	8	advcl
14	euthyroid	euthyroid	JJ	_	13	xcomp
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serum	serum	NN	_	5	compound
4	digitalis	digitalis	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	1	appos
9	when	when	WRB	_	17	advmod
10	hyperthyroid	hyperthyroid	JJ	_	11	amod
11	patients	patient	NNS	_	17	nsubj
12	on	on	IN	_	16	case
13	a	a	DT	_	16	det
14	stable	stable	JJ	_	16	amod
15	drug2	drug2	NN	_	16	compound
16	regimen	regimen	NNS	_	11	nmod
17	become	become	VBP	_	8	advcl
18	euthyroid	euthyroid	JJ	_	17	xcomp
19	;	;	:	_	1	punct

1	reduced	reduce	VBN	_	2	amod
2	dosage	dosage	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	required	require	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	clearance	clearance	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	1	parataxis
7	when	when	WRB	_	15	advmod
8	hyperthyroid	hyperthyroid	JJ	_	9	amod
9	patients	patient	NNS	_	15	nsubj
10	on	on	IN	_	14	case
11	a	a	DT	_	14	det
12	stable	stable	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	regimen	regimen	NNS	_	9	nmod
15	become	become	VBP	_	6	advcl
16	euthyroid	euthyroid	JJ	_	15	xcomp
17	;	;	:	_	1	punct

1	a	a	DT	_	3	det
2	reduced	reduce	VBN	_	3	amod
3	dose	dose	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	needed	need	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	because	because	IN	_	13	mark
11	they	they	PRP	_	13	nsubj
12	may	may	MD	_	13	aux
13	have	have	VB	_	6	advcl
14	additive	additive	JJ	_	15	amod
15	effects	effect	NNS	_	13	dobj
16	.	.	.	_	6	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	4	punct

1	They	they	PRP	_	4	nsubj
2	can	can	MD	_	4	aux
3	either	either	RB	_	4	advmod
4	increase	increase	VB	_	0	ROOT
5	or	or	CC	_	4	cc
6	decrease	decrease	VB	_	4	conj
7	the	the	DT	_	8	det
8	effect	effect	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	4	punct

1	Those	those	DT	_	2	det
2	drug1	drug1	NN	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	drug2	drug2	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug3	drug3	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	drug4	drug4	NN	_	4	conj
10	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	which	which	WDT	_	12	nsubj
12	include	include	VBP	_	9	acl:relcl
13	some	some	DT	_	14	det
14	drug2	drug2	NN	_	12	dobj
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	certain	certain	JJ	_	20	amod
19	heart	heart	NN	_	20	compound
20	medicines	medicine	NNS	_	14	conj
21	,	,	,	_	14	punct
22	birth	birth	NN	_	24	compound
23	control	control	NN	_	24	compound
24	pills	pill	NNS	_	14	conj
25	,	,	,	_	14	punct
26	drug4	drug4	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug5	drug5	NN	_	14	conj
29	and	and	CC	_	14	cc
30	drug6	drug6	NN	_	14	conj
31	Please	please	UH	_	32	discourse
32	note	note	VB	_	4	xcomp
33	that	that	IN	_	36	mark
34	drug7	drug7	NN	_	36	nsubj
35	may	may	MD	_	36	aux
36	interact	interact	VB	_	32	ccomp
37	with	with	IN	_	39	case
38	other	other	JJ	_	39	amod
39	drugs	drug	NNS	_	36	nmod
40	that	that	WDT	_	43	nsubjpass
41	are	be	VBP	_	43	auxpass
42	not	not	RB	_	43	neg
43	listed	list	VBN	_	39	acl:relcl
44	here	here	RB	_	43	advmod
45	.	.	.	_	4	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	:	:	:	_	1	punct
6	The	the	DT	_	8	det
7	depressant	depressant	NN	_	8	compound
8	effects	effect	NNS	_	12	nsubjpass
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	are	be	VBP	_	12	auxpass
12	potentiated	potentiate	VBN	_	1	dep
13	by	by	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	12	nmod
16	of	of	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drug3	drug3	NN	_	15	nmod
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug4	drug4	NN	_	18	nmod
22	,	,	,	_	21	punct
23	drug5	drug5	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug6	drug6	NN	_	21	conj
26	,	,	,	_	21	punct
27	or	or	CC	_	21	cc
28	drug7	drug7	NN	_	21	conj
29	.	.	.	_	12	punct

1	Use	use	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	conjunction	conjunction	NN	_	1	nmod
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	respiratory	respiratory	JJ	_	15	amod
15	depression	depression	NN	_	12	nmod
16	,	,	,	_	15	punct
17	hypotension	hypotension	NN	_	15	conj
18	and	and	CC	_	15	cc
19	profound	profound	JJ	_	20	amod
20	sedation	sedation	NN	_	15	conj
21	or	or	CC	_	20	cc
22	coma	coma	NN	_	20	conj
23	.	.	.	_	10	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	drug2	drug2	NN	_	21	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	i.e.	i.e.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug3	drug3	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	9	punct
15	or	or	CC	_	9	cc
16	drug6	drug6	NN	_	9	conj
17	-RRB-	-rrb-	-RRB-	_	9	punct
18	should	should	MD	_	21	aux
19	NOT	not	RB	_	21	advmod
20	be	be	VB	_	21	auxpass
21	administered	administer	VBN	_	1	dep
22	to	to	TO	_	23	case
23	patients	patient	NNS	_	21	nmod
24	who	who	WP	_	26	nsubj
25	have	have	VBP	_	26	aux
26	received	receive	VBN	_	23	acl:relcl
27	or	or	CC	_	26	cc
28	are	be	VBP	_	29	aux
29	receiving	receive	VBG	_	26	conj
30	a	a	DT	_	31	det
31	course	course	NN	_	26	dobj
32	of	of	IN	_	33	case
33	therapy	therapy	NN	_	31	nmod
34	with	with	IN	_	37	case
35	a	a	DT	_	37	det
36	proof	proof	NN	_	37	compound
37	drug7	drug7	NN	_	26	nmod
38	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	the	the	DT	_	7	det
6	mixed	mixed	JJ	_	7	amod
7	agonist/antagonist	agonist/antagonist	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	alter	alter	VB	_	0	ROOT
10	the	the	DT	_	12	det
11	analgesic	analgesic	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	or	or	CC	_	9	cc
14	may	may	MD	_	15	aux
15	precipitate	precipitate	VB	_	9	conj
16	withdrawal	withdrawal	NN	_	17	compound
17	symptoms	symptom	NNS	_	15	dobj
18	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Use	Use	NNP	_	0	ROOT
2	cautiously	cautiously	RB	_	5	advmod
3	with	with	IN	_	5	case
4	pressor	pressor	NN	_	5	compound
5	agents	agent	NNS	_	1	nmod
6	.	.	.	_	1	punct

1	Human	human	JJ	_	3	amod
2	pharmacologic	pharmacologic	JJ	_	3	amod
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	9	mark
7	drug1	drug1	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	inhibit	inhibit	VB	_	5	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug4	drug4	NN	_	15	dep
18	,	,	,	_	17	punct
19	drug5	drug5	NN	_	17	appos
20	,	,	,	_	17	punct
21	drug6	drug6	NN	_	17	appos
22	-RRB-	-rrb-	-RRB-	_	17	punct
23	,	,	,	_	13	punct
24	drug7	drug7	NN	_	13	conj
25	,	,	,	_	13	punct
26	and	and	CC	_	13	cc
27	drug8	drug8	NN	_	13	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug9	drug9	NN	_	27	dep
30	,	,	,	_	29	punct
31	drug10	drug10	NN	_	29	appos
32	,	,	,	_	29	punct
33	drug11	drug11	NN	_	29	appos
34	-RRB-	-rrb-	-RRB-	_	29	punct
35	.	.	.	_	5	punct

1	Downward	downward	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustments	adjustment	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	when	when	WRB	_	11	advmod
11	given	give	VBN	_	9	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	11	nmod
15	.	.	.	_	9	punct

1	Serious	serious	JJ	_	3	amod
2	adverse	adverse	JJ	_	3	amod
3	events	event	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	6	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	6	punct
13	although	although	IN	_	21	mark
14	no	no	DT	_	15	neg
15	causality	causality	NN	_	21	nsubjpass
16	for	for	IN	_	18	case
17	the	the	DT	_	18	det
18	combination	combination	NN	_	15	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	established	establish	VBN	_	6	advcl
22	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	19	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	centrally	centrally	RB	_	13	advmod
13	acting	act	VBG	_	14	amod
14	drug3	drug3	NN	_	9	conj
15	has	have	VBZ	_	19	aux
16	not	not	RB	_	19	neg
17	been	be	VBN	_	19	auxpass
18	systemically	systemically	RB	_	19	advmod
19	evaluated	evaluate	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Co-administration	co-administration	NN	_	37	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	strong	strong	JJ	_	6	amod
6	inhibitors	inhibitor	NNS	_	1	nmod
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	CYP3A4	cyp3a4	NN	_	10	compound
10	family	family	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug2	drug2	NN	_	6	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug7	drug7	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug8	drug8	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug9	drug9	NN	_	14	conj
29	,	,	,	_	14	punct
30	drug10	drug10	NN	_	14	conj
31	,	,	,	_	14	punct
32	drug11	drug11	NN	_	14	conj
33	,	,	,	_	14	punct
34	drug12	drug12	NN	_	14	appos
35	-RRB-	-rrb-	-RRB-	_	14	punct
36	may	may	MD	_	37	aux
37	increases	increase	NNS	_	0	ROOT
38	drug13	drug13	NN	_	39	compound
39	concentrations	concentration	NNS	_	37	dobj
40	.	.	.	_	37	punct

1	Grapefruit	grapefruit	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	increase	increase	VB	_	0	ROOT
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Co-administration	co-administration	NN	_	32	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	inducers	inducer	NNS	_	1	nmod
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	CYP3A4	cyp3a4	NN	_	9	compound
9	family	family	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug2	drug2	NN	_	5	dep
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug6	drug6	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug7	drug7	NN	_	13	conj
24	,	,	,	_	13	punct
25	drug8	drug8	NN	_	13	conj
26	,	,	,	_	13	punct
27	St.	St.	NNP	_	29	compound
28	Johns	Johns	NNP	_	29	compound
29	Wort	Wort	NNP	_	13	appos
30	-RRB-	-rrb-	-RRB-	_	13	punct
31	may	may	MD	_	32	aux
32	decrease	decrease	VB	_	0	ROOT
33	drug9	drug9	NN	_	34	compound
34	concentrations	concentration	NNS	_	32	dobj
35	.	.	.	_	32	punct

1	St.	St.	NNP	_	0	ROOT

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	unpredictably	unpredictably	RB	_	4	advmod
9	.	.	.	_	4	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	not	not	RB	_	6	neg
6	take	take	VB	_	0	ROOT
7	St.	St.	NNP	_	6	dobj

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	0	ROOT
3	concomitantly	concomitantly	RB	_	2	advmod
4	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	dose	dose	NN	_	3	compound
3	modification	modification	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	using	use	VBG	_	7	acl
9	concomitant	concomitant	JJ	_	11	amod
10	CYP3A4	cyp3a4	NN	_	11	compound
11	inhibitors	inhibitor	NNS	_	8	dobj
12	or	or	CC	_	11	cc
13	inducers	inducer	NNS	_	11	conj
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Excessive	excessive	JJ	_	4	amod
4	reductions	reduction	NNS	_	9	nsubj
5	in	in	IN	_	7	case
6	blood	blood	NN	_	7	compound
7	pressure	pressure	NN	_	4	nmod
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	1	dep
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	14	case
13	diuretic	diuretic	JJ	_	14	amod
14	therapy	therapy	NN	_	11	nmod
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	started	start	VBN	_	9	advcl
19	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	minimized	minimize	VBN	_	0	ROOT
11	by	by	IN	_	12	mark
12	discontinuing	discontinue	VBG	_	10	advcl
13	diuretic	diuretic	JJ	_	14	amod
14	therapy	therapy	NN	_	12	dobj
15	for	for	IN	_	17	case
16	several	several	JJ	_	17	amod
17	days	day	NNS	_	12	nmod
18	or	or	CC	_	12	cc
19	cautiously	cautiously	RB	_	20	advmod
20	increasing	increase	VBG	_	12	conj
21	salt	salt	NN	_	22	compound
22	intake	intake	NN	_	20	dobj
23	before	before	IN	_	24	case
24	initiation	initiation	NN	_	20	nmod
25	of	of	IN	_	26	case
26	treatment	treatment	NN	_	24	nmod
27	with	with	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	.	.	.	_	10	punct
30	If	if	IN	_	34	mark
31	this	this	DT	_	34	nsubj
32	is	be	VBZ	_	34	cop
33	not	not	RB	_	34	neg
34	possible	possible	JJ	_	43	advcl
35	,	,	,	_	43	punct
36	the	the	DT	_	38	det
37	starting	start	VBG	_	38	amod
38	dose	dose	NN	_	43	nsubjpass
39	of	of	IN	_	40	case
40	drug3	drug3	NN	_	38	nmod
41	should	should	MD	_	43	aux
42	be	be	VB	_	43	auxpass
43	reduced	reduce	VBN	_	10	parataxis
44	.	.	.	_	43	punct
45	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	:	:	:	_	2	punct
6	drug3	drug3	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	increase	increase	VB	_	2	dep
9	serum	serum	NN	_	10	compound
10	potassium	potassium	NN	_	8	dobj
11	because	because	IN	_	13	mark
12	it	it	PRP	_	13	nsubj
13	decreases	decrease	VBZ	_	8	advcl
14	aldosterone	aldosterone	NN	_	15	compound
15	secretion	secretion	NN	_	13	dobj
16	.	.	.	_	2	punct

1	Use	use	NN	_	18	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	appos
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	5	punct
11	or	or	CC	_	3	cc
12	drug5	drug5	NN	_	13	compound
13	supplements	supplement	NNS	_	3	conj
14	concomitantly	concomitantly	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug6	drug6	NN	_	14	nmod
17	can	can	MD	_	18	aux
18	increase	increase	VB	_	0	ROOT
19	the	the	DT	_	20	det
20	risk	risk	NN	_	18	dobj
21	of	of	IN	_	22	case
22	hyperkalemia	hyperkalemia	NN	_	20	nmod
23	.	.	.	_	18	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	26	csubjpass
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	patient	patient	NN	_	23	nmod:poss
21	's	's	POS	_	20	case
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	17	conj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	monitored	monitor	VBN	_	0	ROOT
27	.	.	.	_	26	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubj
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	failed	fail	VBD	_	2	dep
9	to	to	TO	_	10	mark
10	identify	identify	VB	_	8	xcomp
11	any	any	DT	_	14	det
12	clinically	clinically	RB	_	13	advmod
13	important	important	JJ	_	14	amod
14	effect	effect	NN	_	10	dobj
15	on	on	IN	_	18	case
16	the	the	DT	_	18	det
17	serum	serum	NN	_	18	compound
18	concentrations	concentration	NNS	_	14	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	drug3	drug3	NN	_	18	nmod
22	or	or	CC	_	18	cc
23	on	on	IN	_	26	case
24	its	its	PRP$	_	26	nmod:poss
25	anticoagulant	anticoagulant	JJ	_	26	amod
26	effect	effect	NN	_	18	conj
27	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	6	amod
4	serum	serum	NN	_	6	compound
5	drug2	drug2	NN	_	6	compound
6	levels	level	NNS	_	14	nsubjpass
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	toxicity	toxicity	NN	_	8	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	appos
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	drug4	drug4	NN	_	17	dobj
19	during	during	IN	_	20	case
20	therapy	therapy	NN	_	17	nmod
21	with	with	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	frequent	frequent	JJ	_	11	amod
11	monitoring	monitoring	NN	_	17	nsubjpass
12	of	of	IN	_	15	case
13	serum	serum	NN	_	15	compound
14	drug1	drug1	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	5	conj
18	.	.	.	_	5	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	also	also	RB	_	6	advmod
6	used	use	VBN	_	15	advcl
7	,	,	,	_	15	punct
8	the	the	DT	_	9	det
9	risk	risk	NN	_	15	nsubjpass
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	increased	increase	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Other	other	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	No	no	DT	_	8	neg
5	clinically	clinically	RB	_	6	advmod
6	important	important	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interactions	interaction	NNS	_	9	nsubj
9	occurred	occur	VBD	_	2	dep
10	when	when	WRB	_	13	advmod
11	drug1	drug1	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	concomitantly	concomitantly	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	or	or	CC	_	16	cc
21	drug4	drug4	NN	_	16	conj
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	4	nmod
8	concomitantly	concomitantly	RB	_	10	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	,	,	,	_	10	punct
18	oral	oral	JJ	_	19	amod
19	drug6	drug6	NN	_	10	conj
20	,	,	,	_	10	punct
21	and	and	CC	_	10	cc
22	cholesterol-lowering	cholesterol-lowering	JJ	_	23	amod
23	agents	agent	NNS	_	10	conj
24	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	of	of	IN	_	9	case
6	clinically	clinically	RB	_	7	advmod
7	important	important	JJ	_	9	amod
8	adverse	adverse	JJ	_	9	amod
9	interactions	interaction	NNS	_	4	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	primarily	primarily	RB	_	4	advmod
4	eliminated	eliminate	VBN	_	0	ROOT
5	unchanged	unchanged	JJ	_	4	xcomp
6	renally	renally	RB	_	4	advmod
7	as	as	IN	_	9	case
8	a	a	DT	_	9	det
9	result	result	NN	_	4	nmod
10	of	of	IN	_	12	case
11	glomerular	glomerular	JJ	_	12	amod
12	filtration	filtration	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	tubular	tubular	JJ	_	15	amod
15	secretion	secretion	NN	_	12	conj
16	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	nephrotoxic	nephrotoxic	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	could	could	MD	_	7	aux
7	result	result	VB	_	0	ROOT
8	in	in	IN	_	10	case
9	delayed	delay	VBN	_	10	amod
10	clearance	clearance	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	7	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	17	nsubj
3	of	of	IN	_	4	case
4	substances	substance	NNS	_	2	nmod
5	that	that	WDT	_	9	nsubjpass
6	are	be	VBP	_	9	auxpass
7	also	also	RB	_	9	advmod
8	tubularly	tubularly	RB	_	9	advmod
9	secreted	secrete	VBN	_	4	acl:relcl
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug1	drug1	NN	_	9	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	could	could	MD	_	17	aux
16	potentially	potentially	RB	_	17	advmod
17	result	result	VB	_	0	ROOT
18	in	in	IN	_	20	case
19	delayed	delay	VBN	_	20	amod
20	clearance	clearance	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	17	punct

1	Although	although	IN	_	10	mark
2	drug1	drug1	NN	_	10	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	400	400	CD	_	6	nummod
5	mg	mg	NN	_	6	compound
6	qid	qid	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	29	advcl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	18	case
16	normal	normal	JJ	_	18	amod
17	renal	renal	JJ	_	18	amod
18	function	function	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	creatinine	creatinine	NN	_	21	compound
21	clearance	clearance	NN	_	18	dep
22	80	80	CD	_	23	nummod
23	mL/min	ml/min	NN	_	21	dep
24	-RRB-	-rrb-	-RRB-	_	21	punct
25	,	,	,	_	29	punct
26	caution	caution	NN	_	29	nsubjpass
27	should	should	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	used	use	VBN	_	0	ROOT
30	when	when	WRB	_	31	advmod
31	administering	administer	VBG	_	29	advcl
32	drug3	drug3	NN	_	31	dobj
33	concurrently	concurrently	RB	_	32	advmod
34	with	with	IN	_	35	case
35	drug4	drug4	NN	_	31	nmod
36	to	to	TO	_	37	case
37	patients	patient	NNS	_	35	nmod
38	with	with	IN	_	39	case
39	mild	mild	JJ	_	37	nmod
40	to	to	TO	_	43	case
41	moderate	moderate	JJ	_	43	amod
42	renal	renal	JJ	_	43	amod
43	insufficiency	insufficiency	NN	_	39	nmod
44	-LRB-	-lrb-	-LRB-	_	46	punct
45	creatinine	creatinine	NN	_	46	compound
46	clearance	clearance	NN	_	39	dep
47	from	from	IN	_	51	case
48	45	45	CD	_	50	compound
49	to	to	TO	_	50	dep
50	79	79	CD	_	51	nummod
51	mL/min	ml/min	NN	_	46	nmod
52	-RRB-	-rrb-	-RRB-	_	46	punct
53	.	.	.	_	29	punct

1	Patients	patient	NNS	_	9	nsubj
2	with	with	IN	_	3	case
3	mild	mild	JJ	_	1	nmod
4	to	to	TO	_	7	case
5	moderate	moderate	JJ	_	7	amod
6	renal	renal	JJ	_	7	amod
7	insufficiency	insufficiency	NN	_	3	nmod
8	should	should	MD	_	9	aux
9	avoid	avoid	VB	_	0	ROOT
10	taking	take	VBG	_	9	xcomp
11	drug1	drug1	NN	_	10	dobj
12	with	with	IN	_	15	case
13	short	short	JJ	_	15	amod
14	elimination	elimination	NN	_	15	compound
15	half-lives	half-life	NNS	_	10	nmod
16	for	for	IN	_	18	case
17	a	a	DT	_	18	det
18	period	period	NN	_	10	nmod
19	of	of	IN	_	21	case
20	2	2	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	before	before	RB	_	10	advmod
23	,	,	,	_	22	punct
24	the	the	DT	_	25	det
25	day	day	NN	_	23	root
26	of	of	IN	_	25	acl
27	,	,	,	_	25	punct
28	and	and	CC	_	25	cc
29	2	2	CD	_	30	nummod
30	days	day	NNS	_	25	conj
31	following	follow	VBG	_	32	case
32	administration	administration	NN	_	30	nmod
33	of	of	IN	_	34	case
34	drug2	drug2	NN	_	32	nmod
35	.	.	.	_	25	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	absence	absence	NN	_	23	nmod
4	of	of	IN	_	5	case
5	data	datum	NNS	_	3	nmod
6	regarding	regard	VBG	_	8	case
7	potential	potential	JJ	_	8	amod
8	interaction	interaction	NN	_	5	nmod
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	with	with	IN	_	15	case
14	longer	longer	JJR	_	15	amod
15	half-lives	half-life	NNS	_	8	nmod
16	,	,	,	_	23	punct
17	all	all	DT	_	18	det
18	patients	patient	NNS	_	23	nsubj
19	taking	take	VBG	_	18	acl
20	these	these	DT	_	21	det
21	drug3	drug3	NN	_	19	dobj
22	should	should	MD	_	23	aux
23	interrupt	interrupt	VB	_	0	ROOT
24	dosing	dosing	NN	_	23	dobj
25	for	for	IN	_	29	case
26	at	at	IN	_	27	case
27	least	least	JJS	_	28	nmod:npmod
28	5	5	CD	_	29	nummod
29	days	day	NNS	_	23	nmod
30	before	before	RB	_	29	advmod
31	,	,	,	_	23	punct
32	the	the	DT	_	33	det
33	day	day	NN	_	31	root
34	of	of	IN	_	33	acl
35	,	,	,	_	33	punct
36	and	and	CC	_	33	cc
37	2	2	CD	_	38	nummod
38	days	day	NNS	_	33	conj
39	following	follow	VBG	_	41	case
40	drug4	drug4	NN	_	41	compound
41	administration	administration	NN	_	38	nmod
42	.	.	.	_	33	punct

1	If	if	IN	_	8	mark
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	an	a	DT	_	6	det
6	drug1	drug1	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	necessary	necessary	JJ	_	13	advcl
9	,	,	,	_	13	punct
10	patients	patient	NNS	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	for	for	IN	_	16	case
16	toxicity	toxicity	NN	_	13	nmod
17	,	,	,	_	13	punct
18	especially	especially	RB	_	19	advmod
19	myelosuppression	myelosuppression	NN	_	13	dobj
20	,	,	,	_	19	punct
21	renal	renal	JJ	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	gastrointestinal	gastrointestinal	JJ	_	25	amod
25	toxicity	toxicity	NN	_	19	conj
26	.	.	.	_	13	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	None	none	NN	_	0	ROOT
5	known	know	VBN	_	4	acl
6	.	.	.	_	4	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	time	time	NN	_	10	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	suitable	suitable	JJ	_	7	amod
6	anticoagulation	anticoagulation	JJ	_	7	amod
7	test	test	NN	_	2	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	if	if	IN	_	14	mark
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	administered	administer	VBN	_	10	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	render	render	VB	_	0	ROOT
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	13	nsubj
12	less	less	RBR	_	13	advmod
13	effective	effective	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	10	neg
7	reported	report	VBN	_	10	amod
8	drug-laboratory	drug-laboratory	JJ	_	10	amod
9	test	test	NN	_	10	compound
10	interactions	interaction	NNS	_	5	nsubj
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	3	nmod
8	:	:	:	_	7	punct
9	drug2	drug2	NN	_	7	dep
10	and	and	CC	_	9	cc
11	other	other	JJ	_	12	amod
12	drug3	drug3	NN	_	9	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	may	may	MD	_	15	aux
15	lower	lower	VB	_	7	dep
16	drug4	drug4	NN	_	17	compound
17	levels	level	NNS	_	15	dobj
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	,	,	,	_	7	punct
20	drug5	drug5	NN	_	7	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	bioavailability	bioavailability	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	oral	oral	JJ	_	25	amod
25	drug6	drug6	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	increased	increase	VBN	_	20	acl:relcl
28	with	with	IN	_	29	case
29	coadministration	coadministration	NN	_	27	nmod
30	-RRB-	-rrb-	-RRB-	_	7	punct
31	,	,	,	_	7	punct
32	drug7	drug7	NN	_	7	appos
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	may	may	MD	_	35	aux
35	decrease	decrease	VB	_	32	dep
36	drug8	drug8	NN	_	37	compound
37	levels	level	NNS	_	35	dobj
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	,	,	,	_	32	punct
40	drug9	drug9	NN	_	42	compound
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	reports	report	NNS	_	58	nsubj
43	of	of	IN	_	45	case
44	psychotic	psychotic	JJ	_	45	amod
45	episodes	episode	NNS	_	42	nmod
46	when	when	WRB	_	47	advmod
47	coadministered	coadminister	VBN	_	58	dep
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	,	,	,	_	58	punct
50	drug10	drug10	NN	_	58	dep
51	-LRB-	-lrb-	-LRB-	_	52	punct
52	coadministration	coadministration	NN	_	58	nsubj
53	of	of	IN	_	54	case
54	drug11	drug11	NN	_	52	nmod
55	with	with	IN	_	56	case
56	drug12	drug12	NN	_	52	nmod
57	can	can	MD	_	58	aux
58	inhibit	inhibit	VB	_	32	dep
59	ovarian	ovarian	JJ	_	60	amod
60	function	function	NN	_	58	dobj
61	in	in	IN	_	62	case
62	women	woman	NNS	_	60	nmod
63	-RRB-	-rrb-	-RRB-	_	58	punct
64	,	,	,	_	32	punct
65	drug13	drug13	NN	_	32	conj
66	and	and	CC	_	32	cc
67	other	other	JJ	_	69	amod
68	sedating	sedate	VBG	_	69	amod
69	drugs	drug	NNS	_	32	conj
70	-LRB-	-lrb-	-LRB-	_	72	punct
71	may	may	MD	_	72	aux
72	result	result	VB	_	7	dep
73	in	in	IN	_	75	case
74	additive	additive	JJ	_	75	amod
75	sedation	sedation	NN	_	72	nmod
76	and	and	CC	_	72	cc
77	an	a	DT	_	79	det
78	increased	increase	VBN	_	79	amod
79	incidence	incidence	NN	_	72	conj
80	of	of	IN	_	82	case
81	adverse	adverse	JJ	_	82	amod
82	effects	effect	NNS	_	79	nmod
83	-RRB-	-rrb-	-RRB-	_	72	punct
84	,	,	,	_	3	punct
85	and	and	CC	_	3	cc
86	drug14	drug14	NN	_	88	compound
87	-LRB-	-lrb-	-LRB-	_	88	punct
88	coadministration	coadministration	NN	_	94	nsubj
89	of	of	IN	_	90	case
90	drug15	drug15	NN	_	88	nmod
91	and	and	CC	_	90	cc
92	drug16	drug16	NN	_	90	conj
93	may	may	MD	_	94	aux
94	interfere	interfere	VB	_	3	conj
95	with	with	IN	_	97	case
96	the	the	DT	_	97	det
97	efficacy	efficacy	NN	_	94	nmod
98	of	of	IN	_	100	case
99	the	the	DT	_	100	det
100	drug17	drug17	NN	_	97	nmod
101	-RRB-	-rrb-	-RRB-	_	3	punct
102	.	.	.	_	3	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	with	with	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	13	mark
10	drug1	drug1	NN	_	13	nsubj
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	inhibit	inhibit	VB	_	8	ccomp
14	the	the	DT	_	15	det
15	metabolism	metabolism	NN	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	and	and	CC	_	17	cc
24	drug5	drug5	NN	_	17	conj
25	.	.	.	_	8	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	6	nsubj
4	have	have	VBP	_	6	aux
5	also	also	RB	_	6	advmod
6	shown	show	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	inhibits	inhibit	VBZ	_	6	ccomp
10	CYP2D6-mediated	cyp2d6-mediated	JJ	_	11	amod
11	metabolism	metabolism	NN	_	9	dobj
12	.	.	.	_	6	punct

1	This	this	DT	_	6	nsubj
2	may	may	MD	_	6	aux
3	be	be	VB	_	6	cop
4	of	of	IN	_	6	case
5	clinical	clinical	JJ	_	6	amod
6	relevance	relevance	NN	_	0	ROOT
7	for	for	IN	_	8	case
8	compounds	compound	NNS	_	6	nmod
9	predominantly	predominantly	RB	_	10	advmod
10	metabolized	metabolize	VBN	_	8	acl
11	by	by	IN	_	13	case
12	this	this	DT	_	13	det
13	enzyme	enzyme	NN	_	10	nmod
14	,	,	,	_	8	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug1	drug1	NN	_	8	nmod
18	,	,	,	_	17	punct
19	-	-	:	_	17	punct
20	blockers	blocker	NNS	_	17	dep
21	,	,	,	_	17	punct
22	drug2	drug2	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug3	drug3	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	drug4	drug4	NN	_	17	conj
29	,	,	,	_	6	punct
30	if	if	IN	_	32	mark
31	they	they	PRP	_	32	nsubj
32	have	have	VBP	_	6	advcl
33	a	a	DT	_	36	det
34	narrow	narrow	JJ	_	36	amod
35	therapeutic	therapeutic	JJ	_	36	amod
36	window	window	NN	_	32	dobj
37	.	.	.	_	6	punct

1	In	in	FW	_	5	amod
2	vivo	vivo	FW	_	1	dep
3	drug-drug	drug-drug	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	11	nsubj
6	conducted	conduct	VBN	_	5	acl
7	in	in	IN	_	10	case
8	normal	normal	JJ	_	10	amod
9	volunteer	volunteer	NN	_	10	compound
10	subjects	subject	NNS	_	6	nmod
11	showed	show	VBD	_	0	ROOT
12	that	that	IN	_	16	mark
13	drug1	drug1	NN	_	16	nsubj
14	does	do	VBZ	_	16	aux
15	not	not	RB	_	16	neg
16	affect	affect	VB	_	11	ccomp
17	the	the	DT	_	18	det
18	clearance	clearance	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	.	.	.	_	11	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	19	19	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	15	15	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	spontaneous	spontaneous	JJ	_	5	amod
5	reports	report	NNS	_	0	ROOT
6	of	of	IN	_	7	case
7	increase	increase	NN	_	5	nmod
8	or	or	CC	_	5	cc
9	decrease	decrease	VB	_	5	conj
10	in	in	IN	_	12	case
11	prothrombin	prothrombin	NN	_	12	compound
12	times	time	NNS	_	9	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	concomitantly	concomitantly	RB	_	16	advmod
16	taking	take	VBG	_	14	acl
17	oral	oral	JJ	_	18	amod
18	drug1	drug1	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	5	punct
22	however	however	RB	_	5	advmod
23	,	,	,	_	5	punct
24	a	a	DT	_	26	det
25	causal	causal	JJ	_	26	amod
26	relationship	relationship	NN	_	36	nsubjpass
27	between	between	IN	_	29	case
28	drug3	drug3	NN	_	29	compound
29	Tablets	tablet	NNS	_	26	nmod
30	and	and	CC	_	29	cc
31	these	these	DT	_	32	det
32	changes	change	NNS	_	29	conj
33	has	have	VBZ	_	36	aux
34	not	not	RB	_	36	neg
35	been	be	VBN	_	36	auxpass
36	established	establish	VBN	_	5	dep
37	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	clearance	clearance	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	increased	increase	VBN	_	25	dep
5	100	100	CD	_	6	nummod
6	%	%	NN	_	4	dobj
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	,	,	,	_	8	punct
10	a	a	DT	_	13	det
11	CyP450	cyp450	NN	_	13	compound
12	enzyme	enzyme	NN	_	13	compound
13	inducer	inducer	NN	_	8	appos
14	,	,	,	_	4	punct
15	and	and	CC	_	4	cc
16	decreased	decrease	VBD	_	4	conj
17	33	33	CD	_	18	nummod
18	%	%	NN	_	16	dobj
19	by	by	IN	_	20	case
20	drug3	drug3	NN	_	16	nmod
21	,	,	,	_	25	punct
22	a	a	DT	_	25	det
23	CyP450	cyp450	NN	_	25	compound
24	enzyme	enzyme	NN	_	25	compound
25	inhibitor	inhibitor	NN	_	0	ROOT
26	.	.	.	_	25	punct

1	drug1	drug1	NN	_	2	compound
2	clearance	clearance	NN	_	4	nsubj
3	is	be	VBZ	_	4	aux
4	unaffected	unaffected	JJ	_	0	ROOT
5	by	by	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	information	information	NN	_	2	nsubj
5	available	available	JJ	_	4	amod
6	from	from	IN	_	10	case
7	adequate	adequate	JJ	_	10	amod
8	drug-drug	drug-drug	JJ	_	10	amod
9	interaction	interaction	NN	_	10	compound
10	studies	study	NNS	_	5	nmod
11	with	with	IN	_	14	case
12	the	the	DT	_	14	det
13	following	follow	VBG	_	14	amod
14	classes	class	NNS	_	10	nmod
15	of	of	IN	_	16	case
16	drugs	drug	NNS	_	14	nmod
17	:	:	:	_	2	punct
18	oral	oral	JJ	_	19	amod
19	drug1	drug1	NN	_	2	dep
20	,	,	,	_	19	punct
21	hormone	hormone	NN	_	23	compound
22	replacement	replacement	NN	_	23	compound
23	therapies	therapy	NNS	_	19	conj
24	,	,	,	_	19	punct
25	drug2	drug2	NN	_	19	conj
26	,	,	,	_	19	punct
27	drug3	drug3	NN	_	19	conj
28	,	,	,	_	19	punct
29	drug4	drug4	NN	_	19	conj
30	,	,	,	_	19	punct
31	drug5	drug5	NN	_	19	conj
32	,	,	,	_	19	punct
33	drug6	drug6	NN	_	19	conj
34	,	,	,	_	19	punct
35	and	and	CC	_	19	cc
36	drug7	drug7	NN	_	19	conj
37	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	demonstrate	demonstrate	VB	_	0	ROOT
4	additive	additive	JJ	_	5	amod
5	toxicity	toxicity	NN	_	3	dobj
6	when	when	WRB	_	7	advmod
7	used	use	VBN	_	5	acl:relcl
8	in	in	IN	_	9	case
9	combination	combination	NN	_	7	nmod
10	with	with	IN	_	13	case
11	other	other	JJ	_	13	amod
12	cytotoxic	cytotoxic	JJ	_	13	amod
13	drugs	drug	NNS	_	9	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	prolong	prolong	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	elimination	elimination	NN	_	9	compound
9	half-life	half-life	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	4	cc
13	may	may	MD	_	14	aux
14	lead	lead	VB	_	4	conj
15	to	to	TO	_	19	case
16	severe	severe	JJ	_	19	amod
17	bone	bone	NN	_	19	compound
18	marrow	marrow	NN	_	19	compound
19	suppression	suppression	NN	_	14	nmod
20	;	;	:	_	4	punct

1	a	a	DT	_	2	det
2	reduction	reduction	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	drug1	drug1	NN	_	6	compound
6	dosage	dosage	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	drug2	drug2	NN	_	12	dobj
14	concurrently	concurrently	RB	_	12	advmod
15	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	one	one	CD	_	13	nummod
13	case	case	NN	_	10	nmod
14	to	to	TO	_	15	mark
15	result	result	VB	_	10	xcomp
16	in	in	IN	_	19	case
17	reduced	reduce	VBN	_	19	amod
18	drug3	drug3	NN	_	19	compound
19	cytotoxicity	cytotoxicity	NN	_	15	nmod
20	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	dep
5	a	a	DT	_	8	det
6	60	60	CD	_	7	compound
7	%	%	NN	_	8	amod
8	reduction	reduction	NN	_	4	dobj
9	in	in	IN	_	14	case
10	the	the	DT	_	14	det
11	absorption	absorption	NN	_	14	amod
12	and	and	CC	_	11	cc
13	enterohepatic	enterohepatic	JJ	_	11	conj
14	cycling	cycling	NN	_	8	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	and	and	CC	_	4	cc
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	4	conj
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	coadministration	coadministration	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	assessed	assess	VBN	_	1	appos
13	under	under	IN	_	15	case
14	chronic	chronic	JJ	_	15	amod
15	conditions	condition	NNS	_	12	nmod
16	.	.	.	_	1	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	10	10	CD	_	4	nummod
4	%	%	NN	_	5	nsubj
5	decreases	decrease	VBZ	_	0	ROOT
6	in	in	IN	_	8	case
7	prothrombin	prothrombin	NN	_	8	compound
8	time	time	NN	_	5	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	observed	observe	VBN	_	5	ccomp
12	in	in	IN	_	14	case
13	single-dose	single-dose	JJ	_	14	amod
14	studies	study	NNS	_	11	nmod
15	.	.	.	_	5	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	given	give	VBN	_	13	advcl
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	13	punct
9	prothrombin	prothrombin	NN	_	10	compound
10	time	time	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Other	other	JJ	_	4	amod
2	Highly	Highly	NNP	_	4	compound
3	Protein-Bound	Protein-Bound	NNP	_	4	compound
4	Drugs	Drugs	NNPS	_	0	ROOT
5	:	:	:	_	4	punct
6	drug1	drug1	NN	_	12	nsubjpass
7	is	be	VBZ	_	12	auxpass
8	more	more	JJR	_	10	advmod
9	than	than	IN	_	8	mwe
10	95	95	CD	_	11	nummod
11	%	%	NN	_	12	dep
12	bound	bind	VBD	_	4	dep
13	to	to	TO	_	15	case
14	plasma	plasma	NN	_	15	compound
15	proteins	protein	NNS	_	12	nmod
16	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	affect	affect	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	binding	binding	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	drug4	drug4	NN	_	11	conj
17	.	.	.	_	7	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	coadministered	coadminister	VBN	_	4	advcl
9	with	with	IN	_	13	case
10	other	other	JJ	_	13	amod
11	highly	highly	RB	_	12	advmod
12	protein-bound	protein-bound	JJ	_	13	amod
13	drugs	drug	NNS	_	8	nmod
14	,	,	,	_	13	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug2	drug2	NN	_	13	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	drug5	drug5	NN	_	17	conj
24	,	,	,	_	17	punct
25	drug6	drug6	NN	_	17	conj
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	drug7	drug7	NN	_	17	conj
29	.	.	.	_	4	punct

1	See	see	VB	_	0	ROOT
2	also	also	RB	_	3	advmod
3	CLINICAL	clinical	JJ	_	4	amod
4	PHARMACOLOGY	pharmacology	NN	_	1	dobj
5	,	,	,	_	1	punct
6	Drug-Drug	Drug-Drug	NNP	_	7	compound
7	Interactions	interaction	NNS	_	5	root

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	increased	increase	VBN	_	9	amod
9	thrombocytopenia	thrombocytopenia	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	6	punct
12	drug2	drug2	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	increased	increase	VBN	_	15	amod
15	nephrotoxicity	nephrotoxicity	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	6	punct
18	drug3	drug3	NN	_	6	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	increased	increase	VBN	_	22	amod
21	hypoglycemic	hypoglycemic	JJ	_	22	amod
22	response	response	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	6	punct
25	drug4	drug4	NN	_	6	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	increased	increase	VBN	_	29	amod
28	anticoagulant	anticoagulant	JJ	_	29	amod
29	effect	effect	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	6	punct
32	drug5	drug5	NN	_	6	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	decreased	decrease	VBN	_	36	amod
35	renal	renal	JJ	_	36	amod
36	excretion	excretion	NN	_	32	dep
37	of	of	IN	_	38	case
38	drug6	drug6	NN	_	36	nmod
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	,	,	,	_	6	punct
41	drug7	drug7	NN	_	6	conj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	decreased	decrease	VBN	_	45	amod
44	hepatic	hepatic	JJ	_	45	amod
45	clearance	clearance	NN	_	41	dep
46	of	of	IN	_	47	case
47	drug8	drug8	NN	_	45	nmod
48	-RRB-	-rrb-	-RRB-	_	45	punct
49	.	.	.	_	4	punct

1	drug1	drug1	NN	_	21	nsubjpass
2	,	,	,	_	1	punct
3	such	such	JJ	_	6	case
4	as	as	IN	_	3	mwe
5	the	the	DT	_	6	det
6	drug2	drug2	NN	_	1	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug3	drug3	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug4	drug4	NN	_	8	appos
11	,	,	,	_	8	punct
12	drug5	drug5	NN	_	8	appos
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	or	or	CC	_	6	cc
15	drug6	drug6	NN	_	6	conj
16	,	,	,	_	1	punct
17	ordinarily	ordinarily	RB	_	21	advmod
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	administered	administer	VBN	_	0	ROOT
22	concurrently	concurrently	RB	_	21	advmod
23	with	with	IN	_	24	case
24	drug7	drug7	NN	_	21	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	a	a	DT	_	27	det
27	drug8	drug8	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	;	;	:	_	21	punct

1	these	these	DT	_	2	det
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	diminish	diminish	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effectiveness	effectiveness	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Because	because	IN	_	7	mark
2	drug1	drug1	NN	_	7	nsubjpass
3	is	be	VBZ	_	7	auxpass
4	approximately	approximately	RB	_	5	advmod
5	90	90	CD	_	6	nummod
6	%	%	NN	_	7	nsubjpass
7	bound	bind	VBD	_	15	advcl
8	to	to	TO	_	10	case
9	plasma	plasma	NN	_	10	compound
10	proteins	protein	NNS	_	7	nmod
11	,	,	,	_	15	punct
12	caution	caution	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	exercised	exercise	VBN	_	0	ROOT
16	if	if	IN	_	19	mark
17	drug2	drug2	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	coadministered	coadminister	VBN	_	15	advcl
20	with	with	IN	_	22	case
21	other	other	JJ	_	22	amod
22	drugs	drug	NNS	_	19	nmod
23	known	know	VBN	_	22	acl
24	to	to	TO	_	25	mark
25	affect	affect	VB	_	23	xcomp
26	protein	protein	NN	_	27	compound
27	binding	binding	NN	_	25	dobj
28	.	.	.	_	15	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Women	woman	NNS	_	9	nsubj
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	2	dep
10	a	a	DT	_	12	det
11	significant	significant	JJ	_	12	amod
12	increase	increase	NN	_	9	dobj
13	in	in	IN	_	16	case
14	plasma	plasma	NN	_	16	compound
15	drug2	drug2	NN	_	16	compound
16	levels	level	NNS	_	12	nmod
17	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	motility	motility	NN	_	2	nmod
8	are	be	VBP	_	9	auxpass
9	antagonized	antagonize	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	.	.	.	_	9	punct

1	Additive	additive	JJ	_	3	amod
2	sedative	sedative	JJ	_	3	amod
3	effects	effect	NNS	_	5	nsubj
4	can	can	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	given	give	VBN	_	5	advcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug5	drug5	NN	_	11	conj
18	,	,	,	_	11	punct
19	or	or	CC	_	11	cc
20	drug6	drug6	NN	_	11	conj
21	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	finding	finding	NN	_	0	ROOT
3	that	that	IN	_	12	mark
4	drug1	drug1	NN	_	6	compound
5	releases	release	NNS	_	6	compound
6	catecholamines	catecholamine	NNS	_	12	nsubj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	essential	essential	JJ	_	11	amod
11	hypertension	hypertension	NN	_	8	nmod
12	suggests	suggest	VBZ	_	2	ccomp
13	that	that	IN	_	17	mark
14	it	it	PRP	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	used	use	VBN	_	12	ccomp
18	cautiously	cautiously	RB	_	17	advmod
19	,	,	,	_	17	punct
20	if	if	IN	_	22	mark
21	at	at	IN	_	22	case
22	all	all	DT	_	17	advcl
23	,	,	,	_	17	punct
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	17	nmod
26	receiving	receive	VBG	_	25	acl
27	drug2	drug2	NN	_	26	dobj
28	.	.	.	_	2	punct

1	Absorption	absorption	NN	_	9	nsubjpass
2	of	of	IN	_	3	case
3	drugs	drug	NNS	_	1	nmod
4	from	from	IN	_	6	case
5	the	the	DT	_	6	det
6	stomach	stomach	NN	_	1	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	diminished	diminish	VBN	_	0	ROOT
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug1	drug1	NN	_	9	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	9	nmod
17	,	,	,	_	9	punct
18	whereas	whereas	IN	_	9	dep
19	the	the	DT	_	20	det
20	rate	rate	NN	_	33	nsubjpass
21	and/or	and/or	CC	_	20	cc
22	extent	extent	NN	_	20	conj
23	of	of	IN	_	24	case
24	absorption	absorption	NN	_	20	nmod
25	of	of	IN	_	26	case
26	drugs	drug	NNS	_	24	nmod
27	from	from	IN	_	30	case
28	the	the	DT	_	30	det
29	small	small	JJ	_	30	amod
30	bowel	bowel	NN	_	26	nmod
31	may	may	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	increased	increase	VBN	_	9	parataxis
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	drug3	drug3	NN	_	33	dep
38	,	,	,	_	37	punct
39	drug4	drug4	NN	_	37	conj
40	,	,	,	_	37	punct
41	drug5	drug5	NN	_	37	conj
42	,	,	,	_	37	punct
43	drug6	drug6	NN	_	37	conj
44	,	,	,	_	37	punct
45	drug7	drug7	NN	_	37	appos
46	-RRB-	-rrb-	-RRB-	_	37	punct
47	.	.	.	_	9	punct

1	Gastroparesis	gastroparesis	NN	_	8	nsubj
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	gastric	gastric	JJ	_	4	amod
4	stasis	stasis	NN	_	1	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	responsible	responsible	JJ	_	0	ROOT
9	for	for	IN	_	12	case
10	poor	poor	JJ	_	12	amod
11	diabetic	diabetic	JJ	_	12	amod
12	control	control	NN	_	8	nmod
13	in	in	IN	_	15	case
14	some	some	DT	_	15	det
15	patients	patient	NNS	_	12	nmod
16	.	.	.	_	8	punct

1	Exogenously	exogenously	RB	_	2	advmod
2	administered	administer	VBN	_	3	amod
3	drug1	drug1	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	begin	begin	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	act	act	VB	_	5	xcomp
8	before	before	IN	_	11	mark
9	food	food	NN	_	11	nsubj
10	has	have	VBZ	_	11	aux
11	left	leave	VBN	_	7	advcl
12	the	the	DT	_	13	det
13	stomach	stomach	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	lead	lead	VB	_	11	conj
16	to	to	TO	_	17	case
17	hypoglycemia	hypoglycemia	NN	_	15	nmod
18	.	.	.	_	5	punct

1	Because	because	IN	_	7	mark
2	the	the	DT	_	3	det
3	action	action	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	will	will	MD	_	7	aux
7	influence	influence	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	delivery	delivery	NN	_	7	dobj
10	of	of	IN	_	11	case
11	food	food	NN	_	9	nmod
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	intestines	intestine	NNS	_	9	nmod
15	and	and	CC	_	7	cc
16	thus	thus	RB	_	29	advmod
17	the	the	DT	_	18	det
18	rate	rate	NN	_	29	nsubj
19	of	of	IN	_	20	case
20	absorption	absorption	NN	_	18	nmod
21	,	,	,	_	18	punct
22	drug2	drug2	NN	_	23	compound
23	dosage	dosage	NN	_	18	appos
24	or	or	CC	_	23	cc
25	timing	timing	NN	_	23	conj
26	of	of	IN	_	27	case
27	dosage	dosage	NN	_	23	nmod
28	may	may	MD	_	29	aux
29	require	require	VB	_	7	conj
30	adjustment	adjustment	NN	_	29	dobj
31	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	and	and	CC	_	8	cc
12	drug3	drug3	NN	_	8	conj
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	and	and	CC	_	14	cc
20	may	may	MD	_	21	aux
21	require	require	VB	_	14	conj
22	increases	increase	NNS	_	21	dobj
23	in	in	IN	_	25	case
24	drug5	drug5	NN	_	25	compound
25	dose	dose	NN	_	22	nmod
26	to	to	TO	_	27	mark
27	achieve	achieve	VB	_	21	xcomp
28	the	the	DT	_	30	det
29	desired	desire	VBN	_	30	amod
30	response	response	NN	_	27	dobj
31	.	.	.	_	14	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	their	they	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	drug2	drug2	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	drug1	drug1	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	drug3	drug3	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Co-administration	co-administration	NN	_	9	nsubj
2	of	of	IN	_	6	case
3	oral	oral	JJ	_	6	amod
4	drug1	drug1	NN	_	6	compound
5	200	200	CD	_	6	nummod
6	mg	mg	NN	_	1	nmod
7	twice	twice	RB	_	9	advmod
8	daily	daily	RB	_	9	advmod
9	increased	increase	VBN	_	0	ROOT
10	drug2	drug2	NN	_	13	compound
11	geometric	geometric	JJ	_	13	amod
12	mean	mean	NN	_	13	compound
13	AUC	auc	NN	_	9	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	0-24	0-24	CD	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	13	cc
18	Cmax	cmax	NN	_	13	conj
19	by	by	IN	_	21	case
20	81	81	CD	_	21	nummod
21	%	%	NN	_	18	nmod
22	after	after	IN	_	24	case
23	topical	topical	JJ	_	24	amod
24	application	application	NN	_	9	nmod
25	of	of	IN	_	27	case
26	drug3	drug3	NN	_	27	compound
27	ointment	ointment	NN	_	24	nmod
28	,	,	,	_	9	punct
29	1	1	CD	_	30	nummod
30	%	%	NN	_	9	dobj
31	on	on	IN	_	34	case
32	the	the	DT	_	34	det
33	abraded	abraded	JJ	_	34	amod
34	skin	skin	NN	_	30	nmod
35	of	of	IN	_	38	case
36	healthy	healthy	JJ	_	38	amod
37	adult	adult	JJ	_	38	amod
38	males	male	NNS	_	34	nmod
39	.	.	.	_	9	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	low	low	JJ	_	4	amod
4	systemic	systemic	JJ	_	5	amod
5	exposure	exposure	NN	_	19	nmod
6	to	to	TO	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	following	follow	VBG	_	10	case
9	topical	topical	JJ	_	10	amod
10	application	application	NN	_	5	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	,	,	,	_	19	punct
14	dosage	dosage	NN	_	15	compound
15	adjustments	adjustment	NNS	_	19	nsubj
16	for	for	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	are	be	VBP	_	19	cop
19	unnecessary	unnecessary	JJ	_	0	ROOT
20	when	when	WRB	_	21	advmod
21	co-administered	co-administer	VBN	_	19	advcl
22	with	with	IN	_	24	case
23	CYP3A4	cyp3a4	NN	_	24	compound
24	inhibitors	inhibitor	NNS	_	21	nmod
25	,	,	,	_	24	punct
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug3	drug3	NN	_	24	nmod
29	.	.	.	_	19	punct

1	Based	base	VBN	_	7	case
2	on	on	IN	_	7	case
3	in	in	FW	_	7	amod
4	vitro	vitro	FW	_	3	dep
5	P450	p450	NN	_	7	compound
6	inhibition	inhibition	NN	_	7	compound
7	studies	study	NNS	_	22	advcl
8	and	and	CC	_	7	cc
9	the	the	DT	_	12	det
10	low	low	JJ	_	12	amod
11	systemic	systemic	JJ	_	12	amod
12	exposure	exposure	NN	_	7	conj
13	observed	observe	VBN	_	12	acl
14	following	follow	VBG	_	16	case
15	topical	topical	JJ	_	16	amod
16	application	application	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	22	punct
20	drug2	drug2	NN	_	22	nsubj
21	is	be	VBZ	_	22	cop
22	unlikely	unlikely	JJ	_	0	ROOT
23	to	to	TO	_	24	mark
24	affect	affect	VB	_	22	xcomp
25	the	the	DT	_	26	det
26	metabolism	metabolism	NN	_	24	dobj
27	of	of	IN	_	30	case
28	other	other	JJ	_	30	amod
29	P450	p450	NN	_	30	compound
30	substrates	substrate	NNS	_	26	nmod
31	.	.	.	_	22	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	21	nsubjpass
3	of	of	IN	_	5	case
4	concurrent	concurrent	JJ	_	5	amod
5	application	application	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	11	amod
10	topical	topical	JJ	_	11	amod
11	products	product	NNS	_	7	conj
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	same	same	JJ	_	15	amod
15	area	area	NN	_	2	nmod
16	of	of	IN	_	17	case
17	skin	skin	NN	_	15	nmod
18	has	have	VBZ	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	drug3	drug3	NN	_	8	compound
8	type	type	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	5	punct
11	drug4	drug4	NN	_	5	conj
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug5	drug5	NN	_	11	dep
16	,	,	,	_	15	punct
17	drug6	drug6	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug7	drug7	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug8	drug8	NN	_	15	conj
22	,	,	,	_	15	punct
23	drug9	drug9	NN	_	15	conj
24	,	,	,	_	15	punct
25	drug10	drug10	NN	_	15	appos
26	-RRB-	-rrb-	-RRB-	_	15	punct
27	,	,	,	_	5	punct
28	drug11	drug11	NN	_	5	conj
29	,	,	,	_	5	punct
30	drug12	drug12	NN	_	5	conj
31	,	,	,	_	5	punct
32	drug13	drug13	NN	_	5	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	e.g.	e.g.	FW	_	36	dep
35	,	,	,	_	36	punct
36	drug14	drug14	NN	_	32	dep
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	,	,	,	_	5	punct
39	other	other	JJ	_	40	amod
40	drug15	drug15	NN	_	5	conj
41	,	,	,	_	5	punct
42	drug16	drug16	NN	_	43	compound
43	supplements	supplement	NNS	_	5	conj
44	,	,	,	_	5	punct
45	drug17	drug17	NN	_	5	conj
46	,	,	,	_	5	punct
47	drug18	drug18	NN	_	5	conj
48	-LRB-	-lrb-	-LRB-	_	51	punct
49	e.g.	e.g.	FW	_	51	dep
50	,	,	,	_	51	punct
51	drug19	drug19	NN	_	47	dep
52	-	-	:	_	51	punct
53	drug20	drug20	NN	_	51	dep
54	-RRB-	-rrb-	-RRB-	_	51	punct
55	,	,	,	_	5	punct
56	drug21	drug21	NN	_	5	conj
57	-LRB-	-lrb-	-LRB-	_	60	punct
58	e.g.	e.g.	FW	_	60	dep
59	,	,	,	_	60	punct
60	drug22	drug22	NN	_	56	dep
61	,	,	,	_	60	punct
62	drug23	drug23	NN	_	60	appos
63	-RRB-	-rrb-	-RRB-	_	60	punct
64	.	.	.	_	3	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	highly	highly	RB	_	5	advmod
4	protein	protein	NN	_	5	nmod:npmod
5	bound	bind	VBD	_	0	ROOT
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	therefore	therefore	RB	_	5	advmod
9	,	,	,	_	5	punct
10	might	might	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	5	ccomp
13	to	to	TO	_	14	mark
14	displace	displace	VB	_	12	xcomp
15	other	other	JJ	_	17	amod
16	protein-bound	protein-bound	JJ	_	17	amod
17	drugs	drug	NNS	_	14	dobj
18	.	.	.	_	5	punct

1	Although	although	IN	_	5	mark
2	this	this	DT	_	5	nsubj
3	has	have	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	occurred	occur	VBN	_	18	advcl
6	in	in	IN	_	9	case
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	studies	study	NNS	_	5	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	interactions	interaction	NNS	_	11	appos
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	since	since	IN	_	22	case
22	marketing	marketing	NN	_	20	nmod
23	,	,	,	_	20	punct
24	therefore	therefore	RB	_	20	advmod
25	,	,	,	_	20	punct
26	physicians	physician	NNS	_	29	nsubj
27	should	should	MD	_	29	aux
28	closely	closely	RB	_	29	advmod
29	monitor	monitor	VB	_	20	dep
30	patients	patient	NNS	_	29	dobj
31	for	for	IN	_	33	case
32	a	a	DT	_	33	det
33	change	change	NN	_	29	nmod
34	in	in	IN	_	36	case
35	dosage	dosage	NN	_	36	compound
36	requirements	requirement	NNS	_	33	nmod
37	when	when	WRB	_	38	advmod
38	administering	administer	VBG	_	29	advcl
39	drug4	drug4	NN	_	38	dobj
40	to	to	TO	_	41	case
41	patients	patient	NNS	_	38	nmod
42	on	on	IN	_	43	case
43	drug5	drug5	NN	_	41	nmod
44	and	and	CC	_	43	cc
45	other	other	JJ	_	48	amod
46	highly	highly	RB	_	47	advmod
47	protein-bound	protein-bound	JJ	_	48	amod
48	drugs	drug	NNS	_	43	conj
49	.	.	.	_	18	punct

1	Plasma	plasma	NN	_	2	compound
2	levels	level	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	depressed	depress	VBN	_	0	ROOT
7	to	to	TO	_	10	case
8	approximately	approximately	RB	_	9	advmod
9	80	80	CD	_	10	nummod
10	%	%	NN	_	6	nmod
11	of	of	IN	_	14	case
12	their	they	PRP$	_	14	nmod:poss
13	normal	normal	JJ	_	14	amod
14	values	value	NNS	_	10	nmod
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	administered	administer	VBN	_	6	advcl
19	in	in	IN	_	20	case
20	conjunction	conjunction	NN	_	18	nmod
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	3900	3900	CD	_	25	nummod
25	mg/day	mg/day	NN	_	22	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	6	punct
28	but	but	CC	_	6	cc
29	concomitant	concomitant	JJ	_	30	amod
30	administration	administration	NN	_	33	nsubj
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	has	have	VBZ	_	6	conj
34	no	no	DT	_	35	neg
35	effect	effect	NN	_	33	dobj
36	on	on	IN	_	39	case
37	drug5	drug5	NN	_	39	compound
38	plasma	plasma	NN	_	39	compound
39	levels	level	NNS	_	33	nmod
40	.	.	.	_	6	punct
41	drug6	drug6	NN	_	48	nsubjpass
42	,	,	,	_	41	punct
43	including	include	VBG	_	44	case
44	drug7	drug7	NN	_	41	nmod
45	,	,	,	_	41	punct
46	have	have	VBP	_	48	aux
47	been	be	VBN	_	48	auxpass
48	reported	report	VBN	_	6	parataxis
49	to	to	TO	_	50	mark
50	increase	increase	VB	_	48	xcomp
51	steady	steady	JJ	_	55	amod
52	state	state	NN	_	55	compound
53	plasma	plasma	NN	_	55	compound
54	drug8	drug8	NN	_	55	compound
55	levels	level	NNS	_	50	dobj
56	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	9	mark
5	plasma	plasma	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	3	ccomp
10	when	when	WRB	_	11	advmod
11	initiating	initiate	VBG	_	9	advcl
12	,	,	,	_	11	punct
13	adjusting	adjust	VBG	_	11	conj
14	and	and	CC	_	11	cc
15	discontinuing	discontinue	VBG	_	11	conj
16	drug2	drug2	NN	_	15	dobj
17	.	.	.	_	3	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	7	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	oral	oral	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	;	;	:	_	7	punct

1	monitor	monitor	NN	_	5	compound
2	and	and	CC	_	1	cc
3	adjust	adjust	VBP	_	1	conj
4	drug1	drug1	NN	_	5	compound
5	dosage	dosage	NN	_	0	ROOT
6	accordingly	accordingly	RB	_	5	advmod
7	.	.	.	_	5	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Physiologic	physiologic	JJ	_	6	amod
6	effects	effect	NNS	_	10	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	may	may	MD	_	10	aux
10	result	result	VB	_	3	dep
11	in	in	IN	_	14	case
12	decreased	decrease	VBN	_	14	amod
13	estradiol	estradiol	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	with	with	IN	_	16	case
16	radioimmunoassays	radioimmunoassay	NNS	_	14	nmod
17	for	for	IN	_	18	case
18	estradiol	estradiol	NN	_	16	nmod
19	,	,	,	_	10	punct
20	increased	increase	VBN	_	23	amod
21	plasma	plasma	NN	_	23	compound
22	calcium	calcium	NN	_	23	compound
23	concentrations	concentration	NNS	_	10	dobj
24	,	,	,	_	10	punct
25	and	and	CC	_	10	cc
26	increased	increase	VBD	_	10	conj
27	24-hour	24-hour	JJ	_	29	amod
28	urinary	urinary	JJ	_	29	amod
29	excretion	excretion	NN	_	26	dobj
30	of	of	IN	_	31	case
31	creatine	creatine	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	17-ketosteroids	17-ketosteroid	NNS	_	31	conj
34	.	.	.	_	3	punct

1	Although	although	IN	_	8	mark
2	a	a	DT	_	4	det
3	causal	causal	JJ	_	4	amod
4	relationship	relationship	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	established	establish	VBN	_	13	advcl
9	,	,	,	_	13	punct
10	there	there	EX	_	13	expl
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	cop
13	reports	report	NNS	_	0	ROOT
14	of	of	IN	_	15	case
15	bleeding	bleeding	NN	_	13	nmod
16	and/or	and/or	CC	_	15	cc
17	prolonged	prolonged	JJ	_	19	amod
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	15	conj
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	13	nmod
22	treated	treat	VBN	_	21	acl
23	with	with	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	with	with	IN	_	28	case
26	and	and	CC	_	25	cc
27	without	without	IN	_	25	conj
28	drug2	drug2	NN	_	24	nmod
29	or	or	CC	_	28	cc
30	drug3	drug3	NN	_	28	conj
31	.	.	.	_	13	punct

1	Patients	patient	NNS	_	5	nsubj
2	on	on	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	should	should	MD	_	5	aux
5	have	have	VB	_	0	ROOT
6	more	more	RBR	_	7	advmod
7	frequent	frequent	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	of	of	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	times	time	NNS	_	8	nmod
12	,	,	,	_	5	punct
13	while	while	IN	_	32	mark
14	patients	patient	NNS	_	32	nsubj
15	with	with	IN	_	18	case
16	other	other	JJ	_	18	amod
17	risk	risk	NN	_	18	compound
18	factors	factor	NNS	_	14	nmod
19	complicated	complicate	VBN	_	18	acl
20	by	by	IN	_	21	case
21	hemorrhage	hemorrhage	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	26	punct
23	e.g.	e.g.	FW	_	26	dep
24	,	,	,	_	26	punct
25	recent	recent	JJ	_	26	amod
26	surgery	surgery	NN	_	21	dep
27	,	,	,	_	26	punct
28	peptic	peptic	JJ	_	29	amod
29	ulceration	ulceration	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	should	should	MD	_	32	aux
32	have	have	VB	_	5	advcl
33	periodic	periodic	JJ	_	34	amod
34	examinations	examination	NNS	_	32	dobj
35	for	for	IN	_	36	case
36	bleeding	bleed	VBG	_	34	nmod
37	including	include	VBG	_	38	case
38	hematocrit	hematocrit	NN	_	36	nmod
39	and/or	and/or	CC	_	38	cc
40	hemoglobin	hemoglobin	NN	_	38	conj
41	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	10	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-	-	:	_	2	punct
8	containing	contain	VBG	_	2	acl
9	drugs	drug	NNS	_	8	dobj
10	leads	lead	VBZ	_	0	ROOT
11	to	to	TO	_	14	case
12	increased	increase	VBN	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	and	and	CC	_	14	cc
16	drug4	drug4	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	individuals	individual	NNS	_	14	nmod
21	.	.	.	_	10	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	be	be	VB	_	6	auxpass
5	closely	closely	RB	_	6	advmod
6	monitored	monitor	VBN	_	0	ROOT
7	for	for	IN	_	8	case
8	signs	sign	NNS	_	6	nmod
9	of	of	IN	_	10	case
10	toxicity	toxicity	NN	_	8	nmod
11	and	and	CC	_	6	cc
12	have	have	VBP	_	16	aux
13	their	they	PRP$	_	15	nmod:poss
14	drug1	drug1	NN	_	15	compound
15	dosage	dosage	NN	_	16	nsubj
16	adjusted	adjust	VBN	_	6	conj
17	as	as	RB	_	18	advmod
18	necessary	necessary	JJ	_	16	xcomp
19	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug5	drug5	NN	_	7	conj
14	,	,	,	_	7	punct
15	drug6	drug6	NN	_	7	conj
16	,	,	,	_	7	punct
17	and	and	CC	_	7	cc
18	drug7	drug7	NN	_	7	conj
19	,	,	,	_	4	punct
20	without	without	IN	_	22	case
21	observed	observe	VBN	_	22	amod
22	problems	problem	NNS	_	4	nmod
23	.	.	.	_	4	punct

1	Small	small	JJ	_	2	amod
2	decreases	decrease	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	blood	blood	NN	_	5	compound
5	pressure	pressure	NN	_	2	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	some	some	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	treated	treat	VBN	_	11	acl
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	;	;	:	_	8	punct

1	periodic	periodic	JJ	_	5	amod
2	systemic	systemic	JJ	_	5	amod
3	blood	blood	NN	_	5	compound
4	pressure	pressure	NN	_	5	compound
5	monitoring	monitoring	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	for	for	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	concomitant	concomitant	JJ	_	13	amod
12	antihypertensive	antihypertensive	JJ	_	13	amod
13	therapy	therapy	NN	_	10	dobj
14	.	.	.	_	7	punct

1	If	if	IN	_	2	mark
2	indicated	indicate	VBN	_	10	advcl
3	,	,	,	_	10	punct
4	dosage	dosage	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	drug1	drug1	NN	_	4	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	5	det
5	use	use	NN	_	31	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	Injection	injection	NN	_	7	dep
12	before	before	IN	_	13	case
13	drug3	drug3	NN	_	5	nmod
14	,	,	,	_	5	punct
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	purpose	purpose	NN	_	5	nmod
18	of	of	IN	_	19	mark
19	attenuating	attenuate	VBG	_	17	acl
20	some	some	DT	_	19	dobj
21	of	of	IN	_	24	case
22	the	the	DT	_	24	det
23	side	side	JJ	_	24	amod
24	effects	effect	NNS	_	20	nmod
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	,	,	,	_	5	punct
28	has	have	VBZ	_	31	aux
29	not	not	RB	_	31	neg
30	been	be	VBN	_	31	auxpass
31	studied	study	VBN	_	2	dep
32	.	.	.	_	31	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	14	advcl
5	following	follow	VBG	_	6	case
6	administration	administration	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	14	punct
10	it	it	PRP	_	14	nsubjpass
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	given	give	VBN	_	0	ROOT
15	until	until	IN	_	21	mark
16	recovery	recovery	NN	_	21	nsubjpass
17	from	from	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	observed	observe	VBN	_	14	advcl
22	.	.	.	_	14	punct

1	The	the	DT	_	3	det
2	median	median	JJ	_	3	amod
3	duration	duration	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	action	action	NN	_	3	nmod
6	of	of	IN	_	9	case
7	drug1	drug1	NN	_	9	compound
8	0.6	0.6	CD	_	9	nummod
9	mg/kg	mg/kg	NN	_	5	nmod
10	administered	administer	VBN	_	0	ROOT
11	after	after	IN	_	15	case
12	a	a	DT	_	15	det
13	1	1	CD	_	15	nummod
14	mg/kg	mg/kg	NN	_	15	compound
15	dose	dose	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	when	when	WRB	_	21	advmod
19	T	t	NN	_	21	nsubj
20	1	1	CD	_	19	nummod
21	returned	return	VBD	_	10	advcl
22	to	to	TO	_	24	case
23	75	75	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	of	of	IN	_	26	case
26	control	control	NN	_	24	nmod
27	was	be	VBD	_	29	cop
28	36	36	CD	_	29	nummod
29	minutes	minute	NNS	_	21	dep
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	range	range	NN	_	29	dep
32	14-57	14-57	CD	_	31	nummod
33	,	,	,	_	31	punct
34	n	n	NN	_	35	nsubj
35	=	=	JJ	_	31	dep
36	12	12	CD	_	35	dobj
37	-RRB-	-rrb-	-RRB-	_	31	punct
38	vs.	vs.	CC	_	29	cc

1	28	28	CD	_	2	nummod
2	minutes	minute	NNS	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	7	punct
4	17-51	17-51	CD	_	7	dep
5	,	,	,	_	7	punct
6	n	n	NN	_	7	nsubj
7	=	=	JJ	_	2	dep
8	12	12	CD	_	7	dobj
9	-RRB-	-rrb-	-RRB-	_	7	punct
10	without	without	IN	_	11	case
11	drug1	drug1	NN	_	2	nmod
12	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	controlled	controlled	JJ	_	5	amod
5	studies	study	NNS	_	2	nsubj
6	documenting	document	VBG	_	5	acl
7	the	the	DT	_	8	det
8	use	use	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	before	before	IN	_	15	nmod
12	or	or	CC	_	11	cc
13	after	after	IN	_	11	conj
14	other	other	JJ	_	15	amod
15	drug2	drug2	NN	_	6	nmod
16	.	.	.	_	2	punct

1	Interactions	interaction	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	when	when	WRB	_	10	advmod
6	other	other	JJ	_	7	amod
7	drug1	drug1	NN	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	administered	administer	VBN	_	4	advcl
11	in	in	IN	_	12	case
12	succession	succession	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	None	none	NN	_	3	dep
6	known	know	VBN	_	5	acl
7	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug2	drug2	NN	_	4	dep
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	may	may	MD	_	13	aux
13	diminish	diminish	VB	_	0	ROOT
14	the	the	DT	_	16	det
15	bactericidal	bactericidal	JJ	_	16	amod
16	effects	effect	NNS	_	13	dobj
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	by	by	IN	_	20	mark
20	slowing	slow	VBG	_	13	advcl
21	the	the	DT	_	22	det
22	rate	rate	NN	_	20	dobj
23	of	of	IN	_	25	case
24	bacterial	bacterial	JJ	_	25	amod
25	growth	growth	NN	_	22	nmod
26	.	.	.	_	13	punct

1	Bactericidal	bactericidal	JJ	_	2	amod
2	agents	agent	NNS	_	3	nsubj
3	work	work	VBP	_	0	ROOT
4	most	most	RBS	_	5	advmod
5	effectively	effectively	RB	_	3	advmod
6	against	against	IN	_	10	case
7	the	the	DT	_	10	det
8	immature	immature	JJ	_	10	amod
9	cell	cell	NN	_	10	compound
10	wall	wall	NN	_	3	nmod
11	of	of	IN	_	14	case
12	rapidly	rapidly	RB	_	13	advmod
13	proliferating	proliferate	VBG	_	14	amod
14	microorganisms	microorganism	NNS	_	10	nmod
15	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	in	in	FW	_	6	compound
6	vitro	vitro	FW	_	4	advmod
7	;	;	:	_	4	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	the	the	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	significance	significance	NN	_	12	nsubjpass
6	of	of	IN	_	8	case
7	this	this	DT	_	8	det
8	interaction	interaction	NN	_	5	nmod
9	is	be	VBZ	_	12	auxpass
10	not	not	RB	_	12	neg
11	well	well	RB	_	12	advmod
12	documented	document	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	few	few	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	situations	situation	NNS	_	2	nsubj
6	in	in	IN	_	7	case
7	which	which	WDT	_	21	nmod
8	the	the	DT	_	10	det
9	concurrent	concurrent	JJ	_	10	amod
10	use	use	NN	_	21	nsubjpass
11	of	of	IN	_	13	case
12	''	''	''	_	13	punct
13	static	static	JJ	_	10	nmod
14	''	''	''	_	13	punct
15	and	and	CC	_	13	cc
16	''	''	''	_	13	punct
17	cidal	cidal	JJ	_	19	amod
18	''	''	''	_	19	punct
19	drug1	drug1	NN	_	13	conj
20	are	be	VBP	_	21	auxpass
21	indicated	indicate	VBN	_	5	acl:relcl
22	.	.	.	_	2	punct

1	However	however	RB	_	26	advmod
2	,	,	,	_	26	punct
3	in	in	IN	_	5	case
4	selected	select	VBN	_	5	amod
5	circumstances	circumstance	NNS	_	26	nmod
6	in	in	IN	_	7	case
7	which	which	WDT	_	11	nmod
8	such	such	JJ	_	9	amod
9	therapy	therapy	NN	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	appropriate	appropriate	JJ	_	5	acl:relcl
12	,	,	,	_	11	punct
13	using	use	VBG	_	11	conj
14	adequate	adequate	JJ	_	15	amod
15	doses	dose	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	drug1	drug1	NN	_	18	compound
18	agents	agent	NNS	_	15	nmod
19	and	and	CC	_	11	cc
20	beginning	begin	VBG	_	22	amod
21	penicillin	penicillin	NN	_	22	compound
22	therapy	therapy	NN	_	11	conj
23	first	first	RB	_	22	advmod
24	,	,	,	_	26	punct
25	should	should	MD	_	26	aux
26	minimize	minimize	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	potential	potential	NN	_	26	dobj
29	for	for	IN	_	30	case
30	interaction	interaction	NN	_	28	nmod
31	.	.	.	_	26	punct

1	drug1	drug1	NN	_	3	compound
2	blood	blood	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	prolonged	prolong	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	which	which	WDT	_	13	nsubj
13	blocks	block	VBZ	_	9	acl:relcl
14	the	the	DT	_	17	det
15	renal	renal	JJ	_	17	amod
16	tubular	tubular	JJ	_	17	amod
17	secretion	secretion	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	6	punct

1	Displacement	displacement	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	from	from	IN	_	8	case
5	plasma	plasma	NN	_	8	compound
6	protein	protein	NN	_	8	compound
7	binding	binding	NN	_	8	compound
8	sites	site	NNS	_	1	nmod
9	will	will	MD	_	10	aux
10	elevate	elevate	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	level	level	NN	_	10	dobj
13	of	of	IN	_	15	case
14	free	free	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	serum	serum	NN	_	10	nmod
19	.	.	.	_	10	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	14	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	plus	plus	CC	_	3	cc
5	a	a	DT	_	7	det
6	catecholamine-depleting	catecholamine-depleting	JJ	_	7	amod
7	agent	agent	NN	_	3	conj
8	should	should	MD	_	14	aux
9	,	,	,	_	14	punct
10	therefore	therefore	RB	_	14	advmod
11	,	,	,	_	14	punct
12	be	be	VB	_	14	auxpass
13	closely	closely	RB	_	14	advmod
14	observed	observe	VBN	_	0	ROOT
15	for	for	IN	_	16	case
16	evidence	evidence	NN	_	14	nmod
17	of	of	IN	_	18	case
18	hypotension	hypotension	NN	_	16	nmod
19	and/or	and/or	CC	_	18	cc
20	marked	marked	JJ	_	21	amod
21	bradycardia	bradycardia	NN	_	18	conj
22	which	which	WDT	_	24	nsubj
23	may	may	MD	_	24	aux
24	produce	produce	VB	_	16	acl:relcl
25	vertigo	vertigo	NN	_	24	dobj
26	,	,	,	_	25	punct
27	syncope	syncope	NN	_	25	conj
28	,	,	,	_	25	punct
29	or	or	CC	_	25	cc
30	postural	postural	JJ	_	31	amod
31	hypotension	hypotension	NN	_	25	conj
32	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	a	a	DT	_	7	det
7	variety	variety	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	7	punct
11	including	include	VBG	_	12	case
12	drug3	drug3	NN	_	7	nmod
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug5	drug5	NN	_	12	conj
18	without	without	IN	_	21	case
19	unexpected	unexpected	JJ	_	21	amod
20	adverse	adverse	JJ	_	21	amod
21	interactions	interaction	NNS	_	12	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	serum	serum	NN	_	9	compound
8	drug2	drug2	NN	_	9	compound
9	levels	level	NNS	_	6	dobj
10	when	when	WRB	_	14	advmod
11	both	both	DT	_	12	det
12	drugs	drug	NNS	_	14	nsubj
13	are	be	VBP	_	14	cop
14	co-administered	co-administered	JJ	_	6	advcl
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	levels	level	NNS	_	6	nsubjpass
3	may	may	MD	_	6	aux
4	also	also	RB	_	6	advmod
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	this	this	DT	_	9	det
9	combination	combination	NN	_	6	nmod
10	.	.	.	_	6	punct

1	Risk	risk	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	anaphylactic	anaphylactic	JJ	_	4	amod
4	reaction	reaction	NN	_	1	nmod
5	:	:	:	_	1	punct
6	While	while	IN	_	7	mark
7	taking	take	VBG	_	26	advcl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	26	punct
10	patients	patient	NNS	_	26	nsubj
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	history	history	NN	_	10	nmod
14	of	of	IN	_	17	case
15	severe	severe	JJ	_	17	amod
16	anaphylactic	anaphylactic	JJ	_	17	amod
17	reaction	reaction	NN	_	13	nmod
18	to	to	TO	_	20	case
19	a	a	DT	_	20	det
20	variety	variety	NN	_	17	nmod
21	of	of	IN	_	22	case
22	allergens	allergen	NNS	_	20	nmod
23	may	may	MD	_	26	aux
24	be	be	VB	_	26	cop
25	more	more	RBR	_	26	advmod
26	reactive	reactive	JJ	_	1	dep
27	to	to	TO	_	29	case
28	repeated	repeat	VBN	_	29	amod
29	challenge	challenge	NN	_	26	nmod
30	,	,	,	_	26	punct
31	either	either	CC	_	32	cc:preconj
32	accidental	accidental	JJ	_	26	dep
33	,	,	,	_	32	punct
34	diagnostic	diagnostic	JJ	_	32	conj
35	,	,	,	_	32	punct
36	or	or	CC	_	32	cc
37	therapeutic	therapeutic	JJ	_	32	conj
38	.	.	.	_	1	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reactions	reaction	NNS	_	14	dobj
17	.	.	.	_	5	punct

1	Although	although	IN	_	12	mark
2	specific	specific	JJ	_	3	amod
3	drug	drug	NN	_	12	nsubjpass
4	or	or	CC	_	3	cc
5	food	food	NN	_	6	compound
6	interactions	interaction	NNS	_	3	conj
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	3	nmod
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	28	advcl
13	,	,	,	_	28	punct
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	basis	basis	NN	_	28	nmod
17	of	of	IN	_	21	case
18	this	this	DT	_	21	det
19	drug	drug	NN	_	21	compound
20	s	s	NNS	_	21	compound
21	metabolism	metabolism	NN	_	16	nmod
22	by	by	IN	_	24	case
23	CYP	cyp	NN	_	24	compound
24	3A4	3a4	NN	_	16	nmod
25	,	,	,	_	28	punct
26	it	it	PRP	_	28	nsubj
27	is	be	VBZ	_	28	cop
28	possible	possible	JJ	_	0	ROOT
29	that	that	IN	_	40	mark
30	drug2	drug2	NN	_	40	nsubj
31	,	,	,	_	30	punct
32	drug3	drug3	NN	_	30	conj
33	,	,	,	_	30	punct
34	drug4	drug4	NN	_	30	conj
35	,	,	,	_	30	punct
36	and	and	CC	_	30	cc
37	grapefruit	grapefruit	NN	_	38	compound
38	juice	juice	NN	_	30	conj
39	may	may	MD	_	40	aux
40	inhibit	inhibit	VB	_	28	ccomp
41	its	its	PRP$	_	42	nmod:poss
42	metabolism	metabolism	NN	_	40	dobj
43	-LRB-	-lrb-	-LRB-	_	46	punct
44	increasing	increase	VBG	_	46	amod
45	serum	serum	NN	_	46	compound
46	levels	level	NNS	_	40	dep
47	of	of	IN	_	48	case
48	drug5	drug5	NN	_	46	nmod
49	-RRB-	-rrb-	-RRB-	_	46	punct
50	.	.	.	_	28	punct

1	Furthermore	furthermore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	compound
4	,	,	,	_	7	punct
5	drug2	drug2	NN	_	7	appos
6	,	,	,	_	7	punct
7	St.	St.	NNP	_	0	ROOT

1	John	John	NNP	_	3	compound
2	s	be	VBZ	_	3	compound
3	Wort	Wort	NNP	_	16	nsubj
4	,	,	,	_	3	punct
5	and	and	CC	_	3	cc
6	certain	certain	JJ	_	7	amod
7	drug1	drug1	NN	_	3	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	dep
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	appos
12	,	,	,	_	9	punct
13	drug4	drug4	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	9	punct
15	may	may	MD	_	16	aux
16	induce	induce	VB	_	0	ROOT
17	drug5	drug5	NN	_	18	compound
18	metabolism	metabolism	NN	_	16	dobj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	lowering	lower	VBG	_	18	dep
21	serum	serum	NN	_	22	compound
22	levels	level	NNS	_	20	dobj
23	of	of	IN	_	24	case
24	drug6	drug6	NN	_	22	nmod
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	.	.	.	_	16	punct

1	Based	base	VBN	_	6	case
2	on	on	IN	_	6	case
3	in	in	FW	_	6	amod
4	vitro	vitro	FW	_	3	dep
5	inhibition	inhibition	NN	_	6	compound
6	information	information	NN	_	12	advcl
7	,	,	,	_	12	punct
8	coadministration	coadministration	NN	_	12	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	12	aux
12	lead	lead	VB	_	0	ROOT
13	to	to	TO	_	15	case
14	an	a	DT	_	15	det
15	increase	increase	NN	_	12	nmod
16	in	in	IN	_	18	case
17	serum	serum	NN	_	18	compound
18	levels	level	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drugs	drug	NNS	_	18	nmod
21	that	that	WDT	_	25	nsubj
22	are	be	VBP	_	25	cop
23	CYP	cyp	NN	_	25	compound
24	3A4	3a4	NN	_	25	compound
25	substrates	substrate	NNS	_	20	acl:relcl
26	.	.	.	_	12	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	slow	slow	JJ	_	5	amod
5	elimination	elimination	NN	_	16	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	from	from	IN	_	10	case
9	the	the	DT	_	10	det
10	body	body	NN	_	5	nmod
11	,	,	,	_	16	punct
12	such	such	JJ	_	13	amod
13	interaction	interaction	NN	_	16	nsubjpass
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	for	for	IN	_	20	case
18	a	a	DT	_	20	det
19	prolonged	prolonged	JJ	_	20	amod
20	period	period	NN	_	16	nmod
21	after	after	IN	_	23	case
22	its	its	PRP$	_	23	nmod:poss
23	administration	administration	NN	_	20	nmod
24	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	that	that	WDT	_	17	nsubj
14	are	be	VBP	_	17	cop
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	substrates	substrate	NNS	_	12	acl:relcl
18	and	and	CC	_	17	cc
19	have	have	VBP	_	17	conj
20	narrow	narrow	JJ	_	22	amod
21	therapeutic	therapeutic	JJ	_	22	amod
22	range	range	NN	_	19	dobj
23	,	,	,	_	22	punct
24	including	include	VBG	_	26	case
25	some	some	DT	_	26	det
26	agents	agent	NNS	_	22	nmod
27	used	use	VBN	_	26	acl
28	during	during	IN	_	30	case
29	general	general	JJ	_	30	amod
30	anesthesia	anesthesia	NN	_	27	nmod
31	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	erythema	erythema	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	histamine-like	histamine-like	JJ	_	14	amod
14	flushing	flushing	NN	_	11	conj
15	and	and	CC	_	11	cc
16	anaphylactoid	anaphylactoid	JJ	_	17	amod
17	reactions	reaction	NNS	_	11	conj
18	.	.	.	_	9	punct

1	Concurrent	concurrent	JJ	_	7	amod
2	and/or	and/or	CC	_	1	cc
3	sequential	sequential	JJ	_	1	conj
4	systemic	systemic	JJ	_	7	amod
5	or	or	CC	_	4	cc
6	topical	topical	JJ	_	4	conj
7	use	use	NN	_	36	nsubj
8	of	of	IN	_	14	case
9	other	other	JJ	_	14	amod
10	potentially	potentially	RB	_	11	advmod
11	neurotoxic	neurotoxic	JJ	_	14	amod
12	and/or	and/or	CC	_	11	cc
13	nephrotoxic	nephrotoxic	JJ	_	11	conj
14	drugs	drug	NNS	_	7	nmod
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug1	drug1	NN	_	14	nmod
19	,	,	,	_	18	punct
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	18	punct
22	drug3	drug3	NN	_	18	conj
23	,	,	,	_	18	punct
24	drug4	drug4	NN	_	18	conj
25	,	,	,	_	18	punct
26	drug5	drug5	NN	_	18	conj
27	,	,	,	_	18	punct
28	drug6	drug6	NN	_	18	conj
29	,	,	,	_	18	punct
30	or	or	CC	_	18	cc
31	drug7	drug7	NN	_	18	conj
32	,	,	,	_	14	punct
33	when	when	WRB	_	34	advmod
34	indicated	indicate	VBN	_	14	acl:relcl
35	,	,	,	_	14	punct
36	requires	require	VBZ	_	0	ROOT
37	careful	careful	JJ	_	38	amod
38	monitoring	monitoring	NN	_	36	dobj
39	.	.	.	_	36	punct

1	Potential	potential	JJ	_	11	nsubjpass
2	for	for	IN	_	5	mark
3	drug1	drug1	NN	_	5	nsubj
4	to	to	TO	_	5	mark
5	Affect	affect	VB	_	1	advcl
6	Other	other	JJ	_	8	amod
7	Drugs	drug	NNS	_	8	compound
8	drug2	drug2	NN	_	5	dobj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	cause	cause	VB	_	11	xcomp
14	clinically	clinically	RB	_	15	advmod
15	important	important	JJ	_	17	amod
16	pharmacokinetic	pharmacokinetic	JJ	_	17	amod
17	interactions	interaction	NNS	_	13	dobj
18	with	with	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	that	that	WDT	_	22	nsubjpass
21	are	be	VBP	_	22	auxpass
22	metabolized	metabolize	VBN	_	19	acl:relcl
23	by	by	IN	_	26	case
24	cytochrome	cytochrome	NN	_	26	compound
25	P450	p450	NN	_	26	compound
26	isozymes	isozyme	NNS	_	22	nmod
27	.	.	.	_	11	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	in	in	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	14	mark
10	drug1	drug1	NN	_	14	nsubj
11	does	do	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	substantially	substantially	RB	_	14	advmod
14	inhibit	inhibit	VB	_	8	ccomp
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	metabolized	metabolize	VBN	_	18	acl
20	by	by	IN	_	23	case
21	cytochrome	cytochrome	NN	_	23	compound
22	P450	p450	NN	_	23	compound
23	isozymes	isozyme	NNS	_	19	nmod
24	,	,	,	_	23	punct
25	including	include	VBG	_	26	case
26	CYP1A2	cyp1a2	NN	_	23	nmod
27	,	,	,	_	26	punct
28	CYP2A6	cyp2a6	NN	_	26	conj
29	,	,	,	_	26	punct
30	CYP2C8/9/10	cyp2c8/9/10	NN	_	26	conj
31	,	,	,	_	26	punct
32	CYP2D6	cyp2d6	NN	_	26	conj
33	,	,	,	_	26	punct
34	CYP2E1	cyp2e1	NN	_	26	conj
35	,	,	,	_	26	punct
36	CYP3A4	cyp3a4	NN	_	26	conj
37	,	,	,	_	26	punct
38	and	and	CC	_	26	cc
39	CYP3A5	cyp3a5	NN	_	26	conj
40	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	expected	expect	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	inhibit	inhibit	VB	_	6	xcomp
9	clearance	clearance	NN	_	8	dobj
10	of	of	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	metabolized	metabolize	VBN	_	11	acl:relcl
15	by	by	IN	_	18	case
16	these	these	DT	_	18	det
17	metabolic	metabolic	JJ	_	18	amod
18	pathways	pathway	NNS	_	14	nmod
19	in	in	IN	_	23	case
20	a	a	DT	_	23	det
21	clinically	clinically	RB	_	22	advmod
22	relevant	relevant	JJ	_	23	amod
23	manner	manner	NN	_	14	nmod
24	.	.	.	_	6	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	also	also	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	enzyme	enzyme	NN	_	7	dobj
9	inducing	induce	VBG	_	8	acl
10	properties	property	NNS	_	9	dobj
11	.	.	.	_	5	punct

1	At	at	IN	_	3	case
2	therapeutic	therapeutic	JJ	_	3	amod
3	concentrations	concentration	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	inhibit	inhibit	VB	_	0	ROOT
9	P-glycoprotein	p-glycoprotein	NN	_	8	dobj
10	.	.	.	_	8	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	therefore	therefore	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	inhibit	inhibit	VB	_	5	xcomp
8	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	9	amod
9	transport	transport	NN	_	7	dobj
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	clinically	clinically	RB	_	16	advmod
16	relevant	relevant	JJ	_	17	amod
17	manner	manner	NN	_	7	nmod
18	.	.	.	_	5	punct

1	Given	give	VBN	_	5	case
2	the	the	DT	_	5	det
3	primary	primary	JJ	_	5	amod
4	CNS	cns	NN	_	5	compound
5	effects	effect	NNS	_	12	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	12	punct
9	drug2	drug2	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	caution	caution	NN	_	12	nmod
15	in	in	IN	_	16	case
16	combination	combination	NN	_	12	nmod
17	with	with	IN	_	19	case
18	other	other	JJ	_	19	amod
19	drug3	drug3	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drug3	drug3	NN	_	7	conj
11	.	.	.	_	3	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	4	nmod:poss
4	potential	potential	NN	_	15	nmod
5	for	for	IN	_	6	mark
6	inducing	induce	VBG	_	4	acl
7	orthostatic	orthostatic	JJ	_	8	amod
8	hypotension	hypotension	NN	_	6	dobj
9	,	,	,	_	8	punct
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	8	appos
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	when	when	WRB	_	19	advmod
17	drug1	drug1	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	15	advcl
20	with	with	IN	_	23	case
21	other	other	JJ	_	23	amod
22	therapeutic	therapeutic	JJ	_	23	amod
23	agents	agent	NNS	_	19	nmod
24	that	that	WDT	_	25	nsubj
25	have	have	VBP	_	23	acl:relcl
26	this	this	DT	_	27	det
27	potential	potential	NN	_	25	dobj
28	.	.	.	_	15	punct

1	Potential	potential	JJ	_	12	nsubj
2	for	for	IN	_	6	mark
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	6	nsubj
5	to	to	TO	_	6	mark
6	Affect	affect	VB	_	1	advcl
7	drug1	drug1	NN	_	8	compound
8	drug2	drug2	NN	_	6	dobj
9	is	be	VBZ	_	12	cop
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	0	ROOT
13	of	of	IN	_	14	case
14	CYP1A2	cyp1a2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	CYP2A6	cyp2a6	NN	_	14	conj
17	,	,	,	_	14	punct
18	CYP2C9	cyp2c9	NN	_	14	conj
19	,	,	,	_	14	punct
20	and	and	CC	_	14	cc
21	CYP2C19	cyp2c19	NN	_	14	conj
22	,	,	,	_	12	punct
23	so	so	RB	_	35	mark
24	that	that	IN	_	23	mwe
25	an	a	DT	_	26	det
26	interaction	interaction	NN	_	35	nsubj
27	with	with	IN	_	28	case
28	inhibitors	inhibitor	NNS	_	26	nmod
29	or	or	CC	_	28	cc
30	inducers	inducer	NNS	_	28	conj
31	of	of	IN	_	33	case
32	these	these	DT	_	33	det
33	isozymes	isozyme	NNS	_	28	nmod
34	is	be	VBZ	_	35	cop
35	unlikely	unlikely	JJ	_	12	advcl
36	.	.	.	_	12	punct

1	While	while	IN	_	5	mark
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	5	nsubj
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	13	mark
7	CYP2D6	cyp2d6	NN	_	13	nsubjpass
8	and	and	CC	_	7	cc
9	CYP3A4	cyp3a4	NN	_	7	conj
10	may	may	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	minimally	minimally	RB	_	13	advmod
13	involved	involve	VBN	_	5	ccomp
14	in	in	IN	_	16	case
15	drug1	drug1	NN	_	16	compound
16	metabolism	metabolism	NN	_	13	nmod
17	,	,	,	_	16	punct
18	in	in	FW	_	20	amod
19	vivo	vivo	FW	_	18	dep
20	studies	study	NNS	_	23	nsubj
21	do	do	VBP	_	23	aux
22	not	not	RB	_	23	neg
23	show	show	VB	_	16	acl:relcl
24	decreased	decrease	VBN	_	25	amod
25	elimination	elimination	NN	_	23	dobj
26	by	by	IN	_	28	case
27	these	these	DT	_	28	det
28	isozymes	isozyme	NNS	_	25	nmod
29	and	and	CC	_	23	cc
30	they	they	PRP	_	31	nsubj
31	contribute	contribute	VBP	_	23	conj
32	to	to	TO	_	36	case
33	only	only	RB	_	36	advmod
34	a	a	DT	_	36	det
35	small	small	JJ	_	36	amod
36	fraction	fraction	NN	_	31	nmod
37	of	of	IN	_	40	case
38	total	total	JJ	_	40	amod
39	body	body	NN	_	40	compound
40	clearance	clearance	NN	_	36	nmod
41	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	in	in	IN	_	16	case
16	humans	human	NNS	_	14	nmod
17	.	.	.	_	14	punct

1	Patients	patient	NNS	_	19	nsubjpass
2	who	who	WP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	receiving	receive	VBG	_	1	acl:relcl
5	drug1	drug1	NN	_	4	dobj
6	concurrently	concurrently	RB	_	4	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	,	,	,	_	9	punct
11	especially	especially	RB	_	12	advmod
12	drugs	drug	NNS	_	9	appos
13	with	with	IN	_	15	case
14	CNS	cns	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	,	,	,	_	19	punct
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	monitored	monitor	VBN	_	0	ROOT
20	carefully	carefully	RB	_	19	advmod
21	.	.	.	_	19	punct

1	Decreased	decrease	VBN	_	3	amod
2	seizure	seizure	NN	_	3	compound
3	threshold	threshold	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	6	punct

1	CYP	cyp	NN	_	3	compound
2	3A4	3a4	NN	_	3	compound
3	Inhibitors	inhibitor	NNS	_	14	nsubj
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	e.g.	e.g.	FW	_	6	dep
6	drug1	drug1	NN	_	3	dep
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	There	there	EX	_	14	expl
11	have	have	VBP	_	14	aux
12	been	be	VBN	_	14	cop
13	rare	rare	JJ	_	14	amod
14	reports	report	NNS	_	0	ROOT
15	of	of	IN	_	18	case
16	serious	serious	JJ	_	18	amod
17	adverse	adverse	JJ	_	18	amod
18	events	event	NNS	_	14	nmod
19	in	in	IN	_	20	case
20	connection	connection	NN	_	18	nmod
21	with	with	IN	_	23	case
22	the	the	DT	_	23	det
23	coadministration	coadministration	NN	_	20	nmod
24	of	of	IN	_	26	case
25	certain	certain	JJ	_	26	amod
26	drug3	drug3	NN	_	23	nmod
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	e.g.	e.g.	FW	_	29	dep
29	drug4	drug4	NN	_	26	dep
30	and	and	CC	_	29	cc
31	drug5	drug5	NN	_	29	conj
32	-RRB-	-rrb-	-RRB-	_	29	punct
33	and	and	CC	_	26	cc
34	potent	potent	JJ	_	37	amod
35	CYP	cyp	NN	_	37	compound
36	3A4	3a4	NN	_	37	compound
37	inhibitors	inhibitor	NNS	_	26	conj
38	,	,	,	_	14	punct
39	resulting	result	VBG	_	14	advcl
40	in	in	IN	_	41	case
41	vasospasm	vasospasm	NN	_	39	nmod
42	leading	lead	VBG	_	41	acl
43	to	to	TO	_	45	case
44	cerebral	cerebral	JJ	_	45	amod
45	ischemia	ischemia	NN	_	42	nmod
46	and/or	and/or	CC	_	45	cc
47	ischemia	ischemia	NN	_	45	conj
48	of	of	IN	_	50	case
49	the	the	DT	_	50	det
50	extremities	extremity	NNS	_	45	nmod
51	.	.	.	_	14	punct

1	Although	although	IN	_	6	mark
2	there	there	EX	_	6	expl
3	have	have	VBP	_	6	aux
4	been	be	VBN	_	6	cop
5	no	no	DT	_	6	neg
6	reports	report	NNS	_	0	ROOT
7	of	of	IN	_	9	case
8	such	such	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	alone	alone	RB	_	11	advmod
13	,	,	,	_	11	punct
14	potent	potent	JJ	_	17	amod
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	21	nsubjpass
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	11	acl:relcl
22	with	with	IN	_	23	case
23	methylergonovine	methylergonovine	NN	_	21	nmod
24	.	.	.	_	6	punct

1	Examples	example	NNS	_	11	nsubj
2	of	of	IN	_	3	case
3	some	some	DT	_	1	nmod
4	of	of	IN	_	10	case
5	the	the	DT	_	10	det
6	more	more	RBR	_	7	advmod
7	potent	potent	JJ	_	10	amod
8	CYP	cyp	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	3	nmod
11	include	include	VBP	_	0	ROOT
12	drug1	drug1	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	12	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	appos
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	,	,	,	_	12	punct
23	drug5	drug5	NN	_	12	conj
24	or	or	CC	_	12	cc
25	drug6	drug6	NN	_	12	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug7	drug7	NN	_	25	dep
30	,	,	,	_	29	punct
31	drug8	drug8	NN	_	29	conj
32	,	,	,	_	29	punct
33	drug9	drug9	NN	_	29	conj
34	,	,	,	_	29	punct
35	drug10	drug10	NN	_	29	conj
36	-RRB-	-rrb-	-RRB-	_	29	punct
37	or	or	CC	_	12	cc
38	drug11	drug11	NN	_	12	conj
39	-LRB-	-lrb-	-LRB-	_	42	punct
40	e.g.	e.g.	FW	_	42	dep
41	,	,	,	_	42	punct
42	drug12	drug12	NN	_	38	dep
43	,	,	,	_	42	punct
44	drug13	drug13	NN	_	42	appos
45	,	,	,	_	42	punct
46	drug14	drug14	NN	_	42	appos
47	-RRB-	-rrb-	-RRB-	_	42	punct
48	.	.	.	_	11	punct

1	Less	less	RBR	_	5	advmod
2	potent	potent	JJ	_	5	amod
3	CYP	cyp	NN	_	5	compound
4	3A4	3a4	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	caution	caution	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Less	less	RBR	_	3	amod
2	potent	potent	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	4	nsubj
4	include	include	VBP	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	grapefruit	grapefruit	NN	_	12	compound
12	juice	juice	NN	_	5	conj
13	,	,	,	_	5	punct
14	drug4	drug4	NN	_	5	conj
15	,	,	,	_	5	punct
16	drug5	drug5	NN	_	5	conj
17	,	,	,	_	5	punct
18	drug6	drug6	NN	_	5	conj
19	,	,	,	_	5	punct
20	and	and	CC	_	5	cc
21	drug7	drug7	NN	_	5	conj
22	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	lists	list	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	not	not	RB	_	5	neg
5	exhaustive	exhaustive	JJ	_	0	ROOT
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	the	the	DT	_	9	det
9	prescriber	prescriber	NN	_	11	nsubj
10	should	should	MD	_	11	aux
11	consider	consider	VB	_	5	conj
12	the	the	DT	_	13	det
13	effects	effect	NNS	_	11	dobj
14	on	on	IN	_	16	case
15	CYP	cyp	NN	_	16	compound
16	3A4	3a4	NN	_	13	nmod
17	of	of	IN	_	19	case
18	other	other	JJ	_	19	amod
19	agents	agent	NNS	_	16	nmod
20	being	be	VBG	_	21	auxpass
21	considered	consider	VBN	_	19	acl
22	for	for	IN	_	24	case
23	concomitant	concomitant	JJ	_	24	amod
24	use	use	NN	_	21	nmod
25	with	with	IN	_	26	case
26	drug1	drug1	NN	_	24	nmod
27	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	10	nsubjpass
4	involving	involve	VBG	_	3	acl
5	other	other	JJ	_	8	amod
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	isoenzymes	isoenzyme	NNS	_	4	dobj
9	are	be	VBP	_	10	auxpass
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	11	advmod
6	drug1	drug1	NN	_	11	nsubjpass
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug2	drug2	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	is	be	VBZ	_	11	auxpass
11	used	use	VBN	_	4	advcl
12	concurrently	concurrently	RB	_	11	advmod
13	with	with	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drug3	drug3	NN	_	11	nmod
16	or	or	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	.	.	.	_	4	punct

1	To	to	TO	_	2	mark
2	minimize	minimize	VB	_	0	ROOT
3	CNS	cns	NN	_	4	compound
4	depression	depression	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	possible	possible	JJ	_	7	amod
7	potentiation	potentiation	NN	_	4	conj
8	,	,	,	_	7	punct
9	drug1	drug1	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug2	drug2	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug3	drug3	NN	_	7	conj
14	,	,	,	_	7	punct
15	drug4	drug4	NN	_	7	conj
16	or	or	CC	_	7	cc
17	drug5	drug5	NN	_	7	conj
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	used	use	VBN	_	2	dep
21	with	with	IN	_	22	case
22	caution	caution	NN	_	20	nmod
23	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	since	since	IN	_	13	mark
7	there	there	EX	_	13	expl
8	may	may	MD	_	13	aux
9	be	be	VB	_	13	cop
10	an	a	DT	_	13	det
11	Antabuse	antabuse	NN	_	13	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	disulfiram	disulfiram	NN	_	5	advcl
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	-	-	:	_	5	punct
16	like	like	IN	_	17	case
17	reaction	reaction	NN	_	5	nmod
18	.	.	.	_	5	punct

1	Because	because	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	exhibits	exhibit	VBZ	_	45	advcl
4	some	some	DT	_	8	det
5	monoamine	monoamine	NN	_	8	compound
6	oxidase	oxidase	NN	_	8	compound
7	inhibitory	inhibitory	JJ	_	8	amod
8	activity	activity	NN	_	3	dobj
9	,	,	,	_	45	punct
10	drug2	drug2	NN	_	45	dep
11	,	,	,	_	45	punct
12	drug3	drug3	NN	_	13	compound
13	drugs	drug	NNS	_	45	nsubjpass
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug4	drug4	NN	_	13	dep
18	,	,	,	_	17	punct
19	drug5	drug5	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	and	and	CC	_	13	cc
22	other	other	JJ	_	23	amod
23	drugs	drug	NNS	_	13	conj
24	and	and	CC	_	23	cc
25	foods	food	NNS	_	23	conj
26	with	with	IN	_	30	case
27	known	known	JJ	_	30	amod
28	high	high	JJ	_	30	amod
29	drug6	drug6	NN	_	30	compound
30	content	content	NN	_	23	nmod
31	,	,	,	_	13	punct
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	wine	wine	NN	_	13	nmod
35	,	,	,	_	34	punct
36	yogurt	yogurt	NN	_	34	conj
37	,	,	,	_	34	punct
38	ripe	ripe	JJ	_	39	amod
39	cheese	cheese	NN	_	34	conj
40	and	and	CC	_	34	cc
41	bananas	banana	NNS	_	34	conj
42	,	,	,	_	13	punct
43	should	should	MD	_	45	aux
44	be	be	VB	_	45	auxpass
45	avoided	avoid	VBN	_	0	ROOT
46	.	.	.	_	45	punct

1	A	a	DT	_	3	det
2	further	further	JJ	_	3	amod
3	phenomenon	phenomenon	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	toxicity	toxicity	NN	_	3	nmod
6	common	common	JJ	_	5	amod
7	to	to	TO	_	9	case
8	many	many	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	is	be	VBZ	_	11	cop
11	hemolysis	hemolysis	NN	_	0	ROOT
12	and	and	CC	_	11	cc
13	the	the	DT	_	14	det
14	appearance	appearance	NN	_	11	conj
15	of	of	IN	_	18	case
16	Heinz-Ehrlich	heinz-ehrlich	JJ	_	18	amod
17	inclusion	inclusion	NN	_	18	compound
18	bodies	body	NNS	_	14	nmod
19	in	in	IN	_	20	case
20	erythrocytes	erythrocyte	NNS	_	14	nmod
21	.	.	.	_	11	punct

1	No	no	DT	_	2	neg
2	cross-resistance	cross-resistance	NN	_	12	nsubjpass
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	5	punct
7	radiotherapy	radiotherapy	NN	_	5	conj
8	or	or	CC	_	5	cc
9	drug2	drug2	NN	_	5	conj
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	demonstrated	demonstrate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	are	be	VBP	_	3	cop
3	capable	capable	JJ	_	0	ROOT
4	of	of	IN	_	5	mark
5	potentiating	potentiate	VBG	_	3	advcl
6	drug2	drug2	NN	_	5	dobj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	e.g.	e.g.	FW	_	10	dep
9	,	,	,	_	10	punct
10	drug3	drug3	NN	_	6	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	etc.	etc.	FW	_	10	dep
19	-RRB-	-rrb-	-RRB-	_	10	punct

1	as	as	RB	_	4	cc
2	well	well	RB	_	1	mwe
3	as	as	IN	_	1	mwe
4	drug1	drug1	NN	_	0	ROOT
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	15	nsubjpass
2	affecting	affect	VBG	_	1	acl
3	pituitary	pituitary	JJ	_	6	amod
4	or	or	CC	_	3	cc
5	adrenocortical	adrenocortical	JJ	_	3	conj
6	function	function	NN	_	2	dobj
7	,	,	,	_	1	punct
8	including	include	VBG	_	11	case
9	all	all	DT	_	11	det
10	corticosteroid	corticosteroid	NN	_	11	compound
11	therapy	therapy	NN	_	1	nmod
12	,	,	,	_	1	punct
13	must	must	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	discontinued	discontinue	VBN	_	0	ROOT
16	prior	prior	RB	_	20	advmod
17	to	to	TO	_	20	case
18	and	and	CC	_	17	cc
19	during	during	IN	_	17	conj
20	testing	testing	NN	_	15	nmod
21	with	with	IN	_	22	case
22	drug1	drug1	NN	_	20	nmod
23	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	metabolism	metabolism	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	accelerated	accelerate	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	;	;	:	_	6	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	results	result	NNS	_	9	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	test	test	NN	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	inaccurate	inaccurate	JJ	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	taking	take	VBG	_	11	acl
13	drug1	drug1	NN	_	12	dobj
14	within	within	IN	_	16	case
15	two	two	CD	_	16	nummod
16	weeks	week	NNS	_	12	nmod
17	before	before	RB	_	16	advmod
18	.	.	.	_	9	punct

1	Asubnormal	asubnormal	JJ	_	2	amod
2	response	response	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	occur	occur	VB	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	on	on	IN	_	9	case
8	estrogen	estrogen	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	glucuronidation	glucuronidation	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	could	could	MD	_	10	aux
9	possibly	possibly	RB	_	10	advmod
10	potentiate	potentiate	VB	_	2	conj
11	drug3	drug3	NN	_	12	compound
12	toxicity	toxicity	NN	_	10	dobj
13	.	.	.	_	2	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	evidence	evidence	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	6	mark
5	drug1	drug1	NN	_	6	nsubj
6	inhibits	inhibit	VBZ	_	3	ccomp
7	drug2	drug2	NN	_	8	compound
8	metabolism	metabolism	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	may	may	MD	_	11	aux
11	result	result	VB	_	6	conj
12	in	in	IN	_	14	case
13	an	a	DT	_	14	det
14	increase	increase	NN	_	11	nmod
15	in	in	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	through	through	IN	_	8	case
5	the	the	DT	_	8	det
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	system	system	NN	_	3	nmod
9	,	,	,	_	3	punct
10	primarily	primarily	RB	_	15	advmod
11	the	the	DT	_	15	det
12	CYP2C19	cyp2c19	NN	_	15	compound
13	and	and	CC	_	12	cc
14	CYP3A4	cyp3a4	NN	_	12	conj
15	isozymes	isozyme	NNS	_	3	dep
16	,	,	,	_	15	punct
17	and	and	CC	_	15	cc
18	subsequently	subsequently	RB	_	19	advmod
19	undergoes	undergo	VBZ	_	15	conj
20	Phase	phase	NN	_	22	compound
21	II	ii	CD	_	22	nummod
22	conjugation	conjugation	NN	_	19	dobj
23	.	.	.	_	3	punct

1	Based	base	VBN	_	3	case
2	on	on	IN	_	3	case
3	studies	study	NNS	_	17	advcl
4	evaluating	evaluate	VBG	_	3	acl
5	possible	possible	JJ	_	6	amod
6	interactions	interaction	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	,	,	,	_	17	punct
13	no	no	DT	_	15	neg
14	dosage	dosage	NN	_	15	compound
15	adjustment	adjustment	NN	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	needed	need	VBN	_	0	ROOT
18	with	with	IN	_	20	case
19	concomitant	concomitant	JJ	_	20	amod
20	use	use	NN	_	17	nmod
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	following	following	NN	_	20	nmod
24	:	:	:	_	17	punct
25	drug2	drug2	NN	_	17	dep
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug4	drug4	NN	_	25	conj
30	,	,	,	_	25	punct
31	drug5	drug5	NN	_	25	conj
32	,	,	,	_	25	punct
33	drug6	drug6	NN	_	25	conj
34	,	,	,	_	25	punct
35	drug7	drug7	NN	_	25	conj
36	-LRB-	-lrb-	-LRB-	_	40	punct
37	and	and	CC	_	40	cc
38	its	its	PRP$	_	40	nmod:poss
39	active	active	JJ	_	40	amod
40	metabolite	metabolite	NN	_	35	dep
41	,	,	,	_	40	punct
42	drug8	drug8	NN	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	,	,	,	_	25	punct
45	drug9	drug9	NN	_	25	conj
46	,	,	,	_	25	punct
47	drug10	drug10	NN	_	25	conj
48	,	,	,	_	25	punct
49	drug11	drug11	NN	_	25	conj
50	,	,	,	_	25	punct
51	drug12	drug12	NN	_	25	conj
52	,	,	,	_	25	punct
53	drug13	drug13	NN	_	25	conj
54	,	,	,	_	25	punct
55	drug14	drug14	NN	_	25	conj
56	,	,	,	_	25	punct
57	an	a	DT	_	59	det
58	oral	oral	JJ	_	59	amod
59	drug15	drug15	NN	_	25	conj
60	-LRB-	-lrb-	-LRB-	_	61	punct
61	drug16	drug16	NN	_	59	appos
62	/	/	:	_	61	punct
63	drug17	drug17	NN	_	61	dep
64	-RRB-	-rrb-	-RRB-	_	61	punct
65	,	,	,	_	25	punct
66	drug18	drug18	NN	_	25	conj
67	,	,	,	_	25	punct
68	drug19	drug19	NN	_	25	conj
69	,	,	,	_	25	punct
70	drug20	drug20	NN	_	25	conj
71	,	,	,	_	25	punct
72	drug21	drug21	NN	_	25	conj
73	,	,	,	_	25	punct
74	drug22	drug22	NN	_	25	conj
75	,	,	,	_	25	punct
76	drug23	drug23	NN	_	25	conj
77	,	,	,	_	25	punct
78	drug24	drug24	NN	_	25	conj
79	,	,	,	_	25	punct
80	or	or	CC	_	25	cc
81	drug25	drug25	NN	_	25	conj
82	.	.	.	_	17	punct

1	Clinically	clinically	RB	_	2	advmod
2	relevant	relevant	JJ	_	3	amod
3	interactions	interaction	NNS	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	3	nmod
9	with	with	IN	_	13	case
10	the	the	DT	_	13	det
11	same	same	JJ	_	13	amod
12	metabolic	metabolic	JJ	_	13	amod
13	pathways	pathway	NNS	_	8	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	expected	expect	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	when	when	WRB	_	4	advmod
4	coadministered	coadminister	VBN	_	21	advcl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	21	punct
8	adjustment	adjustment	NN	_	21	nsubj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	dosage	dosage	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	of	of	IN	_	17	case
16	such	such	JJ	_	17	amod
17	drugs	drug	NNS	_	13	conj
18	may	may	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	cop
21	necessary	necessary	JJ	_	0	ROOT
22	.	.	.	_	21	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	also	also	RB	_	2	advmod
4	no	no	DT	_	5	neg
5	interaction	interaction	NN	_	2	nsubj
6	with	with	IN	_	9	case
7	concomitantly	concomitantly	RB	_	8	advmod
8	administered	administer	VBN	_	9	amod
9	drug1	drug1	NN	_	5	nmod
10	.	.	.	_	2	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	aux
4	postmarketing	postmarket	VBG	_	0	ROOT
5	reports	report	NNS	_	4	dobj
6	of	of	IN	_	8	case
7	increased	increase	VBN	_	8	amod
8	INR	inr	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	prothrombin	prothrombin	NN	_	8	conj
11	time	time	NN	_	8	dep
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	8	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	,	,	,	_	13	punct
17	including	include	VBG	_	18	case
18	drug2	drug2	NN	_	13	nmod
19	,	,	,	_	13	punct
20	and	and	CC	_	13	cc
21	drug3	drug3	NN	_	13	conj
22	concomitantly	concomitantly	RB	_	21	advmod
23	.	.	.	_	4	punct

1	Increases	increase	NNS	_	0	ROOT
2	in	in	IN	_	3	case
3	INR	inr	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	prothrombin	prothrombin	NN	_	3	conj
6	time	time	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	1	acl:relcl
9	to	to	TO	_	11	case
10	abnormal	abnormal	JJ	_	11	amod
11	bleeding	bleeding	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	even	even	RB	_	14	advmod
14	death	death	NN	_	11	conj
15	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	concomitantly	concomitantly	RB	_	10	advmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	for	for	IN	_	12	case
12	increases	increase	NNS	_	10	nmod
13	in	in	IN	_	14	case
14	INR	inr	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	prothrombin	prothrombin	NN	_	17	compound
17	time	time	NN	_	14	conj
18	.	.	.	_	10	punct

1	Because	because	IN	_	7	case
2	of	of	IN	_	1	mwe
3	profound	profound	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	long	long	JJ	_	3	conj
6	lasting	lasting	JJ	_	7	amod
7	inhibition	inhibition	NN	_	15	nmod
8	of	of	IN	_	11	case
9	gastric	gastric	JJ	_	11	amod
10	acid	acid	NN	_	11	compound
11	secretion	secretion	NN	_	7	nmod
12	,	,	,	_	15	punct
13	drug1	drug1	NN	_	15	nsubj
14	may	may	MD	_	15	aux
15	interfere	interfere	VB	_	0	ROOT
16	with	with	IN	_	17	case
17	absorption	absorption	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	where	where	WRB	_	26	advmod
21	gastric	gastric	JJ	_	22	amod
22	pH	ph	NN	_	26	nsubj
23	is	be	VBZ	_	26	cop
24	an	a	DT	_	26	det
25	important	important	JJ	_	26	amod
26	determinant	determinant	NN	_	19	acl:relcl
27	of	of	IN	_	29	case
28	their	they	PRP$	_	29	nmod:poss
29	bioavailability	bioavailability	NN	_	26	nmod
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	eg	eg	FW	_	33	compound
32	,	,	,	_	33	punct
33	drug2	drug2	NN	_	15	dep
34	,	,	,	_	33	punct
35	drug3	drug3	NN	_	36	compound
36	esters	ester	NNS	_	33	conj
37	,	,	,	_	33	punct
38	and	and	CC	_	33	cc
39	drug4	drug4	NN	_	40	compound
40	salts	salt	NNS	_	33	conj
41	-RRB-	-rrb-	-RRB-	_	33	punct
42	.	.	.	_	15	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Tests	Tests	NNP	_	6	nsubj
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	0	ROOT
7	of	of	IN	_	11	case
8	false-positive	false-positive	JJ	_	11	amod
9	urine	urine	NN	_	11	compound
10	screening	screening	NN	_	11	compound
11	tests	test	NNS	_	6	nmod
12	for	for	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug2	drug2	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	13	nmod
19	receiving	receive	VBG	_	18	acl
20	most	most	RBS	_	21	advmod
21	drug3	drug3	RB	_	19	advmod
22	,	,	,	_	18	punct
23	including	include	VBG	_	24	case
24	drug4	drug4	NN	_	18	nmod
25	.	.	.	_	6	punct

1	An	a	DT	_	4	det
2	alternative	alternative	JJ	_	4	amod
3	confirmatory	confirmatory	JJ	_	4	amod
4	method	method	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	considered	consider	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	verify	verify	VB	_	7	xcomp
10	positive	positive	JJ	_	11	amod
11	results	result	NNS	_	9	dobj
12	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	increased	increase	VBN	_	9	amod
9	thrombocytopenia	thrombocytopenia	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	6	punct
12	drug2	drug2	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	increased	increase	VBN	_	15	amod
15	nephrotoxicity	nephrotoxicity	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	6	punct
18	drug3	drug3	NN	_	6	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	increased	increase	VBN	_	22	amod
21	hypoglycemic	hypoglycemic	JJ	_	22	amod
22	response	response	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	6	punct
25	drug4	drug4	NN	_	6	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	increased	increase	VBN	_	29	amod
28	anticoagulant	anticoagulant	JJ	_	29	amod
29	effect	effect	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	6	punct
32	drug5	drug5	NN	_	6	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	decreased	decrease	VBN	_	36	amod
35	renal	renal	JJ	_	36	amod
36	excretion	excretion	NN	_	32	dep
37	of	of	IN	_	38	case
38	drug6	drug6	NN	_	36	nmod
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	,	,	,	_	6	punct
41	drug7	drug7	NN	_	6	conj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	decreased	decrease	VBN	_	45	amod
44	hepatic	hepatic	JJ	_	45	amod
45	clearance	clearance	NN	_	41	dep
46	of	of	IN	_	47	case
47	drug8	drug8	NN	_	45	nmod
48	-RRB-	-rrb-	-RRB-	_	45	punct
49	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	compete	compete	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	,	,	,	_	6	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	6	punct
12	for	for	IN	_	13	case
13	sites	site	NNS	_	6	nmod
14	of	of	IN	_	15	case
15	metabolism	metabolism	NN	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	liver	liver	NN	_	13	nmod
19	,	,	,	_	6	punct
20	thus	thus	RB	_	21	advmod
21	elevating	elevate	VBG	_	6	acl
22	the	the	DT	_	24	det
23	serum	serum	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	of	of	IN	_	27	case
26	such	such	JJ	_	27	amod
27	compounds	compound	NNS	_	24	nmod
28	to	to	TO	_	31	case
29	potentially	potentially	RB	_	30	advmod
30	toxic	toxic	JJ	_	31	amod
31	levels	level	NNS	_	21	nmod
32	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	11	advmod
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	11	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	is	be	VBZ	_	11	auxpass
11	anticipated	anticipate	VBN	_	16	advcl
12	,	,	,	_	16	punct
13	it	it	PRP	_	16	nsubj
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	cop
16	necessary	necessary	JJ	_	0	ROOT
17	to	to	TO	_	18	mark
18	monitor	monitor	VB	_	16	ccomp
19	blood	blood	NN	_	20	compound
20	levels	level	NNS	_	18	dobj
21	and/or	and/or	CC	_	18	cc
22	reduce	reduce	VB	_	18	conj
23	the	the	DT	_	24	det
24	dosage	dosage	NN	_	22	dobj
25	of	of	IN	_	27	case
26	such	such	JJ	_	27	amod
27	compounds	compound	NNS	_	24	nmod
28	.	.	.	_	16	punct

1	Such	such	JJ	_	3	amod
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	under	under	IN	_	10	case
8	careful	careful	JJ	_	10	amod
9	medical	medical	JJ	_	10	amod
10	supervision	supervision	NN	_	6	nmod
11	.	.	.	_	6	punct

1	Administration	administration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	decreases	decrease	VBZ	_	0	ROOT
5	oral	oral	JJ	_	6	amod
6	clearance	clearance	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	by	by	IN	_	12	case
10	about	about	IN	_	11	advmod
11	5	5	CD	_	12	nummod
12	%	%	NN	_	4	nmod
13	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	implication	implication	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	effect	effect	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	Severe	severe	JJ	_	4	amod
4	Hepatic	hepatic	JJ	_	1	nmod
5	or	or	CC	_	4	cc
6	Renal	renal	JJ	_	4	conj
7	Impairment	impairment	NN	_	8	compound
8	Caution	caution	NN	_	4	dep
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	exercised	exercise	VBN	_	0	ROOT
12	when	when	WRB	_	16	advmod
13	drug1	drug1	NN	_	14	compound
14	Capsules	capsule	NNS	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	administered	administer	VBN	_	11	advcl
17	to	to	TO	_	18	case
18	patients	patient	NNS	_	16	nmod
19	with	with	IN	_	21	case
20	severe	severe	JJ	_	21	amod
21	hepatic	hepatic	JJ	_	18	nmod
22	or	or	CC	_	21	cc
23	renal	renal	JJ	_	24	amod
24	impairment	impairment	NN	_	21	conj
25	.	.	.	_	11	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	6	mark
5	there	there	EX	_	6	expl
6	are	be	VBP	_	3	ccomp
7	no	no	DT	_	9	neg
8	significant	significant	JJ	_	9	amod
9	alterations	alteration	NNS	_	6	nsubj
10	in	in	IN	_	12	case
11	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
12	parameters	parameter	NNS	_	9	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	to	to	TO	_	18	mark
18	warrant	warrant	VB	_	9	acl
19	dosage	dosage	NN	_	20	compound
20	adjustment	adjustment	NN	_	18	dobj
21	when	when	WRB	_	24	advmod
22	drug3	drug3	NN	_	24	nsubjpass
23	is	be	VBZ	_	24	auxpass
24	administered	administer	VBN	_	18	advcl
25	with	with	IN	_	27	case
26	these	these	DT	_	27	det
27	drugs	drug	NNS	_	24	nmod
28	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	that	that	IN	_	11	mark
6	coadministration	coadministration	NN	_	11	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	results	result	NNS	_	4	ccomp
12	in	in	IN	_	15	case
13	a	a	DT	_	15	det
14	significant	significant	JJ	_	15	amod
15	decrease	decrease	NN	_	11	nmod
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	pharmacokinetic	pharmacokinetic	JJ	_	19	amod
19	parameters	parameter	NNS	_	15	nmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	~	~	CD	_	22	compound
22	36	36	CD	_	23	nummod
23	%	%	NN	_	15	dep
24	for	for	IN	_	25	case
25	Cmax	cmax	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	~	~	NN	_	29	compound
28	28	28	CD	_	29	nummod
29	%	%	NN	_	23	conj
30	for	for	IN	_	31	case
31	AUC	auc	NN	_	29	nmod
32	-RRB-	-rrb-	-RRB-	_	23	punct
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	15	nmod
35	.	.	.	_	4	punct

1	Administration	administration	NN	_	10	nsubjpass
2	of	of	IN	_	5	case
3	a	a	DT	_	5	det
4	higher	higher	JJR	_	5	amod
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	when	when	WRB	_	12	advmod
12	coadministering	coadminister	VBG	_	10	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	or	or	CC	_	4	cc
8	drug3	drug3	NN	_	4	conj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
12	of	of	IN	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	were	be	VBD	_	16	auxpass
15	not	not	RB	_	16	neg
16	studied	study	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	4	advmod
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	cause	cause	VB	_	0	ROOT
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	arrhythmias	arrhythmia	NNS	_	7	dobj
11	during	during	IN	_	13	case
12	drug3	drug3	NN	_	13	compound
13	anesthesia	anesthesia	NN	_	7	nmod
14	and	and	CC	_	7	cc
15	therefore	therefore	RB	_	18	advmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	7	conj
19	only	only	RB	_	22	advmod
20	with	with	IN	_	22	case
21	great	great	JJ	_	22	amod
22	caution	caution	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	not	not	RB	_	26	neg
25	at	at	IN	_	26	case
26	all	all	DT	_	22	conj
27	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	The	the	DT	_	5	det
4	pressor	pressor	NN	_	5	compound
5	effect	effect	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	is	be	VBZ	_	10	auxpass
9	markedly	markedly	RB	_	10	advmod
10	potentiated	potentiate	VBN	_	1	dep
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug3	drug3	NN	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug4	drug4	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	16	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	9	case
8	these	these	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	16	punct
11	the	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	small	small	JJ	_	0	ROOT
17	and	and	CC	_	16	cc
18	used	use	VBN	_	16	conj
19	with	with	IN	_	21	case
20	due	due	JJ	_	21	amod
21	caution	caution	NN	_	18	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	pressor	pressor	NN	_	3	compound
3	response	response	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	9	aux
7	also	also	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	potentiated	potentiate	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	CNS-depressant	cns-depressant	JJ	_	3	amod
3	effect	effect	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	cop
7	additive	additive	JJ	_	0	ROOT
8	with	with	IN	_	9	case
9	that	that	DT	_	7	nmod
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	,	,	,	_	12	punct
14	including	include	VBG	_	15	case
15	drug3	drug3	NN	_	12	nmod
16	.	.	.	_	7	punct

1	As	as	IN	_	4	mark
2	is	be	VBZ	_	4	cop
3	the	the	DT	_	4	det
4	case	case	NN	_	12	advcl
5	with	with	IN	_	8	case
6	many	many	JJ	_	8	amod
7	medicinal	medicinal	JJ	_	8	amod
8	agents	agent	NNS	_	4	nmod
9	,	,	,	_	12	punct
10	drug1	drug1	NN	_	12	nsubj
11	may	may	MD	_	12	aux
12	slow	slow	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	metabolism	metabolism	NN	_	12	dobj
15	of	of	IN	_	19	case
16	a	a	DT	_	19	det
17	concomitantly	concomitantly	RB	_	18	advmod
18	administered	administer	VBN	_	19	amod
19	drug	drug	NN	_	14	nmod
20	.	.	.	_	12	punct

1	Should	should	MD	_	3	aux
2	this	this	DT	_	3	nsubj
3	occur	occur	VB	_	0	ROOT
4	,	,	,	_	3	punct
5	the	the	DT	_	8	det
6	higher	higher	JJR	_	8	amod
7	serum	serum	NN	_	8	compound
8	concentrations	concentration	NNS	_	13	nsubj
9	of	of	IN	_	11	case
10	that	that	DT	_	11	det
11	drug	drug	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	result	result	VB	_	3	ccomp
14	in	in	IN	_	19	case
15	increased	increase	VBN	_	19	amod
16	pharmacologic	pharmacologic	JJ	_	19	amod
17	or	or	CC	_	16	cc
18	adverse	adverse	JJ	_	16	conj
19	effects	effect	NNS	_	13	nmod
20	of	of	IN	_	22	case
21	that	that	DT	_	22	det
22	drug	drug	NN	_	19	nmod
23	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	occurrences	occurrence	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	administered	administer	VBN	_	5	advcl
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	or	or	CC	_	13	cc
18	drug4	drug4	NN	_	13	conj
19	-	-	:	_	9	punct
20	like	like	IN	_	21	case
21	drugs	drug	NNS	_	9	nmod
22	.	.	.	_	5	punct

1	Sever	sever	VB	_	0	ROOT
2	neurologic	neurologic	JJ	_	3	amod
3	signs	sign	NNS	_	9	nsubj
4	,	,	,	_	3	punct
5	including	include	VBG	_	6	case
6	coma	coma	NN	_	3	nmod
7	,	,	,	_	3	punct
8	have	have	VBP	_	9	aux
9	occurred	occur	VBN	_	1	ccomp
10	with	with	IN	_	12	case
11	concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	1	punct

1	Reduced	reduce	VBN	_	2	amod
2	absorption	absorption	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	when	when	WRB	_	14	advmod
11	those	those	DT	_	12	det
12	agents	agent	NNS	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	14	nmod
18	.	.	.	_	9	punct

1	When	when	WRB	_	16	advmod
2	daily	daily	JJ	_	3	amod
3	doses	dose	NNS	_	16	nsubjpass
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	2	2	CD	_	7	nummod
7	g	g	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	weekly	weekly	JJ	_	10	amod
10	doses	dose	NNS	_	7	conj
11	of	of	IN	_	14	case
12	drug2	drug2	NN	_	14	compound
13	7.5	7.5	CD	_	14	nummod
14	mg	mg	NN	_	10	nmod
15	were	be	VBD	_	16	auxpass
16	coadministered	coadminister	VBN	_	36	advcl
17	to	to	TO	_	21	case
18	15	15	CD	_	21	nummod
19	rheumatoid	rheumatoid	JJ	_	21	amod
20	arthritis	arthritis	NN	_	21	compound
21	patients	patient	NNS	_	16	nmod
22	in	in	IN	_	26	case
23	a	a	DT	_	26	det
24	drug-drug	drug-drug	JJ	_	26	amod
25	interaction	interaction	NN	_	26	compound
26	study	study	NN	_	21	nmod
27	,	,	,	_	36	punct
28	the	the	DT	_	30	det
29	pharmacokinetic	pharmacokinetic	JJ	_	30	amod
30	disposition	disposition	NN	_	36	nsubjpass
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	drugs	drug	NNS	_	30	nmod
34	was	be	VBD	_	36	auxpass
35	not	not	RB	_	36	neg
36	altered	alter	VBN	_	0	ROOT
37	.	.	.	_	36	punct

1	Daily	Daily	NNP	_	2	compound
2	doses	dose	NNS	_	25	nsubjpass
3	of	of	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	2	2	CD	_	6	nummod
6	g	g	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	maximum	maximum	NN	_	10	compound
9	3	3	CD	_	10	nummod
10	g	g	NN	_	6	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	and	and	CC	_	6	cc
13	weekly	weekly	JJ	_	14	amod
14	doses	dose	NNS	_	6	conj
15	of	of	IN	_	18	case
16	drug2	drug2	NN	_	18	compound
17	7.5	7.5	CD	_	18	nummod
18	mg	mg	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	maximum	maximum	NN	_	22	compound
21	15	15	CD	_	22	nummod
22	mg	mg	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	were	be	VBD	_	25	auxpass
25	administered	administer	VBN	_	0	ROOT
26	alone	alone	RB	_	25	advmod
27	or	or	CC	_	25	cc
28	in	in	IN	_	29	case
29	combination	combination	NN	_	25	conj
30	to	to	TO	_	34	case
31	310	310	CD	_	34	nummod
32	rheumatoid	rheumatoid	JJ	_	34	amod
33	arthritis	arthritis	NN	_	34	compound
34	patients	patient	NNS	_	29	nmod
35	in	in	IN	_	40	case
36	two	two	CD	_	40	nummod
37	controlled	controlled	JJ	_	40	amod
38	52-week	52-week	JJ	_	40	amod
39	clinical	clinical	JJ	_	40	amod
40	studies	study	NNS	_	34	nmod
41	.	.	.	_	25	punct

1	The	the	DT	_	4	det
2	overall	overall	JJ	_	4	amod
3	toxicity	toxicity	NN	_	4	compound
4	profile	profile	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	combination	combination	NN	_	4	nmod
8	revealed	reveal	VBD	_	0	ROOT
9	an	a	DT	_	11	det
10	increased	increase	VBN	_	11	amod
11	incidence	incidence	NN	_	8	dobj
12	of	of	IN	_	15	case
13	gastrointestinal	gastrointestinal	JJ	_	15	amod
14	adverse	adverse	JJ	_	15	amod
15	events	event	NNS	_	11	nmod
16	,	,	,	_	15	punct
17	especially	especially	RB	_	18	advmod
18	nausea	nausea	NN	_	15	appos
19	,	,	,	_	15	punct
20	when	when	WRB	_	21	advmod
21	compared	compare	VBN	_	8	advcl
22	to	to	TO	_	24	case
23	the	the	DT	_	24	det
24	incidence	incidence	NN	_	21	nmod
25	associated	associate	VBN	_	24	acl
26	with	with	IN	_	28	case
27	either	either	CC	_	28	det
28	drug	drug	NN	_	25	nmod
29	administered	administer	VBN	_	28	acl
30	alone	alone	RB	_	29	advmod
31	.	.	.	_	8	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	The	the	DT	_	6	det
6	presence	presence	NN	_	18	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	its	its	PRP$	_	11	nmod:poss
11	metabolites	metabolite	NNS	_	8	conj
12	in	in	IN	_	14	case
13	body	body	NN	_	14	compound
14	fluids	fluid	NNS	_	6	nmod
15	has	have	VBZ	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	3	appos
19	to	to	TO	_	20	mark
20	interfere	interfere	VB	_	18	xcomp
21	with	with	IN	_	24	case
22	laboratory	laboratory	NN	_	24	compound
23	test	test	NN	_	24	compound
24	procedures	procedure	NNS	_	20	nmod
25	.	.	.	_	3	punct

1	REFERENCES	reference	NNS	_	0	ROOT
2	7	7	CD	_	1	nummod
3	.	.	.	_	1	punct
4	Farr	Farr	NNP	_	5	compound
5	M	m	NN	_	1	dep
6	,	,	,	_	5	punct
7	et	et	FW	_	8	compound
8	al.	al.	FW	_	5	appos
9	.	.	.	_	1	punct

1	Immunodeficiencies	immunodeficiency	NNS	_	0	ROOT
2	associated	associate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	therapy	therapy	NN	_	2	nmod
6	in	in	IN	_	8	case
7	inflammatory	inflammatory	JJ	_	8	amod
8	arthritis	arthritis	NN	_	5	nmod
9	.	.	.	_	1	punct

1	British	british	JJ	_	3	amod
2	Jnl	jnl	NN	_	3	compound
3	Rheum	Rheum	NNP	_	0	ROOT
4	1991	1991	CD	_	3	nummod
5	;	;	:	_	3	punct
6	30:413	30:413	CD	_	7	compound
7	-417	-417	CD	_	3	dep
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	was	be	VBD	_	1	dep
5	a	a	DT	_	7	det
6	slight	slight	JJ	_	7	amod
7	increase	increase	NN	_	4	nsubj
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	area	area	NN	_	7	nmod
11	under	under	IN	_	13	case
12	the	the	DT	_	13	det
13	curve	curve	NN	_	7	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	AUC	auc	NN	_	13	dep
16	,	,	,	_	15	punct
17	11	11	CD	_	18	nummod
18	%	%	NN	_	15	appos
19	-RRB-	-rrb-	-RRB-	_	15	punct
20	and	and	CC	_	4	cc
21	mean	mean	VB	_	4	conj
22	peak	peak	JJ	_	24	amod
23	drug	drug	NN	_	24	compound
24	concentration	concentration	NN	_	21	dobj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	Cmax	cmax	NN	_	24	dep
27	,	,	,	_	26	punct
28	18	18	CD	_	29	nummod
29	%	%	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	of	of	IN	_	32	case
32	drug2	drug2	NN	_	24	nmod
33	with	with	IN	_	35	case
34	the	the	DT	_	35	det
35	co-administration	co-administration	NN	_	32	nmod
36	of	of	IN	_	39	case
37	100	100	CD	_	38	compound
38	mg	mg	NN	_	39	amod
39	drug3	drug3	NN	_	35	nmod
40	for	for	IN	_	42	case
41	10	10	CD	_	42	nummod
42	days	day	NNS	_	21	nmod
43	.	.	.	_	1	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	appropriately	appropriately	RB	_	6	advmod
8	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	While	while	IN	_	5	mark
2	co-administration	co-administration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	appeared	appear	VBD	_	20	advcl
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	clearance	clearance	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	by	by	IN	_	14	case
13	70	70	CD	_	14	nummod
14	%	%	NN	_	7	nmod
15	,	,	,	_	20	punct
16	these	these	DT	_	17	det
17	results	result	NNS	_	20	nsubj
18	are	be	VBP	_	20	cop
19	not	not	RB	_	20	neg
20	conclusive	conclusive	JJ	_	0	ROOT
21	because	because	IN	_	25	case
22	of	of	IN	_	21	mwe
23	the	the	DT	_	25	det
24	small	small	JJ	_	25	amod
25	number	number	NN	_	20	nmod
26	of	of	IN	_	27	case
27	subjects	subject	NNS	_	25	nmod
28	studied	study	VBN	_	27	acl
29	and	and	CC	_	20	cc
30	because	because	IN	_	32	mark
31	patients	patient	NNS	_	32	nsubj
32	took	take	VBD	_	20	conj
33	variable	variable	JJ	_	34	amod
34	doses	dose	NNS	_	32	dobj
35	of	of	IN	_	36	case
36	drug3	drug3	NN	_	34	nmod
37	.	.	.	_	20	punct

1	Combination	combination	NN	_	2	compound
2	therapy	therapy	NN	_	12	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	and	and	CC	_	4	cc
9	drug3	drug3	NN	_	4	conj
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	indicated	indicate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reverse	reverse	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	analgesic	analgesic	JJ	_	6	amod
6	activity	activity	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	17	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	including	include	VBG	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	e.g.	e.g.	FW	_	14	dep
14	smoking	smoking	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	may	may	MD	_	17	aux
17	result	result	VB	_	0	ROOT
18	in	in	IN	_	20	case
19	enhanced	enhance	VBN	_	20	amod
20	vasoconstriction	vasoconstriction	NN	_	17	nmod
21	.	.	.	_	17	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	drug3	drug3	NN	_	1	dep
9	,	,	,	_	8	punct
10	Oral	oral	JJ	_	11	amod
11	drug4	drug4	NN	_	8	conj
12	,	,	,	_	8	punct
13	drug5	drug5	NN	_	8	conj
14	,	,	,	_	8	punct
15	drug6	drug6	NN	_	8	conj

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	drug3	drug3	NN	_	1	dep
9	-	-	:	_	8	punct
10	impairs	impair	VBZ	_	8	dep
11	the	the	DT	_	13	det
12	intestinal	intestinal	JJ	_	13	amod
13	absorption	absorption	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	5	nsubj
5	decreases	decrease	VBZ	_	0	ROOT
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	;	;	:	_	5	punct

1	requirements	requirement	NNS	_	6	nsubjpass
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	conj
12	,	,	,	_	5	punct
13	and	and	CC	_	5	cc
14	drug6	drug6	NN	_	5	conj
15	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Absorption	absorption	NN	_	11	nsubjpass
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	decreased	decrease	VBN	_	1	appos
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	11	advcl
14	to	to	TO	_	19	case
15	12	12	CD	_	19	nummod
16	stable	stable	JJ	_	19	amod
17	renal	renal	JJ	_	19	amod
18	transplant	transplant	NN	_	19	compound
19	patients	patient	NNS	_	13	nmod
20	also	also	RB	_	21	advmod
21	taking	take	VBG	_	13	dep
22	drug3	drug3	NN	_	21	dobj
23	-	-	:	_	22	punct
24	drug4	drug4	NN	_	23	root
25	containing	contain	VBG	_	24	acl
26	drug5	drug5	NN	_	25	dobj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	30	30	CD	_	29	nummod
29	mL	ml	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	:	:	:	_	24	punct
32	the	the	DT	_	34	det
33	mean	mean	NN	_	34	compound
34	Cmax	cmax	NN	_	45	nsubj
35	and	and	CC	_	34	cc
36	AUC	auc	NN	_	40	compound
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	0-t	0-t	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	values	value	NNS	_	34	conj
41	for	for	IN	_	42	case
42	MPA	MPA	NNP	_	34	nmod
43	were	be	VBD	_	45	cop
44	25	25	CD	_	45	nummod
45	%	%	NN	_	24	dep
46	and	and	CC	_	45	cc
47	37	37	CD	_	48	nummod
48	%	%	NN	_	45	conj
49	lower	lower	JJR	_	45	advmod
50	,	,	,	_	45	punct
51	respectively	respectively	RB	_	45	advmod
52	,	,	,	_	45	punct
53	than	than	IN	_	57	mark
54	when	when	WRB	_	57	advmod
55	drug6	drug6	NN	_	57	nsubjpass
56	was	be	VBD	_	57	auxpass
57	administered	administer	VBN	_	45	advcl
58	alone	alone	RB	_	57	advmod
59	under	under	IN	_	61	case
60	fasting	fasting	NN	_	61	compound
61	conditions	condition	NNS	_	57	nmod
62	.	.	.	_	24	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	drug1	drug1	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	3	ccomp
11	simultaneously	simultaneously	RB	_	10	advmod
12	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	4	advmod
4	studied	study	VBN	_	19	advcl
5	in	in	IN	_	9	case
6	stable	stable	JJ	_	9	amod
7	renal	renal	JJ	_	9	amod
8	transplant	transplant	NN	_	9	compound
9	patients	patient	NNS	_	4	nmod
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	USP	usp	NN	_	17	compound
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	MODIFIED	modify	VBN	_	13	dep
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	pharmacokinetics	pharmacokinetic	NNS	_	9	conj
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	1	dep
20	by	by	IN	_	23	case
21	steady	steady	JJ	_	23	amod
22	state	state	NN	_	23	compound
23	dosing	dosing	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	taken	take	VBN	_	3	dep
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	;	;	:	_	7	punct

1	however	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	during	during	IN	_	5	case
4	the	the	DT	_	5	det
5	period	period	NN	_	11	nmod
6	of	of	IN	_	7	case
7	treatment	treatment	NN	_	5	nmod
8	,	,	,	_	11	punct
9	physicians	physician	NNS	_	11	nsubj
10	should	should	MD	_	11	aux
11	monitor	monitor	VB	_	0	ROOT
12	blood	blood	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	counts	count	NNS	_	11	dobj
15	.	.	.	_	11	punct

1	Both	both	DT	_	2	cc:preconj
2	drug1	drug1	NN	_	0	ROOT
3	/	/	:	_	2	punct
4	drug2	drug2	NN	_	7	compound
5	and	and	CC	_	4	cc
6	drug3	drug3	NN	_	4	conj
7	concentrations	concentration	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	increased	increase	VBN	_	2	dep
10	in	in	IN	_	15	case
11	the	the	DT	_	15	dep
12	presence	presence	NN	_	15	dep
13	of	of	IN	_	15	case
14	renal	renal	JJ	_	15	amod
15	impairment	impairment	NN	_	9	nmod
16	,	,	,	_	9	punct
17	their	they	PRP$	_	18	nmod:poss
18	coexistence	coexistence	NN	_	20	nsubj
19	may	may	MD	_	20	aux
20	compete	compete	VB	_	9	parataxis
21	for	for	IN	_	23	case
22	tubular	tubular	JJ	_	23	amod
23	secretion	secretion	NN	_	20	nmod
24	and	and	CC	_	20	cc
25	further	further	JJ	_	26	amod
26	increase	increase	NN	_	20	conj
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	concentrations	concentration	NNS	_	26	nmod
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	two	two	CD	_	29	nmod
33	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Given	give	VBN	_	10	mark
6	that	that	IN	_	10	mark
7	drug3	drug3	NN	_	10	nsubj
8	and	and	CC	_	7	cc
9	drug4	drug4	NN	_	7	conj
10	inhibit	inhibit	VBP	_	16	advcl
11	purine	purine	NN	_	12	compound
12	metabolism	metabolism	NN	_	10	dobj
13	,	,	,	_	16	punct
14	it	it	PRP	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	3	dep
17	that	that	IN	_	21	mark
18	drug5	drug5	NN	_	21	nsubjpass
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	administered	administer	VBN	_	16	ccomp
22	concomitantly	concomitantly	RB	_	21	advmod
23	with	with	IN	_	24	case
24	drug6	drug6	NN	_	21	nmod
25	or	or	CC	_	24	cc
26	drug7	drug7	NN	_	24	conj
27	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Drugs	drug	NNS	_	1	conj
4	that	that	WDT	_	5	nsubj
5	Bind	bind	VB	_	1	acl:relcl
6	Bile	Bile	NNP	_	7	compound
7	Acids	Acids	NNPS	_	5	dobj
8	:	:	:	_	1	punct
9	These	these	DT	_	10	det
10	drugs	drug	NNS	_	11	nsubj
11	interrupt	interrupt	VBP	_	1	dep
12	enterohepatic	enterohepatic	JJ	_	13	amod
13	recirculation	recirculation	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	reduce	reduce	VB	_	11	conj
16	drug2	drug2	NN	_	17	compound
17	exposure	exposure	NN	_	15	dobj
18	when	when	WRB	_	19	advmod
19	coadministered	coadminister	VBN	_	11	advcl
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	administer	administer	VB	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	or	or	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	agents	agent	NNS	_	8	conj
12	that	that	WDT	_	14	nsubj
13	may	may	MD	_	14	aux
14	interfere	interfere	VB	_	11	acl:relcl
15	with	with	IN	_	17	case
16	enterohepatic	enterohepatic	JJ	_	17	amod
17	recirculation	recirculation	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	drugs	drug	NNS	_	17	conj
20	that	that	WDT	_	22	nsubj
21	may	may	MD	_	22	aux
22	bind	bind	VB	_	17	acl:relcl
23	bile	bile	NN	_	24	compound
24	acids	acid	NNS	_	22	dobj
25	,	,	,	_	5	punct
26	for	for	IN	_	30	case
27	example	example	NN	_	30	compound
28	bile	bile	NN	_	30	compound
29	acid	acid	NN	_	30	compound
30	sequestrates	sequestrate	NNS	_	5	nmod
31	or	or	CC	_	30	cc
32	oral	oral	JJ	_	33	amod
33	drug3	drug3	NN	_	30	conj
34	,	,	,	_	5	punct
35	because	because	IN	_	38	case
36	of	of	IN	_	35	mwe
37	the	the	DT	_	38	det
38	potential	potential	JJ	_	5	nmod
39	to	to	TO	_	40	mark
40	reduce	reduce	VB	_	38	acl
41	the	the	DT	_	42	det
42	efficacy	efficacy	NN	_	40	dobj
43	of	of	IN	_	44	case
44	drug4	drug4	NN	_	42	nmod
45	.	.	.	_	5	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Given	give	VBN	_	7	case
5	the	the	DT	_	7	det
6	different	different	JJ	_	7	amod
7	metabolism	metabolism	NN	_	24	nsubjpass
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	oral	oral	JJ	_	12	amod
12	drug3	drug3	NN	_	9	conj
13	,	,	,	_	7	punct
14	no	no	DT	_	16	neg
15	drug	drug	NN	_	16	compound
16	interaction	interaction	NN	_	7	appos
17	between	between	IN	_	20	case
18	these	these	DT	_	20	det
19	two	two	CD	_	20	nummod
20	classes	class	NNS	_	16	nmod
21	of	of	IN	_	22	case
22	drug	drug	NN	_	20	nmod
23	is	be	VBZ	_	24	auxpass
24	expected	expect	VBN	_	2	dep
25	.	.	.	_	2	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	in	in	IN	_	7	case
4	a	a	DT	_	7	det
5	drug-drug	drug-drug	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	study	study	NN	_	9	nmod
8	,	,	,	_	9	punct
9	mean	mean	VB	_	0	ROOT
10	drug1	drug1	NN	_	11	compound
11	AUC	auc	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	decreased	decrease	VBN	_	9	ccomp
14	by	by	IN	_	16	case
15	15	15	CD	_	16	nummod
16	%	%	NN	_	13	nmod
17	when	when	WRB	_	18	advmod
18	coadministered	coadminister	VBN	_	13	advcl
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	9	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	10	nsubj
9	are	be	VBP	_	10	cop
10	co	co	SYM	_	5	ccomp
11	-	-	:	_	10	punct
12	administered	administer	VBN	_	23	csubjpass
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	additional	additional	JJ	_	21	amod
19	birth	birth	NN	_	21	compound
20	control	control	NN	_	21	compound
21	methods	method	NNS	_	16	conj
22	be	be	VB	_	23	auxpass
23	considered	consider	VBN	_	10	parataxis
24	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	During	during	IN	_	4	case
4	treatment	treatment	NN	_	1	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	4	punct
8	the	the	DT	_	9	det
9	use	use	NN	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	4	acl:relcl
15	and	and	CC	_	14	cc
16	patients	patient	NNS	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	advised	advise	VBN	_	14	conj
20	that	that	IN	_	25	mark
21	vaccinations	vaccination	NNS	_	25	nsubj
22	may	may	MD	_	25	aux
23	be	be	VB	_	25	cop
24	less	less	RBR	_	25	advmod
25	effective	effective	JJ	_	14	ccomp
26	.	.	.	_	1	punct

1	Influenza	influenza	NN	_	2	compound
2	vaccination	vaccination	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	of	of	IN	_	6	case
6	value	value	NN	_	0	ROOT
7	.	.	.	_	6	punct

1	Prescribers	prescriber	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	refer	refer	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	national	national	JJ	_	6	amod
6	guidelines	guideline	NNS	_	3	nmod
7	for	for	IN	_	9	case
8	influenza	influenza	NN	_	9	compound
9	vaccination	vaccination	NN	_	6	nmod
10	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	8	nsubj
2	that	that	WDT	_	3	nsubj
3	alter	alter	VBP	_	1	acl:relcl
4	the	the	DT	_	6	det
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	flora	flora	NN	_	3	dobj
7	may	may	MD	_	8	aux
8	interact	interact	VB	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	by	by	IN	_	12	mark
12	disrupting	disrupt	VBG	_	8	advcl
13	enterohepatic	enterohepatic	JJ	_	14	amod
14	recirculation	recirculation	NN	_	12	dobj
15	.	.	.	_	8	punct

1	Interference	interference	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	hydrolysis	hydrolysis	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	lead	lead	VB	_	0	ROOT
7	to	to	TO	_	9	case
8	less	less	JJR	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	available	available	JJ	_	9	amod
11	for	for	IN	_	12	case
12	absorption	absorption	NN	_	10	nmod
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	commonly	commonly	RB	_	10	advmod
10	used	use	VBN	_	8	acl
11	in	in	IN	_	12	case
12	COPD	copd	NN	_	10	nmod
13	without	without	IN	_	14	case
14	increases	increase	NNS	_	10	nmod
15	in	in	IN	_	18	case
16	adverse	adverse	JJ	_	18	amod
17	drug	drug	NN	_	18	compound
18	reactions	reaction	NNS	_	14	nmod
19	.	.	.	_	4	punct

1	These	these	DT	_	2	nsubj
2	include	include	VBP	_	0	ROOT
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	oral	oral	JJ	_	3	conj
9	and	and	CC	_	2	cc
10	inhaled	inhale	VBD	_	2	conj
11	drug3	drug3	NN	_	10	dobj
12	.	.	.	_	2	punct

1	However	however	RB	_	21	advmod
2	,	,	,	_	21	punct
3	the	the	DT	_	5	det
4	co	co	NN	_	5	compound
5	administration	administration	NN	_	21	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drug2	drug2	NN	_	5	nmod
11	containing	contain	VBG	_	10	acl
12	drugs	drug	NNS	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug3	drug3	NN	_	10	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	has	have	VBZ	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	and	and	CC	_	21	cc
23	is	be	VBZ	_	26	auxpass
24	therefore	therefore	RB	_	26	advmod
25	not	not	RB	_	26	neg
26	recommended	recommend	VBN	_	21	conj
27	.	.	.	_	21	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	:	:	:	_	1	punct
6	drug2	drug2	NN	_	8	nsubj
7	SHOULD	should	MD	_	8	aux
8	BE	be	VB	_	1	parataxis
9	USED	USED	NNP	_	8	dobj
10	WITH	with	IN	_	12	case
11	GREAT	great	JJ	_	12	amod
12	CAUTION	caution	NN	_	9	nmod
13	AND	and	CC	_	9	cc
14	IN	in	IN	_	16	case
15	REDUCED	REDUCED	NNP	_	16	compound
16	DOSAGE	DOSAGE	NNP	_	9	conj
17	IN	in	IN	_	18	case
18	PATIENTS	patient	NNS	_	16	nmod
19	WHO	who	WP	_	22	nsubj
20	ARE	be	VBP	_	22	aux
21	CONCURRENTLY	concurrently	RB	_	22	advmod
22	RECEIVING	receive	VBG	_	18	acl:relcl
23	OTHER	other	JJ	_	24	amod
24	drug3	drug3	NN	_	22	dobj
25	,	,	,	_	9	punct
26	GENERAL	GENERAL	NNP	_	27	compound
27	drug4	drug4	NN	_	9	conj
28	,	,	,	_	9	punct
29	drug5	drug5	NN	_	9	conj
30	,	,	,	_	9	punct
31	OTHER	other	NN	_	32	compound
32	drug6	drug6	NN	_	9	conj
33	,	,	,	_	9	punct
34	drug7	drug7	NN	_	9	conj
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	INCLUDING	include	VBG	_	34	dep
37	drug8	drug8	NN	_	36	dobj
38	-RRB-	-rrb-	-RRB-	_	36	punct
39	,	,	,	_	9	punct
40	drug9	drug9	NN	_	9	conj
41	AND	and	CC	_	9	cc
42	OTHER	other	NN	_	43	compound
43	drug10	drug10	NN	_	9	conj
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	INCLUDING	include	VBG	_	8	parataxis
46	drug11	drug11	NN	_	45	dobj
47	-RRB-	-rrb-	-RRB-	_	45	punct
48	.	.	.	_	1	punct

1	RESPIRATORY	respiratory	JJ	_	2	amod
2	DEPRESSION	depression	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	HYPOTENSION	hypotension	NN	_	2	conj
5	,	,	,	_	2	punct
6	AND	and	CC	_	2	cc
7	PROFOUND	profound	JJ	_	12	amod
8	SEDATION	sedation	NN	_	12	compound
9	OR	or	NN	_	12	compound
10	COMA	COMA	NNP	_	12	compound
11	MAY	MAY	NNP	_	12	compound
12	RESULT	RESULT	NNP	_	2	conj
13	.	.	.	_	2	punct

1	Drug-Drug	Drug-Drug	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	8	det
5	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj
8	interactions	interaction	NNS	_	18	nsubjpass
9	between	between	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	capsules	capsule	NNS	_	8	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	11	conj
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	determined	determine	VBN	_	2	dep
19	.	.	.	_	2	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	interactions	interaction	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	drug1	drug1	NN	_	9	compound
9	capsules	capsule	NNS	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	NOT	not	RB	_	13	advmod
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	6	conj
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drug2	drug2	NN	_	15	nmod
19	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	10	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	capsules	capsule	NNS	_	5	conj
9	was	be	VBD	_	10	auxpass
10	investigated	investigate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	significant	significant	JJ	_	5	amod
5	changes	change	NNS	_	3	dobj
6	in	in	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	clearance	clearance	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	26	26	CD	_	11	compound
11	%	%	NN	_	12	amod
12	decrease	decrease	NN	_	5	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	and	and	CC	_	5	cc
15	AUC	auc	NN	_	5	conj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	44	44	CD	_	18	compound
18	%	%	NN	_	19	amod
19	increase	increase	NN	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	4	compound
4	capsules	capsule	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	in	in	IN	_	11	case
11	combination	combination	NN	_	7	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	7	punct
15	particularly	particularly	RB	_	17	advmod
16	at	at	IN	_	17	case
17	doses	dose	NNS	_	7	nmod
18	higher	higher	JJR	_	17	amod
19	than	than	IN	_	21	case
20	0.4	0.4	CD	_	21	nummod
21	mg	mg	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Results	result	NNS	_	0	ROOT
2	from	from	IN	_	17	case
3	limited	limit	VBN	_	17	dep
4	in	in	FW	_	5	compound
5	vitro	vitro	FW	_	6	advmod
6	and	and	CC	_	17	cc
7	in	in	FW	_	11	amod
8	vivo	vivo	FW	_	7	dep
9	drug-drug	drug-drug	JJ	_	11	amod
10	interaction	interaction	NN	_	11	compound
11	studies	study	NNS	_	17	nsubj
12	between	between	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	are	be	VBP	_	17	cop
17	inconclusive	inconclusive	JJ	_	1	nmod
18	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	14	compound
14	capsules	capsule	NNS	_	11	conj
15	.	.	.	_	6	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	15	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	6	case
4	extended	extended	JJ	_	6	amod
5	release	release	NN	_	6	compound
6	drug1	drug1	NN	_	2	nmod
7	plus	plus	CC	_	6	cc
8	a	a	DT	_	10	det
9	catecholamine	catecholamine	NN	_	10	compound
10	depletor	depletor	NN	_	6	conj
11	should	should	MD	_	15	aux
12	therefore	therefore	RB	_	15	advmod
13	be	be	VB	_	15	auxpass
14	closely	closely	RB	_	15	advmod
15	observed	observe	VBN	_	0	ROOT
16	for	for	IN	_	17	case
17	evidence	evidence	NN	_	15	nmod
18	of	of	IN	_	19	case
19	hypotension	hypotension	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	marked	marked	JJ	_	22	amod
22	bradycardia	bradycardia	NN	_	19	conj
23	,	,	,	_	17	punct
24	which	which	WDT	_	26	nsubj
25	may	may	MD	_	26	aux
26	produce	produce	VB	_	17	acl:relcl
27	vertigo	vertigo	NN	_	26	dobj
28	,	,	,	_	27	punct
29	syncope	syncope	NN	_	27	conj
30	,	,	,	_	27	punct
31	or	or	CC	_	27	cc
32	postural	postural	JJ	_	33	amod
33	hypotension	hypotension	NN	_	27	conj
34	.	.	.	_	15	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	3	nsubj
3	contra-indicated	contra-indicate	VBN	_	0	ROOT
4	:	:	:	_	3	punct
5	-	-	:	_	3	punct
6	Vasoconstrictive	vasoconstrictive	JJ	_	7	amod
7	drug1	drug1	NN	_	3	dobj
8	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administrations	administration	NNS	_	0	ROOT
3	not	not	RB	_	4	neg
4	recommended	recommend	VBN	_	2	acl
5	:	:	:	_	2	punct
6	-	-	:	_	2	punct
7	drug1	drug1	NN	_	2	dep
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	:	:	:	_	2	punct
11	Certain	certain	JJ	_	12	amod
12	drug3	drug3	NN	_	13	nsubj
13	interact	interact	VBP	_	2	dep
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug5	drug5	NN	_	15	conj
18	leading	lead	VBG	_	15	acl
19	to	to	TO	_	22	case
20	increased	increase	VBN	_	22	amod
21	serum	serum	NN	_	22	compound
22	concentrations	concentration	NNS	_	18	nmod
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	latter	latter	JJ	_	22	nmod
26	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	result	result	VB	_	0	ROOT
4	in	in	IN	_	7	case
5	severe	severe	JJ	_	7	amod
6	ventricular	ventricular	JJ	_	7	amod
7	arrhythmia	arrhythmia	NN	_	3	nmod
8	,	,	,	_	7	punct
9	typically	typically	RB	_	12	advmod
10	torsades	torsades	FW	_	12	compound
11	de	de	FW	_	12	compound
12	pointe	pointe	FW	_	7	appos
13	.	.	.	_	3	punct

1	Although	although	IN	_	8	mark
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	reaction	reaction	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	demonstrated	demonstrate	VBN	_	22	advcl
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	22	punct
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	22	nsubjpass
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	drug4	drug4	NN	_	17	conj
20	is	be	VBZ	_	22	auxpass
21	not	not	RB	_	22	neg
22	recommended	recommend	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	3	root
5	:	:	:	_	4	punct
6	Other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	23	nsubjpass
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug3	drug3	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	7	punct
14	which	which	WDT	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	metabolised	metabolise	VBN	_	7	acl:relcl
17	by	by	IN	_	20	case
18	hepatic	hepatic	JJ	_	20	amod
19	CYP3A	cyp3a	NN	_	20	compound
20	isozymes	isozyme	NNS	_	16	nmod
21	have	have	VBP	_	23	aux
22	been	be	VBN	_	23	auxpass
23	associated	associate	VBN	_	4	dep
24	with	with	IN	_	27	case
25	QT	qt	NN	_	27	compound
26	interval	interval	NN	_	27	compound
27	prolongation	prolongation	NN	_	23	nmod
28	and/or	and/or	CC	_	27	cc
29	cardiac	cardiac	JJ	_	30	amod
30	arrythmias	arrythmia	NNS	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	35	punct
32	typically	typically	RB	_	35	advmod
33	torsades	torsades	FW	_	35	compound
34	de	de	FW	_	35	compound
35	pointe	pointe	FW	_	30	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	as	as	IN	_	39	case
38	a	a	DT	_	39	det
39	result	result	NN	_	23	nmod
40	of	of	IN	_	41	case
41	increase	increase	NN	_	39	nmod
42	in	in	IN	_	45	case
43	their	they	PRP$	_	45	nmod:poss
44	serum	serum	NN	_	45	compound
45	level	level	NN	_	41	nmod
46	subsequent	subsequent	JJ	_	41	amod
47	to	to	TO	_	48	case
48	interaction	interaction	NN	_	46	nmod
49	with	with	IN	_	51	case
50	significant	significant	JJ	_	51	amod
51	inhibitors	inhibitor	NNS	_	48	nmod
52	of	of	IN	_	54	case
53	the	the	DT	_	54	det
54	isozyme	isozyme	NN	_	51	nmod
55	,	,	,	_	51	punct
56	including	include	VBG	_	58	case
57	some	some	DT	_	58	det
58	drug5	drug5	NN	_	51	nmod
59	.	.	.	_	4	punct

1	Although	although	IN	_	7	mark
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	risk	risk	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	verified	verify	VBN	_	19	advcl
8	for	for	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	19	punct
11	combination	combination	NN	_	19	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	with	with	IN	_	16	case
15	such	such	JJ	_	16	amod
16	drugs	drug	NNS	_	11	nmod
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	recommended	recommend	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	16	nsubjpass
5	of	of	IN	_	8	case
6	chronic	chronic	JJ	_	8	amod
7	drug2	drug2	NN	_	8	compound
8	use	use	NN	_	4	nmod
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	4	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	known	know	VBN	_	1	appos
17	.	.	.	_	1	punct

1	When	when	WRB	_	10	advmod
2	a	a	DT	_	6	det
3	single	single	JJ	_	6	amod
4	100	100	CD	_	5	compound
5	mg	mg	NN	_	6	amod
6	dose	dose	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	41	advcl
11	one	one	CD	_	12	nummod
12	hour	hour	NN	_	10	nmod
13	after	after	IN	_	12	case
14	the	the	DT	_	15	det
15	initiation	initiation	NN	_	12	dep
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	300	300	CD	_	20	nummod
20	mg	mg	NN	_	17	dep
21	four	four	CD	_	22	nummod
22	times	time	NNS	_	20	nmod:tmod
23	a	a	DT	_	24	det
24	day	day	NN	_	22	nmod:npmod
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	,	,	,	_	41	punct
27	the	the	DT	_	31	det
28	apparent	apparent	JJ	_	31	amod
29	total	total	JJ	_	31	amod
30	drug3	drug3	NN	_	31	compound
31	clearance	clearance	NN	_	41	nsubjpass
32	of	of	IN	_	35	case
33	this	this	DT	_	35	det
34	single	single	JJ	_	35	amod
35	dose	dose	NN	_	31	nmod
36	in	in	IN	_	39	case
37	normal	normal	JJ	_	39	amod
38	healthy	healthy	JJ	_	39	amod
39	adults	adult	NNS	_	31	nmod
40	was	be	VBD	_	41	auxpass
41	reduced	reduce	VBN	_	0	ROOT
42	by	by	IN	_	44	case
43	18	18	CD	_	44	nummod
44	%	%	NN	_	41	nmod
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	compared	compare	VBN	_	41	dep
47	to	to	TO	_	52	case
48	the	the	DT	_	52	det
49	apparent	apparent	JJ	_	52	amod
50	total	total	JJ	_	52	amod
51	drug4	drug4	NN	_	52	compound
52	clearance	clearance	NN	_	46	nmod
53	in	in	IN	_	56	case
54	the	the	DT	_	56	det
55	same	same	JJ	_	56	amod
56	subjects	subject	NNS	_	52	nmod
57	in	in	IN	_	61	case
58	the	the	DT	_	61	dep
59	absence	absence	NN	_	61	dep
60	of	of	IN	_	61	case
61	drug5	drug5	NN	_	52	nmod
62	-RRB-	-rrb-	-RRB-	_	46	punct
63	.	.	.	_	41	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	100	100	CD	_	6	nummod
6	mg	mg	NN	_	3	appos
7	,	,	,	_	3	punct
8	was	be	VBD	_	9	auxpass
9	given	give	VBN	_	1	appos
10	twice	twice	RB	_	11	advmod
11	daily	daily	RB	_	9	advmod
12	for	for	IN	_	14	case
13	13	13	CD	_	14	nummod
14	days	day	NNS	_	9	nmod
15	to	to	TO	_	18	case
16	12	12	CD	_	18	nummod
17	healthy	healthy	JJ	_	18	amod
18	volunteers	volunteer	NNS	_	9	nmod
19	.	.	.	_	1	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	14	nmod
3	11	11	CD	_	2	nummod
4	,	,	,	_	14	punct
5	drug1	drug1	NN	_	14	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	650	650	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	four	four	CD	_	10	compound
10	times	time	NNS	_	8	dep
11	daily	daily	JJ	_	10	advmod
12	-RRB-	-rrb-	-RRB-	_	8	punct
13	was	be	VBD	_	14	auxpass
14	started	start	VBN	_	0	ROOT
15	and	and	CC	_	14	cc
16	continued	continue	VBN	_	14	conj
17	for	for	IN	_	19	case
18	8	8	CD	_	19	nummod
19	days	day	NNS	_	16	nmod
20	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	assessed	assess	VBN	_	0	ROOT
7	on	on	IN	_	8	case
8	days	day	NNS	_	6	nmod
9	11	11	CD	_	8	dep
10	and	and	CC	_	9	cc
11	13	13	CD	_	9	conj
12	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	reduced	reduce	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	peak	peak	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	and	and	CC	_	7	cc
9	AUC	auc	NN	_	10	compound
10	values	value	NNS	_	7	conj
11	for	for	IN	_	12	case
12	drug2	drug2	NN	_	7	nmod
13	by	by	IN	_	16	case
14	approximately	approximately	RB	_	15	advmod
15	11	11	CD	_	16	nummod
16	%	%	NN	_	4	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	100	100	CD	_	6	nummod
6	mg	mg	NN	_	3	appos
7	,	,	,	_	3	punct
8	was	be	VBD	_	9	auxpass
9	given	give	VBN	_	1	appos
10	twice	twice	RB	_	12	advmod
11	daily	daily	JJ	_	12	amod
12	fro	fro	NN	_	9	dobj
13	13	13	CD	_	14	nummod
14	days	day	NNS	_	12	nmod:npmod
15	to	to	TO	_	14	dep
16	12	12	CD	_	18	nummod
17	healthy	healthy	JJ	_	18	amod
18	volunteers	volunteer	NNS	_	14	dep
19	.	.	.	_	1	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	15	nmod
3	11	11	CD	_	2	nummod
4	,	,	,	_	15	punct
5	drug1	drug1	NN	_	15	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	650	650	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	,	,	,	_	8	punct
10	four	four	CD	_	11	compound
11	times	time	NNS	_	8	appos
12	daily	daily	JJ	_	11	advmod
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	was	be	VBD	_	15	auxpass
15	started	start	VBN	_	0	ROOT
16	and	and	CC	_	15	cc
17	continued	continue	VBN	_	15	conj
18	for	for	IN	_	20	case
19	8	8	CD	_	20	nummod
20	days	day	NNS	_	17	nmod
21	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	assessed	assess	VBN	_	0	ROOT
7	on	on	IN	_	8	case
8	days	day	NNS	_	6	nmod
9	11	11	CD	_	8	dep
10	and	and	CC	_	9	cc
11	13	13	CD	_	9	conj
12	.	.	.	_	6	punct

1	Peak	peak	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	9	nsubjpass
4	and	and	CC	_	3	cc
5	AUC	auc	NN	_	3	conj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	were	be	VBD	_	9	auxpass
9	reduced	reduce	VBN	_	0	ROOT
10	approximately	approximately	RB	_	11	advmod
11	10	10	CD	_	12	nummod
12	%	%	NN	_	9	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	9	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	9	punct

1	Because	because	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	19	advcl
6	to	to	TO	_	7	mark
7	depress	depress	VB	_	5	xcomp
8	plasma	plasma	NN	_	10	compound
9	prothrombin	prothrombin	NN	_	10	compound
10	activity	activity	NN	_	7	dobj
11	,	,	,	_	19	punct
12	patients	patient	NNS	_	19	nsubj
13	who	who	WP	_	17	nsubj
14	are	be	VBP	_	17	cop
15	on	on	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	therapy	therapy	NN	_	12	acl:relcl
18	may	may	MD	_	19	aux
19	require	require	VB	_	0	ROOT
20	downward	downward	JJ	_	21	amod
21	adjustment	adjustment	NN	_	19	dobj
22	of	of	IN	_	25	case
23	their	they	PRP$	_	25	nmod:poss
24	drug3	drug3	NN	_	25	compound
25	dosage	dosage	NN	_	21	nmod
26	.	.	.	_	19	punct

1	Since	since	IN	_	5	mark
2	bacteriostatic	bacteriostatic	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	15	advcl
6	with	with	IN	_	9	case
7	the	the	DT	_	9	det
8	bactericidal	bactericidal	JJ	_	9	amod
9	action	action	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	15	punct
13	it	it	PRP	_	15	nsubj
14	is	be	VBZ	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	avoid	avoid	VB	_	15	xcomp
18	giving	give	VBG	_	17	xcomp
19	drug2	drug2	NN	_	18	dobj
20	in	in	IN	_	21	case
21	conjunction	conjunction	NN	_	18	nmod
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	15	punct

1	Absorption	absorption	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	is	be	VBZ	_	5	auxpass
5	impaired	impair	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	containing	contain	VBG	_	7	acl
9	drug3	drug3	NN	_	8	dobj
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	or	or	CC	_	9	cc
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	5	punct
15	and	and	CC	_	5	cc
16	drug6	drug6	NN	_	5	conj
17	-	-	:	_	16	punct
18	containing	contain	VBG	_	16	acl
19	preparations	preparation	NNS	_	18	dobj
20	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	result	result	VB	_	10	xcomp
13	in	in	IN	_	16	case
14	fatal	fatal	JJ	_	16	amod
15	renal	renal	JJ	_	16	amod
16	toxicity	toxicity	NN	_	12	nmod
17	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	render	render	VB	_	0	ROOT
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	13	nsubj
12	less	less	RBR	_	13	advmod
13	effective	effective	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	There	there	EX	_	8	expl
2	have	have	VBP	_	8	aux
3	been	be	VBN	_	8	cop
4	no	no	DT	_	8	neg
5	formal	formal	JJ	_	8	amod
6	drug	drug	NN	_	8	compound
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	0	ROOT
9	performed	perform	VBN	_	8	acl
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	in	in	IN	_	13	case
13	humans	human	NNS	_	11	nmod
14	.	.	.	_	8	punct

1	Administration	administration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	combination	combination	NN	_	1	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	resulted	result	VBD	_	0	ROOT
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	two-fold	two-fold	JJ	_	12	amod
12	decrease	decrease	NN	_	8	nmod
13	in	in	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	clearance	clearance	NN	_	12	nmod
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	non-human	non-human	JJ	_	20	amod
19	primate	primate	JJ	_	20	amod
20	study	study	NN	_	12	nmod
21	and	and	CC	_	12	cc
22	in	in	IN	_	25	case
23	a	a	DT	_	25	det
24	1.5-fold	1.5-fold	JJ	_	25	amod
25	increase	increase	NN	_	12	conj
26	in	in	IN	_	29	case
27	drug4	drug4	NN	_	29	compound
28	serum	serum	NN	_	29	compound
29	levels	level	NNS	_	25	nmod
30	in	in	IN	_	32	case
31	clinical	clinical	JJ	_	32	amod
32	studies	study	NNS	_	25	nmod
33	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	22	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	that	that	WDT	_	10	nsubj
10	produce	produce	VBP	_	8	acl:relcl
11	dry	dry	JJ	_	12	amod
12	mouth	mouth	NN	_	10	dobj
13	,	,	,	_	12	punct
14	constipation	constipation	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	other	other	JJ	_	20	amod
18	anticholinergic	anticholinergic	JJ	_	20	amod
19	pharmacological	pharmacological	JJ	_	20	amod
20	effects	effect	NNS	_	12	conj
21	may	may	MD	_	22	aux
22	increase	increase	VB	_	0	ROOT
23	the	the	DT	_	24	det
24	frequency	frequency	NN	_	22	dobj
25	and/or	and/or	CC	_	24	cc
26	severity	severity	NN	_	24	conj
27	of	of	IN	_	29	case
28	such	such	JJ	_	29	amod
29	effects	effect	NNS	_	24	nmod
30	.	.	.	_	22	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	potentially	potentially	RB	_	4	advmod
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	11	case
8	some	some	DT	_	11	det
9	concomitantly	concomitantly	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	due	due	JJ	_	6	amod
13	to	to	TO	_	15	case
14	anticholinergic	anticholinergic	JJ	_	15	amod
15	effects	effect	NNS	_	12	nmod
16	on	on	IN	_	18	case
17	gastrointestinal	gastrointestinal	JJ	_	18	amod
18	motility	motility	NN	_	15	nmod
19	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Eliminated	eliminate	VBN	_	1	acl
3	by	by	IN	_	6	case
4	Active	active	JJ	_	6	amod
5	Tubular	tubular	JJ	_	6	amod
6	Secretion	secretion	NN	_	2	nmod
7	:	:	:	_	1	punct
8	Although	although	IN	_	19	mark
9	studies	study	NNS	_	19	nsubjpass
10	to	to	TO	_	11	mark
11	assess	assess	VB	_	9	acl
12	drug-drug	drug-drug	JJ	_	13	amod
13	interactions	interaction	NNS	_	11	dobj
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	have	have	VBP	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	conducted	conduct	VBN	_	22	advcl
20	,	,	,	_	22	punct
21	drug2	drug2	NN	_	22	nsubj
22	has	have	VBZ	_	1	dep
23	the	the	DT	_	24	det
24	potential	potential	NN	_	22	dobj
25	for	for	IN	_	27	case
26	pharmacokinetic	pharmacokinetic	JJ	_	27	amod
27	interactions	interaction	NNS	_	24	nmod
28	with	with	IN	_	30	case
29	other	other	JJ	_	30	amod
30	drugs	drug	NNS	_	27	nmod
31	that	that	WDT	_	33	nsubjpass
32	are	be	VBP	_	33	auxpass
33	eliminated	eliminate	VBN	_	30	acl:relcl
34	by	by	IN	_	37	case
35	active	active	JJ	_	37	amod
36	tubular	tubular	JJ	_	37	amod
37	secretion	secretion	NN	_	33	nmod
38	-LRB-	-lrb-	-LRB-	_	22	punct
39	e.g.	e.g.	FW	_	38	root
40	drug3	drug3	FW	_	39	dep
41	,	,	,	_	40	punct
42	drug4	drug4	NN	_	40	conj
43	,	,	,	_	40	punct
44	drug5	drug5	NN	_	40	conj
45	,	,	,	_	40	punct
46	drug6	drug6	NN	_	40	conj
47	,	,	,	_	40	punct
48	drug7	drug7	NN	_	40	conj
49	,	,	,	_	40	punct
50	drug8	drug8	NN	_	40	conj
51	and	and	CC	_	40	cc
52	drug9	drug9	NN	_	40	conj
53	-RRB-	-rrb-	-RRB-	_	39	punct
54	.	.	.	_	39	punct

1	Coadministration	coadministration	NN	_	15	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	eliminated	eliminate	VBN	_	5	acl:relcl
9	by	by	IN	_	13	case
10	active	active	JJ	_	13	amod
11	renal	renal	JJ	_	13	amod
12	tubular	tubular	JJ	_	13	amod
13	secretion	secretion	NN	_	8	nmod
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	18	det
17	serum	serum	NN	_	18	compound
18	concentration	concentration	NN	_	15	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	and/or	and/or	CC	_	20	cc
22	the	the	DT	_	24	det
23	coadministered	coadminister	VBN	_	24	amod
24	drug	drug	NN	_	20	conj
25	due	due	JJ	_	27	case
26	to	to	TO	_	25	mwe
27	competition	competition	NN	_	24	nmod
28	for	for	IN	_	31	case
29	this	this	DT	_	31	det
30	elimination	elimination	NN	_	31	compound
31	pathway	pathway	NN	_	27	nmod
32	.	.	.	_	15	punct

1	Careful	careful	JJ	_	3	amod
2	patient	patient	NN	_	3	compound
3	monitoring	monitoring	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	such	such	JJ	_	10	amod
10	drugs	drug	NNS	_	8	dobj
11	.	.	.	_	5	punct

1	Drug-Laboratory-Test	Drug-Laboratory-Test	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	Interactions	interaction	NNS	_	12	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	laboratory	laboratory	NN	_	8	compound
8	tests	test	NNS	_	5	conj
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	6	mark
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	because	because	IN	_	23	mark
15	the	the	DT	_	17	det
16	extrapyramidal	extrapyramidal	JJ	_	17	amod
17	effects	effect	NNS	_	23	nsubjpass
18	of	of	IN	_	20	case
19	these	these	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	expected	expect	VBN	_	4	advcl
24	to	to	TO	_	26	mark
25	be	be	VB	_	26	auxpass
26	potentiated	potentiate	VBN	_	23	xcomp
27	by	by	IN	_	28	case
28	inhibition	inhibition	NN	_	26	nmod
29	of	of	IN	_	31	case
30	catecholamine	catecholamine	NN	_	31	compound
31	synthesis	synthesis	NN	_	28	nmod
32	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	6	conj
10	can	can	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	their	they	PRP$	_	14	nmod:poss
13	sedative	sedative	JJ	_	14	amod
14	effects	effect	NNS	_	11	dobj
15	.	.	.	_	11	punct

1	You	you	PRP	_	4	nsubj
2	can	can	MD	_	4	aux
3	not	not	RB	_	4	neg
4	take	take	VB	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	if	if	IN	_	9	mark
7	you	you	PRP	_	9	nsubj
8	have	have	VBP	_	9	aux
9	taken	take	VBN	_	4	advcl
10	a	a	DT	_	9	dobj
11	drug2	drug2	NN	_	10	amod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug3	drug3	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug4	drug4	NN	_	11	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug5	drug5	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	drug6	drug6	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug7	drug7	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	or	or	CC	_	17	cc
28	drug8	drug8	NN	_	17	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	drug9	drug9	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	in	in	IN	_	36	case
33	the	the	DT	_	36	det
34	last	last	JJ	_	36	amod
35	14	14	CD	_	36	nummod
36	days	day	NNS	_	11	nmod
37	.	.	.	_	4	punct

1	Changes	change	NNS	_	11	nsubj
2	in	in	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	8	amod
6	diabetes	diabetes	NN	_	8	compound
7	drug	drug	NN	_	8	compound
8	therapies	therapy	NNS	_	3	conj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	necessary	necessary	JJ	_	0	ROOT
12	during	during	IN	_	13	case
13	treatment	treatment	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	an	a	DT	_	6	det
6	increase	increase	NN	_	3	nmod
7	in	in	IN	_	9	case
8	blood	blood	NN	_	9	compound
9	pressure	pressure	NN	_	6	nmod
10	.	.	.	_	3	punct

1	Tell	tell	VB	_	0	ROOT
2	your	you	PRP$	_	3	nmod:poss
3	doctor	doctor	NN	_	1	dobj
4	if	if	IN	_	7	mark
5	you	you	PRP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	taking	take	VBG	_	1	advcl
8	drug1	drug1	NN	_	7	dobj
9	.	.	.	_	1	punct

1	Before	before	IN	_	2	mark
2	taking	take	VBG	_	6	advcl
3	this	this	DT	_	4	det
4	medication	medication	NN	_	2	dobj
5	,	,	,	_	6	punct
6	tell	tell	VB	_	0	ROOT
7	your	you	PRP$	_	8	nmod:poss
8	doctor	doctor	NN	_	6	dobj
9	if	if	IN	_	12	mark
10	you	you	PRP	_	12	nsubj
11	are	be	VBP	_	12	aux
12	taking	take	VBG	_	6	advcl
13	a	a	DT	_	14	det
14	drug1	drug1	NN	_	12	dobj
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug2	drug2	NN	_	14	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug3	drug3	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	drug4	drug4	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug5	drug5	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	drug6	drug6	NN	_	17	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug7	drug7	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	17	punct
32	drug8	drug8	NN	_	17	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	drug9	drug9	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	17	punct
37	drug10	drug10	NN	_	17	conj
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	drug11	drug11	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	,	,	,	_	17	punct
42	drug12	drug12	NN	_	17	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug13	drug13	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	17	punct
47	drug14	drug14	NN	_	17	conj
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	drug15	drug15	NN	_	47	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	,	,	,	_	17	punct
52	or	or	CC	_	17	cc
53	drug16	drug16	NN	_	17	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	drug17	drug17	NN	_	53	appos
56	-RRB-	-rrb-	-RRB-	_	55	punct
57	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	accelerate	accelerate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	by	by	IN	_	13	case
12	the	the	DT	_	13	det
13	mechanism	mechanism	NN	_	6	nmod
14	of	of	IN	_	18	case
15	hepatic	hepatic	JJ	_	18	amod
16	microsomal	microsomal	JJ	_	18	amod
17	enzyme	enzyme	NN	_	18	compound
18	induction	induction	NN	_	13	nmod
19	,	,	,	_	6	punct
20	leading	lead	VBG	_	6	advcl
21	to	to	TO	_	23	case
22	an	a	DT	_	23	det
23	increase	increase	NN	_	20	nmod
24	in	in	IN	_	26	case
25	dosage	dosage	NN	_	26	compound
26	requirements	requirement	NNS	_	23	nmod
27	for	for	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	physicians	physician	NNS	_	6	nsubj
4	should	should	MD	_	6	aux
5	closely	closely	RB	_	6	advmod
6	monitor	monitor	VB	_	0	ROOT
7	patients	patient	NNS	_	6	dobj
8	for	for	IN	_	10	case
9	a	a	DT	_	10	det
10	change	change	NN	_	7	nmod
11	in	in	IN	_	14	case
12	drug1	drug1	NN	_	14	compound
13	dosage	dosage	NN	_	14	compound
14	requirements	requirement	NNS	_	10	nmod
15	when	when	WRB	_	16	advmod
16	administering	administer	VBG	_	6	advcl
17	drug2	drug2	NN	_	16	dobj
18	to	to	TO	_	19	case
19	patients	patient	NNS	_	16	nmod
20	on	on	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	15	nsubj
15	susceptible	susceptible	JJ	_	12	xcomp
16	to	to	TO	_	18	case
17	the	the	DT	_	18	det
18	influence	influence	NN	_	15	nmod
19	of	of	IN	_	22	case
20	hepatic	hepatic	JJ	_	22	amod
21	enzyme	enzyme	NN	_	22	compound
22	induction	induction	NN	_	18	nmod
23	.	.	.	_	7	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-	-	:	_	7	punct
3	containing	contain	VBG	_	7	csubjpass
4	drugs	drug	NNS	_	3	dobj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	cause	cause	VB	_	7	xcomp
10	prolonged	prolonged	JJ	_	12	amod
11	vasospastic	vasospastic	JJ	_	12	amod
12	reactions	reaction	NNS	_	9	dobj
13	.	.	.	_	7	punct

1	Because	because	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	a	a	DT	_	6	det
5	theoretical	theoretical	JJ	_	6	amod
6	basis	basis	NN	_	3	nsubj
7	that	that	IN	_	12	mark
8	these	these	DT	_	9	det
9	effects	effect	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	additive	additive	JJ	_	6	ccomp
13	,	,	,	_	12	punct
14	use	use	NN	_	37	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-	-	:	_	14	punct
18	containing	contain	VBG	_	14	dep
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	like	like	IN	_	23	case
23	drug3	drug3	NN	_	18	nmod
24	or	or	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	and	and	CC	_	18	cc
28	drug5	drug5	NN	_	18	conj
29	within	within	IN	_	31	case
30	24	24	CD	_	31	nummod
31	hours	hour	NNS	_	28	nmod
32	of	of	IN	_	34	case
33	each	each	DT	_	34	det
34	other	other	JJ	_	31	nmod
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	avoided	avoid	VBN	_	12	parataxis
38	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduce	reduce	VB	_	0	ROOT
3	drug2	drug2	NN	_	4	compound
4	clearance	clearance	NN	_	2	dobj
5	,	,	,	_	2	punct
6	significantly	significantly	RB	_	7	advmod
7	increasing	increase	VBG	_	2	advcl
8	systemic	systemic	JJ	_	9	amod
9	exposure	exposure	NN	_	7	dobj
10	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	4	det
4	use	use	NN	_	13	nsubjpass
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	tablets	tablet	NNS	_	4	nmod
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	4	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	is	be	VBZ	_	13	auxpass
13	contraindicated	contraindicate	VBN	_	0	ROOT
14	.	.	.	_	13	punct
15	drug3	drug3	NN	_	32	nsubjpass
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug4	drug4	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug5	drug5	NN	_	15	dep
23	,	,	,	_	22	punct
24	drug6	drug6	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug7	drug7	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug8	drug8	NN	_	22	appos
29	-RRB-	-rrb-	-RRB-	_	22	punct
30	have	have	VBP	_	32	aux
31	been	be	VBN	_	32	auxpass
32	reported	report	VBN	_	13	parataxis
33	,	,	,	_	32	punct
34	rarely	rarely	RB	_	32	advmod
35	,	,	,	_	32	punct
36	to	to	TO	_	37	mark
37	cause	cause	VB	_	32	xcomp
38	weakness	weakness	NN	_	37	dobj
39	,	,	,	_	38	punct
40	hyperreflexia	hyperreflexia	NN	_	38	conj
41	,	,	,	_	38	punct
42	and	and	CC	_	38	cc
43	incoordination	incoordination	NN	_	38	conj
44	when	when	WRB	_	45	advmod
45	coadministered	coadminister	VBN	_	37	advcl
46	with	with	IN	_	47	case
47	drug9	drug9	NN	_	45	nmod
48	.	.	.	_	13	punct

1	If	if	IN	_	11	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	11	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	is	be	VBZ	_	11	auxpass
10	clinically	clinically	RB	_	11	advmod
11	warranted	warrant	VBN	_	19	advcl
12	,	,	,	_	19	punct
13	appropriate	appropriate	JJ	_	14	amod
14	observation	observation	NN	_	19	nsubjpass
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	patient	patient	NN	_	14	nmod
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	80	80	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	10	punct
12	when	when	WRB	_	17	advmod
13	drug3	drug3	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug4	drug4	NN	_	13	conj
16	are	be	VBP	_	17	auxpass
17	administered	administer	VBN	_	10	acl:relcl
18	at	at	IN	_	21	case
19	the	the	DT	_	21	det
20	same	same	JJ	_	21	amod
21	time	time	NN	_	17	nmod
22	,	,	,	_	10	punct
23	and	and	CC	_	10	cc
24	60	60	CD	_	25	nummod
25	%	%	NN	_	10	conj
26	by	by	IN	_	28	case
27	some	some	DT	_	28	det
28	drug5	drug5	NN	_	6	nmod
29	-	-	:	_	28	punct
30	or	or	CC	_	28	cc
31	drug6	drug6	NN	_	28	conj
32	-	-	:	_	28	punct
33	containing	contain	VBG	_	28	acl
34	drug7	drug7	NN	_	33	dobj
35	,	,	,	_	28	punct
36	when	when	WRB	_	37	advmod
37	administered	administer	VBN	_	28	acl:relcl
38	1	1	CD	_	39	nummod
39	hour	hour	NN	_	37	nmod
40	before	before	IN	_	39	case
41	drug8	drug8	NN	_	39	dep
42	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	bioavailability	bioavailability	NN	_	3	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	11	case
8	up	up	RB	_	10	dep
9	to	to	TO	_	8	mwe
10	50	50	CD	_	11	nummod
11	%	%	NN	_	3	nmod
12	when	when	WRB	_	13	advmod
13	taken	take	VBN	_	3	advcl
14	2	2	CD	_	15	nummod
15	hours	hour	NNS	_	13	nmod
16	after	after	IN	_	15	case
17	drug3	drug3	NN	_	15	dep
18	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	2-4	2-4	CD	_	8	nummod
8	fold	fold	NN	_	6	dobj
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	but	but	CC	_	6	cc
12	is	be	VBZ	_	15	auxpass
13	not	not	RB	_	15	neg
14	significantly	significantly	RB	_	15	advmod
15	altered	alter	VBN	_	6	conj
16	by	by	IN	_	17	case
17	coadministration	coadministration	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	parameters	parameter	NNS	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	are	be	VBP	_	9	auxpass
7	not	not	RB	_	9	neg
8	significantly	significantly	RB	_	9	advmod
9	modified	modify	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	coadministration	coadministration	NN	_	9	nmod
13	.	.	.	_	9	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	show	show	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	displace	displace	VB	_	4	ccomp
10	drug2	drug2	NN	_	9	dobj
11	from	from	IN	_	14	case
12	its	its	PRP$	_	14	nmod:poss
13	binding	binding	NN	_	14	amod
14	site	site	NN	_	9	nmod
15	on	on	IN	_	16	case
16	protein	protein	NN	_	14	nmod
17	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	usually	usually	RB	_	2	advmod
4	complete	complete	JJ	_	5	amod
5	cross-resistance	cross-resistance	NN	_	2	nsubj
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	and	and	CC	_	7	cc
12	drug3	drug3	NN	_	14	compound
13	brand	brand	NN	_	14	compound
14	drug4	drug4	NN	_	7	conj
15	.	.	.	_	2	punct

1	As	as	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	27	advcl
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	evidence	evidence	NN	_	3	nsubj
7	that	that	IN	_	19	mark
8	drug1	drug1	NN	_	19	nsubj
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug2	drug2	NN	_	8	dep
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	drug4	drug4	NN	_	12	conj
18	-RRB-	-rrb-	-RRB-	_	12	punct
19	inhibit	inhibit	VBP	_	6	ccomp
20	the	the	DT	_	22	det
21	TPMT	tpmt	NN	_	22	compound
22	enzyme	enzyme	NN	_	19	dobj
23	,	,	,	_	27	punct
24	they	they	PRP	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	administered	administer	VBN	_	0	ROOT
28	with	with	IN	_	29	case
29	caution	caution	NN	_	27	nmod
30	to	to	TO	_	31	case
31	patients	patient	NNS	_	29	nmod
32	receiving	receive	VBG	_	31	acl
33	concurrent	concurrent	JJ	_	35	amod
34	drug5	drug5	NN	_	35	compound
35	therapy	therapy	NN	_	32	dobj
36	.	.	.	_	27	punct

1	Other	other	JJ	_	3	amod
2	eye	eye	NN	_	3	compound
3	drops	drop	NNS	_	20	nsubj
4	or	or	CC	_	3	cc
5	medications	medication	NNS	_	3	conj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug2	drug2	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	and	and	CC	_	8	cc
13	drug3	drug3	NN	_	8	conj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug4	drug4	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug5	drug5	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	may	may	MD	_	20	aux
20	decrease	decrease	VB	_	0	ROOT
21	the	the	DT	_	22	det
22	effects	effect	NNS	_	20	dobj
23	of	of	IN	_	25	case
24	drug6	drug6	NN	_	25	compound
25	ophthalmic	ophthalmic	JJ	_	22	nmod
26	.	.	.	_	20	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	4	advmod
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	cause	cause	VB	_	0	ROOT
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	arrhythmias	arrhythmia	NNS	_	7	dobj
11	during	during	IN	_	13	case
12	drug3	drug3	NN	_	13	compound
13	anesthesia	anesthesia	NN	_	7	nmod
14	and	and	CC	_	7	cc
15	therefore	therefore	RB	_	18	advmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	7	conj
19	only	only	RB	_	22	advmod
20	with	with	IN	_	22	case
21	great	great	JJ	_	22	amod
22	caution	caution	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	not	not	RB	_	26	neg
25	at	at	IN	_	26	case
26	all	all	DT	_	22	conj
27	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	pressor	pressor	NN	_	5	compound
5	effect	effect	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	is	be	VBZ	_	10	auxpass
9	markedly	markedly	RB	_	10	advmod
10	potentiated	potentiate	VBN	_	1	appos
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug3	drug3	NN	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug4	drug4	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	16	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	9	case
8	these	these	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	16	punct
11	the	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	small	small	JJ	_	0	ROOT
17	and	and	CC	_	16	cc
18	used	use	VBN	_	16	conj
19	with	with	IN	_	21	case
20	due	due	JJ	_	21	amod
21	caution	caution	NN	_	18	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	pressor	pressor	NN	_	3	compound
3	response	response	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	9	aux
7	also	also	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	potentiated	potentiate	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	expected	expect	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	inhibit	inhibit	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	metabolized	metabolize	VBN	_	10	acl
12	by	by	IN	_	16	case
13	cytochrome	cytochrome	NN	_	16	compound
14	P450	p450	NN	_	16	compound
15	enzymes	enzyme	NNS	_	16	compound
16	CYP1A2	cyp1a2	NN	_	11	nmod
17	,	,	,	_	16	punct
18	CYP2A6	cyp2a6	NN	_	16	conj
19	,	,	,	_	16	punct
20	CYP2B6	cyp2b6	NN	_	16	conj
21	,	,	,	_	16	punct
22	CYP2C8	cyp2c8	NN	_	16	conj
23	,	,	,	_	16	punct
24	CYP2C9	cyp2c9	NN	_	16	conj
25	,	,	,	_	16	punct
26	CYP2C19	cyp2c19	NN	_	16	conj
27	,	,	,	_	16	punct
28	CYP2D6	cyp2d6	NN	_	29	compound
29	CYP2E1	cyp2e1	NN	_	16	conj
30	or	or	CC	_	16	cc
31	CYP3A	cyp3a	NN	_	16	conj
32	nor	nor	CC	_	6	cc
33	induce	induce	VB	_	6	conj
34	the	the	DT	_	35	det
35	clearance	clearance	NN	_	33	dobj
36	of	of	IN	_	37	case
37	drugs	drug	NNS	_	35	nmod
38	metabolized	metabolize	VBN	_	37	acl
39	by	by	IN	_	40	case
40	CYP2B6	cyp2b6	NN	_	38	nmod
41	,	,	,	_	40	punct
42	CYP2C9	cyp2c9	NN	_	40	conj
43	or	or	CC	_	40	cc
44	CYP3A	cyp3a	NN	_	40	conj
45	.	.	.	_	4	punct

1	A	a	DT	_	6	det
2	multiple	multiple	JJ	_	6	amod
3	dose	dose	NN	_	6	compound
4	drug-drug	drug-drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	study	study	NN	_	7	nsubj
7	demonstrated	demonstrate	VBD	_	0	ROOT
8	that	that	IN	_	11	mark
9	drug1	drug1	NN	_	11	nsubj
10	approximately	approximately	RB	_	11	advmod
11	doubled	double	VBD	_	7	ccomp
12	drug2	drug2	NN	_	13	compound
13	AUC0	auc0	NN	_	11	dobj
14	-	-	:	_	11	punct
15	.	.	.	_	11	punct
16	Since	since	IN	_	20	mark
17	drug3	drug3	NN	_	20	nsubjpass
18	is	be	VBZ	_	20	auxpass
19	partially	partially	RB	_	20	advmod
20	metabolized	metabolize	VBN	_	27	advcl
21	by	by	IN	_	22	case
22	CYP3A	cyp3a	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	le	le	DT	_	22	dep
26	is	be	VBZ	_	27	auxpass
27	known	know	VBN	_	11	parataxis
28	to	to	TO	_	32	mark
29	be	be	VB	_	32	cop
30	a	a	DT	_	32	det
31	strong	strong	JJ	_	32	amod
32	inhibitor	inhibitor	NN	_	27	xcomp
33	of	of	IN	_	37	case
34	cytochrome	cytochrome	NN	_	37	compound
35	P450	p450	NN	_	37	compound
36	3A	3a	NN	_	37	compound
37	enzyme	enzyme	NN	_	32	nmod
38	,	,	,	_	32	punct
39	care	care	NN	_	42	nsubjpass
40	should	should	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	taken	take	VBN	_	32	parataxis
43	while	while	IN	_	42	xcomp
44	dosing	dosing	NN	_	45	compound
45	drug5	drug5	NN	_	43	dep
46	with	with	IN	_	47	case
47	drug6	drug6	NN	_	45	nmod
48	and	and	CC	_	47	cc
49	other	other	JJ	_	53	amod
50	strong	strong	JJ	_	53	amod
51	P450	p450	NN	_	53	compound
52	3A	3a	NN	_	53	compound
53	inhibitors	inhibitor	NNS	_	47	conj
54	including	include	VBG	_	55	case
55	drug7	drug7	NN	_	53	nmod
56	,	,	,	_	55	punct
57	drug8	drug8	NN	_	55	conj
58	,	,	,	_	55	punct
59	drug9	drug9	NN	_	55	conj
60	,	,	,	_	55	punct
61	drug10	drug10	NN	_	55	conj
62	,	,	,	_	55	punct
63	drug11	drug11	NN	_	55	conj
64	,	,	,	_	55	punct
65	drug12	drug12	NN	_	55	conj
66	,	,	,	_	55	punct
67	drug13	drug13	NN	_	55	conj
68	,	,	,	_	55	punct
69	drug14	drug14	NN	_	55	conj
70	,	,	,	_	55	punct
71	drug15	drug15	NN	_	55	conj
72	or	or	CC	_	55	cc
73	drug16	drug16	NN	_	55	conj
74	.	.	.	_	7	punct

1	Dose	dose	NN	_	2	compound
2	adjustment	adjustment	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	Capsules	capsule	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	and	and	CC	_	8	cc
11	iPTH	ipth	NN	_	15	compound
12	and	and	CC	_	11	cc
13	serum	serum	NN	_	11	conj
14	calcium	calcium	NN	_	15	compound
15	concentrations	concentration	NNS	_	19	nsubjpass
16	should	should	MD	_	19	aux
17	be	be	VB	_	19	auxpass
18	closely	closely	RB	_	19	advmod
19	monitored	monitor	VBN	_	8	conj
20	if	if	IN	_	23	mark
21	a	a	DT	_	22	det
22	patient	patient	NN	_	23	nsubj
23	initiates	initiate	VBZ	_	19	advcl
24	or	or	CC	_	23	cc
25	discontinues	discontinue	VBZ	_	23	conj
26	therapy	therapy	NN	_	23	dobj
27	with	with	IN	_	31	case
28	a	a	DT	_	31	det
29	strong	strong	JJ	_	31	amod
30	CYP3A4	cyp3a4	NN	_	31	compound
31	inhibitor	inhibitor	NN	_	26	nmod
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	drug2	drug2	NN	_	31	nmod
35	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	3	nsubj
3	impair	impair	VBP	_	1	acl:relcl
4	intestinal	intestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	5	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug2	drug2	NN	_	5	nmod
12	,	,	,	_	14	punct
13	may	may	MD	_	14	aux
14	interfere	interfere	VB	_	0	ROOT
15	with	with	IN	_	17	case
16	the	the	DT	_	17	det
17	absorption	absorption	NN	_	14	nmod
18	of	of	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	Capsules	capsule	NNS	_	17	nmod
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubj
2	competitively	competitively	RB	_	3	advmod
3	inhibits	inhibit	VBZ	_	0	ROOT
4	the	the	DT	_	6	det
5	intracellular	intracellular	JJ	_	6	amod
6	phosphorylation	phosphorylation	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	7	case
7	combination	combination	NN	_	3	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	12	mark
6	the	the	DT	_	7	det
7	phosphorylation	phosphorylation	NN	_	12	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	is	be	VBZ	_	12	auxpass
11	also	also	RB	_	12	advmod
12	inhibited	inhibit	VBN	_	4	ccomp
13	at	at	IN	_	15	case
14	relevant	relevant	JJ	_	15	amod
15	concentrations	concentration	NNS	_	12	nmod
16	by	by	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	10	nsubj
4	of	of	IN	_	8	case
5	these	these	DT	_	8	det
6	in	in	FW	_	8	amod
7	vitro	vitro	FW	_	6	dep
8	interactions	interaction	NNS	_	3	nmod
9	is	be	VBZ	_	10	cop
10	unknown	unknown	JJ	_	0	ROOT
11	;	;	:	_	10	punct

1	therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	either	either	DT	_	4	nmod
9	of	of	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	undertaken	undertake	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	.	.	.	_	14	punct

1	No	no	DT	_	7	neg
2	specific	specific	JJ	_	7	amod
3	cytochrome	cytochrome	NN	_	7	compound
4	P450-based	p450-based	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	13	nsubjpass
4	between	between	IN	_	7	case
5	85	85	CD	_	7	nummod
6	mg/m2	mg/m2	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	infusional	infusional	JJ	_	10	amod
10	drug2	drug2	NN	_	7	conj
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	treated	treat	VBN	_	15	acl
17	every	every	DT	_	19	det
18	2	2	CD	_	19	nummod
19	weeks	week	NNS	_	16	nmod:tmod
20	.	.	.	_	13	punct

1	Increases	increase	NNS	_	12	nsubjpass
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	1	nmod
6	by	by	IN	_	9	case
7	approximately	approximately	RB	_	8	advmod
8	20	20	CD	_	9	nummod
9	%	%	NN	_	1	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	doses	dose	NNS	_	12	nmod
15	of	of	IN	_	18	case
16	130	130	CD	_	18	nummod
17	mg/m2	mg/m2	NN	_	18	compound
18	drug2	drug2	NN	_	14	nmod
19	dosed	dose	VBD	_	14	acl
20	every	every	DT	_	22	det
21	3	3	CD	_	22	nummod
22	weeks	week	NNS	_	19	nmod:tmod
23	.	.	.	_	12	punct

1	Since	since	IN	_	6	mark
2	platinum	platinum	NN	_	6	nsubjpass
3	containing	contain	VBG	_	2	acl
4	species	species	NNS	_	3	dobj
5	are	be	VBP	_	6	auxpass
6	eliminated	eliminate	VBN	_	18	advcl
7	primarily	primarily	RB	_	6	advmod
8	through	through	IN	_	10	case
9	the	the	DT	_	10	det
10	kidney	kidney	NN	_	6	nmod
11	,	,	,	_	18	punct
12	clearance	clearance	NN	_	18	nsubjpass
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	products	product	NNS	_	12	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	decreased	decrease	VBN	_	0	ROOT
19	by	by	IN	_	20	case
20	coadministration	coadministration	NN	_	18	nmod
21	of	of	IN	_	24	case
22	potentially	potentially	RB	_	23	advmod
23	nephrotoxic	nephrotoxic	JJ	_	24	amod
24	compounds	compound	NNS	_	20	nmod
25	;	;	:	_	18	punct

1	although	although	IN	_	8	mark
2	,	,	,	_	8	punct
3	this	this	DT	_	8	nsubjpass
4	has	have	VBZ	_	8	aux
5	not	not	RB	_	8	neg
6	been	be	VBN	_	8	auxpass
7	specifically	specifically	RB	_	8	advmod
8	studied	study	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interact	interact	VB	_	4	xcomp
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	including	include	VBG	_	12	case
11	drug2	drug2	NN	_	12	compound
12	supplements	supplement	NNS	_	9	nmod
13	;	;	:	_	4	punct

1	interactions	interaction	NNS	_	6	nsubjpass
2	have	have	VBP	_	6	aux
3	not	not	RB	_	6	neg
4	been	be	VBN	_	6	auxpass
5	systematically	systematically	RB	_	6	advmod
6	studied	study	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	chelation	chelation	NN	_	8	compound
8	therapy	therapy	NN	_	2	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug2	drug2	NN	_	8	nmod
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	recommended	recommend	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Drug/Laboratory	Drug/Laboratory	NNP	_	3	compound
2	Tests	Tests	NNP	_	3	compound
3	Interaction	interaction	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	interfere	interfere	VB	_	3	dep
8	with	with	IN	_	9	case
9	serum	serum	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	urinary	urinary	JJ	_	13	amod
12	laboratory	laboratory	NN	_	13	compound
13	tests	test	NNS	_	9	conj
14	.	.	.	_	3	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	to	to	TO	_	8	mark
8	cause	cause	VB	_	6	acl
9	false	false	JJ	_	11	amod
10	positive	positive	JJ	_	11	amod
11	results	result	NNS	_	8	dobj
12	for	for	IN	_	13	case
13	ketones	ketone	NNS	_	11	nmod
14	in	in	IN	_	15	case
15	urine	urine	NN	_	13	nmod
16	using	use	VBG	_	8	xcomp
17	nitroprusside	nitroprusside	NN	_	18	compound
18	reagents	reagent	NNS	_	16	dobj
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	Ketostix	Ketostix	NNP	_	18	nmod
22	and	and	CC	_	5	cc
23	falsely	falsely	RB	_	24	advmod
24	decreased	decrease	VBD	_	25	amod
25	measurements	measurement	NNS	_	5	conj
26	of	of	IN	_	29	case
27	serum	serum	NN	_	29	compound
28	uric	uric	JJ	_	29	amod
29	acid	acid	NN	_	25	nmod
30	and	and	CC	_	29	cc
31	CPK	cpk	NN	_	29	conj
32	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	accentuate	accentuate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	orthostatic	orthostatic	JJ	_	6	amod
6	hypotension	hypotension	NN	_	3	dobj
7	that	that	WDT	_	9	nsubj
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	6	acl:relcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	3	punct

1	Antihypertensive	antihypertensive	JJ	_	2	amod
2	effects	effect	NNS	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	related	related	JJ	_	7	amod
7	compounds	compound	NNS	_	4	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	counteracted	counteract	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug2	drug2	NN	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	used	use	VBN	_	10	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	10	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	results	result	VBZ	_	0	ROOT
8	in	in	IN	_	11	case
9	increased	increase	VBN	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	of	of	IN	_	14	case
13	both	both	DT	_	14	det
14	drugs	drug	NNS	_	11	nmod
15	.	.	.	_	7	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	10	nsubjpass
3	of	of	IN	_	8	case
4	11	11	CD	_	8	nummod
5	clinical	clinical	JJ	_	8	amod
6	drug-drug	drug-drug	JJ	_	8	amod
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	2	nmod
9	were	be	VBD	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	volunteers	volunteer	NNS	_	10	nmod
14	to	to	TO	_	15	mark
15	evaluate	evaluate	VB	_	10	xcomp
16	the	the	DT	_	17	det
17	potential	potential	NN	_	15	dobj
18	for	for	IN	_	19	case
19	interaction	interaction	NN	_	17	nmod
20	between	between	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	drug2	drug2	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug3	drug3	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug4	drug4	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug5	drug5	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug6	drug6	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug7	drug7	NN	_	21	conj
34	,	,	,	_	21	punct
35	drug8	drug8	NN	_	21	conj
36	,	,	,	_	21	punct
37	drug9	drug9	NN	_	21	conj
38	,	,	,	_	21	punct
39	and	and	CC	_	21	cc
40	drug10	drug10	NN	_	21	conj
41	.	.	.	_	10	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	studies	study	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	no	no	DT	_	6	neg
6	interaction	interaction	NN	_	14	nsubjpass
7	that	that	WDT	_	8	nsubj
8	altered	alter	VBD	_	6	acl:relcl
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	single	single	JJ	_	8	amod
8	dose	dose	NN	_	4	nmod
9	or	or	CC	_	8	cc
10	multiple	multiple	JJ	_	11	amod
11	doses	dose	NNS	_	8	conj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	8	nmod
14	on	on	IN	_	15	case
15	drug2	drug2	NN	_	4	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug5	drug5	NN	_	15	conj
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	drug6	drug6	NN	_	25	compound
25	pharmacokinetics	pharmacokinetic	NNS	_	15	conj
26	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	compound
2	AUC	auc	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	increased	increase	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	21	21	CD	_	7	nummod
7	%	%	NN	_	4	nmod
8	with	with	IN	_	10	case
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	4	nmod
11	on	on	IN	_	12	case
12	Cmax	Cmax	NNP	_	10	nmod
13	in	in	IN	_	18	case
14	the	the	DT	_	18	dep
15	presence	presence	NN	_	18	dep
16	of	of	IN	_	18	case
17	steady-state	steady-state	JJ	_	18	amod
18	drug2	drug2	NN	_	10	nmod
19	compared	compare	VBN	_	21	case
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	10	nmod
22	alone	alone	RB	_	21	advmod
23	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	AUC	auc	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	Cmax	cmax	NN	_	2	conj
5	were	be	VBD	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	18	18	CD	_	9	nummod
9	%	%	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	42	42	CD	_	12	nummod
12	%	%	NN	_	9	conj
13	,	,	,	_	6	punct
14	respectively	respectively	RB	_	6	advmod
15	,	,	,	_	6	punct
16	in	in	IN	_	21	case
17	the	the	DT	_	21	dep
18	presence	presence	NN	_	21	dep
19	of	of	IN	_	21	case
20	steady-state	steady-state	JJ	_	21	amod
21	drug2	drug2	NN	_	6	nmod
22	compared	compare	VBN	_	24	case
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	21	nmod
25	alone	alone	RB	_	24	advmod
26	.	.	.	_	6	punct

1	Patients	patient	NNS	_	12	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	or	or	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	2	nmod
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	monitored	monitor	VBN	_	0	ROOT
13	for	for	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	drug5	drug5	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	and	and	CC	_	14	cc
19	drug6	drug6	NN	_	22	compound
20	or	or	CC	_	19	cc
21	drug7	drug7	NN	_	19	conj
22	dosage	dosage	NN	_	14	conj
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	reduced	reduce	VBN	_	12	ccomp
26	if	if	IN	_	27	mark
27	necessary	necessary	JJ	_	25	advcl
28	.	.	.	_	12	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	0	ROOT
6	of	of	IN	_	7	case
7	P-glycoprotein	p-glycoprotein	NN	_	5	nmod
8	and	and	CC	_	5	cc
9	,	,	,	_	5	punct
10	therefore	therefore	RB	_	15	advmod
11	,	,	,	_	15	punct
12	would	would	MD	_	15	aux
13	not	not	RB	_	15	neg
14	be	be	VB	_	15	auxpass
15	expected	expect	VBN	_	5	conj
16	to	to	TO	_	17	mark
17	alter	alter	VB	_	15	xcomp
18	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	21	amod
19	drug	drug	NN	_	21	compound
20	transport	transport	NN	_	21	compound
21	activity	activity	NN	_	17	dobj
22	.	.	.	_	5	punct

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	sensitize	sensitize	VB	_	0	ROOT
4	or	or	CC	_	3	cc
5	exaggerate	exaggerate	VB	_	3	conj
6	the	the	DT	_	7	det
7	response	response	NN	_	3	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	heart	heart	NN	_	7	nmod
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	toxic	toxic	JJ	_	14	amod
14	effects	effect	NNS	_	7	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	e.g.	e.g.	FW	_	16	dep
19	,	,	,	_	18	punct
20	increased	increase	VBD	_	22	amod
21	ventricular	ventricular	JJ	_	22	amod
22	irritability	irritability	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	18	punct
24	.	.	.	_	3	punct

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	develop	develop	VB	_	0	ROOT
4	during	during	IN	_	6	case
5	concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	compound
2	requirements	requirement	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	diabetic	diabetic	JJ	_	5	amod
5	patients	patient	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	decreased	decrease	VBN	_	8	conj
11	,	,	,	_	8	punct
12	or	or	CC	_	8	cc
13	unchanged	unchanged	JJ	_	8	conj
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	arterial	arterial	JJ	_	5	amod
5	responsiveness	responsiveness	NN	_	3	dobj
6	to	to	TO	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	diminution	diminution	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	sufficient	sufficient	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	preclude	preclude	VB	_	5	xcomp
8	effectiveness	effectiveness	NN	_	7	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	pressor	pressor	NN	_	12	compound
12	agent	agent	NN	_	8	nmod
13	for	for	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	use	use	NN	_	7	nmod
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	responsiveness	responsiveness	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	compound
2	renal	renal	JJ	_	3	amod
3	clearance	clearance	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	reduced	reduce	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	increasing	increase	VBG	_	5	xcomp
10	the	the	DT	_	11	det
11	risk	risk	NN	_	9	dobj
12	of	of	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	toxicity	toxicity	NN	_	11	nmod
15	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	add	add	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	or	or	CC	_	4	cc
6	potentiate	potentiate	VB	_	4	conj
7	the	the	DT	_	8	det
8	action	action	NN	_	3	nmod
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	3	punct

1	Potentiation	potentiation	NN	_	2	nsubj
2	occurs	occur	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	7	compound
6	/	/	:	_	7	punct
7	drug4	drug4	NN	_	10	nsubj
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	influence	influence	VB	_	3	dep
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	10	dobj
13	of	of	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	in	in	IN	_	17	case
16	healthy	healthy	JJ	_	17	amod
17	volunteers	volunteer	NNS	_	10	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	N	n	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	10	10	CD	_	20	dep
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	.	.	.	_	3	punct

1	5	5	CD	_	2	nummod
2	hours	hour	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	15	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	N	n	NN	_	5	dep
8	=	=	JJ	_	7	amod
9	11	11	CD	_	8	dep
10	-RRB-	-rrb-	-RRB-	_	7	punct
11	,	,	,	_	15	punct
12	drug2	drug2	NN	_	15	nsubj
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	influence	influence	VB	_	1	appos
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Population	Population	NNP	_	5	compound
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	analysis	analysis	NN	_	6	nsubj
6	suggests	suggest	VBZ	_	1	appos
7	that	that	IN	_	10	mark
8	drug2	drug2	NN	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	unlikely	unlikely	JJ	_	6	ccomp
11	to	to	TO	_	12	mark
12	alter	alter	VB	_	10	xcomp
13	the	the	DT	_	15	det
14	oral	oral	JJ	_	15	amod
15	clearance	clearance	NN	_	12	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	N	n	NN	_	20	nsubj
20	=	=	JJ	_	17	dep
21	54	54	CD	_	20	dobj
22	-RRB-	-rrb-	-RRB-	_	20	punct
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	21	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	known	known	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	tubular	tubular	JJ	_	11	amod
11	secretion	secretion	NN	_	7	nmod
12	of	of	IN	_	14	case
13	organic	organic	JJ	_	14	amod
14	bases	basis	NNS	_	11	nmod
15	via	via	IN	_	19	case
16	the	the	DT	_	19	det
17	cationic	cationic	JJ	_	19	amod
18	transport	transport	NN	_	19	compound
19	system	system	NN	_	7	nmod
20	,	,	,	_	3	punct
21	caused	cause	VBD	_	1	appos
22	a	a	DT	_	25	det
23	50	50	CD	_	24	compound
24	%	%	NN	_	25	amod
25	increase	increase	NN	_	21	dobj
26	in	in	IN	_	28	case
27	drug3	drug3	NN	_	28	compound
28	AUC	auc	NN	_	25	nmod
29	and	and	CC	_	25	cc
30	a	a	DT	_	33	det
31	40	40	CD	_	32	compound
32	%	%	NN	_	33	amod
33	increase	increase	NN	_	25	conj
34	in	in	IN	_	35	case
35	half-life	half-life	NN	_	33	nmod
36	-LRB-	-lrb-	-LRB-	_	38	punct
37	N	n	NN	_	38	nsubj
38	=	=	JJ	_	33	dep
39	12	12	CD	_	38	dobj
40	-RRB-	-rrb-	-RRB-	_	38	punct
41	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	23	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	known	known	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	tubular	tubular	JJ	_	11	amod
11	secretion	secretion	NN	_	7	nmod
12	of	of	IN	_	14	case
13	organic	organic	JJ	_	14	amod
14	acids	acid	NNS	_	11	nmod
15	via	via	IN	_	18	case
16	the	the	DT	_	18	det
17	aruonic	aruonic	JJ	_	18	amod
18	transporter	transporter	NN	_	7	nmod
19	,	,	,	_	3	punct
20	did	do	VBD	_	23	aux
21	not	not	RB	_	23	neg
22	noticeably	noticeably	RB	_	23	advmod
23	influence	influence	VB	_	1	appos
24	drug3	drug3	NN	_	25	compound
25	pharmacokinetics	pharmacokinetic	NNS	_	23	dobj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	N	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	12	12	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	eliminated	eliminate	VBN	_	2	acl
4	via	via	IN	_	6	case
5	renal	renal	JJ	_	6	amod
6	secretion	secretion	NN	_	3	nmod
7	:	:	:	_	2	punct
8	Population	Population	NNP	_	10	compound
9	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
10	analysis	analysis	NN	_	11	nsubj
11	suggests	suggest	VBZ	_	2	dep
12	that	that	IN	_	42	mark
13	coadministration	coadministration	NN	_	42	nsubj
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	that	that	WDT	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	secreted	secrete	VBN	_	15	acl:relcl
19	by	by	IN	_	23	case
20	the	the	DT	_	23	det
21	cationic	cationic	JJ	_	23	amod
22	transport	transport	NN	_	23	compound
23	system	system	NN	_	18	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	e.g.	e.g.	FW	_	27	dep
26	,	,	,	_	27	punct
27	drug1	drug1	NN	_	18	dep
28	,	,	,	_	27	punct
29	drug2	drug2	NN	_	27	conj
30	,	,	,	_	27	punct
31	drug3	drug3	NN	_	27	conj
32	,	,	,	_	27	punct
33	drug4	drug4	NN	_	27	conj
34	,	,	,	_	27	punct
35	drug5	drug5	NN	_	27	conj
36	,	,	,	_	27	punct
37	drug6	drug6	NN	_	27	conj
38	,	,	,	_	27	punct
39	and	and	CC	_	27	cc
40	drug7	drug7	NN	_	27	conj
41	-RRB-	-rrb-	-RRB-	_	27	punct
42	decreases	decrease	VBZ	_	11	ccomp
43	the	the	DT	_	45	det
44	oral	oral	JJ	_	45	amod
45	clearance	clearance	NN	_	42	dobj
46	of	of	IN	_	47	case
47	drug8	drug8	NN	_	45	nmod
48	by	by	IN	_	51	case
49	about	about	RB	_	50	advmod
50	20	20	CD	_	51	nummod
51	%	%	NN	_	42	nmod
52	,	,	,	_	42	punct
53	while	while	IN	_	76	mark
54	those	those	DT	_	76	nsubj
55	secreted	secrete	VBN	_	54	acl
56	by	by	IN	_	60	case
57	the	the	DT	_	60	det
58	anionic	anionic	JJ	_	60	amod
59	transport	transport	NN	_	60	compound
60	system	system	NN	_	55	nmod
61	-LRB-	-lrb-	-LRB-	_	64	punct
62	e.g.	e.g.	FW	_	64	dep
63	,	,	,	_	64	punct
64	drug9	drug9	NN	_	54	dep
65	,	,	,	_	64	punct
66	drug10	drug10	NN	_	64	conj
67	,	,	,	_	64	punct
68	drug11	drug11	NN	_	64	conj
69	,	,	,	_	64	punct
70	drug12	drug12	NN	_	64	conj
71	,	,	,	_	64	punct
72	and	and	CC	_	64	cc
73	drug13	drug13	NN	_	64	conj
74	-RRB-	-rrb-	-RRB-	_	64	punct
75	are	be	VBP	_	76	cop
76	likely	likely	JJ	_	42	advcl
77	to	to	TO	_	78	mark
78	have	have	VB	_	76	xcomp
79	little	little	JJ	_	80	amod
80	effect	effect	NN	_	78	dobj
81	on	on	IN	_	84	case
82	the	the	DT	_	84	det
83	oral	oral	JJ	_	84	amod
84	clearance	clearance	NN	_	78	nmod
85	of	of	IN	_	86	case
86	drug14	drug14	NN	_	84	nmod
87	.	.	.	_	2	punct

1	CYP	cyp	NN	_	2	compound
2	interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Inhibitors	inhibitor	NNS	_	12	nsubjpass
5	of	of	IN	_	8	case
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	enzymes	enzyme	NNS	_	4	nmod
9	would	would	MD	_	12	aux
10	not	not	RB	_	12	neg
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	2	dep
13	to	to	TO	_	14	mark
14	affect	affect	VB	_	12	xcomp
15	drug1	drug1	NN	_	16	compound
16	elimination	elimination	NN	_	14	dobj
17	because	because	IN	_	22	mark
18	drug2	drug2	NN	_	22	nsubjpass
19	is	be	VBZ	_	22	auxpass
20	not	not	RB	_	22	neg
21	appreciably	appreciably	RB	_	22	advmod
22	metabolized	metabolize	VBN	_	12	advcl
23	by	by	IN	_	25	case
24	these	these	DT	_	25	det
25	enzymes	enzyme	NNS	_	22	nmod
26	in	in	FW	_	27	compound
27	vivo	vivo	FW	_	28	advmod
28	or	or	CC	_	22	advmod
29	in	in	FW	_	30	compound
30	vitro	vitro	FW	_	28	advmod
31	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	CYP	cyp	NN	_	7	compound
6	enzymes	enzyme	NNS	_	7	compound
7	CYPIA2	cypia2	NN	_	4	dobj
8	,	,	,	_	7	punct
9	CYP2C9	cyp2c9	NN	_	7	conj
10	,	,	,	_	7	punct
11	CYP2CI9	cyp2ci9	NN	_	7	conj
12	,	,	,	_	7	punct
13	CYP2EI	cyp2ei	NN	_	7	conj
14	,	,	,	_	7	punct
15	and	and	CC	_	7	cc
16	CYP3A4	cyp3a4	NN	_	7	conj
17	.	.	.	_	4	punct

1	Inhibition	inhibition	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	CYP2D6	cyp2d6	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	an	a	DT	_	9	det
8	apparent	apparent	JJ	_	9	amod
9	Ki	ki	NN	_	5	nmod
10	of	of	IN	_	12	case
11	30	30	CD	_	12	nummod
12	uM	um	NN	_	9	nmod
13	,	,	,	_	5	punct
14	indicating	indicate	VBG	_	5	xcomp
15	that	that	IN	_	19	mark
16	drug1	drug1	NN	_	19	nsubj
17	will	will	MD	_	19	aux
18	not	not	RB	_	19	neg
19	inhibit	inhibit	VB	_	14	ccomp
20	CYP	cyp	NN	_	21	compound
21	enzymes	enzyme	NNS	_	19	dobj
22	at	at	IN	_	24	case
23	plasma	plasma	NN	_	24	compound
24	concentrations	concentration	NNS	_	19	nmod
25	observed	observe	VBN	_	24	acl
26	following	follow	VBG	_	31	case
27	the	the	DT	_	31	det
28	highest	highest	JJS	_	31	amod
29	recommended	recommend	VBN	_	31	amod
30	clinical	clinical	JJ	_	31	amod
31	dose	dose	NN	_	25	nmod
32	-LRB-	-lrb-	-LRB-	_	35	punct
33	1.5	1.5	CD	_	35	nummod
34	mg	mg	NN	_	35	compound
35	tid	tid	NN	_	31	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	7	mark
4	drug2	drug2	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	a	a	DT	_	7	det
7	drug3	drug3	NN	_	11	advcl
8	,	,	,	_	11	punct
9	it	it	PRP	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	possible	possible	JJ	_	1	dep
12	that	that	IN	_	30	mark
13	drug4	drug4	NN	_	30	nsubj
14	,	,	,	_	13	punct
15	such	such	JJ	_	18	case
16	as	as	IN	_	15	mwe
17	the	the	DT	_	18	det
18	drug5	drug5	NN	_	13	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug6	drug6	NN	_	18	dep
21	,	,	,	_	20	punct
22	drug7	drug7	NN	_	20	appos
23	,	,	,	_	20	punct
24	drug8	drug8	NN	_	20	appos
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	or	or	CC	_	18	cc
27	drug9	drug9	NN	_	18	conj
28	,	,	,	_	13	punct
29	may	may	MD	_	30	aux
30	diminish	diminish	VB	_	11	ccomp
31	the	the	DT	_	32	det
32	effectiveness	effectiveness	NN	_	30	dobj
33	of	of	IN	_	34	case
34	drug10	drug10	NN	_	32	nmod
35	.	.	.	_	1	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	10	neg
9	known	known	JJ	_	10	amod
10	interactions	interaction	NNS	_	7	nsubj
11	between	between	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	laboratory	laboratory	NN	_	15	compound
15	tests	test	NNS	_	12	conj
16	.	.	.	_	5	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	exceed	exceed	VB	_	0	ROOT
4	a	a	DT	_	8	det
5	5	5	CD	_	6	compound
6	mg	mg	NN	_	8	amod
7	daily	daily	JJ	_	8	amod
8	dose	dose	NN	_	3	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	administered	administer	VBN	_	3	advcl
13	with	with	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	doses	dose	NNS	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	other	other	JJ	_	22	amod
20	potent	potent	JJ	_	22	amod
21	CYP3A4	cyp3a4	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	17	conj
23	.	.	.	_	3	punct

1	Patients	patient	NNS	_	29	dep
2	with	with	IN	_	3	case
3	Congenital	congenital	JJ	_	1	nmod
4	or	or	CC	_	3	cc
5	Acquired	acquire	VBN	_	3	conj
6	QT	QT	NNP	_	7	compound
7	Prolongation	Prolongation	NNP	_	3	dep
8	In	in	IN	_	10	case
9	a	a	DT	_	10	det
10	study	study	NN	_	1	nmod
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	effect	effect	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	on	on	IN	_	19	case
17	the	the	DT	_	19	det
18	QT	QT	NNP	_	19	compound
19	interval	interval	NN	_	13	nmod
20	in	in	IN	_	23	case
21	76	76	CD	_	23	nummod
22	healthy	healthy	JJ	_	23	amod
23	women	woman	NNS	_	13	nmod
24	,	,	,	_	29	punct
25	the	the	DT	_	28	det
26	QT	QT	NNP	_	28	compound
27	prolonging	prolong	VBG	_	28	compound
28	effect	effect	NN	_	29	nsubj
29	appeared	appear	VBD	_	0	ROOT
30	less	less	RBR	_	29	advmod
31	with	with	IN	_	34	case
32	drug2	drug2	NN	_	34	compound
33	10	10	CD	_	34	nummod
34	mg	mg	NN	_	30	nmod
35	than	than	IN	_	38	case
36	with	with	IN	_	38	case
37	30	30	CD	_	38	nummod
38	mg	mg	NN	_	30	nmod
39	-LRB-	-lrb-	-LRB-	_	57	punct
40	three	three	CD	_	41	nummod
41	times	time	NNS	_	57	nsubj
42	the	the	DT	_	43	det
43	maximum	maximum	NN	_	44	nsubj
44	recommended	recommend	VBD	_	41	acl:relcl
45	dose	dose	NN	_	44	dobj
46	-RRB-	-rrb-	-RRB-	_	41	punct
47	,	,	,	_	41	punct
48	and	and	CC	_	41	cc
49	the	the	DT	_	50	det
50	effect	effect	NN	_	41	conj
51	of	of	IN	_	52	case
52	drug3	drug3	NN	_	50	nmod
53	30	30	CD	_	54	nummod
54	mg	mg	NN	_	52	dep
55	did	do	VBD	_	57	aux
56	not	not	RB	_	57	neg
57	appear	appear	VB	_	38	acl:relcl
58	as	as	IN	_	59	advmod
59	large	large	JJ	_	57	xcomp
60	as	as	IN	_	61	case
61	that	that	DT	_	59	nmod
62	of	of	IN	_	66	case
63	the	the	DT	_	66	det
64	positive	positive	JJ	_	66	amod
65	control	control	NN	_	66	compound
66	drug4	drug4	NN	_	61	nmod
67	at	at	IN	_	70	case
68	its	its	PRP$	_	70	nmod:poss
69	therapeutic	therapeutic	JJ	_	70	amod
70	dose	dose	NN	_	66	nmod
71	.	.	.	_	29	punct

1	This	this	DT	_	2	det
2	observation	observation	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	clinical	clinical	JJ	_	8	amod
8	decisions	decision	NNS	_	5	nmod
9	to	to	TO	_	10	mark
10	prescribe	prescribe	VB	_	8	acl
11	drug1	drug1	NN	_	10	dobj
12	for	for	IN	_	13	case
13	patients	patient	NNS	_	10	nmod
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	known	known	JJ	_	17	amod
17	history	history	NN	_	13	nmod
18	of	of	IN	_	20	case
19	QT	QT	NNP	_	20	compound
20	prolongation	prolongation	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	patients	patient	NNS	_	20	conj
23	who	who	WP	_	25	nsubj
24	are	be	VBP	_	25	aux
25	taking	take	VBG	_	13	acl:relcl
26	medications	medication	NNS	_	25	dobj
27	known	know	VBN	_	26	acl
28	to	to	TO	_	29	mark
29	prolong	prolong	VB	_	27	xcomp
30	the	the	DT	_	32	det
31	QT	QT	NNP	_	32	compound
32	interval	interval	NN	_	29	dobj
33	.	.	.	_	5	punct

1	drug1	drug1	NN	_	10	nsubj
2	at	at	IN	_	4	case
3	a	a	DT	_	4	det
4	Dose	dose	NN	_	1	nmod
5	of	of	IN	_	7	case
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	Once	once	RB	_	9	advmod
9	Daily	daily	JJ	_	10	advmod
10	Dosed	dose	VBN	_	0	ROOT
11	to	to	TO	_	14	case
12	Pharmacokinetic	pharmacokinetic	JJ	_	14	amod
13	Steady	steady	JJ	_	14	amod
14	State	state	NN	_	10	nmod
15	-	-	:	_	10	punct
16	did	do	VBD	_	18	aux
17	not	not	RB	_	18	neg
18	cause	cause	VB	_	10	parataxis
19	clinically	clinically	RB	_	20	advmod
20	significant	significant	JJ	_	21	amod
21	changes	change	NNS	_	18	dobj
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	kinetics	kinetics	NNS	_	21	nmod
25	of	of	IN	_	29	case
26	a	a	DT	_	29	det
27	single	single	JJ	_	29	amod
28	intravenous	intravenous	JJ	_	29	amod
29	dose	dose	NN	_	24	nmod
30	of	of	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	38	punct
33	predominantly	predominantly	RB	_	38	advmod
34	a	a	DT	_	38	det
35	cytochrome	cytochrome	NN	_	38	compound
36	P450	p450	NN	_	38	compound
37	1A2	1a2	NN	_	38	compound
38	substrate	substrate	NN	_	29	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	10	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	9	dep
13	of	of	IN	_	16	case
14	cytochromes	cytochrome	NNS	_	16	compound
15	P450	p450	NN	_	16	compound
16	2A6	2a6	NN	_	12	nmod
17	and	and	CC	_	16	cc
18	2C9	2c9	NN	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	12	punct
20	or	or	CC	_	4	cc
21	influence	influence	VB	_	4	conj
22	the	the	DT	_	23	det
23	effect	effect	NN	_	21	dobj
24	of	of	IN	_	29	case
25	a	a	DT	_	29	det
26	single	single	JJ	_	29	amod
27	30-mg	30-mg	JJ	_	29	amod
28	oral	oral	JJ	_	29	amod
29	dose	dose	NN	_	23	nmod
30	of	of	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	on	on	IN	_	34	case
33	prothrombin	prothrombin	NN	_	34	compound
34	time	time	NN	_	23	nmod
35	or	or	CC	_	34	cc
36	the	the	DT	_	37	det
37	INR	inr	NN	_	34	conj
38	-LRB-	-lrb-	-LRB-	_	41	punct
39	International	International	NNP	_	41	compound
40	Normalized	Normalized	NNP	_	41	compound
41	Ratio	Ratio	NNP	_	37	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	.	.	.	_	4	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	or	or	CC	_	7	cc
9	urinary	urinary	JJ	_	10	amod
10	excretion	excretion	NN	_	7	conj
11	of	of	IN	_	13	case
12	immunoreactive	immunoreactive	JJ	_	13	amod
13	drug1	drug1	NN	_	7	nmod
14	.	.	.	_	4	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	plasma	plasma	NN	_	8	compound
7	concentration	concentration	NN	_	8	compound
8	profile	profile	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	a	a	DT	_	13	det
13	substrate	substrate	NN	_	10	dep
14	of	of	IN	_	17	case
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	3A4	3a4	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	13	punct
19	or	or	CC	_	10	cc
20	drug2	drug2	NN	_	10	conj
21	,	,	,	_	4	punct
22	its	its	PRP$	_	24	nmod:poss
23	carboxylated	carboxylate	VBN	_	24	amod
24	metabolite	metabolite	NN	_	4	dobj
25	,	,	,	_	4	punct
26	and	and	CC	_	4	cc
27	did	do	VBD	_	29	aux
28	not	not	RB	_	29	neg
29	prolong	prolong	VB	_	4	conj
30	the	the	DT	_	32	det
31	QTc	qtc	NN	_	32	compound
32	interval	interval	NN	_	29	dobj
33	following	follow	VBG	_	34	case
34	co-administration	co-administration	NN	_	29	nmod
35	with	with	IN	_	38	case
36	drug3	drug3	NN	_	38	compound
37	60	60	CD	_	38	nummod
38	mg	mg	NN	_	34	nmod
39	twice	twice	RB	_	40	advmod
40	daily	daily	RB	_	34	advmod
41	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	at	at	IN	_	3	case
3	Doses	dose	NNS	_	1	nmod
4	of	of	IN	_	8	case
5	100	100	CD	_	8	nummod
6	mg	mg	NN	_	8	compound
7	Daily	Daily	NNP	_	8	compound
8	Dosed	Dosed	NNP	_	3	nmod
9	to	to	TO	_	12	case
10	Pharmacokinetic	pharmacokinetic	JJ	_	12	amod
11	Steady	steady	JJ	_	12	amod
12	State	state	NN	_	1	nmod
13	:	:	:	_	1	punct
14	-	-	:	_	1	punct
15	did	do	VBD	_	18	aux
16	not	not	RB	_	18	neg
17	significantly	significantly	RB	_	18	advmod
18	alter	alter	VB	_	1	dep
19	the	the	DT	_	21	det
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	18	dobj
22	of	of	IN	_	24	case
23	either	either	CC	_	24	det
24	component	component	NN	_	21	nmod
25	of	of	IN	_	28	case
26	an	a	DT	_	28	det
27	oral	oral	JJ	_	28	amod
28	drug2	drug2	NN	_	24	nmod
29	containing	contain	VBG	_	28	acl
30	drug3	drug3	NN	_	35	compound
31	1	1	CD	_	35	nummod
32	mg/ethinyl	mg/ethinyl	NN	_	35	compound
33	drug4	drug4	NN	_	35	compound
34	35	35	CD	_	35	nummod
35	mcg	mcg	NN	_	29	dobj
36	.	.	.	_	1	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	cause	cause	VB	_	0	ROOT
5	any	any	DT	_	8	det
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	change	change	NN	_	4	dobj
9	in	in	IN	_	11	case
10	plasma	plasma	NN	_	11	compound
11	profiles	profile	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	following	follow	VBG	_	17	case
17	administration	administration	NN	_	4	nmod
18	of	of	IN	_	21	case
19	either	either	CC	_	21	cc:preconj
20	oral	oral	JJ	_	21	amod
21	drug3	drug3	NN	_	17	nmod
22	or	or	CC	_	21	cc
23	intravenous	intravenous	JJ	_	24	amod
24	drug4	drug4	NN	_	21	conj
25	.	.	.	_	4	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	which	which	WDT	_	4	nsubj
4	induces	induce	VBZ	_	1	acl:relcl
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	4	dobj
7	,	,	,	_	1	punct
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	approximately	approximately	RB	_	14	advmod
14	40	40	CD	_	15	nummod
15	%	%	NN	_	8	nmod:npmod
16	following	follow	VBG	_	20	case
17	a	a	DT	_	20	det
18	single	single	JJ	_	20	amod
19	10-mg	10-mg	JJ	_	20	amod
20	dose	dose	NN	_	8	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	reasonable	reasonable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	employ	employ	VB	_	3	xcomp
6	appropriate	appropriate	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	when	when	WRB	_	23	advmod
10	potent	potent	JJ	_	14	amod
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	inducers	inducer	NNS	_	23	nsubjpass
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug1	drug1	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	14	punct
22	are	be	VBP	_	23	auxpass
23	co-administered	co-administer	VBN	_	5	advcl
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	therapies	therapy	NNS	_	4	nmod
8	routinely	routinely	RB	_	9	advmod
9	used	use	VBN	_	7	acl
10	in	in	IN	_	15	case
11	the	the	DT	_	15	det
12	prophylaxis	prophylaxis	NN	_	15	amod
13	and	and	CC	_	12	cc
14	chronic	chronic	JJ	_	12	conj
15	treatment	treatment	NN	_	9	nmod
16	of	of	IN	_	17	case
17	asthma	asthma	NN	_	15	nmod
18	with	with	IN	_	21	case
19	no	no	DT	_	21	neg
20	apparent	apparent	JJ	_	21	amod
21	increase	increase	NN	_	9	nmod
22	in	in	IN	_	24	case
23	adverse	adverse	JJ	_	24	amod
24	reactions	reaction	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	drug-interaction	drug-interaction	JJ	_	3	amod
3	studies	study	NNS	_	13	nmod
4	,	,	,	_	13	punct
5	the	the	DT	_	8	det
6	recommended	recommend	VBN	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	dose	dose	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	have	have	VB	_	0	ROOT
14	clinically	clinically	RB	_	15	advmod
15	important	important	JJ	_	16	amod
16	effects	effect	NNS	_	13	dobj
17	on	on	IN	_	19	case
18	the	the	DT	_	19	det
19	pharmacokinetics	pharmacokinetic	NNS	_	13	nmod
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	following	follow	VBG	_	23	amod
23	drugs	drug	NNS	_	19	nmod
24	:	:	:	_	19	punct
25	drug2	drug2	NN	_	19	dep
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug4	drug4	NN	_	25	conj
30	,	,	,	_	25	punct
31	oral	oral	JJ	_	32	amod
32	drug5	drug5	NN	_	25	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	drug6	drug6	NN	_	36	compound
35	1	1	CD	_	36	nummod
36	mg	mg	NN	_	32	appos
37	/	/	:	_	36	punct
38	drug7	drug7	NN	_	40	compound
39	35	35	CD	_	40	nummod
40	mcg	mcg	NN	_	36	dep
41	-RRB-	-rrb-	-RRB-	_	36	punct
42	,	,	,	_	25	punct
43	drug8	drug8	NN	_	25	conj
44	,	,	,	_	25	punct
45	drug9	drug9	NN	_	25	conj
46	,	,	,	_	25	punct
47	and	and	CC	_	25	cc
48	drug10	drug10	NN	_	25	conj
49	.	.	.	_	13	punct

1	Although	although	IN	_	8	mark
2	additional	additional	JJ	_	5	amod
3	specific	specific	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	were	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	performed	perform	VBN	_	12	advcl
9	,	,	,	_	12	punct
10	drug1	drug1	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	wide	wide	JJ	_	17	amod
17	range	range	NN	_	12	nmod
18	of	of	IN	_	21	case
19	commonly	commonly	RB	_	20	advmod
20	prescribed	prescribe	VBN	_	21	amod
21	drugs	drug	NNS	_	17	nmod
22	in	in	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	studies	study	NNS	_	12	nmod
25	without	without	IN	_	26	case
26	evidence	evidence	NN	_	12	nmod
27	of	of	IN	_	30	case
28	clinical	clinical	JJ	_	30	amod
29	adverse	adverse	JJ	_	30	amod
30	interactions	interaction	NNS	_	26	nmod
31	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	medications	medication	NNS	_	3	nsubj
3	included	include	VBD	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	drug5	drug5	NN	_	4	conj
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	which	which	WDT	_	4	nsubj
4	induces	induce	VBZ	_	1	acl:relcl
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	4	dobj
7	,	,	,	_	1	punct
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	approximately	approximately	RB	_	14	advmod
14	40	40	CD	_	15	nummod
15	%	%	NN	_	8	nmod:npmod
16	following	follow	VBG	_	20	case
17	a	a	DT	_	20	det
18	single	single	JJ	_	20	amod
19	10-mg	10-mg	JJ	_	20	amod
20	dose	dose	NN	_	8	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	reasonable	reasonable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	employ	employ	VB	_	3	xcomp
6	appropriate	appropriate	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	when	when	WRB	_	23	advmod
10	potent	potent	JJ	_	14	amod
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	inducers	inducer	NNS	_	23	nsubjpass
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug1	drug1	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	14	punct
22	are	be	VBP	_	23	auxpass
23	co-administered	co-administer	VBN	_	5	advcl
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	study	study	NN	_	24	nmod
5	of	of	IN	_	10	case
6	18	18	CD	_	10	nummod
7	chronic	chronic	JJ	_	10	amod
8	hepatitis	hepatitis	NN	_	10	compound
9	C	c	NN	_	10	compound
10	patients	patient	NNS	_	4	nmod
11	concomitantly	concomitantly	RB	_	12	advmod
12	receiving	receive	VBG	_	10	acl
13	drug1	drug1	NN	_	12	dobj
14	,	,	,	_	24	punct
15	treatment	treatment	NN	_	24	nsubjpass
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	once	once	RB	_	19	advmod
19	weekly	weekly	JJ	_	15	amod
20	for	for	IN	_	22	case
21	4	4	CD	_	22	nummod
22	weeks	week	NNS	_	19	nmod
23	was	be	VBD	_	24	auxpass
24	associated	associate	VBN	_	0	ROOT
25	with	with	IN	_	28	case
26	a	a	DT	_	28	det
27	mean	mean	JJ	_	28	amod
28	increase	increase	NN	_	24	nmod
29	of	of	IN	_	31	case
30	16	16	CD	_	31	nummod
31	%	%	NN	_	28	nmod
32	in	in	IN	_	34	case
33	drug3	drug3	NN	_	34	compound
34	AUC	auc	NN	_	28	nmod
35	;	;	:	_	24	punct

1	in	in	IN	_	2	case
2	2	2	CD	_	10	nmod
3	out	out	IN	_	6	case
4	of	of	IN	_	6	case
5	18	18	CD	_	6	nummod
6	patients	patient	NNS	_	2	nmod
7	,	,	,	_	10	punct
8	drug1	drug1	NN	_	9	compound
9	AUC	auc	NN	_	10	nsubj
10	doubled	double	VBD	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	;	;	:	_	8	punct

1	however	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	for	for	IN	_	9	case
8	the	the	DT	_	9	det
9	signs	sign	NNS	_	6	nmod
10	and	and	CC	_	9	cc
11	symptoms	symptom	NNS	_	9	conj
12	of	of	IN	_	15	case
13	increased	increase	VBN	_	15	amod
14	narcotic	narcotic	JJ	_	15	amod
15	effect	effect	NN	_	9	nmod
16	.	.	.	_	6	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	0	ROOT
5	,	,	,	_	4	punct
6	the	the	DT	_	7	det
7	potential	potential	NN	_	5	root
8	for	for	IN	_	9	case
9	interaction	interaction	NN	_	7	nmod
10	by	by	IN	_	12	case
11	a	a	DT	_	12	det
12	variety	variety	NN	_	9	nmod
13	of	of	IN	_	14	case
14	mechanisms	mechanism	NNS	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	21	punct
16	e.g.	e.g.	FW	_	21	dep
17	,	,	,	_	21	punct
18	pharmacodynamic	pharmacodynamic	JJ	_	21	amod
19	,	,	,	_	21	punct
20	pharmacokinetic	pharmacokinetic	JJ	_	21	amod
21	inhibition	inhibition	NN	_	7	dep
22	or	or	CC	_	21	cc
23	enhancement	enhancement	NN	_	21	conj
24	,	,	,	_	21	punct
25	etc.	etc.	FW	_	21	dep
26	-RRB-	-rrb-	-RRB-	_	21	punct

1	is	be	VBZ	_	3	cop
2	a	a	DT	_	3	det
3	possibility	possibility	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Affecting	affect	VBG	_	1	acl
3	Hepatic	hepatic	JJ	_	4	amod
4	Metabolism	metabolism	NN	_	2	dobj
5	The	the	DT	_	6	det
6	metabolism	metabolism	NN	_	19	nsubjpass
7	and	and	CC	_	6	cc
8	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	Orally	orally	RB	_	15	advmod
15	Disintegrating	disintegrate	VBG	_	16	amod
16	Tablets	tablet	NNS	_	10	dep
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	affected	affect	VBN	_	4	acl:relcl
20	by	by	IN	_	22	case
21	the	the	DT	_	22	det
22	induction	induction	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	inhibition	inhibition	NN	_	22	conj
25	of	of	IN	_	27	case
26	drug-metab-olizing	drug-metab-olizing	JJ	_	27	amod
27	enzymes	enzyme	NNS	_	22	nmod
28	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	14	nsubjpass
2	that	that	WDT	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	Metabolized	metabolize	VBN	_	1	acl:relcl
5	by	by	IN	_	12	case
6	and/or	and/or	CC	_	5	cc
7	Inhibit	inhibit	VB	_	5	conj
8	Cytochrome	cytochrome	NN	_	12	compound
9	P450	p450	NN	_	12	compound
10	Enzymes	enzyme	NNS	_	12	compound
11	Many	many	JJ	_	12	amod
12	drugs	drug	NNS	_	4	nmod
13	are	be	VBP	_	14	auxpass
14	metabolized	metabolize	VBN	_	0	ROOT
15	by	by	IN	_	21	case
16	and/or	and/or	CC	_	15	cc
17	inhibit	inhibit	VB	_	15	conj
18	various	various	JJ	_	21	amod
19	cytochrome	cytochrome	NN	_	21	compound
20	P450	p450	NN	_	21	compound
21	enzymes	enzyme	NNS	_	14	nmod
22	,	,	,	_	21	punct
23	e.g.	e.g.	FW	_	25	dep
24	,	,	,	_	25	punct
25	2D6	2d6	NN	_	21	nmod
26	,	,	,	_	25	punct
27	1A2	1a2	NN	_	25	conj
28	,	,	,	_	25	punct
29	3A4	3a4	NN	_	25	conj
30	,	,	,	_	25	punct
31	etc.	etc.	FW	_	25	dep
32	.	.	.	_	14	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	drug1	drug1	NN	_	10	nsubj
8	is	be	VBZ	_	10	cop
9	a	a	DT	_	10	det
10	substrate	substrate	NN	_	5	ccomp
11	for	for	IN	_	12	case
12	several	several	JJ	_	10	nmod
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	enzymes	enzyme	NNS	_	12	nmod
16	,	,	,	_	12	punct
17	including	include	VBG	_	18	case
18	2D6	2d6	NN	_	12	nmod
19	,	,	,	_	18	punct
20	1A2	1a2	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	3A4	3a4	NN	_	18	conj
24	.	.	.	_	5	punct

1	While	while	IN	_	6	mark
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	shown	show	VBN	_	66	advcl
7	that	that	IN	_	13	mark
8	drug1	drug1	NN	_	13	nsubj
9	is	be	VBZ	_	13	cop
10	not	not	RB	_	13	neg
11	a	a	DT	_	13	det
12	potent	potent	JJ	_	13	amod
13	inhibitor	inhibitor	NN	_	6	ccomp
14	of	of	IN	_	15	case
15	any	any	DT	_	13	nmod
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	enzymes	enzyme	NNS	_	15	nmod
19	,	,	,	_	66	punct
20	an	a	DT	_	21	det
21	indication	indication	NN	_	66	ccomp
22	that	that	WDT	_	26	mark
23	drug2	drug2	NN	_	26	nsubj
24	is	be	VBZ	_	26	cop
25	not	not	RB	_	26	neg
26	likely	likely	JJ	_	21	ccomp
27	to	to	TO	_	28	mark
28	have	have	VB	_	26	xcomp
29	a	a	DT	_	33	det
30	clinically	clinically	RB	_	31	advmod
31	significant	significant	JJ	_	33	amod
32	inhibitory	inhibitory	JJ	_	33	amod
33	effect	effect	NN	_	28	dobj
34	on	on	IN	_	36	case
35	the	the	DT	_	36	det
36	metabolism	metabolism	NN	_	28	nmod
37	of	of	IN	_	39	case
38	other	other	JJ	_	39	amod
39	drugs	drug	NNS	_	36	nmod
40	that	that	WDT	_	42	nsubj
41	are	be	VBP	_	42	cop
42	substrates	substrate	NNS	_	39	acl:relcl
43	for	for	IN	_	47	case
44	these	these	DT	_	47	det
45	cytochrome	cytochrome	NN	_	47	compound
46	P450	p450	NN	_	47	compound
47	enzymes	enzyme	NNS	_	42	nmod
48	,	,	,	_	66	punct
49	the	the	DT	_	51	det
50	concomitant	concomitant	JJ	_	51	amod
51	use	use	NN	_	66	nsubjpass
52	of	of	IN	_	53	case
53	drug3	drug3	NN	_	51	nmod
54	with	with	IN	_	57	case
55	most	most	JJS	_	57	amod
56	other	other	JJ	_	57	amod
57	drugs	drug	NNS	_	51	nmod
58	metabolized	metabolize	VBN	_	57	acl
59	by	by	IN	_	61	case
60	these	these	DT	_	61	det
61	enzymes	enzyme	NNS	_	58	nmod
62	has	have	VBZ	_	66	aux
63	not	not	RB	_	66	neg
64	been	be	VBN	_	66	auxpass
65	formally	formally	RB	_	66	advmod
66	studied	study	VBN	_	0	ROOT
67	.	.	.	_	66	punct

1	Consequently	consequently	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	not	not	RB	_	6	neg
6	possible	possible	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	make	make	VB	_	6	xcomp
9	any	any	DT	_	11	det
10	definitive	definitive	JJ	_	11	amod
11	statements	statement	NNS	_	8	dobj
12	about	about	IN	_	14	case
13	the	the	DT	_	14	det
14	risks	risk	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	coadministration	coadministration	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	with	with	IN	_	21	case
20	such	such	JJ	_	21	amod
21	drugs	drug	NNS	_	16	nmod
22	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	1	dep
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	13	punct
8	equivalent	equivalent	JJ	_	13	dep
9	to	to	TO	_	11	case
10	60	60	CD	_	11	nummod
11	g	g	NN	_	8	nmod
12	-RRB-	-rrb-	-RRB-	_	13	punct
13	had	have	VBD	_	4	dep
14	a	a	DT	_	16	det
15	minimal	minimal	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	on	on	IN	_	19	case
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	13	nmod
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	15	15	CD	_	24	nummod
24	mg	mg	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	in	in	IN	_	30	case
27	6	6	CD	_	30	nummod
28	healthy	healthy	JJ	_	30	amod
29	male	male	JJ	_	30	amod
30	subjects	subject	NNS	_	13	nmod
31	.	.	.	_	13	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	the	the	DT	_	4	det
4	impairment	impairment	NN	_	14	nsubjpass
5	of	of	IN	_	9	case
6	cognitive	cognitive	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	motor	motor	NN	_	6	conj
9	skills	skill	NNS	_	4	nmod
10	produced	produce	VBN	_	9	acl
11	by	by	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	were	be	VBD	_	14	auxpass
14	shown	show	VBN	_	0	ROOT
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	cop
17	additive	additive	JJ	_	14	xcomp
18	with	with	IN	_	19	case
19	those	those	DT	_	17	nmod
20	produced	produce	VBN	_	19	acl
21	by	by	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	14	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	avoid	avoid	VB	_	6	xcomp
9	drug1	drug1	NN	_	8	dobj
10	while	while	IN	_	11	mark
11	taking	take	VBG	_	8	advcl
12	drug2	drug2	NN	_	11	dobj
13	.	.	.	_	6	punct
14	drug3	drug3	NN	_	6	dep
15	:	:	:	_	14	punct
16	Concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	24	nsubj
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	15	15	CD	_	22	nummod
22	mg	mg	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	had	have	VBD	_	14	appos
25	a	a	DT	_	27	det
26	minimal	minimal	JJ	_	27	amod
27	effect	effect	NN	_	24	dobj
28	on	on	IN	_	30	case
29	plasma	plasma	NN	_	30	compound
30	levels	level	NNS	_	27	nmod
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	15	15	CD	_	35	nummod
35	mg	mg	NN	_	32	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	in	in	IN	_	40	case
38	12	12	CD	_	40	nummod
39	healthy	healthy	JJ	_	40	amod
40	subjects	subject	NNS	_	24	nmod
41	.	.	.	_	6	punct

1	However	however	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	4	det
4	impairment	impairment	NN	_	13	nsubjpass
5	of	of	IN	_	7	case
6	motor	motor	NN	_	7	compound
7	skills	skill	NNS	_	4	nmod
8	produced	produce	VBN	_	7	acl
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	shown	show	VBN	_	0	ROOT
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	cop
16	additive	additive	JJ	_	13	xcomp
17	with	with	IN	_	18	case
18	those	those	DT	_	16	nmod
19	caused	cause	VBN	_	18	acl
20	by	by	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	13	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	avoid	avoid	VB	_	6	xcomp
9	drug1	drug1	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	other	other	JJ	_	13	amod
12	similar	similar	JJ	_	13	amod
13	drugs	drug	NNS	_	9	conj
14	while	while	IN	_	15	mark
15	taking	take	VBG	_	8	advcl
16	drug2	drug2	NN	_	15	dobj
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Spontaneous	spontaneous	JJ	_	6	amod
4	adverse	adverse	JJ	_	6	amod
5	reaction	reaction	NN	_	6	compound
6	reports	report	NNS	_	17	nsubj
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	concomitant	concomitant	JJ	_	11	amod
11	drug2	drug2	NN	_	9	dobj
12	with	with	IN	_	14	case
13	recommended	recommend	VBN	_	14	amod
14	doses	dose	NNS	_	9	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	demonstrate	demonstrate	VBP	_	1	dep
18	QT	qt	NN	_	20	compound
19	interval	interval	NN	_	20	compound
20	prolongation	prolongation	NN	_	17	dobj
21	and	and	CC	_	20	cc
22	rare	rare	JJ	_	25	amod
23	serious	serious	JJ	_	25	amod
24	cardiac	cardiac	JJ	_	25	amod
25	events	event	NNS	_	20	conj
26	,	,	,	_	17	punct
27	e.g.	e.g.	FW	_	17	dep

1	death	death	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	cardiac	cardiac	JJ	_	4	amod
4	arrest	arrest	NN	_	1	conj
5	,	,	,	_	1	punct
6	and	and	CC	_	1	cc
7	ventricular	ventricular	JJ	_	8	amod
8	arrhythmia	arrhythmia	NN	_	1	conj
9	including	include	VBG	_	12	case
10	torsades	torsade	NNS	_	12	compound
11	de	de	IN	_	12	amod
12	pointes	pointe	NNS	_	8	nmod
13	.	.	.	_	1	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	markedly	markedly	RB	_	7	advmod
7	inhibits	inhibit	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	7	punct
13	resulting	result	VBG	_	7	advcl
14	in	in	IN	_	18	case
15	elevated	elevated	JJ	_	18	amod
16	plasma	plasma	NN	_	18	compound
17	drug3	drug3	NN	_	18	compound
18	levels	level	NNS	_	13	nmod
19	.	.	.	_	3	punct

1	Presence	presence	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	unchanged	unchanged	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	10	case
8	statistically	statistically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	prolongation	prolongation	NN	_	6	nmod
11	of	of	IN	_	16	case
12	the	the	DT	_	16	det
13	QT	QT	NNP	_	16	compound
14	and	and	CC	_	13	cc
15	QTc	QTc	NNP	_	13	conj
16	intervals	interval	NNS	_	10	nmod
17	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Torsades	Torsades	NNP	_	5	compound
4	de	de	NNP	_	5	compound
5	pointes	pointes	NNP	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	elevated	elevated	JJ	_	10	amod
8	parent	parent	NN	_	10	compound
9	drug2	drug2	NN	_	10	compound
10	levels	level	NNS	_	5	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	appos
14	during	during	IN	_	16	case
15	concomitant	concomitant	JJ	_	16	amod
16	use	use	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	in	in	IN	_	23	case
22	clinical	clinical	JJ	_	23	amod
23	trials	trial	NNS	_	16	nmod
24	of	of	IN	_	25	case
25	drug5	drug5	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	from	from	IN	_	30	case
28	foreign	foreign	JJ	_	30	amod
29	post-marketing	post-marketing	JJ	_	30	amod
30	sources	source	NNS	_	25	conj
31	.	.	.	_	1	punct

1	One	one	CD	_	2	nummod
2	death	death	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	from	from	IN	_	9	case
8	foreign	foreign	JJ	_	9	amod
9	post	post	NN	_	6	nmod
10	-	-	:	_	9	punct
11	marketing	marketing	NN	_	12	compound
12	sources	source	NNS	_	9	dep
13	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	chemical	chemical	NN	_	5	compound
5	similarity	similarity	NN	_	0	ROOT
6	of	of	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	8	punct
10	including	include	VBG	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug4	drug4	NN	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	8	punct
18	to	to	TO	_	19	mark
19	drug5	drug5	VB	_	5	acl
20	,	,	,	_	19	punct
21	and	and	CC	_	19	cc
22	drug6	drug6	NN	_	33	nsubjpass
23	,	,	,	_	22	punct
24	concomitant	concomitant	JJ	_	25	amod
25	use	use	NN	_	22	appos
26	of	of	IN	_	28	case
27	these	these	DT	_	28	det
28	products	product	NNS	_	25	nmod
29	with	with	IN	_	30	case
30	drug7	drug7	NN	_	25	nmod
31	is	be	VBZ	_	33	auxpass
32	not	not	RB	_	33	neg
33	recommended	recommend	VBN	_	19	conj
34	pending	pend	VBG	_	36	case
35	full	full	JJ	_	36	amod
36	examination	examination	NN	_	33	nmod
37	of	of	IN	_	39	case
38	potential	potential	JJ	_	39	amod
39	interactions	interaction	NNS	_	36	nmod
40	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	7	nsubj
7	indicate	indicate	VBP	_	1	appos
8	that	that	IN	_	13	mark
9	drug2	drug2	NN	_	13	nsubj
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	can	can	MD	_	13	aux
13	exert	exert	VB	_	7	ccomp
14	an	a	DT	_	15	det
15	effect	effect	NN	_	13	dobj
16	on	on	IN	_	18	case
17	drug4	drug4	NN	_	18	compound
18	metabolism	metabolism	NN	_	15	nmod
19	by	by	IN	_	21	case
20	a	a	DT	_	21	det
21	mechanism	mechanism	NN	_	13	nmod
22	which	which	WDT	_	25	nsubj
23	may	may	MD	_	25	aux
24	be	be	VB	_	25	cop
25	similar	similar	JJ	_	21	acl:relcl
26	to	to	TO	_	27	case
27	that	that	DT	_	25	nmod
28	of	of	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	,	,	,	_	13	punct
31	but	but	CC	_	13	cc
32	to	to	TO	_	35	case
33	a	a	DT	_	35	det
34	lesser	lesser	JJR	_	35	amod
35	extent	extent	NN	_	13	conj
36	.	.	.	_	1	punct

1	Although	although	IN	_	4	mark
2	erythromycin	erythromycin	NN	_	4	nsubj
3	measurably	measurably	RB	_	4	advmod
4	decreases	decrease	VBZ	_	22	advcl
5	the	the	DT	_	6	det
6	clearance	clearance	NN	_	4	dobj
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	drug1	drug1	NN	_	11	compound
10	acid	acid	NN	_	11	compound
11	metabolite	metabolite	NN	_	6	nmod
12	,	,	,	_	22	punct
13	its	its	PRP$	_	14	nmod:poss
14	influence	influence	NN	_	22	nsubj
15	on	on	IN	_	18	case
16	terfenadine	terfenadine	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	is	be	VBZ	_	22	cop
20	still	still	RB	_	22	advmod
21	under	under	IN	_	22	case
22	investigation	investigation	NN	_	0	ROOT
23	.	.	.	_	22	punct

1	A	a	DT	_	4	det
2	few	few	JJ	_	4	amod
3	spontaneous	spontaneous	JJ	_	4	amod
4	accounts	account	NNS	_	19	nsubjpass
5	of	of	IN	_	8	case
6	QT	qt	NN	_	8	compound
7	interval	interval	NN	_	8	compound
8	prolongation	prolongation	NN	_	4	nmod
9	with	with	IN	_	11	case
10	ventricular	ventricular	JJ	_	11	amod
11	arrhythmia	arrhythmia	NN	_	8	nmod
12	including	include	VBG	_	15	case
13	torsades	torsade	NNS	_	15	compound
14	de	de	IN	_	15	amod
15	pointes	pointe	NNS	_	11	nmod
16	,	,	,	_	4	punct
17	have	have	VBP	_	19	aux
18	been	be	VBN	_	19	auxpass
19	reported	report	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	receiving	receive	VBG	_	21	acl
23	drug1	drug1	NN	_	22	dobj
24	or	or	CC	_	23	cc
25	drug2	drug2	NN	_	23	conj
26	.	.	.	_	19	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	or	or	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	is	be	VBZ	_	13	auxpass
13	contraindicated	contraindicate	VBN	_	0	ROOT
14	:	:	:	_	13	punct
15	Pending	pend	VBG	_	35	advcl
16	full	full	JJ	_	17	amod
17	characterization	characterization	NN	_	15	dobj
18	of	of	IN	_	20	case
19	potential	potential	JJ	_	20	amod
20	interactions	interaction	NNS	_	17	nmod
21	,	,	,	_	35	punct
22	concomitant	concomitant	JJ	_	23	amod
23	administration	administration	NN	_	35	nsubjpass
24	of	of	IN	_	25	case
25	drug5	drug5	NN	_	23	nmod
26	with	with	IN	_	28	case
27	other	other	JJ	_	28	amod
28	drug6	drug6	NN	_	23	nmod
29	,	,	,	_	28	punct
30	including	include	VBG	_	31	case
31	drug7	drug7	NN	_	28	nmod
32	,	,	,	_	28	punct
33	is	be	VBZ	_	35	auxpass
34	not	not	RB	_	35	neg
35	recommended	recommend	VBN	_	13	parataxis
36	.	.	.	_	13	punct

1	Studies	study	NNS	_	12	nsubj
2	to	to	TO	_	3	mark
3	evaluate	evaluate	VB	_	1	acl
4	potential	potential	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	are	be	VBP	_	12	cop
11	in	in	IN	_	12	case
12	progress	progress	NN	_	0	ROOT
13	.	.	.	_	12	punct

1	Acromegalic	acromegalic	JJ	_	2	amod
2	patients	patient	NNS	_	7	nsubjpass
3	with	with	IN	_	5	case
4	diabetes	diabetes	NN	_	5	compound
5	mellitus	mellitus	NN	_	2	nmod
6	being	be	VBG	_	7	auxpass
7	treated	treat	VBN	_	15	csubj
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and/or	and/or	CC	_	9	cc
11	oral	oral	JJ	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	agents	agent	NNS	_	9	conj
14	may	may	MD	_	15	aux
15	require	require	VB	_	0	ROOT
16	dose	dose	NN	_	17	compound
17	reductions	reduction	NNS	_	15	dobj
18	of	of	IN	_	21	case
19	these	these	DT	_	21	det
20	therapeutic	therapeutic	JJ	_	21	amod
21	agents	agent	NNS	_	17	nmod
22	after	after	IN	_	24	case
23	the	the	DT	_	24	det
24	initiation	initiation	NN	_	15	nmod
25	of	of	IN	_	26	case
26	therapy	therapy	NN	_	24	nmod
27	with	with	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	.	.	.	_	15	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	patients	patient	NNS	_	9	nsubj
6	on	on	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	often	often	RB	_	9	advmod
9	needed	need	VBD	_	0	ROOT
10	higher	higher	JJR	_	13	amod
11	serum	serum	NN	_	13	compound
12	drug2	drug2	NN	_	13	compound
13	concentrations	concentration	NNS	_	9	dobj
14	to	to	TO	_	15	mark
15	achieve	achieve	VB	_	9	advcl
16	appropriate	appropriate	JJ	_	18	amod
17	IGF-I	igf-i	NN	_	18	compound
18	suppression	suppression	NN	_	15	dobj
19	compared	compare	VBN	_	21	case
20	with	with	IN	_	21	case
21	patients	patient	NNS	_	15	advcl
22	not	not	RB	_	23	neg
23	receiving	receive	VBG	_	21	acl
24	drug3	drug3	NN	_	23	dobj
25	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	known	know	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	19	csubj
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	9	case
8	digitalized	digitalized	JJ	_	9	amod
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	4	punct
11	since	since	IN	_	13	case
12	the	the	DT	_	13	det
13	combination	combination	NN	_	4	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	may	may	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	ectopic	ectopic	JJ	_	21	amod
21	arrhythmias	arrhythmia	NNS	_	19	dobj
22	.	.	.	_	19	punct

1	drug1	drug1	NN	_	5	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	potentiate	potentiate	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	action	action	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	18	advmod
2	,	,	,	_	18	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	18	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	9	dobj
12	,	,	,	_	18	punct
13	the	the	DT	_	15	det
14	initial	initial	JJ	_	15	amod
15	dose	dose	NN	_	18	nsubj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	cop
18	small	small	JJ	_	0	ROOT
19	and	and	CC	_	18	cc
20	given	give	VBN	_	22	case
21	with	with	IN	_	22	case
22	caution	caution	NN	_	18	conj
23	.	.	.	_	18	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	a	a	DT	_	5	det
4	bacteriostatic	bacteriostatic	JJ	_	5	amod
5	drug2	drug2	NN	_	1	appos
6	,	,	,	_	1	punct
7	may	may	MD	_	8	aux
8	antagonize	antagonize	VB	_	22	csubjpass
9	the	the	DT	_	11	det
10	bactericidal	bactericidal	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	concurrent	concurrent	JJ	_	16	amod
16	use	use	NN	_	13	conj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	drugs	drug	NNS	_	13	nmod
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	avoided	avoid	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	may	may	MD	_	8	aux
8	result	result	VB	_	0	ROOT
9	in	in	IN	_	13	case
10	an	a	DT	_	13	det
11	adverse	adverse	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	interaction	interaction	NN	_	8	nmod
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	on	on	IN	_	7	case
6	a	a	DT	_	7	det
7	background	background	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	2	punct
6	in	in	IN	_	7	case
7	combination	combination	NN	_	2	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	2	punct
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	associated	associate	VBN	_	28	ccomp
16	with	with	IN	_	18	case
17	an	a	DT	_	18	det
18	increase	increase	NN	_	15	nmod
19	in	in	IN	_	20	mark
20	bleeding	bleed	VBG	_	18	acl
21	compared	compare	VBN	_	23	case
22	to	to	TO	_	23	case
23	drug4	drug4	NN	_	20	advcl
24	and	and	CC	_	23	cc
25	drug5	drug5	NN	_	23	conj
26	alone	alone	RB	_	23	advmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	see	see	VB	_	0	ROOT

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Inhibitors	inhibitor	NNS	_	2	dep
5	of	of	IN	_	7	case
6	CYP3A4	cyp3a4	NN	_	7	compound
7	Isozymes	isozyme	NNS	_	4	nmod
8	:	:	:	_	4	punct
9	Caution	caution	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	advised	advise	VBN	_	4	dep
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	administered	administer	VBN	_	11	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	with	with	IN	_	18	case
18	drugs	drug	NNS	_	15	nmod
19	that	that	WDT	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	known	know	VBN	_	18	acl:relcl
22	to	to	TO	_	23	mark
23	inhibit	inhibit	VB	_	21	xcomp
24	the	the	DT	_	29	det
25	cytochrome	cytochrome	NN	_	29	compound
26	P450	p450	NN	_	29	compound
27	3A4	3a4	NN	_	29	compound
28	enzyme	enzyme	NN	_	29	compound
29	system	system	NN	_	23	dobj
30	-LRB-	-lrb-	-LRB-	_	29	punct
31	ie	ie	FW	_	30	root
32	,	,	,	_	31	punct
33	some	some	DT	_	34	det
34	drugs	drug	NNS	_	32	root
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	drug	drug	NN	_	38	compound
38	classes	class	NNS	_	34	nmod
39	of	of	IN	_	40	case
40	drug2	drug2	NN	_	38	nmod
41	,	,	,	_	40	punct
42	drug3	drug3	NN	_	40	conj
43	,	,	,	_	40	punct
44	drug4	drug4	NN	_	40	conj
45	,	,	,	_	40	punct
46	and	and	CC	_	40	cc
47	drug5	drug5	NN	_	40	conj
48	-RRB-	-rrb-	-RRB-	_	34	punct
49	.	.	.	_	34	punct

1	Drugs	drug	NNS	_	16	nsubjpass
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	and	and	CC	_	4	cc
14	drug6	drug6	NN	_	4	conj
15	were	be	VBD	_	16	auxpass
16	shown	show	VBN	_	0	ROOT
17	to	to	TO	_	19	mark
18	significantly	significantly	RB	_	19	advmod
19	increase	increase	VB	_	16	xcomp
20	the	the	DT	_	22	det
21	C	c	NN	_	22	compound
22	max	max	NN	_	19	dobj
23	and	and	CC	_	22	cc
24	AUC	auc	NN	_	22	conj
25	of	of	IN	_	28	case
26	orally	orally	RB	_	27	advmod
27	administered	administer	VBN	_	28	amod
28	drug7	drug7	NN	_	22	nmod
29	.	.	.	_	16	punct

1	These	these	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	result	result	VB	_	0	ROOT
6	in	in	IN	_	10	case
7	increased	increase	VBN	_	10	amod
8	and	and	CC	_	7	cc
9	prolonged	prolong	VBN	_	7	conj
10	sedation	sedation	NN	_	5	nmod
11	due	due	JJ	_	14	case
12	to	to	TO	_	11	mwe
13	a	a	DT	_	14	det
14	decrease	decrease	NN	_	10	nmod
15	in	in	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	clearance	clearance	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	5	punct

1	Although	although	IN	_	3	mark
2	not	not	RB	_	3	neg
3	studied	study	VBN	_	15	advcl
4	,	,	,	_	15	punct
5	the	the	DT	_	10	det
6	potent	potent	JJ	_	10	amod
7	cytochrome	cytochrome	NN	_	10	compound
8	P450	p450	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	15	nsubj
11	drug1	drug1	NN	_	10	dep
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	0	ROOT
16	intense	intense	JJ	_	19	amod
17	and	and	CC	_	16	cc
18	prolonged	prolonged	JJ	_	16	conj
19	sedation	sedation	NN	_	15	dobj
20	and	and	CC	_	19	cc
21	respiratory	respiratory	JJ	_	22	amod
22	depression	depression	NN	_	19	conj
23	due	due	JJ	_	26	case
24	to	to	TO	_	23	mwe
25	a	a	DT	_	26	det
26	decrease	decrease	NN	_	19	nmod
27	in	in	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	clearance	clearance	NN	_	26	nmod
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	.	.	.	_	15	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	7	advmod
5	drug1	drug1	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	used	use	VBN	_	3	advcl
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	7	nmod
12	.	.	.	_	3	punct

1	Dose	dose	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	and	and	CC	_	5	cc
7	possible	possible	JJ	_	8	amod
8	prolongation	prolongation	NN	_	15	nsubjpass
9	and	and	CC	_	8	cc
10	intensity	intensity	NN	_	8	conj
11	of	of	IN	_	12	case
12	effect	effect	NN	_	8	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	anticipated	anticipate	VBN	_	5	conj
16	.	.	.	_	5	punct

1	Inducers	inducer	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	CYP3A4	cyp3a4	NN	_	4	compound
4	Isozymes	isozyme	NNS	_	1	nmod
5	:	:	:	_	1	punct
6	Cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	inducers	inducer	NNS	_	19	nsubj
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug1	drug1	NN	_	8	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug3	drug3	NN	_	12	conj
18	,	,	,	_	8	punct
19	induce	induce	VBP	_	1	dep
20	metabolism	metabolism	NN	_	19	dobj
21	and	and	CC	_	19	cc
22	caused	cause	VBD	_	19	conj
23	a	a	DT	_	27	det
24	markedly	markedly	RB	_	25	advmod
25	decreased	decrease	VBN	_	27	amod
26	C	c	NN	_	27	compound
27	max	max	NN	_	22	dobj
28	and	and	CC	_	27	cc
29	AUC	auc	NN	_	27	conj
30	of	of	IN	_	32	case
31	oral	oral	JJ	_	32	amod
32	drug4	drug4	NN	_	27	nmod
33	in	in	IN	_	35	case
34	adult	adult	JJ	_	35	amod
35	studies	study	NNS	_	27	nmod
36	.	.	.	_	1	punct

1	Although	although	IN	_	7	mark
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	11	advcl
8	,	,	,	_	11	punct
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	have	have	VB	_	11	xcomp
14	the	the	DT	_	16	det
15	same	same	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	.	.	.	_	11	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	these	these	DT	_	11	det
11	medications	medication	NNS	_	9	dobj
12	and	and	CC	_	5	cc
13	if	if	IN	_	19	mark
14	necessary	necessary	JJ	_	16	amod
15	dose	dose	NN	_	16	compound
16	adjustments	adjustment	NNS	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	considered	consider	VBN	_	5	conj
20	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	difficulty	difficulty	NN	_	11	nsubj
3	in	in	IN	_	4	mark
4	achieving	achieve	VBG	_	2	acl
5	adequate	adequate	JJ	_	6	amod
6	sedation	sedation	NN	_	4	dobj
7	may	may	MD	_	11	aux
8	have	have	VB	_	11	aux
9	been	be	VBN	_	11	cop
10	the	the	DT	_	11	det
11	result	result	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	decreased	decrease	VBN	_	14	amod
14	absorption	absorption	NN	_	11	nmod
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	drug1	drug1	NN	_	14	nmod
18	due	due	JJ	_	23	case
19	to	to	TO	_	18	mwe
20	both	both	CC	_	23	cc:preconj
21	the	the	DT	_	23	det
22	gastrointestinal	gastrointestinal	JJ	_	23	amod
23	effects	effect	NNS	_	14	nmod
24	and	and	CC	_	23	cc
25	stimulant	stimulant	NN	_	26	compound
26	effects	effect	NNS	_	23	conj
27	of	of	IN	_	28	case
28	drug2	drug2	NN	_	23	nmod
29	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	sedative	sedative	JJ	_	3	amod
3	effect	effect	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	accentuated	accentuate	VBN	_	0	ROOT
8	by	by	IN	_	12	case
9	any	any	DT	_	12	det
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	12	amod
12	medication	medication	NN	_	7	nmod
13	which	which	WDT	_	14	nsubj
14	depresses	depress	VBZ	_	12	acl:relcl
15	the	the	DT	_	18	det
16	central	central	JJ	_	18	amod
17	nervous	nervous	JJ	_	18	amod
18	system	system	NN	_	14	dobj
19	,	,	,	_	12	punct
20	particularly	particularly	RB	_	21	advmod
21	drug2	drug2	NN	_	12	appos
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	eg	eg	FW	_	25	compound
24	,	,	,	_	25	punct
25	drug3	drug3	NN	_	21	dep
26	,	,	,	_	25	punct
27	drug4	drug4	NN	_	25	conj
28	and	and	CC	_	25	cc
29	drug5	drug5	NN	_	25	conj
30	-RRB-	-rrb-	-RRB-	_	25	punct
31	,	,	,	_	21	punct
32	drug6	drug6	NN	_	21	conj
33	,	,	,	_	21	punct
34	drug7	drug7	NN	_	21	conj
35	,	,	,	_	21	punct
36	drug8	drug8	NN	_	21	conj
37	,	,	,	_	21	punct
38	drug9	drug9	NN	_	21	conj
39	and	and	CC	_	21	cc
40	drug10	drug10	NN	_	21	conj
41	.	.	.	_	7	punct

1	Consequently	consequently	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	adjusted	adjust	VBN	_	0	ROOT
10	according	accord	VBG	_	13	case
11	to	to	TO	_	10	mwe
12	the	the	DT	_	13	det
13	type	type	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	amount	amount	NN	_	13	conj
16	of	of	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	medications	medication	NNS	_	13	nmod
19	administered	administer	VBN	_	18	acl
20	and	and	CC	_	13	cc
21	the	the	DT	_	24	det
22	desired	desire	VBN	_	24	amod
23	clinical	clinical	JJ	_	24	amod
24	response	response	NN	_	13	conj
25	.	.	.	_	9	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	interactions	interaction	NNS	_	30	nsubjpass
5	with	with	IN	_	7	case
6	common	common	JJ	_	7	amod
7	premedications	premedication	NNS	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug1	drug1	NN	_	7	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug4	drug4	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug5	drug5	NN	_	11	conj
20	,	,	,	_	11	punct
21	and	and	CC	_	11	cc
22	other	other	JJ	_	23	amod
23	drug6	drug6	NN	_	11	conj
24	-RRB-	-rrb-	-RRB-	_	11	punct
25	or	or	CC	_	7	cc
26	local	local	JJ	_	27	amod
27	drug7	drug7	NN	_	7	conj
28	have	have	VBP	_	30	aux
29	been	be	VBN	_	30	auxpass
30	observed	observe	VBN	_	0	ROOT
31	.	.	.	_	30	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	29	nsubj
4	of	of	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	including	include	VBG	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	general	general	JJ	_	15	amod
15	drug5	drug5	NN	_	8	conj
16	,	,	,	_	8	punct
17	drug6	drug6	NN	_	8	conj
18	,	,	,	_	8	punct
19	other	other	JJ	_	20	amod
20	drug7	drug7	NN	_	8	conj
21	,	,	,	_	8	punct
22	drug8	drug8	NN	_	8	conj
23	,	,	,	_	8	punct
24	drug9	drug9	NN	_	8	conj
25	,	,	,	_	8	punct
26	and	and	CC	_	8	cc
27	drug10	drug10	NN	_	8	conj
28	may	may	MD	_	29	aux
29	produce	produce	VB	_	0	ROOT
30	additive	additive	JJ	_	33	amod
31	CNS	cn	NNS	_	33	compound
32	depressant	depressant	NN	_	33	compound
33	effects	effect	NNS	_	29	dobj
34	.	.	.	_	29	punct

1	When	when	WRB	_	6	advmod
2	such	such	JJ	_	4	amod
3	combined	combined	JJ	_	4	amod
4	therapy	therapy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contemplated	contemplate	VBN	_	17	advcl
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	14	nsubj
2	or	or	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	medications	medication	NNS	_	1	conj
5	with	with	IN	_	7	case
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	activity	activity	NN	_	1	nmod
8	when	when	WRB	_	9	advmod
9	used	use	VBN	_	1	acl:relcl
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	result	result	VB	_	0	ROOT
15	in	in	IN	_	17	case
16	increased	increase	VBN	_	17	amod
17	risk	risk	NN	_	14	nmod
18	of	of	IN	_	20	case
19	urinary	urinary	JJ	_	20	amod
20	retention	retention	NN	_	17	nmod
21	and/or	and/or	CC	_	20	cc
22	severe	severe	JJ	_	23	amod
23	constipation	constipation	NN	_	20	conj
24	,	,	,	_	17	punct
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	lead	lead	VB	_	17	acl:relcl
28	to	to	TO	_	30	case
29	paralytic	paralytic	JJ	_	30	amod
30	ileus	ileus	NN	_	27	nmod
31	.	.	.	_	14	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	11	mark
6	the	the	DT	_	7	det
7	incidence	incidence	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	bradycardia	bradycardia	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	increased	increase	VBN	_	4	ccomp
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	combined	combine	VBN	_	11	advcl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	for	for	IN	_	19	case
19	induction	induction	NN	_	17	nmod
20	of	of	IN	_	21	case
21	anesthesia	anesthesia	NN	_	19	nmod
22	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	CNS	cns	NN	_	5	compound
5	toxicity	toxicity	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	confusion	confusion	NN	_	8	dep
11	,	,	,	_	10	punct
12	disorientation	disorientation	NN	_	10	conj
13	,	,	,	_	10	punct
14	respiratory	respiratory	JJ	_	15	amod
15	depression	depression	NN	_	10	conj
16	,	,	,	_	10	punct
17	apnea	apnea	NN	_	10	conj
18	,	,	,	_	10	punct
19	seizures	seizure	NNS	_	10	appos
20	-RRB-	-rrb-	-RRB-	_	10	punct
21	following	follow	VBG	_	22	case
22	coadministration	coadministration	NN	_	8	nmod
23	of	of	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	22	nmod
27	;	;	:	_	8	punct

1	no	no	DT	_	3	neg
2	clear-cut	clear-cut	JJ	_	3	amod
3	cause	cause	NN	_	8	nsubjpass
4	and	and	CC	_	3	cc
5	effect	effect	NN	_	6	compound
6	relationship	relationship	NN	_	3	conj
7	was	be	VBD	_	8	auxpass
8	established	establish	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Dosages	dosage	NNS	_	8	nsubjpass
2	of	of	IN	_	5	case
3	concomitantly	concomitantly	RB	_	4	advmod
4	administered	administer	VBN	_	5	amod
5	drug1	drug1	NN	_	1	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	reduced	reduce	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	approximately	approximately	RB	_	11	advmod
11	half	half	RB	_	8	nmod
12	,	,	,	_	8	punct
13	because	because	IN	_	15	mark
14	drug2	drug2	NN	_	15	nsubj
15	amplifies	amplify	VBZ	_	8	advcl
16	the	the	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	actions	action	NNS	_	15	dobj
19	and	and	CC	_	18	cc
20	side-effects	side-effect	NNS	_	18	conj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	8	punct

1	Combination	combination	NN	_	8	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	increased	increase	VBN	_	11	amod
11	risk	risk	NN	_	8	nmod
12	of	of	IN	_	13	case
13	seizures	seizure	NNS	_	11	nmod
14	.	.	.	_	8	punct

1	Additive	additive	JJ	_	3	amod
2	sedative	sedative	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	and	and	CC	_	3	cc
5	confusional	confusional	JJ	_	6	amod
6	states	state	NNS	_	3	conj
7	may	may	MD	_	8	aux
8	emerge	emerge	VB	_	0	ROOT
9	if	if	IN	_	12	mark
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	8	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	.	.	.	_	8	punct

1	This	this	DT	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	avoided	avoid	VBN	_	0	ROOT
5	by	by	IN	_	6	mark
6	using	use	VBG	_	4	advcl
7	the	the	DT	_	9	det
8	lowest	lowest	JJS	_	9	amod
9	dose	dose	NN	_	6	dobj
10	possible	possible	JJ	_	9	amod
11	with	with	IN	_	13	case
12	the	the	DT	_	13	det
13	substances	substance	NNS	_	10	nmod
14	in	in	IN	_	15	case
15	question	question	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Exert	exert	VB	_	0	ROOT
2	particular	particular	JJ	_	3	amod
3	caution	caution	NN	_	1	dobj
4	in	in	IN	_	5	mark
5	combining	combine	VBG	_	1	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	dep
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	:	:	:	_	1	punct
16	Particularly	particularly	RB	_	18	advmod
17	the	the	DT	_	18	det
18	elderly	elderly	JJ	_	20	nsubj
19	may	may	MD	_	20	aux
20	develop	develop	VB	_	1	parataxis
21	delirium	delirium	NN	_	20	dobj
22	,	,	,	_	21	punct
23	high	high	JJ	_	24	amod
24	fever	fever	NN	_	21	conj
25	,	,	,	_	21	punct
26	severe	severe	JJ	_	27	amod
27	obstipation	obstipation	NN	_	21	conj
28	,	,	,	_	21	punct
29	even	even	RB	_	30	advmod
30	ileus	ileus	NN	_	21	conj
31	and	and	CC	_	21	cc
32	glaucoma	glaucoma	NN	_	21	conj
33	.	.	.	_	1	punct

1	Reduce	reduce	VB	_	0	ROOT
2	both	both	CC	_	4	cc:preconj
3	the	the	DT	_	4	det
4	dose	dose	NN	_	1	dobj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	the	the	DT	_	9	det
9	dose	dose	NN	_	4	conj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	other	other	JJ	_	13	amod
13	drug	drug	NN	_	9	nmod
14	.	.	.	_	1	punct

1	If	if	IN	_	2	mark
2	possible	possible	JJ	_	4	advcl
3	,	,	,	_	4	punct
4	avoid	avoid	VB	_	0	ROOT
5	such	such	JJ	_	6	amod
6	combinations	combination	NNS	_	4	dobj
7	.	.	.	_	4	punct

1	drug1	drug1	NN	_	11	nsubj
2	and/or	and/or	CC	_	1	cc
3	stimulantes	stimulante	NNS	_	1	conj
4	of	of	IN	_	9	case
5	the	the	DT	_	9	det
6	drug2	drug2	NN	_	9	compound
7	/	/	:	_	9	punct
8	drug3	drug3	NN	_	9	compound
9	type	type	NN	_	1	nmod
10	may	may	MD	_	11	aux
11	counteract	counteract	VB	_	0	ROOT
12	the	the	DT	_	14	det
13	specific	specific	JJ	_	14	amod
14	actions	action	NNS	_	11	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	11	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	substances	substance	NNS	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	avoided	avoid	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Coffee	Coffee	NNP	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	black	black	JJ	_	4	amod
4	tea	tea	NN	_	1	conj
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	0	ROOT
8	because	because	IN	_	10	mark
9	they	they	PRP	_	10	nsubj
10	decrease	decrease	VBP	_	7	advcl
11	the	the	DT	_	12	det
12	absorption	absorption	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	considerably	considerably	RB	_	10	advmod
16	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	same	same	JJ	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	true	true	JJ	_	0	ROOT
5	for	for	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	;	;	:	_	4	punct

1	these	these	DT	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	given	give	VBN	_	0	ROOT
5	1	1	CD	_	7	compound
6	to	to	TO	_	7	dep
7	2	2	CD	_	8	nummod
8	hours	hour	NNS	_	4	dobj
9	before	before	IN	_	13	nmod
10	or	or	CC	_	9	cc
11	after	after	IN	_	9	conj
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	8	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Usage	usage	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Due	due	JJ	_	18	advmod
6	to	to	TO	_	8	case
7	the	the	DT	_	8	det
8	potential	potential	NN	_	5	nmod
9	for	for	IN	_	13	case
10	increased	increase	VBN	_	13	amod
11	CNS	cns	NN	_	13	compound
12	depressants	depressant	NNS	_	13	compound
13	effects	effect	NNS	_	8	nmod
14	,	,	,	_	18	punct
15	drug2	drug2	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	1	dep
19	with	with	IN	_	20	case
20	caution	caution	NN	_	18	nmod
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	who	who	WP	_	26	nsubj
24	are	be	VBP	_	26	aux
25	currently	currently	RB	_	26	advmod
26	receiving	receive	VBG	_	22	acl:relcl
27	drug3	drug3	NN	_	26	dobj
28	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	CNS	cns	NN	_	4	compound
3	depressant	depressant	NN	_	4	compound
4	effects	effect	NNS	_	9	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	additive	additive	JJ	_	0	ROOT
10	with	with	IN	_	11	case
11	that	that	DT	_	9	nmod
12	of	of	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	.	.	.	_	9	punct
16	.	.	.	_	9	punct

1	Limited	limited	JJ	_	2	amod
2	evidence	evidence	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	influence	influence	VB	_	3	ccomp
8	the	the	DT	_	9	det
9	intensity	intensity	NN	_	7	dobj
10	and	and	CC	_	9	cc
11	duration	duration	NN	_	9	conj
12	of	of	IN	_	13	case
13	action	action	NN	_	9	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	multiple-dose	multiple-dose	JJ	_	6	amod
6	study	study	NN	_	32	nmod
7	in	in	IN	_	11	case
8	30	30	CD	_	11	nummod
9	normal	normal	JJ	_	11	amod
10	weight	weight	NN	_	11	compound
11	subjects	subject	NNS	_	6	nmod
12	,	,	,	_	6	punct
13	coadministration	coadministration	NN	_	32	nsubj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	40	40	CD	_	18	nummod
18	grams	gram	NNS	_	15	conj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	15	nmod
21	-LRB-	-lrb-	-LRB-	_	26	punct
22	e.g.	e.g.	FW	_	26	dep
23	,	,	,	_	26	punct
24	approximately	approximately	RB	_	25	advmod
25	3	3	CD	_	26	nummod
26	glasses	glass	NNS	_	20	dep
27	of	of	IN	_	28	case
28	wine	wine	NN	_	26	nmod
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	did	do	VBD	_	32	aux
31	not	not	RB	_	32	neg
32	result	result	VB	_	1	appos
33	in	in	IN	_	34	case
34	alteration	alteration	NN	_	32	nmod
35	of	of	IN	_	37	case
36	drug4	drug4	NN	_	37	compound
37	pharmacokinetics	pharmacokinetic	NNS	_	34	nmod
38	,	,	,	_	34	punct
39	drug5	drug5	NN	_	40	compound
40	pharmacodynamics	pharmacodynamic	NNS	_	34	conj
41	-LRB-	-lrb-	-LRB-	_	44	punct
42	fecal	fecal	JJ	_	44	amod
43	fat	fat	JJ	_	44	amod
44	excretion	excretion	NN	_	40	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	34	punct
47	or	or	CC	_	34	cc
48	systemic	systemic	JJ	_	49	amod
49	exposure	exposure	NN	_	34	conj
50	to	to	TO	_	51	case
51	drug6	drug6	NN	_	49	nmod
52	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Preliminary	preliminary	JJ	_	4	amod
4	data	datum	NNS	_	13	nsubj
5	from	from	IN	_	12	case
6	a	a	DT	_	12	det
7	drug2	drug2	NN	_	12	compound
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	drug	drug	NN	_	12	compound
11	interaction	interaction	NN	_	12	compound
12	study	study	NN	_	4	nmod
13	indicate	indicate	VBP	_	1	appos
14	a	a	DT	_	15	det
15	reduction	reduction	NN	_	13	dobj
16	in	in	IN	_	19	case
17	drug4	drug4	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	when	when	WRB	_	23	advmod
21	drug5	drug5	NN	_	23	nsubjpass
22	was	be	VBD	_	23	auxpass
23	coadministered	coadminister	VBN	_	13	advcl
24	with	with	IN	_	25	case
25	drug6	drug6	NN	_	23	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	10	compound
9	120	120	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:tmod
13	a	a	DT	_	14	det
14	day	day	NN	_	12	nmod:npmod
15	for	for	IN	_	17	case
16	6	6	CD	_	17	nummod
17	days	day	NNS	_	7	nmod
18	,	,	,	_	22	punct
19	drug3	drug3	NN	_	22	nsubj
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	alter	alter	VB	_	1	appos
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	22	dobj
25	of	of	IN	_	28	case
26	a	a	DT	_	28	det
27	single	single	JJ	_	28	amod
28	dose	dose	NN	_	24	nmod
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Analogues	analogue	NNS	_	1	conj
4	:	:	:	_	1	punct
5	A	a	DT	_	8	det
6	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
7	interaction	interaction	NN	_	8	compound
8	study	study	NN	_	9	nsubj
9	showed	show	VBD	_	1	dep
10	a	a	DT	_	13	det
11	30	30	CD	_	12	compound
12	%	%	NN	_	13	amod
13	reduction	reduction	NN	_	9	dobj
14	in	in	IN	_	17	case
15	drug2	drug2	NN	_	17	compound
16	supplement	supplement	NN	_	17	compound
17	absorption	absorption	NN	_	13	nmod
18	when	when	WRB	_	20	advmod
19	concomitantly	concomitantly	RB	_	20	advmod
20	administered	administer	VBN	_	9	advcl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibited	inhibit	VBD	_	0	ROOT
3	absorption	absorption	NN	_	2	dobj
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	drug2	drug2	NN	_	7	compound
7	supplement	supplement	NN	_	3	nmod
8	by	by	IN	_	11	case
9	approximately	approximately	RB	_	10	advmod
10	60	60	CD	_	11	nummod
11	%	%	NN	_	2	nmod
12	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	2	nmod
8	of	of	IN	_	10	case
9	supplemental	supplemental	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	and	and	CC	_	10	cc
15	nutritionally-derived	nutritionally-derived	JJ	_	16	amod
16	drug4	drug4	NN	_	10	conj
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	known	know	VBN	_	0	ROOT
20	at	at	IN	_	22	case
21	this	this	DT	_	22	det
22	time	time	NN	_	19	nmod
23	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	10	compound
9	80	80	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:tmod
13	a	a	DT	_	14	det
14	day	day	NN	_	12	nmod:npmod
15	for	for	IN	_	17	case
16	5	5	CD	_	17	nummod
17	days	day	NNS	_	7	nmod
18	,	,	,	_	22	punct
19	drug3	drug3	NN	_	22	nsubj
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	alter	alter	VB	_	1	appos
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	22	dobj
25	or	or	CC	_	24	cc
26	pharmacodynamics	pharmacodynamic	NNS	_	24	conj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	blood	blood	NN	_	29	compound
29	glucose-lowering	glucose-lowering	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	24	nmod
33	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	extended-release	extended-release	JJ	_	4	amod
4	tablets	tablet	NNS	_	1	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	:	:	:	_	1	punct
7	In	in	IN	_	10	case
8	17	17	CD	_	10	nummod
9	normal-weight	normal-weight	JJ	_	10	amod
10	subjects	subject	NNS	_	26	nmod
11	receiving	receive	VBG	_	10	acl
12	drug2	drug2	NN	_	14	compound
13	120	120	CD	_	14	nummod
14	mg	mg	NN	_	11	dobj
15	three	three	CD	_	16	nummod
16	times	time	NNS	_	11	nmod:tmod
17	a	a	DT	_	18	det
18	day	day	NN	_	16	nmod:npmod
19	for	for	IN	_	21	case
20	6	6	CD	_	21	nummod
21	days	day	NNS	_	11	nmod
22	,	,	,	_	26	punct
23	drug3	drug3	NN	_	26	nsubj
24	did	do	VBD	_	26	aux
25	not	not	RB	_	26	neg
26	alter	alter	VB	_	1	dep
27	the	the	DT	_	28	det
28	bioavailability	bioavailability	NN	_	26	dobj
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	extended-release	extended-release	JJ	_	33	amod
33	tablets	tablet	NNS	_	30	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	.	.	.	_	1	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	8	case
5	20	20	CD	_	8	nummod
6	normal-weight	normal-weight	JJ	_	8	amod
7	female	female	JJ	_	8	amod
8	subjects	subject	NNS	_	2	nmod
9	,	,	,	_	8	punct
10	the	the	DT	_	11	det
11	treatment	treatment	NN	_	23	nsubj
12	of	of	IN	_	15	case
13	drug2	drug2	NN	_	15	compound
14	120	120	CD	_	15	nummod
15	mg	mg	NN	_	11	nmod
16	three	three	CD	_	17	nummod
17	times	time	NNS	_	11	nmod:tmod
18	a	a	DT	_	19	det
19	day	day	NN	_	17	nmod:npmod
20	for	for	IN	_	22	case
21	23	23	CD	_	22	nummod
22	days	day	NNS	_	11	nmod
23	resulted	result	VBD	_	8	acl:relcl
24	in	in	IN	_	26	case
25	no	no	DT	_	26	neg
26	changes	change	NNS	_	23	nmod
27	in	in	IN	_	30	case
28	the	the	DT	_	30	det
29	ovulation-suppressing	ovulation-suppressing	JJ	_	30	amod
30	action	action	NN	_	26	nmod
31	of	of	IN	_	33	case
32	oral	oral	JJ	_	33	amod
33	drug3	drug3	NN	_	30	nmod
34	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	10	compound
9	120	120	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:tmod
13	a	a	DT	_	14	det
14	day	day	NN	_	12	nmod:npmod
15	for	for	IN	_	17	case
16	7	7	CD	_	17	nummod
17	days	day	NNS	_	7	nmod
18	,	,	,	_	22	punct
19	drug3	drug3	NN	_	22	nsubj
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	alter	alter	VB	_	1	appos
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	22	dobj
25	of	of	IN	_	29	case
26	a	a	DT	_	29	det
27	single	single	JJ	_	29	amod
28	300-mg	300-mg	JJ	_	29	amod
29	dose	dose	NN	_	24	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	2-way	2-way	JJ	_	7	amod
6	crossover	crossover	NN	_	7	compound
7	study	study	NN	_	1	nmod
8	of	of	IN	_	10	case
9	24	24	CD	_	10	nummod
10	normal-weight	normal-weight	JJ	_	7	nmod
11	,	,	,	_	10	punct
12	mildly	mildly	RB	_	13	advmod
13	hypercholesterolemic	hypercholesterolemic	JJ	_	14	amod
14	patients	patient	NNS	_	10	appos
15	receiving	receive	VBG	_	14	acl
16	drug2	drug2	NN	_	18	compound
17	120	120	CD	_	18	nummod
18	mg	mg	NN	_	15	dobj
19	three	three	CD	_	20	nummod
20	times	time	NNS	_	14	dep
21	a	a	DT	_	22	det
22	day	day	NN	_	20	nmod:npmod
23	for	for	IN	_	25	case
24	6	6	CD	_	25	nummod
25	days	day	NNS	_	20	nmod
26	,	,	,	_	14	punct
27	drug3	drug3	NN	_	30	nsubj
28	did	do	VBD	_	30	aux
29	not	not	RB	_	30	neg
30	affect	affect	VB	_	14	acl:relcl
31	the	the	DT	_	32	det
32	pharmacokinetics	pharmacokinetic	NNS	_	30	dobj
33	of	of	IN	_	34	case
34	drug4	drug4	NN	_	32	nmod
35	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	,	,	,	_	6	punct
8	administration	administration	NN	_	22	nsubj
9	of	of	IN	_	12	case
10	drug2	drug2	NN	_	12	compound
11	120	120	CD	_	12	nummod
12	mg	mg	NN	_	8	nmod
13	three	three	CD	_	14	nummod
14	times	time	NNS	_	8	nmod:tmod
15	a	a	DT	_	16	det
16	day	day	NN	_	14	nmod:npmod
17	for	for	IN	_	19	case
18	16	16	CD	_	19	nummod
19	days	day	NNS	_	8	nmod
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	result	result	VB	_	1	appos
23	in	in	IN	_	25	case
24	any	any	DT	_	25	det
25	change	change	NN	_	22	nmod
26	in	in	IN	_	29	case
27	either	either	CC	_	29	cc:preconj
28	drug3	drug3	NN	_	29	compound
29	pharmacokinetics	pharmacokinetic	NNS	_	25	nmod
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	both	both	CC	_	32	cc:preconj
32	R	r	NN	_	29	dep
33	-	-	:	_	32	punct
34	and	and	CC	_	32	cc
35	S-enantiomers	s-enantiomer	NNS	_	32	conj
36	-RRB-	-rrb-	-RRB-	_	32	punct
37	or	or	CC	_	29	cc
38	pharmacodynamics	pharmacodynamic	NNS	_	29	conj
39	-LRB-	-lrb-	-LRB-	_	41	punct
40	prothrombin	prothrombin	NN	_	41	compound
41	time	time	NN	_	38	dep
42	and	and	CC	_	41	cc
43	serum	serum	NN	_	45	compound
44	Factor	factor	NN	_	45	compound
45	VII	vii	NN	_	41	conj
46	-RRB-	-rrb-	-RRB-	_	41	punct
47	.	.	.	_	1	punct

1	Although	although	IN	_	14	mark
2	undercarboxylated	undercarboxylated	JJ	_	3	amod
3	osteocalcin	osteocalcin	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	6	det
6	marker	marker	NN	_	3	appos
7	of	of	IN	_	11	case
8	vitamin	vitamin	NN	_	11	compound
9	K	k	NN	_	11	compound
10	nutritional	nutritional	JJ	_	11	amod
11	status	status	NN	_	6	nmod
12	,	,	,	_	3	punct
13	was	be	VBD	_	14	cop
14	unaltered	unaltered	JJ	_	22	advcl
15	with	with	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	administration	administration	NN	_	14	nmod
18	,	,	,	_	22	punct
19	vitamin	vitamin	NN	_	21	compound
20	K	k	NN	_	21	compound
21	levels	level	NNS	_	22	nsubj
22	tended	tend	VBD	_	0	ROOT
23	to	to	TO	_	24	mark
24	decline	decline	VB	_	22	xcomp
25	in	in	IN	_	26	case
26	subjects	subject	NNS	_	24	nmod
27	taking	take	VBG	_	26	acl
28	drug2	drug2	NN	_	27	dobj
29	.	.	.	_	22	punct

1	Therefore	therefore	RB	_	25	advmod
2	,	,	,	_	25	punct
3	as	as	IN	_	8	mark
4	drug1	drug1	NN	_	5	compound
5	absorption	absorption	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	decreased	decrease	VBN	_	25	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	25	punct
12	patients	patient	NNS	_	25	nsubjpass
13	on	on	IN	_	16	case
14	chronic	chronic	JJ	_	16	amod
15	stable	stable	JJ	_	16	amod
16	doses	dose	NNS	_	12	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	who	who	WP	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	prescribed	prescribe	VBN	_	16	acl:relcl
22	drug4	drug4	NN	_	21	dobj
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	monitored	monitor	VBN	_	0	ROOT
26	closely	closely	RB	_	25	advmod
27	for	for	IN	_	28	case
28	changes	change	NNS	_	25	nmod
29	in	in	IN	_	31	case
30	coagulation	coagulation	NN	_	31	compound
31	parameters	parameter	NNS	_	28	nmod
32	.	.	.	_	25	punct

1	drug1	drug1	NN	_	2	nsubj
2	competes	compete	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	drug2	drug2	NN	_	2	nmod
5	for	for	IN	_	8	case
6	active	active	JJ	_	8	amod
7	tubular	tubular	JJ	_	8	amod
8	secretion	secretion	NN	_	2	nmod
9	and	and	CC	_	2	cc
10	thus	thus	RB	_	11	advmod
11	inhibits	inhibit	VBZ	_	2	conj
12	the	the	DT	_	14	det
13	renal	renal	JJ	_	14	amod
14	excretion	excretion	NN	_	11	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	led	lead	VBD	_	0	ROOT
3	to	to	TO	_	6	case
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	nmod
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	elimination	elimination	NN	_	10	compound
10	half-life	half-life	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	38	38	CD	_	13	nummod
13	%	%	NN	_	6	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	6	cc
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	extent	extent	NN	_	6	conj
19	of	of	IN	_	21	case
20	systemic	systemic	JJ	_	21	amod
21	exposure	exposure	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	56	56	CD	_	24	nummod
24	%	%	NN	_	18	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	coadministration	coadministration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	evidence	evidence	NN	_	2	nsubj
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	reduce	reduce	VB	_	3	ccomp
8	serum	serum	NN	_	9	compound
9	levels	level	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	to	to	TO	_	14	case
13	subtherapeutic	subtherapeutic	JJ	_	14	amod
14	levels	level	NNS	_	7	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	therapeutic	therapeutic	JJ	_	17	amod
17	range	range	NN	_	14	dep
18	considered	consider	VBN	_	17	acl
19	to	to	TO	_	26	mark
20	be	be	VB	_	26	cop
21	50	50	CD	_	23	compound
22	to	to	TO	_	23	dep
23	100	100	CD	_	26	nummod
24	g/mL	g/ml	NN	_	26	compound
25	total	total	JJ	_	26	amod
26	drug3	drug3	NN	_	18	xcomp
27	-RRB-	-rrb-	-RRB-	_	17	punct
28	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubj
2	does	do	VBZ	_	5	aux
3	not	not	RB	_	5	neg
4	itself	itself	PRP	_	5	nsubj
5	appear	appear	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	or	or	CC	_	7	cc
9	inhibit	inhibit	VB	_	7	conj
10	the	the	DT	_	15	det
11	cytochrome	cytochrome	NN	_	15	compound
12	P-450	p-450	NN	_	15	compound
13	drug-metabolizing	drug-metabolizing	JJ	_	15	amod
14	enzyme	enzyme	NN	_	15	compound
15	system	system	NN	_	7	dobj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	liver	liver	NN	_	15	nmod
19	.	.	.	_	5	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	26	csubj
5	by	by	IN	_	10	case
6	hepatic	hepatic	JJ	_	10	amod
7	cytochrome	cytochrome	NN	_	10	compound
8	P-450	p-450	NN	_	10	compound
9	drug-metabolizing	drug-metabolizing	JJ	_	10	amod
10	enzymes	enzyme	NNS	_	4	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	CYP3A4	cyp3a4	NN	_	10	dep
13	,	,	,	_	12	punct
14	CYP2D6	cyp2d6	NN	_	12	appos
15	,	,	,	_	12	punct
16	CYP1A2	cyp1a2	NN	_	12	appos
17	-RRB-	-rrb-	-RRB-	_	12	punct
18	,	,	,	_	10	punct
19	inducers	inducer	NNS	_	10	conj
20	or	or	CC	_	10	cc
21	inhibitors	inhibitor	NNS	_	10	conj
22	of	of	IN	_	24	case
23	these	these	DT	_	24	det
24	enzymes	enzyme	NNS	_	21	nmod
25	may	may	MD	_	26	aux
26	change	change	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	clearance	clearance	NN	_	26	dobj
29	and	and	CC	_	26	cc
30	,	,	,	_	26	punct
31	hence	hence	RB	_	26	advmod
32	,	,	,	_	26	punct
33	the	the	DT	_	34	det
34	half-life	half-life	NN	_	26	dobj
35	of	of	IN	_	36	case
36	drug2	drug2	NN	_	34	nmod
37	.	.	.	_	26	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	13	nmod
4	of	of	IN	_	7	case
5	limited	limited	JJ	_	7	amod
6	available	available	JJ	_	7	amod
7	data	datum	NNS	_	3	nmod
8	,	,	,	_	13	punct
9	no	no	DT	_	11	neg
10	dosage	dosage	NN	_	11	compound
11	adjustment	adjustment	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	for	for	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	on	on	IN	_	18	case
17	these	these	DT	_	18	det
18	drugs	drug	NNS	_	15	nmod
19	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	:	:	:	_	1	punct
8	In	in	IN	_	9	case
9	patients	patient	NNS	_	33	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	13	case
12	potent	potent	JJ	_	13	amod
13	inducers	inducer	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	CYP3A4	cyp3a4	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	i.e.	i.e.	FW	_	19	dep
18	,	,	,	_	19	punct
19	drug4	drug4	NN	_	9	dep
20	,	,	,	_	19	punct
21	drug5	drug5	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug6	drug6	NN	_	19	conj
25	-RRB-	-rrb-	-RRB-	_	19	punct
26	,	,	,	_	9	punct
27	the	the	DT	_	28	det
28	clearance	clearance	NN	_	33	nsubjpass
29	of	of	IN	_	30	case
30	drug7	drug7	NN	_	28	nmod
31	was	be	VBD	_	33	auxpass
32	significantly	significantly	RB	_	33	advmod
33	increased	increase	VBN	_	1	dep
34	and	and	CC	_	33	cc
35	drug8	drug8	VBN	_	37	amod
36	blood	blood	NN	_	37	compound
37	concentrations	concentration	NNS	_	39	nsubjpass
38	were	be	VBD	_	39	auxpass
39	decreased	decrease	VBN	_	33	conj
40	.	.	.	_	1	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	basis	basis	NN	_	16	nmod
6	of	of	IN	_	8	case
7	available	available	JJ	_	8	amod
8	data	datum	NNS	_	5	nmod
9	,	,	,	_	16	punct
10	no	no	DT	_	12	neg
11	dosage	dosage	NN	_	12	compound
12	adjustment	adjustment	NN	_	16	nsubjpass
13	for	for	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	for	for	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	on	on	IN	_	21	case
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	18	nmod
22	.1,3	.1,3	CD	_	23	nummod
23	drug2	drug2	NN	_	21	dep
24	:	:	:	_	16	punct
25	Although	although	IN	_	36	mark
26	no	no	DT	_	29	neg
27	pharmacokinetic	pharmacokinetic	JJ	_	29	amod
28	drug	drug	NN	_	29	compound
29	interaction	interaction	NN	_	36	nsubjpass
30	between	between	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	drug4	drug4	NN	_	31	conj
34	has	have	VBZ	_	36	aux
35	been	be	VBN	_	36	auxpass
36	observed	observe	VBN	_	43	advcl
37	,	,	,	_	43	punct
38	data	datum	NNS	_	43	nsubj
39	from	from	IN	_	42	case
40	2	2	CD	_	42	nummod
41	small	small	JJ	_	42	amod
42	studies	study	NNS	_	38	nmod
43	indicate	indicate	VBP	_	16	parataxis
44	that	that	IN	_	48	mark
45	drug5	drug5	NN	_	48	nsubjpass
46	may	may	MD	_	48	aux
47	be	be	VB	_	48	auxpass
48	associated	associate	VBN	_	43	ccomp
49	with	with	IN	_	51	case
50	an	a	DT	_	51	det
51	increase	increase	NN	_	48	nmod
52	in	in	IN	_	55	case
53	patient	patient	NN	_	55	compound
54	controlled	controlled	JJ	_	55	amod
55	administration	administration	NN	_	51	nmod
56	of	of	IN	_	57	case
57	drug6	drug6	NN	_	55	nmod
58	.4,5	.4,5	CD	_	59	nummod
59	Chemotherapy	Chemotherapy	NNP	_	57	dep
60	:	:	:	_	48	punct
61	Tumor	tumor	NN	_	62	compound
62	response	response	NN	_	74	nsubjpass
63	to	to	TO	_	64	case
64	chemotherapy	chemotherapy	NN	_	62	nmod
65	in	in	IN	_	71	case
66	the	the	DT	_	71	det
67	P	p	NN	_	71	compound
68	388	388	CD	_	71	nummod
69	mouse	mouse	NN	_	71	compound
70	leukemia	leukemia	NN	_	71	compound
71	model	model	NN	_	64	nmod
72	is	be	VBZ	_	74	auxpass
73	not	not	RB	_	74	neg
74	affected	affect	VBN	_	48	parataxis
75	by	by	IN	_	76	case
76	drug7	drug7	NN	_	74	nmod
77	.	.	.	_	16	punct

1	In	in	IN	_	2	case
2	humans	human	NNS	_	12	nmod
3	,	,	,	_	12	punct
4	drug1	drug1	NN	_	12	nsubj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	drug3	drug3	NN	_	4	conj
10	do	do	VBP	_	12	aux
11	not	not	RB	_	12	neg
12	affect	affect	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	12	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	crossover	crossover	NN	_	4	compound
4	study	study	NN	_	10	nmod
5	in	in	IN	_	8	case
6	76	76	CD	_	8	nummod
7	pediatric	pediatric	JJ	_	8	amod
8	patients	patient	NNS	_	4	nmod
9	,	,	,	_	10	punct
10	I.V.	I.V.	NNP	_	0	ROOT

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	increase	increase	VB	_	0	ROOT
5	blood	blood	NN	_	6	compound
6	levels	level	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	high-dose	high-dose	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	.	.	.	_	4	punct

1	CYP3A4	cyp3a4	NN	_	2	compound
2	Inhibitors	inhibitor	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	2	dep
5	,	,	,	_	4	punct
6	an	a	DT	_	7	det
7	inhibitor	inhibitor	NN	_	4	appos
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	drug	drug	NN	_	7	nmod
11	metabolizing	metabolize	VBG	_	10	acl
12	enzyme	enzyme	NN	_	13	compound
13	CYP3A4	cyp3a4	NN	_	11	dobj
14	,	,	,	_	4	punct
15	significantly	significantly	RB	_	16	advmod
16	increased	increase	VBN	_	18	amod
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	4	appos
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	when	when	WRB	_	22	advmod
22	coadministered	coadminister	VBN	_	18	acl:relcl
23	to	to	TO	_	24	case
24	subjects	subject	NNS	_	22	nmod
25	who	who	WP	_	28	nsubj
26	were	be	VBD	_	28	cop
27	poor	poor	JJ	_	28	amod
28	metabolizers	metabolizer	NNS	_	24	acl:relcl
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	see	see	VB	_	28	dep
31	CLINICAL	CLINICAL	NNP	_	32	compound
32	PHARMACOLOGY	PHARMACOLOGY	NNP	_	30	dobj
33	,	,	,	_	32	punct
34	Variability	variability	NN	_	32	appos
35	in	in	IN	_	36	case
36	Metabolism	metabolism	NN	_	34	nmod
37	and	and	CC	_	36	cc
38	Drug-Drug	Drug-Drug	NNP	_	39	compound
39	Interactions	interaction	NNS	_	36	conj
40	-RRB-	-rrb-	-RRB-	_	30	punct
41	.	.	.	_	2	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	42	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	or	or	CC	_	4	cc
6	other	other	JJ	_	9	amod
7	potent	potent	JJ	_	9	amod
8	CYP3A4	cyp3a4	NN	_	9	compound
9	inhibitors	inhibitor	NNS	_	4	conj
10	such	such	JJ	_	13	case
11	as	as	IN	_	10	mwe
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	2	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	eg	eg	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug3	drug3	NN	_	13	dep
18	,	,	,	_	17	punct
19	drug4	drug4	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	or	or	CC	_	13	cc
22	drug5	drug5	NN	_	13	conj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	eg	eg	FW	_	26	dep
25	,	,	,	_	26	punct
26	drug6	drug6	NN	_	22	dep
27	,	,	,	_	26	punct
28	drug7	drug7	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	or	or	CC	_	13	cc
31	drug8	drug8	NN	_	13	conj
32	or	or	CC	_	31	cc
33	drug9	drug9	NN	_	31	conj
34	,	,	,	_	42	punct
35	the	the	DT	_	37	det
36	recommended	recommend	VBN	_	37	amod
37	dose	dose	NN	_	42	nsubj
38	of	of	IN	_	39	case
39	drug10	drug10	NN	_	37	nmod
40	is	be	VBZ	_	42	cop
41	2	2	CD	_	42	nummod
42	mg	mg	NN	_	0	ROOT
43	daily	daily	RB	_	42	advmod
44	.	.	.	_	42	punct

1	Drug-Laboratory-Test	Drug-Laboratory-Test	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	Interactions	interaction	NNS	_	12	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	laboratory	laboratory	NN	_	8	compound
8	tests	test	NNS	_	5	conj
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Since	since	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	22	advcl
5	by	by	IN	_	9	case
6	a	a	DT	_	9	det
7	P450	p450	NN	_	9	compound
8	enzyme	enzyme	NN	_	9	compound
9	system	system	NN	_	4	nmod
10	,	,	,	_	22	punct
11	drugs	drug	NNS	_	22	nsubj
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	this	this	DT	_	17	det
17	drug	drug	NN	_	20	compound
18	metabolizing	metabolize	VBG	_	20	amod
19	enzyme	enzyme	NN	_	20	compound
20	system	system	NN	_	13	dobj
21	may	may	MD	_	22	aux
22	elicit	elicit	VB	_	0	ROOT
23	important	important	JJ	_	25	amod
24	drug-drug	drug-drug	JJ	_	25	amod
25	interactions	interaction	NNS	_	22	dobj
26	that	that	WDT	_	28	nsubj
27	may	may	MD	_	28	aux
28	alter	alter	VB	_	25	acl:relcl
29	drug2	drug2	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	.	.	.	_	22	punct

1	Agents	agent	NNS	_	19	nsubj
2	that	that	WDT	_	5	nsubjpass
3	might	might	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	1	acl:relcl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	10	case
9	AIDS	aids	NN	_	10	compound
10	patients	patient	NNS	_	7	nmod
11	for	for	IN	_	13	case
12	other	other	JJ	_	13	amod
13	indications	indication	NNS	_	10	nmod
14	that	that	WDT	_	16	nsubj
15	could	could	MD	_	16	aux
16	elicit	elicit	VB	_	13	acl:relcl
17	this	this	DT	_	18	det
18	activity	activity	NN	_	16	dobj
19	include	include	VBP	_	0	ROOT
20	drug2	drug2	NN	_	19	dobj
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug4	drug4	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug5	drug5	NN	_	20	conj
27	,	,	,	_	20	punct
28	and	and	CC	_	20	cc
29	drug6	drug6	NN	_	20	conj
30	.	.	.	_	19	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	perfusion	perfusion	NN	_	9	nsubj
4	of	of	IN	_	7	case
5	isolated	isolate	VBN	_	7	amod
6	rat	rat	NN	_	7	compound
7	liver	liver	NN	_	3	nmod
8	has	have	VBZ	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	that	that	IN	_	12	mark
11	drug1	drug1	NN	_	12	nsubj
12	caused	cause	VBD	_	9	ccomp
13	a	a	DT	_	15	det
14	significant	significant	JJ	_	15	amod
15	reduction	reduction	NN	_	12	dobj
16	in	in	IN	_	18	case
17	drug2	drug2	NN	_	18	compound
18	metabolism	metabolism	NN	_	15	nmod
19	and	and	CC	_	12	cc
20	that	that	IN	_	22	mark
21	drug3	drug3	NN	_	22	nsubj
22	altered	alter	VBD	_	12	conj
23	the	the	DT	_	25	det
24	relative	relative	JJ	_	25	amod
25	concentration	concentration	NN	_	22	dobj
26	of	of	IN	_	28	case
27	trimetrexate	trimetrexate	NN	_	28	compound
28	metabolites	metabolite	NNS	_	25	nmod
29	possibly	possibly	RB	_	22	advmod
30	by	by	IN	_	31	mark
31	competing	compete	VBG	_	22	advcl
32	for	for	IN	_	34	case
33	sulfate	sulfate	NN	_	34	compound
34	metabolites	metabolite	NNS	_	31	nmod
35	.	.	.	_	9	punct

1	Based	base	VBN	_	8	case
2	on	on	IN	_	8	case
3	an	a	DT	_	8	det
4	in	in	FW	_	8	amod
5	vitro	vitro	FW	_	4	dep
6	rat	rat	NN	_	8	compound
7	liver	liver	NN	_	8	compound
8	model	model	NN	_	11	advcl
9	,	,	,	_	11	punct
10	nitrogen	nitrogen	NN	_	11	nsubj
11	substituted	substitute	VBN	_	0	ROOT
12	drug1	drug1	NN	_	21	nsubj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug2	drug2	NN	_	12	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	appos
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	appos
19	-RRB-	-rrb-	-RRB-	_	14	punct
20	were	be	VBD	_	21	cop
21	potent	potent	JJ	_	11	ccomp
22	,	,	,	_	21	punct
23	non-competitive	non-competitive	JJ	_	24	amod
24	inhibitors	inhibitor	NNS	_	21	appos
25	of	of	IN	_	27	case
26	drug5	drug5	NN	_	27	compound
27	metabolism	metabolism	NN	_	24	nmod
28	.	.	.	_	11	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	medicated	medicate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	these	these	DT	_	5	det
5	drugs	drug	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	drug1	drug1	NN	_	5	conj
8	should	should	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	carefully	carefully	RB	_	11	advmod
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Prolongation	prolongation	NN	_	18	nsubjpass
4	of	of	IN	_	6	case
5	prothrombin	prothrombin	NN	_	6	compound
6	time	time	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	PT	pt	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	6	cc
11	International	International	NNP	_	13	compound
12	Normalized	Normalized	NNP	_	13	compound
13	Ratio	Ratio	NNP	_	6	conj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	INR	INR	NNP	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	were	be	VBD	_	18	auxpass
18	observed	observe	VBN	_	1	appos
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	receiving	receive	VBG	_	20	acl
22	drug2	drug2	NN	_	21	dobj
23	concomitantly	concomitantly	RB	_	21	advmod
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	21	nmod
26	.	.	.	_	1	punct

1	Physicians	Physicians	NNP	_	4	nsubj
2	should	should	MD	_	4	aux
3	carefully	carefully	RB	_	4	advmod
4	monitor	monitor	VB	_	0	ROOT
5	PT	pt	NN	_	4	dobj
6	and	and	CC	_	5	cc
7	INR	inr	NN	_	5	conj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	4	nmod
10	concurrently	concurrently	RB	_	11	advmod
11	administered	administer	VBN	_	12	amod
12	drug1	drug1	NN	_	9	dep
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	.	.	.	_	4	punct

1	Other	other	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	Severe	severe	JJ	_	4	amod
4	thrombocytopenia	thrombocytopenia	NN	_	10	nsubjpass
5	and	and	CC	_	4	cc
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	bleeding	bleeding	NN	_	4	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	with	with	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	use	use	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	other	other	JJ	_	18	amod
18	drug3	drug3	NN	_	15	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug4	drug4	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	.	.	.	_	10	punct

1	Monitor	Monitor	NNP	_	3	compound
2	platelet	platelet	NN	_	3	compound
3	count	count	NN	_	0	ROOT
4	every	every	DT	_	6	det
5	2	2	CD	_	6	nummod
6	weeks	week	NNS	_	3	nmod:tmod
7	for	for	IN	_	11	case
8	the	the	DT	_	11	det
9	first	first	JJ	_	11	amod
10	2	2	CD	_	11	nummod
11	months	month	NNS	_	3	nmod
12	.	.	.	_	3	punct

1	Nasal	nasal	JJ	_	2	amod
2	Spray	spray	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Formal	formal	JJ	_	5	amod
5	studies	study	NNS	_	16	nsubjpass
6	designed	design	VBN	_	5	acl
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	8	dobj
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	have	have	VBP	_	16	aux
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	done	do	VBN	_	2	dep
17	.	.	.	_	2	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	with	with	IN	_	12	case
9	drug1	drug1	NN	_	12	compound
10	nasal	nasal	JJ	_	12	amod
11	spray	spray	NN	_	12	compound
12	ingredients	ingredient	NNS	_	7	nmod
13	.	.	.	_	7	punct

1	Currently	currently	RB	_	10	advmod
2	,	,	,	_	10	punct
3	no	no	DT	_	5	neg
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	10	nsubjpass
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	15	nsubjpass
3	of	of	IN	_	5	case
4	prior	prior	JJ	_	5	amod
5	use	use	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	11	case
9	postmenopausal	postmenopausal	JJ	_	11	amod
10	osteoporosis	osteoporosis	NN	_	11	compound
11	patients	patient	NNS	_	2	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	assessed	assess	VBN	_	0	ROOT
16	;	;	:	_	15	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	12	nmod
5	with	with	IN	_	8	case
6	Paget	paget	NN	_	8	nmod:poss
7	's	's	POS	_	6	case
8	Disease	disease	NN	_	4	nmod
9	prior	prior	RB	_	11	advmod
10	drug1	drug1	NN	_	11	compound
11	use	use	NN	_	12	nsubj
12	appears	appear	VBZ	_	0	ROOT
13	to	to	TO	_	14	mark
14	reduce	reduce	VB	_	12	xcomp
15	the	the	DT	_	17	det
16	anti-resorptive	anti-resorptive	JJ	_	17	amod
17	response	response	NN	_	14	dobj
18	to	to	TO	_	21	case
19	drug2	drug2	NN	_	21	compound
20	nasal	nasal	JJ	_	21	amod
21	spray	spray	NN	_	17	nmod
22	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	absorption	absorption	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	medications	medication	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	decreased	decrease	VBN	_	0	ROOT
9	during	during	IN	_	12	case
10	the	the	DT	_	12	det
11	concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	because	because	IN	_	19	case
16	of	of	IN	_	15	mwe
17	decreased	decrease	VBN	_	19	amod
18	gastric	gastric	JJ	_	19	amod
19	motility	motility	NN	_	8	nmod
20	and	and	CC	_	19	cc
21	delayed	delay	VBN	_	23	amod
22	gastric	gastric	JJ	_	23	amod
23	emptying	emptying	NN	_	19	conj
24	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	care	care	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	9	dobj
12	that	that	WDT	_	14	nsubj
13	are	be	VBP	_	14	cop
14	capable	capable	JJ	_	11	acl:relcl
15	of	of	IN	_	16	mark
16	causing	cause	VBG	_	14	advcl
17	CNS	cns	NN	_	18	compound
18	effects	effect	NNS	_	16	dobj
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug2	drug2	NN	_	18	nmod
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	,	,	,	_	21	punct
25	or	or	CC	_	21	cc
26	drug4	drug4	NN	_	21	conj
27	.	.	.	_	4	punct

1	Special	special	JJ	_	2	amod
2	attention	attention	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	paid	pay	VBN	_	0	ROOT
6	to	to	TO	_	8	case
7	potential	potential	JJ	_	8	amod
8	interactions	interaction	NNS	_	5	nmod
9	with	with	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	having	have	VBG	_	10	acl
12	anticholinergic	anticholinergic	JJ	_	13	amod
13	properties	property	NNS	_	11	dobj
14	;	;	:	_	5	punct

1	e.g.	e.g.	FW	_	4	dep
2	,	,	,	_	4	punct
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	including	include	VBG	_	9	case
9	drug3	drug3	NN	_	6	nmod
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	4	punct
12	drug4	drug4	NN	_	4	conj
13	,	,	,	_	4	punct
14	and	and	CC	_	4	cc
15	drug5	drug5	NN	_	4	conj
16	.	.	.	_	4	punct

1	Laboratory	Laboratory	NNP	_	4	compound
2	Test	Test	NNP	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	will	will	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	11	case
8	the	the	DT	_	11	det
9	gastric	gastric	JJ	_	11	amod
10	secretion	secretion	NN	_	11	compound
11	test	test	NN	_	6	nmod
12	.	.	.	_	6	punct

1	Formal	formal	JJ	_	3	amod
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	performed	perform	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	studied	study	VBN	_	1	acl
3	in	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	were	be	VBD	_	10	auxpass
9	routinely	routinely	RB	_	10	advmod
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	10	punct

1	drug1	drug1	NN	_	28	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	dep
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	and	and	CC	_	1	cc
10	drugs	drug	NNS	_	1	conj
11	that	that	WDT	_	12	nsubj
12	alter	alter	VBP	_	1	acl:relcl
13	platelet	platelet	NN	_	14	compound
14	function	function	NN	_	12	dobj
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug4	drug4	NN	_	14	nmod
19	,	,	,	_	18	punct
20	drug5	drug5	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	GP	gp	NN	_	25	compound
24	IIb/IIIa	iib/iiia	NN	_	25	compound
25	inhibitors	inhibitor	NNS	_	18	conj
26	-RRB-	-rrb-	-RRB-	_	18	punct
27	may	may	MD	_	28	aux
28	increase	increase	VB	_	0	ROOT
29	the	the	DT	_	30	det
30	risk	risk	NN	_	28	dobj
31	of	of	IN	_	32	case
32	bleeding	bleed	VBG	_	30	nmod
33	if	if	IN	_	34	mark
34	administered	administer	VBN	_	28	advcl
35	prior	prior	RB	_	34	advmod
36	to	to	TO	_	43	nmod
37	,	,	,	_	43	punct
38	during	during	IN	_	43	conj
39	,	,	,	_	43	punct
40	or	or	CC	_	43	cc
41	after	after	IN	_	43	conj
42	drug6	drug6	NN	_	43	compound
43	therapy	therapy	NN	_	34	nmod
44	.	.	.	_	28	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	19	nsubj
4	During	during	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	therapy	therapy	NN	_	3	nmod
7	,	,	,	_	3	punct
8	results	result	NNS	_	3	appos
9	of	of	IN	_	11	case
10	coagulation	coagulation	NN	_	11	compound
11	tests	test	NNS	_	8	nmod
12	and/or	and/or	CC	_	11	cc
13	measures	measure	NNS	_	11	conj
14	of	of	IN	_	16	case
15	fibrinolytic	fibrinolytic	JJ	_	16	amod
16	activity	activity	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	unreliable	unreliable	JJ	_	0	ROOT
20	unless	unless	IN	_	24	mark
21	specific	specific	JJ	_	22	amod
22	precautions	precaution	NNS	_	24	nsubjpass
23	are	be	VBP	_	24	auxpass
24	taken	take	VBN	_	19	advcl
25	to	to	TO	_	26	mark
26	prevent	prevent	VB	_	24	xcomp
27	in	in	FW	_	29	amod
28	vitro	vitro	FW	_	27	dep
29	artifacts	artifact	NNS	_	26	dobj
30	.	.	.	_	19	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	enzyme	enzyme	NN	_	0	ROOT
5	that	that	IN	_	15	nsubj
6	,	,	,	_	15	punct
7	when	when	WRB	_	8	advmod
8	present	present	JJ	_	15	dep
9	in	in	IN	_	10	case
10	blood	blood	NN	_	8	nmod
11	in	in	IN	_	13	case
12	pharmacologic	pharmacologic	JJ	_	13	amod
13	concentrations	concentration	NNS	_	8	nmod
14	,	,	,	_	15	punct
15	remains	remain	VBZ	_	4	acl:relcl
16	active	active	JJ	_	15	xcomp
17	under	under	IN	_	20	case
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	conditions	condition	NNS	_	16	nmod
21	.	.	.	_	4	punct

1	This	this	DT	_	3	nsubj
2	can	can	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	5	case
5	degradation	degradation	NN	_	3	nmod
6	of	of	IN	_	7	case
7	fibrinogen	fibrinogen	NN	_	5	nmod
8	in	in	IN	_	10	case
9	blood	blood	NN	_	10	compound
10	samples	sample	NNS	_	5	nmod
11	removed	remove	VBD	_	3	xcomp
12	for	for	IN	_	13	case
13	analysis	analysis	NN	_	11	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	causing	cause	VBG	_	3	dep
10	too	too	RB	_	11	advmod
11	great	great	JJ	_	13	amod
12	a	a	DT	_	13	det
13	decrease	decrease	NN	_	9	dobj
14	in	in	IN	_	16	case
15	adrenal	adrenal	JJ	_	16	amod
16	function	function	NN	_	13	nmod
17	-RRB-	-rrb-	-RRB-	_	9	punct
18	.	.	.	_	3	punct

1	Although	although	IN	_	12	mark
2	drug1	drug1	NN	_	12	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	a	a	DT	_	5	det
5	mixture	mixture	NN	_	2	dep
6	of	of	IN	_	8	case
7	three	three	CD	_	8	nummod
8	stereoisomers	stereoisomer	NNS	_	5	nmod
9	-RRB-	-rrb-	-RRB-	_	5	punct
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	administered	administer	VBN	_	29	advcl
13	safely	safely	RB	_	12	advmod
14	following	follow	VBG	_	17	case
15	succinylcholine-facilitated	succinylcholine-facilitated	JJ	_	17	amod
16	tracheal	tracheal	NN	_	17	compound
17	intubation	intubation	NN	_	12	nmod
18	,	,	,	_	29	punct
19	the	the	DT	_	20	det
20	interaction	interaction	NN	_	29	nsubjpass
21	between	between	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	has	have	VBZ	_	29	aux
26	not	not	RB	_	29	neg
27	been	be	VBN	_	29	auxpass
28	systematically	systematically	RB	_	29	advmod
29	studied	study	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	Prior	prior	RB	_	6	advmod
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	can	can	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	10	det
8	neuromuscular	neuromuscular	JJ	_	10	amod
9	blocking	blocking	NN	_	10	compound
10	effects	effect	NNS	_	6	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	6	punct

1	Evidence	evidence	NN	_	9	nsubjpass
2	of	of	IN	_	4	case
3	spontaneous	spontaneous	JJ	_	4	amod
4	recovery	recovery	NN	_	1	nmod
5	from	from	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	before	before	IN	_	12	case
11	the	the	DT	_	12	det
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	before	before	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	to	to	TO	_	8	mark
8	attenuate	attenuate	VB	_	2	acl
9	some	some	DT	_	8	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	side	side	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	studied	study	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	clinical	clinical	JJ	_	5	amod
5	data	datum	NNS	_	2	nsubj
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	8	nmod
14	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	administered	administer	VBN	_	1	dep
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	5	nmod
8	/	/	:	_	5	punct
9	drug4	drug4	NN	_	5	dep
10	to	to	TO	_	11	mark
11	achieve	achieve	VB	_	9	acl
12	1.25	1.25	CD	_	13	nummod
13	M.C.	M.C.	NNP	_	11	dobj

1	decrease	decrease	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	ED50	ed50	NN	_	1	dobj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	by	by	IN	_	11	case
7	as	as	RB	_	10	advmod
8	much	much	JJ	_	10	advmod
9	as	as	IN	_	10	advmod
10	25	25	CD	_	11	nummod
11	%	%	NN	_	1	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	see	see	VB	_	1	dep
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	13	dobj
16	:	:	:	_	15	punct
17	Pharmacodynamics	pharmacodynamic	NNS	_	15	dep
18	and	and	CC	_	17	cc
19	Individualization	individualization	NN	_	17	conj
20	of	of	IN	_	21	case
21	Dosages	dosage	NNS	_	17	nmod
22	-RRB-	-rrb-	-RRB-	_	13	punct
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	also	also	RB	_	5	advmod
5	prolong	prolong	VB	_	0	ROOT
6	the	the	DT	_	9	det
7	clinically	clinically	RB	_	8	advmod
8	effective	effective	JJ	_	9	amod
9	duration	duration	NN	_	5	dobj
10	of	of	IN	_	11	case
11	action	action	NN	_	9	nmod
12	and	and	CC	_	5	cc
13	decrease	decrease	VB	_	5	conj
14	the	the	DT	_	17	det
15	average	average	JJ	_	17	amod
16	infusion	infusion	NN	_	17	compound
17	requirement	requirement	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	by	by	IN	_	25	case
21	as	as	RB	_	24	advmod
22	much	much	JJ	_	24	advmod
23	as	as	IN	_	24	advmod
24	35	35	CD	_	25	nummod
25	%	%	NN	_	13	nmod
26	to	to	TO	_	28	case
27	40	40	CD	_	28	nummod
28	%	%	NN	_	13	nmod
29	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	greater	greater	JJR	_	3	amod
3	potentiation	potentiation	NN	_	13	nsubjpass
4	of	of	IN	_	8	case
5	the	the	DT	_	8	det
6	neuromuscular	neuromuscular	JJ	_	8	amod
7	blocking	blocking	NN	_	8	compound
8	effects	effect	NNS	_	3	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	expected	expect	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	higher	higher	JJR	_	16	amod
16	concentrations	concentration	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	little	little	JJ	_	2	dobj
4	or	or	CC	_	3	cc
5	no	no	DT	_	3	conj
6	effect	effect	NN	_	3	dep
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	ED50	ed50	NN	_	2	nmod
10	,	,	,	_	2	punct
11	but	but	CC	_	2	cc
12	may	may	MD	_	13	aux
13	prolong	prolong	VB	_	2	conj
14	the	the	DT	_	15	det
15	duration	duration	NN	_	13	dobj
16	of	of	IN	_	17	case
17	action	action	NN	_	15	nmod
18	and	and	CC	_	13	cc
19	decrease	decrease	VB	_	13	conj
20	the	the	DT	_	23	det
21	average	average	JJ	_	23	amod
22	infusion	infusion	NN	_	23	compound
23	requirement	requirement	NN	_	19	dobj
24	by	by	IN	_	29	case
25	as	as	RB	_	28	advmod
26	much	much	JJ	_	28	advmod
27	as	as	IN	_	28	advmod
28	20	20	CD	_	29	nummod
29	%	%	NN	_	19	nmod
30	.	.	.	_	2	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	15	nsubj
3	which	which	WDT	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	2	acl:relcl
6	the	the	DT	_	9	det
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	amod
9	action	action	NN	_	5	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	11	nmod
15	include	include	VBP	_	0	ROOT
16	certain	certain	JJ	_	17	amod
17	drug3	drug3	NN	_	15	dobj
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	e.g.	e.g.	FW	_	21	dep
20	,	,	,	_	21	punct
21	drug4	drug4	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug5	drug5	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug6	drug6	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug7	drug7	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug8	drug8	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug9	drug9	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug10	drug10	NN	_	21	conj
34	,	,	,	_	21	punct
35	and	and	CC	_	21	cc
36	drug11	drug11	NN	_	21	conj
37	-RRB-	-rrb-	-RRB-	_	21	punct
38	,	,	,	_	17	punct
39	drug12	drug12	NN	_	40	compound
40	salts	salt	NNS	_	17	conj
41	,	,	,	_	17	punct
42	drug13	drug13	NN	_	17	conj
43	,	,	,	_	17	punct
44	local	local	JJ	_	45	amod
45	drug14	drug14	NN	_	17	conj
46	,	,	,	_	17	punct
47	drug15	drug15	NN	_	17	conj
48	,	,	,	_	17	punct
49	and	and	CC	_	17	cc
50	drug16	drug16	NN	_	17	conj
51	.	.	.	_	15	punct

1	The	the	DT	_	4	det
2	neuromuscular	neuromuscular	JJ	_	4	amod
3	blocking	blocking	NN	_	4	compound
4	effect	effect	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	enhanced	enhance	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	13	nsubj
13	reduce	reduce	VBP	_	11	acl:relcl
14	plasma	plasma	NN	_	16	compound
15	cholinesterase	cholinesterase	NN	_	16	compound
16	activity	activity	NN	_	13	dobj
17	-LRB-	-lrb-	-LRB-	_	23	punct
18	e.g.	e.g.	FW	_	23	dep
19	,	,	,	_	23	punct
20	chronically	chronically	RB	_	21	advmod
21	administered	administer	VBN	_	23	amod
22	oral	oral	JJ	_	23	amod
23	drug2	drug2	NN	_	11	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	or	or	CC	_	23	cc
28	certain	certain	JJ	_	29	amod
29	drug4	drug4	NN	_	23	conj
30	-RRB-	-rrb-	-RRB-	_	23	punct
31	or	or	CC	_	11	cc
32	by	by	IN	_	33	case
33	drugs	drug	NNS	_	11	conj
34	that	that	WDT	_	36	nsubj
35	irreversibly	irreversibly	RB	_	36	advmod
36	inhibit	inhibit	VBP	_	33	acl:relcl
37	plasma	plasma	NN	_	38	compound
38	cholinesterase	cholinesterase	NN	_	36	dobj
39	.	.	.	_	9	punct
40	Resistance	resistance	NN	_	51	nsubjpass
41	to	to	TO	_	45	case
42	the	the	DT	_	45	det
43	neuromuscular	neuromuscular	JJ	_	45	amod
44	blocking	block	VBG	_	45	amod
45	action	action	NN	_	40	nmod
46	of	of	IN	_	48	case
47	nondepolarizing	nondepolarizing	JJ	_	48	amod
48	drug5	drug5	NN	_	45	nmod
49	has	have	VBZ	_	51	aux
50	been	be	VBN	_	51	auxpass
51	demonstrated	demonstrate	VBN	_	9	parataxis
52	in	in	IN	_	53	case
53	patients	patient	NNS	_	51	nmod
54	chronically	chronically	RB	_	55	advmod
55	administered	administer	VBN	_	53	acl
56	drug6	drug6	NN	_	55	dobj
57	or	or	CC	_	56	cc
58	drug7	drug7	NN	_	56	conj
59	.	.	.	_	9	punct

1	While	while	IN	_	16	mark
2	the	the	DT	_	3	det
3	effects	effect	NNS	_	16	nsubj
4	of	of	IN	_	6	case
5	chronic	chronic	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	6	conj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	action	action	NN	_	3	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	20	advcl
17	,	,	,	_	20	punct
18	slightly	slightly	RB	_	19	advmod
19	shorter	shorter	JJR	_	20	amod
20	durations	duration	NNS	_	33	nmod
21	of	of	IN	_	23	case
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	block	block	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	anticipated	anticipate	VBN	_	33	csubj
27	and	and	CC	_	26	cc
28	infusion	infusion	NN	_	30	compound
29	rate	rate	NN	_	30	compound
30	requirements	requirement	NNS	_	26	conj
31	may	may	MD	_	33	aux
32	be	be	VB	_	33	cop
33	higher	higher	JJR	_	0	ROOT
34	.	.	.	_	33	punct

1	Some	some	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	9	nsubj
4	are	be	VBP	_	9	cop
5	:	:	:	_	9	punct
6	-	-	:	_	9	punct
7	birth	birth	NN	_	9	compound
8	control	control	NN	_	9	compound
9	pills	pill	NNS	_	0	ROOT
10	-	-	:	_	9	punct
11	drug1	drug1	NN	_	13	compound
12	-	-	:	_	13	punct
13	medicines	medicine	NNS	_	9	dep
14	for	for	IN	_	15	case
15	angina	angina	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	high	high	JJ	_	19	amod
18	blood	blood	NN	_	19	compound
19	pressure	pressure	NN	_	15	conj
20	-	-	:	_	13	punct
21	medicines	medicine	NNS	_	13	dep
22	for	for	IN	_	23	case
23	pain	pain	NN	_	21	nmod
24	-	-	:	_	13	punct
25	medicines	medicine	NNS	_	13	dep
26	to	to	TO	_	27	mark
27	control	control	VB	_	25	acl
28	seizures	seizure	NNS	_	27	dobj
29	such	such	JJ	_	31	case
30	as	as	IN	_	29	mwe
31	drug2	drug2	NN	_	28	nmod
32	or	or	CC	_	31	cc
33	drug3	drug3	NN	_	31	conj
34	-	-	:	_	13	punct
35	certain	certain	JJ	_	36	amod
36	drug4	drug4	NN	_	13	dep
37	given	give	VBN	_	36	acl
38	by	by	IN	_	39	case
39	injection	injection	NN	_	37	nmod
40	-	-	:	_	39	punct
41	drug5	drug5	NN	_	39	dep
42	-	-	:	_	39	punct
43	drug6	drug6	NN	_	39	dep
44	-	-	:	_	39	punct
45	drug7	drug7	NN	_	39	dep
46	-	-	:	_	45	punct
47	drug8	drug8	NN	_	45	dep
48	or	or	CC	_	47	cc
49	drug9	drug9	NN	_	47	conj
50	-	-	:	_	39	punct
51	local	local	JJ	_	52	amod
52	drug10	drug10	NN	_	39	dep
53	such	such	JJ	_	55	case
54	as	as	IN	_	53	mwe
55	drug11	drug11	NN	_	52	nmod
56	-	-	:	_	55	punct
57	general	general	JJ	_	58	amod
58	drug12	drug12	NN	_	55	dep
59	-	-	:	_	58	punct
60	drug13	drug13	NN	_	58	dep
61	or	or	CC	_	60	cc
62	other	other	JJ	_	63	amod
63	drug14	drug14	NN	_	60	conj

1	Clinically	clinically	RB	_	4	advmod
2	or	or	CC	_	1	cc
3	potentially	potentially	RB	_	1	conj
4	significant	significant	JJ	_	6	amod
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	15	nsubjpass
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	following	follow	VBG	_	12	amod
12	agents/classes	agents/classes	NNS	_	8	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	These	these	DT	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	described	describe	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	greater	greater	JJR	_	6	amod
6	detail	detail	NN	_	3	nmod
7	below	below	IN	_	6	advmod
8	:	:	:	_	3	punct
9	drug1	drug1	NN	_	16	nsubjpass
10	and	and	CC	_	9	cc
11	the	the	DT	_	13	det
12	following	follow	VBG	_	13	amod
13	agents/classes	agents/classes	NNS	_	9	conj
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	observed	observe	VBN	_	3	parataxis
17	.	.	.	_	3	punct

1	These	these	DT	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	described	describe	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	greater	greater	JJR	_	6	amod
6	detail	detail	NN	_	3	nmod
7	below	below	IN	_	6	advmod
8	:	:	:	_	3	punct
9	Oral	oral	JJ	_	10	amod
10	drug1	drug1	NN	_	3	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug4	drug4	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug5	drug5	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug6	drug6	NN	_	10	conj
21	,	,	,	_	10	punct
22	drug7	drug7	NN	_	10	conj
23	,	,	,	_	10	punct
24	drug8	drug8	NN	_	10	conj
25	,	,	,	_	10	punct
26	drug9	drug9	NN	_	10	conj
27	,	,	,	_	10	punct
28	drug10	drug10	NN	_	10	conj
29	,	,	,	_	10	punct
30	drug11	drug11	NN	_	10	conj
31	,	,	,	_	10	punct
32	drug12	drug12	NN	_	10	conj
33	,	,	,	_	10	punct
34	Oral	oral	JJ	_	35	amod
35	drug13	drug13	NN	_	10	conj
36	:	:	:	_	10	punct
37	Clinically	clinically	RB	_	39	advmod
38	significant	significant	JJ	_	39	amod
39	hypoglycemia	hypoglycemia	NN	_	42	nsubjpass
40	may	may	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	precipitated	precipitate	VBN	_	10	dep
43	by	by	IN	_	45	case
44	the	the	DT	_	45	det
45	use	use	NN	_	42	nmod
46	of	of	IN	_	47	case
47	drug14	drug14	NN	_	45	nmod
48	with	with	IN	_	50	case
49	oral	oral	JJ	_	50	amod
50	drug15	drug15	NN	_	45	nmod
51	;	;	:	_	42	punct

1	one	one	CD	_	2	nummod
2	fatality	fatality	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	from	from	IN	_	7	case
7	hypoglycemia	hypoglycemia	NN	_	5	nmod
8	in	in	IN	_	9	case
9	association	association	NN	_	5	nmod
10	with	with	IN	_	12	case
11	combined	combined	JJ	_	12	amod
12	drug1	drug1	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	15	compound
15	use	use	NN	_	12	conj
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduces	reduce	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	and	and	CC	_	2	cc
13	increases	increase	VBZ	_	2	conj
14	the	the	DT	_	16	det
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	dobj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	agents	agent	NNS	_	16	nmod
20	.	.	.	_	2	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	18	csubjpass
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	7	case
7	these	these	DT	_	4	nmod
8	or	or	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drug2	drug2	NN	_	7	conj
11	,	,	,	_	10	punct
12	blood	blood	NN	_	14	compound
13	glucose	glucose	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	appos
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	and	and	CC	_	18	cc
20	the	the	DT	_	21	det
21	dose	dose	NN	_	27	nsubjpass
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	drug3	drug3	NN	_	21	nmod
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	adjusted	adjust	VBN	_	18	conj
28	as	as	RB	_	29	advmod
29	necessary	necessary	JJ	_	27	xcomp
30	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Prothrombin	Prothrombin	NNP	_	4	compound
4	time	time	NN	_	7	nsubjpass
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	increased	increase	VBN	_	1	dep
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	concomitant	concomitant	JJ	_	12	amod
12	drug2	drug2	NN	_	10	dobj
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	post-marketing	post-marketing	JJ	_	3	amod
3	experience	experience	NN	_	27	nmod
4	,	,	,	_	27	punct
5	as	as	IN	_	8	case
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	27	nmod
9	,	,	,	_	27	punct
10	bleeding	bleed	VBG	_	11	amod
11	events	event	NNS	_	27	nsubjpass
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	bruising	bruise	VBG	_	11	dep
14	,	,	,	_	13	punct
15	epistaxis	epistaxis	NN	_	13	conj
16	,	,	,	_	13	punct
17	gastrointestinal	gastrointestinal	JJ	_	18	amod
18	bleeding	bleeding	NN	_	13	conj
19	,	,	,	_	13	punct
20	hematuria	hematuria	NN	_	13	conj
21	,	,	,	_	13	punct
22	and	and	CC	_	13	cc
23	melena	melena	NN	_	13	conj
24	-RRB-	-rrb-	-RRB-	_	13	punct
25	have	have	VBP	_	27	aux
26	been	be	VBN	_	27	auxpass
27	reported	report	VBN	_	0	ROOT
28	in	in	IN	_	29	case
29	association	association	NN	_	27	nmod
30	with	with	IN	_	31	case
31	increases	increase	NNS	_	29	nmod
32	in	in	IN	_	34	case
33	prothrombin	prothrombin	NN	_	34	compound
34	time	time	NN	_	31	nmod
35	in	in	IN	_	36	case
36	patients	patient	NNS	_	34	nmod
37	receiving	receive	VBG	_	36	acl
38	drug2	drug2	NN	_	37	dobj
39	concurrently	concurrently	RB	_	37	advmod
40	with	with	IN	_	41	case
41	drug3	drug3	NN	_	37	nmod
42	.	.	.	_	27	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	<	<	JJR	_	6	advmod
4	a	a	DT	_	5	det
5	href	href	NN	_	6	nsubj
6	=	=	JJ	_	2	ccomp
7	``	``	``	_	6	punct
8	flucon_cp	flucon_cp	NN	_	6	dobj
9	.	.	.	_	2	punct
10	htm	htm	NN	_	11	compound
11	#CP	#cp	NN	_	2	dep
12	''	''	''	_	11	punct
13	>	>	JJR	_	15	dep
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	11	nmod
16	:	:	:	_	15	punct
17	Drug	Drug	NNP	_	19	compound
18	Interaction	interaction	NN	_	19	compound
19	Studies	study	NNS	_	15	dep
20	.	.	.	_	2	punct
21	-RRB-	-rrb-	-RRB-	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	<	<	JJR	_	6	advmod
4	a	a	DT	_	5	det
5	href	href	NN	_	6	nsubj
6	=	=	JJ	_	2	ccomp
7	``	``	``	_	6	punct
8	flucon_cp	flucon_cp	NN	_	6	dobj
9	.	.	.	_	2	punct
10	htm	htm	NN	_	11	compound
11	#CP	#cp	NN	_	2	dep
12	''	''	''	_	11	punct
13	>	>	JJR	_	15	dep
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	11	nmod
16	:	:	:	_	15	punct
17	Drug	Drug	NNP	_	19	compound
18	Interaction	interaction	NN	_	19	compound
19	Studies	study	NNS	_	15	dep
20	.	.	.	_	2	punct
21	-RRB-	-rrb-	-RRB-	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubj
4	may	may	MD	_	6	aux
5	significantly	significantly	RB	_	6	advmod
6	increase	increase	VB	_	1	dep
7	drug3	drug3	NN	_	8	compound
8	levels	level	NNS	_	6	dobj
9	in	in	IN	_	12	case
10	renal	renal	JJ	_	12	amod
11	transplant	transplant	NN	_	12	compound
12	patients	patient	NNS	_	6	nmod
13	with	with	IN	_	17	nmod
14	or	or	CC	_	13	cc
15	without	without	IN	_	13	conj
16	renal	renal	JJ	_	17	amod
17	impairment	impairment	NN	_	12	nmod
18	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	serum	serum	NN	_	8	compound
8	creatinine	creatinine	NN	_	5	conj
9	is	be	VBZ	_	10	auxpass
10	recommended	recommend	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug2	drug2	NN	_	13	dobj
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	.	.	.	_	10	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	CLINICAL	CLINICAL	NNP	_	4	compound
4	PHARMACOLOGY	PHARMACOLOGY	NNP	_	2	dobj
5	:	:	:	_	4	punct
6	Drug	Drug	NNP	_	8	compound
7	Interaction	interaction	NN	_	8	compound
8	Studies	study	NNS	_	4	dep
9	.	.	.	_	2	punct
10	-RRB-	-rrb-	-RRB-	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	enhances	enhance	VBZ	_	1	appos
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	4	dobj
7	of	of	IN	_	10	case
8	concurrently	concurrently	RB	_	9	advmod
9	administered	administer	VBN	_	10	amod
10	drug3	drug3	NN	_	6	nmod
11	.	.	.	_	1	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	clinical	clinical	JJ	_	4	amod
4	circumstances	circumstance	NNS	_	9	advcl
5	,	,	,	_	9	punct
6	consideration	consideration	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	given	give	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	increasing	increase	VBG	_	9	advcl
12	the	the	DT	_	13	det
13	dose	dose	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	when	when	WRB	_	19	advmod
17	it	it	PRP	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	11	advcl
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	serum	serum	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	14	nsubjpass
3	of	of	IN	_	6	case
4	serum	serum	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	is	be	VBZ	_	14	auxpass
14	recommended	recommend	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	6	case
4	of	of	IN	_	3	mwe
5	the	the	DT	_	6	det
6	occurrence	occurrence	NN	_	31	nmod
7	of	of	IN	_	10	case
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	dysrhythmias	dysrhythmia	NNS	_	6	nmod
11	secondary	secondary	JJ	_	10	amod
12	to	to	TO	_	13	case
13	prolongation	prolongation	NN	_	11	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	QTc	qtc	NN	_	17	compound
17	interval	interval	NN	_	13	nmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	receiving	receive	VBG	_	19	acl
21	drug2	drug2	NN	_	20	dobj
22	in	in	IN	_	23	case
23	conjunction	conjunction	NN	_	20	nmod
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	,	,	,	_	31	punct
27	interaction	interaction	NN	_	28	compound
28	studies	study	NNS	_	31	nsubjpass
29	have	have	VBP	_	31	aux
30	been	be	VBN	_	31	auxpass
31	performed	perform	VBN	_	1	appos
32	.	.	.	_	1	punct

1	One	one	CD	_	2	nummod
2	study	study	NN	_	10	nsubj
3	at	at	IN	_	7	case
4	a	a	DT	_	7	det
5	200-mg	200-mg	JJ	_	7	amod
6	daily	daily	JJ	_	7	amod
7	dose	dose	NN	_	2	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	failed	fail	VBD	_	0	ROOT
11	to	to	TO	_	12	mark
12	demonstrate	demonstrate	VB	_	10	xcomp
13	a	a	DT	_	14	det
14	prolongation	prolongation	NN	_	12	dobj
15	in	in	IN	_	17	case
16	QTc	qtc	NN	_	17	compound
17	interval	interval	NN	_	14	nmod
18	.	.	.	_	10	punct

1	Another	another	DT	_	2	det
2	study	study	NN	_	12	nsubj
3	at	at	IN	_	9	case
4	a	a	DT	_	9	det
5	400-mg	400-mg	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	800-mg	800-mg	JJ	_	5	conj
8	daily	daily	JJ	_	9	amod
9	dose	dose	NN	_	2	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	demonstrated	demonstrate	VBD	_	0	ROOT
13	that	that	IN	_	12	dobj
14	drug2	drug2	NN	_	13	dep
15	taken	take	VBN	_	14	acl
16	in	in	IN	_	17	case
17	doses	dose	NNS	_	15	nmod
18	of	of	IN	_	20	case
19	400	400	CD	_	20	nummod
20	mg	mg	NN	_	17	nmod
21	per	per	IN	_	22	case
22	day	day	NN	_	20	nmod
23	or	or	CC	_	20	cc
24	greater	greater	JJR	_	26	dep
25	significantly	significantly	RB	_	26	advmod
26	increases	increase	VBZ	_	20	conj
27	plasma	plasma	NN	_	28	compound
28	levels	level	NNS	_	26	dobj
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	when	when	WRB	_	32	advmod
32	taken	take	VBN	_	15	advcl
33	concomitantly	concomitantly	RB	_	32	advmod
34	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	at	at	IN	_	7	case
7	doses	dose	NNS	_	3	nmod
8	of	of	IN	_	10	case
9	400	400	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	greater	greater	JJR	_	10	conj
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	3	nmod
15	is	be	VBZ	_	16	auxpass
16	contraindicated	contraindicate	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	coadministration	coadministration	NN	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	2	nmod
7	lower	lower	JJR	_	6	amod
8	than	than	IN	_	10	case
9	400	400	CD	_	10	nummod
10	mg/day	mg/day	NN	_	7	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	should	should	MD	_	16	aux
14	be	be	VB	_	16	auxpass
15	carefully	carefully	RB	_	16	advmod
16	monitored	monitor	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	appos
7	of	of	IN	_	9	case
8	cardiac	cardiac	JJ	_	9	amod
9	events	event	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	14	case
12	torsade	torsade	NN	_	14	compound
13	de	de	IN	_	14	amod
14	pointes	pointe	NNS	_	9	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	to	to	TO	_	18	case
18	whom	whom	WP	_	23	nmod
19	drug2	drug2	NN	_	23	nsubjpass
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	were	be	VBD	_	23	auxpass
23	coadministered	coadminister	VBN	_	16	acl:relcl
24	.	.	.	_	1	punct

1	A	a	DT	_	3	det
2	controlled	controlled	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	that	that	IN	_	20	mark
6	concomitant	concomitant	JJ	_	9	amod
7	drug1	drug1	NN	_	9	compound
8	200	200	CD	_	9	nummod
9	mg	mg	NN	_	20	nsubj
10	once	once	RB	_	11	advmod
11	daily	daily	JJ	_	9	amod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	15	compound
14	20	20	CD	_	15	nummod
15	mg	mg	NN	_	11	conj
16	four	four	CD	_	17	nummod
17	times	time	NNS	_	11	nmod:tmod
18	a	a	DT	_	19	det
19	day	day	NN	_	17	nmod:npmod
20	yielded	yield	VBD	_	4	ccomp
21	a	a	DT	_	23	det
22	significant	significant	JJ	_	23	amod
23	increase	increase	NN	_	20	dobj
24	in	in	IN	_	27	case
25	drug3	drug3	NN	_	27	compound
26	plasma	plasma	NN	_	27	compound
27	levels	level	NNS	_	23	nmod
28	and	and	CC	_	23	cc
29	prolongation	prolongation	NN	_	23	conj
30	of	of	IN	_	32	case
31	QTc	qtc	NN	_	32	compound
32	interval	interval	NN	_	29	nmod
33	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	is	be	VBZ	_	9	auxpass
9	contraindicated	contraindicate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	use	use	NN	_	23	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	4	nmod
9	concurrently	concurrently	RB	_	10	advmod
10	taking	take	VBG	_	8	acl
11	drug3	drug3	NN	_	10	dobj
12	or	or	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	metabolized	metabolize	VBN	_	11	acl
16	by	by	IN	_	20	case
17	the	the	DT	_	20	det
18	cytochrome	cytochrome	NN	_	20	compound
19	P450	p450	NN	_	20	compound
20	system	system	NN	_	15	nmod
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	associated	associate	VBN	_	1	appos
24	with	with	IN	_	25	case
25	elevations	elevation	NNS	_	23	nmod
26	in	in	IN	_	28	case
27	serum	serum	NN	_	28	compound
28	levels	level	NNS	_	25	nmod
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	drugs	drug	NNS	_	28	nmod
32	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	absence	absence	NN	_	11	nmod
4	of	of	IN	_	6	case
5	definitive	definitive	JJ	_	6	amod
6	information	information	NN	_	3	nmod
7	,	,	,	_	11	punct
8	caution	caution	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	coadministering	coadminister	VBG	_	11	advcl
14	drug1	drug1	NN	_	13	dobj
15	.	.	.	_	11	punct

1	Patients	patient	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	be	be	VB	_	5	auxpass
4	carefully	carefully	RB	_	5	advmod
5	monitored	monitor	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	dep
7	of	of	IN	_	8	case
8	uveitis	uveitis	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	whom	whom	WP	_	17	nmod
13	drug2	drug2	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	were	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	acl:relcl
18	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	dep
7	of	of	IN	_	8	case
8	nephrotoxicity	nephrotoxicity	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	whom	whom	WP	_	17	nmod
13	drug2	drug2	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	were	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	acl:relcl
18	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Following	follow	VBG	_	5	case
4	oral	oral	JJ	_	5	amod
5	administration	administration	NN	_	10	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	10	punct
9	drug3	drug3	NN	_	10	nsubj
10	resulted	result	VBD	_	1	appos
11	in	in	IN	_	13	case
12	substantial	substantial	JJ	_	13	amod
13	increases	increase	NNS	_	10	nmod
14	in	in	IN	_	16	case
15	drug4	drug4	NN	_	16	compound
16	concentrations	concentration	NNS	_	13	nmod
17	and	and	CC	_	16	cc
18	psychomotor	psychomotor	JJ	_	19	amod
19	effects	effect	NNS	_	16	conj
20	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubj
3	on	on	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	appears	appear	VBZ	_	0	ROOT
6	to	to	TO	_	9	mark
7	be	be	VB	_	9	cop
8	more	more	RBR	_	9	advmod
9	pronounced	pronounced	JJ	_	5	xcomp
10	following	follow	VBG	_	12	case
11	oral	oral	JJ	_	12	amod
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	than	than	IN	_	17	case
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	9	nmod
18	administered	administer	VBN	_	17	acl
19	intravenously	intravenously	RB	_	18	advmod
20	.	.	.	_	5	punct

1	If	if	IN	_	15	mark
2	drug1	drug1	NN	_	15	nsubjpass
3	,	,	,	_	2	punct
4	which	which	WDT	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	metabolized	metabolize	VBN	_	2	acl:relcl
7	by	by	IN	_	11	case
8	the	the	DT	_	11	det
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	system	system	NN	_	6	nmod
12	,	,	,	_	2	punct
13	are	be	VBP	_	15	auxpass
14	concomitantly	concomitantly	RB	_	15	advmod
15	administered	administer	VBN	_	22	advcl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	22	punct
19	consideration	consideration	NN	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	given	give	VBN	_	0	ROOT
23	to	to	TO	_	24	mark
24	decreasing	decrease	VBG	_	22	advcl
25	the	the	DT	_	27	det
26	drug3	drug3	NN	_	27	compound
27	dosage	dosage	NN	_	24	dobj
28	,	,	,	_	22	punct
29	and	and	CC	_	22	cc
30	the	the	DT	_	31	det
31	patients	patient	NNS	_	35	nsubjpass
32	should	should	MD	_	35	aux
33	be	be	VB	_	35	auxpass
34	appropriately	appropriately	RB	_	35	advmod
35	monitored	monitor	VBN	_	22	conj
36	.	.	.	_	22	punct

1	drug1	drug1	NN	_	2	compound
2	tablets	tablet	NNS	_	13	nsubj
3	coadministered	coadminister	VBN	_	2	acl
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-	-	:	_	2	punct
7	and	and	CC	_	2	cc
8	drug3	drug3	NN	_	2	conj
9	-	-	:	_	8	punct
10	containing	contain	VBG	_	8	acl
11	oral	oral	JJ	_	12	amod
12	drug4	drug4	NN	_	10	dobj
13	produced	produce	VBD	_	0	ROOT
14	an	a	DT	_	17	det
15	overall	overall	JJ	_	17	amod
16	mean	mean	JJ	_	17	amod
17	increase	increase	NN	_	13	dobj
18	in	in	IN	_	22	case
19	drug5	drug5	NN	_	22	compound
20	and	and	CC	_	19	cc
21	drug6	drug6	NN	_	19	conj
22	levels	level	NNS	_	17	nmod
23	;	;	:	_	13	punct

1	however	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	in	in	IN	_	5	case
4	some	some	DT	_	5	det
5	patients	patient	NNS	_	8	nmod
6	there	there	EX	_	8	expl
7	were	be	VBD	_	8	auxpass
8	decreases	decrease	VBZ	_	0	ROOT
9	up	up	RP	_	11	dep
10	to	to	TO	_	9	mwe
11	47	47	CD	_	12	nummod
12	%	%	NN	_	8	dobj
13	and	and	CC	_	12	cc
14	33	33	CD	_	15	nummod
15	%	%	NN	_	12	conj
16	of	of	IN	_	20	case
17	drug1	drug1	NN	_	20	compound
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	levels	level	NNS	_	12	nmod
21	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	5	nsubj
3	presently	presently	RB	_	4	advmod
4	available	available	JJ	_	2	amod
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	21	mark
7	the	the	DT	_	8	det
8	decreases	decrease	NNS	_	21	nsubj
9	in	in	IN	_	12	case
10	some	some	DT	_	12	det
11	individual	individual	JJ	_	12	amod
12	drug1	drug1	NN	_	8	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	16	compound
15	AUC	auc	NN	_	16	compound
16	values	value	NNS	_	12	conj
17	with	with	IN	_	19	case
18	drug3	drug3	NN	_	19	compound
19	treatment	treatment	NN	_	8	nmod
20	are	be	VBP	_	21	cop
21	likely	likely	JJ	_	5	ccomp
22	the	the	DT	_	23	det
23	result	result	NN	_	21	dobj
24	of	of	IN	_	26	case
25	random	random	JJ	_	26	amod
26	variation	variation	NN	_	23	nmod
27	.	.	.	_	5	punct

1	While	while	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	17	advcl
4	evidence	evidence	NN	_	3	nsubj
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	inhibit	inhibit	VB	_	4	ccomp
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	17	punct
16	there	there	EX	_	17	expl
17	is	be	VBZ	_	0	ROOT
18	no	no	DT	_	19	neg
19	evidence	evidence	NN	_	17	nsubj
20	that	that	IN	_	25	mark
21	drug4	drug4	NN	_	25	nsubj
22	is	be	VBZ	_	25	cop
23	a	a	DT	_	25	det
24	net	net	JJ	_	25	amod
25	inducer	inducer	NN	_	19	ccomp
26	of	of	IN	_	27	case
27	drug5	drug5	NN	_	25	nmod
28	or	or	CC	_	27	cc
29	drug6	drug6	NN	_	30	compound
30	metabolism	metabolism	NN	_	27	conj
31	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	effects	effect	NNS	_	3	nmod
7	is	be	VBZ	_	9	cop
8	presently	presently	RB	_	9	advmod
9	unknown	unknown	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Physicians	Physicians	NNP	_	4	nsubj
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	cop
4	aware	aware	JJ	_	0	ROOT
5	that	that	IN	_	19	mark
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	19	nsubj
8	with	with	IN	_	9	case
9	medications	medication	NNS	_	7	nmod
10	other	other	JJ	_	9	amod
11	than	than	IN	_	12	case
12	those	those	DT	_	10	nmod
13	listed	list	VBN	_	12	acl
14	in	in	IN	_	18	case
15	the	the	DT	_	18	det
16	<	<	JJR	_	18	amod
17	a	a	DT	_	18	det
18	href	href	NN	_	13	nmod
19	=	=	JJ	_	4	ccomp
20	``	``	``	_	19	punct
21	flucon_cp	flucon_cp	NN	_	19	dobj
22	.	.	.	_	4	punct
23	htm	htm	NN	_	24	compound
24	#CP	#cp	NN	_	33	dep
25	''	''	''	_	24	punct
26	>	>	JJR	_	29	amod
27	CLINICAL	CLINICAL	NNP	_	29	compound
28	PHARMACOLOGY	PHARMACOLOGY	NNP	_	29	compound
29	section	section	NN	_	33	nsubjpass
30	have	have	VBP	_	33	aux
31	not	not	RB	_	33	neg
32	been	be	VBN	_	33	auxpass
33	conducted	conduct	VBN	_	4	parataxis
34	,	,	,	_	33	punct
35	but	but	CC	_	33	cc
36	such	such	JJ	_	37	amod
37	interactions	interaction	NNS	_	39	nsubj
38	may	may	MD	_	39	aux
39	occur	occur	VB	_	33	conj
40	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	appos
7	,	,	,	_	4	punct
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	well	well	RB	_	15	advmod
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Use	use	NN	_	21	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	--	--	:	_	1	punct
7	drug3	drug3	NN	_	1	dep
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	alone	alone	RB	_	7	conj
12	or	or	CC	_	7	cc
13	in	in	IN	_	14	case
14	combination	combination	NN	_	7	conj
15	with	with	IN	_	16	case
16	drug5	drug5	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug6	drug6	NN	_	16	conj
19	,	,	,	_	1	punct
20	may	may	MD	_	21	aux
21	cause	cause	VB	_	0	ROOT
22	bleeding	bleeding	JJ	_	23	amod
23	complications	complication	NNS	_	21	dobj
24	.	.	.	_	21	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	careful	careful	JJ	_	4	amod
4	monitoring	monitoring	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	treatment	treatment	NN	_	17	nmod
4	of	of	IN	_	6	case
5	acute	acute	JJ	_	6	amod
6	MI	MI	NNP	_	3	nmod
7	,	,	,	_	6	punct
8	drug1	drug1	NN	_	6	appos
9	,	,	,	_	6	punct
10	when	when	WRB	_	13	advmod
11	not	not	RB	_	13	neg
12	otherwise	otherwise	RB	_	13	advmod
13	contraindicated	contraindicate	VBN	_	17	dep
14	,	,	,	_	17	punct
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	administered	administer	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	see	see	VB	_	17	dep
22	below	below	IN	_	21	advmod
23	-RRB-	-rrb-	-RRB-	_	21	punct
24	.	.	.	_	17	punct

1	Anticoagulation	anticoagulation	NN	_	24	nsubjpass
2	and	and	CC	_	1	cc
3	drug1	drug1	NN	_	1	conj
4	After	after	IN	_	5	case
5	Treatment	treatment	NN	_	1	nmod
6	for	for	IN	_	8	case
7	Myocardial	myocardial	JJ	_	8	amod
8	Infarction	infarction	NN	_	5	nmod
9	--	--	:	_	1	punct
10	In	in	IN	_	12	case
11	the	the	DT	_	12	det
12	treatment	treatment	NN	_	24	nmod
13	of	of	IN	_	16	case
14	acute	acute	JJ	_	16	amod
15	myocardial	myocardial	JJ	_	16	amod
16	infarction	infarction	NN	_	12	nmod
17	,	,	,	_	24	punct
18	the	the	DT	_	19	det
19	use	use	NN	_	24	nsubjpass
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	has	have	VBZ	_	24	aux
23	been	be	VBN	_	24	auxpass
24	shown	show	VBN	_	0	ROOT
25	to	to	TO	_	26	mark
26	reduce	reduce	VB	_	24	xcomp
27	the	the	DT	_	28	det
28	incidence	incidence	NN	_	26	dobj
29	of	of	IN	_	30	case
30	reinfarction	reinfarction	NN	_	28	nmod
31	and	and	CC	_	30	cc
32	stroke	stroke	NN	_	30	conj
33	.	.	.	_	24	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	causes	cause	VBZ	_	0	ROOT
8	a	a	DT	_	10	det
9	minimal	minimal	JJ	_	10	amod
10	increase	increase	NN	_	37	nsubj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	16	case
15	minor	minor	JJ	_	16	amod
16	bleeding	bleeding	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	37	punct
18	3.9	3.9	CD	_	19	nummod
19	%	%	NN	_	37	dep
20	vs.	vs.	CC	_	19	cc
21	3.1	3.1	CD	_	22	nummod
22	%	%	NN	_	19	conj
23	-RRB-	-rrb-	-RRB-	_	19	punct
24	,	,	,	_	19	punct
25	but	but	CC	_	19	cc
26	does	do	VBZ	_	28	aux
27	not	not	RB	_	28	neg
28	appear	appear	VB	_	19	conj
29	to	to	TO	_	30	mark
30	increase	increase	VB	_	28	xcomp
31	the	the	DT	_	32	det
32	incidence	incidence	NN	_	30	dobj
33	of	of	IN	_	35	case
34	major	major	JJ	_	35	amod
35	bleeding	bleeding	NN	_	32	nmod
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	see	see	VB	_	7	ccomp

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	14	advcl
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	14	punct
9	potentiation	potentiation	NN	_	14	nsubj
10	of	of	IN	_	12	case
11	antihypertensive	antihypertensive	JJ	_	12	amod
12	effect	effect	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	0	ROOT
15	.	.	.	_	14	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	followed	follow	VBN	_	0	ROOT
5	carefully	carefully	RB	_	4	advmod
6	to	to	TO	_	7	mark
7	detect	detect	VB	_	4	xcomp
8	side	side	JJ	_	9	amod
9	reactions	reaction	NNS	_	7	dobj
10	or	or	CC	_	9	cc
11	unusual	unusual	JJ	_	12	amod
12	manifestations	manifestation	NNS	_	9	conj
13	of	of	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	idiosyncrasy	idiosyncrasy	NN	_	12	nmod
16	.	.	.	_	4	punct

1	Patients	patient	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	require	require	VB	_	0	ROOT
4	reduced	reduced	JJ	_	5	amod
5	doses	dose	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	when	when	WRB	_	10	advmod
9	on	on	IN	_	10	case
10	drug2	drug2	NN	_	3	advcl
11	.	.	.	_	3	punct

1	If	if	IN	_	4	mark
2	hypotension	hypotension	NN	_	4	nsubj
3	does	do	VBZ	_	4	aux
4	occur	occur	VB	_	12	advcl
5	during	during	IN	_	6	case
6	anesthesia	anesthesia	NN	_	4	nmod
7	,	,	,	_	12	punct
8	it	it	PRP	_	12	nsubjpass
9	usually	usually	RB	_	12	advmod
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	controlled	control	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	adrenergic	adrenergic	JJ	_	3	amod
3	receptors	receptor	NNS	_	4	nsubj
4	remain	remain	VBP	_	0	ROOT
5	sensitive	sensitive	JJ	_	4	xcomp
6	during	during	IN	_	7	case
7	treatment	treatment	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	4	punct

1	When	when	WRB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	13	advmod
8	the	the	DT	_	9	det
9	patient	patient	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	carefully	carefully	RB	_	13	advmod
13	monitored	monitor	VBN	_	6	ccomp
14	for	for	IN	_	15	case
15	symptoms	symptom	NNS	_	13	nmod
16	of	of	IN	_	18	case
17	drug3	drug3	NN	_	18	compound
18	toxicity	toxicity	NN	_	15	nmod
19	.	.	.	_	6	punct

1	Read	read	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	circular	circular	JJ	_	1	dobj
4	for	for	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	preparations	preparation	NNS	_	3	nmod
7	.	.	.	_	1	punct

1	Several	several	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	3	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	bioavailability	bioavailability	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	when	when	WRB	_	14	advmod
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	ingested	ingest	VBN	_	3	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubj
2	may	may	MD	_	4	aux
3	adversely	adversely	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	blood	blood	NN	_	7	compound
6	pressure	pressure	NN	_	7	compound
7	control	control	NN	_	4	dobj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	10	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	or	or	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	See	see	VB	_	1	dep
4	CONTRAINDICATIONS	contraindication	NNS	_	3	dobj
5	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	8	case
8	measurement	measurement	NN	_	6	nmod
9	of	of	IN	_	13	case
10	:	:	:	_	13	punct
11	urinary	urinary	JJ	_	13	amod
12	uric	uric	JJ	_	13	amod
13	acid	acid	NN	_	8	nmod
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	phosphotungstate	phosphotungstate	NN	_	17	compound
17	method	method	NN	_	6	nmod
18	,	,	,	_	17	punct
19	serum	serum	NN	_	20	compound
20	creatinine	creatinine	NN	_	17	conj
21	by	by	IN	_	25	case
22	the	the	DT	_	25	det
23	alkaline	alkaline	NN	_	25	compound
24	picrate	picrate	NN	_	25	compound
25	method	method	NN	_	20	nmod
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	SGOT	sgot	NN	_	17	conj
29	by	by	IN	_	31	case
30	colorimetric	colorimetric	JJ	_	31	amod
31	methods	method	NNS	_	28	nmod
32	.	.	.	_	6	punct

1	Interference	interference	NN	_	11	nsubjpass
2	with	with	IN	_	4	case
3	spectrophotometric	spectrophotometric	JJ	_	4	amod
4	methods	method	NNS	_	1	nmod
5	for	for	IN	_	7	case
6	SGOT	sgot	NN	_	7	compound
7	analysis	analysis	NN	_	4	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Since	since	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	causes	cause	VBZ	_	24	advcl
4	fluorescence	fluorescence	NN	_	3	dobj
5	in	in	IN	_	7	case
6	urine	urine	NN	_	7	compound
7	samples	sample	NNS	_	4	nmod
8	at	at	IN	_	12	case
9	the	the	DT	_	12	det
10	same	same	JJ	_	12	amod
11	wave	wave	NN	_	12	compound
12	lengths	length	NNS	_	3	nmod
13	as	as	IN	_	14	case
14	catecholamines	catecholamine	NNS	_	12	nmod
15	,	,	,	_	24	punct
16	falsely	falsely	RB	_	17	advmod
17	high	high	JJ	_	18	amod
18	levels	level	NNS	_	24	nsubjpass
19	of	of	IN	_	21	case
20	urinary	urinary	JJ	_	21	amod
21	catecholamines	catecholamine	NNS	_	18	nmod
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	reported	report	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	This	this	DT	_	3	nsubj
2	will	will	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	diagnosis	diagnosis	NN	_	3	nmod
7	of	of	IN	_	8	case
8	pheochromocytoma	pheochromocytoma	NN	_	6	nmod
9	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	important	important	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	recognize	recognize	VB	_	3	xcomp
6	this	this	DT	_	7	det
7	phenomenon	phenomenon	NN	_	5	dobj
8	before	before	IN	_	10	case
9	a	a	DT	_	10	det
10	patient	patient	NN	_	5	nmod
11	with	with	IN	_	14	case
12	a	a	DT	_	14	det
13	possible	possible	JJ	_	14	amod
14	pheochromocytoma	pheochromocytoma	NN	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	subjected	subject	VBN	_	3	dep
17	to	to	TO	_	18	case
18	surgery	surgery	NN	_	16	nmod
19	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	measurement	measurement	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	8	punct
13	a	a	DT	_	14	det
14	test	test	NN	_	8	appos
15	for	for	IN	_	16	case
16	pheochromocytoma	pheochromocytoma	NN	_	14	nmod
17	,	,	,	_	8	punct
18	by	by	IN	_	20	case
19	those	those	DT	_	20	det
20	methods	method	NNS	_	6	nmod
21	which	which	WDT	_	22	nsubj
22	convert	convert	VBP	_	20	acl:relcl
23	drug4	drug4	NN	_	22	dobj
24	to	to	TO	_	25	case
25	drug5	drug5	NN	_	22	nmod
26	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	recommended	recommend	VBN	_	0	ROOT
5	for	for	IN	_	7	case
6	the	the	DT	_	7	det
7	treatment	treatment	NN	_	4	nmod
8	of	of	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	with	with	IN	_	11	case
11	pheochromocytoma	pheochromocytoma	NN	_	9	nmod
12	.	.	.	_	4	punct

1	Rarely	rarely	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	6	advmod
4	urine	urine	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	exposed	expose	VBN	_	14	advcl
7	to	to	TO	_	8	case
8	air	air	NN	_	6	nmod
9	after	after	IN	_	10	mark
10	voiding	void	VBG	_	6	advcl
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubj
13	may	may	MD	_	14	aux
14	darken	darken	VB	_	0	ROOT
15	because	because	IN	_	17	case
16	of	of	IN	_	15	mwe
17	breakdown	breakdown	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	its	its	PRP$	_	22	nmod:poss
22	metabolites	metabolite	NNS	_	19	conj
23	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	result	result	VB	_	1	dep
11	in	in	IN	_	14	case
12	increased	increase	VBN	_	14	amod
13	systemic	systemic	JJ	_	14	amod
14	toxicity	toxicity	NN	_	10	nmod
15	since	since	IN	_	17	mark
16	drug4	drug4	NN	_	17	nsubj
17	inhibit	inhibit	VBP	_	10	advcl
18	the	the	DT	_	19	det
19	breakdown	breakdown	NN	_	17	dobj
20	of	of	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	.	.	.	_	1	punct

1	Antimyasthenics	Antimyasthenics	NNP	_	3	compound
2	Concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	antimyasthenics	antimyasthenic	NNS	_	5	conj
8	may	may	MD	_	9	aux
9	result	result	VB	_	0	ROOT
10	in	in	IN	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	13	case
13	control	control	NN	_	11	nmod
14	of	of	IN	_	15	case
15	symptoms	symptom	NNS	_	13	nmod
16	of	of	IN	_	18	case
17	myasthenia	myasthenia	NN	_	18	compound
18	gravis	gravis	NN	_	15	nmod
19	due	due	JJ	_	21	case
20	to	to	TO	_	19	mwe
21	antagonism	antagonism	NN	_	11	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	effects	effect	NNS	_	21	nmod
25	of	of	IN	_	26	case
26	antimyasthenics	antimyasthenic	NNS	_	24	nmod
27	on	on	IN	_	29	case
28	skeletal	skeletal	JJ	_	29	amod
29	muscle	muscle	NN	_	24	nmod
30	.	.	.	_	9	punct

1	Temporary	temporary	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	antimyasthenics	antimyasthenic	NNS	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Also	also	RB	_	4	advmod
2	antimyasthenics	antimyasthenic	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	have	have	VB	_	0	ROOT
5	anticholinesterase	anticholinesterase	JJ	_	6	amod
6	activity	activity	NN	_	4	dobj
7	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	medications	medication	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Concurrent	concurrent	JJ	_	5	amod
5	use	use	NN	_	11	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	may	may	MD	_	11	aux
11	result	result	VB	_	2	dep
12	in	in	IN	_	15	case
13	additive	additive	JJ	_	15	amod
14	depressant	depressant	NN	_	15	compound
15	effects	effect	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	dep
6	the	the	DT	_	8	det
7	diffusion	diffusion	NN	_	8	compound
8	rate	rate	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	5	punct
12	resulting	result	VBG	_	5	advcl
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	decreased	decrease	VBN	_	16	amod
16	time	time	NN	_	12	nmod
17	of	of	IN	_	18	case
18	onset	onset	NN	_	16	nmod
19	,	,	,	_	5	punct
20	but	but	CC	_	5	cc
21	an	a	DT	_	22	det
22	increase	increase	NN	_	5	conj
23	in	in	IN	_	25	case
24	systemic	systemic	JJ	_	25	amod
25	toxicity	toxicity	NN	_	22	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	Concurrent	concurrent	JJ	_	9	amod
9	use	use	NN	_	15	nsubj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	may	may	MD	_	15	aux
15	result	result	VB	_	1	dep
16	in	in	IN	_	17	case
17	prolongation	prolongation	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	enhancement	enhancement	NN	_	17	conj
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	blockade	blockade	NN	_	17	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	result	result	VB	_	1	dep
11	in	in	IN	_	13	case
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	10	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	antibacterial	antibacterial	JJ	_	17	amod
17	action	action	NN	_	13	nmod
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	drug4	drug4	NN	_	17	nmod
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	extend	extend	VB	_	1	dep
11	the	the	DT	_	13	det
12	plasma	plasma	NN	_	13	compound
13	half-life	half-life	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	15	nsubj
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	especially	especially	RB	_	9	advmod
9	those	those	DT	_	3	conj
10	started	start	VBN	_	9	acl
11	recently	recently	RB	_	10	advmod
12	,	,	,	_	3	punct
13	may	may	MD	_	15	aux
14	occasionally	occasionally	RB	_	15	advmod
15	experience	experience	VB	_	1	dep
16	an	a	DT	_	18	det
17	excessive	excessive	JJ	_	18	amod
18	reduction	reduction	NN	_	15	dobj
19	of	of	IN	_	21	case
20	blood	blood	NN	_	21	compound
21	pressure	pressure	NN	_	18	nmod
22	after	after	IN	_	23	case
23	initiation	initiation	NN	_	15	nmod
24	of	of	IN	_	27	case
25	drug3	drug3	NN	_	27	compound
26	Tablets	tablet	NNS	_	27	compound
27	therapy	therapy	NN	_	23	nmod
28	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	minimized	minimize	VBN	_	0	ROOT
9	by	by	IN	_	11	mark
10	either	either	CC	_	11	cc:preconj
11	discontinuing	discontinue	VBG	_	8	advcl
12	the	the	DT	_	13	det
13	drug1	drug1	NN	_	11	dobj
14	or	or	CC	_	11	cc
15	increasing	increase	VBG	_	11	conj
16	the	the	DT	_	18	det
17	salt	salt	NN	_	18	compound
18	intake	intake	NN	_	15	dobj
19	prior	prior	RB	_	15	advmod
20	to	to	TO	_	21	case
21	initiation	initiation	NN	_	19	nmod
22	of	of	IN	_	23	case
23	treatment	treatment	NN	_	21	nmod
24	with	with	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	8	punct

1	If	if	IN	_	6	mark
2	drug1	drug1	NN	_	6	nsubj
3	can	can	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	cop
6	interrupted	interrupted	JJ	_	13	advcl
7	,	,	,	_	13	punct
8	close	close	JJ	_	10	amod
9	medical	medical	JJ	_	10	amod
10	supervision	supervision	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	provided	provide	VBN	_	0	ROOT
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	first	first	JJ	_	17	amod
17	dose	dose	NN	_	13	nmod
18	of	of	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	Tablets	tablet	NNS	_	17	nmod
21	,	,	,	_	17	punct
22	for	for	IN	_	26	case
23	at	at	IN	_	24	case
24	least	least	JJS	_	25	nmod:npmod
25	two	two	CD	_	26	nummod
26	hours	hour	NNS	_	17	nmod
27	and	and	CC	_	26	cc
28	until	until	IN	_	32	mark
29	blood	blood	NN	_	30	compound
30	pressure	pressure	NN	_	32	nsubj
31	has	have	VBZ	_	32	aux
32	stabilized	stabilize	VBN	_	26	conj
33	for	for	IN	_	35	case
34	another	another	DT	_	35	det
35	hour	hour	NN	_	32	nmod
36	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	rate	rate	NN	_	12	nsubjpass
3	and	and	CC	_	2	cc
4	extent	extent	NN	_	2	conj
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	absorption	absorption	NN	_	2	nmod
8	and	and	CC	_	7	cc
9	elimination	elimination	NN	_	7	conj
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	reduced	reduce	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	6	punct
10	however	however	RB	_	6	advmod
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	this	this	DT	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	6	conj
16	with	with	IN	_	18	case
17	a	a	DT	_	18	det
18	decrease	decrease	NN	_	15	nmod
19	in	in	IN	_	22	case
20	plasma	plasma	NN	_	22	compound
21	ACE	ace	NN	_	22	compound
22	inhibition	inhibition	NN	_	18	nmod
23	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	:	:	:	_	2	punct
6	drug3	drug3	NN	_	7	compound
7	Tablets	tablet	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	2	dep
10	serum	serum	NN	_	11	compound
11	potassium	potassium	NN	_	9	dobj
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	its	its	PRP$	_	15	nmod:poss
15	potential	potential	JJ	_	9	nmod
16	to	to	TO	_	17	mark
17	decrease	decrease	VB	_	15	acl
18	aldosterone	aldosterone	NN	_	19	compound
19	production	production	NN	_	17	dobj
20	.	.	.	_	2	punct

1	Use	use	NN	_	34	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	and	and	CC	_	5	cc
11	others	other	NNS	_	5	conj
12	-RRB-	-rrb-	-RRB-	_	5	punct
13	,	,	,	_	3	punct
14	drug5	drug5	NN	_	15	compound
15	supplements	supplement	NNS	_	3	conj
16	or	or	CC	_	3	cc
17	other	other	JJ	_	18	amod
18	drugs	drug	NNS	_	3	conj
19	capable	capable	JJ	_	3	amod
20	of	of	IN	_	21	mark
21	increasing	increase	VBG	_	19	advcl
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	21	dobj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug6	drug6	NN	_	23	dep
26	,	,	,	_	25	punct
27	drug7	drug7	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug8	drug8	NN	_	25	conj
30	and	and	CC	_	25	cc
31	others	other	NNS	_	25	conj
32	-RRB-	-rrb-	-RRB-	_	25	punct
33	can	can	MD	_	34	aux
34	increase	increase	VB	_	0	ROOT
35	the	the	DT	_	36	det
36	risk	risk	NN	_	34	dobj
37	of	of	IN	_	38	case
38	hyperkalemia	hyperkalemia	NN	_	36	nmod
39	.	.	.	_	34	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	patient	patient	NN	_	23	nmod:poss
21	's	's	POS	_	20	case
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	17	conj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	monitored	monitor	VBN	_	15	dep
27	frequently	frequently	RB	_	26	advmod
28	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	5	amod
4	serum	serum	NN	_	5	compound
5	drug2	drug2	NN	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	symptoms	symptom	NNS	_	5	conj
8	of	of	IN	_	10	case
9	drug3	drug3	NN	_	10	compound
10	toxicity	toxicity	NN	_	7	nmod
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	dep
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	concomitant	concomitant	JJ	_	18	amod
18	drug4	drug4	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	ACE	ace	NN	_	22	compound
21	inhibitor	inhibitor	NN	_	22	compound
22	therapy	therapy	NN	_	18	conj
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	16	csubjpass
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	conj
11	of	of	IN	_	14	case
12	serum	serum	NN	_	14	compound
13	drug1	drug1	NN	_	14	compound
14	concentration	concentration	NN	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Use	use	NN	_	7	nsubj
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	7	aux
6	further	further	RB	_	7	advmod
7	increase	increase	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	risk	risk	NN	_	7	dobj
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	6	det
4	controlled	controlled	JJ	_	6	amod
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	8	nsubj
7	has	have	VBZ	_	8	aux
8	shown	show	VBN	_	1	dep
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	8	dobj
11	on	on	IN	_	14	case
12	plasma	plasma	NN	_	14	compound
13	drug2	drug2	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	when	when	WRB	_	16	advmod
16	coadministered	coadminister	VBN	_	8	advcl
17	with	with	IN	_	19	case
18	drug3	drug3	NN	_	19	compound
19	Tablets	tablet	NNS	_	16	nmod
20	,	,	,	_	8	punct
21	but	but	CC	_	8	cc
22	an	a	DT	_	23	det
23	effect	effect	NN	_	8	conj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	on	on	IN	_	29	case
27	the	the	DT	_	29	det
28	plasma	plasma	NN	_	29	compound
29	concentration	concentration	NN	_	23	nmod
30	of	of	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	/	/	:	_	23	punct
33	drug6	drug6	NN	_	37	nsubjpass
34	has	have	VBZ	_	37	aux
35	not	not	RB	_	37	neg
36	been	be	VBN	_	37	auxpass
37	excluded	exclude	VBN	_	23	acl:relcl
38	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Animal	Animal	NNP	_	4	compound
4	data	datum	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	suggested	suggest	VBN	_	1	appos
7	the	the	DT	_	8	det
8	possibility	possibility	NN	_	6	dobj
9	of	of	IN	_	10	case
10	interaction	interaction	NN	_	8	nmod
11	between	between	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	1	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	this	this	DT	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	investigated	investigate	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	human	human	JJ	_	10	amod
10	studies	study	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	Coadministration	Coadministration	NNP	_	6	nsubj
2	of	of	IN	_	4	case
3	both	both	DT	_	4	det
4	drugs	drug	NNS	_	1	nmod
5	should	should	MD	_	6	aux
6	proceed	proceed	VB	_	0	ROOT
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Food	Food	NNP	_	2	compound
2	Interaction	interaction	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Oral	oral	JJ	_	5	amod
5	administration	administration	NN	_	14	nsubj
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	nmod
9	with	with	IN	_	10	case
10	food	food	NN	_	5	nmod
11	does	do	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	significantly	significantly	RB	_	14	advmod
14	lower	lower	JJR	_	2	dep
15	the	the	DT	_	16	det
16	rate	rate	NN	_	14	dobj
17	or	or	CC	_	16	cc
18	extent	extent	NN	_	16	conj
19	of	of	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	absorption	absorption	NN	_	16	nmod
22	relative	relative	JJ	_	16	amod
23	to	to	TO	_	26	case
24	the	the	DT	_	26	det
25	fasted	fasted	JJ	_	26	amod
26	state	state	NN	_	22	nmod
27	.	.	.	_	2	punct

1	However	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	the	the	DT	_	4	det
4	extent	extent	NN	_	17	nsubjpass
5	of	of	IN	_	6	case
6	biotransformation	biotransformation	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	to	to	TO	_	12	case
10	the	the	DT	_	12	det
11	active	active	JJ	_	12	amod
12	metabolite	metabolite	NN	_	4	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	appos
15	,	,	,	_	12	punct
16	is	be	VBZ	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	approximately	approximately	RB	_	19	advmod
19	43	43	CD	_	20	nummod
20	%	%	NN	_	17	dobj
21	,	,	,	_	17	punct
22	resulting	result	VBG	_	17	advcl
23	in	in	IN	_	25	case
24	a	a	DT	_	25	det
25	reduction	reduction	NN	_	22	nmod
26	in	in	IN	_	31	case
27	the	the	DT	_	31	det
28	plasma	plasma	NN	_	31	compound
29	ACE	ace	NN	_	31	compound
30	inhibition	inhibition	NN	_	31	compound
31	curve	curve	NN	_	25	nmod
32	of	of	IN	_	35	case
33	approximately	approximately	RB	_	34	advmod
34	20	20	CD	_	35	nummod
35	%	%	NN	_	31	nmod
36	,	,	,	_	17	punct
37	probably	probably	RB	_	39	advmod
38	clinically	clinically	RB	_	39	advmod
39	insignificant	insignificant	JJ	_	17	dep
40	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	generally	generally	RB	_	8	advmod
8	administered	administer	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	non-fasting	non-fasting	JJ	_	12	amod
12	state	state	NN	_	8	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	following	follow	VBG	_	10	amod
10	categories	category	NNS	_	6	nmod
11	:	:	:	_	3	punct
12	-	-	:	_	3	punct
13	Blood	blood	NN	_	14	compound
14	dyscrasia	dyscrasia	NN	_	26	nsubj
15	:	:	:	_	14	punct
16	can	can	MD	_	17	aux
17	cause	cause	VB	_	14	dep
18	unpredictable	unpredictable	JJ	_	19	amod
19	myelotoxicity	myelotoxicity	NN	_	17	dobj
20	-	-	:	_	19	punct
21	Bone	bone	NN	_	23	compound
22	marrow	marrow	NN	_	23	compound
23	depressants	depressant	NNS	_	19	dep
24	:	:	:	_	14	punct
25	can	can	MD	_	26	aux
26	cause	cause	VB	_	3	parataxis
27	a	a	DT	_	30	det
28	predictable	predictable	JJ	_	30	amod
29	dose-related	dose-related	JJ	_	30	amod
30	myelotoxicity	myelotoxicity	NN	_	26	dobj
31	-	-	:	_	30	punct
32	Radiation	Radiation	NNP	_	33	compound
33	therapy	therapy	NN	_	30	dep
34	:	:	:	_	26	punct
35	may	may	MD	_	36	aux
36	cause	cause	VB	_	26	dep
37	marrow	marrow	NN	_	38	compound
38	depression	depression	NN	_	36	dobj
39	-	-	:	_	38	punct
40	Neurotoxic	neurotoxic	JJ	_	41	amod
41	medications	medication	NNS	_	38	dep
42	:	:	:	_	36	punct
43	can	can	MD	_	44	aux
44	cause	cause	VB	_	36	parataxis
45	neurologic	neurologic	JJ	_	46	amod
46	toxicity	toxicity	NN	_	44	dobj
47	-	-	:	_	46	punct
48	drug2	drug2	NN	_	46	dep
49	:	:	:	_	44	punct
50	can	can	MD	_	51	aux
51	increase	increase	VB	_	44	parataxis
52	seizure	seizure	NN	_	53	compound
53	activity	activity	NN	_	51	dobj
54	-	-	:	_	51	punct
55	drug3	drug3	NN	_	51	dep
56	:	:	:	_	51	punct
57	may	may	MD	_	58	aux
58	potentiate	potentiate	VB	_	51	dep
59	the	the	DT	_	60	det
60	replication	replication	NN	_	58	dobj
61	of	of	IN	_	64	case
62	the	the	DT	_	64	det
63	drug4	drug4	NN	_	64	compound
64	virus	virus	NN	_	60	nmod
65	,	,	,	_	58	punct
66	may	may	MD	_	67	aux
67	increase	increase	VB	_	58	conj
68	the	the	DT	_	70	det
69	side	side	JJ	_	70	amod
70	effects	effect	NNS	_	67	dobj
71	of	of	IN	_	73	case
72	the	the	DT	_	73	det
73	vaccination	vaccination	NN	_	70	nmod
74	,	,	,	_	58	punct
75	and	and	CC	_	58	cc
76	decrease	decrease	VB	_	58	conj
77	patient	patient	NN	_	79	nmod:poss
78	's	's	POS	_	77	case
79	response	response	NN	_	76	dobj
80	to	to	TO	_	82	case
81	the	the	DT	_	82	det
82	vaccine	vaccine	NN	_	79	nmod
83	-	-	:	_	82	punct
84	drug5	drug5	NN	_	82	dep
85	:	:	:	_	51	punct
86	may	may	MD	_	87	aux
87	cause	cause	VB	_	51	dep
88	shortness	shortness	NN	_	87	dobj
89	of	of	IN	_	90	case
90	breath	breath	NN	_	88	nmod
91	and	and	CC	_	90	cc
92	bronchospasm	bronchospasm	NN	_	90	conj
93	-	-	:	_	87	punct
94	drug6	drug6	NN	_	87	dep
95	:	:	:	_	94	punct
96	may	may	MD	_	97	aux
97	decrease	decrease	VB	_	94	dep
98	patient	patient	NN	_	100	nmod:poss
99	's	's	POS	_	98	case
100	response	response	NN	_	97	dobj
101	to	to	TO	_	103	case
102	the	the	DT	_	103	det
103	drug7	drug7	NN	_	100	nmod

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	some	some	DT	_	2	dobj
4	of	of	IN	_	8	case
5	the	the	DT	_	6	det
6	liver	liver	NN	_	8	nmod:poss
7	's	's	POS	_	6	case
8	ability	ability	NN	_	3	nmod
9	to	to	TO	_	10	mark
10	metabolize	metabolize	VB	_	8	acl
11	some	some	DT	_	13	det
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	dobj
14	-	-	:	_	13	punct
15	drug2	drug2	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug5	drug5	NN	_	15	conj
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	drug6	drug6	NN	_	15	conj
25	.	.	.	_	2	punct

1	Thus	thus	RB	_	8	advmod
2	the	the	DT	_	3	det
3	concentrations	concentration	NNS	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	would	would	MD	_	8	aux
8	increase	increase	VB	_	14	csubjpass
9	meaning	mean	VBG	_	8	xcomp
10	side	side	JJ	_	11	amod
11	effects	effect	NNS	_	9	dobj
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	seen	see	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	required	require	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	30	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	or	or	CC	_	8	cc
10	with	with	IN	_	12	case
11	other	other	JJ	_	12	amod
12	agents	agent	NNS	_	8	conj
13	which	which	WDT	_	14	nsubj
14	produce	produce	VBP	_	12	acl:relcl
15	dry	dry	JJ	_	16	amod
16	mouth	mouth	NN	_	14	dobj
17	,	,	,	_	16	punct
18	constipation	constipation	NN	_	16	conj
19	,	,	,	_	16	punct
20	somnolence	somnolence	NN	_	16	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drowsiness	drowsiness	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	16	punct
25	and/or	and/or	CC	_	16	cc
26	other	other	JJ	_	28	amod
27	anticholinergic-like	anticholinergic-like	JJ	_	28	amod
28	effects	effect	NNS	_	16	conj
29	may	may	MD	_	30	aux
30	increase	increase	VB	_	0	ROOT
31	the	the	DT	_	32	det
32	frequency	frequency	NN	_	30	dobj
33	and/or	and/or	CC	_	32	cc
34	severity	severity	NN	_	32	conj
35	of	of	IN	_	37	case
36	such	such	JJ	_	37	amod
37	effects	effect	NNS	_	32	nmod
38	.	.	.	_	30	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	potentially	potentially	RB	_	4	advmod
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	11	case
8	some	some	DT	_	11	det
9	concomitantly	concomitantly	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	due	due	JJ	_	6	amod
13	to	to	TO	_	15	case
14	anticholinergic	anticholinergic	JJ	_	15	amod
15	effects	effect	NNS	_	12	nmod
16	on	on	IN	_	18	case
17	gastrointestinal	gastrointestinal	JJ	_	18	amod
18	motility	motility	NN	_	15	nmod
19	.	.	.	_	4	punct

1	This	this	DT	_	5	nsubj
2	may	may	MD	_	5	aux
3	be	be	VB	_	5	cop
4	of	of	IN	_	5	case
5	concern	concern	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	with	with	IN	_	12	case
9	a	a	DT	_	12	det
10	narrow	narrow	JJ	_	12	amod
11	therapeutic	therapeutic	JJ	_	12	amod
12	index	index	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Mean	mean	NN	_	4	compound
2	drug1	drug1	NN	_	4	compound
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	9	nsubj
5	were	be	VBD	_	9	cop
6	approximately	approximately	RB	_	7	advmod
7	2	2	CD	_	8	nummod
8	fold	fold	NN	_	9	nmod:npmod
9	higher	higher	JJR	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	drug2	drug2	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	15	punct
17	a	a	DT	_	20	det
18	potent	potent	JJ	_	20	amod
19	CYP3A4	cyp3a4	NN	_	20	compound
20	inhibitor	inhibitor	NN	_	15	appos
21	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	inhibitors	inhibitor	NNS	_	32	nsubj
3	of	of	IN	_	9	case
4	the	the	DT	_	9	det
5	cytochrome	cytochrome	NN	_	9	compound
6	P450	p450	NN	_	9	compound
7	3A4	3a4	NN	_	9	compound
8	enzyme	enzyme	NN	_	9	compound
9	system	system	NN	_	2	nmod
10	,	,	,	_	2	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug1	drug1	NN	_	2	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug2	drug2	NN	_	13	dep
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	or	or	CC	_	13	cc
22	drug4	drug4	NN	_	13	conj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	e.g.	e.g.	FW	_	26	dep
25	,	,	,	_	26	punct
26	drug5	drug5	NN	_	22	dep
27	and	and	CC	_	26	cc
28	drug6	drug6	NN	_	26	conj
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	,	,	,	_	2	punct
31	may	may	MD	_	32	aux
32	alter	alter	VB	_	0	ROOT
33	drug7	drug7	NN	_	34	nsubj
34	mean	mean	VB	_	32	ccomp
35	pharmacokinetic	pharmacokinetic	JJ	_	36	amod
36	parameters	parameter	NNS	_	34	dobj
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	i.e.	i.e.	FW	_	40	dep
39	,	,	,	_	40	punct
40	Cmax	cmax	NN	_	36	dep
41	and	and	CC	_	40	cc
42	AUC	auc	NN	_	40	conj
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	.	.	.	_	32	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	such	such	JJ	_	7	amod
6	potential	potential	JJ	_	7	amod
7	interactions	interaction	NNS	_	3	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	such	such	JJ	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	are	be	VBP	_	9	cop
9	co-administered	co-administered	JJ	_	4	advcl
10	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	ingestion	ingestion	NN	_	21	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	20	20	CD	_	7	nummod
7	mL	ml	NN	_	4	dep
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	containing	contain	VBG	_	9	acl
11	drug3	drug3	NN	_	10	dobj
12	,	,	,	_	11	punct
13	drug4	drug4	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug5	drug5	NN	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	7	punct
18	did	do	VBD	_	21	aux
19	not	not	RB	_	21	neg
20	significantly	significantly	RB	_	21	advmod
21	affect	affect	VB	_	0	ROOT
22	the	the	DT	_	23	det
23	exposure	exposure	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug6	drug6	NN	_	23	nmod
26	or	or	CC	_	25	cc
27	drug7	drug7	NN	_	25	conj
28	.	.	.	_	21	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	6	case
4	concomitant	concomitant	JJ	_	6	amod
5	phenytoin	phenytoin	NN	_	6	compound
6	administration	administration	NN	_	2	nmod
7	on	on	IN	_	12	case
8	the	the	DT	_	12	det
9	steady	steady	JJ	_	12	amod
10	-	-	:	_	12	punct
11	state	state	NN	_	12	compound
12	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
13	of	of	IN	_	14	case
14	quetiapine	quetiapine	NN	_	12	nmod
15	.	.	.	_	2	punct

1	Quetiapine	quetiapine	NN	_	3	compound
2	fumarate	fumarate	NN	_	3	compound
3	(	(	NN	_	0	ROOT
4	'	'	''	_	3	punct
5	Seroquel	Seroquel	NNP	_	7	nmod:poss
6	'	'	POS	_	5	case
7	)	)	NN	_	13	nsubj
8	is	be	VBZ	_	13	cop
9	a	a	DT	_	13	det
10	newly	newly	RB	_	11	advmod
11	introduced	introduce	VBN	_	13	amod
12	atypical	atypical	JJ	_	13	amod
13	antipsychotic	antipsychotic	JJ	_	3	acl:relcl
14	with	with	IN	_	16	case
15	demonstrated	demonstrate	VBN	_	16	amod
16	efficacy	efficacy	NN	_	13	nmod
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	treatment	treatment	NN	_	16	nmod
20	of	of	IN	_	24	case
21	positive	positive	JJ	_	24	amod
22	and	and	CC	_	21	cc
23	negative	negative	JJ	_	21	conj
24	symptoms	symptom	NNS	_	19	nmod
25	of	of	IN	_	26	case
26	schizophrenia	schizophrenia	NN	_	24	nmod
27	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	,	,	,	_	4	punct
6	predominantly	predominantly	RB	_	10	advmod
7	by	by	IN	_	10	case
8	cytochrome	cytochrome	NN	_	10	compound
9	P450	p450	NN	_	10	compound
10	3A4	3a4	NN	_	4	nmod
11	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	14	nsubj
5	of	of	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	that	that	WDT	_	8	nsubj
8	induce	induce	VBP	_	6	acl:relcl
9	or	or	CC	_	8	cc
10	inhibit	inhibit	VBP	_	8	conj
11	this	this	DT	_	12	det
12	enzyme	enzyme	NN	_	8	dobj
13	may	may	MD	_	14	aux
14	affect	affect	VB	_	0	ROOT
15	quetiapine	quetiapine	NN	_	16	compound
16	pharmacokinetics	pharmacokinetic	NNS	_	14	dobj
17	.	.	.	_	14	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	that	that	IN	_	44	mark
5	the	the	DT	_	9	det
6	potent	potent	JJ	_	9	amod
7	cytochrome	cytochrome	NN	_	9	compound
8	P450	p450	NN	_	9	compound
9	enzyme	enzyme	NN	_	44	nsubj
10	-	-	:	_	9	punct
11	inducer	inducer	NN	_	12	compound
12	phenytoin	phenytoin	NN	_	15	nsubj
13	did	do	VBD	_	15	aux
14	indeed	indeed	RB	_	15	advmod
15	have	have	VB	_	9	acl:relcl
16	a	a	DT	_	18	det
17	marked	marked	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	21	case
20	the	the	DT	_	21	det
21	metabolism	metabolism	NN	_	15	nmod
22	of	of	IN	_	23	case
23	quetiapine	quetiapine	NN	_	21	nmod
24	,	,	,	_	15	punct
25	resulting	result	VBG	_	15	advcl
26	in	in	IN	_	31	case
27	a	a	DT	_	31	det
28	5	5	CD	_	31	nummod
29	-	-	:	_	31	punct
30	fold	fold	JJ	_	31	amod
31	increase	increase	NN	_	25	nmod
32	in	in	IN	_	33	case
33	clearance	clearance	NN	_	31	nmod
34	when	when	WRB	_	35	advmod
35	administered	administer	VBN	_	25	advcl
36	concomitantly	concomitantly	RB	_	35	advmod
37	to	to	TO	_	38	case
38	patients	patient	NNS	_	35	nmod
39	with	with	IN	_	40	case
40	DSM	DSM	NNP	_	38	nmod
41	-	-	:	_	40	punct
42	IV	iv	CD	_	40	nummod
43	-	-	:	_	9	punct
44	diagnosed	diagnose	VBD	_	3	ccomp
45	schizophrenia	schizophrenia	NN	_	44	dobj
46	,	,	,	_	45	punct
47	schizoaffective	schizoaffective	JJ	_	48	amod
48	disorder	disorder	NN	_	45	conj
49	,	,	,	_	45	punct
50	or	or	CC	_	45	cc
51	bipolar	bipolar	JJ	_	52	amod
52	disorder	disorder	NN	_	45	conj
53	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	dosage	dosage	NN	_	6	compound
6	adjustment	adjustment	NN	_	11	nsubj
7	of	of	IN	_	8	case
8	quetiapine	quetiapine	NN	_	6	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	necessary	necessary	JJ	_	3	ccomp
12	when	when	WRB	_	17	advmod
13	the	the	DT	_	15	det
14	two	two	CD	_	15	nummod
15	drugs	drug	NNS	_	17	nsubjpass
16	are	be	VBP	_	17	auxpass
17	given	give	VBN	_	11	dep
18	concurrently	concurrently	RB	_	17	advmod
19	and	and	CC	_	17	cc
20	that	that	IN	_	24	mark
21	caution	caution	NN	_	24	nsubjpass
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	required	require	VBN	_	17	conj
25	when	when	WRB	_	26	advmod
26	administering	administer	VBG	_	24	advcl
27	other	other	JJ	_	28	amod
28	drugs	drug	NNS	_	26	dobj
29	that	that	WDT	_	30	nsubj
30	inhibit	inhibit	VBP	_	28	acl:relcl
31	or	or	CC	_	30	cc
32	induce	induce	VBP	_	30	conj
33	cytochromes	cytochrome	NNS	_	30	dobj
34	,	,	,	_	11	punct
35	particularly	particularly	RB	_	37	advmod
36	P450	p450	NN	_	37	compound
37	3A4	3a4	NN	_	11	dep
38	.	.	.	_	3	punct

1	[	[	NN	_	3	compound
2	Drug	drug	NN	_	3	compound
3	treatment	treatment	NN	_	18	nsubj
4	of	of	IN	_	6	case
5	erection	erection	NN	_	6	compound
6	disorders	disorder	NNS	_	3	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	3	nmod
9	with	with	IN	_	11	case
10	cardiovascular	cardiovascular	JJ	_	11	amod
11	disease	disease	NN	_	8	nmod
12	]	]	CD	_	14	nummod
13	Erectile	Erectile	NNP	_	14	compound
14	dysfunction	dysfunction	NN	_	11	dep
15	is	be	VBZ	_	18	cop
16	a	a	DT	_	18	det
17	frequent	frequent	JJ	_	18	amod
18	condition	condition	NN	_	0	ROOT
19	in	in	IN	_	21	case
20	cardiovascular	cardiovascular	JJ	_	21	amod
21	patients	patient	NNS	_	18	nmod
22	.	.	.	_	18	punct

1	Since	since	IN	_	12	mark
2	the	the	DT	_	3	det
3	arrival	arrival	NN	_	12	nsubj
4	of	of	IN	_	6	case
5	oral	oral	JJ	_	6	amod
6	erection	erection	NN	_	3	nmod
7	-	-	:	_	12	punct
8	supporting	support	VBG	_	12	advcl
9	medication	medication	NN	_	8	dobj
10	,	,	,	_	12	punct
11	patients	patient	NNS	_	12	nsubj
12	want	want	VBP	_	0	ROOT
13	to	to	TO	_	14	mark
14	know	know	VB	_	12	xcomp
15	how	how	WRB	_	16	advmod
16	safe	safe	JJ	_	22	dep
17	sexual	sexual	JJ	_	18	amod
18	activity	activity	NN	_	22	nsubj
19	is	be	VBZ	_	22	cop
20	in	in	IN	_	22	case
21	cardiovascular	cardiovascular	JJ	_	22	amod
22	disease	disease	NN	_	14	ccomp
23	in	in	IN	_	24	case
24	general	general	JJ	_	22	nmod
25	and	and	CC	_	22	cc
26	during	during	IN	_	27	case
27	use	use	NN	_	22	conj
28	of	of	IN	_	29	case
29	erection	erection	NN	_	27	nmod
30	-	-	:	_	22	punct
31	supporting	support	VBG	_	22	dep
32	medication	medication	NN	_	31	dobj
33	in	in	IN	_	34	case
34	particular	particular	JJ	_	31	nmod
35	.	.	.	_	12	punct

1	Sexual	sexual	JJ	_	2	amod
2	intercourse	intercourse	NN	_	7	nsubj
3	with	with	IN	_	6	case
4	a	a	DT	_	6	det
5	steady	steady	JJ	_	6	amod
6	partner	partner	NN	_	2	nmod
7	causes	cause	VBZ	_	0	ROOT
8	no	no	RB	_	11	neg
9	more	more	RBR	_	10	advmod
10	cardiovascular	cardiovascular	JJ	_	11	amod
11	risk	risk	NN	_	7	dobj
12	than	than	IN	_	15	case
13	normal	normal	JJ	_	15	amod
14	daily	daily	JJ	_	15	amod
15	activities	activity	NNS	_	11	nmod
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	ironing	ironing	NN	_	15	nmod
19	,	,	,	_	18	punct
20	2	2	CD	_	21	nummod
21	kilometers	kilometer	NNS	_	18	appos
22	of	of	IN	_	23	mark
23	walking	walk	VBG	_	21	acl
24	without	without	IN	_	25	mark
25	climbing	climb	VBG	_	23	advcl
26	,	,	,	_	25	punct
27	paperhanging	paperhanging	NN	_	25	conj
28	,	,	,	_	25	punct
29	playing	play	VBG	_	25	advcl
30	golf	golf	NN	_	29	dobj
31	or	or	CC	_	30	cc
32	gardening	gardening	NN	_	30	conj
33	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	relative	relative	JJ	_	3	amod
3	risk	risk	NN	_	13	nsubj
4	of	of	IN	_	6	case
5	myocardial	myocardial	JJ	_	6	amod
6	infarction	infarction	NN	_	3	nmod
7	during	during	IN	_	9	case
8	sexual	sexual	JJ	_	9	amod
9	activity	activity	NN	_	3	nmod
10	is	be	VBZ	_	13	cop
11	not	not	RB	_	13	neg
12	significantly	significantly	RB	_	13	advmod
13	higher	higher	JJR	_	0	ROOT
14	than	than	IN	_	17	case
15	for	for	IN	_	17	case
16	healthy	healthy	JJ	_	17	amod
17	persons	person	NNS	_	13	nmod
18	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	10	nsubj
3	of	of	IN	_	5	case
4	cardiovascular	cardiovascular	JJ	_	5	amod
5	morbidity	morbidity	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	mortality	mortality	NN	_	5	conj
8	is	be	VBZ	_	10	cop
9	not	not	RB	_	10	neg
10	higher	higher	JJR	_	0	ROOT
11	among	among	IN	_	12	case
12	users	user	NNS	_	10	nmod
13	of	of	IN	_	14	case
14	sildenafil	sildenafil	NN	_	12	nmod
15	.	.	.	_	10	punct

1	Sildenafil	Sildenafil	NNP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	contraindicated	contraindicate	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	using	use	VBG	_	5	acl
7	long	long	JJ	_	10	amod
8	-	-	:	_	10	punct
9	acting	act	VBG	_	10	amod
10	nitrates	nitrate	NNS	_	6	dobj
11	or	or	CC	_	10	cc
12	who	who	WP	_	14	nsubj
13	may	may	MD	_	14	aux
14	need	need	VB	_	10	conj
15	to	to	TO	_	16	mark
16	use	use	VB	_	14	xcomp
17	short	short	JJ	_	20	amod
18	-	-	:	_	20	punct
19	acting	act	VBG	_	20	amod
20	nitrates	nitrate	NNS	_	16	dobj
21	,	,	,	_	3	punct
22	because	because	IN	_	26	mark
23	the	the	DT	_	24	det
24	combination	combination	NN	_	26	nsubj
25	may	may	MD	_	26	aux
26	cause	cause	VB	_	3	advcl
27	a	a	DT	_	29	det
28	sharp	sharp	JJ	_	29	amod
29	fall	fall	NN	_	26	dobj
30	of	of	IN	_	33	case
31	the	the	DT	_	33	det
32	blood	blood	NN	_	33	compound
33	pressure	pressure	NN	_	29	nmod
34	.	.	.	_	3	punct

1	No	no	DT	_	2	neg
2	interactions	interaction	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	beta	beta	NN	_	5	nmod
8	-	-	:	_	7	punct
9	receptor	receptor	NN	_	10	compound
10	blockers	blocker	NNS	_	7	dep
11	,	,	,	_	7	punct
12	calcium	calcium	NN	_	13	compound
13	antagonists	antagonist	NNS	_	7	conj
14	,	,	,	_	7	punct
15	thiazide	thiazide	NN	_	7	conj
16	and	and	CC	_	7	cc
17	loop	loop	NN	_	18	compound
18	diuretics	diuretic	NNS	_	7	conj
19	and	and	CC	_	7	cc
20	ACE	ace	NN	_	21	compound
21	inhibitors	inhibitor	NNS	_	7	conj
22	.	.	.	_	5	punct

1	Before	before	IN	_	2	mark
2	prescribing	prescribe	VBG	_	19	advcl
3	a	a	DT	_	8	det
4	symptomatic	symptomatic	JJ	_	8	amod
5	(	(	NN	_	8	compound
6	pharmaceutical	pharmaceutical	JJ	_	8	amod
7	)	)	NN	_	8	compound
8	treatment	treatment	NN	_	2	dobj
9	for	for	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	with	with	IN	_	14	case
12	an	a	DT	_	14	det
13	erection	erection	NN	_	14	compound
14	disorder	disorder	NN	_	10	nmod
15	,	,	,	_	19	punct
16	attention	attention	NN	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	given	give	VBN	_	0	ROOT
20	tot	tot	NN	_	19	iobj
21	the	the	DT	_	27	det
22	sexological	sexological	JJ	_	27	amod
23	,	,	,	_	22	punct
24	psychological	psychological	JJ	_	22	conj
25	and	and	CC	_	22	cc
26	medical	medical	JJ	_	22	conj
27	backgrounds	background	NNS	_	19	dobj
28	of	of	IN	_	30	case
29	the	the	DT	_	30	det
30	disorder	disorder	NN	_	27	nmod
31	.	.	.	_	19	punct

1	Secondary	secondary	JJ	_	2	amod
2	prevention	prevention	NN	_	9	nsubj
3	of	of	IN	_	6	case
4	atherosclerotic	atherosclerotic	JJ	_	6	amod
5	risk	risk	NN	_	6	compound
6	factors	factor	NNS	_	2	nmod
7	is	be	VBZ	_	9	cop
8	also	also	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	:	:	:	_	9	punct
11	regulation	regulation	NN	_	9	dep
12	of	of	IN	_	14	case
13	blood	blood	NN	_	14	compound
14	pressure	pressure	NN	_	11	nmod
15	and	and	CC	_	14	cc
16	blood	blood	NN	_	18	compound
17	sugar	sugar	NN	_	18	compound
18	level	level	NN	_	14	conj
19	,	,	,	_	11	punct
20	hyperlipidaemia	hyperlipidaemia	NN	_	11	conj
21	and	and	CC	_	11	cc
22	obesity	obesity	NN	_	11	conj
23	,	,	,	_	11	punct
24	as	as	RB	_	11	cc
25	well	well	RB	_	24	mwe
26	as	as	IN	_	24	mwe
27	a	a	DT	_	28	det
28	change	change	NN	_	11	conj
29	of	of	IN	_	30	case
30	lifestyle	lifestyle	NN	_	28	nmod
31	(	(	CD	_	30	nummod
32	giving	give	VBG	_	28	acl
33	up	up	RP	_	32	compound:prt
34	smoking	smoking	NN	_	32	dobj
35	,	,	,	_	34	punct
36	adapting	adapting	NN	_	34	conj
37	of	of	IN	_	38	case
38	diet	diet	NN	_	36	nmod
39	and	and	CC	_	34	cc
40	more	more	JJR	_	43	amod
41	physical	physical	JJ	_	43	amod
42	exertion	exertion	NN	_	43	compound
43	)	)	NN	_	34	conj
44	.	.	.	_	9	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	with	with	IN	_	7	case
3	a	a	DT	_	7	det
4	very	very	RB	_	5	advmod
5	low	low	JJ	_	7	amod
6	cardiac	cardiac	JJ	_	7	amod
7	capacity	capacity	NN	_	1	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	advised	advise	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	refrain	refrain	VB	_	10	xcomp
13	from	from	IN	_	14	case
14	treatment	treatment	NN	_	12	nmod
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	erection	erection	NN	_	18	compound
18	disorder	disorder	NN	_	14	nmod
19	.	.	.	_	10	punct

1	Failure	failure	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	neomycin	neomycin	NN	_	1	nmod
4	to	to	TO	_	5	mark
5	modify	modify	VB	_	1	acl
6	ACTH	acth	NN	_	8	compound
7	induced	induce	VBN	_	8	amod
8	hypertension	hypertension	NN	_	5	dobj
9	in	in	IN	_	10	case
10	sheep	sheep	NN	_	8	nmod
11	.	.	.	_	1	punct

1	Studies	study	NNS	_	5	nsubj
2	in	in	IN	_	3	case
3	rats	rat	NNS	_	1	nmod
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	9	mark
7	neomycin	neomycin	NN	_	8	compound
8	administration	administration	NN	_	9	nsubj
9	attenuates	attenuate	VBZ	_	5	ccomp
10	certain	certain	JJ	_	11	amod
11	types	type	NNS	_	9	dobj
12	of	of	IN	_	16	case
13	adrenocortical	adrenocortical	JJ	_	16	amod
14	steroid	steroid	NN	_	15	nmod:npmod
15	dependent	dependent	JJ	_	16	amod
16	hypertension	hypertension	NN	_	11	nmod
17	,	,	,	_	11	punct
18	including	include	VBG	_	20	case
19	ACTH	acth	NN	_	20	compound
20	hypertension	hypertension	NN	_	11	nmod
21	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	8	nsubj
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	neomycin	neomycin	NN	_	2	nmod
6	on	on	IN	_	7	case
7	ACTH	acth	NN	_	2	nmod
8	induced	induce	VBD	_	0	ROOT
9	hypertension	hypertension	NN	_	8	dobj
10	were	be	VBD	_	11	auxpass
11	examined	examine	VBN	_	8	dep
12	in	in	IN	_	14	case
13	conscious	conscious	JJ	_	14	amod
14	sheep	sheep	NN	_	11	nmod
15	.	.	.	_	8	punct

1	Neomycin	neomycin	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	blood	blood	NN	_	8	compound
8	pressure	pressure	NN	_	2	nmod
9	or	or	CC	_	8	cc
10	metabolic	metabolic	JJ	_	11	amod
11	responses	response	NNS	_	8	conj
12	to	to	TO	_	13	case
13	ACTH	acth	NN	_	11	nmod
14	in	in	IN	_	15	case
15	sheep	sheep	NN	_	8	nmod
16	.	.	.	_	2	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	Interaction	interaction	NN	_	0	ROOT
3	between	between	IN	_	4	case
4	amprenavir	amprenavir	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	rifabutin	rifabutin	NN	_	4	conj
7	or	or	CC	_	6	cc
8	rifampin	rifampin	NN	_	6	conj
9	in	in	IN	_	11	case
10	healthy	healthy	JJ	_	11	amod
11	males	male	NNS	_	2	nmod
12	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	determine	determine	VB	_	6	xcomp
9	if	if	IN	_	11	mark
10	there	there	EX	_	11	expl
11	is	be	VBZ	_	8	advcl
12	a	a	DT	_	14	det
13	pharmacokinetic	pharmacokinetic	JJ	_	14	amod
14	interaction	interaction	NN	_	11	nsubj
15	when	when	WRB	_	18	advmod
16	amprenavir	amprenavir	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	given	give	VBN	_	11	advcl
19	with	with	IN	_	20	case
20	rifabutin	rifabutin	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	rifampin	rifampin	NN	_	20	conj
23	and	and	CC	_	18	cc
24	to	to	TO	_	25	mark
25	determine	determine	VB	_	18	conj
26	the	the	DT	_	27	det
27	effects	effect	NNS	_	25	dobj
28	of	of	IN	_	30	case
29	these	these	DT	_	30	det
30	drugs	drug	NNS	_	27	nmod
31	on	on	IN	_	35	case
32	the	the	DT	_	35	det
33	erythromycin	erythromycin	NN	_	35	compound
34	breath	breath	NN	_	35	compound
35	test	test	NN	_	27	nmod
36	(	(	CD	_	37	nummod
37	ERMBT	ERMBT	NNP	_	35	dep
38	)	)	CD	_	37	nummod
39	.	.	.	_	6	punct

1	Twenty	twenty	CD	_	8	dep
2	-	-	:	_	8	punct
3	four	four	CD	_	6	nummod
4	healthy	healthy	JJ	_	6	amod
5	male	male	JJ	_	6	amod
6	subjects	subject	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	randomized	randomize	VBN	_	0	ROOT
9	to	to	TO	_	10	case
10	one	one	CD	_	8	nmod
11	of	of	IN	_	13	case
12	two	two	CD	_	13	nummod
13	cohorts	cohort	NNS	_	10	nmod
14	.	.	.	_	8	punct

1	All	all	DT	_	2	det
2	subjects	subject	NNS	_	3	nsubj
3	received	receive	VBD	_	0	ROOT
4	amprenavir	amprenavir	JJ	_	5	amod
5	(	(	NN	_	3	dobj
6	1,200	1,200	CD	_	7	nummod
7	mg	mg	NN	_	5	dep
8	twice	twice	RB	_	10	advmod
9	a	a	DT	_	10	det
10	day	day	NN	_	3	nmod:tmod
11	)	)	CD	_	10	nummod
12	for	for	IN	_	14	case
13	4	4	CD	_	14	nummod
14	days	day	NNS	_	3	nmod
15	,	,	,	_	3	punct
16	followed	follow	VBN	_	3	dep
17	by	by	IN	_	23	case
18	a	a	DT	_	23	det
19	7	7	CD	_	23	nummod
20	-	-	:	_	23	punct
21	day	day	NN	_	23	compound
22	washout	washout	NN	_	23	compound
23	period	period	NN	_	16	nmod
24	,	,	,	_	16	punct
25	followed	follow	VBN	_	16	dep
26	by	by	IN	_	29	case
27	either	either	CC	_	29	cc:preconj
28	rifabutin	rifabutin	NN	_	29	compound
29	(	(	NN	_	25	nmod
30	300	300	CD	_	31	nummod
31	mg	mg	NN	_	29	dep
32	once	once	RB	_	34	advmod
33	a	a	DT	_	34	det
34	day	day	NN	_	31	nmod:tmod
35	[	[	CD	_	36	nummod
36	QD	qd	NN	_	34	dep
37	]	]	CD	_	38	compound
38	)	)	CD	_	40	nummod
39	(	(	NN	_	40	compound
40	cohort	cohort	NN	_	36	dep
41	1	1	CD	_	42	compound
42	)	)	CD	_	40	nummod
43	or	or	CC	_	40	cc
44	rifampin	rifampin	NN	_	40	conj
45	(	(	NN	_	44	dep
46	600	600	CD	_	47	compound
47	mg	mg	NN	_	45	dep
48	QD	qd	NN	_	47	amod
49	)	)	CD	_	50	compound
50	(	(	CD	_	51	nummod
51	cohort	cohort	NN	_	48	dep
52	2	2	CD	_	53	nummod
53	)	)	NN	_	51	dep
54	for	for	IN	_	56	case
55	14	14	CD	_	56	nummod
56	days	day	NNS	_	51	nmod
57	.	.	.	_	3	punct

1	Cohort	cohort	NN	_	4	nsubj
2	1	1	CD	_	1	nummod
3	then	then	RB	_	4	advmod
4	received	receive	VBD	_	0	ROOT
5	amprenavir	amprenavir	NN	_	4	dobj
6	plus	plus	CC	_	5	cc
7	rifabutin	rifabutin	NN	_	5	conj
8	for	for	IN	_	10	case
9	10	10	CD	_	10	nummod
10	days	day	NNS	_	4	nmod
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	cohort	cohort	NN	_	15	nsubj
14	2	2	CD	_	13	nummod
15	received	receive	VBD	_	4	conj
16	amprenavir	amprenavir	NN	_	15	dobj
17	plus	plus	CC	_	16	cc
18	rifampin	rifampin	NN	_	16	conj
19	for	for	IN	_	21	case
20	4	4	CD	_	21	nummod
21	days	day	NNS	_	15	nmod
22	.	.	.	_	4	punct

1	Serial	serial	JJ	_	2	amod
2	plasma	plasma	NN	_	25	nsubjpass
3	and	and	CC	_	2	cc
4	urine	urine	NN	_	2	conj
5	samples	sample	NNS	_	2	dep
6	for	for	IN	_	7	case
7	measurement	measurement	NN	_	2	nmod
8	of	of	IN	_	9	case
9	amprenavir	amprenavir	NN	_	7	nmod
10	,	,	,	_	9	punct
11	rifabutin	rifabutin	NN	_	9	conj
12	,	,	,	_	9	punct
13	and	and	CC	_	9	cc
14	rifampin	rifampin	NN	_	9	conj
15	and	and	CC	_	2	cc
16	their	they	PRP$	_	22	nmod:poss
17	25	25	CD	_	22	nummod
18	-	-	:	_	22	punct
19	O	o	SYM	_	22	dep
20	-	-	:	_	22	punct
21	desacetyl	desacetyl	NN	_	22	compound
22	metabolites	metabolite	NNS	_	2	conj
23	,	,	,	_	2	punct
24	were	be	VBD	_	25	auxpass
25	measured	measure	VBN	_	0	ROOT
26	by	by	IN	_	31	case
27	high	high	JJ	_	31	amod
28	-	-	:	_	31	punct
29	performance	performance	NN	_	31	compound
30	liquid	liquid	JJ	_	31	amod
31	chromatography	chromatography	NN	_	25	nmod
32	.	.	.	_	25	punct

1	Rifabutin	rifabutin	NN	_	5	nsubj
2	did	do	VBD	_	5	aux
3	not	not	RB	_	5	neg
4	significantly	significantly	RB	_	5	advmod
5	affect	affect	VB	_	0	ROOT
6	amprenavir	amprenavir	NN	_	9	compound
7	'	'	''	_	9	punct
8	s	s	NNS	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	5	dobj
10	.	.	.	_	5	punct

1	Amprenavir	Amprenavir	NNP	_	3	nsubj
2	significantly	significantly	RB	_	3	advmod
3	increased	increase	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	area	area	NN	_	3	dobj
6	under	under	IN	_	8	case
7	the	the	DT	_	8	det
8	curve	curve	NN	_	3	nmod
9	at	at	IN	_	13	case
10	steady	steady	JJ	_	13	amod
11	state	state	NN	_	13	compound
12	(	(	CD	_	13	nummod
13	AUC	auc	NN	_	8	nmod
14	(	(	CD	_	15	nummod
15	ss	ss	NN	_	13	dep
16	)	)	CD	_	17	nummod
17	)	)	NN	_	15	dep
18	of	of	IN	_	19	case
19	rifabutin	rifabutin	NN	_	17	nmod
20	by	by	IN	_	21	case
21	2.93	2.93	CD	_	3	nmod
22	-	-	:	_	21	punct
23	fold	fold	JJ	_	21	dep
24	and	and	CC	_	23	cc
25	the	the	DT	_	29	det
26	AUC	auc	NN	_	29	compound
27	(	(	CD	_	29	nummod
28	ss	ss	NN	_	29	compound
29	)	)	NN	_	23	conj
30	of	of	IN	_	31	case
31	25	25	CD	_	29	nmod
32	-	-	:	_	21	punct
33	O	o	SYM	_	21	dep
34	-	-	:	_	21	punct
35	desacetylrifabutin	desacetylrifabutin	NN	_	21	dep
36	by	by	IN	_	37	case
37	13.3	13.3	CD	_	35	nmod
38	-	-	:	_	37	punct
39	fold	fold	NN	_	37	dep
40	.	.	.	_	3	punct

1	Rifampin	Rifampin	NNP	_	3	nsubj
2	significantly	significantly	RB	_	3	advmod
3	decreased	decrease	VBD	_	0	ROOT
4	the	the	DT	_	8	det
5	AUC	auc	NN	_	8	compound
6	(	(	CD	_	8	nummod
7	ss	ss	NN	_	8	compound
8	)	)	NN	_	3	dobj
9	of	of	IN	_	10	case
10	amprenavir	amprenavir	NN	_	8	nmod
11	by	by	IN	_	13	case
12	82	82	CD	_	13	nummod
13	%	%	NN	_	3	nmod
14	,	,	,	_	3	punct
15	but	but	CC	_	3	cc
16	amprenavir	amprenavir	NN	_	17	nsubj
17	had	have	VBD	_	3	conj
18	no	no	DT	_	19	neg
19	effect	effect	NN	_	17	dobj
20	on	on	IN	_	22	case
21	rifampin	rifampin	NN	_	22	compound
22	pharmacokinetics	pharmacokinetic	NNS	_	17	nmod
23	.	.	.	_	3	punct

1	Amprenavir	Amprenavir	NNP	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	results	result	NNS	_	2	dobj
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	ERMBT	ermbt	NN	_	4	nmod
8	by	by	IN	_	10	case
9	83	83	CD	_	10	nummod
10	%	%	NN	_	2	nmod
11	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	15	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	ERMBT	ERMBT	NNP	_	2	nmod
6	after	after	IN	_	8	case
7	2	2	CD	_	8	nummod
8	weeks	week	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	rifabutin	rifabutin	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	rifampin	rifampin	NN	_	13	compound
13	therapy	therapy	NN	_	10	conj
14	were	be	VBD	_	15	auxpass
15	increased	increase	VBN	_	0	ROOT
16	187	187	CD	_	19	nummod
17	and	and	CC	_	16	cc
18	156	156	CD	_	16	conj
19	%	%	NN	_	15	dobj
20	,	,	,	_	15	punct
21	respectively	respectively	RB	_	15	advmod
22	.	.	.	_	15	punct

1	Amprenavir	Amprenavir	NNP	_	6	nsubjpass
2	plus	plus	CC	_	1	cc
3	rifampin	rifampin	NN	_	1	conj
4	was	be	VBD	_	6	auxpass
5	well	well	RB	_	6	advmod
6	tolerated	tolerate	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Amprenavir	Amprenavir	NNP	_	6	nsubjpass
2	plus	plus	CC	_	1	cc
3	rifabutin	rifabutin	NN	_	1	conj
4	was	be	VBD	_	6	auxpass
5	poorly	poorly	RB	_	6	advmod
6	tolerated	tolerate	VBN	_	0	ROOT
7	,	,	,	_	6	punct
8	and	and	CC	_	6	cc
9	5	5	CD	_	6	conj
10	of	of	IN	_	12	case
11	11	11	CD	_	12	nummod
12	subjects	subject	NNS	_	9	nmod
13	discontinued	discontinued	JJ	_	14	amod
14	therapy	therapy	NN	_	12	dep
15	.	.	.	_	6	punct

1	Rifampin	Rifampin	NNP	_	3	nsubj
2	markedly	markedly	RB	_	3	advmod
3	increases	increase	VBZ	_	0	ROOT
4	the	the	DT	_	6	det
5	metabolic	metabolic	JJ	_	6	amod
6	clearance	clearance	NN	_	3	dobj
7	of	of	IN	_	8	case
8	amprenavir	amprenavir	NN	_	6	nmod
9	,	,	,	_	3	punct
10	and	and	CC	_	3	cc
11	coadministration	coadministration	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	contraindicated	contraindicate	VBN	_	3	conj
14	.	.	.	_	3	punct

1	Amprenavir	Amprenavir	NNP	_	3	nsubj
2	significantly	significantly	RB	_	3	advmod
3	decreases	decrease	VBZ	_	0	ROOT
4	clearance	clearance	NN	_	3	dobj
5	of	of	IN	_	6	case
6	rifabutin	rifabutin	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	25	25	CD	_	6	conj
9	-	-	:	_	4	punct
10	O	o	SYM	_	12	dep
11	-	-	:	_	12	punct
12	desacetylrifabutin	desacetylrifabutin	NN	_	4	dep
13	,	,	,	_	12	punct
14	and	and	CC	_	12	cc
15	the	the	DT	_	16	det
16	combination	combination	NN	_	19	nsubjpass
17	is	be	VBZ	_	19	auxpass
18	poorly	poorly	RB	_	19	advmod
19	tolerated	tolerate	VBN	_	12	conj
20	.	.	.	_	3	punct

1	Amprenavir	amprenavir	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	ERMBT	ERMBT	NNP	_	2	dobj
5	,	,	,	_	2	punct
6	and	and	CC	_	2	cc
7	rifampin	rifampin	NN	_	12	nsubj
8	and	and	CC	_	7	cc
9	rifabutin	rifabutin	NN	_	7	conj
10	are	be	VBP	_	12	cop
11	equipotent	equipotent	JJ	_	12	amod
12	inducers	inducer	NNS	_	2	conj
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	ERMBT	ERMBT	NNP	_	12	nmod
16	.	.	.	_	2	punct

1	[	[	NN	_	3	compound
2	The	the	DT	_	3	det
3	effect	effect	NN	_	20	nsubj
4	of	of	IN	_	5	case
5	sandimmune	sandimmune	NN	_	3	nmod
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	activity	activity	NN	_	3	nmod
9	of	of	IN	_	12	case
10	mixed	mixed	JJ	_	12	amod
11	-	-	:	_	12	punct
12	function	function	NN	_	8	nmod
13	mono	mono	SYM	_	15	dep
14	-	-	:	_	15	punct
15	oxidases	oxidase	NNS	_	12	nmod
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	liver	liver	NN	_	19	compound
19	microsomes	microsome	NNS	_	15	nmod
20	]	]	VBP	_	0	ROOT
21	The	the	DT	_	22	det
22	effects	effect	NNS	_	37	nsubjpass
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	immunodepressant	immunodepressant	NN	_	22	nmod
26	--	--	:	_	25	punct
27	the	the	DT	_	29	det
28	drug	drug	NN	_	29	compound
29	sandimmune	sandimmune	NN	_	25	dep
30	--	--	:	_	25	punct
31	on	on	IN	_	35	case
32	hepatic	hepatic	JJ	_	35	amod
33	microsomal	microsomal	JJ	_	35	amod
34	monooxygenase	monooxygenase	NN	_	35	compound
35	activities	activity	NNS	_	22	nmod
36	were	be	VBD	_	37	auxpass
37	studied	study	VBN	_	20	ccomp
38	.	.	.	_	20	punct

1	The	the	DT	_	2	det
2	agent	agent	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	found	find	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	produce	produce	VB	_	4	xcomp
7	some	some	DT	_	9	det
8	inhibiting	inhibiting	NN	_	9	compound
9	activity	activity	NN	_	6	dobj
10	against	against	IN	_	16	case
11	hepatic	hepatic	JJ	_	16	amod
12	microsomal	microsomal	JJ	_	16	amod
13	7	7	CD	_	16	nummod
14	-	-	:	_	16	punct
15	ethoxycoumarine	ethoxycoumarine	NN	_	16	compound
16	deethylase	deethylase	NN	_	9	nmod
17	in	in	IN	_	20	case
18	male	male	JJ	_	20	amod
19	Wistar	Wistar	NNP	_	20	compound
20	rats	rat	NNS	_	9	nmod
21	in	in	FW	_	22	compound
22	vitro	vitro	FW	_	23	advmod
23	and	and	CC	_	6	advmod
24	in	in	FW	_	26	amod
25	vivo	vivo	FW	_	24	dep
26	experiments	experiment	NNS	_	23	advmod
27	.	.	.	_	4	punct

1	When	when	WRB	_	2	advmod
2	given	give	VBN	_	0	ROOT
3	in	in	IN	_	5	case
4	a	a	DT	_	5	det
5	dose	dose	NN	_	2	nmod
6	of	of	IN	_	8	case
7	50	50	CD	_	8	nummod
8	mg	mg	NN	_	5	nmod
9	/	/	:	_	8	punct
10	kg	kg	NN	_	8	dep
11	,	,	,	_	8	punct
12	sandimmune	sandimmune	NN	_	13	nsubj
13	produced	produce	VBD	_	8	acl:relcl
14	no	no	DT	_	17	neg
15	statistically	statistically	RB	_	16	advmod
16	significant	significant	JJ	_	17	amod
17	effect	effect	NN	_	13	dobj
18	on	on	IN	_	20	case
19	the	the	DT	_	20	det
20	duration	duration	NN	_	13	nmod
21	of	of	IN	_	25	case
22	hexanal	hexanal	JJ	_	25	amod
23	-	-	:	_	25	punct
24	induced	induce	VBN	_	25	amod
25	sleep	sleep	NN	_	20	nmod
26	in	in	IN	_	27	case
27	mice	mouse	NNS	_	25	nmod
28	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	the	the	DT	_	6	det
6	agent	agent	NN	_	7	nsubj
7	has	have	VBZ	_	3	ccomp
8	slight	slight	JJ	_	9	amod
9	effects	effect	NNS	_	7	dobj
10	on	on	IN	_	13	case
11	the	the	DT	_	13	det
12	tested	test	VBN	_	13	amod
13	activities	activity	NNS	_	7	nmod
14	.	.	.	_	3	punct

1	Repeated	repeat	VBN	_	3	amod
2	oral	oral	JJ	_	3	amod
3	administration	administration	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	coumaphos	coumapho	NNS	_	3	nmod
6	in	in	IN	_	7	case
7	sheep	sheep	NN	_	3	nmod
8	:	:	:	_	3	punct
9	interactions	interaction	NNS	_	3	dep
10	of	of	IN	_	11	case
11	coumaphos	coumapho	NNS	_	9	nmod
12	with	with	IN	_	13	case
13	bishydroxycoumarin	bishydroxycoumarin	NN	_	9	nmod
14	,	,	,	_	13	punct
15	trichlorfon	trichlorfon	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	phenobarbital	phenobarbital	JJ	_	19	amod
19	sodium	sodium	NN	_	13	conj
20	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	31	nsubjpass
2	between	between	IN	_	3	case
3	treatments	treatment	NNS	_	1	nmod
4	with	with	IN	_	5	case
5	coumaphos	coumapho	NNS	_	3	nmod
6	,	,	,	_	1	punct
7	bishydroxycoumarin	bishydroxycoumarin	NN	_	1	conj
8	(	(	CD	_	7	nummod
9	an	a	DT	_	11	det
10	anticoagulant	anticoagulant	JJ	_	11	amod
11	)	)	NN	_	7	dep
12	,	,	,	_	1	punct
13	trichlorfon	trichlorfon	NN	_	1	conj
14	(	(	CD	_	13	nummod
15	an	a	DT	_	18	det
16	organophosphorous	organophosphorous	JJ	_	18	amod
17	compound	compound	NN	_	18	compound
18	)	)	NN	_	13	nmod:npmod
19	,	,	,	_	1	punct
20	and	and	CC	_	1	cc
21	phenobarbital	phenobarbital	JJ	_	22	amod
22	sodium	sodium	NN	_	1	conj
23	(	(	CD	_	22	nummod
24	an	a	DT	_	25	det
25	inducer	inducer	NN	_	22	dep
26	of	of	IN	_	28	case
27	microsomal	microsomal	JJ	_	28	amod
28	enzymes	enzyme	NNS	_	25	nmod
29	)	)	CD	_	28	nummod
30	were	be	VBD	_	31	auxpass
31	investigated	investigate	VBN	_	0	ROOT
32	in	in	IN	_	33	case
33	sheep	sheep	NN	_	31	nmod
34	.	.	.	_	31	punct

1	A	a	DT	_	3	det
2	daily	daily	JJ	_	3	amod
3	dose	dose	NN	_	19	nsubj
4	of	of	IN	_	6	case
5	2	2	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	of	of	IN	_	8	case
8	coumaphos	coumapho	NNS	_	6	nmod
9	/	/	:	_	3	punct
10	kg	kg	NN	_	3	dep
11	of	of	IN	_	13	case
12	body	body	NN	_	13	compound
13	weight	weight	NN	_	10	nmod
14	for	for	IN	_	16	case
15	6	6	CD	_	16	nummod
16	days	day	NNS	_	10	nmod
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	affect	affect	VB	_	0	ROOT
20	the	the	DT	_	22	det
21	plasma	plasma	NN	_	22	compound
22	enzymes	enzyme	NNS	_	19	dobj
23	or	or	CC	_	22	cc
24	the	the	DT	_	26	det
25	antiprothrombinemic	antiprothrombinemic	JJ	_	26	amod
26	effect	effect	NN	_	22	conj
27	of	of	IN	_	28	case
28	bishydroxy	bishydroxy	NN	_	26	nmod
29	-	-	:	_	28	punct
30	coumarin	coumarin	NN	_	28	dep
31	in	in	IN	_	32	case
32	wethers	wether	NNS	_	30	nmod
33	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	treatment	treatment	NN	_	28	nsubj
3	of	of	IN	_	4	case
4	ewes	ewe	NNS	_	2	nmod
5	with	with	IN	_	11	case
6	an	a	DT	_	11	det
7	intravenous	intravenous	JJ	_	11	amod
8	(	(	NN	_	11	compound
9	IV	iv	CD	_	11	nummod
10	)	)	NN	_	11	compound
11	injection	injection	NN	_	2	nmod
12	of	of	IN	_	13	case
13	trichlorfon	trichlorfon	NN	_	11	nmod
14	,	,	,	_	2	punct
15	insufficient	insufficient	JJ	_	2	amod
16	to	to	TO	_	17	mark
17	produce	produce	VB	_	15	xcomp
18	significant	significant	JJ	_	19	amod
19	inhibition	inhibition	NN	_	17	dobj
20	of	of	IN	_	26	case
21	erythrocyte	erythrocyte	NN	_	26	compound
22	acetylcholinesterase	acetylcholinesterase	NN	_	26	compound
23	(	(	CD	_	26	nummod
24	AChE	ache	NN	_	26	compound
25	)	)	NN	_	26	compound
26	activity	activity	NN	_	19	nmod
27	,	,	,	_	2	punct
28	appeared	appear	VBD	_	0	ROOT
29	to	to	TO	_	30	mark
30	produce	produce	VB	_	28	xcomp
31	additive	additive	JJ	_	32	amod
32	effects	effect	NNS	_	30	dobj
33	with	with	IN	_	34	case
34	those	those	DT	_	32	nmod
35	produced	produce	VBN	_	34	acl
36	by	by	IN	_	38	case
37	subsequent	subsequent	JJ	_	38	amod
38	treatment	treatment	NN	_	35	nmod
39	with	with	IN	_	41	case
40	4	4	CD	_	41	nummod
41	mg	mg	NN	_	38	nmod
42	of	of	IN	_	43	case
43	coumaphos	coumapho	NNS	_	41	nmod
44	/	/	:	_	41	punct
45	kg	kg	NN	_	41	dep
46	/	/	:	_	41	punct
47	day	day	NN	_	41	dep
48	.	.	.	_	28	punct

1	In	in	IN	_	2	case
2	ewes	ewe	NNS	_	0	ROOT
3	given	give	VBN	_	5	case
4	40	40	CD	_	5	nummod
5	mg	mg	NN	_	2	nmod
6	of	of	IN	_	8	case
7	phenobarbital	phenobarbital	JJ	_	8	amod
8	sodium	sodium	NN	_	5	nmod
9	/	/	:	_	10	punct
10	kg	kg	NN	_	2	dep
11	for	for	IN	_	13	case
12	5	5	CD	_	13	nummod
13	days	day	NNS	_	10	nmod
14	intraperitoneally	intraperitoneally	RB	_	13	advmod
15	(	(	CD	_	16	nummod
16	IP	IP	NNP	_	14	dep
17	)	)	CD	_	16	nummod
18	,	,	,	_	16	punct
19	the	the	DT	_	21	det
20	anticholinesterase	anticholinesterase	JJ	_	21	amod
21	effect	effect	NN	_	16	appos
22	of	of	IN	_	24	case
23	4	4	CD	_	24	nummod
24	mg	mg	NN	_	21	nmod
25	of	of	IN	_	26	case
26	coumaphos	coumapho	NNS	_	24	nmod
27	/	/	:	_	16	punct
28	kg	kg	NN	_	31	nsubjpass
29	was	be	VBD	_	31	auxpass
30	significantly	significantly	RB	_	31	advmod
31	reduced	reduce	VBN	_	16	dep
32	and	and	CC	_	31	cc
33	signs	sign	NNS	_	38	nsubj
34	of	of	IN	_	35	case
35	toxicity	toxicity	NN	_	33	nmod
36	were	be	VBD	_	38	cop
37	not	not	RB	_	38	neg
38	present	present	JJ	_	31	conj
39	.	.	.	_	2	punct

1	Treatment	treatment	NN	_	11	nsubj
2	with	with	IN	_	4	case
3	daily	daily	JJ	_	4	amod
4	doses	dose	NNS	_	1	nmod
5	of	of	IN	_	7	case
6	2	2	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	of	of	IN	_	9	case
9	coumaphos	coumapho	NNS	_	7	nmod
10	/	/	:	_	11	punct
11	kg	kg	NN	_	0	ROOT
12	for	for	IN	_	14	case
13	6	6	CD	_	14	nummod
14	days	day	NNS	_	11	nmod
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	modify	modify	VB	_	11	dep
18	the	the	DT	_	20	det
19	anticholinesterase	anticholinesterase	NN	_	20	compound
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	24	case
22	a	a	DT	_	24	det
23	2nd	2nd	JJ	_	24	amod
24	series	series	NN	_	20	nmod
25	of	of	IN	_	26	case
26	treatments	treatment	NNS	_	24	nmod
27	given	give	VBN	_	24	acl
28	6	6	CD	_	29	nummod
29	weeks	week	NNS	_	30	nmod:npmod
30	later	later	RB	_	27	advmod
31	.	.	.	_	11	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	profile	profile	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	etodolac	etodolac	NN	_	2	nmod
5	in	in	IN	_	7	case
6	special	special	JJ	_	7	amod
7	populations	population	NNS	_	2	nmod
8	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	12	nsubjpass
3	of	of	IN	_	4	case
4	etodolac	etodolac	NN	_	2	nmod
5	in	in	IN	_	8	case
6	healthy	healthy	JJ	_	8	amod
7	normal	normal	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	2	nmod
9	has	have	VBZ	_	12	aux
10	been	be	VBN	_	12	auxpass
11	extensively	extensively	RB	_	12	advmod
12	studied	study	VBN	_	0	ROOT
13	and	and	CC	_	12	cc
14	is	be	VBZ	_	16	auxpass
15	well	well	RB	_	16	advmod
16	described	describe	VBN	_	12	conj
17	.	.	.	_	12	punct

1	Etodolac	Etodolac	NNP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	characterised	characterise	VBN	_	0	ROOT
4	by	by	IN	_	8	case
5	a	a	DT	_	8	det
6	high	high	JJ	_	8	amod
7	oral	oral	JJ	_	8	amod
8	bioavailability	bioavailability	NN	_	3	nmod
9	,	,	,	_	8	punct
10	low	low	JJ	_	11	amod
11	clearance	clearance	NN	_	8	conj
12	,	,	,	_	8	punct
13	a	a	DT	_	15	det
14	small	small	JJ	_	15	amod
15	volume	volume	NN	_	8	conj
16	of	of	IN	_	17	case
17	distribution	distribution	NN	_	15	nmod
18	,	,	,	_	8	punct
19	and	and	CC	_	8	cc
20	a	a	DT	_	24	det
21	7	7	CD	_	24	nummod
22	-	-	:	_	24	punct
23	hour	hour	NN	_	24	compound
24	half	half	NN	_	8	conj
25	-	-	:	_	24	punct
26	life	life	NN	_	24	dep
27	.	.	.	_	3	punct

1	It	it	PRP	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	essentially	essentially	RB	_	5	advmod
4	completely	completely	RB	_	5	advmod
5	metabolised	metabolise	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	therefore	therefore	RB	_	8	advmod
8	little	little	JJ	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	excreted	excrete	VBN	_	5	ccomp
11	unchanged	unchanged	JJ	_	10	xcomp
12	.	.	.	_	5	punct

1	Etodolac	Etodolac	NNP	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	highly	highly	RB	_	4	advmod
4	protein	protein	NN	_	0	ROOT
5	bound	bind	VBD	_	4	acl
6	.	.	.	_	4	punct

1	To	to	TO	_	2	mark
2	investigate	investigate	VB	_	0	ROOT
3	the	the	DT	_	4	det
4	effect	effect	NN	_	2	dobj
5	of	of	IN	_	7	case
6	disease	disease	NN	_	7	compound
7	states	state	NNS	_	4	nmod
8	or	or	CC	_	7	cc
9	concomitant	concomitant	JJ	_	11	amod
10	drug	drug	NN	_	11	compound
11	administration	administration	NN	_	7	conj
12	on	on	IN	_	17	case
13	a	a	DT	_	14	det
14	patient	patient	NN	_	17	nmod:poss
15	'	'	POS	_	14	case
16	s	s	NNS	_	17	compound
17	response	response	NN	_	4	nmod
18	to	to	TO	_	19	case
19	etodolac	etodolac	NN	_	17	nmod
20	,	,	,	_	2	punct
21	additional	additional	JJ	_	23	amod
22	pharmacokinetic	pharmacokinetic	JJ	_	23	amod
23	studies	study	NNS	_	25	nsubjpass
24	were	be	VBD	_	25	auxpass
25	carried	carry	VBN	_	2	parataxis
26	out	out	RP	_	25	compound:prt
27	in	in	IN	_	29	case
28	special	special	JJ	_	29	amod
29	populations	population	NNS	_	25	nmod
30	.	.	.	_	2	punct

1	Since	since	IN	_	3	mark
2	etodolac	etodolac	NN	_	3	nsubj
3	has	have	VBZ	_	19	advcl
4	a	a	DT	_	11	det
5	well	well	RB	_	7	advmod
6	-	-	:	_	7	punct
7	defined	define	VBN	_	11	amod
8	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
9	-	-	:	_	11	punct
10	pharmacodynamic	pharmacodynamic	JJ	_	11	amod
11	relationship	relationship	NN	_	3	dobj
12	,	,	,	_	19	punct
13	measurement	measurement	NN	_	19	nsubj
14	of	of	IN	_	16	case
15	pharmacokinetic	pharmacokinetic	JJ	_	16	amod
16	parameters	parameter	NNS	_	13	nmod
17	is	be	VBZ	_	19	cop
18	clinically	clinically	RB	_	19	advmod
19	relevant	relevant	JJ	_	0	ROOT
20	.	.	.	_	19	punct

1	Data	datum	NNS	_	6	nsubj
2	from	from	IN	_	3	case
3	studies	study	NNS	_	1	nmod
4	to	to	TO	_	5	case
5	date	date	NN	_	3	nmod
6	show	show	VBP	_	0	ROOT
7	that	that	IN	_	22	mark
8	disease	disease	NN	_	9	compound
9	states	state	NNS	_	22	nsubj
10	,	,	,	_	9	punct
11	underlying	underlie	VBG	_	12	amod
12	conditions	condition	NNS	_	9	conj
13	,	,	,	_	9	punct
14	and	and	CC	_	9	cc
15	concomitantly	concomitantly	RB	_	16	advmod
16	administered	administer	VBN	_	18	amod
17	highly	highly	RB	_	18	advmod
18	protein	protein	NN	_	9	conj
19	-	-	:	_	18	punct
20	bound	bind	VBN	_	21	amod
21	drugs	drug	NNS	_	18	dep
22	have	have	VBP	_	6	ccomp
23	essentially	essentially	RB	_	25	advmod
24	no	no	DT	_	25	neg
25	effect	effect	NN	_	22	dobj
26	on	on	IN	_	28	case
27	etodolac	etodolac	NN	_	28	compound
28	pharmacokinetics	pharmacokinetic	NNS	_	25	nmod
29	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	etodolac	etodolac	NN	_	7	nsubjpass
4	can	can	MD	_	7	aux
5	generally	generally	RB	_	7	advmod
6	be	be	VB	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	without	without	IN	_	10	case
9	the	the	DT	_	10	det
10	need	need	NN	_	7	nmod
11	for	for	IN	_	13	case
12	dosage	dosage	NN	_	13	compound
13	modifications	modification	NNS	_	10	nmod
14	in	in	IN	_	16	case
15	special	special	JJ	_	16	amod
16	populations	population	NNS	_	13	nmod
17	such	such	JJ	_	21	case
18	as	as	IN	_	17	mwe
19	uncompromised	uncompromised	JJ	_	21	amod
20	elderly	elderly	JJ	_	21	amod
21	patients	patient	NNS	_	16	nmod
22	,	,	,	_	7	punct
23	those	those	DT	_	7	conj
24	with	with	IN	_	27	case
25	moderate	moderate	JJ	_	27	amod
26	renal	renal	JJ	_	27	amod
27	impairment	impairment	NN	_	23	nmod
28	,	,	,	_	7	punct
29	and	and	CC	_	7	cc
30	patients	patient	NNS	_	7	conj
31	with	with	IN	_	34	case
32	stable	stable	JJ	_	34	amod
33	hepatic	hepatic	JJ	_	34	amod
34	disease	disease	NN	_	30	nmod
35	.	.	.	_	7	punct

1	Enhanced	enhance	VBN	_	3	amod
2	theophylline	theophylline	JJ	_	3	amod
3	clearance	clearance	NN	_	0	ROOT
4	secondary	secondary	JJ	_	3	amod
5	to	to	TO	_	7	case
6	phenytoin	phenytoin	NN	_	7	compound
7	therapy	therapy	NN	_	4	nmod
8	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	report	report	NN	_	3	nsubj
3	describes	describe	VBZ	_	0	ROOT
4	two	two	CD	_	5	nummod
5	cases	case	NNS	_	3	dobj
6	in	in	IN	_	7	case
7	which	which	WDT	_	10	nmod
8	theophylline	theophylline	NN	_	9	compound
9	clearance	clearance	NN	_	10	nsubj
10	accelerated	accelerate	VBD	_	5	acl:relcl
11	markedly	markedly	RB	_	10	advmod
12	with	with	IN	_	15	case
13	concomitant	concomitant	JJ	_	15	amod
14	phenytoin	phenytoin	NN	_	15	compound
15	administration	administration	NN	_	10	nmod
16	.	.	.	_	3	punct

1	Maximum	Maximum	NNP	_	2	nsubj
2	calculated	calculate	VBD	_	0	ROOT
3	theophylline	theophylline	NN	_	4	compound
4	clearance	clearance	NN	_	5	nsubj
5	ranged	range	VBD	_	2	ccomp
6	from	from	IN	_	8	case
7	2	2	CD	_	8	nummod
8	1	1	CD	_	5	nmod
9	/	/	:	_	8	punct
10	2	2	CD	_	12	compound
11	to	to	TO	_	12	dep
12	3	3	CD	_	13	nummod
13	1	1	CD	_	8	dep
14	/	/	:	_	13	punct
15	2	2	CD	_	16	compound
16	times	time	NNS	_	17	nummod
17	baseline	baseline	NN	_	13	dep
18	.	.	.	_	2	punct

1	Onset	onset	NN	_	5	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	interaction	interaction	NN	_	1	nmod
5	began	begin	VBD	_	0	ROOT
6	within	within	IN	_	8	case
7	five	five	CD	_	8	nummod
8	days	day	NNS	_	5	nmod
9	of	of	IN	_	10	mark
10	beginning	begin	VBG	_	8	acl
11	concurrent	concurrent	JJ	_	12	amod
12	therapy	therapy	NN	_	10	dobj
13	.	.	.	_	5	punct

1	With	with	IN	_	3	case
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	8	nmod
4	,	,	,	_	8	punct
5	clinicians	clinician	NNS	_	8	nsubj
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	cop
8	aware	aware	JJ	_	0	ROOT
9	,	,	,	_	8	punct
10	when	when	WRB	_	13	advmod
11	phenytoin	phenytoin	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	added	add	VBN	_	8	advcl
14	,	,	,	_	13	punct
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	potential	potential	NN	_	13	nmod
18	for	for	IN	_	19	case
19	reexacerbation	reexacerbation	NN	_	17	nmod
20	of	of	IN	_	22	case
21	pulmonary	pulmonary	JJ	_	22	amod
22	symptomatology	symptomatology	NN	_	19	nmod
23	due	due	JJ	_	28	case
24	to	to	TO	_	23	mwe
25	lowered	lowered	JJ	_	28	amod
26	serum	serum	NN	_	28	compound
27	theophylline	theophylline	NN	_	28	compound
28	concentrations	concentration	NNS	_	17	nmod
29	.	.	.	_	8	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	activity	activity	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	KRM	KRM	NNP	_	3	nmod
6	-	-	:	_	5	punct
7	1648	1648	CD	_	5	nummod
8	,	,	,	_	5	punct
9	either	either	CC	_	5	dep
10	singly	singly	RB	_	9	dep
11	or	or	CC	_	9	cc
12	in	in	IN	_	13	case
13	combination	combination	NN	_	9	conj
14	with	with	IN	_	15	case
15	ofloxacin	ofloxacin	NN	_	13	nmod
16	,	,	,	_	5	punct
17	against	against	IN	_	19	case
18	Mycobacterium	mycobacterium	NN	_	19	compound
19	ulcerans	ulceran	NNS	_	5	nmod
20	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	antimicrobial	antimicrobial	JJ	_	3	amod
3	effect	effect	NN	_	21	nsubjpass
4	of	of	IN	_	6	case
5	a	a	DT	_	6	det
6	benzoxazinorifamycin	benzoxazinorifamycin	NN	_	3	nmod
7	,	,	,	_	6	punct
8	KRM	krm	NN	_	10	dep
9	-	-	:	_	10	punct
10	1648	1648	CD	_	6	appos
11	,	,	,	_	6	punct
12	either	either	CC	_	6	dep
13	alone	alone	RB	_	12	dep
14	or	or	CC	_	12	cc
15	in	in	IN	_	16	case
16	combination	combination	NN	_	12	conj
17	with	with	IN	_	18	case
18	ofloxacin	ofloxacin	NN	_	16	nmod
19	,	,	,	_	3	punct
20	was	be	VBD	_	21	auxpass
21	evaluated	evaluate	VBN	_	0	ROOT
22	in	in	FW	_	23	compound
23	vitro	vitro	FW	_	21	advmod
24	against	against	IN	_	27	case
25	two	two	CD	_	27	nummod
26	type	type	NN	_	27	compound
27	strains	strain	NNS	_	21	nmod
28	and	and	CC	_	27	cc
29	six	six	CD	_	31	nummod
30	clinical	clinical	JJ	_	31	amod
31	isolates	isolate	NNS	_	27	conj
32	of	of	IN	_	34	case
33	Mycobacterium	mycobacterium	NN	_	34	compound
34	ulcerans	ulceran	NNS	_	31	nmod
35	.	.	.	_	21	punct

1	Growth	growth	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	M	m	NN	_	1	nmod
4	.	.	.	_	1	punct

1	ulcerans	ulceran	NNS	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	measured	measure	VBN	_	0	ROOT
4	by	by	IN	_	6	case
5	plate	plate	NN	_	6	compound
6	counts	count	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	the	the	DT	_	11	det
9	BACTEC	bactec	NN	_	11	compound
10	radiometric	radiometric	JJ	_	11	amod
11	method	method	NN	_	6	conj
12	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	minimal	minimal	JJ	_	4	amod
3	inhibitory	inhibitory	JJ	_	4	amod
4	concentration	concentration	NN	_	0	ROOT
5	as	as	RB	_	4	cc
6	well	well	RB	_	5	mwe
7	as	as	IN	_	5	mwe
8	minimal	minimal	JJ	_	10	amod
9	bactericidal	bactericidal	JJ	_	10	amod
10	concentration	concentration	NN	_	4	conj
11	of	of	IN	_	12	case
12	KRM	KRM	NNP	_	10	nmod
13	-	-	:	_	4	punct
14	1648	1648	CD	_	4	dep
15	against	against	IN	_	16	case
16	M	m	NN	_	14	nmod
17	.	.	.	_	4	punct

1	ulcerans	ulceran	NNS	_	4	nsubj
2	was	be	VBD	_	4	cop
3	between	between	IN	_	4	case
4	0.012	0.012	CD	_	0	ROOT
5	and	and	CC	_	4	cc
6	0.025	0.025	CD	_	7	nummod
7	mg	mg	NN	_	4	conj
8	/	/	:	_	4	punct
9	l	l	NN	_	4	dep
10	,	,	,	_	4	punct
11	while	while	IN	_	21	mark
12	corresponding	correspond	VBG	_	13	amod
13	values	value	NNS	_	21	nsubj
14	for	for	IN	_	15	case
15	rifampicin	rifampicin	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	rifabutin	rifabutin	NN	_	15	conj
18	were	be	VBD	_	21	cop
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	range	range	NN	_	4	advcl
22	of	of	IN	_	26	case
23	0.1	0.1	CD	_	26	nummod
24	-	-	:	_	26	punct
25	0.8	0.8	CD	_	26	nummod
26	mg	mg	NN	_	21	nmod
27	/	/	:	_	26	punct
28	l	l	NN	_	26	dep
29	and	and	CC	_	28	cc
30	0.1	0.1	CD	_	28	conj
31	-	-	:	_	26	punct
32	0.4	0.4	CD	_	33	nummod
33	mg	mg	NN	_	26	dep
34	/	/	:	_	26	punct
35	l	l	NN	_	26	dep
36	respectively	respectively	RB	_	35	advmod
37	.	.	.	_	4	punct

1	When	when	WRB	_	2	advmod
2	combined	combine	VBN	_	9	advcl
3	with	with	IN	_	4	case
4	ofloxacin	ofloxacin	NN	_	2	nmod
5	,	,	,	_	9	punct
6	KRM	krm	NN	_	9	dep
7	-	-	:	_	9	punct
8	1648	1648	CD	_	9	nsubj
9	exhibited	exhibit	VBD	_	0	ROOT
10	strong	strong	JJ	_	12	amod
11	synergistic	synergistic	JJ	_	12	amod
12	activity	activity	NN	_	9	dobj
13	while	while	IN	_	18	mark
14	only	only	RB	_	16	advmod
15	additive	additive	JJ	_	16	amod
16	effects	effect	NNS	_	18	nsubjpass
17	were	be	VBD	_	18	auxpass
18	observed	observe	VBN	_	9	advcl
19	with	with	IN	_	21	case
20	the	the	DT	_	21	det
21	combination	combination	NN	_	18	nmod
22	of	of	IN	_	23	case
23	rifampicin	rifampicin	NN	_	21	nmod
24	(	(	CD	_	23	nummod
25	or	or	CC	_	23	cc
26	rifabutin	rifabutin	NN	_	27	compound
27	)	)	NN	_	23	conj
28	and	and	CC	_	27	cc
29	ofloxacin	ofloxacin	NN	_	27	conj
30	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	KRM	krm	NN	_	8	nsubj
6	-	-	:	_	8	punct
7	1648	1648	CD	_	8	nsubj
8	has	have	VBZ	_	3	ccomp
9	a	a	DT	_	11	det
10	great	great	JJ	_	11	amod
11	potential	potential	JJ	_	8	dobj
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	treatment	treatment	NN	_	8	nmod
15	of	of	IN	_	16	case
16	M	m	NN	_	14	nmod
17	.	.	.	_	3	punct

1	ulcerans	ulcerans	JJ	_	2	amod
2	infection	infection	NN	_	0	ROOT
3	.	.	.	_	2	punct

1	Pharmacokinetics	pharmacokinetic	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	calcium	calcium	NN	_	1	nmod
4	-	-	:	_	1	punct
5	entry	entry	NN	_	6	compound
6	blockers	blocker	NNS	_	1	dep
7	.	.	.	_	1	punct

1	Effective	effective	JJ	_	2	amod
2	use	use	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	in	in	IN	_	6	case
6	therapy	therapy	NN	_	2	nmod
7	depends	depend	VBZ	_	0	ROOT
8	not	not	RB	_	9	neg
9	only	only	RB	_	12	cc:preconj
10	on	on	IN	_	12	case
11	clinical	clinical	JJ	_	12	amod
12	acumen	acumen	NNS	_	7	nmod
13	but	but	CC	_	12	cc
14	also	also	RB	_	17	advmod
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	availability	availability	NN	_	12	conj
18	of	of	IN	_	23	case
19	relevant	relevant	JJ	_	23	amod
20	pharmacokinetic	pharmacokinetic	JJ	_	23	amod
21	and	and	CC	_	20	cc
22	pharmacodynamic	pharmacodynamic	JJ	_	20	conj
23	data	datum	NNS	_	17	nmod
24	.	.	.	_	7	punct

1	Such	such	JJ	_	2	amod
2	information	information	NN	_	3	nsubj
3	assists	assist	VBZ	_	0	ROOT
4	in	in	IN	_	5	case
5	development	development	NN	_	3	nmod
6	of	of	IN	_	9	case
7	safe	safe	JJ	_	9	amod
8	dosing	dosing	NN	_	9	compound
9	regimens	regimen	NNS	_	5	nmod
10	,	,	,	_	3	punct
11	prediction	prediction	NN	_	3	dobj
12	of	of	IN	_	14	case
13	abnormal	abnormal	JJ	_	14	amod
14	handling	handling	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drugs	drug	NNS	_	14	nmod
17	in	in	IN	_	18	case
18	states	state	NNS	_	11	nmod
19	of	of	IN	_	20	case
20	disease	disease	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	disorder	disorder	NN	_	20	conj
23	and	and	CC	_	11	cc
24	anticipation	anticipation	NN	_	11	conj
25	of	of	IN	_	27	case
26	drug	drug	NN	_	27	compound
27	interactions	interaction	NNS	_	24	nmod
28	.	.	.	_	3	punct

1	For	for	IN	_	3	case
2	the	the	DT	_	3	det
3	calcium	calcium	NN	_	0	ROOT
4	-	-	:	_	7	punct
5	entry	entry	NN	_	7	compound
6	blocking	block	VBG	_	7	compound
7	agents	agent	NNS	_	3	dep
8	now	now	RB	_	9	advmod
9	available	available	JJ	_	7	amod
10	in	in	IN	_	13	case
11	the	the	DT	_	13	det
12	United	United	NNP	_	13	compound
13	States	States	NNPS	_	9	nmod
14	(	(	CD	_	15	nummod
15	verapamil	verapamil	NN	_	13	dep
16	,	,	,	_	15	punct
17	nifedipine	nifedipine	NN	_	15	conj
18	and	and	CC	_	15	cc
19	diltiazem	diltiazem	NN	_	20	compound
20	)	)	NN	_	15	conj
21	,	,	,	_	7	punct
22	these	these	DT	_	23	det
23	data	datum	NNS	_	24	nsubj
24	appeared	appear	VBD	_	7	acl:relcl
25	well	well	RB	_	24	advmod
26	after	after	IN	_	28	case
27	clinical	clinical	JJ	_	28	amod
28	patterns	pattern	NNS	_	24	nmod
29	of	of	IN	_	30	case
30	use	use	NN	_	28	nmod
31	evolved	evolve	VBD	_	24	xcomp
32	.	.	.	_	3	punct

1	Nonetheless	nonetheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	their	they	PRP$	_	4	nmod:poss
4	relevance	relevance	NN	_	5	nsubj
5	continues	continue	VBZ	_	0	ROOT
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	demonstrated	demonstrate	VBN	_	5	xcomp
9	by	by	IN	_	11	case
10	the	the	DT	_	11	det
11	dependence	dependence	NN	_	8	nmod
12	of	of	IN	_	14	case
13	each	each	DT	_	14	det
14	agent	agent	NN	_	11	nmod
15	on	on	IN	_	19	case
16	intact	intact	JJ	_	19	amod
17	liver	liver	NN	_	19	compound
18	blood	blood	NN	_	19	compound
19	flow	flow	NN	_	11	nmod
20	and	and	CC	_	19	cc
21	function	function	NN	_	19	conj
22	for	for	IN	_	24	case
23	normal	normal	JJ	_	24	amod
24	rates	rate	NNS	_	19	nmod
25	of	of	IN	_	26	case
26	elimination	elimination	NN	_	24	nmod
27	;	;	:	_	5	punct

1	by	by	IN	_	5	case
2	the	the	DT	_	5	det
3	nonlinear	nonlinear	JJ	_	5	amod
4	kinetic	kinetic	JJ	_	5	amod
5	characteristics	characteristic	NNS	_	0	ROOT
6	for	for	IN	_	7	case
7	verapamil	verapamil	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	diltiazem	diltiazem	NN	_	10	compound
10	(	(	NN	_	7	conj
11	and	and	CC	_	5	cc
12	probably	probably	RB	_	14	advmod
13	for	for	IN	_	14	case
14	nifedipine	nifedipine	NN	_	5	conj
15	,	,	,	_	14	punct
16	as	as	RB	_	14	cc
17	well	well	RB	_	16	mwe
18	)	)	CD	_	16	mwe
19	and	and	CC	_	14	cc
20	the	the	DT	_	22	det
21	derivative	derivative	JJ	_	22	amod
22	implications	implication	NNS	_	14	conj
23	for	for	IN	_	27	case
24	decreased	decrease	VBN	_	27	amod
25	dosing	dosing	NN	_	27	compound
26	frequency	frequency	NN	_	27	compound
27	requirements	requirement	NNS	_	22	nmod
28	;	;	:	_	5	punct

1	and	and	CC	_	0	ROOT
2	by	by	IN	_	3	case
3	observations	observation	NNS	_	1	nmod
4	now	now	RB	_	5	advmod
5	appearing	appear	VBG	_	3	acl
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	relation	relation	NN	_	5	nmod
9	between	between	IN	_	12	case
10	plasma	plasma	NN	_	12	compound
11	drug	drug	NN	_	12	compound
12	levels	level	NNS	_	8	nmod
13	and	and	CC	_	12	cc
14	drug	drug	NN	_	15	compound
15	effects	effect	NNS	_	12	conj
16	,	,	,	_	3	punct
17	both	both	DT	_	18	cc:preconj
18	therapeutic	therapeutic	JJ	_	16	root
19	and	and	CC	_	18	cc
20	toxic	toxic	JJ	_	18	conj
21	.	.	.	_	18	punct

1	Such	such	JJ	_	2	amod
2	data	datum	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	discussed	discuss	VBN	_	0	ROOT
5	herein	herein	RB	_	4	advmod
6	,	,	,	_	4	punct
7	with	with	IN	_	8	case
8	emphasis	emphasis	NN	_	4	nmod
9	on	on	IN	_	11	case
10	those	those	DT	_	11	det
11	aspects	aspect	NNS	_	8	nmod
12	that	that	WDT	_	13	nsubj
13	impact	impact	VBP	_	11	acl:relcl
14	on	on	IN	_	17	case
15	the	the	DT	_	17	det
16	clinical	clinical	JJ	_	17	amod
17	use	use	NN	_	13	nmod
18	of	of	IN	_	23	case
19	the	the	DT	_	23	det
20	calcium	calcium	NN	_	23	compound
21	-	-	:	_	23	punct
22	entry	entry	NN	_	23	compound
23	antagonists	antagonist	NNS	_	17	nmod
24	.	.	.	_	4	punct

1	Herbal	herbal	JJ	_	2	amod
2	remedies	remedy	NNS	_	0	ROOT
3	,	,	,	_	2	punct
4	nephropathies	nephropathy	NNS	_	2	conj
5	,	,	,	_	2	punct
6	and	and	CC	_	2	cc
7	renal	renal	JJ	_	8	amod
8	disease	disease	NN	_	2	conj
9	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	herbal	herbal	JJ	_	5	amod
5	remedies	remedy	NNS	_	2	nmod
6	is	be	VBZ	_	7	aux
7	becoming	become	VBG	_	0	ROOT
8	increasingly	increasingly	RB	_	9	advmod
9	popular	popular	JJ	_	7	xcomp
10	in	in	IN	_	13	case
11	the	the	DT	_	13	det
12	United	United	NNP	_	13	compound
13	States	States	NNPS	_	7	nmod
14	.	.	.	_	7	punct

1	Research	Research	NNP	_	3	nsubj
2	has	have	VBZ	_	3	aux
3	shown	show	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	herbal	herbal	JJ	_	7	amod
6	remedy	remedy	NN	_	7	compound
7	use	use	NN	_	10	nsubjpass
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	associated	associate	VBN	_	3	ccomp
11	with	with	IN	_	14	case
12	acute	acute	JJ	_	14	amod
13	renal	renal	JJ	_	14	amod
14	failure	failure	NN	_	10	nmod
15	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	11	nmod
3	,	,	,	_	11	punct
4	the	the	DT	_	5	det
5	use	use	NN	_	11	nsubj
6	of	of	IN	_	8	case
7	herbal	herbal	JJ	_	8	amod
8	remedies	remedy	NNS	_	5	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	detrimental	detrimental	JJ	_	0	ROOT
12	for	for	IN	_	14	case
13	the	the	DT	_	14	det
14	patient	patient	NN	_	11	nmod
15	with	with	IN	_	18	case
16	compromised	compromise	VBN	_	18	amod
17	renal	renal	JJ	_	18	amod
18	function	function	NN	_	14	nmod
19	.	.	.	_	11	punct

1	Patients	patient	NNS	_	11	nsubj
2	with	with	IN	_	4	case
3	renal	renal	JJ	_	4	amod
4	insufficiency	insufficiency	NN	_	1	nmod
5	or	or	CC	_	4	cc
6	renal	renal	JJ	_	7	amod
7	failure	failure	NN	_	4	conj
8	may	may	MD	_	11	aux
9	be	be	VB	_	11	cop
10	at	at	IN	_	11	case
11	risk	risk	NN	_	0	ROOT
12	for	for	IN	_	15	case
13	further	further	JJ	_	15	amod
14	kidney	kidney	NN	_	15	compound
15	damage	damage	NN	_	11	nmod
16	as	as	RB	_	15	cc
17	well	well	RB	_	16	mwe
18	as	as	IN	_	16	mwe
19	complications	complication	NNS	_	15	conj
20	related	relate	VBN	_	19	acl
21	to	to	TO	_	22	case
22	interactions	interaction	NNS	_	20	nmod
23	of	of	IN	_	25	case
24	herbal	herbal	JJ	_	25	amod
25	remedies	remedy	NNS	_	22	nmod
26	with	with	IN	_	30	case
27	complex	complex	JJ	_	30	amod
28	renal	renal	JJ	_	30	amod
29	therapy	therapy	NN	_	30	compound
30	regimens	regimen	NNS	_	22	nmod
31	.	.	.	_	11	punct

1	This	this	DT	_	2	det
2	article	article	NN	_	4	nsubj
3	will	will	MD	_	4	aux
4	describe	describe	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	escalating	escalate	VBG	_	7	amod
7	use	use	NN	_	4	dobj
8	of	of	IN	_	10	case
9	herbal	herbal	JJ	_	10	amod
10	therapy	therapy	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	the	the	DT	_	13	det
13	hazards	hazard	NNS	_	10	conj
14	of	of	IN	_	17	case
15	herbal	herbal	JJ	_	17	amod
16	remedy	remedy	NN	_	17	compound
17	use	use	NN	_	13	nmod
18	among	among	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	.	.	.	_	4	punct

1	Immunosuppressive	immunosuppressive	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	their	they	PRP$	_	5	nmod:poss
5	complications	complication	NNS	_	2	conj
6	.	.	.	_	2	punct

1	Drugs	drug	NNS	_	9	nsubjpass
2	that	that	WDT	_	3	nsubj
3	suppress	suppress	VBP	_	1	acl:relcl
4	the	the	DT	_	6	det
5	immune	immune	JJ	_	6	amod
6	system	system	NN	_	3	dobj
7	are	be	VBP	_	9	auxpass
8	widely	widely	RB	_	9	advmod
9	used	use	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	They	they	PRP	_	3	nsubj
2	are	be	VBP	_	3	cop
3	part	part	NN	_	0	ROOT
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	treatment	treatment	NN	_	3	nmod
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	organ	organ	NN	_	11	compound
11	transplants	transplant	NNS	_	8	nmod
12	,	,	,	_	11	punct
13	malignancy	malignancy	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	increasingly	increasingly	RB	_	17	advmod
17	those	those	DT	_	11	conj
18	with	with	IN	_	19	case
19	conditions	condition	NNS	_	17	nmod
20	such	such	JJ	_	22	case
21	as	as	IN	_	20	mwe
22	psoriasis	psoriasis	NN	_	19	nmod
23	,	,	,	_	22	punct
24	rheumatoid	rheumatoid	JJ	_	25	amod
25	arthritis	arthritis	NN	_	22	conj
26	,	,	,	_	22	punct
27	and	and	CC	_	22	cc
28	liver	liver	NN	_	31	compound
29	and	and	CC	_	28	cc
30	bowel	bowel	NN	_	28	conj
31	disease	disease	NN	_	22	conj
32	in	in	IN	_	33	case
33	which	which	WDT	_	38	nmod
34	inflammation	inflammation	NN	_	38	nsubj
35	is	be	VBZ	_	38	cop
36	an	a	DT	_	38	det
37	aetiological	aetiological	JJ	_	38	amod
38	factor	factor	NN	_	22	acl:relcl
39	.	.	.	_	3	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	5	det
4	broadening	broaden	VBG	_	5	amod
5	indications	indication	NNS	_	29	nmod
6	for	for	IN	_	8	case
7	immunosuppressive	immunosuppressive	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	the	the	DT	_	13	det
12	prolonged	prolonged	JJ	_	13	amod
13	survival	survival	NN	_	5	conj
14	in	in	IN	_	15	case
15	conditions	condition	NNS	_	13	nmod
16	for	for	IN	_	17	case
17	which	which	WDT	_	21	nmod
18	they	they	PRP	_	21	nsubjpass
19	are	be	VBP	_	21	aux
20	being	be	VBG	_	21	auxpass
21	used	use	VBN	_	15	acl:relcl
22	,	,	,	_	29	punct
23	many	many	JJ	_	24	amod
24	patients	patient	NNS	_	29	nsubjpass
25	on	on	IN	_	26	case
26	immunosuppression	immunosuppression	NN	_	24	nmod
27	are	be	VBP	_	29	auxpass
28	now	now	RB	_	29	advmod
29	cared	care	VBN	_	0	ROOT
30	for	for	IN	_	33	case
31	in	in	IN	_	33	case
32	the	the	DT	_	33	det
33	community	community	NN	_	29	nmod
34	or	or	CC	_	33	cc
35	seen	see	VBN	_	33	conj
36	in	in	IN	_	40	case
37	non	non	JJ	_	40	amod
38	-	-	:	_	40	punct
39	specialist	specialist	NN	_	40	compound
40	hospitals	hospital	NNS	_	35	nmod
41	,	,	,	_	29	punct
42	usually	usually	RB	_	45	advmod
43	in	in	IN	_	45	case
44	close	close	JJ	_	45	amod
45	collaboration	collaboration	NN	_	29	nmod
46	with	with	IN	_	48	case
47	a	a	DT	_	48	det
48	specialist	specialist	NN	_	45	nmod
49	.	.	.	_	29	punct

1	This	this	DT	_	2	det
2	article	article	NN	_	3	nsubj
3	looks	look	VBZ	_	0	ROOT
4	at	at	IN	_	9	case
5	five	five	CD	_	9	nummod
6	commonly	commonly	RB	_	7	advmod
7	used	use	VBN	_	9	amod
8	immunosuppressive	immunosuppressive	JJ	_	9	amod
9	drugs	drug	NNS	_	3	nmod
10	in	in	IN	_	11	case
11	turn	turn	NN	_	9	nmod
12	(	(	CD	_	13	nummod
13	corticosteroids	corticosteroid	NNS	_	11	dep
14	,	,	,	_	13	punct
15	cyclosporin	cyclosporin	NN	_	13	appos
16	,	,	,	_	15	punct
17	azathioprine	azathioprine	NN	_	15	conj
18	,	,	,	_	15	punct
19	methotrexate	methotrexate	NN	_	15	conj
20	,	,	,	_	15	punct
21	cyclophosphamide	cyclophosphamide	NN	_	22	compound
22	)	)	NN	_	15	conj
23	,	,	,	_	15	punct
24	discussing	discuss	VBG	_	15	conj
25	the	the	DT	_	30	det
26	main	main	JJ	_	30	amod
27	,	,	,	_	26	punct
28	non	non	JJ	_	26	dep
29	-	-	:	_	26	punct
30	infection	infection	NN	_	24	dobj
31	,	,	,	_	15	punct
32	unwanted	unwanted	JJ	_	33	amod
33	effects	effect	NNS	_	15	conj
34	,	,	,	_	15	punct
35	ways	way	NNS	_	15	conj
36	to	to	TO	_	37	mark
37	avoid	avoid	VB	_	35	acl
38	them	they	PRP	_	37	dobj
39	and	and	CC	_	37	cc
40	what	what	WP	_	42	nsubj
41	to	to	TO	_	42	mark
42	do	do	VB	_	37	conj
43	if	if	IN	_	45	mark
44	problems	problem	NNS	_	45	nsubj
45	arise	arise	VBP	_	42	advcl
46	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	management	management	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	infection	infection	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	dealt	deal	VBN	_	0	ROOT
7	with	with	IN	_	11	case
8	as	as	IN	_	11	case
9	a	a	DT	_	11	det
10	separate	separate	JJ	_	11	amod
11	section	section	NN	_	6	nmod
12	.	.	.	_	6	punct

1	Dexamethasone	dexamethasone	NN	_	6	nsubj
2	and	and	CC	_	1	cc
3	retinyl	retinyl	NN	_	4	compound
4	acetate	acetate	NN	_	1	conj
5	similarly	similarly	RB	_	6	advmod
6	inhibit	inhibit	VBP	_	0	ROOT
7	and	and	CC	_	6	cc
8	stimulate	stimulate	VBP	_	6	conj
9	EGF	egf	NN	_	6	dobj
10	-	-	:	_	9	punct
11	or	or	CC	_	9	cc
12	insulin	insulin	NN	_	9	conj
13	-	-	:	_	9	punct
14	induced	induce	VBN	_	15	amod
15	proliferation	proliferation	NN	_	9	dep
16	of	of	IN	_	18	case
17	prostatic	prostatic	JJ	_	18	amod
18	epithelium	epithelium	NN	_	15	nmod
19	.	.	.	_	6	punct

1	Prostatic	prostatic	JJ	_	2	amod
2	epithelium	epithelium	NN	_	3	nsubj
3	proliferates	proliferate	VBZ	_	0	ROOT
4	in	in	IN	_	7	case
5	a	a	DT	_	7	det
6	defined	define	VBN	_	7	amod
7	medium	medium	NN	_	3	nmod
8	consisting	consist	VBG	_	7	acl
9	of	of	IN	_	12	case
10	basal	basal	JJ	_	12	amod
11	medium	medium	NN	_	12	compound
12	RPMI1640	rpmi1640	NN	_	8	nmod
13	containing	contain	VBG	_	12	acl
14	transferrin	transferrin	NN	_	17	compound
15	(	(	NN	_	17	compound
16	1	1	CD	_	17	nummod
17	microgram	microgram	NN	_	13	dobj
18	/	/	:	_	20	punct
19	ml	ml	NN	_	20	compound
20	)	)	NN	_	17	dep
21	,	,	,	_	20	punct
22	EGF	egf	NN	_	20	appos
23	(	(	CD	_	24	compound
24	10	10	CD	_	25	nummod
25	ng	ng	NN	_	22	dep
26	/	/	:	_	25	punct
27	ml	ml	NN	_	28	compound
28	)	)	NN	_	25	conj
29	,	,	,	_	25	punct
30	and	and	CC	_	25	cc
31	insulin	insulin	NN	_	34	compound
32	(	(	NN	_	34	compound
33	3.7	3.7	CD	_	34	nummod
34	micrograms	microgram	NNS	_	25	conj
35	/	/	:	_	20	punct
36	ml	ml	NN	_	20	dep
37	or	or	CC	_	36	cc
38	0.1	0.1	CD	_	36	conj
39	IU	iu	NN	_	36	dep
40	/	/	:	_	20	punct
41	ml	ml	NN	_	42	compound
42	)	)	NN	_	20	dep
43	.	.	.	_	3	punct

1	Although	although	IN	_	7	mark
2	neither	neither	DT	_	3	cc:preconj
3	dexamethasone	dexamethasone	NN	_	7	nsubj
4	nor	nor	CC	_	3	cc
5	retinyl	retinyl	NN	_	6	compound
6	acetate	acetate	NN	_	3	conj
7	affected	affect	VBD	_	20	advcl
8	the	the	DT	_	9	det
9	proliferation	proliferation	NN	_	7	dobj
10	of	of	IN	_	12	case
11	prostatic	prostatic	JJ	_	12	amod
12	epithelium	epithelium	NN	_	9	nmod
13	in	in	IN	_	14	case
14	RPMI1640	rpmi1640	NN	_	9	nmod
15	containing	contain	VBG	_	14	acl
16	transferrin	transferrin	NN	_	15	dobj
17	alone	alone	RB	_	16	advmod
18	,	,	,	_	20	punct
19	they	they	PRP	_	20	nsubj
20	modify	modify	VBP	_	0	ROOT
21	the	the	DT	_	23	det
22	mitogenic	mitogenic	JJ	_	23	amod
23	effect	effect	NN	_	20	dobj
24	of	of	IN	_	25	case
25	EGF	egf	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	insulin	insulin	NN	_	25	conj
28	.	.	.	_	20	punct

1	Dexamethasone	dexamethasone	NN	_	22	nsubj
2	at	at	IN	_	8	case
3	10	10	CD	_	8	compound
4	(	(	SYM	_	8	dep
5	-	-	:	_	8	punct
6	10	10	CD	_	7	compound
7	)	)	CD	_	8	nummod
8	M	m	NN	_	1	nmod
9	or	or	CC	_	8	cc
10	retinyl	retinyl	NN	_	11	compound
11	acetate	acetate	NN	_	8	conj
12	at	at	IN	_	15	case
13	about	about	IN	_	14	advmod
14	3	3	CD	_	15	nummod
15	X	x	NN	_	1	nmod
16	10	10	CD	_	15	nummod
17	(	(	SYM	_	15	dep
18	-	-	:	_	15	punct
19	9	9	CD	_	20	compound
20	)	)	CD	_	21	nummod
21	M	m	NN	_	15	dep
22	inhibits	inhibit	VBZ	_	0	ROOT
23	proliferation	proliferation	NN	_	22	dobj
24	stimulated	stimulate	VBN	_	23	acl
25	by	by	IN	_	26	case
26	EGF	egf	NN	_	24	nmod
27	.	.	.	_	22	punct

1	Higher	higher	JJR	_	2	amod
2	concentrations	concentration	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	dexamethasone	dexamethasone	NN	_	2	nmod
5	(	(	CD	_	6	nummod
6	10	10	CD	_	17	dep
7	(	(	SYM	_	17	dep
8	-	-	:	_	17	punct
9	8	8	CD	_	17	compound
10	)	)	SYM	_	17	dep
11	-	-	:	_	17	punct
12	10	10	CD	_	17	compound
13	(	(	SYM	_	17	dep
14	-	-	:	_	17	punct
15	6	6	CD	_	16	compound
16	)	)	CD	_	17	nummod
17	M	m	NN	_	41	dep
18	)	)	CD	_	17	nummod
19	or	or	CC	_	17	cc
20	retinyl	retinyl	NN	_	21	compound
21	acetate	acetate	NN	_	38	dep
22	(	(	CD	_	38	dep
23	3	3	CD	_	38	dep
24	X	x	NN	_	38	dep
25	10	10	CD	_	38	dep
26	(	(	SYM	_	38	dep
27	-	-	:	_	38	punct
28	8	8	CD	_	38	dep
29	)	)	SYM	_	38	dep
30	-	-	:	_	38	punct
31	10	10	CD	_	38	dep
32	(	(	SYM	_	38	dep
33	-	-	:	_	38	punct
34	7	7	CD	_	35	compound
35	)	)	CD	_	36	nummod
36	M	m	NN	_	38	nsubj
37	)	)	CD	_	36	nummod
38	enhance	enhance	VBP	_	17	conj
39	the	the	DT	_	41	det
40	mitogenic	mitogenic	JJ	_	41	amod
41	activity	activity	NN	_	4	dep
42	of	of	IN	_	43	case
43	EGF	egf	NN	_	41	nmod
44	.	.	.	_	2	punct

1	Dexamethasone	dexamethasone	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	a	a	DT	_	5	det
4	similar	similar	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	presence	presence	NN	_	2	nmod
9	of	of	IN	_	10	case
10	insulin	insulin	NN	_	8	nmod
11	.	.	.	_	2	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	retinyl	retinyl	NN	_	4	compound
4	acetate	acetate	NN	_	5	nsubj
5	stimulated	stimulate	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	but	but	CC	_	5	cc
8	did	do	VBD	_	11	aux
9	not	not	RB	_	11	neg
10	significantly	significantly	RB	_	11	advmod
11	inhibit	inhibit	VB	_	5	conj
12	,	,	,	_	11	punct
13	proliferation	proliferation	NN	_	11	dobj
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	presence	presence	NN	_	13	nmod
17	of	of	IN	_	18	case
18	insulin	insulin	NN	_	16	nmod
19	.	.	.	_	5	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	19	mark
5	both	both	CC	_	6	cc:preconj
6	dexamethasone	dexamethasone	NN	_	19	nsubj
7	and	and	CC	_	6	cc
8	retinyl	retinyl	NN	_	9	compound
9	acetate	acetate	NN	_	6	conj
10	,	,	,	_	6	punct
11	and	and	CC	_	6	cc
12	possibly	possibly	RB	_	14	advmod
13	other	other	JJ	_	14	amod
14	glucocorticoids	glucocorticoid	NNS	_	6	conj
15	and	and	CC	_	14	cc
16	retinoids	retinoid	NNS	_	14	conj
17	,	,	,	_	6	punct
18	may	may	MD	_	19	aux
19	regulate	regulate	VB	_	3	ccomp
20	the	the	DT	_	21	det
21	proliferation	proliferation	NN	_	19	dobj
22	of	of	IN	_	24	case
23	prostate	prostate	NN	_	24	compound
24	epithelium	epithelium	NN	_	21	nmod
25	by	by	IN	_	30	case
26	a	a	DT	_	30	det
27	dose	dose	NN	_	30	compound
28	-	-	:	_	30	punct
29	dependent	dependent	JJ	_	30	amod
30	modification	modification	NN	_	19	nmod
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	activity	activity	NN	_	30	nmod
34	of	of	IN	_	35	case
35	insulin	insulin	NN	_	33	nmod
36	and	and	CC	_	35	cc
37	EGF	egf	NN	_	35	conj
38	.	.	.	_	3	punct

1	Death	death	NN	_	0	ROOT
2	in	in	IN	_	4	case
3	amphetamine	amphetamine	NN	_	4	compound
4	users	user	NNS	_	1	nmod
5	:	:	:	_	1	punct
6	causes	cause	NNS	_	1	dep
7	and	and	CC	_	6	cc
8	rates	rate	NNS	_	6	conj
9	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	world	world	NN	_	4	compound
3	medical	medical	JJ	_	4	amod
4	literature	literature	NN	_	5	nsubj
5	contains	contain	VBZ	_	0	ROOT
6	43	43	CD	_	7	nummod
7	reports	report	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	deaths	death	NNS	_	7	nmod
10	associated	associate	VBN	_	9	acl
11	with	with	IN	_	12	case
12	amphetamines	amphetamine	NNS	_	10	nmod
13	in	in	IN	_	18	case
14	a	a	DT	_	18	det
15	35	35	CD	_	18	nummod
16	-	-	:	_	18	punct
17	year	year	NN	_	18	compound
18	period	period	NN	_	12	nmod
19	.	.	.	_	5	punct

1	These	these	DT	_	2	nsubj
2	included	include	VBD	_	0	ROOT
3	seven	seven	CD	_	5	nummod
4	cerebrovascular	cerebrovascular	JJ	_	5	amod
5	accidents	accident	NNS	_	2	dobj
6	,	,	,	_	5	punct
7	six	six	CD	_	10	nummod
8	sudden	sudden	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	deaths	death	NNS	_	5	conj
11	,	,	,	_	5	punct
12	three	three	CD	_	13	nummod
13	cases	case	NNS	_	5	conj
14	of	of	IN	_	15	case
15	hyperpyrexia	hyperpyrexia	NN	_	13	nmod
16	,	,	,	_	5	punct
17	eight	eight	CD	_	18	nummod
18	poisonings	poisoning	NNS	_	5	conj
19	of	of	IN	_	21	case
20	uncertain	uncertain	JJ	_	21	amod
21	mechanism	mechanism	NN	_	18	nmod
22	and	and	CC	_	5	cc
23	seven	seven	CD	_	24	nummod
24	cases	case	NNS	_	5	conj
25	of	of	IN	_	27	case
26	medical	medical	JJ	_	27	amod
27	complications	complication	NNS	_	24	nmod
28	of	of	IN	_	30	case
29	intravenous	intravenous	JJ	_	30	amod
30	injection	injection	NN	_	27	nmod
31	;	;	:	_	2	punct

1	the	the	DT	_	2	det
2	remainder	remainder	NN	_	6	nsubj
3	were	be	VBD	_	6	cop
4	of	of	IN	_	6	case
5	uncertain	uncertain	JJ	_	6	amod
6	cause	cause	NN	_	0	ROOT
7	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	13	nmod
3	,	,	,	_	13	punct
4	in	in	IN	_	5	case
5	Ontario	Ontario	NNP	_	13	nmod
6	alone	alone	RB	_	5	advmod
7	,	,	,	_	13	punct
8	in	in	IN	_	9	case
9	1972	1972	CD	_	13	nmod
10	and	and	CC	_	9	cc
11	1973	1973	CD	_	9	conj
12	there	there	EX	_	13	expl
13	were	be	VBD	_	0	ROOT
14	26	26	CD	_	15	nummod
15	deaths	death	NNS	_	13	nsubj
16	in	in	IN	_	18	case
17	amphetamine	amphetamine	NN	_	18	compound
18	users	user	NNS	_	15	nmod
19	,	,	,	_	15	punct
20	of	of	IN	_	21	case
21	which	which	WDT	_	24	nmod
22	16	16	CD	_	24	nsubj
23	were	be	VBD	_	24	cop
24	due	due	JJ	_	15	acl:relcl
25	to	to	TO	_	27	case
26	accident	accident	NN	_	27	compound
27	suicide	suicide	NN	_	24	nmod
28	or	or	CC	_	27	cc
29	homicide	homicide	NN	_	27	conj
30	.	.	.	_	13	punct

1	Of	of	IN	_	4	case
2	the	the	DT	_	4	det
3	remaining	remain	VBG	_	4	amod
4	cases	case	NNS	_	8	nmod
5	,	,	,	_	8	punct
6	two	two	CD	_	8	nsubj
7	were	be	VBD	_	8	cop
8	cardiac	cardiac	JJ	_	0	ROOT
9	,	,	,	_	8	punct
10	two	two	CD	_	11	nummod
11	hepatic	hepatic	JJ	_	8	conj
12	and	and	CC	_	8	cc
13	the	the	DT	_	14	det
14	rest	rest	NN	_	18	nsubj
15	were	be	VBD	_	18	cop
16	mixed	mixed	JJ	_	18	amod
17	drug	drug	NN	_	18	compound
18	overdose	overdose	NN	_	8	conj
19	.	.	.	_	8	punct

1	Pulmonary	pulmonary	JJ	_	2	amod
2	granulomata	granulomata	NN	_	16	nsubj
3	,	,	,	_	2	punct
4	subacute	subacute	NN	_	5	compound
5	hepatitis	hepatitis	NN	_	2	conj
6	and	and	CC	_	2	cc
7	other	other	JJ	_	8	amod
8	lesions	lesion	NNS	_	2	conj
9	resulting	result	VBG	_	8	acl
10	from	from	IN	_	13	case
11	intravenous	intravenous	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	use	use	NN	_	9	nmod
14	were	be	VBD	_	16	cop
15	common	common	JJ	_	16	amod
16	findings	finding	NNS	_	0	ROOT
17	at	at	IN	_	18	case
18	autopsy	autopsy	NN	_	16	nmod
19	.	.	.	_	16	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	27	nmod
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	estimated	estimate	VBN	_	7	amod
7	number	number	NN	_	3	nmod
8	of	of	IN	_	10	case
9	regular	regular	JJ	_	10	amod
10	users	user	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	intravenous	intravenous	JJ	_	13	amod
13	amphetamine	amphetamine	NN	_	10	nmod
14	in	in	IN	_	15	case
15	Ontario	Ontario	NNP	_	13	nmod
16	,	,	,	_	27	punct
17	the	the	DT	_	19	det
18	mortality	mortality	NN	_	19	compound
19	rate	rate	NN	_	27	nsubj
20	in	in	IN	_	22	case
21	such	such	JJ	_	22	amod
22	users	user	NNS	_	19	nmod
23	is	be	VBZ	_	27	cop
24	at	at	IN	_	25	case
25	least	least	JJS	_	26	nmod:npmod
26	four	four	CD	_	27	nummod
27	times	time	NNS	_	0	ROOT
28	as	as	RB	_	29	advmod
29	high	high	JJ	_	27	advmod
30	as	as	IN	_	34	case
31	in	in	IN	_	34	case
32	the	the	DT	_	34	det
33	general	general	JJ	_	34	amod
34	population	population	NN	_	29	nmod
35	of	of	IN	_	38	case
36	the	the	DT	_	38	det
37	same	same	JJ	_	38	amod
38	age	age	NN	_	34	nmod
39	,	,	,	_	27	punct
40	and	and	CC	_	27	cc
41	is	be	VBZ	_	42	cop
42	comparable	comparable	JJ	_	27	conj
43	to	to	TO	_	44	case
44	that	that	DT	_	42	nmod
45	in	in	IN	_	46	case
46	alcoholics	alcoholic	NNS	_	44	nmod
47	and	and	CC	_	46	cc
48	heroin	heroin	NN	_	49	compound
49	addicts	addict	NNS	_	46	conj
50	.	.	.	_	27	punct

1	However	however	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	5	det
4	absolute	absolute	JJ	_	5	amod
5	number	number	NN	_	13	nsubj
6	of	of	IN	_	7	case
7	alcohol	alcohol	NN	_	5	nmod
8	-	-	:	_	7	punct
9	related	related	JJ	_	10	amod
10	deaths	death	NNS	_	7	dep
11	is	be	VBZ	_	13	cop
12	far	far	RB	_	13	advmod
13	greater	greater	JJR	_	0	ROOT
14	than	than	IN	_	16	case
15	the	the	DT	_	16	det
16	number	number	NN	_	13	nmod
17	of	of	IN	_	18	case
18	deaths	death	NNS	_	16	nmod
19	in	in	IN	_	20	case
20	amphetamine	amphetamine	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	heroin	heroin	NN	_	23	compound
23	users	user	NNS	_	20	conj
24	.	.	.	_	13	punct

1	[	[	NN	_	4	compound
2	A	a	NN	_	4	compound
3	pharmacological	pharmacological	JJ	_	4	amod
4	analysis	analysis	NN	_	23	nsubjpass
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	effect	effect	NN	_	4	nmod
8	of	of	IN	_	9	case
9	angiotensin	angiotensin	NN	_	7	nmod
10	on	on	IN	_	16	case
11	stimulated	stimulate	VBN	_	16	amod
12	gastric	gastric	JJ	_	16	amod
13	secretion	secretion	NN	_	16	compound
14	]	]	NN	_	16	compound
15	Chronic	chronic	JJ	_	16	amod
16	experiments	experiment	NNS	_	7	nmod
17	on	on	IN	_	18	case
18	dogs	dog	NNS	_	16	nmod
19	with	with	IN	_	21	case
20	gastric	gastric	JJ	_	21	amod
21	fistulas	fistula	NNS	_	18	nmod
22	were	be	VBD	_	23	auxpass
23	carried	carry	VBN	_	0	ROOT
24	out	out	RP	_	23	compound:prt
25	to	to	TO	_	26	mark
26	study	study	VB	_	23	xcomp
27	the	the	DT	_	28	det
28	influence	influence	NN	_	26	dobj
29	of	of	IN	_	30	case
30	angiotensin	angiotensin	NN	_	28	nmod
31	1	1	CD	_	30	nummod
32	and	and	CC	_	30	cc
33	angiotensin	angiotensin	NN	_	30	conj
34	2	2	CD	_	33	nummod
35	on	on	IN	_	36	case
36	pentagastrin	pentagastrin	NN	_	28	nmod
37	-	-	:	_	23	punct
38	and	and	CC	_	23	cc
39	histamine	histamine	NN	_	23	conj
40	-	-	:	_	39	punct
41	induced	induce	VBN	_	44	amod
42	gastric	gastric	JJ	_	44	amod
43	acid	acid	NN	_	44	compound
44	secretion	secretion	NN	_	39	dep
45	.	.	.	_	23	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	established	establish	VBN	_	0	ROOT
4	that	that	IN	_	7	mark
5	both	both	CC	_	6	det
6	angiotensins	angiotensin	NNS	_	7	nsubj
7	inhibited	inhibit	VBD	_	3	ccomp
8	gastric	gastric	JJ	_	10	amod
9	acid	acid	NN	_	10	compound
10	secretion	secretion	NN	_	7	dobj
11	stimulated	stimulate	VBN	_	10	acl
12	by	by	IN	_	13	case
13	pentagastrin	pentagastrin	NN	_	11	nmod
14	but	but	CC	_	13	cc
15	not	not	RB	_	17	neg
16	by	by	IN	_	17	case
17	histamine	histamine	NN	_	13	conj
18	.	.	.	_	3	punct

1	Comparative	comparative	JJ	_	2	amod
2	analysis	analysis	NN	_	21	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	stimulation	stimulation	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	inhibition	inhibition	NN	_	7	conj
10	of	of	IN	_	11	case
11	cholino	cholino	NN	_	7	nmod
12	-	-	:	_	11	punct
13	and	and	CC	_	11	cc
14	adrenoreceptors	adrenoreceptor	NNS	_	11	conj
15	on	on	IN	_	18	case
16	this	this	DT	_	18	det
17	inhibitory	inhibitory	JJ	_	18	amod
18	action	action	NN	_	5	nmod
19	of	of	IN	_	20	case
20	angiotensins	angiotensin	NNS	_	18	nmod
21	suggested	suggest	VBD	_	0	ROOT
22	the	the	DT	_	23	det
23	mediation	mediation	NN	_	21	dobj
24	of	of	IN	_	26	case
25	angiotensin	angiotensin	NN	_	26	compound
26	influence	influence	NN	_	23	nmod
27	through	through	IN	_	29	case
28	the	the	DT	_	29	det
29	modulation	modulation	NN	_	21	nmod
30	of	of	IN	_	32	case
31	cholinergic	cholinergic	JJ	_	32	amod
32	reactions	reaction	NNS	_	29	nmod
33	of	of	IN	_	35	case
34	parietal	parietal	JJ	_	35	amod
35	cells	cell	NNS	_	32	nmod
36	in	in	IN	_	38	case
37	the	the	DT	_	38	det
38	stomach	stomach	NN	_	32	nmod
39	.	.	.	_	21	punct

1	[	[	NN	_	2	compound
2	Stimulation	stimulation	NN	_	0	ROOT
3	by	by	IN	_	4	case
4	cerulein	cerulein	NN	_	2	nmod
5	--	--	:	_	4	punct
6	an	a	DT	_	7	det
7	analog	analog	NN	_	4	dep
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	octapeptide	octapeptide	NN	_	11	compound
11	cholecystokinin	cholecystokinin	NN	_	7	nmod
12	--	--	:	_	4	punct
13	of	of	IN	_	14	case
14	3H	3h	NN	_	4	nmod
15	-	-	:	_	4	punct
16	spiroperidol	spiroperidol	NN	_	17	compound
17	binding	binding	NN	_	4	dep
18	after	after	IN	_	23	case
19	the	the	DT	_	23	det
20	long	long	JJ	_	23	amod
21	-	-	:	_	23	punct
22	term	term	NN	_	23	compound
23	administration	administration	NN	_	17	nmod
24	of	of	IN	_	25	case
25	neuroleptics	neuroleptic	NNS	_	23	nmod
26	]	]	CD	_	25	nummod
27	It	it	PRP	_	30	nsubjpass
28	has	have	VBZ	_	30	aux
29	been	be	VBN	_	30	auxpass
30	established	establish	VBN	_	4	dep
31	in	in	IN	_	32	case
32	experiments	experiment	NNS	_	30	nmod
33	on	on	IN	_	36	case
34	white	white	JJ	_	36	amod
35	male	male	JJ	_	36	amod
36	rats	rat	NNS	_	32	nmod
37	that	that	WDT	_	38	nsubj
38	prolonged	prolong	VBD	_	36	acl:relcl
39	administration	administration	NN	_	38	dobj
40	(	(	CD	_	39	nummod
41	twice	twice	RB	_	43	advmod
42	a	a	DT	_	43	det
43	day	day	NN	_	38	nmod:tmod
44	for	for	IN	_	46	case
45	14	14	CD	_	46	nummod
46	days	day	NNS	_	64	nmod
47	)	)	CD	_	46	nummod
48	of	of	IN	_	49	case
49	haloperidol	haloperidol	NN	_	46	nmod
50	(	(	CD	_	51	compound
51	0.25	0.25	CD	_	49	nummod
52	mg	mg	NN	_	55	compound
53	/	/	:	_	55	punct
54	kg	kg	NN	_	55	compound
55	)	)	NN	_	64	nsubj
56	and	and	CC	_	55	cc
57	pyreneperone	pyreneperone	NN	_	60	compound
58	(	(	CD	_	59	compound
59	0.25	0.25	CD	_	60	nummod
60	mg	mg	NN	_	55	conj
61	/	/	:	_	55	punct
62	kg	kg	NN	_	63	compound
63	)	)	NN	_	55	dep
64	resulted	result	VBD	_	38	advcl
65	in	in	IN	_	68	case
66	the	the	DT	_	68	det
67	reduced	reduce	VBN	_	68	amod
68	interaction	interaction	NN	_	64	nmod
69	between	between	IN	_	70	case
70	3H	3h	NN	_	68	nmod
71	-	-	:	_	70	punct
72	spiroperidol	spiroperidol	NN	_	70	dep
73	and	and	CC	_	72	cc
74	low	low	JJ	_	72	conj
75	affinity	affinity	NN	_	77	compound
76	binding	binding	NN	_	77	compound
77	sites	site	NNS	_	72	dep
78	for	for	IN	_	79	case
79	apomorphine	apomorphine	NN	_	70	nmod
80	in	in	IN	_	82	case
81	subcortical	subcortical	JJ	_	82	amod
82	structures	structure	NNS	_	68	nmod
83	,	,	,	_	2	punct
84	whereas	whereas	IN	_	96	mark
85	3H	3h	NN	_	88	compound
86	-	-	:	_	88	punct
87	spiroperidol	spiroperidol	NN	_	88	compound
88	binding	binding	NN	_	96	nsubj
89	with	with	IN	_	93	case
90	high	high	JJ	_	93	amod
91	affinity	affinity	NN	_	93	compound
92	binding	binding	NN	_	93	compound
93	sites	site	NNS	_	88	nmod
94	for	for	IN	_	95	case
95	apomorphine	apomorphine	NN	_	93	nmod
96	increased	increase	VBD	_	2	advcl
97	both	both	CC	_	101	cc:preconj
98	in	in	IN	_	101	case
99	the	the	DT	_	101	det
100	frontal	frontal	JJ	_	101	amod
101	cortex	cortex	NN	_	96	nmod
102	and	and	CC	_	101	cc
103	subcortical	subcortical	JJ	_	104	amod
104	structures	structure	NNS	_	101	conj
105	of	of	IN	_	107	case
106	the	the	DT	_	107	det
107	forebrain	forebrain	NN	_	104	nmod
108	.	.	.	_	2	punct

1	After	after	IN	_	3	case
2	prolonged	prolonged	JJ	_	3	amod
3	administration	administration	NN	_	19	nmod
4	of	of	IN	_	5	case
5	neuroleptics	neuroleptic	NNS	_	3	nmod
6	the	the	DT	_	8	det
7	displacing	displacing	NN	_	8	compound
8	effect	effect	NN	_	19	nsubjpass
9	of	of	IN	_	10	case
10	cerulein	cerulein	NN	_	8	nmod
11	,	,	,	_	10	punct
12	an	a	DT	_	13	det
13	analog	analog	NN	_	10	appos
14	of	of	IN	_	16	case
15	cholecystokinin	cholecystokinin	NN	_	16	compound
16	octapeptide	octapeptide	NN	_	13	nmod
17	,	,	,	_	10	punct
18	was	be	VBD	_	19	auxpass
19	replaced	replace	VBN	_	0	ROOT
20	by	by	IN	_	23	case
21	the	the	DT	_	23	det
22	stimulant	stimulant	NN	_	23	compound
23	action	action	NN	_	19	nmod
24	on	on	IN	_	28	case
25	3H	3h	NN	_	28	compound
26	-	-	:	_	28	punct
27	spiroperidol	spiroperidol	NN	_	28	compound
28	binding	binding	NN	_	23	nmod
29	.	.	.	_	19	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	assumed	assume	VBN	_	0	ROOT
4	that	that	IN	_	25	mark
5	increased	increase	VBN	_	6	amod
6	interaction	interaction	NN	_	25	nsubj
7	between	between	IN	_	8	case
8	3H	3h	NN	_	6	nmod
9	-	-	:	_	8	punct
10	spiroperidol	spiroperidol	NN	_	8	dep
11	and	and	CC	_	8	cc
12	high	high	JJ	_	15	amod
13	affinity	affinity	NN	_	15	compound
14	binding	binding	NN	_	15	compound
15	sites	site	NNS	_	8	conj
16	for	for	IN	_	17	case
17	apomorphine	apomorphine	NN	_	15	nmod
18	on	on	IN	_	19	case
19	dopamine2	dopamine2	NN	_	17	nmod
20	-	-	:	_	8	punct
21	and	and	CC	_	8	cc
22	serotonin2	serotonin2	NN	_	8	conj
23	-	-	:	_	6	punct
24	receptors	receptor	NNS	_	6	dep
25	underlies	underlie	VBZ	_	3	ccomp
26	the	the	DT	_	28	det
27	antipsychotic	antipsychotic	JJ	_	28	amod
28	action	action	NN	_	25	dobj
29	of	of	IN	_	30	case
30	neuroleptics	neuroleptic	NNS	_	28	nmod
31	after	after	IN	_	34	case
32	their	they	PRP$	_	34	nmod:poss
33	prolonged	prolonged	JJ	_	34	amod
34	administration	administration	NN	_	25	nmod
35	.	.	.	_	3	punct

1	Cholecystokinin	cholecystokinin	NN	_	2	compound
2	octapeptide	octapeptide	NN	_	6	nsubj
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	necessary	necessary	JJ	_	6	amod
6	factor	factor	NN	_	0	ROOT
7	for	for	IN	_	8	case
8	realization	realization	NN	_	6	nmod
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	action	action	NN	_	8	nmod
12	of	of	IN	_	13	case
13	neuroleptics	neuroleptic	NNS	_	11	nmod
14	.	.	.	_	6	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	ketamine	ketamine	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	halothane	halothane	NN	_	3	conj
6	in	in	IN	_	7	case
7	rats	rat	NNS	_	1	nmod
8	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	20	nsubjpass
3	of	of	IN	_	6	case
4	intramuscularly	intramuscularly	JJ	_	6	amod
5	injected	inject	VBN	_	6	amod
6	ketamine	ketamine	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	its	its	PRP$	_	9	nmod:poss
9	N	n	NN	_	6	conj
10	-	-	:	_	6	punct
11	demethylated	demethylate	VBN	_	14	amod
12	metabolite	metabolite	NN	_	14	compound
13	(	(	NN	_	14	compound
14	metabolite	metabolite	NN	_	6	dep
15	I	I	PRP	_	16	nsubj
16	)	)	VBP	_	14	acl:relcl
17	with	with	IN	_	18	case
18	halothane	halothane	NN	_	16	nmod
19	was	be	VBD	_	20	auxpass
20	evaluated	evaluate	VBN	_	0	ROOT
21	in	in	IN	_	22	case
22	rats	rat	NNS	_	20	nmod
23	.	.	.	_	20	punct

1	Five	five	CD	_	29	nsubj
2	,	,	,	_	1	punct
3	10	10	CD	_	9	nummod
4	,	,	,	_	3	punct
5	20	20	CD	_	3	conj
6	,	,	,	_	3	punct
7	or	or	CC	_	3	cc
8	50	50	CD	_	3	conj
9	mg	mg	NN	_	1	appos
10	/	/	:	_	11	punct
11	kg	kg	NN	_	1	dep
12	of	of	IN	_	13	case
13	ketamine	ketamine	NN	_	11	nmod
14	alone	alone	RB	_	13	advmod
15	or	or	CC	_	13	cc
16	20	20	CD	_	22	nummod
17	,	,	,	_	16	punct
18	50	50	CD	_	16	conj
19	,	,	,	_	16	punct
20	or	or	CC	_	16	cc
21	100	100	CD	_	16	conj
22	mg	mg	NN	_	13	conj
23	/	/	:	_	11	punct
24	kg	kg	NN	_	1	dep
25	of	of	IN	_	27	case
26	metabolite	metabolite	NN	_	27	compound
27	I	i	NN	_	24	nmod
28	alone	alone	RB	_	24	advmod
29	produced	produce	VBD	_	0	ROOT
30	less	less	JJR	_	32	advmod
31	than	than	IN	_	30	mwe
32	10	10	CD	_	33	nummod
33	minutes	minute	NNS	_	29	dobj
34	of	of	IN	_	35	case
35	hypnosis	hypnosis	NN	_	33	nmod
36	.	.	.	_	29	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	halothane	halothane	NN	_	5	compound
4	anesthetic	anesthetic	NN	_	5	compound
5	requirement	requirement	NN	_	7	nsubj
6	(	(	CD	_	5	nummod
7	i	i	LS	_	0	ROOT
8	.	.	.	_	7	punct
9	e	e	LS	_	15	dep
10	.	.	.	_	9	punct
11	,	,	,	_	9	punct
12	MAC	MAC	NNP	_	15	nsubjpass
13	)	)	CD	_	12	nummod
14	was	be	VBD	_	15	auxpass
15	depressed	depress	VBN	_	7	parataxis
16	in	in	IN	_	21	case
17	a	a	DT	_	21	det
18	dose	dose	NN	_	21	compound
19	-	-	:	_	21	punct
20	dependent	dependent	JJ	_	21	amod
21	fashion	fashion	NN	_	15	nmod
22	as	as	RB	_	25	advmod
23	much	much	RB	_	25	advmod
24	as	as	IN	_	25	advmod
25	56	56	CD	_	26	nummod
26	%	%	NN	_	15	dobj
27	1	1	CD	_	26	nummod
28	-	-	:	_	26	punct
29	2	2	CD	_	30	nummod
30	hours	hour	NNS	_	26	dep
31	and	and	CC	_	30	cc
32	as	as	RB	_	35	advmod
33	much	much	JJ	_	35	advmod
34	as	as	IN	_	35	advmod
35	14	14	CD	_	36	nummod
36	%	%	NN	_	30	conj
37	5	5	CD	_	36	nummod
38	-	-	:	_	36	punct
39	6	6	CD	_	40	nummod
40	hours	hour	NNS	_	36	nmod
41	after	after	IN	_	40	case
42	injection	injection	NN	_	40	dep
43	of	of	IN	_	44	case
44	ketamine	ketamine	NN	_	42	nmod
45	,	,	,	_	26	punct
46	50	50	CD	_	47	nummod
47	mg	mg	NN	_	26	appos
48	/	/	:	_	26	punct
49	kg	kg	NN	_	26	dep
50	,	,	,	_	49	punct
51	im	im	NN	_	49	appos
52	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	reduction	reduction	NN	_	6	nsubjpass
3	in	in	IN	_	4	case
4	MAC	MAC	NNP	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	correlated	correlate	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	brain	brain	NN	_	9	compound
9	levels	level	NNS	_	6	nmod
10	of	of	IN	_	11	case
11	ketamine	ketamine	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	metabolite	metabolite	NN	_	11	conj
14	I	I	PRP	_	11	dep
15	,	,	,	_	6	punct
16	suggesting	suggest	VBG	_	6	xcomp
17	a	a	DT	_	18	det
18	ketamine	ketamine	NN	_	16	dobj
19	:	:	:	_	18	punct
20	metabolite	metabolite	NN	_	23	compound
21	I	I	PRP	_	23	compound
22	potency	potency	NN	_	23	compound
23	ration	ration	NN	_	18	dep
24	of	of	IN	_	25	case
25	3	3	CD	_	23	nmod
26	:	:	:	_	23	punct
27	1	1	CD	_	23	dep
28	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	half	half	NN	_	12	nsubj
3	-	-	:	_	2	punct
4	life	life	NN	_	2	dep
5	of	of	IN	_	6	case
6	ketamine	ketamine	NN	_	2	nmod
7	in	in	IN	_	8	case
8	plasma	plasma	NN	_	2	nmod
9	and	and	CC	_	8	cc
10	brain	brain	NN	_	8	conj
11	was	be	VBD	_	12	cop
12	longer	longer	RBR	_	0	ROOT
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	12	nmod
16	of	of	IN	_	17	case
17	halothane	halothane	NN	_	15	nmod
18	than	than	IN	_	22	mark
19	when	when	WRB	_	22	advmod
20	ketamine	ketamine	NN	_	22	nsubjpass
21	was	be	VBD	_	22	auxpass
22	given	give	VBN	_	12	advcl
23	alone	alone	RB	_	22	advmod
24	.	.	.	_	12	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	concluded	conclude	VBN	_	0	ROOT
4	that	that	IN	_	12	mark
5	ketamine	ketamine	NN	_	12	nsubj
6	is	be	VBZ	_	12	cop
7	not	not	RB	_	12	neg
8	a	a	DT	_	12	det
9	short	short	JJ	_	12	amod
10	-	-	:	_	12	punct
11	acting	act	VBG	_	12	amod
12	drug	drug	NN	_	3	ccomp
13	and	and	CC	_	12	cc
14	that	that	IN	_	21	mark
15	concomitant	concomitant	JJ	_	16	amod
16	use	use	NN	_	21	nsubjpass
17	with	with	IN	_	18	case
18	halothane	halothane	NN	_	16	nmod
19	would	would	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	expected	expect	VBN	_	12	conj
22	to	to	TO	_	23	mark
23	prolong	prolong	VB	_	21	xcomp
24	further	further	RB	_	23	advmod
25	the	the	DT	_	26	det
26	duration	duration	NN	_	23	dobj
27	of	of	IN	_	29	case
28	its	its	PRP$	_	29	nmod:poss
29	action	action	NN	_	26	nmod
30	on	on	IN	_	34	case
31	the	the	DT	_	34	det
32	central	central	JJ	_	34	amod
33	nervous	nervous	JJ	_	34	amod
34	system	system	NN	_	29	nmod
35	.	.	.	_	3	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	interaction	interaction	NN	_	0	ROOT
4	of	of	IN	_	6	case
5	prostaglandin	prostaglandin	NN	_	6	compound
6	F2alpha	f2alpha	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	oxytocin	oxytocin	NN	_	6	conj
9	in	in	IN	_	11	case
10	placental	placental	JJ	_	11	amod
11	vessels	vessel	NNS	_	3	nmod
12	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	prostaglandin	prostaglandin	NN	_	5	compound
5	F2alpha	f2alpha	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	synthetic	synthetic	JJ	_	8	amod
8	oxytocin	oxytocin	NN	_	5	conj
9	on	on	IN	_	11	case
10	placental	placental	JJ	_	11	amod
11	vessels	vessel	NNS	_	2	nmod
12	was	be	VBD	_	13	auxpass
13	studied	study	VBN	_	0	ROOT
14	in	in	FW	_	15	compound
15	vitro	vitro	FW	_	13	advmod
16	.	.	.	_	13	punct

1	Resistance	resistance	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	measured	measure	VBN	_	0	ROOT
4	near	near	IN	_	7	case
5	the	the	DT	_	7	det
6	placental	placental	JJ	_	7	amod
7	margin	margin	NN	_	3	nmod
8	after	after	IN	_	11	case
9	spontaneous	spontaneous	JJ	_	11	amod
10	term	term	NN	_	11	compound
11	delivery	delivery	NN	_	3	nmod
12	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	seven	seven	CD	_	4	nummod
3	experiments	experiment	NNS	_	4	compound
4	reactions	reaction	NNS	_	10	nmod
5	to	to	TO	_	6	case
6	norepinephrine	norepinephrine	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	oxytocin	oxytocin	NN	_	6	conj
9	were	be	VBD	_	10	cop
10	PGF2alpha	pgf2alpha	NN	_	0	ROOT
11	.	.	.	_	10	punct

1	PGF2alpha	pgf2alpha	NN	_	2	nsubj
2	produced	produce	VBD	_	0	ROOT
3	significantly	significantly	RB	_	4	advmod
4	increased	increase	VBN	_	5	amod
5	vasoconstriction	vasoconstriction	NN	_	2	dobj
6	after	after	IN	_	9	case
7	a	a	DT	_	9	det
8	single	single	JJ	_	9	amod
9	administration	administration	NN	_	2	nmod
10	of	of	IN	_	11	case
11	oxytocin	oxytocin	NN	_	9	nmod
12	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	eight	eight	CD	_	3	nummod
3	experiments	experiment	NNS	_	7	nmod
4	the	the	DT	_	6	det
5	perfusion	perfusion	NN	_	6	compound
6	medium	medium	NN	_	7	nsubj
7	contained	contain	VBD	_	0	ROOT
8	oxytocin	oxytocin	NN	_	7	dobj
9	.	.	.	_	7	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	change	change	NN	_	2	nsubj
5	after	after	IN	_	8	case
6	a	a	DT	_	8	det
7	single	single	JJ	_	8	amod
8	dose	dose	NN	_	2	nmod
9	of	of	IN	_	10	case
10	PGF2alpha	pgf2alpha	NN	_	8	nmod
11	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	reaction	reaction	NN	_	5	nsubj
3	after	after	IN	_	4	case
4	norepinephrine	norepinephrine	NN	_	2	nmod
5	remained	remain	VBD	_	0	ROOT
6	the	the	DT	_	7	det
7	same	same	JJ	_	5	xcomp
8	in	in	IN	_	10	case
9	both	both	DT	_	10	det
10	groups	group	NNS	_	7	nmod
11	of	of	IN	_	12	case
12	experiments	experiment	NNS	_	10	nmod
13	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	thus	thus	RB	_	2	advmod
4	an	a	DT	_	6	det
5	enhancement	enhancement	NN	_	6	compound
6	effect	effect	NN	_	2	nsubj

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	thus	thus	RB	_	2	advmod
4	an	a	DT	_	6	det
5	enhancement	enhancement	NN	_	6	compound
6	effect	effect	NN	_	2	nsubj
7	of	of	IN	_	8	case
8	PGF2alpha	pgf2alpha	NN	_	6	nmod
9	upon	upon	IN	_	11	case
10	the	the	DT	_	11	det
11	reaction	reaction	NN	_	2	nmod
12	of	of	IN	_	14	case
13	placental	placental	JJ	_	14	amod
14	vessels	vessel	NNS	_	11	nmod
15	to	to	TO	_	16	case
16	oxytocin	oxytocin	NN	_	11	nmod
17	in	in	FW	_	18	compound
18	vitro	vitro	FW	_	16	advmod
19	.	.	.	_	2	punct

1	Note	note	VB	_	0	ROOT
2	:	:	:	_	1	punct
3	dissolution	dissolution	NN	_	1	dep
4	of	of	IN	_	6	case
5	aerosol	aerosol	NN	_	6	compound
6	particles	particle	NNS	_	3	nmod
7	of	of	IN	_	8	case
8	budesonide	budesonide	NN	_	6	nmod
9	in	in	IN	_	10	case
10	Survanta	survanta	NN	_	3	nmod
11	,	,	,	_	3	punct
12	a	a	DT	_	15	det
13	model	model	NN	_	15	compound
14	lung	lung	NN	_	15	compound
15	surfactant	surfactant	NN	_	3	appos
16	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	24	nsubjpass
3	of	of	IN	_	7	case
4	a	a	DT	_	7	det
5	pulmonary	pulmonary	JJ	_	7	amod
6	surfactant	surfactant	NN	_	7	compound
7	extract	extract	NN	_	2	nmod
8	from	from	IN	_	10	case
9	bovine	bovine	JJ	_	10	amod
10	lung	lung	NN	_	7	nmod
11	,	,	,	_	10	punct
12	Survanta	survanta	NN	_	10	appos
13	,	,	,	_	10	punct
14	on	on	IN	_	17	case
15	the	the	DT	_	17	det
16	dissolution	dissolution	NN	_	17	compound
17	rate	rate	NN	_	2	nmod
18	of	of	IN	_	20	case
19	aerosol	aerosol	NN	_	20	compound
20	particles	particle	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	budesonide	budesonide	NN	_	20	nmod
23	was	be	VBD	_	24	auxpass
24	determined	determine	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	Aerosol	Aerosol	NNP	_	2	compound
2	particles	particle	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	budesonide	budesonide	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	generated	generate	VBN	_	0	ROOT
7	from	from	IN	_	10	case
8	an	a	DT	_	10	det
9	ethanol	ethanol	NN	_	10	compound
10	solution	solution	NN	_	6	nmod
11	,	,	,	_	6	punct
12	dried	dry	VBD	_	6	conj
13	,	,	,	_	6	punct
14	and	and	CC	_	6	cc
15	collected	collect	VBN	_	6	conj
16	by	by	IN	_	19	case
17	a	a	DT	_	19	det
18	cascade	cascade	NN	_	19	compound
19	impactor	impactor	NN	_	15	nmod
20	for	for	IN	_	21	case
21	characterization	characterization	NN	_	19	nmod
22	or	or	CC	_	19	cc
23	by	by	IN	_	26	case
24	a	a	DT	_	26	det
25	liquid	liquid	JJ	_	26	amod
26	impinger	impinger	NN	_	19	conj
27	for	for	IN	_	29	case
28	dissolution	dissolution	NN	_	29	compound
29	experiments	experiment	NNS	_	26	nmod
30	.	.	.	_	6	punct

1	Powder	Powder	NNP	_	2	compound
2	x	x	SYM	_	20	nsubjpass
3	-	-	:	_	2	punct
4	ray	ray	NN	_	5	compound
5	diffraction	diffraction	NN	_	2	dep
6	,	,	,	_	5	punct
7	differential	differential	JJ	_	9	amod
8	scanning	scanning	NN	_	9	compound
9	calorimetry	calorimetry	NN	_	5	appos
10	,	,	,	_	5	punct
11	differential	differential	JJ	_	13	amod
12	thermal	thermal	JJ	_	13	amod
13	analysis	analysis	NN	_	5	conj
14	,	,	,	_	5	punct
15	and	and	CC	_	5	cc
16	scanning	scanning	NN	_	18	compound
17	electron	electron	NN	_	18	compound
18	microscopy	microscopy	NN	_	5	conj
19	were	be	VBD	_	20	auxpass
20	used	use	VBN	_	0	ROOT
21	to	to	TO	_	22	mark
22	characterize	characterize	VB	_	20	xcomp
23	the	the	DT	_	25	det
24	aerosol	aerosol	NN	_	25	compound
25	particles	particle	NNS	_	22	dobj
26	and	and	CC	_	22	cc
27	starting	start	VBG	_	28	case
28	material	material	NN	_	22	conj
29	.	.	.	_	20	punct

1	No	no	DT	_	2	neg
2	change	change	NN	_	6	nsubjpass
3	in	in	IN	_	4	case
4	phase	phase	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	detected	detect	VBN	_	0	ROOT
7	,	,	,	_	6	punct
8	although	although	IN	_	12	mark
9	the	the	DT	_	11	det
10	aerosol	aerosol	NN	_	11	compound
11	particles	particle	NNS	_	12	nsubj
12	appeared	appear	VBD	_	6	advcl
13	to	to	TO	_	14	mark
14	contain	contain	VB	_	12	xcomp
15	residual	residual	JJ	_	16	amod
16	solvent	solvent	JJ	_	14	dobj
17	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	dissolution	dissolution	NN	_	3	compound
3	rate	rate	NN	_	11	nsubj
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	aerosol	aerosol	NN	_	7	compound
7	particles	particle	NNS	_	3	nmod
8	in	in	IN	_	9	case
9	saline	saline	NN	_	3	nmod
10	was	be	VBD	_	11	cop
11	low	low	JJ	_	0	ROOT
12	and	and	CC	_	11	cc
13	variable	variable	JJ	_	11	conj
14	.	.	.	_	11	punct

1	Survanta	survanta	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	extent	extent	NN	_	2	dobj
5	of	of	IN	_	6	case
6	dissolution	dissolution	NN	_	4	nmod
7	of	of	IN	_	8	case
8	budesonide	budesonide	NN	_	6	nmod
9	in	in	IN	_	10	case
10	proportion	proportion	NN	_	2	nmod
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	added	add	VBN	_	14	amod
14	concentration	concentration	NN	_	10	nmod
15	,	,	,	_	14	punct
16	which	which	WDT	_	19	nsubjpass
17	was	be	VBD	_	19	auxpass
18	also	also	RB	_	19	advmod
19	verified	verify	VBN	_	14	acl:relcl
20	by	by	IN	_	23	case
21	equilibrium	equilibrium	NN	_	23	compound
22	solubilization	solubilization	NN	_	23	compound
23	studies	study	NNS	_	19	nmod
24	.	.	.	_	2	punct

1	Survanta	survanta	NN	_	3	nsubj
2	also	also	RB	_	3	advmod
3	increased	increase	VBD	_	0	ROOT
4	rate	rate	NN	_	3	dobj
5	of	of	IN	_	6	case
6	dissolution	dissolution	NN	_	4	nmod
7	,	,	,	_	3	punct
8	in	in	IN	_	10	case
9	a	a	DT	_	10	det
10	manner	manner	NN	_	3	nmod
11	similar	similar	JJ	_	10	amod
12	to	to	TO	_	15	case
13	sodium	sodium	NN	_	15	compound
14	dodecyl	dodecyl	NN	_	15	compound
15	sulfate	sulfate	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Analysis	analysis	NN	_	9	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	concentration	concentration	NN	_	1	nmod
5	of	of	IN	_	6	case
6	budesonide	budesonide	NN	_	4	nmod
7	following	follow	VBG	_	8	case
8	ultracentrifugation	ultracentrifugation	NN	_	4	nmod
9	indicated	indicate	VBD	_	0	ROOT
10	that	that	IN	_	12	mark
11	there	there	EX	_	12	expl
12	is	be	VBZ	_	9	ccomp
13	rapid	rapid	JJ	_	14	amod
14	equilibration	equilibration	NN	_	12	nsubj
15	of	of	IN	_	16	case
16	budesonide	budesonide	NN	_	14	nmod
17	between	between	IN	_	22	case
18	the	the	DT	_	22	det
19	Survanta	survanta	NN	_	22	amod
20	and	and	CC	_	19	cc
21	aqueous	aqueous	JJ	_	19	conj
22	phase	phase	NN	_	12	nmod
23	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	lung	lung	NN	_	6	compound
6	surfactant	surfactant	NN	_	7	nsubj
7	has	have	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	potential	potential	NN	_	7	dobj
10	of	of	IN	_	11	mark
11	enhancing	enhance	VBG	_	9	acl
12	the	the	DT	_	13	det
13	rate	rate	NN	_	11	dobj
14	and	and	CC	_	13	cc
15	extent	extent	NN	_	13	conj
16	of	of	IN	_	17	case
17	dissolution	dissolution	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	administered	administer	VBN	_	19	acl
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	lung	lung	NN	_	20	nmod
24	.	.	.	_	3	punct

1	Anaesthesia	Anaesthesia	NNP	_	0	ROOT
2	and	and	CC	_	1	cc
3	the	the	DT	_	5	det
4	epileptic	epileptic	JJ	_	5	amod
5	pateint	pateint	NN	_	1	conj
6	.	.	.	_	1	punct

1	A	a	DT	_	2	det
2	review	review	NN	_	0	ROOT
3	.	.	.	_	2	punct

1	A	a	DT	_	2	det
2	review	review	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	presented	present	VBN	_	0	ROOT
5	of	of	IN	_	6	case
6	some	some	DT	_	4	nmod
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	problems	problem	NNS	_	6	nmod
10	that	that	WDT	_	12	nsubj
11	may	may	MD	_	12	aux
12	arise	arise	VB	_	9	acl:relcl
13	in	in	IN	_	14	case
14	association	association	NN	_	12	nmod
15	with	with	IN	_	16	case
16	anaesthesia	anaesthesia	NN	_	14	nmod
17	for	for	IN	_	19	case
18	epileptic	epileptic	JJ	_	19	amod
19	patients	patient	NNS	_	14	nmod
20	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	possibility	possibility	NN	_	2	nsubj
5	of	of	IN	_	6	mark
6	precipitating	precipitate	VBG	_	4	acl
7	anticonvulsant	anticonvulsant	JJ	_	9	amod
8	drug	drug	NN	_	9	compound
9	toxicity	toxicity	NN	_	6	dobj
10	.	.	.	_	2	punct

1	Numerous	numerous	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	possible	possible	JJ	_	0	ROOT
6	with	with	IN	_	9	case
7	some	some	DT	_	9	det
8	anticonvulsant	anticonvulsant	JJ	_	9	amod
9	agents	agent	NNS	_	5	nmod
10	,	,	,	_	9	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	phenobarbitone	phenobarbitone	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	phenytoin	phenytoin	NN	_	13	conj
16	,	,	,	_	9	punct
17	which	which	WDT	_	18	nsubj
18	affect	affect	VBP	_	9	acl:relcl
19	hepatic	hepatic	JJ	_	22	amod
20	microsomal	microsomal	JJ	_	22	amod
21	enzyme	enzyme	NN	_	22	compound
22	systems	system	NNS	_	18	dobj
23	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	risk	risk	NN	_	2	nsubj
5	of	of	IN	_	6	case
6	convulsions	convulsion	NNS	_	4	nmod
7	occurring	occur	VBG	_	6	acl
8	in	in	IN	_	10	case
9	susceptible	susceptible	JJ	_	10	amod
10	patients	patient	NNS	_	7	nmod
11	following	follow	VBG	_	13	case
12	the	the	DT	_	13	det
13	use	use	NN	_	7	nmod
14	of	of	IN	_	18	case
15	the	the	DT	_	18	det
16	new	new	JJ	_	18	amod
17	anaesthetic	anaesthetic	JJ	_	18	amod
18	agents	agent	NNS	_	13	nmod
19	which	which	WDT	_	21	nsubj
20	are	be	VBP	_	21	cop
21	capable	capable	JJ	_	18	acl:relcl
22	of	of	IN	_	23	mark
23	inducing	induce	VBG	_	21	advcl
24	CNS	cns	NN	_	25	compound
25	excitability	excitability	NN	_	23	dobj
26	.	.	.	_	2	punct

1	Interaction	interaction	NN	_	0	ROOT
2	between	between	IN	_	3	case
3	glycine	glycine	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	glutamate	glutamate	NN	_	3	conj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	development	development	NN	_	1	nmod
9	of	of	IN	_	11	case
10	spontaneous	spontaneous	JJ	_	11	amod
11	motility	motility	NN	_	8	nmod
12	in	in	IN	_	14	case
13	chick	chick	NN	_	14	compound
14	embryos	embryo	NNS	_	11	nmod
15	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	5	nmod
4	we	we	PRP	_	5	nsubj
5	investigated	investigate	VBD	_	0	ROOT
6	whether	whether	IN	_	9	mark
7	also	also	RB	_	9	advmod
8	glycine	glycine	NN	_	9	nsubj
9	fulfils	fulfil	VBZ	_	5	ccomp
10	the	the	DT	_	11	det
11	function	function	NN	_	9	dobj
12	as	as	IN	_	13	case
13	co	co	NN	_	9	nmod
14	-	-	:	_	13	punct
15	activator	activator	NN	_	13	dep
16	in	in	IN	_	18	case
17	glutamatergic	glutamatergic	JJ	_	18	amod
18	activation	activation	NN	_	9	nmod
19	of	of	IN	_	21	case
20	NMDA	nmda	NN	_	21	compound
21	receptors	receptor	NNS	_	18	nmod
22	in	in	IN	_	25	case
23	the	the	DT	_	25	det
24	neuronal	neuronal	JJ	_	25	amod
25	apparatus	apparatus	NN	_	18	nmod
26	of	of	IN	_	28	case
27	spontaneous	spontaneous	JJ	_	28	amod
28	motility	motility	NN	_	25	nmod
29	in	in	IN	_	31	case
30	chick	chick	NN	_	31	compound
31	embryos	embryo	NNS	_	28	nmod
32	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	successive	successive	JJ	_	3	amod
3	application	application	NN	_	16	nsubj
4	of	of	IN	_	5	case
5	glycine	glycine	NN	_	3	nmod
6	(	(	CD	_	7	nummod
7	5	5	CD	_	10	nummod
8	or	or	CC	_	7	cc
9	10	10	CD	_	7	conj
10	mg	mg	NN	_	5	dep
11	/	/	:	_	5	punct
12	kg	kg	NN	_	14	compound
13	egg	egg	NN	_	14	compound
14	weight	weight	NN	_	5	dep
15	(	(	CD	_	14	nummod
16	e	e	LS	_	0	ROOT
17	.	.	.	_	16	punct
18	w	w	NN	_	16	dep
19	.	.	.	_	18	punct
20	)	)	SYM	_	18	dep

1	and	and	CC	_	3	cc
2	glutamate	glutamate	JJ	_	3	conj
3	(	(	NN	_	10	dep
4	15	15	CD	_	5	nummod
5	mg	mg	NN	_	10	dep
6	/	/	:	_	7	punct
7	kg	kg	NN	_	10	dep
8	e	e	SYM	_	10	dep
9	.	.	.	_	10	punct
10	w	w	NN	_	0	ROOT
11	.	.	.	_	10	punct
12	)	)	SYM	_	10	dep

1	The	the	DT	_	3	det
2	successive	successive	JJ	_	3	amod
3	application	application	NN	_	16	nsubj
4	of	of	IN	_	5	case
5	glycine	glycine	NN	_	3	nmod
6	(	(	CD	_	7	nummod
7	5	5	CD	_	10	nummod
8	or	or	CC	_	7	cc
9	10	10	CD	_	7	conj
10	mg	mg	NN	_	5	dep
11	/	/	:	_	5	punct
12	kg	kg	NN	_	14	compound
13	egg	egg	NN	_	14	compound
14	weight	weight	NN	_	5	dep
15	(	(	CD	_	14	nummod
16	e	e	LS	_	0	ROOT
17	.	.	.	_	16	punct
18	w	w	NN	_	30	dep
19	.	.	.	_	18	punct
20	)	)	NN	_	18	conj
21	and	and	CC	_	18	cc
22	glutamate	glutamate	NN	_	25	compound
23	(	(	CD	_	25	nummod
24	15	15	CD	_	25	nummod
25	mg	mg	NN	_	18	conj
26	/	/	:	_	27	punct
27	kg	kg	NN	_	30	dep
28	e	e	SYM	_	30	dep
29	.	.	.	_	30	punct
30	w	w	NN	_	16	dep
31	.	.	.	_	30	punct
32	)	)	NN	_	39	nsubj
33	in	in	IN	_	37	case
34	a	a	DT	_	37	det
35	10	10	CD	_	36	compound
36	min	min	NN	_	37	amod
37	interval	interval	NN	_	32	nmod
38	significantly	significantly	RB	_	39	advmod
39	increased	increase	VBD	_	30	parataxis
40	the	the	DT	_	41	det
41	activation	activation	NN	_	39	dobj
42	of	of	IN	_	44	case
43	spontaneous	spontaneous	JJ	_	44	amod
44	motility	motility	NN	_	41	nmod
45	of	of	IN	_	46	case
46	17	17	CD	_	44	nmod
47	-	-	:	_	46	punct
48	day	day	NN	_	46	dep
49	-	-	:	_	46	punct
50	old	old	JJ	_	52	amod
51	chick	chick	NN	_	52	compound
52	embryos	embryo	NNS	_	46	dep
53	in	in	IN	_	54	case
54	comparison	comparison	NN	_	52	nmod
55	with	with	IN	_	57	case
56	the	the	DT	_	57	det
57	effect	effect	NN	_	54	nmod
58	of	of	IN	_	59	case
59	glutamate	glutamate	NN	_	57	nmod
60	alone	alone	RB	_	59	advmod
61	.	.	.	_	16	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubj
3	did	do	VBD	_	5	aux
4	not	not	RB	_	5	neg
5	depend	depend	VB	_	0	ROOT
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	order	order	NN	_	5	nmod
9	of	of	IN	_	10	case
10	application	application	NN	_	8	nmod
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	drugs	drug	NNS	_	10	nmod
14	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	13	13	CD	_	4	nmod
3	-	-	:	_	4	punct
4	day	day	NN	_	0	ROOT
5	-	-	:	_	4	punct
6	old	old	JJ	_	7	amod
7	embryos	embryo	NNS	_	11	nsubj
8	,	,	,	_	7	punct
9	glycine	glycine	NN	_	7	appos
10	was	be	VBD	_	11	cop
11	ineffective	ineffective	JJ	_	4	dep
12	in	in	IN	_	14	case
13	both	both	CC	_	14	det
14	doses	dose	NNS	_	11	nmod
15	.	.	.	_	4	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	concluded	conclude	VBN	_	0	ROOT
4	from	from	IN	_	6	case
5	these	these	DT	_	6	det
6	results	result	NNS	_	3	nmod
7	that	that	IN	_	19	mark
8	the	the	DT	_	10	det
9	modulatory	modulatory	JJ	_	10	amod
10	effect	effect	NN	_	19	nsubj
11	of	of	IN	_	12	case
12	glycine	glycine	NN	_	10	nmod
13	is	be	VBZ	_	19	cop
14	evidently	evidently	RB	_	19	advmod
15	a	a	DT	_	19	det
16	later	later	JJ	_	19	amod
17	developmental	developmental	JJ	_	19	amod
18	acquisition	acquisition	NN	_	19	compound
19	(	(	NN	_	3	ccomp
20	after	after	IN	_	21	case
21	day	day	NN	_	19	nmod
22	15	15	CD	_	21	nummod
23	of	of	IN	_	25	case
24	incubation	incubation	NN	_	25	compound
25	)	)	NN	_	21	nmod
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	embryogenesis	embryogenesis	NN	_	25	nmod
29	of	of	IN	_	30	case
30	NMDA	nmda	NN	_	28	nmod
31	-	-	:	_	19	punct
32	ergic	ergic	JJ	_	33	amod
33	activation	activation	NN	_	19	dep
34	of	of	IN	_	36	case
35	spontaneous	spontaneous	JJ	_	36	amod
36	motility	motility	NN	_	33	nmod
37	in	in	IN	_	39	case
38	chick	chick	NN	_	39	compound
39	embryos	embryo	NNS	_	33	nmod
40	similarly	similarly	RB	_	43	advmod
41	as	as	IN	_	43	case
42	glycinergic	glycinergic	JJ	_	43	amod
43	inhibition	inhibition	NN	_	33	nmod
44	.	.	.	_	3	punct

1	Acute	acute	JJ	_	2	amod
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	different	different	JJ	_	5	amod
5	antidepressants	antidepressant	NNS	_	2	nmod
6	on	on	IN	_	7	case
7	glycemia	glycemia	NN	_	2	nmod
8	in	in	IN	_	9	case
9	diabetic	diabetic	JJ	_	2	nmod
10	and	and	CC	_	9	cc
11	non	non	JJ	_	9	conj
12	-	-	:	_	9	punct
13	diabetic	diabetic	JJ	_	14	amod
14	rats	rat	NNS	_	9	dep
15	.	.	.	_	2	punct

1	Diabetic	Diabetic	NNP	_	2	compound
2	patients	patient	NNS	_	3	nsubj
3	have	have	VBP	_	0	ROOT
4	a	a	DT	_	8	det
5	20	20	CD	_	6	compound
6	%	%	NN	_	7	nmod:npmod
7	higher	higher	JJR	_	8	amod
8	risk	risk	NN	_	3	dobj
9	of	of	IN	_	10	case
10	depression	depression	NN	_	8	nmod
11	than	than	IN	_	14	case
12	the	the	DT	_	14	det
13	general	general	JJ	_	14	amod
14	population	population	NN	_	8	nmod
15	.	.	.	_	3	punct

1	Treatment	treatment	NN	_	7	nsubj
2	with	with	IN	_	4	case
3	antidepressant	antidepressant	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	can	can	MD	_	7	aux
6	directly	directly	RB	_	7	advmod
7	interfere	interfere	VB	_	0	ROOT
8	with	with	IN	_	11	case
9	blood	blood	NN	_	11	compound
10	glucose	glucose	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	or	or	CC	_	7	cc
13	may	may	MD	_	14	aux
14	interact	interact	VB	_	7	conj
15	with	with	IN	_	17	case
16	hypoglycemic	hypoglycemic	JJ	_	17	amod
17	agents	agent	NNS	_	14	nmod
18	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	treatment	treatment	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	depression	depression	NN	_	2	nmod
5	in	in	IN	_	7	case
6	diabetic	diabetic	JJ	_	7	amod
7	patients	patient	NNS	_	2	nmod
8	must	must	MD	_	9	aux
9	take	take	VB	_	0	ROOT
10	into	into	IN	_	12	case
11	account	account	NN	_	12	compound
12	variations	variation	NNS	_	9	nmod
13	of	of	IN	_	15	case
14	glycemic	glycemic	JJ	_	15	amod
15	levels	level	NNS	_	12	nmod
16	at	at	IN	_	18	case
17	different	different	JJ	_	18	amod
18	times	time	NNS	_	9	nmod
19	and	and	CC	_	9	cc
20	a	a	DT	_	21	det
21	comparison	comparison	NN	_	28	nsubj
22	of	of	IN	_	26	case
23	the	the	DT	_	26	det
24	available	available	JJ	_	26	amod
25	antidepressant	antidepressant	JJ	_	26	amod
26	agents	agent	NNS	_	21	nmod
27	is	be	VBZ	_	28	cop
28	important	important	JJ	_	9	conj
29	.	.	.	_	9	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	6	nmod
5	we	we	PRP	_	6	nsubj
6	evaluated	evaluate	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	interference	interference	NN	_	6	dobj
9	of	of	IN	_	10	case
10	antidepressants	antidepressant	NNS	_	8	nmod
11	with	with	IN	_	14	case
12	blood	blood	NN	_	14	compound
13	glucose	glucose	NN	_	14	compound
14	levels	level	NNS	_	8	nmod
15	of	of	IN	_	16	case
16	diabetic	diabetic	JJ	_	14	nmod
17	and	and	CC	_	16	cc
18	non	non	JJ	_	16	conj
19	-	-	:	_	16	punct
20	diabetic	diabetic	JJ	_	21	amod
21	rats	rat	NNS	_	16	dep
22	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	first	first	JJ	_	4	amod
4	experiment	experiment	NN	_	11	nmod
5	,	,	,	_	11	punct
6	male	male	JJ	_	9	amod
7	adult	adult	JJ	_	9	amod
8	Wistar	Wistar	NNP	_	9	compound
9	rats	rat	NNS	_	11	nsubjpass
10	were	be	VBD	_	11	auxpass
11	fasted	fast	VBN	_	0	ROOT
12	for	for	IN	_	14	case
13	12	12	CD	_	14	nummod
14	h	h	NN	_	11	nmod
15	.	.	.	_	11	punct

1	Imipramine	imipramine	NN	_	0	ROOT
2	(	(	CD	_	3	compound
3	5	5	CD	_	4	nummod
4	mg	mg	NN	_	42	nsubjpass
5	/	/	:	_	4	punct
6	kg	kg	NN	_	7	compound
7	)	)	NN	_	4	dep
8	,	,	,	_	4	punct
9	moclobemide	moclobemide	NN	_	4	appos
10	(	(	CD	_	11	compound
11	30	30	CD	_	12	nummod
12	mg	mg	NN	_	9	dep
13	/	/	:	_	12	punct
14	kg	kg	NN	_	15	compound
15	)	)	NN	_	12	dep
16	,	,	,	_	12	punct
17	clonazepam	clonazepam	NN	_	20	compound
18	(	(	CD	_	19	compound
19	0.25	0.25	CD	_	20	nummod
20	mg	mg	NN	_	12	appos
21	/	/	:	_	12	punct
22	kg	kg	NN	_	23	compound
23	)	)	NN	_	12	dep
24	,	,	,	_	12	punct
25	fluoxetine	fluoxetine	NN	_	12	appos
26	(	(	CD	_	27	compound
27	20	20	CD	_	28	nummod
28	mg	mg	NN	_	25	dep
29	/	/	:	_	28	punct
30	kg	kg	NN	_	32	compound
31	)	)	NN	_	32	compound
32	sertraline	sertraline	NN	_	28	dep
33	(	(	CD	_	34	compound
34	30	30	CD	_	35	nummod
35	mg	mg	NN	_	32	dep
36	/	/	:	_	28	punct
37	kg	kg	NN	_	38	compound
38	)	)	NN	_	28	dep
39	or	or	CC	_	38	cc
40	vehicle	vehicle	NN	_	38	conj
41	was	be	VBD	_	42	auxpass
42	administered	administer	VBN	_	1	acl:relcl
43	.	.	.	_	1	punct

1	After	after	IN	_	3	case
2	30	30	CD	_	3	nummod
3	min	min	NN	_	8	nmod
4	,	,	,	_	8	punct
5	fasting	fast	VBG	_	6	amod
6	glycemia	glycemia	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	measured	measure	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	An	a	DT	_	4	det
2	oral	oral	JJ	_	4	amod
3	glucose	glucose	NN	_	4	compound
4	overload	overload	NN	_	15	nsubjpass
5	of	of	IN	_	7	case
6	1	1	CD	_	7	nummod
7	ml	ml	NN	_	4	nmod
8	of	of	IN	_	13	case
9	a	a	DT	_	13	det
10	50	50	CD	_	11	compound
11	%	%	NN	_	13	amod
12	glucose	glucose	NN	_	13	compound
13	solution	solution	NN	_	7	nmod
14	was	be	VBD	_	15	auxpass
15	given	give	VBN	_	22	csubjpass
16	to	to	TO	_	17	case
17	rats	rat	NNS	_	15	nmod
18	and	and	CC	_	17	cc
19	blood	blood	NN	_	20	compound
20	glucose	glucose	NN	_	17	conj
21	was	be	VBD	_	22	auxpass
22	determined	determine	VBN	_	0	ROOT
23	after	after	IN	_	24	case
24	30	30	CD	_	22	nmod
25	,	,	,	_	24	punct
26	60	60	CD	_	24	conj
27	and	and	CC	_	24	cc
28	90	90	CD	_	24	conj
29	min	min	NN	_	24	dep
30	.	.	.	_	22	punct

1	Imipramine	imipramine	NN	_	6	nsubj
2	and	and	CC	_	1	cc
3	clonazepam	clonazepam	NN	_	1	conj
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	change	change	VB	_	0	ROOT
7	fasting	fasting	NN	_	10	compound
8	or	or	CC	_	7	cc
9	overload	overload	NN	_	7	conj
10	glycemia	glycemia	NN	_	6	dobj
11	.	.	.	_	6	punct

1	Fluoxetine	Fluoxetine	NNP	_	4	nsubj
2	and	and	CC	_	1	cc
3	moclobemide	moclobemide	NN	_	1	conj
4	increased	increase	VBD	_	0	ROOT
5	blood	blood	NN	_	6	compound
6	glucose	glucose	NN	_	4	dobj
7	at	at	IN	_	9	case
8	different	different	JJ	_	9	amod
9	times	time	NNS	_	4	nmod
10	after	after	IN	_	13	case
11	the	the	DT	_	13	det
12	glucose	glucose	NN	_	13	compound
13	overload	overload	NN	_	4	nmod
14	.	.	.	_	4	punct

1	Sertraline	sertraline	NN	_	2	nsubj
2	neutralized	neutralize	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	increase	increase	NN	_	2	dobj
5	of	of	IN	_	6	case
6	glycemia	glycemia	NN	_	4	nmod
7	induced	induce	VBN	_	6	acl
8	by	by	IN	_	11	case
9	oral	oral	JJ	_	11	amod
10	glucose	glucose	NN	_	11	compound
11	overload	overload	NN	_	7	nmod
12	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	second	second	JJ	_	4	amod
4	experiment	experiment	NN	_	8	nmod
5	,	,	,	_	8	punct
6	non	non	JJ	_	8	dep
7	-	-	:	_	8	punct
8	diabetic	diabetic	JJ	_	0	ROOT
9	and	and	CC	_	8	cc
10	streptozotocin	streptozotocin	NN	_	16	dep
11	-	-	:	_	16	punct
12	induced	induce	VBN	_	14	amod
13	diabetic	diabetic	JJ	_	14	amod
14	rats	rat	NNS	_	16	nsubjpass
15	were	be	VBD	_	16	auxpass
16	fasted	fast	VBN	_	8	conj
17	,	,	,	_	8	punct
18	and	and	CC	_	8	cc
19	the	the	DT	_	21	det
20	same	same	JJ	_	21	amod
21	procedures	procedure	NNS	_	23	nsubjpass
22	were	be	VBD	_	23	auxpass
23	followed	follow	VBN	_	8	conj
24	for	for	IN	_	25	case
25	estimation	estimation	NN	_	23	nmod
26	of	of	IN	_	28	case
27	glucose	glucose	NN	_	28	compound
28	tolerance	tolerance	NN	_	25	nmod
29	30	30	CD	_	30	nummod
30	min	min	NN	_	28	nmod
31	after	after	IN	_	30	case
32	glucose	glucose	NN	_	33	compound
33	overload	overload	NN	_	30	dep
34	.	.	.	_	8	punct

1	Again	again	RB	_	4	advmod
2	,	,	,	_	4	punct
3	sertraline	sertraline	NN	_	4	nsubj
4	neutralized	neutralize	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	increase	increase	NN	_	4	dobj
7	in	in	IN	_	8	case
8	glycemia	glycemia	NN	_	6	nmod
9	after	after	IN	_	11	case
10	glucose	glucose	NN	_	11	compound
11	overload	overload	NN	_	6	nmod
12	both	both	CC	_	14	cc:preconj
13	in	in	IN	_	14	case
14	diabetic	diabetic	JJ	_	11	nmod
15	and	and	CC	_	14	cc
16	non	non	JJ	_	14	conj
17	-	-	:	_	19	punct
18	diabetic	diabetic	JJ	_	19	amod
19	rats	rat	NNS	_	14	dep
20	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	raise	raise	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	question	question	NN	_	3	dobj
6	of	of	IN	_	12	mark
7	whether	whether	IN	_	12	mark
8	sertraline	sertraline	NN	_	12	nsubj
9	is	be	VBZ	_	12	cop
10	the	the	DT	_	12	det
11	best	best	JJS	_	12	amod
12	choice	choice	NN	_	5	acl
13	for	for	IN	_	15	case
14	prolonged	prolonged	JJ	_	15	amod
15	use	use	NN	_	12	nmod
16	for	for	IN	_	18	case
17	diabetic	diabetic	JJ	_	18	amod
18	individuals	individual	NNS	_	15	nmod
19	,	,	,	_	12	punct
20	because	because	IN	_	24	case
21	of	of	IN	_	20	mwe
22	its	its	PRP$	_	24	nmod:poss
23	antihyperglycemic	antihyperglycemic	JJ	_	24	amod
24	effects	effect	NNS	_	12	nmod
25	.	.	.	_	3	punct

1	Clonazepam	Clonazepam	NNP	_	4	nsubj
2	would	would	MD	_	4	aux
3	be	be	VB	_	4	cop
4	useful	useful	JJ	_	0	ROOT
5	in	in	IN	_	6	case
6	cases	case	NNS	_	4	nmod
7	with	with	IN	_	9	case
8	potential	potential	JJ	_	9	amod
9	risk	risk	NN	_	6	nmod
10	of	of	IN	_	11	case
11	hypoglycemia	hypoglycemia	NN	_	9	nmod
12	.	.	.	_	4	punct

1	Spermine	spermine	NN	_	2	nsubj
2	promotes	promote	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	translocation	translocation	NN	_	2	dobj
5	of	of	IN	_	7	case
6	phosphatidate	phosphatidate	NN	_	7	compound
7	phosphohydrolase	phosphohydrolase	NN	_	4	nmod
8	from	from	IN	_	10	case
9	the	the	DT	_	10	det
10	cytosol	cytosol	NN	_	4	nmod
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	microsomal	microsomal	JJ	_	14	amod
14	fraction	fraction	NN	_	4	nmod
15	of	of	IN	_	17	case
16	rat	rat	NN	_	17	compound
17	liver	liver	NN	_	14	nmod
18	and	and	CC	_	2	cc
19	it	it	PRP	_	20	nsubj
20	enhances	enhance	VBZ	_	2	conj
21	the	the	DT	_	22	det
22	effects	effect	NNS	_	20	dobj
23	of	of	IN	_	24	case
24	oleate	oleate	NN	_	22	nmod
25	in	in	IN	_	27	case
26	this	this	DT	_	27	det
27	respect	respect	NN	_	22	nmod
28	.	.	.	_	2	punct

1	Spermine	spermine	NN	_	8	nsubj
2	(	(	CD	_	3	compound
3	0.5	0.5	CD	_	1	nummod
4	-	-	:	_	1	punct
5	2	2	CD	_	6	compound
6	mM	mm	NN	_	7	amod
7	)	)	NN	_	1	dep
8	promoted	promote	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	translocation	translocation	NN	_	8	dobj
11	of	of	IN	_	13	case
12	phosphatidate	phosphatidate	NN	_	13	compound
13	phosphohydrolase	phosphohydrolase	NN	_	10	nmod
14	from	from	IN	_	16	case
15	the	the	DT	_	16	det
16	soluble	soluble	JJ	_	10	nmod
17	to	to	TO	_	20	case
18	the	the	DT	_	20	det
19	microsomal	microsomal	JJ	_	20	amod
20	fraction	fraction	NN	_	10	nmod
21	in	in	IN	_	26	case
22	a	a	DT	_	26	det
23	cell	cell	NN	_	26	compound
24	-	-	:	_	26	punct
25	free	free	JJ	_	26	amod
26	system	system	NN	_	8	nmod
27	derived	derive	VBN	_	26	acl
28	from	from	IN	_	30	case
29	rat	rat	NN	_	30	compound
30	liver	liver	NN	_	27	nmod
31	.	.	.	_	8	punct

1	By	by	IN	_	2	case
2	contrast	contrast	NN	_	15	nmod
3	,	,	,	_	15	punct
4	spermidine	spermidine	NN	_	8	compound
5	(	(	NN	_	8	compound
6	1	1	CD	_	7	compound
7	mM	mm	NN	_	8	amod
8	)	)	NN	_	15	nsubj
9	and	and	CC	_	8	cc
10	putrescine	putrescine	NN	_	14	compound
11	(	(	NN	_	14	compound
12	1	1	CD	_	13	compound
13	mM	mm	NN	_	14	amod
14	)	)	NN	_	8	conj
15	had	have	VBD	_	0	ROOT
16	no	no	DT	_	18	neg
17	significant	significant	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	21	case
20	the	the	DT	_	21	det
21	translocation	translocation	NN	_	15	nmod
22	when	when	WRB	_	23	advmod
23	added	add	VBN	_	15	advcl
24	alone	alone	RB	_	23	advmod
25	.	.	.	_	15	punct

1	Spermine	spermine	NN	_	11	nsubj
2	,	,	,	_	1	punct
3	and	and	CC	_	1	cc
4	to	to	TO	_	7	case
5	a	a	DT	_	7	det
6	lesser	lesser	JJR	_	7	amod
7	extent	extent	NN	_	1	conj
8	,	,	,	_	7	punct
9	spermidine	spermidine	NN	_	7	appos
10	,	,	,	_	7	punct
11	enhanced	enhance	VBD	_	0	ROOT
12	the	the	DT	_	14	det
13	translocating	translocating	JJ	_	14	amod
14	action	action	NN	_	11	dobj
15	of	of	IN	_	16	case
16	oleate	oleate	NN	_	14	nmod
17	and	and	CC	_	11	cc
18	increased	increase	VBD	_	11	conj
19	its	its	PRP$	_	20	nmod:poss
20	effectiveness	effectiveness	NN	_	18	dobj
21	in	in	IN	_	22	mark
22	transferring	transfer	VBG	_	18	advcl
23	the	the	DT	_	24	det
24	phosphohydrolase	phosphohydrolase	NN	_	22	dobj
25	from	from	IN	_	27	case
26	the	the	DT	_	27	det
27	soluble	soluble	JJ	_	22	nmod
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	microsomal	microsomal	JJ	_	31	amod
31	fraction	fraction	NN	_	22	nmod
32	.	.	.	_	11	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	proposed	propose	VBN	_	0	ROOT
4	that	that	IN	_	7	mark
5	the	the	DT	_	6	det
6	phosphohydrolase	phosphohydrolase	NN	_	7	nsubj
7	becomes	become	VBZ	_	3	ccomp
8	metabolically	metabolically	RB	_	9	advmod
9	active	active	JJ	_	7	xcomp
10	when	when	WRB	_	12	advmod
11	it	it	PRP	_	12	nsubj
12	combines	combine	VBZ	_	7	advcl
13	with	with	IN	_	14	case
14	membranes	membrane	NNS	_	12	nmod
15	and	and	CC	_	12	cc
16	that	that	IN	_	19	mark
17	polyamines	polyamine	NNS	_	19	nsubj
18	might	might	MD	_	19	aux
19	help	help	VB	_	12	conj
20	to	to	TO	_	21	mark
21	regulate	regulate	VB	_	19	xcomp
22	this	this	DT	_	23	det
23	interaction	interaction	NN	_	21	dobj
24	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	facilitate	facilitate	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	action	action	NN	_	3	dobj
6	of	of	IN	_	8	case
7	fatty	fatty	JJ	_	8	amod
8	acids	acid	NNS	_	5	nmod
9	and	and	CC	_	3	cc
10	enable	enable	VBP	_	3	conj
11	cells	cell	NNS	_	10	dobj
12	to	to	TO	_	13	mark
13	increase	increase	VB	_	10	xcomp
14	their	they	PRP$	_	15	nmod:poss
15	capacity	capacity	NN	_	13	dobj
16	for	for	IN	_	18	case
17	triacylglycerol	triacylglycerol	NN	_	18	compound
18	synthesis	synthesis	NN	_	15	nmod
19	to	to	TO	_	20	mark
20	match	match	VB	_	13	advcl
21	an	a	DT	_	23	det
22	increased	increase	VBN	_	23	amod
23	availability	availability	NN	_	20	dobj
24	of	of	IN	_	26	case
25	fatty	fatty	JJ	_	26	amod
26	acids	acid	NNS	_	23	nmod
27	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	ketamine	ketamine	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	of	of	IN	_	8	case
7	Innovar	innovar	JJ	_	8	amod
8	anesthesia	anesthesia	NN	_	4	conj
9	on	on	IN	_	11	case
10	digitalis	digitalis	NN	_	11	compound
11	tolerance	tolerance	NN	_	2	nmod
12	in	in	IN	_	13	case
13	dogs	dog	NNS	_	11	nmod
14	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	comparison	comparison	NN	_	30	nmod
4	of	of	IN	_	6	case
5	digitalis	digitalis	NN	_	6	compound
6	tolerance	tolerance	NN	_	3	nmod
7	in	in	IN	_	8	case
8	dogs	dog	NNS	_	6	nmod
9	anesthetized	anesthetized	JJ	_	8	amod
10	with	with	IN	_	11	case
11	ketamine	ketamine	NN	_	9	nmod
12	,	,	,	_	30	punct
13	Innovar	Innovar	NNP	_	14	compound
14	Vet	Vet	NNP	_	30	nsubj
15	,	,	,	_	14	punct
16	or	or	CC	_	14	cc
17	pentobarbital	pentobarbital	JJ	_	14	conj
18	,	,	,	_	14	punct
19	the	the	DT	_	20	det
20	dosage	dosage	NN	_	14	appos
21	of	of	IN	_	22	case
22	ouabain	ouabain	NN	_	20	nmod
23	needed	need	VBN	_	20	acl
24	to	to	TO	_	25	mark
25	cause	cause	VB	_	23	xcomp
26	ventricular	ventricular	JJ	_	27	amod
27	tachycardia	tachycardia	NN	_	25	dobj
28	was	be	VBD	_	30	cop
29	significantly	significantly	RB	_	30	advmod
30	higher	higher	JJR	_	0	ROOT
31	,	,	,	_	30	punct
32	as	as	IN	_	35	mark
33	was	be	VBD	_	35	cop
34	the	the	DT	_	35	det
35	LD50	ld50	NN	_	30	advcl
36	of	of	IN	_	37	case
37	ouabain	ouabain	NN	_	35	nmod
38	,	,	,	_	30	punct
39	with	with	IN	_	40	case
40	ketamine	ketamine	NN	_	30	nmod
41	or	or	CC	_	40	cc
42	Innovar	innovar	JJ	_	40	conj
43	than	than	IN	_	45	case
44	with	with	IN	_	45	case
45	pentobarbital	pentobarbital	NN	_	40	nmod
46	.	.	.	_	30	punct

1	Ventricular	ventricular	JJ	_	2	amod
2	tachycardia	tachycardia	NN	_	8	nsubjpass
3	induced	induce	VBN	_	2	acl
4	by	by	IN	_	5	case
5	ouabain	ouabain	NN	_	3	nmod
6	was	be	VBD	_	8	auxpass
7	generally	generally	RB	_	8	advmod
8	converted	convert	VBN	_	0	ROOT
9	to	to	TO	_	11	case
10	sinus	sinus	NN	_	11	compound
11	rhythm	rhythm	NN	_	8	nmod
12	following	follow	VBG	_	13	case
13	administration	administration	NN	_	8	nmod
14	of	of	IN	_	15	case
15	Innovar	Innovar	NNP	_	13	nmod
16	,	,	,	_	15	punct
17	ketamine	ketamine	NN	_	15	conj
18	,	,	,	_	15	punct
19	or	or	CC	_	15	cc
20	droperidol	droperidol	NN	_	15	conj
21	but	but	CC	_	13	cc
22	not	not	RB	_	24	neg
23	after	after	IN	_	24	case
24	administration	administration	NN	_	13	conj
25	of	of	IN	_	26	case
26	fentayl	fentayl	NN	_	24	nmod
27	alone	alone	RB	_	26	advmod
28	or	or	CC	_	24	cc
29	after	after	IN	_	30	case
30	pentobarbital	pentobarbital	NN	_	24	conj
31	.	.	.	_	8	punct

1	Excretion	excretion	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	thioethers	thioether	NNS	_	1	nmod
4	in	in	IN	_	5	case
5	urine	urine	NN	_	1	nmod
6	after	after	IN	_	7	case
7	exposure	exposure	NN	_	1	nmod
8	to	to	TO	_	10	case
9	electrophilic	electrophilic	JJ	_	10	amod
10	chemicals	chemical	NNS	_	7	nmod
11	.	.	.	_	1	punct

1	Electrophilic	electrophilic	JJ	_	2	amod
2	agents	agent	NNS	_	16	nsubjpass
3	--	--	:	_	2	punct
4	a	a	DT	_	5	det
5	class	class	NN	_	2	dep
6	of	of	IN	_	7	case
7	chemicals	chemical	NNS	_	5	nmod
8	that	that	WDT	_	9	nsubj
9	includes	include	VBZ	_	5	acl:relcl
10	most	most	RBS	_	11	advmod
11	genotoxic	genotoxic	JJ	_	12	amod
12	compounds	compound	NNS	_	9	dobj
13	--	--	:	_	2	punct
14	can	can	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	inactivated	inactivate	VBN	_	0	ROOT
17	by	by	IN	_	18	case
18	reaction	reaction	NN	_	16	nmod
19	with	with	IN	_	20	case
20	glutathione	glutathione	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	other	other	JJ	_	23	amod
23	SH	sh	NN	_	20	conj
24	-	-	:	_	16	punct
25	bearing	bear	VBG	_	16	xcomp
26	molecules	molecule	NNS	_	25	dobj
27	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	conjugates	conjugate	NNS	_	4	nsubj
3	so	so	RB	_	4	advmod
4	formed	form	VBD	_	0	ROOT
5	often	often	RB	_	6	advmod
6	appear	appear	VB	_	4	ccomp
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	urine	urine	NN	_	6	nmod
10	as	as	IN	_	12	case
11	mercapturic	mercapturic	JJ	_	12	amod
12	acids	acid	NNS	_	6	nmod
13	or	or	CC	_	12	cc
14	other	other	JJ	_	16	amod
15	thioether	thioether	NN	_	16	compound
16	products	product	NNS	_	12	conj
17	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	paper	paper	NN	_	4	nsubj
3	critically	critically	RB	_	4	advmod
4	reviews	review	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	suitability	suitability	NN	_	4	dobj
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	urinary	urinary	JJ	_	11	amod
10	thioether	thioether	NN	_	11	compound
11	assay	assay	NN	_	6	nmod
12	as	as	IN	_	14	case
13	a	a	DT	_	14	det
14	method	method	NN	_	4	nmod
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	detection	detection	NN	_	14	nmod
18	of	of	IN	_	19	case
19	exposure	exposure	NN	_	17	nmod
20	to	to	TO	_	22	case
21	electrophilic	electrophilic	JJ	_	22	amod
22	agents	agent	NNS	_	19	nmod
23	or	or	CC	_	22	cc
24	their	they	PRP$	_	25	nmod:poss
25	precursors	precursor	NNS	_	22	conj
26	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	practice	practice	NN	_	11	nmod
3	,	,	,	_	11	punct
4	the	the	DT	_	6	det
5	greatest	greatest	JJS	_	6	amod
6	value	value	NN	_	11	nsubj
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	thioether	thioether	NN	_	10	compound
10	assay	assay	NN	_	6	nmod
11	appears	appear	VBZ	_	0	ROOT
12	to	to	TO	_	13	mark
13	lie	lie	VB	_	11	xcomp
14	in	in	IN	_	17	case
15	its	its	PRP$	_	17	nmod:poss
16	signal	signal	NN	_	17	compound
17	function	function	NN	_	13	nmod
18	.	.	.	_	11	punct

1	This	this	DT	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	demonstrated	demonstrate	VBN	_	0	ROOT
4	for	for	IN	_	6	case
5	cigarette	cigarette	NN	_	6	compound
6	smokers	smoker	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	industrial	industrial	JJ	_	9	amod
9	workers	worker	NNS	_	6	conj
10	involved	involve	VBN	_	6	acl
11	in	in	IN	_	14	case
12	chemical	chemical	NN	_	14	compound
13	waste	waste	NN	_	14	compound
14	incineration	incineration	NN	_	10	nmod
15	.	.	.	_	3	punct

1	Whenever	Whenever	NNP	_	2	nsubj
2	increased	increase	VBD	_	10	advcl
3	thioether	thioether	RB	_	4	advmod
4	excretion	excretion	NN	_	2	dobj
5	is	be	VBZ	_	6	auxpass
6	observed	observe	VBN	_	2	dep
7	,	,	,	_	10	punct
8	it	it	PRP	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	likely	likely	JJ	_	0	ROOT
11	to	to	TO	_	15	mark
12	be	be	VB	_	15	cop
13	due	due	JJ	_	15	case
14	to	to	TO	_	13	mwe
15	exposure	exposure	NN	_	10	xcomp
16	to	to	TO	_	17	case
17	one	one	CD	_	15	nmod
18	or	or	CC	_	17	cc
19	more	more	JJR	_	17	conj
20	suspect	suspect	JJ	_	21	amod
21	compounds	compound	NNS	_	17	dep
22	.	.	.	_	10	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	when	when	WRB	_	2	root
4	the	the	DT	_	7	det
5	thioether	thioether	JJ	_	7	amod
6	concentration	concentration	NN	_	7	compound
7	ranges	range	NNS	_	3	dep
8	within	within	IN	_	10	case
9	the	the	DT	_	10	det
10	limits	limit	NNS	_	7	nmod
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	normal	normal	JJ	_	14	amod
14	value	value	NN	_	10	nmod
15	,	,	,	_	7	punct
16	one	one	CD	_	19	nsubj
17	must	must	MD	_	19	aux
18	not	not	RB	_	19	neg
19	conclude	conclude	VB	_	7	acl:relcl
20	that	that	IN	_	22	mark
21	there	there	EX	_	22	expl
22	is	be	VBZ	_	19	ccomp
23	no	no	DT	_	28	neg
24	,	,	,	_	23	punct
25	or	or	CC	_	23	cc
26	negligible	negligible	JJ	_	23	conj
27	,	,	,	_	28	punct
28	exposure	exposure	NN	_	22	nsubj
29	.	.	.	_	3	punct

1	More	more	RBR	_	2	advmod
2	specific	specific	JJ	_	3	amod
3	applications	application	NNS	_	12	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	assay	assay	NN	_	3	nmod
7	of	of	IN	_	9	case
8	thio	thio	NN	_	9	compound
9	compounds	compound	NNS	_	6	nmod
10	in	in	IN	_	11	case
11	urine	urine	NN	_	6	nmod
12	allow	allow	VBP	_	0	ROOT
13	development	development	NN	_	12	dobj
14	of	of	IN	_	16	case
15	selective	selective	JJ	_	16	amod
16	methods	method	NNS	_	13	nmod
17	that	that	WDT	_	20	nsubj
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	cop
20	useful	useful	JJ	_	16	acl:relcl
21	for	for	IN	_	23	case
22	biological	biological	JJ	_	23	amod
23	monitoring	monitoring	NN	_	20	nmod
24	.	.	.	_	12	punct

1	Rhabdomyolysis	Rhabdomyolysis	NNP	_	0	ROOT
2	secondary	secondary	JJ	_	1	amod
3	to	to	TO	_	6	case
4	a	a	DT	_	6	det
5	drug	drug	NN	_	6	compound
6	interaction	interaction	NN	_	2	nmod
7	between	between	IN	_	8	case
8	simvastatin	simvastatin	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	clarithromycin	clarithromycin	NN	_	8	conj
11	.	.	.	_	1	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	To	to	TO	_	4	mark
4	report	report	VB	_	1	acl
5	a	a	DT	_	6	det
6	case	case	NN	_	4	dobj
7	of	of	IN	_	8	case
8	rhabdomyolysis	rhabdomyolysis	NN	_	6	nmod
9	resulting	result	VBG	_	8	acl
10	from	from	IN	_	12	case
11	concomitant	concomitant	JJ	_	12	amod
12	use	use	NN	_	9	nmod
13	of	of	IN	_	14	case
14	clarithromycin	clarithromycin	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	simvastatin	simvastatin	NN	_	14	conj
17	.	.	.	_	1	punct

1	CASE	case	NN	_	2	compound
2	SUMMARY	summary	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	A	a	DT	_	7	det
5	64	64	CD	_	7	nummod
6	-	-	:	_	7	punct
7	year	year	NN	_	15	nsubjpass
8	-	-	:	_	7	punct
9	old	old	JJ	_	13	amod
10	African	african	JJ	_	13	amod
11	-	-	:	_	13	punct
12	American	american	JJ	_	13	amod
13	man	man	NN	_	7	dep
14	was	be	VBD	_	15	auxpass
15	admitted	admit	VBN	_	2	dep
16	to	to	TO	_	18	case
17	the	the	DT	_	18	det
18	hospital	hospital	NN	_	15	nmod
19	for	for	IN	_	20	mark
20	worsening	worsen	VBG	_	15	advcl
21	renal	renal	JJ	_	22	amod
22	failure	failure	NN	_	20	dobj
23	,	,	,	_	15	punct
24	elevated	elevated	JJ	_	26	amod
25	creatine	creatine	NN	_	26	compound
26	phosphokinase	phosphokinase	NN	_	15	xcomp
27	,	,	,	_	26	punct
28	diffuse	diffuse	JJ	_	30	amod
29	muscle	muscle	NN	_	30	compound
30	pain	pain	NN	_	26	conj
31	,	,	,	_	26	punct
32	and	and	CC	_	26	cc
33	severe	severe	JJ	_	35	amod
34	muscle	muscle	NN	_	35	compound
35	weakness	weakness	NN	_	26	conj
36	.	.	.	_	2	punct

1	About	about	IN	_	3	amod
2	three	three	CD	_	3	nummod
3	weeks	week	NNS	_	11	nmod:tmod
4	prior	prior	RB	_	3	advmod
5	to	to	TO	_	6	case
6	admission	admission	NN	_	4	nmod
7	,	,	,	_	11	punct
8	the	the	DT	_	9	det
9	patient	patient	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	started	start	VBN	_	0	ROOT
12	on	on	IN	_	13	case
13	clarithromycin	clarithromycin	NN	_	11	nmod
14	for	for	IN	_	15	case
15	sinusitis	sinusitis	NN	_	13	nmod
16	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	patient	patient	NN	_	5	nsubj
3	had	have	VBD	_	5	aux
4	been	be	VBN	_	5	aux
5	receiving	receive	VBG	_	0	ROOT
6	simvastatin	simvastatin	NN	_	5	dobj
7	for	for	IN	_	10	case
8	approximately	approximately	RB	_	9	advmod
9	six	six	CD	_	10	nummod
10	months	month	NNS	_	5	nmod
11	.	.	.	_	5	punct

1	He	he	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	treated	treat	VBN	_	0	ROOT
4	aggressively	aggressively	RB	_	3	advmod
5	with	with	IN	_	7	case
6	intravenous	intravenous	JJ	_	7	amod
7	hydration	hydration	NN	_	3	nmod
8	,	,	,	_	7	punct
9	sodium	sodium	NN	_	10	compound
10	bicarbonate	bicarbonate	NN	_	7	conj
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	hemodialysis	hemodialysis	NN	_	7	conj
14	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	muscle	muscle	NN	_	3	compound
3	biopsy	biopsy	NN	_	4	nsubj
4	revealed	reveal	VBD	_	0	ROOT
5	necrotizing	necrotizing	JJ	_	6	amod
6	myopathy	myopathy	NN	_	4	dobj
7	secondary	secondary	JJ	_	6	amod
8	to	to	TO	_	10	case
9	a	a	DT	_	10	det
10	toxin	toxin	NN	_	7	nmod
11	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	patient	patient	NN	_	3	nsubj
3	continued	continue	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	receive	receive	VB	_	3	xcomp
6	intermittent	intermittent	JJ	_	7	amod
7	hemodialysis	hemodialysis	NN	_	5	dobj
8	until	until	IN	_	10	case
9	his	he	PRP$	_	10	nmod:poss
10	death	death	NN	_	5	nmod
11	from	from	IN	_	13	case
12	infectious	infectious	JJ	_	13	amod
13	complications	complication	NNS	_	10	nmod
14	that	that	WDT	_	15	nsubj
15	occurred	occur	VBD	_	13	acl:relcl
16	three	three	CD	_	17	nummod
17	months	month	NNS	_	15	nmod
18	after	after	IN	_	17	case
19	admission	admission	NN	_	17	dep
20	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	several	several	JJ	_	4	amod
4	factors	factor	NNS	_	2	nsubj
5	that	that	WDT	_	8	nsubj
6	could	could	MD	_	8	aux
7	have	have	VB	_	8	aux
8	increased	increase	VBN	_	4	acl:relcl
9	his	he	PRP$	_	10	nmod:poss
10	risk	risk	NN	_	8	dobj
11	for	for	IN	_	12	mark
12	developing	develop	VBG	_	10	acl
13	rhabdomyolysis	rhabdomyolysis	NN	_	12	dobj
14	,	,	,	_	13	punct
15	including	include	VBG	_	18	case
16	chronic	chronic	JJ	_	18	amod
17	renal	renal	JJ	_	18	amod
18	failure	failure	NN	_	13	nmod
19	.	.	.	_	2	punct

1	DISCUSSION	discussion	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clarithromycin	Clarithromycin	NNP	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	a	a	DT	_	7	det
6	potent	potent	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	1	parataxis
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	7	punct
11	the	the	DT	_	13	det
12	major	major	JJ	_	13	amod
13	enzyme	enzyme	NN	_	7	appos
14	responsible	responsible	JJ	_	13	amod
15	for	for	IN	_	17	case
16	simvastatin	simvastatin	NN	_	17	compound
17	metabolism	metabolism	NN	_	14	nmod
18	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	20	nsubj
4	of	of	IN	_	6	case
5	macrolide	macrolide	NN	_	6	compound
6	antibiotics	antibiotic	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	other	other	JJ	_	13	amod
9	hydroxymethylglutaryl	hydroxymethylglutaryl	NN	_	13	compound
10	coenzyme	coenzyme	NN	_	13	compound
11	A	a	NN	_	13	compound
12	(	(	CD	_	13	nummod
13	HMG	hmg	NN	_	6	conj
14	-	-	:	_	13	punct
15	CoA	coa	NN	_	18	compound
16	)	)	CD	_	18	nummod
17	reductase	reductase	NN	_	18	compound
18	inhibitors	inhibitor	NNS	_	13	dep
19	have	have	VBP	_	20	aux
20	resulted	result	VBN	_	0	ROOT
21	in	in	IN	_	23	case
22	previous	previous	JJ	_	23	amod
23	reports	report	NNS	_	20	nmod
24	of	of	IN	_	25	case
25	rhabdomyolysis	rhabdomyolysis	NN	_	23	nmod
26	.	.	.	_	20	punct

1	Other	other	JJ	_	2	amod
2	factors	factor	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	risk	risk	NN	_	4	dobj
7	of	of	IN	_	10	case
8	this	this	DT	_	10	det
9	drug	drug	NN	_	10	compound
10	interaction	interaction	NN	_	6	nmod
11	,	,	,	_	6	punct
12	including	include	VBG	_	14	case
13	the	the	DT	_	14	det
14	administration	administration	NN	_	6	nmod
15	of	of	IN	_	17	case
16	other	other	JJ	_	17	amod
17	medications	medication	NNS	_	14	nmod
18	that	that	WDT	_	20	nsubjpass
19	are	be	VBP	_	20	auxpass
20	associated	associate	VBN	_	17	acl:relcl
21	with	with	IN	_	22	case
22	myopathy	myopathy	NN	_	20	nmod
23	,	,	,	_	6	punct
24	underlying	underlie	VBG	_	6	acl
25	renal	renal	JJ	_	26	amod
26	insufficiency	insufficiency	NN	_	24	dobj
27	,	,	,	_	4	punct
28	and	and	CC	_	4	cc
29	administration	administration	NN	_	4	conj
30	of	of	IN	_	32	case
31	high	high	JJ	_	32	amod
32	doses	dose	NNS	_	29	nmod
33	of	of	IN	_	38	case
34	HMG	hmg	NN	_	38	compound
35	-	-	:	_	38	punct
36	CoA	coa	NN	_	38	compound
37	reductase	reductase	NN	_	38	compound
38	inhibitors	inhibitor	NNS	_	32	nmod
39	.	.	.	_	4	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Macrolide	Macrolide	NNP	_	4	compound
4	antibiotics	antibiotic	NNS	_	5	nsubj
5	inhibit	inhibit	VBP	_	1	dep
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	13	case
9	HMG	hmg	NN	_	13	compound
10	-	-	:	_	13	punct
11	CoA	coa	NN	_	13	compound
12	reductase	reductase	NN	_	13	compound
13	inhibitors	inhibitor	NNS	_	7	nmod
14	that	that	WDT	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	metabolized	metabolize	VBN	_	13	acl:relcl
17	by	by	IN	_	18	case
18	CYP3A4	cyp3a4	NN	_	16	nmod
19	(	(	CD	_	18	nummod
20	i	i	LS	_	5	dep
21	.	.	.	_	20	punct
22	e	e	LS	_	20	dep
23	.	.	.	_	22	punct
24	,	,	,	_	22	punct
25	atorvastatin	atorvastatin	NN	_	22	dep
26	,	,	,	_	25	punct
27	cerivastatin	cerivastatin	NN	_	25	conj
28	,	,	,	_	25	punct
29	lovastatin	lovastatin	NN	_	25	conj
30	,	,	,	_	25	punct
31	simvastatin	simvastatin	NN	_	32	compound
32	)	)	NN	_	25	conj
33	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	in	in	IN	_	6	case
6	myopathy	myopathy	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	rhabdomyolysis	rhabdomyolysis	NN	_	6	conj
9	,	,	,	_	6	punct
10	particularly	particularly	RB	_	12	advmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	6	nmod
13	with	with	IN	_	15	case
14	renal	renal	JJ	_	15	amod
15	insufficiency	insufficiency	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	those	those	DT	_	15	conj
18	who	who	WP	_	21	nsubj
19	are	be	VBP	_	21	aux
20	concurrently	concurrently	RB	_	21	advmod
21	taking	take	VBG	_	17	acl:relcl
22	medications	medication	NNS	_	21	dobj
23	associated	associate	VBN	_	22	acl
24	with	with	IN	_	25	case
25	myopathy	myopathy	NN	_	23	nmod
26	.	.	.	_	4	punct

1	Optimal	optimal	JJ	_	2	amod
2	designs	design	NNS	_	0	ROOT
3	for	for	IN	_	12	case
4	the	the	DT	_	12	det
5	individual	individual	JJ	_	12	amod
6	and	and	CC	_	5	cc
7	joint	joint	JJ	_	5	conj
8	exposure	exposure	NN	_	12	compound
9	general	general	JJ	_	12	amod
10	logistic	logistic	JJ	_	12	amod
11	regression	regression	NN	_	12	compound
12	models	model	NNS	_	2	nmod
13	.	.	.	_	2	punct

1	Interest	interest	NN	_	7	nsubj
2	in	in	IN	_	3	mark
3	administering	administer	VBG	_	1	acl
4	compounds	compound	NNS	_	3	dobj
5	in	in	IN	_	6	case
6	combination	combination	NN	_	3	nmod
7	lies	lie	VBZ	_	0	ROOT
8	both	both	CC	_	10	cc:preconj
9	in	in	IN	_	10	mark
10	enhancing	enhance	VBG	_	7	dep
11	efficacious	efficacious	JJ	_	12	amod
12	effects	effect	NNS	_	10	dobj
13	and	and	CC	_	10	cc
14	in	in	IN	_	15	mark
15	limiting	limit	VBG	_	10	conj
16	adverse	adverse	JJ	_	17	amod
17	effects	effect	NNS	_	15	dobj
18	.	.	.	_	7	punct

1	Although	although	IN	_	6	mark
2	much	much	JJ	_	4	amod
3	statistical	statistical	JJ	_	4	amod
4	work	work	NN	_	6	nsubj
5	has	have	VBZ	_	6	aux
6	focused	focus	VBN	_	0	ROOT
7	on	on	IN	_	8	mark
8	developing	develop	VBG	_	6	advcl
9	mathematical	mathematical	JJ	_	10	amod
10	functions	function	NNS	_	8	dobj
11	to	to	TO	_	12	mark
12	model	model	VB	_	10	acl
13	the	the	DT	_	15	det
14	joint	joint	JJ	_	15	amod
15	dose	dose	NN	_	12	dobj
16	-	-	:	_	15	punct
17	response	response	NN	_	18	compound
18	curves	curve	NNS	_	15	dep
19	,	,	,	_	15	punct
20	relatively	relatively	RB	_	21	advmod
21	little	little	JJ	_	22	amod
22	work	work	NN	_	23	nsubj
23	exists	exist	VBZ	_	15	acl:relcl
24	in	in	IN	_	25	case
25	regard	regard	NN	_	23	nmod
26	to	to	TO	_	27	mark
27	designing	design	VBG	_	25	acl
28	experiments	experiment	NNS	_	27	dobj
29	for	for	IN	_	30	mark
30	assessing	assess	VBG	_	28	acl
31	joint	joint	JJ	_	32	amod
32	action	action	NN	_	30	dobj
33	.	.	.	_	6	punct

1	A	a	DT	_	2	det
2	variety	variety	NN	_	20	nsubjpass
3	of	of	IN	_	5	case
4	parametric	parametric	JJ	_	5	amod
5	dose	dose	NN	_	2	nmod
6	-	-	:	_	5	punct
7	response	response	NN	_	8	compound
8	models	model	NNS	_	5	dep
9	based	base	VBN	_	5	acl
10	on	on	IN	_	17	case
11	either	either	CC	_	17	cc:preconj
12	the	the	DT	_	17	det
13	normal	normal	JJ	_	17	amod
14	or	or	CC	_	13	cc
15	logistic	logistic	JJ	_	13	conj
16	probability	probability	NN	_	17	compound
17	distribution	distribution	NN	_	9	nmod
18	have	have	VBP	_	20	aux
19	been	be	VBN	_	20	auxpass
20	proposed	propose	VBN	_	0	ROOT
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	literature	literature	NN	_	20	nmod
24	.	.	.	_	20	punct

1	These	these	DT	_	2	det
2	models	model	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	typically	typically	RB	_	5	advmod
5	nonlinear	nonlinear	JJ	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	parameters	parameter	NNS	_	5	nmod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	as	as	IN	_	12	case
12	such	such	JJ	_	22	nmod
13	,	,	,	_	22	punct
14	a	a	DT	_	19	det
15	nonlinear	nonlinear	JJ	_	19	amod
16	weighted	weighted	JJ	_	19	amod
17	least	least	JJS	_	19	amod
18	squares	square	NNS	_	19	compound
19	approach	approach	NN	_	22	nsubjpass
20	can	can	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	employed	employ	VBN	_	5	conj
23	for	for	IN	_	25	case
24	the	the	DT	_	25	det
25	purpose	purpose	NN	_	22	nmod
26	of	of	IN	_	27	mark
27	designing	design	VBG	_	25	acl
28	experiments	experiment	NNS	_	27	dobj
29	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	approach	approach	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	applicable	applicable	JJ	_	0	ROOT
5	across	across	IN	_	8	case
6	a	a	DT	_	8	det
7	wide	wide	JJ	_	8	amod
8	variety	variety	NN	_	4	nmod
9	of	of	IN	_	10	case
10	settings	setting	NNS	_	8	nmod
11	commonly	commonly	RB	_	12	advmod
12	associated	associate	VBN	_	10	acl
13	with	with	IN	_	16	case
14	joint	joint	JJ	_	16	amod
15	action	action	NN	_	16	compound
16	data	datum	NNS	_	12	nmod
17	,	,	,	_	16	punct
18	including	include	VBG	_	22	case
19	continuous	continuous	JJ	_	22	amod
20	and	and	CC	_	19	cc
21	discrete	discrete	JJ	_	19	conj
22	responses	response	NNS	_	16	nmod
23	,	,	,	_	22	punct
24	alternative	alternative	JJ	_	26	amod
25	error	error	NN	_	26	compound
26	structures	structure	NNS	_	22	conj
27	,	,	,	_	22	punct
28	and	and	CC	_	22	cc
29	nonzero	nonzero	NN	_	31	compound
30	background	background	NN	_	31	compound
31	response	response	NN	_	22	conj
32	.	.	.	_	4	punct

1	Further	further	RB	_	6	advmod
2	,	,	,	_	6	punct
3	designs	design	NNS	_	6	nsubjpass
4	can	can	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expressed	express	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	terms	term	NNS	_	6	nmod
9	of	of	IN	_	11	case
10	proportionate	proportionate	JJ	_	11	amod
11	responses	response	NNS	_	8	nmod
12	associated	associate	VBN	_	11	acl
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	individual	individual	JJ	_	16	amod
16	compounds	compound	NNS	_	12	nmod
17	rather	rather	RB	_	16	cc
18	than	than	IN	_	17	mwe
19	dose	dose	NN	_	20	compound
20	levels	level	NNS	_	16	conj
21	,	,	,	_	6	punct
22	thereby	thereby	RB	_	23	advmod
23	providing	provide	VBG	_	6	advcl
24	for	for	IN	_	25	case
25	results	result	NNS	_	23	nmod
26	that	that	WDT	_	28	nsubj
27	are	be	VBP	_	28	cop
28	applicable	applicable	JJ	_	25	acl:relcl
29	across	across	IN	_	30	case
30	compounds	compound	NNS	_	28	nmod
31	.	.	.	_	6	punct

1	As	as	IN	_	3	case
2	a	a	DT	_	3	det
3	precursor	precursor	NN	_	26	nmod
4	to	to	TO	_	6	case
5	this	this	DT	_	6	det
6	effort	effort	NN	_	3	nmod
7	,	,	,	_	26	punct
8	optimal	optimal	JJ	_	12	amod
9	and	and	CC	_	8	cc
10	minimal	minimal	JJ	_	8	conj
11	experimental	experimental	JJ	_	12	amod
12	designs	design	NNS	_	26	nsubjpass
13	for	for	IN	_	15	case
14	the	the	DT	_	15	det
15	case	case	NN	_	12	nmod
16	in	in	IN	_	17	case
17	which	which	WDT	_	22	nmod
18	a	a	DT	_	20	det
19	single	single	JJ	_	20	amod
20	compound	compound	NN	_	22	nsubjpass
21	is	be	VBZ	_	22	auxpass
22	administered	administer	VBN	_	15	acl:relcl
23	have	have	VBP	_	26	aux
24	also	also	RB	_	26	advmod
25	been	be	VBN	_	26	auxpass
26	developed	develop	VBN	_	0	ROOT
27	.	.	.	_	26	punct

1	Although	although	IN	_	11	mark
2	the	the	DT	_	4	det
3	proposed	propose	VBN	_	4	amod
4	methodology	methodology	NN	_	11	nsubjpass
5	for	for	IN	_	6	mark
6	deriving	derive	VBG	_	4	acl
7	experimental	experimental	JJ	_	8	amod
8	designs	design	NNS	_	6	dobj
9	can	can	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	applied	apply	VBN	_	21	advcl
12	to	to	TO	_	16	case
13	any	any	DT	_	16	det
14	nonlinear	nonlinear	JJ	_	16	amod
15	regression	regression	NN	_	16	compound
16	model	model	NN	_	11	nmod
17	,	,	,	_	21	punct
18	primary	primary	JJ	_	19	amod
19	focus	focus	NN	_	21	nsubjpass
20	is	be	VBZ	_	21	auxpass
21	given	give	VBN	_	0	ROOT
22	to	to	TO	_	29	case
23	the	the	DT	_	29	det
24	additive	additive	JJ	_	29	amod
25	and	and	CC	_	24	cc
26	nonadditive	nonadditive	JJ	_	24	conj
27	independent	independent	JJ	_	29	amod
28	joint	joint	JJ	_	29	amod
29	action	action	NN	_	21	nmod
30	(	(	CD	_	33	nummod
31	IJA	IJA	NNP	_	33	compound
32	)	)	CD	_	33	nummod
33	models	model	NNS	_	29	dep
34	for	for	IN	_	38	case
35	individual	individual	JJ	_	38	amod
36	and	and	CC	_	35	cc
37	combined	combined	JJ	_	35	conj
38	exposures	exposure	NNS	_	33	nmod
39	proposed	propose	VBN	_	38	acl
40	by	by	IN	_	41	case
41	Barton	Barton	NNP	_	39	nmod
42	,	,	,	_	41	punct
43	Braunberg	Braunberg	NNP	_	41	conj
44	,	,	,	_	41	punct
45	and	and	CC	_	41	cc
46	Friedman	Friedman	NNP	_	49	compound
47	(	(	CD	_	49	nummod
48	1	1	CD	_	49	nummod
49	)	)	NN	_	41	conj
50	.	.	.	_	21	punct

1	[	[	NN	_	6	compound
2	The	the	DT	_	6	det
3	GABA	gaba	NN	_	6	compound
4	-	-	:	_	6	punct
5	ergic	ergic	JJ	_	6	amod
6	system	system	NN	_	0	ROOT
7	and	and	CC	_	6	cc
8	brain	brain	NN	_	9	compound
9	edema	edema	NN	_	6	conj
10	]	]	CD	_	9	nummod
11	It	it	PRP	_	14	nsubjpass
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	shown	show	VBN	_	6	acl:relcl
15	in	in	IN	_	16	case
16	rats	rat	NNS	_	14	nmod
17	with	with	IN	_	19	case
18	experimental	experimental	JJ	_	19	amod
19	toxic	toxic	JJ	_	16	nmod
20	and	and	CC	_	19	cc
21	traumatic	traumatic	JJ	_	19	conj
22	edemas	edema	NNS	_	19	dep
23	that	that	WDT	_	31	mark
24	picrotoxin	picrotoxin	NN	_	27	compound
25	(	(	NN	_	27	compound
26	1	1	CD	_	27	nummod
27	mg	mg	NN	_	31	nsubj
28	/	/	:	_	27	punct
29	kg	kg	NN	_	30	compound
30	)	)	NN	_	27	dep
31	removes	remove	VBZ	_	19	ccomp
32	the	the	DT	_	34	det
33	antiedematous	antiedematous	JJ	_	34	amod
34	action	action	NN	_	31	dobj
35	of	of	IN	_	36	case
36	diazepam	diazepam	NN	_	34	nmod
37	,	,	,	_	36	punct
38	phenazepam	phenazepam	NN	_	36	conj
39	,	,	,	_	36	punct
40	phenibut	phenibut	NN	_	36	conj
41	and	and	CC	_	36	cc
42	amizyl	amizyl	NN	_	36	conj
43	and	and	CC	_	31	cc
44	reduces	reduce	VBZ	_	31	conj
45	the	the	DT	_	46	det
46	action	action	NN	_	44	dobj
47	of	of	IN	_	48	case
48	phentolamine	phentolamine	NN	_	46	nmod
49	.	.	.	_	6	punct

1	When	when	WRB	_	7	advmod
2	the	the	DT	_	3	det
3	dose	dose	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	picrotoxin	picrotoxin	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	minimized	minimize	VBN	_	18	advcl
8	to	to	TO	_	10	case
9	0.5	0.5	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	/	/	:	_	18	punct
12	kg	kg	NN	_	15	compound
13	such	such	JJ	_	15	amod
14	an	a	DT	_	15	det
15	effect	effect	NN	_	18	nsubjpass
16	is	be	VBZ	_	18	auxpass
17	not	not	RB	_	18	neg
18	observed	observe	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Prolonged	prolonged	JJ	_	3	amod
2	daily	daily	JJ	_	3	amod
3	administration	administration	NN	_	14	nsubj
4	of	of	IN	_	5	case
5	picrotoxin	picrotoxin	NN	_	3	nmod
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	dose	dose	NN	_	3	nmod
9	of	of	IN	_	11	case
10	1	1	CD	_	11	nummod
11	mg	mg	NN	_	8	nmod
12	/	/	:	_	14	punct
13	kg	kg	NN	_	14	compound
14	results	result	VBZ	_	0	ROOT
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	development	development	NN	_	14	nmod
18	of	of	IN	_	20	case
19	brain	brain	NN	_	20	compound
20	edema	edema	NN	_	17	nmod
21	.	.	.	_	14	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	GABA	gaba	NN	_	8	compound
6	-	-	:	_	8	punct
7	positive	positive	JJ	_	8	amod
8	drugs	drug	NNS	_	10	nsubjpass
9	be	be	VB	_	10	auxpass
10	included	include	VBN	_	3	ccomp
11	into	into	IN	_	13	case
12	a	a	DT	_	13	det
13	complex	complex	NN	_	10	nmod
14	of	of	IN	_	16	case
15	treatment	treatment	NN	_	16	compound
16	measures	measure	NNS	_	13	nmod
17	for	for	IN	_	18	case
18	edema	edema	NN	_	16	nmod
19	.	.	.	_	3	punct

1	New	New	NNP	_	3	amod
2	oral	oral	JJ	_	3	amod
3	therapies	therapy	NNS	_	0	ROOT
4	for	for	IN	_	8	case
5	type	type	NN	_	8	compound
6	2	2	CD	_	8	nummod
7	diabetes	diabetes	NN	_	8	compound
8	mellitus	mellitus	NN	_	3	nmod
9	:	:	:	_	3	punct
10	The	the	DT	_	11	det
11	glitazones	glitazone	NNS	_	3	dep
12	or	or	CC	_	11	cc
13	insulin	insulin	NN	_	14	compound
14	sensitizers	sensitizer	NNS	_	11	conj
15	.	.	.	_	3	punct

1	Type	type	NN	_	4	compound
2	2	2	CD	_	4	nummod
3	diabetes	diabetes	NN	_	4	compound
4	mellitus	mellitus	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	a	a	DT	_	8	det
7	growing	grow	VBG	_	8	amod
8	problem	problem	NN	_	0	ROOT
9	not	not	RB	_	10	neg
10	only	only	RB	_	14	cc:preconj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	United	United	NNP	_	14	compound
14	States	States	NNPS	_	8	nmod
15	but	but	CC	_	14	cc
16	also	also	RB	_	19	advmod
17	across	across	IN	_	19	case
18	the	the	DT	_	19	det
19	world	world	NN	_	14	conj
20	.	.	.	_	8	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	now	now	RB	_	2	advmod
4	strong	strong	JJ	_	5	amod
5	evidence	evidence	NN	_	2	nsubj
6	that	that	IN	_	14	mark
7	intensive	intensive	JJ	_	8	amod
8	control	control	NN	_	14	nsubj
9	of	of	IN	_	11	case
10	blood	blood	NN	_	11	compound
11	glucose	glucose	NN	_	8	nmod
12	can	can	MD	_	14	aux
13	significantly	significantly	RB	_	14	advmod
14	reduce	reduce	VB	_	5	ccomp
15	and	and	CC	_	14	cc
16	retard	retard	VB	_	14	conj
17	the	the	DT	_	19	det
18	microvascular	microvascular	JJ	_	19	amod
19	complications	complication	NNS	_	14	dobj
20	of	of	IN	_	21	case
21	retinopathy	retinopathy	NN	_	19	nmod
22	,	,	,	_	21	punct
23	nephropathy	nephropathy	NN	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	neuropathy	neuropathy	NN	_	21	conj
27	.	.	.	_	2	punct

1	Ultimately	ultimately	RB	_	2	advmod
2	however	however	RB	_	12	advmod
3	,	,	,	_	12	punct
4	up	up	IN	_	6	dep
5	to	to	TO	_	4	mwe
6	80	80	CD	_	7	nummod
7	%	%	NN	_	12	nsubj
8	of	of	IN	_	11	case
9	type	type	NN	_	11	compound
10	2	2	CD	_	11	nummod
11	diabetics	diabetic	NNS	_	7	nmod
12	die	die	VBP	_	0	ROOT
13	from	from	IN	_	16	case
14	macrovascular	macrovascular	JJ	_	16	amod
15	cardiovascular	cardiovascular	JJ	_	16	amod
16	disease	disease	NN	_	12	nmod
17	.	.	.	_	12	punct

1	This	this	DT	_	2	nsubj
2	increased	increase	VBD	_	9	csubjpass
3	incidence	incidence	NN	_	2	dobj
4	of	of	IN	_	6	case
5	atherosclerotic	atherosclerotic	JJ	_	6	amod
6	disease	disease	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	intricately	intricately	RB	_	9	advmod
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	12	case
11	insulin	insulin	NN	_	12	compound
12	resistance	resistance	NN	_	9	nmod
13	,	,	,	_	12	punct
14	which	which	WDT	_	19	nsubj
15	is	be	VBZ	_	19	cop
16	a	a	DT	_	19	det
17	major	major	JJ	_	19	amod
18	pathophysiologic	pathophysiologic	JJ	_	19	amod
19	abnormality	abnormality	NN	_	12	acl:relcl
20	in	in	IN	_	23	case
21	type	type	NN	_	23	compound
22	2	2	CD	_	23	nummod
23	diabetes	diabetes	NN	_	19	nmod
24	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	strong	strong	JJ	_	4	amod
4	evidence	evidence	NN	_	2	nsubj
5	that	that	IN	_	9	mark
6	insulin	insulin	NN	_	7	compound
7	resistance	resistance	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	involved	involve	VBN	_	4	ccomp
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	development	development	NN	_	9	nmod
13	of	of	IN	_	16	case
14	not	not	RB	_	15	neg
15	only	only	RB	_	16	cc:preconj
16	hyperglycemia	hyperglycemia	NN	_	12	nmod
17	,	,	,	_	2	punct
18	but	but	CC	_	2	cc
19	also	also	RB	_	2	advmod
20	dyslipidemia	dyslipidemia	NN	_	2	nsubj
21	,	,	,	_	20	punct
22	hypertension	hypertension	NN	_	20	conj
23	,	,	,	_	20	punct
24	hypercoagulation	hypercoagulation	NN	_	20	conj
25	,	,	,	_	20	punct
26	vasculopathy	vasculopathy	NN	_	20	conj
27	,	,	,	_	20	punct
28	and	and	CC	_	20	cc
29	ultimately	ultimately	RB	_	30	advmod
30	atherosclerotic	atherosclerotic	JJ	_	32	amod
31	cardiovascular	cardiovascular	JJ	_	32	amod
32	disease	disease	NN	_	20	conj
33	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	cluster	cluster	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	metabolic	metabolic	JJ	_	5	amod
5	abnormalities	abnormality	NNS	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	termed	term	VBN	_	0	ROOT
9	the	the	DT	_	11	det
10	insulin	insulin	NN	_	11	compound
11	resistance	resistance	NN	_	8	xcomp
12	or	or	CC	_	11	cc
13	cardiovascular	cardiovascular	JJ	_	15	amod
14	dysmetabolic	dysmetabolic	JJ	_	15	amod
15	syndrome	syndrome	NN	_	11	conj
16	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	thiazolidinediones	thiazolidinedione	NNS	_	3	nsubj
3	(	(	VBP	_	0	ROOT
4	rosiglitazone	rosiglitazone	NN	_	7	compound
5	and	and	CC	_	4	cc
6	pioglitazone	pioglitazone	NN	_	4	conj
7	)	)	NN	_	18	nsubjpass
8	,	,	,	_	7	punct
9	a	a	DT	_	11	det
10	new	new	JJ	_	11	amod
11	class	class	NN	_	7	appos
12	of	of	IN	_	15	case
13	oral	oral	JJ	_	15	amod
14	antidiabetic	antidiabetic	JJ	_	15	amod
15	agents	agent	NNS	_	11	nmod
16	,	,	,	_	7	punct
17	are	be	VBP	_	18	auxpass
18	&quot	&quot	VBN	_	3	ccomp
19	;	;	:	_	3	punct
20	insulin	insulin	NN	_	21	compound
21	sensitizers&quot	sensitizers&quot	NN	_	3	dep
22	;	;	:	_	3	punct

1	and	and	CC	_	2	cc
2	exert	exert	VB	_	0	ROOT
3	direct	direct	JJ	_	4	amod
4	effects	effect	NNS	_	2	dobj
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	mechanisms	mechanism	NNS	_	2	nmod
8	of	of	IN	_	10	case
9	insulin	insulin	NN	_	10	compound
10	resistance	resistance	NN	_	7	nmod
11	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubj
3	not	not	RB	_	4	neg
4	only	only	RB	_	5	cc:preconj
5	improve	improve	VB	_	0	ROOT
6	insulin	insulin	NN	_	7	compound
7	sensitivity	sensitivity	NN	_	5	dobj
8	and	and	CC	_	7	cc
9	glycemic	glycemic	JJ	_	10	amod
10	control	control	NN	_	7	conj
11	with	with	IN	_	14	case
12	reduced	reduce	VBN	_	14	amod
13	insulin	insulin	NN	_	14	compound
14	requirements	requirement	NNS	_	7	nmod
15	,	,	,	_	5	punct
16	but	but	CC	_	5	cc
17	also	also	RB	_	18	advmod
18	have	have	VBP	_	5	conj
19	potentially	potentially	RB	_	20	advmod
20	favorable	favorable	JJ	_	21	amod
21	effects	effect	NNS	_	18	dobj
22	on	on	IN	_	24	case
23	other	other	JJ	_	24	amod
24	components	component	NNS	_	18	nmod
25	of	of	IN	_	29	case
26	the	the	DT	_	29	det
27	cardiovascular	cardiovascular	JJ	_	29	amod
28	dysmetabolic	dysmetabolic	JJ	_	29	amod
29	syndrome	syndrome	NN	_	24	nmod
30	.	.	.	_	5	punct

1	Long	long	JJ	_	4	amod
2	-	-	:	_	4	punct
3	term	term	NN	_	4	compound
4	studies	study	NNS	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	needed	need	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	determine	determine	VB	_	6	xcomp
9	whether	whether	IN	_	14	mark
10	the	the	DT	_	11	det
11	insulin	insulin	NN	_	14	nsubj
12	-	-	:	_	14	punct
13	sensitizing	sensitize	VBG	_	14	amod
14	effects	effect	NNS	_	8	ccomp
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	glitazones	glitazone	NNS	_	14	nmod
18	can	can	MD	_	19	aux
19	prevent	prevent	VB	_	14	dep
20	or	or	CC	_	19	cc
21	delay	delay	VB	_	19	conj
22	premature	premature	JJ	_	25	amod
23	atherosclerotic	atherosclerotic	JJ	_	25	amod
24	cardiovascular	cardiovascular	JJ	_	25	amod
25	disease	disease	NN	_	19	dobj
26	,	,	,	_	25	punct
27	morbidity	morbidity	NN	_	25	conj
28	,	,	,	_	25	punct
29	and	and	CC	_	25	cc
30	death	death	NN	_	25	conj
31	.	.	.	_	6	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	probenecid	probenecid	NN	_	1	nmod
4	on	on	IN	_	7	case
5	the	the	DT	_	7	det
6	apparent	apparent	JJ	_	7	amod
7	volume	volume	NN	_	1	nmod
8	of	of	IN	_	9	case
9	distribution	distribution	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	elimination	elimination	NN	_	9	conj
12	of	of	IN	_	13	case
13	cloxacillin	cloxacillin	NN	_	9	nmod
14	.	.	.	_	1	punct

1	According	accord	VBG	_	5	case
2	to	to	TO	_	1	mwe
3	Gibaldi	Gibaldi	NNP	_	5	compound
4	et	et	FW	_	5	compound
5	al	al	FW	_	0	ROOT
6	.	.	.	_	5	punct

1	(	(	SYM	_	2	dep
2	1968	1968	CD	_	0	ROOT
3	,	,	,	_	2	punct
4	1970	1970	CD	_	5	nummod
5	)	)	NN	_	2	appos
6	,	,	,	_	2	punct
7	the	the	DT	_	10	det
8	higher	higher	JJR	_	10	amod
9	serum	serum	NN	_	10	compound
10	concentrations	concentration	NNS	_	15	nsubj
11	of	of	IN	_	12	case
12	penicillins	penicillin	NNS	_	10	nmod
13	and	and	CC	_	12	cc
14	cephaloridine	cephaloridine	NN	_	12	conj
15	reached	reach	VBD	_	2	acl:relcl
16	after	after	IN	_	21	mark
17	administration	administration	NN	_	21	nsubj
18	of	of	IN	_	19	case
19	probenecid	probenecid	NN	_	17	nmod
20	are	be	VBP	_	21	cop
21	due	due	JJ	_	15	advcl
22	not	not	RB	_	23	neg
23	only	only	RB	_	27	cc:preconj
24	to	to	TO	_	27	case
25	slower	slower	JJR	_	27	amod
26	renal	renal	JJ	_	27	amod
27	elimination	elimination	NN	_	21	nmod
28	but	but	CC	_	27	cc
29	also	also	RB	_	33	advmod
30	to	to	TO	_	33	case
31	an	a	DT	_	33	det
32	altered	altered	JJ	_	33	amod
33	distribution	distribution	NN	_	27	conj
34	in	in	IN	_	36	case
35	the	the	DT	_	36	det
36	body	body	NN	_	33	nmod
37	.	.	.	_	2	punct

1	To	to	TO	_	2	mark
2	determine	determine	VB	_	22	advcl
3	whether	whether	IN	_	5	mark
4	probenecid	probenecid	NN	_	5	nsubj
5	has	have	VBZ	_	2	ccomp
6	a	a	DT	_	8	det
7	direct	direct	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	distribution	distribution	NN	_	5	nmod
12	of	of	IN	_	13	case
13	cloxacillin	cloxacillin	NN	_	11	nmod
14	,	,	,	_	22	punct
15	the	the	DT	_	16	det
16	elimination	elimination	NN	_	22	nsubjpass
17	and	and	CC	_	16	cc
18	distribution	distribution	NN	_	16	conj
19	of	of	IN	_	20	case
20	cloxacillin	cloxacillin	NN	_	16	nmod
21	was	be	VBD	_	22	auxpass
22	studied	study	VBN	_	0	ROOT
23	in	in	IN	_	25	case
24	six	six	CD	_	25	nummod
25	patients	patient	NNS	_	22	nmod
26	,	,	,	_	25	punct
27	five	five	CD	_	25	appos
28	lacking	lack	VBG	_	27	acl
29	kidney	kidney	NN	_	30	compound
30	function	function	NN	_	28	dobj
31	and	and	CC	_	27	cc
32	one	one	CD	_	27	conj
33	with	with	IN	_	38	case
34	a	a	DT	_	38	det
35	partially	partially	RB	_	36	advmod
36	impaired	impaired	JJ	_	38	amod
37	renal	renal	JJ	_	38	amod
38	function	function	NN	_	32	nmod
39	,	,	,	_	25	punct
40	in	in	IN	_	42	case
41	the	the	DT	_	42	dep
42	presence	presence	NN	_	25	nmod
43	or	or	CC	_	42	cc
44	absence	absence	NN	_	42	conj
45	of	of	IN	_	46	case
46	probenecid	probenecid	NN	_	42	nmod
47	.	.	.	_	22	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	difference	difference	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	found	find	VBN	_	0	ROOT
6	between	between	IN	_	9	case
7	the	the	DT	_	9	det
8	mean	mean	NN	_	9	compound
9	values	value	NNS	_	5	nmod
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	volume	volume	NN	_	9	nmod
13	of	of	IN	_	14	case
14	distribution	distribution	NN	_	12	nmod
15	of	of	IN	_	16	case
16	cloxacillin	cloxacillin	NN	_	14	nmod
17	with	with	IN	_	5	nmod
18	and	and	CC	_	17	dep
19	without	without	IN	_	20	case
20	probenecid	probenecid	NN	_	18	conj
21	(	(	CD	_	22	compound
22	13.0	13.0	CD	_	20	nummod
23	and	and	CC	_	20	cc
24	12.6	12.6	CD	_	25	nummod
25	liters	liter	NNS	_	20	conj
26	,	,	,	_	20	punct
27	respectively	respectively	RB	_	28	advmod
28	)	)	CD	_	20	appos
29	.	.	.	_	5	punct

1	Thus	thus	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	hypothesis	hypothesis	NN	_	2	root
5	of	of	IN	_	6	case
6	Gibaldi	Gibaldi	NNP	_	4	nmod
7	et	et	FW	_	6	compound
8	al	al	FW	_	6	dep
9	.	.	.	_	4	punct

1	could	could	MD	_	4	aux
2	not	not	RB	_	4	neg
3	be	be	VB	_	4	auxpass
4	confirmed	confirm	VBN	_	0	ROOT
5	for	for	IN	_	6	case
6	cloxacillin	cloxacillin	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	lacking	lack	VBG	_	8	acl
10	kidney	kidney	NN	_	11	compound
11	function	function	NN	_	9	dobj
12	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	spite	spite	NN	_	19	nmod
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	absence	absence	NN	_	2	nmod
6	of	of	IN	_	8	case
7	kidney	kidney	NN	_	8	compound
8	function	function	NN	_	5	nmod
9	,	,	,	_	19	punct
10	the	the	DT	_	11	det
11	value	value	NN	_	19	nsubjpass
12	of	of	IN	_	16	case
13	the	the	DT	_	16	det
14	elimination	elimination	NN	_	16	compound
15	rate	rate	NN	_	16	compound
16	constant	constant	NN	_	11	nmod
17	was	be	VBD	_	19	auxpass
18	significantly	significantly	RB	_	19	advmod
19	decreased	decrease	VBN	_	0	ROOT
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	presence	presence	NN	_	19	nmod
23	of	of	IN	_	24	case
24	probenecid	probenecid	NN	_	22	nmod
25	(	(	CD	_	24	nummod
26	from	from	IN	_	27	case
27	0.326	0.326	CD	_	19	nmod
28	to	to	TO	_	29	dep
29	0.263	0.263	CD	_	27	nmod
30	/	/	:	_	27	punct
31	h	h	NN	_	32	compound
32	)	)	NN	_	27	dep
33	.	.	.	_	19	punct

1	This	this	DT	_	4	nsubjpass
2	might	might	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	explained	explain	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	a	a	DT	_	7	det
7	blockade	blockade	NN	_	4	nmod
8	by	by	IN	_	9	case
9	probenecid	probenecid	NN	_	7	nmod
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	elimination	elimination	NN	_	9	nmod
13	of	of	IN	_	14	case
14	cloxacillin	cloxacillin	NN	_	12	nmod
15	by	by	IN	_	17	case
16	the	the	DT	_	17	det
17	liver	liver	NN	_	7	nmod
18	.	.	.	_	4	punct

1	Stereoselective	stereoselective	JJ	_	3	amod
2	behavioral	behavioral	JJ	_	3	amod
3	effects	effect	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	N	n	NN	_	3	nmod
6	-	-	:	_	5	punct
7	allylnormetazocine	allylnormetazocine	NN	_	5	dep
8	in	in	IN	_	9	case
9	pigeons	pigeon	NNS	_	7	nmod
10	and	and	CC	_	9	cc
11	squirrel	squirrel	NN	_	12	compound
12	monkeys	monkey	NNS	_	9	conj
13	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	behavioral	behavioral	JJ	_	3	amod
3	effects	effect	NNS	_	15	nsubjpass
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	stereoisomers	stereoisomer	NNS	_	3	nmod
7	of	of	IN	_	8	case
8	N	n	NN	_	6	nmod
9	-	-	:	_	8	punct
10	allylnormetazocine	allylnormetazocine	NN	_	12	compound
11	(	(	CD	_	12	nummod
12	NANM	NANM	NNP	_	8	dep
13	)	)	CD	_	12	nummod
14	were	be	VBD	_	15	auxpass
15	compared	compare	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	those	those	DT	_	15	nmod
18	of	of	IN	_	22	case
19	phencyclidine	phencyclidine	NN	_	22	compound
20	(	(	CD	_	22	nummod
21	PCP	pcp	NN	_	22	compound
22	)	)	NN	_	17	nmod
23	in	in	IN	_	24	case
24	pigeons	pigeon	NNS	_	22	nmod
25	and	and	CC	_	24	cc
26	squirrel	squirrel	NN	_	27	compound
27	monkeys	monkey	NNS	_	24	conj
28	responding	respond	VBG	_	17	acl
29	under	under	IN	_	34	case
30	a	a	DT	_	34	det
31	multiple	multiple	JJ	_	34	amod
32	fixed	fixed	JJ	_	34	amod
33	-	-	:	_	34	punct
34	interval	interval	NN	_	28	nmod
35	fixed	fix	VBN	_	34	acl
36	-	-	:	_	17	punct
37	ratio	ratio	NN	_	42	compound
38	(	(	CD	_	42	nummod
39	FI	fi	NN	_	42	compound
40	FR	fr	NN	_	42	compound
41	)	)	CD	_	42	nummod
42	schedule	schedule	NN	_	17	dep
43	of	of	IN	_	45	case
44	food	food	NN	_	45	compound
45	presentation	presentation	NN	_	42	nmod
46	.	.	.	_	15	punct

1	Intermediate	Intermediate	NNP	_	2	compound
2	doses	dose	NNS	_	11	nsubj
3	of	of	IN	_	4	case
4	(	(	NN	_	2	nmod
5	+	+	CC	_	4	cc
6	)	)	SYM	_	8	dep
7	-	-	:	_	8	punct
8	NANM	nanm	NN	_	4	conj
9	or	or	CC	_	8	cc
10	PCP	pcp	NN	_	8	conj
11	produced	produce	VBD	_	0	ROOT
12	transient	transient	JJ	_	13	amod
13	increases	increase	NNS	_	11	dobj
14	in	in	IN	_	15	case
15	FI	fi	NN	_	13	nmod
16	responding	respond	VBG	_	15	acl
17	in	in	IN	_	18	case
18	monkeys	monkey	NNS	_	16	nmod
19	and	and	CC	_	18	cc
20	sustained	sustained	JJ	_	21	amod
21	increases	increase	NNS	_	18	conj
22	in	in	IN	_	23	case
23	FI	fi	NN	_	16	nmod
24	responding	respond	VBG	_	23	acl
25	in	in	IN	_	26	case
26	pigeons	pigeon	NNS	_	24	nmod
27	;	;	:	_	11	punct

1	higher	higher	JJR	_	2	amod
2	doses	dose	NNS	_	3	nsubj
3	decreased	decrease	VBD	_	0	ROOT
4	FI	fi	NN	_	3	dobj
5	and	and	CC	_	4	cc
6	FR	fr	NN	_	4	conj
7	responding	respond	VBG	_	4	acl
8	in	in	IN	_	10	case
9	both	both	CC	_	10	det
10	species	species	NNS	_	7	nmod
11	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	12	nmod
3	to	to	TO	_	5	case
4	its	its	PRP$	_	5	nmod:poss
5	enantiomer	enantiomer	NN	_	2	nmod
6	,	,	,	_	12	punct
7	(	(	SYM	_	12	dep
8	-	-	:	_	12	punct
9	)	)	SYM	_	12	dep
10	-	-	:	_	12	punct
11	NANM	nanm	NN	_	12	nsubj
12	failed	fail	VBD	_	0	ROOT
13	to	to	TO	_	14	mark
14	increase	increase	VB	_	12	xcomp
15	FI	fi	NN	_	14	dobj
16	responding	respond	VBG	_	15	acl
17	significantly	significantly	RB	_	16	advmod
18	in	in	IN	_	20	case
19	either	either	CC	_	20	det
20	species	species	NNS	_	16	nmod
21	;	;	:	_	12	punct

1	at	at	IN	_	3	case
2	high	high	JJ	_	3	amod
3	doses	dose	NNS	_	10	nmod
4	,	,	,	_	10	punct
5	(	(	SYM	_	10	dep
6	-	-	:	_	10	punct
7	)	)	SYM	_	10	dep
8	-	-	:	_	10	punct
9	NANM	NANM	NNP	_	10	nsubj
10	decreased	decrease	VBD	_	0	ROOT
11	FI	fi	NN	_	10	dobj
12	and	and	CC	_	11	cc
13	FR	fr	NN	_	11	conj
14	responding	respond	VBG	_	11	dep
15	.	.	.	_	10	punct

1	In	in	IN	_	2	case
2	monkeys	monkey	NNS	_	14	nmod
3	,	,	,	_	14	punct
4	(	(	SYM	_	14	dep
5	-	-	:	_	14	punct
6	)	)	SYM	_	14	dep
7	-	-	:	_	14	punct
8	NANM	nanm	NN	_	14	nsubj
9	was	be	VBD	_	14	cop
10	about	about	IN	_	12	advmod
11	10	10	CD	_	12	compound
12	times	time	NNS	_	14	nummod
13	more	more	RBR	_	12	advmod
14	potent	potent	JJ	_	0	ROOT
15	than	than	IN	_	16	case
16	(	(	CD	_	14	nmod
17	+	+	CC	_	16	cc
18	)	)	SYM	_	16	conj
19	-	-	:	_	14	punct
20	NANM	NANM	NNP	_	14	dep
21	in	in	IN	_	22	mark
22	decreasing	decrease	VBG	_	20	acl
23	responding	respond	VBG	_	22	xcomp
24	,	,	,	_	20	punct
25	whereas	whereas	IN	_	35	mark
26	in	in	IN	_	27	case
27	pigeons	pigeon	NNS	_	35	nmod
28	(	(	SYM	_	35	dep
29	-	-	:	_	35	punct
30	)	)	SYM	_	35	dep
31	-	-	:	_	35	punct
32	NANM	nanm	NN	_	35	nsubj
33	was	be	VBD	_	35	cop
34	about	about	IN	_	35	advmod
35	equipotent	equipotent	JJ	_	20	advcl
36	with	with	IN	_	37	case
37	(	(	NN	_	35	nmod
38	+	+	CC	_	37	cc
39	)	)	SYM	_	41	dep
40	-	-	:	_	41	punct
41	NANM	nanm	NN	_	37	conj
42	.	.	.	_	14	punct

1	In	in	IN	_	3	case
2	both	both	DT	_	3	det
3	species	species	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	(	(	SYM	_	9	dep
6	-	-	:	_	9	punct
7	)	)	SYM	_	9	dep
8	-	-	:	_	9	punct
9	NANM	NANM	NNP	_	0	ROOT
10	,	,	,	_	9	punct
11	but	but	CC	_	12	cc
12	not	not	RB	_	9	cc
13	(	(	NN	_	17	compound
14	+	+	CC	_	13	cc
15	)	)	SYM	_	13	conj
16	-	-	:	_	17	punct
17	NANM	NANM	NNP	_	9	conj
18	,	,	,	_	9	punct
19	antagonized	antagonize	VBD	_	9	dep
20	the	the	DT	_	21	det
21	rate	rate	NN	_	19	dobj
22	-	-	:	_	9	punct
23	decreasing	decrease	VBG	_	24	amod
24	effects	effect	NNS	_	9	dep
25	of	of	IN	_	26	case
26	morphine	morphine	NN	_	24	nmod
27	on	on	IN	_	28	case
28	FI	fi	NN	_	24	nmod
29	and	and	CC	_	28	cc
30	FR	fr	NN	_	28	conj
31	responding	respond	VBG	_	28	acl
32	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	monkeys	monkey	NNS	_	24	nmod
3	,	,	,	_	24	punct
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	24	nsubjpass
6	of	of	IN	_	11	case
7	(	(	SYM	_	11	dep
8	-	-	:	_	11	punct
9	)	)	SYM	_	11	dep
10	-	-	:	_	11	punct
11	NANM	NANM	NNP	_	5	nmod
12	,	,	,	_	11	punct
13	but	but	CC	_	14	cc
14	not	not	RB	_	11	cc
15	(	(	NN	_	11	conj
16	+	+	CC	_	15	cc
17	)	)	SYM	_	15	conj
18	-	-	:	_	15	punct
19	NANM	nanm	NN	_	15	dep
20	or	or	CC	_	19	cc
21	PCP	pcp	NN	_	19	conj
22	,	,	,	_	11	punct
23	were	be	VBD	_	24	auxpass
24	antagonized	antagonize	VBN	_	0	ROOT
25	by	by	IN	_	26	case
26	naloxone	naloxone	NN	_	24	nmod
27	;	;	:	_	24	punct

1	the	the	DT	_	2	det
2	doses	dose	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	naloxone	naloxone	NN	_	2	nmod
5	required	require	VBN	_	2	acl
6	to	to	TO	_	7	mark
7	antagonize	antagonize	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	21	case
11	(	(	SYM	_	21	dep
12	-	-	:	_	21	punct
13	)	)	SYM	_	21	dep
14	-	-	:	_	21	punct
15	NANM	nanm	NN	_	21	nsubj
16	were	be	VBD	_	21	cop
17	more	more	JJR	_	20	advmod
18	than	than	IN	_	17	mwe
19	100	100	CD	_	20	compound
20	times	time	NNS	_	21	nmod:npmod
21	higher	higher	JJR	_	9	nmod
22	than	than	IN	_	23	case
23	those	those	DT	_	21	nmod
24	required	require	VBN	_	23	acl
25	to	to	TO	_	26	mark
26	antagonize	antagonize	VB	_	24	xcomp
27	the	the	DT	_	28	det
28	effects	effect	NNS	_	26	dobj
29	of	of	IN	_	30	case
30	morphine	morphine	NN	_	28	nmod
31	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	pigeons	pigeon	NNS	_	8	nmod
3	,	,	,	_	8	punct
4	naloxone	naloxone	NN	_	8	nsubj
5	did	do	VBD	_	8	aux
6	not	not	RB	_	8	neg
7	systematically	systematically	RB	_	8	advmod
8	alter	alter	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	effects	effect	NNS	_	8	dobj
11	of	of	IN	_	16	case
12	(	(	SYM	_	16	dep
13	-	-	:	_	16	punct
14	)	)	SYM	_	16	dep
15	-	-	:	_	16	punct
16	NANM	nanm	NN	_	10	nmod
17	,	,	,	_	16	punct
18	(	(	NN	_	16	conj
19	+	+	CC	_	16	cc
20	)	)	SYM	_	22	dep
21	-	-	:	_	22	punct
22	NANM	nanm	NN	_	16	conj
23	or	or	CC	_	22	cc
24	PCP	pcp	NN	_	22	conj
25	.	.	.	_	8	punct

1	Haloperidol	Haloperidol	NNP	_	2	nsubj
2	reduced	reduce	VBD	_	0	ROOT
3	or	or	CC	_	2	cc
4	eliminated	eliminate	VBD	_	2	conj
5	the	the	DT	_	6	det
6	increases	increase	NNS	_	2	dobj
7	in	in	IN	_	8	case
8	FI	fi	NN	_	6	nmod
9	responding	respond	VBG	_	8	acl
10	produced	produce	VBN	_	9	dobj
11	by	by	IN	_	13	case
12	intermediate	intermediate	JJ	_	13	amod
13	doses	dose	NNS	_	10	nmod
14	of	of	IN	_	16	case
15	either	either	CC	_	16	cc:preconj
16	(	(	NN	_	13	nmod
17	+	+	CC	_	16	cc
18	)	)	SYM	_	16	conj
19	-	-	:	_	16	punct
20	NANM	nanm	NN	_	16	conj
21	or	or	CC	_	16	cc
22	PCP	pcp	NN	_	16	conj
23	in	in	IN	_	24	case
24	pigeons	pigeon	NNS	_	13	nmod
25	,	,	,	_	2	punct
26	but	but	CC	_	2	cc
27	did	do	VBD	_	29	aux
28	not	not	RB	_	29	neg
29	antagonize	antagonize	VB	_	2	conj
30	the	the	DT	_	31	det
31	decreases	decrease	NNS	_	29	dobj
32	in	in	IN	_	33	case
33	FI	fi	NN	_	31	nmod
34	or	or	CC	_	33	cc
35	FR	fr	NN	_	33	conj
36	responding	respond	VBG	_	33	dep
37	produced	produce	VBN	_	36	acl
38	by	by	IN	_	40	case
39	high	high	JJ	_	40	amod
40	doses	dose	NNS	_	37	nmod
41	of	of	IN	_	42	case
42	PCP	pcp	NN	_	40	nmod
43	or	or	CC	_	40	cc
44	either	either	CC	_	45	cc:preconj
45	stereoisomer	stereoisomer	NN	_	40	conj
46	of	of	IN	_	47	case
47	NANM	NANM	NNP	_	45	nmod
48	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	a	a	DT	_	6	det
5	high	high	JJ	_	6	amod
6	degree	degree	NN	_	3	dobj
7	of	of	IN	_	8	case
8	stereoselectivity	stereoselectivity	NN	_	6	nmod
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	behavioral	behavioral	JJ	_	12	amod
12	effects	effect	NNS	_	6	nmod
13	of	of	IN	_	14	case
14	NANM	NANM	NNP	_	12	nmod
15	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	levorotatory	levorotatory	JJ	_	3	amod
3	isomer	isomer	NN	_	5	nsubj
4	had	have	VBD	_	5	aux
5	opioid	opioid	VBN	_	0	ROOT
6	-	-	:	_	5	punct
7	antagonist	antagonist	NN	_	5	dobj
8	and	and	CC	_	7	cc
9	non	non	JJ	_	7	conj
10	-	-	:	_	7	punct
11	opioid	opioid	NN	_	13	compound
12	agonist	agonist	NN	_	13	compound
13	effects	effect	NNS	_	7	conj
14	in	in	IN	_	15	case
15	pigeons	pigeon	NNS	_	13	nmod
16	and	and	CC	_	15	cc
17	mixed	mixed	JJ	_	19	amod
18	opioid	opioid	NN	_	19	compound
19	agonist	agonist	NN	_	15	conj
20	-	-	:	_	7	punct
21	antagonist	antagonist	NN	_	22	compound
22	effects	effect	NNS	_	7	dep
23	in	in	IN	_	24	case
24	monkeys	monkey	NNS	_	22	nmod
25	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	dextrorotatory	dextrorotatory	JJ	_	3	amod
3	isomer	isomer	NN	_	10	nsubj
4	,	,	,	_	10	punct
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	other	other	JJ	_	8	amod
8	hand	hand	NN	_	10	nmod
9	,	,	,	_	10	punct
10	had	have	VBD	_	0	ROOT
11	effects	effect	NNS	_	10	dobj
12	similar	similar	JJ	_	11	amod
13	to	to	TO	_	14	case
14	those	those	DT	_	12	nmod
15	of	of	IN	_	16	case
16	PCP	pcp	NN	_	14	nmod
17	in	in	IN	_	19	case
18	both	both	CC	_	19	det
19	species	species	NNS	_	14	nmod
20	.	.	.	_	10	punct

1	Cancer	cancer	NN	_	0	ROOT
2	in	in	IN	_	4	case
3	the	the	DT	_	4	det
4	elderly	elderly	JJ	_	1	nmod
5	:	:	:	_	1	punct
6	basic	basic	JJ	_	7	amod
7	science	science	NN	_	1	dep
8	and	and	CC	_	7	cc
9	clinical	clinical	JJ	_	10	amod
10	aspects	aspect	NNS	_	7	conj
11	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	cancer	cancer	NN	_	2	nmod
5	increases	increase	VBZ	_	0	ROOT
6	progressively	progressively	RB	_	5	advmod
7	with	with	IN	_	8	case
8	age	age	NN	_	5	nmod
9	.	.	.	_	5	punct

1	Rearrangements	rearrangement	NNS	_	6	nsubjpass
2	of	of	IN	_	3	case
3	genomes	genome	NNS	_	1	nmod
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	found	find	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	accompany	accompany	VB	_	6	xcomp
9	cellular	cellular	JJ	_	10	amod
10	aging	aging	NN	_	8	dobj
11	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	factors	factor	NNS	_	10	nsubj
3	,	,	,	_	10	punct
4	in	in	IN	_	7	case
5	concert	concert	NN	_	7	dep
6	with	with	IN	_	7	case
7	age	age	NN	_	10	nmod
8	-	-	:	_	10	punct
9	dependent	dependent	JJ	_	10	amod
10	alterations	alteration	NNS	_	0	ROOT
11	in	in	IN	_	13	case
12	immune	immune	JJ	_	13	amod
13	function	function	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	host	host	NN	_	16	compound
16	defense	defense	NN	_	13	conj
17	,	,	,	_	10	punct
18	may	may	MD	_	19	aux
19	help	help	VB	_	10	dep
20	to	to	TO	_	21	mark
21	explain	explain	VB	_	19	xcomp
22	the	the	DT	_	24	det
23	increased	increase	VBN	_	24	amod
24	risk	risk	NN	_	21	dobj
25	of	of	IN	_	27	case
26	malignant	malignant	JJ	_	27	amod
27	disease	disease	NN	_	24	nmod
28	in	in	IN	_	30	case
29	aged	aged	JJ	_	30	amod
30	persons	person	NNS	_	24	nmod
31	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	presentation	presentation	NN	_	11	nsubjpass
4	and	and	CC	_	3	cc
5	natural	natural	JJ	_	6	amod
6	history	history	NN	_	3	conj
7	of	of	IN	_	8	case
8	neoplasia	neoplasia	NN	_	3	nmod
9	are	be	VBP	_	11	auxpass
10	also	also	RB	_	11	advmod
11	affected	affect	VBN	_	0	ROOT
12	by	by	IN	_	13	case
13	aging	aging	NN	_	11	nmod
14	.	.	.	_	11	punct

1	This	this	DT	_	2	det
2	conference	conference	NN	_	3	nsubj
3	reviews	review	VBZ	_	0	ROOT
4	recent	recent	JJ	_	5	amod
5	developments	development	NNS	_	3	dobj
6	in	in	IN	_	8	case
7	these	these	DT	_	8	det
8	areas	area	NNS	_	5	nmod
9	,	,	,	_	3	punct
10	examines	examine	VBZ	_	3	conj
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	10	dobj
13	of	of	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	use	use	NN	_	12	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	elderly	elderly	JJ	_	12	nmod
19	and	and	CC	_	18	cc
20	implications	implication	NNS	_	18	conj
21	for	for	IN	_	22	case
22	management	management	NN	_	12	nmod
23	,	,	,	_	3	punct
24	and	and	CC	_	3	cc
25	discusses	discuss	VBZ	_	3	conj
26	current	current	JJ	_	27	amod
27	information	information	NN	_	25	dobj
28	on	on	IN	_	32	mark
29	how	how	WRB	_	32	advmod
30	age	age	NN	_	32	nsubj
31	may	may	MD	_	32	aux
32	influence	influence	VB	_	25	advcl
33	the	the	DT	_	34	det
34	response	response	NN	_	32	dobj
35	of	of	IN	_	36	case
36	cancer	cancer	NN	_	34	nmod
37	to	to	TO	_	38	case
38	therapy	therapy	NN	_	34	nmod
39	.	.	.	_	3	punct

1	Prescribing	prescribe	VBG	_	0	ROOT
2	.	.	.	_	1	punct

1	Keys	Keys	NNP	_	0	ROOT
2	to	to	TO	_	3	mark
3	maximizing	maximize	VBG	_	1	acl
4	benefit	benefit	NN	_	3	dobj
5	while	while	IN	_	6	mark
6	avoiding	avoid	VBG	_	1	advcl
7	adverse	adverse	JJ	_	9	amod
8	drug	drug	NN	_	9	compound
9	effects	effect	NNS	_	6	dobj
10	.	.	.	_	1	punct

1	When	when	WRB	_	2	advmod
2	prescribing	prescribe	VBG	_	11	advcl
3	for	for	IN	_	5	case
4	older	older	JJR	_	5	amod
5	patients	patient	NNS	_	2	nmod
6	,	,	,	_	11	punct
7	some	some	DT	_	8	det
8	physicians	physician	NNS	_	11	nsubj
9	are	be	VBP	_	11	cop
10	overly	overly	RB	_	11	advmod
11	cautious	cautious	JJ	_	0	ROOT
12	,	,	,	_	11	punct
13	and	and	CC	_	11	cc
14	this	this	DT	_	15	det
15	strategy	strategy	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	result	result	VB	_	11	conj
18	in	in	IN	_	17	nmod
19	a	a	DT	_	18	dep
20	less	less	JJR	_	19	amod
21	than	than	IN	_	24	case
22	optimal	optimal	JJ	_	24	amod
23	treatment	treatment	NN	_	24	compound
24	outcome	outcome	NN	_	20	nmod
25	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	reluctance	reluctance	NN	_	7	nsubj
3	to	to	TO	_	4	mark
4	treat	treat	VB	_	2	acl
5	aggressively	aggressively	RB	_	4	advmod
6	is	be	VBZ	_	7	cop
7	understandable	understandable	JJ	_	0	ROOT
8	because	because	IN	_	13	mark
9	the	the	DT	_	11	det
10	geriatric	geriatric	JJ	_	11	amod
11	population	population	NN	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	susceptible	susceptible	JJ	_	7	advcl
14	to	to	TO	_	17	case
15	adverse	adverse	JJ	_	17	amod
16	drug	drug	NN	_	17	compound
17	reactions	reaction	NNS	_	13	nmod
18	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	key	key	NN	_	6	nsubj
3	to	to	TO	_	4	mark
4	maximizing	maximize	VBG	_	2	acl
5	therapy	therapy	NN	_	4	dobj
6	lies	lie	VBZ	_	0	ROOT
7	in	in	IN	_	8	mark
8	individualizing	individualize	VBG	_	6	advcl
9	it	it	PRP	_	8	dobj
10	as	as	RB	_	11	advmod
11	much	much	RB	_	8	advmod
12	as	as	IN	_	13	case
13	possible	possible	JJ	_	11	advcl
14	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	a	a	DT	_	4	det
4	number	number	NN	_	9	nsubj
5	of	of	IN	_	7	case
6	steps	step	NNS	_	7	compound
7	physicians	physician	NNS	_	4	nmod
8	can	can	MD	_	9	aux
9	take	take	VB	_	2	ccomp
10	to	to	TO	_	11	mark
11	ensure	ensure	VB	_	9	xcomp
12	that	that	IN	_	18	mark
13	their	they	PRP$	_	14	nmod:poss
14	patients	patient	NNS	_	18	nsubj
15	are	be	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	being	be	VBG	_	18	cop
18	undertreated	undertreated	JJ	_	11	ccomp
19	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	steps	step	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	regular	regular	JJ	_	5	amod
5	reevaluations	reevaluation	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	dosages	dosage	NNS	_	5	nmod
8	and	and	CC	_	7	cc
9	plasma	plasma	NN	_	11	compound
10	drug	drug	NN	_	11	compound
11	concentrations	concentration	NNS	_	7	conj
12	,	,	,	_	7	punct
13	recognition	recognition	NN	_	7	conj
14	and	and	CC	_	7	cc
15	understanding	understanding	NN	_	7	conj
16	of	of	IN	_	19	case
17	drug	drug	NN	_	19	compound
18	side	side	NN	_	19	compound
19	effects	effect	NNS	_	15	nmod
20	,	,	,	_	5	punct
21	and	and	CC	_	5	cc
22	avoidance	avoidance	NN	_	5	conj
23	of	of	IN	_	25	case
24	certain	certain	JJ	_	25	amod
25	agents	agent	NNS	_	22	nmod
26	.	.	.	_	3	punct

1	Close	close	JJ	_	2	amod
2	monitoring	monitoring	NN	_	3	nsubj
3	allows	allow	VBZ	_	0	ROOT
4	physicians	physician	NNS	_	3	dobj
5	to	to	TO	_	6	mark
6	minimize	minimize	VB	_	3	xcomp
7	risks	risk	NNS	_	6	dobj
8	,	,	,	_	6	punct
9	maximize	maximize	VB	_	6	conj
10	benefits	benefit	NNS	_	9	dobj
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	get	get	VB	_	6	conj
14	the	the	DT	_	16	det
15	most	most	RBS	_	16	advmod
16	out	out	RB	_	13	dobj
17	of	of	IN	_	22	mark
18	what	what	WP	_	22	dobj
19	modern	modern	JJ	_	20	amod
20	medications	medication	NNS	_	22	nsubj
21	can	can	MD	_	22	aux
22	do	do	VB	_	16	acl
23	to	to	TO	_	24	mark
24	help	help	VB	_	22	xcomp
25	older	older	JJR	_	26	amod
26	patients	patient	NNS	_	24	dobj
27	.	.	.	_	3	punct

1	Determinants	determinant	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	cellular	cellular	JJ	_	4	amod
4	sensitivity	sensitivity	NN	_	1	nmod
5	to	to	TO	_	6	case
6	topoisomerase	topoisomerase	NN	_	4	nmod
7	-	-	:	_	1	punct
8	targeting	target	VBG	_	1	dep
9	antitumor	antitumor	NN	_	10	compound
10	drugs	drug	NNS	_	8	dobj
11	.	.	.	_	1	punct

1	It	it	PRP	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	now	now	RB	_	4	advmod
4	clear	clear	JJ	_	0	ROOT
5	that	that	IN	_	12	mark
6	topoisomerase	topoisomerase	NN	_	8	compound
7	activity	activity	NN	_	8	compound
8	level	level	NN	_	12	nsubj
9	is	be	VBZ	_	12	cop
10	an	a	DT	_	12	det
11	important	important	JJ	_	12	amod
12	determinant	determinant	NN	_	4	ccomp
13	of	of	IN	_	14	case
14	sensitivity	sensitivity	NN	_	12	nmod
15	to	to	TO	_	17	case
16	topo	topo	NN	_	17	compound
17	drugs	drug	NNS	_	14	nmod
18	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	regulation	regulation	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	topoisomerases	topoisomerase	NNS	_	2	nmod
5	is	be	VBZ	_	8	cop
6	no	no	DT	_	8	neg
7	doubt	doubt	NN	_	8	compound
8	complex	complex	NN	_	0	ROOT
9	and	and	CC	_	8	cc
10	multifaceted	multifaceted	JJ	_	8	conj
11	and	and	CC	_	8	cc
12	is	be	VBZ	_	14	auxpass
13	probably	probably	RB	_	14	advmod
14	accomplished	accomplish	VBN	_	8	conj
15	through	through	IN	_	16	case
16	redundancy	redundancy	NN	_	14	nmod
17	at	at	IN	_	20	case
18	many	many	JJ	_	20	amod
19	control	control	NN	_	20	compound
20	levels	level	NNS	_	14	nmod
21	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	mechanism	mechanism	NN	_	3	compound
3	(	(	NN	_	5	nsubj
4	s	be	VBZ	_	5	compound
5	)	)	NN	_	16	nsubj
6	of	of	IN	_	10	case
7	altered	altered	JJ	_	10	amod
8	topo	topo	NN	_	10	compound
9	I	i	NN	_	10	compound
10	expression	expression	NN	_	5	nmod
11	in	in	IN	_	14	case
12	certain	certain	JJ	_	14	amod
13	tumor	tumor	NN	_	14	compound
14	types	type	NNS	_	10	nmod
15	is	be	VBZ	_	16	cop
16	unknown	unknown	JJ	_	0	ROOT
17	,	,	,	_	16	punct
18	but	but	CC	_	16	cc
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	cop
21	related	relate	VBN	_	16	conj
22	to	to	TO	_	25	case
23	the	the	DT	_	25	det
24	central	central	JJ	_	25	amod
25	importance	importance	NN	_	21	nmod
26	of	of	IN	_	27	case
27	topoisomerases	topoisomerase	NNS	_	25	nmod
28	in	in	IN	_	31	case
29	proliferating	proliferate	VBG	_	31	amod
30	cell	cell	NN	_	31	compound
31	functions	function	NNS	_	25	nmod
32	(	(	VBP	_	21	dep
33	transcription	transcription	NN	_	32	dobj
34	,	,	,	_	33	punct
35	replication	replication	NN	_	33	conj
36	,	,	,	_	33	punct
37	etc	etc	FW	_	33	conj
38	.	.	.	_	33	punct
39	)	)	NN	_	33	conj
40	,	,	,	_	33	punct
41	and	and	CC	_	33	cc
42	the	the	DT	_	46	det
43	aberrant	aberrant	JJ	_	46	amod
44	and	and	CC	_	43	cc
45	chronic	chronic	JJ	_	43	conj
46	activation	activation	NN	_	33	conj
47	of	of	IN	_	49	case
48	these	these	DT	_	49	det
49	functions	function	NNS	_	46	nmod
50	as	as	IN	_	52	case
51	a	a	DT	_	52	det
52	result	result	NN	_	46	nmod
53	of	of	IN	_	56	case
54	specific	specific	JJ	_	56	amod
55	tumorigenic	tumorigenic	JJ	_	56	amod
56	alterations	alteration	NNS	_	52	nmod
57	.	.	.	_	16	punct

1	Small	small	JJ	_	2	amod
2	differences	difference	NNS	_	8	nsubj
3	in	in	IN	_	4	case
4	sensitivity	sensitivity	NN	_	2	nmod
5	to	to	TO	_	6	case
6	chemotherapy	chemotherapy	NN	_	4	nmod
7	can	can	MD	_	8	aux
8	have	have	VB	_	0	ROOT
9	a	a	DT	_	11	det
10	dramatic	dramatic	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	on	on	IN	_	14	case
13	cure	cure	NN	_	14	compound
14	rates	rate	NNS	_	11	nmod
15	,	,	,	_	8	punct
16	and	and	CC	_	8	cc
17	therefore	therefore	RB	_	18	advmod
18	subtle	subtle	JJ	_	20	amod
19	cell	cell	NN	_	20	compound
20	type	type	NN	_	8	conj
21	-	-	:	_	20	punct
22	specific	specific	JJ	_	23	amod
23	differences	difference	NNS	_	27	nsubj
24	may	may	MD	_	27	aux
25	be	be	VB	_	27	cop
26	important	important	JJ	_	27	amod
27	determinants	determinant	NNS	_	20	acl:relcl
28	of	of	IN	_	30	case
29	drug	drug	NN	_	30	compound
30	sensitivity	sensitivity	NN	_	27	nmod
31	.	.	.	_	8	punct

1	Whether	whether	IN	_	9	mark
2	abnormal	abnormal	JJ	_	4	amod
3	topoisomerase	topoisomerase	NN	_	4	compound
4	quantity	quantity	NN	_	9	nsubjpass
5	and	and	CC	_	4	cc
6	specific	specific	JJ	_	7	amod
7	activity	activity	NN	_	4	conj
8	are	be	VBP	_	9	auxpass
9	associated	associate	VBN	_	25	advcl
10	with	with	IN	_	11	case
11	resistance	resistance	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	sensitivity	sensitivity	NN	_	11	conj
14	to	to	TO	_	15	case
15	topoisomerase	topoisomerase	NN	_	13	nmod
16	-	-	:	_	18	punct
17	targeted	target	VBN	_	18	amod
18	chemotherapy	chemotherapy	NN	_	25	nsubjpass
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	clinic	clinic	NN	_	18	nmod
22	is	be	VBZ	_	25	aux
23	now	now	RB	_	25	advmod
24	being	be	VBG	_	25	auxpass
25	studied	study	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	Determinants	determinant	NNS	_	0	ROOT
2	downstream	downstream	RB	_	1	advmod
3	of	of	IN	_	6	case
4	cleavable	cleavable	JJ	_	6	amod
5	complex	complex	NN	_	6	compound
6	formation	formation	NN	_	2	nmod
7	that	that	WDT	_	8	nsubj
8	affect	affect	VBP	_	1	acl:relcl
9	the	the	DT	_	10	det
10	sensitivity	sensitivity	NN	_	8	dobj
11	of	of	IN	_	12	case
12	tumor	tumor	NN	_	10	nmod
13	versus	versus	CC	_	12	cc
14	normal	normal	JJ	_	15	amod
15	cells	cell	NNS	_	12	conj
16	to	to	TO	_	18	case
17	topo	topo	NN	_	18	compound
18	drugs	drug	NNS	_	10	nmod
19	in	in	IN	_	20	case
20	particular	particular	JJ	_	10	nmod
21	and	and	CC	_	20	cc
22	DNA	dna	NN	_	20	conj
23	-	-	:	_	1	punct
24	damaging	damage	VBG	_	25	amod
25	agents	agent	NNS	_	30	nsubj
26	in	in	IN	_	27	case
27	general	general	JJ	_	25	nmod
28	are	be	VBP	_	30	cop
29	little	little	JJ	_	30	advmod
30	known	known	JJ	_	1	dep
31	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	goal	goal	NN	_	0	ROOT
3	of	of	IN	_	4	mark
4	enhancing	enhance	VBG	_	2	acl
5	selective	selective	JJ	_	8	amod
6	tumor	tumor	NN	_	8	compound
7	cell	cell	NN	_	8	compound
8	killing	killing	NN	_	4	dobj
9	relative	relative	JJ	_	4	advmod
10	to	to	TO	_	13	case
11	the	the	DT	_	13	det
12	normal	normal	JJ	_	13	amod
13	cells	cell	NNS	_	9	nmod
14	that	that	WDT	_	20	nsubjpass
15	are	be	VBP	_	20	auxpass
16	dose	dose	NN	_	20	nsubjpass
17	limiting	limit	VBG	_	16	acl
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	achieved	achieve	VBN	_	13	acl:relcl
21	either	either	CC	_	23	cc:preconj
22	by	by	IN	_	23	mark
23	overcoming	overcome	VBG	_	20	dep
24	tumor	tumor	NN	_	26	compound
25	cell	cell	NN	_	26	compound
26	resistance	resistance	NN	_	23	dobj
27	or	or	CC	_	23	cc
28	by	by	IN	_	29	mark
29	protecting	protect	VBG	_	23	conj
30	normal	normal	JJ	_	31	amod
31	cells	cell	NNS	_	29	dobj
32	.	.	.	_	2	punct

1	Both	both	DT	_	6	nsubj
2	of	of	IN	_	4	case
3	these	these	DT	_	4	det
4	strategies	strategy	NNS	_	1	nmod
5	will	will	MD	_	6	aux
6	become	become	VB	_	0	ROOT
7	more	more	RBR	_	8	advmod
8	feasible	feasible	JJ	_	6	xcomp
9	as	as	IN	_	12	case
10	specific	specific	JJ	_	12	amod
11	molecular	molecular	JJ	_	12	amod
12	differences	difference	NNS	_	6	nmod
13	between	between	IN	_	14	case
14	tumor	tumor	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	normal	normal	JJ	_	17	amod
17	cells	cell	NNS	_	14	conj
18	are	be	VBP	_	21	aux
19	being	be	VBG	_	21	auxpass
20	rapidly	rapidly	RB	_	21	advmod
21	identified	identify	VBN	_	6	dep
22	and	and	CC	_	21	cc
23	new	new	JJ	_	25	amod
24	combination	combination	NN	_	25	compound
25	therapies	therapy	NNS	_	34	nsubjpass
26	that	that	WDT	_	27	nsubj
27	take	take	VBP	_	25	acl:relcl
28	advantage	advantage	NN	_	27	dobj
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	differences	difference	NNS	_	27	nmod
32	are	be	VBP	_	34	aux
33	being	be	VBG	_	34	auxpass
34	designed	design	VBN	_	21	conj
35	and	and	CC	_	21	cc
36	tested	test	VBN	_	21	conj
37	.	.	.	_	6	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	cobalt	cobalt	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	iron	iron	NN	_	3	conj
6	in	in	IN	_	7	case
7	absorption	absorption	NN	_	1	nmod
8	and	and	CC	_	7	cc
9	retention	retention	NN	_	7	conj
10	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	36	nsubjpass
3	of	of	IN	_	6	case
4	supplementary	supplementary	JJ	_	6	amod
5	oral	oral	JJ	_	6	amod
6	cobalt	cobalt	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	iron	iron	NN	_	6	conj
9	,	,	,	_	6	punct
10	as	as	RB	_	6	cc
11	well	well	RB	_	10	mwe
12	as	as	IN	_	10	mwe
13	the	the	DT	_	14	det
14	interaction	interaction	NN	_	6	conj
15	between	between	IN	_	16	case
16	both	both	DT	_	14	nmod
17	at	at	IN	_	20	case
18	the	the	DT	_	20	det
19	absorption	absorption	NN	_	20	compound
20	site	site	NN	_	14	nmod
21	,	,	,	_	20	punct
22	fecal	fecal	JJ	_	25	amod
23	and	and	CC	_	22	cc
24	urinary	urinary	JJ	_	22	conj
25	excretion	excretion	NN	_	20	appos
26	as	as	RB	_	25	cc
27	well	well	RB	_	26	mwe
28	as	as	IN	_	26	mwe
29	the	the	DT	_	30	det
30	retention	retention	NN	_	25	conj
31	of	of	IN	_	34	case
32	these	these	DT	_	34	det
33	trace	trace	NN	_	34	compound
34	elements	element	NNS	_	30	nmod
35	were	be	VBD	_	36	auxpass
36	determined	determine	VBN	_	0	ROOT
37	by	by	IN	_	38	mark
38	using	use	VBG	_	36	advcl
39	four	four	CD	_	40	nummod
40	diets	diet	NNS	_	38	dobj
41	containing	contain	VBG	_	40	acl
42	either	either	CC	_	46	cc:preconj
43	9	9	CD	_	46	nummod
44	or	or	CC	_	43	cc
45	63	63	CD	_	43	conj
46	micrograms	microgram	NNS	_	41	dobj
47	/	/	:	_	46	punct
48	kg	kg	NN	_	46	dep
49	of	of	IN	_	50	case
50	Co	Co	NNP	_	48	nmod
51	and	and	CC	_	50	cc
52	48	48	CD	_	55	nummod
53	or	or	CC	_	52	cc
54	446	446	CD	_	52	conj
55	mg	mg	NN	_	50	conj
56	/	/	:	_	46	punct
57	kg	kg	NN	_	46	dep
58	of	of	IN	_	59	case
59	Fe	Fe	NNP	_	57	nmod
60	over	over	IN	_	62	case
61	a	a	DT	_	62	det
62	period	period	NN	_	57	nmod
63	of	of	IN	_	65	case
64	19	19	CD	_	65	nummod
65	days	day	NNS	_	62	nmod
66	in	in	IN	_	68	case
67	a	a	DT	_	68	det
68	total	total	NN	_	62	nmod
69	of	of	IN	_	71	case
70	24	24	CD	_	71	nummod
71	rats	rat	NNS	_	68	nmod
72	.	.	.	_	36	punct

1	Retention	retention	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	calculated	calculate	VBN	_	0	ROOT
4	by	by	IN	_	7	case
5	the	the	DT	_	7	det
6	balance	balance	NN	_	7	compound
7	technique	technique	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	by	by	IN	_	13	case
10	the	the	DT	_	13	det
11	comparative	comparative	JJ	_	13	amod
12	slaughter	slaughter	NN	_	13	compound
13	technique	technique	NN	_	7	conj
14	.	.	.	_	3	punct

1	After	after	IN	_	3	case
2	one	one	CD	_	3	nummod
3	day	day	NN	_	16	nmod
4	,	,	,	_	16	punct
5	fecal	fecal	JJ	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	urinary	urinary	JJ	_	5	conj
10	excretion	excretion	NN	_	16	nsubj
11	of	of	IN	_	13	case
12	both	both	CC	_	13	det
13	elements	element	NNS	_	10	nmod
14	had	have	VBD	_	16	aux
15	already	already	RB	_	16	advmod
16	responded	respond	VBN	_	0	ROOT
17	to	to	TO	_	20	case
18	the	the	DT	_	20	det
19	dietary	dietary	JJ	_	20	amod
20	treatments	treatment	NNS	_	16	nmod
21	,	,	,	_	16	punct
22	with	with	IN	_	26	mark
23	constant	constant	JJ	_	24	amod
24	values	value	NNS	_	26	nsubjpass
25	being	be	VBG	_	26	auxpass
26	reached	reach	VBN	_	16	advcl
27	after	after	IN	_	30	case
28	approximately	approximately	RB	_	29	advmod
29	three	three	CD	_	30	nummod
30	days	day	NNS	_	26	nmod
31	.	.	.	_	16	punct

1	Cobalt	cobalt	NN	_	2	compound
2	excretion	excretion	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	enhanced	enhance	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	supplementary	supplementary	JJ	_	7	amod
7	cobalt	cobalt	NN	_	4	nmod
8	;	;	:	_	4	punct

1	fecal	fecal	JJ	_	2	amod
2	excretion	excretion	NN	_	7	nsubjpass
3	,	,	,	_	7	punct
4	too	too	RB	_	7	advmod
5	,	,	,	_	7	punct
6	was	be	VBD	_	7	auxpass
7	increased	increase	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	supplementary	supplementary	JJ	_	10	amod
10	iron	iron	NN	_	7	nmod
11	;	;	:	_	7	punct

1	whereas	whereas	IN	_	5	mark
2	urinary	urinary	JJ	_	3	amod
3	excretion	excretion	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	both	both	DT	_	8	det
8	cases	case	NNS	_	5	nmod
9	.	.	.	_	5	punct

1	Additional	additional	JJ	_	2	amod
2	iron	iron	NN	_	4	nsubj
3	significantly	significantly	RB	_	4	advmod
4	inhibited	inhibit	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	8	case
8	cobalt	cobalt	NN	_	6	nmod
9	in	in	IN	_	13	case
10	both	both	CC	_	13	det
11	dietary	dietary	JJ	_	13	amod
12	cobalt	cobalt	NN	_	13	compound
13	treatments	treatment	NNS	_	6	nmod
14	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	lower	lower	JJR	_	3	amod
3	rate	rate	NN	_	22	nsubj
4	of	of	IN	_	5	case
5	absorption	absorption	NN	_	3	nmod
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	groups	group	NNS	_	3	nmod
9	receiving	receive	VBG	_	8	acl
10	446	446	CD	_	11	nummod
11	mg	mg	NN	_	9	dobj
12	Fe	Fe	NNP	_	11	dep
13	instead	instead	RB	_	16	case
14	of	of	IN	_	13	mwe
15	48	48	CD	_	16	nummod
16	mg	mg	NN	_	3	nmod
17	of	of	IN	_	18	case
18	Fe	Fe	NNP	_	16	nmod
19	per	per	IN	_	21	case
20	kg	kg	NN	_	21	compound
21	diet	diet	NN	_	16	nmod
22	resulted	result	VBD	_	0	ROOT
23	in	in	IN	_	27	case
24	a	a	DT	_	27	det
25	decreased	decrease	VBN	_	27	amod
26	renal	renal	JJ	_	27	amod
27	excretion	excretion	NN	_	22	nmod
28	of	of	IN	_	29	case
29	cobalt	cobalt	NN	_	27	nmod
30	.	.	.	_	22	punct

1	Consequently	consequently	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	4	det
4	effect	effect	NN	_	13	nsubj
5	of	of	IN	_	6	case
6	iron	iron	NN	_	4	nmod
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	retention	retention	NN	_	4	nmod
10	of	of	IN	_	11	case
11	cobalt	cobalt	NN	_	9	nmod
12	was	be	VBD	_	13	cop
13	lower	lower	JJR	_	0	ROOT
14	than	than	IN	_	16	case
15	on	on	IN	_	16	case
16	absorption	absorption	NN	_	13	nmod
17	.	.	.	_	13	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	that	that	IN	_	10	mark
4	interactions	interaction	NNS	_	10	nsubj
5	between	between	IN	_	8	case
6	the	the	DT	_	8	det
7	two	two	CD	_	8	nummod
8	elements	element	NNS	_	4	nmod
9	only	only	RB	_	10	advmod
10	take	take	VB	_	2	ccomp
11	place	place	NN	_	10	dobj
12	at	at	IN	_	14	case
13	the	the	DT	_	14	det
14	site	site	NN	_	10	nmod
15	of	of	IN	_	16	case
16	absorption	absorption	NN	_	14	nmod
17	.	.	.	_	2	punct

1	Because	because	IN	_	7	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	7	det
4	low	low	JJ	_	7	amod
5	dietary	dietary	JJ	_	7	amod
6	cobalt	cobalt	NN	_	7	compound
7	concentration	concentration	NN	_	27	nmod
8	as	as	IN	_	9	mark
9	compared	compare	VBN	_	7	dep
10	to	to	TO	_	13	case
11	the	the	DT	_	13	det
12	iron	iron	NN	_	13	compound
13	contents	contents	NNS	_	9	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	diets	diet	NNS	_	13	nmod
17	,	,	,	_	27	punct
18	no	no	DT	_	19	neg
19	effect	effect	NN	_	27	nsubj
20	of	of	IN	_	21	case
21	cobalt	cobalt	NN	_	19	nmod
22	on	on	IN	_	24	case
23	iron	iron	NN	_	24	compound
24	absorption	absorption	NN	_	19	nmod
25	and	and	CC	_	24	cc
26	excretion	excretion	NN	_	24	conj
27	occurred	occur	VBD	_	0	ROOT
28	.	.	.	_	27	punct

1	Differences	difference	NNS	_	7	nsubjpass
2	in	in	IN	_	4	case
3	iron	iron	NN	_	4	compound
4	balance	balance	NN	_	1	nmod
5	were	be	VBD	_	7	auxpass
6	only	only	RB	_	7	advmod
7	observed	observe	VBN	_	0	ROOT
8	between	between	IN	_	11	case
9	both	both	DT	_	11	det
10	dietary	dietary	JJ	_	11	amod
11	concentrations	concentration	NNS	_	7	nmod
12	,	,	,	_	7	punct
13	showing	show	VBG	_	7	advcl
14	a	a	DT	_	16	det
15	higher	higher	JJR	_	16	amod
16	absolute	absolute	JJ	_	13	dobj
17	but	but	CC	_	16	cc
18	a	a	DT	_	21	det
19	lower	lower	JJR	_	21	amod
20	relative	relative	JJ	_	21	amod
21	absorption	absorption	NN	_	16	conj
22	as	as	RB	_	21	cc
23	well	well	RB	_	22	mwe
24	as	as	IN	_	22	mwe
25	retention	retention	NN	_	21	conj
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	groups	group	NNS	_	25	nmod
29	fed	feed	VBN	_	28	acl
30	further	further	RB	_	31	advmod
31	Fe	Fe	NNP	_	29	dobj
32	.	.	.	_	31	punct
33	(	(	CD	_	34	nummod
34	ABSTRACT	abstract	NN	_	35	nsubj
35	TRUNCATED	truncate	VBD	_	31	parataxis
36	AT	at	IN	_	38	case
37	250	250	CD	_	38	nummod
38	WORDS	word	NNS	_	35	nmod
39	)	)	IN	_	13	dep

1	[	[	NN	_	2	compound
2	Importance	importance	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	pharmacogenetics	pharmacogenetic	NNS	_	2	nmod
5	]	]	VBP	_	0	ROOT
6	Pharmacogenetics	pharmacogenetic	NNS	_	7	compound
7	deals	deal	NNS	_	5	dobj
8	with	with	IN	_	10	case
9	the	the	DT	_	10	det
10	differences	difference	NNS	_	5	nmod
11	in	in	IN	_	12	case
12	effect	effect	NN	_	10	nmod
13	of	of	IN	_	14	case
14	drugs	drug	NNS	_	12	nmod
15	caused	cause	VBN	_	14	acl
16	by	by	IN	_	18	case
17	genetic	genetic	JJ	_	18	amod
18	variation	variation	NN	_	15	nmod
19	.	.	.	_	5	punct

1	Differences	difference	NNS	_	3	nsubj
2	can	can	MD	_	3	aux
3	occur	occur	VB	_	0	ROOT
4	in	in	IN	_	6	case
5	therapeutic	therapeutic	JJ	_	6	amod
6	effect	effect	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	in	in	IN	_	10	case
9	adverse	adverse	JJ	_	10	amod
10	events	event	NNS	_	6	conj
11	.	.	.	_	3	punct

1	Genetic	genetic	JJ	_	2	amod
2	variation	variation	NN	_	6	nsubj
3	in	in	IN	_	4	case
4	metabolism	metabolism	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	9	case
8	high	high	JJ	_	9	amod
9	concentrations	concentration	NNS	_	6	nmod
10	of	of	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	and	and	CC	_	9	cc
13	an	a	DT	_	15	det
14	increased	increase	VBN	_	15	amod
15	risk	risk	NN	_	9	conj
16	of	of	IN	_	18	case
17	adverse	adverse	JJ	_	18	amod
18	effects	effect	NNS	_	15	nmod
19	in	in	IN	_	21	case
20	slow	slow	JJ	_	21	amod
21	metabolizers	metabolizer	NNS	_	18	nmod
22	,	,	,	_	21	punct
23	which	which	WDT	_	25	nsubj
24	is	be	VBZ	_	25	cop
25	important	important	JJ	_	21	acl:relcl
26	when	when	WRB	_	27	advmod
27	using	use	VBG	_	25	advcl
28	for	for	IN	_	30	case
29	example	example	NN	_	30	compound
30	antidepressants	antidepressant	NNS	_	27	nmod
31	or	or	CC	_	30	cc
32	chemotherapy	chemotherapy	NN	_	30	conj
33	.	.	.	_	6	punct

1	Genetic	genetic	JJ	_	2	amod
2	variation	variation	NN	_	4	nsubj
3	also	also	RB	_	4	advmod
4	occurs	occur	VBZ	_	0	ROOT
5	in	in	IN	_	6	case
6	proteins	protein	NNS	_	4	nmod
7	interacting	interact	VBG	_	6	acl
8	with	with	IN	_	9	case
9	drugs	drug	NNS	_	7	nmod
10	,	,	,	_	6	punct
11	which	which	WDT	_	13	nsubj
12	may	may	MD	_	13	aux
13	change	change	VB	_	6	acl:relcl
14	the	the	DT	_	15	det
15	effect	effect	NN	_	13	dobj
16	of	of	IN	_	17	case
17	e	e	LS	_	15	nmod
18	.	.	.	_	4	punct
19	g	g	NN	_	4	dep
20	.	.	.	_	4	punct

1	asthma	asthma	NN	_	2	compound
2	drugs	drug	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	antipsychotics	antipsychotic	NNS	_	2	conj
5	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	selection	selection	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	and	and	CC	_	4	cc
6	their	they	PRP$	_	7	nmod:poss
7	dosages	dosage	NNS	_	4	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	improved	improve	VBN	_	0	ROOT
11	,	,	,	_	10	punct
12	and	and	CC	_	10	cc
13	the	the	DT	_	14	det
14	number	number	NN	_	10	conj
15	of	of	IN	_	17	case
16	adverse	adverse	JJ	_	17	amod
17	effects	effect	NNS	_	14	nmod
18	reduced	reduce	VBN	_	17	acl
19	by	by	IN	_	21	case
20	pharmacogenetic	pharmacogenetic	JJ	_	21	amod
21	investigations	investigation	NNS	_	18	nmod
22	.	.	.	_	10	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	cop
6	important	important	JJ	_	0	ROOT
7	also	also	RB	_	9	advmod
8	in	in	IN	_	9	case
9	case	case	NN	_	6	nmod
10	of	of	IN	_	12	case
11	medical	medical	JJ	_	12	amod
12	examinations	examination	NNS	_	9	nmod
13	for	for	IN	_	14	case
14	insurances	insurance	NNS	_	12	nmod
15	and	and	CC	_	14	cc
16	job	job	NN	_	17	compound
17	appointments	appointment	NNS	_	14	conj
18	,	,	,	_	6	punct
19	since	since	IN	_	23	mark
20	some	some	DT	_	21	det
21	patients	patient	NNS	_	23	nsubj
22	may	may	MD	_	23	aux
23	turn	turn	VB	_	6	advcl
24	out	out	RP	_	23	compound:prt
25	to	to	TO	_	26	mark
26	need	need	VB	_	23	xcomp
27	expensive	expensive	JJ	_	28	amod
28	drugs	drug	NNS	_	26	dobj
29	or	or	CC	_	26	cc
30	to	to	TO	_	32	mark
31	be	be	VB	_	32	cop
32	susceptible	susceptible	JJ	_	26	conj
33	to	to	TO	_	36	case
34	a	a	DT	_	36	det
35	certain	certain	JJ	_	36	amod
36	disease	disease	NN	_	32	nmod
37	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	use	use	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	genetic	genetic	JJ	_	7	amod
7	data	datum	NNS	_	4	nmod
8	in	in	IN	_	10	case
9	these	these	DT	_	10	det
10	instances	instance	NNS	_	4	nmod
11	has	have	VBZ	_	0	ROOT
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	regulated	regulate	VBN	_	11	xcomp
15	.	.	.	_	11	punct

1	Carbamazepine	Carbamazepine	NNP	_	2	compound
2	overdose	overdose	NN	_	0	ROOT
3	recognized	recognize	VBN	_	2	acl
4	by	by	IN	_	8	case
5	a	a	DT	_	8	det
6	tricyclic	tricyclic	JJ	_	8	amod
7	antidepressant	antidepressant	JJ	_	8	amod
8	assay	assay	NN	_	3	nmod
9	.	.	.	_	2	punct

1	Altered	altered	JJ	_	3	amod
2	mental	mental	JJ	_	3	amod
3	status	status	NN	_	7	nsubj
4	in	in	IN	_	6	case
5	an	a	DT	_	6	det
6	adolescent	adolescent	JJ	_	3	nmod
7	presents	present	VBZ	_	0	ROOT
8	a	a	DT	_	10	det
9	diagnostic	diagnostic	JJ	_	10	amod
10	challenge	challenge	NN	_	7	dobj
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	the	the	DT	_	14	det
14	clinician	clinician	NN	_	15	nsubj
15	depends	depend	VBZ	_	7	conj
16	on	on	IN	_	18	case
17	clinical	clinical	JJ	_	18	amod
18	evaluation	evaluation	NN	_	15	nmod
19	and	and	CC	_	18	cc
20	laboratory	laboratory	NN	_	21	compound
21	studies	study	NNS	_	18	conj
22	to	to	TO	_	23	mark
23	determine	determine	VB	_	15	xcomp
24	therapy	therapy	NN	_	23	dobj
25	and	and	CC	_	24	cc
26	prognosis	prognosis	NN	_	24	conj
27	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	report	report	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	case	case	NN	_	2	dobj
5	of	of	IN	_	7	case
6	an	a	DT	_	7	det
7	adolescent	adolescent	JJ	_	4	nmod
8	with	with	IN	_	10	case
9	altered	altered	JJ	_	10	amod
10	consciousness	consciousness	NN	_	7	nmod
11	caused	cause	VBN	_	10	acl
12	by	by	IN	_	14	case
13	carbamazepine	carbamazepine	NN	_	14	compound
14	overdose	overdose	NN	_	11	nmod
15	with	with	IN	_	20	case
16	a	a	DT	_	20	det
17	positive	positive	JJ	_	20	amod
18	tricyclic	tricyclic	JJ	_	20	amod
19	antidepressant	antidepressant	JJ	_	20	amod
20	level	level	NN	_	14	nmod
21	to	to	TO	_	23	case
22	alert	alert	JJ	_	23	amod
23	clinicians	clinician	NNS	_	20	nmod
24	to	to	TO	_	26	case
25	the	the	DT	_	26	det
26	cross	cross	NN	_	23	nmod
27	-	-	:	_	4	punct
28	reactivity	reactivity	NN	_	4	dep
29	of	of	IN	_	30	case
30	carbamazepine	carbamazepine	NN	_	28	nmod
31	with	with	IN	_	34	case
32	a	a	DT	_	34	det
33	toxicology	toxicology	NN	_	34	compound
34	screen	screen	NN	_	28	nmod
35	for	for	IN	_	37	case
36	tricyclic	tricyclic	JJ	_	37	amod
37	antidepressants	antidepressant	NNS	_	34	nmod
38	.	.	.	_	2	punct

1	Anticoagulants	Anticoagulants	NNPS	_	0	ROOT
2	.	.	.	_	1	punct

1	Treatment	treatment	NN	_	2	compound
2	plans	plan	NNS	_	8	nsubj
3	for	for	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	taking	take	VBG	_	4	acl
6	anticoagulants	anticoagulant	NNS	_	5	dobj
7	can	can	MD	_	8	aux
8	become	become	VB	_	0	ROOT
9	complicated	complicated	JJ	_	8	xcomp
10	.	.	.	_	8	punct

1	Anticoagulants	anticoagulant	NNS	_	2	nsubj
2	predispose	predispose	VBP	_	0	ROOT
3	a	a	DT	_	4	det
4	patient	patient	NN	_	2	dobj
5	to	to	TO	_	6	mark
6	bleeding	bleed	VBG	_	4	acl
7	problems	problem	NNS	_	6	dobj
8	.	.	.	_	2	punct

1	Many	many	JJ	_	2	amod
2	drugs	drug	NNS	_	8	nsubjpass
3	used	use	VBN	_	2	acl
4	in	in	IN	_	6	case
5	dentistry	dentistry	NN	_	6	compound
6	cannot	cannot	NN	_	3	nmod
7	be	be	VB	_	8	auxpass
8	taken	take	VBN	_	0	ROOT
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	12	case
11	these	these	DT	_	12	det
12	medications	medication	NNS	_	8	nmod
13	.	.	.	_	8	punct

1	Acute	acute	JJ	_	3	amod
2	hydrocortisone	hydrocortisone	NN	_	3	compound
3	administration	administration	NN	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	affect	affect	VB	_	0	ROOT
7	subjective	subjective	JJ	_	8	amod
8	responses	response	NNS	_	6	dobj
9	to	to	TO	_	10	case
10	d	d	SYM	_	8	nmod
11	-	-	:	_	10	punct
12	amphetamine	amphetamine	NN	_	10	dep
13	in	in	IN	_	14	case
14	humans	human	NNS	_	12	nmod
15	.	.	.	_	6	punct

1	RATIONALE	rationale	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Stress	stress	NN	_	6	nsubj
4	and	and	CC	_	3	cc
5	glucocorticoids	glucocorticoid	NNS	_	3	conj
6	facilitate	facilitate	VBP	_	1	appos
7	and	and	CC	_	6	cc
8	reinstate	reinstate	VBP	_	6	conj
9	psychostimulant	psychostimulant	JJ	_	10	amod
10	self	self	NN	_	6	dobj
11	-	-	:	_	10	punct
12	administration	administration	NN	_	10	dep
13	in	in	IN	_	14	case
14	rodents	rodent	NNS	_	12	nmod
15	.	.	.	_	1	punct

1	However	however	RB	_	21	advmod
2	,	,	,	_	21	punct
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	21	nsubjpass
5	of	of	IN	_	6	case
6	stress	stress	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	glucocorticoids	glucocorticoid	NNS	_	6	conj
9	on	on	IN	_	14	case
10	the	the	DT	_	14	det
11	subjective	subjective	JJ	_	14	amod
12	and	and	CC	_	11	cc
13	behavioral	behavioral	JJ	_	11	conj
14	effects	effect	NNS	_	4	nmod
15	of	of	IN	_	16	case
16	psychostimulants	psychostimulant	NNS	_	14	nmod
17	have	have	VBP	_	21	aux
18	not	not	RB	_	21	neg
19	been	be	VBN	_	21	auxpass
20	well	well	RB	_	21	advmod
21	studied	study	VBN	_	0	ROOT
22	in	in	IN	_	23	case
23	humans	human	NNS	_	21	nmod
24	.	.	.	_	21	punct

1	OBJECTIVES	objective	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	To	to	TO	_	4	mark
4	examine	examine	VB	_	1	acl
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	10	case
8	acute	acute	JJ	_	10	amod
9	hydrocortisone	hydrocortisone	NN	_	10	compound
10	pretreatment	pretreatment	NN	_	6	nmod
11	on	on	IN	_	16	case
12	the	the	DT	_	16	det
13	subjective	subjective	JJ	_	16	amod
14	and	and	CC	_	13	cc
15	behavioral	behavioral	JJ	_	13	conj
16	effects	effect	NNS	_	6	nmod
17	of	of	IN	_	18	case
18	d	d	NN	_	16	nmod
19	-	-	:	_	18	punct
20	amphetamine	amphetamine	NN	_	18	dep
21	.	.	.	_	4	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Hydrocortisone	hydrocortisone	NN	_	7	compound
4	(	(	NN	_	7	compound
5	100	100	CD	_	6	compound
6	mg	mg	NN	_	7	amod
7	)	)	NN	_	1	dep
8	and	and	CC	_	7	cc
9	d	d	SYM	_	17	dep
10	-	-	:	_	17	punct
11	amphetamine	amphetamine	NN	_	15	compound
12	(	(	NN	_	15	compound
13	20	20	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	)	)	NN	_	17	nsubjpass
16	were	be	VBD	_	17	auxpass
17	administered	administer	VBN	_	7	conj
18	orally	orally	RB	_	17	advmod
19	to	to	TO	_	22	case
20	16	16	CD	_	22	nummod
21	healthy	healthy	JJ	_	22	amod
22	male	male	NN	_	17	nmod
23	and	and	CC	_	22	cc
24	female	female	JJ	_	25	amod
25	volunteers	volunteer	NNS	_	22	conj
26	in	in	IN	_	30	case
27	a	a	DT	_	30	det
28	four	four	CD	_	30	nummod
29	-	-	:	_	30	punct
30	session	session	NN	_	17	nmod
31	,	,	,	_	7	punct
32	placebo	placebo	NN	_	34	dep
33	-	-	:	_	34	punct
34	controlled	control	VBN	_	7	acl:relcl
35	,	,	,	_	34	punct
36	within	within	IN	_	38	case
37	-	-	:	_	38	punct
38	subject	subject	JJ	_	34	nmod
39	,	,	,	_	38	punct
40	crossover	crossover	NN	_	41	compound
41	design	design	NN	_	38	appos
42	.	.	.	_	1	punct

1	To	to	TO	_	2	mark
2	prevent	prevent	VB	_	7	advcl
3	stomach	stomach	NN	_	4	compound
4	irritation	irritation	NN	_	2	dobj
5	,	,	,	_	7	punct
6	subjects	subject	NNS	_	7	nsubj
7	received	receive	VBD	_	0	ROOT
8	rantidine	rantidine	NN	_	9	compound
9	hydrochloride	hydrochloride	NN	_	7	dobj
10	before	before	IN	_	13	case
11	each	each	DT	_	13	det
12	experimental	experimental	JJ	_	13	amod
13	session	session	NN	_	7	nmod
14	.	.	.	_	7	punct

1	Dependent	dependent	JJ	_	2	amod
2	measures	measure	NNS	_	11	nsubj
3	included	include	VBN	_	2	acl
4	self	self	NN	_	7	compound
5	-	-	:	_	7	punct
6	reported	report	VBN	_	7	amod
7	mood	mood	NN	_	3	dobj
8	and	and	CC	_	7	cc
9	subjective	subjective	JJ	_	10	amod
10	effects	effect	NNS	_	7	conj
11	(	(	VBP	_	0	ROOT
12	Addiction	Addiction	NNP	_	15	compound
13	Research	Research	NNP	_	15	compound
14	Center	Center	NNP	_	15	compound
15	inventory	inventory	NN	_	11	dobj
16	,	,	,	_	15	punct
17	the	the	DT	_	18	det
18	profile	profile	NN	_	15	appos
19	of	of	IN	_	21	case
20	mood	mood	NN	_	21	compound
21	states	state	NNS	_	18	nmod
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	a	a	DT	_	25	det
25	series	series	NN	_	15	conj
26	of	of	IN	_	29	case
27	visual	visual	JJ	_	29	amod
28	analogue	analogue	NN	_	29	compound
29	scales	scale	NNS	_	25	nmod
30	)	)	VBP	_	11	dep
31	,	,	,	_	30	punct
32	vital	vital	JJ	_	33	amod
33	signs	sign	NNS	_	30	conj
34	,	,	,	_	30	punct
35	salivary	salivary	JJ	_	36	amod
36	cortisol	cortisol	NN	_	30	conj
37	,	,	,	_	30	punct
38	and	and	CC	_	30	cc
39	psychomotor	psychomotor	NN	_	40	compound
40	performance	performance	NN	_	30	conj
41	.	.	.	_	11	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Hydrocortisone	hydrocortisone	NN	_	7	compound
4	elevated	elevated	JJ	_	7	amod
5	salivary	salivary	JJ	_	7	amod
6	cortisol	cortisol	NN	_	7	compound
7	levels	level	NNS	_	1	dep
8	,	,	,	_	7	punct
9	produced	produce	VBD	_	7	conj
10	modest	modest	JJ	_	11	amod
11	dysphoria	dysphoria	NN	_	9	dobj
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	reduced	reduce	VBD	_	7	conj
15	subjects	subject	NNS	_	17	nmod:poss
16	'	'	POS	_	15	case
17	reports	report	NNS	_	14	dobj
18	of	of	IN	_	19	mark
19	wanting	want	VBG	_	17	acl
20	more	more	RBR	_	21	amod
21	drug	drug	NN	_	19	dobj
22	.	.	.	_	1	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	hydrocortisone	hydrocortisone	NN	_	4	compound
4	pretreatment	pretreatment	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	affect	affect	VB	_	0	ROOT
8	any	any	DT	_	7	dobj
9	of	of	IN	_	17	case
10	the	the	DT	_	17	det
11	physiological	physiological	JJ	_	17	amod
12	,	,	,	_	11	punct
13	behavioral	behavioral	JJ	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	subjective	subjective	JJ	_	11	conj
17	effects	effect	NNS	_	8	nmod
18	of	of	IN	_	19	case
19	d	d	NN	_	17	nmod
20	-	-	:	_	19	punct
21	amphetamine	amphetamine	NN	_	19	dep
22	.	.	.	_	7	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	contrast	contrast	NN	_	16	nmod
5	to	to	TO	_	7	case
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	glucocorticoids	glucocorticoid	NNS	_	7	nmod
10	in	in	IN	_	12	case
11	rodent	rodent	JJ	_	12	amod
12	studies	study	NNS	_	7	nmod
13	,	,	,	_	16	punct
14	these	these	DT	_	15	det
15	results	result	NNS	_	16	nsubj
16	indicate	indicate	VBP	_	1	appos
17	that	that	IN	_	25	mark
18	an	a	DT	_	20	det
19	acute	acute	JJ	_	20	amod
20	increase	increase	NN	_	25	nsubj
21	in	in	IN	_	22	case
22	cortisol	cortisol	NN	_	20	nmod
23	does	do	VBZ	_	25	aux
24	not	not	RB	_	25	neg
25	enhance	enhance	VB	_	16	ccomp
26	the	the	DT	_	28	det
27	psychostimulant	psychostimulant	JJ	_	28	amod
28	effects	effect	NNS	_	25	dobj
29	of	of	IN	_	30	case
30	d	d	NN	_	28	nmod
31	-	-	:	_	30	punct
32	amphetamine	amphetamine	NN	_	30	dep
33	in	in	IN	_	34	case
34	humans	human	NNS	_	32	nmod
35	.	.	.	_	1	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	estradiol	estradiol	NN	_	1	nmod
4	on	on	IN	_	5	case
5	endotoxin	endotoxin	NN	_	1	nmod
6	-	-	:	_	1	punct
7	induced	induce	VBN	_	8	amod
8	changes	change	NNS	_	1	dep
9	in	in	IN	_	12	case
10	steroid	steroid	NN	_	12	compound
11	hormone	hormone	NN	_	12	compound
12	levels	level	NNS	_	8	nmod
13	and	and	CC	_	12	cc
14	lethality	lethality	NN	_	12	conj
15	in	in	IN	_	17	case
16	male	male	JJ	_	17	amod
17	rats	rat	NNS	_	8	nmod
18	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	examined	examine	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effect	effect	NN	_	2	dobj
5	of	of	IN	_	7	case
6	exogenous	exogenous	JJ	_	7	amod
7	estradiol	estradiol	NN	_	4	nmod
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	changes	change	NNS	_	4	nmod
11	in	in	IN	_	15	case
12	serum	serum	NN	_	15	compound
13	steroid	steroid	NN	_	15	compound
14	hormone	hormone	NN	_	15	compound
15	levels	level	NNS	_	10	nmod
16	induced	induce	VBN	_	15	acl
17	by	by	IN	_	20	case
18	a	a	DT	_	20	det
19	nonlethal	nonlethal	JJ	_	20	amod
20	dose	dose	NN	_	16	nmod
21	of	of	IN	_	24	case
22	Escherichia	escherichia	FW	_	24	compound
23	coli	coli	FW	_	24	compound
24	endotoxin	endotoxin	NN	_	20	nmod
25	in	in	IN	_	27	case
26	male	male	JJ	_	27	amod
27	rats	rat	NNS	_	16	nmod
28	and	and	CC	_	4	cc
29	the	the	DT	_	30	det
30	deaths	death	NNS	_	4	conj
31	due	due	JJ	_	36	case
32	to	to	TO	_	31	mwe
33	nonlethal	nonlethal	JJ	_	36	amod
34	and	and	CC	_	33	cc
35	lethal	lethal	JJ	_	33	conj
36	doses	dose	NNS	_	30	nmod
37	of	of	IN	_	38	case
38	endotoxin	endotoxin	NN	_	36	nmod
39	.	.	.	_	2	punct

1	Injection	injection	NN	_	12	nsubj
2	of	of	IN	_	3	case
3	estradiol	estradiol	NN	_	1	nmod
4	5	5	CD	_	5	nummod
5	min	min	NN	_	3	dep
6	before	before	IN	_	9	case
7	a	a	DT	_	9	det
8	nonlethal	nonlethal	JJ	_	9	amod
9	dose	dose	NN	_	1	nmod
10	of	of	IN	_	11	case
11	endotoxin	endotoxin	NN	_	9	nmod
12	changed	change	VBD	_	0	ROOT
13	the	the	DT	_	18	det
14	serum	serum	NN	_	18	compound
15	sex	sex	NN	_	18	compound
16	steroid	steroid	NN	_	18	compound
17	hormone	hormone	NN	_	18	compound
18	response	response	NN	_	12	dobj
19	of	of	IN	_	21	case
20	male	male	JJ	_	21	amod
21	rats	rat	NNS	_	18	nmod
22	to	to	TO	_	23	case
23	endotoxin	endotoxin	NN	_	18	nmod
24	.	.	.	_	12	punct

1	The	the	DT	_	4	det
2	serum	serum	NN	_	4	compound
3	estrogen	estrogen	NN	_	4	compound
4	concentrations	concentration	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	estradiol	estradiol	NN	_	4	nmod
7	+	+	CC	_	6	cc
8	endotoxin	endotoxin	NN	_	6	conj
9	-	-	:	_	6	punct
10	treated	treat	VBN	_	11	amod
11	rats	rat	NNS	_	6	dep
12	decreased	decrease	VBN	_	11	acl
13	by	by	IN	_	15	case
14	50	50	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	,	,	,	_	4	punct
17	while	while	IN	_	25	mark
18	those	those	DT	_	25	nsubj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	endotoxin	endotoxin	NN	_	18	nmod
22	-	-	:	_	21	punct
23	treated	treat	VBN	_	24	amod
24	rats	rat	NNS	_	21	dep
25	increased	increase	VBD	_	16	root
26	(	(	CD	_	27	nummod
27	2	2	LS	_	25	dobj
28	-	-	:	_	27	punct
29	to	to	TO	_	33	case
30	5	5	LS	_	33	dep
31	-	-	:	_	33	punct
32	fold	fold	JJ	_	33	amod
33	)	)	NN	_	27	nmod
34	.	.	.	_	25	punct

1	The	the	DT	_	4	det
2	serum	serum	NN	_	4	compound
3	androgen	androgen	NN	_	4	compound
4	concentrations	concentration	NNS	_	14	nsubj
5	of	of	IN	_	6	case
6	estradiol	estradiol	NN	_	4	nmod
7	+	+	CC	_	6	cc
8	endotoxin	endotoxin	NN	_	6	conj
9	-	-	:	_	6	punct
10	treated	treat	VBN	_	11	amod
11	rats	rat	NNS	_	6	dep
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	change	change	VB	_	0	ROOT
15	significantly	significantly	RB	_	14	advmod
16	,	,	,	_	14	punct
17	while	while	IN	_	24	mark
18	those	those	DT	_	24	nsubj
19	of	of	IN	_	20	case
20	endotoxin	endotoxin	NN	_	18	nmod
21	-	-	:	_	20	punct
22	treated	treat	VBN	_	23	amod
23	rats	rat	NNS	_	20	dep
24	dropped	drop	VBD	_	14	advcl
25	to	to	TO	_	26	case
26	30	30	CD	_	24	nmod
27	-	-	:	_	24	punct
28	40	40	CD	_	29	nummod
29	%	%	NN	_	24	dobj

1	0.001	0.001	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Exogenous	exogenous	JJ	_	2	amod
2	estradiol	estradiol	NN	_	4	nsubj
3	also	also	RB	_	4	advmod
4	appeared	appear	VBD	_	0	ROOT
5	to	to	TO	_	6	mark
6	influence	influence	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	percentage	percentage	NN	_	6	dobj
9	of	of	IN	_	10	case
10	endotoxin	endotoxin	NN	_	8	nmod
11	-	-	:	_	8	punct
12	induced	induce	VBN	_	13	amod
13	deaths	death	NNS	_	8	dep
14	in	in	IN	_	19	case
15	a	a	DT	_	19	det
16	dose	dose	NN	_	19	compound
17	-	-	:	_	19	punct
18	dependent	dependent	JJ	_	19	amod
19	manner	manner	NN	_	13	nmod
20	.	.	.	_	4	punct

1	It	it	PRP	_	2	nsubj
2	reduced	reduce	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	number	number	NN	_	2	dobj
5	of	of	IN	_	6	case
6	deaths	death	NNS	_	4	nmod
7	induced	induce	VBN	_	6	acl
8	by	by	IN	_	12	case
9	nonlethal	nonlethal	JJ	_	12	amod
10	(	(	NN	_	12	compound
11	2	2	CD	_	12	nummod
12	mg	mg	NN	_	7	nmod
13	/	/	:	_	2	punct
14	kg	kg	NN	_	16	compound
15	)	)	NN	_	16	compound
16	dose	dose	NN	_	2	dep
17	of	of	IN	_	18	case
18	endotoxin	endotoxin	NN	_	16	nmod
19	but	but	CC	_	16	cc
20	increased	increase	VBD	_	16	conj
21	the	the	DT	_	22	det
22	number	number	NN	_	20	dobj
23	of	of	IN	_	24	case
24	deaths	death	NNS	_	22	nmod
25	induced	induce	VBN	_	24	acl
26	by	by	IN	_	33	case
27	a	a	DT	_	33	det
28	highly	highly	RB	_	29	advmod
29	lethal	lethal	JJ	_	33	amod
30	dose	dose	NN	_	33	compound
31	(	(	NN	_	33	compound
32	8	8	CD	_	33	nummod
33	mg	mg	NN	_	25	nmod
34	/	/	:	_	16	punct
35	kg	kg	NN	_	36	compound
36	)	)	NN	_	16	dep
37	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	16	nsubj
3	,	,	,	_	2	punct
4	together	together	RB	_	8	advmod
5	with	with	IN	_	8	case
6	the	the	DT	_	8	det
7	known	known	JJ	_	8	amod
8	relationships	relationship	NNS	_	2	nmod
9	between	between	IN	_	10	case
10	estrogen	estrogen	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	the	the	DT	_	14	det
13	immune	immune	JJ	_	14	amod
14	response	response	NN	_	10	conj
15	,	,	,	_	2	punct
16	suggest	suggest	VBP	_	0	ROOT
17	that	that	IN	_	19	mark
18	estrogens	estrogen	NNS	_	19	nsubj
19	affect	affect	VBP	_	16	ccomp
20	the	the	DT	_	21	det
21	course	course	NN	_	19	dobj
22	of	of	IN	_	24	case
23	septic	septic	JJ	_	24	amod
24	shock	shock	NN	_	21	nmod
25	in	in	IN	_	28	case
26	a	a	DT	_	28	det
27	complex	complex	JJ	_	28	amod
28	fashion	fashion	NN	_	19	nmod
29	and	and	CC	_	19	cc
30	may	may	MD	_	31	aux
31	have	have	VB	_	19	conj
32	either	either	CC	_	33	cc:preconj
33	protective	protective	JJ	_	36	amod
34	or	or	CC	_	33	cc
35	deleterious	deleterious	JJ	_	33	conj
36	effect	effect	NN	_	31	dobj
37	.	.	.	_	16	punct

1	Studies	study	NNS	_	0	ROOT
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	mechanism	mechanism	NN	_	1	nmod
5	of	of	IN	_	6	case
6	action	action	NN	_	4	nmod
7	of	of	IN	_	8	case
8	miconazole	miconazole	NN	_	6	nmod
9	:	:	:	_	1	punct
10	effect	effect	NN	_	1	dep
11	of	of	IN	_	12	case
12	miconazole	miconazole	NN	_	10	nmod
13	on	on	IN	_	14	case
14	respiration	respiration	NN	_	10	nmod
15	and	and	CC	_	14	cc
16	cell	cell	NN	_	17	compound
17	permeability	permeability	NN	_	14	conj
18	of	of	IN	_	20	case
19	Candida	candida	NN	_	20	compound
20	albicans	albican	NNS	_	14	nmod
21	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	antifungal	antifungal	JJ	_	3	amod
3	drug	drug	NN	_	8	nsubj
4	,	,	,	_	3	punct
5	miconazole	miconazole	NN	_	6	compound
6	nitrate	nitrate	NN	_	3	appos
7	,	,	,	_	3	punct
8	inhibits	inhibit	VBZ	_	0	ROOT
9	the	the	DT	_	10	det
10	growth	growth	NN	_	8	dobj
11	of	of	IN	_	13	case
12	several	several	JJ	_	13	amod
13	species	species	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	Candida	candida	NN	_	13	nmod
16	.	.	.	_	8	punct

1	Candida	candida	NN	_	2	compound
2	albicans	albican	NNS	_	12	nsubjpass
3	,	,	,	_	2	punct
4	one	one	CD	_	2	appos
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	pathogenic	pathogenic	JJ	_	8	amod
8	species	species	NNS	_	4	nmod
9	,	,	,	_	2	punct
10	was	be	VBD	_	12	auxpass
11	totally	totally	RB	_	12	advmod
12	inhibited	inhibit	VBN	_	0	ROOT
13	at	at	IN	_	15	case
14	a	a	DT	_	15	det
15	concentration	concentration	NN	_	12	nmod
16	of	of	IN	_	19	case
17	approximately	approximately	RB	_	18	advmod
18	10	10	CD	_	19	nummod
19	mug	mug	NN	_	15	nmod
20	/	/	:	_	19	punct
21	ml	ml	NN	_	19	dep
22	.	.	.	_	12	punct

1	Endogenous	endogenous	JJ	_	2	amod
2	respiration	respiration	NN	_	4	nsubj
3	was	be	VBD	_	4	aux
4	unaffected	unaffected	JJ	_	0	ROOT
5	by	by	IN	_	7	case
6	the	the	DT	_	7	det
7	drug	drug	NN	_	4	nmod
8	at	at	IN	_	10	case
9	a	a	DT	_	10	det
10	concentration	concentration	NN	_	4	nmod
11	as	as	RB	_	12	advmod
12	high	high	JJ	_	10	amod
13	as	as	IN	_	15	case
14	100	100	CD	_	15	nummod
15	mug	mug	NN	_	12	nmod
16	/	/	:	_	15	punct
17	ml	ml	NN	_	15	dep
18	,	,	,	_	4	punct
19	whereas	whereas	IN	_	4	dep
20	exogenous	exogenous	JJ	_	21	amod
21	respiration	respiration	NN	_	24	nsubj
22	was	be	VBD	_	24	cop
23	markedly	markedly	RB	_	24	advmod
24	sensitive	sensitive	JJ	_	4	parataxis
25	and	and	CC	_	24	cc
26	inhibited	inhibit	VBD	_	24	conj
27	to	to	TO	_	29	case
28	an	a	DT	_	29	det
29	extent	extent	NN	_	26	nmod
30	of	of	IN	_	32	case
31	85	85	CD	_	32	nummod
32	%	%	NN	_	29	nmod
33	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	permeability	permeability	NN	_	8	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	cell	cell	NN	_	6	compound
6	membrane	membrane	NN	_	2	nmod
7	was	be	VBD	_	8	auxpass
8	changed	change	VBN	_	0	ROOT
9	as	as	IN	_	10	mark
10	evidenced	evidence	VBN	_	8	advcl
11	by	by	IN	_	13	case
12	the	the	DT	_	13	det
13	leakage	leakage	NN	_	10	nmod
14	of	of	IN	_	15	case
15	260	260	CD	_	13	nmod
16	-	-	:	_	15	punct
17	nm	nm	NN	_	19	compound
18	absorbing	absorb	VBG	_	19	amod
19	materials	material	NNS	_	15	dep
20	,	,	,	_	19	punct
21	amino	amino	NN	_	22	compound
22	acids	acid	NNS	_	19	conj
23	,	,	,	_	19	punct
24	proteins	protein	NNS	_	19	conj
25	,	,	,	_	19	punct
26	and	and	CC	_	19	cc
27	inorganic	inorganic	JJ	_	28	amod
28	cations	cation	NNS	_	19	conj
29	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	6	nsubj
3	we	we	PRP	_	4	nsubj
4	present	present	VBP	_	2	acl:relcl
5	clearly	clearly	RB	_	4	advmod
6	show	show	VB	_	0	ROOT
7	that	that	IN	_	10	mark
8	the	the	DT	_	9	det
9	drug	drug	NN	_	10	nsubj
10	alters	alter	VBZ	_	6	ccomp
11	the	the	DT	_	13	det
12	cellular	cellular	JJ	_	13	amod
13	permeability	permeability	NN	_	10	dobj
14	,	,	,	_	10	punct
15	and	and	CC	_	10	cc
16	thus	thus	RB	_	20	advmod
17	the	the	DT	_	19	det
18	exogenous	exogenous	JJ	_	19	amod
19	respiration	respiration	NN	_	20	nsubj
20	becomes	become	VBZ	_	10	conj
21	sensitive	sensitive	JJ	_	20	xcomp
22	to	to	TO	_	24	case
23	the	the	DT	_	24	det
24	drug	drug	NN	_	21	nmod
25	.	.	.	_	6	punct

1	Interferon	interferon	NN	_	2	compound
2	induction	induction	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	tool	tool	NN	_	2	dep
5	for	for	IN	_	6	mark
6	establishing	establish	VBG	_	4	acl
7	interactions	interaction	NNS	_	6	dobj
8	among	among	IN	_	9	case
9	homopolyribonucleotides	homopolyribonucleotide	NNS	_	7	nmod
10	.	.	.	_	2	punct

1	Hitherto	hitherto	RB	_	2	advmod
2	unrecognized	unrecognized	JJ	_	3	amod
3	interactions	interaction	NNS	_	10	nsubjpass
4	between	between	IN	_	5	case
5	homopolyribonucleotides	homopolyribonucleotide	NNS	_	3	nmod
6	and	and	CC	_	5	cc
7	complexes	complex	NNS	_	5	conj
8	thereof	thereof	RB	_	10	advmod
9	are	be	VBP	_	10	auxpass
10	suggested	suggest	VBN	_	0	ROOT
11	by	by	IN	_	14	case
12	interferon	interferon	NN	_	14	compound
13	induction	induction	NN	_	14	compound
14	data	datum	NNS	_	10	nmod
15	obtained	obtain	VBN	_	14	acl
16	in	in	IN	_	21	case
17	a	a	DT	_	21	det
18	highly	highly	RB	_	19	advmod
19	sensitive	sensitive	JJ	_	21	amod
20	assay	assay	NN	_	21	compound
21	system	system	NN	_	15	nmod
22	of	of	IN	_	27	case
23	primary	primary	JJ	_	27	amod
24	rabbit	rabbit	NN	_	27	compound
25	kidney	kidney	NN	_	27	compound
26	cell	cell	NN	_	27	compound
27	cultures	culture	NNS	_	21	nmod
28	superinduced	superinduce	VBN	_	27	acl
29	by	by	IN	_	31	case
30	metabolic	metabolic	JJ	_	31	amod
31	inhibitors	inhibitor	NNS	_	28	nmod
32	.	.	.	_	10	punct

1	Sildenafil	sildenafil	NN	_	2	compound
2	citrate	citrate	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	a	a	DT	_	5	det
5	therapeutic	therapeutic	JJ	_	6	nsubj
6	update	update	VBP	_	2	dep
7	.	.	.	_	2	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	5	case
4	its	its	PRP$	_	5	nmod:poss
5	approval	approval	NN	_	21	nmod
6	by	by	IN	_	9	case
7	the	the	DT	_	9	det
8	US	US	NNP	_	9	compound
9	Food	Food	NNP	_	5	nmod
10	and	and	CC	_	9	cc
11	Drug	Drug	NNP	_	12	compound
12	Administration	Administration	NNP	_	9	conj
13	in	in	IN	_	14	case
14	March	March	NNP	_	5	nmod
15	1998	1998	CD	_	14	nummod
16	,	,	,	_	21	punct
17	sildenafil	sildenafil	NN	_	18	compound
18	citrate	citrate	NN	_	21	nsubjpass
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	used	use	VBN	_	1	dep
22	by	by	IN	_	23	case
23	millions	million	NNS	_	21	nmod
24	of	of	IN	_	25	case
25	men	man	NNS	_	23	nmod
26	for	for	IN	_	28	case
27	the	the	DT	_	28	det
28	treatment	treatment	NN	_	21	nmod
29	of	of	IN	_	31	case
30	erectile	erectile	JJ	_	31	amod
31	dysfunction	dysfunction	NN	_	28	nmod
32	.	.	.	_	1	punct

1	Recent	recent	JJ	_	2	amod
2	studies	study	NNS	_	7	nsubj
3	and	and	CC	_	2	cc
4	consensus	consensus	NN	_	5	compound
5	reports	report	NNS	_	2	conj
6	have	have	VBP	_	7	aux
7	expanded	expand	VBN	_	0	ROOT
8	our	we	PRP$	_	9	nmod:poss
9	understanding	understanding	NN	_	7	dobj
10	of	of	IN	_	12	case
11	its	its	PRP$	_	12	nmod:poss
12	efficacy	efficacy	NN	_	9	nmod
13	,	,	,	_	12	punct
14	safety	safety	NN	_	12	conj
15	,	,	,	_	12	punct
16	contraindications	contraindication	NNS	_	12	conj
17	,	,	,	_	12	punct
18	and	and	CC	_	12	cc
19	drug	drug	NN	_	20	compound
20	interactions	interaction	NNS	_	12	conj
21	.	.	.	_	7	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	This	this	DT	_	4	det
4	paper	paper	NN	_	5	nsubj
5	reviews	review	VBZ	_	1	dep
6	recent	recent	JJ	_	7	amod
7	studies	study	NNS	_	5	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	efficacy	efficacy	NN	_	7	nmod
11	of	of	IN	_	12	case
12	sildenafil	sildenafil	NN	_	10	nmod
13	,	,	,	_	10	punct
14	its	its	PRP$	_	16	nmod:poss
15	adverse	adverse	JJ	_	16	amod
16	effects	effect	NNS	_	10	conj
17	and	and	CC	_	10	cc
18	drug	drug	NN	_	19	compound
19	interactions	interaction	NNS	_	10	conj
20	,	,	,	_	5	punct
21	and	and	CC	_	5	cc
22	socioeconomic	socioeconomic	JJ	_	23	amod
23	factors	factor	NNS	_	36	nsubj
24	involved	involve	VBN	_	23	acl
25	in	in	IN	_	27	case
26	its	its	PRP$	_	27	nmod:poss
27	use	use	NN	_	24	nmod
28	,	,	,	_	23	punct
29	with	with	IN	_	31	case
30	a	a	DT	_	31	det
31	focus	focus	NN	_	23	nmod
32	on	on	IN	_	35	case
33	specific	specific	JJ	_	35	amod
34	patient	patient	NN	_	35	compound
35	populations	population	NNS	_	31	nmod
36	(	(	VBP	_	5	conj
37	prostate	prostate	NN	_	38	compound
38	cancer	cancer	NN	_	36	dobj
39	,	,	,	_	38	punct
40	diabetes	diabetes	NN	_	41	compound
41	mellitus	mellitus	NN	_	38	conj
42	,	,	,	_	38	punct
43	ischemic	ischemic	JJ	_	45	amod
44	heart	heart	NN	_	45	compound
45	disease	disease	NN	_	38	conj
46	,	,	,	_	38	punct
47	spinal	spinal	JJ	_	49	amod
48	cord	cord	NN	_	49	compound
49	injuries	injury	NNS	_	38	conj
50	,	,	,	_	38	punct
51	neurologic	neurologic	JJ	_	52	amod
52	disorders	disorder	NNS	_	53	nsubj
53	)	)	VBP	_	38	acl:relcl
54	.	.	.	_	1	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	27	nsubjpass
5	,	,	,	_	4	punct
6	case	case	NN	_	7	compound
7	reports	report	NNS	_	4	conj
8	,	,	,	_	4	punct
9	and	and	CC	_	4	cc
10	commentaries	commentary	NNS	_	4	conj
11	and	and	CC	_	10	cc
12	editorials	editorial	NNS	_	10	conj
13	concerning	concern	VBG	_	14	case
14	sildenafil	sildenafil	NN	_	10	nmod
15	published	publish	VBN	_	14	acl
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	international	international	JJ	_	19	amod
19	literature	literature	NN	_	15	nmod
20	between	between	IN	_	21	case
21	January	January	NNP	_	19	nmod
22	1999	1999	CD	_	21	nummod
23	and	and	CC	_	21	cc
24	August	August	NNP	_	21	conj
25	2000	2000	CD	_	24	nummod
26	were	be	VBD	_	27	auxpass
27	identified	identify	VBN	_	1	dep
28	through	through	IN	_	29	case
29	searches	search	NNS	_	27	nmod
30	of	of	IN	_	31	case
31	MEDLINE	medline	NN	_	29	nmod
32	,	,	,	_	31	punct
33	PREMEDLINE	premedline	NN	_	31	conj
34	,	,	,	_	31	punct
35	and	and	CC	_	31	cc
36	International	International	NNP	_	38	compound
37	Pharmaceutical	Pharmaceutical	NNP	_	38	compound
38	Abstracts	Abstracts	NNPS	_	31	conj
39	,	,	,	_	27	punct
40	using	use	VBG	_	27	xcomp
41	the	the	DT	_	42	det
42	terms	term	NNS	_	40	dobj
43	sildenafil	sildenafil	NN	_	42	dep
44	,	,	,	_	43	punct
45	Viagra	Viagra	NNP	_	43	conj
46	,	,	,	_	43	punct
47	and	and	CC	_	43	cc
48	erectile	erectile	NN	_	49	compound
49	dysfunction	dysfunction	NN	_	43	conj
50	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Sildenafil	Sildenafil	NNP	_	5	nsubj
4	has	have	VBZ	_	5	aux
5	demonstrated	demonstrate	VBN	_	1	dep
6	effectiveness	effectiveness	NN	_	5	dobj
7	in	in	IN	_	8	case
8	men	man	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	erectile	erectile	JJ	_	11	amod
11	dysfunction	dysfunction	NN	_	8	nmod
12	associated	associate	VBN	_	11	acl
13	with	with	IN	_	14	case
14	prostatectomy	prostatectomy	NN	_	12	nmod
15	,	,	,	_	14	punct
16	radiation	radiation	NN	_	17	compound
17	therapy	therapy	NN	_	14	conj
18	,	,	,	_	14	punct
19	diabetes	diabetes	NN	_	20	compound
20	mellitus	mellitus	NN	_	14	conj
21	,	,	,	_	14	punct
22	certain	certain	JJ	_	24	amod
23	neurologic	neurologic	JJ	_	24	amod
24	disorders	disorder	NNS	_	14	conj
25	,	,	,	_	14	punct
26	and	and	CC	_	14	cc
27	drug	drug	NN	_	28	compound
28	therapy	therapy	NN	_	14	conj
29	(	(	CD	_	30	compound
30	eg	eg	FW	_	28	dep
31	,	,	,	_	6	punct
32	selective	selective	JJ	_	35	amod
33	serotonin	serotonin	NN	_	35	compound
34	reuptake	reuptake	NN	_	35	compound
35	inhibitors	inhibitor	NNS	_	6	appos
36	[	[	VBN	_	37	amod
37	SSRIs	ssri	NNS	_	38	nsubj
38	]	]	VBP	_	35	acl:relcl
39	)	)	NN	_	38	dobj
40	.	.	.	_	1	punct

1	It	it	PRP	_	6	nsubj
2	has	have	VBZ	_	6	aux
3	not	not	RB	_	6	neg
4	been	be	VBN	_	6	cop
5	as	as	IN	_	6	advmod
6	effective	effective	JJ	_	0	ROOT
7	in	in	IN	_	8	case
8	women	woman	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	sexual	sexual	JJ	_	11	amod
11	dysfunction	dysfunction	NN	_	8	nmod
12	,	,	,	_	6	punct
13	with	with	IN	_	15	case
14	the	the	DT	_	15	det
15	exception	exception	NN	_	6	nmod
16	of	of	IN	_	17	case
17	SSRI	SSRI	NNP	_	15	nmod
18	-	-	:	_	15	punct
19	associated	associate	VBN	_	21	amod
20	sexual	sexual	JJ	_	21	amod
21	dysfunction	dysfunction	NN	_	15	dep
22	.	.	.	_	6	punct

1	Some	some	DT	_	2	det
2	disorders	disorder	NNS	_	16	nsubj
3	unrelated	unrelated	JJ	_	2	amod
4	to	to	TO	_	7	case
5	sexual	sexual	JJ	_	7	amod
6	dysfunction	dysfunction	NN	_	7	compound
7	(	(	NN	_	3	nmod
8	eg	eg	FW	_	7	dep
9	,	,	,	_	2	punct
10	esophageal	esophageal	JJ	_	13	amod
11	motility	motility	NN	_	13	compound
12	dysfunction	dysfunction	NN	_	13	compound
13	)	)	NN	_	2	appos
14	may	may	MD	_	16	aux
15	also	also	RB	_	16	advmod
16	respond	respond	VB	_	0	ROOT
17	to	to	TO	_	18	case
18	sildenafil	sildenafil	NN	_	16	nmod
19	.	.	.	_	16	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	general	general	JJ	_	4	amod
4	population	population	NN	_	8	nmod
5	,	,	,	_	8	punct
6	sildenafil	sildenafil	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	considered	consider	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	have	have	VB	_	8	xcomp
11	an	a	DT	_	14	det
12	acceptable	acceptable	JJ	_	14	amod
13	tolerability	tolerability	NN	_	14	compound
14	profile	profile	NN	_	10	dobj
15	;	;	:	_	8	punct

1	however	however	RB	_	18	advmod
2	,	,	,	_	18	punct
3	patients	patient	NNS	_	18	nsubj
4	with	with	IN	_	5	case
5	moderate	moderate	JJ	_	3	nmod
6	to	to	TO	_	9	case
7	severe	severe	JJ	_	9	amod
8	cardiovascular	cardiovascular	JJ	_	9	amod
9	disease	disease	NN	_	5	nmod
10	or	or	CC	_	5	cc
11	those	those	DT	_	5	conj
12	taking	take	VBG	_	11	acl
13	nitrate	nitrate	JJ	_	14	amod
14	therapy	therapy	NN	_	12	dobj
15	are	be	VBP	_	18	cop
16	at	at	IN	_	18	case
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	0	ROOT
19	for	for	IN	_	24	case
20	potentially	potentially	RB	_	21	advmod
21	serious	serious	JJ	_	24	amod
22	cardiovascular	cardiovascular	JJ	_	24	amod
23	adverse	adverse	JJ	_	24	amod
24	effects	effect	NNS	_	18	nmod
25	with	with	IN	_	27	case
26	sildenafil	sildenafil	NN	_	27	compound
27	therapy	therapy	NN	_	24	nmod
28	.	.	.	_	18	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	20	nmod
3	,	,	,	_	20	punct
4	patients	patient	NNS	_	20	nsubj
5	taking	take	VBG	_	4	acl
6	drugs	drug	NNS	_	5	dobj
7	that	that	WDT	_	8	nsubj
8	inhibit	inhibit	VBP	_	6	acl:relcl
9	the	the	DT	_	13	det
10	cytochrome	cytochrome	NN	_	13	compound
11	P450	p450	NN	_	13	compound
12	3A4	3a4	NN	_	13	compound
13	isozyme	isozyme	NN	_	8	dobj
14	,	,	,	_	13	punct
15	which	which	WDT	_	16	nsubj
16	metabolizes	metabolize	VBZ	_	13	acl:relcl
17	sildenafil	sildenafil	NN	_	16	dobj
18	,	,	,	_	20	punct
19	may	may	MD	_	20	aux
20	experience	experience	VB	_	0	ROOT
21	increased	increase	VBN	_	23	amod
22	drug	drug	NN	_	23	compound
23	concentrations	concentration	NNS	_	20	dobj
24	and	and	CC	_	23	cc
25	possible	possible	JJ	_	26	amod
26	toxicity	toxicity	NN	_	23	conj
27	from	from	IN	_	29	case
28	normal	normal	JJ	_	29	amod
29	doses	dose	NNS	_	20	nmod
30	of	of	IN	_	31	case
31	sildenafil	sildenafil	NN	_	29	nmod
32	.	.	.	_	20	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Sildenafil	sildenafil	NN	_	10	nsubj
4	is	be	VBZ	_	10	cop
5	an	a	DT	_	10	det
6	effective	effective	JJ	_	10	amod
7	first	first	JJ	_	10	amod
8	-	-	:	_	10	punct
9	line	line	NN	_	10	compound
10	therapy	therapy	NN	_	1	dep
11	for	for	IN	_	13	case
12	erectile	erectile	JJ	_	13	amod
13	dysfunction	dysfunction	NN	_	10	nmod
14	in	in	IN	_	15	case
15	men	man	NNS	_	13	nmod
16	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	decision	decision	NN	_	8	nsubj
3	to	to	TO	_	4	mark
4	prescribe	prescribe	VB	_	2	acl
5	this	this	DT	_	6	det
6	agent	agent	NN	_	4	dobj
7	should	should	MD	_	8	aux
8	include	include	VB	_	0	ROOT
9	such	such	JJ	_	10	amod
10	considerations	consideration	NNS	_	8	dobj
11	as	as	IN	_	13	case
12	the	the	DT	_	13	det
13	cost	cost	NN	_	10	nmod
14	-	-	:	_	13	punct
15	risk	risk	NN	_	13	dep
16	-	-	:	_	13	punct
17	benefit	benefit	NN	_	18	compound
18	balance	balance	NN	_	13	dep
19	,	,	,	_	13	punct
20	patient	patient	NN	_	21	compound
21	access	access	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug	drug	NN	_	25	compound
24	distribution	distribution	NN	_	25	compound
25	pathways	pathway	NNS	_	13	conj
26	,	,	,	_	13	punct
27	and	and	CC	_	13	cc
28	prescription	prescription	NN	_	30	compound
29	drug	drug	NN	_	30	compound
30	coverage	coverage	NN	_	13	conj
31	.	.	.	_	8	punct

1	Tumor	tumor	NN	_	2	compound
2	phenotype	phenotype	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	susceptibility	susceptibility	NN	_	2	conj
5	to	to	TO	_	6	case
6	progression	progression	NN	_	4	nmod
7	as	as	IN	_	9	case
8	an	a	DT	_	9	det
9	expression	expression	NN	_	2	nmod
10	of	of	IN	_	11	case
11	subpopulations	subpopulation	NNS	_	9	nmod
12	of	of	IN	_	15	case
13	initiated	initiate	VBN	_	15	amod
14	murine	murine	JJ	_	15	amod
15	cells	cell	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	Currently	currently	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	conceived	conceive	VBN	_	0	ROOT
6	that	that	IN	_	16	mark
7	a	a	DT	_	8	det
8	number	number	NN	_	16	nsubjpass
9	of	of	IN	_	10	case
10	events	event	NNS	_	8	nmod
11	,	,	,	_	10	punct
12	or	or	CC	_	10	cc
13	hits	hit	NNS	_	10	conj
14	,	,	,	_	8	punct
15	are	be	VBP	_	16	auxpass
16	required	require	VBN	_	5	ccomp
17	for	for	IN	_	19	case
18	the	the	DT	_	19	det
19	induction	induction	NN	_	16	nmod
20	of	of	IN	_	21	case
21	tumors	tumor	NNS	_	19	nmod
22	by	by	IN	_	24	case
23	chemical	chemical	NN	_	24	compound
24	agents	agent	NNS	_	19	nmod
25	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	first	first	JJ	_	3	amod
3	phase	phase	NN	_	11	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	sequence	sequence	NN	_	3	nmod
7	,	,	,	_	3	punct
8	initiation	initiation	NN	_	3	appos
9	,	,	,	_	3	punct
10	is	be	VBZ	_	11	auxpass
11	considered	consider	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	result	result	VB	_	11	xcomp
14	from	from	IN	_	18	case
15	at	at	IN	_	16	case
16	least	least	JJS	_	17	nmod:npmod
17	one	one	CD	_	18	nummod
18	event	event	NN	_	13	nmod
19	in	in	IN	_	22	case
20	the	the	DT	_	22	det
21	genetic	genetic	JJ	_	22	amod
22	apparatus	apparatus	NN	_	18	nmod
23	.	.	.	_	11	punct

1	Analyses	analysis	NNS	_	9	nsubj
2	of	of	IN	_	4	case
3	this	this	DT	_	4	det
4	sequence	sequence	NN	_	1	nmod
5	,	,	,	_	9	punct
6	however	however	RB	_	9	advmod
7	,	,	,	_	9	punct
8	usually	usually	RB	_	9	advmod
9	give	give	VBP	_	0	ROOT
10	little	little	JJ	_	11	amod
11	consideration	consideration	NN	_	9	dobj
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	nature	nature	NN	_	9	nmod
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	target	target	NN	_	18	compound
18	cell	cell	NN	_	14	nmod
19	or	or	CC	_	14	cc
20	to	to	TO	_	22	case
21	the	the	DT	_	22	det
22	characteristics	characteristic	NNS	_	14	conj
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	resultant	resultant	JJ	_	26	amod
26	tumors	tumor	NNS	_	22	nmod
27	.	.	.	_	9	punct

1	Vesselinovitch	Vesselinovitch	NNP	_	3	compound
2	et	et	FW	_	3	compound
3	al	al	FW	_	0	ROOT
4	.	.	.	_	3	punct

1	(	(	NN	_	3	compound
2	Cancer	cancer	NN	_	3	compound
3	Res	Res	NNP	_	0	ROOT
4	.	.	.	_	3	punct
5	,	,	,	_	3	punct
6	38	38	CD	_	3	dep
7	:	:	:	_	6	punct
8	2003	2003	CD	_	10	nummod
9	-	-	:	_	10	punct
10	2010	2010	CD	_	15	nsubj
11	,	,	,	_	10	punct
12	1978	1978	CD	_	13	compound
13	)	)	CD	_	10	nummod
14	have	have	VBP	_	15	aux
15	reported	report	VBN	_	6	dep
16	that	that	IN	_	25	mark
17	a	a	DT	_	21	det
18	single	single	JJ	_	21	amod
19	,	,	,	_	21	punct
20	small	small	JJ	_	21	amod
21	pulse	pulse	NN	_	25	nsubj
22	of	of	IN	_	23	case
23	carcinogen	carcinogen	NN	_	21	nmod
24	can	can	MD	_	25	aux
25	induce	induce	VB	_	15	ccomp
26	early	early	JJ	_	30	amod
27	and	and	CC	_	26	cc
28	numerous	numerous	JJ	_	26	conj
29	liver	liver	NN	_	30	compound
30	tumors	tumor	NNS	_	25	dobj
31	when	when	WRB	_	32	advmod
32	administered	administer	VBN	_	25	advcl
33	neonatally	neonatally	RB	_	32	advmod
34	to	to	TO	_	35	case
35	mice	mouse	NNS	_	32	nmod
36	with	with	IN	_	39	case
37	a	a	DT	_	39	det
38	genetic	genetic	JJ	_	39	amod
39	predisposition	predisposition	NN	_	32	nmod
40	to	to	TO	_	41	case
41	hepatotumorigenesis	hepatotumorigenesis	NN	_	39	nmod
42	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	current	current	JJ	_	4	amod
4	study	study	NN	_	14	nmod
5	,	,	,	_	14	punct
6	the	the	DT	_	9	det
7	nonpredisposed	nonpredisposed	JJ	_	9	amod
8	strain	strain	NN	_	9	compound
9	C57BL	c57bl	NN	_	14	nsubjpass
10	/	/	:	_	11	punct
11	6N	6n	NN	_	14	nsubjpass
12	was	be	VBD	_	14	auxpass
13	also	also	RB	_	14	advmod
14	shown	show	VBN	_	0	ROOT
15	to	to	TO	_	18	mark
16	be	be	VB	_	18	cop
17	highly	highly	RB	_	18	advmod
18	susceptible	susceptible	JJ	_	14	xcomp
19	to	to	TO	_	20	case
20	diethylnitrosamine	diethylnitrosamine	NN	_	18	nmod
21	during	during	IN	_	24	case
22	the	the	DT	_	24	det
23	neonatal	neonatal	JJ	_	24	amod
24	period	period	NN	_	18	nmod
25	.	.	.	_	14	punct

1	C57BL	c57bl	NN	_	4	dep
2	/	/	:	_	4	punct
3	6N	6n	NN	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	large	large	JJ	_	6	amod
6	numbers	number	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	two	two	CD	_	6	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	three	three	CD	_	12	nummod
12	types	type	NNS	_	8	nmod
13	of	of	IN	_	15	case
14	liver	liver	NN	_	15	compound
15	tumors	tumor	NNS	_	12	nmod
16	seen	see	VBN	_	12	acl
17	in	in	IN	_	18	case
18	livers	liver	NNS	_	16	nmod
19	of	of	IN	_	22	case
20	genetically	genetically	RB	_	21	advmod
21	predisposed	predispose	VBN	_	22	amod
22	mice	mouse	NNS	_	18	nmod
23	,	,	,	_	6	punct
24	one	one	CD	_	27	nsubj
25	of	of	IN	_	26	case
26	which	which	WDT	_	24	nmod
27	required	require	VBD	_	6	acl:relcl
28	the	the	DT	_	30	det
29	additional	additional	JJ	_	30	amod
30	stimulus	stimulus	NN	_	27	dobj
31	of	of	IN	_	33	case
32	dietary	dietary	JJ	_	33	amod
33	phenobarbital	phenobarbital	NN	_	30	nmod
34	for	for	IN	_	35	case
35	growth	growth	NN	_	27	nmod
36	.	.	.	_	4	punct

1	Tumors	tumor	NNS	_	7	nsubjpass
2	of	of	IN	_	5	case
3	more	more	JJR	_	5	amod
4	malignant	malignant	JJ	_	5	amod
5	phenotype	phenotype	NN	_	1	nmod
6	were	be	VBD	_	7	auxpass
7	demonstrated	demonstrate	VBN	_	0	ROOT
8	only	only	RB	_	12	advmod
9	in	in	IN	_	12	case
10	genetically	genetically	RB	_	11	advmod
11	predisposed	predispose	VBN	_	12	amod
12	mice	mouse	NNS	_	7	nmod
13	(	(	VBP	_	12	acl
14	C57BL	c57bl	NN	_	18	compound
15	/	/	:	_	18	punct
16	6N	6n	NN	_	18	compound
17	X	x	NN	_	18	compound
18	C3H	c3h	NN	_	13	dobj
19	/	/	:	_	18	punct
20	HeN	hen	NN	_	22	compound
21	F1	f1	NN	_	22	compound
22	)	)	NN	_	18	dep
23	that	that	WDT	_	24	nsubj
24	received	receive	VBD	_	22	acl:relcl
25	one	one	CD	_	26	nummod
26	dose	dose	NN	_	24	dobj
27	of	of	IN	_	28	case
28	carcinogen	carcinogen	NN	_	26	nmod
29	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	20	mark
5	the	the	DT	_	6	det
6	phenotype	phenotype	NN	_	20	nsubj
7	of	of	IN	_	9	case
8	a	a	DT	_	9	det
9	tumor	tumor	NN	_	6	nmod
10	that	that	WDT	_	11	nsubj
11	results	result	VBZ	_	9	acl:relcl
12	from	from	IN	_	14	case
13	a	a	DT	_	14	det
14	pulse	pulse	NN	_	11	nmod
15	of	of	IN	_	18	case
16	a	a	DT	_	18	det
17	chemical	chemical	NN	_	18	compound
18	carcinogen	carcinogen	NN	_	14	nmod
19	may	may	MD	_	20	aux
20	depend	depend	VB	_	3	ccomp
21	upon	upon	IN	_	24	case
22	the	the	DT	_	24	det
23	target	target	NN	_	24	compound
24	cell	cell	NN	_	20	nmod
25	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	initiated	initiate	VBN	_	3	amod
3	cells	cell	NNS	_	10	nsubj
4	that	that	WDT	_	5	nsubj
5	result	result	VBP	_	3	acl:relcl
6	from	from	IN	_	8	case
7	this	this	DT	_	8	det
8	hit	hit	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	vary	vary	VB	_	0	ROOT
11	from	from	IN	_	12	case
12	those	those	DT	_	10	nmod
13	that	that	WDT	_	14	nsubj
14	demonstrate	demonstrate	VBP	_	12	acl:relcl
15	very	very	RB	_	16	advmod
16	little	little	JJ	_	17	amod
17	progression	progression	NN	_	14	dobj
18	in	in	IN	_	20	case
19	cell	cell	NN	_	20	compound
20	type	type	NN	_	17	nmod
21	and	and	CC	_	14	cc
22	may	may	MD	_	26	aux
23	or	or	CC	_	26	cc
24	may	may	MD	_	26	aux
25	not	not	RB	_	26	neg
26	require	require	VB	_	14	conj
27	exogenous	exogenous	JJ	_	28	amod
28	enhancement	enhancement	NN	_	26	dobj
29	of	of	IN	_	30	case
30	growth	growth	NN	_	28	nmod
31	to	to	TO	_	32	case
32	those	those	DT	_	28	nmod
33	that	that	WDT	_	35	nsubj
34	can	can	MD	_	35	aux
35	progress	progress	VB	_	32	acl:relcl
36	very	very	RB	_	37	advmod
37	rapidly	rapidly	RB	_	35	advmod
38	to	to	TO	_	41	case
39	fully	fully	RB	_	40	advmod
40	malignant	malignant	JJ	_	41	amod
41	behavior	behavior	NN	_	35	nmod
42	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	latter	latter	JJ	_	4	nsubj
3	might	might	MD	_	4	aux
4	arise	arise	VB	_	0	ROOT
5	from	from	IN	_	7	case
6	a	a	DT	_	7	det
7	hit	hit	NN	_	4	nmod
8	in	in	IN	_	12	case
9	a	a	DT	_	12	det
10	genetically	genetically	RB	_	11	advmod
11	initiated	initiate	VBN	_	12	amod
12	cell	cell	NN	_	7	nmod
13	,	,	,	_	4	punct
14	the	the	DT	_	15	det
15	result	result	NN	_	22	nsubj
16	of	of	IN	_	17	case
17	which	which	WDT	_	15	nmod
18	is	be	VBZ	_	22	cop
19	a	a	DT	_	22	det
20	more	more	RBR	_	21	advmod
21	rapid	rapid	JJ	_	22	amod
22	progression	progression	NN	_	4	ccomp
23	in	in	IN	_	25	case
24	tumor	tumor	NN	_	25	compound
25	type	type	NN	_	22	nmod
26	.	.	.	_	4	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	etofibrate	etofibrate	NN	_	1	nmod
4	upon	upon	IN	_	6	case
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	1	nmod
7	of	of	IN	_	8	case
8	chylomicron	chylomicron	NN	_	6	nmod
9	-	-	:	_	1	punct
10	like	like	IN	_	11	case
11	emulsions	emulsion	NNS	_	1	nmod
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	with	with	IN	_	17	case
15	coronary	coronary	JJ	_	17	amod
16	artery	artery	NN	_	17	compound
17	disease	disease	NN	_	13	nmod
18	.	.	.	_	1	punct

1	Slow	slow	JJ	_	4	amod
2	chylomicron	chylomicron	NN	_	4	compound
3	intravascular	intravascular	JJ	_	4	amod
4	catabolism	catabolism	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	associated	associate	VBN	_	25	csubj
8	with	with	IN	_	11	case
9	coronary	coronary	JJ	_	11	amod
10	artery	artery	NN	_	11	compound
11	disease	disease	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	screening	screening	NN	_	11	conj
14	for	for	IN	_	15	case
15	drugs	drug	NNS	_	7	nmod
16	that	that	WDT	_	18	nsubj
17	can	can	MD	_	18	aux
18	speed	speed	VB	_	15	acl:relcl
19	-	-	:	_	18	punct
20	up	up	RP	_	22	case
21	this	this	DT	_	22	det
22	process	process	NN	_	18	nmod
23	can	can	MD	_	25	aux
24	be	be	VB	_	25	cop
25	important	important	JJ	_	0	ROOT
26	.	.	.	_	25	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	13	nmod
4	,	,	,	_	13	punct
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	13	nsubjpass
7	of	of	IN	_	8	case
8	etofibrate	etofibrate	NN	_	6	nmod
9	upon	upon	IN	_	11	case
10	chylomicron	chylomicron	NN	_	11	compound
11	metabolism	metabolism	NN	_	6	nmod
12	was	be	VBD	_	13	auxpass
13	tested	test	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	determination	determination	NN	_	13	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	plasma	plasma	NN	_	19	compound
19	kinetics	kinetics	NNS	_	15	nmod
20	of	of	IN	_	22	case
21	a	a	DT	_	22	det
22	chylomicron	chylomicron	NN	_	19	nmod
23	-	-	:	_	22	punct
24	like	like	IN	_	26	case
25	emulsion	emulsion	NN	_	26	compound
26	model	model	NN	_	22	nmod
27	in	in	IN	_	29	case
28	12	12	CD	_	29	nummod
29	patients	patient	NNS	_	26	nmod
30	with	with	IN	_	33	case
31	coronary	coronary	JJ	_	33	amod
32	artery	artery	NN	_	33	compound
33	disease	disease	NN	_	29	nmod
34	,	,	,	_	29	punct
35	aged	aged	JJ	_	29	amod
36	59	59	CD	_	35	dep
37	+	+	CC	_	36	cc
38	/	/	:	_	36	punct
39	-	-	:	_	38	punct
40	11	11	CD	_	41	nummod
41	years	year	NNS	_	39	root
42	,	,	,	_	41	punct
43	(	(	CD	_	45	nummod
44	total	total	JJ	_	45	amod
45	cholesterol	cholesterol	NN	_	41	appos
46	:	:	:	_	41	punct
47	240	240	CD	_	41	dep
48	+	+	CC	_	47	cc
49	/	/	:	_	52	punct
50	-	-	:	_	52	punct
51	41	41	CD	_	52	nummod
52	mg	mg	NN	_	47	conj
53	/	/	:	_	52	punct
54	dl	dl	NN	_	52	dep
55	;	;	:	_	41	punct
56	triglycerides	triglyceride	NNS	_	41	dep
57	:	:	:	_	56	punct
58	188	188	CD	_	56	dep
59	+	+	CC	_	58	cc
60	/	/	:	_	63	punct
61	-	-	:	_	63	punct
62	42	42	CD	_	63	nummod
63	mg	mg	NN	_	58	conj
64	/	/	:	_	63	punct
65	dl	dl	NN	_	66	compound
66	)	)	NN	_	63	dep
67	submitted	submit	VBN	_	66	acl
68	to	to	TO	_	67	nmod
69	a	a	DT	_	68	dep
70	randomized	randomize	VBN	_	69	dep
71	,	,	,	_	70	punct
72	crossover	crossover	NN	_	71	root
73	,	,	,	_	72	punct
74	double	double	JJ	_	76	dep
75	-	-	:	_	76	punct
76	blind	blind	JJ	_	81	amod
77	,	,	,	_	76	punct
78	placebo	placebo	NN	_	76	dep
79	-	-	:	_	76	punct
80	controlled	controlled	JJ	_	81	amod
81	study	study	NN	_	72	appos
82	with	with	IN	_	83	case
83	administration	administration	NN	_	81	nmod
84	of	of	IN	_	86	case
85	1	1	CD	_	86	nummod
86	g	g	NN	_	83	nmod
87	per	per	IN	_	89	case
88	day	day	NN	_	89	compound
89	etofibrate	etofibrate	NN	_	81	nmod
90	or	or	CC	_	89	cc
91	placebo	placebo	NN	_	89	conj
92	for	for	IN	_	93	case
93	1	1	LS	_	81	nmod
94	-	-	:	_	93	punct
95	month	month	NN	_	93	nmod:tmod
96	.	.	.	_	72	punct

1	A	a	DT	_	0	ROOT
2	1	1	LS	_	8	dep
3	-	-	:	_	2	punct
4	month	month	NN	_	6	compound
5	washout	washout	NN	_	6	compound
6	period	period	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	inserted	insert	VBN	_	1	dep
9	between	between	IN	_	12	case
10	the	the	DT	_	12	det
11	treatment	treatment	NN	_	12	compound
12	periods	period	NNS	_	8	nmod
13	.	.	.	_	1	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	were	be	VBD	_	4	auxpass
3	intravenously	intravenously	RB	_	4	advmod
4	injected	inject	VBN	_	0	ROOT
5	a	a	DT	_	6	det
6	chylomicron	chylomicron	NN	_	4	dobj
7	-	-	:	_	6	punct
8	like	like	IN	_	9	case
9	emulsion	emulsion	NN	_	6	nmod
10	doubly	doubly	RB	_	11	advmod
11	labeled	label	VBN	_	9	acl
12	with	with	IN	_	13	case
13	14C	14c	NN	_	11	nmod
14	-	-	:	_	13	punct
15	cholesteryl	cholesteryl	NN	_	16	compound
16	oleate	oleate	NN	_	13	dep
17	and	and	CC	_	16	cc
18	3H	3h	NN	_	16	conj
19	-	-	:	_	13	punct
20	triolein	triolein	NN	_	13	dep
21	at	at	IN	_	22	case
22	baseline	baseline	NN	_	20	nmod
23	and	and	CC	_	20	cc
24	after	after	IN	_	25	case
25	treatments	treatment	NNS	_	20	conj
26	.	.	.	_	4	punct

1	After	after	IN	_	3	case
2	etofibrate	etofibrate	NN	_	3	compound
3	treatment	treatment	NN	_	6	nmod
4	,	,	,	_	6	punct
5	there	there	EX	_	6	expl
6	was	be	VBD	_	0	ROOT
7	decrease	decrease	NN	_	6	nsubj
8	of	of	IN	_	10	case
9	total	total	JJ	_	10	amod
10	cholesterol	cholesterol	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	triglyceride	triglyceride	NN	_	14	compound
13	plasma	plasma	NN	_	14	compound
14	levels	level	NNS	_	10	conj
15	and	and	CC	_	7	cc
16	a	a	DT	_	17	det
17	trend	trend	NN	_	7	conj
18	to	to	TO	_	19	mark
19	increase	increase	VB	_	17	acl
20	high	high	JJ	_	26	amod
21	-	-	:	_	26	punct
22	density	density	NN	_	26	compound
23	lipoprotein	lipoprotein	NN	_	26	compound
24	cholesterol	cholesterol	NN	_	26	compound
25	plasma	plasma	NN	_	26	compound
26	levels	level	NNS	_	19	dobj
27	.	.	.	_	6	punct

1	Etofibrate	etofibrate	NN	_	2	nsubj
2	elicited	elicit	VBD	_	0	ROOT
3	62	62	CD	_	4	compound
4	%	%	NN	_	5	amod
5	enhancement	enhancement	NN	_	2	dobj
6	of	of	IN	_	11	case
7	post	post	NN	_	11	compound
8	-	-	:	_	11	punct
9	heparin	heparin	NN	_	11	compound
10	lipolytic	lipolytic	JJ	_	11	amod
11	activity	activity	NN	_	5	nmod
12	and	and	CC	_	5	cc
13	100	100	CD	_	14	compound
14	%	%	NN	_	15	amod
15	increase	increase	NN	_	5	conj
16	of	of	IN	_	17	case
17	3H	3h	NN	_	15	nmod
18	-	-	:	_	5	punct
19	triglyceride	triglyceride	NN	_	22	compound
20	fractional	fractional	JJ	_	22	amod
21	clearance	clearance	NN	_	22	compound
22	rate	rate	NN	_	5	dep
23	compared	compare	VBN	_	26	case
24	with	with	IN	_	26	case
25	placebo	placebo	NN	_	26	compound
26	treatment	treatment	NN	_	22	nmod
27	.	.	.	_	2	punct

1	14C	14c	SYM	_	11	dep
2	-	-	:	_	11	punct
3	cholesterol	cholesterol	NN	_	7	compound
4	ester	ester	NN	_	7	compound
5	fractional	fractional	JJ	_	7	amod
6	clearance	clearance	NN	_	7	compound
7	rate	rate	NN	_	11	nsubj
8	was	be	VBD	_	11	cop
9	260	260	CD	_	10	nummod
10	%	%	NN	_	11	nmod:npmod
11	greater	greater	JJR	_	0	ROOT
12	after	after	IN	_	13	case
13	etofibrate	etofibrate	NN	_	11	nmod
14	than	than	IN	_	16	case
15	after	after	IN	_	16	case
16	placebo	placebo	NN	_	11	nmod
17	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	a	a	DT	_	5	det
4	potent	potent	JJ	_	5	amod
5	effect	effect	NN	_	16	nsubjpass
6	of	of	IN	_	7	case
7	etofibrate	etofibrate	NN	_	5	nmod
8	on	on	IN	_	11	case
9	both	both	DT	_	11	cc:preconj
10	chylomicron	chylomicron	NN	_	11	compound
11	lipolysis	lipolysis	NN	_	5	nmod
12	and	and	CC	_	11	cc
13	remnant	remnant	NN	_	14	compound
14	removal	removal	NN	_	11	conj
15	was	be	VBD	_	16	auxpass
16	achieved	achieve	VBN	_	0	ROOT
17	,	,	,	_	16	punct
18	indicating	indicate	VBG	_	16	xcomp
19	that	that	IN	_	24	mark
20	this	this	DT	_	21	det
21	drug	drug	NN	_	24	nsubjpass
22	can	can	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	used	use	VBN	_	18	ccomp
25	to	to	TO	_	26	mark
26	improve	improve	VB	_	24	xcomp
27	this	this	DT	_	28	det
28	metabolism	metabolism	NN	_	26	dobj
29	in	in	IN	_	32	case
30	future	future	JJ	_	32	amod
31	prospective	prospective	JJ	_	32	amod
32	studies	study	NNS	_	26	nmod
33	.	.	.	_	16	punct

1	Selective	selective	JJ	_	2	amod
2	survival	survival	NN	_	0	ROOT
3	in	in	IN	_	4	case
4	pentazocine	pentazocine	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	tripelennamine	tripelennamine	NN	_	4	conj
7	of	of	IN	_	11	case
8	Pseudomonas	pseudomonas	FW	_	11	compound
9	aeruginosa	aeruginosa	FW	_	11	compound
10	serotype	serotype	NN	_	11	compound
11	O11	o11	NN	_	4	nmod
12	from	from	IN	_	14	case
13	drug	drug	NN	_	14	compound
14	addicts	addict	NNS	_	11	nmod
15	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	growth	growth	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	Pseudomonas	pseudomonas	FW	_	5	compound
5	aeruginosa	aeruginosa	FW	_	2	nmod
6	,	,	,	_	5	punct
7	particularly	particularly	RB	_	8	advmod
8	serotype	serotype	NN	_	9	amod
9	O11	o11	NN	_	5	appos
10	,	,	,	_	5	punct
11	in	in	IN	_	12	case
12	pentazocine	pentazocine	NN	_	2	nmod
13	and	and	CC	_	12	cc
14	tripelennamine	tripelennamine	NN	_	12	conj

1	was	be	VBD	_	2	auxpass
2	evaluated	evaluate	VBN	_	0	ROOT
3	as	as	IN	_	6	case
4	a	a	DT	_	6	det
5	possible	possible	JJ	_	6	amod
6	explanation	explanation	NN	_	2	nmod
7	for	for	IN	_	9	case
8	the	the	DT	_	9	det
9	association	association	NN	_	6	nmod
10	of	of	IN	_	14	case
11	deep	deep	JJ	_	14	amod
12	-	-	:	_	14	punct
13	seated	seat	VBN	_	14	amod
14	infection	infection	NN	_	9	nmod
15	with	with	IN	_	17	case
16	this	this	DT	_	17	det
17	organism	organism	NN	_	14	nmod
18	and	and	CC	_	14	cc
19	abuse	abuse	NN	_	14	conj
20	of	of	IN	_	22	case
21	these	these	DT	_	22	det
22	drugs	drug	NNS	_	19	nmod
23	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	mean	mean	JJ	_	3	amod
3	reduction	reduction	NN	_	14	nsubj
4	of	of	IN	_	5	case
5	growth	growth	NN	_	3	nmod
6	caused	cause	VBN	_	5	acl
7	by	by	IN	_	9	case
8	the	the	DT	_	9	det
9	drugs	drug	NNS	_	6	nmod
10	was	be	VBD	_	14	cop
11	1,000	1,000	CD	_	13	dep
12	-	-	:	_	13	punct
13	fold	fold	JJ	_	14	dep
14	greater	greater	JJR	_	0	ROOT
15	for	for	IN	_	18	case
16	49	49	CD	_	18	nummod
17	Pseudomonas	pseudomonas	FW	_	18	compound
18	strains	strain	NNS	_	14	nmod
19	from	from	IN	_	21	case
20	normal	normal	JJ	_	21	amod
21	subjects	subject	NNS	_	18	nmod
22	than	than	IN	_	25	case
23	for	for	IN	_	25	case
24	32	32	CD	_	25	nummod
25	strains	strain	NNS	_	14	nmod
26	from	from	IN	_	28	case
27	drug	drug	NN	_	28	compound
28	addicts	addict	NNS	_	25	nmod
29	(	(	VBP	_	46	dep
30	4.2	4.2	CD	_	46	dep
31	vs	vs	CC	_	46	dep
32	.	.	.	_	46	punct
33	1.3	1.3	CD	_	34	nummod
34	logs	log	NNS	_	46	dep
35	of	of	IN	_	36	case
36	reduction	reduction	NN	_	34	nmod
37	at	at	IN	_	39	case
38	2	2	CD	_	39	nummod
39	hr	hr	NN	_	34	nmod
40	,	,	,	_	34	punct
41	P	p	NN	_	46	dep
42	less	less	JJR	_	46	advmod
43	than	than	IN	_	42	mwe
44	.	.	.	_	46	punct
45	0005	0005	CD	_	46	compound
46	)	)	CD	_	25	dep
47	.	.	.	_	14	punct

1	A	a	DT	_	4	det
2	common	common	JJ	_	4	amod
3	phenotypic	phenotypic	JJ	_	4	amod
4	subset	subset	NN	_	15	nsubj
5	of	of	IN	_	9	case
6	the	the	DT	_	9	det
7	serotype	serotype	NN	_	9	compound
8	O11	o11	NN	_	9	compound
9	strains	strain	NNS	_	4	nmod
10	from	from	IN	_	12	case
11	drug	drug	NN	_	12	compound
12	addicts	addict	NNS	_	9	nmod
13	was	be	VBD	_	15	cop
14	especially	especially	RB	_	15	advmod
15	resistant	resistant	JJ	_	0	ROOT
16	to	to	TO	_	19	case
17	the	the	DT	_	19	det
18	inhibitory	inhibitory	JJ	_	19	amod
19	effects	effect	NNS	_	15	nmod
20	.	.	.	_	15	punct

1	Twelve	twelve	CD	_	2	nummod
2	strains	strain	NNS	_	0	ROOT
3	of	of	IN	_	6	case
4	Staphylococcus	staphylococcus	FW	_	6	compound
5	aureus	aureus	FW	_	6	compound
6	(	(	FW	_	2	nmod
7	a	a	DT	_	9	det
8	frequent	frequent	JJ	_	9	amod
9	cause	cause	NN	_	26	nsubjpass
10	of	of	IN	_	11	case
11	infection	infection	NN	_	9	nmod
12	in	in	IN	_	13	case
13	heroin	heroin	NN	_	11	nmod
14	,	,	,	_	9	punct
15	but	but	CC	_	16	cc
16	not	not	RB	_	9	cc
17	in	in	IN	_	18	case
18	pentazocine	pentazocine	NN	_	9	conj
19	and	and	CC	_	18	cc
20	tripelennamine	tripelennamine	NN	_	18	conj
21	,	,	,	_	9	punct
22	addicts	addict	NNS	_	9	appos
23	)	)	CD	_	22	nummod
24	were	be	VBD	_	26	auxpass
25	completely	completely	RB	_	26	advmod
26	inhibited	inhibit	VBN	_	2	acl:relcl
27	by	by	IN	_	30	case
28	the	the	DT	_	30	det
29	drug	drug	NN	_	30	compound
30	combination	combination	NN	_	26	nmod
31	.	.	.	_	2	punct

1	Dose	dose	NN	_	20	nsubj
2	-	-	:	_	20	punct
3	response	response	NN	_	4	compound
4	curves	curve	NNS	_	20	nsubj
5	(	(	VBP	_	4	amod
6	derived	derive	VBN	_	5	acl
7	from	from	IN	_	9	case
8	the	the	DT	_	9	det
9	results	result	NNS	_	6	nmod
10	of	of	IN	_	11	mark
11	using	use	VBG	_	9	acl
12	the	the	DT	_	13	det
13	tablets	tablet	NNS	_	11	dobj
14	as	as	RB	_	13	cc
15	well	well	RB	_	14	mwe
16	as	as	IN	_	14	mwe
17	pure	pure	JJ	_	19	amod
18	powders	powder	NNS	_	19	compound
19	)	)	NN	_	13	conj
20	showed	show	VBD	_	0	ROOT
21	that	that	IN	_	24	mark
22	tripelennamine	tripelennamine	NN	_	24	nsubj
23	was	be	VBD	_	24	cop
24	responsible	responsible	JJ	_	20	ccomp
25	for	for	IN	_	28	case
26	the	the	DT	_	28	det
27	inhibitory	inhibitory	JJ	_	28	amod
28	activity	activity	NN	_	24	nmod
29	,	,	,	_	28	punct
30	which	which	WDT	_	33	nsubjpass
31	was	be	VBD	_	33	auxpass
32	partially	partially	RB	_	33	advmod
33	antagonized	antagonize	VBN	_	28	acl:relcl
34	by	by	IN	_	35	case
35	pentazocine	pentazocine	NN	_	33	nmod
36	.	.	.	_	20	punct

1	We	we	PRP	_	2	nsubj
2	conclude	conclude	VBP	_	0	ROOT
3	that	that	IN	_	2	dobj
4	an	a	DT	_	5	det
5	ability	ability	NN	_	3	dep
6	of	of	IN	_	8	case
7	some	some	DT	_	8	det
8	P	p	NN	_	5	nmod
9	.	.	.	_	2	punct

1	aeruginosa	aeruginosa	FW	_	4	compound
2	serotype	serotype	NN	_	4	compound
3	O11	o11	NN	_	4	compound
4	strains	strain	NNS	_	0	ROOT
5	,	,	,	_	4	punct
6	but	but	CC	_	7	cc
7	not	not	RB	_	4	cc
8	S	s	NN	_	4	conj
9	.	.	.	_	4	punct

1	aureus	aureus	NN	_	0	ROOT
2	,	,	,	_	4	punct
3	to	to	TO	_	4	mark
4	survive	survive	VB	_	1	dep
5	in	in	IN	_	6	case
6	pentazocine	pentazocine	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	tripelennamine	tripelennamine	NN	_	10	nsubj
9	may	may	MD	_	10	aux
10	explain	explain	VB	_	4	conj
11	in	in	IN	_	12	case
12	part	part	NN	_	10	nmod
13	a	a	DT	_	14	det
14	shift	shift	NN	_	10	dobj
15	from	from	IN	_	16	case
16	S	s	NN	_	14	nmod
17	.	.	.	_	1	punct

1	aureus	aureus	NN	_	0	ROOT
2	to	to	TO	_	3	case
3	P	p	NN	_	1	nmod
4	.	.	.	_	1	punct

1	aeruginosa	aeruginosa	FW	_	0	ROOT
2	as	as	IN	_	4	case
3	common	common	JJ	_	4	amod
4	pathogens	pathogen	NNS	_	1	nmod
5	of	of	IN	_	7	case
6	drug	drug	NN	_	7	compound
7	addicts	addict	NNS	_	4	nmod
8	in	in	IN	_	9	case
9	areas	area	NNS	_	7	nmod
10	where	where	WRB	_	18	advmod
11	abuse	abuse	NN	_	18	nsubj
12	of	of	IN	_	14	case
13	this	this	DT	_	14	det
14	combination	combination	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drugs	drug	NNS	_	14	nmod
17	has	have	VBZ	_	18	aux
18	increased	increase	VBN	_	9	acl:relcl
19	.	.	.	_	1	punct

1	Influence	influence	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	coadministration	coadministration	NN	_	1	nmod
4	of	of	IN	_	5	case
5	fluoxetine	fluoxetine	NN	_	3	nmod
6	on	on	IN	_	8	case
7	cisapride	cisapride	NN	_	8	compound
8	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
9	and	and	CC	_	8	cc
10	QTc	qtc	NN	_	11	compound
11	intervals	interval	NNS	_	8	conj
12	in	in	IN	_	14	case
13	healthy	healthy	JJ	_	14	amod
14	volunteers	volunteer	NNS	_	8	nmod
15	.	.	.	_	1	punct

1	STUDY	study	NN	_	2	compound
2	OBJECTIVE	objective	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	To	to	TO	_	5	mark
5	evaluate	evaluate	VB	_	2	acl
6	the	the	DT	_	7	det
7	effect	effect	NN	_	5	dobj
8	of	of	IN	_	9	case
9	fluoxetine	fluoxetine	NN	_	7	nmod
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
13	and	and	CC	_	12	cc
14	cardiovascular	cardiovascular	JJ	_	15	amod
15	safety	safety	NN	_	12	conj
16	of	of	IN	_	17	case
17	cisapride	cisapride	NN	_	12	nmod
18	at	at	IN	_	20	case
19	steady	steady	JJ	_	20	amod
20	state	state	NN	_	5	nmod
21	in	in	IN	_	23	case
22	healthy	healthy	JJ	_	23	amod
23	men	man	NNS	_	5	nmod
24	.	.	.	_	2	punct

1	DESIGN	design	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Open	open	VB	_	1	dep
4	-	-	:	_	3	punct
5	label	label	NN	_	3	dep
6	,	,	,	_	5	punct
7	three	three	CD	_	9	nummod
8	-	-	:	_	9	punct
9	phase	phase	NN	_	5	appos
10	,	,	,	_	5	punct
11	sequential	sequential	JJ	_	12	amod
12	study	study	NN	_	5	appos
13	.	.	.	_	1	punct

1	SETTING	SETTING	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	5	amod
4	research	research	NN	_	5	compound
5	center	center	NN	_	1	dep
6	.	.	.	_	1	punct

1	SUBJECTS	subject	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Twelve	twelve	CD	_	6	nummod
4	healthy	healthy	JJ	_	6	amod
5	male	male	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	1	dep
7	.	.	.	_	1	punct

1	INTERVENTIONS	intervention	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Each	each	DT	_	4	det
4	subject	subject	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	treated	treat	VBN	_	1	appos
7	according	accord	VBG	_	11	case
8	to	to	TO	_	7	mwe
9	the	the	DT	_	11	det
10	following	following	JJ	_	11	amod
11	sequence	sequence	NN	_	6	nmod
12	:	:	:	_	6	punct
13	baseline	baseline	NN	_	6	dep
14	;	;	:	_	1	punct

1	phase	phase	NN	_	0	ROOT
2	1	1	CD	_	3	compound
3	(	(	CD	_	4	nummod
4	days	day	NNS	_	1	dep
5	1	1	LS	_	4	dep
6	-	-	:	_	5	punct
7	6	6	CD	_	8	compound
8	)	)	CD	_	5	dep
9	:	:	:	_	8	punct
10	cisapride	cisapride	NN	_	12	compound
11	10	10	CD	_	12	nummod
12	mg	mg	NN	_	8	dep
13	4	4	CD	_	14	nummod
14	times	time	NNS	_	12	nmod:npmod
15	/	/	:	_	12	punct
16	day	day	NN	_	12	nmod:npmod
17	;	;	:	_	1	punct

1	washout	washout	NN	_	0	ROOT
2	(	(	CD	_	3	nummod
3	days	day	NNS	_	1	dep
4	7	7	CD	_	3	nummod
5	-	-	:	_	3	punct
6	13	13	CD	_	7	nummod
7	)	)	NN	_	3	dep
8	;	;	:	_	1	punct

1	phase	phase	NN	_	0	ROOT
2	2	2	CD	_	3	compound
3	(	(	CD	_	4	nummod
4	days	day	NNS	_	1	nmod:tmod
5	14	14	CD	_	4	dep
6	-	-	:	_	4	punct
7	44	44	CD	_	8	compound
8	)	)	CD	_	4	dep
9	:	:	:	_	4	punct
10	fluoxetine	fluoxetine	NN	_	4	dep
11	20	20	CD	_	12	nummod
12	mg	mg	NN	_	10	dep
13	/	/	:	_	4	punct
14	day	day	NN	_	4	dep
15	;	;	:	_	1	punct

1	and	and	CC	_	5	cc
2	phase	phase	NN	_	5	conj
3	3	3	CD	_	4	compound
4	(	(	CD	_	5	nummod
5	days	day	NNS	_	0	ROOT
6	45	45	CD	_	5	nummod
7	-	-	:	_	5	punct
8	52	52	CD	_	9	nummod
9	)	)	CD	_	5	dep
10	:	:	:	_	5	punct
11	cisapride	cisapride	NN	_	5	dep
12	10	10	CD	_	13	nummod
13	mg	mg	NN	_	11	dep
14	4	4	CD	_	15	nummod
15	times	time	NNS	_	13	nmod:npmod
16	/	/	:	_	11	punct
17	day	day	NN	_	19	compound
18	(	(	CD	_	19	nummod
19	days	day	NNS	_	11	dep
20	45	45	CD	_	19	nummod
21	-	-	:	_	11	punct
22	51	51	CD	_	23	nummod
23	)	)	NN	_	11	dep
24	plus	plus	CC	_	23	cc
25	fluoxetine	fluoxetine	NN	_	27	compound
26	20	20	CD	_	27	nummod
27	mg	mg	NN	_	23	conj
28	/	/	:	_	11	punct
29	day	day	NN	_	31	compound
30	(	(	CD	_	31	nummod
31	days	day	NNS	_	11	dep
32	45	45	CD	_	31	nummod
33	-	-	:	_	11	punct
34	52	52	CD	_	35	nummod
35	)	)	NN	_	11	dep
36	.	.	.	_	5	punct

1	MEASUREMENTS	measurement	NNS	_	4	compound
2	and	and	CC	_	1	cc
3	MAIN	MAIN	NNP	_	1	conj
4	RESULTS	result	NNS	_	0	ROOT
5	:	:	:	_	4	punct
6	Blood	blood	NN	_	7	compound
7	samples	sample	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	drawn	draw	VBN	_	4	dep
10	and	and	CC	_	9	cc
11	12	12	CD	_	14	nummod
12	-	-	:	_	14	punct
13	lead	lead	JJ	_	14	amod
14	electrocardiograms	electrocardiogram	NNS	_	9	conj
15	performed	perform	VBN	_	14	acl
16	at	at	IN	_	19	case
17	specified	specify	VBN	_	19	amod
18	time	time	NN	_	19	compound
19	points	point	NNS	_	15	nmod
20	after	after	IN	_	24	case
21	the	the	DT	_	24	det
22	last	last	JJ	_	24	amod
23	morning	morning	NN	_	24	compound
24	dose	dose	NN	_	15	nmod
25	of	of	IN	_	26	case
26	cisapride	cisapride	NN	_	24	nmod
27	in	in	IN	_	28	case
28	phases	phase	NNS	_	24	nmod
29	1	1	CD	_	28	dep
30	and	and	CC	_	29	cc
31	3	3	CD	_	29	conj
32	.	.	.	_	4	punct

1	Blood	blood	NN	_	2	compound
2	samples	sample	NNS	_	5	nsubjpass
3	also	also	RB	_	5	advmod
4	were	be	VBD	_	5	auxpass
5	taken	take	VBN	_	0	ROOT
6	before	before	IN	_	8	case
7	morning	morning	NN	_	8	compound
8	doses	dose	NNS	_	5	nmod
9	on	on	IN	_	17	case
10	the	the	DT	_	17	det
11	3rd	3rd	JJ	_	17	amod
12	,	,	,	_	11	punct
13	4th	4th	JJ	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	5th	5th	JJ	_	11	conj
17	days	day	NNS	_	5	nmod
18	of	of	IN	_	19	case
19	phases	phase	NNS	_	17	nmod
20	1	1	CD	_	19	dep
21	and	and	CC	_	20	cc
22	3	3	CD	_	20	conj
23	.	.	.	_	5	punct

1	Electrocardiograms	electrocardiogram	NNS	_	3	nsubjpass
2	were	be	VBD	_	3	auxpass
3	done	do	VBN	_	0	ROOT
4	at	at	IN	_	5	case
5	baseline	baseline	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	last	last	JJ	_	10	amod
10	day	day	NN	_	5	conj
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	washout	washout	NN	_	14	compound
14	period	period	NN	_	10	nmod
15	and	and	CC	_	5	cc
16	phase	phase	NN	_	5	conj
17	2	2	CD	_	16	nummod
18	.	.	.	_	3	punct

1	Coadministration	coadministration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	fluoxetine	fluoxetine	NN	_	1	nmod
4	significantly	significantly	RB	_	5	advmod
5	decreased	decrease	VBD	_	0	ROOT
6	cisapride	cisapride	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	5	dobj
9	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	changes	change	NNS	_	2	nsubj
7	in	in	IN	_	10	case
8	corrected	correct	VBN	_	10	amod
9	QT	qt	NN	_	10	compound
10	intervals	interval	NNS	_	6	nmod
11	during	during	IN	_	12	case
12	administration	administration	NN	_	2	nmod
13	of	of	IN	_	14	case
14	cisapride	cisapride	NN	_	12	nmod
15	alone	alone	RB	_	14	advmod
16	or	or	CC	_	14	cc
17	with	with	IN	_	18	case
18	fluoxetine	fluoxetine	NN	_	14	conj
19	.	.	.	_	2	punct

1	Cisapride	Cisapride	NNP	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	well	well	RB	_	4	advmod
4	tolerated	tolerate	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administered	administer	VBN	_	4	advcl
7	alone	alone	RB	_	6	advmod
8	or	or	CC	_	6	cc
9	with	with	IN	_	10	case
10	fluoxetine	fluoxetine	NN	_	6	conj
11	.	.	.	_	4	punct

1	CONCLUSION	conclusion	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Cisapride	Cisapride	NNP	_	6	nsubjpass
4	can	can	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	1	dep
7	safely	safely	RB	_	6	advmod
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	low	low	JJ	_	13	amod
12	therapeutic	therapeutic	JJ	_	13	amod
13	dosages	dosage	NNS	_	10	dobj
14	of	of	IN	_	15	case
15	fluoxetine	fluoxetine	NN	_	13	nmod
16	.	.	.	_	1	punct

1	Activity	activity	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	buforin	buforin	NN	_	1	nmod
4	II	ii	CD	_	3	nummod
5	alone	alone	RB	_	3	advmod
6	and	and	CC	_	1	cc
7	in	in	IN	_	8	case
8	combination	combination	NN	_	1	conj
9	with	with	IN	_	10	case
10	azithromycin	azithromycin	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	minocycline	minocycline	NN	_	10	conj
13	against	against	IN	_	15	case
14	Cryptosporidium	cryptosporidium	NN	_	15	compound
15	parvum	parvum	NN	_	10	nmod
16	in	in	IN	_	18	case
17	cell	cell	NN	_	18	compound
18	culture	culture	NN	_	15	nmod
19	.	.	.	_	1	punct

1	The	the	DT	_	20	dep
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	anti	anti	JJ	_	20	nsubjpass
5	-	-	:	_	4	punct
6	cryptosporidial	cryptosporidial	JJ	_	7	amod
7	activity	activity	NN	_	4	conj
8	of	of	IN	_	9	case
9	buforin	buforin	NN	_	7	nmod
10	II	ii	CD	_	9	nummod
11	alone	alone	RB	_	9	advmod
12	and	and	CC	_	4	cc
13	in	in	IN	_	14	case
14	combination	combination	NN	_	4	conj
15	with	with	IN	_	16	case
16	azithromycin	azithromycin	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	minocycline	minocycline	NN	_	16	conj
19	was	be	VBD	_	20	auxpass
20	investigated	investigate	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	Buforin	Buforin	NNP	_	2	compound
2	II	II	NNP	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	moderate	moderate	JJ	_	5	amod
5	activity	activity	NN	_	3	dobj
6	,	,	,	_	5	punct
7	which	which	WDT	_	8	nsubj
8	increased	increase	VBD	_	5	acl:relcl
9	with	with	IN	_	11	case
10	increasing	increase	VBG	_	11	amod
11	concentration	concentration	NN	_	8	nmod
12	to	to	TO	_	15	case
13	55.7	55.7	CD	_	14	compound
14	%	%	NN	_	15	amod
15	suppression	suppression	NN	_	8	nmod
16	of	of	IN	_	17	case
17	growth	growth	NN	_	15	nmod
18	at	at	IN	_	20	case
19	20	20	CD	_	20	nummod
20	microM	microm	NN	_	8	nmod
21	.	.	.	_	3	punct

1	Moreover	moreover	RB	_	6	advmod
2	,	,	,	_	6	punct
3	its	its	PRP$	_	4	nmod:poss
4	activity	activity	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	enhanced	enhance	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	it	it	PRP	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	combined	combine	VBN	_	6	advcl
11	with	with	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	azithromycin	azithromycin	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	minocycline	minocycline	NN	_	13	conj
16	with	with	IN	_	20	case
17	90	90	CD	_	18	compound
18	%	%	NN	_	20	amod
19	parasite	parasite	JJ	_	20	amod
20	reduction	reduction	NN	_	10	nmod
21	at	at	IN	_	24	case
22	the	the	DT	_	24	det
23	highest	highest	JJS	_	24	amod
24	concentration	concentration	NN	_	20	nmod
25	tested	test	VBN	_	24	acl
26	.	.	.	_	6	punct

1	Buforin	Buforin	NNP	_	2	compound
2	II	II	NNP	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	active	active	JJ	_	0	ROOT
6	in	in	IN	_	7	mark
7	inhibiting	inhibit	VBG	_	5	advcl
8	Cryptosporidium	cryptosporidium	NN	_	10	compound
9	parvum	parvum	NN	_	10	compound
10	growth	growth	NN	_	7	dobj
11	in	in	FW	_	12	compound
12	vitro	vitro	FW	_	7	advmod
13	upon	upon	IN	_	14	case
14	combination	combination	NN	_	7	nmod
15	with	with	IN	_	17	case
16	either	either	CC	_	17	cc:preconj
17	azithromycin	azithromycin	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	minocycline	minocycline	NN	_	17	conj
20	.	.	.	_	5	punct

1	Modification	modification	NN	_	6	nsubj
2	of	of	IN	_	5	case
3	surface	surface	NN	_	5	compound
4	histidine	histidine	NN	_	5	compound
5	residues	residue	NNS	_	1	nmod
6	abolishes	abolish	VBZ	_	0	ROOT
7	the	the	DT	_	9	det
8	cytotoxic	cytotoxic	JJ	_	9	amod
9	activity	activity	NN	_	6	dobj
10	of	of	IN	_	14	case
11	Clostridium	Clostridium	NNP	_	14	compound
12	difficile	difficile	NN	_	14	compound
13	toxin	toxin	NN	_	14	compound
14	A	a	NN	_	9	nmod
15	.	.	.	_	6	punct

1	Clostridium	clostridium	NN	_	4	compound
2	difficile	difficile	NN	_	4	compound
3	toxin	toxin	NN	_	4	compound
4	A	a	NN	_	5	nsubj
5	displays	display	VBZ	_	0	ROOT
6	both	both	CC	_	7	cc:preconj
7	cytotoxic	cytotoxic	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	enterotoxic	enterotoxic	JJ	_	7	conj
10	activities	activity	NNS	_	5	dobj
11	.	.	.	_	5	punct

1	It	it	PRP	_	5	nsubjpass
2	has	have	VBZ	_	5	aux
3	recently	recently	RB	_	5	advmod
4	been	be	VBN	_	5	auxpass
5	demonstrated	demonstrate	VBN	_	0	ROOT
6	that	that	IN	_	9	mark
7	toxin	toxin	NN	_	8	compound
8	A	a	NN	_	9	nsubj
9	exerts	exert	VBZ	_	5	ccomp
10	its	its	PRP$	_	12	nmod:poss
11	cytotoxic	cytotoxic	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	by	by	IN	_	15	case
14	the	the	DT	_	15	det
15	glucosylation	glucosylation	NN	_	9	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	small	small	JJ	_	19	amod
19	GTP	gtp	NN	_	15	nmod
20	-	-	:	_	19	punct
21	binding	binding	NN	_	22	compound
22	proteins	protein	NNS	_	19	dep
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	Rho	rho	NN	_	26	compound
26	family	family	NN	_	19	nmod
27	.	.	.	_	5	punct

1	Diethyl	diethyl	NN	_	2	compound
2	pyrocarbonate	pyrocarbonate	NN	_	9	nsubjpass
3	,	,	,	_	2	punct
4	at	at	IN	_	5	case
5	pH	ph	NN	_	2	nmod
6	7.0	7.0	CD	_	5	nummod
7	,	,	,	_	2	punct
8	was	be	VBD	_	9	auxpass
9	used	use	VBN	_	0	ROOT
10	to	to	TO	_	12	mark
11	chemically	chemically	RB	_	12	advmod
12	modify	modify	VB	_	9	xcomp
13	exposed	expose	VBN	_	15	amod
14	histidine	histidine	NN	_	15	compound
15	residues	residue	NNS	_	12	dobj
16	on	on	IN	_	18	case
17	toxin	toxin	NN	_	18	compound
18	A	a	NN	_	12	nmod
19	.	.	.	_	9	punct

1	Modification	modification	NN	_	8	nsubj
2	of	of	IN	_	4	case
3	toxin	toxin	NN	_	4	compound
4	A	a	NN	_	1	nmod
5	with	with	IN	_	7	case
6	diethyl	diethyl	NN	_	7	compound
7	pyrocarbonate	pyrocarbonate	NN	_	1	nmod
8	abolished	abolish	VBD	_	0	ROOT
9	both	both	CC	_	12	cc:preconj
10	its	its	PRP$	_	12	nmod:poss
11	cytotoxic	cytotoxic	JJ	_	12	amod
12	activity	activity	NN	_	8	dobj
13	and	and	CC	_	12	cc
14	the	the	DT	_	15	det
15	ability	ability	NN	_	12	conj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	toxin	toxin	NN	_	15	nmod
19	to	to	TO	_	20	mark
20	bind	bind	VB	_	15	acl
21	Zn	zn	NN	_	20	dobj
22	-	-	:	_	21	punct
23	Sepharose	sepharose	NN	_	24	compound
24	gel	gel	NN	_	21	dep
25	.	.	.	_	8	punct

1	Treatment	treatment	NN	_	15	nsubj
2	of	of	IN	_	4	case
3	toxin	toxin	NN	_	4	compound
4	A	a	NN	_	1	nmod
5	with	with	IN	_	10	case
6	[	[	CD	_	8	compound
7	(	(	CD	_	8	compound
8	14	14	CD	_	10	nummod
9	)	)	NN	_	10	compound
10	C	c	NN	_	15	nmod
11	]	]	SYM	_	15	dep
12	-	-	:	_	15	punct
13	diethyl	diethyl	NN	_	14	compound
14	pyrocarbonate	pyrocarbonate	NN	_	15	nsubj
15	revealed	reveal	VBD	_	0	ROOT
16	concentration	concentration	NN	_	17	nmod:npmod
17	dependent	dependent	JJ	_	18	amod
18	labelling	labelling	NN	_	15	dobj
19	of	of	IN	_	21	case
20	histidine	histidine	NN	_	21	compound
21	residues	residue	NNS	_	18	nmod
22	on	on	IN	_	25	case
23	the	the	DT	_	25	det
24	toxin	toxin	NN	_	25	compound
25	molecules	molecule	NNS	_	18	nmod
26	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	8	nsubjpass
3	of	of	IN	_	5	case
4	diethyl	diethyl	NN	_	5	compound
5	pyrocarbonate	pyrocarbonate	NN	_	2	nmod
6	could	could	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	reversed	reverse	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	hydroxylamine	hydroxylamine	NN	_	11	compound
11	treatment	treatment	NN	_	8	nmod
12	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	the	the	DT	_	7	det
5	modified	modify	VBN	_	7	amod
6	histidine	histidine	NN	_	7	compound
7	residues	residue	NNS	_	12	nsubj
8	on	on	IN	_	10	case
9	toxin	toxin	NN	_	10	compound
10	A	a	NN	_	7	nmod
11	are	be	VBP	_	12	cop
12	critical	critical	JJ	_	3	ccomp
13	to	to	TO	_	16	case
14	its	its	PRP$	_	16	nmod:poss
15	cytotoxic	cytotoxic	JJ	_	16	amod
16	activity	activity	NN	_	12	nmod
17	.	.	.	_	3	punct

1	Histidine	histidine	NN	_	2	compound
2	modification	modification	NN	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	dobj
6	on	on	IN	_	11	case
7	the	the	DT	_	11	det
8	glucosyl	glucosyl	NN	_	11	compound
9	transferase	transferase	NN	_	11	compound
10	enzyme	enzyme	NN	_	11	compound
11	activity	activity	NN	_	3	nmod
12	of	of	IN	_	14	case
13	toxin	toxin	NN	_	14	compound
14	A	a	NN	_	11	nmod
15	.	.	.	_	3	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	modification	modification	NN	_	4	nsubj
4	abolished	abolish	VBD	_	0	ROOT
5	the	the	DT	_	9	det
6	'	'	''	_	9	punct
7	cold	cold	JJ	_	9	amod
8	'	'	''	_	9	punct
9	binding	binding	NN	_	4	dobj
10	of	of	IN	_	11	case
11	toxin	toxin	NN	_	9	nmod
12	to	to	TO	_	14	case
13	bovine	bovine	JJ	_	14	amod
14	thyroglobulin	thyroglobulin	NN	_	9	nmod
15	in	in	IN	_	17	case
16	an	a	DT	_	17	det
17	ELISA	elisa	NN	_	9	nmod
18	and	and	CC	_	4	cc
19	reduced	reduce	VBD	_	4	conj
20	ligand	ligand	NN	_	22	compound
21	binding	binding	NN	_	22	compound
22	activity	activity	NN	_	19	dobj
23	in	in	IN	_	28	case
24	a	a	DT	_	28	det
25	rabbit	rabbit	NN	_	28	compound
26	erythrocyte	erythrocyte	NN	_	28	compound
27	haemagglutination	haemagglutination	NN	_	28	compound
28	assay	assay	NN	_	19	nmod
29	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	the	the	DT	_	7	det
6	histidine	histidine	NN	_	7	compound
7	residues	residue	NNS	_	10	nsubj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	cop
10	crucial	crucial	JJ	_	3	ccomp
11	to	to	TO	_	13	case
12	the	the	DT	_	13	det
13	receptor	receptor	NN	_	10	nmod
14	-	-	:	_	13	punct
15	binding	binding	NN	_	16	compound
16	activity	activity	NN	_	13	dep
17	of	of	IN	_	19	case
18	toxin	toxin	NN	_	19	compound
19	A	a	NN	_	16	nmod
20	.	.	.	_	3	punct

1	Exposed	expose	VBN	_	2	amod
2	histidines	histidine	NNS	_	7	nsubj
3	on	on	IN	_	5	case
4	toxin	toxin	NN	_	5	compound
5	A	a	NN	_	2	nmod
6	are	be	VBP	_	7	cop
7	available	available	JJ	_	0	ROOT
8	for	for	IN	_	10	case
9	zinc	zinc	NN	_	10	compound
10	chelation	chelation	NN	_	7	nmod
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	these	these	DT	_	16	nsubjpass
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	exploited	exploit	VBN	_	7	conj
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	development	development	NN	_	16	nmod
20	of	of	IN	_	24	case
21	a	a	DT	_	24	det
22	novel	novel	JJ	_	24	amod
23	purification	purification	NN	_	24	compound
24	protocol	protocol	NN	_	19	nmod
25	for	for	IN	_	27	case
26	toxin	toxin	NN	_	27	compound
27	A	a	NN	_	24	nmod
28	using	use	VBG	_	27	acl
29	zinc	zinc	NN	_	28	dobj
30	-	-	:	_	16	punct
31	chelating	chelate	VBG	_	16	xcomp
32	chromatography	chromatography	NN	_	31	dobj
33	.	.	.	_	7	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	clindamycin	clindamycin	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	gentamicin	gentamicin	NN	_	3	conj
6	in	in	FW	_	7	compound
7	vitro	vitro	FW	_	1	advmod
8	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	minimal	minimal	JJ	_	4	amod
3	inhibitory	inhibitory	JJ	_	4	amod
4	concentrations	concentration	NNS	_	14	nsubjpass
5	of	of	IN	_	6	case
6	clindamycin	clindamycin	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	gentamicin	gentamicin	NN	_	6	conj
9	alone	alone	RB	_	6	advmod
10	and	and	CC	_	6	cc
11	in	in	IN	_	12	case
12	combinations	combination	NNS	_	6	conj
13	were	be	VBD	_	14	auxpass
14	determined	determine	VBN	_	0	ROOT
15	by	by	IN	_	18	case
16	a	a	DT	_	18	det
17	microdilution	microdilution	NN	_	18	compound
18	method	method	NN	_	14	nmod
19	for	for	IN	_	28	case
20	163	163	CD	_	28	nummod
21	aerobic	aerobic	JJ	_	28	amod
22	,	,	,	_	21	punct
23	facultative	facultative	JJ	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	anaerobic	anaerobic	JJ	_	21	conj
27	clinical	clinical	JJ	_	28	amod
28	isolates	isolate	NNS	_	18	nmod
29	.	.	.	_	14	punct

1	All	all	DT	_	3	det
2	77	77	CD	_	3	nummod
3	strains	strain	NNS	_	17	nsubj
4	of	of	IN	_	6	case
5	Staphylococcus	staphylococcus	FW	_	6	compound
6	aureus	aureus	FW	_	3	nmod
7	,	,	,	_	3	punct
8	Diplococcus	diplococcus	NN	_	9	compound
9	pneumoniae	pneumoniae	FW	_	3	appos
10	,	,	,	_	9	punct
11	Streptococcus	streptococcus	NN	_	12	compound
12	pyogenes	pyogene	NNS	_	9	conj
13	,	,	,	_	9	punct
14	and	and	CC	_	9	cc
15	anaerobic	anaerobic	JJ	_	16	amod
16	bacteria	bacterium	NNS	_	9	conj
17	(	(	VBP	_	26	csubjpass
18	except	except	IN	_	21	case
19	for	for	IN	_	21	case
20	three	three	CD	_	21	nummod
21	strains	strain	NNS	_	17	nmod
22	of	of	IN	_	24	case
23	Clostridium	clostridium	NN	_	24	compound
24	)	)	NN	_	21	nmod
25	were	be	VBD	_	26	auxpass
26	inhibited	inhibit	VBN	_	0	ROOT
27	by	by	IN	_	29	case
28	1.6	1.6	CD	_	29	nummod
29	mug	mug	NN	_	26	nmod
30	or	or	CC	_	29	cc
31	less	less	JJR	_	29	conj
32	of	of	IN	_	33	case
33	clindamycin	clindamycin	NN	_	31	nmod
34	per	per	IN	_	35	case
35	ml	ml	NN	_	33	nmod
36	.	.	.	_	26	punct

1	Gentamicin	gentamicin	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	activity	activity	NN	_	4	nmod
8	of	of	IN	_	9	case
9	clindamycin	clindamycin	NN	_	7	nmod
10	within	within	IN	_	12	case
11	the	the	DT	_	12	det
12	range	range	NN	_	7	nmod
13	of	of	IN	_	14	case
14	concentrations	concentration	NNS	_	12	nmod
15	tested	test	VBN	_	14	acl
16	(	(	CD	_	19	compound
17	0.1	0.1	CD	_	19	compound
18	to	to	TO	_	19	dep
19	100	100	CD	_	20	nummod
20	mug	mug	NN	_	15	dobj
21	/	/	:	_	20	punct
22	ml	ml	NN	_	23	compound
23	)	)	NN	_	20	dep
24	;	;	:	_	4	punct

1	for	for	IN	_	4	case
2	some	some	DT	_	4	det
3	strains	strain	NNS	_	4	compound
4	combinations	combination	NNS	_	6	nmod
5	were	be	VBD	_	6	cop
6	synergistic	synergistic	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	Sixty	sixty	CD	_	0	ROOT
2	-	-	:	_	1	punct
3	two	two	CD	_	6	nummod
4	(	(	CD	_	5	compound
5	94	94	CD	_	6	nummod
6	%	%	NN	_	1	dep
7	)	)	CD	_	9	compound
8	of	of	IN	_	9	advmod
9	66	66	CD	_	10	nummod
10	strains	strain	NNS	_	17	nsubjpass
11	of	of	IN	_	12	case
12	Enterobacteriaceae	Enterobacteriaceae	NNP	_	10	nmod
13	and	and	CC	_	12	cc
14	Pseudomonas	pseudomonas	FW	_	15	compound
15	aeruginosa	aeruginosa	FW	_	12	conj
16	were	be	VBD	_	17	auxpass
17	inhibited	inhibit	VBN	_	6	acl:relcl
18	by	by	IN	_	20	case
19	6.2	6.2	CD	_	20	nummod
20	mug	mug	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	less	less	JJR	_	20	conj
23	of	of	IN	_	24	case
24	gentamicin	gentamicin	NN	_	22	nmod
25	per	per	IN	_	26	case
26	ml	ml	NN	_	24	nmod
27	.	.	.	_	1	punct

1	Combinations	combination	NNS	_	7	nsubj
2	of	of	IN	_	3	case
3	clindamycin	clindamycin	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	gentamicin	gentamicin	NN	_	3	conj
6	were	be	VBD	_	7	cop
7	indifferent	indifferent	JJ	_	0	ROOT
8	for	for	IN	_	10	case
9	29	29	CD	_	10	nummod
10	strains	strain	NNS	_	7	nmod
11	and	and	CC	_	10	cc
12	synergistic	synergistic	JJ	_	10	conj
13	for	for	IN	_	15	case
14	33	33	CD	_	15	nummod
15	strains	strain	NNS	_	12	nmod
16	.	.	.	_	7	punct

1	All	all	DT	_	3	det
2	20	20	CD	_	3	nummod
3	strains	strain	NNS	_	25	nsubj
4	of	of	IN	_	5	case
5	enterococcus	enterococcus	NN	_	3	nmod
6	,	,	,	_	3	punct
7	three	three	CD	_	8	nummod
8	strains	strain	NNS	_	3	conj
9	of	of	IN	_	10	case
10	Clostridium	Clostridium	NNP	_	8	nmod
11	,	,	,	_	3	punct
12	three	three	CD	_	13	nummod
13	strains	strain	NNS	_	3	conj
14	of	of	IN	_	16	case
15	Escherichia	escherichia	FW	_	16	compound
16	coli	coli	FW	_	13	nmod
17	,	,	,	_	3	punct
18	and	and	CC	_	3	cc
19	one	one	CD	_	20	nummod
20	strain	strain	NN	_	3	conj
21	of	of	IN	_	23	case
22	Proteus	Proteus	NNP	_	23	compound
23	rettgeri	rettgeri	NN	_	20	nmod
24	were	be	VBD	_	25	cop
25	resistant	resistant	JJ	_	0	ROOT
26	to	to	TO	_	32	case
27	both	both	DT	_	32	det
28	clindamycin	clindamycin	NN	_	32	compound
29	(	(	NN	_	32	compound
30	minimal	minimal	JJ	_	32	amod
31	inhibitory	inhibitory	JJ	_	32	amod
32	concentration	concentration	NN	_	25	nmod
33	greater	greater	JJR	_	32	amod
34	than	than	IN	_	36	case
35	3.1	3.1	CD	_	36	nummod
36	mug	mug	NN	_	33	nmod
37	/	/	:	_	32	punct
38	ml	ml	NN	_	39	compound
39	)	)	NN	_	32	dep
40	and	and	CC	_	39	cc
41	gentamicin	gentamicin	NN	_	45	compound
42	(	(	CD	_	45	nummod
43	minimal	minimal	JJ	_	45	amod
44	inhibitory	inhibitory	JJ	_	45	amod
45	concentration	concentration	NN	_	39	conj
46	greater	greater	JJR	_	32	amod
47	than	than	IN	_	49	case
48	6.2	6.2	CD	_	49	nummod
49	mug	mug	NN	_	46	nmod
50	/	/	:	_	25	punct
51	ml	ml	NN	_	52	compound
52	)	)	NN	_	25	dep
53	.	.	.	_	25	punct

1	Combinations	combination	NNS	_	7	nsubj
2	of	of	IN	_	3	case
3	clindamycin	clindamycin	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	gentamicin	gentamicin	NN	_	3	conj
6	were	be	VBD	_	7	cop
7	indifferent	indifferent	JJ	_	0	ROOT
8	for	for	IN	_	9	case
9	16	16	CD	_	7	nmod
10	and	and	CC	_	7	cc
11	synergistic	synergistic	JJ	_	7	conj
12	for	for	IN	_	13	case
13	11	11	CD	_	11	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	resistant	resistant	JJ	_	17	amod
17	strains	strain	NNS	_	13	nmod
18	.	.	.	_	7	punct

1	Except	except	IN	_	3	case
2	for	for	IN	_	3	case
3	clindamycin	clindamycin	NN	_	11	nmod
4	-	-	:	_	3	punct
5	sensitive	sensitive	JJ	_	6	amod
6	isolates	isolate	NNS	_	3	dep
7	,	,	,	_	11	punct
8	synergy	synergy	NN	_	11	nsubjpass
9	was	be	VBD	_	11	auxpass
10	usually	usually	RB	_	11	advmod
11	observed	observe	VBN	_	0	ROOT
12	only	only	RB	_	14	advmod
13	at	at	IN	_	14	case
14	concentrations	concentration	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	one	one	CD	_	14	nmod
17	or	or	CC	_	16	cc
18	both	both	DT	_	16	conj
19	drugs	drug	NNS	_	16	dep
20	which	which	WDT	_	24	nsubj
21	are	be	VBP	_	24	cop
22	not	not	RB	_	24	neg
23	readily	readily	RB	_	24	advmod
24	obtainable	obtainable	JJ	_	16	acl:relcl
25	in	in	FW	_	26	compound
26	vivo	vivo	FW	_	24	advmod
27	.	.	.	_	11	punct

1	Antagonism	antagonism	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	never	never	RB	_	4	neg
4	observed	observe	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	Ascorbic	ascorbic	JJ	_	2	amod
2	acid	acid	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	the	the	DT	_	6	det
5	common	common	JJ	_	6	amod
6	cold	cold	NN	_	2	conj
7	.	.	.	_	2	punct

1	Evaluation	evaluation	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	its	its	PRP$	_	4	nmod:poss
4	efficacy	efficacy	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	toxicity	toxicity	NN	_	4	conj
7	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	reviewed	review	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	data	datum	NNS	_	2	dobj
6	relating	relate	VBG	_	5	acl
7	to	to	TO	_	9	case
8	the	the	DT	_	9	det
9	efficacy	efficacy	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	safety	safety	NN	_	9	conj
12	of	of	IN	_	14	case
13	pharmacologic	pharmacologic	JJ	_	14	amod
14	doses	dose	NNS	_	9	nmod
15	of	of	IN	_	17	case
16	ascorbic	ascorbic	JJ	_	17	amod
17	acid	acid	NN	_	14	nmod
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	prevention	prevention	NN	_	9	nmod
21	and	and	CC	_	20	cc
22	treatment	treatment	NN	_	20	conj
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	common	common	JJ	_	26	amod
26	cold	cold	NN	_	20	nmod
27	.	.	.	_	2	punct

1	Although	although	IN	_	5	mark
2	one	one	CD	_	3	nummod
3	study	study	NN	_	5	nsubj
4	tentatively	tentatively	RB	_	5	advmod
5	supports	support	VBZ	_	0	ROOT
6	the	the	DT	_	7	det
7	hypothesis	hypothesis	NN	_	5	dobj
8	that	that	IN	_	16	mark
9	such	such	JJ	_	10	amod
10	doses	dose	NNS	_	16	nsubj
11	of	of	IN	_	13	case
12	ascorbic	ascorbic	JJ	_	13	amod
13	acid	acid	NN	_	10	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	cop
16	efficacious	efficacious	JJ	_	7	ccomp
17	,	,	,	_	16	punct
18	a	a	DT	_	20	det
19	second	second	JJ	_	20	amod
20	study	study	NN	_	27	nsubj
21	by	by	IN	_	24	case
22	the	the	DT	_	24	det
23	same	same	JJ	_	24	amod
24	group	group	NN	_	20	nmod
25	did	do	VBD	_	27	aux
26	not	not	RB	_	27	neg
27	confirm	confirm	VB	_	16	ccomp
28	the	the	DT	_	30	det
29	significant	significant	JJ	_	30	amod
30	findings	finding	NNS	_	27	dobj
31	,	,	,	_	16	punct
32	and	and	CC	_	16	cc
33	no	no	DT	_	37	neg
34	clear	clear	JJ	_	37	amod
35	,	,	,	_	37	punct
36	reproducible	reproducible	JJ	_	37	amod
37	pattern	pattern	NN	_	41	nsubj
38	of	of	IN	_	39	case
39	efficacy	efficacy	NN	_	37	nmod
40	has	have	VBZ	_	41	aux
41	emerged	emerge	VBN	_	16	conj
42	from	from	IN	_	44	case
43	the	the	DT	_	44	det
44	review	review	NN	_	41	nmod
45	of	of	IN	_	48	case
46	all	all	PDT	_	48	det:predet
47	the	the	DT	_	48	det
48	evidence	evidence	NN	_	44	nmod
49	.	.	.	_	5	punct

1	Similarly	similarly	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	is	be	VBZ	_	0	ROOT
5	currently	currently	RB	_	8	advmod
6	little	little	JJ	_	8	amod
7	adequate	adequate	JJ	_	8	amod
8	evidence	evidence	NN	_	4	nsubj
9	on	on	IN	_	12	case
10	either	either	CC	_	12	cc:preconj
11	the	the	DT	_	12	det
12	presence	presence	NN	_	8	nmod
13	or	or	CC	_	12	cc
14	the	the	DT	_	15	det
15	absence	absence	NN	_	12	conj
16	of	of	IN	_	19	case
17	serious	serious	JJ	_	19	amod
18	adverse	adverse	JJ	_	19	amod
19	reactions	reaction	NNS	_	15	nmod
20	to	to	TO	_	22	case
21	such	such	JJ	_	22	amod
22	doses	dose	NNS	_	19	nmod
23	of	of	IN	_	25	case
24	ascorbic	ascorbic	JJ	_	25	amod
25	acid	acid	NN	_	22	nmod
26	,	,	,	_	8	punct
27	although	although	IN	_	33	mark
28	many	many	JJ	_	30	amod
29	such	such	JJ	_	30	amod
30	reactions	reaction	NNS	_	33	nsubjpass
31	have	have	VBP	_	33	aux
32	been	be	VBN	_	33	auxpass
33	hypothesized	hypothesize	VBN	_	8	advcl
34	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	unrestricted	unrestricted	JJ	_	3	amod
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	6	case
5	ascorbic	ascorbic	JJ	_	6	amod
6	acid	acid	NN	_	3	nmod
7	for	for	IN	_	9	case
8	these	these	DT	_	9	det
9	purposes	purpose	NNS	_	3	nmod
10	cannot	cannot	VBP	_	12	aux
11	be	be	VB	_	12	auxpass
12	advocated	advocate	VBN	_	0	ROOT
13	on	on	IN	_	15	case
14	the	the	DT	_	15	det
15	basis	basis	NN	_	12	nmod
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	evidence	evidence	NN	_	15	nmod
19	currently	currently	RB	_	20	advmod
20	available	available	JJ	_	18	amod
21	.	.	.	_	12	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	xanthine	xanthine	NN	_	4	compound
4	derivatives	derivative	NNS	_	1	nmod
5	in	in	IN	_	10	case
6	a	a	DT	_	10	det
7	light	light	JJ	_	10	amod
8	/	/	:	_	10	punct
9	dark	dark	JJ	_	10	amod
10	test	test	NN	_	1	nmod
11	in	in	IN	_	12	case
12	mice	mouse	NNS	_	10	nmod
13	and	and	CC	_	1	cc
14	the	the	DT	_	15	det
15	contribution	contribution	NN	_	1	conj
16	of	of	IN	_	18	case
17	adenosine	adenosine	NN	_	18	compound
18	receptors	receptor	NNS	_	15	nmod
19	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	investigated	investigate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	8	case
6	adenosine	adenosine	NN	_	8	compound
7	receptor	receptor	NN	_	8	compound
8	antagonists	antagonist	NNS	_	4	nmod
9	,	,	,	_	8	punct
10	caffeine	caffeine	NN	_	8	conj
11	,	,	,	_	8	punct
12	theophylline	theophylline	NN	_	8	conj
13	,	,	,	_	8	punct
14	8	8	CD	_	16	nummod
15	-	-	:	_	16	punct
16	phenyltheophylline	phenyltheophylline	NN	_	8	conj
17	,	,	,	_	8	punct
18	and	and	CC	_	8	cc
19	8	8	CD	_	21	nummod
20	-	-	:	_	21	punct
21	cyclopentyl	cyclopentyl	NN	_	8	conj
22	-	-	:	_	21	punct
23	1,3	1,3	SYM	_	21	dep
24	-	-	:	_	21	punct
25	dipropylxanthine	dipropylxanthine	NN	_	27	compound
26	(	(	CD	_	27	nummod
27	DPCPX	DPCPX	NNP	_	21	dep
28	)	)	CD	_	27	nummod
29	,	,	,	_	4	punct
30	in	in	IN	_	35	case
31	a	a	DT	_	35	det
32	light	light	JJ	_	35	amod
33	/	/	:	_	35	punct
34	dark	dark	JJ	_	35	amod
35	test	test	NN	_	4	nmod
36	in	in	IN	_	37	case
37	mice	mouse	NNS	_	35	nmod
38	.	.	.	_	2	punct

1	All	all	DT	_	2	det
2	antagonists	antagonist	NNS	_	3	nsubj
3	decreased	decrease	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	time	time	NN	_	3	dobj
6	spent	spend	VBN	_	5	acl
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	light	light	JJ	_	10	amod
10	zone	zone	NN	_	6	nmod
11	in	in	IN	_	13	case
12	this	this	DT	_	13	det
13	test	test	NN	_	6	nmod
14	,	,	,	_	5	punct
15	which	which	WDT	_	16	nsubj
16	suggested	suggest	VBD	_	5	acl:relcl
17	that	that	IN	_	20	mark
18	these	these	DT	_	19	det
19	compounds	compound	NNS	_	20	nsubj
20	have	have	VBP	_	16	ccomp
21	anxiogenic	anxiogenic	JJ	_	22	amod
22	effects	effect	NNS	_	20	dobj
23	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	anxiogenic	anxiogenic	JJ	_	3	amod
3	effects	effect	NNS	_	7	nsubjpass
4	of	of	IN	_	5	case
5	theophylline	theophylline	NN	_	3	nmod
6	were	be	VBD	_	7	auxpass
7	reduced	reduce	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	pretreatment	pretreatment	NN	_	7	nmod
10	with	with	IN	_	11	case
11	CGS	cgs	NN	_	9	nmod
12	21680	21680	CD	_	11	nummod
13	,	,	,	_	11	punct
14	an	a	DT	_	18	det
15	A2	a2	NN	_	18	compound
16	-	-	:	_	18	punct
17	selective	selective	JJ	_	18	amod
18	agonist	agonist	NN	_	11	appos
19	,	,	,	_	11	punct
20	but	but	CC	_	11	cc
21	not	not	RB	_	23	neg
22	by	by	IN	_	23	case
23	N6	n6	NN	_	11	conj
24	-	-	:	_	23	punct
25	cyclopentyladenosine	cyclopentyladenosine	NN	_	27	compound
26	(	(	CD	_	27	nummod
27	CPA	CPA	NNP	_	23	dep
28	)	)	CD	_	27	nummod
29	,	,	,	_	27	punct
30	an	a	DT	_	34	det
31	A1	a1	NN	_	34	compound
32	-	-	:	_	34	punct
33	selective	selective	JJ	_	34	amod
34	agonist	agonist	NN	_	27	appos
35	.	.	.	_	7	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	the	the	DT	_	4	det
4	antagonism	antagonism	NN	_	16	nsubjpass
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	theophylline	theophylline	NN	_	4	nmod
8	-	-	:	_	7	punct
9	induced	induce	VBN	_	11	amod
10	anxiogenic	anxiogenic	JJ	_	11	amod
11	effects	effect	NNS	_	7	dep
12	by	by	IN	_	13	case
13	CGS21680	cgs21680	NN	_	11	nmod
14	was	be	VBD	_	16	auxpass
15	only	only	RB	_	16	advmod
16	observed	observe	VBN	_	0	ROOT
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	time	time	NN	_	16	nmod
20	spent	spend	VBN	_	19	acl
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	light	light	JJ	_	24	amod
24	zone	zone	NN	_	20	nmod
25	,	,	,	_	16	punct
26	and	and	CC	_	16	cc
27	DPCPX	DPCPX	NNP	_	34	dep
28	-	-	:	_	34	punct
29	induced	induce	VBD	_	31	amod
30	anxiogenic	anxiogenic	JJ	_	31	amod
31	effects	effect	NNS	_	34	nsubjpass
32	were	be	VBD	_	34	auxpass
33	neither	neither	DT	_	34	dep
34	reversed	reverse	VBN	_	16	conj
35	by	by	IN	_	36	case
36	CGS	CGS	NNP	_	34	nmod
37	21680	21680	CD	_	36	nummod
38	nor	nor	CC	_	36	cc
39	by	by	IN	_	40	case
40	CPA	CPA	NNP	_	36	conj
41	.	.	.	_	16	punct

1	Finally	finally	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	notable	notable	JJ	_	0	ROOT
6	that	that	IN	_	5	dep
7	xanthine	xanthine	NN	_	6	root
8	-	-	:	_	7	punct
9	derived	derive	VBN	_	11	amod
10	adenosine	adenosine	NN	_	11	compound
11	antagonists	antagonist	NNS	_	15	nsubj
12	tested	test	VBN	_	11	acl
13	here	here	RB	_	12	advmod
14	commonly	commonly	RB	_	15	advmod
15	showed	show	VBD	_	7	dep
16	anxiogenic	anxiogenic	JJ	_	17	amod
17	effects	effect	NNS	_	15	dobj
18	in	in	IN	_	23	case
19	the	the	DT	_	23	det
20	light	light	JJ	_	23	amod
21	/	/	:	_	23	punct
22	dark	dark	JJ	_	23	amod
23	test	test	NN	_	17	nmod
24	in	in	IN	_	25	case
25	mice	mouse	NNS	_	23	nmod
26	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	suggested	suggest	VBN	_	0	ROOT
4	that	that	IN	_	6	mark
5	there	there	EX	_	6	expl
6	is	be	VBZ	_	3	ccomp
7	a	a	DT	_	9	det
8	minor	minor	JJ	_	9	amod
9	contribution	contribution	NN	_	6	nsubj
10	of	of	IN	_	12	case
11	adenosine	adenosine	NN	_	12	compound
12	receptors	receptor	NNS	_	9	nmod
13	to	to	TO	_	15	case
14	these	these	DT	_	15	det
15	effects	effect	NNS	_	9	nmod
16	,	,	,	_	6	punct
17	although	although	IN	_	24	mark
18	theophylline	theophylline	NN	_	24	dep
19	-	-	:	_	18	punct
20	induced	induce	VBN	_	22	amod
21	anxiogenic	anxiogenic	JJ	_	22	amod
22	effects	effect	NNS	_	24	nsubjpass
23	were	be	VBD	_	24	auxpass
24	antagonized	antagonize	VBN	_	6	advcl
25	by	by	IN	_	29	case
26	an	a	DT	_	29	det
27	A2	a2	NN	_	29	compound
28	receptor	receptor	NN	_	29	compound
29	agonist	agonist	NN	_	24	nmod
30	.	.	.	_	3	punct

1	Restoration	restoration	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	vancomycin	vancomycin	NN	_	4	compound
4	susceptibility	susceptibility	NN	_	1	nmod
5	in	in	IN	_	7	case
6	Enterococcus	enterococcus	NN	_	7	compound
7	faecalis	faecalis	NN	_	4	nmod
8	by	by	IN	_	12	case
9	antiresistance	antiresistance	JJ	_	12	amod
10	determinant	determinant	NN	_	12	compound
11	gene	gene	NN	_	12	compound
12	transfer	transfer	NN	_	1	nmod
13	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	assessed	assess	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	ability	ability	NN	_	2	dobj
5	of	of	IN	_	7	case
6	gene	gene	NN	_	7	compound
7	transfer	transfer	NN	_	4	nmod
8	to	to	TO	_	9	mark
9	reverse	reverse	VB	_	4	acl
10	vancomycin	vancomycin	NN	_	11	compound
11	resistance	resistance	NN	_	9	dobj
12	in	in	IN	_	16	case
13	class	class	NN	_	16	compound
14	A	a	NN	_	16	compound
15	(	(	CD	_	16	nummod
16	VanA	vana	NN	_	11	nmod
17	)	)	CD	_	18	nummod
18	glycopeptide	glycopeptide	NN	_	16	dep
19	-	-	:	_	16	punct
20	resistant	resistant	JJ	_	22	amod
21	Enterococcus	enterococcus	NN	_	22	compound
22	faecalis	faecalis	NN	_	16	dep
23	.	.	.	_	2	punct

1	Recombinant	recombinant	JJ	_	3	amod
2	shuttle	shuttle	NN	_	3	compound
3	vectors	vector	NNS	_	0	ROOT
4	containing	contain	VBG	_	3	acl
5	a	a	DT	_	7	det
6	vanH	vanh	NN	_	7	compound
7	promoter	promoter	NN	_	4	dobj
8	-	-	:	_	7	punct
9	vanA	vana	NN	_	12	compound
10	antisense	antisense	JJ	_	12	amod
11	gene	gene	NN	_	12	compound
12	cassette	cassette	NN	_	14	nsubj
13	fully	fully	RB	_	14	advmod
14	restored	restore	VBD	_	7	dep
15	vancomycin	vancomycin	NN	_	16	compound
16	susceptibility	susceptibility	NN	_	14	dobj
17	through	through	IN	_	24	case
18	a	a	DT	_	24	det
19	combined	combined	JJ	_	24	amod
20	transcriptional	transcriptional	JJ	_	24	amod
21	activator	activator	NN	_	24	compound
22	binding	binding	NN	_	24	compound
23	domain	domain	NN	_	24	compound
24	decoy	decoy	NN	_	14	nmod
25	and	and	CC	_	24	cc
26	inducible	inducible	JJ	_	30	amod
27	vanA	vana	NN	_	30	compound
28	antisense	antisense	JJ	_	30	amod
29	RNA	rna	NN	_	30	compound
30	effect	effect	NN	_	24	conj
31	.	.	.	_	3	punct

1	Induction	induction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	apoptosis	apoptosis	NN	_	1	nmod
4	in	in	IN	_	7	case
5	breast	breast	NN	_	7	compound
6	cancer	cancer	NN	_	7	compound
7	cells	cell	NNS	_	1	nmod
8	in	in	IN	_	9	case
9	response	response	NN	_	1	nmod
10	to	to	TO	_	12	case
11	vitamin	vitamin	NN	_	12	compound
12	D	d	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	antiestrogens	antiestrogen	NNS	_	12	conj
15	.	.	.	_	1	punct

1	1,25	1,25	CD	_	4	nummod
2	-	-	:	_	4	punct
3	Dihydroxycholecalciferol	dihydroxycholecalciferol	NN	_	4	compound
4	D3	d3	NN	_	23	nsubj
5	(	(	CD	_	11	nummod
6	1,25	1,25	CD	_	11	nummod
7	(	(	CD	_	11	nummod
8	OH	oh	NN	_	11	compound
9	)	)	CD	_	11	nummod
10	2D3	2d3	NN	_	11	compound
11	)	)	NN	_	4	dep
12	,	,	,	_	4	punct
13	the	the	DT	_	15	det
14	active	active	JJ	_	15	amod
15	metabolite	metabolite	NN	_	4	appos
16	of	of	IN	_	18	case
17	vitamin	vitamin	NN	_	18	compound
18	D	d	NN	_	15	nmod
19	,	,	,	_	4	punct
20	is	be	VBZ	_	23	cop
21	a	a	DT	_	23	det
22	potent	potent	JJ	_	23	amod
23	inhibitor	inhibitor	NN	_	0	ROOT
24	of	of	IN	_	28	case
25	breast	breast	NN	_	28	compound
26	cancer	cancer	NN	_	28	compound
27	cell	cell	NN	_	28	compound
28	growth	growth	NN	_	23	nmod
29	both	both	CC	_	32	cc:preconj
30	in	in	FW	_	31	compound
31	vivo	vivo	FW	_	32	advmod
32	and	and	CC	_	23	advmod
33	in	in	FW	_	34	compound
34	vitro	vitro	FW	_	32	advmod
35	.	.	.	_	23	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	shown	show	VBN	_	0	ROOT
4	that	that	IN	_	3	dobj
5	MCF	mcf	NN	_	4	dep
6	-	-	:	_	5	punct
7	7	7	CD	_	8	nummod
8	cells	cell	NNS	_	5	dep
9	treated	treat	VBN	_	8	acl
10	with	with	IN	_	9	nmod
11	100	100	CD	_	12	compound
12	nM	nm	NN	_	10	dobj
13	1,25	1,25	CD	_	14	compound
14	(	(	CD	_	18	nummod
15	OH	oh	NN	_	18	compound
16	)	)	CD	_	18	nummod
17	2D3	2d3	NN	_	18	compound
18	exhibit	exhibit	NN	_	12	dep
19	characteristic	characteristic	JJ	_	24	amod
20	apoptotic	apoptotic	JJ	_	24	amod
21	morphology	morphology	NN	_	24	compound
22	(	(	NN	_	24	compound
23	pyknotic	pyknotic	JJ	_	24	amod
24	nuclei	nucleus	NNS	_	18	dep
25	,	,	,	_	18	punct
26	chromatin	chromatin	NN	_	18	conj
27	and	and	CC	_	18	cc
28	cytoplasmic	cytoplasmic	JJ	_	29	amod
29	condensation	condensation	NN	_	18	conj
30	,	,	,	_	12	punct
31	nuclear	nuclear	JJ	_	35	amod
32	matrix	matrix	NN	_	35	compound
33	protein	protein	NN	_	35	compound
34	reorganization	reorganization	NN	_	35	compound
35	)	)	NN	_	12	appos
36	within	within	IN	_	38	case
37	48	48	CD	_	38	nummod
38	h	h	NN	_	35	nmod
39	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	experiments	experiment	NNS	_	8	nmod
4	reported	report	VBN	_	3	acl
5	here	here	RB	_	4	advmod
6	,	,	,	_	8	punct
7	we	we	PRP	_	8	nsubj
8	examined	examine	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	interactions	interaction	NNS	_	8	dobj
11	between	between	IN	_	16	case
12	1,25	1,25	CD	_	16	nummod
13	(	(	CD	_	16	nummod
14	OH	oh	NN	_	16	compound
15	)	)	CD	_	16	nummod
16	2D3	2d3	NN	_	10	nmod
17	and	and	CC	_	16	cc
18	the	the	DT	_	19	det
19	antiestrogen	antiestrogen	JJ	_	16	conj
20	4	4	LS	_	10	acl
21	-	-	:	_	20	punct
22	hydroxytamoxifen	hydroxytamoxifen	NN	_	25	compound
23	(	(	CD	_	25	nummod
24	TAM	tam	NN	_	25	compound
25	)	)	NN	_	20	dep
26	,	,	,	_	25	punct
27	which	which	WDT	_	29	nsubj
28	also	also	RB	_	29	advmod
29	induces	induce	VBZ	_	25	acl:relcl
30	apoptosis	apoptosis	NN	_	29	dobj
31	in	in	IN	_	32	case
32	MCF	mcf	NN	_	30	nmod
33	-	-	:	_	32	punct
34	7	7	CD	_	35	nummod
35	cells	cell	NNS	_	32	dep
36	.	.	.	_	8	punct

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	TAM	tam	NN	_	7	nsubj
6	significantly	significantly	RB	_	7	advmod
7	potentiates	potentiate	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	reduction	reduction	NN	_	7	dobj
10	in	in	IN	_	12	case
11	cell	cell	NN	_	12	compound
12	number	number	NN	_	9	nmod
13	induced	induce	VBN	_	12	acl
14	by	by	IN	_	19	case
15	1,25	1,25	CD	_	19	nummod
16	(	(	CD	_	19	nummod
17	OH	oh	NN	_	19	compound
18	)	)	CD	_	19	nummod
19	2D3	2d3	NN	_	13	nmod
20	alone	alone	RB	_	19	advmod
21	.	.	.	_	3	punct

1	Combined	combined	JJ	_	2	amod
2	treatment	treatment	NN	_	11	nsubj
3	with	with	IN	_	8	case
4	1,25	1,25	CD	_	8	nummod
5	(	(	CD	_	8	nummod
6	OH	oh	NN	_	8	compound
7	)	)	CD	_	8	nummod
8	2D3	2d3	NN	_	2	nmod
9	and	and	CC	_	8	cc
10	TAM	tam	NN	_	8	conj
11	enhances	enhance	VBZ	_	0	ROOT
12	the	the	DT	_	13	det
13	degree	degree	NN	_	11	dobj
14	of	of	IN	_	15	case
15	apoptosis	apoptosis	NN	_	13	nmod
16	assessed	assess	VBN	_	15	acl
17	using	use	VBG	_	16	xcomp
18	morphological	morphological	JJ	_	19	amod
19	markers	marker	NNS	_	17	dobj
20	that	that	WDT	_	21	nsubj
21	identify	identify	VBP	_	19	acl:relcl
22	chromatin	chromatin	NN	_	27	compound
23	and	and	CC	_	22	cc
24	nuclear	nuclear	JJ	_	26	amod
25	matrix	matrix	NN	_	26	compound
26	protein	protein	NN	_	22	conj
27	condensation	condensation	NN	_	21	dobj
28	.	.	.	_	11	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	selected	select	VBN	_	0	ROOT
4	a	a	DT	_	5	det
5	subclone	subclone	NN	_	3	dobj
6	of	of	IN	_	7	case
7	MCF	mcf	NN	_	5	nmod
8	-	-	:	_	7	punct
9	7	7	CD	_	10	nummod
10	cells	cell	NNS	_	7	dep
11	resistant	resistant	JJ	_	10	amod
12	to	to	TO	_	17	case
13	1,25	1,25	CD	_	17	nummod
14	(	(	CD	_	17	nummod
15	OH	oh	NN	_	17	compound
16	)	)	CD	_	17	nummod
17	2D3	2d3	NN	_	11	nmod
18	(	(	CD	_	19	nummod
19	MCF	mcf	NN	_	17	dep
20	-	-	:	_	7	punct
21	7D3Res	7d3re	NNS	_	7	dep
22	)	)	CD	_	21	nummod
23	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	cells	cell	NNS	_	3	nsubj
3	express	express	VBP	_	0	ROOT
4	the	the	DT	_	7	det
5	vitamin	vitamin	NN	_	7	compound
6	D	d	NN	_	7	compound
7	receptor	receptor	NN	_	3	dobj
8	and	and	CC	_	3	cc
9	exhibit	exhibit	VBP	_	3	conj
10	doubling	double	VBG	_	9	xcomp
11	times	time	NNS	_	10	dobj
12	comparable	comparable	JJ	_	11	amod
13	to	to	TO	_	16	case
14	the	the	DT	_	16	det
15	parental	parental	JJ	_	16	amod
16	MCF	mcf	NN	_	12	nmod
17	-	-	:	_	16	punct
18	7	7	CD	_	19	nummod
19	cells	cell	NNS	_	16	dep
20	,	,	,	_	10	punct
21	even	even	RB	_	22	advmod
22	when	when	WRB	_	23	advmod
23	grown	grow	VBN	_	10	advcl
24	in	in	IN	_	26	case
25	100	100	CD	_	26	nummod
26	mM	mm	NN	_	23	nmod
27	1,25	1,25	CD	_	28	compound
28	(	(	CD	_	29	nummod
29	OH	oh	NN	_	26	dep
30	)	)	CD	_	31	nummod
31	2D3	2d3	NN	_	29	dep
32	.	.	.	_	3	punct

1	Treatment	treatment	NN	_	13	nsubj
2	of	of	IN	_	7	case
3	both	both	CC	_	4	cc:preconj
4	parental	parental	JJ	_	7	amod
5	and	and	CC	_	4	cc
6	resistant	resistant	JJ	_	4	conj
7	MCF	mcf	NN	_	1	nmod
8	-	-	:	_	7	punct
9	7	7	CD	_	10	nummod
10	cells	cell	NNS	_	7	dep
11	with	with	IN	_	12	case
12	TAM	tam	NN	_	10	nmod
13	induces	induce	VBZ	_	0	ROOT
14	apoptosis	apoptosis	NN	_	13	dobj
15	and	and	CC	_	14	cc
16	clusterin	clusterin	NN	_	14	conj
17	.	.	.	_	13	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	emphasize	emphasize	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	apoptosis	apoptosis	NN	_	8	nsubjpass
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	induced	induce	VBN	_	3	ccomp
9	in	in	IN	_	13	case
10	MCF	mcf	NN	_	13	compound
11	-	-	:	_	13	punct
12	7	7	CD	_	13	nummod
13	cells	cell	NNS	_	8	nmod
14	either	either	CC	_	16	cc:preconj
15	by	by	IN	_	16	case
16	activation	activation	NN	_	8	nmod
17	of	of	IN	_	20	case
18	vitamin	vitamin	NN	_	20	compound
19	-	-	:	_	20	punct
20	D	d	NN	_	16	nmod
21	-	-	:	_	8	punct
22	mediated	mediate	VBN	_	23	amod
23	signalling	signalling	NN	_	8	dep
24	or	or	CC	_	23	cc
25	disruption	disruption	NN	_	23	conj
26	of	of	IN	_	27	case
27	estrogen	estrogen	NN	_	23	nmod
28	-	-	:	_	27	punct
29	dependent	dependent	JJ	_	30	amod
30	signalling	signalling	NN	_	27	dep
31	.	.	.	_	3	punct

1	Cholinergic	cholinergic	JJ	_	2	amod
2	role	role	NN	_	0	ROOT
3	in	in	IN	_	7	case
4	alcohol	alcohol	NN	_	7	compound
5	'	'	''	_	7	punct
6	s	s	NNS	_	7	compound
7	effects	effect	NNS	_	2	nmod
8	on	on	IN	_	10	case
9	evoked	evoke	VBN	_	10	amod
10	potentials	potential	NNS	_	7	nmod
11	in	in	IN	_	13	case
12	visual	visual	JJ	_	13	amod
13	cortex	cortex	NN	_	10	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	albino	albino	NN	_	17	compound
17	rat	rat	NN	_	13	nmod
18	.	.	.	_	2	punct

1	Photic	photic	JJ	_	3	amod
2	evoked	evoke	VBN	_	3	amod
3	potentials	potential	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	recorded	record	VBN	_	0	ROOT
6	from	from	IN	_	9	case
7	the	the	DT	_	9	det
8	visual	visual	JJ	_	9	amod
9	cortex	cortex	NN	_	5	nmod
10	of	of	IN	_	14	case
11	chronically	chronically	RB	_	12	advmod
12	implanted	implant	VBN	_	14	amod
13	albino	albino	NN	_	14	compound
14	rats	rat	NNS	_	9	nmod
15	.	.	.	_	5	punct

1	Since	since	IN	_	7	mark
2	photic	photic	JJ	_	5	amod
3	evoked	evoke	VBN	_	5	amod
4	potential	potential	JJ	_	5	amod
5	components	component	NNS	_	7	nsubj
6	are	be	VBP	_	7	cop
7	representations	representation	NNS	_	28	advcl
8	of	of	IN	_	10	case
9	neural	neural	JJ	_	10	amod
10	pathways	pathway	NNS	_	7	nmod
11	which	which	WDT	_	13	nsubjpass
12	are	be	VBP	_	13	auxpass
13	activated	activate	VBN	_	10	acl:relcl
14	during	during	IN	_	16	case
15	photic	photic	JJ	_	16	amod
16	stimulation	stimulation	NN	_	13	nmod
17	,	,	,	_	28	punct
18	study	study	NN	_	28	nsubj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	effects	effect	NNS	_	18	nmod
22	of	of	IN	_	23	case
23	alcohol	alcohol	NN	_	21	nmod
24	on	on	IN	_	26	case
25	these	these	DT	_	26	det
26	components	component	NNS	_	21	nmod
27	may	may	MD	_	28	aux
28	help	help	VB	_	0	ROOT
29	to	to	TO	_	31	case
30	trace	trace	NN	_	31	compound
31	pathways	pathway	NNS	_	28	nmod
32	which	which	WDT	_	34	nsubjpass
33	are	be	VBP	_	34	auxpass
34	affected	affect	VBN	_	31	acl:relcl
35	by	by	IN	_	36	case
36	alcohol	alcohol	NN	_	34	nmod
37	.	.	.	_	28	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	9	nmod
5	,	,	,	_	9	punct
6	evoked	evoke	VBD	_	7	amod
7	potentials	potential	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	recorded	record	VBN	_	0	ROOT
10	at	at	IN	_	11	case
11	5	5	CD	_	9	nmod
12	,	,	,	_	11	punct
13	20	20	CD	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	40	40	CD	_	11	conj
17	min	min	NN	_	11	dep
18	following	follow	VBG	_	20	case
19	IP	IP	NNP	_	20	compound
20	injections	injection	NNS	_	9	nmod
21	of	of	IN	_	22	case
22	saline	saline	NN	_	20	nmod
23	,	,	,	_	20	punct
24	ethanol	ethanol	NN	_	25	compound
25	(	(	NN	_	20	appos
26	2.0	2.0	CD	_	27	nummod
27	g	g	NN	_	25	dep
28	/	/	:	_	20	punct
29	kg	kg	NN	_	30	compound
30	)	)	NN	_	20	dep
31	,	,	,	_	30	punct
32	physostigmine	physostigmine	NN	_	35	compound
33	(	(	CD	_	34	compound
34	0.6	0.6	CD	_	35	nummod
35	mg	mg	NN	_	30	appos
36	/	/	:	_	30	punct
37	kg	kg	NN	_	38	compound
38	)	)	NN	_	30	dep
39	or	or	CC	_	38	cc
40	atropine	atropine	NN	_	43	compound
41	(	(	CD	_	42	compound
42	15.0	15.0	CD	_	43	nummod
43	mg	mg	NN	_	38	conj
44	/	/	:	_	30	punct
45	kg	kg	NN	_	46	compound
46	)	)	NN	_	30	dep
47	on	on	IN	_	49	case
48	separate	separate	JJ	_	49	amod
49	days	day	NNS	_	30	nmod
50	.	.	.	_	9	punct

1	Ethanol	ethanol	NN	_	2	nsubj
2	depressed	depress	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	amplitudes	amplitude	NNS	_	2	dobj
5	of	of	IN	_	9	case
6	most	most	JJS	_	9	amod
7	evoked	evoke	VBN	_	9	amod
8	potential	potential	JJ	_	9	amod
9	components	component	NNS	_	4	nmod
10	in	in	IN	_	11	case
11	comparison	comparison	NN	_	2	nmod
12	to	to	TO	_	14	case
13	saline	saline	NN	_	14	compound
14	administration	administration	NN	_	11	nmod
15	.	.	.	_	2	punct

1	Component	component	NN	_	2	compound
2	P2	p2	NN	_	7	nsubjpass
3	,	,	,	_	7	punct
4	however	however	RB	_	7	advmod
5	,	,	,	_	7	punct
6	was	be	VBD	_	7	auxpass
7	increased	increase	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	amplitude	amplitude	NN	_	7	nmod
10	.	.	.	_	7	punct

1	Physostigmine	physostigmine	NN	_	2	compound
2	briefly	briefly	NN	_	3	nsubj
3	reduced	reduce	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	amplitude	amplitude	NN	_	3	dobj
6	of	of	IN	_	8	case
7	most	most	JJS	_	8	amod
8	components	component	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	including	include	VBG	_	11	case
11	P2	p2	NN	_	8	nmod
12	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	5	nmod
3	,	,	,	_	5	punct
4	atropine	atropine	NN	_	5	nsubj
5	increased	increase	VBD	_	0	ROOT
6	the	the	DT	_	7	det
7	amplitudes	amplitude	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	components	component	NNS	_	7	nmod
10	P1	p1	NN	_	9	dep
11	and	and	CC	_	10	cc
12	P2	p2	NN	_	10	conj
13	,	,	,	_	5	punct
14	while	while	IN	_	5	dep
15	decreasing	decrease	VBG	_	17	amod
16	components	component	NNS	_	17	compound
17	N1	n1	NN	_	14	root
18	,	,	,	_	17	punct
19	N2	n2	NN	_	17	conj
20	and	and	CC	_	17	cc
21	N3	n3	NN	_	17	conj
22	for	for	IN	_	24	case
23	varying	vary	VBG	_	24	amod
24	durations	duration	NNS	_	21	nmod
25	of	of	IN	_	26	case
26	time	time	NN	_	24	nmod
27	.	.	.	_	17	punct

1	Physostigmine	Physostigmine	NNP	_	2	compound
2	pretreatment	pretreatment	NN	_	3	nsubj
3	augmented	augment	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	depressant	depressant	NN	_	6	compound
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	8	case
8	alcohol	alcohol	NN	_	6	nmod
9	on	on	IN	_	12	case
10	the	the	DT	_	12	det
11	early	early	JJ	_	12	amod
12	components	component	NNS	_	3	nmod
13	P1	p1	NN	_	12	dep
14	and	and	CC	_	13	cc
15	N1	n1	NN	_	13	conj
16	,	,	,	_	3	punct
17	while	while	IN	_	18	mark
18	attenuating	attenuate	VBG	_	3	advcl
19	alcohol	alcohol	NN	_	21	compound
20	'	'	''	_	21	punct
21	s	s	NNS	_	22	nsubj
22	influence	influence	VBP	_	18	ccomp
23	on	on	IN	_	25	case
24	components	component	NNS	_	25	compound
25	P2	p2	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	P3	p3	NN	_	25	conj
28	.	.	.	_	3	punct

1	Pretreatment	pretreatment	NN	_	6	nsubj
2	with	with	IN	_	3	case
3	atropine	atropine	NN	_	1	nmod
4	likewise	likewise	RB	_	6	advmod
5	further	further	RB	_	6	advmod
6	reduced	reduce	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	amplitudes	amplitude	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	components	component	NNS	_	8	nmod
11	P1	p1	NN	_	10	dep
12	and	and	CC	_	11	cc
13	N1	n1	NN	_	11	conj
14	,	,	,	_	6	punct
15	and	and	CC	_	6	cc
16	produced	produce	VBD	_	6	conj
17	a	a	DT	_	19	det
18	similar	similar	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	on	on	IN	_	22	case
21	component	component	NN	_	22	compound
22	N3	n3	NN	_	19	nmod
23	.	.	.	_	6	punct

1	Atropine	Atropine	NNP	_	11	nsubj
2	,	,	,	_	1	punct
3	either	either	DT	_	1	appos
4	alone	alone	RB	_	5	advmod
5	or	or	CC	_	3	advmod
6	in	in	IN	_	7	case
7	combination	combination	NN	_	5	conj
8	with	with	IN	_	9	case
9	alcohol	alcohol	NN	_	7	nmod
10	,	,	,	_	1	punct
11	produced	produce	VBD	_	0	ROOT
12	approximately	approximately	RB	_	15	advmod
13	the	the	DT	_	15	det
14	same	same	JJ	_	15	amod
15	degree	degree	NN	_	11	dobj
16	of	of	IN	_	17	case
17	enhancement	enhancement	NN	_	15	nmod
18	of	of	IN	_	20	case
19	component	component	NN	_	20	compound
20	P2	p2	NN	_	17	nmod
21	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	comparison	comparison	NN	_	10	nmod
3	to	to	TO	_	5	case
4	saline	saline	NN	_	5	compound
5	values	value	NNS	_	2	nmod
6	,	,	,	_	10	punct
7	all	all	DT	_	9	det
8	three	three	CD	_	9	nummod
9	agents	agent	NNS	_	10	nsubj
10	produced	produce	VBD	_	0	ROOT
11	reliable	reliable	JJ	_	12	amod
12	increases	increase	NNS	_	10	dobj
13	in	in	IN	_	15	case
14	peak	peak	JJ	_	15	amod
15	latency	latency	NN	_	12	nmod
16	for	for	IN	_	17	case
17	most	most	JJS	_	12	nmod
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	components	component	NNS	_	17	nmod
21	,	,	,	_	10	punct
22	with	with	IN	_	25	mark
23	only	only	RB	_	24	advmod
24	N3	n3	NN	_	25	nsubj
25	showing	show	VBG	_	10	advcl
26	no	no	DT	_	27	neg
27	effects	effect	NNS	_	25	dobj
28	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	amplitude	amplitude	NN	_	3	compound
3	data	datum	NNS	_	7	nsubj
4	from	from	IN	_	6	case
5	this	this	DT	_	6	det
6	study	study	NN	_	3	nmod
7	suggest	suggest	VBP	_	0	ROOT
8	that	that	IN	_	17	mark
9	ethanol	ethanol	NN	_	12	compound
10	'	'	''	_	12	punct
11	s	s	NNS	_	12	compound
12	augmentation	augmentation	NN	_	17	nsubj
13	of	of	IN	_	15	case
14	component	component	NN	_	15	compound
15	P2	p2	NN	_	12	nmod
16	may	may	MD	_	17	aux
17	result	result	VB	_	7	ccomp
18	,	,	,	_	17	punct
19	at	at	IN	_	22	advmod
20	least	least	JJS	_	19	mwe
21	in	in	IN	_	22	case
22	part	part	NN	_	17	nmod
23	,	,	,	_	17	punct
24	from	from	IN	_	25	case
25	alterations	alteration	NNS	_	17	nmod
26	in	in	IN	_	28	case
27	cholinergic	cholinergic	JJ	_	28	amod
28	functions	function	NNS	_	25	nmod
29	.	.	.	_	7	punct

1	Increased	increase	VBN	_	2	amod
2	hepatotoxicity	hepatotoxicity	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	acetaminophen	acetaminophen	NN	_	2	nmod
5	by	by	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	2	nmod
8	of	of	IN	_	9	case
9	caffeine	caffeine	NN	_	7	nmod
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	rat	rat	NN	_	7	nmod
13	.	.	.	_	2	punct

1	Since	since	IN	_	5	mark
2	caffeine	caffeine	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	frequently	frequently	RB	_	5	advmod
5	co	co	SYM	_	15	advcl
6	-	-	:	_	7	punct
7	administered	administer	VBN	_	15	parataxis
8	with	with	IN	_	9	case
9	acetaminophen	acetaminophen	NN	_	7	nmod
10	,	,	,	_	7	punct
11	it	it	PRP	_	15	nsubj
12	is	be	VBZ	_	15	cop
13	of	of	IN	_	15	case
14	clinical	clinical	JJ	_	15	amod
15	interest	interest	NN	_	0	ROOT
16	to	to	TO	_	17	mark
17	study	study	VB	_	15	acl
18	the	the	DT	_	19	det
19	effect	effect	NN	_	17	dobj
20	of	of	IN	_	21	case
21	caffeine	caffeine	NN	_	19	nmod
22	on	on	IN	_	24	case
23	the	the	DT	_	24	det
24	hepatotoxicity	hepatotoxicity	NN	_	19	nmod
25	of	of	IN	_	26	case
26	acetaminophen	acetaminophen	NN	_	24	nmod
27	.	.	.	_	15	punct

1	In	in	IN	_	3	case
2	male	male	JJ	_	3	amod
3	Sprague	sprague	NN	_	7	nmod
4	-	-	:	_	7	punct
5	Dawley	Dawley	NNP	_	6	compound
6	rats	rat	NNS	_	7	nsubj
7	fasted	fast	VBD	_	0	ROOT
8	for	for	IN	_	10	case
9	18	18	CD	_	10	nummod
10	h	h	NN	_	7	nmod
11	,	,	,	_	7	punct
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	7	dobj
14	of	of	IN	_	15	case
15	caffeine	caffeine	NN	_	13	nmod
16	(	(	CD	_	17	compound
17	0.1	0.1	CD	_	15	nummod
18	g	g	NN	_	15	dep
19	/	/	:	_	13	punct
20	kg	kg	NN	_	13	dep
21	,	,	,	_	20	punct
22	i	i	FW	_	24	compound
23	.	.	.	_	24	punct
24	p	p	NN	_	20	appos
25	.	.	.	_	7	punct
26	)	)	SYM	_	7	punct

1	as	as	IN	_	2	mark
2	judged	judge	VBN	_	0	ROOT
3	by	by	IN	_	7	case
4	increased	increase	VBN	_	7	amod
5	serum	serum	NN	_	7	compound
6	enzyme	enzyme	NN	_	7	compound
7	activities	activity	NNS	_	2	nmod
8	and	and	CC	_	7	cc
9	increased	increase	VBD	_	10	amod
10	incidence	incidence	NN	_	7	conj
11	of	of	IN	_	13	case
12	hepatic	hepatic	JJ	_	13	amod
13	necrosis	necrosis	NN	_	10	nmod
14	.	.	.	_	2	punct

1	Careful	careful	JJ	_	2	amod
2	observations	observation	NNS	_	6	nsubjpass
3	on	on	IN	_	4	case
4	hepatotoxicity	hepatotoxicity	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	suggested	suggest	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	acetaminophen	acetaminophen	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	prescribed	prescribe	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	caffeine	caffeine	NN	_	10	nmod
13	.	.	.	_	6	punct

1	Dual	dual	JJ	_	2	amod
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	ouabain	ouabain	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	palytoxin	palytoxin	NN	_	2	nmod
8	-	-	:	_	2	punct
9	induced	induce	VBN	_	10	amod
10	contraction	contraction	NN	_	2	dep
11	and	and	CC	_	10	cc
12	norepinephrine	norepinephrine	NN	_	13	compound
13	release	release	NN	_	10	conj
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	guinea	guinea	NN	_	10	nmod
17	-	-	:	_	16	punct
18	pig	pig	NN	_	20	compound
19	vas	vas	FW	_	20	compound
20	deferens	deferens	FW	_	16	dep
21	.	.	.	_	2	punct

1	Palytoxin	palytoxin	NN	_	4	compound
2	(	(	CD	_	4	nummod
3	PTX	ptx	NN	_	4	compound
4	)	)	NN	_	16	nsubj
5	,	,	,	_	4	punct
6	C129H223N3O54	c129h223n3o54	NN	_	4	appos
7	,	,	,	_	4	punct
8	isolated	isolate	VBN	_	4	acl
9	from	from	IN	_	11	case
10	marine	marine	JJ	_	11	amod
11	coelenterates	coelenterate	NNS	_	8	nmod
12	of	of	IN	_	14	case
13	Palythoa	palythoa	NN	_	14	compound
14	tuberculosa	tuberculosa	NN	_	11	nmod
15	,	,	,	_	4	punct
16	caused	cause	VBD	_	0	ROOT
17	a	a	DT	_	20	det
18	first	first	JJ	_	20	amod
19	rapid	rapid	JJ	_	20	amod
20	contraction	contraction	NN	_	16	dobj
21	followed	follow	VBN	_	20	acl
22	by	by	IN	_	26	case
23	the	the	DT	_	26	det
24	slow	slow	JJ	_	26	amod
25	phasic	phasic	JJ	_	26	amod
26	contraction	contraction	NN	_	21	nmod
27	of	of	IN	_	28	case
28	guinea	guinea	NN	_	26	nmod
29	-	-	:	_	28	punct
30	pig	pig	NN	_	32	compound
31	vas	vas	FW	_	32	compound
32	deferens	deferens	FW	_	28	dep
33	.	.	.	_	16	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	presence	presence	NN	_	24	nmod
4	of	of	IN	_	5	case
5	ouabain	ouabain	NN	_	3	nmod
6	(	(	CD	_	7	nummod
7	10	10	CD	_	13	dep
8	(	(	SYM	_	13	dep
9	-	-	:	_	13	punct
10	5	5	CD	_	11	compound
11	)	)	CD	_	12	dep
12	M	m	NN	_	13	dep
13	)	)	NN	_	23	dep
14	,	,	,	_	13	punct
15	PTX	ptx	NN	_	23	dep
16	(	(	CD	_	17	compound
17	10	10	CD	_	15	nummod
18	(	(	SYM	_	15	dep
19	-	-	:	_	15	punct
20	8	8	CD	_	21	compound
21	)	)	CD	_	22	dep
22	M	m	NN	_	23	dep
23	)	)	NN	_	5	dep
24	failed	fail	VBD	_	0	ROOT
25	to	to	TO	_	26	mark
26	cause	cause	VB	_	24	xcomp
27	the	the	DT	_	29	det
28	first	first	JJ	_	29	amod
29	contraction	contraction	NN	_	26	dobj
30	;	;	:	_	24	punct

1	however	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	the	the	DT	_	5	det
4	second	second	JJ	_	5	amod
5	contraction	contraction	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	potentiated	potentiate	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	presence	presence	NN	_	19	nmod
4	of	of	IN	_	5	case
5	phentolamine	phentolamine	NN	_	3	nmod
6	(	(	CD	_	7	nummod
7	10	10	CD	_	13	dep
8	(	(	SYM	_	13	dep
9	-	-	:	_	13	punct
10	6	6	CD	_	11	compound
11	)	)	CD	_	12	dep
12	M	m	NN	_	13	dep
13	)	)	NN	_	5	dep
14	,	,	,	_	19	punct
15	the	the	DT	_	17	det
16	second	second	JJ	_	17	amod
17	contraction	contraction	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	inhibited	inhibit	VBN	_	0	ROOT
20	selectively	selectively	RB	_	19	advmod
21	.	.	.	_	19	punct

1	When	when	WRB	_	4	advmod
2	ouabain	ouabain	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	applied	apply	VBN	_	23	advcl
5	to	to	TO	_	7	case
6	the	the	DT	_	7	det
7	muscle	muscle	NN	_	4	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	presence	presence	NN	_	4	nmod
11	of	of	IN	_	12	case
12	phentolamine	phentolamine	NN	_	10	nmod
13	,	,	,	_	23	punct
14	both	both	CC	_	15	cc:preconj
15	first	first	RB	_	23	advmod
16	and	and	CC	_	15	cc
17	second	second	RB	_	15	conj
18	contractile	contractile	JJ	_	19	amod
19	responses	response	NNS	_	23	nsubjpass
20	to	to	TO	_	21	case
21	PTX	ptx	NN	_	19	nmod
22	were	be	VBD	_	23	auxpass
23	abolished	abolish	VBN	_	0	ROOT
24	.	.	.	_	23	punct

1	When	when	WRB	_	5	advmod
2	the	the	DT	_	3	det
3	muscle	muscle	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	exposed	expose	VBN	_	11	dep
6	to	to	TO	_	8	case
7	the	the	DT	_	8	det
8	potassium	potassium	NN	_	5	nmod
9	-	-	:	_	11	punct
10	depleted	deplete	VBN	_	11	amod
11	solution	solution	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	the	the	DT	_	16	det
14	first	first	JJ	_	16	amod
15	contractile	contractile	NN	_	16	compound
16	response	response	NN	_	21	nsubj
17	to	to	TO	_	18	case
18	PTX	ptx	NN	_	16	nmod
19	was	be	VBD	_	21	cop
20	rather	rather	RB	_	21	advmod
21	potentiated	potentiated	JJ	_	11	acl:relcl
22	.	.	.	_	11	punct

1	PTX	ptx	NN	_	2	nsubj
2	caused	cause	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	release	release	NN	_	2	dobj
5	of	of	IN	_	6	case
6	norepinephrine	norepinephrine	NN	_	4	nmod
7	from	from	IN	_	9	case
8	the	the	DT	_	9	det
9	muscle	muscle	NN	_	4	nmod
10	.	.	.	_	2	punct

1	Exposure	exposure	NN	_	16	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	muscle	muscle	NN	_	1	nmod
5	to	to	TO	_	6	case
6	ouabain	ouabain	NN	_	1	nmod
7	(	(	CD	_	8	nummod
8	10	10	CD	_	14	dep
9	(	(	SYM	_	14	dep
10	-	-	:	_	14	punct
11	5	5	CD	_	12	compound
12	)	)	CD	_	13	dep
13	M	m	NN	_	14	dep
14	)	)	NN	_	6	dep
15	markedly	markedly	RB	_	16	advmod
16	increased	increase	VBD	_	0	ROOT
17	the	the	DT	_	18	det
18	PTX	ptx	NN	_	16	dobj
19	-	-	:	_	18	punct
20	induced	induce	VBN	_	21	amod
21	release	release	NN	_	18	dep
22	.	.	.	_	16	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	indicated	indicate	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	the	the	DT	_	10	det
6	first	first	JJ	_	10	amod
7	and	and	CC	_	6	cc
8	second	second	JJ	_	6	conj
9	contractile	contractile	NN	_	10	compound
10	responses	response	NNS	_	13	nsubj
11	to	to	TO	_	12	case
12	PTX	ptx	NN	_	10	nmod
13	have	have	VBP	_	3	ccomp
14	entirely	entirely	RB	_	15	advmod
15	different	different	JJ	_	16	amod
16	properties	property	NNS	_	13	dobj
17	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	second	second	JJ	_	3	amod
3	response	response	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	due	due	JJ	_	0	ROOT
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	release	release	NN	_	5	nmod
9	of	of	IN	_	10	case
10	norepinephrine	norepinephrine	NN	_	8	nmod
11	from	from	IN	_	12	case
12	nerves	nerve	NNS	_	8	nmod
13	and	and	CC	_	5	cc
14	was	be	VBD	_	15	auxpass
15	potentiated	potentiate	VBN	_	5	conj
16	by	by	IN	_	17	case
17	ouabain	ouabain	NN	_	15	nmod
18	through	through	IN	_	20	case
19	the	the	DT	_	20	det
20	increase	increase	NN	_	15	nmod
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	norepinephrine	norepinephrine	NN	_	24	compound
24	release	release	NN	_	20	nmod
25	,	,	,	_	5	punct
26	whereas	whereas	IN	_	36	mark
27	the	the	DT	_	29	det
28	first	first	JJ	_	29	amod
29	response	response	NN	_	36	nsubj
30	was	be	VBD	_	36	cop
31	not	not	RB	_	36	neg
32	due	due	JJ	_	36	case
33	to	to	TO	_	32	mwe
34	the	the	DT	_	36	det
35	norepinephrine	norepinephrine	NN	_	36	compound
36	release	release	NN	_	5	advcl
37	but	but	CC	_	36	cc
38	presumably	presumably	RB	_	42	advmod
39	to	to	TO	_	42	case
40	a	a	DT	_	42	det
41	direct	direct	JJ	_	42	amod
42	action	action	NN	_	36	conj
43	on	on	IN	_	46	case
44	smooth	smooth	JJ	_	46	amod
45	muscle	muscle	NN	_	46	compound
46	cell	cell	NN	_	42	nmod
47	and	and	CC	_	5	cc
48	was	be	VBD	_	49	auxpass
49	inhibited	inhibit	VBN	_	5	conj
50	by	by	IN	_	51	case
51	ouabain	ouabain	NN	_	49	nmod
52	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	action	action	NN	_	2	nmod
6	of	of	IN	_	7	case
7	PTX	ptx	NN	_	5	nmod
8	was	be	VBD	_	9	auxpass
9	discussed	discuss	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	relation	relation	NN	_	9	nmod
13	with	with	IN	_	14	case
14	Na	na	NN	_	12	nmod
15	,	,	,	_	14	punct
16	K	k	NN	_	18	compound
17	-	-	:	_	18	punct
18	ATPase	atpase	NN	_	14	appos
19	.	.	.	_	9	punct

1	Analgesic	analgesic	JJ	_	2	amod
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	antihistaminics	antihistaminic	NNS	_	2	nmod
5	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	literature	literature	NN	_	3	nsubj
3	provides	provide	VBZ	_	0	ROOT
4	considerable	considerable	JJ	_	5	amod
5	evidence	evidence	NN	_	3	dobj
6	indicating	indicate	VBG	_	5	acl
7	that	that	IN	_	18	mark
8	several	several	JJ	_	18	nsubj
9	,	,	,	_	8	punct
10	but	but	CC	_	8	cc
11	not	not	RB	_	13	neg
12	all	all	DT	_	13	det
13	antihistaminics	antihistaminic	NNS	_	8	conj
14	,	,	,	_	18	punct
15	are	be	VBP	_	18	cop
16	indeed	indeed	RB	_	18	advmod
17	analgesic	analgesic	JJ	_	18	amod
18	agents	agent	NNS	_	6	ccomp
19	and	and	CC	_	18	cc
20	some	some	DT	_	23	nsubj
21	are	be	VBP	_	23	cop
22	analgesic	analgesic	JJ	_	23	amod
23	adjuvants	adjuvant	NNS	_	18	conj
24	as	as	RB	_	23	advmod
25	well	well	RB	_	24	mwe
26	.	.	.	_	3	punct

1	Those	those	DT	_	7	nsubj
2	for	for	IN	_	3	case
3	which	which	WDT	_	6	nmod
4	effectiveness	effectiveness	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	reported	report	VBN	_	1	acl:relcl
7	includes	include	VBZ	_	0	ROOT
8	diphenhydramine	diphenhydramine	NN	_	7	dobj
9	,	,	,	_	8	punct
10	hydroxyzine	hydroxyzine	NN	_	8	conj
11	,	,	,	_	8	punct
12	orphenadrine	orphenadrine	NN	_	8	conj
13	,	,	,	_	8	punct
14	pyrilamine	pyrilamine	NN	_	8	conj
15	,	,	,	_	8	punct
16	phenyltoloxamine	phenyltoloxamine	NN	_	8	conj
17	,	,	,	_	8	punct
18	promethazine	promethazine	NN	_	8	conj
19	,	,	,	_	8	punct
20	methdilazine	methdilazine	NN	_	8	conj
21	,	,	,	_	8	punct
22	and	and	CC	_	8	cc
23	tripelennamine	tripelennamine	NN	_	8	conj
24	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	proposed	proposed	JJ	_	3	amod
3	mechanisms	mechanism	NNS	_	10	nsubjpass
4	of	of	IN	_	6	case
5	analgesic	analgesic	JJ	_	6	amod
6	action	action	NN	_	3	nmod
7	of	of	IN	_	8	case
8	antihistaminics	antihistaminic	NNS	_	6	nmod
9	are	be	VBP	_	10	auxpass
10	reviewed	review	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	discussed	discuss	VBN	_	10	conj
13	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	literature	literature	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	11	mark
5	more	more	JJR	_	7	advmod
6	than	than	IN	_	5	mwe
7	one	one	CD	_	8	nummod
8	mechanism	mechanism	NN	_	11	nsubj
9	of	of	IN	_	10	case
10	action	action	NN	_	8	nmod
11	exists	exist	VBZ	_	3	ccomp
12	for	for	IN	_	13	case
13	them	they	PRP	_	11	nmod
14	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	considerable	considerable	JJ	_	4	amod
4	evidence	evidence	NN	_	2	nsubj
5	suggesting	suggest	VBG	_	4	acl
6	that	that	IN	_	13	mark
7	histaminergic	histaminergic	JJ	_	11	amod
8	and	and	CC	_	7	cc
9	serotoninergic	serotoninergic	JJ	_	7	conj
10	central	central	JJ	_	11	amod
11	pathways	pathway	NNS	_	13	nsubjpass
12	are	be	VBP	_	13	auxpass
13	involved	involve	VBN	_	5	ccomp
14	in	in	IN	_	15	case
15	nociception	nociception	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	that	that	IN	_	21	mark
18	antihistaminic	antihistaminic	JJ	_	19	amod
19	drugs	drug	NNS	_	21	nsubj
20	can	can	MD	_	21	aux
21	modulate	modulate	VB	_	13	conj
22	their	they	PRP$	_	23	nmod:poss
23	responses	response	NNS	_	21	dobj
24	(	(	VBP	_	21	dep
25	1	1	CD	_	26	compound
26	)	)	CD	_	24	dobj
27	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	evidence	evidence	NN	_	20	nsubjpass
3	for	for	IN	_	5	case
4	a	a	DT	_	5	det
5	role	role	NN	_	2	nmod
6	for	for	IN	_	7	case
7	norepinephrine	norepinephrine	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	dopamine	dopamine	NN	_	7	conj
10	and	and	CC	_	5	cc
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	5	conj
13	of	of	IN	_	14	case
14	antihistaminics	antihistaminic	NNS	_	12	nmod
15	on	on	IN	_	16	case
16	them	they	PRP	_	12	nmod
17	are	be	VBP	_	20	auxpass
18	less	less	RBR	_	19	advmod
19	well	well	RB	_	20	advmod
20	established	establish	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	Still	still	RB	_	6	advmod
2	other	other	JJ	_	3	amod
3	pathways	pathway	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	proposed	propose	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	A	a	DT	_	3	det
2	greater	greater	JJR	_	3	amod
3	understanding	understanding	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	pain	pain	NN	_	6	compound
6	mechanisms	mechanism	NNS	_	3	nmod
7	will	will	MD	_	8	aux
8	aid	aid	VB	_	0	ROOT
9	in	in	IN	_	10	mark
10	elucidating	elucidate	VBG	_	8	advcl
11	the	the	DT	_	12	det
12	role	role	NN	_	10	dobj
13	of	of	IN	_	14	case
14	antihistaminics	antihistaminic	NNS	_	12	nmod
15	in	in	IN	_	16	case
16	analgesia	analgesia	NN	_	12	nmod
17	.	.	.	_	8	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	ginsenosides	ginsenoside	NNS	_	1	nmod
4	on	on	IN	_	5	case
5	voltage	voltage	NN	_	1	nmod
6	-	-	:	_	1	punct
7	dependent	dependent	JJ	_	9	amod
8	Ca	ca	NN	_	9	compound
9	(	(	NN	_	1	dep
10	2	2	CD	_	9	nummod
11	+	+	CC	_	9	cc
12	)	)	CD	_	14	nummod
13	channel	channel	NN	_	14	compound
14	subtypes	subtype	NNS	_	9	conj
15	in	in	IN	_	18	case
16	bovine	bovine	JJ	_	18	amod
17	chromaffin	chromaffin	NN	_	18	compound
18	cells	cell	NNS	_	9	nmod
19	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	previous	previous	JJ	_	3	amod
3	reports	report	NNS	_	6	nmod
4	we	we	PRP	_	6	nsubj
5	have	have	VBP	_	6	aux
6	shown	show	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	ginsenosides	ginsenoside	NNS	_	9	nsubj
9	inhibit	inhibit	VBP	_	6	ccomp
10	high	high	JJ	_	12	amod
11	threshold	threshold	NN	_	12	compound
12	voltage	voltage	NN	_	9	dobj
13	-	-	:	_	12	punct
14	dependent	dependent	JJ	_	16	amod
15	Ca	ca	NN	_	16	compound
16	(	(	NN	_	12	dep
17	2	2	CD	_	16	nummod
18	+	+	CC	_	16	cc
19	)	)	CD	_	20	nummod
20	channels	channel	NNS	_	16	conj
21	in	in	IN	_	23	case
22	neuronal	neuronal	JJ	_	23	amod
23	cells	cell	NNS	_	12	nmod
24	.	.	.	_	6	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	these	these	DT	_	4	det
4	studies	study	NNS	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	show	show	VB	_	0	ROOT
8	whether	whether	IN	_	7	dobj
9	ginsenosides	ginsenoside	NNS	_	8	dep
10	-	-	:	_	9	punct
11	induced	induce	VBN	_	12	amod
12	inhibition	inhibition	NN	_	20	nsubj
13	of	of	IN	_	15	case
14	Ca	ca	NN	_	15	compound
15	(	(	NN	_	12	nmod
16	2	2	CD	_	15	nummod
17	+	+	CC	_	15	cc
18	)	)	CD	_	19	nummod
19	currents	current	NNS	_	15	conj
20	discriminates	discriminate	VBZ	_	9	dep
21	among	among	IN	_	25	case
22	the	the	DT	_	25	det
23	various	various	JJ	_	25	amod
24	Ca	ca	NN	_	25	compound
25	(	(	NN	_	20	nmod
26	2	2	CD	_	30	nummod
27	+	+	CC	_	26	cc
28	)	)	CD	_	26	conj
29	channel	channel	NN	_	30	compound
30	subtypes	subtype	NNS	_	25	dep
31	,	,	,	_	20	punct
32	although	although	IN	_	35	mark
33	it	it	PRP	_	35	nsubjpass
34	is	be	VBZ	_	35	auxpass
35	known	know	VBN	_	20	advcl
36	that	that	IN	_	38	mark
37	there	there	EX	_	38	expl
38	are	be	VBP	_	35	ccomp
39	at	at	IN	_	40	case
40	least	least	JJS	_	41	nmod:npmod
41	five	five	CD	_	44	nummod
42	different	different	JJ	_	44	amod
43	Ca	ca	NN	_	44	compound
44	(	(	NN	_	38	nsubj
45	2	2	CD	_	49	nummod
46	+	+	CC	_	45	cc
47	)	)	CD	_	45	conj
48	channel	channel	NN	_	49	compound
49	subtypes	subtype	NNS	_	44	dep
50	in	in	IN	_	52	case
51	neuronal	neuronal	JJ	_	52	amod
52	cells	cell	NNS	_	49	nmod
53	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	5	nmod
4	we	we	PRP	_	5	nsubj
5	investigated	investigate	VBD	_	0	ROOT
6	the	the	DT	_	7	det
7	effect	effect	NN	_	5	dobj
8	of	of	IN	_	9	case
9	ginsenosides	ginsenoside	NNS	_	7	nmod
10	on	on	IN	_	13	case
11	high	high	JJ	_	13	amod
12	threshold	threshold	NN	_	13	compound
13	voltage	voltage	NN	_	7	nmod
14	-	-	:	_	13	punct
15	dependent	dependent	JJ	_	17	amod
16	Ca	ca	NN	_	17	compound
17	(	(	NN	_	13	dep
18	2	2	CD	_	17	nummod
19	+	+	CC	_	17	cc
20	)	)	CD	_	22	nummod
21	channel	channel	NN	_	22	compound
22	subtypes	subtype	NNS	_	17	conj
23	using	use	VBG	_	17	acl
24	their	they	PRP$	_	27	nmod:poss
25	selective	selective	JJ	_	27	amod
26	Ca	ca	NN	_	27	compound
27	(	(	NN	_	23	dobj
28	2	2	CD	_	32	nummod
29	+	+	CC	_	28	cc
30	)	)	CD	_	28	conj
31	channel	channel	NN	_	32	compound
32	blockers	blocker	NNS	_	33	nsubj
33	nimodipine	nimodipine	VBP	_	27	acl:relcl
34	(	(	CD	_	35	nummod
35	L	l	NN	_	33	dobj
36	-	-	:	_	35	punct
37	type	type	NN	_	35	dep
38	)	)	CD	_	37	nummod
39	,	,	,	_	35	punct
40	omega	omega	SYM	_	45	dep
41	-	-	:	_	45	punct
42	conotoxin	conotoxin	NN	_	45	compound
43	GVIA	gvia	NN	_	45	compound
44	(	(	CD	_	45	nummod
45	N	n	NN	_	35	appos
46	-	-	:	_	45	punct
47	type	type	NN	_	45	dep
48	)	)	CD	_	47	nummod
49	,	,	,	_	45	punct
50	or	or	CC	_	45	cc
51	omega	omega	SYM	_	45	conj
52	-	-	:	_	45	punct
53	agatoxin	agatoxin	NN	_	56	compound
54	IVA	IVA	NNP	_	56	compound
55	(	(	CD	_	56	nummod
56	P	p	NN	_	45	dep
57	-	-	:	_	56	punct
58	type	type	NN	_	56	dep
59	)	)	CD	_	58	nummod
60	in	in	IN	_	63	case
61	bovine	bovine	JJ	_	63	amod
62	chromaffin	chromaffin	NN	_	63	compound
63	cells	cell	NNS	_	58	nmod
64	.	.	.	_	5	punct

1	We	we	PRP	_	3	nsubj
2	could	could	MD	_	3	aux
3	observe	observe	VB	_	0	ROOT
4	that	that	IN	_	6	mark
5	ginsenosides	ginsenoside	NNS	_	6	nsubj
6	inhibited	inhibit	VBD	_	3	ccomp
7	high	high	JJ	_	9	amod
8	threshold	threshold	NN	_	9	compound
9	voltage	voltage	NN	_	6	dobj
10	-	-	:	_	9	punct
11	dependent	dependent	JJ	_	13	amod
12	Ca	ca	NN	_	13	compound
13	(	(	NN	_	9	dep
14	2	2	CD	_	13	nummod
15	+	+	CC	_	13	cc
16	)	)	CD	_	17	nummod
17	currents	current	NNS	_	13	conj
18	in	in	IN	_	23	case
19	a	a	DT	_	23	det
20	dose	dose	NN	_	23	compound
21	-	-	:	_	23	punct
22	dependent	dependent	JJ	_	23	amod
23	manner	manner	NN	_	6	nmod
24	.	.	.	_	3	punct

1	The	the	DT	_	5	det
2	IC	ic	NN	_	5	compound
3	(	(	CD	_	4	compound
4	50	50	CD	_	5	nummod
5	)	)	NN	_	9	nsubj
6	was	be	VBD	_	9	cop
7	about	about	RB	_	8	advmod
8	120	120	CD	_	9	nummod
9	microgram	microgram	NN	_	0	ROOT
10	/	/	:	_	9	punct
11	ml	ml	NN	_	9	dep
12	.	.	.	_	9	punct

1	Nimodipine	Nimodipine	NNP	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	7	case
6	ginsenosides	ginsenoside	NNS	_	7	compound
7	response	response	NN	_	2	nmod
8	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	ginsenosides	ginsenoside	NNS	_	8	nsubjpass
6	are	be	VBP	_	8	auxpass
7	negatively	negatively	RB	_	8	advmod
8	coupled	couple	VBN	_	3	ccomp
9	to	to	TO	_	11	case
10	three	three	CD	_	11	nummod
11	types	type	NNS	_	8	nmod
12	of	of	IN	_	14	case
13	calcium	calcium	NN	_	14	compound
14	channels	channel	NNS	_	11	nmod
15	in	in	IN	_	18	case
16	bovine	bovine	JJ	_	18	amod
17	chromaffin	chromaffin	NN	_	18	compound
18	cell	cell	NN	_	11	nmod
19	,	,	,	_	11	punct
20	including	include	VBG	_	25	case
21	an	a	DT	_	25	det
22	omega	omega	NN	_	25	compound
23	-	-	:	_	25	punct
24	conotoxin	conotoxin	NN	_	25	compound
25	GVIA	gvia	NN	_	11	nmod
26	-	-	:	_	25	punct
27	sensitive	sensitive	JJ	_	33	amod
28	(	(	NN	_	33	compound
29	N	n	NN	_	33	compound
30	-	-	:	_	33	punct
31	type	type	NN	_	33	compound
32	)	)	CD	_	33	nummod
33	channel	channel	NN	_	25	conj
34	,	,	,	_	25	punct
35	an	a	DT	_	39	det
36	omega	omega	NN	_	39	compound
37	-	-	:	_	39	punct
38	agatoxin	agatoxin	NN	_	39	compound
39	IVA	iva	NN	_	25	conj
40	-	-	:	_	25	punct
41	sensitive	sensitive	JJ	_	43	amod
42	(	(	NN	_	43	compound
43	P	p	NN	_	25	dep
44	-	-	:	_	43	punct
45	type	type	NN	_	47	compound
46	)	)	CD	_	47	nummod
47	channel	channel	NN	_	43	dep
48	and	and	CC	_	47	cc
49	nimodipine	nimodipine	NN	_	47	conj
50	/	/	:	_	43	punct
51	omega	omega	SYM	_	43	dep
52	-	-	:	_	43	punct
53	conotoxin	conotoxin	NN	_	54	compound
54	GVIA	gvia	NN	_	43	dep
55	/	/	:	_	43	punct
56	omega	omega	SYM	_	43	dep
57	-	-	:	_	43	punct
58	agatoxin	agatoxin	NN	_	59	compound
59	VIA	via	NN	_	43	dep
60	-	-	:	_	43	punct
61	resistant	resistant	JJ	_	68	amod
62	(	(	NN	_	68	compound
63	presumptive	presumptive	JJ	_	68	amod
64	Q	Q	NNP	_	68	compound
65	-	-	:	_	68	punct
66	type	type	NN	_	68	compound
67	)	)	CD	_	68	nummod
68	channel	channel	NN	_	43	dep
69	.	.	.	_	3	punct

1	Thus	thus	RB	_	26	advmod
2	,	,	,	_	26	punct
3	the	the	DT	_	5	det
4	selective	selective	JJ	_	5	amod
5	regulation	regulation	NN	_	26	nsubj
6	of	of	IN	_	7	case
7	voltage	voltage	NN	_	5	nmod
8	-	-	:	_	7	punct
9	dependent	dependent	JJ	_	11	amod
10	Ca	ca	NN	_	11	compound
11	(	(	NN	_	7	dep
12	2	2	CD	_	11	nummod
13	+	+	CC	_	11	cc
14	)	)	CD	_	15	nummod
15	subtypes	subtype	NNS	_	11	conj
16	by	by	IN	_	17	case
17	ginsenosides	ginsenoside	NNS	_	5	nmod
18	in	in	IN	_	21	case
19	bovine	bovine	JJ	_	21	amod
20	chromaffin	chromaffin	NN	_	21	compound
21	cell	cell	NN	_	17	nmod
22	could	could	MD	_	26	aux
23	be	be	VB	_	26	cop
24	the	the	DT	_	26	det
25	cellular	cellular	JJ	_	26	amod
26	basis	basis	NN	_	0	ROOT
27	of	of	IN	_	29	case
28	antistress	antistress	JJ	_	29	amod
29	effects	effect	NNS	_	26	nmod
30	induced	induce	VBN	_	29	acl
31	by	by	IN	_	32	case
32	ginseng	ginseng	NN	_	30	nmod
33	.	.	.	_	26	punct

1	A	a	DT	_	3	det
2	proposed	propose	VBN	_	3	amod
3	mechanism	mechanism	NN	_	0	ROOT
4	for	for	IN	_	6	case
5	the	the	DT	_	6	det
6	potentiation	potentiation	NN	_	3	nmod
7	of	of	IN	_	8	case
8	cAMP	camp	NN	_	6	nmod
9	-	-	:	_	8	punct
10	mediated	mediated	JJ	_	12	amod
11	acid	acid	NN	_	12	compound
12	secretion	secretion	NN	_	8	dep
13	by	by	IN	_	14	case
14	carbachol	carbachol	NN	_	12	nmod
15	.	.	.	_	3	punct

1	Acid	acid	NN	_	2	compound
2	secretion	secretion	NN	_	9	nsubjpass
3	in	in	IN	_	7	case
4	isolated	isolate	VBN	_	7	amod
5	rabbit	rabbit	NN	_	7	compound
6	gastric	gastric	JJ	_	7	amod
7	glands	gland	NNS	_	2	nmod
8	was	be	VBD	_	9	auxpass
9	monitored	monitor	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	the	the	DT	_	12	det
12	accumulation	accumulation	NN	_	9	nmod
13	of	of	IN	_	20	case
14	[	[	CD	_	20	nummod
15	(	(	CD	_	20	nummod
16	14	14	CD	_	20	nummod
17	)	)	NN	_	20	compound
18	C	c	NN	_	20	compound
19	]	]	CD	_	20	nummod
20	aminopyrine	aminopyrine	NN	_	12	nmod
21	.	.	.	_	9	punct

1	Stimulation	stimulation	NN	_	8	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	glands	gland	NNS	_	1	nmod
5	with	with	IN	_	6	case
6	carbachol	carbachol	NN	_	1	nmod
7	synergistically	synergistically	RB	_	8	advmod
8	augmented	augment	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	response	response	NN	_	8	dobj
11	to	to	TO	_	13	case
12	dibutyryl	dibutyryl	NN	_	13	compound
13	cAMP	camp	NN	_	10	nmod
14	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	augmentation	augmentation	NN	_	3	nsubj
3	persisted	persist	VBD	_	0	ROOT
4	even	even	RB	_	8	advmod
5	after	after	IN	_	8	mark
6	carbachol	carbachol	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	washed	wash	VBN	_	3	advcl
9	out	out	RP	_	8	compound:prt
10	and	and	CC	_	8	cc
11	was	be	VBD	_	12	cop
12	resistant	resistant	JJ	_	8	conj
13	to	to	TO	_	17	case
14	chelated	chelated	JJ	_	17	amod
15	extracellular	extracellular	JJ	_	17	amod
16	Ca	ca	NN	_	17	compound
17	(	(	NN	_	12	nmod
18	2	2	CD	_	17	nummod
19	+	+	CC	_	17	cc
20	)	)	CD	_	17	conj
21	and	and	CC	_	17	cc
22	to	to	TO	_	23	case
23	inhibitors	inhibitor	NNS	_	17	conj
24	of	of	IN	_	28	case
25	either	either	CC	_	28	cc:preconj
26	protein	protein	NN	_	28	compound
27	kinase	kinase	NN	_	28	compound
28	C	c	NN	_	23	nmod
29	or	or	CC	_	28	cc
30	calmodulin	calmodulin	NN	_	31	compound
31	kinase	kinase	NN	_	28	conj
32	II	ii	CD	_	31	nummod
33	.	.	.	_	3	punct

1	Cytochalasin	cytochalasin	NN	_	2	compound
2	D	d	NN	_	7	nsubj
3	at	at	IN	_	5	case
4	10	10	CD	_	5	nummod
5	microM	microm	NN	_	2	nmod
6	preferentially	preferentially	RB	_	7	advmod
7	blocked	block	VBD	_	0	ROOT
8	the	the	DT	_	10	det
9	secretory	secretory	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	carbachol	carbachol	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	its	its	PRP$	_	15	nmod:poss
15	synergism	synergism	NN	_	12	conj
16	with	with	IN	_	17	case
17	cAMP	camp	NN	_	15	nmod
18	,	,	,	_	7	punct
19	whereas	whereas	IN	_	7	dep
20	it	it	PRP	_	21	nsubj
21	had	have	VBD	_	7	parataxis
22	no	no	DT	_	23	neg
23	effect	effect	NN	_	21	dobj
24	on	on	IN	_	25	case
25	histamine	histamine	NN	_	23	nmod
26	-	-	:	_	25	punct
27	or	or	CC	_	25	cc
28	cAMP	camp	NN	_	32	compound
29	-	-	:	_	32	punct
30	stimulated	stimulated	JJ	_	32	amod
31	acid	acid	NN	_	32	compound
32	secretion	secretion	NN	_	25	conj
33	within	within	IN	_	35	case
34	15	15	CD	_	35	nummod
35	min	min	NN	_	21	nmod
36	.	.	.	_	7	punct

1	Cytochalasin	cytochalasin	NN	_	2	compound
2	D	d	NN	_	3	nsubj
3	inhibited	inhibit	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	carbachol	carbachol	NN	_	3	dobj
6	-	-	:	_	5	punct
7	stimulated	stimulate	VBN	_	10	amod
8	intracellular	intracellular	JJ	_	10	amod
9	Ca	ca	NN	_	10	compound
10	(	(	NN	_	5	dep
11	2	2	CD	_	10	nummod
12	+	+	CC	_	10	cc
13	)	)	CD	_	14	nummod
14	concentration	concentration	NN	_	10	conj
15	(	(	CD	_	16	compound
16	[	[	CD	_	18	nummod
17	Ca	ca	NN	_	18	compound
18	(	(	NN	_	14	dep
19	2	2	CD	_	23	nummod
20	+	+	CC	_	19	cc
21	)	)	CD	_	22	compound
22	]	]	CD	_	19	conj
23	(	(	NN	_	27	amod
24	i	i	FW	_	27	compound
25	)	)	FW	_	27	compound
26	)	)	FW	_	27	compound
27	increase	increase	NN	_	18	dep
28	due	due	JJ	_	18	amod
29	to	to	TO	_	30	mark
30	release	release	VB	_	28	xcomp
31	from	from	IN	_	34	case
32	the	the	DT	_	34	det
33	Ca	ca	NN	_	34	compound
34	(	(	NN	_	30	nmod
35	2	2	CD	_	38	nummod
36	+	+	CC	_	35	cc
37	)	)	CD	_	35	conj
38	store	store	NN	_	34	dep
39	.	.	.	_	3	punct

1	Treatment	treatment	NN	_	8	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	glands	gland	NNS	_	1	nmod
5	with	with	IN	_	7	case
6	cytochalasin	cytochalasin	NN	_	7	compound
7	D	d	NN	_	1	nmod
8	redistributed	redistribute	VBD	_	0	ROOT
9	type	type	NN	_	11	compound
10	3	3	CD	_	11	nummod
11	inositol	inositol	NN	_	8	dobj
12	1,4,5	1,4,5	CD	_	11	nummod
13	-	-	:	_	11	punct
14	trisphosphate	trisphosphate	NN	_	15	compound
15	receptor	receptor	NN	_	16	nsubj
16	(	(	VBP	_	11	acl:relcl
17	the	the	DT	_	19	det
18	major	major	JJ	_	19	amod
19	subtype	subtype	NN	_	16	dobj
20	in	in	IN	_	24	case
21	the	the	DT	_	24	det
22	parietal	parietal	JJ	_	24	amod
23	cell	cell	NN	_	24	compound
24	)	)	NN	_	16	nmod
25	from	from	IN	_	27	case
26	the	the	DT	_	27	det
27	fraction	fraction	NN	_	24	nmod
28	containing	contain	VBG	_	27	acl
29	membranes	membrane	NNS	_	28	dobj
30	of	of	IN	_	32	case
31	large	large	JJ	_	32	amod
32	size	size	NN	_	29	nmod
33	to	to	TO	_	36	case
34	the	the	DT	_	36	det
35	microsomal	microsomal	JJ	_	36	amod
36	fraction	fraction	NN	_	16	nmod
37	,	,	,	_	16	punct
38	suggesting	suggest	VBG	_	16	xcomp
39	a	a	DT	_	40	det
40	dissociation	dissociation	NN	_	38	dobj
41	of	of	IN	_	43	case
42	the	the	DT	_	43	det
43	store	store	NN	_	40	nmod
44	from	from	IN	_	47	case
45	the	the	DT	_	47	det
46	plasma	plasma	NN	_	47	compound
47	membrane	membrane	NN	_	40	nmod
48	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	16	mark
5	intracellular	intracellular	JJ	_	7	amod
6	Ca	ca	NN	_	7	compound
7	(	(	NN	_	16	nsubj
8	2	2	CD	_	7	nummod
9	+	+	CC	_	7	cc
10	)	)	CD	_	11	nummod
11	release	release	NN	_	7	conj
12	by	by	IN	_	14	case
13	cholinergic	cholinergic	JJ	_	14	amod
14	stimulation	stimulation	NN	_	7	nmod
15	is	be	VBZ	_	16	cop
16	critical	critical	JJ	_	3	ccomp
17	for	for	IN	_	18	mark
18	determining	determine	VBG	_	16	advcl
19	synergism	synergism	NN	_	18	dobj
20	with	with	IN	_	21	case
21	cAMP	camp	NN	_	19	nmod
22	in	in	IN	_	25	case
23	parietal	parietal	JJ	_	25	amod
24	cell	cell	NN	_	25	compound
25	activation	activation	NN	_	18	nmod
26	and	and	CC	_	16	cc
27	that	that	IN	_	42	mark
28	functional	functional	JJ	_	29	amod
29	coupling	coupling	NN	_	42	nsubjpass
30	between	between	IN	_	33	case
31	the	the	DT	_	33	det
32	Ca	ca	NN	_	33	compound
33	(	(	NN	_	29	nmod
34	2	2	CD	_	33	nummod
35	+	+	CC	_	33	cc
36	)	)	CD	_	37	nummod
37	store	store	NN	_	33	conj
38	and	and	CC	_	33	cc
39	the	the	DT	_	40	det
40	receptor	receptor	NN	_	33	conj
41	is	be	VBZ	_	42	auxpass
42	maintained	maintain	VBN	_	16	conj
43	by	by	IN	_	45	case
44	actin	actin	NN	_	45	compound
45	microfilaments	microfilament	NNS	_	42	nmod
46	.	.	.	_	3	punct

1	Phenytoin	Phenytoin	NNP	_	2	compound
2	intoxication	intoxication	NN	_	0	ROOT
3	induced	induce	VBN	_	2	acl
4	by	by	IN	_	5	case
5	fluvoxamine	fluvoxamine	NN	_	3	nmod
6	.	.	.	_	2	punct

1	A	a	DT	_	2	det
2	patient	patient	NN	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	phenytoin	phenytoin	NN	_	5	compound
5	intoxication	intoxication	NN	_	3	dobj
6	after	after	IN	_	7	case
7	administration	administration	NN	_	3	nmod
8	of	of	IN	_	9	case
9	fluvoxamine	fluvoxamine	NN	_	7	nmod
10	,	,	,	_	9	punct
11	a	a	DT	_	15	det
12	selective	selective	JJ	_	15	amod
13	serotonin	serotonin	NN	_	15	compound
14	reuptake	reuptake	NN	_	15	compound
15	inhibitor	inhibitor	NN	_	9	appos
16	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	serum	serum	NN	_	3	compound
3	concentration	concentration	NN	_	6	nsubj
4	of	of	IN	_	5	case
5	phenytoin	phenytoin	NN	_	3	nmod
6	increased	increase	VBD	_	0	ROOT
7	dramatically	dramatically	RB	_	6	advmod
8	from	from	IN	_	9	case
9	16.6	16.6	CD	_	6	nmod
10	to	to	TO	_	12	case
11	49.1	49.1	CD	_	12	nummod
12	microg	microg	NN	_	6	nmod
13	/	/	:	_	12	punct
14	mL	ml	NN	_	12	dep
15	when	when	WRB	_	18	advmod
16	fluvoxamine	fluvoxamine	NN	_	18	nsubjpass
17	was	be	VBD	_	18	auxpass
18	coadministered	coadminister	VBN	_	14	acl:relcl
19	,	,	,	_	6	punct
20	although	although	IN	_	31	mark
21	the	the	DT	_	23	det
22	daily	daily	JJ	_	23	amod
23	dosage	dosage	NN	_	31	nsubjpass
24	of	of	IN	_	25	case
25	phenytoin	phenytoin	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	other	other	JJ	_	28	amod
28	drugs	drug	NNS	_	25	conj
29	had	have	VBD	_	31	aux
30	not	not	RB	_	31	neg
31	changed	change	VBN	_	6	advcl
32	.	.	.	_	6	punct

1	During	during	IN	_	2	case
2	phenytoin	phenytoin	NN	_	17	nmod
3	and	and	CC	_	2	cc
4	fluvoxamine	fluvoxamine	NN	_	5	compound
5	treatment	treatment	NN	_	2	conj
6	,	,	,	_	17	punct
7	ataxia	ataxia	NN	_	17	nsubjpass
8	,	,	,	_	7	punct
9	a	a	DT	_	12	det
10	typical	typical	JJ	_	12	amod
11	side	side	NN	_	12	compound
12	effect	effect	NN	_	7	appos
13	of	of	IN	_	14	case
14	phenytoin	phenytoin	NN	_	12	nmod
15	,	,	,	_	7	punct
16	was	be	VBD	_	17	auxpass
17	observed	observe	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	genotypes	genotype	NNS	_	16	nsubj
3	of	of	IN	_	4	case
4	CYP2C9	cyp2c9	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	2C19	2c19	NN	_	4	conj
7	,	,	,	_	2	punct
8	the	the	DT	_	9	det
9	enzymes	enzyme	NNS	_	2	appos
10	responsible	responsible	JJ	_	9	amod
11	for	for	IN	_	13	case
12	phenytoin	phenytoin	NN	_	13	compound
13	metabolism	metabolism	NN	_	10	nmod
14	,	,	,	_	2	punct
15	were	be	VBD	_	16	cop
16	homozygous	homozygous	JJ	_	0	ROOT
17	for	for	IN	_	18	case
18	the	the	DT	_	16	nmod
19	wild	wild	JJ	_	23	dep
20	-	-	:	_	23	punct
21	type	type	NN	_	22	compound
22	alleles	allele	NNS	_	23	nsubj
23	(	(	VBP	_	18	root
24	CYP2C9	cyp2c9	NN	_	23	xcomp
25	*	*	SYM	_	26	dep
26	1	1	CD	_	24	dep
27	/	/	:	_	26	punct
28	*	*	SYM	_	29	dep
29	1	1	CD	_	26	dep
30	and	and	CC	_	29	cc
31	2C19	2c19	CD	_	33	compound
32	*	*	SYM	_	33	dep
33	1	1	CD	_	29	conj
34	/	/	:	_	26	punct
35	*	*	SYM	_	37	dep
36	1	1	CD	_	37	nummod
37	)	)	NN	_	26	dep
38	.	.	.	_	23	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	a	a	DT	_	6	det
6	result	result	NN	_	0	ROOT
7	of	of	IN	_	8	case
8	inhibition	inhibition	NN	_	6	nmod
9	of	of	IN	_	11	case
10	both	both	CC	_	11	cc:preconj
11	CYP2C9	cyp2c9	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	2C19	2c19	NN	_	11	conj
14	by	by	IN	_	15	case
15	fluvoxamine	fluvoxamine	NN	_	8	nmod
16	.	.	.	_	6	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	evaluation	evaluation	NN	_	0	ROOT
3	of	of	IN	_	8	case
4	the	the	DT	_	8	det
5	digoxin	digoxin	NN	_	8	compound
6	-	-	:	_	8	punct
7	amiodarone	amiodarone	NN	_	8	compound
8	interaction	interaction	NN	_	2	nmod
9	.	.	.	_	2	punct

1	Amiodarone	Amiodarone	NNP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	raise	raise	VB	_	3	xcomp
6	serum	serum	NN	_	8	compound
7	digoxin	digoxin	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	designed	design	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	evaluate	evaluate	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
9	basis	basis	NN	_	6	dobj
10	of	of	IN	_	12	case
11	this	this	DT	_	12	det
12	interaction	interaction	NN	_	9	nmod
13	in	in	IN	_	16	case
14	10	10	CD	_	16	nummod
15	normal	normal	JJ	_	16	amod
16	subjects	subject	NNS	_	12	nmod
17	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	variables	variable	NNS	_	7	nsubjpass
4	for	for	IN	_	5	case
5	digoxin	digoxin	NN	_	3	nmod
6	were	be	VBD	_	7	auxpass
7	determined	determine	VBN	_	0	ROOT
8	after	after	IN	_	13	case
9	a	a	DT	_	13	det
10	1.0	1.0	CD	_	11	compound
11	mg	mg	NN	_	13	amod
12	intravenous	intravenous	JJ	_	13	amod
13	dose	dose	NN	_	7	nmod
14	of	of	IN	_	15	case
15	digoxin	digoxin	NN	_	13	nmod
16	in	in	IN	_	18	case
17	each	each	DT	_	18	det
18	subject	subject	NN	_	13	nmod
19	,	,	,	_	7	punct
20	before	before	IN	_	24	nmod
21	and	and	CC	_	20	cc
22	after	after	IN	_	20	conj
23	oral	oral	JJ	_	24	amod
24	amiodarone	amiodarone	NN	_	7	nmod
25	,	,	,	_	24	punct
26	400	400	CD	_	27	nummod
27	mg	mg	NN	_	24	appos
28	daily	daily	RB	_	27	advmod
29	for	for	IN	_	31	case
30	3	3	CD	_	31	nummod
31	weeks	week	NNS	_	27	nmod
32	.	.	.	_	7	punct

1	During	during	IN	_	3	case
2	amiodarone	amiodarone	NN	_	3	compound
3	administration	administration	NN	_	10	nmod
4	,	,	,	_	10	punct
5	systemic	systemic	JJ	_	6	amod
6	clearance	clearance	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	digoxin	digoxin	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	from	from	IN	_	12	case
12	234	234	CD	_	10	nmod
13	+	+	CC	_	12	cc
14	/	/	:	_	17	punct
15	-	-	:	_	17	punct
16	72	72	CD	_	17	nummod
17	ml	ml	NN	_	12	conj
18	/	/	:	_	17	punct
19	min	min	NN	_	21	compound
20	(	(	CD	_	21	nummod
21	mean	mean	NN	_	17	dep
22	+	+	CC	_	21	cc
23	/	/	:	_	26	punct
24	-	-	:	_	26	punct
25	standard	standard	JJ	_	26	amod
26	deviation	deviation	NN	_	21	conj
27	)	)	CD	_	29	compound
28	to	to	TO	_	29	dep
29	172	172	CD	_	26	nummod
30	+	+	CC	_	26	cc
31	/	/	:	_	26	punct
32	-	-	:	_	26	punct
33	33	33	CD	_	34	nummod
34	ml	ml	NN	_	26	dep
35	/	/	:	_	26	punct
36	min	min	NN	_	38	compound
37	(	(	NN	_	38	compound
38	p	p	NN	_	26	dep
39	less	less	JJR	_	41	advmod
40	than	than	IN	_	39	mwe
41	0.01	0.01	CD	_	42	nummod
42	)	)	CD	_	38	nummod
43	.	.	.	_	10	punct

1	This	this	DT	_	3	nsubj
2	was	be	VBD	_	3	cop
3	due	due	JJ	_	0	ROOT
4	to	to	TO	_	5	case
5	reductions	reduction	NNS	_	3	nmod
6	in	in	IN	_	9	case
7	both	both	DT	_	9	det
8	renal	renal	JJ	_	9	amod
9	clearance	clearance	NN	_	5	nmod
10	(	(	CD	_	9	nummod
11	from	from	IN	_	12	case
12	105	105	CD	_	9	nmod
13	+	+	CC	_	12	cc
14	/	/	:	_	12	punct
15	-	-	:	_	14	punct
16	39	39	CD	_	18	compound
17	to	to	TO	_	18	dep
18	84	84	CD	_	15	root
19	+	+	CC	_	18	cc
20	/	/	:	_	23	punct
21	-	-	:	_	23	punct
22	15	15	CD	_	23	nummod
23	ml	ml	NN	_	18	conj
24	/	/	:	_	23	punct
25	min	min	NN	_	28	compound
26	)	)	CD	_	28	nummod
27	(	(	NN	_	28	compound
28	p	p	NN	_	23	dep
29	less	less	JJR	_	31	advmod
30	than	than	IN	_	29	mwe
31	0.05	0.05	CD	_	32	nummod
32	)	)	NN	_	28	dep
33	and	and	CC	_	32	cc
34	nonrenal	nonrenal	JJ	_	35	amod
35	clearance	clearance	NN	_	32	conj
36	(	(	CD	_	35	nummod
37	from	from	IN	_	38	case
38	130	130	CD	_	35	nmod
39	+	+	CC	_	38	cc
40	/	/	:	_	38	punct
41	-	-	:	_	40	punct
42	38	38	CD	_	44	compound
43	to	to	TO	_	44	dep
44	88	88	CD	_	41	root
45	+	+	CC	_	44	cc
46	/	/	:	_	49	punct
47	-	-	:	_	49	punct
48	20	20	CD	_	49	nummod
49	ml	ml	NN	_	44	conj
50	/	/	:	_	49	punct
51	min	min	NN	_	54	compound
52	)	)	CD	_	54	nummod
53	(	(	NN	_	54	compound
54	p	p	NN	_	49	dep
55	less	less	JJR	_	57	advmod
56	than	than	IN	_	55	mwe
57	0.01	0.01	CD	_	58	nummod
58	)	)	CD	_	54	dep
59	.	.	.	_	44	punct

1	Digoxin	Digoxin	NNP	_	2	compound
2	half	half	NN	_	8	nsubjpass
3	-	-	:	_	2	punct
4	life	life	NN	_	2	dep
5	of	of	IN	_	6	case
6	elimination	elimination	NN	_	4	nmod
7	was	be	VBD	_	8	auxpass
8	prolonged	prolong	VBN	_	0	ROOT
9	from	from	IN	_	10	case
10	34	34	CD	_	8	nmod
11	+	+	CC	_	10	cc
12	/	/	:	_	10	punct
13	-	-	:	_	12	punct
14	13	13	CD	_	16	compound
15	to	to	TO	_	16	dep
16	40	40	CD	_	13	root
17	+	+	CC	_	16	cc
18	/	/	:	_	16	punct
19	-	-	:	_	18	punct
20	16	16	CD	_	21	nummod
21	hours	hour	NNS	_	19	root
22	(	(	CD	_	23	nummod
23	p	p	NN	_	21	dep
24	less	less	JJR	_	27	advmod
25	than	than	IN	_	24	mwe
26	0.05	0.05	CD	_	27	compound
27	)	)	CD	_	23	nummod
28	.	.	.	_	21	punct

1	Digoxin	digoxin	NN	_	2	compound
2	volume	volume	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	distribution	distribution	NN	_	2	nmod
5	was	be	VBD	_	8	auxpass
6	not	not	RB	_	8	neg
7	significantly	significantly	RB	_	8	advmod
8	changed	change	VBD	_	0	ROOT
9	.	.	.	_	8	punct

1	Amiodarone	amiodarone	NN	_	2	nsubj
2	caused	cause	VBD	_	0	ROOT
3	a	a	DT	_	8	det
4	three	three	CD	_	7	dep
5	-	-	:	_	4	punct
6	to	to	TO	_	7	dep
7	fivefold	fivefold	JJ	_	8	amod
8	increase	increase	NN	_	2	dobj
9	in	in	IN	_	13	case
10	serum	serum	NN	_	13	compound
11	reverse	reverse	JJ	_	13	amod
12	triiodothyronine	triiodothyronine	NN	_	13	compound
13	levels	level	NNS	_	8	nmod
14	,	,	,	_	2	punct
15	but	but	CC	_	2	cc
16	changes	change	NNS	_	23	nsubj
17	in	in	IN	_	19	case
18	thyroid	thyroid	NN	_	19	compound
19	function	function	NN	_	16	nmod
20	were	be	VBD	_	23	cop
21	not	not	RB	_	23	neg
22	quantitatively	quantitatively	RB	_	23	advmod
23	related	related	JJ	_	2	conj
24	to	to	TO	_	26	case
25	the	the	DT	_	26	det
26	changes	change	NNS	_	23	nmod
27	in	in	IN	_	29	case
28	digoxin	digoxin	NN	_	29	compound
29	pharmacokinetics	pharmacokinetic	NNS	_	26	nmod
30	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	alterations	alteration	NNS	_	9	nsubj
3	in	in	IN	_	5	case
4	digoxin	digoxin	NN	_	5	compound
5	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
6	produced	produce	VBN	_	5	acl
7	by	by	IN	_	8	case
8	amiodarone	amiodarone	NN	_	6	nmod
9	explain	explain	VBP	_	0	ROOT
10	the	the	DT	_	11	det
11	increase	increase	NN	_	9	dobj
12	in	in	IN	_	15	case
13	serum	serum	NN	_	15	compound
14	digoxin	digoxin	NN	_	15	compound
15	level	level	NN	_	11	nmod
16	that	that	WDT	_	19	nsubjpass
17	has	have	VBZ	_	19	aux
18	been	be	VBN	_	19	auxpass
19	observed	observe	VBN	_	11	acl:relcl
20	when	when	WRB	_	26	advmod
21	this	this	DT	_	23	det
22	drug	drug	NN	_	23	compound
23	combination	combination	NN	_	26	nsubjpass
24	has	have	VBZ	_	26	aux
25	been	be	VBN	_	26	auxpass
26	used	use	VBN	_	19	advcl
27	clinically	clinically	RB	_	26	advmod
28	.	.	.	_	9	punct

1	Activation	activation	NN	_	0	ROOT
2	of	of	IN	_	9	case
3	an	a	DT	_	9	det
4	effector	effector	NN	_	9	compound
5	immediate	immediate	JJ	_	9	amod
6	-	-	:	_	9	punct
7	early	early	JJ	_	9	amod
8	gene	gene	NN	_	9	compound
9	arc	arc	NN	_	1	nmod
10	by	by	IN	_	11	case
11	methamphetamine	methamphetamine	NN	_	1	nmod
12	.	.	.	_	1	punct

1	As	as	IN	_	0	ROOT
2	immediate	immediate	JJ	_	6	dep
3	-	-	:	_	6	punct
4	early	early	JJ	_	5	amod
5	genes	gene	NNS	_	6	nsubj
6	(	(	VBP	_	1	root
7	IEGs	ieg	NNS	_	10	nsubjpass
8	)	)	CD	_	7	nummod
9	are	be	VBP	_	10	auxpass
10	thought	think	VBN	_	6	ccomp
11	to	to	TO	_	12	mark
12	play	play	VB	_	10	xcomp
13	a	a	DT	_	15	det
14	critical	critical	JJ	_	15	amod
15	role	role	NN	_	12	dobj
16	in	in	IN	_	17	mark
17	mediating	mediate	VBG	_	12	advcl
18	stimulus	stimulus	NN	_	17	dobj
19	-	-	:	_	18	punct
20	induced	induce	VBN	_	22	amod
21	neural	neural	JJ	_	22	amod
22	plasticity	plasticity	NN	_	34	nsubjpass
23	,	,	,	_	22	punct
24	IEG	ieg	NN	_	25	compound
25	response	response	NN	_	22	appos
26	induced	induce	VBN	_	25	acl
27	by	by	IN	_	31	case
28	methamphetamine	methamphetamine	NN	_	31	compound
29	(	(	CD	_	31	nummod
30	METH	meth	NN	_	31	compound
31	)	)	NN	_	26	nmod
32	has	have	VBZ	_	34	aux
33	been	be	VBN	_	34	auxpass
34	characterized	characterize	VBN	_	18	dep
35	to	to	TO	_	36	mark
36	define	define	VB	_	34	xcomp
37	the	the	DT	_	38	det
38	changes	change	NNS	_	36	dobj
39	in	in	IN	_	41	case
40	gene	gene	NN	_	41	compound
41	expression	expression	NN	_	38	nmod
42	that	that	WDT	_	44	nsubj
43	may	may	MD	_	44	aux
44	underlie	underlie	VB	_	38	acl:relcl
45	its	its	PRP$	_	50	nmod:poss
46	long	long	JJ	_	50	amod
47	-	-	:	_	50	punct
48	lasting	lasting	JJ	_	50	amod
49	behavioral	behavioral	JJ	_	50	amod
50	effects	effect	NNS	_	44	dobj
51	.	.	.	_	6	punct

1	Although	although	IN	_	10	mark
2	activation	activation	NN	_	10	nsubjpass
3	of	of	IN	_	7	case
4	several	several	JJ	_	7	amod
5	transcription	transcription	NN	_	7	compound
6	factor	factor	NN	_	7	compound
7	IEGs	ieg	NNS	_	2	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	described	describe	VBN	_	14	advcl
11	,	,	,	_	14	punct
12	little	little	JJ	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	known	know	VBN	_	0	ROOT
15	about	about	IN	_	17	case
16	effector	effector	NN	_	17	compound
17	IEGs	ieg	NNS	_	14	nmod
18	.	.	.	_	14	punct

1	Here	here	RB	_	5	advmod
2	,	,	,	_	5	punct
3	we	we	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	examined	examine	VBN	_	0	ROOT
6	whether	whether	IN	_	9	mark
7	METH	METH	NNP	_	8	compound
8	administration	administration	NN	_	9	nsubj
9	affects	affect	VBZ	_	5	ccomp
10	expression	expression	NN	_	9	dobj
11	of	of	IN	_	17	case
12	an	a	DT	_	17	det
13	effector	effector	NN	_	17	compound
14	IEG	IEG	NNP	_	17	compound
15	arc	arc	NN	_	17	compound
16	(	(	NN	_	17	compound
17	activity	activity	NN	_	10	nmod
18	-	-	:	_	17	punct
19	regulated	regulate	VBN	_	17	acl
20	,	,	,	_	19	punct
21	cytoskeleton	cytoskeleton	NN	_	24	compound
22	-	-	:	_	24	punct
23	associated	associate	VBN	_	24	amod
24	)	)	NN	_	19	dobj
25	that	that	WDT	_	26	nsubj
26	encodes	encode	VBZ	_	24	acl:relcl
27	a	a	DT	_	28	det
28	protein	protein	NN	_	26	dobj
29	with	with	IN	_	30	case
30	homology	homology	NN	_	28	nmod
31	to	to	TO	_	32	case
32	spectrin	spectrin	NN	_	30	nmod
33	.	.	.	_	5	punct

1	Using	use	VBG	_	7	advcl
2	in	in	FW	_	4	amod
3	situ	situ	FW	_	2	dep
4	hybridization	hybridization	NN	_	1	dobj
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	observed	observe	VBD	_	0	ROOT
8	that	that	IN	_	10	mark
9	METH	meth	NN	_	10	nsubj
10	caused	cause	VBD	_	7	ccomp
11	a	a	DT	_	15	det
12	rapid	rapid	JJ	_	15	amod
13	and	and	CC	_	12	cc
14	transient	transient	JJ	_	12	conj
15	dose	dose	NN	_	10	dobj
16	-	-	:	_	15	punct
17	dependent	dependent	JJ	_	18	amod
18	increase	increase	NN	_	15	dep
19	in	in	IN	_	22	case
20	arc	arc	NN	_	22	compound
21	mRNA	mrna	NN	_	22	compound
22	level	level	NN	_	18	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	striatum	striatum	NN	_	18	nmod
26	and	and	CC	_	25	cc
27	cortex	cortex	NN	_	25	conj
28	that	that	WDT	_	30	nsubjpass
29	was	be	VBD	_	30	auxpass
30	abolished	abolish	VBN	_	25	acl:relcl
31	by	by	IN	_	32	case
32	pretreatment	pretreatment	NN	_	30	nmod
33	with	with	IN	_	40	case
34	the	the	DT	_	40	det
35	specific	specific	JJ	_	40	amod
36	dopamine	dopamine	NN	_	40	compound
37	D1	d1	NN	_	40	compound
38	receptor	receptor	NN	_	40	compound
39	antagonist	antagonist	NN	_	40	compound
40	SCH	sch	NN	_	32	nmod
41	-	-	:	_	40	punct
42	23390	23390	CD	_	40	dep
43	but	but	CC	_	44	cc
44	not	not	RB	_	42	cc
45	by	by	IN	_	49	case
46	an	a	DT	_	49	det
47	atypical	atypical	JJ	_	49	amod
48	neuroleptic	neuroleptic	JJ	_	49	amod
49	clozapine	clozapine	NN	_	42	conj
50	.	.	.	_	7	punct

1	METH	meth	NN	_	2	nsubj
2	induced	induce	VBD	_	17	csubj
3	arc	arc	NN	_	4	compound
4	mRNA	mrna	NN	_	2	dobj
5	in	in	IN	_	6	case
6	layers	layer	NNS	_	2	nmod
7	IV	iv	CD	_	6	nummod
8	and	and	CC	_	6	cc
9	VI	VI	NNP	_	6	conj
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	cortex	cortex	NN	_	6	nmod
13	which	which	WDT	_	15	det
14	dopamine	dopamine	NN	_	15	compound
15	receptor	receptor	NN	_	12	dep
16	are	be	VBP	_	17	cop
17	localized	localized	JJ	_	0	ROOT
18	to	to	TO	_	17	nmod
19	.	.	.	_	17	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	D1	d1	NN	_	6	compound
6	receptors	receptor	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	coupled	couple	VBN	_	3	ccomp
9	to	to	TO	_	10	case
10	activation	activation	NN	_	8	nmod
11	of	of	IN	_	13	case
12	arc	arc	NN	_	13	compound
13	gene	gene	NN	_	10	nmod
14	,	,	,	_	10	punct
15	which	which	WDT	_	18	nsubjpass
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	involved	involve	VBN	_	10	acl:relcl
19	in	in	IN	_	23	case
20	functional	functional	JJ	_	23	amod
21	or	or	CC	_	20	cc
22	structural	structural	JJ	_	20	conj
23	alterations	alteration	NNS	_	18	nmod
24	underlying	underlie	VBG	_	23	acl
25	neural	neural	JJ	_	26	amod
26	plasticity	plasticity	NN	_	24	dobj
27	triggered	trigger	VBN	_	26	acl
28	by	by	IN	_	29	case
29	METH	meth	NN	_	27	nmod
30	.	.	.	_	3	punct

1	Differential	differential	JJ	_	2	amod
2	actions	action	NNS	_	0	ROOT
3	of	of	IN	_	5	case
4	intrathecal	intrathecal	JJ	_	5	amod
5	naloxone	naloxone	NN	_	2	nmod
6	on	on	IN	_	7	mark
7	blocking	block	VBG	_	2	acl
8	the	the	DT	_	9	det
9	tail	tail	NN	_	7	dobj
10	-	-	:	_	2	punct
11	flick	flick	NN	_	12	compound
12	inhibition	inhibition	NN	_	2	dep
13	induced	induce	VBN	_	12	acl
14	by	by	IN	_	16	case
15	intraventricular	intraventricular	JJ	_	16	amod
16	beta	beta	NN	_	13	nmod
17	-	-	:	_	16	punct
18	endorphin	endorphin	NN	_	16	dep
19	and	and	CC	_	18	cc
20	morphine	morphine	NN	_	18	conj
21	in	in	IN	_	22	case
22	rats	rat	NNS	_	12	nmod
23	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	8	nmod
5	,	,	,	_	8	punct
6	it	it	PRP	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	proposed	propose	VBN	_	0	ROOT
9	that	that	IN	_	12	mark
10	the	the	DT	_	11	det
11	opioids	opioid	NNS	_	12	nsubj
12	applied	apply	VBD	_	8	ccomp
13	to	to	TO	_	16	case
14	supraspinal	supraspinal	JJ	_	16	amod
15	brain	brain	NN	_	16	compound
16	sites	site	NNS	_	12	nmod
17	produced	produce	VBD	_	12	xcomp
18	their	they	PRP$	_	20	nmod:poss
19	analgesic	analgesic	JJ	_	20	amod
20	effects	effect	NNS	_	17	dobj
21	by	by	IN	_	23	case
22	the	the	DT	_	23	det
23	activation	activation	NN	_	17	nmod
24	of	of	IN	_	29	case
25	different	different	JJ	_	29	amod
26	descending	descend	VBG	_	29	amod
27	pain	pain	NN	_	29	compound
28	inhibitory	inhibitory	JJ	_	29	amod
29	systems	system	NNS	_	23	nmod
30	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	blockade	blockade	NN	_	29	nsubjpass
3	of	of	IN	_	7	case
4	the	the	DT	_	7	det
5	spinal	spinal	JJ	_	7	amod
6	endorphinergic	endorphinergic	JJ	_	7	amod
7	system	system	NN	_	2	nmod
8	by	by	IN	_	10	case
9	intrathecal	intrathecal	JJ	_	10	amod
10	naloxone	naloxone	NN	_	2	nmod
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	production	production	NN	_	2	nmod
14	of	of	IN	_	15	case
15	tail	tail	NN	_	13	nmod
16	-	-	:	_	2	punct
17	flick	flick	NN	_	18	compound
18	inhibition	inhibition	NN	_	2	dep
19	induced	induce	VBN	_	18	acl
20	by	by	IN	_	22	case
21	intraventricular	intraventricular	JJ	_	22	amod
22	beta	beta	NN	_	19	nmod
23	-	-	:	_	22	punct
24	endorphin	endorphin	NN	_	22	dep
25	and	and	CC	_	24	cc
26	morphine	morphine	NN	_	24	conj
27	was	be	VBD	_	29	auxpass
28	then	then	RB	_	29	advmod
29	studied	study	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	Intraventricular	intraventricular	JJ	_	2	amod
2	injection	injection	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	beta	beta	NN	_	2	nmod
5	-	-	:	_	4	punct
6	endorphin	endorphin	NN	_	4	dep
7	and	and	CC	_	6	cc
8	morphine	morphine	NN	_	6	conj
9	produced	produce	VBD	_	0	ROOT
10	an	a	DT	_	11	det
11	inhibition	inhibition	NN	_	9	dobj
12	of	of	IN	_	17	case
13	the	the	DT	_	17	det
14	tail	tail	NN	_	17	compound
15	-	-	:	_	17	punct
16	flick	flick	NN	_	17	compound
17	response	response	NN	_	11	nmod
18	to	to	TO	_	21	case
19	the	the	DT	_	21	det
20	heat	heat	NN	_	21	compound
21	stimulus	stimulus	NN	_	17	nmod
22	in	in	IN	_	23	case
23	rats	rat	NNS	_	17	nmod
24	.	.	.	_	9	punct

1	Intrathecal	intrathecal	JJ	_	2	amod
2	injection	injection	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	naloxone	naloxone	NN	_	2	nmod
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	2	nmod
7	of	of	IN	_	11	case
8	0.4	0.4	CD	_	10	compound
9	to	to	TO	_	10	dep
10	40	40	CD	_	11	nummod
11	micrograms	microgram	NNS	_	6	nmod
12	caused	cause	VBD	_	0	ROOT
13	a	a	DT	_	14	det
14	dose	dose	NN	_	12	dobj
15	-	-	:	_	14	punct
16	related	related	JJ	_	17	amod
17	blockade	blockade	NN	_	14	dep
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	inhibition	inhibition	NN	_	17	nmod
21	of	of	IN	_	26	case
22	the	the	DT	_	26	det
23	tail	tail	NN	_	26	compound
24	-	-	:	_	26	punct
25	flick	flick	NN	_	26	compound
26	response	response	NN	_	20	nmod
27	induced	induce	VBN	_	26	acl
28	by	by	IN	_	30	case
29	intraventricular	intraventricular	JJ	_	30	amod
30	injection	injection	NN	_	27	nmod
31	of	of	IN	_	32	case
32	beta	beta	NN	_	30	nmod
33	-	-	:	_	17	punct
34	endorphin	endorphin	NN	_	17	dep
35	,	,	,	_	17	punct
36	and	and	CC	_	17	cc
37	a	a	DT	_	39	det
38	high	high	JJ	_	39	amod
39	dose	dose	NN	_	17	conj
40	of	of	IN	_	41	case
41	naloxone	naloxone	NN	_	39	nmod
42	(	(	CD	_	43	compound
43	40	40	CD	_	41	nummod
44	micrograms	microgram	NNS	_	47	nsubj
45	)	)	VBP	_	47	aux
46	completely	completely	RB	_	47	advmod
47	blocked	block	VBN	_	39	acl:relcl
48	the	the	DT	_	49	det
49	tail	tail	NN	_	47	dobj
50	-	-	:	_	39	punct
51	flick	flick	NN	_	52	compound
52	inhibition	inhibition	NN	_	39	dep
53	induced	induce	VBN	_	52	acl
54	by	by	IN	_	56	case
55	intraventricular	intraventricular	JJ	_	56	amod
56	beta	beta	NN	_	53	nmod
57	-	-	:	_	39	punct
58	endorphin	endorphin	JJ	_	61	amod
59	(	(	NN	_	61	compound
60	16	16	CD	_	61	nummod
61	micrograms	microgram	NNS	_	62	compound
62	)	)	NN	_	39	dep
63	.	.	.	_	12	punct

1	On	on	IN	_	4	case
2	the	the	DT	_	4	det
3	other	other	JJ	_	4	amod
4	hand	hand	NN	_	8	nmod
5	,	,	,	_	8	punct
6	intrathecal	intrathecal	JJ	_	8	amod
7	naloxone	naloxone	NN	_	8	compound
8	(	(	NN	_	0	ROOT
9	12	12	CD	_	14	dep
10	-	-	:	_	14	punct
11	120	120	CD	_	13	nummod
12	micrograms	microgram	NNS	_	13	compound
13	)	)	NN	_	14	nsubj
14	had	have	VBD	_	8	ccomp
15	only	only	RB	_	19	advmod
16	a	a	DT	_	19	det
17	very	very	RB	_	18	advmod
18	weak	weak	JJ	_	19	amod
19	effect	effect	NN	_	14	dobj
20	on	on	IN	_	22	case
21	the	the	DT	_	22	det
22	tail	tail	NN	_	19	nmod
23	-	-	:	_	22	punct
24	flick	flick	NN	_	25	compound
25	inhibition	inhibition	NN	_	22	dep
26	induced	induce	VBN	_	25	acl
27	by	by	IN	_	29	case
28	intraventricular	intraventricular	JJ	_	29	amod
29	morphine	morphine	NN	_	26	nmod
30	(	(	CD	_	31	compound
31	40	40	CD	_	32	nummod
32	micrograms	microgram	NNS	_	29	dep
33	)	)	NN	_	32	dep
34	.	.	.	_	8	punct

1	Intraventricular	intraventricular	JJ	_	2	amod
2	injection	injection	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	naloxone	naloxone	NN	_	2	nmod
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	2	nmod
7	of	of	IN	_	11	case
8	1.2	1.2	CD	_	10	compound
9	to	to	TO	_	10	dep
10	12	12	CD	_	11	nummod
11	micrograms	microgram	NNS	_	6	nmod
12	equally	equally	RB	_	13	advmod
13	antagonized	antagonize	VBD	_	0	ROOT
14	in	in	IN	_	19	case
15	a	a	DT	_	19	det
16	dose	dose	NN	_	19	compound
17	-	-	:	_	19	punct
18	dependent	dependent	JJ	_	19	amod
19	manner	manner	NN	_	13	nmod
20	the	the	DT	_	21	det
21	tail	tail	NN	_	19	dep
22	-	-	:	_	21	punct
23	flick	flick	NN	_	24	compound
24	inhibition	inhibition	NN	_	21	dep
25	induced	induce	VBN	_	24	acl
26	by	by	IN	_	28	case
27	intraventricular	intraventricular	JJ	_	28	amod
28	beta	beta	NN	_	25	nmod
29	-	-	:	_	28	punct
30	endorphin	endorphin	NN	_	28	dep
31	and	and	CC	_	30	cc
32	morphine	morphine	NN	_	30	conj
33	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	13	mark
5	a	a	DT	_	7	det
6	spinal	spinal	JJ	_	7	amod
7	naloxone	naloxone	NN	_	13	nsubjpass
8	-	-	:	_	7	punct
9	sensitive	sensitive	JJ	_	11	amod
10	endorphinergic	endorphinergic	JJ	_	11	amod
11	system	system	NN	_	7	dep
12	is	be	VBZ	_	13	auxpass
13	involved	involve	VBN	_	3	ccomp
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	production	production	NN	_	13	nmod
17	of	of	IN	_	18	case
18	beta	beta	NN	_	16	nmod
19	-	-	:	_	18	punct
20	endorphin	endorphin	NN	_	18	dep
21	but	but	CC	_	22	cc
22	not	not	RB	_	20	cc
23	morphine	morphine	NN	_	20	conj
24	-	-	:	_	18	punct
25	induced	induce	VBN	_	29	amod
26	tail	tail	NN	_	29	compound
27	-	-	:	_	29	punct
28	flick	flick	NN	_	29	compound
29	inhibition	inhibition	NN	_	18	dep
30	,	,	,	_	13	punct
31	and	and	CC	_	13	cc
32	suggest	suggest	VBP	_	13	conj
33	that	that	IN	_	40	mark
34	intraventricular	intraventricular	JJ	_	35	amod
35	beta	beta	NN	_	40	nsubj
36	-	-	:	_	35	punct
37	endorphin	endorphin	NN	_	35	dep
38	and	and	CC	_	37	cc
39	morphine	morphine	NN	_	37	conj
40	elicit	elicit	VBP	_	32	ccomp
41	their	they	PRP$	_	43	nmod:poss
42	pharmacological	pharmacological	JJ	_	43	amod
43	actions	action	NNS	_	40	dobj
44	via	via	IN	_	46	case
45	the	the	DT	_	46	det
46	activation	activation	NN	_	40	nmod
47	of	of	IN	_	52	case
48	different	different	JJ	_	52	amod
49	descending	descend	VBG	_	52	amod
50	pain	pain	NN	_	52	compound
51	inhibitory	inhibitory	JJ	_	52	amod
52	systems	system	NNS	_	46	nmod
53	;	;	:	_	3	punct

1	descending	descend	VBG	_	16	advcl
2	epsilon	epsilon	NN	_	5	compound
3	and	and	CC	_	2	cc
4	mu	mu	NN	_	2	conj
5	systems	system	NNS	_	1	dobj
6	for	for	IN	_	7	case
7	beta	beta	NN	_	5	nmod
8	-	-	:	_	7	punct
9	endorphin	endorphin	NN	_	7	dep
10	and	and	CC	_	9	cc
11	morphine	morphine	NN	_	9	conj
12	,	,	,	_	7	punct
13	respectively	respectively	RB	_	7	advmod
14	,	,	,	_	16	punct
15	are	be	VBP	_	16	auxpass
16	proposed	propose	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Pharmacological	pharmacological	JJ	_	2	amod
2	treatment	treatment	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	depression	depression	NN	_	2	nmod
5	:	:	:	_	2	punct
6	the	the	DT	_	7	det
7	role	role	NN	_	2	dep
8	of	of	IN	_	9	case
9	paroxetine	paroxetine	NN	_	7	nmod
10	.	.	.	_	2	punct

1	Depression	depression	NN	_	3	nsubj
2	is	be	VBZ	_	3	aux
3	reaching	reach	VBG	_	0	ROOT
4	epidemic	epidemic	JJ	_	5	amod
5	proportions	proportion	NNS	_	3	dobj
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	western	western	JJ	_	9	amod
9	world	world	NN	_	3	nmod
10	.	.	.	_	3	punct

1	With	with	IN	_	0	ROOT
2	each	each	DT	_	4	det
3	successive	successive	JJ	_	4	amod
4	generation	generation	NN	_	1	dep
5	more	more	JJR	_	6	amod
6	people	people	NNS	_	8	nsubj
7	are	be	VBP	_	8	aux
8	becoming	become	VBG	_	4	acl:relcl
9	more	more	RBR	_	10	advmod
10	severely	severely	RB	_	11	advmod
11	depressed	depress	VBN	_	8	xcomp
12	at	at	IN	_	15	case
13	a	a	DT	_	15	det
14	younger	younger	JJR	_	15	amod
15	age	age	NN	_	11	nmod
16	.	.	.	_	1	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	How	how	WRB	_	6	advmod
5	to	to	TO	_	6	mark
6	identify	identify	VB	_	2	dep
7	them	they	PRP	_	6	dobj
8	.	.	.	_	2	punct

1	Interactions	interaction	NNS	_	7	nsubjpass
2	between	between	IN	_	4	case
3	theraputic	theraputic	JJ	_	4	amod
4	agents	agent	NNS	_	1	nmod
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	recognized	recognize	VBN	_	25	csubj
8	as	as	IN	_	11	case
9	increasingly	increasingly	RB	_	10	advmod
10	important	important	JJ	_	11	amod
11	causes	cause	NNS	_	7	nmod
12	of	of	IN	_	13	case
13	drug	drug	NN	_	11	nmod
14	at	at	IN	_	18	case
15	their	they	PRP$	_	18	nmod:poss
16	usual	usual	JJ	_	18	amod
17	recommended	recommend	VBN	_	18	amod
18	dose	dose	NN	_	11	nmod
19	may	may	MD	_	25	aux
20	,	,	,	_	25	punct
21	under	under	IN	_	23	case
22	certain	certain	JJ	_	23	amod
23	conditions	condition	NNS	_	25	nmod
24	,	,	,	_	25	punct
25	produce	produce	VBP	_	0	ROOT
26	toxicity	toxicity	NN	_	25	dobj
27	of	of	IN	_	28	case
28	life	life	NN	_	26	nmod
29	-	-	:	_	25	punct
30	endangering	endanger	VBG	_	25	advcl
31	proportions	proportion	NNS	_	30	dobj
32	.	.	.	_	25	punct

1	While	while	IN	_	12	mark
2	the	the	DT	_	3	det
3	recognition	recognition	NN	_	12	nsubj
4	of	of	IN	_	6	case
5	drug	drug	NN	_	6	compound
6	toxicity	toxicity	NN	_	3	nmod
7	resulting	result	VBG	_	3	acl
8	from	from	IN	_	9	case
9	interactions	interaction	NNS	_	7	nmod
10	is	be	VBZ	_	12	cop
11	of	of	IN	_	12	case
12	importance	importance	NN	_	0	ROOT
13	to	to	TO	_	15	case
14	all	all	DT	_	15	det
15	physciains	physciain	NNS	_	12	nmod
16	,	,	,	_	12	punct
17	it	it	PRP	_	16	root
18	is	be	VBZ	_	17	dep
19	especially	especially	RB	_	20	advmod
20	so	so	RB	_	18	advmod
21	for	for	IN	_	23	case
22	the	the	DT	_	23	det
23	clinician	clinician	NN	_	20	nmod
24	responsible	responsible	JJ	_	23	amod
25	for	for	IN	_	27	case
26	the	the	DT	_	27	det
27	welfare	welfare	NN	_	24	nmod
28	of	of	IN	_	29	case
29	those	those	DT	_	27	nmod
30	in	in	IN	_	33	case
31	the	the	DT	_	33	det
32	aerospace	aerospace	NN	_	33	compound
33	environment	environment	NN	_	29	nmod
34	.	.	.	_	18	punct

1	This	this	DT	_	2	det
2	paper	paper	NN	_	3	nsubj
3	attempts	attempt	VBZ	_	0	ROOT
4	to	to	TO	_	5	mark
5	provide	provide	VB	_	3	xcomp
6	a	a	DT	_	7	det
7	basis	basis	NN	_	5	dobj
8	for	for	IN	_	10	case
9	the	the	DT	_	10	det
10	understanding	understanding	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	identifications	identification	NNS	_	10	conj
13	of	of	IN	_	16	case
14	important	important	JJ	_	16	amod
15	drug	drug	NN	_	16	compound
16	interactions	interaction	NNS	_	10	nmod
17	.	.	.	_	3	punct

1	Guidelines	guideline	NNS	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	provided	provide	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	assist	assist	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	clinician	clinician	NN	_	5	dobj
8	in	in	IN	_	11	case
9	his	he	PRP$	_	11	nmod:poss
10	logical	logical	JJ	_	11	amod
11	approach	approach	NN	_	5	nmod
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	identification	identification	NN	_	11	nmod
15	of	of	IN	_	17	case
16	drug	drug	NN	_	17	compound
17	interactions	interaction	NNS	_	14	nmod
18	when	when	WRB	_	23	advmod
19	serious	serious	JJ	_	21	amod
20	drug	drug	NN	_	21	compound
21	toxicity	toxicity	NN	_	23	nsubjpass
22	is	be	VBZ	_	23	auxpass
23	encountered	encounter	VBN	_	5	advcl
24	in	in	IN	_	26	case
25	a	a	DT	_	26	det
26	pateint	pateint	NN	_	23	nmod
27	.	.	.	_	3	punct

1	Only	only	RB	_	3	advmod
2	with	with	IN	_	3	case
3	knowledge	knowledge	NN	_	12	nmod
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	can	can	MD	_	12	aux
8	the	the	DT	_	10	det
9	therapeutic	therapeutic	JJ	_	10	amod
10	regimen	regimen	NN	_	12	nsubjpass
11	be	be	VB	_	12	auxpass
12	altered	alter	VBN	_	0	ROOT
13	so	so	RB	_	16	advmod
14	as	as	IN	_	16	mark
15	to	to	TO	_	16	mark
16	provide	provide	VB	_	12	advcl
17	therapeutic	therapeutic	JJ	_	18	amod
18	levels	level	NNS	_	16	dobj
19	of	of	IN	_	21	case
20	necessary	necessary	JJ	_	21	amod
21	drugs	drug	NNS	_	18	nmod
22	while	while	IN	_	23	mark
23	avoiding	avoid	VBG	_	16	advcl
24	toxicity	toxicity	NN	_	23	dobj
25	.	.	.	_	12	punct

1	Changes	change	NNS	_	0	ROOT
2	in	in	IN	_	4	case
3	urinary	urinary	JJ	_	4	amod
4	homocysteine	homocysteine	NN	_	1	nmod
5	following	follow	VBG	_	8	case
6	synthetic	synthetic	JJ	_	8	amod
7	steroidal	steroidal	JJ	_	8	amod
8	estrogen	estrogen	NN	_	1	nmod
9	and	and	CC	_	8	cc
10	progestogen	progestogen	NN	_	11	compound
11	administration	administration	NN	_	8	conj
12	to	to	TO	_	13	case
13	rats	rat	NNS	_	8	nmod
14	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	present	present	JJ	_	3	amod
3	work	work	NN	_	4	nsubj
4	involved	involve	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	administration	administration	NN	_	4	dobj
7	of	of	IN	_	10	case
8	both	both	DT	_	10	cc:preconj
9	ethynyl	ethynyl	FW	_	10	compound
10	estradiol	estradiol	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	levonorgestrel	levonorgestrel	NN	_	10	conj
13	to	to	TO	_	14	case
14	groups	group	NNS	_	6	nmod
15	of	of	IN	_	16	case
16	rats	rat	NNS	_	14	nmod
17	,	,	,	_	4	punct
18	followed	follow	VBN	_	4	advcl
19	by	by	IN	_	20	case
20	determination	determination	NN	_	18	nmod
21	of	of	IN	_	25	case
22	the	the	DT	_	25	det
23	homocysteine	homocysteine	NN	_	25	compound
24	excretion	excretion	NN	_	25	compound
25	rate	rate	NN	_	20	nmod
26	in	in	IN	_	27	case
27	urine	urine	NN	_	25	nmod
28	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	a	a	DT	_	8	det
6	statistically	statistically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	difference	difference	NN	_	9	nsubj
9	exists	exist	VBZ	_	3	ccomp
10	between	between	IN	_	13	case
11	the	the	DT	_	13	det
12	excreted	excreted	JJ	_	13	amod
13	levels	level	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	homocysteine	homocysteine	NN	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	urine	urine	NN	_	13	nmod
19	of	of	IN	_	21	case
20	both	both	DT	_	21	cc:preconj
21	control	control	NN	_	18	nmod
22	and	and	CC	_	21	cc
23	levonorgestrel	levonorgestrel	NN	_	21	conj
24	-	-	:	_	9	punct
25	treated	treat	VBN	_	26	amod
26	rats	rat	NNS	_	9	dobj
27	and	and	CC	_	26	cc
28	the	the	DT	_	29	det
29	levels	level	NNS	_	26	conj
30	shown	show	VBN	_	29	acl
31	by	by	IN	_	32	case
32	rats	rat	NNS	_	30	nmod
33	treated	treat	VBN	_	32	acl
34	with	with	IN	_	36	case
35	ethynyl	ethynyl	NN	_	36	compound
36	estradiol	estradiol	NN	_	33	nmod
37	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	implications	implication	NNS	_	7	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	results	result	NNS	_	2	nmod
6	are	be	VBP	_	7	auxpass
7	discussed	discuss	VBN	_	0	ROOT
8	,	,	,	_	7	punct
9	especially	especially	RB	_	11	advmod
10	with	with	IN	_	11	case
11	respect	respect	NN	_	7	nmod
12	to	to	TO	_	13	case
13	observations	observation	NNS	_	11	nmod
14	which	which	WDT	_	15	nsubj
15	indicate	indicate	VBP	_	13	acl:relcl
16	that	that	IN	_	22	mark
17	homocysteine	homocysteine	NN	_	22	nsubj
18	may	may	MD	_	22	aux
19	be	be	VB	_	22	cop
20	a	a	DT	_	22	det
21	precipitating	precipitate	VBG	_	22	amod
22	factor	factor	NN	_	15	ccomp
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	development	development	NN	_	22	nmod
26	of	of	IN	_	27	case
27	thrombosis	thrombosis	NN	_	25	nmod
28	.	.	.	_	7	punct

1	Also	also	RB	_	2	advmod
2	included	include	VBN	_	0	ROOT
3	in	in	IN	_	5	case
4	this	this	DT	_	5	det
5	paper	paper	NN	_	2	nmod
6	is	be	VBZ	_	2	auxpass
7	a	a	DT	_	8	det
8	study	study	NN	_	2	nsubjpass
9	which	which	WDT	_	10	nsubj
10	confirms	confirm	VBZ	_	8	acl:relcl
11	the	the	DT	_	12	det
12	identity	identity	NN	_	10	dobj
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	HPLC	hplc	NN	_	16	compound
16	peak	peak	NN	_	12	nmod
17	as	as	IN	_	19	mark
18	being	be	VBG	_	19	cop
19	homocysteine	homocysteine	NN	_	10	advcl
20	by	by	IN	_	21	mark
21	forming	form	VBG	_	19	acl
22	a	a	DT	_	24	det
23	radioactive	radioactive	JJ	_	24	amod
24	derivative	derivative	NN	_	21	dobj
25	of	of	IN	_	28	case
26	this	this	DT	_	28	det
27	particular	particular	JJ	_	28	amod
28	sulphydryl	sulphydryl	NN	_	24	nmod
29	-	-	:	_	24	punct
30	containing	contain	VBG	_	24	acl
31	amino	amino	NN	_	32	compound
32	acid	acid	NN	_	30	dobj
33	,	,	,	_	10	punct
34	and	and	CC	_	10	cc
35	then	then	RB	_	36	advmod
36	analysing	analyse	VBG	_	10	conj
37	the	the	DT	_	39	det
38	resulting	result	VBG	_	39	amod
39	mixture	mixture	NN	_	36	dobj
40	by	by	IN	_	41	case
41	TLC	tlc	NN	_	36	nmod
42	.	.	.	_	2	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	diazepam	diazepam	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	midazolam	midazolam	NN	_	3	conj
6	on	on	IN	_	9	case
7	the	the	DT	_	9	det
8	antinociceptive	antinociceptive	JJ	_	9	amod
9	effect	effect	NN	_	1	nmod
10	of	of	IN	_	11	case
11	morphine	morphine	NN	_	9	nmod
12	,	,	,	_	11	punct
13	metamizol	metamizol	NN	_	11	conj
14	and	and	CC	_	11	cc
15	indomethacin	indomethacin	NN	_	11	conj
16	in	in	IN	_	17	case
17	mice	mouse	NNS	_	9	nmod
18	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	influence	influence	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	midazolam	midazolam	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	diazepam	diazepam	NN	_	4	conj
7	on	on	IN	_	9	case
8	antinociceptive	antinociceptive	JJ	_	9	amod
9	effect	effect	NN	_	2	nmod
10	of	of	IN	_	14	case
11	morphine	morphine	NN	_	14	compound
12	(	(	CD	_	13	compound
13	10	10	CD	_	14	nummod
14	mg	mg	NN	_	9	nmod
15	/	/	:	_	2	punct
16	kg	kg	NN	_	17	compound
17	)	)	NN	_	35	nsubjpass
18	,	,	,	_	17	punct
19	metamizol	metamizol	NN	_	22	compound
20	(	(	NN	_	22	compound
21	500	500	CD	_	22	nummod
22	mg	mg	NN	_	17	appos
23	/	/	:	_	17	punct
24	kg	kg	NN	_	25	compound
25	)	)	NN	_	17	dep
26	and	and	CC	_	25	cc
27	indomethacin	indomethacin	NN	_	25	conj
28	(	(	CD	_	29	compound
29	10	10	CD	_	30	nummod
30	mg	mg	NN	_	27	dep
31	/	/	:	_	30	punct
32	kg	kg	NN	_	33	compound
33	)	)	NN	_	30	dep
34	was	be	VBD	_	35	auxpass
35	investigated	investigate	VBN	_	49	dep
36	in	in	IN	_	39	case
37	a	a	DT	_	39	det
38	mouse	mouse	NN	_	39	compound
39	model	model	NN	_	35	nmod
40	using	use	VBG	_	39	acl
41	the	the	DT	_	42	det
42	tail	tail	NN	_	40	dobj
43	-	-	:	_	42	punct
44	flick	flick	NN	_	42	dep
45	and	and	CC	_	44	cc
46	hot	hot	JJ	_	44	conj
47	-	-	:	_	49	punct
48	plate	plate	NN	_	49	compound
49	tests	test	NNS	_	2	dep
50	.	.	.	_	2	punct

1	All	all	DT	_	2	det
2	drugs	drug	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	injected	inject	VBN	_	0	ROOT
5	intraperitoneally	intraperitoneally	RB	_	4	advmod
6	.	.	.	_	4	punct

1	Benzodiazepines	benzodiazepine	NNS	_	3	nsubjpass
2	were	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	0	ROOT
4	to	to	TO	_	5	case
5	mice	mouse	NNS	_	3	nmod
6	30	30	CD	_	7	nummod
7	min	min	NN	_	5	nmod
8	before	before	IN	_	7	mark
9	applying	apply	VBG	_	7	dep
10	the	the	DT	_	12	det
11	analgesic	analgesic	JJ	_	12	amod
12	drugs	drug	NNS	_	9	dobj
13	.	.	.	_	3	punct

1	Measurement	measurement	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	nociception	nociception	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	performed	perform	VBN	_	0	ROOT
6	within	within	IN	_	8	case
7	2	2	CD	_	8	nummod
8	h	h	NN	_	5	nmod
9	after	after	IN	_	11	case
10	benzodiazepine	benzodiazepine	NN	_	11	compound
11	administration	administration	NN	_	5	nmod
12	.	.	.	_	5	punct

1	Diazepam	diazepam	NN	_	18	nsubjpass
2	at	at	IN	_	3	case
3	doses	dose	NNS	_	1	nmod
4	of	of	IN	_	6	case
5	0.25	0.25	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	/	/	:	_	6	punct
8	kg	kg	NN	_	6	dep
9	and	and	CC	_	8	cc
10	2.5	2.5	CD	_	11	nummod
11	mg	mg	NN	_	8	conj
12	/	/	:	_	6	punct
13	kg	kg	NN	_	6	dep
14	injected	inject	VBN	_	13	acl
15	with	with	IN	_	16	case
16	morphine	morphine	NN	_	14	nmod
17	was	be	VBD	_	18	auxpass
18	found	find	VBN	_	0	ROOT
19	to	to	TO	_	20	mark
20	decrease	decrease	VB	_	18	xcomp
21	the	the	DT	_	23	det
22	antinociceptive	antinociceptive	JJ	_	23	amod
23	effect	effect	NN	_	20	dobj
24	of	of	IN	_	25	case
25	morphine	morphine	NN	_	23	nmod
26	.	.	.	_	18	punct

1	Similarly	similarly	RB	_	4	advmod
2	,	,	,	_	4	punct
3	diazepam	diazepam	NN	_	4	nsubj
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	antinociceptive	antinociceptive	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	metamizol	metamizol	NN	_	7	nmod
10	(	(	CD	_	9	nummod
11	only	only	RB	_	18	advmod
12	in	in	IN	_	18	case
13	the	the	DT	_	18	det
14	tail	tail	NN	_	18	compound
15	-	-	:	_	18	punct
16	flick	flick	NN	_	18	compound
17	test	test	NN	_	18	compound
18	)	)	NN	_	4	nmod
19	and	and	CC	_	18	cc
20	indomethacin	indomethacin	NN	_	18	conj
21	.	.	.	_	4	punct

1	Midazolam	Midazolam	NNP	_	2	nsubj
2	used	use	VBD	_	0	ROOT
3	at	at	IN	_	4	case
4	doses	dose	NNS	_	2	nmod
5	of	of	IN	_	7	case
6	1.25	1.25	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	/	/	:	_	7	punct
9	kg	kg	NN	_	7	dep
10	and	and	CC	_	9	cc
11	2.5	2.5	CD	_	12	nummod
12	mg	mg	NN	_	9	conj
13	/	/	:	_	7	punct
14	kg	kg	NN	_	7	dep
15	decreased	decrease	VBD	_	2	dep
16	the	the	DT	_	18	det
17	antinociceptive	antinociceptive	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	of	of	IN	_	20	case
20	morphine	morphine	NN	_	18	nmod
21	,	,	,	_	20	punct
22	metamizol	metamizol	NN	_	20	appos
23	(	(	CD	_	22	nummod
24	only	only	RB	_	31	advmod
25	in	in	IN	_	31	case
26	the	the	DT	_	31	det
27	tail	tail	NN	_	31	compound
28	-	-	:	_	31	punct
29	flick	flick	NN	_	31	compound
30	test	test	NN	_	31	compound
31	)	)	NN	_	15	nmod
32	and	and	CC	_	31	cc
33	indomethacin	indomethacin	NN	_	31	conj
34	.	.	.	_	2	punct

1	[	[	NN	_	3	compound
2	The	the	DT	_	3	det
3	effect	effect	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	cimetidine	cimetidine	NN	_	3	nmod
6	on	on	IN	_	9	case
7	the	the	DT	_	9	det
8	renal	renal	JJ	_	9	amod
9	excretion	excretion	NN	_	3	nmod
10	of	of	IN	_	11	case
11	verografin	verografin	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	iodamide	iodamide	NN	_	11	conj
14	in	in	IN	_	15	case
15	dogs	dog	NNS	_	9	nmod
16	]	]	CD	_	15	nummod
17	The	the	DT	_	19	det
18	intravenous	intravenous	JJ	_	19	amod
19	injection	injection	NN	_	15	dep
20	of	of	IN	_	21	case
21	cimetidine	cimetidine	NN	_	19	nmod
22	in	in	IN	_	24	case
23	a	a	DT	_	24	det
24	dose	dose	NN	_	19	nmod
25	of	of	IN	_	27	case
26	20	20	CD	_	27	nummod
27	mg	mg	NN	_	24	nmod
28	/	/	:	_	3	punct
29	kg	kg	NN	_	30	nsubj
30	enhanced	enhance	VBD	_	3	acl:relcl
31	verografine	verografine	NN	_	34	compound
32	and	and	CC	_	31	cc
33	iodamide	iodamide	NN	_	31	conj
34	excretion	excretion	NN	_	30	dobj
35	in	in	IN	_	38	case
36	chronic	chronic	JJ	_	38	amod
37	canine	canine	JJ	_	38	amod
38	experiments	experiment	NNS	_	30	nmod
39	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	higher	higher	JJR	_	3	amod
3	verografine	verografine	NN	_	8	nsubj
4	and	and	CC	_	3	cc
5	iodamide	iodamide	NN	_	6	compound
6	excretion	excretion	NN	_	3	conj
7	was	be	VBD	_	8	cop
8	due	due	JJ	_	0	ROOT
9	to	to	TO	_	14	case
10	their	they	PRP$	_	14	nmod:poss
11	increased	increase	VBN	_	14	amod
12	renal	renal	JJ	_	14	amod
13	tubular	tubular	JJ	_	14	amod
14	secretion	secretion	NN	_	8	nmod
15	.	.	.	_	8	punct

1	In	in	IN	_	2	case
2	dogs	dog	NNS	_	5	nmod
3	,	,	,	_	5	punct
4	cimetidine	cimetidine	NN	_	5	nsubj
5	unchanged	unchanged	JJ	_	0	ROOT
6	the	the	DT	_	7	det
7	secretion	secretion	NN	_	5	dobj
8	of	of	IN	_	9	case
9	cardiotrast	cardiotrast	NN	_	7	nmod
10	,	,	,	_	7	punct
11	a	a	DT	_	13	det
12	test	test	NN	_	13	compound
13	agent	agent	NN	_	7	appos
14	for	for	IN	_	16	case
15	anionic	anionic	JJ	_	16	amod
16	transport	transport	NN	_	13	nmod
17	.	.	.	_	5	punct

1	Possible	possible	JJ	_	3	amod
2	extrarenal	extrarenal	JJ	_	3	amod
3	mechanisms	mechanism	NNS	_	15	nsubjpass
4	of	of	IN	_	5	case
5	action	action	NN	_	3	nmod
6	of	of	IN	_	7	case
7	cimetidine	cimetidine	NN	_	5	nmod
8	on	on	IN	_	9	case
9	verografine	verografine	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	iodamide	iodamide	NN	_	12	compound
12	transport	transport	NN	_	9	conj
13	were	be	VBD	_	15	auxpass
14	also	also	RB	_	15	advmod
15	examined	examine	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Differential	differential	JJ	_	2	amod
2	regulation	regulation	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	tyrosine	tyrosine	NN	_	5	compound
5	phosphorylation	phosphorylation	NN	_	2	nmod
6	in	in	IN	_	8	case
7	tumor	tumor	NN	_	8	compound
8	cells	cell	NNS	_	5	nmod
9	by	by	IN	_	10	case
10	contortrostatin	contortrostatin	NN	_	2	nmod
11	,	,	,	_	10	punct
12	a	a	DT	_	14	det
13	homodimeric	homodimeric	JJ	_	14	amod
14	disintegrin	disintegrin	NN	_	10	appos
15	,	,	,	_	10	punct
16	and	and	CC	_	10	cc
17	monomeric	monomeric	JJ	_	19	amod
18	disintegrins	disintegrin	NNS	_	19	compound
19	echistatin	echistatin	NN	_	10	conj
20	and	and	CC	_	19	cc
21	flavoridin	flavoridin	NN	_	19	conj
22	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	homodimeric	homodimeric	JJ	_	4	amod
3	disintegrin	disintegrin	NN	_	4	compound
4	contortrostatin	contortrostatin	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	compared	compare	VBN	_	0	ROOT
7	directly	directly	RB	_	6	advmod
8	to	to	TO	_	12	case
9	the	the	DT	_	12	det
10	monomeric	monomeric	JJ	_	12	amod
11	disintegrins	disintegrin	NNS	_	12	compound
12	echistatin	echistatin	NN	_	6	nmod
13	and	and	CC	_	12	cc
14	flavoridin	flavoridin	NN	_	12	conj
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	ability	ability	NN	_	6	nmod
18	to	to	TO	_	19	mark
19	affect	affect	VB	_	17	acl
20	protein	protein	NN	_	22	compound
21	tyrosine	tyrosine	NN	_	22	compound
22	phosphorylation	phosphorylation	NN	_	19	dobj
23	in	in	IN	_	25	case
24	tumor	tumor	NN	_	25	compound
25	cells	cell	NNS	_	22	nmod
26	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	observed	observe	VBN	_	0	ROOT
4	that	that	IN	_	6	mark
5	contortrostatin	contortrostatin	NN	_	6	nsubj
6	had	have	VBD	_	3	ccomp
7	a	a	DT	_	9	det
8	dramatic	dramatic	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	tyrosine	tyrosine	NN	_	14	compound
13	phosphorylation	phosphorylation	NN	_	14	compound
14	status	status	NN	_	6	nmod
15	of	of	IN	_	17	case
16	several	several	JJ	_	17	amod
17	proteins	protein	NNS	_	14	nmod
18	in	in	IN	_	23	case
19	T24	t24	NN	_	23	compound
20	human	human	JJ	_	23	amod
21	bladder	bladder	NN	_	23	compound
22	cancer	cancer	NN	_	23	compound
23	cells	cell	NNS	_	14	nmod
24	,	,	,	_	23	punct
25	including	include	VBG	_	27	case
26	robust	robust	JJ	_	27	amod
27	induction	induction	NN	_	23	nmod
28	of	of	IN	_	29	case
29	phosphorylation	phosphorylation	NN	_	27	nmod
30	of	of	IN	_	31	case
31	proteins	protein	NNS	_	29	nmod
32	in	in	IN	_	34	case
33	the	the	DT	_	34	det
34	range	range	NN	_	27	nmod
35	of	of	IN	_	39	case
36	120	120	CD	_	39	nummod
37	-	-	:	_	39	punct
38	140	140	CD	_	39	nummod
39	kDa	kda	NN	_	34	nmod
40	.	.	.	_	3	punct

1	Echistatin	echistatin	NN	_	3	nsubj
2	alone	alone	RB	_	1	advmod
3	had	have	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	dobj
6	on	on	IN	_	8	case
7	tyrosine	tyrosine	NN	_	8	compound
8	phosphorylation	phosphorylation	NN	_	3	nmod
9	in	in	IN	_	11	case
10	T24	t24	NN	_	11	compound
11	cells	cell	NNS	_	8	nmod
12	,	,	,	_	3	punct
13	but	but	CC	_	3	cc
14	dose	dose	NN	_	17	nsubj
15	-	-	:	_	14	punct
16	dependently	dependently	RB	_	17	advmod
17	inhibits	inhibit	VBZ	_	3	conj
18	the	the	DT	_	19	det
19	effects	effect	NNS	_	17	dobj
20	of	of	IN	_	21	case
21	contortrostatin	contortrostatin	NN	_	19	nmod
22	when	when	WRB	_	25	advmod
23	both	both	DT	_	25	nsubjpass
24	are	be	VBP	_	25	auxpass
25	added	add	VBN	_	17	advcl
26	simultaneously	simultaneously	RB	_	25	advmod
27	.	.	.	_	3	punct

1	Among	among	IN	_	3	case
2	the	the	DT	_	3	det
3	proteins	protein	NNS	_	13	nmod
4	that	that	WDT	_	5	nsubj
5	undergo	undergo	VBP	_	3	acl:relcl
6	tyrosine	tyrosine	NN	_	7	compound
7	phosphorylation	phosphorylation	NN	_	5	dobj
8	in	in	IN	_	9	case
9	response	response	NN	_	5	nmod
10	to	to	TO	_	12	case
11	contortrostatin	contortrostatin	NN	_	12	compound
12	treatment	treatment	NN	_	9	nmod
13	is	be	VBZ	_	0	ROOT
14	CAS	CAS	NNP	_	13	nsubj
15	,	,	,	_	14	punct
16	a	a	DT	_	20	det
17	130	130	CD	_	18	compound
18	kDa	kda	NN	_	20	amod
19	adapter	adapter	NN	_	20	compound
20	protein	protein	NN	_	14	appos
21	involved	involve	VBN	_	20	acl
22	in	in	IN	_	24	case
23	integrin	integrin	NN	_	24	compound
24	signaling	signaling	NN	_	21	nmod
25	.	.	.	_	13	punct

1	Flavoridin	flavoridin	NN	_	4	nsubjpass
2	alone	alone	RB	_	1	advmod
3	was	be	VBD	_	4	auxpass
4	found	find	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	no	no	DT	_	8	neg
8	effect	effect	NN	_	6	dobj
9	on	on	IN	_	10	case
10	CAS	CAS	NNP	_	6	nmod
11	,	,	,	_	4	punct
12	but	but	CC	_	4	cc
13	can	can	MD	_	15	aux
14	completely	completely	RB	_	15	advmod
15	block	block	VB	_	4	conj
16	contortrostatin	contortrostatin	NN	_	15	dobj
17	-	-	:	_	16	punct
18	induced	induce	VBN	_	19	amod
19	phosphorylation	phosphorylation	NN	_	16	dep
20	of	of	IN	_	22	case
21	this	this	DT	_	22	det
22	protein	protein	NN	_	19	nmod
23	in	in	IN	_	24	case
24	MDA	MDA	NNP	_	19	nmod
25	-	-	:	_	24	punct
26	MB	mb	SYM	_	24	dep
27	-	-	:	_	24	punct
28	435	435	CD	_	29	nummod
29	cells	cell	NNS	_	24	dep
30	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	observations	observation	NNS	_	4	nsubj
3	strongly	strongly	RB	_	4	advmod
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	12	mark
6	the	the	DT	_	8	det
7	homodimeric	homodimeric	JJ	_	8	amod
8	structure	structure	NN	_	12	nsubj
9	of	of	IN	_	10	case
10	contortrostatin	contortrostatin	NN	_	8	nmod
11	functionally	functionally	RB	_	12	advmod
12	distinguishes	distinguish	VBZ	_	4	ccomp
13	it	it	PRP	_	12	dobj
14	from	from	IN	_	17	case
15	other	other	JJ	_	17	amod
16	monomeric	monomeric	JJ	_	17	amod
17	members	member	NNS	_	12	nmod
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	disintegrin	disintegrin	NN	_	21	compound
21	family	family	NN	_	17	nmod
22	.	.	.	_	4	punct

1	Toxicity	toxicity	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	cadmium	cadmium	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	zinc	zinc	NN	_	3	conj
6	to	to	TO	_	7	case
7	miracidia	miracidia	NN	_	1	nmod
8	of	of	IN	_	10	case
9	Schistosoma	schistosoma	NN	_	10	compound
10	mansoni	mansonus	NNS	_	7	nmod
11	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	specific	specific	JJ	_	3	amod
3	objectives	objective	NNS	_	7	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	study	study	NN	_	3	nmod
7	were	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	elucidate	elucidate	VB	_	7	xcomp
10	metal	metal	NN	_	11	compound
11	toxicity	toxicity	NN	_	9	dobj
12	to	to	TO	_	13	case
13	hatching	hatching	NN	_	11	nmod
14	,	,	,	_	13	punct
15	survival	survival	NN	_	13	conj
16	and	and	CC	_	13	cc
17	avoidance	avoidance	NN	_	18	compound
18	behaviour	behaviour	NN	_	13	conj
19	of	of	IN	_	22	case
20	Schistosoma	schistosoma	NN	_	22	compound
21	mansoni	mansoni	NN	_	22	compound
22	miracidia	miracidia	NN	_	13	nmod
23	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	toxicity	toxicity	NN	_	24	nsubjpass
3	of	of	IN	_	4	case
4	cadmium	cadmium	NN	_	2	nmod
5	,	,	,	_	4	punct
6	zinc	zinc	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	cadmium	cadmium	NN	_	4	conj
10	/	/	:	_	2	punct
11	zinc	zinc	NN	_	12	compound
12	mixtures	mixture	NNS	_	2	dep
13	at	at	IN	_	14	case
14	concentrations	concentration	NNS	_	12	nmod
15	ranging	range	VBG	_	14	acl
16	from	from	IN	_	20	case
17	10000	10000	CD	_	19	compound
18	to	to	TO	_	19	dep
19	10	10	CD	_	20	nummod
20	microg	microg	NN	_	15	nmod
21	/	/	:	_	2	punct
22	l	l	NN	_	2	dep
23	was	be	VBD	_	24	auxpass
24	investigated	investigate	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	Metal	metal	NN	_	4	compound
2	mixture	mixture	NN	_	4	compound
3	toxicity	toxicity	NN	_	4	compound
4	investigation	investigation	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	undertaken	undertake	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	equal	equal	JJ	_	9	amod
9	concentrations	concentration	NNS	_	6	nmod
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	metals	metal	NNS	_	9	nmod
13	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	hatching	hatching	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	miracidia	miracidia	NN	_	2	nmod
5	from	from	IN	_	6	case
6	eggs	egg	NNS	_	2	nmod
7	was	be	VBD	_	8	auxpass
8	inhibited	inhibit	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	concentrations	concentration	NNS	_	8	nmod
11	of	of	IN	_	15	case
12	1000	1000	CD	_	15	nummod
13	-	-	:	_	15	punct
14	10000	10000	CD	_	15	nummod
15	microg	microg	NN	_	10	nmod
16	/	/	:	_	15	punct
17	l	l	NN	_	15	dep
18	of	of	IN	_	20	case
19	single	single	JJ	_	20	amod
20	metals	metal	NNS	_	17	nmod
21	.	.	.	_	8	punct

1	Metal	metal	NN	_	2	compound
2	mixtures	mixture	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	dobj
6	on	on	IN	_	8	case
7	egg	egg	NN	_	8	compound
8	hatching	hatching	NN	_	3	nmod
9	.	.	.	_	3	punct

1	Survival	survival	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	miracidia	miracidia	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	reduced	reduce	VBN	_	0	ROOT
6	by	by	IN	_	7	mark
7	increasing	increase	VBG	_	5	advcl
8	metal	metal	NN	_	9	compound
9	concentration	concentration	NN	_	7	dobj
10	except	except	IN	_	12	case
11	at	at	IN	_	12	case
12	concentrations	concentration	NNS	_	7	nmod
13	of	of	IN	_	15	case
14	10	10	CD	_	15	nummod
15	microg	microg	NN	_	12	nmod
16	/	/	:	_	15	punct
17	l	l	NN	_	15	dep
18	for	for	IN	_	21	case
19	single	single	JJ	_	21	amod
20	metal	metal	NN	_	21	compound
21	toxicity	toxicity	NN	_	15	nmod
22	where	where	WRB	_	25	advmod
23	survival	survival	NN	_	25	nsubjpass
24	was	be	VBD	_	25	auxpass
25	increased	increase	VBN	_	21	acl:relcl
26	above	above	IN	_	28	case
27	the	the	DT	_	28	det
28	control	control	NN	_	25	nmod
29	.	.	.	_	5	punct

1	Miracidia	Miracidia	NNP	_	2	nsubj
2	demonstrated	demonstrate	VBD	_	0	ROOT
3	a	a	DT	_	6	det
4	rapid	rapid	JJ	_	6	amod
5	avoidance	avoidance	NN	_	6	compound
6	behaviour	behaviour	NN	_	2	dobj
7	when	when	WRB	_	9	advmod
8	briefly	briefly	NN	_	9	nsubj
9	exposed	expose	VBN	_	2	advcl
10	to	to	TO	_	12	case
11	heavy	heavy	JJ	_	12	amod
12	metals	metal	NNS	_	9	nmod
13	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	mechanisms	mechanism	NNS	_	10	nsubjpass
3	of	of	IN	_	5	case
4	metal	metal	NN	_	5	compound
5	toxicity	toxicity	NN	_	2	nmod
6	to	to	TO	_	7	case
7	miracidia	miracidia	NN	_	5	nmod
8	are	be	VBP	_	10	auxpass
9	briefly	briefly	RB	_	10	advmod
10	discussed	discuss	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Drug	drug	NN	_	4	compound
2	-	-	:	_	4	punct
3	lab	lab	NN	_	4	compound
4	interactions	interaction	NNS	_	0	ROOT
5	:	:	:	_	4	punct
6	implications	implication	NNS	_	4	dep
7	for	for	IN	_	9	case
8	nutrition	nutrition	NN	_	9	compound
9	support	support	NN	_	6	nmod
10	.	.	.	_	4	punct

1	Acetylcysteine	acetylcysteine	NN	_	2	compound
2	interference	interference	NN	_	0	ROOT
3	with	with	IN	_	6	case
4	urine	urine	NN	_	6	compound
5	ketone	ketone	NN	_	6	compound
6	test	test	NN	_	2	nmod
7	.	.	.	_	2	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	important	important	JJ	_	0	ROOT
4	that	that	IN	_	9	mark
5	health	health	NN	_	7	compound
6	care	care	NN	_	7	compound
7	professionals	professional	NNS	_	9	nsubj
8	be	be	VB	_	9	cop
9	aware	aware	JJ	_	3	ccomp
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	potential	potential	NN	_	9	nmod
13	for	for	IN	_	16	mark
14	medications	medication	NNS	_	16	nsubj
15	to	to	TO	_	16	mark
16	interfere	interfere	VB	_	12	acl
17	with	with	IN	_	20	case
18	clinical	clinical	JJ	_	20	amod
19	laboratory	laboratory	NN	_	20	compound
20	tests	test	NNS	_	16	nmod
21	.	.	.	_	3	punct

1	Medications	medication	NNS	_	3	nsubj
2	can	can	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	in	in	FW	_	6	amod
5	vivo	vivo	FW	_	4	dep
6	effects	effect	NNS	_	3	dobj
7	when	when	WRB	_	16	advmod
8	the	the	DT	_	9	det
9	concentration	concentration	NN	_	16	nsubjpass
10	or	or	CC	_	9	cc
11	activity	activity	NN	_	9	conj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	analyte	analyte	NN	_	9	nmod
15	is	be	VBZ	_	16	auxpass
16	altered	alter	VBN	_	3	advcl
17	before	before	IN	_	19	case
18	the	the	DT	_	19	det
19	analysis	analysis	NN	_	16	nmod
20	and	and	CC	_	16	cc
21	therefore	therefore	RB	_	26	advmod
22	the	the	DT	_	24	det
23	assay	assay	NN	_	24	compound
24	result	result	NN	_	26	nsubj
25	is	be	VBZ	_	26	cop
26	true	true	JJ	_	16	conj
27	and	and	CC	_	26	cc
28	accurate	accurate	JJ	_	26	conj
29	.	.	.	_	3	punct

1	An	a	DT	_	4	det
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	effect	effect	NN	_	5	nsubj
5	occurs	occur	VBZ	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	the	the	DT	_	8	det
8	medication	medication	NN	_	9	nsubj
9	interferes	interfere	VBZ	_	5	advcl
10	with	with	IN	_	12	case
11	the	the	DT	_	12	det
12	assay	assay	NN	_	9	nmod
13	,	,	,	_	5	punct
14	and	and	CC	_	5	cc
15	the	the	DT	_	16	det
16	result	result	NN	_	18	nsubj
17	is	be	VBZ	_	18	cop
18	erroneous	erroneous	JJ	_	5	conj
19	and	and	CC	_	18	cc
20	cannot	cannot	NN	_	22	nsubjpass
21	be	be	VB	_	22	auxpass
22	interpreted	interpret	VBN	_	18	conj
23	.	.	.	_	5	punct

1	This	this	DT	_	2	det
2	report	report	NN	_	3	nsubj
3	describes	describe	VBZ	_	0	ROOT
4	a	a	DT	_	7	det
5	recently	recently	RB	_	6	advmod
6	identified	identify	VBN	_	7	amod
7	case	case	NN	_	3	dobj
8	of	of	IN	_	9	case
9	interference	interference	NN	_	7	nmod
10	of	of	IN	_	11	case
11	acetylcysteine	acetylcysteine	NN	_	9	nmod
12	with	with	IN	_	15	case
13	the	the	DT	_	15	det
14	urine	urine	NN	_	15	compound
15	test	test	NN	_	9	nmod
16	for	for	IN	_	17	case
17	ketones	ketone	NNS	_	15	nmod
18	and	and	CC	_	3	cc
19	demonstrates	demonstrate	VBZ	_	3	conj
20	the	the	DT	_	21	det
21	importance	importance	NN	_	19	dobj
22	of	of	IN	_	26	case
23	a	a	DT	_	26	det
24	thorough	thorough	JJ	_	26	amod
25	medication	medication	NN	_	26	compound
26	review	review	NN	_	21	nmod
27	in	in	IN	_	28	mark
28	evaluating	evaluate	VBG	_	26	acl
29	abnormal	abnormal	JJ	_	31	amod
30	laboratory	laboratory	NN	_	31	compound
31	tests	test	NNS	_	28	dobj
32	.	.	.	_	3	punct

1	[	[	RB	_	3	advmod
2	Pharmacologic	pharmacologic	JJ	_	3	amod
3	interactions	interaction	NNS	_	0	ROOT
4	in	in	IN	_	6	case
5	chronic	chronic	JJ	_	6	amod
6	treatments	treatment	NNS	_	3	nmod
7	:	:	:	_	3	punct
8	corrective	corrective	JJ	_	9	amod
9	measures	measure	NNS	_	3	dep
10	for	for	IN	_	12	case
11	its	its	PRP$	_	12	nmod:poss
12	prevention	prevention	NN	_	9	nmod
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	basic	basic	JJ	_	16	amod
16	area	area	NN	_	12	nmod
17	of	of	IN	_	21	case
18	rural	rural	JJ	_	21	amod
19	health	health	NN	_	21	compound
20	]	]	CD	_	21	nummod
21	OBJECTIVES	objective	NNS	_	16	nmod
22	:	:	:	_	9	punct
23	To	to	TO	_	24	mark
24	identify	identify	VB	_	9	dep
25	the	the	DT	_	27	det
26	pharmacological	pharmacological	JJ	_	27	amod
27	interactions	interaction	NNS	_	24	dobj
28	of	of	IN	_	33	case
29	clinical	clinical	JJ	_	33	amod
30	relevance	relevance	NN	_	33	compound
31	(	(	CD	_	33	nummod
32	PICR	picr	NN	_	33	compound
33	)	)	NN	_	27	nmod
34	in	in	IN	_	38	case
35	the	the	DT	_	38	det
36	medication	medication	NN	_	38	compound
37	authorization	authorization	NN	_	38	compound
38	cards	card	NNS	_	27	nmod
39	(	(	VBP	_	24	dep
40	MAC	MAC	NNP	_	39	dobj
41	)	)	CD	_	40	nummod
42	of	of	IN	_	45	case
43	the	the	DT	_	45	det
44	chronically	chronically	RB	_	45	advmod
45	ill	ill	JJ	_	40	nmod
46	and	and	CC	_	39	cc
47	to	to	TO	_	48	mark
48	establish	establish	VB	_	39	conj
49	strategies	strategy	NNS	_	48	dobj
50	to	to	TO	_	51	mark
51	minimise	minimise	VB	_	49	acl
52	their	they	PRP$	_	53	nmod:poss
53	appearance	appearance	NN	_	51	dobj
54	.	.	.	_	3	punct

1	DESIGN	design	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Cross	Cross	NNP	_	7	compound
4	-	-	:	_	7	punct
5	sectional	sectional	JJ	_	7	amod
6	descriptive	descriptive	JJ	_	7	amod
7	study	study	NN	_	1	dep
8	.	.	.	_	1	punct

1	SETTING	SETTING	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Rural	Rural	NNP	_	6	compound
4	primary	primary	JJ	_	6	amod
5	care	care	NN	_	6	compound
6	centre	centre	NN	_	1	dep
7	.	.	.	_	1	punct

1	PATIENTS	patient	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Random	Random	NNP	_	4	compound
4	sample	sample	NN	_	1	dep
5	of	of	IN	_	7	case
6	626	626	CD	_	7	nummod
7	MAC	MAC	NNP	_	4	nmod
8	out	out	IN	_	11	case
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	total	total	NN	_	4	nmod
12	of	of	IN	_	13	case
13	1306	1306	CD	_	11	nmod
14	.	.	.	_	1	punct

1	MEASUREMENTS	measurement	NNS	_	4	compound
2	AND	and	CC	_	1	cc
3	MAIN	main	NNS	_	1	conj
4	RESULTS	result	NNS	_	0	ROOT
5	:	:	:	_	4	punct
6	In	in	IN	_	7	case
7	December	December	NNP	_	13	nmod
8	1998	1998	CD	_	7	nummod
9	,	,	,	_	13	punct
10	the	the	DT	_	11	det
11	following	following	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	gathered	gather	VBN	_	4	dep
14	for	for	IN	_	16	case
15	every	every	DT	_	16	det
16	MAC	MAC	NNP	_	13	nmod
17	with	with	IN	_	22	case
18	more	more	JJR	_	20	advmod
19	than	than	IN	_	18	mwe
20	one	one	CD	_	22	nummod
21	drug	drug	NN	_	22	compound
22	treatment	treatment	NN	_	13	nmod
23	:	:	:	_	22	punct
24	age	age	NN	_	43	nsubj
25	,	,	,	_	24	punct
26	sex	sex	NN	_	24	conj
27	,	,	,	_	24	punct
28	number	number	NN	_	24	conj
29	of	of	IN	_	30	case
30	drugs	drug	NNS	_	28	nmod
31	,	,	,	_	24	punct
32	intrinsic	intrinsic	JJ	_	33	amod
33	value	value	NN	_	24	conj
34	,	,	,	_	24	punct
35	drugs	drug	NNS	_	42	compound
36	prescribed	prescribe	VBN	_	42	amod
37	,	,	,	_	36	punct
38	daily	daily	RB	_	39	advmod
39	dose	dose	NN	_	36	conj
40	and	and	CC	_	36	cc
41	pharmacological	pharmacological	JJ	_	36	conj
42	interactions	interaction	NNS	_	24	conj
43	(	(	VBP	_	22	dep
44	PI	pi	NN	_	45	compound
45	)	)	NN	_	43	dobj
46	,	,	,	_	45	punct
47	classified	classify	VBN	_	48	amod
48	(	(	NN	_	45	appos
49	using	use	VBG	_	48	acl
50	the	the	DT	_	51	det
51	scale	scale	NN	_	49	dobj
52	of	of	IN	_	53	case
53	Hansten	Hansten	NNP	_	51	nmod
54	1996	1996	CD	_	55	compound
55	)	)	CD	_	53	nummod
56	into	into	IN	_	60	case
57	light	light	JJ	_	60	amod
58	and	and	CC	_	57	cc
59	clinically	clinically	RB	_	57	conj
60	relevant	relevant	JJ	_	49	nmod
61	.	.	.	_	4	punct

1	Statistical	statistical	JJ	_	2	amod
2	analysis	analysis	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Mantel	Mantel	NNP	_	2	dep
5	-	-	:	_	4	punct
6	Haenszel	Haenszel	NNP	_	8	compound
7	(	(	NN	_	8	compound
8	alpha	alpha	NN	_	9	nsubj
9	=	=	JJ	_	4	dep
10	0.05	0.05	CD	_	11	nummod
11	)	)	NN	_	9	dobj
12	.	.	.	_	2	punct

1	Patients	patient	NNS	_	4	nmod:poss
2	'	'	POS	_	1	case
3	mean	mean	NN	_	4	compound
4	age	age	NN	_	10	nsubj
5	was	be	VBD	_	10	cop
6	69.1	69.1	CD	_	8	compound
7	(	(	CD	_	8	compound
8	95	95	CD	_	9	dep
9	%	%	NN	_	10	dep
10	CI	ci	NN	_	0	ROOT
11	,	,	,	_	10	punct
12	+	+	CC	_	10	cc
13	/	/	:	_	16	punct
14	-	-	:	_	16	punct
15	1.2	1.2	CD	_	16	nummod
16	)	)	NN	_	10	conj
17	.	.	.	_	10	punct

1	Mean	mean	NN	_	2	compound
2	number	number	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	per	per	IN	_	6	case
6	MAC	MAC	NNP	_	4	nmod
7	was	be	VBD	_	12	cop
8	4	4	CD	_	10	compound
9	(	(	CD	_	10	compound
10	95	95	CD	_	11	dep
11	%	%	NN	_	12	dep
12	CI	ci	NN	_	0	ROOT
13	,	,	,	_	12	punct
14	+	+	CC	_	12	cc
15	/	/	:	_	12	punct
16	-	-	:	_	12	punct
17	0.2	0.2	CD	_	18	nummod
18	)	)	NN	_	12	dep
19	.	.	.	_	12	punct

1	341	341	CD	_	2	nummod
2	PI	pi	NN	_	0	ROOT
3	affecting	affect	VBG	_	2	acl
4	197	197	CD	_	5	nummod
5	patients	patient	NNS	_	3	dobj
6	(	(	IN	_	8	case
7	31.5	31.5	CD	_	8	nummod
8	%	%	NN	_	5	nmod
9	,	,	,	_	2	punct
10	95	95	CD	_	11	compound
11	%	%	NN	_	12	amod
12	CI	ci	NN	_	2	appos
13	,	,	,	_	2	punct
14	+	+	CC	_	2	cc
15	/	/	:	_	20	punct
16	-	-	:	_	20	punct
17	3.6	3.6	CD	_	18	nummod
18	)	)	CD	_	20	nsubjpass
19	were	be	VBD	_	20	auxpass
20	identified	identify	VBN	_	2	conj
21	.	.	.	_	2	punct

1	24.9	24.9	CD	_	2	nummod
2	%	%	NN	_	6	amod
3	(	(	CD	_	4	compound
4	95	95	CD	_	5	dep
5	%	%	NN	_	6	dep
6	CI	ci	NN	_	0	ROOT
7	,	,	,	_	6	punct
8	+	+	CC	_	6	cc
9	/	/	:	_	6	punct
10	-	-	:	_	6	punct
11	4.5	4.5	CD	_	12	compound
12	)	)	CD	_	14	nsubj
13	were	be	VBD	_	14	cop
14	PICR	picr	NN	_	6	dep
15	,	,	,	_	14	punct
16	detected	detect	VBN	_	14	acl
17	in	in	IN	_	19	case
18	11.7	11.7	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	(	(	CD	_	21	compound
21	95	95	CD	_	22	dep
22	%	%	NN	_	23	dep
23	CI	ci	NN	_	19	dep
24	,	,	,	_	14	punct
25	+	+	CC	_	14	cc
26	/	/	:	_	14	punct
27	-	-	:	_	14	punct
28	2.5	2.5	CD	_	29	nummod
29	)	)	NN	_	14	dep
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	MAC	MAC	NNP	_	29	nmod
33	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	existence	existence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	PI	pi	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	related	relate	VBN	_	0	ROOT
7	to	to	TO	_	9	case
8	the	the	DT	_	9	det
9	number	number	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	prescribed	prescribe	VBN	_	11	acl
13	to	to	TO	_	15	case
14	each	each	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	(	(	CD	_	18	nummod
17	p	p	NN	_	18	compound
18	&lt	&lt	NN	_	15	dep
19	;	;	:	_	6	punct
20	0.01	0.01	CD	_	21	compound
21	)	)	CD	_	6	parataxis
22	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	26	26	CD	_	4	nummod
4	PI	pi	NN	_	2	nsubj
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	of	of	IN	_	10	case
8	low	low	JJ	_	10	amod
9	intrinsic	intrinsic	JJ	_	10	amod
10	value	value	NN	_	6	nmod
11	(	(	CD	_	13	nummod
12	7.6	7.6	CD	_	13	nummod
13	%	%	NN	_	10	dep
14	;	;	:	_	2	punct
15	95	95	CD	_	16	compound
16	%	%	NN	_	17	amod
17	CI	ci	NN	_	2	parataxis
18	,	,	,	_	17	punct
19	+	+	CC	_	17	cc
20	/	/	:	_	17	punct
21	-	-	:	_	17	punct
22	2.8	2.8	CD	_	23	nummod
23	)	)	NN	_	17	dep
24	.	.	.	_	2	punct

1	74.1	74.1	CD	_	2	nummod
2	%	%	NN	_	6	amod
3	(	(	CD	_	4	compound
4	95	95	CD	_	5	dep
5	%	%	NN	_	6	dep
6	CI	ci	NN	_	0	ROOT
7	,	,	,	_	6	punct
8	+	+	CC	_	6	cc
9	/	/	:	_	6	punct
10	-	-	:	_	6	punct
11	9.3	9.3	CD	_	12	nummod
12	)	)	NN	_	19	nsubjpass
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	total	total	JJ	_	16	amod
16	PICR	picr	NN	_	12	nmod
17	could	could	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	avoided	avoid	VBN	_	6	parataxis
20	by	by	IN	_	22	case
21	simple	simple	JJ	_	22	amod
22	recommendations	recommendation	NNS	_	19	nmod
23	;	;	:	_	6	punct

1	and	and	CC	_	0	ROOT
2	the	the	DT	_	9	det
3	remaining	remain	VBG	_	9	amod
4	25.9	25.9	CD	_	5	nummod
5	%	%	NN	_	9	amod
6	(	(	CD	_	7	compound
7	95	95	CD	_	8	dep
8	%	%	NN	_	9	dep
9	CI	ci	NN	_	1	dep
10	,	,	,	_	9	punct
11	+	+	CC	_	9	cc
12	/	/	:	_	15	punct
13	-	-	:	_	15	punct
14	9.3	9.3	CD	_	15	compound
15	)	)	CD	_	9	conj
16	by	by	IN	_	17	case
17	monitoring	monitoring	NN	_	15	nmod
18	and	and	CC	_	15	cc
19	follow	follow	VB	_	15	conj
20	-	-	:	_	19	punct
21	up	up	IN	_	23	case
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	19	nmod
24	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	It	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	important	important	JJ	_	1	dep
6	to	to	TO	_	7	mark
7	identify	identify	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	medications	medication	NNS	_	7	dobj
10	most	most	RBS	_	11	advmod
11	commonly	commonly	RB	_	12	advmod
12	involved	involve	VBN	_	9	acl
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	PICR	picr	NN	_	12	nmod
16	so	so	RB	_	19	advmod
17	as	as	IN	_	19	mark
18	to	to	TO	_	19	mark
19	establish	establish	VB	_	7	advcl
20	corrective	corrective	JJ	_	21	amod
21	measures	measure	NNS	_	19	dobj
22	to	to	TO	_	23	mark
23	minimise	minimise	VB	_	21	acl
24	the	the	DT	_	25	det
25	risks	risk	NNS	_	23	dobj
26	arising	arise	VBG	_	25	acl
27	from	from	IN	_	29	case
28	multiple	multiple	JJ	_	29	amod
29	medication	medication	NN	_	26	nmod
30	.	.	.	_	1	punct

1	Four	four	CD	_	3	nummod
2	educational	educational	JJ	_	3	amod
3	messages	message	NNS	_	4	nsubj
4	advise	advise	VBP	_	0	ROOT
5	on	on	IN	_	4	compound:prt
6	over	over	IN	_	7	advmod
7	60	60	CD	_	8	nummod
8	%	%	NN	_	4	dobj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	PICR	picr	NN	_	8	nmod
12	detected	detect	VBN	_	11	acl
13	.	.	.	_	4	punct

1	Neurochemical	neurochemical	JJ	_	4	amod
2	and	and	CC	_	1	cc
3	functional	functional	JJ	_	1	conj
4	consequences	consequence	NNS	_	0	ROOT
5	following	follow	VBG	_	4	acl
6	1	1	LS	_	5	dobj
7	-	-	:	_	6	punct
8	methyl	methyl	NN	_	6	dep
9	-	-	:	_	10	punct
10	4	4	LS	_	8	dep
11	-	-	:	_	10	punct
12	phenyl	phenyl	NN	_	10	dep
13	-	-	:	_	12	punct
14	1,2,5,6	1,2,5,6	CD	_	12	dep
15	-	-	:	_	12	punct
16	tetrahydropyridine	tetrahydropyridine	NN	_	19	compound
17	(	(	CD	_	19	nummod
18	MPTP	mptp	NN	_	19	compound
19	)	)	NN	_	12	dep
20	and	and	CC	_	19	cc
21	methamphetamine	methamphetamine	NN	_	19	conj
22	.	.	.	_	4	punct

1	The	the	DT	_	5	det
2	neurochemical	neurochemical	JJ	_	5	amod
3	and	and	CC	_	2	cc
4	functional	functional	JJ	_	2	conj
5	consequences	consequence	NNS	_	13	nsubjpass
6	following	follow	VBG	_	8	case
7	MPTP	MPTP	NNP	_	8	compound
8	administration	administration	NN	_	5	nmod
9	to	to	TO	_	11	case
10	the	the	DT	_	11	det
11	rat	rat	NN	_	8	nmod
12	were	be	VBD	_	13	auxpass
13	evaluated	evaluate	VBN	_	0	ROOT
14	and	and	CC	_	13	cc
15	compared	compare	VBN	_	18	case
16	to	to	TO	_	18	case
17	similar	similar	JJ	_	18	amod
18	effects	effect	NNS	_	13	conj
19	following	follow	VBG	_	21	case
20	methamphetamine	methamphetamine	NN	_	21	compound
21	administration	administration	NN	_	18	nmod
22	.	.	.	_	13	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	observed	observe	VBN	_	0	ROOT
4	that	that	IN	_	6	mark
5	MPTP	mptp	NN	_	6	nsubj
6	induced	induce	VBD	_	3	ccomp
7	long	long	JJ	_	9	amod
8	lasting	lasting	JJ	_	9	amod
9	depletions	depletion	NNS	_	6	dobj
10	of	of	IN	_	13	case
11	striatal	striatal	JJ	_	13	amod
12	dopamine	dopamine	NN	_	13	compound
13	concentrations	concentration	NNS	_	9	nmod
14	and	and	CC	_	6	cc
15	this	this	DT	_	17	det
16	neurotoxic	neurotoxic	JJ	_	17	amod
17	effect	effect	NN	_	20	nsubjpass
18	could	could	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	prevented	prevent	VBN	_	6	conj
21	by	by	IN	_	23	case
22	pargyline	pargyline	NN	_	23	compound
23	pretreatment	pretreatment	NN	_	20	nmod
24	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	MPTP	mptp	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	induced	induce	VBN	_	6	amod
5	neuronal	neuronal	JJ	_	6	amod
6	damage	damage	NN	_	7	nsubj
7	produced	produce	VBD	_	2	dep
8	a	a	DT	_	9	det
9	tolerance	tolerance	NN	_	7	dobj
10	to	to	TO	_	13	case
11	the	the	DT	_	13	det
12	disruptive	disruptive	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	amphetamine	amphetamine	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	a	a	DT	_	18	det
18	supersensitivity	supersensitivity	NN	_	15	conj
19	to	to	TO	_	22	case
20	the	the	DT	_	22	det
21	disruptive	disruptive	JJ	_	22	amod
22	effects	effect	NNS	_	18	nmod
23	of	of	IN	_	24	case
24	apomorphine	apomorphine	NN	_	22	nmod
25	in	in	IN	_	26	case
26	rats	rat	NNS	_	22	nmod
27	responding	respond	VBG	_	26	acl
28	in	in	IN	_	30	case
29	a	a	DT	_	30	det
30	schedule	schedule	NN	_	27	nmod
31	controlled	control	VBN	_	32	amod
32	paradigm	paradigm	NN	_	30	dep
33	.	.	.	_	2	punct

1	Methamphetamine	Methamphetamine	NNP	_	6	nsubj
2	,	,	,	_	6	punct
3	like	like	IN	_	4	case
4	MPTP	MPTP	NNP	_	6	nmod
5	,	,	,	_	6	punct
6	produced	produce	VBD	_	0	ROOT
7	depletions	depletion	NNS	_	6	dobj
8	of	of	IN	_	10	case
9	striatal	striatal	JJ	_	10	amod
10	dopamine	dopamine	NN	_	7	nmod
11	but	but	CC	_	6	cc
12	these	these	DT	_	13	det
13	actions	action	NNS	_	15	nsubjpass
14	were	be	VBD	_	15	auxpass
15	potentiated	potentiate	VBN	_	6	conj
16	by	by	IN	_	18	case
17	pargyline	pargyline	NN	_	18	compound
18	pretreatment	pretreatment	NN	_	15	nmod
19	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	observations	observation	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	discussed	discuss	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	reference	reference	NN	_	4	nmod
7	to	to	TO	_	10	case
8	possible	possible	JJ	_	10	amod
9	deleterious	deleterious	JJ	_	10	amod
10	effects	effect	NNS	_	6	nmod
11	following	follow	VBG	_	13	case
12	the	the	DT	_	13	det
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	15	case
15	pargyline	pargyline	NN	_	13	nmod
16	to	to	TO	_	17	case
17	patients	patient	NNS	_	13	nmod
18	with	with	IN	_	22	case
19	Parkinson	Parkinson	NNP	_	22	nmod:poss
20	'	'	POS	_	19	case
21	s	s	NNS	_	22	compound
22	Disease	disease	NN	_	17	nmod
23	.	.	.	_	4	punct

1	Responses	response	NNS	_	0	ROOT
2	to	to	TO	_	3	case
3	arginine	arginine	NN	_	1	nmod
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	perfused	perfused	JJ	_	7	amod
7	pancreas	pancreas	NN	_	3	nmod
8	of	of	IN	_	13	case
9	the	the	DT	_	13	det
10	genetically	genetically	RB	_	11	advmod
11	diabetic	diabetic	JJ	_	13	amod
12	Chinese	chinese	JJ	_	13	amod
13	hamster	hamster	NN	_	7	nmod
14	.	.	.	_	1	punct

1	Nonketotic	Nonketotic	NNP	_	0	ROOT
2	,	,	,	_	1	punct
3	genetically	genetically	RB	_	4	advmod
4	diabetic	diabetic	JJ	_	6	amod
5	Cinese	cinese	JJ	_	6	amod
6	hamsters	hamster	NNS	_	7	nsubj
7	show	show	VBP	_	1	acl:relcl
8	subnormal	subnormal	JJ	_	11	amod
9	pancreatic	pancreatic	JJ	_	11	amod
10	insulin	insulin	NN	_	11	compound
11	release	release	NN	_	7	dobj
12	and	and	CC	_	11	cc
13	impaired	impaired	JJ	_	14	amod
14	suppression	suppression	NN	_	11	conj
15	of	of	IN	_	16	case
16	glucagon	glucagon	NN	_	14	nmod
17	in	in	IN	_	18	case
18	response	response	NN	_	7	nmod
19	to	to	TO	_	20	case
20	glucose	glucose	NN	_	18	nmod
21	.	.	.	_	1	punct

1	To	to	TO	_	2	mark
2	study	study	VB	_	16	csubjpass
3	the	the	DT	_	5	det
4	pancreatic	pancreatic	JJ	_	5	amod
5	effects	effect	NNS	_	2	dobj
6	of	of	IN	_	8	case
7	other	other	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	dynamic	dynamic	JJ	_	11	amod
11	insulin	insulin	NN	_	8	conj
12	and	and	CC	_	8	cc
13	glucagon	glucagon	NN	_	14	compound
14	release	release	NN	_	8	conj
15	was	be	VBD	_	16	auxpass
16	measured	measure	VBN	_	0	ROOT
17	from	from	IN	_	22	case
18	the	the	DT	_	22	det
19	in	in	FW	_	22	amod
20	vitro	vitro	FW	_	19	dep
21	perfused	perfused	JJ	_	22	amod
22	pancreases	pancreas	NNS	_	16	nmod
23	of	of	IN	_	28	case
24	normal	normal	JJ	_	28	amod
25	and	and	CC	_	24	cc
26	diabetic	diabetic	JJ	_	24	conj
27	Chinese	chinese	JJ	_	28	amod
28	hamsters	hamster	NNS	_	22	nmod
29	in	in	IN	_	30	case
30	response	response	NN	_	16	nmod
31	to	to	TO	_	33	case
32	various	various	JJ	_	33	amod
33	combinations	combination	NNS	_	30	nmod
34	of	of	IN	_	38	case
35	arginine	arginine	NN	_	38	compound
36	(	(	CD	_	38	nummod
37	20mM	20mm	NN	_	38	compound
38	)	)	NN	_	33	nmod
39	,	,	,	_	16	punct
40	glucose	glucose	NN	_	41	compound
41	(	(	NN	_	16	dep
42	100	100	CD	_	41	nummod
43	or	or	CC	_	41	cc
44	150	150	CD	_	45	nummod
45	mg	mg	NN	_	41	conj
46	.	.	.	_	41	punct
47	per	per	IN	_	49	case
48	100	100	CD	_	49	nummod
49	ml	ml	NN	_	41	nmod
50	.	.	.	_	49	punct
51	)	)	NN	_	49	conj
52	,	,	,	_	49	punct
53	and	and	CC	_	49	cc
54	theophylline	theophylline	NN	_	58	compound
55	(	(	CD	_	56	compound
56	10	10	CD	_	57	dep
57	mM	mm	NN	_	58	dep
58	)	)	NN	_	49	conj
59	.	.	.	_	16	punct

1	Theophylline	theophylline	NN	_	3	nsubj
2	alone	alone	RB	_	1	advmod
3	caused	cause	VBD	_	0	ROOT
4	identical	identical	JJ	_	5	amod
5	insulin	insulin	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	glucagon	glucagon	NN	_	8	compound
8	release	release	NN	_	5	conj
9	in	in	IN	_	10	case
10	diabetics	diabetic	NNS	_	5	nmod
11	and	and	CC	_	10	cc
12	normals	normal	NNS	_	10	conj
13	.	.	.	_	3	punct

1	Glucose	glucose	NN	_	11	nsubj
2	,	,	,	_	1	punct
3	alone	alone	RB	_	1	conj
4	and	and	CC	_	1	cc
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	presence	presence	NN	_	1	conj
8	of	of	IN	_	9	case
9	theophylline	theophylline	NN	_	7	nmod
10	,	,	,	_	1	punct
11	caused	cause	VBD	_	0	ROOT
12	subnormal	subnormal	JJ	_	14	amod
13	insulin	insulin	NN	_	14	compound
14	release	release	NN	_	11	dobj
15	and	and	CC	_	14	cc
16	less	less	JJR	_	17	amod
17	suppression	suppression	NN	_	14	conj
18	of	of	IN	_	20	case
19	glucagon	glucagon	NN	_	20	compound
20	release	release	NN	_	17	nmod
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	diabectics	diabectic	NNS	_	20	nmod
24	than	than	IN	_	27	case
25	in	in	IN	_	27	case
26	the	the	DT	_	27	det
27	normals	normal	NNS	_	14	nmod
28	.	.	.	_	11	punct

1	Arginine	arginine	NN	_	11	nsubj
2	,	,	,	_	11	punct
3	in	in	IN	_	5	case
4	the	the	DT	_	5	det
5	presence	presence	NN	_	11	nmod
6	of	of	IN	_	7	case
7	glucose	glucose	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	theophylline	theophylline	NN	_	7	conj
10	,	,	,	_	11	punct
11	caused	cause	VBD	_	0	ROOT
12	excessive	excessive	JJ	_	14	amod
13	glucagon	glucagon	NN	_	14	compound
14	release	release	NN	_	11	dobj
15	but	but	CC	_	14	cc
16	nearly	nearly	RB	_	17	advmod
17	normal	normal	JJ	_	19	amod
18	insulin	insulin	NN	_	19	compound
19	release	release	NN	_	14	conj
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	diabetics	diabetic	NNS	_	19	nmod
23	.	.	.	_	11	punct

1	Arginine	arginine	NN	_	11	nsubj
2	,	,	,	_	11	punct
3	in	in	IN	_	5	case
4	the	the	DT	_	5	det
5	absence	absence	NN	_	11	nmod
6	of	of	IN	_	7	case
7	glucose	glucose	NN	_	5	nmod
8	or	or	CC	_	7	cc
9	theophylline	theophylline	NN	_	7	conj
10	,	,	,	_	11	punct
11	caused	cause	VBD	_	0	ROOT
12	excessive	excessive	JJ	_	14	amod
13	glucagon	glucagon	NN	_	14	compound
14	release	release	NN	_	11	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	diabetics	diabetic	NNS	_	14	nmod
18	and	and	CC	_	14	cc
19	undetectable	undetectable	JJ	_	21	amod
20	insulin	insulin	NN	_	21	compound
21	release	release	NN	_	14	conj
22	in	in	IN	_	24	case
23	either	either	CC	_	24	cc:preconj
24	diabetics	diabetic	NNS	_	21	nmod
25	or	or	CC	_	24	cc
26	normals	normal	NNS	_	24	conj
27	.	.	.	_	11	punct

1	Pancreatic	pancreatic	JJ	_	2	amod
2	content	content	NN	_	7	nsubj
3	after	after	IN	_	4	case
4	perfusion	perfusion	NN	_	2	nmod
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	correlate	correlate	VB	_	0	ROOT
8	with	with	IN	_	9	case
9	release	release	NN	_	7	nmod
10	during	during	IN	_	11	case
11	perfusion	perfusion	NN	_	7	nmod
12	.	.	.	_	7	punct

1	Infusion	infusion	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	arginine	arginine	NN	_	1	nmod
4	alone	alone	RB	_	1	advmod
5	markedly	markedly	RB	_	6	advmod
6	decreased	decrease	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	amount	amount	NN	_	6	dobj
9	of	of	IN	_	12	case
10	extractable	extractable	JJ	_	12	amod
11	pancreatic	pancreatic	JJ	_	12	amod
12	insulin	insulin	NN	_	8	nmod
13	and	and	CC	_	12	cc
14	glucagon	glucagon	NN	_	12	conj
15	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	14	mark
5	the	the	DT	_	8	det
6	pancreatic	pancreatic	JJ	_	8	amod
7	alpha	alpha	NN	_	8	compound
8	cell	cell	NN	_	14	nsubj
9	of	of	IN	_	13	case
10	the	the	DT	_	13	det
11	diabetic	diabetic	JJ	_	13	amod
12	Chinese	chinese	JJ	_	13	amod
13	hamster	hamster	NN	_	8	nmod
14	responds	respond	VBZ	_	3	ccomp
15	excessively	excessively	RB	_	14	advmod
16	to	to	TO	_	17	case
17	arginine	arginine	NN	_	14	nmod
18	,	,	,	_	14	punct
19	as	as	RB	_	21	mark
20	is	be	VBZ	_	21	auxpass
21	seen	see	VBN	_	14	advcl
22	in	in	IN	_	25	case
23	the	the	DT	_	25	det
24	human	human	JJ	_	25	amod
25	diabetic	diabetic	JJ	_	21	nmod
26	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	defect	defect	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	related	relate	VBN	_	0	ROOT
6	to	to	TO	_	9	case
7	acute	acute	JJ	_	9	amod
8	insulin	insulin	NN	_	9	compound
9	release	release	NN	_	5	nmod
10	or	or	CC	_	9	cc
11	the	the	DT	_	12	det
12	presence	presence	NN	_	9	conj
13	of	of	IN	_	14	case
14	glucose	glucose	NN	_	12	nmod
15	.	.	.	_	5	punct

1	Further	further	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	results	result	NNS	_	5	nsubj
5	confirm	confirm	VBP	_	0	ROOT
6	that	that	IN	_	17	mark
7	the	the	DT	_	13	dep
8	diabetic	diabetic	JJ	_	13	amod
9	Chinese	chinese	JJ	_	13	amod
10	hamster	hamster	NN	_	13	compound
11	'	'	''	_	13	punct
12	s	s	NNS	_	13	compound
13	alpha	alpha	NN	_	17	nsubj
14	and	and	CC	_	13	cc
15	beta	beta	NN	_	13	conj
16	cells	cell	NNS	_	13	dep
17	respond	respond	VBP	_	5	ccomp
18	normally	normally	RB	_	17	advmod
19	to	to	TO	_	20	case
20	theophylline	theophylline	NN	_	17	nmod
21	,	,	,	_	17	punct
22	but	but	CC	_	17	cc
23	are	be	VBP	_	25	cop
24	relatively	relatively	RB	_	25	advmod
25	insensitive	insensitive	JJ	_	17	conj
26	to	to	TO	_	27	case
27	glucose	glucose	NN	_	25	nmod
28	.	.	.	_	5	punct

1	Interference	interference	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	biocytin	biocytin	NN	_	1	nmod
4	with	with	IN	_	5	case
5	opioid	opioid	NN	_	1	nmod
6	-	-	:	_	1	punct
7	evoked	evoke	VBN	_	8	amod
8	hyperpolarization	hyperpolarization	NN	_	1	dep
9	and	and	CC	_	8	cc
10	membrane	membrane	NN	_	11	compound
11	properties	property	NNS	_	8	conj
12	of	of	IN	_	17	case
13	rat	rat	NN	_	17	compound
14	spinal	spinal	JJ	_	17	amod
15	substantia	substantia	NN	_	17	compound
16	gelatinosa	gelatinosa	NN	_	17	compound
17	neurons	neuron	NNS	_	8	nmod
18	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	our	we	PRP$	_	3	nmod:poss
3	laboratory	laboratory	NN	_	25	nmod
4	,	,	,	_	25	punct
5	preliminary	preliminary	JJ	_	6	amod
6	whole	whole	NN	_	25	nsubj
7	-	-	:	_	6	punct
8	cell	cell	NN	_	6	dep
9	,	,	,	_	6	punct
10	tight	tight	JJ	_	12	amod
11	seal	seal	NN	_	12	compound
12	recordings	recording	NNS	_	6	appos
13	of	of	IN	_	18	case
14	rat	rat	NN	_	18	compound
15	spinal	spinal	JJ	_	18	amod
16	substantia	substantia	NN	_	18	compound
17	gelatinosa	gelatinosa	NN	_	18	compound
18	neurons	neuron	NNS	_	12	nmod
19	including	include	VBG	_	20	case
20	biocytin	biocytin	NN	_	18	nmod
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	patch	patch	NN	_	24	compound
24	pipette	pipette	NN	_	20	nmod
25	yielded	yield	VBD	_	0	ROOT
26	a	a	DT	_	29	det
27	significantly	significantly	RB	_	28	advmod
28	smaller	smaller	JJR	_	29	amod
29	proportion	proportion	NN	_	25	dobj
30	of	of	IN	_	31	case
31	neurons	neuron	NNS	_	29	nmod
32	hyperpolarized	hyperpolarize	VBN	_	31	acl
33	by	by	IN	_	36	case
34	selective	selective	JJ	_	36	amod
35	opioid	opioid	JJ	_	36	amod
36	agonists	agonist	NNS	_	32	nmod
37	compared	compare	VBN	_	39	case
38	with	with	IN	_	39	case
39	recordings	recording	NNS	_	25	advcl
40	without	without	IN	_	41	case
41	biocytin	biocytin	NN	_	39	nmod
42	.	.	.	_	25	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	investigated	investigate	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	biocytin	biocytin	NN	_	9	compound
9	inclusion	inclusion	NN	_	6	nmod
10	on	on	IN	_	12	case
11	opioid	opioid	JJ	_	12	amod
12	responses	response	NNS	_	6	nmod
13	and	and	CC	_	12	cc
14	other	other	JJ	_	16	amod
15	membrane	membrane	NN	_	16	compound
16	properties	property	NNS	_	12	conj
17	during	during	IN	_	20	case
18	whole	whole	NN	_	20	compound
19	-	-	:	_	20	punct
20	cell	cell	NN	_	6	nmod
21	,	,	,	_	20	punct
22	tight	tight	JJ	_	24	amod
23	seal	seal	NN	_	24	compound
24	recordings	recording	NNS	_	20	appos
25	of	of	IN	_	27	case
26	these	these	DT	_	27	det
27	neurons	neuron	NNS	_	24	nmod
28	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	percentage	percentage	NN	_	23	nsubjpass
3	of	of	IN	_	4	case
4	neurons	neuron	NNS	_	2	nmod
5	hyperpolarized	hyperpolarize	VBN	_	4	acl
6	by	by	IN	_	7	case
7	mu	mu	NN	_	5	nmod
8	-	-	:	_	2	punct
9	,	,	,	_	2	punct
10	delta	delta	NN	_	11	compound
11	(	(	NN	_	2	conj
12	1	1	CD	_	11	nummod
13	)	)	SYM	_	11	dep
14	-	-	:	_	11	punct
15	,	,	,	_	2	punct
16	and	and	CC	_	2	cc
17	kappa	kappa	NN	_	20	compound
18	-	-	:	_	20	punct
19	selective	selective	JJ	_	20	amod
20	opioids	opioid	NNS	_	2	conj
21	was	be	VBD	_	23	auxpass
22	significantly	significantly	RB	_	23	advmod
23	reduced	reduce	VBN	_	0	ROOT
24	when	when	WRB	_	23	dep
25	1	1	CD	_	26	nummod
26	%	%	NN	_	24	dep
27	but	but	CC	_	26	cc
28	not	not	RB	_	29	neg
29	&lt	&lt	VBN	_	26	conj
30	;	;	:	_	23	punct

1	or	or	CC	_	7	cc
2	=	=	JJ	_	5	amod
3	0.2	0.2	CD	_	4	compound
4	%	%	NN	_	5	amod
5	biocytin	biocytin	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	included	include	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	recording	recording	NN	_	11	compound
11	pipette	pipette	NN	_	7	nmod
12	,	,	,	_	7	punct
13	compared	compare	VBN	_	15	case
14	with	with	IN	_	15	case
15	neurons	neuron	NNS	_	7	advcl
16	recorded	record	VBN	_	15	acl
17	without	without	IN	_	18	case
18	biocytin	biocytin	NN	_	16	nmod
19	.	.	.	_	7	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	a	a	DT	_	6	det
4	significantly	significantly	RB	_	5	advmod
5	higher	higher	JJR	_	6	amod
6	proportion	proportion	NN	_	9	nsubj
7	of	of	IN	_	8	case
8	neurons	neuron	NNS	_	6	nmod
9	fired	fire	VBD	_	0	ROOT
10	spontaneous	spontaneous	JJ	_	12	amod
11	action	action	NN	_	12	compound
12	potentials	potential	NNS	_	9	dobj
13	with	with	IN	_	15	case
14	either	either	CC	_	15	dep
15	0.05	0.05	CD	_	9	nmod
16	-	-	:	_	15	punct
17	0.2	0.2	CD	_	20	compound
18	or	or	CC	_	17	cc
19	1	1	CD	_	17	conj
20	%	%	NN	_	21	amod
21	biocytin	biocytin	NN	_	15	dep
22	compared	compare	VBN	_	21	acl
23	to	to	TO	_	25	case
24	no	no	DT	_	25	neg
25	biocytin	biocytin	NN	_	22	nmod
26	.	.	.	_	9	punct

1	Resting	rest	VBG	_	3	amod
2	membrane	membrane	NN	_	3	compound
3	potential	potential	NN	_	19	nsubjpass
4	,	,	,	_	3	punct
5	input	input	NN	_	6	compound
6	impedance	impedance	NN	_	3	conj
7	and	and	CC	_	3	cc
8	the	the	DT	_	9	det
9	proportion	proportion	NN	_	3	conj
10	of	of	IN	_	11	case
11	neurons	neuron	NNS	_	9	nmod
12	displaying	display	VBG	_	11	acl
13	transient	transient	JJ	_	15	amod
14	outward	outward	JJ	_	15	amod
15	rectification	rectification	NN	_	12	dobj
16	were	be	VBD	_	19	auxpass
17	each	each	DT	_	19	dep
18	significantly	significantly	RB	_	19	advmod
19	altered	alter	VBN	_	0	ROOT
20	for	for	IN	_	21	case
21	neurons	neuron	NNS	_	19	nmod
22	recorded	record	VBN	_	21	acl
23	with	with	IN	_	25	case
24	1	1	CD	_	25	nummod
25	%	%	NN	_	22	nmod
26	but	but	CC	_	25	cc
27	not	not	RB	_	28	neg
28	0.05	0.05	CD	_	25	conj
29	-	-	:	_	25	punct
30	0.2	0.2	CD	_	31	compound
31	%	%	NN	_	32	amod
32	biocytin	biocytin	NN	_	25	dep
33	.	.	.	_	19	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	10	nsubj
3	may	may	MD	_	10	aux
4	be	be	VB	_	10	cop
5	due	due	JJ	_	10	case
6	to	to	TO	_	5	mwe
7	a	a	DT	_	10	det
8	relatively	relatively	RB	_	9	advmod
9	specific	specific	JJ	_	10	amod
10	blockade	blockade	NN	_	0	ROOT
11	of	of	IN	_	15	case
12	diverse	diverse	JJ	_	15	amod
13	potassium	potassium	NN	_	15	compound
14	channel	channel	NN	_	15	compound
15	types	type	NNS	_	10	nmod
16	.	.	.	_	10	punct

1	Because	because	IN	_	6	mark
2	efficient	efficient	JJ	_	3	amod
3	labeling	labeling	NN	_	6	nsubjpass
4	can	can	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	achieved	achieve	VBN	_	20	advcl
7	with	with	IN	_	10	case
8	0.1	0.1	CD	_	9	compound
9	%	%	NN	_	10	amod
10	biocytin	biocytin	NN	_	6	nmod
11	with	with	IN	_	15	case
12	whole	whole	JJ	_	15	amod
13	-	-	:	_	15	punct
14	cell	cell	NN	_	15	compound
15	recording	recording	NN	_	10	nmod
16	,	,	,	_	20	punct
17	higher	higher	JJR	_	18	amod
18	concentrations	concentration	NNS	_	20	nsubjpass
19	are	be	VBP	_	20	auxpass
20	contraindicated	contraindicate	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	Thiolated	thiolate	VBN	_	2	amod
2	carboxymethylcellulose	carboxymethylcellulose	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	evaluation	evaluation	NN	_	2	dep
7	of	of	IN	_	9	case
8	its	its	PRP$	_	9	nmod:poss
9	permeation	permeation	NN	_	6	nmod
10	enhancing	enhance	VBG	_	11	amod
11	effect	effect	NN	_	6	dep
12	on	on	IN	_	14	case
13	peptide	peptide	NN	_	14	compound
14	drugs	drug	NNS	_	11	nmod
15	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	purpose	purpose	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	16	case
12	sodium	sodium	NN	_	16	compound
13	carboxymethylcellulose	carboxymethylcellulose	NN	_	16	compound
14	(	(	CD	_	16	nummod
15	NaCMC	nacmc	NN	_	16	compound
16	)	)	NN	_	10	nmod
17	and	and	CC	_	16	cc
18	carboxymethylcellulose	carboxymethylcellulose	NN	_	16	conj
19	-	-	:	_	16	punct
20	cysteine	cysteine	NN	_	22	compound
21	(	(	NN	_	22	compound
22	CMC	cmc	NN	_	16	dep
23	-	-	:	_	22	punct
24	Cys	cys	NN	_	26	compound
25	)	)	CD	_	26	nummod
26	conjugates	conjugate	NNS	_	22	dep
27	on	on	IN	_	30	case
28	the	the	DT	_	30	det
29	intestinal	intestinal	JJ	_	30	amod
30	permeation	permeation	NN	_	26	nmod
31	of	of	IN	_	36	case
32	sodium	sodium	NN	_	36	compound
33	fluorescein	fluorescein	NN	_	36	compound
34	(	(	CD	_	36	nummod
35	NaFlu	naflu	NN	_	36	compound
36	)	)	NN	_	30	nmod
37	and	and	CC	_	36	cc
38	model	model	NN	_	40	compound
39	peptide	peptide	NN	_	40	compound
40	drugs	drug	NNS	_	36	conj
41	,	,	,	_	36	punct
42	bacitracin	bacitracin	NN	_	36	conj
43	and	and	CC	_	36	cc
44	insulin	insulin	NN	_	36	conj
45	.	.	.	_	6	punct

1	Cysteine	cysteine	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	covalently	covalently	RB	_	4	advmod
4	linked	link	VBN	_	0	ROOT
5	to	to	TO	_	6	case
6	carbodiimide	carbodiimide	NN	_	4	nmod
7	activated	activate	VBD	_	8	amod
8	NaCMC	nacmc	NN	_	6	dep
9	.	.	.	_	4	punct

1	Iodometric	iodometric	JJ	_	2	amod
2	titration	titration	NN	_	8	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	polymer	polymer	NN	_	6	compound
6	conjugates	conjugate	NNS	_	2	nmod
7	was	be	VBD	_	8	auxpass
8	used	use	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	determine	determine	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	extent	extent	NN	_	10	dobj
13	of	of	IN	_	15	case
14	immobilised	immobilise	VBN	_	15	amod
15	cysteine	cysteine	NN	_	12	nmod
16	.	.	.	_	8	punct

1	Permeation	permeation	NN	_	2	compound
2	studies	study	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	performed	perform	VBN	_	0	ROOT
5	on	on	IN	_	10	case
6	guinea	guinea	NN	_	10	compound
7	pig	pig	NN	_	10	compound
8	small	small	JJ	_	10	amod
9	intestinal	intestinal	JJ	_	10	amod
10	mucosa	mucosa	NN	_	4	nmod
11	mounted	mount	VBD	_	4	dep
12	in	in	IN	_	13	case
13	Ussing	Ussing	NNP	_	11	nmod
14	-	-	:	_	4	punct
15	type	type	NN	_	16	compound
16	chamber	chamber	NN	_	4	dep
17	.	.	.	_	4	punct

1	Unmodified	unmodified	JJ	_	3	amod
2	NaCMC	nacmc	NN	_	3	compound
3	(	(	NN	_	6	amod
4	1	1	CD	_	5	compound
5	%	%	NN	_	6	amod
6	m	m	NN	_	0	ROOT
7	/	/	:	_	6	punct
8	v	v	LS	_	6	dep
9	)	)	CD	_	11	nsubj
10	significantly	significantly	RB	_	11	advmod
11	improved	improve	VBD	_	8	ccomp
12	the	the	DT	_	16	det
13	transport	transport	NN	_	16	compound
14	ratio	ratio	NN	_	16	compound
15	(	(	CD	_	16	nummod
16	R	r	NN	_	17	nsubj
17	=	=	JJ	_	11	ccomp
18	P	p	NN	_	20	compound
19	(	(	CD	_	20	nummod
20	app	app	NN	_	17	dobj
21	)	)	CD	_	22	nummod
22	polymer	polymer	NN	_	20	dep
23	/	/	:	_	20	punct
24	P	p	NN	_	20	dep
25	(	(	CD	_	26	nummod
26	app	app	NN	_	24	dep
27	)	)	CD	_	28	nummod
28	control	control	NN	_	26	dep
29	)	)	CD	_	28	nummod
30	of	of	IN	_	31	case
31	NaFlu	naflu	NN	_	26	nmod
32	to	to	TO	_	33	case
33	1.3	1.3	CD	_	26	nmod
34	and	and	CC	_	26	cc
35	1	1	CD	_	36	nummod
36	%	%	NN	_	26	conj
37	(	(	CD	_	38	nummod
38	m	m	NN	_	36	dep
39	/	/	:	_	20	punct
40	v	v	LS	_	20	dep
41	)	)	CD	_	42	nummod
42	NaCMC	nacmc	NN	_	47	nsubj
43	conjugated	conjugate	VBN	_	42	acl
44	with	with	IN	_	45	case
45	cysteine	cysteine	NN	_	43	nmod
46	further	further	RB	_	47	advmod
47	enhanced	enhance	VBD	_	40	ccomp
48	the	the	DT	_	49	det
49	permeation	permeation	NN	_	47	dobj
50	.	.	.	_	6	punct

1	Cysteine	cysteine	NN	_	2	compound
2	conjugation	conjugation	NN	_	15	nsubj
3	at	at	IN	_	4	case
4	3.6	3.6	CD	_	2	nmod
5	,	,	,	_	4	punct
6	5.3	5.3	CD	_	4	conj
7	and	and	CC	_	4	cc
8	7.3	7.3	CD	_	9	compound
9	%	%	NN	_	11	dep
10	(	(	CD	_	11	nummod
11	m	m	NN	_	4	conj
12	/	/	:	_	2	punct
13	m	m	NN	_	14	compound
14	)	)	NN	_	2	dep
15	resulted	result	VBD	_	0	ROOT
16	in	in	IN	_	17	case
17	R	r	NN	_	15	nmod
18	-	-	:	_	17	punct
19	values	value	NNS	_	17	dep
20	of	of	IN	_	21	case
21	1.4	1.4	CD	_	19	nmod
22	,	,	,	_	21	punct
23	1.7	1.7	CD	_	21	conj
24	and	and	CC	_	21	cc
25	1.8	1.8	CD	_	21	conj
26	,	,	,	_	17	punct
27	respectively	respectively	RB	_	17	advmod
28	.	.	.	_	15	punct

1	Decreasing	decrease	VBG	_	0	ROOT
2	the	the	DT	_	3	det
3	concentration	concentration	NN	_	1	dobj
4	of	of	IN	_	5	case
5	CMC	CMC	NNP	_	3	nmod
6	-	-	:	_	5	punct
7	Cys	cys	NN	_	5	dep
8	,	,	,	_	5	punct
9	exhibiting	exhibit	VBG	_	5	acl
10	7.3	7.3	CD	_	11	nummod
11	%	%	NN	_	9	dobj
12	(	(	CD	_	13	nummod
13	m	m	NN	_	11	dep
14	/	/	:	_	11	punct
15	m	m	NN	_	16	compound
16	)	)	NN	_	11	dep
17	of	of	IN	_	21	case
18	immobilised	immobilise	VBN	_	21	amod
19	cysteine	cysteine	NN	_	21	compound
20	(	(	NN	_	21	compound
21	CMC	cmc	NN	_	16	nmod
22	-	-	:	_	21	punct
23	Cys7	cys7	NN	_	21	dep
24	.	.	.	_	1	punct
25	3	3	CD	_	26	compound
26	)	)	CD	_	43	dep
27	from	from	IN	_	29	case
28	1	1	CD	_	29	nummod
29	%	%	NN	_	26	nmod
30	(	(	CD	_	31	nummod
31	m	m	NN	_	29	dep
32	/	/	:	_	26	punct
33	v	v	LS	_	43	dep
34	)	)	CD	_	36	compound
35	to	to	TO	_	36	dep
36	0.5	0.5	CD	_	37	nummod
37	%	%	NN	_	43	dep
38	(	(	CD	_	39	nummod
39	m	m	NN	_	37	dep
40	/	/	:	_	43	punct
41	v	v	LS	_	43	dep
42	)	)	CD	_	43	nsubj
43	decreased	decrease	VBD	_	1	parataxis
44	the	the	DT	_	45	det
45	R	r	NN	_	43	dobj
46	-	-	:	_	45	punct
47	value	value	NN	_	45	dep
48	of	of	IN	_	49	case
49	NaFlu	naflu	NN	_	47	nmod
50	from	from	IN	_	51	case
51	1.8	1.8	CD	_	47	nmod
52	to	to	TO	_	53	case
53	1.2	1.2	CD	_	51	nmod
54	.	.	.	_	1	punct

1	NaCMC	nacmc	NN	_	0	ROOT
2	at	at	IN	_	6	case
3	1	1	CD	_	4	compound
4	%	%	NN	_	6	amod
5	(	(	CD	_	6	nummod
6	m	m	NN	_	1	nmod
7	/	/	:	_	1	punct
8	v	v	LS	_	16	dep
9	)	)	CD	_	16	nsubj
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	presence	presence	NN	_	9	nmod
13	of	of	IN	_	15	case
14	free	free	JJ	_	15	amod
15	cysteine	cysteine	NN	_	12	nmod
16	had	have	VBD	_	1	dep
17	no	no	DT	_	19	neg
18	significant	significant	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	on	on	IN	_	22	case
21	the	the	DT	_	22	det
22	R	r	NN	_	16	nmod
23	-	-	:	_	16	punct
24	value	value	NN	_	16	dobj
25	of	of	IN	_	26	case
26	NaFlu	naflu	NN	_	24	nmod
27	compared	compare	VBN	_	24	acl
28	to	to	TO	_	29	case
29	NaCMC	nacmc	NN	_	27	nmod
30	alone	alone	RB	_	29	advmod
31	.	.	.	_	1	punct

1	Formulation	Formulation	NNP	_	0	ROOT
2	of	of	IN	_	5	case
3	fluorescence	fluorescence	NN	_	5	compound
4	labelled	label	VBN	_	5	amod
5	bacitracin	bacitracin	NN	_	1	nmod
6	and	and	CC	_	5	cc
7	insulin	insulin	NN	_	5	conj
8	in	in	IN	_	11	case
9	unconjugated	unconjugated	JJ	_	11	amod
10	NaCMC	nacmc	NN	_	11	compound
11	(	(	NN	_	1	nmod
12	1	1	CD	_	13	compound
13	%	%	NN	_	14	amod
14	m	m	NN	_	11	dep
15	/	/	:	_	1	punct
16	v	v	LS	_	21	dep
17	)	)	CD	_	21	nsubj
18	did	do	VBD	_	21	aux
19	not	not	RB	_	21	neg
20	significantly	significantly	RB	_	21	advmod
21	improve	improve	VB	_	1	dep
22	the	the	DT	_	23	det
23	permeation	permeation	NN	_	21	dobj
24	,	,	,	_	21	punct
25	however	however	RB	_	21	advmod
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	presence	presence	NN	_	25	nmod
29	of	of	IN	_	33	case
30	1	1	CD	_	31	compound
31	%	%	NN	_	33	amod
32	(	(	CD	_	33	nummod
33	m	m	NN	_	28	nmod
34	/	/	:	_	21	punct
35	v	v	LS	_	21	dep
36	)	)	FW	_	39	compound
37	CMC	cmc	SYM	_	39	dep
38	-	-	:	_	39	punct
39	Cys7	cys7	NN	_	35	dep
40	.	.	.	_	39	punct
41	3	3	CD	_	45	nummod
42	a	a	DT	_	45	det
43	significantly	significantly	RB	_	44	advmod
44	improved	improve	VBN	_	45	amod
45	permeation	permeation	NN	_	47	nsubjpass
46	was	be	VBD	_	47	auxpass
47	observed	observe	VBN	_	39	dep
48	(	(	RB	_	49	advmod
49	R	r	NN	_	47	dobj
50	=	=	JJ	_	49	amod
51	1.3	1.3	CD	_	52	nummod
52	)	)	NN	_	50	dep
53	.	.	.	_	1	punct

1	Conjugation	conjugation	NN	_	8	nsubj
2	at	at	IN	_	3	case
3	NaCMC	nacmc	NN	_	1	nmod
4	with	with	IN	_	6	case
5	cysteine	cysteine	NN	_	6	compound
6	moieties	moiety	NNS	_	3	nmod
7	significantly	significantly	RB	_	8	advmod
8	improves	improve	VBZ	_	0	ROOT
9	the	the	DT	_	11	det
10	intestinal	intestinal	JJ	_	11	amod
11	permeation	permeation	NN	_	8	dobj
12	of	of	IN	_	16	case
13	the	the	DT	_	16	det
14	hydrophilic	hydrophilic	JJ	_	16	amod
15	molecule	molecule	NN	_	16	compound
16	NaFlu	naflu	NN	_	11	nmod
17	and	and	CC	_	11	cc
18	the	the	DT	_	21	det
19	model	model	NN	_	21	compound
20	peptide	peptide	NN	_	21	compound
21	drugs	drug	NNS	_	11	conj
22	bacitracin	bacitracin	NN	_	21	dep
23	and	and	CC	_	22	cc
24	insulin	insulin	NN	_	22	conj
25	in	in	FW	_	26	compound
26	vitro	vitro	FW	_	8	advmod
27	,	,	,	_	8	punct
28	therefore	therefore	RB	_	31	advmod
29	this	this	DT	_	31	det
30	conjugated	conjugate	VBN	_	31	amod
31	system	system	NN	_	8	dobj
32	maybe	maybe	RB	_	33	advmod
33	useful	useful	JJ	_	31	amod
34	for	for	IN	_	36	case
35	peroral	peroral	JJ	_	36	amod
36	administration	administration	NN	_	33	nmod
37	of	of	IN	_	39	case
38	peptide	peptide	NN	_	39	compound
39	drugs	drug	NNS	_	36	nmod
40	in	in	IN	_	42	case
41	the	the	DT	_	42	det
42	future	future	NN	_	33	nmod
43	.	.	.	_	8	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	low	low	JJ	_	4	amod
4	temperatures	temperature	NNS	_	1	nmod
5	on	on	IN	_	6	case
6	microtubules	microtubule	NNS	_	1	nmod
7	in	in	IN	_	12	case
8	the	the	DT	_	12	det
9	non	non	JJ	_	12	amod
10	-	-	:	_	12	punct
11	myelinated	myelinated	JJ	_	12	amod
12	axons	axon	NNS	_	6	nmod
13	of	of	IN	_	14	case
14	post	post	NN	_	12	nmod
15	-	-	:	_	1	punct
16	ganglionic	ganglionic	JJ	_	18	amod
17	sympathetic	sympathetic	JJ	_	18	amod
18	nerves	nerve	NNS	_	1	dep
19	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	18	nsubjpass
3	of	of	IN	_	5	case
4	temperature	temperature	NN	_	5	compound
5	changes	change	NNS	_	2	nmod
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	number	number	NN	_	5	nmod
9	of	of	IN	_	10	case
10	microtubules	microtubule	NNS	_	8	nmod
11	in	in	IN	_	15	case
12	non	non	JJ	_	15	amod
13	-	-	:	_	15	punct
14	myelinated	myelinated	JJ	_	15	amod
15	axons	axon	NNS	_	8	nmod
16	has	have	VBZ	_	18	aux
17	been	be	VBN	_	18	auxpass
18	studied	study	VBN	_	0	ROOT
19	in	in	IN	_	23	case
20	cat	cat	NN	_	23	compound
21	inferior	inferior	JJ	_	23	amod
22	mesenteric	mesenteric	JJ	_	23	amod
23	ganglion	ganglion	NN	_	18	nmod
24	/	/	:	_	23	punct
25	hypogastric	hypogastric	JJ	_	27	amod
26	nerve	nerve	NN	_	27	compound
27	preparations	preparation	NNS	_	23	dep
28	incubated	incubate	VBN	_	27	acl
29	at	at	IN	_	31	case
30	various	various	JJ	_	31	amod
31	temperatures	temperature	NNS	_	28	nmod
32	in	in	IN	_	38	case
33	Eagles	Eagles	NNPS	_	38	compound
34	minimal	minimal	JJ	_	38	amod
35	essential	essential	JJ	_	38	amod
36	tissue	tissue	NN	_	38	compound
37	culture	culture	NN	_	38	compound
38	medium	medium	NN	_	31	nmod
39	in	in	FW	_	40	compound
40	vitro	vitro	FW	_	28	advmod
41	.	.	.	_	18	punct

1	At	at	IN	_	4	case
2	37	37	CD	_	4	nummod
3	degrees	degree	NNS	_	4	compound
4	C	c	NN	_	10	nmod
5	the	the	DT	_	9	det
6	non	non	JJ	_	9	amod
7	-	-	:	_	9	punct
8	myelinated	myelinated	JJ	_	9	amod
9	axons	axon	NNS	_	10	nsubj
10	contained	contain	VBD	_	0	ROOT
11	28.4	28.4	CD	_	10	dobj
12	plus	plus	CC	_	11	cc
13	or	or	CC	_	11	cc
14	minus	minus	CC	_	16	dep
15	0.8	0.8	CD	_	16	nummod
16	S	s	NN	_	11	conj
17	.	.	.	_	10	punct
18	E	e	NN	_	10	dep
19	.	.	.	_	18	punct
20	M	m	NN	_	18	dep
21	.	.	.	_	10	punct

1	(	(	NN	_	4	compound
2	54	54	CD	_	3	compound
3	)	)	CD	_	4	nummod
4	microtubules	microtubule	NNS	_	0	ROOT
5	per	per	IN	_	6	case
6	axon	axon	NN	_	4	nmod
7	.	.	.	_	4	punct

1	After	after	IN	_	2	case
2	incubation	incubation	NN	_	12	nmod
3	at	at	IN	_	6	case
4	0	0	CD	_	6	nummod
5	degrees	degree	NNS	_	6	compound
6	C	c	NN	_	2	nmod
7	for	for	IN	_	9	case
8	4	4	CD	_	9	nummod
9	h	h	NN	_	2	nmod
10	this	this	DT	_	11	det
11	number	number	NN	_	12	nsubj
12	fell	fall	VBD	_	0	ROOT
13	to	to	TO	_	14	case
14	2.3	2.3	CD	_	12	nmod
15	plus	plus	CC	_	14	cc
16	or	or	CC	_	14	cc
17	minus	minus	CC	_	19	dep
18	0.1	0.1	CD	_	19	nummod
19	S	s	NN	_	14	conj
20	.	.	.	_	12	punct
21	E	e	NN	_	12	dep
22	.	.	.	_	21	punct
23	M	m	NN	_	21	dep
24	.	.	.	_	12	punct

1	(	(	NN	_	3	compound
2	41	41	CD	_	3	nummod
3	)	)	NN	_	0	ROOT
4	but	but	CC	_	3	cc
5	returned	return	VBD	_	3	conj
6	to	to	TO	_	8	case
7	normal	normal	JJ	_	8	amod
8	levels	level	NNS	_	5	nmod
9	when	when	WRB	_	13	advmod
10	the	the	DT	_	11	det
11	nerves	nerve	NNS	_	13	nsubjpass
12	were	be	VBD	_	13	auxpass
13	rewarmed	rewarm	VBN	_	5	advcl
14	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	loss	loss	NN	_	17	nsubj
3	of	of	IN	_	4	case
4	microtubules	microtubule	NNS	_	2	nmod
5	on	on	IN	_	6	mark
6	cooling	cool	VBG	_	2	acl
7	the	the	DT	_	8	det
8	nerves	nerve	NNS	_	6	dobj
9	and	and	CC	_	8	cc
10	their	they	PRP$	_	11	nmod:poss
11	reappearance	reappearance	NN	_	8	conj
12	on	on	IN	_	13	case
13	rewarming	rewarm	VBG	_	6	nmod
14	was	be	VBD	_	17	cop
15	a	a	DT	_	17	det
16	rapid	rapid	JJ	_	17	amod
17	process	process	NN	_	0	ROOT
18	;	;	:	_	17	punct

1	it	it	PRP	_	3	nsubj
2	was	be	VBD	_	3	cop
3	independent	independent	JJ	_	0	ROOT
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	influence	influence	NN	_	3	nmod
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	nueronal	nueronal	JJ	_	11	amod
10	cell	cell	NN	_	11	compound
11	body	body	NN	_	6	nmod
12	and	and	CC	_	11	cc
13	of	of	IN	_	15	case
14	protein	protein	NN	_	15	compound
15	synthesis	synthesis	NN	_	11	conj
16	within	within	IN	_	18	case
17	the	the	DT	_	18	det
18	axon	axon	NN	_	6	nmod
19	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	preservation	preservation	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	microtubules	microtubule	NNS	_	2	nmod
6	was	be	VBD	_	7	auxpass
7	improved	improve	VBN	_	0	ROOT
8	when	when	WRB	_	11	advmod
9	D2O	d2o	NN	_	11	nsubj
10	was	be	VBD	_	11	cop
11	present	present	JJ	_	7	advcl
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	incubation	incubation	NN	_	15	compound
15	medium	medium	NN	_	11	nmod
16	.	.	.	_	7	punct

1	Reformed	Reformed	NNP	_	2	compound
2	microtubules	microtubule	NNS	_	3	nsubj
3	appeared	appear	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	function	function	VB	_	3	xcomp
6	normally	normally	RB	_	5	advmod
7	with	with	IN	_	8	case
8	respect	respect	NN	_	5	nmod
9	to	to	TO	_	12	case
10	their	they	PRP$	_	12	nmod:poss
11	possible	possible	JJ	_	12	amod
12	role	role	NN	_	8	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	transport	transport	NN	_	12	nmod
16	of	of	IN	_	19	case
17	noradrenaline	noradrenaline	NN	_	19	compound
18	storage	storage	NN	_	19	compound
19	vesicles	vesicle	NNS	_	15	nmod
20	along	along	IN	_	22	case
21	the	the	DT	_	22	det
22	axons	axon	NNS	_	12	nmod
23	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	fluoroquinolones	fluoroquinolone	NNS	_	0	ROOT
3	for	for	IN	_	6	case
4	urinary	urinary	JJ	_	6	amod
5	tract	tract	NN	_	6	compound
6	infections	infection	NNS	_	2	nmod
7	:	:	:	_	2	punct
8	a	a	DT	_	9	det
9	review	review	NN	_	2	dep
10	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	fluoroquinolones	fluoroquinolone	NNS	_	7	nsubj
3	are	be	VBP	_	7	cop
4	a	a	DT	_	7	det
5	rapidly	rapidly	RB	_	6	advmod
6	growing	grow	VBG	_	7	amod
7	class	class	NN	_	0	ROOT
8	of	of	IN	_	9	case
9	antibiotics	antibiotic	NNS	_	7	nmod
10	with	with	IN	_	13	case
11	a	a	DT	_	13	det
12	broad	broad	JJ	_	13	amod
13	spectrum	spectrum	NN	_	7	nmod
14	of	of	IN	_	15	case
15	activity	activity	NN	_	13	nmod
16	against	against	IN	_	17	case
17	gram	gram	NN	_	15	nmod
18	-	-	:	_	17	punct
19	negative	negative	JJ	_	22	amod
20	and	and	CC	_	19	cc
21	some	some	DT	_	19	conj
22	gram	gram	NN	_	17	dep
23	-	-	:	_	17	punct
24	positive	positive	JJ	_	26	amod
25	aerobic	aerobic	JJ	_	26	amod
26	bacteria	bacterium	NNS	_	17	dep
27	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	19	nsubjpass
3	,	,	,	_	2	punct
4	including	include	VBG	_	5	case
5	norfloxacin	norfloxacin	NN	_	2	nmod
6	,	,	,	_	5	punct
7	ciprofloxacin	ciprofloxacin	NN	_	5	conj
8	,	,	,	_	5	punct
9	ofloxacin	ofloxacin	NN	_	5	conj
10	,	,	,	_	5	punct
11	enoxacin	enoxacin	NN	_	5	conj
12	,	,	,	_	5	punct
13	and	and	CC	_	5	cc
14	lomefloxacin	lomefloxacin	NN	_	5	conj
15	,	,	,	_	2	punct
16	have	have	VBP	_	19	aux
17	been	be	VBN	_	19	auxpass
18	extensively	extensively	RB	_	19	advmod
19	studied	study	VBN	_	0	ROOT
20	and	and	CC	_	19	cc
21	have	have	VBP	_	22	aux
22	demonstrated	demonstrate	VBN	_	19	conj
23	efficacy	efficacy	NN	_	26	compound
24	and	and	CC	_	23	cc
25	safety	safety	NN	_	23	conj
26	profiles	profile	NNS	_	22	dobj
27	comparable	comparable	JJ	_	26	amod
28	to	to	TO	_	29	case
29	those	those	DT	_	27	nmod
30	of	of	IN	_	33	case
31	other	other	JJ	_	33	amod
32	traditional	traditional	JJ	_	33	amod
33	agents	agent	NNS	_	29	nmod
34	for	for	IN	_	36	case
35	the	the	DT	_	36	det
36	treatment	treatment	NN	_	29	nmod
37	of	of	IN	_	43	case
38	complicated	complicated	JJ	_	43	amod
39	or	or	CC	_	38	cc
40	uncomplicated	uncomplicated	JJ	_	38	conj
41	urinary	urinary	JJ	_	43	amod
42	tract	tract	NN	_	43	compound
43	infections	infection	NNS	_	36	nmod
44	and	and	CC	_	43	cc
45	prostatitis	prostatitis	NN	_	43	conj
46	.	.	.	_	19	punct

1	Advantages	advantage	NNS	_	8	nsubj
2	offered	offer	VBN	_	1	acl
3	by	by	IN	_	5	case
4	this	this	DT	_	5	det
5	class	class	NN	_	2	nmod
6	of	of	IN	_	7	case
7	antibiotics	antibiotic	NNS	_	5	nmod
8	include	include	VBP	_	0	ROOT
9	optimal	optimal	JJ	_	10	amod
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	,	,	,	_	10	punct
12	effectiveness	effectiveness	NN	_	10	conj
13	against	against	IN	_	17	case
14	multidrug	multidrug	JJ	_	17	amod
15	-	-	:	_	17	punct
16	resistant	resistant	JJ	_	17	amod
17	organisms	organism	NNS	_	12	nmod
18	,	,	,	_	10	punct
19	and	and	CC	_	10	cc
20	oral	oral	JJ	_	21	amod
21	administration	administration	NN	_	10	conj
22	even	even	RB	_	23	advmod
23	when	when	WRB	_	28	advmod
24	parenteral	parenteral	JJ	_	25	amod
25	antibiotics	antibiotic	NNS	_	28	nsubjpass
26	are	be	VBP	_	28	auxpass
27	generally	generally	RB	_	28	advmod
28	used	use	VBN	_	8	advcl
29	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	fluoroquinolones	fluoroquinolone	NNS	_	6	nsubjpass
3	are	be	VBP	_	6	auxpass
4	also	also	RB	_	6	advmod
5	extensively	extensively	RB	_	6	advmod
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	urologic	urologic	JJ	_	9	amod
9	surgery	surgery	NN	_	6	nmod
10	.	.	.	_	6	punct

1	If	if	IN	_	2	mark
2	taken	take	VBN	_	14	advcl
3	1	1	CD	_	4	nummod
4	hour	hour	NN	_	2	nmod
5	before	before	IN	_	4	case
6	indinavir	indinavir	NN	_	8	compound
7	(	(	CD	_	8	nummod
8	IDV	IDV	NNP	_	4	dep
9	)	)	CD	_	8	nummod
10	,	,	,	_	14	punct
11	didanosine	didanosine	NN	_	14	nsubj
12	does	do	VBZ	_	14	aux
13	not	not	RB	_	14	neg
14	affect	affect	VB	_	0	ROOT
15	IDV	IDV	NNP	_	16	compound
16	exposure	exposure	NN	_	14	dobj
17	,	,	,	_	14	punct
18	despite	despite	IN	_	21	case
19	persistent	persistent	JJ	_	21	amod
20	buffering	buffering	NN	_	21	compound
21	effects	effect	NNS	_	14	nmod
22	.	.	.	_	14	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	indinavir	indinavir	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	didanosine	didanosine	NN	_	4	conj
7	significantly	significantly	RB	_	8	advmod
8	reduces	reduce	VBZ	_	0	ROOT
9	the	the	DT	_	10	det
10	level	level	NN	_	8	dobj
11	of	of	IN	_	12	case
12	exposure	exposure	NN	_	10	nmod
13	to	to	TO	_	14	case
14	indinavir	indinavir	NN	_	12	nmod
15	,	,	,	_	8	punct
16	but	but	CC	_	8	cc
17	it	it	PRP	_	19	nsubj
18	is	be	VBZ	_	19	cop
19	unclear	unclear	JJ	_	8	conj
20	how	how	WRB	_	21	advmod
21	soon	soon	RB	_	28	advmod
22	after	after	IN	_	28	mark
23	didanosine	didanosine	NN	_	25	compound
24	administration	administration	NN	_	25	compound
25	indinavir	indinavir	NN	_	28	nsubjpass
26	may	may	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	given	give	VBN	_	19	advcl
29	safely	safely	RB	_	28	advmod
30	.	.	.	_	8	punct

1	We	we	PRP	_	2	nsubj
2	compared	compare	VBD	_	0	ROOT
3	indinavir	indinavir	NN	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	2	dobj
5	and	and	CC	_	4	cc
6	gastric	gastric	JJ	_	7	amod
7	pH	ph	NN	_	4	conj
8	in	in	IN	_	12	case
9	12	12	CD	_	12	nummod
10	human	human	JJ	_	12	amod
11	immunodeficiency	immunodeficiency	NN	_	12	compound
12	virus	virus	NN	_	4	nmod
13	-	-	:	_	12	punct
14	positive	positive	JJ	_	15	amod
15	patients	patient	NNS	_	12	dep
16	by	by	IN	_	17	case
17	use	use	NN	_	15	nmod
18	of	of	IN	_	20	case
19	800	800	CD	_	20	nummod
20	mg	mg	NN	_	17	nmod
21	of	of	IN	_	22	case
22	indinavir	indinavir	NN	_	20	nmod
23	alone	alone	RB	_	22	advmod
24	versus	versus	CC	_	20	cc
25	800	800	CD	_	26	nummod
26	mg	mg	NN	_	20	conj
27	of	of	IN	_	28	case
28	indinavir	indinavir	NN	_	26	nmod
29	administered	administer	VBN	_	15	acl
30	1	1	CD	_	31	nummod
31	h	h	NN	_	29	nmod
32	after	after	IN	_	31	case
33	didanosine	didanosine	NN	_	34	compound
34	administration	administration	NN	_	31	dep
35	.	.	.	_	2	punct

1	Median	median	JJ	_	3	amod
2	gastric	gastric	JJ	_	3	amod
3	pH	ph	NN	_	6	nsubj
4	was	be	VBD	_	6	cop
5	significantly	significantly	RB	_	6	advmod
6	higher	higher	JJR	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	indinavir	indinavir	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	taken	take	VBN	_	6	advcl
11	after	after	IN	_	13	case
12	didanosine	didanosine	NN	_	13	compound
13	administration	administration	NN	_	10	nmod
14	;	;	:	_	6	punct

1	however	however	RB	_	28	advmod
2	,	,	,	_	28	punct
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	difference	difference	NN	_	28	nsubjpass
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	maximum	maximum	NN	_	9	compound
9	concentration	concentration	NN	_	5	nmod
10	in	in	IN	_	11	case
11	plasma	plasma	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	the	the	DT	_	14	det
14	area	area	NN	_	11	conj
15	under	under	IN	_	17	case
16	the	the	DT	_	17	det
17	concentration	concentration	NN	_	5	nmod
18	-	-	:	_	5	punct
19	time	time	NN	_	20	compound
20	curve	curve	NN	_	5	dep
21	from	from	IN	_	22	case
22	time	time	NN	_	20	nmod
23	zero	zero	CD	_	22	nummod
24	to	to	TO	_	26	case
25	8	8	CD	_	26	nummod
26	h	h	NN	_	22	nmod
27	was	be	VBD	_	28	auxpass
28	observed	observe	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	Indinavir	Indinavir	NNP	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	with	with	IN	_	10	case
6	a	a	DT	_	10	det
7	light	light	JJ	_	10	amod
8	meal	meal	NN	_	10	compound
9	1	1	CD	_	10	nummod
10	h	h	NN	_	4	nmod
11	following	follow	VBG	_	13	case
12	the	the	DT	_	13	det
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	16	case
15	400	400	CD	_	16	nummod
16	mg	mg	NN	_	13	nmod
17	of	of	IN	_	18	case
18	didanosine	didanosine	NN	_	16	nmod
19	.	.	.	_	4	punct

1	Progestin	progestin	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	only	only	RB	_	5	advmod
4	oral	oral	JJ	_	5	amod
5	contraception	contraception	NN	_	1	dep
6	:	:	:	_	5	punct
7	a	a	DT	_	9	det
8	comprehensive	comprehensive	JJ	_	9	amod
9	review	review	NN	_	5	dep
10	.	.	.	_	1	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	provide	provide	VB	_	18	advcl
5	information	information	NN	_	4	dobj
6	for	for	IN	_	11	case
7	the	the	DT	_	11	det
8	appropriate	appropriate	JJ	_	11	amod
9	package	package	NN	_	11	compound
10	insert	insert	NN	_	11	compound
11	labeling	labeling	NN	_	5	nmod
12	of	of	IN	_	13	case
13	progestin	progestin	NN	_	11	nmod
14	-	-	:	_	18	punct
15	only	only	RB	_	17	advmod
16	oral	oral	JJ	_	17	amod
17	contraceptives	contraceptive	NNS	_	18	nsubj
18	(	(	VBP	_	0	ROOT
19	POC	poc	NN	_	20	compound
20	)	)	NN	_	18	dobj
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	US	US	NNP	_	20	nmod
24	,	,	,	_	23	punct
25	a	a	DT	_	27	det
26	comprehensive	comprehensive	JJ	_	27	amod
27	review	review	NN	_	29	nsubjpass
28	was	be	VBD	_	29	auxpass
29	made	make	VBN	_	23	acl:relcl
30	of	of	IN	_	34	case
31	norgestrel	norgestrel	JJ	_	34	amod
32	(	(	NN	_	34	compound
33	0.075	0.075	CD	_	34	compound
34	mg	mg	NN	_	29	nmod
35	)	)	NN	_	34	dep
36	and	and	CC	_	34	cc
37	norethindrone	norethindrone	NN	_	41	compound
38	(	(	CD	_	39	compound
39	0.35	0.35	CD	_	40	dep
40	mg	mg	NN	_	41	dep
41	)	)	NN	_	34	conj
42	,	,	,	_	23	punct
43	with	with	IN	_	46	case
44	the	the	DT	_	46	det
45	clinical	clinical	JJ	_	46	amod
46	differences	difference	NNS	_	18	nmod
47	indicated	indicate	VBD	_	46	acl
48	where	where	WRB	_	49	advmod
49	applicable	applicable	JJ	_	47	advcl
50	.	.	.	_	18	punct

1	The	the	DT	_	2	det
2	goal	goal	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	review	review	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	cite	cite	VB	_	6	xcomp
9	primary	primary	JJ	_	10	amod
10	sources	source	NNS	_	8	dobj
11	for	for	IN	_	10	acl
12	virtually	virtually	RB	_	13	advmod
13	all	all	DT	_	11	nmod
14	research	research	NN	_	13	dep
15	specific	specific	JJ	_	14	amod
16	to	to	TO	_	17	case
17	POPs	pop	NNS	_	15	nmod
18	since	since	IN	_	19	case
19	1975	1975	CD	_	14	nmod
20	.	.	.	_	6	punct

1	Conclusions	conclusion	NNS	_	12	nsubjpass
2	and	and	CC	_	1	cc
3	the	the	DT	_	4	det
4	types	type	NNS	_	1	conj
5	of	of	IN	_	6	case
6	studies	study	NNS	_	4	nmod
7	which	which	WDT	_	8	nsubj
8	support	support	VBP	_	4	acl:relcl
9	these	these	DT	_	10	det
10	conclusions	conclusion	NNS	_	8	dobj
11	are	be	VBP	_	12	auxpass
12	given	give	VBN	_	0	ROOT
13	for	for	IN	_	16	case
14	each	each	DT	_	16	det
15	major	major	JJ	_	16	amod
16	section	section	NN	_	12	nmod
17	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	introductory	introductory	JJ	_	3	amod
3	chapter	chapter	NN	_	4	nsubj
4	discusses	discuss	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	advantages	advantage	NNS	_	4	dobj
7	and	and	CC	_	6	cc
8	disadvantages	disadvantage	NNS	_	6	conj
9	of	of	IN	_	10	case
10	POCs	poc	NNS	_	6	nmod
11	and	and	CC	_	10	cc
12	the	the	DT	_	13	det
13	magnitude	magnitude	NN	_	10	conj
14	and	and	CC	_	13	cc
15	prevalence	prevalence	NN	_	13	conj
16	of	of	IN	_	18	case
17	their	they	PRP$	_	18	nmod:poss
18	use	use	NN	_	13	nmod
19	.	.	.	_	4	punct

1	Future	future	JJ	_	2	amod
2	trends	trend	NNS	_	5	nsubjpass
3	are	be	VBP	_	5	auxpass
4	also	also	RB	_	5	advmod
5	predicted	predict	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	Chapter	chapter	NN	_	3	nsubj
2	2	2	CD	_	1	nummod
3	considers	consider	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	mode	mode	NN	_	3	dobj
6	of	of	IN	_	7	case
7	action	action	NN	_	5	nmod
8	,	,	,	_	5	punct
9	including	include	VBG	_	11	case
10	ovulation	ovulation	NN	_	11	compound
11	prevention	prevention	NN	_	5	nmod
12	;	;	:	_	3	punct

1	suppression	suppression	NN	_	5	nsubj
2	of	of	IN	_	4	case
3	midcycle	midcycle	NN	_	4	compound
4	gonadotropin	gonadotropin	NN	_	1	nmod
5	peaks	peak	VBZ	_	0	ROOT
6	;	;	:	_	5	punct

1	changes	change	NNS	_	0	ROOT
2	in	in	IN	_	4	case
3	cervical	cervical	JJ	_	4	amod
4	mucus	mucus	NN	_	1	nmod
5	,	,	,	_	1	punct
6	the	the	DT	_	7	det
7	endometrium	endometrium	NN	_	1	conj
8	,	,	,	_	1	punct
9	and	and	CC	_	1	cc
10	the	the	DT	_	12	det
11	fallopian	fallopian	JJ	_	12	amod
12	tubes	tube	NNS	_	1	conj
13	;	;	:	_	1	punct

1	and	and	CC	_	3	cc
2	clinical	clinical	JJ	_	3	amod
3	implications	implication	NNS	_	0	ROOT
4	.	.	.	_	3	punct

1	Chapter	chapter	NN	_	3	nsubj
2	3	3	CD	_	1	nummod
3	covers	cover	VBZ	_	0	ROOT
4	pharmacology	pharmacology	NN	_	6	compound
5	(	(	NN	_	6	compound
6	pharmacokinetics	pharmacokinetic	NNS	_	3	dobj
7	,	,	,	_	6	punct
8	pharmacodynamics	pharmacodynamic	NNS	_	6	conj
9	and	and	CC	_	6	cc
10	potency	potency	NN	_	6	conj
11	,	,	,	_	3	punct
12	and	and	CC	_	3	cc
13	clinical	clinical	JJ	_	14	amod
14	implications	implication	NNS	_	15	nsubj
15	)	)	VBP	_	3	conj
16	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	next	next	JJ	_	3	amod
3	chapter	chapter	NN	_	4	nsubj
4	presents	present	VBZ	_	0	ROOT
5	information	information	NN	_	4	dobj
6	on	on	IN	_	7	case
7	efficacy	efficacy	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	pregnancy	pregnancy	NN	_	10	compound
10	outcomes	outcome	NNS	_	7	conj
11	in	in	IN	_	12	case
12	terms	term	NNS	_	5	nmod
13	of	of	IN	_	15	case
14	pregnancy	pregnancy	NN	_	15	compound
15	rates	rate	NNS	_	12	nmod
16	,	,	,	_	15	punct
17	compliance	compliance	NN	_	15	conj
18	and	and	CC	_	15	cc
19	efficacy	efficacy	NN	_	15	conj
20	,	,	,	_	19	punct
21	ectopic	ectopic	JJ	_	22	amod
22	pregnancies	pregnancy	NNS	_	19	conj
23	,	,	,	_	19	punct
24	the	the	DT	_	25	det
25	outcome	outcome	NN	_	19	conj
26	of	of	IN	_	27	case
27	pregnancies	pregnancy	NNS	_	25	nmod
28	conceived	conceive	VBN	_	25	acl
29	while	while	IN	_	30	mark
30	using	use	VBG	_	28	advcl
31	POCs	poc	NNS	_	30	dobj
32	,	,	,	_	19	punct
33	and	and	CC	_	19	cc
34	fertility	fertility	NN	_	19	conj
35	following	follow	VBG	_	36	case
36	discontinuation	discontinuation	NN	_	4	nmod
37	.	.	.	_	4	punct

1	Chapter	Chapter	NNP	_	3	nsubj
2	5	5	CD	_	1	nummod
3	focuses	focus	VBZ	_	0	ROOT
4	on	on	IN	_	6	case
5	metabolic	metabolic	JJ	_	6	amod
6	effects	effect	NNS	_	3	nmod
7	,	,	,	_	6	punct
8	specifically	specifically	RB	_	10	advmod
9	lipid	lipid	NN	_	10	compound
10	metabolism	metabolism	NN	_	6	appos
11	,	,	,	_	10	punct
12	carbohydrate	carbohydrate	NN	_	13	compound
13	metabolism	metabolism	NN	_	10	conj
14	and	and	CC	_	10	cc
15	diabetes	diabetes	NN	_	10	conj
16	,	,	,	_	6	punct
17	coagulation	coagulation	NN	_	18	compound
18	factors	factor	NNS	_	6	conj
19	,	,	,	_	6	punct
20	and	and	CC	_	6	cc
21	blood	blood	NN	_	22	compound
22	pressure	pressure	NN	_	6	conj
23	.	.	.	_	3	punct

1	Cardiovascular	Cardiovascular	NNP	_	2	compound
2	disease	disease	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	considered	consider	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	next	next	JJ	_	8	amod
8	chapter	chapter	NN	_	4	nmod
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	chapter	chapter	NN	_	13	nsubj
12	7	7	CD	_	11	nummod
13	presents	present	VBZ	_	4	conj
14	findings	finding	NNS	_	13	dobj
15	on	on	IN	_	26	case
16	endometrial	endometrial	JJ	_	26	amod
17	,	,	,	_	16	punct
18	ovarian	ovarian	JJ	_	16	conj
19	,	,	,	_	16	punct
20	cervical	cervical	JJ	_	16	conj
21	,	,	,	_	16	punct
22	breast	breast	NN	_	16	conj
23	,	,	,	_	16	punct
24	and	and	CC	_	16	cc
25	other	other	JJ	_	16	conj
26	cancers	cancer	NNS	_	14	nmod
27	.	.	.	_	4	punct

1	A	a	DT	_	2	det
2	host	host	NN	_	8	nsubjpass
3	of	of	IN	_	6	case
4	other	other	JJ	_	6	amod
5	medical	medical	JJ	_	6	amod
6	considerations	consideration	NNS	_	2	nmod
7	are	be	VBP	_	8	auxpass
8	discussed	discuss	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	chapter	chapter	NN	_	8	nmod
11	8	8	CD	_	10	nummod
12	,	,	,	_	10	punct
13	including	include	VBG	_	16	case
14	persistent	persistent	JJ	_	16	amod
15	ovarian	ovarian	JJ	_	16	amod
16	follicles	follicle	NNS	_	10	nmod
17	;	;	:	_	8	punct

1	reproductive	reproductive	JJ	_	3	amod
2	tract	tract	NN	_	3	compound
3	infections	infection	NNS	_	0	ROOT
4	;	;	:	_	3	punct

1	abnormal	abnormal	JJ	_	3	amod
2	vaginal	vaginal	JJ	_	3	amod
3	bleeding	bleeding	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	uterine	uterine	JJ	_	2	amod
2	fibroids	fibroid	NNS	_	0	ROOT
3	;	;	:	_	2	punct

1	gestational	gestational	JJ	_	3	amod
2	trophoblastic	trophoblastic	JJ	_	3	amod
3	disease	disease	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	benign	benign	JJ	_	3	amod
2	breast	breast	NN	_	3	compound
3	disease	disease	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	diseases	disease	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	liver	liver	NN	_	1	nmod
5	,	,	,	_	4	punct
6	gallbladder	gallbladder	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	bowel	bowel	NN	_	4	conj
10	;	;	:	_	1	punct

1	endocrine	endocrine	JJ	_	2	amod
2	dysfunction	dysfunction	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	epilepsy	epilepsy	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	bone	bone	NN	_	2	compound
2	density	density	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	sickle	sickle	JJ	_	3	amod
2	cell	cell	NN	_	3	compound
3	disease	disease	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	ocular	ocular	JJ	_	2	amod
2	effects	effect	NNS	_	0	ROOT
3	;	;	:	_	2	punct

1	surgery	surgery	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	and	and	CC	_	2	cc
2	overdose	overdose	NN	_	0	ROOT
3	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	last	last	JJ	_	4	amod
3	4	4	CD	_	4	nummod
4	chapters	chapter	NNS	_	5	nsubj
5	cover	cover	VBP	_	0	ROOT
6	interactions	interaction	NNS	_	5	dobj
7	with	with	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	and	and	CC	_	8	cc
10	laboratory	laboratory	NN	_	11	compound
11	tests	test	NNS	_	8	conj
12	,	,	,	_	8	punct
13	common	common	JJ	_	15	amod
14	side	side	NN	_	15	compound
15	effects	effect	NNS	_	8	conj
16	,	,	,	_	8	punct
17	breast	breast	NN	_	18	compound
18	feeding	feeding	NN	_	8	conj
19	,	,	,	_	8	punct
20	and	and	CC	_	8	cc
21	effective	effective	JJ	_	22	amod
22	use	use	NN	_	8	conj
23	of	of	IN	_	24	case
24	POCs	poc	NNS	_	22	nmod
25	.	.	.	_	5	punct

1	Information	information	NN	_	9	nsubj
2	on	on	IN	_	3	case
3	precautions	precaution	NNS	_	1	nmod
4	and	and	CC	_	3	cc
5	contraindications	contraindication	NNS	_	3	conj
6	,	,	,	_	3	punct
7	indications	indication	NNS	_	3	conj
8	,	,	,	_	3	punct
9	use	use	VBP	_	0	ROOT
10	instructions	instruction	NNS	_	9	dobj
11	,	,	,	_	9	punct
12	and	and	CC	_	9	cc
13	instructions	instruction	NNS	_	22	nsubjpass
14	for	for	IN	_	16	case
15	appropriate	appropriate	JJ	_	16	amod
16	actions	action	NNS	_	13	nmod
17	after	after	IN	_	18	mark
18	missing	miss	VBG	_	13	acl
19	a	a	DT	_	20	det
20	pill	pill	NN	_	18	dobj
21	is	be	VBZ	_	22	auxpass
22	appended	append	VBN	_	9	conj
23	.	.	.	_	9	punct

1	Hypothermia	Hypothermia	NNP	_	0	ROOT
2	as	as	IN	_	4	case
3	an	a	DT	_	4	det
4	index	index	NN	_	1	nmod
5	of	of	IN	_	10	case
6	the	the	DT	_	10	det
7	disulfiram	disulfiram	NN	_	10	compound
8	-	-	:	_	10	punct
9	ethanol	ethanol	NN	_	10	compound
10	reaction	reaction	NN	_	4	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	rat	rat	NN	_	10	nmod
14	.	.	.	_	1	punct

1	Decreased	decrease	VBN	_	3	amod
2	core	core	NN	_	3	compound
3	temperature	temperature	NN	_	8	nsubjpass
4	in	in	IN	_	6	case
5	female	female	JJ	_	6	amod
6	rats	rat	NNS	_	3	nmod
7	was	be	VBD	_	8	auxpass
8	investigated	investigate	VBN	_	0	ROOT
9	as	as	IN	_	12	case
10	one	one	CD	_	12	nummod
11	possible	possible	JJ	_	12	amod
12	index	index	NN	_	8	nmod
13	of	of	IN	_	18	case
14	the	the	DT	_	18	det
15	disulfiram	disulfiram	NN	_	18	compound
16	-	-	:	_	18	punct
17	ethanol	ethanol	NN	_	18	compound
18	reaction	reaction	NN	_	12	nmod
19	(	(	CD	_	20	nummod
20	DER	DER	NNP	_	18	dep
21	)	)	CD	_	20	nummod
22	.	.	.	_	8	punct

1	Core	core	NN	_	2	compound
2	temperature	temperature	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	decreased	decrease	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	rats	rat	NNS	_	4	nmod
7	in	in	IN	_	12	case
8	a	a	DT	_	12	det
9	dose	dose	NN	_	12	compound
10	-	-	:	_	12	punct
11	dependent	dependent	JJ	_	12	amod
12	manner	manner	NN	_	4	nmod
13	when	when	WRB	_	16	advmod
14	ethanol	ethanol	NN	_	16	nsubjpass
15	was	be	VBD	_	16	auxpass
16	administered	administer	VBN	_	4	advcl
17	to	to	TO	_	18	case
18	rats	rat	NNS	_	16	nmod
19	treated	treat	VBN	_	18	acl
20	with	with	IN	_	21	case
21	disulfiram	disulfiram	NN	_	19	nmod
22	8	8	CD	_	23	nummod
23	hours	hour	NNS	_	19	nmod
24	before	before	IN	_	23	case
25	the	the	DT	_	27	det
26	ethanol	ethanol	NN	_	27	compound
27	challenge	challenge	NN	_	23	dep
28	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	decrease	decrease	NN	_	5	nsubj
3	in	in	IN	_	4	case
4	temperature	temperature	NN	_	2	nmod
5	began	begin	VBD	_	0	ROOT
6	within	within	IN	_	8	case
7	20	20	CD	_	8	nummod
8	minutes	minute	NNS	_	5	nmod
9	after	after	IN	_	11	case
10	ethanol	ethanol	NN	_	11	compound
11	administration	administration	NN	_	8	nmod
12	,	,	,	_	5	punct
13	reaching	reach	VBG	_	5	advcl
14	a	a	DT	_	16	det
15	maximal	maximal	JJ	_	16	amod
16	decrease	decrease	NN	_	13	dobj
17	between	between	IN	_	21	case
18	60	60	CD	_	21	nummod
19	and	and	CC	_	18	cc
20	120	120	CD	_	18	conj
21	minutes	minute	NNS	_	16	nmod
22	post	post	JJ	_	23	amod
23	ethanol	ethanol	NN	_	21	dep
24	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	core	core	NN	_	3	compound
3	temperature	temperature	NN	_	4	nsubj
4	returned	return	VBD	_	0	ROOT
5	to	to	TO	_	8	case
6	normal	normal	JJ	_	8	amod
7	300	300	CD	_	8	nummod
8	minutes	minute	NNS	_	4	nmod
9	after	after	IN	_	10	case
10	ethanol	ethanol	NN	_	4	nmod
11	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	blood	blood	NN	_	3	compound
3	pressure	pressure	NN	_	8	nsubj
4	(	(	CD	_	7	nummod
5	carotid	carotid	NN	_	7	compound
6	cannulation	cannulation	NN	_	7	compound
7	)	)	NN	_	3	dep
8	decreased	decrease	VBD	_	0	ROOT
9	along	along	IN	_	13	case
10	with	with	IN	_	13	case
11	the	the	DT	_	13	det
12	core	core	NN	_	13	compound
13	temperature	temperature	NN	_	8	nmod
14	.	.	.	_	8	punct

1	Maximal	maximal	JJ	_	2	amod
2	hypotension	hypotension	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	found	find	VBN	_	0	ROOT
5	120	120	CD	_	6	nummod
6	minutes	minute	NNS	_	4	nmod:tmod
7	post	post	JJ	_	8	amod
8	ethanol	ethanol	NN	_	6	dep
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	returned	return	VBD	_	4	conj
12	to	to	TO	_	15	case
13	normal	normal	JJ	_	15	amod
14	300	300	CD	_	15	nummod
15	minutes	minute	NNS	_	11	nmod
16	after	after	IN	_	17	case
17	ethanol	ethanol	NN	_	11	nmod
18	.	.	.	_	4	punct

1	Heart	Heart	NNP	_	2	compound
2	rate	rate	NN	_	3	nsubj
3	increased	increase	VBD	_	0	ROOT
4	initially	initially	RB	_	3	advmod
5	and	and	CC	_	3	cc
6	returned	return	VBD	_	3	conj
7	to	to	TO	_	10	case
8	normal	normal	JJ	_	10	amod
9	40	40	CD	_	10	nummod
10	minutes	minute	NNS	_	6	nmod
11	after	after	IN	_	13	case
12	ethanol	ethanol	NN	_	13	compound
13	challenge	challenge	NN	_	6	nmod
14	.	.	.	_	3	punct

1	Intestinal	intestinal	JJ	_	2	amod
2	absorption	absorption	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	arsenate	arsenate	NN	_	2	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	chick	chick	NN	_	2	nmod
8	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	intestinal	intestinal	JJ	_	3	amod
3	absorption	absorption	NN	_	14	nsubjpass
4	of	of	IN	_	5	case
5	arsenate	arsenate	NN	_	3	nmod
6	(	(	CD	_	5	nummod
7	As	as	IN	_	9	case
8	(	(	CD	_	9	nummod
9	V	v	NN	_	3	nmod
10	)	)	CD	_	11	nummod
11	)	)	NN	_	9	dep
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	investigated	investigate	VBN	_	0	ROOT
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	chick	chick	NN	_	14	nmod
18	by	by	IN	_	19	case
19	means	means	NNS	_	14	nmod
20	of	of	IN	_	27	case
21	the	the	DT	_	27	det
22	in	in	FW	_	27	amod
23	situ	situ	FW	_	22	dep
24	ligated	ligate	VBN	_	27	amod
25	duodenal	duodenal	JJ	_	27	amod
26	loop	loop	NN	_	27	compound
27	technique	technique	NN	_	19	nmod
28	.	.	.	_	14	punct

1	By	by	IN	_	3	case
2	this	this	DT	_	3	det
3	procedure	procedure	NN	_	7	nmod
4	,	,	,	_	7	punct
5	it	it	PRP	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	that	that	IN	_	15	mark
9	arsenate	arsenate	NN	_	15	nsubjpass
10	is	be	VBZ	_	15	auxpass
11	rapidly	rapidly	RB	_	12	advmod
12	and	and	CC	_	15	advmod
13	essentially	essentially	RB	_	12	advmod
14	completely	completely	RB	_	12	advmod
15	absorbed	absorb	VBN	_	7	ccomp
16	(	(	NN	_	15	dobj
17	80	80	CD	_	16	nummod
18	-	-	:	_	16	punct
19	95	95	CD	_	20	nummod
20	%	%	NN	_	16	dep
21	)	)	CD	_	20	nummod
22	from	from	IN	_	24	case
23	the	the	DT	_	24	det
24	lumen	lumen	NN	_	20	nmod
25	at	at	IN	_	30	case
26	As	as	IN	_	30	case
27	(	(	CD	_	30	nummod
28	V	v	NN	_	30	compound
29	)	)	NN	_	30	compound
30	concentrations	concentration	NNS	_	20	nmod
31	up	up	IN	_	33	advmod
32	to	to	TO	_	33	dep
33	5	5	CD	_	34	nummod
34	mM	mm	NN	_	30	dep
35	,	,	,	_	16	punct
36	declining	decline	VBG	_	16	acl
37	to	to	TO	_	41	case
38	about	about	IN	_	39	advmod
39	50	50	CD	_	40	dep
40	%	%	NN	_	41	dep
41	absorption	absorption	NN	_	36	nmod
42	at	at	IN	_	44	case
43	50	50	CD	_	44	nummod
44	mM	mm	NN	_	36	nmod
45	.	.	.	_	7	punct

1	Transfer	transfer	NN	_	0	ROOT
2	from	from	IN	_	5	case
3	the	the	DT	_	5	det
4	intestinal	intestinal	JJ	_	5	amod
5	lumen	lumen	NN	_	1	nmod
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	mucosal	mucosal	JJ	_	9	amod
9	cells	cell	NNS	_	1	nmod
10	at	at	IN	_	11	case
11	low	low	JJ	_	1	nmod
12	As	as	IN	_	14	case
13	(	(	CD	_	14	nummod
14	V	v	NN	_	22	nmod
15	)	)	CD	_	16	nummod
16	concentration	concentration	NN	_	22	nsubj
17	(	(	CD	_	18	compound
18	0.1	0.1	CD	_	20	nummod
19	mM	mm	NN	_	20	compound
20	)	)	NN	_	16	dep
21	is	be	VBZ	_	22	cop
22	rapid	rapid	JJ	_	11	nmod
23	,	,	,	_	1	punct
24	while	while	IN	_	33	mark
25	transfer	transfer	NN	_	33	nsubj
26	from	from	IN	_	29	case
27	the	the	DT	_	29	det
28	mucosal	mucosal	JJ	_	29	amod
29	cells	cell	NNS	_	25	nmod
30	to	to	TO	_	32	case
31	the	the	DT	_	32	det
32	body	body	NN	_	25	nmod
33	occurs	occur	VBZ	_	1	advcl
34	more	more	RBR	_	35	advmod
35	slowly	slowly	RB	_	33	advmod
36	.	.	.	_	1	punct

1	At	at	IN	_	2	case
2	stable	stable	JJ	_	0	ROOT
3	As	as	IN	_	2	dep
4	(	(	CD	_	7	nummod
5	V	v	NN	_	7	compound
6	)	)	NN	_	7	compound
7	concentrations	concentration	NNS	_	3	dep
8	greater	greater	JJR	_	7	amod
9	than	than	IN	_	11	case
10	1	1	CD	_	11	nummod
11	mM	mm	NN	_	8	nmod
12	,	,	,	_	7	punct
13	fractional	fractional	JJ	_	16	amod
14	mucosal	mucosal	JJ	_	16	amod
15	cell	cell	NN	_	16	compound
16	accumulation	accumulation	NN	_	7	appos
17	of	of	IN	_	22	mark
18	As	as	IN	_	22	mark
19	(	(	CD	_	21	nummod
20	V	v	NN	_	21	compound
21	)	)	NN	_	22	nsubj
22	remains	remain	VBZ	_	16	acl
23	constant	constant	JJ	_	22	xcomp
24	,	,	,	_	7	punct
25	while	while	IN	_	7	dep
26	fractional	fractional	JJ	_	27	amod
27	transfer	transfer	NN	_	25	dep
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	body	body	NN	_	31	compound
31	declines	decline	NNS	_	27	nmod
32	.	.	.	_	2	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	total	total	JJ	_	5	amod
4	mucosal	mucosal	JJ	_	5	amod
5	accumulation	accumulation	NN	_	2	root
6	of	of	IN	_	10	case
7	As	as	IN	_	10	case
8	(	(	CD	_	10	nummod
9	V	v	NN	_	10	compound
10	)	)	NN	_	5	nmod
11	and	and	CC	_	5	cc
12	that	that	IN	_	5	conj
13	transferred	transfer	VBN	_	12	acl
14	to	to	TO	_	17	case
15	the	the	DT	_	17	det
16	body	body	NN	_	17	compound
17	increase	increase	NN	_	13	nmod
18	in	in	IN	_	22	case
19	a	a	DT	_	22	det
20	linear	linear	JJ	_	22	amod
21	logarithmic	logarithmic	JJ	_	22	amod
22	fashion	fashion	NN	_	17	nmod
23	from	from	IN	_	27	case
24	0.05	0.05	CD	_	26	compound
25	to	to	TO	_	26	dep
26	5	5	CD	_	27	nummod
27	mm	mm	NN	_	17	nmod
28	As	as	IN	_	31	case
29	(	(	CD	_	31	nummod
30	V	v	NN	_	31	compound
31	)	)	NN	_	27	nmod
32	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	As	as	IN	_	7	case
6	(	(	CD	_	7	nummod
7	V	v	NN	_	10	nmod
8	)	)	CD	_	7	nummod
9	readily	readily	RB	_	10	advmod
10	penetrates	penetrate	VBZ	_	3	ccomp
11	both	both	CC	_	13	cc:preconj
12	the	the	DT	_	13	dep
13	mucosal	mucosal	JJ	_	10	dobj
14	and	and	CC	_	13	cc
15	serosal	serosal	JJ	_	13	conj
16	surfaces	surface	NNS	_	13	dep
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	epithelial	epithelial	JJ	_	20	amod
20	membrane	membrane	NN	_	13	nmod
21	.	.	.	_	3	punct

1	Furthermore	furthermore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	arsenate	arsenate	NN	_	8	nsubj
4	and	and	CC	_	3	cc
5	phosphate	phosphate	NN	_	3	conj
6	do	do	VBP	_	8	aux
7	not	not	RB	_	8	neg
8	appear	appear	VB	_	0	ROOT
9	to	to	TO	_	10	mark
10	share	share	VB	_	8	xcomp
11	a	a	DT	_	14	det
12	common	common	JJ	_	14	amod
13	transport	transport	NN	_	14	compound
14	pathway	pathway	NN	_	10	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	duodenum	duodenum	NN	_	14	nmod
18	and	and	CC	_	8	cc
19	no	no	DT	_	20	neg
20	evidence	evidence	NN	_	22	nsubjpass
21	was	be	VBD	_	22	auxpass
22	obtained	obtain	VBN	_	8	conj
23	for	for	IN	_	25	case
24	any	any	DT	_	25	det
25	interaction	interaction	NN	_	22	nmod
26	between	between	IN	_	28	case
27	the	the	DT	_	28	det
28	two	two	CD	_	25	nmod
29	at	at	IN	_	31	case
30	this	this	DT	_	31	det
31	level	level	NN	_	22	nmod
32	.	.	.	_	8	punct

1	Vitamin	vitamin	NN	_	3	compound
2	D3	d3	NN	_	3	compound
3	administration	administration	NN	_	8	nsubj
4	to	to	TO	_	6	case
5	rachitic	rachitic	JJ	_	6	amod
6	chicks	chick	NNS	_	3	nmod
7	was	be	VBD	_	8	cop
8	effective	effective	JJ	_	0	ROOT
9	in	in	IN	_	11	mark
10	significantly	significantly	RB	_	11	advmod
11	elevating	elevate	VBG	_	8	advcl
12	duodenal	duodenal	JJ	_	14	amod
13	arsenate	arsenate	NN	_	14	compound
14	absorption	absorption	NN	_	11	dobj
15	,	,	,	_	8	punct
16	acting	act	VBG	_	8	xcomp
17	primarily	primarily	RB	_	16	advmod
18	to	to	TO	_	19	mark
19	enhance	enhance	VB	_	16	xcomp
20	serosal	serosal	JJ	_	21	amod
21	transport	transport	NN	_	19	dobj
22	.	.	.	_	8	punct

1	Olanzapine	Olanzapine	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	an	a	DT	_	5	det
4	updated	update	VBN	_	5	amod
5	review	review	NN	_	1	dep
6	of	of	IN	_	8	case
7	its	its	PRP$	_	8	nmod:poss
8	use	use	NN	_	5	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	management	management	NN	_	8	nmod
12	of	of	IN	_	13	case
13	schizophrenia	schizophrenia	NN	_	11	nmod
14	.	.	.	_	1	punct

1	Olanzapine	Olanzapine	NNP	_	15	nsubj
2	,	,	,	_	1	punct
3	a	a	DT	_	5	det
4	thienobenzodiazepine	thienobenzodiazepine	NN	_	5	compound
5	derivative	derivative	NN	_	1	appos
6	,	,	,	_	1	punct
7	is	be	VBZ	_	15	cop
8	a	a	DT	_	15	det
9	second	second	JJ	_	15	amod
10	generation	generation	NN	_	15	compound
11	(	(	NN	_	15	compound
12	atypical	atypical	JJ	_	15	amod
13	)	)	NN	_	15	compound
14	antipsychotic	antipsychotic	JJ	_	15	amod
15	agent	agent	NN	_	0	ROOT
16	which	which	WDT	_	18	nsubj
17	has	have	VBZ	_	18	aux
18	proven	prove	VBN	_	15	acl:relcl
19	efficacy	efficacy	NN	_	18	dobj
20	against	against	IN	_	25	case
21	the	the	DT	_	25	det
22	positive	positive	JJ	_	25	amod
23	and	and	CC	_	22	cc
24	negative	negative	JJ	_	22	conj
25	symptoms	symptom	NNS	_	19	nmod
26	of	of	IN	_	27	case
27	schizophrenia	schizophrenia	NN	_	25	nmod
28	.	.	.	_	15	punct

1	Compared	compare	VBN	_	4	case
2	with	with	IN	_	4	case
3	conventional	conventional	JJ	_	4	amod
4	antipsychotics	antipsychotic	NNS	_	7	advcl
5	,	,	,	_	7	punct
6	it	it	PRP	_	7	nsubj
7	has	have	VBZ	_	0	ROOT
8	greater	greater	JJR	_	9	amod
9	affinity	affinity	NN	_	7	dobj
10	for	for	IN	_	11	case
11	serotonin	serotonin	NN	_	9	nmod
12	5	5	CD	_	11	nummod
13	-	-	:	_	9	punct
14	HT2A	ht2a	NN	_	9	dep
15	than	than	IN	_	19	case
16	for	for	IN	_	19	case
17	dopamine	dopamine	NN	_	19	compound
18	D2	d2	NN	_	19	compound
19	receptors	receptor	NNS	_	9	nmod
20	.	.	.	_	7	punct

1	In	in	IN	_	6	case
2	large	large	JJ	_	6	amod
3	,	,	,	_	6	punct
4	well	well	RB	_	5	advmod
5	controlled	controlled	JJ	_	6	amod
6	trials	trial	NNS	_	21	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	10	case
10	schizophrenia	schizophrenia	NN	_	8	nmod
11	or	or	CC	_	10	cc
12	related	related	JJ	_	13	amod
13	psychoses	psychosis	NNS	_	10	conj
14	,	,	,	_	21	punct
15	olanzapine	olanzapine	NN	_	21	dep
16	5	5	CD	_	18	compound
17	to	to	TO	_	18	dep
18	20	20	CD	_	19	nummod
19	mg	mg	NN	_	21	dep
20	/	/	:	_	21	punct
21	day	day	NN	_	32	dep
22	was	be	VBD	_	24	cop
23	significantly	significantly	RB	_	24	advmod
24	superior	superior	JJ	_	32	dep
25	to	to	TO	_	26	case
26	haloperidol	haloperidol	NN	_	32	nmod
27	5	5	CD	_	29	compound
28	to	to	TO	_	29	dep
29	20	20	CD	_	30	nummod
30	mg	mg	NN	_	32	dep
31	/	/	:	_	32	punct
32	day	day	NN	_	0	ROOT
33	in	in	IN	_	35	case
34	overall	overall	JJ	_	35	amod
35	improvements	improvement	NNS	_	32	nmod
36	in	in	IN	_	39	case
37	psychopathology	psychopathology	NN	_	39	compound
38	rating	rating	NN	_	39	compound
39	scales	scale	NNS	_	35	nmod
40	and	and	CC	_	39	cc
41	in	in	IN	_	43	case
42	the	the	DT	_	43	det
43	treatment	treatment	NN	_	39	conj
44	of	of	IN	_	48	case
45	depressive	depressive	JJ	_	48	amod
46	and	and	CC	_	45	cc
47	negative	negative	JJ	_	45	conj
48	symptoms	symptom	NNS	_	43	nmod
49	,	,	,	_	32	punct
50	and	and	CC	_	32	cc
51	was	be	VBD	_	52	cop
52	comparable	comparable	JJ	_	32	conj
53	in	in	IN	_	54	case
54	effects	effect	NNS	_	52	nmod
55	on	on	IN	_	58	case
56	positive	positive	JJ	_	58	amod
57	psychotic	psychotic	JJ	_	58	amod
58	symptoms	symptom	NNS	_	54	nmod
59	.	.	.	_	32	punct

1	The	the	DT	_	5	det
2	1	1	LS	_	5	dep
3	-	-	:	_	5	punct
4	year	year	NN	_	5	compound
5	risk	risk	NN	_	13	nsubj
6	of	of	IN	_	10	case
7	relapse	relapse	NN	_	10	compound
8	(	(	CD	_	10	nummod
9	rehospitalisation	rehospitalisation	NN	_	10	compound
10	)	)	NN	_	5	nmod
11	was	be	VBD	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	lower	lower	JJR	_	0	ROOT
14	with	with	IN	_	15	case
15	olanzapine	olanzapine	NN	_	13	nmod
16	than	than	IN	_	19	case
17	with	with	IN	_	19	case
18	haloperidol	haloperidol	NN	_	19	compound
19	treatment	treatment	NN	_	13	nmod
20	.	.	.	_	13	punct

1	In	in	IN	_	8	case
2	the	the	DT	_	8	det
3	first	first	JJ	_	8	amod
4	double	double	JJ	_	8	amod
5	-	-	:	_	8	punct
6	blind	blind	JJ	_	8	amod
7	comparative	comparative	JJ	_	8	amod
8	study	study	NN	_	0	ROOT
9	(	(	CD	_	10	nummod
10	28	28	CD	_	8	dep
11	-	-	:	_	10	punct
12	week	week	NN	_	13	compound
13	)	)	NN	_	10	dep
14	of	of	IN	_	15	case
15	olanzapine	olanzapine	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	risperidone	risperidone	NN	_	15	conj
18	,	,	,	_	13	punct
19	olanzapine	olanzapine	NN	_	25	compound
20	10	10	CD	_	22	compound
21	to	to	TO	_	22	dep
22	20	20	CD	_	23	nummod
23	mg	mg	NN	_	25	dep
24	/	/	:	_	25	punct
25	day	day	NN	_	26	nsubj
26	proved	prove	VBD	_	13	dep
27	to	to	TO	_	31	mark
28	be	be	VB	_	31	cop
29	significantly	significantly	RB	_	31	advmod
30	more	more	RBR	_	31	advmod
31	effective	effective	JJ	_	26	xcomp
32	than	than	IN	_	33	case
33	risperidone	risperidone	NN	_	31	nmod
34	4	4	CD	_	33	nummod
35	to	to	TO	_	33	dep
36	12	12	CD	_	33	compound
37	mg	mg	NN	_	33	dep
38	/	/	:	_	10	punct
39	day	day	NN	_	10	dep
40	in	in	IN	_	42	case
41	the	the	DT	_	42	det
42	treatment	treatment	NN	_	39	nmod
43	of	of	IN	_	47	case
44	negative	negative	JJ	_	47	amod
45	and	and	CC	_	44	cc
46	depressive	depressive	JJ	_	44	conj
47	symptoms	symptom	NNS	_	42	nmod
48	but	but	CC	_	47	cc
49	not	not	RB	_	53	neg
50	on	on	IN	_	53	case
51	overall	overall	JJ	_	53	amod
52	psychopathology	psychopathology	NN	_	53	compound
53	symptoms	symptom	NNS	_	47	conj
54	.	.	.	_	8	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	22	nmod
3	,	,	,	_	22	punct
4	preliminary	preliminary	JJ	_	5	amod
5	results	result	NNS	_	22	nsubj
6	from	from	IN	_	20	case
7	an	a	DT	_	20	det
8	8	8	CD	_	13	dep
9	-	-	:	_	13	punct
10	week	week	NN	_	12	compound
11	controlled	control	VBN	_	12	amod
12	study	study	NN	_	13	nsubj
13	suggested	suggest	VBD	_	20	dep
14	risperidone	risperidone	NN	_	20	compound
15	2	2	CD	_	17	compound
16	to	to	TO	_	17	dep
17	6	6	CD	_	18	nummod
18	mg	mg	NN	_	20	dep
19	/	/	:	_	20	punct
20	day	day	NN	_	5	nmod
21	was	be	VBD	_	22	cop
22	superior	superior	JJ	_	0	ROOT
23	to	to	TO	_	24	case
24	olanzapine	olanzapine	NN	_	30	nmod
25	5	5	CD	_	27	compound
26	to	to	TO	_	27	dep
27	20	20	CD	_	28	nummod
28	mg	mg	NN	_	30	dep
29	/	/	:	_	30	punct
30	day	day	NN	_	22	nmod
31	against	against	IN	_	32	case
32	positive	positive	JJ	_	22	nmod
33	and	and	CC	_	32	cc
34	anxiety	anxiety	NN	_	32	conj
35	/	/	:	_	37	punct
36	depressive	depressive	JJ	_	37	amod
37	symptoms	symptom	NNS	_	38	nsubj
38	(	(	VBP	_	32	acl:relcl
39	p	p	NN	_	40	compound
40	&lt	&lt	NN	_	38	dobj
41	;	;	:	_	22	punct
42	0.05	0.05	CD	_	43	nummod
43	)	)	NN	_	22	parataxis
44	,	,	,	_	43	punct
45	although	although	IN	_	54	mark
46	consistent	consistent	JJ	_	54	advmod
47	with	with	IN	_	50	case
48	the	the	DT	_	50	det
49	first	first	JJ	_	50	amod
50	study	study	NN	_	46	nmod
51	,	,	,	_	54	punct
52	both	both	DT	_	53	det
53	agents	agent	NNS	_	54	nsubj
54	demonstrated	demonstrate	VBD	_	43	dep
55	similar	similar	JJ	_	56	amod
56	efficacy	efficacy	NN	_	54	dobj
57	on	on	IN	_	58	case
58	measures	measure	NNS	_	56	nmod
59	of	of	IN	_	61	case
60	overall	overall	JJ	_	61	amod
61	psychopathology	psychopathology	NN	_	58	nmod
62	.	.	.	_	22	punct

1	Improvements	Improvements	NNP	_	27	nsubj
2	in	in	IN	_	5	case
3	general	general	JJ	_	5	amod
4	cognitive	cognitive	JJ	_	5	amod
5	function	function	NN	_	1	nmod
6	seen	see	VBN	_	5	acl
7	with	with	IN	_	9	case
8	olanzapine	olanzapine	NN	_	9	compound
9	treatment	treatment	NN	_	6	nmod
10	in	in	IN	_	16	case
11	a	a	DT	_	16	det
12	1	1	LS	_	16	dep
13	-	-	:	_	12	punct
14	year	year	NN	_	16	compound
15	controlled	controlled	JJ	_	16	amod
16	study	study	NN	_	9	nmod
17	of	of	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	with	with	IN	_	23	case
20	early	early	JJ	_	23	amod
21	-	-	:	_	23	punct
22	phase	phase	NN	_	23	compound
23	schizophrenia	schizophrenia	NN	_	18	nmod
24	,	,	,	_	1	punct
25	were	be	VBD	_	27	cop
26	significantly	significantly	RB	_	27	advmod
27	greater	greater	JJR	_	0	ROOT
28	than	than	IN	_	29	case
29	changes	change	NNS	_	27	nmod
30	seen	see	VBN	_	29	acl
31	with	with	IN	_	33	case
32	either	either	CC	_	33	cc:preconj
33	risperidone	risperidone	NN	_	30	nmod
34	or	or	CC	_	33	cc
35	haloperidol	haloperidol	NN	_	33	conj
36	.	.	.	_	27	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	preliminary	preliminary	JJ	_	4	amod
4	results	result	NNS	_	2	root
5	from	from	IN	_	6	case
6	an	a	DT	_	4	nmod
7	8	8	CD	_	11	dep
8	-	-	:	_	11	punct
9	week	week	NN	_	10	compound
10	trial	trial	NN	_	11	nsubj
11	showed	show	VBD	_	6	root
12	comparable	comparable	JJ	_	15	amod
13	cognitive	cognitive	JJ	_	15	amod
14	enhancing	enhancing	JJ	_	15	amod
15	effects	effect	NNS	_	11	dobj
16	of	of	IN	_	17	case
17	olanzapine	olanzapine	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	risperidone	risperidone	NN	_	20	compound
20	treatment	treatment	NN	_	17	conj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	11	nmod
23	with	with	IN	_	24	case
24	schizophrenia	schizophrenia	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	schizoaffective	schizoaffective	JJ	_	27	amod
27	disorder	disorder	NN	_	24	conj
28	.	.	.	_	11	punct

1	Several	several	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	6	mark
5	olanzapine	olanzapine	NN	_	6	nsubj
6	has	have	VBZ	_	3	ccomp
7	benefits	benefit	NNS	_	6	dobj
8	against	against	IN	_	9	case
9	symptoms	symptom	NNS	_	7	nmod
10	of	of	IN	_	11	case
11	aggression	aggression	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	agitation	agitation	NN	_	11	conj
14	,	,	,	_	6	punct
15	while	while	IN	_	19	mark
16	other	other	JJ	_	17	amod
17	studies	study	NNS	_	19	nsubj
18	strongly	strongly	RB	_	19	advmod
19	support	support	VBP	_	6	advcl
20	the	the	DT	_	21	det
21	effectiveness	effectiveness	NN	_	19	dobj
22	of	of	IN	_	23	case
23	olanzapine	olanzapine	NN	_	21	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	treatment	treatment	NN	_	19	nmod
27	of	of	IN	_	29	case
28	depressive	depressive	JJ	_	29	amod
29	symptomatology	symptomatology	NN	_	26	nmod
30	.	.	.	_	3	punct

1	Olanzapine	Olanzapine	NNP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	associated	associate	VBN	_	0	ROOT
4	with	with	IN	_	8	case
5	significantly	significantly	RB	_	6	advmod
6	fewer	fewer	JJR	_	8	amod
7	extrapyramidal	extrapyramidal	JJ	_	8	amod
8	symptoms	symptom	NNS	_	3	nmod
9	than	than	IN	_	10	case
10	haloperidol	haloperidol	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	risperidone	risperidone	NN	_	10	conj
13	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	olanzapine	olanzapine	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	a	a	DT	_	10	det
10	risk	risk	NN	_	7	nmod
11	of	of	IN	_	12	case
12	agranulocytosis	agranulocytosis	NN	_	10	nmod
13	as	as	IN	_	14	mark
14	seen	see	VBN	_	7	advcl
15	with	with	IN	_	16	case
16	clozapine	clozapine	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	clinically	clinically	RB	_	19	advmod
19	significant	significant	JJ	_	20	amod
20	hyperprolactinaemia	hyperprolactinaemia	NN	_	16	conj
21	as	as	IN	_	22	mark
22	seen	see	VBN	_	14	advcl
23	with	with	IN	_	24	case
24	risperidone	risperidone	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	prolongation	prolongation	NN	_	24	conj
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	QT	QT	NNP	_	30	compound
30	interval	interval	NN	_	24	nmod
31	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	most	most	RBS	_	3	advmod
3	common	common	JJ	_	5	amod
4	adverse	adverse	JJ	_	5	amod
5	effects	effect	NNS	_	11	nsubj
6	reported	report	VBN	_	5	acl
7	with	with	IN	_	8	case
8	olanzapine	olanzapine	NN	_	6	nmod
9	are	be	VBP	_	11	cop
10	bodyweight	bodyweight	JJ	_	11	amod
11	gain	gain	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	somnolence	somnolence	NN	_	11	conj
14	,	,	,	_	11	punct
15	dizziness	dizziness	NN	_	11	conj
16	,	,	,	_	11	punct
17	anticholinergic	anticholinergic	JJ	_	18	amod
18	effects	effect	NNS	_	19	nsubj
19	(	(	VBP	_	11	conj
20	constipation	constipation	NN	_	24	compound
21	and	and	CC	_	20	cc
22	dry	dry	JJ	_	20	conj
23	mouth	mouth	NN	_	24	compound
24	)	)	NN	_	19	dobj
25	and	and	CC	_	24	cc
26	transient	transient	JJ	_	30	amod
27	asymptomatic	asymptomatic	JJ	_	30	amod
28	liver	liver	NN	_	30	compound
29	enzyme	enzyme	NN	_	30	compound
30	elevations	elevation	NNS	_	24	conj
31	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	comparison	comparison	NN	_	9	nmod
3	with	with	IN	_	4	case
4	haloperidol	haloperidol	NN	_	2	nmod
5	,	,	,	_	9	punct
6	the	the	DT	_	8	det
7	adverse	adverse	JJ	_	8	amod
8	events	event	NNS	_	9	nsubj
9	reported	report	VBD	_	0	ROOT
10	significantly	significantly	RB	_	11	advmod
11	more	more	RBR	_	12	advmod
12	frequently	frequently	RB	_	9	advmod
13	with	with	IN	_	14	case
14	olanzapine	olanzapine	NN	_	9	nmod
15	in	in	IN	_	20	case
16	>	>	JJR	_	20	dep
17	or	or	CC	_	16	cc
18	=	=	JJ	_	16	conj
19	3.5	3.5	CD	_	20	nummod
20	%	%	NN	_	9	nmod
21	of	of	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	were	be	VBD	_	25	cop
24	dry	dry	JJ	_	25	amod
25	mouth	mouth	NN	_	9	dep
26	,	,	,	_	25	punct
27	bodyweight	bodyweight	NN	_	28	compound
28	gain	gain	NN	_	25	conj
29	and	and	CC	_	25	cc
30	increased	increase	VBD	_	31	amod
31	appetite	appetite	NN	_	25	conj
32	and	and	CC	_	25	cc
33	compared	compare	VBN	_	35	case
34	with	with	IN	_	35	case
35	risperidone	risperidone	NN	_	25	conj
36	,	,	,	_	35	punct
37	only	only	RB	_	39	advmod
38	bodyweight	bodyweight	JJ	_	39	amod
39	gain	gain	NN	_	40	nsubj
40	occurred	occur	VBD	_	35	acl:relcl
41	significantly	significantly	RB	_	42	advmod
42	more	more	RBR	_	43	advmod
43	frequently	frequently	RB	_	40	advmod
44	with	with	IN	_	45	case
45	olanzapine	olanzapine	NN	_	43	nmod
46	.	.	.	_	9	punct

1	The	the	DT	_	4	det
2	high	high	JJ	_	4	amod
3	acquisition	acquisition	NN	_	4	compound
4	cost	cost	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	olanzapine	olanzapine	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	offset	offset	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	reductions	reduction	NNS	_	8	nmod
11	in	in	IN	_	14	case
12	other	other	JJ	_	14	amod
13	treatment	treatment	NN	_	14	compound
14	costs	cost	NNS	_	10	nmod
15	(	(	VBP	_	10	acl
16	inpatient	inpatient	JJ	_	22	amod
17	and	and	CC	_	16	cc
18	/	/	:	_	21	punct
19	or	or	CC	_	21	cc
20	outpatient	outpatient	JJ	_	21	conj
21	services	service	NNS	_	16	conj
22	)	)	NN	_	15	dobj
23	of	of	IN	_	24	case
24	schizophrenia	schizophrenia	NN	_	22	nmod
25	.	.	.	_	8	punct

1	Pharmacoeconomic	pharmacoeconomic	JJ	_	2	amod
2	analyses	analysis	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	olanzapine	olanzapine	NN	_	9	nsubj
6	does	do	VBZ	_	9	aux
7	not	not	RB	_	9	neg
8	significantly	significantly	RB	_	9	advmod
9	increase	increase	VB	_	3	ccomp
10	,	,	,	_	9	punct
11	and	and	CC	_	9	cc
12	may	may	MD	_	14	aux
13	even	even	RB	_	14	advmod
14	decrease	decrease	VB	_	9	conj
15	,	,	,	_	14	punct
16	the	the	DT	_	20	det
17	overall	overall	JJ	_	20	amod
18	direct	direct	JJ	_	20	amod
19	treatment	treatment	NN	_	20	compound
20	costs	cost	NNS	_	14	dobj
21	of	of	IN	_	22	case
22	schizophrenia	schizophrenia	NN	_	20	nmod
23	,	,	,	_	20	punct
24	compared	compare	VBN	_	26	case
25	with	with	IN	_	26	case
26	haloperidol	haloperidol	NN	_	20	nmod
27	.	.	.	_	3	punct

1	Compared	compare	VBN	_	3	case
2	with	with	IN	_	3	case
3	risperidone	risperidone	NN	_	9	advcl
4	,	,	,	_	9	punct
5	olanzapine	olanzapine	NN	_	9	nsubjpass
6	has	have	VBZ	_	9	aux
7	also	also	RB	_	9	advmod
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	decrease	decrease	VB	_	9	xcomp
12	overall	overall	JJ	_	14	amod
13	treatment	treatment	NN	_	14	compound
14	costs	cost	NNS	_	11	dobj
15	,	,	,	_	9	punct
16	despite	despite	IN	_	24	case
17	the	the	DT	_	24	det
18	several	several	JJ	_	24	amod
19	-	-	:	_	24	punct
20	fold	fold	RB	_	21	advmod
21	higher	higher	JJR	_	24	amod
22	daily	daily	JJ	_	24	amod
23	acquisition	acquisition	NN	_	24	compound
24	cost	cost	NN	_	9	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	drug	drug	NN	_	24	nmod
28	.	.	.	_	9	punct

1	Olanzapine	olanzapine	JJ	_	2	amod
2	treatment	treatment	NN	_	3	nsubj
3	improves	improve	VBZ	_	0	ROOT
4	quality	quality	NN	_	3	dobj
5	of	of	IN	_	6	case
6	life	life	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	3	nmod
9	with	with	IN	_	10	case
10	schizophrenia	schizophrenia	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	related	related	JJ	_	13	amod
13	psychoses	psychosis	NNS	_	10	conj
14	to	to	TO	_	17	case
15	a	a	DT	_	17	det
16	greater	greater	JJR	_	17	amod
17	extent	extent	NN	_	8	nmod
18	than	than	IN	_	19	case
19	haloperidol	haloperidol	NN	_	8	nmod
20	,	,	,	_	3	punct
21	and	and	CC	_	3	cc
22	to	to	TO	_	26	case
23	broadly	broadly	RB	_	26	advmod
24	the	the	DT	_	26	det
25	same	same	JJ	_	26	amod
26	extent	extent	NN	_	3	conj
27	as	as	IN	_	28	case
28	risperidone	risperidone	NN	_	26	nmod
29	.	.	.	_	3	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Olanzapine	Olanzapine	NNP	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	1	appos
5	superior	superior	JJ	_	7	amod
6	antipsychotic	antipsychotic	JJ	_	7	amod
7	efficacy	efficacy	NN	_	4	dobj
8	compared	compare	VBN	_	10	case
9	with	with	IN	_	10	case
10	haloperidol	haloperidol	NN	_	7	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	treatment	treatment	NN	_	10	nmod
14	of	of	IN	_	17	case
15	acute	acute	JJ	_	17	amod
16	phase	phase	NN	_	17	compound
17	schizophrenia	schizophrenia	NN	_	13	nmod
18	,	,	,	_	10	punct
19	and	and	CC	_	10	cc
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	treatment	treatment	NN	_	10	conj
23	of	of	IN	_	25	case
24	some	some	DT	_	25	det
25	patients	patient	NNS	_	22	nmod
26	with	with	IN	_	29	case
27	first	first	JJ	_	29	amod
28	-	-	:	_	29	punct
29	episode	episode	NN	_	25	nmod
30	or	or	CC	_	29	cc
31	treatment	treatment	NN	_	29	conj
32	-	-	:	_	7	punct
33	resistant	resistant	JJ	_	34	amod
34	schizophrenia	schizophrenia	NN	_	7	dep
35	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	reduced	reduce	VBN	_	3	amod
3	risk	risk	NN	_	23	nsubj
4	of	of	IN	_	6	case
5	adverse	adverse	JJ	_	6	amod
6	events	event	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	therapeutic	therapeutic	JJ	_	9	amod
9	superiority	superiority	NN	_	6	conj
10	compared	compare	VBN	_	12	case
11	with	with	IN	_	12	case
12	haloperidol	haloperidol	NN	_	3	nmod
13	and	and	CC	_	12	cc
14	risperidone	risperidone	NN	_	12	conj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	treatment	treatment	NN	_	12	nmod
18	of	of	IN	_	22	case
19	negative	negative	JJ	_	22	amod
20	and	and	CC	_	19	cc
21	depressive	depressive	JJ	_	19	conj
22	symptoms	symptom	NNS	_	17	nmod
23	support	support	VBP	_	0	ROOT
24	the	the	DT	_	25	det
25	choice	choice	NN	_	23	dobj
26	of	of	IN	_	27	case
27	olanzapine	olanzapine	NN	_	25	nmod
28	as	as	IN	_	33	case
29	a	a	DT	_	33	det
30	first	first	JJ	_	33	amod
31	-	-	:	_	33	punct
32	line	line	NN	_	33	compound
33	option	option	NN	_	23	nmod
34	in	in	IN	_	36	case
35	the	the	DT	_	36	det
36	management	management	NN	_	33	nmod
37	of	of	IN	_	38	case
38	schizophrenia	schizophrenia	NN	_	36	nmod
39	in	in	IN	_	42	case
40	the	the	DT	_	42	det
41	acute	acute	JJ	_	42	amod
42	phase	phase	NN	_	33	nmod
43	and	and	CC	_	42	cc
44	for	for	IN	_	46	case
45	the	the	DT	_	46	det
46	maintenance	maintenance	NN	_	42	conj
47	of	of	IN	_	49	case
48	treatment	treatment	NN	_	49	compound
49	response	response	NN	_	46	nmod
50	.	.	.	_	23	punct

1	Antimicrobial	antimicrobial	JJ	_	2	amod
2	activity	activity	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	Ganoderma	ganoderma	NN	_	6	compound
5	lucidum	lucidum	NN	_	6	compound
6	extract	extract	NN	_	2	nmod
7	alone	alone	RB	_	6	advmod
8	and	and	CC	_	6	cc
9	in	in	IN	_	10	case
10	combination	combination	NN	_	6	conj
11	with	with	IN	_	13	case
12	some	some	DT	_	13	det
13	antibiotics	antibiotic	NNS	_	10	nmod
14	.	.	.	_	2	punct

1	Antimicrobial	antimicrobial	JJ	_	2	amod
2	activity	activity	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	GL	GL	NNP	_	2	nmod
5	(	(	VBD	_	21	csubjpass
6	the	the	DT	_	8	det
7	aqueous	aqueous	JJ	_	8	amod
8	extract	extract	NN	_	5	dobj
9	from	from	IN	_	11	case
10	the	the	DT	_	11	det
11	carpophores	carpophore	NNS	_	5	nmod
12	of	of	IN	_	19	case
13	Ganoderma	ganoderma	NN	_	19	compound
14	lucidum	lucidum	NN	_	19	compound
15	(	(	CD	_	19	nummod
16	FR	fr	NN	_	19	compound
17	)	)	CD	_	19	nummod
18	KARST	karst	JJ	_	19	amod
19	)	)	NN	_	11	nmod
20	was	be	VBD	_	21	auxpass
21	tested	test	VBN	_	0	ROOT
22	in	in	FW	_	23	compound
23	vitro	vitro	FW	_	21	advmod
24	against	against	IN	_	26	case
25	Gram	gram	NN	_	26	nmod:npmod
26	positive	positive	JJ	_	21	nmod
27	and	and	CC	_	26	cc
28	Gram	gram	NN	_	30	compound
29	negative	negative	JJ	_	30	amod
30	bacteria	bacterium	NNS	_	26	conj
31	by	by	IN	_	35	case
32	serial	serial	NN	_	35	compound
33	broth	broth	NN	_	35	compound
34	dilution	dilution	NN	_	35	compound
35	method	method	NN	_	26	nmod
36	,	,	,	_	21	punct
37	and	and	CC	_	21	cc
38	the	the	DT	_	40	det
39	antimicrobial	antimicrobial	JJ	_	40	amod
40	activity	activity	NN	_	42	nsubjpass
41	was	be	VBD	_	42	auxpass
42	expressed	express	VBN	_	21	conj
43	by	by	IN	_	46	case
44	minimal	minimal	JJ	_	46	amod
45	inhibitory	inhibitory	JJ	_	46	amod
46	concentration	concentration	NN	_	42	nmod
47	(	(	CD	_	49	nummod
48	MIC	mic	NN	_	49	compound
49	)	)	NN	_	46	dep
50	.	.	.	_	21	punct

1	Among	among	IN	_	3	case
2	fifteen	fifteen	CD	_	3	nummod
3	species	species	NNS	_	16	nmod
4	of	of	IN	_	5	case
5	bacteria	bacterium	NNS	_	3	nmod
6	tested	test	VBN	_	5	acl
7	,	,	,	_	16	punct
8	the	the	DT	_	10	det
9	antimicrobial	antimicrobial	JJ	_	10	amod
10	activity	activity	NN	_	16	nsubj
11	of	of	IN	_	12	case
12	GL	GL	NNP	_	10	nmod
13	was	be	VBD	_	16	cop
14	the	the	DT	_	16	det
15	most	most	RBS	_	16	advmod
16	potent	potent	JJ	_	0	ROOT
17	against	against	IN	_	19	case
18	Micrococcus	micrococcus	NN	_	19	compound
19	luteus	luteus	NN	_	16	nmod
20	(	(	CD	_	21	nummod
21	MIC	mic	NN	_	19	dep
22	,	,	,	_	21	punct
23	0.75	0.75	CD	_	24	nummod
24	mg	mg	NN	_	21	appos
25	/	/	:	_	16	punct
26	ml	ml	NN	_	27	compound
27	)	)	NN	_	16	dep
28	.	.	.	_	16	punct

1	To	to	TO	_	2	mark
2	investigate	investigate	VB	_	34	advcl
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	7	case
6	antimicrobial	antimicrobial	JJ	_	7	amod
7	combinations	combination	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	GL	gl	NN	_	7	nmod
10	with	with	IN	_	12	case
11	four	four	CD	_	12	nummod
12	kinds	kind	NNS	_	4	nmod
13	of	of	IN	_	14	case
14	antibiotics	antibiotic	NNS	_	12	nmod
15	(	(	CD	_	16	nummod
16	ampicillin	ampicillin	NN	_	14	dep
17	,	,	,	_	16	punct
18	cefazolin	cefazolin	NN	_	16	conj
19	,	,	,	_	16	punct
20	oxytetracycline	oxytetracycline	NN	_	16	conj
21	and	and	CC	_	16	cc
22	chloramphenicol	chloramphenicol	NN	_	23	compound
23	)	)	NN	_	16	conj
24	,	,	,	_	34	punct
25	the	the	DT	_	29	det
26	fractional	fractional	JJ	_	29	amod
27	inhibitory	inhibitory	JJ	_	29	amod
28	concentration	concentration	NN	_	29	compound
29	index	index	NN	_	34	nsubjpass
30	(	(	CD	_	32	nummod
31	FICI	fici	NN	_	32	compound
32	)	)	NN	_	29	dep
33	was	be	VBD	_	34	auxpass
34	determined	determine	VBN	_	0	ROOT
35	by	by	IN	_	37	case
36	checkerboard	checkerboard	NN	_	37	compound
37	assay	assay	NN	_	34	nmod
38	for	for	IN	_	40	case
39	each	each	DT	_	40	det
40	strain	strain	NN	_	37	nmod
41	.	.	.	_	34	punct

1	The	the	DT	_	3	det
2	antimicrobial	antimicrobial	JJ	_	3	amod
3	combinations	combination	NNS	_	9	nsubj
4	of	of	IN	_	5	case
5	GL	gl	NN	_	3	nmod
6	with	with	IN	_	8	case
7	four	four	CD	_	8	nummod
8	antibiotics	antibiotic	NNS	_	3	nmod
9	resulted	result	VBD	_	0	ROOT
10	in	in	IN	_	12	case
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	nmod
13	in	in	IN	_	15	case
14	most	most	JJS	_	15	amod
15	instances	instance	NNS	_	12	nmod
16	,	,	,	_	15	punct
17	synergism	synergism	NN	_	15	conj
18	in	in	IN	_	20	case
19	two	two	CD	_	20	nummod
20	instances	instance	NNS	_	17	nmod
21	,	,	,	_	15	punct
22	and	and	CC	_	15	cc
23	antagonism	antagonism	NN	_	15	conj
24	in	in	IN	_	26	case
25	two	two	CD	_	26	nummod
26	instances	instance	NNS	_	23	nmod
27	.	.	.	_	9	punct

1	Synergism	synergism	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	observed	observe	VBN	_	0	ROOT
4	when	when	WRB	_	7	advmod
5	GL	GL	NNP	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	combined	combine	VBN	_	3	advcl
8	with	with	IN	_	9	case
9	cefazolin	cefazolin	NN	_	7	nmod
10	against	against	IN	_	12	case
11	Bacillus	bacillus	NN	_	12	compound
12	subtilis	subtilis	NNS	_	9	nmod
13	and	and	CC	_	12	cc
14	Klebsiella	klebsiella	NN	_	15	compound
15	oxytoca	oxytoca	NN	_	12	conj
16	.	.	.	_	3	punct

1	Misonidazole	Misonidazole	NNP	_	2	nsubj
2	protects	protect	VBZ	_	0	ROOT
3	mouse	mouse	NN	_	4	compound
4	tumour	tumour	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	normal	normal	JJ	_	7	amod
7	tissues	tissue	NNS	_	4	conj
8	from	from	IN	_	10	case
9	the	the	DT	_	10	det
10	toxicity	toxicity	NN	_	2	nmod
11	of	of	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	CCNU	ccnu	NN	_	10	nmod
14	.	.	.	_	2	punct

1	Because	because	IN	_	6	mark
2	the	the	DT	_	4	det
3	nitrosourea	nitrosourea	JJ	_	4	amod
4	CCNU	ccnu	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	given	give	VBN	_	17	advcl
7	exclusively	exclusively	RB	_	6	advmod
8	by	by	IN	_	11	case
9	the	the	DT	_	11	det
10	oral	oral	JJ	_	11	amod
11	route	route	NN	_	6	nmod
12	in	in	IN	_	13	case
13	man	man	NN	_	11	nmod
14	,	,	,	_	17	punct
15	we	we	PRP	_	17	nsubj
16	have	have	VBP	_	17	aux
17	carried	carry	VBN	_	0	ROOT
18	out	out	RP	_	17	compound:prt
19	studies	study	NNS	_	17	dobj
20	in	in	IN	_	21	case
21	mice	mouse	NNS	_	19	nmod
22	on	on	IN	_	25	case
23	the	the	DT	_	25	det
24	antitumour	antitumour	NN	_	25	compound
25	activity	activity	NN	_	19	nmod
26	,	,	,	_	25	punct
27	acute	acute	JJ	_	28	amod
28	toxicity	toxicity	NN	_	25	conj
29	and	and	CC	_	25	cc
30	pharmacokinetics	pharmacokinetic	NNS	_	25	conj
31	of	of	IN	_	33	case
32	oral	oral	JJ	_	33	amod
33	CCNU	ccnu	NN	_	30	nmod
34	,	,	,	_	25	punct
35	either	either	CC	_	25	dep
36	alone	alone	RB	_	35	dep
37	or	or	CC	_	35	cc
38	in	in	IN	_	39	case
39	combination	combination	NN	_	35	conj
40	with	with	IN	_	43	case
41	the	the	DT	_	43	det
42	chemosensitizer	chemosensitizer	NN	_	43	compound
43	misonidazole	misonidazole	NN	_	39	nmod
44	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	both	both	DT	_	3	cc:preconj
3	plasma	plasma	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	KHT	kht	NN	_	6	compound
6	tumour	tumour	NN	_	3	conj
7	the	the	DT	_	9	det
8	peak	peak	NN	_	9	compound
9	concentration	concentration	NN	_	3	dep
10	and	and	CC	_	9	cc
11	&quot	&quot	NN	_	9	conj
12	;	;	:	_	3	punct
13	early&quot	early&quot	NN	_	3	dep
14	;	;	:	_	3	punct

1	AUC	auc	NN	_	11	nsubj
2	for	for	IN	_	4	case
3	total	total	JJ	_	4	amod
4	nitrosoureas	nitrosourea	NNS	_	1	nmod
5	were	be	VBD	_	11	cop
6	about	about	RB	_	7	advmod
7	1.4	1.4	CD	_	11	nummod
8	-	-	:	_	11	punct
9	1.5	1.5	CD	_	10	nummod
10	fold	fold	NN	_	11	nmod:npmod
11	greater	greater	JJR	_	0	ROOT
12	for	for	IN	_	14	case
13	the	the	DT	_	14	det
14	oral	oral	JJ	_	11	nmod
15	compared	compare	VBN	_	18	case
16	to	to	TO	_	18	case
17	the	the	DT	_	18	det
18	i	i	FW	_	11	advcl
19	.	.	.	_	11	punct
20	p	p	NN	_	11	dep
21	.	.	.	_	11	punct

1	route	route	NN	_	0	ROOT
2	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	differences	difference	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	reflected	reflect	VBN	_	0	ROOT
5	in	in	IN	_	11	case
6	the	the	DT	_	11	det
7	roughly	roughly	RB	_	8	advmod
8	twofold	twofold	RB	_	9	advmod
9	greater	greater	JJR	_	11	amod
10	antitumour	antitumour	NN	_	11	compound
11	activity	activity	NN	_	4	nmod
12	for	for	IN	_	15	case
13	the	the	DT	_	15	det
14	oral	oral	JJ	_	15	amod
15	route	route	NN	_	11	nmod
16	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	7	nmod
3	,	,	,	_	7	punct
4	acute	acute	JJ	_	6	amod
5	toxicity	toxicity	NN	_	6	compound
6	tests	test	NNS	_	7	nsubj
7	showed	show	VBD	_	0	ROOT
8	that	that	IN	_	15	mark
9	oral	oral	JJ	_	10	amod
10	CCNU	ccnu	NN	_	15	nsubj
11	was	be	VBD	_	15	cop
12	1.45	1.45	CD	_	13	compound
13	times	time	NNS	_	15	dep
14	less	less	RBR	_	15	advmod
15	toxic	toxic	JJ	_	7	ccomp
16	to	to	TO	_	18	case
17	normal	normal	JJ	_	18	amod
18	tissue	tissue	NN	_	15	nmod
19	,	,	,	_	15	punct
20	although	although	IN	_	28	mark
21	the	the	DT	_	22	det
22	dose	dose	NN	_	25	dep
23	-	-	:	_	25	punct
24	limiting	limit	VBG	_	25	amod
25	organ	organ	NN	_	28	nsubj
26	may	may	MD	_	28	aux
27	be	be	VB	_	28	cop
28	different	different	JJ	_	15	advcl
29	for	for	IN	_	32	case
30	the	the	DT	_	32	det
31	two	two	CD	_	32	nummod
32	routes	route	NNS	_	28	nmod
33	.	.	.	_	7	punct

1	Misonidazole	Misonidazole	NNP	_	2	nsubj
2	reduced	reduce	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	antitumour	antitumour	NN	_	5	compound
5	activity	activity	NN	_	2	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	CCNU	ccnu	NN	_	5	nmod
9	by	by	IN	_	12	case
10	dose	dose	NN	_	12	compound
11	modifying	modifying	NN	_	12	compound
12	factors	factor	NNS	_	2	nmod
13	(	(	VBP	_	2	dep
14	DMF	dmf	NN	_	15	compound
15	)	)	NN	_	13	dobj
16	of	of	IN	_	17	case
17	0.58	0.58	CD	_	15	nmod
18	-	-	:	_	19	punct
19	0.71	0.71	CD	_	17	dep
20	.	.	.	_	2	punct

1	Similarly	similarly	RB	_	8	advmod
2	,	,	,	_	8	punct
3	the	the	DT	_	5	det
4	acute	acute	JJ	_	5	amod
5	toxicity	toxicity	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	also	also	RB	_	8	advmod
8	diminished	diminish	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	a	a	DT	_	11	det
11	DMF	dmf	NN	_	8	nmod
12	of	of	IN	_	13	case
13	0.74	0.74	CD	_	11	nmod
14	.	.	.	_	8	punct

1	Misonidazole	Misonidazole	NNP	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	a	a	DT	_	5	det
4	complex	complex	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	on	on	IN	_	9	case
7	oral	oral	JJ	_	9	amod
8	CCNU	ccnu	NN	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
10	.	.	.	_	2	punct

1	The	the	DT	_	8	det
2	plasma	plasma	NN	_	8	compound
3	and	and	CC	_	2	cc
4	tumour	tumour	NN	_	2	conj
5	total	total	JJ	_	8	amod
6	nitrosourea	nitrosourea	JJ	_	8	amod
7	peak	peak	NN	_	8	compound
8	concentrations	concentration	NNS	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	by	by	IN	_	12	case
12	1.5	1.5	CD	_	10	nmod
13	and	and	CC	_	12	cc
14	1.7	1.7	CD	_	12	conj
15	fold	fold	JJ	_	12	dep
16	respectively	respectively	RB	_	12	advmod
17	.	.	.	_	10	punct

1	Misonidazole	Misonidazole	NNP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	reduced	reduce	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	&quot	&quot	NN	_	3	dobj
6	;	;	:	_	5	punct
7	early&quot	early&quot	NN	_	5	dep
8	;	;	:	_	3	punct

1	nitrosourea	nitrosourea	NN	_	2	compound
2	AUC	auc	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	extent	extent	NN	_	2	nmod
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	reduction	reduction	NN	_	6	nmod
10	depending	depend	VBG	_	15	case
11	on	on	IN	_	15	case
12	the	the	DT	_	15	det
13	minimum	minimum	JJ	_	15	amod
14	effective	effective	JJ	_	15	amod
15	concentration	concentration	NN	_	6	nmod
16	(	(	CD	_	17	nummod
17	MEC	mec	NN	_	15	dep
18	)	)	CD	_	17	nummod
19	chosen	choose	VBN	_	17	acl
20	.	.	.	_	2	punct

1	For	for	IN	_	2	case
2	example	example	NN	_	9	nmod
3	,	,	,	_	9	punct
4	the	the	DT	_	7	det
5	plasma	plasma	NN	_	7	compound
6	nitrosourea	nitrosourea	NN	_	7	compound
7	AUC	auc	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	reduced	reduce	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	factors	factor	NNS	_	9	nmod
12	of	of	IN	_	13	case
13	1.05	1.05	CD	_	11	nmod
14	and	and	CC	_	13	cc
15	9.6	9.6	CD	_	13	conj
16	for	for	IN	_	18	case
17	MEC	mec	NN	_	18	compound
18	values	value	NNS	_	11	nmod
19	of	of	IN	_	24	case
20	1	1	CD	_	24	nummod
21	and	and	CC	_	20	cc
22	2	2	CD	_	20	conj
23	micrograms	microgram	NNS	_	24	compound
24	ml	ml	NN	_	18	nmod
25	-	-	:	_	24	punct
26	1	1	CD	_	24	dep
27	respectively	respectively	RB	_	26	advmod
28	.	.	.	_	9	punct

1	We	we	PRP	_	2	nsubj
2	propose	propose	VBP	_	0	ROOT
3	these	these	DT	_	5	det
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	changes	change	NNS	_	2	dobj
6	to	to	TO	_	10	mark
7	be	be	VB	_	10	cop
8	the	the	DT	_	10	det
9	underlying	underlie	VBG	_	10	amod
10	mechanism	mechanism	NN	_	5	acl
11	for	for	IN	_	13	case
12	the	the	DT	_	13	det
13	reduction	reduction	NN	_	10	nmod
14	of	of	IN	_	17	case
15	oral	oral	JJ	_	17	amod
16	CCNU	ccnu	NN	_	17	compound
17	cytotoxicity	cytotoxicity	NN	_	13	nmod
18	by	by	IN	_	19	case
19	misonidazole	misonidazole	NN	_	13	nmod
20	.	.	.	_	2	punct

1	Clinical	clinical	JJ	_	2	amod
2	trials	trial	NNS	_	8	nsubjpass
3	of	of	IN	_	5	case
4	such	such	JJ	_	5	amod
5	combinations	combination	NNS	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	accompanied	accompany	VBN	_	0	ROOT
9	by	by	IN	_	12	case
10	detailed	detailed	JJ	_	12	amod
11	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
12	evaluation	evaluation	NN	_	8	nmod
13	.	.	.	_	8	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	interaction	interaction	NN	_	0	ROOT
3	between	between	IN	_	6	case
4	single	single	JJ	_	6	amod
5	oral	oral	JJ	_	6	amod
6	doses	dose	NNS	_	2	nmod
7	of	of	IN	_	8	case
8	diltiazem	diltiazem	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	sirolimus	sirolimus	NN	_	8	conj
11	in	in	IN	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	volunteers	volunteer	NNS	_	2	nmod
14	.	.	.	_	2	punct

1	AIM	aim	NN	_	0	ROOT
2	AND	and	CC	_	1	cc
3	BACKGROUND	background	NN	_	1	conj
4	:	:	:	_	1	punct
5	The	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	interaction	interaction	NN	_	25	nsubjpass
8	between	between	IN	_	9	case
9	sirolimus	sirolimus	NN	_	7	nmod
10	,	,	,	_	9	punct
11	a	a	DT	_	12	det
12	macrolide	macrolide	NN	_	9	appos
13	immunosuppressant	immunosuppressant	JJ	_	12	amod
14	metabolized	metabolize	VBN	_	13	acl
15	by	by	IN	_	16	case
16	CYP3A4	cyp3a4	NN	_	14	nmod
17	,	,	,	_	9	punct
18	and	and	CC	_	9	cc
19	the	the	DT	_	23	det
20	calcium	calcium	NN	_	23	compound
21	channel	channel	NN	_	23	compound
22	blocker	blocker	NN	_	23	compound
23	diltiazem	diltiazem	NN	_	9	conj
24	was	be	VBD	_	25	auxpass
25	studied	study	VBN	_	1	dep
26	in	in	IN	_	29	case
27	18	18	CD	_	29	nummod
28	healthy	healthy	JJ	_	29	amod
29	subjects	subject	NNS	_	25	nmod
30	.	.	.	_	25	punct

1	Several	several	JJ	_	4	amod
2	clinically	clinically	RB	_	3	advmod
3	important	important	JJ	_	4	amod
4	interactions	interaction	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	previously	previously	RB	_	8	advmod
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	for	for	IN	_	12	case
10	other	other	JJ	_	12	amod
11	immunosuppressive	immunosuppressive	JJ	_	12	amod
12	drugs	drug	NNS	_	8	nmod
13	that	that	WDT	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	metabolized	metabolize	VBN	_	12	acl:relcl
16	by	by	IN	_	19	case
17	the	the	DT	_	19	det
18	same	same	JJ	_	19	amod
19	enzyme	enzyme	NN	_	15	nmod
20	and	and	CC	_	19	cc
21	for	for	IN	_	23	case
22	calcium	calcium	NN	_	23	compound
23	antagonists	antagonist	NNS	_	19	conj
24	.	.	.	_	8	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Healthy	healthy	JJ	_	4	amod
4	subjects	subject	NNS	_	12	nsubj
5	who	who	WP	_	11	nsubj
6	were	be	VBD	_	11	cop
7	20	20	CD	_	9	compound
8	to	to	TO	_	9	dep
9	43	43	CD	_	10	nummod
10	years	year	NNS	_	11	nmod:npmod
11	old	old	JJ	_	4	acl:relcl
12	participated	participate	VBD	_	1	dep
13	in	in	IN	_	19	case
14	an	a	DT	_	19	det
15	open	open	JJ	_	19	amod
16	,	,	,	_	15	punct
17	three	three	CD	_	15	dep
18	-	-	:	_	15	punct
19	period	period	NN	_	12	nmod
20	,	,	,	_	12	punct
21	randomized	randomize	VBN	_	12	dep
22	,	,	,	_	12	punct
23	crossover	crossover	NN	_	24	compound
24	study	study	NN	_	12	dobj
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	pharmacokinetics	pharmacokinetic	NNS	_	24	nmod
28	of	of	IN	_	35	case
29	a	a	DT	_	35	det
30	single	single	JJ	_	35	amod
31	10	10	CD	_	35	nummod
32	-	-	:	_	35	punct
33	mg	mg	NN	_	35	compound
34	oral	oral	JJ	_	35	amod
35	dose	dose	NN	_	27	nmod
36	of	of	IN	_	37	case
37	sirolimus	sirolimus	NN	_	35	nmod
38	,	,	,	_	35	punct
39	a	a	DT	_	45	det
40	single	single	JJ	_	45	amod
41	oral	oral	JJ	_	45	amod
42	120	120	CD	_	45	nummod
43	-	-	:	_	45	punct
44	mg	mg	NN	_	45	compound
45	dose	dose	NN	_	35	conj
46	of	of	IN	_	47	case
47	diltiazem	diltiazem	NN	_	45	nmod
48	,	,	,	_	35	punct
49	and	and	CC	_	35	cc
50	the	the	DT	_	52	det
51	two	two	CD	_	52	nummod
52	drugs	drug	NNS	_	35	conj
53	given	give	VBN	_	52	acl
54	together	together	RB	_	53	advmod
55	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	three	three	CD	_	4	nummod
3	study	study	NN	_	4	compound
4	periods	period	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	separated	separate	VBN	_	0	ROOT
7	by	by	IN	_	13	case
8	a	a	DT	_	13	det
9	21	21	CD	_	13	nummod
10	-	-	:	_	13	punct
11	day	day	NN	_	13	compound
12	washout	washout	NN	_	13	compound
13	phase	phase	NN	_	6	nmod
14	.	.	.	_	6	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	15	det
4	geometric	geometric	JJ	_	15	amod
5	mean	mean	NN	_	15	compound
6	(	(	NN	_	15	compound
7	90	90	CD	_	8	compound
8	%	%	NN	_	15	amod
9	confidence	confidence	NN	_	15	compound
10	interval	interval	NN	_	15	compound
11	)	)	CD	_	15	nummod
12	whole	whole	JJ	_	15	amod
13	blood	blood	NN	_	15	compound
14	sirolimus	sirolimus	NN	_	15	compound
15	area	area	NN	_	23	nsubj
16	under	under	IN	_	20	case
17	the	the	DT	_	20	det
18	plasma	plasma	NN	_	20	compound
19	concentration	concentration	NN	_	20	compound
20	time	time	NN	_	15	nmod
21	-	-	:	_	15	punct
22	curve	curve	NN	_	15	dep
23	increased	increase	VBD	_	1	dep
24	60	60	CD	_	25	nummod
25	%	%	NN	_	23	dobj
26	(	(	CD	_	28	nummod
27	35	35	CD	_	28	nummod
28	%	%	NN	_	25	dep
29	-	-	:	_	25	punct
30	90	90	CD	_	31	nummod
31	%	%	NN	_	25	dep
32	)	)	CD	_	31	nummod
33	,	,	,	_	25	punct
34	from	from	IN	_	35	case
35	736	736	CD	_	47	nmod
36	to	to	TO	_	37	dep
37	1178	1178	CD	_	40	nummod
38	ng	ng	NN	_	40	compound
39	x	x	CC	_	40	compound
40	h	h	NN	_	47	nsubj
41	/	/	:	_	40	punct
42	mL	ml	NN	_	40	dep
43	,	,	,	_	40	punct
44	and	and	CC	_	40	cc
45	maximum	maximum	NN	_	46	compound
46	concentration	concentration	NN	_	40	conj
47	increased	increase	VBD	_	23	advcl
48	43	43	CD	_	49	nummod
49	%	%	NN	_	47	dobj
50	(	(	CD	_	52	nummod
51	14	14	CD	_	52	nummod
52	%	%	NN	_	49	dep
53	-	-	:	_	49	punct
54	81	81	CD	_	55	nummod
55	%	%	NN	_	49	dep
56	)	)	CD	_	55	nummod
57	,	,	,	_	49	punct
58	from	from	IN	_	59	case
59	67	67	CD	_	47	nmod
60	to	to	TO	_	61	dep
61	96	96	CD	_	64	nummod
62	ng	ng	NN	_	64	compound
63	/	/	:	_	64	punct
64	mL	ml	NN	_	59	dep
65	,	,	,	_	47	punct
66	with	with	IN	_	68	case
67	diltiazem	diltiazem	NN	_	68	compound
68	coadministration	coadministration	NN	_	47	nmod
69	,	,	,	_	47	punct
70	whereas	whereas	IN	_	47	dep
71	the	the	DT	_	74	det
72	mean	mean	NN	_	74	compound
73	elimination	elimination	NN	_	74	compound
74	half	half	NN	_	79	nsubj
75	-	-	:	_	74	punct
76	life	life	NN	_	74	dep
77	of	of	IN	_	78	case
78	sirolimus	sirolimus	NN	_	76	nmod
79	decreased	decrease	VBD	_	47	parataxis
80	slightly	slightly	RB	_	79	advmod
81	,	,	,	_	79	punct
82	from	from	IN	_	86	case
83	79	79	CD	_	85	compound
84	to	to	TO	_	85	dep
85	67	67	CD	_	86	nummod
86	hours	hour	NNS	_	79	nmod
87	.	.	.	_	1	punct

1	Apparent	apparent	JJ	_	3	amod
2	oral	oral	JJ	_	3	amod
3	clearance	clearance	NN	_	10	nsubj
4	and	and	CC	_	3	cc
5	volume	volume	NN	_	3	conj
6	of	of	IN	_	7	case
7	distribution	distribution	NN	_	5	nmod
8	of	of	IN	_	9	case
9	sirolimus	sirolimus	NN	_	7	nmod
10	decreased	decrease	VBD	_	0	ROOT
11	with	with	IN	_	13	case
12	38	38	CD	_	13	nummod
13	%	%	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	45	45	CD	_	16	nummod
16	%	%	NN	_	13	conj
17	,	,	,	_	13	punct
18	respectively	respectively	RB	_	13	advmod
19	,	,	,	_	13	punct
20	when	when	WRB	_	23	advmod
21	sirolimus	sirolimus	NN	_	23	nsubjpass
22	was	be	VBD	_	23	auxpass
23	given	give	VBN	_	13	acl:relcl
24	with	with	IN	_	25	case
25	diltiazem	diltiazem	NN	_	23	nmod
26	.	.	.	_	10	punct

1	The	the	DT	_	4	det
2	plasma	plasma	NN	_	4	compound
3	maximum	maximum	NN	_	4	compound
4	concentration	concentration	NN	_	22	nsubj
5	and	and	CC	_	4	cc
6	area	area	NN	_	4	conj
7	under	under	IN	_	10	case
8	the	the	DT	_	10	det
9	plasma	plasma	NN	_	10	compound
10	concentration	concentration	NN	_	4	nmod
11	-	-	:	_	4	punct
12	time	time	NN	_	13	compound
13	curve	curve	NN	_	4	dep
14	of	of	IN	_	15	case
15	diltiazem	diltiazem	NN	_	13	nmod
16	,	,	,	_	15	punct
17	desacetyldiltiazem	desacetyldiltiazem	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	desmethyldiltiazem	desmethyldiltiazem	NN	_	15	conj
21	were	be	VBD	_	22	cop
22	unchanged	unchanged	JJ	_	0	ROOT
23	after	after	IN	_	24	case
24	coadministration	coadministration	NN	_	22	nmod
25	of	of	IN	_	26	case
26	sirolimus	sirolimus	NN	_	24	nmod
27	,	,	,	_	22	punct
28	and	and	CC	_	22	cc
29	no	no	DT	_	30	neg
30	potentiation	potentiation	NN	_	48	nsubjpass
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	effects	effect	NNS	_	30	nmod
34	of	of	IN	_	35	case
35	diltiazem	diltiazem	NN	_	33	nmod
36	on	on	IN	_	41	case
37	diastolic	diastolic	JJ	_	41	amod
38	or	or	CC	_	37	cc
39	systolic	systolic	JJ	_	37	conj
40	blood	blood	NN	_	41	compound
41	pressure	pressure	NN	_	33	nmod
42	or	or	CC	_	41	cc
43	on	on	IN	_	46	case
44	the	the	DT	_	46	det
45	electrocardiographic	electrocardiographic	JJ	_	46	amod
46	parameters	parameter	NNS	_	41	conj
47	was	be	VBD	_	48	auxpass
48	seen	see	VBN	_	22	conj
49	.	.	.	_	22	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Single	single	JJ	_	7	amod
4	-	-	:	_	7	punct
5	dose	dose	NN	_	7	compound
6	diltiazem	diltiazem	NN	_	7	compound
7	coadministration	coadministration	NN	_	8	nsubj
8	leads	lead	VBZ	_	1	dep
9	to	to	TO	_	12	case
10	higher	higher	JJR	_	12	amod
11	sirolimus	sirolimus	NN	_	12	compound
12	exposure	exposure	NN	_	8	nmod
13	,	,	,	_	12	punct
14	presumably	presumably	RB	_	16	advmod
15	by	by	IN	_	16	case
16	inhibition	inhibition	NN	_	12	nmod
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	first	first	JJ	_	16	nmod
20	-	-	:	_	12	punct
21	pass	pass	VB	_	12	dep
22	metabolism	metabolism	NN	_	21	dobj
23	of	of	IN	_	24	case
24	sirolimus	sirolimus	NN	_	22	nmod
25	.	.	.	_	1	punct

1	Because	because	IN	_	6	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	6	det
4	pronounced	pronounced	JJ	_	6	amod
5	intersubject	intersubject	NN	_	6	compound
6	variability	variability	NN	_	23	nmod
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	extent	extent	NN	_	6	nmod
10	of	of	IN	_	15	case
11	the	the	DT	_	15	det
12	sirolimus	sirolimus	NN	_	15	compound
13	-	-	:	_	15	punct
14	diltiazem	diltiazem	NN	_	15	compound
15	interaction	interaction	NN	_	9	nmod
16	,	,	,	_	23	punct
17	whole	whole	JJ	_	20	amod
18	blood	blood	NN	_	20	compound
19	sirolimus	sirolimus	NN	_	20	compound
20	concentrations	concentration	NNS	_	23	nsubjpass
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	monitored	monitor	VBN	_	0	ROOT
24	closely	closely	RB	_	23	advmod
25	in	in	IN	_	26	case
26	patients	patient	NNS	_	23	nmod
27	treated	treat	VBN	_	26	acl
28	with	with	IN	_	31	case
29	the	the	DT	_	31	det
30	two	two	CD	_	31	nummod
31	drugs	drug	NNS	_	27	nmod
32	.	.	.	_	23	punct

1	ADL	adl	NN	_	0	ROOT
2	8	8	CD	_	1	nummod
3	-	-	:	_	1	punct
4	2698	2698	CD	_	1	nummod
5	,	,	,	_	1	punct
6	a	a	DT	_	11	det
7	trans	trans	JJ	_	11	amod
8	-	-	:	_	11	punct
9	3,4	3,4	SYM	_	11	dep
10	-	-	:	_	11	punct
11	dimethyl	dimethyl	JJ	_	1	appos
12	-	-	:	_	1	punct
13	4	4	LS	_	20	dep
14	-	-	:	_	20	punct
15	(	(	CD	_	20	compound
16	3	3	LS	_	20	dep
17	-	-	:	_	20	punct
18	hydroxyphenyl	hydroxyphenyl	NN	_	20	compound
19	)	)	NN	_	20	compound
20	piperidine	piperidine	NN	_	1	dep
21	,	,	,	_	20	punct
22	prevents	prevent	VBZ	_	20	dep
23	gastrointestinal	gastrointestinal	JJ	_	24	amod
24	effects	effect	NNS	_	22	dobj
25	of	of	IN	_	27	case
26	intravenous	intravenous	JJ	_	27	amod
27	morphine	morphine	NN	_	24	nmod
28	without	without	IN	_	29	mark
29	affecting	affect	VBG	_	22	advcl
30	analgesia	analgesia	NN	_	29	dobj
31	.	.	.	_	1	punct

1	ADL	adl	SYM	_	12	dep
2	-	-	:	_	12	punct
3	8	8	CD	_	12	nummod
4	-	-	:	_	12	punct
5	2698	2698	CD	_	12	nsubj
6	is	be	VBZ	_	12	cop
7	a	a	DT	_	12	det
8	novel	novel	JJ	_	12	amod
9	peripherally	peripherally	RB	_	10	advmod
10	restricted	restricted	JJ	_	12	amod
11	opioid	opioid	JJ	_	12	amod
12	antagonist	antagonist	NN	_	0	ROOT
13	that	that	WDT	_	16	nsubj
14	may	may	MD	_	16	aux
15	selectively	selectively	RB	_	16	advmod
16	prevent	prevent	VB	_	12	acl:relcl
17	opioid	opioid	NN	_	16	dobj
18	-	-	:	_	16	punct
19	induced	induce	VBN	_	21	amod
20	gastrointestinal	gastrointestinal	JJ	_	21	amod
21	effects	effect	NNS	_	16	dobj
22	without	without	IN	_	23	mark
23	reversing	reverse	VBG	_	21	acl
24	analgesia	analgesia	NN	_	23	dobj
25	.	.	.	_	12	punct

1	Gastrointestinal	gastrointestinal	JJ	_	3	amod
2	transit	transit	NN	_	3	compound
3	time	time	NN	_	11	nmod:tmod
4	(	(	CD	_	9	nummod
5	lactulose	lactulose	NN	_	9	compound
6	hydrogen	hydrogen	NN	_	9	compound
7	breath	breath	NN	_	9	compound
8	test	test	NN	_	9	compound
9	)	)	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	measured	measure	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	14	14	CD	_	14	nummod
14	volunteers	volunteer	NNS	_	11	nmod
15	with	with	IN	_	19	case
16	oral	oral	JJ	_	19	amod
17	and	and	CC	_	16	cc
18	intravenous	intravenous	JJ	_	16	conj
19	placebo	placebo	NN	_	14	nmod
20	,	,	,	_	14	punct
21	oral	oral	JJ	_	22	amod
22	placebo	placebo	NN	_	14	conj
23	and	and	CC	_	22	cc
24	intravenous	intravenous	JJ	_	25	amod
25	morphine	morphine	NN	_	22	conj
26	(	(	CD	_	27	compound
27	0.05	0.05	CD	_	28	nummod
28	mg	mg	NN	_	25	dep
29	x	x	CC	_	28	cc
30	kg	kg	NN	_	28	conj
31	(	(	SYM	_	22	dep
32	-	-	:	_	22	punct
33	1	1	CD	_	34	compound
34	)	)	CD	_	35	nummod
35	)	)	NN	_	22	dep
36	,	,	,	_	14	punct
37	and	and	CC	_	14	cc
38	oral	oral	JJ	_	39	amod
39	ADL	adl	NN	_	14	conj
40	8	8	CD	_	39	nummod
41	-	-	:	_	39	punct
42	2698	2698	CD	_	44	compound
43	(	(	CD	_	44	compound
44	4	4	CD	_	46	nummod
45	mg	mg	NN	_	46	compound
46	)	)	NN	_	39	dep
47	and	and	CC	_	46	cc
48	intravenous	intravenous	JJ	_	49	amod
49	morphine	morphine	NN	_	46	conj
50	(	(	CD	_	51	compound
51	0.05	0.05	CD	_	52	nummod
52	mg	mg	NN	_	49	dep
53	x	x	CC	_	52	cc
54	kg	kg	NN	_	52	conj
55	(	(	SYM	_	46	dep
56	-	-	:	_	39	punct
57	1	1	CD	_	58	compound
58	)	)	CD	_	59	nummod
59	)	)	NN	_	39	dep
60	in	in	IN	_	63	case
61	a	a	DT	_	63	det
62	double	double	JJ	_	63	amod
63	blind	blind	JJ	_	59	nmod
64	,	,	,	_	14	punct
65	cross	cross	JJ	_	68	dep
66	-	-	:	_	68	punct
67	over	over	IN	_	68	case
68	study	study	NN	_	14	conj
69	.	.	.	_	11	punct

1	Morphine	Morphine	NNP	_	2	nsubj
2	prolonged	prolong	VBD	_	0	ROOT
3	gastrointestinal	gastrointestinal	JJ	_	5	amod
4	transit	transit	NN	_	5	compound
5	time	time	NN	_	2	dobj
6	from	from	IN	_	10	case
7	69	69	CD	_	9	compound
8	to	to	TO	_	9	dep
9	103	103	CD	_	10	nummod
10	minutes	minute	NNS	_	2	nmod
11	(	(	CD	_	12	nummod
12	P	p	NN	_	10	dep
13	=	=	JJ	_	12	amod
14	.	.	.	_	2	punct
15	005	005	CD	_	16	nummod
16	)	)	NN	_	2	nmod:npmod
17	;	;	:	_	2	punct

1	Morphine	Morphine	NNP	_	2	nsubj
2	prolonged	prolong	VBD	_	0	ROOT
3	gastrointestinal	gastrointestinal	JJ	_	5	amod
4	transit	transit	NN	_	5	compound
5	time	time	NN	_	2	dobj
6	from	from	IN	_	10	case
7	69	69	CD	_	9	compound
8	to	to	TO	_	9	dep
9	103	103	CD	_	10	nummod
10	minutes	minute	NNS	_	2	nmod
11	(	(	CD	_	12	nummod
12	P	p	NN	_	10	dep
13	=	=	JJ	_	12	amod
14	.	.	.	_	2	punct
15	005	005	CD	_	16	nummod
16	)	)	NN	_	2	dobj
17	;	;	:	_	2	punct
18	this	this	DT	_	20	nsubjpass
19	was	be	VBD	_	20	auxpass
20	prevented	prevent	VBN	_	2	parataxis
21	by	by	IN	_	22	case
22	ADL	adl	NN	_	20	nmod
23	8	8	CD	_	22	nummod
24	-	-	:	_	22	punct
25	2698	2698	CD	_	26	compound
26	(	(	CD	_	27	nummod
27	P	p	NN	_	22	dep
28	=	=	JJ	_	27	amod
29	.	.	.	_	20	punct
30	004	004	CD	_	31	nummod
31	)	)	NN	_	20	dep
32	.	.	.	_	2	punct

1	Postoperatively	postoperatively	RB	_	7	advmod
2	,	,	,	_	7	punct
3	45	45	CD	_	4	nummod
4	patients	patient	NNS	_	7	nsubjpass
5	were	be	VBD	_	7	auxpass
6	randomly	randomly	RB	_	7	advmod
7	assigned	assign	VBN	_	0	ROOT
8	in	in	IN	_	13	case
9	a	a	DT	_	13	det
10	double	double	JJ	_	13	amod
11	-	-	:	_	13	punct
12	blind	blind	JJ	_	13	amod
13	fashion	fashion	NN	_	7	nmod
14	to	to	TO	_	15	mark
15	receive	receive	VB	_	7	xcomp
16	ADL	adl	NN	_	15	dobj
17	8	8	CD	_	16	nummod
18	-	-	:	_	16	punct
19	2698	2698	CD	_	21	compound
20	(	(	CD	_	21	compound
21	4	4	CD	_	22	dep
22	mg	mg	NN	_	23	dep
23	)	)	NN	_	16	dep
24	or	or	CC	_	23	cc
25	placebo	placebo	NN	_	23	conj
26	and	and	CC	_	23	cc
27	intravenous	intravenous	JJ	_	28	amod
28	morphine	morphine	NN	_	23	conj
29	(	(	CD	_	30	compound
30	0.15	0.15	CD	_	31	nummod
31	mg	mg	NN	_	28	dep
32	/	/	:	_	16	punct
33	kg	kg	NN	_	34	compound
34	)	)	NN	_	16	dep
35	or	or	CC	_	16	cc
36	to	to	TO	_	37	mark
37	receive	receive	VB	_	16	conj
38	oral	oral	JJ	_	41	amod
39	and	and	CC	_	38	cc
40	intravenous	intravenous	JJ	_	38	conj
41	placebo	placebo	NN	_	37	dobj
42	.	.	.	_	7	punct

1	Analgesia	Analgesia	NNP	_	4	compound
2	and	and	CC	_	1	cc
3	pupil	pupil	NN	_	1	conj
4	constriction	constriction	NN	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	measured	measure	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Morphine	morphine	NN	_	2	compound
2	analgesia	analgesia	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	pupil	pupil	NN	_	5	compound
5	constriction	constriction	NN	_	2	conj
6	were	be	VBD	_	7	aux
7	unaffected	unaffected	JJ	_	0	ROOT
8	by	by	IN	_	9	case
9	ADL	adl	NN	_	7	nmod
10	8	8	CD	_	9	nummod
11	-	-	:	_	9	punct
12	2698	2698	CD	_	9	nummod
13	and	and	CC	_	7	cc
14	differed	differ	VBD	_	7	conj
15	from	from	IN	_	19	case
16	placebo	placebo	NN	_	19	compound
17	(	(	CD	_	19	nummod
18	P	p	NN	_	19	compound
19	&lt	&lt	NN	_	14	nmod
20	;	;	:	_	7	punct
21	.	.	.	_	7	punct
22	002	002	CD	_	23	nummod
23	)	)	NN	_	7	dep
24	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	conclude	conclude	VBP	_	0	ROOT
3	that	that	IN	_	8	mark
4	ADL	adl	NN	_	8	nsubj
5	8	8	CD	_	4	nummod
6	-	-	:	_	4	punct
7	2698	2698	CD	_	4	nummod
8	prevents	prevent	VBZ	_	2	ccomp
9	morphine	morphine	NN	_	12	nsubj
10	-	-	:	_	12	punct
11	induced	induce	VBN	_	12	amod
12	increases	increase	NNS	_	8	ccomp
13	in	in	IN	_	16	case
14	gastrointestinal	gastrointestinal	JJ	_	16	amod
15	transit	transit	NN	_	16	compound
16	time	time	NN	_	12	nmod
17	by	by	IN	_	18	case
18	means	means	NNS	_	12	nmod
19	of	of	IN	_	23	case
20	selective	selective	JJ	_	23	amod
21	peripheral	peripheral	JJ	_	23	amod
22	opioid	opioid	NN	_	23	compound
23	anitagonism	anitagonism	NN	_	18	nmod
24	without	without	IN	_	25	mark
25	affecting	affect	VBG	_	12	advcl
26	central	central	JJ	_	28	amod
27	opioid	opioid	JJ	_	28	amod
28	analgesia	analgesia	NN	_	25	dobj
29	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	chlordiazepoxide	chlordiazepoxide	NN	_	2	nmod
5	,	,	,	_	4	punct
6	amphetamine	amphetamine	NN	_	4	conj
7	and	and	CC	_	4	cc
8	cocaine	cocaine	NN	_	4	conj
9	on	on	IN	_	13	case
10	bar	bar	NN	_	13	compound
11	-	-	:	_	13	punct
12	press	press	NN	_	13	compound
13	behavior	behavior	NN	_	2	nmod
14	in	in	IN	_	15	case
15	normal	normal	JJ	_	13	nmod
16	and	and	CC	_	15	cc
17	genetically	genetically	RB	_	18	advmod
18	nervous	nervous	JJ	_	15	conj
19	dogs	dog	NNS	_	15	dep
20	.	.	.	_	2	punct

1	Studies	study	NNS	_	9	nsubj
2	on	on	IN	_	4	case
3	two	two	CD	_	4	nummod
4	strains	strain	NNS	_	1	nmod
5	of	of	IN	_	7	case
6	pointer	pointer	NN	_	7	compound
7	dogs	dog	NNS	_	4	nmod
8	have	have	VBP	_	9	aux
9	demonstrated	demonstrate	VBN	_	0	ROOT
10	that	that	IN	_	18	mark
11	administration	administration	NN	_	18	nsubj
12	of	of	IN	_	17	case
13	a	a	DT	_	17	det
14	benzodiazepine	benzodiazepine	NN	_	17	compound
15	(	(	NN	_	17	compound
16	chlordiazepoxide	chlordiazepoxide	NN	_	17	compound
17	)	)	NN	_	11	nmod
18	facilitates	facilitate	VBZ	_	9	ccomp
19	acquisition	acquisition	NN	_	18	dobj
20	of	of	IN	_	21	case
21	goal	goal	NN	_	19	nmod
22	-	-	:	_	18	punct
23	directed	direct	VBN	_	24	amod
24	behavior	behavior	NN	_	18	dep
25	in	in	IN	_	26	case
26	&quot	&quot	NN	_	24	nmod
27	;	;	:	_	9	punct
28	genetically	genetically	RB	_	29	advmod
29	nervous&quot	nervous&quot	NN	_	9	parataxis
30	;	;	:	_	9	punct

1	subjects	subject	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	Continued	continue	VBN	_	2	amod
2	admistration	admistration	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	drug	drug	NN	_	2	nmod
6	is	be	VBZ	_	7	auxpass
7	required	require	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	barpress	barpress	NN	_	11	compound
11	response	response	NN	_	9	dobj
12	in	in	IN	_	14	case
13	this	this	DT	_	14	det
14	strain	strain	NN	_	11	nmod
15	of	of	IN	_	16	case
16	dogs	dog	NNS	_	14	nmod
17	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	18	nsubj
4	of	of	IN	_	6	case
5	either	either	CC	_	6	cc:preconj
6	cocaine	cocaine	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	amphetamine	amphetamine	NN	_	6	conj
9	,	,	,	_	6	punct
10	compounds	compound	NNS	_	6	appos
11	which	which	WDT	_	12	nsubj
12	inhibit	inhibit	VBP	_	10	acl:relcl
13	neuronal	neuronal	JJ	_	14	amod
14	reuptake	reuptake	NN	_	12	dobj
15	of	of	IN	_	16	case
16	norepinephrine	norepinephrine	NN	_	14	nmod
17	,	,	,	_	6	punct
18	disrupts	disrupt	VBZ	_	0	ROOT
19	the	the	DT	_	21	det
20	behavioral	behavioral	JJ	_	21	amod
21	response	response	NN	_	18	dobj
22	of	of	IN	_	26	case
23	the	the	DT	_	26	det
24	genetically	genetically	RB	_	25	advmod
25	nervous	nervous	JJ	_	26	amod
26	E	e	NN	_	21	nmod
27	-	-	:	_	26	punct
28	strain	strain	NN	_	29	compound
29	subjects	subject	NNS	_	26	dep
30	to	to	TO	_	34	case
31	a	a	DT	_	34	det
32	far	far	RB	_	33	advmod
33	greater	greater	JJR	_	34	amod
34	extent	extent	NN	_	21	nmod
35	than	than	IN	_	38	case
36	the	the	DT	_	38	det
37	stable	stable	JJ	_	38	amod
38	A	a	NN	_	34	nmod
39	-	-	:	_	18	punct
40	strain	strain	NN	_	41	compound
41	subjects	subject	NNS	_	18	dep
42	.	.	.	_	18	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	also	also	RB	_	4	advmod
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	21	mark
6	after	after	IN	_	8	case
7	14	14	CD	_	8	nummod
8	days	day	NNS	_	21	nmod
9	of	of	IN	_	11	case
10	daily	daily	JJ	_	11	amod
11	administration	administration	NN	_	8	nmod
12	of	of	IN	_	13	case
13	chlordiazepoxide	chlordiazepoxide	NN	_	11	nmod
14	,	,	,	_	21	punct
15	withdrawal	withdrawal	NN	_	21	nsubj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	drug	drug	NN	_	15	nmod
19	not	not	RB	_	20	neg
20	only	only	RB	_	21	cc:preconj
21	re	re	SYM	_	4	ccomp
22	-	-	:	_	21	punct
23	results	result	NNS	_	21	dep
24	in	in	IN	_	27	case
25	almost	almost	RB	_	26	advmod
26	complete	complete	JJ	_	27	amod
27	loss	loss	NN	_	23	nmod
28	of	of	IN	_	32	case
29	bar	bar	NN	_	32	compound
30	-	-	:	_	32	punct
31	press	press	NN	_	32	compound
32	response	response	NN	_	27	nmod
33	in	in	IN	_	38	case
34	the	the	DT	_	38	det
35	E	e	NN	_	38	compound
36	-	-	:	_	38	punct
37	strain	strain	NN	_	38	compound
38	subjects	subject	NNS	_	27	nmod
39	but	but	CC	_	23	cc
40	also	also	RB	_	41	advmod
41	results	result	VBZ	_	23	conj
42	in	in	IN	_	45	case
43	a	a	DT	_	45	det
44	temporary	temporary	JJ	_	45	amod
45	decrease	decrease	NN	_	41	nmod
46	in	in	IN	_	50	case
47	the	the	DT	_	50	det
48	acquired	acquire	VBN	_	50	amod
49	behavioral	behavioral	JJ	_	50	amod
50	response	response	NN	_	45	nmod
51	of	of	IN	_	54	case
52	the	the	DT	_	54	det
53	stable	stable	JJ	_	54	amod
54	A	a	NN	_	50	nmod
55	-	-	:	_	54	punct
56	strain	strain	NN	_	57	compound
57	subjects	subject	NNS	_	54	dep
58	.	.	.	_	4	punct

1	Therapeutic	therapeutic	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	monitoring	monitoring	NN	_	5	nsubj
4	can	can	MD	_	5	aux
5	avoid	avoid	VB	_	0	ROOT
6	iatrogenic	iatrogenic	JJ	_	7	amod
7	alterations	alteration	NNS	_	5	dobj
8	caused	cause	VBN	_	7	acl
9	by	by	IN	_	10	case
10	99mTc	99mtc	NN	_	8	nmod
11	-	-	:	_	10	punct
12	methylene	methylene	NN	_	15	compound
13	diphosphonate	diphosphonate	NN	_	15	compound
14	(	(	CD	_	15	nummod
15	MDP	mdp	NN	_	19	dep
16	)	)	SYM	_	19	dep
17	-	-	:	_	19	punct
18	gentamicin	gentamicin	NN	_	19	compound
19	interaction	interaction	NN	_	10	dep
20	.	.	.	_	5	punct

1	Gentamicin	gentamicin	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	an	a	DT	_	5	det
4	aminoglycoside	aminoglycoside	JJ	_	5	amod
5	antibiotic	antibiotic	JJ	_	0	ROOT
6	used	use	VBN	_	5	acl
7	to	to	TO	_	8	mark
8	treat	treat	VB	_	6	xcomp
9	a	a	DT	_	11	det
10	wide	wide	JJ	_	11	amod
11	variety	variety	NN	_	8	dobj
12	of	of	IN	_	13	case
13	infections	infection	NNS	_	11	nmod
14	caused	cause	VBN	_	13	acl
15	by	by	IN	_	16	case
16	gram	gram	NN	_	14	nmod
17	-	-	:	_	16	punct
18	negative	negative	JJ	_	19	amod
19	organisms	organism	NNS	_	16	dep
20	,	,	,	_	5	punct
21	but	but	CC	_	5	cc
22	it	it	PRP	_	25	nsubj
23	is	be	VBZ	_	25	cop
24	potentially	potentially	RB	_	25	advmod
25	toxic	toxic	JJ	_	5	conj
26	to	to	TO	_	28	case
27	the	the	DT	_	28	det
28	kidneys	kidney	NNS	_	25	nmod
29	.	.	.	_	5	punct

1	Due	due	JJ	_	8	advmod
2	to	to	TO	_	4	case
3	its	its	PRP$	_	4	nmod:poss
4	nephrotoxicity	nephrotoxicity	NN	_	1	nmod
5	,	,	,	_	8	punct
6	gentamicin	gentamicin	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	cause	cause	VB	_	0	ROOT
9	abnormal	abnormal	JJ	_	11	amod
10	renal	renal	JJ	_	11	amod
11	uptake	uptake	NN	_	8	dobj
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	seen	see	VBN	_	11	acl
15	on	on	IN	_	16	case
16	99mTc	99mtc	NN	_	14	nmod
17	-	-	:	_	16	punct
18	MDP	mdp	NN	_	20	compound
19	bone	bone	NN	_	20	compound
20	scintigraphy	scintigraphy	NN	_	16	dep
21	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	radiopharmaceutical	radiopharmaceutical	JJ	_	2	nmod
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	kidneys	kidney	NNS	_	2	nmod
9	,	,	,	_	2	punct
10	along	along	IN	_	13	case
11	with	with	IN	_	13	case
12	an	a	DT	_	13	det
13	increase	increase	NN	_	2	nmod
14	in	in	IN	_	16	case
15	renal	renal	JJ	_	16	amod
16	retention	retention	NN	_	13	nmod
17	,	,	,	_	2	punct
18	tend	tend	VB	_	2	conj
19	to	to	TO	_	20	mark
20	produce	produce	VB	_	18	xcomp
21	scintigraphic	scintigraphic	JJ	_	22	amod
22	results	result	NNS	_	20	dobj
23	that	that	WDT	_	25	nsubj
24	falsely	falsely	RB	_	25	advmod
25	identify	identify	VBP	_	22	acl:relcl
26	characteristics	characteristic	NNS	_	25	dobj
27	related	related	JJ	_	26	amod
28	to	to	TO	_	29	case
29	diseases	disease	NNS	_	27	nmod
30	such	such	JJ	_	33	case
31	as	as	IN	_	30	mwe
32	renal	renal	JJ	_	33	amod
33	vascular	vascular	JJ	_	29	nmod
34	,	,	,	_	33	punct
35	or	or	CC	_	33	cc
36	urinary	urinary	JJ	_	38	amod
37	tract	tract	NN	_	38	compound
38	obstruction	obstruction	NN	_	33	conj
39	,	,	,	_	2	punct
40	and	and	CC	_	2	cc
41	even	even	RB	_	43	advmod
42	renal	renal	JJ	_	43	amod
43	cancer	cancer	NN	_	2	conj
44	.	.	.	_	2	punct

1	An	a	DT	_	3	det
2	altered	altered	JJ	_	3	amod
3	biodistribution	biodistribution	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	provide	provide	VB	_	0	ROOT
6	misleading	misleading	JJ	_	7	amod
7	information	information	NN	_	5	dobj
8	that	that	WDT	_	11	nsubj
9	can	can	MD	_	11	aux
10	either	either	CC	_	11	cc:preconj
11	mask	mask	NN	_	7	acl:relcl
12	or	or	CC	_	11	cc
13	mimic	mimic	VB	_	11	conj
14	certain	certain	JJ	_	16	amod
15	disease	disease	NN	_	16	compound
16	symptoms	symptom	NNS	_	11	dobj
17	.	.	.	_	5	punct

1	A	a	DT	_	2	det
2	method	method	NN	_	26	nsubj
3	to	to	TO	_	4	mark
4	maximize	maximize	VB	_	2	acl
5	the	the	DT	_	7	det
6	therapeutic	therapeutic	JJ	_	7	amod
7	benefit	benefit	NN	_	4	dobj
8	of	of	IN	_	9	case
9	gentamicin	gentamicin	NN	_	7	nmod
10	while	while	IN	_	11	mark
11	minimizing	minimize	VBG	_	4	advcl
12	the	the	DT	_	13	det
13	risk	risk	NN	_	11	dobj
14	of	of	IN	_	15	case
15	nephrotoxicity	nephrotoxicity	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	the	the	DT	_	18	det
18	appearance	appearance	NN	_	13	conj
19	of	of	IN	_	22	case
20	a	a	DT	_	22	det
21	hot	hot	JJ	_	22	amod
22	kidney	kidney	NN	_	18	nmod
23	on	on	IN	_	24	case
24	scintigraphy	scintigraphy	NN	_	18	nmod
25	is	be	VBZ	_	26	cop
26	desirable	desirable	JJ	_	0	ROOT
27	.	.	.	_	26	punct

1	Serial	serial	JJ	_	3	amod
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	dosing	dosing	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	proposed	propose	VBN	_	0	ROOT
7	as	as	IN	_	9	case
8	a	a	DT	_	9	det
9	method	method	NN	_	6	nmod
10	to	to	TO	_	11	mark
11	accomplish	accomplish	VB	_	9	acl
12	this	this	DT	_	13	det
13	goal	goal	NN	_	11	dobj
14	.	.	.	_	6	punct

1	Therapeutic	therapeutic	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	monitoring	monitoring	NN	_	0	ROOT
4	(	(	CD	_	6	nummod
5	TDM	tdm	NN	_	6	compound
6	)	)	NN	_	3	dep
7	of	of	IN	_	9	case
8	gentamicin	gentamicin	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	,	,	,	_	6	punct
11	and	and	CC	_	6	cc
12	bone	bone	NN	_	13	compound
13	scintigraphy	scintigraphy	NN	_	6	conj
14	employing	employ	VBG	_	13	acl
15	99mTc	99mtc	NN	_	17	compound
16	-	-	:	_	17	punct
17	MDP	mdp	NN	_	14	dobj
18	as	as	IN	_	22	mark
19	the	the	DT	_	20	det
20	radiopharmaceutical	radiopharmaceutical	NN	_	22	nsubjpass
21	was	be	VBD	_	22	auxpass
22	carried	carry	VBN	_	14	advcl
23	out	out	RP	_	22	compound:prt
24	in	in	IN	_	26	case
25	22	22	CD	_	26	nummod
26	patients	patient	NNS	_	22	nmod
27	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	5	nsubj
3	presented	present	VBN	_	2	acl
4	here	here	RB	_	3	advmod
5	demonstrate	demonstrate	VBP	_	0	ROOT
6	that	that	IN	_	23	mark
7	with	with	IN	_	10	case
8	serial	serial	JJ	_	10	amod
9	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
10	dosing	dosing	NN	_	23	nmod
11	of	of	IN	_	12	case
12	gentamicin	gentamicin	NN	_	10	nmod
13	,	,	,	_	23	punct
14	the	the	DT	_	16	det
15	iatrogenic	iatrogenic	JJ	_	16	amod
16	alteration	alteration	NN	_	23	nsubjpass
17	caused	cause	VBN	_	16	acl
18	by	by	IN	_	20	case
19	gentamicin	gentamicin	NN	_	20	compound
20	therapy	therapy	NN	_	17	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	avoided	avoid	VBN	_	5	ccomp
24	.	.	.	_	5	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	gentamycin	gentamycin	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	atracurium	atracurium	NN	_	3	conj
6	in	in	IN	_	8	case
7	anaesthetised	anaesthetised	JJ	_	8	amod
8	horses	horse	NNS	_	1	nmod
9	.	.	.	_	1	punct

1	Evoked	evoke	VBN	_	12	nsubjpass
2	hind	hind	JJ	_	6	amod
3	limb	limb	NN	_	6	compound
4	digital	digital	JJ	_	6	amod
5	extensor	extensor	NN	_	6	compound
6	tension	tension	NN	_	1	xcomp
7	(	(	CD	_	8	nummod
8	hoof	hoof	NN	_	6	dep
9	twitch	twitch	VB	_	10	compound
10	)	)	NN	_	8	dep
11	was	be	VBD	_	12	auxpass
12	maintained	maintain	VBN	_	0	ROOT
13	at	at	IN	_	15	case
14	40	40	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	of	of	IN	_	17	case
17	baseline	baseline	NN	_	15	nmod
18	for	for	IN	_	20	case
19	1	1	CD	_	20	nummod
20	h	h	NN	_	12	nmod
21	by	by	IN	_	23	case
22	atracurium	atracurium	NN	_	23	compound
23	infusion	infusion	NN	_	12	nmod
24	in	in	IN	_	26	case
25	7	7	CD	_	26	nummod
26	horses	horse	NNS	_	23	nmod
27	anaesthetised	anaesthetise	VBN	_	26	acl
28	with	with	IN	_	29	case
29	halothane	halothane	NN	_	27	nmod
30	.	.	.	_	12	punct

1	After	after	IN	_	3	case
2	1	1	CD	_	3	nummod
3	h	h	NN	_	7	nmod
4	,	,	,	_	7	punct
5	atracurium	atracurium	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	discontinued	discontinue	VBN	_	0	ROOT
8	and	and	CC	_	7	cc
9	hoof	hoof	JJ	_	10	amod
10	twitch	twitch	VB	_	7	conj
11	allowed	allow	VBN	_	10	acl
12	to	to	TO	_	13	mark
13	recover	recover	VB	_	11	xcomp
14	to	to	TO	_	16	case
15	75	75	CD	_	16	nummod
16	%	%	NN	_	13	nmod
17	.	.	.	_	7	punct

1	Atracurium	Atracurium	NNP	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	again	again	RB	_	4	advmod
4	given	give	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	infusion	infusion	NN	_	4	nmod
7	to	to	TO	_	8	mark
8	maintain	maintain	VB	_	4	xcomp
9	40	40	CD	_	10	nummod
10	%	%	NN	_	11	nsubj
11	twitch	twitch	VB	_	8	ccomp
12	for	for	IN	_	15	case
13	a	a	DT	_	15	det
14	second	second	JJ	_	15	amod
15	hour	hour	NN	_	11	nmod
16	,	,	,	_	4	punct
17	then	then	RB	_	20	advmod
18	2	2	CD	_	19	compound
19	mg	mg	NN	_	20	amod
20	gentamycin	gentamycin	NN	_	4	dobj
21	/	/	:	_	23	punct
22	kg	kg	NN	_	23	compound
23	bwt	bwt	NN	_	25	nsubjpass
24	were	be	VBD	_	25	auxpass
25	given	give	VBN	_	20	acl:relcl
26	i	i	LS	_	28	dep
27	.	.	.	_	26	punct
28	v	v	LS	_	25	advcl
29	.	.	.	_	4	punct

1	Atracurium	Atracurium	NNP	_	2	compound
2	infusion	infusion	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	continued	continue	VBN	_	0	ROOT
5	for	for	IN	_	8	case
6	a	a	DT	_	8	det
7	third	third	JJ	_	8	amod
8	hour	hour	NN	_	4	nmod
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	then	then	RB	_	13	advmod
12	hoof	hoof	NN	_	13	compound
13	twitch	twitch	VB	_	16	nsubjpass
14	was	be	VBD	_	16	auxpass
15	again	again	RB	_	16	advmod
16	allowed	allow	VBN	_	4	conj
17	to	to	TO	_	18	mark
18	recover	recover	VB	_	16	xcomp
19	spontaneously	spontaneously	RB	_	18	advmod
20	to	to	TO	_	22	case
21	75	75	CD	_	22	nummod
22	%	%	NN	_	18	nmod
23	.	.	.	_	4	punct

1	Gentamycin	gentamycin	NN	_	2	nsubj
2	reduced	reduce	VBD	_	0	ROOT
3	twitch	twitch	VB	_	2	xcomp
4	strength	strength	NN	_	3	dobj
5	from	from	IN	_	6	case
6	40	40	CD	_	3	nmod
7	+	+	CC	_	6	cc
8	/	/	:	_	6	punct
9	-	-	:	_	8	punct
10	1	1	CD	_	11	nummod
11	%	%	NN	_	9	root
12	(	(	CD	_	13	nummod
13	mean	mean	NN	_	11	dep
14	+	+	CC	_	13	dep
15	/	/	:	_	20	punct
16	-	-	:	_	20	punct
17	sem	sem	NN	_	20	dep
18	)	)	CD	_	20	compound
19	to	to	TO	_	20	dep
20	29	29	CD	_	14	dep
21	+	+	CC	_	20	cc
22	/	/	:	_	20	punct
23	-	-	:	_	20	punct
24	4	4	CD	_	25	nummod
25	%	%	NN	_	20	dep
26	within	within	IN	_	27	case
27	7.0	7.0	CD	_	25	nmod
28	+	+	CC	_	27	cc
29	/	/	:	_	27	punct
30	-	-	:	_	29	punct
31	1.5	1.5	CD	_	32	nummod
32	min	min	NN	_	30	root
33	(	(	CD	_	34	nummod
34	P	p	NN	_	35	nsubj
35	=	=	JJ	_	32	acl:relcl
36	0.02	0.02	CD	_	37	nummod
37	)	)	NN	_	35	dobj
38	.	.	.	_	32	punct

1	Twitch	twitch	VB	_	0	ROOT
2	gradually	gradually	RB	_	3	advmod
3	returned	return	VBN	_	1	dep
4	to	to	TO	_	5	case
5	pre	pre	JJ	_	3	nmod
6	-	-	:	_	1	punct
7	gentamycin	gentamycin	NN	_	8	compound
8	strength	strength	NN	_	1	dep
9	over	over	IN	_	11	case
10	the	the	DT	_	11	det
11	course	course	NN	_	8	nmod
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	next	next	JJ	_	15	amod
15	hour	hour	NN	_	11	nmod
16	.	.	.	_	1	punct

1	Recovery	recovery	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	hoof	hoof	NN	_	1	nmod
4	twitch	twitch	VB	_	0	ROOT
5	from	from	IN	_	7	case
6	50	50	CD	_	7	nummod
7	%	%	NN	_	4	nmod
8	to	to	TO	_	10	case
9	75	75	CD	_	10	nummod
10	%	%	NN	_	7	nmod
11	took	take	VBD	_	4	dep
12	7.7	7.7	CD	_	11	dobj
13	+	+	CC	_	12	cc
14	/	/	:	_	17	punct
15	-	-	:	_	17	punct
16	0.7	0.7	CD	_	17	nummod
17	min	min	NN	_	12	conj
18	for	for	IN	_	19	case
19	atracurium	atracurium	NN	_	17	nmod
20	alone	alone	RB	_	19	advmod
21	and	and	CC	_	19	cc
22	11.5	11.5	CD	_	27	nummod
23	+	+	CC	_	22	cc
24	/	/	:	_	27	punct
25	-	-	:	_	27	punct
26	2.7	2.7	CD	_	27	nummod
27	min	min	NN	_	19	conj
28	for	for	IN	_	29	case
29	atracurium	atracurium	NN	_	27	nmod
30	plus	plus	CC	_	29	cc
31	gentamycin	gentamycin	NN	_	33	compound
32	(	(	CD	_	33	nummod
33	P	p	NN	_	29	conj
34	=	=	JJ	_	27	amod
35	0.03	0.03	CD	_	36	nummod
36	)	)	NN	_	34	dep
37	.	.	.	_	4	punct

1	Recovery	recovery	NN	_	5	nsubj
2	from	from	IN	_	4	case
3	50	50	CD	_	4	nummod
4	%	%	NN	_	1	nmod
5	twitch	twitch	VBP	_	0	ROOT
6	to	to	TO	_	10	case
7	75	75	CD	_	8	compound
8	%	%	NN	_	10	amod
9	fade	fade	VB	_	10	compound
10	recovery	recovery	NN	_	5	nmod
11	took	take	VBD	_	5	dep
12	13.8	13.8	CD	_	11	dobj
13	+	+	CC	_	12	cc
14	/	/	:	_	17	punct
15	-	-	:	_	17	punct
16	0.8	0.8	CD	_	17	nummod
17	min	min	NN	_	12	conj
18	for	for	IN	_	19	case
19	atracurium	atracurium	NN	_	17	nmod
20	alone	alone	RB	_	19	advmod
21	and	and	CC	_	19	cc
22	13.7	13.7	CD	_	27	nummod
23	+	+	CC	_	22	cc
24	/	/	:	_	27	punct
25	-	-	:	_	27	punct
26	1.2	1.2	CD	_	27	nummod
27	min	min	NN	_	19	conj
28	for	for	IN	_	29	case
29	atracurium	atracurium	NN	_	27	nmod
30	plus	plus	CC	_	29	cc
31	gentamycin	gentamycin	NN	_	29	conj
32	.	.	.	_	5	punct

1	At	at	IN	_	4	case
2	75	75	CD	_	3	compound
3	%	%	NN	_	4	amod
4	recovery	recovery	NN	_	0	ROOT
5	of	of	IN	_	6	case
6	fade	fade	VB	_	4	nmod
7	,	,	,	_	4	punct
8	hoof	hoof	JJ	_	9	amod
9	twitch	twitch	VB	_	7	root
10	was	be	VBD	_	9	dep
11	87	87	CD	_	10	nsubj
12	+	+	CC	_	11	cc
13	/	/	:	_	11	punct
14	-	-	:	_	13	punct
15	3	3	CD	_	16	nummod
16	%	%	NN	_	14	root
17	for	for	IN	_	18	case
18	atracurium	atracurium	NN	_	16	nmod
19	alone	alone	RB	_	18	advmod
20	and	and	CC	_	18	cc
21	82	82	CD	_	18	conj
22	+	+	CC	_	21	cc
23	/	/	:	_	21	punct
24	-	-	:	_	23	punct
25	4	4	CD	_	26	nummod
26	%	%	NN	_	24	root
27	for	for	IN	_	28	case
28	atracurium	atracurium	NN	_	26	nmod
29	plus	plus	CC	_	28	cc
30	gentamycin	gentamycin	NN	_	28	conj
31	.	.	.	_	26	punct

1	Reversal	reversal	NN	_	16	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	block	block	NN	_	1	nmod
5	with	with	IN	_	6	case
6	edrophonium	edrophonium	NN	_	1	nmod
7	and	and	CC	_	6	cc
8	subsequent	subsequent	JJ	_	9	amod
9	recovery	recovery	NN	_	6	conj
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	horses	horse	NNS	_	6	nmod
13	from	from	IN	_	14	case
14	anaesthesia	anaesthesia	NN	_	12	nmod
15	were	be	VBD	_	16	cop
16	uneventful	uneventful	JJ	_	0	ROOT
17	.	.	.	_	16	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	concluded	conclude	VBN	_	0	ROOT
4	that	that	IN	_	19	mark
5	,	,	,	_	19	punct
6	although	although	IN	_	9	mark
7	gentamycin	gentamycin	NN	_	9	nsubj
8	did	do	VBD	_	9	aux
9	augment	augment	VB	_	19	advcl
10	the	the	DT	_	12	det
11	neuromuscular	neuromuscular	JJ	_	12	amod
12	blockade	blockade	NN	_	9	dobj
13	of	of	IN	_	14	case
14	atracurium	atracurium	NN	_	12	nmod
15	,	,	,	_	19	punct
16	the	the	DT	_	17	det
17	effect	effect	NN	_	19	nsubj
18	was	be	VBD	_	19	cop
19	minimal	minimal	JJ	_	3	ccomp
20	.	.	.	_	3	punct

1	Diagnostic	diagnostic	JJ	_	0	ROOT
2	,	,	,	_	1	punct
3	treatment	treatment	NN	_	2	root
4	and	and	CC	_	3	cc
5	aftercare	aftercare	JJ	_	6	amod
6	approaches	approach	NNS	_	3	conj
7	to	to	TO	_	9	case
8	cocaine	cocaine	NN	_	9	compound
9	abuse	abuse	NN	_	6	nmod
10	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	general	general	JJ	_	3	amod
3	public	public	JJ	_	4	nsubj
4	feels	feel	VBZ	_	0	ROOT
5	that	that	IN	_	10	mark
6	cocaine	cocaine	NN	_	10	nsubj
7	is	be	VBZ	_	10	cop
8	not	not	RB	_	10	neg
9	particularly	particularly	RB	_	10	advmod
10	dangerous	dangerous	JJ	_	4	ccomp
11	because	because	IN	_	15	mark
12	it	it	PRP	_	15	nsubj
13	does	do	VBZ	_	15	aux
14	not	not	RB	_	15	neg
15	produce	produce	VB	_	10	advcl
16	a	a	DT	_	20	det
17	well	well	RB	_	18	advmod
18	defined	define	VBN	_	20	amod
19	physical	physical	JJ	_	20	amod
20	dependency	dependency	NN	_	15	dobj
21	and	and	CC	_	20	cc
22	abstinence	abstinence	NN	_	23	compound
23	syndrome	syndrome	NN	_	20	conj
24	.	.	.	_	4	punct

1	However	however	RB	_	27	advmod
2	,	,	,	_	27	punct
3	when	when	WRB	_	6	advmod
4	addiction	addiction	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	defined	define	VBN	_	27	advcl
7	as	as	IN	_	8	case
8	compulsion	compulsion	NN	_	6	nmod
9	,	,	,	_	27	punct
10	loss	loss	NN	_	27	dep
11	of	of	IN	_	12	case
12	control	control	NN	_	10	nmod
13	and	and	CC	_	10	cc
14	continued	continue	VBD	_	15	amod
15	use	use	NN	_	10	conj
16	in	in	IN	_	17	case
17	spite	spite	NN	_	15	nmod
18	of	of	IN	_	20	case
19	adverse	adverse	JJ	_	20	amod
20	consequences	consequence	NNS	_	17	nmod
21	,	,	,	_	27	punct
22	cocaine	cocaine	NN	_	24	compound
23	drug	drug	NN	_	24	compound
24	hunger	hunger	NN	_	27	nsubjpass
25	can	can	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	seen	see	VBN	_	0	ROOT
28	as	as	IN	_	30	case
29	an	a	DT	_	30	det
30	agent	agent	NN	_	27	nmod
31	of	of	IN	_	33	case
32	addictive	addictive	JJ	_	33	amod
33	disease	disease	NN	_	30	nmod
34	.	.	.	_	27	punct

1	Withdrawal	withdrawal	NN	_	6	nsubj
2	from	from	IN	_	4	case
3	cocaine	cocaine	NN	_	4	compound
4	dependence	dependence	NN	_	1	nmod
5	usually	usually	RB	_	6	advmod
6	involves	involve	VBZ	_	0	ROOT
7	depression	depression	NN	_	6	dobj
8	,	,	,	_	7	punct
9	anxiety	anxiety	NN	_	7	conj
10	and	and	CC	_	7	cc
11	lethargy	lethargy	NN	_	7	conj
12	.	.	.	_	6	punct

1	These	these	DT	_	3	nsubj
2	usually	usually	RB	_	3	advmod
3	clear	clear	JJ	_	0	ROOT
4	within	within	IN	_	6	case
5	a	a	DT	_	6	det
6	week	week	NN	_	3	nmod
7	,	,	,	_	3	punct
8	leaving	leave	VBG	_	3	xcomp
9	only	only	RB	_	11	advmod
10	the	the	DT	_	11	det
11	&quot	&quot	NN	_	8	dobj
12	;	;	:	_	3	punct
13	drug	drug	NN	_	14	compound
14	hunger&quot	hunger&quot	NN	_	3	dep
15	;	;	:	_	3	punct

1	to	to	TO	_	2	mark
2	contend	contend	VB	_	0	ROOT
3	with	with	IN	_	2	nmod
4	.	.	.	_	2	punct

1	Medication	medication	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	rarely	rarely	RB	_	4	advmod
4	needed	need	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	When	when	WRB	_	6	advmod
2	cocaine	cocaine	NN	_	6	nsubj
3	is	be	VBZ	_	6	cop
4	the	the	DT	_	6	det
5	primary	primary	JJ	_	6	amod
6	addiction	addiction	NN	_	16	advcl
7	,	,	,	_	16	punct
8	after	after	IN	_	9	case
9	withdrawal	withdrawal	NN	_	16	nmod
10	the	the	DT	_	13	det
11	most	most	RBS	_	12	advmod
12	effective	effective	JJ	_	13	amod
13	treatment	treatment	NN	_	16	nsubj
14	is	be	VBZ	_	16	cop
15	group	group	NN	_	16	compound
16	therapy	therapy	NN	_	0	ROOT
17	with	with	IN	_	21	case
18	other	other	JJ	_	21	amod
19	recovering	recover	VBG	_	21	amod
20	cocaine	cocaine	NN	_	21	compound
21	abusers	abuser	NNS	_	16	nmod
22	.	.	.	_	16	punct

1	We	we	PRP	_	2	nsubj
2	incorporate	incorporate	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	principles	principle	NNS	_	2	dobj
5	of	of	IN	_	6	case
6	recovery	recovery	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	define	define	VB	_	2	conj
9	positive	positive	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	constructive	constructive	JJ	_	9	conj
12	alternatives	alternative	NNS	_	8	dobj
13	in	in	IN	_	14	mark
14	dealing	deal	VBG	_	12	acl
15	with	with	IN	_	17	case
16	cocaine	cocaine	NN	_	17	compound
17	hunger	hunger	NN	_	14	nmod
18	.	.	.	_	2	punct

1	Recovery	recovery	NN	_	2	compound
2	programs	program	NNS	_	5	nsubj
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	cop
5	flexible	flexible	JJ	_	0	ROOT
6	and	and	CC	_	5	cc
7	involve	involve	VB	_	5	conj
8	individual	individual	JJ	_	11	amod
9	and	and	CC	_	8	cc
10	family	family	NN	_	8	conj
11	education	education	NN	_	7	dobj
12	on	on	IN	_	13	case
13	recovery	recovery	NN	_	11	nmod
14	and	and	CC	_	11	cc
15	the	the	DT	_	16	det
16	nature	nature	NN	_	11	conj
17	of	of	IN	_	19	case
18	addictive	addictive	JJ	_	19	amod
19	disease	disease	NN	_	16	nmod
20	.	.	.	_	5	punct

1	Exercise	exercise	NN	_	9	nsubj
2	that	that	WDT	_	3	nsubj
3	produces	produce	VBZ	_	1	acl:relcl
4	cardiopulmonary	cardiopulmonary	JJ	_	5	amod
5	stimulation	stimulation	NN	_	3	dobj
6	is	be	VBZ	_	9	cop
7	a	a	DT	_	9	det
8	helpful	helpful	JJ	_	9	amod
9	means	means	NNS	_	0	ROOT
10	of	of	IN	_	11	mark
11	reducing	reduce	VBG	_	9	acl
12	drug	drug	NN	_	13	compound
13	hunger	hunger	NN	_	11	dobj
14	and	and	CC	_	13	cc
15	anxiety	anxiety	NN	_	13	conj
16	during	during	IN	_	18	case
17	recovery	recovery	NN	_	18	compound
18	therapy	therapy	NN	_	11	nmod
19	.	.	.	_	9	punct

1	Systemic	systemic	JJ	_	3	amod
2	antibiotic	antibiotic	JJ	_	3	amod
3	agents	agent	NNS	_	0	ROOT
4	.	.	.	_	3	punct

1	Understanding	understand	VBG	_	0	ROOT
2	the	the	DT	_	3	det
3	breadth	breadth	NN	_	1	dobj
4	of	of	IN	_	7	case
5	systemic	systemic	JJ	_	7	amod
6	antimicrobial	antimicrobial	JJ	_	7	amod
7	agents	agent	NNS	_	3	nmod
8	available	available	JJ	_	7	amod
9	for	for	IN	_	10	case
10	use	use	NN	_	8	nmod
11	by	by	IN	_	13	case
12	the	the	DT	_	13	det
13	dermatologist	dermatologist	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	their	they	PRP$	_	17	nmod:poss
16	associated	associated	JJ	_	17	amod
17	side	side	NN	_	13	conj
18	-	-	:	_	1	punct
19	effect	effect	NN	_	20	compound
20	profiles	profile	NNS	_	24	nsubj
21	and	and	CC	_	20	cc
22	drug	drug	NN	_	23	compound
23	interactions	interaction	NNS	_	20	conj
24	allows	allow	VBZ	_	1	parataxis
25	the	the	DT	_	26	det
26	clinician	clinician	NN	_	24	dobj
27	to	to	TO	_	28	mark
28	offer	offer	VB	_	24	xcomp
29	patients	patient	NNS	_	31	compound
30	optimal	optimal	JJ	_	31	amod
31	care	care	NN	_	28	dobj
32	in	in	IN	_	34	case
33	the	the	DT	_	34	det
34	management	management	NN	_	28	nmod
35	of	of	IN	_	38	case
36	cutaneous	cutaneous	JJ	_	38	amod
37	infectious	infectious	JJ	_	38	amod
38	disease	disease	NN	_	34	nmod
39	.	.	.	_	1	punct

1	Altered	altered	JJ	_	2	amod
2	responsiveness	responsiveness	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	alcohol	alcohol	NN	_	2	nmod
5	after	after	IN	_	6	case
6	exposure	exposure	NN	_	2	nmod
7	to	to	TO	_	9	case
8	organic	organic	JJ	_	9	amod
9	lead	lead	NN	_	6	nmod
10	.	.	.	_	2	punct

1	Ethyl	Ethyl	NNP	_	2	compound
2	alcohol	alcohol	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	effect	effect	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	functional	functional	JJ	_	9	amod
9	integrity	integrity	NN	_	6	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	limbic	limbic	JJ	_	13	amod
13	system	system	NN	_	9	nmod
14	,	,	,	_	6	punct
15	particularly	particularly	RB	_	17	advmod
16	the	the	DT	_	17	det
17	hippocampus	hippocampus	NN	_	6	dobj
18	,	,	,	_	17	punct
19	and	and	CC	_	17	cc
20	to	to	TO	_	21	mark
21	alter	alter	VB	_	17	conj
22	behaviors	behavior	NNS	_	21	dobj
23	which	which	WDT	_	25	nsubjpass
24	are	be	VBP	_	25	auxpass
25	thought	think	VBN	_	22	acl:relcl
26	to	to	TO	_	28	mark
27	be	be	VB	_	28	auxpass
28	mediated	mediate	VBN	_	25	xcomp
29	through	through	IN	_	31	case
30	limbic	limbic	JJ	_	31	amod
31	function	function	NN	_	28	nmod
32	.	.	.	_	4	punct

1	Organometals	organometal	NNS	_	3	nsubj
2	also	also	RB	_	3	advmod
3	compromise	compromise	VBP	_	0	ROOT
4	the	the	DT	_	6	det
5	limbic	limbic	JJ	_	6	amod
6	system	system	NN	_	3	dobj
7	and	and	CC	_	6	cc
8	result	result	NN	_	6	conj
9	in	in	IN	_	10	case
10	deficits	deficit	NNS	_	6	nmod
11	in	in	IN	_	12	case
12	learning	learning	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	memory	memory	NN	_	12	conj
15	.	.	.	_	3	punct

1	Since	since	IN	_	7	mark
2	both	both	DT	_	3	cc:preconj
3	alcohol	alcohol	NN	_	7	nsubj
4	and	and	CC	_	3	cc
5	organoleads	organolead	NNS	_	3	conj
6	are	be	VBP	_	7	cop
7	present	present	JJ	_	25	advcl
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	environment	environment	NN	_	7	nmod
11	and	and	CC	_	7	cc
12	seem	seem	VBP	_	7	conj
13	to	to	TO	_	14	mark
14	influence	influence	VB	_	12	xcomp
15	limbic	limbic	JJ	_	16	amod
16	integration	integration	NN	_	14	dobj
17	,	,	,	_	25	punct
18	the	the	DT	_	19	det
19	interaction	interaction	NN	_	25	nsubjpass
20	of	of	IN	_	23	case
21	these	these	DT	_	23	det
22	two	two	CD	_	23	nummod
23	compounds	compound	NNS	_	19	nmod
24	was	be	VBD	_	25	auxpass
25	assessed	assess	VBN	_	0	ROOT
26	in	in	IN	_	29	case
27	the	the	DT	_	29	det
28	present	present	JJ	_	29	amod
29	experiment	experiment	NN	_	25	nmod
30	.	.	.	_	25	punct

1	Thirty	thirty	CD	_	3	nummod
2	male	male	JJ	_	3	amod
3	rats	rat	NNS	_	0	ROOT
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	Fischer	Fischer	NNP	_	3	nmod
7	-	-	:	_	3	punct
8	344	344	CD	_	9	nummod
9	strain	strain	NN	_	11	nsubjpass
10	were	be	VBD	_	11	auxpass
11	divided	divide	VBN	_	3	dep
12	into	into	IN	_	15	case
13	three	three	CD	_	15	nummod
14	equal	equal	JJ	_	15	amod
15	groups	group	NNS	_	11	nmod
16	and	and	CC	_	11	cc
17	were	be	VBD	_	18	auxpass
18	given	give	VBN	_	11	conj
19	injections	injection	NNS	_	18	dobj
20	of	of	IN	_	24	case
21	trimethyl	trimethyl	NN	_	24	compound
22	lead	lead	NN	_	24	compound
23	(	(	CD	_	24	nummod
24	TML	tml	NN	_	19	nmod
25	)	)	CD	_	26	compound
26	(	(	CD	_	27	nummod
27	8.0	8.0	CD	_	30	nummod
28	or	or	CC	_	27	cc
29	17.0	17.0	CD	_	27	conj
30	mg	mg	NN	_	24	dep
31	/	/	:	_	30	punct
32	kg	kg	NN	_	30	dep
33	/	/	:	_	30	punct
34	ml	ml	NN	_	35	compound
35	SC	sc	NN	_	30	dep
36	)	)	CD	_	35	nummod
37	or	or	CC	_	35	cc
38	the	the	DT	_	40	det
39	saline	saline	NN	_	40	compound
40	vehicle	vehicle	NN	_	35	conj
41	.	.	.	_	3	punct

1	Fourteen	fourteen	CD	_	2	nummod
2	days	day	NNS	_	3	nmod:npmod
3	later	later	RB	_	8	advmod
4	,	,	,	_	8	punct
5	all	all	DT	_	6	det
6	animals	animal	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	challenged	challenge	VBN	_	0	ROOT
9	with	with	IN	_	13	case
10	a	a	DT	_	13	det
11	single	single	JJ	_	13	amod
12	hypnotic	hypnotic	JJ	_	13	amod
13	dose	dose	NN	_	8	nmod
14	of	of	IN	_	15	case
15	ethanol	ethanol	NN	_	13	nmod
16	(	(	CD	_	17	compound
17	3.5	3.5	CD	_	15	nummod
18	g	g	NN	_	15	dep
19	/	/	:	_	13	punct
20	kg	kg	NN	_	21	compound
21	IP	IP	NNP	_	13	dep
22	)	)	CD	_	21	nummod
23	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	20	20	CD	_	3	nummod
3	%	%	NN	_	4	nsubj
4	v	v	LS	_	0	ROOT
5	/	/	:	_	4	punct
6	v	v	LS	_	11	dep
7	solution	solution	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	alcohol	alcohol	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	prepared	prepare	VBN	_	4	ccomp
12	in	in	IN	_	13	case
13	water	water	NN	_	11	nmod
14	from	from	IN	_	17	case
15	a	a	DT	_	17	det
16	stock	stock	NN	_	17	compound
17	solution	solution	NN	_	11	nmod
18	of	of	IN	_	21	case
19	95	95	CD	_	20	compound
20	%	%	NN	_	21	amod
21	ethanol	ethanol	NN	_	17	nmod
22	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	latency	latency	NN	_	15	nsubjpass
3	to	to	TO	_	4	case
4	loss	loss	NN	_	2	nmod
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	righting	right	VBG	_	8	amod
8	reflex	reflex	JJ	_	4	nmod
9	and	and	CC	_	4	cc
10	duration	duration	NN	_	4	conj
11	of	of	IN	_	13	case
12	sleep	sleep	NN	_	13	compound
13	time	time	NN	_	10	nmod
14	were	be	VBD	_	15	auxpass
15	recorded	record	VBN	_	0	ROOT
16	while	while	IN	_	20	mark
17	the	the	DT	_	18	det
18	rats	rat	NNS	_	20	nsubjpass
19	were	be	VBD	_	20	auxpass
20	kept	keep	VBN	_	15	advcl
21	in	in	IN	_	22	case
22	sound	sound	NN	_	20	nmod
23	-	-	:	_	15	punct
24	attenuating	attenuate	VBG	_	15	xcomp
25	chambers	chamber	NNS	_	24	dobj
26	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	rats	rat	NNS	_	10	nsubj
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	highest	highest	JJS	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	9	case
9	TML	tml	NN	_	7	nmod
10	manifested	manifest	VBN	_	0	ROOT
11	significantly	significantly	RB	_	12	advmod
12	longer	longer	RBR	_	13	amod
13	latencies	latency	NNS	_	10	dobj
14	to	to	TO	_	15	mark
15	lose	lose	VB	_	10	xcomp
16	the	the	DT	_	21	det
17	righting	right	VBG	_	21	amod
18	reflex	reflex	JJ	_	21	amod
19	and	and	CC	_	18	cc
20	shorter	shorter	JJR	_	18	conj
21	durations	duration	NNS	_	15	dobj
22	of	of	IN	_	23	case
23	sleep	sleep	NN	_	21	nmod
24	than	than	IN	_	25	dep
25	did	do	VBD	_	10	advcl
26	controls	control	NNS	_	25	nsubj
27	.	.	.	_	10	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	exposure	exposure	NN	_	10	nsubj
6	to	to	TO	_	8	case
7	environmental	environmental	JJ	_	8	amod
8	lead	lead	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	alter	alter	VB	_	3	ccomp
11	the	the	DT	_	15	det
12	biological	biological	JJ	_	15	amod
13	and	and	CC	_	12	cc
14	behavioral	behavioral	JJ	_	12	conj
15	responsiveness	responsiveness	NN	_	10	dobj
16	of	of	IN	_	18	case
17	an	a	DT	_	18	det
18	animal	animal	NN	_	15	nmod
19	to	to	TO	_	20	case
20	alcohol	alcohol	NN	_	15	nmod
21	.	.	.	_	3	punct

1	Evidence	evidence	NN	_	0	ROOT
2	for	for	IN	_	3	case
3	reduction	reduction	NN	_	1	nmod
4	of	of	IN	_	7	case
5	norepinephrine	norepinephrine	NN	_	7	compound
6	uptake	uptake	NN	_	7	compound
7	sites	site	NNS	_	3	nmod
8	in	in	IN	_	12	case
9	the	the	DT	_	12	det
10	failing	fail	VBG	_	12	amod
11	human	human	JJ	_	12	amod
12	heart	heart	NN	_	3	nmod
13	.	.	.	_	1	punct

1	OBJECTIVES	objective	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	investigated	investigate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	role	role	NN	_	3	dobj
6	of	of	IN	_	8	case
7	neuronal	neuronal	JJ	_	8	amod
8	uptake	uptake	NN	_	5	nmod
9	of	of	IN	_	12	case
10	norepinephrine	norepinephrine	NN	_	12	compound
11	(	(	CD	_	12	nummod
12	uptake	uptake	NN	_	8	nmod
13	-	-	:	_	12	punct
14	1	1	CD	_	15	nummod
15	)	)	NN	_	12	dep
16	in	in	IN	_	19	case
17	human	human	JJ	_	19	amod
18	heart	heart	NN	_	19	compound
19	failure	failure	NN	_	15	nmod
20	as	as	IN	_	23	case
21	a	a	DT	_	23	det
22	local	local	JJ	_	23	amod
23	factor	factor	NN	_	15	nmod
24	for	for	IN	_	26	case
25	altering	alter	VBG	_	26	amod
26	concentrations	concentration	NNS	_	23	nmod
27	of	of	IN	_	28	case
28	norepinephrine	norepinephrine	NN	_	26	nmod
29	at	at	IN	_	33	case
30	the	the	DT	_	33	det
31	cardiac	cardiac	JJ	_	33	amod
32	myocyte	myocyte	NN	_	33	compound
33	membranes	membrane	NNS	_	26	nmod
34	.	.	.	_	3	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	.	.	.	_	1	punct

1	Several	several	JJ	_	2	amod
2	beta	beta	NN	_	7	nsubj
3	-	-	:	_	2	punct
4	adrenergic	adrenergic	JJ	_	6	amod
5	neuroeffector	neuroeffector	NN	_	6	compound
6	defects	defect	NNS	_	2	dep
7	occur	occur	VBP	_	0	ROOT
8	in	in	IN	_	10	case
9	heart	heart	NN	_	10	compound
10	failure	failure	NN	_	7	nmod
11	.	.	.	_	7	punct

1	Whether	whether	IN	_	3	case
2	an	a	DT	_	3	det
3	alteration	alteration	NN	_	9	nmod
4	in	in	IN	_	6	case
5	norepinephrine	norepinephrine	NN	_	6	compound
6	uptake	uptake	NN	_	3	nmod
7	-	-	:	_	9	punct
8	1	1	CD	_	9	nsubj
9	occurs	occur	VBZ	_	12	csubj
10	is	be	VBZ	_	12	cop
11	still	still	RB	_	12	advmod
12	unresolved	unresolved	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	METHODS	method	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	role	role	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	norepinephrine	norepinephrine	NN	_	5	compound
5	uptake	uptake	NN	_	2	nmod
6	-	-	:	_	2	punct
7	1	1	CD	_	2	nummod
8	was	be	VBD	_	9	auxpass
9	studied	study	VBN	_	0	ROOT
10	in	in	IN	_	15	case
11	electrically	electrically	RB	_	12	advmod
12	stimulated	stimulate	VBN	_	15	amod
13	(	(	NN	_	15	compound
14	1	1	CD	_	15	nummod
15	Hz	hz	NN	_	9	nmod
16	,	,	,	_	15	punct
17	37	37	CD	_	24	nummod
18	degrees	degree	NNS	_	24	compound
19	C	c	NN	_	24	compound
20	)	)	CD	_	24	nummod
21	human	human	JJ	_	24	amod
22	ventricular	ventricular	JJ	_	24	amod
23	cardiac	cardiac	JJ	_	24	amod
24	preparations	preparation	NNS	_	15	conj
25	and	and	CC	_	15	cc
26	isolated	isolate	VBN	_	28	amod
27	myocardial	myocardial	JJ	_	28	amod
28	membranes	membrane	NNS	_	15	conj
29	.	.	.	_	9	punct

1	RESULTS	result	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effectiveness	effectiveness	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	norepinephrine	norepinephrine	NN	_	2	nmod
5	in	in	IN	_	6	mark
6	increasing	increase	VBG	_	2	acl
7	the	the	DT	_	8	det
8	force	force	NN	_	6	dobj
9	of	of	IN	_	10	case
10	contraction	contraction	NN	_	8	nmod
11	was	be	VBD	_	12	auxpass
12	decreased	decrease	VBN	_	0	ROOT
13	in	in	IN	_	14	case
14	relation	relation	NN	_	12	nmod
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	degree	degree	NN	_	14	nmod
18	of	of	IN	_	20	case
19	heart	heart	NN	_	20	compound
20	failure	failure	NN	_	17	nmod
21	.	.	.	_	12	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	9	nmod
3	,	,	,	_	9	punct
4	the	the	DT	_	5	det
5	potency	potency	NN	_	9	nsubjpass
6	of	of	IN	_	7	case
7	norepinephrine	norepinephrine	NN	_	5	nmod
8	was	be	VBD	_	9	auxpass
9	increased	increase	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	failing	fail	VBG	_	12	amod
12	hearts	heart	NNS	_	9	nmod
13	(	(	CD	_	21	nummod
14	New	New	NNP	_	21	compound
15	York	York	NNP	_	21	compound
16	Heart	Heart	NNP	_	21	compound
17	Association	Association	NNP	_	21	compound
18	functional	functional	JJ	_	21	amod
19	class	class	NN	_	21	compound
20	IV	iv	CD	_	21	nummod
21	)	)	NN	_	12	dep
22	in	in	IN	_	23	case
23	relation	relation	NN	_	21	nmod
24	to	to	TO	_	26	case
25	the	the	DT	_	26	det
26	concentrations	concentration	NNS	_	23	nmod
27	producing	produce	VBG	_	26	acl
28	50	50	CD	_	29	nummod
29	%	%	NN	_	27	dobj
30	of	of	IN	_	33	case
31	the	the	DT	_	33	det
32	maximal	maximal	JJ	_	33	amod
33	effect	effect	NN	_	29	nmod
34	(	(	CD	_	36	nummod
35	EC50	ec50	NN	_	36	compound
36	)	)	NN	_	33	dep
37	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	EC50	ec50	NN	_	3	compound
3	values	value	NNS	_	19	nsubjpass
4	for	for	IN	_	5	case
5	isoproterenol	isoproterenol	NN	_	3	nmod
6	,	,	,	_	5	punct
7	which	which	WDT	_	11	nsubj
8	is	be	VBZ	_	11	cop
9	not	not	RB	_	11	neg
10	a	a	DT	_	11	det
11	substrate	substrate	NN	_	5	acl:relcl
12	for	for	IN	_	14	case
13	norepinephrine	norepinephrine	NN	_	14	compound
14	uptake	uptake	NN	_	11	nmod
15	-	-	:	_	3	punct
16	1	1	CD	_	3	dep
17	,	,	,	_	3	punct
18	were	be	VBD	_	19	auxpass
19	reduced	reduce	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	myocardium	myocardium	NN	_	19	nmod
22	in	in	IN	_	24	case
23	functional	functional	JJ	_	24	amod
24	classes	class	NNS	_	19	nmod
25	II	ii	CD	_	24	nummod
26	to	to	TO	_	24	dep
27	III	iii	CD	_	24	nummod
28	and	and	CC	_	24	cc
29	IV	iv	CD	_	24	conj
30	compared	compare	VBN	_	32	case
31	with	with	IN	_	32	case
32	those	those	DT	_	19	advcl
33	in	in	IN	_	35	case
34	nonfailing	nonfailing	JJ	_	35	amod
35	myocardium	myocardium	NN	_	32	nmod
36	.	.	.	_	19	punct

1	The	the	DT	_	3	det
2	uptake	uptake	NN	_	3	compound
3	inhibitors	inhibitor	NNS	_	13	nsubj
4	cocaine	cocaine	NN	_	3	dep
5	and	and	CC	_	4	cc
6	desipramine	desipramine	NN	_	9	compound
7	(	(	CD	_	8	compound
8	3	3	CD	_	9	nummod
9	mumol	mumol	NN	_	4	conj
10	/	/	:	_	3	punct
11	liter	liter	NN	_	12	compound
12	)	)	NN	_	3	dep
13	potentiated	potentiate	VBD	_	0	ROOT
14	the	the	DT	_	17	det
15	positive	positive	JJ	_	17	amod
16	inotropic	inotropic	JJ	_	17	amod
17	effects	effect	NNS	_	13	dobj
18	of	of	IN	_	19	case
19	norepinephrine	norepinephrine	NN	_	17	nmod
20	in	in	IN	_	25	case
21	nonfailing	nonfailing	JJ	_	25	amod
22	myocardium	myocardium	NN	_	25	compound
23	(	(	NN	_	25	compound
24	p	p	NN	_	25	compound
25	&lt	&lt	NN	_	17	nmod
26	;	;	:	_	13	punct
27	0.05	0.05	CD	_	28	nummod
28	)	)	NN	_	13	dep
29	but	but	CC	_	28	cc
30	not	not	RB	_	35	neg
31	in	in	IN	_	35	case
32	functional	functional	JJ	_	35	amod
33	class	class	NN	_	35	compound
34	IV	iv	CD	_	35	nummod
35	myocardium	myocardium	NN	_	28	conj
36	.	.	.	_	13	punct

1	Radioligand	radioligand	NN	_	3	compound
2	binding	binding	NN	_	3	compound
3	experiments	experiment	NNS	_	12	nsubj
4	using	use	VBG	_	3	acl
5	the	the	DT	_	8	det
6	uptake	uptake	NN	_	8	compound
7	inhibitor	inhibitor	NN	_	8	compound
8	hydrogen	hydrogen	NN	_	4	dobj
9	-	-	:	_	8	punct
10	3	3	CD	_	11	nummod
11	mazindol	mazindol	NN	_	8	dep
12	revealed	reveal	VBD	_	0	ROOT
13	a	a	DT	_	15	det
14	significant	significant	JJ	_	15	amod
15	decrease	decrease	NN	_	12	dobj
16	by	by	IN	_	19	case
17	approximately	approximately	RB	_	18	advmod
18	30	30	CD	_	19	nummod
19	%	%	NN	_	15	nmod
20	in	in	IN	_	22	case
21	norepinephrine	norepinephrine	NN	_	22	compound
22	uptake	uptake	NN	_	15	nmod
23	-	-	:	_	15	punct
24	1	1	CD	_	26	nummod
25	carrier	carrier	NN	_	26	compound
26	density	density	NN	_	15	dep
27	in	in	IN	_	29	case
28	functional	functional	JJ	_	29	amod
29	classes	class	NNS	_	26	nmod
30	II	ii	CD	_	29	nummod
31	to	to	TO	_	29	dep
32	III	iii	CD	_	29	dep
33	and	and	CC	_	26	cc
34	IV	iv	CD	_	35	nummod
35	myocardium	myocardium	NN	_	26	conj
36	versus	versus	CC	_	35	cc
37	nonfailing	nonfailing	JJ	_	41	amod
38	myocardium	myocardium	NN	_	41	compound
39	(	(	NN	_	41	compound
40	p	p	NN	_	41	compound
41	&lt	&lt	NN	_	35	conj
42	;	;	:	_	15	punct
43	0.05	0.05	CD	_	44	compound
44	)	)	CD	_	15	dep
45	.	.	.	_	12	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	human	human	JJ	_	4	amod
3	heart	heart	NN	_	4	compound
4	failure	failure	NN	_	7	nmod
5	,	,	,	_	7	punct
6	there	there	EX	_	7	expl
7	is	be	VBZ	_	0	ROOT
8	a	a	DT	_	10	det
9	presynaptic	presynaptic	JJ	_	10	amod
10	defect	defect	NN	_	7	nsubj
11	in	in	IN	_	15	case
12	the	the	DT	_	15	det
13	sympathetic	sympathetic	JJ	_	15	amod
14	nervous	nervous	JJ	_	15	amod
15	system	system	NN	_	10	nmod
16	,	,	,	_	10	punct
17	leading	lead	VBG	_	10	acl
18	to	to	TO	_	20	case
19	reduced	reduce	VBN	_	20	amod
20	uptake	uptake	NN	_	17	nmod
21	-	-	:	_	10	punct
22	1	1	CD	_	23	nummod
23	activity	activity	NN	_	10	dep
24	.	.	.	_	7	punct

1	This	this	DT	_	2	det
2	defect	defect	NN	_	9	nsubjpass
3	in	in	IN	_	6	case
4	the	the	DT	_	6	det
5	failing	fail	VBG	_	6	amod
6	heart	heart	NN	_	2	nmod
7	can	can	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	mimicked	mimic	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	9	nmod
13	of	of	IN	_	14	case
14	uptake	uptake	NN	_	12	nmod
15	blocking	block	VBG	_	16	compound
16	agents	agent	NNS	_	14	dep
17	,	,	,	_	14	punct
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	cocaine	cocaine	NN	_	14	nmod
21	and	and	CC	_	20	cc
22	desipramine	desipramine	NN	_	20	conj
23	,	,	,	_	14	punct
24	in	in	IN	_	27	case
25	the	the	DT	_	27	det
26	nonfailing	nonfailing	JJ	_	27	amod
27	heart	heart	NN	_	14	nmod
28	only	only	RB	_	27	advmod
29	.	.	.	_	9	punct

1	Compromised	compromise	VBN	_	3	amod
2	norepinephrine	norepinephrine	NN	_	3	compound
3	uptake	uptake	NN	_	13	nsubjpass
4	-	-	:	_	3	punct
5	1	1	CD	_	3	nummod
6	in	in	IN	_	10	case
7	functional	functional	JJ	_	10	amod
8	class	class	NN	_	10	compound
9	IV	iv	CD	_	10	nummod
10	cannot	cannot	NN	_	3	nmod
11	be	be	VB	_	13	auxpass
12	further	further	RB	_	13	advmod
13	increased	increase	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	cocaine	cocaine	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	desipramine	desipramine	NN	_	15	conj
18	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	pathophysiologic	pathophysiologic	JJ	_	3	amod
3	consequences	consequence	NNS	_	9	nsubj
4	could	could	MD	_	9	aux
5	be	be	VB	_	9	cop
6	an	a	DT	_	9	det
7	increased	increase	VBN	_	9	amod
8	synaptic	synaptic	JJ	_	9	amod
9	concentration	concentration	NN	_	0	ROOT
10	of	of	IN	_	11	case
11	norepinephrine	norepinephrine	NN	_	9	nmod
12	predisposing	predispose	VBG	_	11	acl
13	to	to	TO	_	16	case
14	adenylyl	adenylyl	JJ	_	16	amod
15	cyclase	cyclase	NN	_	16	compound
16	desensitization	desensitization	NN	_	12	nmod
17	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	resveratrol	resveratrol	NN	_	2	nmod
5	-	-	:	_	2	punct
6	induced	induce	VBN	_	7	amod
7	vasorelaxation	vasorelaxation	NN	_	8	nsubj
8	differs	differ	VBZ	_	2	dep
9	in	in	IN	_	13	case
10	the	the	DT	_	13	det
11	mesenteric	mesenteric	JJ	_	13	amod
12	resistance	resistance	NN	_	13	compound
13	arteries	artery	NNS	_	8	nmod
14	of	of	IN	_	18	case
15	lean	lean	JJ	_	18	amod
16	and	and	CC	_	15	cc
17	obese	obese	JJ	_	15	conj
18	rats	rat	NNS	_	13	nmod
19	.	.	.	_	2	punct

1	Resveratrol	Resveratrol	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	induce	induce	VB	_	4	xcomp
7	vasorelaxation	vasorelaxation	NN	_	6	dobj
8	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	6	nmod
4	,	,	,	_	6	punct
5	we	we	PRP	_	6	nsubj
6	investigated	investigate	VBD	_	0	ROOT
7	the	the	DT	_	9	det
8	mechanism	mechanism	NN	_	9	compound
9	(	(	NN	_	6	dobj
10	s	be	VBZ	_	11	compound
11	)	)	NN	_	9	dep
12	of	of	IN	_	13	case
13	resveratrol	resveratrol	NN	_	9	nmod
14	-	-	:	_	9	punct
15	induced	induce	VBN	_	16	amod
16	vasorelaxation	vasorelaxation	NN	_	9	dep
17	in	in	IN	_	18	case
18	resistance	resistance	NN	_	16	nmod
19	mesenteric	mesenteric	JJ	_	20	amod
20	arteries	artery	NNS	_	18	dep
21	from	from	IN	_	23	case
22	male	male	JJ	_	23	amod
23	lean	lean	JJ	_	20	nmod
24	and	and	CC	_	23	cc
25	dietary	dietary	JJ	_	23	conj
26	-	-	:	_	9	punct
27	induced	induce	VBN	_	29	amod
28	obese	obese	JJ	_	29	amod
29	rats	rat	NNS	_	9	dep
30	.	.	.	_	6	punct

1	Compared	compare	VBN	_	4	case
2	with	with	IN	_	4	case
3	lean	lean	JJ	_	4	amod
4	rats	rat	NNS	_	12	advcl
5	,	,	,	_	12	punct
6	arteries	artery	NNS	_	12	nsubj
7	from	from	IN	_	11	case
8	dietary	dietary	JJ	_	11	amod
9	-	-	:	_	11	punct
10	obese	obese	JJ	_	11	amod
11	rats	rat	NNS	_	6	nmod
12	showed	show	VBD	_	0	ROOT
13	significant	significant	JJ	_	15	amod
14	(	(	NN	_	15	compound
15	P&lt	p&lt	NN	_	12	dobj
16	;	;	:	_	15	punct
17	0.001	0.001	CD	_	20	nummod
18	)	)	CD	_	20	nummod
19	endothelial	endothelial	JJ	_	20	amod
20	dysfunction	dysfunction	NN	_	15	dep
21	,	,	,	_	15	punct
22	as	as	IN	_	23	mark
23	indicated	indicate	VBN	_	15	dep
24	by	by	IN	_	23	nmod
25	a	a	DT	_	24	dep
26	decrease	decrease	NN	_	25	dep
27	(	(	CD	_	28	compound
28	>20	>20	CD	_	29	nummod
29	%	%	NN	_	26	dep
30	)	)	CD	_	29	nummod
31	in	in	IN	_	33	case
32	maximal	maximal	JJ	_	33	amod
33	acetylcholine	acetylcholine	NN	_	29	nmod
34	-	-	:	_	29	punct
35	induced	induce	VBN	_	36	amod
36	vasorelaxation	vasorelaxation	NN	_	29	dep
37	.	.	.	_	12	punct

1	Resveratrol	Resveratrol	NNP	_	3	nsubj
2	(	(	CD	_	1	nummod
3	5	5	LS	_	0	ROOT
4	-	-	:	_	3	punct
5	35	35	CD	_	6	nummod
6	micromol	micromol	NN	_	3	dobj
7	/	/	:	_	6	punct
8	l	l	NN	_	9	compound
9	)	)	NN	_	10	nsubj
10	induced	induce	VBD	_	6	dep
11	concentration	concentration	NN	_	10	dobj
12	-	-	:	_	11	punct
13	dependent	dependent	JJ	_	14	amod
14	relaxation	relaxation	NN	_	11	dep
15	of	of	IN	_	17	case
16	mesenteric	mesenteric	JJ	_	17	amod
17	arteries	artery	NNS	_	14	nmod
18	preconstricted	preconstrict	VBN	_	17	acl
19	with	with	IN	_	23	case
20	noradrenaline	noradrenaline	NN	_	23	compound
21	(	(	CD	_	23	nummod
22	8	8	CD	_	23	nummod
23	micromol	micromol	NN	_	18	nmod
24	/	/	:	_	23	punct
25	l	l	NN	_	23	dep
26	)	)	CD	_	25	nummod
27	or	or	CC	_	25	cc
28	KCl	kcl	NN	_	31	compound
29	(	(	NN	_	31	compound
30	125	125	CD	_	31	nummod
31	mmol	mmol	NN	_	25	conj
32	/	/	:	_	23	punct
33	l	l	NN	_	23	dep
34	)	)	CD	_	33	nummod
35	from	from	IN	_	37	case
36	both	both	CC	_	37	cc:preconj
37	lean	lean	JJ	_	23	nmod
38	and	and	CC	_	37	cc
39	dietary	dietary	JJ	_	37	conj
40	-	-	:	_	37	punct
41	obese	obese	JJ	_	42	amod
42	rats	rat	NNS	_	37	dep
43	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	differences	difference	NNS	_	2	nsubj
6	between	between	IN	_	9	case
7	the	the	DT	_	9	det
8	two	two	CD	_	9	nummod
9	groups	group	NNS	_	5	nmod
10	,	,	,	_	2	punct
11	achieving	achieve	VBG	_	2	advcl
12	a	a	DT	_	14	det
13	maximum	maximum	NN	_	14	compound
14	relaxation	relaxation	NN	_	11	dobj
15	of	of	IN	_	17	case
16	>95	>95	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	at	at	IN	_	20	case
19	a	a	DT	_	20	det
20	concentration	concentration	NN	_	11	nmod
21	of	of	IN	_	23	case
22	35	35	CD	_	23	nummod
23	micromol	micromol	NN	_	20	nmod
24	/	/	:	_	23	punct
25	l	l	NN	_	23	dep
26	.	.	.	_	2	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	L	l	NN	_	5	compound
4	-	-	:	_	5	punct
5	NAME	name	NN	_	2	root
6	(	(	CD	_	7	compound
7	100	100	CD	_	5	nummod
8	and	and	CC	_	5	cc
9	300	300	CD	_	10	nummod
10	micromol	micromol	NN	_	5	conj
11	/	/	:	_	5	punct
12	l	l	NN	_	13	compound
13	)	)	NN	_	16	nsubj
14	did	do	VBD	_	16	aux
15	not	not	RB	_	16	neg
16	alter	alter	VB	_	5	acl:relcl
17	the	the	DT	_	18	det
18	effects	effect	NNS	_	16	dobj
19	of	of	IN	_	20	case
20	reseveratrol	reseveratrol	NN	_	18	nmod
21	on	on	IN	_	22	case
22	arteries	artery	NNS	_	18	nmod
23	from	from	IN	_	27	case
24	dietary	dietary	JJ	_	27	amod
25	-	-	:	_	27	punct
26	obese	obese	JJ	_	27	amod
27	rats	rat	NNS	_	22	nmod
28	,	,	,	_	16	punct
29	giving	give	VBG	_	16	advcl
30	superimposed	superimpose	VBN	_	31	amod
31	concentration	concentration	NN	_	29	dobj
32	-	-	:	_	5	punct
33	responses	response	NNS	_	34	compound
34	curves	curve	NNS	_	5	dep
35	.	.	.	_	5	punct

1	Indomethacin	indomethacin	NN	_	4	nsubj
2	was	be	VBD	_	4	cop
3	also	also	RB	_	4	advmod
4	ineffective	ineffective	JJ	_	0	ROOT
5	in	in	IN	_	6	mark
6	altering	alter	VBG	_	4	advcl
7	resveratrol	resveratrol	NN	_	8	compound
8	activity	activity	NN	_	6	dobj
9	in	in	IN	_	10	case
10	arteries	artery	NNS	_	8	nmod
11	from	from	IN	_	13	case
12	both	both	DT	_	13	cc:preconj
13	lean	lean	JJ	_	10	nmod
14	and	and	CC	_	13	cc
15	dietary	dietary	JJ	_	13	conj
16	-	-	:	_	13	punct
17	obese	obese	JJ	_	18	amod
18	rats	rat	NNS	_	13	dep
19	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	noradrenaline	noradrenaline	NN	_	5	nmod
3	-	-	:	_	5	punct
4	precontracted	precontracted	JJ	_	5	amod
5	arteries	artery	NNS	_	0	ROOT
6	from	from	IN	_	10	case
7	dietary	dietary	JJ	_	10	amod
8	-	-	:	_	10	punct
9	obese	obese	JJ	_	10	amod
10	rats	rat	NNS	_	5	nmod
11	,	,	,	_	5	punct
12	responses	response	NNS	_	17	nsubjpass
13	to	to	TO	_	14	case
14	resveratrol	resveratrol	NN	_	12	nmod
15	were	be	VBD	_	17	auxpass
16	not	not	RB	_	17	neg
17	attenuated	attenuate	VBN	_	5	acl:relcl
18	by	by	IN	_	20	case
19	endothelial	endothelial	JJ	_	20	amod
20	denudation	denudation	NN	_	17	nmod
21	,	,	,	_	17	punct
22	indicating	indicate	VBG	_	17	xcomp
23	an	a	DT	_	24	det
24	action	action	NN	_	22	dobj
25	independent	independent	JJ	_	24	amod
26	of	of	IN	_	28	case
27	the	the	DT	_	28	det
28	endothelium	endothelium	NN	_	25	nmod
29	.	.	.	_	5	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	indicates	indicate	VBZ	_	0	ROOT
4	that	that	IN	_	34	mark
5	:	:	:	_	34	punct
6	(	(	CD	_	8	nummod
7	a	a	DT	_	8	det
8	)	)	NN	_	34	nsubj
9	the	the	DT	_	11	det
10	maximal	maximal	JJ	_	11	amod
11	effects	effect	NNS	_	26	nsubjpass
12	of	of	IN	_	13	case
13	resveratrol	resveratrol	NN	_	11	nmod
14	on	on	IN	_	16	case
15	resistance	resistance	NN	_	16	compound
16	arteries	artery	NNS	_	11	nmod
17	from	from	IN	_	18	case
18	lean	lean	JJ	_	16	nmod
19	and	and	CC	_	18	cc
20	dietary	dietary	JJ	_	18	conj
21	-	-	:	_	18	punct
22	obese	obese	JJ	_	23	amod
23	rats	rat	NNS	_	18	dep
24	are	be	VBP	_	26	auxpass
25	not	not	RB	_	26	neg
26	effected	effect	VBN	_	8	acl:relcl
27	by	by	IN	_	29	case
28	endothelial	endothelial	JJ	_	29	amod
29	dysfunction	dysfunction	NN	_	26	nmod
30	,	,	,	_	8	punct
31	and	and	CC	_	8	cc
32	(	(	NN	_	33	compound
33	b	b	NN	_	8	conj
34	)	)	VBD	_	3	ccomp
35	the	the	DT	_	36	det
36	effects	effect	NNS	_	34	dobj
37	of	of	IN	_	38	case
38	resveratrol	resveratrol	NN	_	36	nmod
39	in	in	IN	_	41	case
40	lean	lean	JJ	_	41	amod
41	animals	animal	NNS	_	36	nmod
42	(	(	CD	_	41	nummod
43	where	where	WRB	_	49	advmod
44	endothelial	endothelial	JJ	_	45	amod
45	function	function	NN	_	49	nsubj
46	is	be	VBZ	_	49	cop
47	not	not	RB	_	49	neg
48	impaired	impaired	JJ	_	49	amod
49	)	)	NN	_	41	acl:relcl
50	,	,	,	_	41	punct
51	but	but	CC	_	41	cc
52	not	not	RB	_	54	neg
53	in	in	IN	_	54	case
54	dietary	dietary	JJ	_	41	conj
55	-	-	:	_	54	punct
56	obese	obese	JJ	_	57	amod
57	rats	rat	NNS	_	54	dep
58	,	,	,	_	34	punct
59	are	be	VBP	_	60	auxpass
60	mediated	mediate	VBN	_	34	dep
61	via	via	IN	_	62	case
62	NO	no	NN	_	60	nmod
63	.	.	.	_	3	punct

1	Jacalin	Jacalin	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	an	a	DT	_	4	det
4	IgA	iga	NN	_	7	dep
5	-	-	:	_	7	punct
6	binding	bind	VBG	_	7	amod
7	lectin	lectin	NN	_	1	dep
8	.	.	.	_	1	punct

1	We	we	PRP	_	3	nsubj
2	previously	previously	RB	_	3	advmod
3	reported	report	VBD	_	0	ROOT
4	that	that	IN	_	12	mark
5	seeds	seed	NNS	_	12	nsubj
6	of	of	IN	_	10	case
7	Artocarpus	artocarpus	NN	_	10	compound
8	integrifolia	integrifolia	NN	_	10	compound
9	(	(	NN	_	10	compound
10	jackfruit	jackfruit	NN	_	5	nmod
11	)	)	CD	_	10	nummod
12	contain	contain	VBP	_	3	ccomp
13	a	a	DT	_	14	det
14	lectin	lectin	NN	_	12	dobj
15	,	,	,	_	14	punct
16	which	which	WDT	_	18	dobj
17	we	we	PRP	_	18	nsubj
18	call	call	VBP	_	14	acl:relcl
19	jacalin	jacalin	NN	_	18	xcomp
20	,	,	,	_	14	punct
21	that	that	WDT	_	28	nsubj
22	is	be	VBZ	_	28	cop
23	both	both	DT	_	28	cc:preconj
24	a	a	DT	_	28	det
25	potent	potent	JJ	_	28	amod
26	T	t	NN	_	28	compound
27	cell	cell	NN	_	28	compound
28	mitogen	mitogen	NN	_	14	acl:relcl
29	and	and	CC	_	28	cc
30	an	a	DT	_	33	det
31	apparently	apparently	RB	_	33	advmod
32	T	t	NN	_	33	compound
33	cell	cell	NN	_	28	conj
34	-	-	:	_	33	punct
35	independent	independent	JJ	_	36	amod
36	activator	activator	NN	_	33	dep
37	of	of	IN	_	40	case
38	human	human	JJ	_	40	amod
39	B	b	NN	_	40	compound
40	cells	cell	NNS	_	36	nmod
41	for	for	IN	_	43	case
42	the	the	DT	_	43	det
43	secretion	secretion	NN	_	36	nmod
44	of	of	IN	_	45	case
45	immunoglobulins	immunoglobulin	NNS	_	43	nmod
46	.	.	.	_	3	punct

1	During	during	IN	_	4	case
2	the	the	DT	_	4	det
3	above	above	JJ	_	4	amod
4	experiments	experiment	NNS	_	6	nmod
5	we	we	PRP	_	6	nsubj
6	noted	note	VBD	_	0	ROOT
7	a	a	DT	_	9	det
8	massive	massive	JJ	_	9	amod
9	precipitation	precipitation	NN	_	6	dobj
10	in	in	IN	_	12	case
11	cell	cell	NN	_	12	compound
12	cultures	culture	NNS	_	9	nmod
13	stimulated	stimulate	VBN	_	12	acl
14	with	with	IN	_	13	nmod
15	greater	greater	JJR	_	14	dep
16	than	than	IN	_	18	case
17	or	or	CC	_	18	cc
18	equal	equal	JJ	_	15	nmod
19	to	to	TO	_	21	case
20	100	100	CD	_	21	nummod
21	micrograms	microgram	NNS	_	18	nmod
22	of	of	IN	_	23	case
23	lectin	lectin	NN	_	21	nmod
24	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	paper	paper	NN	_	6	nmod
4	,	,	,	_	6	punct
5	we	we	PRP	_	6	nsubj
6	show	show	VBP	_	0	ROOT
7	that	that	IN	_	11	mark
8	the	the	DT	_	9	det
9	precipitate	precipitate	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	formed	form	VBN	_	6	ccomp
12	after	after	IN	_	14	case
13	the	the	DT	_	14	det
14	interaction	interaction	NN	_	11	nmod
15	of	of	IN	_	16	case
16	jacalin	jacalin	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	the	the	DT	_	20	det
19	serum	serum	NN	_	20	compound
20	protein	protein	NN	_	16	conj
21	added	add	VBD	_	14	acl
22	to	to	TO	_	25	case
23	the	the	DT	_	25	det
24	culture	culture	NN	_	25	compound
25	medium	medium	NN	_	21	nmod
26	.	.	.	_	6	punct

1	More	more	RBR	_	2	advmod
2	importantly	importantly	RB	_	5	advmod
3	,	,	,	_	5	punct
4	we	we	PRP	_	5	nsubj
5	demonstrate	demonstrate	VBP	_	0	ROOT
6	that	that	IN	_	13	mark
7	IgA	iga	NN	_	13	nsubj
8	is	be	VBZ	_	13	cop
9	probably	probably	RB	_	13	advmod
10	the	the	DT	_	13	det
11	major	major	JJ	_	13	amod
12	serum	serum	NN	_	13	compound
13	constituent	constituent	NN	_	5	ccomp
14	precipitated	precipitate	VBN	_	13	acl
15	by	by	IN	_	17	case
16	the	the	DT	_	17	det
17	lectin	lectin	NN	_	14	nmod
18	and	and	CC	_	13	cc
19	that	that	IN	_	26	mark
20	no	no	DT	_	21	neg
21	IgG	igg	NN	_	26	nsubjpass
22	or	or	CC	_	21	cc
23	IgM	igm	NN	_	21	conj
24	can	can	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	detected	detect	VBN	_	13	conj
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	precipitates	precipitate	NNS	_	26	nmod
30	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	secretions	secretion	NNS	_	11	nmod
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	colostrum	colostrum	NN	_	2	nmod
6	,	,	,	_	11	punct
7	IgA	iga	NN	_	11	nsubj
8	is	be	VBZ	_	11	cop
9	the	the	DT	_	11	det
10	only	only	JJ	_	11	amod
11	protein	protein	NN	_	0	ROOT
12	precipitated	precipitate	VBN	_	11	acl
13	by	by	IN	_	14	case
14	jacalin	jacalin	NN	_	12	nmod
15	.	.	.	_	11	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	8	nmod
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	specificity	specificity	NN	_	3	nmod
7	we	we	PRP	_	8	nsubj
8	describe	describe	VBP	_	0	ROOT
9	a	a	DT	_	15	det
10	simple	simple	JJ	_	15	amod
11	and	and	CC	_	10	cc
12	reliable	reliable	JJ	_	10	conj
13	affinity	affinity	NN	_	15	compound
14	chromatography	chromatography	NN	_	15	compound
15	procedure	procedure	NN	_	8	dobj
16	for	for	IN	_	18	case
17	the	the	DT	_	18	det
18	purification	purification	NN	_	15	nmod
19	of	of	IN	_	22	case
20	both	both	CC	_	22	cc:preconj
21	human	human	JJ	_	22	amod
22	serum	serum	NN	_	18	nmod
23	and	and	CC	_	22	cc
24	colostrum	colostrum	NN	_	25	compound
25	IgA	iga	NN	_	22	conj
26	.	.	.	_	8	punct

1	Jacalin	jacalin	NN	_	8	nsubj
2	is	be	VBZ	_	8	cop
3	a	a	DT	_	8	det
4	D	d	NN	_	8	compound
5	-	-	:	_	8	punct
6	Gal	gal	NN	_	8	compound
7	binding	binding	NN	_	8	compound
8	lectin	lectin	NN	_	0	ROOT
9	and	and	CC	_	8	cc
10	should	should	MD	_	14	aux
11	be	be	VB	_	14	cop
12	a	a	DT	_	14	det
13	useful	useful	JJ	_	14	amod
14	tool	tool	NN	_	8	conj
15	for	for	IN	_	16	mark
16	studying	study	VBG	_	14	acl
17	of	of	IN	_	18	case
18	serum	serum	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	secretory	secretory	JJ	_	21	amod
21	IgA	iga	NN	_	18	conj
22	.	.	.	_	8	punct

1	[	[	NN	_	3	compound
2	2	2	CD	_	3	nummod
3	epidemics	epidemic	NNS	_	34	nsubj
4	of	of	IN	_	6	case
5	arsenical	arsenical	JJ	_	6	amod
6	encephalopathy	encephalopathy	NN	_	3	nmod
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	treatment	treatment	NN	_	3	nmod
10	of	of	IN	_	11	case
11	trypanosomiasis	trypanosomiasis	NN	_	9	nmod
12	,	,	,	_	11	punct
13	Uganda	Uganda	NNP	_	11	conj
14	,	,	,	_	11	punct
15	1992	1992	CD	_	18	compound
16	-	-	:	_	18	punct
17	1993	1993	CD	_	18	compound
18	]	]	CD	_	11	conj
19	Since	since	IN	_	20	case
20	1988	1988	CD	_	18	nmod
21	,	,	,	_	11	punct
22	the	the	DT	_	29	det
23	french	french	JJ	_	29	amod
24	non	non	JJ	_	29	amod
25	-	-	:	_	29	punct
26	governmental	governmental	JJ	_	29	amod
27	organisation	organisation	NN	_	29	compound
28	M	m	NN	_	29	compound
29	decins	decin	NNS	_	30	nsubj
30	Sans	san	VBZ	_	11	acl:relcl
31	Fronti	Fronti	NNP	_	32	compound
32	res	re	NNS	_	30	dobj
33	is	be	VBZ	_	34	aux
34	running	run	VBG	_	0	ROOT
35	a	a	DT	_	37	det
36	control	control	NN	_	37	amod
37	program	program	NN	_	34	dobj
38	of	of	IN	_	41	case
39	human	human	JJ	_	41	amod
40	african	african	JJ	_	41	amod
41	trypanosomiasis	trypanosomiasis	NN	_	37	nmod
42	in	in	IN	_	44	case
43	the	the	DT	_	44	det
44	district	district	NN	_	37	nmod
45	of	of	IN	_	46	case
46	Moyo	Moyo	NNP	_	44	nmod
47	,	,	,	_	46	punct
48	North	North	NNP	_	50	compound
49	-	-	:	_	50	punct
50	Uganda	Uganda	NNP	_	46	appos
51	.	.	.	_	34	punct

1	Between	between	IN	_	2	case
2	1988	1988	CD	_	11	nmod
3	and	and	CC	_	2	cc
4	1993	1993	CD	_	2	conj
5	,	,	,	_	11	punct
6	more	more	JJR	_	8	advmod
7	than	than	IN	_	6	mwe
8	7,000	7,000	CD	_	9	nummod
9	patients	patient	NNS	_	11	nsubjpass
10	were	be	VBD	_	11	auxpass
11	diagnosed	diagnose	VBN	_	0	ROOT
12	and	and	CC	_	11	cc
13	treated	treat	VBN	_	11	conj
14	.	.	.	_	11	punct

1	Since	since	IN	_	2	case
2	1988	1988	CD	_	7	nmod
3	,	,	,	_	7	punct
4	it	it	PRP	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	noted	note	VBN	_	0	ROOT
8	that	that	IN	_	14	mark
9	incidence	incidence	NN	_	14	nsubj
10	of	of	IN	_	12	case
11	melarsoprol	melarsoprol	NN	_	12	compound
12	reaction	reaction	NN	_	9	nmod
13	had	have	VBD	_	14	aux
14	increased	increase	VBN	_	7	ccomp
15	systematically	systematically	RB	_	14	advmod
16	between	between	IN	_	17	case
17	June	June	NNP	_	14	nmod
18	and	and	CC	_	17	cc
19	October	October	NNP	_	17	conj
20	of	of	IN	_	22	case
21	each	each	DT	_	22	det
22	year	year	NN	_	17	nmod
23	,	,	,	_	14	punct
24	indicating	indicate	VBG	_	14	advcl
25	strong	strong	JJ	_	27	amod
26	seasonal	seasonal	JJ	_	27	amod
27	variation	variation	NN	_	24	dobj
28	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	1992	1992	CD	_	13	nmod
3	and	and	CC	_	2	cc
4	1993	1993	CD	_	2	conj
5	,	,	,	_	13	punct
6	two	two	CD	_	7	nummod
7	outbreaks	outbreak	NNS	_	13	nsubj
8	of	of	IN	_	11	case
9	arsenical	arsenical	JJ	_	11	amod
10	reactive	reactive	JJ	_	11	amod
11	encephalopathy	encephalopathy	NN	_	7	nmod
12	(	(	CD	_	11	nummod
13	ARE	be	VBP	_	0	ROOT
14	)	)	CD	_	15	nsubj
15	occurred	occur	VBD	_	13	ccomp
16	in	in	IN	_	20	case
17	the	the	DT	_	20	det
18	sleeping	sleep	VBG	_	20	amod
19	sickness	sickness	NN	_	20	compound
20	center	center	NN	_	15	nmod
21	of	of	IN	_	22	case
22	Adjumani	Adjumani	NNP	_	20	nmod
23	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	0	ROOT
3	of	of	IN	_	6	mark
4	ARE	be	VBP	_	6	auxpass
5	suddenly	suddenly	RB	_	6	advmod
6	exceeded	exceed	VBN	_	2	acl
7	10	10	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	treated	treat	VBN	_	11	acl
13	by	by	IN	_	14	case
14	melarsoprol	melarsoprol	NN	_	12	nmod
15	during	during	IN	_	16	case
16	August	August	NNP	_	12	nmod
17	1992	1992	CD	_	16	nummod
18	and	and	CC	_	16	cc
19	September	September	NNP	_	16	conj
20	1993	1993	CD	_	19	nummod
21	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	onset	onset	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	80	80	CD	_	5	nummod
5	%	%	NN	_	2	nmod
6	of	of	IN	_	7	case
7	those	those	DT	_	5	nmod
8	&quot	&quot	VBN	_	7	acl
9	;	;	:	_	2	punct
10	epidemic&quot	epidemic&quot	VBN	_	2	dep
11	;	;	:	_	2	punct

1	cases	case	NNS	_	3	nsubj
2	,	,	,	_	3	punct
3	occurred	occur	VBD	_	0	ROOT
4	between	between	IN	_	6	case
5	the	the	DT	_	6	det
6	5th	5th	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	the	the	DT	_	10	det
9	11th	11th	JJ	_	10	amod
10	day	day	NN	_	6	conj
11	of	of	IN	_	12	case
12	treatment	treatment	NN	_	10	nmod
13	.	.	.	_	3	punct

1	Two	two	CD	_	3	nummod
2	retrospective	retrospective	JJ	_	3	amod
3	studies	study	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	conducted	conduct	VBN	_	0	ROOT
6	in	in	IN	_	10	case
7	1992	1992	CD	_	9	compound
8	(	(	CD	_	9	compound
9	75	75	CD	_	10	nummod
10	cases	case	NNS	_	5	nmod
11	)	)	CD	_	10	nummod
12	and	and	CC	_	10	cc
13	in	in	IN	_	17	case
14	1993	1993	CD	_	17	nummod
15	(	(	CD	_	17	nummod
16	51	51	CD	_	17	nummod
17	cases	case	NNS	_	10	conj
18	)	)	CD	_	17	nummod
19	.	.	.	_	5	punct

1	Among	among	IN	_	4	case
2	the	the	DT	_	4	det
3	risk	risk	NN	_	4	compound
4	factors	factor	NNS	_	8	nmod
5	studied	study	VBN	_	4	acl
6	,	,	,	_	8	punct
7	two	two	CD	_	8	nsubj
8	appear	appear	VBP	_	0	ROOT
9	to	to	TO	_	10	mark
10	increase	increase	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	14	case
14	ARE	be	VBP	_	12	nmod
15	:	:	:	_	8	punct
16	the	the	DT	_	17	det
17	prescription	prescription	NN	_	8	dep
18	of	of	IN	_	19	case
19	thiabendazole	thiabendazole	NN	_	17	nmod
20	to	to	TO	_	21	mark
21	treat	treat	VB	_	17	acl
22	strongyloidiasis	strongyloidiasis	NN	_	21	dobj
23	during	during	IN	_	26	case
24	the	the	DT	_	26	det
25	melarsoprol	melarsoprol	NN	_	26	compound
26	cure	cure	NN	_	21	nmod
27	and	and	CC	_	17	cc
28	the	the	DT	_	32	det
29	bad	bad	JJ	_	32	amod
30	general	general	JJ	_	32	amod
31	clinical	clinical	JJ	_	32	amod
32	conditions	condition	NNS	_	17	conj
33	of	of	IN	_	34	case
34	patients	patient	NNS	_	32	nmod
35	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	observations	observation	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	exogenous	exogenous	JJ	_	6	amod
6	co	co	NN	_	11	dep
7	-	-	:	_	11	punct
8	factors	factor	NNS	_	11	nsubjpass
9	could	could	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	involved	involve	VBN	_	3	ccomp
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	occurrence	occurrence	NN	_	11	nmod
15	of	of	IN	_	16	case
16	ARE	be	VBP	_	14	nmod
17	.	.	.	_	3	punct

1	Recommendations	recommendation	NNS	_	2	nsubj
2	were	be	VBD	_	0	ROOT
3	to	to	TO	_	4	mark
4	avoid	avoid	VB	_	2	xcomp
5	administration	administration	NN	_	4	dobj
6	of	of	IN	_	11	case
7	diffusible	diffusible	JJ	_	11	amod
8	anti	anti	JJ	_	11	amod
9	-	-	:	_	11	punct
10	helminthic	helminthic	JJ	_	11	amod
11	treatment	treatment	NN	_	5	nmod
12	during	during	IN	_	14	case
13	the	the	DT	_	14	det
14	cure	cure	NN	_	4	nmod
15	,	,	,	_	4	punct
16	and	and	CC	_	4	cc
17	to	to	TO	_	18	mark
18	improve	improve	VB	_	4	conj
19	the	the	DT	_	21	det
20	general	general	JJ	_	21	amod
21	conditions	condition	NNS	_	18	dobj
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	before	before	IN	_	26	case
25	the	the	DT	_	26	det
26	cure	cure	NN	_	18	nmod
27	of	of	IN	_	28	case
28	melarsoprol	melarsoprol	NN	_	26	nmod
29	.	.	.	_	2	punct

1	Behavioral	behavioral	JJ	_	2	amod
2	responses	response	NNS	_	10	nsubj
3	to	to	TO	_	6	case
4	repeated	repeat	VBN	_	6	amod
5	cocaine	cocaine	NN	_	6	compound
6	exposure	exposure	NN	_	2	nmod
7	in	in	IN	_	8	case
8	mice	mouse	NNS	_	6	nmod
9	selectively	selectively	RB	_	10	advmod
10	bred	breed	VBD	_	0	ROOT
11	for	for	IN	_	13	case
12	differential	differential	JJ	_	13	amod
13	sensitivity	sensitivity	NN	_	10	nmod
14	to	to	TO	_	15	case
15	pentobarbital	pentobarbital	NN	_	13	nmod
16	.	.	.	_	10	punct

1	Mice	mouse	NNS	_	0	ROOT
2	from	from	IN	_	5	case
3	the	the	DT	_	5	det
4	20th	20th	JJ	_	5	amod
5	generation	generation	NN	_	1	nmod
6	of	of	IN	_	8	case
7	three	three	CD	_	8	nummod
8	lines	line	NNS	_	5	nmod
9	divergently	divergently	RB	_	10	advmod
10	selected	select	VBN	_	8	acl
11	for	for	IN	_	12	case
12	response	response	NN	_	10	nmod
13	to	to	TO	_	14	case
14	pentobarbital	pentobarbital	JJ	_	12	nmod
15	-	-	:	_	1	punct
16	induced	induce	VBN	_	18	amod
17	sedation	sedation	NN	_	18	compound
18	times	time	NNS	_	1	dep
19	[	[	RB	_	20	advmod
20	long	long	RB	_	18	advmod
21	-	-	:	_	18	punct
22	sedation	sedation	NN	_	23	compound
23	time	time	NN	_	37	nsubj
24	(	(	CD	_	26	nummod
25	LST	lst	NN	_	26	compound
26	)	)	NN	_	23	dep
27	,	,	,	_	23	punct
28	short	short	JJ	_	30	amod
29	sedation	sedation	NN	_	30	compound
30	time	time	NN	_	23	conj
31	(	(	JJ	_	33	amod
32	SST	sst	NN	_	33	compound
33	)	)	NN	_	30	dep
34	,	,	,	_	23	punct
35	and	and	CC	_	23	cc
36	randomly	randomly	RB	_	23	conj
37	bred	breed	VBD	_	18	dep
38	control	control	NN	_	40	compound
39	(	(	CD	_	40	nummod
40	RBC	rbc	NNS	_	41	nsubj
41	)	)	VBP	_	37	ccomp
42	]	]	CD	_	44	nsubjpass
43	were	be	VBD	_	44	auxpass
44	used	use	VBN	_	41	ccomp
45	to	to	TO	_	46	mark
46	study	study	VB	_	44	xcomp
47	cocaine	cocaine	NN	_	46	dobj
48	-	-	:	_	47	punct
49	induced	induce	VBN	_	51	amod
50	behavioral	behavioral	JJ	_	51	amod
51	sensitization	sensitization	NN	_	47	dep
52	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	lines	line	NNS	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	variable	variable	JJ	_	5	amod
5	degrees	degree	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	locomotor	locomotor	NN	_	8	compound
8	activities	activity	NNS	_	5	nmod
9	in	in	IN	_	12	case
10	response	response	NN	_	12	dep
11	to	to	TO	_	12	case
12	cocaine	cocaine	NN	_	3	nmod
13	.	.	.	_	3	punct

1	At	at	IN	_	5	case
2	a	a	DT	_	5	det
3	low	low	JJ	_	5	amod
4	cocaine	cocaine	NN	_	5	compound
5	dose	dose	NN	_	34	nmod
6	and	and	CC	_	5	cc
7	long	long	JJ	_	9	amod
8	withdrawal	withdrawal	NN	_	9	compound
9	period	period	NN	_	5	conj
10	(	(	CD	_	12	nummod
11	10	10	CD	_	12	nummod
12	mg	mg	NN	_	9	dep
13	/	/	:	_	14	punct
14	kg	kg	NN	_	34	dep
15	,	,	,	_	14	punct
16	twice	twice	RB	_	18	advmod
17	a	a	DT	_	18	det
18	day	day	NN	_	14	appos
19	for	for	IN	_	21	case
20	5	5	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	followed	follow	VBN	_	18	acl
23	by	by	IN	_	29	case
24	a	a	DT	_	29	det
25	14	14	CD	_	29	nummod
26	-	-	:	_	29	punct
27	day	day	NN	_	29	compound
28	withdrawal	withdrawal	NN	_	29	compound
29	)	)	NN	_	22	nmod
30	,	,	,	_	14	punct
31	the	the	DT	_	33	det
32	LST	LST	NNP	_	33	compound
33	mice	mouse	NNS	_	34	nsubj
34	showed	show	VBD	_	0	ROOT
35	tolerance	tolerance	NN	_	36	compound
36	development	development	NN	_	34	dobj
37	.	.	.	_	34	punct

1	In	in	IN	_	2	case
2	response	response	NN	_	15	nmod
3	to	to	TO	_	4	case
4	cocaine	cocaine	NN	_	2	nmod
5	,	,	,	_	15	punct
6	the	the	DT	_	8	det
7	locomotor	locomotor	NN	_	8	compound
8	activities	activity	NNS	_	15	nsubj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	SST	SST	NNP	_	8	nmod
12	were	be	VBD	_	15	cop
13	not	not	RB	_	15	neg
14	significantly	significantly	RB	_	15	advmod
15	different	different	JJ	_	0	ROOT
16	from	from	IN	_	19	case
17	the	the	DT	_	19	det
18	RBC	rbc	NN	_	19	compound
19	group	group	NN	_	15	nmod
20	.	.	.	_	15	punct

1	At	at	IN	_	4	case
2	a	a	DT	_	4	det
3	higher	higher	JJR	_	4	amod
4	dose	dose	NN	_	0	ROOT
5	and	and	CC	_	4	cc
6	a	a	DT	_	9	det
7	shorter	shorter	JJR	_	9	amod
8	withdrawal	withdrawal	NN	_	9	compound
9	period	period	NN	_	4	conj
10	(	(	CD	_	11	compound
11	20	20	CD	_	12	nummod
12	mg	mg	NN	_	9	dep
13	/	/	:	_	12	punct
14	kg	kg	NN	_	12	dep
15	,	,	,	_	12	punct
16	daily	daily	RB	_	19	advmod
17	for	for	IN	_	19	case
18	7	7	CD	_	19	nummod
19	days	day	NNS	_	12	nmod
20	followed	follow	VBN	_	19	acl
21	by	by	IN	_	22	case
22	a	a	DT	_	20	nmod
23	3	3	LS	_	22	root
24	-	-	:	_	23	punct
25	day	day	NN	_	27	compound
26	withdrawal	withdrawal	NN	_	27	compound
27	)	)	NN	_	23	dep
28	,	,	,	_	27	punct
29	the	the	DT	_	31	det
30	SST	SST	NNP	_	31	compound
31	mice	mouse	NNS	_	32	nsubj
32	showed	show	VBD	_	27	acl:relcl
33	behavioral	behavioral	JJ	_	34	amod
34	sensitization	sensitization	NN	_	32	dobj
35	similar	similar	JJ	_	34	amod
36	to	to	TO	_	39	case
37	the	the	DT	_	39	det
38	RBC	rbc	NN	_	39	compound
39	mice	mouse	NNS	_	35	nmod
40	,	,	,	_	32	punct
41	but	but	CC	_	32	cc
42	the	the	DT	_	44	det
43	LST	lst	NN	_	44	compound
44	mice	mouse	NNS	_	47	nsubj
45	did	do	VBD	_	47	aux
46	not	not	RB	_	47	neg
47	develop	develop	VB	_	32	conj
48	sensitization	sensitization	NN	_	47	dobj
49	.	.	.	_	23	punct

1	The	the	DT	_	3	det
2	different	different	JJ	_	3	amod
3	responses	response	NNS	_	10	nsubj
4	in	in	IN	_	6	case
5	locomotor	locomotor	NN	_	6	compound
6	activity	activity	NN	_	3	nmod
7	induced	induce	VBN	_	6	acl
8	by	by	IN	_	9	case
9	cocaine	cocaine	NN	_	7	nmod
10	suggest	suggest	VBP	_	0	ROOT
11	that	that	IN	_	15	mark
12	genetic	genetic	JJ	_	13	amod
13	factors	factor	NNS	_	15	nsubj
14	may	may	MD	_	15	aux
15	play	play	VB	_	10	ccomp
16	a	a	DT	_	17	det
17	role	role	NN	_	15	dobj
18	in	in	IN	_	19	mark
19	determining	determine	VBG	_	15	advcl
20	the	the	DT	_	21	det
21	magnitude	magnitude	NN	_	19	dobj
22	of	of	IN	_	23	case
23	response	response	NN	_	21	nmod
24	to	to	TO	_	26	case
25	this	this	DT	_	26	det
26	drug	drug	NN	_	23	nmod
27	.	.	.	_	10	punct

1	Dopamine	dopamine	NN	_	5	compound
2	(	(	CD	_	5	nummod
3	DA	DA	NNP	_	5	compound
4	)	)	NN	_	5	compound
5	levels	level	NNS	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	differ	differ	VB	_	0	ROOT
9	significantly	significantly	RB	_	8	advmod
10	in	in	IN	_	14	case
11	either	either	CC	_	14	cc:preconj
12	striatum	striatum	NN	_	14	compound
13	(	(	CD	_	14	nummod
14	STR	str	NN	_	8	nmod
15	)	)	CD	_	14	nummod
16	or	or	CC	_	14	cc
17	nucleus	nucleus	NN	_	18	compound
18	accumbens	accumben	NNS	_	14	conj
19	(	(	VBP	_	8	dep
20	NAC	nac	NN	_	21	compound
21	)	)	NN	_	19	dobj
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	cocaine	cocaine	NN	_	19	nmod
25	-	-	:	_	24	punct
26	treated	treat	VBN	_	27	amod
27	animals	animal	NNS	_	24	dep
28	to	to	TO	_	31	case
29	their	they	PRP$	_	31	nmod:poss
30	corresponding	corresponding	JJ	_	31	amod
31	saline	saline	NN	_	27	nmod
32	-	-	:	_	24	punct
33	treated	treat	VBN	_	34	amod
34	controls	control	NNS	_	24	dep
35	.	.	.	_	8	punct

1	The	the	DT	_	5	det
2	affinity	affinity	NN	_	5	compound
3	(	(	NN	_	5	compound
4	Kd	kd	NN	_	5	compound
5	)	)	NN	_	11	nsubj
6	of	of	IN	_	7	case
7	D2	d2	NN	_	5	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	NAC	nac	NN	_	5	nmod
11	decreased	decrease	VBD	_	0	ROOT
12	significantly	significantly	RB	_	11	advmod
13	,	,	,	_	11	punct
14	without	without	IN	_	15	case
15	changes	change	NNS	_	11	nmod
16	in	in	IN	_	20	case
17	density	density	NN	_	20	compound
18	(	(	CD	_	20	nummod
19	Bmax	bmax	NN	_	20	compound
20	)	)	NN	_	15	nmod
21	,	,	,	_	11	punct
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	cocaine	cocaine	NN	_	11	nmod
25	-	-	:	_	24	punct
26	treated	treat	VBN	_	30	amod
27	SST	SST	NNP	_	30	compound
28	and	and	CC	_	27	cc
29	RBC	RBC	NNP	_	27	conj
30	mice	mouse	NNS	_	24	dep
31	.	.	.	_	11	punct

1	On	on	IN	_	4	case
2	the	the	DT	_	4	det
3	other	other	JJ	_	4	amod
4	hand	hand	NN	_	24	nmod
5	,	,	,	_	24	punct
6	the	the	DT	_	7	det
7	density	density	NN	_	24	nsubjpass
8	of	of	IN	_	11	case
9	D2	d2	NN	_	11	compound
10	binding	binding	NN	_	11	compound
11	sites	site	NNS	_	7	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	SST	SST	NNP	_	11	nmod
15	and	and	CC	_	14	cc
16	the	the	DT	_	18	det
17	RBC	rbc	NN	_	18	compound
18	mice	mouse	NNS	_	14	conj
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	STR	str	NN	_	7	nmod
22	was	be	VBD	_	24	auxpass
23	significantly	significantly	RB	_	24	advmod
24	increased	increase	VBN	_	0	ROOT
25	in	in	IN	_	26	case
26	cocaine	cocaine	NN	_	24	nmod
27	-	-	:	_	26	punct
28	treated	treated	JJ	_	29	amod
29	groups	group	NNS	_	26	dep
30	without	without	IN	_	31	case
31	change	change	NN	_	29	nmod
32	in	in	IN	_	33	case
33	Kd	kd	NN	_	31	nmod
34	.	.	.	_	24	punct

1	The	the	DT	_	3	det
2	LST	lst	NN	_	3	compound
3	mice	mouse	NNS	_	6	nsubj
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	show	show	VB	_	0	ROOT
7	any	any	DT	_	8	det
8	changes	change	NNS	_	6	dobj
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	Kd	kd	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	Bmax	bmax	NN	_	11	conj
14	in	in	IN	_	17	case
15	either	either	CC	_	17	cc:preconj
16	the	the	DT	_	17	det
17	STR	str	NN	_	8	nmod
18	or	or	CC	_	17	cc
19	the	the	DT	_	20	det
20	NAC	nac	NN	_	17	conj
21	.	.	.	_	6	punct

1	Taken	take	VBN	_	6	advcl
2	together	together	RB	_	1	advmod
3	,	,	,	_	6	punct
4	these	these	DT	_	5	det
5	findings	finding	NNS	_	6	nsubj
6	suggest	suggest	VBP	_	0	ROOT
7	that	that	IN	_	27	mark
8	the	the	DT	_	9	det
9	changes	change	NNS	_	27	nsubj
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	Kd	kd	NN	_	9	nmod
13	of	of	IN	_	14	case
14	D2	d2	NN	_	12	nmod
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	NAC	nac	NN	_	12	nmod
18	and	and	CC	_	12	cc
19	the	the	DT	_	20	det
20	Bmax	bmax	NN	_	12	conj
21	of	of	IN	_	22	case
22	D2	d2	NN	_	20	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	STR	str	NN	_	20	nmod
26	may	may	MD	_	27	aux
27	contribute	contribute	VB	_	6	ccomp
28	to	to	TO	_	30	case
29	the	the	DT	_	30	det
30	differences	difference	NNS	_	27	nmod
31	in	in	IN	_	33	case
32	locomotor	locomotor	JJ	_	33	amod
33	responses	response	NNS	_	30	nmod
34	to	to	TO	_	36	case
35	cocaine	cocaine	NN	_	36	compound
36	exposure	exposure	NN	_	33	nmod
37	in	in	IN	_	40	case
38	these	these	DT	_	40	det
39	mouse	mouse	NN	_	40	compound
40	lines	line	NNS	_	36	nmod
41	.	.	.	_	6	punct

1	Fluvoxamine	fluvoxamine	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	CYP2C9	cyp2c9	NN	_	2	dobj
5	catalyzed	catalyze	VBN	_	6	amod
6	biotransformation	biotransformation	NN	_	4	dep
7	of	of	IN	_	8	case
8	tolbutamide	tolbutamide	NN	_	6	nmod
9	.	.	.	_	2	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Our	we	PRP$	_	4	nmod:poss
4	objective	objective	NN	_	5	nsubj
5	was	be	VBD	_	1	dep
6	to	to	TO	_	7	mark
7	examine	examine	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	interaction	interaction	NN	_	7	dobj
10	between	between	IN	_	11	case
11	fluvoxamine	fluvoxamine	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	tolbutamide	tolbutamide	NN	_	11	conj
14	to	to	TO	_	15	mark
15	confirm	confirm	VB	_	9	acl
16	that	that	IN	_	18	mark
17	fluvoxamine	fluvoxamine	NN	_	18	nsubj
18	inhibits	inhibit	VBZ	_	15	ccomp
19	CYP2C9	cyp2c9	NN	_	18	dobj
20	.	.	.	_	1	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	study	study	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	carried	carry	VBN	_	1	appos
7	out	out	RP	_	6	compound:prt
8	as	as	IN	_	15	case
9	an	a	DT	_	15	det
10	open	open	JJ	_	15	dep
11	,	,	,	_	10	punct
12	randomized	randomize	VBN	_	10	dep
13	,	,	,	_	10	punct
14	crossover	crossover	NN	_	15	compound
15	design	design	NN	_	6	nmod
16	with	with	IN	_	19	case
17	14	14	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	participants	participant	NNS	_	15	nmod
20	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	period	period	NN	_	3	compound
3	A	a	NN	_	7	nmod
4	,	,	,	_	7	punct
5	all	all	DT	_	6	det
6	volunteers	volunteer	NNS	_	7	nsubj
7	took	take	VBD	_	0	ROOT
8	500	500	CD	_	9	nummod
9	mg	mg	NN	_	7	dobj
10	of	of	IN	_	11	case
11	tolbutamide	tolbutamide	NN	_	9	nmod
12	orally	orally	RB	_	7	advmod
13	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	period	period	NN	_	3	compound
3	B	b	NN	_	9	nmod
4	,	,	,	_	9	punct
5	the	the	DT	_	6	det
6	volunteers	volunteer	NNS	_	9	nsubjpass
7	were	be	VBD	_	9	auxpass
8	randomly	randomly	RB	_	9	advmod
9	assigned	assign	VBN	_	0	ROOT
10	to	to	TO	_	11	case
11	one	one	CD	_	9	nmod
12	of	of	IN	_	14	case
13	two	two	CD	_	14	nummod
14	groups	group	NNS	_	11	nmod
15	.	.	.	_	9	punct

1	Each	each	DT	_	2	det
2	group	group	NN	_	3	nsubj
3	took	take	VBD	_	0	ROOT
4	either	either	CC	_	6	cc:preconj
5	150	150	CD	_	6	nummod
6	mg	mg	NN	_	3	dobj
7	or	or	CC	_	6	cc
8	75	75	CD	_	9	nummod
9	mg	mg	NN	_	6	conj
10	of	of	IN	_	11	case
11	fluvoxamine	fluvoxamine	NN	_	6	nmod
12	a	a	DT	_	13	det
13	day	day	NN	_	6	nmod:npmod
14	for	for	IN	_	16	case
15	5	5	CD	_	16	nummod
16	days	day	NNS	_	3	nmod
17	(	(	RB	_	18	advmod
18	day	day	NN	_	16	dep
19	-	-	:	_	18	punct
20	3	3	CD	_	22	compound
21	to	to	TO	_	22	dep
22	day	day	NN	_	24	nummod
23	2	2	CD	_	24	nummod
24	)	)	NN	_	18	dep
25	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	groups	group	NNS	_	4	nsubj
3	then	then	RB	_	4	advmod
4	took	take	VBD	_	0	ROOT
5	500	500	CD	_	6	nummod
6	mg	mg	NN	_	4	dobj
7	of	of	IN	_	8	case
8	tolbutamide	tolbutamide	NN	_	6	nmod
9	as	as	IN	_	14	case
10	a	a	DT	_	14	det
11	single	single	JJ	_	14	amod
12	dose	dose	NN	_	14	compound
13	(	(	NN	_	14	compound
14	day	day	NN	_	4	nmod
15	0	0	CD	_	16	nummod
16	)	)	NN	_	14	dep
17	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	both	both	DT	_	3	det
3	periods	period	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	blood	blood	NN	_	9	nsubjpass
6	and	and	CC	_	5	cc
7	urine	urine	NN	_	5	conj
8	were	be	VBD	_	9	auxpass
9	sampled	sample	VBN	_	0	ROOT
10	at	at	IN	_	12	case
11	regular	regular	JJ	_	12	amod
12	intervals	interval	NNS	_	9	nmod
13	.	.	.	_	9	punct

1	Plasma	plasma	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	analyzed	analyze	VBN	_	0	ROOT
4	for	for	IN	_	5	case
5	tolbutamide	tolbutamide	NN	_	3	nmod
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	urine	urine	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	analyzed	analyze	VBN	_	3	conj
11	for	for	IN	_	12	case
12	tolbutamide	tolbutamide	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	its	its	PRP$	_	16	nmod:poss
15	two	two	CD	_	16	nummod
16	metabolites	metabolite	NNS	_	12	conj
17	,	,	,	_	10	punct
18	4	4	LS	_	10	dep
19	-	-	:	_	18	punct
20	hydroxytolbutamide	hydroxytolbutamide	NN	_	18	dep
21	and	and	CC	_	20	cc
22	carboxytolbutamide	carboxytolbutamide	NN	_	20	conj
23	by	by	IN	_	24	case
24	means	means	NNS	_	20	nmod
25	of	of	IN	_	26	case
26	HPLC	hplc	NN	_	24	nmod
27	.	.	.	_	3	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	During	during	IN	_	4	case
4	treatment	treatment	NN	_	9	nmod
5	with	with	IN	_	6	case
6	fluvoxamine	fluvoxamine	NN	_	4	nmod
7	,	,	,	_	9	punct
8	there	there	EX	_	9	expl
9	was	be	VBD	_	1	dep
10	a	a	DT	_	13	det
11	statistically	statistically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	decrease	decrease	NN	_	9	nsubj
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	median	median	NN	_	13	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	total	total	JJ	_	20	amod
20	clearance	clearance	NN	_	16	nmod
21	of	of	IN	_	22	case
22	tolbutamide	tolbutamide	NN	_	20	nmod
23	,	,	,	_	13	punct
24	from	from	IN	_	26	case
25	845	845	CD	_	26	nummod
26	mL	ml	NN	_	13	nmod
27	/	/	:	_	26	punct
28	h	h	NN	_	26	dep
29	to	to	TO	_	31	case
30	688	688	CD	_	31	nummod
31	mL	ml	NN	_	28	nmod
32	/	/	:	_	26	punct
33	h	h	NN	_	26	dep
34	,	,	,	_	13	punct
35	among	among	IN	_	37	case
36	the	the	DT	_	37	det
37	volunteers	volunteer	NNS	_	13	nmod
38	who	who	WP	_	39	nsubj
39	received	receive	VBD	_	37	acl:relcl
40	75	75	CD	_	41	nummod
41	mg	mg	NN	_	39	dobj
42	/	/	:	_	41	punct
43	d	d	NN	_	41	dep
44	.	.	.	_	1	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	a	a	DT	_	4	det
4	reduction	reduction	NN	_	2	nsubj
5	that	that	WDT	_	6	nsubj
6	reached	reach	VBD	_	4	acl:relcl
7	borderline	borderline	JJ	_	9	amod
8	statistical	statistical	JJ	_	9	amod
9	significance	significance	NN	_	6	dobj
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	group	group	NN	_	9	nmod
13	that	that	WDT	_	14	nsubj
14	received	receive	VBD	_	9	acl:relcl
15	150	150	CD	_	16	nummod
16	mg	mg	NN	_	14	dobj
17	/	/	:	_	16	punct
18	d	d	NN	_	16	dep
19	of	of	IN	_	20	case
20	tolbutamide	tolbutamide	NN	_	18	nmod
21	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	clearance	clearance	NN	_	17	nsubj
3	by	by	IN	_	4	case
4	means	means	NNS	_	2	nmod
5	of	of	IN	_	13	mark
6	4	4	LS	_	13	dep
7	-	-	:	_	6	punct
8	hydroxytolbutamide	hydroxytolbutamide	NN	_	13	nsubjpass
9	and	and	CC	_	8	cc
10	carboxytolbutamide	carboxytolbutamide	NN	_	8	conj
11	was	be	VBD	_	13	auxpass
12	significantly	significantly	RB	_	13	advmod
13	reduced	reduce	VBN	_	4	acl
14	in	in	IN	_	16	case
15	both	both	DT	_	16	det
16	groups	group	NNS	_	13	nmod
17	(	(	VBP	_	0	ROOT
18	ie	ie	FW	_	17	dobj
19	,	,	,	_	18	punct
20	from	from	IN	_	22	case
21	901	901	CD	_	22	nummod
22	mL	ml	NN	_	18	nmod
23	/	/	:	_	18	punct
24	h	h	NN	_	29	dep
25	to	to	TO	_	27	case
26	318	318	CD	_	27	nummod
27	mL	ml	NN	_	24	nmod
28	/	/	:	_	29	punct
29	h	h	NN	_	18	dep
30	in	in	IN	_	32	case
31	the	the	DT	_	32	det
32	group	group	NN	_	29	nmod
33	that	that	WDT	_	34	nsubj
34	received	receive	VBD	_	32	acl:relcl
35	150	150	CD	_	36	nummod
36	mg	mg	NN	_	34	dobj
37	of	of	IN	_	38	case
38	tolbutamide	tolbutamide	NN	_	36	nmod
39	per	per	IN	_	40	case
40	day	day	NN	_	34	nmod
41	and	and	CC	_	34	cc
42	from	from	IN	_	44	case
43	723	723	CD	_	44	nummod
44	mL	ml	NN	_	34	conj
45	/	/	:	_	44	punct
46	h	h	NN	_	44	dep
47	to	to	TO	_	49	case
48	457	457	CD	_	49	nummod
49	mL	ml	NN	_	46	nmod
50	/	/	:	_	29	punct
51	h	h	NN	_	29	dep
52	in	in	IN	_	54	case
53	the	the	DT	_	54	det
54	group	group	NN	_	51	nmod
55	that	that	WDT	_	56	nsubj
56	received	receive	VBD	_	54	acl:relcl
57	75	75	CD	_	58	nummod
58	mg	mg	NN	_	56	dobj
59	of	of	IN	_	60	case
60	tolbutamide	tolbutamide	NN	_	58	nmod
61	per	per	IN	_	62	case
62	day	day	NN	_	56	nmod
63	)	)	CD	_	62	nummod
64	.	.	.	_	17	punct

1	Thus	thus	RB	_	3	advmod
2	there	there	EX	_	3	expl
3	was	be	VBD	_	0	ROOT
4	a	a	DT	_	5	det
5	tendency	tendency	NN	_	3	nsubj
6	toward	toward	IN	_	10	case
7	a	a	DT	_	10	det
8	more	more	RBR	_	9	advmod
9	pronounced	pronounced	JJ	_	10	amod
10	inhibition	inhibition	NN	_	5	nmod
11	of	of	IN	_	15	case
12	the	the	DT	_	15	det
13	4	4	CD	_	15	nummod
14	-	-	:	_	15	punct
15	hydroxylation	hydroxylation	NN	_	10	nmod
16	during	during	IN	_	17	case
17	treatment	treatment	NN	_	10	nmod
18	with	with	IN	_	20	case
19	150	150	CD	_	20	nummod
20	mg	mg	NN	_	17	nmod
21	/	/	:	_	3	punct
22	d	d	NN	_	3	nsubj
23	of	of	IN	_	24	case
24	fluvoxamine	fluvoxamine	NN	_	22	nmod
25	compared	compare	VBN	_	28	case
26	with	with	IN	_	28	case
27	75	75	CD	_	28	nummod
28	mg	mg	NN	_	22	advcl
29	/	/	:	_	28	punct
30	d	d	NN	_	28	dep
31	,	,	,	_	22	punct
32	but	but	CC	_	22	cc
33	the	the	DT	_	34	det
34	difference	difference	NN	_	38	nsubj
35	was	be	VBD	_	38	cop
36	not	not	RB	_	38	neg
37	statistically	statistically	RB	_	38	advmod
38	significant	significant	JJ	_	22	conj
39	.	.	.	_	3	punct

1	CONCLUSION	conclusion	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Fluvoxamine	fluvoxamine	NN	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	a	a	DT	_	7	det
6	moderate	moderate	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	1	dep
8	of	of	IN	_	9	case
9	CYP2C9	cyp2c9	NN	_	7	nmod
10	in	in	FW	_	11	compound
11	vivo	vivo	FW	_	7	advmod
12	.	.	.	_	1	punct

1	Influence	influence	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	calcium	calcium	NN	_	1	nmod
4	-	-	:	_	1	punct
5	channel	channel	NN	_	6	compound
6	blockers	blocker	NNS	_	1	dep
7	on	on	IN	_	9	case
8	platelet	platelet	NN	_	9	compound
9	function	function	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	arachidonic	arachidonic	JJ	_	13	amod
12	acid	acid	NN	_	13	compound
13	metabolism	metabolism	NN	_	9	conj
14	.	.	.	_	1	punct

1	Available	available	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	13	mark
5	platelet	platelet	NN	_	6	compound
6	function	function	NN	_	13	nsubj
7	and	and	CC	_	6	cc
8	arachidonic	arachidonic	JJ	_	10	amod
9	acid	acid	NN	_	10	compound
10	metabolism	metabolism	NN	_	6	conj
11	are	be	VBP	_	13	cop
12	important	important	JJ	_	13	amod
13	factors	factor	NNS	_	3	ccomp
14	in	in	IN	_	15	case
15	hemostasis	hemostasis	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	regulation	regulation	NN	_	15	conj
18	of	of	IN	_	20	case
19	vascular	vascular	JJ	_	20	amod
20	tone	tone	NN	_	15	nmod
21	.	.	.	_	3	punct

1	Plasma	plasma	NN	_	2	compound
2	membrane	membrane	NN	_	11	nsubj
3	and	and	CC	_	2	cc
4	intracellular	intracellular	JJ	_	5	amod
5	mobilization	mobilization	NN	_	2	conj
6	of	of	IN	_	8	case
7	calcium	calcium	NN	_	8	compound
8	ions	ion	NNS	_	2	nmod
9	are	be	VBP	_	11	cop
10	intimately	intimately	RB	_	11	advmod
11	related	relate	VBN	_	0	ROOT
12	to	to	TO	_	14	case
13	platelet	platelet	NN	_	14	compound
14	activation	activation	NN	_	11	nmod
15	and	and	CC	_	14	cc
16	release	release	NN	_	14	conj
17	of	of	IN	_	19	case
18	platelet	platelet	NN	_	19	compound
19	contents	contents	NNS	_	16	nmod
20	.	.	.	_	11	punct

1	Release	Release	NNP	_	21	nsubjpass
2	of	of	IN	_	4	case
3	arachidonic	arachidonic	JJ	_	4	amod
4	acid	acid	NN	_	1	nmod
5	from	from	IN	_	7	case
6	membrane	membrane	NN	_	7	compound
7	phospholipids	phospholipid	NNS	_	1	nmod
8	as	as	RB	_	1	cc
9	well	well	RB	_	8	mwe
10	as	as	IN	_	8	mwe
11	subsequent	subsequent	JJ	_	12	amod
12	synthesis	synthesis	NN	_	1	conj
13	and	and	CC	_	12	cc
14	release	release	NN	_	12	conj
15	of	of	IN	_	18	case
16	vasoconstrictor	vasoconstrictor	NN	_	18	compound
17	thromboxane	thromboxane	NN	_	18	compound
18	A2	a2	NN	_	12	nmod
19	are	be	VBP	_	21	auxpass
20	also	also	RB	_	21	advmod
21	regulated	regulate	VBN	_	0	ROOT
22	by	by	IN	_	23	case
23	movement	movement	NN	_	21	nmod
24	of	of	IN	_	26	case
25	calcium	calcium	NN	_	26	compound
26	ions	ion	NNS	_	23	nmod
27	.	.	.	_	21	punct

1	Adenosine	adenosine	NN	_	0	ROOT
2	3	3	CD	_	1	nummod
3	'	'	''	_	1	punct
4	:	:	:	_	1	punct
5	5	5	CD	_	9	nummod
6	'	'	''	_	9	punct
7	-	-	:	_	9	punct
8	cyclic	cyclic	JJ	_	9	amod
9	phosphate	phosphate	NN	_	1	dep
10	in	in	IN	_	13	case
11	turn	turn	NN	_	13	compound
12	controls	control	NNS	_	13	compound
13	levels	level	NNS	_	9	nmod
14	of	of	IN	_	17	case
15	free	free	JJ	_	17	amod
16	calcium	calcium	NN	_	17	compound
17	ions	ion	NNS	_	13	nmod
18	in	in	IN	_	19	case
19	platelets	platelet	NNS	_	17	nmod
20	and	and	CC	_	9	cc
21	regulates	regulate	VBZ	_	9	conj
22	calcium	calcium	NN	_	21	dobj
23	-	-	:	_	22	punct
24	dependent	dependent	JJ	_	25	amod
25	reactions	reaction	NNS	_	22	dep
26	.	.	.	_	1	punct

1	Slow	slow	SYM	_	5	dep
2	-	-	:	_	5	punct
3	channel	channel	NN	_	5	compound
4	calcium	calcium	NN	_	5	compound
5	blockers	blocker	NNS	_	15	nsubj
6	,	,	,	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	verapamil	verapamil	NN	_	5	nmod
10	,	,	,	_	9	punct
11	diltiazem	diltiazem	NN	_	9	conj
12	and	and	CC	_	9	cc
13	nifedipine	nifedipine	NN	_	9	conj
14	,	,	,	_	5	punct
15	inhibit	inhibit	VBP	_	0	ROOT
16	platelet	platelet	NN	_	17	compound
17	activation	activation	NN	_	15	dobj
18	in	in	FW	_	19	compound
19	vitro	vitro	FW	_	15	advmod
20	,	,	,	_	15	punct
21	and	and	CC	_	15	cc
22	decrease	decrease	VB	_	15	conj
23	platelet	platelet	NN	_	24	compound
24	adhesion	adhesion	NN	_	22	dobj
25	intravascularly	intravascularly	RB	_	22	advmod
26	.	.	.	_	15	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	6	nsubjpass
3	have	have	VBP	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	decrease	decrease	VB	_	6	xcomp
9	platelet	platelet	NN	_	11	compound
10	nucleotide	nucleotide	NN	_	11	compound
11	release	release	NN	_	8	dobj
12	and	and	CC	_	11	cc
13	thromboxane	thromboxane	NN	_	15	compound
14	A2	a2	NN	_	15	compound
15	generation	generation	NN	_	11	conj
16	.	.	.	_	6	punct

1	Some	some	DT	_	3	det
2	preliminary	preliminary	JJ	_	3	amod
3	data	datum	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	calcium	calcium	NN	_	7	compound
7	blockers	blocker	NNS	_	9	nsubj
8	also	also	RB	_	9	advmod
9	increase	increase	VBP	_	4	ccomp
10	generation	generation	NN	_	9	dobj
11	of	of	IN	_	12	case
12	vasodilator	vasodilator	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	platelet	platelet	NN	_	16	compound
15	antiaggregant	antiaggregant	JJ	_	16	amod
16	prostacyclin	prostacyclin	NN	_	12	conj
17	,	,	,	_	10	punct
18	which	which	WDT	_	20	nsubj
19	could	could	MD	_	20	aux
20	contribute	contribute	VB	_	10	acl:relcl
21	to	to	TO	_	22	mark
22	decrease	decrease	VB	_	20	xcomp
23	in	in	IN	_	25	case
24	platelet	platelet	NN	_	25	compound
25	function	function	NN	_	22	nmod
26	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	14	nsubj
3	of	of	IN	_	5	case
4	calcium	calcium	NN	_	5	compound
5	blockers	blocker	NNS	_	2	nmod
6	on	on	IN	_	8	case
7	platelet	platelet	NN	_	8	compound
8	function	function	NN	_	2	nmod
9	and	and	CC	_	8	cc
10	arachidonic	arachidonic	JJ	_	12	amod
11	acid	acid	NN	_	12	compound
12	metabolism	metabolism	NN	_	8	conj
13	could	could	MD	_	14	aux
14	contribute	contribute	VB	_	0	ROOT
15	in	in	IN	_	16	case
16	part	part	NN	_	14	nmod
17	to	to	TO	_	19	case
18	their	they	PRP$	_	19	nmod:poss
19	efficacy	efficacy	NN	_	14	nmod
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	with	with	IN	_	25	case
23	ischemic	ischemic	JJ	_	25	amod
24	heart	heart	NN	_	25	compound
25	disease	disease	NN	_	21	nmod
26	.	.	.	_	14	punct

1	Pharmacology	pharmacology	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	pharmacotherapy	pharmacotherapy	NN	_	1	conj
4	of	of	IN	_	6	case
5	cardiovascular	cardiovascular	JJ	_	6	amod
6	drugs	drug	NNS	_	1	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	12	case
10	chronic	chronic	JJ	_	12	amod
11	renal	renal	JJ	_	12	amod
12	disease	disease	NN	_	8	nmod
13	.	.	.	_	1	punct

1	Cardiovascular	Cardiovascular	NNP	_	2	compound
2	disease	disease	NN	_	6	nsubj
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	common	common	JJ	_	6	amod
6	comorbidity	comorbidity	NN	_	0	ROOT
7	and	and	CC	_	6	cc
8	a	a	DT	_	10	det
9	major	major	JJ	_	10	amod
10	cause	cause	NN	_	6	conj
11	of	of	IN	_	12	case
12	mortality	mortality	NN	_	10	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	18	case
16	chronic	chronic	JJ	_	18	amod
17	renal	renal	JJ	_	18	amod
18	disease	disease	NN	_	14	nmod
19	.	.	.	_	6	punct

1	Drug	drug	NN	_	2	compound
2	regimens	regimen	NNS	_	10	nsubj
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	with	with	IN	_	7	case
6	cardiovascular	cardiovascular	JJ	_	7	amod
7	disease	disease	NN	_	4	nmod
8	are	be	VBP	_	10	cop
9	frequently	frequently	RB	_	10	advmod
10	complex	complex	JJ	_	0	ROOT
11	and	and	CC	_	10	cc
12	can	can	MD	_	15	aux
13	be	be	VB	_	15	auxpass
14	significantly	significantly	RB	_	15	advmod
15	affected	affect	VBN	_	10	conj
16	by	by	IN	_	17	case
17	alterations	alteration	NNS	_	15	nmod
18	in	in	IN	_	20	case
19	renal	renal	JJ	_	20	amod
20	function	function	NN	_	17	nmod
21	.	.	.	_	10	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	several	several	JJ	_	6	amod
5	cardiovascular	cardiovascular	JJ	_	6	amod
6	drugs	drug	NNS	_	8	nsubj
7	directly	directly	RB	_	8	advmod
8	affect	affect	VBP	_	0	ROOT
9	renal	renal	JJ	_	10	amod
10	function	function	NN	_	8	dobj
11	and	and	CC	_	10	cc
12	the	the	DT	_	13	det
13	management	management	NN	_	10	conj
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	with	with	IN	_	18	case
17	renal	renal	JJ	_	18	amod
18	disease	disease	NN	_	15	nmod
19	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	article	article	NN	_	3	nsubj
3	reviews	review	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	impact	impact	NN	_	3	dobj
6	of	of	IN	_	8	case
7	renal	renal	JJ	_	8	amod
8	disease	disease	NN	_	5	nmod
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
12	of	of	IN	_	14	case
13	cardiovascular	cardiovascular	JJ	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	and	and	CC	_	3	cc
16	identifies	identify	VBZ	_	3	conj
17	clinically	clinically	RB	_	18	advmod
18	important	important	JJ	_	19	amod
19	interactions	interaction	NNS	_	16	dobj
20	between	between	IN	_	21	case
21	these	these	DT	_	19	nmod
22	and	and	CC	_	21	cc
23	other	other	JJ	_	24	amod
24	drugs	drug	NNS	_	21	conj
25	commonly	commonly	RB	_	26	advmod
26	used	use	VBN	_	21	acl
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	management	management	NN	_	26	nmod
30	of	of	IN	_	33	case
31	chronic	chronic	JJ	_	33	amod
32	renal	renal	JJ	_	33	amod
33	disease	disease	NN	_	29	nmod
34	.	.	.	_	3	punct

1	Several	several	JJ	_	2	amod
2	classes	class	NNS	_	8	nsubjpass
3	of	of	IN	_	5	case
4	cardiovascular	cardiovascular	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	are	be	VBP	_	8	auxpass
7	also	also	RB	_	8	advmod
8	discussed	discuss	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	relationship	relationship	NN	_	8	nmod
11	to	to	TO	_	14	case
12	their	they	PRP$	_	14	nmod:poss
13	differential	differential	JJ	_	14	amod
14	effects	effect	NNS	_	10	nmod
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	management	management	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	progression	progression	NN	_	17	conj
20	of	of	IN	_	22	case
21	renal	renal	JJ	_	22	amod
22	disease	disease	NN	_	17	nmod
23	.	.	.	_	8	punct

1	Influence	influence	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	estradiol	estradiol	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	progesterone	progesterone	NN	_	3	conj
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	sensitivity	sensitivity	NN	_	1	nmod
9	of	of	IN	_	12	case
10	rat	rat	NN	_	12	compound
11	thoracic	thoracic	JJ	_	12	amod
12	aorta	aorta	NN	_	8	nmod
13	to	to	TO	_	14	case
14	noradrenaline	noradrenaline	NN	_	8	nmod
15	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	investigate	investigate	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effects	effect	NNS	_	8	dobj
11	of	of	IN	_	15	case
12	low	low	JJ	_	15	amod
13	and	and	CC	_	12	cc
14	high	high	JJ	_	12	conj
15	doses	dose	NNS	_	10	nmod
16	of	of	IN	_	17	case
17	estradiol	estradiol	NN	_	15	nmod
18	,	,	,	_	8	punct
19	and	and	CC	_	8	cc
20	of	of	IN	_	21	case
21	progesterone	progesterone	NN	_	8	conj
22	on	on	IN	_	24	case
23	the	the	DT	_	24	det
24	response	response	NN	_	21	nmod
25	to	to	TO	_	26	case
26	noradrenaline	noradrenaline	NN	_	24	nmod
27	in	in	IN	_	30	case
28	rat	rat	NN	_	30	compound
29	thoracic	thoracic	JJ	_	30	amod
30	aorta	aorta	NN	_	24	nmod
31	.	.	.	_	6	punct

1	Two	two	CD	_	2	nummod
2	weeks	week	NNS	_	9	nmod
3	after	after	IN	_	2	case
4	bilateral	bilateral	JJ	_	5	amod
5	ovariectomy	ovariectomy	NN	_	2	dep
6	,	,	,	_	9	punct
7	female	female	JJ	_	8	amod
8	rats	rat	NNS	_	9	nsubj
9	received	receive	VBD	_	0	ROOT
10	a	a	DT	_	11	det
11	s	s	NNS	_	9	dobj
12	.	.	.	_	9	punct
13	c	c	LS	_	9	dep
14	.	.	.	_	9	punct

1	injection	injection	NN	_	0	ROOT
2	of	of	IN	_	6	case
3	vehicle	vehicle	NN	_	6	compound
4	(	(	CD	_	6	nummod
5	corn	corn	NN	_	6	compound
6	oil	oil	NN	_	1	nmod
7	,	,	,	_	6	punct
8	0.1	0.1	CD	_	9	nummod
9	mL	ml	NN	_	6	appos
10	/	/	:	_	1	punct
11	day	day	NN	_	1	dep
12	)	)	CD	_	11	nummod
13	,	,	,	_	11	punct
14	estradiol	estradiol	NN	_	11	appos
15	(	(	CD	_	16	compound
16	10	10	CD	_	17	nummod
17	microg	microg	NN	_	14	dep
18	/	/	:	_	17	punct
19	kg	kg	NN	_	17	dep
20	/	/	:	_	17	punct
21	day	day	NN	_	24	compound
22	or	or	CC	_	21	cc
23	4	4	CD	_	21	conj
24	mg	mg	NN	_	17	dep
25	/	/	:	_	17	punct
26	kg	kg	NN	_	17	dep
27	/	/	:	_	17	punct
28	day	day	NN	_	17	dep
29	)	)	CD	_	28	nummod
30	and	and	CC	_	28	cc
31	/	/	:	_	36	punct
32	or	or	CC	_	36	cc
33	progesterone	progesterone	NN	_	36	compound
34	(	(	CD	_	35	compound
35	20	20	CD	_	36	nummod
36	mg	mg	NN	_	28	conj
37	/	/	:	_	17	punct
38	kg	kg	NN	_	17	dep
39	/	/	:	_	17	punct
40	day	day	NN	_	17	dep
41	)	)	CD	_	40	nummod
42	,	,	,	_	17	punct
43	for	for	IN	_	45	case
44	eight	eight	CD	_	45	nummod
45	days	day	NNS	_	17	nmod
46	.	.	.	_	1	punct

1	On	on	IN	_	4	case
2	the	the	DT	_	4	det
3	ninth	ninth	JJ	_	4	amod
4	day	day	NN	_	9	nmod
5	,	,	,	_	9	punct
6	the	the	DT	_	7	det
7	rats	rat	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	sacrificed	sacrifice	VBN	_	0	ROOT
10	and	and	CC	_	9	cc
11	aortic	aortic	JJ	_	12	amod
12	rings	ring	NNS	_	20	nsubjpass
13	,	,	,	_	12	punct
14	with	with	IN	_	17	nmod
15	or	or	CC	_	14	cc
16	without	without	IN	_	14	conj
17	endothelium	endothelium	NN	_	12	nmod
18	,	,	,	_	12	punct
19	were	be	VBD	_	20	auxpass
20	used	use	VBN	_	9	conj
21	to	to	TO	_	22	mark
22	generate	generate	VB	_	20	xcomp
23	concentration	concentration	NN	_	22	dobj
24	-	-	:	_	23	punct
25	response	response	NN	_	26	compound
26	curves	curve	NNS	_	23	dep
27	to	to	TO	_	28	case
28	noradrenaline	noradrenaline	NN	_	26	nmod
29	.	.	.	_	9	punct

1	Aortic	aortic	JJ	_	2	amod
2	rings	ring	NNS	_	22	nsubj
3	with	with	IN	_	5	case
4	intact	intact	JJ	_	5	amod
5	endothelium	endothelium	NN	_	2	nmod
6	from	from	IN	_	13	case
7	the	the	DT	_	13	det
8	high	high	JJ	_	13	amod
9	-	-	:	_	13	punct
10	dose	dose	NN	_	13	compound
11	(	(	NN	_	13	compound
12	4	4	CD	_	13	nummod
13	mg	mg	NN	_	2	nmod
14	/	/	:	_	13	punct
15	kg	kg	NN	_	13	dep
16	/	/	:	_	13	punct
17	day	day	NN	_	20	compound
18	)	)	CD	_	20	nummod
19	estradiol	estradiol	NN	_	20	compound
20	group	group	NN	_	13	dep
21	were	be	VBD	_	22	cop
22	supersensitive	supersensitive	JJ	_	0	ROOT
23	to	to	TO	_	24	case
24	noradrenaline	noradrenaline	NN	_	22	nmod
25	compared	compare	VBN	_	28	case
26	to	to	TO	_	28	case
27	the	the	DT	_	28	det
28	vehicle	vehicle	NN	_	22	advcl
29	or	or	CC	_	28	cc
30	low	low	JJ	_	28	conj
31	-	-	:	_	22	punct
32	dose	dose	NN	_	35	compound
33	(	(	NN	_	35	compound
34	10	10	CD	_	35	nummod
35	microg	microg	NN	_	43	nsubj
36	/	/	:	_	35	punct
37	kg	kg	NN	_	35	dep
38	/	/	:	_	35	punct
39	day	day	NN	_	42	compound
40	)	)	CD	_	42	nummod
41	estradiol	estradiol	NN	_	42	compound
42	groups	group	NNS	_	35	dep
43	(	(	VBP	_	22	parataxis
44	pD2	pd2	NN	_	45	compound
45	values	value	NNS	_	43	dobj
46	=	=	JJ	_	43	dep
47	7.86	7.86	CD	_	46	dep
48	+	+	CC	_	47	cc
49	/	/	:	_	47	punct
50	-	-	:	_	49	punct
51	0.09	0.09	CD	_	50	root
52	,	,	,	_	51	punct
53	7.30	7.30	CD	_	52	root
54	+	+	CC	_	53	cc
55	/	/	:	_	53	conj
56	-	-	:	_	55	punct
57	0.11	0.11	CD	_	56	root
58	and	and	CC	_	57	cc
59	7.35	7.35	CD	_	57	conj
60	+	+	CC	_	57	cc
61	/	/	:	_	63	punct
62	-	-	:	_	63	punct
63	0.04	0.04	CD	_	57	conj
64	,	,	,	_	63	punct
65	respectively	respectively	RB	_	66	advmod
66	)	)	CD	_	63	appos
67	.	.	.	_	57	punct

1	Endothelium	endothelium	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	intact	intact	JJ	_	5	amod
4	aortic	aortic	JJ	_	5	amod
5	rings	ring	NNS	_	12	nsubj
6	from	from	IN	_	10	case
7	high	high	JJ	_	10	amod
8	-	-	:	_	10	punct
9	estradiol	estradiol	NN	_	10	compound
10	rats	rat	NNS	_	5	nmod
11	were	be	VBD	_	12	cop
12	supersensitive	supersensitive	JJ	_	1	dep
13	to	to	TO	_	14	case
14	noradrenaline	noradrenaline	NN	_	12	nmod
15	when	when	WRB	_	16	advmod
16	compared	compare	VBN	_	12	advcl
17	to	to	TO	_	18	case
18	vehicle	vehicle	NN	_	16	nmod
19	-	-	:	_	12	punct
20	,	,	,	_	12	punct
21	progesterone	progesterone	NN	_	12	dep
22	-	-	:	_	24	punct
23	and	and	CC	_	24	cc
24	progesterone	progesterone	NN	_	21	dep
25	+	+	CC	_	24	cc
26	high	high	JJ	_	28	amod
27	-	-	:	_	28	punct
28	estradiol	estradiol	NN	_	24	conj
29	-	-	:	_	24	punct
30	treated	treat	VBN	_	31	amod
31	rats	rat	NNS	_	32	nsubj
32	(	(	VBP	_	24	parataxis
33	pD2	pd2	NN	_	34	compound
34	values	value	NNS	_	32	dobj
35	=	=	JJ	_	32	dep
36	7.77	7.77	CD	_	35	dep
37	+	+	CC	_	36	cc
38	/	/	:	_	36	punct
39	-	-	:	_	38	punct
40	0.12	0.12	CD	_	39	root
41	,	,	,	_	40	punct
42	7.21	7.21	CD	_	41	root
43	+	+	CC	_	42	cc
44	/	/	:	_	42	conj
45	-	-	:	_	44	punct
46	0.13	0.13	CD	_	45	root
47	,	,	,	_	46	punct
48	6.93	6.93	CD	_	47	root
49	+	+	CC	_	48	cc
50	/	/	:	_	48	conj
51	-	-	:	_	50	punct
52	0.04	0.04	CD	_	51	root
53	and	and	CC	_	52	cc
54	7.22	7.22	CD	_	52	conj
55	+	+	CC	_	52	cc
56	/	/	:	_	58	punct
57	-	-	:	_	58	punct
58	0.18	0.18	CD	_	52	conj
59	,	,	,	_	58	punct
60	respectively	respectively	RB	_	61	advmod
61	)	)	CD	_	58	appos
62	.	.	.	_	52	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	differences	difference	NNS	_	2	nsubj
6	among	among	IN	_	9	case
7	the	the	DT	_	9	det
8	pD2	pd2	NN	_	9	compound
9	values	value	NNS	_	5	nmod
10	for	for	IN	_	11	case
11	noradrenaline	noradrenaline	NN	_	5	nmod
12	in	in	IN	_	14	case
13	aortic	aortic	JJ	_	14	amod
14	rings	ring	NNS	_	11	nmod
15	without	without	IN	_	16	case
16	endothelium	endothelium	NN	_	11	nmod
17	.	.	.	_	2	punct

1	Both	both	DT	_	6	nsubj
2	of	of	IN	_	4	case
3	these	these	DT	_	4	det
4	effects	effect	NNS	_	1	nmod
5	were	be	VBD	_	6	cop
6	endothelium	endothelium	NN	_	0	ROOT
7	-	-	:	_	6	punct
8	dependent	dependent	JJ	_	6	amod
9	.	.	.	_	6	punct

1	Magnesium	magnesium	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	therapeutics	therapeutics	NNS	_	1	conj
4	.	.	.	_	1	punct

1	Two	two	CD	_	3	nummod
2	different	different	JJ	_	3	amod
3	types	type	NNS	_	9	nsubjpass
4	of	of	IN	_	5	case
5	therapy	therapy	NN	_	3	nmod
6	with	with	IN	_	7	case
7	magnesium	magnesium	NN	_	5	nmod
8	are	be	VBP	_	9	auxpass
9	used	use	VBN	_	0	ROOT
10	:	:	:	_	9	punct
11	physiological	physiological	JJ	_	14	amod
12	oral	oral	JJ	_	14	amod
13	magnesium	magnesium	NN	_	14	compound
14	supplementation	supplementation	NN	_	9	dep
15	which	which	WDT	_	18	nsubj
16	is	be	VBZ	_	18	cop
17	totally	totally	RB	_	18	advmod
18	atoxic	atoxic	JJ	_	14	acl:relcl
19	since	since	IN	_	21	mark
20	it	it	PRP	_	21	nsubj
21	palliates	palliate	VBZ	_	18	advcl
22	magnesium	magnesium	NN	_	23	compound
23	deficiencies	deficiency	NNS	_	21	dobj
24	by	by	IN	_	26	mark
25	simply	simply	RB	_	26	advmod
26	normalizing	normalize	VBG	_	21	advcl
27	the	the	DT	_	29	det
28	magnesium	magnesium	NN	_	29	compound
29	intake	intake	NN	_	26	dobj
30	and	and	CC	_	29	cc
31	pharmacological	pharmacological	JJ	_	33	amod
32	magnesium	magnesium	NN	_	33	compound
33	therapy	therapy	NN	_	29	conj
34	which	which	WDT	_	36	nsubj
35	may	may	MD	_	36	aux
36	induce	induce	VB	_	29	acl:relcl
37	toxicity	toxicity	NN	_	36	dobj
38	since	since	IN	_	40	mark
39	it	it	PRP	_	40	nsubj
40	creates	create	VBZ	_	36	advcl
41	iatrogenic	iatrogenic	JJ	_	43	amod
42	magnesium	magnesium	NN	_	43	compound
43	overload	overload	NN	_	40	dobj
44	.	.	.	_	9	punct

1	Primary	primary	JJ	_	5	amod
2	and	and	CC	_	1	cc
3	secondary	secondary	JJ	_	1	conj
4	magnesium	magnesium	NN	_	5	compound
5	deficiencies	deficiency	NNS	_	6	nsubj
6	constitute	constitute	VBP	_	0	ROOT
7	the	the	DT	_	9	det
8	sole	sole	JJ	_	9	amod
9	indication	indication	NN	_	6	dobj
10	of	of	IN	_	14	case
11	physiological	physiological	JJ	_	14	amod
12	oral	oral	JJ	_	14	amod
13	magnesium	magnesium	NN	_	14	compound
14	therapy	therapy	NN	_	9	nmod
15	.	.	.	_	6	punct

1	It	it	PRP	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	therefore	therefore	RB	_	4	advmod
4	necessary	necessary	JJ	_	0	ROOT
5	to	to	TO	_	8	mark
6	be	be	VB	_	8	auxpass
7	well	well	RB	_	8	advmod
8	acquainted	acquaint	VBN	_	4	xcomp
9	with	with	IN	_	14	case
10	the	the	DT	_	14	det
11	clinical	clinical	JJ	_	14	amod
12	and	and	CC	_	11	cc
13	paraclinical	paraclinical	JJ	_	11	conj
14	pattern	pattern	NN	_	8	nmod
15	of	of	IN	_	17	case
16	magnesium	magnesium	NN	_	17	compound
17	deficit	deficit	NN	_	14	nmod
18	and	and	CC	_	14	cc
19	to	to	TO	_	20	mark
20	discriminate	discriminate	VB	_	14	conj
21	between	between	IN	_	23	case
22	magnesium	magnesium	NN	_	23	compound
23	deficiency	deficiency	NN	_	20	nmod
24	due	due	JJ	_	29	case
25	to	to	TO	_	24	mwe
26	an	a	DT	_	29	det
27	insufficient	insufficient	JJ	_	29	amod
28	magnesium	magnesium	NN	_	29	compound
29	intake	intake	NN	_	20	nmod
30	which	which	WDT	_	32	nsubj
31	only	only	RB	_	32	advmod
32	requires	require	VBZ	_	29	acl:relcl
33	oral	oral	JJ	_	35	amod
34	physiological	physiological	JJ	_	35	amod
35	supplementation	supplementation	NN	_	32	dobj
36	and	and	CC	_	35	cc
37	magnesium	magnesium	NN	_	38	compound
38	depletion	depletion	NN	_	35	conj
39	related	related	JJ	_	35	amod
40	to	to	TO	_	42	case
41	a	a	DT	_	42	det
42	dysregulation	dysregulation	NN	_	39	nmod
43	of	of	IN	_	46	case
44	the	the	DT	_	46	det
45	control	control	NN	_	46	compound
46	mechanisms	mechanism	NNS	_	42	nmod
47	of	of	IN	_	49	case
48	magnesium	magnesium	NN	_	49	compound
49	status	status	NN	_	46	nmod
50	which	which	WDT	_	51	nsubj
51	requires	require	VBZ	_	46	acl:relcl
52	more	more	RBR	_	56	advmod
53	or	or	CC	_	52	cc
54	less	less	RBR	_	52	conj
55	specific	specific	JJ	_	56	amod
56	regulation	regulation	NN	_	51	dobj
57	of	of	IN	_	60	case
58	its	its	PRP$	_	60	nmod:poss
59	causal	causal	JJ	_	60	amod
60	dysregulation	dysregulation	NN	_	56	nmod
61	.	.	.	_	4	punct

1	Physiological	physiological	JJ	_	4	amod
2	oral	oral	JJ	_	4	amod
3	magnesium	magnesium	NN	_	4	compound
4	load	load	NN	_	5	nsubj
5	constitutes	constitute	VBZ	_	0	ROOT
6	the	the	DT	_	8	det
7	best	best	JJS	_	8	amod
8	tool	tool	NN	_	5	dobj
9	for	for	IN	_	10	case
10	diagnosis	diagnosis	NN	_	8	nmod
11	of	of	IN	_	13	case
12	magnesium	magnesium	NN	_	13	compound
13	deficiency	deficiency	NN	_	10	nmod
14	and	and	CC	_	8	cc
15	the	the	DT	_	17	det
16	first	first	JJ	_	17	amod
17	step	step	NN	_	8	conj
18	of	of	IN	_	20	case
19	its	its	PRP$	_	20	nmod:poss
20	treatment	treatment	NN	_	17	nmod
21	.	.	.	_	5	punct

1	Physiological	physiological	JJ	_	4	amod
2	oral	oral	JJ	_	4	amod
3	magnesium	magnesium	NN	_	4	compound
4	supplementation	supplementation	NN	_	14	nsubj
5	(	(	CD	_	7	nummod
6	5	5	CD	_	7	nummod
7	mg	mg	NN	_	4	dep
8	/	/	:	_	4	punct
9	kg	kg	NN	_	4	dep
10	/	/	:	_	4	punct
11	day	day	NN	_	4	dep
12	)	)	CD	_	11	nummod
13	is	be	VBZ	_	14	cop
14	easy	easy	JJ	_	0	ROOT
15	and	and	CC	_	14	cc
16	can	can	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	carried	carry	VBN	_	14	conj
19	out	out	RP	_	18	compound:prt
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	diet	diet	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	with	with	IN	_	26	case
25	magnesium	magnesium	NN	_	26	compound
26	salts	salt	NNS	_	22	conj
27	,	,	,	_	14	punct
28	with	with	IN	_	32	case
29	practically	practically	RB	_	31	advmod
30	only	only	RB	_	31	advmod
31	one	one	CD	_	32	nummod
32	contra	contra	NN	_	14	nmod
33	-	-	:	_	32	punct
34	indication	indication	NN	_	32	dep
35	:	:	:	_	32	punct
36	overt	overt	JJ	_	38	amod
37	renal	renal	JJ	_	38	amod
38	failure	failure	NN	_	32	dep
39	.	.	.	_	14	punct

1	Specific	specific	JJ	_	4	amod
2	and	and	CC	_	1	cc
3	aspecific	aspecific	JJ	_	1	conj
4	treatments	treatment	NNS	_	9	nsubj
5	of	of	IN	_	7	case
6	magnesium	magnesium	NN	_	7	compound
7	depletion	depletion	NN	_	4	nmod
8	are	be	VBP	_	9	cop
9	tricky	tricky	JJ	_	0	ROOT
10	using	use	VBG	_	9	xcomp
11	for	for	IN	_	15	case
12	example	example	NN	_	15	compound
13	magnesium	magnesium	NN	_	15	compound
14	sparing	spare	VBG	_	15	amod
15	diuretics	diuretic	NNS	_	10	nmod
16	,	,	,	_	15	punct
17	pharmacological	pharmacological	JJ	_	18	amod
18	doses	dose	NNS	_	15	appos
19	of	of	IN	_	21	case
20	vitamin	vitamin	NN	_	21	compound
21	B6	b6	NN	_	18	nmod
22	,	,	,	_	21	punct
23	physiological	physiological	JJ	_	24	amod
24	doses	dose	NNS	_	21	appos
25	of	of	IN	_	27	case
26	vitamin	vitamin	NN	_	27	compound
27	D	d	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	of	of	IN	_	30	case
30	selenium	selenium	NN	_	27	conj
31	.	.	.	_	9	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	use	use	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacological	pharmacological	JJ	_	7	amod
7	properties	property	NNS	_	4	dobj
8	of	of	IN	_	11	case
9	induced	induce	VBN	_	11	amod
10	therapeutic	therapeutic	JJ	_	11	amod
11	hypermagnesaemia	hypermagnesaemia	NN	_	7	nmod
12	,	,	,	_	11	punct
13	high	high	JJ	_	15	amod
14	oral	oral	JJ	_	15	amod
15	doses	dose	NNS	_	11	appos
16	of	of	IN	_	17	case
17	magnesium	magnesium	NN	_	28	nmod
18	(	(	CD	_	17	nummod
19	>	>	JJR	_	21	dep
20	10	10	CD	_	21	nummod
21	mg	mg	NN	_	28	nsubj
22	/	/	:	_	21	punct
23	kg	kg	NN	_	21	dep
24	/	/	:	_	21	punct
25	day	day	NN	_	21	dep
26	)	)	CD	_	25	nummod
27	are	be	VBP	_	28	cop
28	advisable	advisable	JJ	_	15	nmod
29	for	for	IN	_	31	case
30	chronic	chronic	JJ	_	31	amod
31	indications	indication	NNS	_	28	nmod
32	and	and	CC	_	28	cc
33	the	the	DT	_	35	det
34	parenteral	parenteral	JJ	_	35	amod
35	route	route	NN	_	37	nsubj
36	is	be	VBZ	_	37	cop
37	suitable	suitable	JJ	_	28	conj
38	for	for	IN	_	40	case
39	acute	acute	JJ	_	40	amod
40	indications	indication	NNS	_	37	nmod
41	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	3	3	CD	_	4	nummod
4	types	type	NNS	_	2	nsubj
5	of	of	IN	_	6	case
6	indications	indication	NNS	_	4	nmod
7	:	:	:	_	4	punct
8	specific	specific	JJ	_	9	amod
9	(	(	NN	_	4	dep
10	for	for	IN	_	12	case
11	the	the	DT	_	12	det
12	treatment	treatment	NN	_	9	nmod
13	of	of	IN	_	15	case
14	some	some	DT	_	15	det
15	forms	form	NNS	_	12	nmod
16	of	of	IN	_	19	case
17	magnesium	magnesium	NN	_	19	compound
18	deficit	deficit	NN	_	19	compound
19	i	i	FW	_	15	nmod
20	.	.	.	_	2	punct
21	e	e	LS	_	2	dep
22	.	.	.	_	21	punct
23	acute	acute	JJ	_	24	amod
24	)	)	NN	_	21	dep
25	,	,	,	_	24	punct
26	pharmacological	pharmacological	JJ	_	28	amod
27	(	(	NN	_	28	compound
28	i	i	FW	_	24	appos
29	.	.	.	_	24	punct
30	e	e	LS	_	24	dep
31	.	.	.	_	30	punct
32	without	without	IN	_	33	case
33	alterations	alteration	NNS	_	30	nmod
34	of	of	IN	_	37	case
35	magnesium	magnesium	NN	_	37	compound
36	status	status	NN	_	37	compound
37	)	)	NN	_	33	nmod
38	and	and	CC	_	37	cc
39	mixed	mixed	JJ	_	45	amod
40	--	--	:	_	39	punct
41	pharmacological	pharmacological	JJ	_	39	dep
42	and	and	CC	_	41	cc
43	aetiopathogenic	aetiopathogenic	JJ	_	41	conj
44	--	--	:	_	39	punct
45	(	(	NN	_	37	conj
46	for	for	IN	_	48	case
47	example	example	NN	_	48	compound
48	complications	complication	NNS	_	33	nmod
49	of	of	IN	_	52	case
50	chronic	chronic	JJ	_	52	amod
51	alcoholism	alcoholism	NN	_	52	compound
52	)	)	NN	_	48	nmod
53	.	.	.	_	2	punct

1	Today	today	NN	_	4	compound
2	pharmacological	pharmacological	JJ	_	4	amod
3	magnesium	magnesium	NN	_	4	compound
4	therapy	therapy	NN	_	6	nsubj
5	mainly	mainly	RB	_	6	advmod
6	concerns	concern	VBZ	_	0	ROOT
7	the	the	DT	_	13	det
8	obstetrical	obstetrical	JJ	_	13	amod
9	,	,	,	_	8	punct
10	cardiological	cardiological	JJ	_	8	conj
11	and	and	CC	_	8	cc
12	anaesthesiological	anaesthesiological	JJ	_	8	conj
13	fields	field	NNS	_	6	dobj
14	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	main	main	JJ	_	3	amod
3	indications	indication	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	eclampsia	eclampsia	NN	_	0	ROOT
6	,	,	,	_	5	punct
7	some	some	DT	_	8	det
8	dysrhythmias	dysrhythmia	NNS	_	9	nsubj
9	(	(	VBP	_	5	acl:relcl
10	torsades	torsade	NNS	_	12	compound
11	de	de	IN	_	12	amod
12	pointe	pointe	FW	_	9	dobj
13	particularly	particularly	RB	_	14	advmod
14	)	)	CD	_	12	nummod
15	and	and	CC	_	12	cc
16	myocardial	myocardial	JJ	_	17	amod
17	ischaemias	ischaemia	NNS	_	12	conj
18	.	.	.	_	5	punct

1	But	but	CC	_	5	cc
2	it	it	PRP	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	now	now	RB	_	5	advmod
5	difficult	difficult	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	situate	situate	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	exact	exact	JJ	_	10	amod
10	place	place	NN	_	7	dobj
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	pharmacological	pharmacological	JJ	_	14	amod
14	indications	indication	NNS	_	10	nmod
15	of	of	IN	_	16	case
16	magnesium	magnesium	NN	_	14	nmod
17	.	.	.	_	5	punct

1	Magnesium	magnesium	NN	_	2	compound
2	infusions	infusion	NNS	_	6	nsubjpass
3	can	can	MD	_	6	aux
4	only	only	RB	_	6	advmod
5	be	be	VB	_	6	auxpass
6	envisaged	envisage	VBN	_	0	ROOT
7	in	in	IN	_	10	case
8	intensive	intensive	JJ	_	10	amod
9	care	care	NN	_	10	compound
10	units	unit	NNS	_	6	nmod
11	with	with	IN	_	13	case
12	careful	careful	JJ	_	13	amod
13	monitoring	monitoring	NN	_	10	nmod
14	of	of	IN	_	15	case
15	pulse	pulse	NN	_	13	nmod
16	,	,	,	_	6	punct
17	arterial	arterial	JJ	_	18	amod
18	pressure	pressure	NN	_	6	dobj
19	,	,	,	_	18	punct
20	deep	deep	JJ	_	22	amod
21	tendon	tendon	NN	_	22	compound
22	reflexes	reflex	NNS	_	18	conj
23	,	,	,	_	18	punct
24	hourly	hourly	JJ	_	25	amod
25	diuresis	diuresis	NN	_	18	conj
26	,	,	,	_	18	punct
27	electrocardiogram	electrocardiogram	NN	_	18	conj
28	and	and	CC	_	18	cc
29	respiratory	respiratory	JJ	_	30	amod
30	recordings	recording	NNS	_	18	conj
31	.	.	.	_	6	punct

1	High	high	JJ	_	4	amod
2	oral	oral	JJ	_	4	amod
3	magnesium	magnesium	NN	_	4	compound
4	doses	dose	NNS	_	10	nsubj
5	besides	besides	IN	_	8	case
6	their	they	PRP$	_	8	nmod:poss
7	laxative	laxative	NN	_	8	compound
8	action	action	NN	_	4	nmod
9	may	may	MD	_	10	aux
10	bring	bring	VB	_	0	ROOT
11	latent	latent	JJ	_	12	amod
12	complications	complication	NNS	_	10	dobj
13	which	which	WDT	_	15	nsubj
14	may	may	MD	_	15	aux
15	reduce	reduce	VB	_	12	acl:relcl
16	lifespan	lifespan	NN	_	15	dobj
17	.	.	.	_	10	punct

1	There	there	EX	_	3	expl
2	may	may	MD	_	3	aux
3	remain	remain	VB	_	0	ROOT
4	some	some	DT	_	5	det
5	indications	indication	NNS	_	3	xcomp
6	of	of	IN	_	11	case
7	the	the	DT	_	11	det
8	laxative	laxative	NN	_	11	compound
9	and	and	CC	_	8	cc
10	antacid	antacid	NN	_	8	conj
11	properties	property	NNS	_	5	nmod
12	of	of	IN	_	15	case
13	non	non	JJ	_	15	amod
14	soluble	soluble	JJ	_	15	amod
15	magnesium	magnesium	NN	_	11	nmod
16	,	,	,	_	15	punct
17	particularly	particularly	RB	_	20	advmod
18	during	during	IN	_	20	case
19	intermittent	intermittent	JJ	_	20	amod
20	haemodialysis	haemodialysis	NN	_	15	nmod
21	.	.	.	_	3	punct

1	Lastly	lastly	RB	_	2	advmod
2	local	local	JJ	_	3	amod
3	use	use	NN	_	14	nsubj
4	of	of	IN	_	9	case
5	the	the	DT	_	9	det
6	mucocutaneous	mucocutaneous	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	cytoprotective	cytoprotective	JJ	_	6	conj
9	properties	property	NNS	_	3	nmod
10	of	of	IN	_	11	case
11	magnesium	magnesium	NN	_	9	nmod
12	is	be	VBZ	_	14	cop
13	still	still	RB	_	14	advmod
14	valid	valid	JJ	_	0	ROOT
15	,	,	,	_	14	punct
16	in	in	IN	_	18	case
17	cardioplegic	cardioplegic	JJ	_	18	amod
18	solutions	solution	NNS	_	14	nmod
19	and	and	CC	_	18	cc
20	for	for	IN	_	21	case
21	preservation	preservation	NN	_	18	conj
22	of	of	IN	_	23	case
23	transplants	transplant	NNS	_	21	nmod
24	particularly	particularly	RB	_	14	advmod
25	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	DCG	dcg	NN	_	2	nmod
5	-	-	:	_	4	punct
6	IV	iv	CD	_	4	nummod
7	and	and	CC	_	4	cc
8	L	l	NN	_	4	conj
9	-	-	:	_	4	punct
10	CCG	ccg	SYM	_	4	dep
11	-	-	:	_	10	punct
12	1	1	CD	_	11	root
13	upon	upon	IN	_	16	case
14	phencyclidine	phencyclidine	NN	_	16	compound
15	(	(	CD	_	16	nummod
16	PCP	pcp	NN	_	12	nmod
17	)	)	SYM	_	20	dep
18	-	-	:	_	20	punct
19	induced	induce	VBN	_	20	amod
20	locomotion	locomotion	NN	_	23	amod
21	and	and	CC	_	20	cc
22	behavioral	behavioral	JJ	_	20	conj
23	changes	change	NNS	_	16	dobj
24	in	in	IN	_	25	case
25	mice	mouse	NNS	_	23	nmod
26	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	behavioral	behavioral	JJ	_	3	amod
3	changes	change	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	mice	mouse	NNS	_	3	nmod
6	induced	induce	VBN	_	5	acl
7	by	by	IN	_	8	case
8	acute	acute	JJ	_	6	nmod
9	and	and	CC	_	8	cc
10	repeated	repeated	JJ	_	8	conj
11	i	i	LS	_	8	dep
12	.	.	.	_	3	punct
13	p	p	NN	_	3	dep
14	.	.	.	_	3	punct

1	injection	injection	NN	_	8	nsubjpass
2	of	of	IN	_	6	case
3	phencyclidine	phencyclidine	NN	_	6	compound
4	(	(	CD	_	6	nummod
5	PCP	pcp	NN	_	6	compound
6	)	)	NN	_	1	nmod
7	were	be	VBD	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	by	by	IN	_	10	mark
10	measuring	measure	VBG	_	8	advcl
11	locomotor	locomotor	NN	_	12	compound
12	activity	activity	NN	_	10	dobj
13	and	and	CC	_	12	cc
14	stereotyped	stereotyped	JJ	_	15	amod
15	behavior	behavior	NN	_	12	conj
16	.	.	.	_	8	punct

1	Then	then	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	root
5	of	of	IN	_	12	case
6	metabotropic	metabotropic	JJ	_	12	amod
7	glutamate	glutamate	NN	_	12	compound
8	receptor	receptor	NN	_	12	compound
9	(	(	NN	_	12	compound
10	mGluR	mglur	NN	_	12	compound
11	)	)	CD	_	12	nummod
12	agonists	agonist	NNS	_	4	nmod
13	,	,	,	_	12	punct
14	DCG	dcg	SYM	_	16	dep
15	-	-	:	_	16	punct
16	IV	iv	CD	_	12	appos
17	and	and	CC	_	16	cc
18	L	l	NN	_	16	conj
19	-	-	:	_	16	punct
20	CCG	ccg	SYM	_	22	dep
21	-	-	:	_	22	punct
22	1	1	CD	_	33	nsubjpass
23	,	,	,	_	22	punct
24	on	on	IN	_	28	case
25	the	the	DT	_	28	det
26	above	above	JJ	_	28	amod
27	behavioral	behavioral	JJ	_	28	amod
28	changes	change	NNS	_	22	nmod
29	induced	induce	VBN	_	28	acl
30	by	by	IN	_	31	case
31	PCP	pcp	NN	_	29	nmod
32	were	be	VBD	_	33	auxpass
33	found	find	VBN	_	16	acl:relcl
34	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	9	nsubj
3	of	of	IN	_	4	case
4	DCG	dcg	NN	_	2	nmod
5	-	-	:	_	4	punct
6	IV	iv	CD	_	4	nummod
7	were	be	VBD	_	9	cop
8	very	very	RB	_	9	advmod
9	strong	strong	JJ	_	0	ROOT
10	and	and	CC	_	9	cc
11	completely	completely	RB	_	12	advmod
12	depressed	depress	VBD	_	9	conj
13	the	the	DT	_	14	det
14	PCP	pcp	NN	_	12	dobj
15	-	-	:	_	14	punct
16	induced	induce	VBN	_	17	amod
17	hyperlocomotion	hyperlocomotion	NN	_	14	dep
18	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	L	l	NN	_	2	nmod
5	-	-	:	_	4	punct
6	CCG	ccg	SYM	_	12	dep
7	-	-	:	_	12	punct
8	1	1	CD	_	12	nsubj
9	were	be	VBD	_	12	cop
10	not	not	RB	_	12	neg
11	so	so	RB	_	12	advmod
12	strong	strong	JJ	_	4	dep
13	.	.	.	_	2	punct

1	Repeated	repeated	JJ	_	2	amod
2	injection	injection	NN	_	10	nsubj
3	of	of	IN	_	4	case
4	PCP	pcp	NN	_	2	nmod
5	for	for	IN	_	7	case
6	20	20	CD	_	7	nummod
7	days	day	NNS	_	2	nmod
8	into	into	IN	_	9	case
9	mice	mouse	NNS	_	7	nmod
10	induced	induce	VBD	_	0	ROOT
11	lower	lower	JJR	_	13	amod
12	locomotor	locomotor	NN	_	13	compound
13	activity	activity	NN	_	10	dobj
14	than	than	IN	_	15	case
15	that	that	DT	_	13	nmod
16	in	in	IN	_	19	case
17	acutely	acutely	RB	_	18	advmod
18	injected	inject	VBN	_	19	amod
19	mice	mouse	NNS	_	15	nmod
20	.	.	.	_	10	punct

1	These	these	DT	_	3	det
2	behavioral	behavioral	JJ	_	3	amod
3	changes	change	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	related	relate	VBN	_	0	ROOT
7	with	with	IN	_	10	case
8	the	the	DT	_	10	det
9	negative	negative	JJ	_	10	amod
10	symptoms	symptom	NNS	_	6	nmod
11	of	of	IN	_	12	case
12	schizophrenia	schizophrenia	NN	_	10	nmod
13	.	.	.	_	6	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	examine	examine	VB	_	0	ROOT
5	some	some	DT	_	7	det
6	molecular	molecular	JJ	_	7	amod
7	mechanisms	mechanism	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	PCP	pcp	NN	_	7	nmod
10	-	-	:	_	7	punct
11	induced	induce	VBN	_	13	amod
12	behavioral	behavioral	JJ	_	13	amod
13	changes	change	NNS	_	7	dep
14	,	,	,	_	13	punct
15	Northern	northern	NN	_	17	compound
16	blot	blot	NN	_	17	compound
17	analysis	analysis	NN	_	13	appos
18	of	of	IN	_	20	case
19	total	total	JJ	_	20	amod
20	RNA	rna	NN	_	17	nmod
21	from	from	IN	_	24	case
22	prefrontal	prefrontal	JJ	_	24	amod
23	cortical	cortical	JJ	_	24	amod
24	tissues	tissue	NNS	_	20	nmod
25	of	of	IN	_	26	case
26	mice	mouse	NNS	_	24	nmod
27	treated	treat	VBN	_	26	acl
28	with	with	IN	_	29	case
29	PCP	pcp	NN	_	27	nmod
30	,	,	,	_	29	punct
31	DCG	dcg	NN	_	33	dep
32	-	-	:	_	33	punct
33	IV	iv	CD	_	29	conj
34	,	,	,	_	29	punct
35	and	and	CC	_	29	cc
36	L	l	NN	_	42	dep
37	-	-	:	_	42	punct
38	CCG	ccg	SYM	_	42	dep
39	-	-	:	_	42	punct
40	1	1	CD	_	42	nsubjpass
41	was	be	VBD	_	42	auxpass
42	carried	carry	VBN	_	29	conj
43	out	out	RP	_	42	compound:prt
44	.	.	.	_	4	punct

1	Lack	lack	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	an	a	DT	_	4	det
4	effect	effect	NN	_	1	nmod
5	of	of	IN	_	6	case
6	azithromycin	azithromycin	NN	_	4	nmod
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	disposition	disposition	NN	_	4	nmod
10	of	of	IN	_	11	case
11	zidovudine	zidovudine	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	dideoxyinosine	dideoxyinosine	NN	_	11	conj
14	in	in	IN	_	15	case
15	HIV	hiv	NN	_	9	nmod
16	-	-	:	_	1	punct
17	infected	infected	JJ	_	18	amod
18	patients	patient	NNS	_	1	dep
19	.	.	.	_	1	punct

1	Two	two	CD	_	2	nummod
2	studies	study	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	conducted	conduct	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	HIV	hiv	NN	_	4	nmod
7	-	-	:	_	6	punct
8	infected	infected	JJ	_	9	amod
9	subjects	subject	NNS	_	6	dep
10	to	to	TO	_	11	mark
11	assess	assess	VB	_	9	acl
12	the	the	DT	_	13	det
13	potential	potential	NN	_	11	dobj
14	for	for	IN	_	15	case
15	azithromycin	azithromycin	NN	_	13	nmod
16	to	to	TO	_	17	mark
17	interact	interact	VB	_	13	acl
18	with	with	IN	_	19	case
19	zidovudine	zidovudine	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	dideoxyinosine	dideoxyinosine	NN	_	19	conj
22	.	.	.	_	4	punct

1	Both	both	DT	_	2	det
2	studies	study	NNS	_	3	nsubj
3	used	use	VBD	_	0	ROOT
4	12	12	CD	_	5	nummod
5	subjects	subject	NNS	_	3	dobj
6	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	zidovudine	zidovudine	NN	_	3	compound
3	study	study	NN	_	4	nsubj
4	dosed	dose	VBD	_	0	ROOT
5	subjects	subject	NNS	_	4	dobj
6	with	with	IN	_	8	case
7	1200	1200	CD	_	8	nummod
8	mg	mg	NN	_	5	nmod
9	/	/	:	_	4	punct
10	day	day	NN	_	4	nmod:tmod
11	of	of	IN	_	14	case
12	azithromycin	azithromycin	NN	_	14	compound
13	(	(	CD	_	14	nummod
14	n	n	NN	_	10	nmod
15	=	=	JJ	_	10	amod
16	7	7	CD	_	17	compound
17	)	)	CD	_	18	nummod
18	(	(	NN	_	20	nsubj
19	later	later	RB	_	20	advmod
20	changed	change	VBD	_	15	dep
21	to	to	TO	_	23	case
22	600	600	CD	_	23	nummod
23	mg	mg	NN	_	20	nmod
24	/	/	:	_	20	punct
25	day	day	NN	_	27	compound
26	[	[	CD	_	27	nummod
27	n	n	NN	_	28	nsubj
28	=	=	JJ	_	20	parataxis
29	5	5	CD	_	30	compound
30	]	]	CD	_	31	nummod
31	)	)	NN	_	28	dobj
32	for	for	IN	_	33	case
33	Days	day	NNS	_	28	nmod
34	8	8	CD	_	33	nummod
35	to	to	TO	_	36	case
36	21	21	CD	_	28	nmod
37	of	of	IN	_	42	case
38	a	a	DT	_	42	det
39	21	21	CD	_	42	nummod
40	-	-	:	_	42	punct
41	day	day	NN	_	42	compound
42	course	course	NN	_	36	nmod
43	of	of	IN	_	45	case
44	100	100	CD	_	45	nummod
45	mg	mg	NN	_	42	nmod
46	,	,	,	_	45	punct
47	five	five	CD	_	48	nummod
48	times	time	NNS	_	45	appos
49	/	/	:	_	28	punct
50	day	day	NN	_	28	dep
51	of	of	IN	_	52	case
52	zidovudine	zidovudine	NN	_	50	nmod
53	.	.	.	_	4	punct

1	Subjects	subject	NNS	_	13	nsubj
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	5	case
4	200	200	CD	_	5	nummod
5	mg	mg	NN	_	2	nmod
6	of	of	IN	_	7	case
7	dideoxyinosine	dideoxyinosine	NN	_	5	nmod
8	twice	twice	RB	_	9	advmod
9	daily	daily	RB	_	13	advmod
10	for	for	IN	_	12	case
11	21	21	CD	_	12	nummod
12	days	day	NNS	_	13	nmod
13	received	receive	VBD	_	0	ROOT
14	1200	1200	CD	_	15	nummod
15	mg	mg	NN	_	13	dobj
16	of	of	IN	_	17	case
17	azithromycin	azithromycin	NN	_	15	nmod
18	or	or	CC	_	15	cc
19	an	a	DT	_	21	det
20	equivalent	equivalent	JJ	_	21	amod
21	amount	amount	NN	_	15	conj
22	of	of	IN	_	23	case
23	placebo	placebo	NN	_	21	nmod
24	/	/	:	_	15	punct
25	day	day	NN	_	15	dep
26	for	for	IN	_	27	case
27	Days	day	NNS	_	25	nmod
28	8	8	CD	_	30	compound
29	to	to	TO	_	30	dep
30	21	21	CD	_	27	nummod
31	.	.	.	_	13	punct

1	Antiretroviral	antiretroviral	JJ	_	2	amod
2	plasma	plasma	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	urine	urine	NN	_	5	compound
5	sampling	sampling	NN	_	2	conj
6	were	be	VBD	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	on	on	IN	_	9	case
9	Days	day	NNS	_	7	nmod
10	1	1	CD	_	9	nummod
11	,	,	,	_	9	punct
12	7	7	CD	_	9	nummod
13	,	,	,	_	9	punct
14	and	and	CC	_	9	cc
15	21	21	CD	_	9	conj
16	for	for	IN	_	17	case
17	zidovudine	zidovudine	NN	_	15	nmod
18	and	and	CC	_	7	cc
19	on	on	IN	_	20	case
20	Days	day	NNS	_	7	conj
21	7	7	CD	_	20	nummod
22	and	and	CC	_	20	cc
23	21	21	CD	_	20	conj
24	for	for	IN	_	25	case
25	dideoxyinosine	dideoxyinosine	NN	_	20	nmod
26	.	.	.	_	7	punct

1	Peripheral	peripheral	JJ	_	3	amod
2	mononuclear	mononuclear	JJ	_	3	amod
3	cells	cell	NNS	_	6	nsubjpass
4	were	be	VBD	_	6	auxpass
5	also	also	RB	_	6	advmod
6	collected	collect	VBN	_	0	ROOT
7	for	for	IN	_	8	case
8	quantitation	quantitation	NN	_	6	nmod
9	of	of	IN	_	11	case
10	phosphorylated	phosphorylate	VBN	_	11	amod
11	zidovudine	zidovudine	NN	_	8	nmod
12	.	.	.	_	6	punct

1	Azithromycin	Azithromycin	NNP	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	impact	impact	NN	_	2	dobj
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	Cmax	cmax	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	AUC	auc	NN	_	8	conj
11	of	of	IN	_	12	case
12	zidovudine	zidovudine	NN	_	8	nmod
13	,	,	,	_	2	punct
14	although	although	IN	_	17	mark
15	it	it	PRP	_	17	nsubj
16	significantly	significantly	RB	_	17	advmod
17	decreased	decrease	VBD	_	2	advcl
18	the	the	DT	_	20	det
19	zidovudine	zidovudine	NN	_	20	compound
20	tmax	tmax	NN	_	17	dobj
21	by	by	IN	_	23	case
22	44	44	CD	_	23	nummod
23	%	%	NN	_	17	nmod
24	and	and	CC	_	17	cc
25	increased	increase	VBD	_	17	conj
26	the	the	DT	_	28	det
27	intracellular	intracellular	JJ	_	28	amod
28	exposure	exposure	NN	_	25	dobj
29	to	to	TO	_	31	case
30	phosphorylated	phosphorylate	VBN	_	31	amod
31	zidovudine	zidovudine	NN	_	28	nmod
32	by	by	IN	_	34	case
33	110	110	CD	_	34	nummod
34	%	%	NN	_	25	nmod
35	.	.	.	_	2	punct

1	Azithromycin	Azithromycin	NNP	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	on	on	IN	_	8	case
7	dideoxyinosine	dideoxyinosine	NN	_	8	compound
8	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
9	.	.	.	_	2	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	results	result	NNS	_	11	advcl
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	studies	study	NNS	_	4	nmod
8	,	,	,	_	11	punct
9	it	it	PRP	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	concluded	conclude	VBN	_	0	ROOT
12	that	that	IN	_	17	mark
13	azithromycin	azithromycin	NN	_	17	nsubjpass
14	may	may	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	safely	safely	RB	_	17	advmod
17	coadministered	coadminister	VBN	_	11	ccomp
18	with	with	IN	_	20	case
19	both	both	CC	_	20	cc:preconj
20	zidovudine	zidovudine	NN	_	17	nmod
21	and	and	CC	_	20	cc
22	dideoxyinosine	dideoxyinosine	NN	_	20	conj
23	.	.	.	_	11	punct

1	Clinical	clinical	JJ	_	2	amod
2	implications	implication	NNS	_	0	ROOT
3	of	of	IN	_	5	case
4	warfarin	warfarin	NN	_	5	compound
5	interactions	interaction	NNS	_	2	nmod
6	with	with	IN	_	8	case
7	five	five	CD	_	8	nummod
8	sedatives	sedative	NNS	_	5	nmod
9	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	intensity	intensity	NN	_	24	nsubjpass
3	,	,	,	_	2	punct
4	uniformity	uniformity	NN	_	2	conj
5	and	and	CC	_	2	cc
6	time	time	NN	_	7	compound
7	course	course	NN	_	2	conj
8	of	of	IN	_	10	case
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	interference	interference	NN	_	2	nmod
11	by	by	IN	_	12	case
12	phenobarbital	phenobarbital	NN	_	10	nmod
13	,	,	,	_	12	punct
14	secobarbital	secobarbital	NN	_	12	conj
15	,	,	,	_	12	punct
16	glutethimide	glutethimide	NN	_	12	conj
17	,	,	,	_	12	punct
18	chloral	chloral	JJ	_	19	amod
19	hydrate	hydrate	NN	_	12	conj
20	and	and	CC	_	12	cc
21	methaqualone	methaqualone	NN	_	12	conj
22	were	be	VBD	_	24	auxpass
23	systematically	systematically	RB	_	24	advmod
24	investigated	investigate	VBN	_	0	ROOT
25	in	in	IN	_	27	case
26	16	16	CD	_	27	nummod
27	patients	patient	NNS	_	24	nmod
28	receiving	receive	VBG	_	27	acl
29	coumarin	coumarin	NN	_	30	compound
30	therapy	therapy	NN	_	28	dobj
31	.	.	.	_	24	punct

1	Each	each	DT	_	2	det
2	subject	subject	JJ	_	3	nsubj
3	received	receive	VBD	_	0	ROOT
4	an	a	DT	_	8	det
5	individualized	individualized	JJ	_	8	amod
6	fixed	fixed	JJ	_	8	amod
7	daily	daily	JJ	_	8	amod
8	dose	dose	NN	_	3	dobj
9	of	of	IN	_	10	case
10	warfarin	warfarin	NN	_	8	nmod
11	and	and	CC	_	3	cc
12	served	serve	VBD	_	3	conj
13	as	as	IN	_	16	case
14	his	he	PRP$	_	16	nmod:poss
15	own	own	JJ	_	16	amod
16	pre	pre	JJ	_	12	nmod
17	-	-	:	_	3	punct
18	and	and	CC	_	3	cc
19	postsedative	postsedative	JJ	_	21	amod
20	treatment	treatment	NN	_	21	compound
21	control	control	NN	_	3	conj
22	.	.	.	_	3	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	times	time	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	measured	measure	VBN	_	0	ROOT
5	four	four	CD	_	6	compound
6	times	time	NNS	_	7	nummod
7	weekly	weekly	JJ	_	4	xcomp
8	during	during	IN	_	13	case
9	five	five	CD	_	13	nummod
10	long	long	JJ	_	13	amod
11	-	-	:	_	13	punct
12	term	term	NN	_	13	compound
13	experiments	experiment	NNS	_	7	nmod
14	.	.	.	_	4	punct

1	Anticoagulant	anticoagulant	JJ	_	2	amod
2	inhibition	inhibition	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	during	during	IN	_	7	case
6	the	the	DT	_	7	det
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	phenobarbital	phenobarbital	NN	_	7	nmod
10	,	,	,	_	9	punct
11	secobarbital	secobarbital	NN	_	9	conj
12	and	and	CC	_	9	cc
13	glutethimide	glutethimide	NN	_	9	conj
14	;	;	:	_	4	punct

1	there	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	change	change	NN	_	2	nsubj
6	in	in	IN	_	8	case
7	prothrombin	prothrombin	NN	_	8	compound
8	test	test	NN	_	2	nmod
9	results	result	VBZ	_	2	nsubj
10	during	during	IN	_	12	case
11	the	the	DT	_	12	det
12	trials	trial	NNS	_	9	nmod
13	of	of	IN	_	15	case
14	chloral	chloral	JJ	_	15	amod
15	hydrate	hydrate	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	methaqualone	methaqualone	NN	_	15	conj
18	.	.	.	_	2	punct

1	Barbiturates	barbiturate	NNS	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	glutethimide	glutethimide	NN	_	1	conj
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	coumarin	coumarin	NN	_	12	compound
12	drugs	drug	NNS	_	10	dobj
13	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drugs	drug	NNS	_	3	nmod
6	from	from	IN	_	8	case
7	these	these	DT	_	8	det
8	groups	group	NNS	_	5	nmod
9	is	be	VBZ	_	10	aux
10	decreasing	decrease	VBG	_	0	ROOT
11	according	accord	VBG	_	14	case
12	to	to	TO	_	11	mwe
13	a	a	DT	_	14	det
14	survey	survey	NN	_	10	nmod
15	of	of	IN	_	19	case
16	200	200	CD	_	19	nummod
17	hospital	hospital	NN	_	19	compound
18	medical	medical	JJ	_	19	amod
19	records	record	NNS	_	14	nmod
20	.	.	.	_	10	punct

1	Chloral	chloral	JJ	_	2	amod
2	hydrate	hydrate	NN	_	5	nsubj
3	and	and	CC	_	2	cc
4	methaqualone	methaqualone	NN	_	2	conj
5	interact	interact	VBP	_	0	ROOT
6	pharmacologically	pharmacologically	RB	_	5	advmod
7	with	with	IN	_	11	case
8	orally	orally	RB	_	9	advmod
9	administered	administer	VBN	_	11	amod
10	anticoagulant	anticoagulant	JJ	_	11	amod
11	agents	agent	NNS	_	5	nmod
12	,	,	,	_	5	punct
13	but	but	CC	_	5	cc
14	the	the	DT	_	15	det
15	effect	effect	NN	_	19	nsubj
16	is	be	VBZ	_	19	cop
17	not	not	RB	_	19	neg
18	clinically	clinically	RB	_	19	advmod
19	significant	significant	JJ	_	5	conj
20	.	.	.	_	5	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	concluded	conclude	VBN	_	0	ROOT
4	that	that	IN	_	11	mark
5	chloral	chloral	JJ	_	6	amod
6	hydrate	hydrate	NN	_	11	nsubjpass
7	and	and	CC	_	6	cc
8	methaqualone	methaqualone	NN	_	6	conj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	administered	administer	VBN	_	3	ccomp
12	safely	safely	RB	_	11	advmod
13	without	without	IN	_	15	case
14	additional	additional	JJ	_	15	amod
15	caution	caution	NN	_	11	nmod
16	in	in	IN	_	19	case
17	prothrombin	prothrombin	NN	_	19	compound
18	test	test	NN	_	19	compound
19	monitoring	monitoring	NN	_	15	nmod
20	during	during	IN	_	23	case
21	oral	oral	JJ	_	23	amod
22	anticoagulant	anticoagulant	JJ	_	23	amod
23	therapy	therapy	NN	_	11	nmod
24	.	.	.	_	3	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	constituents	constituent	NNS	_	1	nmod
5	of	of	IN	_	7	case
6	alcoholic	alcoholic	JJ	_	7	amod
7	beverages	beverage	NNS	_	4	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	promotion	promotion	NN	_	1	nmod
11	of	of	IN	_	13	case
12	liver	liver	NN	_	13	compound
13	damage	damage	NN	_	10	nmod
14	.	.	.	_	1	punct

1	Little	Little	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	adverse	adverse	JJ	_	8	amod
8	effects	effect	NNS	_	4	nmod
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	exposure	exposure	NN	_	8	nmod
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	liver	liver	NN	_	11	nmod
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	interaction	interaction	NN	_	8	nmod
18	of	of	IN	_	19	case
19	ethanol	ethanol	NN	_	17	nmod
20	with	with	IN	_	22	case
21	its	its	PRP$	_	22	nmod:poss
22	congeners	congener	NNS	_	17	nmod
23	and	and	CC	_	22	cc
24	acetaldehyde	acetaldehyde	NN	_	22	conj
25	,	,	,	_	4	punct
26	coexisting	coexist	VBG	_	4	advcl
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	contents	contents	NNS	_	26	nmod
30	of	of	IN	_	32	case
31	alcoholic	alcoholic	JJ	_	32	amod
32	beverages	beverage	NNS	_	29	nmod
33	.	.	.	_	4	punct

1	Twenty	twenty	CD	_	5	nummod
2	four	four	CD	_	5	nummod
3	male	male	JJ	_	5	amod
4	Wistar	Wistar	NNP	_	5	compound
5	rats	rat	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	divided	divide	VBN	_	0	ROOT
8	into	into	IN	_	10	case
9	four	four	CD	_	10	nummod
10	groups	group	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	Two	two	CD	_	2	nummod
2	groups	group	NNS	_	0	ROOT
3	(	(	CD	_	4	nummod
4	SH	sh	NN	_	2	dep
5	/	/	:	_	4	punct
6	DA	DA	NNP	_	4	dep
7	;	;	:	_	4	punct
8	SH	SH	NNP	_	13	dep
9	/	/	:	_	13	punct
10	FA	FA	NNP	_	13	nsubjpass
11	)	)	CD	_	10	nummod
12	were	be	VBD	_	13	auxpass
13	submitted	submit	VBN	_	4	parataxis
14	to	to	TO	_	16	case
15	daily	daily	JJ	_	16	amod
16	treatment	treatment	NN	_	13	nmod
17	with	with	IN	_	20	case
18	synthetic	synthetic	JJ	_	20	amod
19	hydroalcoholic	hydroalcoholic	JJ	_	20	amod
20	solutions	solution	NNS	_	16	nmod
21	containing	contain	VBG	_	20	acl
22	ethanol	ethanol	NN	_	21	dobj
23	,	,	,	_	22	punct
24	methanol	methanol	NN	_	22	conj
25	,	,	,	_	22	punct
26	higher	higher	JJR	_	27	amod
27	alcohols	alcohol	NNS	_	22	conj
28	and	and	CC	_	22	cc
29	acetaldehyde	acetaldehyde	NN	_	22	conj
30	in	in	IN	_	33	case
31	the	the	DT	_	33	det
32	same	same	JJ	_	33	amod
33	proportions	proportion	NNS	_	21	nmod
34	as	as	IN	_	35	case
35	those	those	DT	_	33	nmod
36	found	find	VBN	_	35	acl
37	in	in	IN	_	40	case
38	most	most	JJS	_	39	advmod
39	common	common	JJ	_	40	amod
40	distilled	distil	VBN	_	36	nmod
41	and	and	CC	_	40	cc
42	fermented	ferment	VBN	_	44	amod
43	alcoholic	alcoholic	JJ	_	44	amod
44	beverages	beverage	NNS	_	40	conj
45	;	;	:	_	2	punct

1	the	the	DT	_	3	det
2	third	third	JJ	_	3	amod
3	group	group	NN	_	0	ROOT
4	(	(	CD	_	5	nummod
5	SH	sh	NN	_	3	dep
6	/	/	:	_	8	punct
7	EA	ea	NN	_	8	compound
8	)	)	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	treated	treat	VBN	_	5	acl:relcl
11	with	with	IN	_	14	case
12	a	a	DT	_	14	det
13	hydroalcoholic	hydroalcoholic	JJ	_	14	amod
14	solution	solution	NN	_	10	nmod
15	of	of	IN	_	16	case
16	ethanol	ethanol	NN	_	14	nmod
17	;	;	:	_	3	punct

1	the	the	DT	_	3	det
2	fourth	fourth	JJ	_	3	amod
3	group	group	NN	_	4	nsubj
4	served	serve	VBD	_	0	ROOT
5	as	as	IN	_	6	case
6	control	control	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	received	receive	VBD	_	4	conj
9	an	a	DT	_	11	det
10	equivalent	equivalent	JJ	_	11	amod
11	volume	volume	NN	_	8	dobj
12	of	of	IN	_	15	case
13	an	a	DT	_	15	det
14	isocaloric	isocaloric	JJ	_	15	amod
15	solution	solution	NN	_	11	nmod
16	of	of	IN	_	17	case
17	dextrose	dextrose	NN	_	15	nmod
18	.	.	.	_	4	punct

1	All	all	PDT	_	3	det:predet
2	the	the	DT	_	3	det
3	animals	animal	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	killed	kill	VBN	_	0	ROOT
6	at	at	IN	_	8	case
7	the	the	DT	_	8	det
8	end	end	NN	_	5	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	9th	9th	JJ	_	12	amod
12	week	week	NN	_	8	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	experiment	experiment	NN	_	12	nmod
16	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	ratio	ratio	NN	_	11	nsubjpass
3	between	between	IN	_	6	case
4	the	the	DT	_	6	det
5	liver	liver	NN	_	6	compound
6	weight	weight	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	body	body	NN	_	9	compound
9	weight	weight	NN	_	6	conj
10	was	be	VBD	_	11	auxpass
11	found	find	VBN	_	0	ROOT
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	cop
14	lower	lower	JJR	_	11	xcomp
15	in	in	IN	_	18	case
16	the	the	DT	_	18	det
17	treated	treated	JJ	_	18	amod
18	animals	animal	NNS	_	14	nmod
19	than	than	IN	_	23	case
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	control	control	NN	_	23	compound
23	group	group	NN	_	14	nmod
24	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	histology	histology	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	liver	liver	NN	_	2	nmod
6	was	be	VBD	_	7	auxpass
7	altered	alter	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	three	three	CD	_	11	nummod
11	groups	group	NNS	_	7	nmod
12	which	which	WDT	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	submitted	submit	VBN	_	11	acl:relcl
15	to	to	TO	_	16	case
16	treatment	treatment	NN	_	14	nmod
17	with	with	IN	_	20	case
18	the	the	DT	_	20	det
19	hydroalcoholic	hydroalcoholic	JJ	_	20	amod
20	solutions	solution	NNS	_	16	nmod
21	,	,	,	_	7	punct
22	with	with	IN	_	26	case
23	quantitative	quantitative	JJ	_	26	amod
24	and	and	CC	_	23	cc
25	qualitative	qualitative	JJ	_	23	conj
26	differences	difference	NNS	_	7	nmod
27	between	between	IN	_	29	case
28	the	the	DT	_	29	det
29	groups	group	NNS	_	26	nmod
30	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	13	mark
5	the	the	DT	_	6	det
6	hepatoxicity	hepatoxicity	NN	_	13	nsubjpass
7	of	of	IN	_	8	case
8	ethanol	ethanol	NN	_	6	nmod
9	in	in	IN	_	11	case
10	alcoholic	alcoholic	JJ	_	11	amod
11	beverages	beverage	NNS	_	6	nmod
12	is	be	VBZ	_	13	auxpass
13	enhanced	enhance	VBN	_	3	ccomp
14	by	by	IN	_	15	case
15	interaction	interaction	NN	_	13	nmod
16	with	with	IN	_	18	case
17	its	its	PRP$	_	18	nmod:poss
18	congeners	congener	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	acetaldehyde	acetaldehyde	NN	_	18	conj
21	;	;	:	_	3	punct

1	they	they	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	alcoholic	alcoholic	JJ	_	6	amod
6	beverages	beverage	NNS	_	9	nsubj
7	are	be	VBP	_	9	cop
8	not	not	RB	_	9	neg
9	equivalent	equivalent	JJ	_	3	ccomp
10	in	in	IN	_	12	case
11	their	they	PRP$	_	12	nmod:poss
12	potential	potential	JJ	_	9	nmod
13	to	to	TO	_	14	mark
14	cause	cause	VB	_	12	acl
15	liver	liver	NN	_	16	compound
16	damage	damage	NN	_	14	dobj
17	.	.	.	_	3	punct

1	Administration	administration	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	lithium	lithium	NN	_	4	compound
4	prophylaxis	prophylaxis	NN	_	1	nmod
5	.	.	.	_	1	punct

1	Successful	successful	JJ	_	2	amod
2	prophylaxis	prophylaxis	NN	_	8	nsubj
3	of	of	IN	_	7	case
4	manic	manic	JJ	_	7	amod
5	-	-	:	_	7	punct
6	depressive	depressive	JJ	_	7	amod
7	disorder	disorder	NN	_	2	nmod
8	requires	require	VBZ	_	0	ROOT
9	more	more	JJR	_	8	dobj
10	than	than	IN	_	12	case
11	the	the	DT	_	12	det
12	prescription	prescription	NN	_	9	nmod
13	of	of	IN	_	15	case
14	lithium	lithium	NN	_	15	compound
15	carbonate	carbonate	NN	_	12	nmod
16	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	administrative	administrative	JJ	_	3	amod
3	arrangements	arrangement	NNS	_	10	nsubjpass
4	in	in	IN	_	6	case
5	an	a	DT	_	6	det
6	area	area	NN	_	3	nmod
7	of	of	IN	_	8	case
8	Scotland	Scotland	NNP	_	6	nmod
9	were	be	VBD	_	10	auxpass
10	accompanied	accompany	VBN	_	0	ROOT
11	by	by	IN	_	15	case
12	a	a	DT	_	15	det
13	300	300	CD	_	14	compound
14	%	%	NN	_	15	amod
15	increase	increase	NN	_	10	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	frequency	frequency	NN	_	15	nmod
19	of	of	IN	_	20	case
20	admissions	admission	NNS	_	18	nmod
21	for	for	IN	_	22	case
22	mania	mania	NN	_	20	nmod
23	,	,	,	_	10	punct
24	whereas	whereas	IN	_	10	dep
25	in	in	IN	_	27	case
26	an	a	DT	_	27	det
27	area	area	NN	_	24	nmod
28	of	of	IN	_	31	case
29	the	the	DT	_	31	det
30	West	West	NNP	_	31	compound
31	Midlands	Midlands	NNPS	_	27	nmod
32	,	,	,	_	31	punct
33	a	a	DT	_	35	det
34	large	large	JJ	_	35	amod
35	decrease	decrease	NN	_	37	nsubjpass
36	was	be	VBD	_	37	auxpass
37	achieved	achieve	VBN	_	31	acl:relcl
38	.	.	.	_	10	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	rofecoxib	rofecoxib	NN	_	1	nmod
4	on	on	IN	_	6	case
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
7	of	of	IN	_	8	case
8	digoxin	digoxin	NN	_	6	nmod
9	in	in	IN	_	11	case
10	healthy	healthy	JJ	_	11	amod
11	volunteers	volunteer	NNS	_	6	nmod
12	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	3	nsubj
3	examined	examine	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	cyclooxygenase	cyclooxygenase	NN	_	5	nmod
9	-	-	:	_	8	punct
10	2	2	CD	_	12	nummod
11	(	(	CD	_	12	nummod
12	COX	COX	NNP	_	8	dep
13	-	-	:	_	12	punct
14	2	2	CD	_	15	compound
15	)	)	CD	_	16	nummod
16	inhibitor	inhibitor	NN	_	12	dep
17	,	,	,	_	12	punct
18	rofecoxib	rofecoxib	NN	_	12	appos
19	,	,	,	_	12	punct
20	at	at	IN	_	22	case
21	steady	steady	JJ	_	22	amod
22	state	state	NN	_	12	nmod
23	on	on	IN	_	25	case
24	the	the	DT	_	25	det
25	pharmacokinetics	pharmacokinetic	NNS	_	22	nmod
26	of	of	IN	_	27	case
27	digoxin	digoxin	NN	_	25	nmod
28	following	follow	VBG	_	31	case
29	a	a	DT	_	31	det
30	single	single	JJ	_	31	amod
31	dose	dose	NN	_	12	nmod
32	in	in	IN	_	34	case
33	healthy	healthy	JJ	_	34	amod
34	subjects	subject	NNS	_	31	nmod
35	.	.	.	_	3	punct

1	Each	each	DT	_	5	det
2	healthy	healthy	JJ	_	5	amod
3	subject	subject	JJ	_	5	amod
4	(	(	NN	_	5	compound
5	N	n	NN	_	9	nsubj
6	=	=	JJ	_	5	amod
7	10	10	CD	_	8	compound
8	)	)	CD	_	6	dep
9	received	receive	VBD	_	0	ROOT
10	rofecoxib	rofecoxib	NN	_	13	compound
11	(	(	CD	_	13	nummod
12	75	75	CD	_	13	nummod
13	mg	mg	NN	_	9	dobj
14	once	once	RB	_	16	advmod
15	daily	daily	JJ	_	16	amod
16	)	)	NN	_	9	nmod
17	or	or	CC	_	16	cc
18	placebo	placebo	NN	_	16	conj
19	for	for	IN	_	21	case
20	11	11	CD	_	21	nummod
21	days	day	NNS	_	16	nmod
22	in	in	IN	_	26	case
23	a	a	DT	_	26	det
24	double	double	JJ	_	26	amod
25	-	-	:	_	26	punct
26	blind	blind	JJ	_	16	nmod
27	,	,	,	_	26	punct
28	randomized	randomize	VBN	_	36	amod
29	,	,	,	_	28	punct
30	balanced	balanced	JJ	_	28	conj
31	,	,	,	_	28	punct
32	two	two	CD	_	28	conj
33	-	-	:	_	28	punct
34	period	period	NN	_	36	compound
35	crossover	crossover	NN	_	36	compound
36	study	study	NN	_	26	appos
37	.	.	.	_	9	punct

1	A	a	DT	_	4	det
2	single	single	JJ	_	4	amod
3	0.5	0.5	CD	_	4	nummod
4	mg	mg	NN	_	11	nsubjpass
5	oral	oral	JJ	_	6	amod
6	dose	dose	NN	_	4	dep
7	of	of	IN	_	9	case
8	digoxin	digoxin	NN	_	9	compound
9	elixir	elixir	NN	_	6	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	0	ROOT
12	on	on	IN	_	15	case
13	the	the	DT	_	15	det
14	7th	7th	JJ	_	15	amod
15	day	day	NN	_	11	nmod
16	of	of	IN	_	21	case
17	each	each	DT	_	21	det
18	11	11	CD	_	21	nummod
19	-	-	:	_	21	punct
20	day	day	NN	_	21	compound
21	period	period	NN	_	15	nmod
22	.	.	.	_	11	punct

1	Each	each	DT	_	3	det
2	treatment	treatment	NN	_	3	compound
3	period	period	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	separated	separate	VBN	_	0	ROOT
6	by	by	IN	_	10	case
7	14	14	CD	_	9	compound
8	to	to	TO	_	9	dep
9	21	21	CD	_	10	nummod
10	days	day	NNS	_	5	nmod
11	.	.	.	_	5	punct

1	Samples	sample	NNS	_	10	nsubjpass
2	for	for	IN	_	3	case
3	plasma	plasma	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	urine	urine	NN	_	3	conj
6	immunoreactive	immunoreactive	JJ	_	8	amod
7	digoxin	digoxin	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	dep
9	were	be	VBD	_	10	auxpass
10	collected	collect	VBN	_	0	ROOT
11	through	through	IN	_	13	case
12	120	120	CD	_	13	nummod
13	hours	hour	NNS	_	10	nmod
14	following	follow	VBG	_	17	case
15	the	the	DT	_	17	det
16	digoxin	digoxin	NN	_	17	compound
17	dose	dose	NN	_	10	nmod
18	.	.	.	_	10	punct

1	No	no	DT	_	4	neg
2	statistically	statistically	RB	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	differences	difference	NNS	_	9	nsubjpass
5	between	between	IN	_	7	case
6	treatment	treatment	NN	_	7	compound
7	groups	group	NNS	_	4	nmod
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	for	for	IN	_	11	case
11	any	any	DT	_	9	nmod
12	of	of	IN	_	17	case
13	the	the	DT	_	17	det
14	calculated	calculate	VBN	_	17	amod
15	digoxin	digoxin	NN	_	17	compound
16	pharmacokinetic	pharmacokinetic	JJ	_	17	amod
17	parameters	parameter	NNS	_	11	nmod
18	.	.	.	_	9	punct

1	For	for	IN	_	3	case
2	digoxin	digoxin	NN	_	3	compound
3	AUC	auc	NN	_	0	ROOT
4	(	(	CD	_	5	compound
5	0	0	CD	_	3	nummod
6	-	-	:	_	8	punct
7	infinity	infinity	NN	_	8	compound
8	)	)	NN	_	3	dep
9	,	,	,	_	8	punct
10	AUC	auc	NN	_	11	compound
11	(	(	NN	_	8	conj
12	0	0	CD	_	11	nummod
13	-	-	:	_	11	punct
14	24	24	CD	_	15	nummod
15	)	)	NN	_	11	dep
16	,	,	,	_	8	punct
17	and	and	CC	_	8	cc
18	Cmax	Cmax	NNP	_	8	conj
19	,	,	,	_	18	punct
20	the	the	DT	_	23	det
21	geometric	geometric	JJ	_	23	amod
22	mean	mean	JJ	_	23	amod
23	ratios	ratio	NNS	_	24	nsubj
24	(	(	VBP	_	18	acl:relcl
25	90	90	CD	_	26	compound
26	%	%	NN	_	29	amod
27	confidence	confidence	NN	_	29	compound
28	interval	interval	NN	_	29	compound
29	)	)	NN	_	24	dobj
30	for	for	IN	_	32	case
31	(	(	CD	_	32	nummod
32	rofecoxib	rofecoxib	NN	_	24	nmod
33	+	+	CC	_	32	cc
34	digoxin	digoxin	NN	_	32	conj
35	/	/	:	_	32	punct
36	placebo	placebo	NN	_	39	compound
37	+	+	CC	_	36	cc
38	digoxin	digoxin	NN	_	36	conj
39	)	)	NN	_	43	nsubj
40	were	be	VBD	_	43	cop
41	1.04	1.04	CD	_	42	compound
42	(	(	CD	_	43	nummod
43	0.94	0.94	CD	_	32	acl:relcl
44	,	,	,	_	43	punct
45	1.14	1.14	CD	_	46	compound
46	)	)	CD	_	43	conj
47	,	,	,	_	43	punct
48	1.02	1.02	CD	_	49	compound
49	(	(	CD	_	50	nummod
50	0.94	0.94	CD	_	43	conj
51	,	,	,	_	43	punct
52	1.09	1.09	CD	_	53	nummod
53	)	)	NN	_	43	conj
54	,	,	,	_	43	punct
55	and	and	CC	_	43	cc
56	1.00	1.00	CD	_	57	compound
57	(	(	CD	_	58	nummod
58	0.91	0.91	CD	_	43	conj
59	,	,	,	_	43	punct
60	1.10	1.10	CD	_	61	nummod
61	)	)	NN	_	43	conj
62	,	,	,	_	43	punct
63	respectively	respectively	RB	_	43	advmod
64	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	digoxin	digoxin	NN	_	4	compound
3	median	median	NN	_	4	compound
4	tmax	tmax	NN	_	7	nsubj
5	was	be	VBD	_	7	cop
6	0.5	0.5	CD	_	7	nummod
7	hours	hour	NNS	_	0	ROOT
8	for	for	IN	_	10	case
9	both	both	DT	_	10	det
10	treatments	treatment	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	harmonic	harmonic	JJ	_	5	amod
3	mean	mean	NN	_	5	compound
4	elimination	elimination	NN	_	5	compound
5	half	half	NN	_	12	nsubj
6	-	-	:	_	5	punct
7	life	life	NN	_	5	dep
8	was	be	VBD	_	12	cop
9	45.7	45.7	CD	_	12	nummod
10	and	and	CC	_	9	cc
11	43.4	43.4	CD	_	9	conj
12	hours	hour	NNS	_	0	ROOT
13	for	for	IN	_	14	case
14	rofecoxib	rofecoxib	NN	_	12	nmod
15	+	+	CC	_	14	cc
16	digoxin	digoxin	NN	_	14	conj
17	and	and	CC	_	14	cc
18	placebo	placebo	NN	_	21	compound
19	+	+	CC	_	18	cc
20	digoxin	digoxin	NN	_	18	conj
21	treatments	treatment	NNS	_	14	conj
22	,	,	,	_	12	punct
23	respectively	respectively	RB	_	12	advmod
24	.	.	.	_	12	punct

1	Digoxin	digoxin	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	eliminated	eliminate	VBN	_	0	ROOT
4	renally	renally	RB	_	3	advmod
5	.	.	.	_	3	punct

1	The	the	DT	_	8	det
2	mean	mean	NN	_	8	compound
3	(	(	CD	_	8	nummod
4	SD	sd	NN	_	8	compound
5	)	)	CD	_	8	nummod
6	cumulative	cumulative	JJ	_	8	amod
7	urinary	urinary	JJ	_	8	amod
8	excretion	excretion	NN	_	21	nsubj
9	of	of	IN	_	11	case
10	immunoreactive	immunoreactive	JJ	_	11	amod
11	digoxin	digoxin	NN	_	8	nmod
12	after	after	IN	_	14	case
13	concurrent	concurrent	JJ	_	14	amod
14	treatment	treatment	NN	_	8	nmod
15	with	with	IN	_	16	case
16	rofecoxib	rofecoxib	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	placebo	placebo	NN	_	16	conj
19	was	be	VBD	_	21	cop
20	228.2	228.2	CD	_	21	nummod
21	(	(	NN	_	0	ROOT
22	+	+	CC	_	21	cc
23	/	/	:	_	21	punct
24	-	-	:	_	21	punct
25	30.8	30.8	CD	_	26	nummod
26	)	)	NN	_	21	dep
27	and	and	CC	_	26	cc
28	235.1	235.1	CD	_	29	nummod
29	(	(	NN	_	26	conj
30	+	+	CC	_	26	cc
31	/	/	:	_	26	punct
32	-	-	:	_	26	punct
33	39.1	39.1	CD	_	34	compound
34	)	)	CD	_	35	nummod
35	micrograms	microgram	NNS	_	26	dep
36	/	/	:	_	35	punct
37	120	120	CD	_	38	nummod
38	hours	hour	NNS	_	35	dep
39	,	,	,	_	35	punct
40	respectively	respectively	RB	_	35	advmod
41	.	.	.	_	21	punct

1	Transient	transient	JJ	_	5	amod
2	and	and	CC	_	1	cc
3	minor	minor	JJ	_	1	conj
4	adverse	adverse	JJ	_	5	amod
5	events	event	NNS	_	6	nsubj
6	occurred	occur	VBD	_	0	ROOT
7	with	with	IN	_	9	case
8	similar	similar	JJ	_	9	amod
9	frequency	frequency	NN	_	6	nmod
10	on	on	IN	_	11	case
11	placebo	placebo	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	rofecoxib	rofecoxib	NN	_	14	compound
14	treatments	treatment	NNS	_	11	conj
15	,	,	,	_	6	punct
16	and	and	CC	_	6	cc
17	no	no	DT	_	18	neg
18	treatment	treatment	NN	_	6	conj
19	-	-	:	_	18	punct
20	related	related	JJ	_	21	amod
21	pattern	pattern	NN	_	23	nsubj
22	was	be	VBD	_	23	cop
23	apparent	apparent	JJ	_	18	dep
24	.	.	.	_	6	punct

1	Rofecoxib	Rofecoxib	NNP	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	influence	influence	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	pharmacokinetics	pharmacokinetic	NNS	_	4	dobj
8	or	or	CC	_	7	cc
9	renal	renal	JJ	_	10	amod
10	elimination	elimination	NN	_	7	conj
11	of	of	IN	_	15	case
12	a	a	DT	_	15	det
13	single	single	JJ	_	15	amod
14	oral	oral	JJ	_	15	amod
15	dose	dose	NN	_	7	nmod
16	of	of	IN	_	17	case
17	digoxin	digoxin	NN	_	15	nmod
18	.	.	.	_	4	punct

1	18	18	CD	_	4	nummod
2	-	-	:	_	4	punct
3	Methoxycoronaridine	methoxycoronaridine	NN	_	4	compound
4	(	(	NN	_	0	ROOT
5	18	18	CD	_	4	nummod
6	-	-	:	_	4	punct
7	MC	MC	NNP	_	4	dep
8	)	)	CD	_	7	nummod
9	and	and	CC	_	7	cc
10	ibogaine	ibogaine	NN	_	7	conj
11	:	:	:	_	4	punct
12	comparison	comparison	NN	_	4	dep
13	of	of	IN	_	15	case
14	antiaddictive	antiaddictive	JJ	_	15	amod
15	efficacy	efficacy	NN	_	12	nmod
16	,	,	,	_	15	punct
17	toxicity	toxicity	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	mechanisms	mechanism	NNS	_	15	conj
21	of	of	IN	_	22	case
22	action	action	NN	_	20	nmod
23	.	.	.	_	4	punct

1	18	18	CD	_	3	nummod
2	-	-	:	_	3	punct
3	MC	MC	NNP	_	13	nsubjpass
4	,	,	,	_	3	punct
5	a	a	DT	_	9	det
6	novel	novel	JJ	_	9	amod
7	iboga	iboga	NN	_	9	compound
8	alkaloid	alkaloid	NN	_	9	compound
9	congener	congener	NN	_	3	appos
10	,	,	,	_	3	punct
11	is	be	VBZ	_	13	aux
12	being	be	VBG	_	13	auxpass
13	developed	develop	VBN	_	0	ROOT
14	as	as	IN	_	17	case
15	a	a	DT	_	17	det
16	potential	potential	JJ	_	17	amod
17	treatment	treatment	NN	_	13	nmod
18	for	for	IN	_	20	case
19	multiple	multiple	JJ	_	20	amod
20	forms	form	NNS	_	17	nmod
21	of	of	IN	_	23	case
22	drug	drug	NN	_	23	compound
23	abuse	abuse	NN	_	20	nmod
24	.	.	.	_	13	punct

1	Like	like	IN	_	2	case
2	ibogaine	ibogaine	NN	_	0	ROOT
3	(	(	CD	_	4	compound
4	40	40	CD	_	5	nummod
5	mg	mg	NN	_	2	dep
6	/	/	:	_	5	punct
7	kg	kg	NN	_	8	compound
8	)	)	NN	_	5	dep
9	,	,	,	_	5	punct
10	18	18	CD	_	15	nummod
11	-	-	:	_	15	punct
12	MC	MC	NNP	_	15	compound
13	(	(	CD	_	14	compound
14	40	40	CD	_	15	nummod
15	mg	mg	NN	_	5	appos
16	/	/	:	_	15	punct
17	kg	kg	NN	_	18	compound
18	)	)	NN	_	19	nsubj
19	decreases	decrease	VBZ	_	15	acl:relcl
20	the	the	DT	_	22	det
21	intravenous	intravenous	JJ	_	22	amod
22	self	self	NN	_	19	dobj
23	-	-	:	_	22	punct
24	administration	administration	NN	_	22	dep
25	of	of	IN	_	26	case
26	morphine	morphine	NN	_	24	nmod
27	and	and	CC	_	26	cc
28	cocaine	cocaine	NN	_	26	conj
29	and	and	CC	_	24	cc
30	the	the	DT	_	32	det
31	oral	oral	JJ	_	32	amod
32	self	self	NN	_	24	conj
33	-	-	:	_	32	punct
34	administration	administration	NN	_	32	dep
35	of	of	IN	_	36	case
36	ethanol	ethanol	NN	_	34	nmod
37	and	and	CC	_	36	cc
38	nicotine	nicotine	NN	_	36	conj
39	in	in	IN	_	40	case
40	rats	rat	NNS	_	34	nmod
41	;	;	:	_	2	punct

1	unlike	unlike	IN	_	2	case
2	ibogaine	ibogaine	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	18	18	CD	_	2	amod
5	-	-	:	_	2	punct
6	MC	MC	NNP	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	affect	affect	VB	_	2	acl:relcl
10	responding	respond	VBG	_	9	xcomp
11	for	for	IN	_	17	case
12	a	a	DT	_	17	det
13	nondrug	nondrug	JJ	_	17	amod
14	reinforcer	reinforcer	NN	_	17	compound
15	(	(	NN	_	17	compound
16	water	water	NN	_	17	compound
17	)	)	NN	_	10	nmod
18	.	.	.	_	2	punct

1	Both	both	DT	_	2	cc:preconj
2	ibogaine	ibogaine	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	18	18	CD	_	2	conj
5	-	-	:	_	2	punct
6	MC	MC	NNP	_	7	nsubj
7	ameliorate	ameliorate	VB	_	2	dep
8	opioid	opioid	JJ	_	10	amod
9	withdrawal	withdrawal	NN	_	10	compound
10	signs	sign	NNS	_	7	dobj
11	.	.	.	_	2	punct

1	Both	both	DT	_	2	cc:preconj
2	ibogaine	ibogaine	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	18	18	CD	_	2	conj
5	-	-	:	_	2	punct
6	MC	MC	NNP	_	7	nsubj
7	decrease	decrease	VB	_	2	dep
8	extracellular	extracellular	JJ	_	9	amod
9	levels	level	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	dopamine	dopamine	NN	_	9	nmod
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	nucleus	nucleus	NN	_	15	compound
15	accumbens	accumben	NNS	_	7	nmod
16	,	,	,	_	7	punct
17	but	but	CC	_	7	cc
18	only	only	RB	_	19	advmod
19	ibogaine	ibogaine	NN	_	20	nsubj
20	increases	increase	VBZ	_	7	conj
21	extracellular	extracellular	JJ	_	22	amod
22	levels	level	NNS	_	20	dobj
23	of	of	IN	_	24	case
24	serotonin	serotonin	NN	_	22	nmod
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	nucleus	nucleus	NN	_	28	compound
28	accumbens	accumben	NNS	_	20	nmod
29	.	.	.	_	2	punct

1	Both	both	DT	_	2	cc:preconj
2	ibogaine	ibogaine	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	18	18	CD	_	2	conj
5	-	-	:	_	2	punct
6	MC	MC	NNP	_	8	compound
7	block	block	NN	_	8	compound
8	morphine	morphine	NN	_	2	dep
9	-	-	:	_	8	punct
10	induced	induce	VBN	_	8	dep
11	and	and	CC	_	10	cc
12	nicotine	nicotine	NN	_	10	conj
13	-	-	:	_	8	punct
14	induced	induce	VBN	_	16	amod
15	dopamine	dopamine	NN	_	16	compound
16	release	release	NN	_	8	dep
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	nucleus	nucleus	NN	_	20	compound
20	accumbens	accumben	NNS	_	16	nmod
21	;	;	:	_	2	punct

1	only	only	RB	_	2	advmod
2	ibogaine	ibogaine	NN	_	3	nsubj
3	enhances	enhance	VBZ	_	0	ROOT
4	cocaine	cocaine	NN	_	3	dobj
5	-	-	:	_	4	punct
6	induced	induce	VBN	_	7	amod
7	increases	increase	NNS	_	4	dep
8	in	in	IN	_	10	case
9	accumbal	accumbal	JJ	_	10	amod
10	dopamine	dopamine	NN	_	7	nmod
11	.	.	.	_	3	punct

1	Both	both	DT	_	2	cc:preconj
2	ibogaine	ibogaine	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	18	18	CD	_	2	conj
5	-	-	:	_	2	punct
6	MC	MC	NNP	_	7	nsubj
7	enhance	enhance	VBP	_	2	dep
8	the	the	DT	_	9	det
9	locomotor	locomotor	NN	_	7	dobj
10	and	and	CC	_	9	cc
11	/	/	:	_	14	punct
12	or	or	CC	_	14	cc
13	stereotypic	stereotypic	JJ	_	14	amod
14	effects	effect	NNS	_	9	conj
15	of	of	IN	_	16	case
16	stimulants	stimulant	NNS	_	14	nmod
17	.	.	.	_	2	punct

1	Ibogaine	Ibogaine	NNP	_	2	nsubj
2	attenuates	attenuate	VBZ	_	0	ROOT
3	,	,	,	_	2	punct
4	but	but	CC	_	2	cc
5	18	18	CD	_	8	dep
6	-	-	:	_	8	punct
7	MC	MC	NNP	_	8	nsubj
8	potentiates	potentiate	VBZ	_	2	conj
9	,	,	,	_	8	punct
10	the	the	DT	_	13	det
11	acute	acute	JJ	_	13	amod
12	locomotor	locomotor	JJ	_	13	amod
13	effects	effect	NNS	_	8	dobj
14	of	of	IN	_	15	case
15	morphine	morphine	NN	_	13	nmod
16	;	;	:	_	2	punct

1	both	both	DT	_	2	det
2	compounds	compound	NNS	_	3	nsubj
3	attenuate	attenuate	VBP	_	0	ROOT
4	morphine	morphine	NN	_	7	compound
5	-	-	:	_	7	punct
6	induced	induce	VBN	_	7	amod
7	locomotion	locomotion	NN	_	3	dobj
8	in	in	IN	_	9	case
9	morphine	morphine	NN	_	7	nmod
10	-	-	:	_	7	punct
11	experienced	experienced	JJ	_	12	amod
12	rats	rat	NNS	_	7	dep
13	.	.	.	_	3	punct

1	Ibogaine	Ibogaine	NNP	_	2	nsubj
2	produces	produce	VBZ	_	0	ROOT
3	whole	whole	JJ	_	5	amod
4	body	body	NN	_	5	compound
5	tremors	tremor	NNS	_	2	dobj
6	and	and	CC	_	2	cc
7	,	,	,	_	2	punct
8	at	at	IN	_	10	case
9	high	high	JJ	_	10	amod
10	doses	dose	NNS	_	2	nmod
11	(	(	VBP	_	10	acl
12	>	>	JJR	_	11	dep
13	or	or	CC	_	12	cc
14	=	=	JJ	_	12	conj
15	100	100	CD	_	16	nummod
16	mg	mg	NN	_	14	dep
17	/	/	:	_	12	punct
18	kg	kg	NN	_	19	compound
19	)	)	NN	_	12	dep
20	,	,	,	_	19	punct
21	cerebellar	cerebellar	NN	_	22	compound
22	damage	damage	NN	_	19	appos
23	;	;	:	_	2	punct

1	18	18	CD	_	6	dep
2	-	-	:	_	6	punct
3	MC	MC	NNP	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	produce	produce	VB	_	0	ROOT
7	these	these	DT	_	8	det
8	effects	effect	NNS	_	6	dobj
9	.	.	.	_	6	punct

1	Ibogaine	Ibogaine	NNP	_	9	nsubj
2	,	,	,	_	1	punct
3	but	but	CC	_	4	cc
4	not	not	RB	_	1	cc
5	18	18	CD	_	7	nummod
6	-	-	:	_	7	punct
7	MC	MC	NNP	_	1	conj
8	,	,	,	_	1	punct
9	decreases	decrease	VBZ	_	0	ROOT
10	heart	heart	NN	_	11	compound
11	rate	rate	NN	_	9	dobj
12	at	at	IN	_	14	case
13	high	high	JJ	_	14	amod
14	doses	dose	NNS	_	9	nmod
15	.	.	.	_	9	punct

1	While	while	IN	_	7	mark
2	18	18	CD	_	4	nummod
3	-	-	:	_	4	punct
4	MC	MC	NNP	_	7	nsubj
5	and	and	CC	_	4	cc
6	ibogaine	ibogaine	NN	_	4	conj
7	have	have	VBP	_	0	ROOT
8	similar	similar	JJ	_	9	amod
9	affinities	affinity	NNS	_	7	dobj
10	for	for	IN	_	12	case
11	kappa	kappa	NN	_	12	compound
12	opioid	opioid	NN	_	9	nmod
13	and	and	CC	_	7	cc
14	possibly	possibly	RB	_	15	advmod
15	nicotinic	nicotinic	JJ	_	16	amod
16	receptors	receptor	NNS	_	7	conj
17	,	,	,	_	16	punct
18	18	18	CD	_	21	dep
19	-	-	:	_	21	punct
20	MC	MC	NNP	_	21	nsubj
21	has	have	VBZ	_	16	acl:relcl
22	much	much	RB	_	23	advmod
23	lower	lower	JJR	_	24	amod
24	affinities	affinity	NNS	_	21	dobj
25	than	than	IN	_	26	case
26	ibogaine	ibogaine	NN	_	24	nmod
27	for	for	IN	_	28	case
28	NMDA	nmda	NN	_	24	nmod
29	and	and	CC	_	28	cc
30	sigma	sigma	NN	_	28	conj
31	-	-	:	_	21	punct
32	2	2	CD	_	33	nummod
33	receptors	receptor	NNS	_	21	dep
34	,	,	,	_	33	punct
35	sodium	sodium	NN	_	36	compound
36	channels	channel	NNS	_	33	conj
37	,	,	,	_	33	punct
38	and	and	CC	_	33	cc
39	the	the	DT	_	43	det
40	5	5	CD	_	43	nummod
41	-	-	:	_	43	punct
42	HT	HT	NNP	_	43	compound
43	transporter	transporter	NN	_	33	conj
44	.	.	.	_	7	punct

1	Both	both	DT	_	2	cc:preconj
2	18	18	CD	_	8	nsubjpass
3	-	-	:	_	2	punct
4	MC	MC	NNP	_	2	dep
5	and	and	CC	_	4	cc
6	ibogaine	ibogaine	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	sequestered	sequester	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	fat	fat	JJ	_	8	nmod
11	and	and	CC	_	10	cc
12	,	,	,	_	20	punct
13	like	like	IN	_	14	case
14	ibogaine	ibogaine	NN	_	20	nmod
15	,	,	,	_	20	punct
16	18	18	CD	_	18	nummod
17	-	-	:	_	18	punct
18	MC	MC	NNP	_	20	nsubj
19	probably	probably	RB	_	20	advmod
20	has	have	VBZ	_	10	conj
21	an	a	DT	_	23	det
22	active	active	JJ	_	23	amod
23	metabolite	metabolite	NN	_	20	dobj
24	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	18	18	CD	_	8	nsubj
6	-	-	:	_	8	punct
7	MC	MC	NNP	_	8	nsubj
8	has	have	VBZ	_	3	ccomp
9	a	a	DT	_	11	det
10	narrower	narrower	JJR	_	11	amod
11	spectrum	spectrum	NN	_	8	dobj
12	of	of	IN	_	13	case
13	actions	action	NNS	_	11	nmod
14	and	and	CC	_	8	cc
15	will	will	MD	_	16	aux
16	have	have	VB	_	8	conj
17	a	a	DT	_	21	det
18	substantially	substantially	RB	_	19	advmod
19	greater	greater	JJR	_	21	amod
20	therapeutic	therapeutic	JJ	_	21	amod
21	index	index	NN	_	16	dobj
22	than	than	IN	_	23	case
23	ibogaine	ibogaine	NN	_	21	nmod
24	.	.	.	_	3	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	coadministered	coadministered	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	ethanol	ethanol	NN	_	4	conj
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	binding	binding	NN	_	1	nmod
10	of	of	IN	_	12	case
11	therapeutic	therapeutic	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	to	to	TO	_	15	case
14	human	human	JJ	_	15	amod
15	serum	serum	NN	_	9	nmod
16	in	in	FW	_	17	compound
17	vitro	vitro	FW	_	9	advmod
18	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	20	nsubjpass
3	of	of	IN	_	5	case
4	coadministered	coadministered	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	ethanol	ethanol	NN	_	5	conj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	binding	binding	NN	_	2	nmod
11	of	of	IN	_	13	case
12	therapeutic	therapeutic	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	to	to	TO	_	16	case
15	human	human	JJ	_	16	amod
16	serum	serum	NN	_	10	nmod
17	in	in	FW	_	18	compound
18	vitro	vitro	FW	_	10	advmod
19	was	be	VBD	_	20	auxpass
20	investigated	investigate	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	Acetaminophen	acetaminophen	NN	_	15	nsubjpass
2	,	,	,	_	1	punct
3	lidocaine	lidocaine	NN	_	1	conj
4	,	,	,	_	1	punct
5	phenobarbital	phenobarbital	NN	_	1	conj
6	,	,	,	_	1	punct
7	quinidine	quinidine	NN	_	1	conj
8	,	,	,	_	1	punct
9	theophylline	theophylline	NN	_	1	conj
10	,	,	,	_	1	punct
11	and	and	CC	_	1	cc
12	valproic	valproic	JJ	_	13	amod
13	acid	acid	NN	_	1	conj
14	were	be	VBD	_	15	auxpass
15	added	add	VBN	_	0	ROOT
16	to	to	TO	_	19	case
17	pooled	pooled	JJ	_	19	amod
18	human	human	JJ	_	19	amod
19	serum	serum	NN	_	15	nmod
20	at	at	IN	_	22	case
21	therapeutic	therapeutic	JJ	_	22	amod
22	concentrations	concentration	NNS	_	15	nmod
23	.	.	.	_	15	punct

1	To	to	TO	_	3	case
2	each	each	DT	_	3	det
3	preparation	preparation	NN	_	5	nmod
4	was	be	VBD	_	5	auxpass
5	added	add	VBN	_	0	ROOT
6	one	one	CD	_	8	nummod
7	additional	additional	JJ	_	8	amod
8	drug	drug	NN	_	5	dobj
9	at	at	IN	_	11	case
10	three	three	CD	_	11	nummod
11	concentrations	concentration	NNS	_	5	nmod
12	ranging	range	VBG	_	11	acl
13	from	from	IN	_	14	case
14	therapeutic	therapeutic	JJ	_	12	nmod
15	to	to	TO	_	16	case
16	toxic	toxic	JJ	_	14	nmod
17	.	.	.	_	5	punct

1	The	the	DT	_	0	ROOT
2	following	follow	VBG	_	5	case
3	eight	eight	CD	_	5	nummod
4	target	target	NN	_	5	compound
5	drug	drug	NN	_	1	nmod
6	/	/	:	_	11	punct
7	added	add	VBN	_	9	amod
8	drug	drug	NN	_	9	compound
9	combinations	combination	NNS	_	11	nsubjpass
10	were	be	VBD	_	11	auxpass
11	studied	study	VBN	_	5	dep
12	:	:	:	_	11	punct
13	acetaminophen	acetaminophen	NN	_	15	compound
14	/	/	:	_	15	punct
15	phenobarbital	phenobarbital	NN	_	11	dep
16	.	.	.	_	1	punct

1	acetaminophen	acetaminophen	NN	_	3	compound
2	/	/	:	_	3	punct
3	theophylline	theophylline	NN	_	0	ROOT
4	,	,	,	_	3	punct
5	lidocaine	lidocaine	NN	_	7	compound
6	/	/	:	_	7	punct
7	quinidine	quinidine	NN	_	3	conj
8	,	,	,	_	3	punct
9	phenobarbital	phenobarbital	JJ	_	11	amod
10	/	/	:	_	11	punct
11	acetaminophen	acetaminophen	NN	_	3	conj
12	,	,	,	_	3	punct
13	phenobarbital	phenobarbital	JJ	_	16	amod
14	/	/	:	_	16	punct
15	valproic	valproic	JJ	_	16	amod
16	acid	acid	NN	_	3	conj
17	,	,	,	_	3	punct
18	quinidine	quinidine	NN	_	20	compound
19	/	/	:	_	20	punct
20	lidocaine	lidocaine	NN	_	3	conj
21	,	,	,	_	3	punct
22	theophylline	theophylline	NN	_	24	compound
23	/	/	:	_	24	punct
24	acetaminophen	acetaminophen	NN	_	3	conj
25	,	,	,	_	3	punct
26	and	and	CC	_	3	cc
27	valproic	valproic	JJ	_	28	amod
28	acid	acid	NN	_	3	conj
29	/	/	:	_	28	punct
30	phenobarbital	phenobarbital	NN	_	28	dep
31	.	.	.	_	3	punct

1	Each	each	DT	_	2	det
2	serum	serum	NN	_	23	nsubjpass
3	without	without	IN	_	7	case
4	the	the	DT	_	7	det
5	other	other	JJ	_	7	amod
6	added	add	VBN	_	7	amod
7	drug	drug	NN	_	2	nmod
8	as	as	RB	_	2	cc
9	well	well	RB	_	8	mwe
10	as	as	IN	_	8	mwe
11	the	the	DT	_	12	det
12	serum	serum	NN	_	2	conj
13	supplemented	supplement	VBN	_	12	acl
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	other	other	JJ	_	17	amod
17	drug	drug	NN	_	13	nmod
18	at	at	IN	_	21	case
19	the	the	DT	_	21	det
20	three	three	CD	_	21	nummod
21	concentrations	concentration	NNS	_	13	nmod
22	was	be	VBD	_	23	auxpass
23	dialyzed	dialyze	VBN	_	0	ROOT
24	against	against	IN	_	26	case
25	phosphate	phosphate	NN	_	26	compound
26	buffer	buffer	NN	_	23	nmod
27	.	.	.	_	23	punct

1	Similarly	similarly	RB	_	2	advmod
2	dialyzed	dialyze	VBN	_	0	ROOT
3	were	be	VBD	_	2	auxpass
4	phenobarbital	phenobarbital	JJ	_	2	nsubjpass
5	,	,	,	_	4	punct
6	quinidine	quinidine	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	theophylline	theophylline	NN	_	4	conj
10	,	,	,	_	2	punct
11	both	both	CC	_	15	dep
12	alone	alone	RB	_	11	advmod
13	at	at	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	concentrations	concentration	NNS	_	2	nmod
16	in	in	IN	_	17	case
17	serum	serum	NN	_	15	nmod
18	and	and	CC	_	15	cc
19	with	with	IN	_	20	case
20	ethanol	ethanol	NN	_	15	conj
21	at	at	IN	_	24	case
22	three	three	CD	_	24	nummod
23	different	different	JJ	_	24	amod
24	concentrations	concentration	NNS	_	20	nmod
25	in	in	IN	_	26	case
26	serum	serum	NN	_	24	nmod
27	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	percentage	percentage	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	drug	drug	NN	_	5	compound
5	binding	binding	NN	_	2	nmod
6	in	in	IN	_	8	case
7	each	each	DT	_	8	det
8	preparation	preparation	NN	_	2	nmod
9	was	be	VBD	_	10	auxpass
10	calculated	calculate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Acetaminophen	acetaminophen	NN	_	2	nsubj
2	diminished	diminish	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	binding	binding	NN	_	2	dobj
5	of	of	IN	_	6	case
6	theophylline	theophylline	NN	_	4	nmod
7	to	to	TO	_	9	case
8	human	human	JJ	_	9	amod
9	serum	serum	NN	_	4	nmod
10	by	by	IN	_	13	case
11	a	a	DT	_	13	det
12	net	net	JJ	_	13	amod
13	change	change	NN	_	4	nmod
14	of	of	IN	_	19	case
15	5.7	5.7	CD	_	16	compound
16	%	%	NN	_	19	amod
17	(	(	CD	_	19	nummod
18	percentage	percentage	NN	_	19	compound
19	increase	increase	NN	_	13	nmod
20	in	in	IN	_	23	case
21	free	free	JJ	_	23	amod
22	drug	drug	NN	_	23	compound
23	fraction	fraction	NN	_	19	nmod
24	[	[	CD	_	26	nummod
25	FDF	fdf	NN	_	26	compound
26	]	]	NN	_	23	dep
27	,	,	,	_	26	punct
28	11.0	11.0	CD	_	29	nummod
29	%	%	NN	_	26	appos
30	)	)	CD	_	29	nummod
31	at	at	IN	_	33	case
32	662	662	CD	_	33	nummod
33	micromol	micromol	NN	_	29	nmod
34	/	/	:	_	2	punct
35	L	l	NN	_	57	compound
36	and	and	CC	_	35	cc
37	by	by	IN	_	40	case
38	a	a	DT	_	40	det
39	net	net	JJ	_	40	amod
40	change	change	NN	_	35	conj
41	of	of	IN	_	46	case
42	7.1	7.1	CD	_	43	compound
43	%	%	NN	_	46	amod
44	(	(	CD	_	46	nummod
45	percentage	percentage	NN	_	46	compound
46	increase	increase	NN	_	40	nmod
47	in	in	IN	_	48	case
48	FDF	FDF	NNP	_	46	nmod
49	,	,	,	_	35	punct
50	13.7	13.7	CD	_	51	nummod
51	%	%	NN	_	35	appos
52	)	)	CD	_	51	nummod
53	at	at	IN	_	55	case
54	1324	1324	CD	_	55	nummod
55	micromol	micromol	NN	_	51	nmod
56	/	/	:	_	35	punct
57	L	l	NN	_	2	dep
58	.	.	.	_	2	punct

1	Theophylline	Theophylline	NNP	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	binding	binding	NN	_	2	dobj
5	of	of	IN	_	6	case
6	acetaminophen	acetaminophen	NN	_	4	nmod
7	by	by	IN	_	10	case
8	a	a	DT	_	10	det
9	net	net	JJ	_	10	amod
10	change	change	NN	_	4	nmod
11	of	of	IN	_	16	case
12	6.8	6.8	CD	_	13	compound
13	%	%	NN	_	16	amod
14	(	(	CD	_	16	nummod
15	percentage	percentage	NN	_	16	compound
16	increase	increase	NN	_	10	nmod
17	in	in	IN	_	18	case
18	FDF	FDF	NNP	_	16	nmod
19	,	,	,	_	2	punct
20	8.8	8.8	CD	_	21	nummod
21	%	%	NN	_	2	dobj
22	)	)	CD	_	21	nummod
23	at	at	IN	_	25	case
24	277.5	277.5	CD	_	25	nummod
25	micromol	micromol	NN	_	21	nmod
26	/	/	:	_	25	punct
27	L	l	NN	_	25	dep
28	;	;	:	_	2	punct

1	phenobarbital	phenobarbital	NN	_	2	nsubj
2	reduced	reduce	VBD	_	0	ROOT
3	it	it	PRP	_	2	dobj
4	by	by	IN	_	7	case
5	a	a	DT	_	7	det
6	net	net	JJ	_	7	amod
7	change	change	NN	_	2	nmod
8	of	of	IN	_	13	case
9	6.6	6.6	CD	_	10	compound
10	%	%	NN	_	13	amod
11	(	(	CD	_	13	nummod
12	percentage	percentage	NN	_	13	compound
13	increase	increase	NN	_	7	nmod
14	in	in	IN	_	15	case
15	FDF	FDF	NNP	_	13	nmod
16	,	,	,	_	2	punct
17	8.5	8.5	CD	_	18	nummod
18	%	%	NN	_	2	dobj
19	)	)	CD	_	18	nummod
20	at	at	IN	_	22	case
21	431	431	CD	_	22	nummod
22	micromol	micromol	NN	_	18	nmod
23	/	/	:	_	22	punct
24	L	l	NN	_	22	dep
25	.	.	.	_	2	punct

1	Valproic	valproic	JJ	_	2	amod
2	acid	acid	NN	_	3	nsubj
3	diminished	diminish	VBD	_	0	ROOT
4	binding	binding	NN	_	3	dobj
5	of	of	IN	_	6	case
6	phenobarbital	phenobarbital	JJ	_	4	nmod
7	by	by	IN	_	10	case
8	a	a	DT	_	10	det
9	net	net	JJ	_	10	amod
10	change	change	NN	_	4	nmod
11	of	of	IN	_	16	case
12	9.9	9.9	CD	_	13	compound
13	%	%	NN	_	16	amod
14	(	(	CD	_	16	nummod
15	percentage	percentage	NN	_	16	compound
16	increase	increase	NN	_	10	nmod
17	in	in	IN	_	18	case
18	FDF	FDF	NNP	_	16	nmod
19	,	,	,	_	3	punct
20	21.2	21.2	CD	_	21	nummod
21	%	%	NN	_	3	dobj
22	)	)	CD	_	21	nummod
23	at	at	IN	_	25	case
24	1732	1732	CD	_	25	nummod
25	micromol	micromol	NN	_	21	nmod
26	/	/	:	_	25	punct
27	L	l	NN	_	25	dep
28	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	effects	effect	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	noted	note	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	other	other	JJ	_	9	amod
8	drug	drug	NN	_	9	compound
9	combinations	combination	NNS	_	5	nmod
10	or	or	CC	_	9	cc
11	with	with	IN	_	13	case
12	the	the	DT	_	13	det
13	addition	addition	NN	_	9	conj
14	of	of	IN	_	15	case
15	ethanol	ethanol	NN	_	13	nmod
16	.	.	.	_	5	punct

1	Coingestion	coingestion	NN	_	21	nsubj
2	of	of	IN	_	3	case
3	acetaminophen	acetaminophen	NN	_	1	nmod
4	with	with	IN	_	5	case
5	theophylline	theophylline	NN	_	1	nmod
6	,	,	,	_	1	punct
7	phenobarbital	phenobarbital	JJ	_	1	conj
8	with	with	IN	_	9	case
9	acetaminophen	acetaminophen	NN	_	7	nmod
10	,	,	,	_	1	punct
11	and	and	CC	_	1	cc
12	valproic	valproic	JJ	_	13	amod
13	acid	acid	NN	_	1	conj
14	with	with	IN	_	15	case
15	phenobarbital	phenobarbital	NN	_	13	nmod
16	at	at	IN	_	17	case
17	high	high	JJ	_	1	nmod
18	to	to	TO	_	20	case
19	toxic	toxic	JJ	_	20	amod
20	concentrations	concentration	NNS	_	17	nmod
21	decreases	decrease	VBZ	_	0	ROOT
22	the	the	DT	_	23	det
23	binding	binding	NN	_	21	dobj
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	target	target	NN	_	27	compound
27	drug	drug	NN	_	23	nmod
28	.	.	.	_	21	punct

1	The	the	DT	_	3	det
2	resulting	result	VBG	_	3	amod
3	increase	increase	NN	_	9	nsubj
4	in	in	IN	_	7	case
5	free	free	JJ	_	7	amod
6	drug	drug	NN	_	7	compound
7	concentration	concentration	NN	_	3	nmod
8	may	may	MD	_	9	aux
9	lead	lead	VB	_	0	ROOT
10	to	to	TO	_	13	case
11	enhanced	enhance	VBN	_	13	amod
12	drug	drug	NN	_	13	compound
13	effect	effect	NN	_	9	nmod
14	in	in	FW	_	15	compound
15	vivo	vivo	FW	_	13	advmod
16	.	.	.	_	9	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	dofetillide	dofetillide	NN	_	1	nmod
4	on	on	IN	_	6	case
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
7	of	of	IN	_	8	case
8	digoxin	digoxin	NN	_	6	nmod
9	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	dofetilide	dofetilide	NN	_	2	nmod
5	on	on	IN	_	10	case
6	the	the	DT	_	10	det
7	steady	steady	JJ	_	10	amod
8	-	-	:	_	10	punct
9	state	state	NN	_	10	compound
10	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
11	of	of	IN	_	12	case
12	digoxin	digoxin	NN	_	10	nmod
13	was	be	VBD	_	14	auxpass
14	evaluated	evaluate	VBN	_	0	ROOT
15	in	in	IN	_	22	case
16	a	a	DT	_	22	det
17	randomized	randomize	VBN	_	22	amod
18	,	,	,	_	17	punct
19	double	double	JJ	_	17	dep
20	-	-	:	_	17	punct
21	blind	blind	JJ	_	17	dep
22	study	study	NN	_	14	nmod
23	.	.	.	_	14	punct

1	Five	five	CD	_	2	nummod
2	days	day	NNS	_	9	nsubj
3	of	of	IN	_	5	case
4	dofetilide	dofetilide	NN	_	5	compound
5	treatment	treatment	NN	_	2	nmod
6	did	do	VBD	_	9	aux
7	not	not	RB	_	9	neg
8	significantly	significantly	RB	_	9	advmod
9	affect	affect	VB	_	0	ROOT
10	steady	steady	JJ	_	14	amod
11	-	-	:	_	14	punct
12	state	state	NN	_	14	compound
13	pharmacokinetic	pharmacokinetic	JJ	_	14	amod
14	variables	variable	NNS	_	9	dobj
15	of	of	IN	_	16	case
16	digoxin	digoxin	NN	_	14	nmod
17	compared	compare	VBN	_	19	case
18	with	with	IN	_	19	case
19	placebo	placebo	NN	_	14	nmod
20	;	;	:	_	9	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	use	use	NN	_	9	nsubj
5	of	of	IN	_	6	case
6	dofetilide	dofetilide	NN	_	4	nmod
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	necessitate	necessitate	VB	_	0	ROOT
10	an	a	DT	_	11	det
11	adjustment	adjustment	NN	_	9	dobj
12	in	in	IN	_	14	case
13	digoxin	digoxin	NN	_	14	compound
14	dose	dose	NN	_	11	nmod
15	to	to	TO	_	16	mark
16	maintain	maintain	VB	_	11	acl
17	therapeutic	therapeutic	JJ	_	19	amod
18	digoxin	digoxin	NN	_	19	compound
19	levels	level	NNS	_	16	dobj
20	.	.	.	_	9	punct

1	Acid	acid	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	catalyzed	catalyze	VBN	_	4	amod
4	ethanolysis	ethanolysis	NN	_	1	dep
5	of	of	IN	_	6	case
6	temazepam	temazepam	NN	_	4	nmod
7	in	in	IN	_	12	case
8	anhydrous	anhydrous	JJ	_	12	amod
9	and	and	CC	_	8	cc
10	aqueous	aqueous	JJ	_	8	conj
11	ethanol	ethanol	NN	_	12	compound
12	solutions	solution	NNS	_	4	nmod
13	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	benzodiazepines	benzodiazepine	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	a	a	DT	_	5	det
5	family	family	NN	_	0	ROOT
6	of	of	IN	_	10	case
7	anxiolytic	anxiolytic	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	hypnotic	hypnotic	JJ	_	7	conj
10	drugs	drug	NNS	_	5	nmod
11	.	.	.	_	5	punct

1	When	when	WRB	_	2	advmod
2	taken	take	VBN	_	11	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	with	with	IN	_	5	case
5	ethanol	ethanol	NN	_	2	nmod
6	,	,	,	_	11	punct
7	a	a	DT	_	9	det
8	pharmacological	pharmacological	JJ	_	9	amod
9	interaction	interaction	NN	_	11	nsubj
10	may	may	MD	_	11	aux
11	occur	occur	VB	_	0	ROOT
12	,	,	,	_	11	punct
13	potentiating	potentiate	VBG	_	11	xcomp
14	the	the	DT	_	18	det
15	central	central	JJ	_	18	amod
16	nervous	nervous	JJ	_	18	amod
17	system	system	NN	_	18	compound
18	depression	depression	NN	_	13	dobj
19	produced	produce	VBN	_	18	acl
20	by	by	IN	_	22	case
21	either	either	CC	_	22	det
22	drug	drug	NN	_	19	nmod
23	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	10	nmod
3	to	to	TO	_	6	case
4	this	this	DT	_	6	det
5	pharmacological	pharmacological	JJ	_	6	amod
6	interaction	interaction	NN	_	2	nmod
7	,	,	,	_	10	punct
8	this	this	DT	_	9	det
9	report	report	NN	_	10	nsubj
10	describes	describe	VBZ	_	0	ROOT
11	a	a	DT	_	14	det
12	novel	novel	JJ	_	14	amod
13	chemical	chemical	NN	_	14	compound
14	reaction	reaction	NN	_	10	dobj
15	between	between	IN	_	16	case
16	temazepam	temazepam	NN	_	14	nmod
17	(	(	CD	_	16	nummod
18	a	a	DT	_	20	det
19	benzodiazepine	benzodiazepine	NN	_	20	compound
20	)	)	NN	_	16	dep
21	and	and	CC	_	20	cc
22	ethanol	ethanol	NN	_	20	conj
23	under	under	IN	_	25	case
24	acidic	acidic	JJ	_	25	amod
25	conditions	condition	NNS	_	14	nmod
26	similar	similar	JJ	_	25	amod
27	to	to	TO	_	28	case
28	those	those	DT	_	26	nmod
29	found	find	VBN	_	28	acl
30	in	in	FW	_	31	compound
31	vivo	vivo	FW	_	29	advmod
32	,	,	,	_	10	punct
33	resulting	result	VBG	_	10	advcl
34	in	in	IN	_	39	case
35	a	a	DT	_	39	det
36	3	3	LS	_	39	dep
37	-	-	:	_	39	punct
38	ethoxylated	ethoxylate	VBN	_	39	amod
39	product	product	NN	_	33	nmod
40	.	.	.	_	10	punct

1	Optimal	optimal	JJ	_	2	amod
2	conditions	condition	NNS	_	0	ROOT
3	,	,	,	_	2	punct
4	kinetics	kinetics	NNS	_	2	conj
5	,	,	,	_	2	punct
6	equilibrium	equilibrium	NN	_	2	conj
7	,	,	,	_	2	punct
8	and	and	CC	_	2	cc
9	the	the	DT	_	10	det
10	mechanism	mechanism	NN	_	2	conj
11	of	of	IN	_	13	case
12	this	this	DT	_	13	det
13	acid	acid	NN	_	10	nmod
14	-	-	:	_	10	punct
15	catalyzed	catalyze	VBN	_	16	amod
16	ethanolysis	ethanolysis	NN	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	reported	report	VBN	_	10	dep
19	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	raise	raise	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	possibility	possibility	NN	_	3	dobj
6	that	that	IN	_	11	mark
7	the	the	DT	_	9	det
8	ethanolysis	ethanolysis	NN	_	9	compound
9	reaction	reaction	NN	_	11	nsubj
10	may	may	MD	_	11	aux
11	occur	occur	VB	_	5	ccomp
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	stomach	stomach	NN	_	11	nmod
15	of	of	IN	_	16	case
16	people	people	NNS	_	14	nmod
17	who	who	WP	_	18	nsubj
18	consume	consume	VBP	_	16	acl:relcl
19	alcohol	alcohol	NN	_	18	dobj
20	and	and	CC	_	18	cc
21	3	3	LS	_	18	conj
22	-	-	:	_	21	punct
23	hydroxy	hydroxy	NN	_	27	dep
24	-	-	:	_	27	punct
25	1,4	1,4	SYM	_	27	dep
26	-	-	:	_	27	punct
27	benzodiazepine	benzodiazepine	NN	_	21	dep
28	on	on	IN	_	31	case
29	a	a	DT	_	31	det
30	regular	regular	JJ	_	31	amod
31	basis	basis	NN	_	27	nmod
32	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	acid	acid	NN	_	13	nsubj
3	-	-	:	_	2	punct
4	catalyzed	catalyze	VBN	_	8	amod
5	ethanol	ethanol	NN	_	8	compound
6	-	-	:	_	8	punct
7	drug	drug	NN	_	8	compound
8	reaction	reaction	NN	_	2	dep
9	is	be	VBZ	_	13	cop
10	a	a	DT	_	13	det
11	relatively	relatively	RB	_	12	advmod
12	unexplored	unexplored	JJ	_	13	amod
13	area	area	NN	_	0	ROOT
14	and	and	CC	_	13	cc
15	may	may	MD	_	16	aux
16	alter	alter	VB	_	13	conj
17	the	the	DT	_	19	det
18	pharmacological	pharmacological	JJ	_	19	amod
19	action	action	NN	_	16	dobj
20	of	of	IN	_	22	case
21	some	some	DT	_	22	det
22	drugs	drug	NNS	_	19	nmod
23	.	.	.	_	13	punct

1	Inhibitory	inhibitory	JJ	_	2	amod
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	5	case
4	ruthenium	ruthenium	NN	_	5	compound
5	red	red	NN	_	2	nmod
6	on	on	IN	_	7	case
7	inositol	inositol	NN	_	2	nmod
8	1,4	1,4	CD	_	7	nummod
9	,	,	,	_	7	punct
10	5	5	CD	_	7	nummod
11	-	-	:	_	7	punct
12	trisphosphate	trisphosphate	NN	_	7	dep
13	-	-	:	_	7	punct
14	induced	induce	VBN	_	15	amod
15	responses	response	NNS	_	7	dep
16	in	in	IN	_	18	case
17	rat	rat	NN	_	18	compound
18	megakaryocytes	megakaryocyte	NNS	_	15	nmod
19	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	24	nsubjpass
3	of	of	IN	_	8	case
4	ruthenium	ruthenium	NN	_	8	compound
5	red	red	JJ	_	8	amod
6	(	(	NN	_	8	compound
7	RR	rr	NN	_	8	compound
8	)	)	NN	_	2	nmod
9	on	on	IN	_	15	case
10	inositol	inositol	NN	_	15	compound
11	1,4,5	1,4,5	CD	_	15	nummod
12	-	-	:	_	15	punct
13	trisphosphate	trisphosphate	NN	_	15	compound
14	(	(	CD	_	15	nummod
15	InsP	insp	NN	_	2	nmod
16	(	(	CD	_	17	compound
17	3	3	CD	_	15	nummod
18	)	)	NN	_	15	dep
19	)	)	SYM	_	15	dep
20	-	-	:	_	15	punct
21	induced	induced	JJ	_	22	amod
22	responses	response	NNS	_	15	dep
23	were	be	VBD	_	24	auxpass
24	studied	study	VBN	_	0	ROOT
25	in	in	IN	_	29	case
26	rat	rat	NN	_	29	compound
27	bone	bone	NN	_	29	compound
28	marrow	marrow	NN	_	29	compound
29	megakaryocytes	megakaryocyte	NNS	_	24	nmod
30	with	with	IN	_	35	case
31	the	the	DT	_	35	det
32	patch	patch	NN	_	35	compound
33	-	-	:	_	35	punct
34	clamp	clamp	NN	_	35	compound
35	whole	whole	NN	_	29	nmod
36	-	-	:	_	35	punct
37	cell	cell	NN	_	39	compound
38	recording	recording	NN	_	39	compound
39	technique	technique	NN	_	35	dep
40	in	in	IN	_	41	case
41	combination	combination	NN	_	24	nmod
42	with	with	IN	_	43	case
43	fura	fura	NN	_	41	nmod
44	-	-	:	_	43	punct
45	2	2	CD	_	46	nummod
46	microfluorometry	microfluorometry	NN	_	43	dep
47	.	.	.	_	24	punct

1	Internal	internal	JJ	_	2	amod
2	application	application	NN	_	12	nsubj
3	of	of	IN	_	10	case
4	InsP	insp	NN	_	10	compound
5	(	(	CD	_	6	compound
6	3	3	CD	_	10	nummod
7	)	)	NN	_	10	compound
8	(	(	NN	_	10	compound
9	100	100	CD	_	10	nummod
10	microM	microm	NN	_	2	nmod
11	)	)	CD	_	10	nummod
12	increased	increase	VBN	_	0	ROOT
13	intracellular	intracellular	JJ	_	15	amod
14	Ca	ca	NN	_	15	compound
15	(	(	NN	_	12	dobj
16	2	2	CD	_	15	nummod
17	+	+	CC	_	15	cc
18	)	)	CD	_	19	nummod
19	concentration	concentration	NN	_	15	conj
20	(	(	CD	_	21	compound
21	[	[	CD	_	23	nummod
22	Ca	ca	NN	_	23	compound
23	(	(	NN	_	19	dep
24	2	2	CD	_	28	nummod
25	+	+	CC	_	24	cc
26	)	)	CD	_	27	compound
27	]	]	CD	_	24	conj
28	(	(	NN	_	23	dep
29	i	i	FW	_	31	compound
30	)	)	FW	_	31	compound
31	)	)	NN	_	28	advmod
32	and	and	CC	_	12	cc
33	activated	activate	VBD	_	12	conj
34	the	the	DT	_	36	det
35	Ca	ca	NN	_	36	compound
36	(	(	NN	_	33	dobj
37	2	2	CD	_	36	nummod
38	+	+	CC	_	36	cc
39	)	)	SYM	_	43	dep
40	-	-	:	_	43	punct
41	dependent	dependent	JJ	_	43	amod
42	K	k	NN	_	43	compound
43	(	(	NN	_	36	conj
44	+	+	CC	_	43	cc
45	)	)	CD	_	46	nummod
46	current	current	JJ	_	43	conj
47	.	.	.	_	12	punct

1	Administering	administer	VBG	_	15	csubj
2	InsP	insp	NN	_	5	compound
3	(	(	CD	_	4	compound
4	3	3	CD	_	5	nummod
5	)	)	NN	_	1	dobj
6	together	together	RB	_	1	advmod
7	with	with	IN	_	9	case
8	RR	rr	NN	_	9	compound
9	(	(	NN	_	1	nmod
10	100	100	CD	_	9	nummod
11	-	-	:	_	9	punct
12	500	500	CD	_	13	compound
13	microM	microm	NN	_	14	amod
14	)	)	NN	_	9	dep
15	inhibited	inhibit	VBD	_	0	ROOT
16	InsP	insp	NN	_	23	nsubj
17	(	(	CD	_	18	compound
18	3	3	CD	_	16	nummod
19	)	)	SYM	_	16	dep
20	-	-	:	_	16	punct
21	induced	induced	JJ	_	22	amod
22	responses	response	NNS	_	16	dep
23	(	(	VBP	_	15	ccomp
24	both	both	CC	_	26	cc:preconj
25	Ca	can	MD	_	26	aux
26	(	(	VB	_	23	ccomp
27	2	2	CD	_	32	compound
28	+	+	CC	_	27	cc
29	)	)	CD	_	27	conj
30	and	and	CC	_	27	cc
31	current	current	JJ	_	27	conj
32	responses	response	NNS	_	33	nsubj
33	)	)	VBP	_	26	ccomp
34	in	in	IN	_	39	case
35	a	a	DT	_	39	det
36	dose	dose	NN	_	39	compound
37	-	-	:	_	39	punct
38	dependent	dependent	JJ	_	39	amod
39	fashion	fashion	NN	_	33	nmod
40	.	.	.	_	15	punct

1	Pretreatment	pretreatment	NN	_	12	nsubj
2	of	of	IN	_	3	case
3	megakaryocytes	megakaryocyte	NNS	_	1	nmod
4	with	with	IN	_	10	case
5	extracellular	extracellular	JJ	_	10	amod
6	RR	rr	NN	_	10	compound
7	(	(	NN	_	10	compound
8	50	50	CD	_	10	nummod
9	microM	microm	NN	_	10	compound
10	)	)	NN	_	1	nmod
11	also	also	RB	_	12	advmod
12	inhibited	inhibit	VBD	_	0	ROOT
13	InsP	insp	NN	_	12	dobj
14	(	(	CD	_	15	compound
15	3	3	CD	_	13	nummod
16	)	)	SYM	_	13	dep
17	-	-	:	_	13	punct
18	induced	induced	JJ	_	19	amod
19	responses	response	NNS	_	13	dep
20	.	.	.	_	12	punct

1	Intracellular	intracellular	JJ	_	7	nsubj
2	and	and	CC	_	1	cc
3	extracellular	extracellular	JJ	_	1	conj
4	application	application	NN	_	1	dep
5	of	of	IN	_	6	case
6	RR	rr	NN	_	1	nmod
7	reduced	reduce	VBD	_	0	ROOT
8	ADP	adp	NN	_	11	compound
9	-	-	:	_	11	punct
10	induced	induce	VBN	_	11	amod
11	increases	increase	NNS	_	7	dobj
12	in	in	IN	_	15	case
13	[	[	CD	_	15	nummod
14	Ca	ca	NN	_	15	compound
15	(	(	NN	_	11	nmod
16	2	2	CD	_	15	nummod
17	+	+	CC	_	15	cc
18	)	)	CD	_	19	compound
19	]	]	CD	_	20	nummod
20	(	(	NN	_	15	conj
21	i	i	FW	_	22	compound
22	)	)	FW	_	20	dep
23	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	12	nmod
3	,	,	,	_	12	punct
4	in	in	IN	_	9	case
5	isolated	isolate	VBN	_	9	amod
6	single	single	JJ	_	9	amod
7	pancreatic	pancreatic	JJ	_	9	amod
8	acinar	acinar	JJ	_	9	amod
9	cells	cell	NNS	_	12	nmod
10	,	,	,	_	12	punct
11	RR	rr	NN	_	12	nsubj
12	had	have	VBD	_	0	ROOT
13	no	no	DT	_	14	neg
14	effect	effect	NN	_	12	dobj
15	on	on	IN	_	16	case
16	InsP	insp	NN	_	12	nmod
17	(	(	CD	_	18	compound
18	3	3	CD	_	16	nummod
19	)	)	SYM	_	16	dep
20	-	-	:	_	16	punct
21	induced	induced	JJ	_	22	amod
22	responses	response	NNS	_	16	dep
23	.	.	.	_	12	punct

1	Taken	take	VBN	_	6	advcl
2	together	together	RB	_	1	advmod
3	,	,	,	_	6	punct
4	these	these	DT	_	5	det
5	results	result	NNS	_	6	nsubj
6	suggest	suggest	VBP	_	0	ROOT
7	that	that	IN	_	23	mark
8	the	the	DT	_	9	det
9	site	site	NN	_	23	nsubj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	inhibitory	inhibitory	JJ	_	13	amod
13	action	action	NN	_	9	nmod
14	of	of	IN	_	15	case
15	RR	rr	NN	_	13	nmod
16	is	be	VBZ	_	23	cop
17	at	at	IN	_	23	case
18	the	the	DT	_	23	det
19	InsP	insp	NN	_	23	compound
20	(	(	CD	_	21	compound
21	3	3	CD	_	23	nummod
22	)	)	NN	_	23	compound
23	receptor	receptor	NN	_	6	ccomp
24	,	,	,	_	23	punct
25	or	or	CC	_	23	cc
26	its	its	PRP$	_	29	nmod:poss
27	closely	closely	RB	_	28	advmod
28	associated	associated	JJ	_	29	amod
29	proteins	protein	NNS	_	23	conj
30	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	we	we	PRP	_	6	nsubj
5	have	have	VBP	_	6	aux
6	shown	show	VBN	_	0	ROOT
7	that	that	IN	_	13	mark
8	RR	rr	NN	_	13	nsubj
9	is	be	VBZ	_	13	cop
10	a	a	DT	_	13	det
11	useful	useful	JJ	_	13	amod
12	pharmacological	pharmacological	JJ	_	13	amod
13	tool	tool	NN	_	6	ccomp
14	with	with	IN	_	15	case
15	which	which	WDT	_	17	nmod
16	to	to	TO	_	17	mark
17	examine	examine	VB	_	13	acl:relcl
18	the	the	DT	_	25	det
19	InsP	insp	NN	_	25	compound
20	(	(	CD	_	21	compound
21	3	3	CD	_	25	nummod
22	)	)	SYM	_	25	dep
23	-	-	:	_	25	punct
24	mediated	mediated	JJ	_	25	amod
25	responses	response	NNS	_	17	dobj
26	of	of	IN	_	27	case
27	megakaryocytes	megakaryocyte	NNS	_	25	nmod
28	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	cyclophosphamide	cyclophosphamide	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	doxorubicin	doxorubicin	NN	_	2	conj
5	,	,	,	_	2	punct
6	vincristine	vincristine	NN	_	2	conj
7	,	,	,	_	2	punct
8	and	and	CC	_	2	cc
9	prednisone	prednisone	NN	_	10	compound
10	chemotherapy	chemotherapy	NN	_	2	conj
11	plus	plus	CC	_	10	cc
12	highly	highly	RB	_	13	advmod
13	active	active	JJ	_	15	amod
14	antiretroviral	antiretroviral	JJ	_	15	amod
15	therapy	therapy	NN	_	10	conj
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	2	nmod
18	with	with	IN	_	21	case
19	human	human	JJ	_	21	amod
20	immunodeficiency	immunodeficiency	NN	_	21	compound
21	virus	virus	NN	_	17	nmod
22	-	-	:	_	21	punct
23	related	related	JJ	_	21	amod
24	,	,	,	_	21	punct
25	non	non	JJ	_	28	amod
26	-	-	:	_	28	punct
27	Hodgkin	hodgkin	NN	_	28	compound
28	lymphoma	lymphoma	NN	_	21	appos
29	.	.	.	_	2	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	feasibility	feasibility	NN	_	20	nsubj
5	and	and	CC	_	4	cc
6	efficacy	efficacy	NN	_	4	conj
7	of	of	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	chemotherapy	chemotherapy	NN	_	4	nmod
10	and	and	CC	_	9	cc
11	highly	highly	RB	_	12	advmod
12	active	active	JJ	_	14	amod
13	antiretroviral	antiretroviral	JJ	_	14	amod
14	therapy	therapy	NN	_	9	conj
15	(	(	CD	_	16	nummod
16	HAART	HAART	NNP	_	14	dep
17	)	)	CD	_	16	nummod
18	is	be	VBZ	_	20	cop
19	still	still	RB	_	20	advmod
20	unknown	unknown	JJ	_	1	dep
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	with	with	IN	_	28	case
24	human	human	JJ	_	28	amod
25	immunodeficiency	immunodeficiency	NN	_	28	compound
26	virus	virus	NN	_	28	compound
27	(	(	CD	_	28	nummod
28	HIV	hiv	NN	_	22	nmod
29	)	)	SYM	_	28	dep
30	-	-	:	_	20	punct
31	related	related	JJ	_	32	amod
32	malignancies	malignancy	NNS	_	20	dep
33	.	.	.	_	1	punct

1	To	to	TO	_	2	mark
2	evaluate	evaluate	VB	_	0	ROOT
3	the	the	DT	_	4	det
4	impact	impact	NN	_	2	dobj
5	of	of	IN	_	6	case
6	chemotherapy	chemotherapy	NN	_	4	nmod
7	plus	plus	CC	_	6	cc
8	HAART	haart	NN	_	6	conj
9	on	on	IN	_	12	case
10	the	the	DT	_	12	det
11	clinical	clinical	JJ	_	12	amod
12	course	course	NN	_	4	nmod
13	of	of	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	16	case
16	HIV	hiv	NN	_	14	nmod
17	-	-	:	_	16	punct
18	related	related	JJ	_	16	dep
19	,	,	,	_	18	punct
20	systemic	systemic	JJ	_	18	conj
21	,	,	,	_	18	punct
22	non	non	JJ	_	18	conj
23	-	-	:	_	18	punct
24	Hodgkin	hodgkin	NN	_	27	compound
25	lymphoma	lymphoma	NN	_	27	compound
26	(	(	CD	_	27	nummod
27	HIV	hiv	NN	_	18	conj
28	-	-	:	_	27	punct
29	NHL	nhl	NN	_	30	compound
30	)	)	NN	_	27	dep
31	,	,	,	_	18	punct
32	the	the	DT	_	33	det
33	authors	author	NNS	_	18	conj
34	compared	compare	VBN	_	84	case
35	retrospectively	retrospectively	RB	_	84	advmod
36	a	a	DT	_	37	det
37	group	group	NN	_	84	nsubj
38	of	of	IN	_	40	case
39	24	24	CD	_	40	nummod
40	patients	patient	NNS	_	37	nmod
41	with	with	IN	_	42	case
42	HIV	hiv	NN	_	40	nmod
43	-	-	:	_	37	punct
44	NHL	nhl	NN	_	37	dep
45	who	who	WP	_	47	nsubjpass
46	were	be	VBD	_	47	auxpass
47	treated	treat	VBN	_	44	acl:relcl
48	with	with	IN	_	50	case
49	the	the	DT	_	50	det
50	cyclophosphamide	cyclophosphamide	NN	_	47	nmod
51	,	,	,	_	50	punct
52	doxorubicin	doxorubicin	NN	_	50	conj
53	,	,	,	_	50	punct
54	vincristine	vincristine	NN	_	50	conj
55	,	,	,	_	50	punct
56	and	and	CC	_	50	cc
57	prednisone	prednisone	NN	_	62	compound
58	(	(	CD	_	62	nummod
59	CHOP	chop	NN	_	62	compound
60	)	)	CD	_	62	nummod
61	chemotherapy	chemotherapy	NN	_	62	compound
62	regimen	regimen	NN	_	50	conj
63	plus	plus	CC	_	62	cc
64	HAART	haart	NN	_	62	conj
65	with	with	IN	_	67	case
66	a	a	DT	_	67	det
67	group	group	NN	_	62	nmod
68	of	of	IN	_	70	case
69	80	80	CD	_	70	nummod
70	patients	patient	NNS	_	67	nmod
71	who	who	WP	_	73	nsubjpass
72	were	be	VBD	_	73	auxpass
73	treated	treat	VBN	_	70	acl:relcl
74	with	with	IN	_	76	case
75	CHOP	chop	NN	_	76	compound
76	chemotherapy	chemotherapy	NN	_	73	nmod
77	or	or	CC	_	76	cc
78	a	a	DT	_	79	det
79	CHOP	chop	NN	_	76	conj
80	-	-	:	_	37	punct
81	like	like	IN	_	82	case
82	regimen	regimen	NN	_	37	nmod
83	(	(	CD	_	82	nummod
84	i	i	LS	_	33	nmod
85	.	.	.	_	84	punct
86	e	e	LS	_	84	dep
87	.	.	.	_	86	punct
88	,	,	,	_	86	punct
89	cyclophosphamide	cyclophosphamide	NN	_	86	dep
90	,	,	,	_	89	punct
91	doxorubicin	doxorubicin	NN	_	89	conj
92	,	,	,	_	89	punct
93	teniposide	teniposide	NN	_	89	conj
94	,	,	,	_	89	punct
95	and	and	CC	_	89	cc
96	prednisone	prednisone	NN	_	89	conj
97	with	with	IN	_	98	case
98	vincristine	vincristine	NN	_	96	nmod
99	plus	plus	CC	_	98	cc
100	bleomycin	bleomycin	NN	_	101	compound
101	)	)	NN	_	98	conj
102	without	without	IN	_	103	mark
103	receiving	receive	VBG	_	89	acl
104	antiretroviral	antiretroviral	JJ	_	105	amod
105	therapy	therapy	NN	_	103	dobj
106	.	.	.	_	2	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	All	all	DT	_	4	det
4	patients	patient	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	enrolled	enrol	VBN	_	1	appos
7	in	in	IN	_	10	case
8	two	two	CD	_	10	nummod
9	sequential	sequential	JJ	_	10	amod
10	trials	trial	NNS	_	6	nmod
11	performed	perform	VBN	_	10	acl
12	at	at	IN	_	16	case
13	the	the	DT	_	16	det
14	Aviano	Aviano	NNP	_	16	compound
15	Cancer	Cancer	NNP	_	16	compound
16	Center	Center	NNP	_	11	nmod
17	,	,	,	_	16	punct
18	Italy	Italy	NNP	_	16	appos
19	,	,	,	_	16	punct
20	from	from	IN	_	21	case
21	April	April	NNP	_	6	nmod
22	1988	1988	CD	_	21	nummod
23	to	to	TO	_	24	case
24	December	December	NNP	_	21	nmod
25	1998	1998	CD	_	24	nummod
26	.	.	.	_	1	punct

1	HAART	HAART	NNP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	included	include	VBN	_	0	ROOT
4	with	with	IN	_	6	case
5	combination	combination	NN	_	6	compound
6	therapy	therapy	NN	_	3	nmod
7	from	from	IN	_	8	case
8	January	January	NNP	_	6	nmod
9	1997	1997	CD	_	8	nummod
10	.	.	.	_	3	punct

1	Antiretroviral	antiretroviral	JJ	_	2	amod
2	regimens	regimen	NNS	_	3	nsubj
3	consisted	consist	VBD	_	0	ROOT
4	of	of	IN	_	8	case
5	two	two	CD	_	8	nummod
6	reverse	reverse	JJ	_	8	amod
7	transcriptase	transcriptase	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	3	nmod
9	and	and	CC	_	8	cc
10	one	one	CD	_	12	nummod
11	protease	protease	NN	_	12	compound
12	inhibitor	inhibitor	NN	_	8	conj
13	.	.	.	_	3	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	6	det
4	two	two	CD	_	6	nummod
5	treatment	treatment	NN	_	6	compound
6	groups	group	NNS	_	9	nsubjpass
7	were	be	VBD	_	9	auxpass
8	well	well	RB	_	9	advmod
9	matched	match	VBN	_	1	dep
10	with	with	IN	_	11	case
11	regard	regard	NN	_	9	nmod
12	to	to	TO	_	14	case
13	patient	patient	NN	_	14	compound
14	demographics	demographic	NNS	_	11	nmod
15	,	,	,	_	14	punct
16	NHL	nhl	NN	_	17	compound
17	characteristics	characteristic	NNS	_	14	conj
18	,	,	,	_	14	punct
19	HIV	hiv	NN	_	20	compound
20	status	status	NN	_	14	conj
21	,	,	,	_	14	punct
22	and	and	CC	_	14	cc
23	treatment	treatment	NN	_	14	conj
24	,	,	,	_	23	punct
25	i	i	FW	_	23	dep
26	.	.	.	_	9	punct
27	e	e	LS	_	9	dep
28	.	.	.	_	27	punct
29	,	,	,	_	27	punct
30	the	the	DT	_	31	det
31	number	number	NN	_	27	appos
32	of	of	IN	_	33	case
33	cycles	cycle	NNS	_	31	nmod
34	and	and	CC	_	33	cc
35	chemotherapy	chemotherapy	NN	_	36	compound
36	dose	dose	NN	_	33	conj
37	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	response	response	NN	_	3	compound
3	rates	rate	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	similar	similar	JJ	_	0	ROOT
6	between	between	IN	_	9	case
7	the	the	DT	_	9	det
8	two	two	CD	_	9	nummod
9	groups	group	NNS	_	5	nmod
10	.	.	.	_	5	punct

1	Severe	severe	JJ	_	2	amod
2	anemia	anemia	NN	_	0	ROOT
3	(	(	CD	_	4	nummod
4	Grade	Grade	NNP	_	5	nsubj
5	3	3	LS	_	2	acl:relcl
6	-	-	:	_	5	punct
7	4	4	CD	_	18	nsubj
8	according	accord	VBG	_	14	case
9	to	to	TO	_	8	mwe
10	the	the	DT	_	14	det
11	World	World	NNP	_	14	compound
12	Health	Health	NNP	_	14	compound
13	Organization	Organization	NNP	_	14	compound
14	criteria	criterion	NNS	_	7	nmod
15	)	)	CD	_	14	nummod
16	was	be	VBD	_	18	cop
17	significantly	significantly	RB	_	18	advmod
18	greater	greater	JJR	_	5	dep
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	patients	patient	NNS	_	18	nmod
22	who	who	WP	_	23	nsubj
23	received	receive	VBD	_	21	acl:relcl
24	CHOP	chop	NN	_	23	dobj
25	-	-	:	_	18	punct
26	HAART	haart	NN	_	41	dep
27	compared	compare	VBN	_	30	case
28	with	with	IN	_	30	case
29	the	the	DT	_	30	det
30	patients	patient	NNS	_	26	nmod
31	who	who	WP	_	32	nsubj
32	received	receive	VBD	_	30	acl:relcl
33	CHOP	chop	NN	_	32	dobj
34	alone	alone	RB	_	32	advmod
35	(	(	RB	_	38	advmod
36	33	33	CD	_	37	nummod
37	%	%	NN	_	38	nmod:npmod
38	vs	vs	CC	_	32	advcl
39	.	.	.	_	26	punct
40	7	7	CD	_	41	nummod
41	%	%	NN	_	18	dep
42	,	,	,	_	41	punct
43	respectively	respectively	RB	_	41	advmod
44	;	;	:	_	41	punct
45	P	p	NN	_	46	nsubj
46	=	=	JJ	_	41	parataxis
47	0.001	0.001	CD	_	48	nummod
48	)	)	NN	_	46	dobj
49	.	.	.	_	2	punct

1	Leukopenia	leukopenia	NN	_	3	nsubj
2	was	be	VBD	_	3	cop
3	similar	similar	JJ	_	0	ROOT
4	between	between	IN	_	7	case
5	the	the	DT	_	7	det
6	two	two	CD	_	7	nummod
7	groups	group	NNS	_	3	nmod
8	,	,	,	_	3	punct
9	but	but	CC	_	3	cc
10	colony	colony	NN	_	13	compound
11	stimulating	stimulating	NN	_	13	compound
12	factor	factor	NN	_	13	compound
13	support	support	NN	_	16	nsubj
14	was	be	VBD	_	16	cop
15	significantly	significantly	RB	_	16	advmod
16	greater	greater	JJR	_	3	conj
17	in	in	IN	_	22	case
18	the	the	DT	_	22	det
19	CHOP	chop	NN	_	22	compound
20	-	-	:	_	22	punct
21	HAART	haart	NN	_	22	compound
22	group	group	NN	_	16	nmod
23	than	than	IN	_	27	case
24	in	in	IN	_	27	case
25	the	the	DT	_	27	det
26	control	control	NN	_	27	compound
27	group	group	NN	_	16	nmod
28	(	(	CD	_	29	compound
29	92	92	CD	_	30	nummod
30	%	%	NN	_	27	dep
31	vs	vs	CC	_	30	advmod
32	.	.	.	_	3	punct
33	66	66	CD	_	34	nummod
34	%	%	NN	_	3	conj
35	,	,	,	_	34	punct
36	respectively	respectively	RB	_	34	advmod
37	;	;	:	_	3	punct
38	P	p	NN	_	39	nsubj
39	=	=	JJ	_	3	parataxis
40	0.03	0.03	CD	_	41	nummod
41	)	)	NN	_	39	dobj
42	.	.	.	_	3	punct

1	Seventeen	seventeen	CD	_	2	nummod
2	percent	percent	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	CHOP	chop	NN	_	2	nmod
5	-	-	:	_	2	punct
6	HAART	haart	NN	_	7	compound
7	patients	patient	NNS	_	8	nsubj
8	developed	develop	VBD	_	2	dep
9	severe	severe	JJ	_	11	amod
10	autonomic	autonomic	JJ	_	11	amod
11	neurotoxicity	neurotoxicity	NN	_	8	dobj
12	,	,	,	_	2	punct
13	whereas	whereas	IN	_	2	dep
14	none	none	NN	_	19	nsubj
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	CHOP	chop	NN	_	18	compound
18	patients	patient	NNS	_	14	nmod
19	developed	develop	VBD	_	2	parataxis
20	neurotoxicity	neurotoxicity	NN	_	22	compound
21	(	(	CD	_	22	nummod
22	P	p	NN	_	23	nsubj
23	=	=	JJ	_	19	ccomp
24	0.002	0.002	CD	_	25	nummod
25	)	)	NN	_	23	dobj
26	.	.	.	_	2	punct

1	At	at	IN	_	3	case
2	similar	similar	JJ	_	3	amod
3	median	median	NN	_	4	nmod
4	follow	follow	VB	_	0	ROOT
5	-	-	:	_	4	punct
6	up	up	RP	_	4	advmod
7	,	,	,	_	4	punct
8	opportunistic	opportunistic	JJ	_	9	amod
9	infection	infection	NN	_	18	nsubj
10	(	(	CD	_	13	nummod
11	OI	oi	NN	_	13	compound
12	)	)	NN	_	13	compound
13	rates	rate	NNS	_	9	dep
14	and	and	CC	_	9	cc
15	mortality	mortality	NN	_	9	conj
16	were	be	VBD	_	18	cop
17	significantly	significantly	RB	_	18	advmod
18	lower	lower	JJR	_	4	ccomp
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	CHOP	chop	NN	_	18	nmod
22	-	-	:	_	18	punct
23	HAART	haart	NN	_	24	compound
24	patients	patient	NNS	_	30	nsubj
25	than	than	IN	_	29	case
26	in	in	IN	_	29	case
27	the	the	DT	_	29	det
28	CHOP	chop	NN	_	29	compound
29	patients	patient	NNS	_	24	nmod
30	(	(	VBP	_	18	ccomp
31	18	18	CD	_	32	nummod
32	%	%	NN	_	30	dobj
33	vs	vs	CC	_	30	advmod
34	.	.	.	_	4	punct
35	52	52	CD	_	36	nummod
36	%	%	NN	_	4	dep
37	,	,	,	_	36	punct
38	respectively	respectively	RB	_	36	advmod
39	;	;	:	_	36	punct
40	P	p	NN	_	41	nsubj
41	=	=	JJ	_	36	dep
42	0.05	0.05	CD	_	41	dobj
43	;	;	:	_	36	punct
44	and	and	CC	_	36	cc
45	38	38	CD	_	46	nummod
46	%	%	NN	_	36	conj
47	vs	vs	CC	_	46	amod
48	.	.	.	_	36	punct
49	85	85	CD	_	50	nummod
50	%	%	NN	_	36	dep
51	,	,	,	_	36	punct
52	respectively	respectively	RB	_	36	advmod
53	;	;	:	_	36	punct
54	P	p	NN	_	55	nsubj
55	=	=	JJ	_	36	parataxis
56	0.001	0.001	CD	_	57	nummod
57	)	)	NN	_	55	dobj
58	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	median	median	JJ	_	3	amod
3	survival	survival	NN	_	11	nsubjpass
4	for	for	IN	_	5	case
5	CHOP	chop	NN	_	3	nmod
6	-	-	:	_	5	punct
7	HAART	haart	NN	_	8	compound
8	patients	patient	NNS	_	5	dep
9	was	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	reached	reach	VBN	_	0	ROOT
12	,	,	,	_	11	punct
13	whereas	whereas	IN	_	11	dep
14	the	the	DT	_	16	det
15	medial	medial	JJ	_	16	amod
16	survival	survival	NN	_	22	nsubj
17	of	of	IN	_	19	case
18	CHOP	chop	NN	_	19	compound
19	patients	patient	NNS	_	16	nmod
20	was	be	VBD	_	22	cop
21	7	7	CD	_	22	nummod
22	months	month	NNS	_	11	parataxis
23	(	(	CD	_	24	nummod
24	P	p	NN	_	25	nsubj
25	=	=	JJ	_	22	acl:relcl
26	0.03	0.03	CD	_	27	nummod
27	)	)	NN	_	25	dobj
28	.	.	.	_	11	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	combination	combination	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	CHOP	chop	NN	_	4	nmod
7	plus	plus	CC	_	6	cc
8	HAART	haart	NN	_	6	conj
9	is	be	VBZ	_	10	cop
10	feasible	feasible	JJ	_	1	dep
11	and	and	CC	_	10	cc
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	10	conj
14	the	the	DT	_	15	det
15	morbidity	morbidity	NN	_	13	dobj
16	from	from	IN	_	17	case
17	OIs	oi	NNS	_	15	nmod
18	in	in	IN	_	19	case
19	HIV	hiv	NN	_	15	nmod
20	-	-	:	_	10	punct
21	NHL	nhl	NN	_	22	compound
22	patients	patient	NNS	_	10	conj
23	.	.	.	_	1	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	careful	careful	JJ	_	4	amod
4	attention	attention	NN	_	7	nsubjpass
5	must	must	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	directed	direct	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	cross	cross	VB	_	7	xcomp
10	toxicity	toxicity	NN	_	9	dobj
11	and	and	CC	_	10	cc
12	possible	possible	JJ	_	14	amod
13	pharmacokinetic	pharmacokinetic	JJ	_	14	amod
14	interactions	interaction	NNS	_	10	conj
15	between	between	IN	_	19	case
16	antiretroviral	antiretroviral	JJ	_	19	amod
17	and	and	CC	_	16	cc
18	antineoplastic	antineoplastic	JJ	_	16	conj
19	drugs	drug	NNS	_	9	nmod
20	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	impact	impact	NN	_	13	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	combined	combined	JJ	_	6	amod
6	chemotherapy	chemotherapy	NN	_	2	nmod
7	plus	plus	CC	_	6	cc
8	HAART	haart	NN	_	9	compound
9	treatment	treatment	NN	_	6	conj
10	on	on	IN	_	12	case
11	patient	patient	NN	_	12	compound
12	survival	survival	NN	_	2	nmod
13	needs	need	VBZ	_	0	ROOT
14	urgently	urgently	RB	_	13	advmod
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	auxpass
17	evaluated	evaluate	VBN	_	13	xcomp
18	in	in	IN	_	20	case
19	prospective	prospective	JJ	_	20	amod
20	studies	study	NNS	_	17	nmod
21	.	.	.	_	13	punct

1	Rifampin	Rifampin	NNP	_	0	ROOT
2	and	and	CC	_	1	cc
3	warfarin	warfarin	NN	_	1	conj
4	:	:	:	_	1	punct
5	a	a	DT	_	7	det
6	drug	drug	NN	_	7	compound
7	interaction	interaction	NN	_	1	dep
8	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interaction	interaction	NN	_	11	nsubjpass
4	between	between	IN	_	5	case
5	warfarin	warfarin	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	rifampin	rifampin	NN	_	5	conj
8	is	be	VBZ	_	11	auxpass
9	not	not	RB	_	11	neg
10	well	well	RB	_	11	advmod
11	known	know	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Rifampin	Rifampin	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	warfarin	warfarin	NN	_	9	compound
9	requirements	requirement	NNS	_	6	dobj
10	in	in	IN	_	12	case
11	human	human	JJ	_	12	amod
12	subjects	subject	NNS	_	9	nmod
13	ingesting	ingest	VBG	_	12	acl
14	these	these	DT	_	15	det
15	agents	agent	NNS	_	13	dobj
16	simultaneously	simultaneously	RB	_	13	advmod
17	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	rifampin	rifampin	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	warfarin	warfarin	NN	_	5	conj
8	resulted	result	VBD	_	0	ROOT
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	need	need	NN	_	8	nmod
12	for	for	IN	_	17	case
13	an	a	DT	_	17	det
14	unusually	unusually	RB	_	15	advmod
15	high	high	JJ	_	17	amod
16	maintenance	maintenance	NN	_	17	compound
17	dose	dose	NN	_	11	nmod
18	of	of	IN	_	19	case
19	warfarin	warfarin	NN	_	17	nmod
20	(	(	CD	_	21	compound
21	20	20	CD	_	22	nummod
22	mg	mg	NN	_	19	dep
23	per	per	IN	_	24	case
24	day	day	NN	_	17	nmod
25	)	)	CD	_	24	nummod
26	in	in	IN	_	29	mark
27	order	order	NN	_	26	mwe
28	to	to	TO	_	29	mark
29	produce	produce	VB	_	11	acl
30	a	a	DT	_	32	det
31	therapeutic	therapeutic	JJ	_	32	amod
32	effect	effect	NN	_	29	dobj
33	.	.	.	_	8	punct

1	Withdrawal	withdrawal	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	rifampin	rifampin	NN	_	1	nmod
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	warfarin	warfarin	NN	_	7	compound
7	requirement	requirement	NN	_	4	dobj
8	by	by	IN	_	10	case
9	50	50	CD	_	10	nummod
10	%	%	NN	_	4	nmod
11	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	mediated	mediate	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	the	the	DT	_	8	det
8	ability	ability	NN	_	5	nmod
9	of	of	IN	_	10	case
10	rifampin	rifampin	NN	_	8	nmod
11	to	to	TO	_	12	mark
12	induce	induce	VB	_	8	acl
13	microsomal	microsomal	JJ	_	14	amod
14	enzymes	enzyme	NNS	_	12	dobj
15	and	and	CC	_	5	cc
16	,	,	,	_	5	punct
17	thus	thus	RB	_	5	advmod
18	,	,	,	_	5	punct
19	the	the	DT	_	20	det
20	catabolism	catabolism	NN	_	5	dobj
21	of	of	IN	_	22	case
22	warfarin	warfarin	NN	_	20	nmod
23	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	rifampin	rifampin	NN	_	2	nmod
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	warfarin	warfarin	NN	_	8	compound
8	requirement	requirement	NN	_	2	nmod
9	of	of	IN	_	11	case
10	our	we	PRP$	_	11	nmod:poss
11	patient	patient	NN	_	8	nmod
12	appeared	appear	VBD	_	0	ROOT
13	to	to	TO	_	19	mark
14	be	be	VB	_	19	cop
15	maximal	maximal	JJ	_	19	amod
16	5	5	CD	_	18	compound
17	to	to	TO	_	18	dep
18	7	7	CD	_	19	nummod
19	days	day	NNS	_	12	xcomp
20	after	after	IN	_	22	case
21	the	the	DT	_	22	det
22	initiation	initiation	NN	_	19	nmod
23	of	of	IN	_	24	case
24	rifampin	rifampin	NN	_	22	nmod
25	and	and	CC	_	12	cc
26	extended	extend	VBD	_	12	conj
27	a	a	DT	_	29	det
28	similar	similar	JJ	_	29	amod
29	length	length	NN	_	26	dobj
30	of	of	IN	_	31	case
31	time	time	NN	_	29	nmod
32	after	after	IN	_	34	case
33	rifampin	rifampin	NN	_	34	compound
34	withdrawal	withdrawal	NN	_	26	nmod
35	.	.	.	_	12	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	3	nsubj
3	appears	appear	VBZ	_	0	ROOT
4	to	to	TO	_	7	mark
5	be	be	VB	_	7	cop
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	3	xcomp
8	.	.	.	_	3	punct

1	Increased	increase	VBN	_	2	amod
2	stability	stability	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	nucleophosmin	nucleophosmin	JJ	_	6	amod
5	/	/	:	_	6	punct
6	B23	b23	NN	_	2	nmod
7	in	in	IN	_	11	case
8	anti	anti	JJ	_	11	amod
9	-	-	:	_	11	punct
10	apoptotic	apoptotic	JJ	_	11	amod
11	effect	effect	NN	_	2	nmod
12	of	of	IN	_	13	case
13	ras	ras	NN	_	11	nmod
14	during	during	IN	_	16	case
15	serum	serum	NN	_	16	compound
16	deprivation	deprivation	NN	_	11	nmod
17	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	obtained	obtain	VBD	_	0	ROOT
3	evidence	evidence	NN	_	2	dobj
4	that	that	IN	_	12	mark
5	increased	increase	VBN	_	6	amod
6	stability	stability	NN	_	12	nsubjpass
7	of	of	IN	_	10	case
8	nucleophosmin	nucleophosmin	JJ	_	10	amod
9	/	/	:	_	10	punct
10	B23	b23	NN	_	6	nmod
11	is	be	VBZ	_	12	auxpass
12	involved	involve	VBN	_	3	ccomp
13	in	in	IN	_	15	case
14	antiapoptotic	antiapoptotic	JJ	_	15	amod
15	effect	effect	NN	_	12	nmod
16	of	of	IN	_	17	case
17	ras	ras	NN	_	15	nmod
18	during	during	IN	_	20	case
19	serum	serum	NN	_	20	compound
20	deprivation	deprivation	NN	_	15	nmod
21	.	.	.	_	2	punct

1	Nucleophosmin	nucleophosmin	JJ	_	3	amod
2	/	/	:	_	3	punct
3	B23	b23	NN	_	18	nsubjpass
4	in	in	IN	_	5	case
5	serum	serum	NN	_	3	nmod
6	-	-	:	_	3	punct
7	deprived	deprive	VBN	_	3	acl
8	(	(	CD	_	10	compound
9	0	0	CD	_	10	compound
10	%	%	NN	_	7	dobj
11	serum	serum	NN	_	13	compound
12	)	)	CD	_	13	nummod
13	NIH	NIH	NNP	_	10	dep
14	-	-	:	_	13	punct
15	3T3	3t3	NN	_	16	compound
16	cells	cell	NNS	_	13	dep
17	was	be	VBD	_	18	auxpass
18	found	find	VBN	_	0	ROOT
19	to	to	TO	_	22	mark
20	be	be	VB	_	22	cop
21	highly	highly	RB	_	22	advmod
22	unstable	unstable	JJ	_	18	xcomp
23	with	with	IN	_	27	case
24	a	a	DT	_	27	det
25	half	half	NN	_	27	amod
26	-	-	:	_	27	punct
27	life	life	NN	_	22	nmod
28	less	less	JJR	_	30	advmod
29	than	than	IN	_	28	mwe
30	4	4	CD	_	31	nummod
31	h	h	NN	_	27	dep
32	.	.	.	_	18	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	22	nmod
3	,	,	,	_	22	punct
4	nucleophosmin	nucleophosmin	JJ	_	6	amod
5	/	/	:	_	6	punct
6	B23	b23	NN	_	22	nsubj
7	in	in	IN	_	8	case
8	serum	serum	NN	_	6	nmod
9	-	-	:	_	6	punct
10	deprived	deprive	VBN	_	11	amod
11	ras	ras	NN	_	6	dep
12	-	-	:	_	11	punct
13	transformed	transform	VBN	_	11	acl
14	(	(	CD	_	15	nummod
15	RAS	ras	NN	_	13	dobj
16	-	-	:	_	15	punct
17	3T3	3t3	NN	_	19	compound
18	)	)	NN	_	19	compound
19	cells	cell	NNS	_	15	dep
20	was	be	VBD	_	22	cop
21	as	as	IN	_	22	advmod
22	stable	stable	JJ	_	0	ROOT
23	as	as	IN	_	24	case
24	that	that	DT	_	22	nmod
25	in	in	IN	_	26	case
26	serum	serum	NN	_	24	nmod
27	-	-	:	_	26	punct
28	supplemented	supplement	VBN	_	27	root
29	NIH	NIH	NNP	_	28	dobj
30	-	-	:	_	29	punct
31	3T3	3t3	NN	_	29	dep
32	or	or	CC	_	31	cc
33	RAS	ras	NN	_	31	conj
34	-	-	:	_	29	punct
35	3T3	3t3	NN	_	36	compound
36	cells	cell	NNS	_	29	dep
37	.	.	.	_	28	punct

1	Treatment	treatment	NN	_	14	nsubj
2	of	of	IN	_	3	case
3	RAS	ras	NN	_	1	nmod
4	-	-	:	_	3	punct
5	3T3	3t3	NN	_	6	compound
6	cells	cell	NNS	_	3	dep
7	with	with	IN	_	12	case
8	nucleophosmin	nucleophosmin	JJ	_	12	amod
9	/	/	:	_	12	punct
10	B23	b23	NN	_	12	compound
11	antisense	antisense	JJ	_	12	amod
12	oligomer	oligomer	NN	_	6	nmod
13	significantly	significantly	RB	_	14	advmod
14	potentiated	potentiate	VBD	_	0	ROOT
15	the	the	DT	_	16	det
16	apoptosis	apoptosis	NN	_	14	dobj
17	induced	induce	VBN	_	16	acl
18	by	by	IN	_	20	case
19	serum	serum	NN	_	20	compound
20	deprivation	deprivation	NN	_	17	nmod
21	.	.	.	_	14	punct

1	Much	much	RB	_	2	advmod
2	less	less	JJR	_	3	amod
3	caspase	caspase	NN	_	8	nsubjpass
4	-	-	:	_	3	punct
5	3	3	CD	_	6	nummod
6	activity	activity	NN	_	3	dep
7	was	be	VBD	_	8	auxpass
8	noted	note	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	lysate	lysate	NN	_	8	nmod
12	derived	derive	VBN	_	11	acl
13	from	from	IN	_	14	case
14	serum	serum	NN	_	12	nmod
15	-	-	:	_	8	punct
16	deprived	deprive	VBN	_	20	amod
17	RAS	ras	SYM	_	20	dep
18	-	-	:	_	20	punct
19	3T3	3t3	NN	_	20	compound
20	cells	cell	NNS	_	8	dep
21	compared	compare	VBN	_	23	case
22	with	with	IN	_	23	case
23	that	that	DT	_	20	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	lysate	lysate	NN	_	23	nmod
27	of	of	IN	_	28	case
28	serum	serum	NN	_	26	nmod
29	-	-	:	_	20	punct
30	deprived	deprive	VBN	_	20	acl
31	NIH	NIH	NNP	_	30	dobj
32	-	-	:	_	31	punct
33	3T3	3t3	NN	_	34	compound
34	cells	cell	NNS	_	31	dep
35	.	.	.	_	8	punct

1	Cell	cell	NN	_	3	compound
2	permeable	permeable	JJ	_	3	amod
3	caspase	caspase	NN	_	11	nsubj
4	-	-	:	_	3	punct
5	3	3	CD	_	6	nummod
6	inhibitor	inhibitor	NN	_	3	dep
7	added	add	VBN	_	6	acl
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	medium	medium	NN	_	7	nmod
11	blocked	block	VBD	_	0	ROOT
12	the	the	DT	_	13	det
13	decrease	decrease	NN	_	11	dobj
14	of	of	IN	_	17	case
15	nucleophosmin	nucleophosmin	JJ	_	17	amod
16	/	/	:	_	17	punct
17	B23	b23	NN	_	13	nmod
18	and	and	CC	_	17	cc
19	apoptosis	apoptosis	NN	_	17	conj
20	induced	induce	VBN	_	17	acl
21	by	by	IN	_	23	case
22	serum	serum	NN	_	23	compound
23	deprivation	deprivation	NN	_	20	nmod
24	in	in	IN	_	25	case
25	NIH	NIH	NNP	_	23	nmod
26	-	-	:	_	17	punct
27	3T3	3t3	NN	_	28	compound
28	cells	cell	NNS	_	17	dep
29	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	inhibitor	inhibitor	NN	_	9	nsubj
3	,	,	,	_	9	punct
4	on	on	IN	_	7	case
5	the	the	DT	_	7	det
6	other	other	JJ	_	7	amod
7	hand	hand	NN	_	9	nmod
8	,	,	,	_	9	punct
9	promoted	promote	VBD	_	0	ROOT
10	significant	significant	JJ	_	11	amod
11	decrease	decrease	NN	_	9	dobj
12	of	of	IN	_	13	case
13	nucleolin	nucleolin	NN	_	11	nmod
14	/	/	:	_	11	punct
15	C23	c23	NN	_	11	dep
16	in	in	IN	_	17	case
17	NIH	NIH	NNP	_	15	nmod
18	-	-	:	_	11	punct
19	3T3	3t3	NN	_	20	compound
20	cells	cell	NNS	_	11	dep
21	during	during	IN	_	23	case
22	serum	serum	NN	_	23	compound
23	deprivation	deprivation	NN	_	20	nmod
24	.	.	.	_	9	punct

1	Unlike	unlike	IN	_	2	case
2	nucleolin	nucleolin	NN	_	8	nmod
3	/	/	:	_	4	punct
4	C23	c23	NN	_	8	dep
5	,	,	,	_	4	punct
6	down	down	IN	_	4	dep
7	-	-	:	_	4	punct
8	regulation	regulation	NN	_	16	nsubj
9	of	of	IN	_	12	case
10	nucleophosmin	nucleophosmin	JJ	_	12	amod
11	/	/	:	_	12	punct
12	B23	b23	NN	_	8	nmod
13	was	be	VBD	_	16	cop
14	thus	thus	RB	_	16	advmod
15	not	not	RB	_	16	neg
16	proliferation	proliferation	NN	_	0	ROOT
17	-	-	:	_	16	punct
18	dependent	dependent	JJ	_	16	dep
19	but	but	CC	_	18	cc
20	caspase	caspase	NN	_	18	conj
21	-	-	:	_	16	punct
22	3	3	LS	_	16	dep
23	-	-	:	_	22	punct
24	and	and	CC	_	22	cc
25	apoptosis	apoptosis	NN	_	22	conj
26	-	-	:	_	25	punct
27	dependent	dependent	JJ	_	25	amod
28	.	.	.	_	16	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	important	important	JJ	_	5	amod
5	relationships	relationship	NNS	_	3	dobj
6	among	among	IN	_	7	case
7	ras	ras	NN	_	5	nmod
8	,	,	,	_	7	punct
9	nucleophosmin	nucleophosmin	JJ	_	11	amod
10	/	/	:	_	11	punct
11	B23	b23	NN	_	7	conj
12	,	,	,	_	7	punct
13	activation	activation	NN	_	7	conj
14	of	of	IN	_	15	case
15	caspase	caspase	NN	_	13	nmod
16	-	-	:	_	15	punct
17	3	3	CD	_	15	nummod
18	,	,	,	_	7	punct
19	and	and	CC	_	7	cc
20	induction	induction	NN	_	7	conj
21	of	of	IN	_	22	case
22	apoptosis	apoptosis	NN	_	20	nmod
23	.	.	.	_	3	punct

1	Sirolimus	Sirolimus	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	mammalian	mammalian	JJ	_	4	amod
4	target	target	NN	_	1	dep
5	of	of	IN	_	7	case
6	rapamycin	rapamycin	NN	_	7	compound
7	inhibitor	inhibitor	NN	_	4	nmod
8	to	to	TO	_	9	mark
9	prevent	prevent	VB	_	4	acl
10	kidney	kidney	NN	_	11	compound
11	rejection	rejection	NN	_	9	dobj
12	.	.	.	_	1	punct

1	Current	current	JJ	_	3	amod
2	immunosuppressive	immunosuppressive	JJ	_	3	amod
3	therapies	therapy	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	effective	effective	JJ	_	0	ROOT
6	but	but	CC	_	5	cc
7	can	can	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	associated	associate	VBN	_	5	conj
10	with	with	IN	_	13	case
11	significant	significant	JJ	_	13	amod
12	adverse	adverse	JJ	_	13	amod
13	reactions	reaction	NNS	_	9	nmod
14	.	.	.	_	5	punct

1	Sirolimus	Sirolimus	NNP	_	2	nsubj
2	works	work	VBZ	_	0	ROOT
3	differently	differently	RB	_	2	advmod
4	from	from	IN	_	6	case
5	the	the	DT	_	6	det
6	immunosuppressants	immunosuppressant	NNS	_	2	nmod
7	currently	currently	RB	_	8	advmod
8	available	available	JJ	_	6	amod
9	,	,	,	_	2	punct
10	and	and	CC	_	2	cc
11	except	except	IN	_	15	case
12	for	for	IN	_	15	case
13	increased	increase	VBN	_	15	amod
14	lipid	lipid	NN	_	15	compound
15	levels	level	NNS	_	2	conj
16	,	,	,	_	15	punct
17	the	the	DT	_	20	det
18	adverse	adverse	JJ	_	20	amod
19	reaction	reaction	NN	_	20	compound
20	profile	profile	NN	_	25	nsubj
21	of	of	IN	_	22	case
22	sirolimus	sirolimus	NN	_	20	nmod
23	does	do	VBZ	_	25	aux
24	not	not	RB	_	25	neg
25	appear	appear	VB	_	15	acl:relcl
26	to	to	TO	_	27	mark
27	overlap	overlap	VB	_	25	xcomp
28	to	to	TO	_	31	case
29	any	any	DT	_	31	det
30	great	great	JJ	_	31	amod
31	extent	extent	NN	_	27	nmod
32	with	with	IN	_	33	case
33	that	that	DT	_	31	nmod
34	associated	associate	VBN	_	33	acl
35	with	with	IN	_	36	case
36	cyclosporine	cyclosporine	NN	_	34	nmod
37	or	or	CC	_	36	cc
38	tacrolimus	tacrolimus	NN	_	36	conj
39	.	.	.	_	2	punct

1	While	while	IN	_	5	mark
2	additional	additional	JJ	_	3	amod
3	research	research	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	needed	need	VBN	_	14	advcl
6	,	,	,	_	14	punct
7	the	the	DT	_	10	det
8	initial	initial	JJ	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	data	datum	NNS	_	14	nsubj
11	in	in	IN	_	13	case
12	kidney	kidney	NN	_	13	compound
13	recipients	recipient	NNS	_	10	nmod
14	suggest	suggest	VBP	_	0	ROOT
15	that	that	IN	_	26	mark
16	sirolimus	sirolimus	NN	_	26	nsubj
17	,	,	,	_	26	punct
18	in	in	IN	_	19	case
19	combination	combination	NN	_	26	nmod
20	with	with	IN	_	21	case
21	cyclosporine	cyclosporine	NN	_	19	nmod
22	or	or	CC	_	21	cc
23	tacrolimus	tacrolimus	NN	_	21	conj
24	,	,	,	_	26	punct
25	might	might	MD	_	26	aux
26	have	have	VB	_	14	ccomp
27	the	the	DT	_	28	det
28	potential	potential	JJ	_	26	dobj
29	to	to	TO	_	30	mark
30	reduce	reduce	VB	_	28	acl
31	the	the	DT	_	32	det
32	frequency	frequency	NN	_	30	dobj
33	of	of	IN	_	35	case
34	rejection	rejection	NN	_	35	compound
35	episodes	episode	NNS	_	32	nmod
36	,	,	,	_	14	punct
37	permit	permit	VBP	_	14	conj
38	reductions	reduction	NNS	_	37	dobj
39	in	in	IN	_	40	case
40	cyclosporine	cyclosporine	NN	_	38	nmod
41	or	or	CC	_	40	cc
42	tacrolimus	tacrolimus	NN	_	43	compound
43	dosage	dosage	NN	_	40	conj
44	,	,	,	_	14	punct
45	and	and	CC	_	14	cc
46	permit	permit	VB	_	14	conj
47	steroid	steroid	NN	_	48	compound
48	withdrawal	withdrawal	NN	_	46	dobj
49	(	(	CD	_	50	nummod
50	Kelly	Kelly	NNP	_	48	dep
51	,	,	,	_	50	punct
52	1999	1999	CD	_	53	nummod
53	)	)	NN	_	50	appos
54	.	.	.	_	14	punct

1	Development	Development	NNP	_	0	ROOT
2	and	and	CC	_	1	cc
3	pharmacology	pharmacology	NN	_	1	conj
4	of	of	IN	_	5	case
5	fluvastatin	fluvastatin	NN	_	1	nmod
6	.	.	.	_	1	punct

1	Fluvastatin	Fluvastatin	NNP	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	the	the	DT	_	5	det
4	first	first	JJ	_	5	amod
5	synthetic	synthetic	JJ	_	0	ROOT
6	3	3	LS	_	8	dep
7	-	-	:	_	8	punct
8	hydroxy	hydroxy	NN	_	5	dep
9	-	-	:	_	8	punct
10	3	3	LS	_	19	dep
11	-	-	:	_	19	punct
12	methylglutaryl	methylglutaryl	NN	_	19	compound
13	coenzyme	coenzyme	NN	_	19	compound
14	A	a	NN	_	19	compound
15	(	(	CD	_	19	nummod
16	HMGCoA	hmgcoa	NN	_	19	compound
17	)	)	CD	_	19	nummod
18	reductase	reductase	NN	_	19	compound
19	inhibitor	inhibitor	NN	_	8	dep
20	to	to	TO	_	22	mark
21	be	be	VB	_	22	auxpass
22	approved	approve	VBN	_	19	acl
23	for	for	IN	_	25	case
24	clinical	clinical	JJ	_	25	amod
25	use	use	NN	_	22	nmod
26	,	,	,	_	8	punct
27	and	and	CC	_	5	cc
28	has	have	VBZ	_	30	aux
29	been	be	VBN	_	30	auxpass
30	studied	study	VBN	_	5	conj
31	extensively	extensively	RB	_	30	advmod
32	in	in	IN	_	33	case
33	humans	human	NNS	_	30	nmod
34	since	since	IN	_	35	case
35	1986	1986	CD	_	30	nmod
36	.	.	.	_	5	punct

1	It	it	PRP	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	structurally	structurally	RB	_	4	advmod
4	distinct	distinct	JJ	_	0	ROOT
5	from	from	IN	_	12	case
6	the	the	DT	_	12	det
7	other	other	JJ	_	12	amod
8	currently	currently	RB	_	9	advmod
9	available	available	JJ	_	12	amod
10	HMGCoA	hmgcoa	NN	_	12	compound
11	reductase	reductase	NN	_	12	compound
12	inhibitors	inhibitor	NNS	_	4	nmod
13	(	(	VBP	_	12	acl
14	lovastatin	lovastatin	NN	_	13	dobj
15	,	,	,	_	14	punct
16	simvastatin	simvastatin	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	pravastatin	pravastatin	NN	_	20	compound
20	)	)	NN	_	14	conj
21	,	,	,	_	4	punct
22	leading	lead	VBG	_	4	xcomp
23	to	to	TO	_	26	case
24	unique	unique	JJ	_	26	amod
25	biopharmaceutical	biopharmaceutical	JJ	_	26	amod
26	properties	property	NNS	_	22	nmod
27	relative	relative	JJ	_	26	amod
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	other	other	JJ	_	31	amod
31	agents	agent	NNS	_	27	nmod
32	of	of	IN	_	34	case
33	this	this	DT	_	34	det
34	class	class	NN	_	31	nmod
35	.	.	.	_	4	punct

1	Absorption	absorption	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	fluvastatin	fluvastatin	NN	_	1	nmod
4	is	be	VBZ	_	6	cop
5	virtually	virtually	RB	_	6	advmod
6	complete	complete	JJ	_	0	ROOT
7	across	across	IN	_	9	case
8	all	all	DT	_	9	det
9	species	species	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	12	case
12	man	man	NN	_	9	nmod
13	,	,	,	_	9	punct
14	and	and	CC	_	9	cc
15	is	be	VBZ	_	17	auxpass
16	not	not	RB	_	17	neg
17	affected	affect	VBN	_	9	conj
18	by	by	IN	_	20	case
19	the	the	DT	_	20	det
20	presence	presence	NN	_	17	nmod
21	of	of	IN	_	22	case
22	food	food	NN	_	20	nmod
23	.	.	.	_	6	punct

1	Systemic	systemic	JJ	_	2	amod
2	exposure	exposure	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	limited	limit	VBN	_	0	ROOT
5	,	,	,	_	4	punct
6	as	as	IN	_	9	mark
7	fluvastatin	fluvastatin	NN	_	9	nsubj
8	is	be	VBZ	_	9	cop
9	subject	subject	JJ	_	4	advcl
10	to	to	TO	_	11	case
11	first	first	JJ	_	9	nmod
12	-	-	:	_	4	punct
13	pass	pass	VB	_	4	conj
14	metabolism	metabolism	NN	_	13	dobj
15	,	,	,	_	4	punct
16	and	and	CC	_	4	cc
17	the	the	DT	_	19	det
18	plasma	plasma	NN	_	19	compound
19	half	half	NN	_	28	nsubj
20	-	-	:	_	19	punct
21	life	life	NN	_	19	dep
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	drug	drug	NN	_	21	nmod
25	is	be	VBZ	_	28	cop
26	approximately	approximately	RB	_	27	advmod
27	30	30	CD	_	28	nummod
28	minutes	minute	NNS	_	4	conj
29	.	.	.	_	4	punct

1	Some	some	DT	_	2	advmod
2	95	95	CD	_	3	nummod
3	%	%	NN	_	11	nsubjpass
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dosage	dosage	NN	_	3	nmod
8	of	of	IN	_	9	case
9	fluvastatin	fluvastatin	NN	_	7	nmod
10	is	be	VBZ	_	11	auxpass
11	excreted	excrete	VBN	_	0	ROOT
12	via	via	IN	_	15	case
13	the	the	DT	_	15	det
14	biliary	biliary	JJ	_	15	amod
15	route	route	NN	_	11	nmod
16	,	,	,	_	11	punct
17	with	with	IN	_	21	case
18	less	less	JJR	_	20	advmod
19	than	than	IN	_	18	mwe
20	2	2	CD	_	21	nummod
21	%	%	NN	_	11	nmod
22	of	of	IN	_	23	case
23	this	this	DT	_	21	nmod
24	being	be	VBG	_	27	cop
25	the	the	DT	_	27	det
26	parent	parent	NN	_	27	compound
27	compound	compound	NN	_	21	dep
28	.	.	.	_	11	punct

1	Additionally	additionally	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	is	be	VBZ	_	0	ROOT
5	no	no	DT	_	6	neg
6	evidence	evidence	NN	_	4	nsubj
7	of	of	IN	_	10	case
8	circulating	circulate	VBG	_	10	amod
9	active	active	JJ	_	10	amod
10	metabolites	metabolite	NNS	_	6	nmod
11	or	or	CC	_	10	cc
12	accumulation	accumulation	NN	_	10	conj
13	during	during	IN	_	15	case
14	chronic	chronic	JJ	_	15	amod
15	dosing	dosing	NN	_	10	nmod
16	.	.	.	_	4	punct

1	Studies	study	NNS	_	13	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	effect	effect	NN	_	1	nmod
5	of	of	IN	_	6	case
6	food	food	NN	_	4	nmod
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	4	nmod
10	of	of	IN	_	11	case
11	fluvastatin	fluvastatin	NN	_	9	nmod
12	have	have	VBP	_	13	aux
13	demonstrated	demonstrate	VBN	_	0	ROOT
14	marked	marked	JJ	_	15	amod
15	reductions	reduction	NNS	_	13	dobj
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	rate	rate	NN	_	15	nmod
19	of	of	IN	_	20	case
20	bioavailability	bioavailability	NN	_	18	nmod
21	--	--	:	_	15	punct
22	from	from	IN	_	24	case
23	40	40	CD	_	24	nummod
24	%	%	NN	_	15	nmod
25	to	to	TO	_	27	case
26	60	60	CD	_	27	nummod
27	%	%	NN	_	24	nmod
28	;	;	:	_	13	punct

1	however	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	a	a	DT	_	4	det
4	comparison	comparison	NN	_	16	nsubj
5	of	of	IN	_	7	case
6	fluvastatin	fluvastatin	NN	_	7	compound
7	administration	administration	NN	_	4	nmod
8	with	with	IN	_	11	case
9	the	the	DT	_	11	det
10	evening	evening	NN	_	11	compound
11	meal	meal	NN	_	4	nmod
12	or	or	CC	_	11	cc
13	at	at	IN	_	14	case
14	bedtime	bedtime	NN	_	11	conj
15	has	have	VBZ	_	16	aux
16	revealed	reveal	VBN	_	0	ROOT
17	no	no	DT	_	19	neg
18	significant	significant	JJ	_	19	amod
19	differences	difference	NNS	_	16	dobj
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	extent	extent	NN	_	19	nmod
23	of	of	IN	_	26	case
24	bioavailability	bioavailability	NN	_	26	compound
25	(	(	CD	_	26	nummod
26	area	area	NN	_	22	nmod
27	under	under	IN	_	30	case
28	the	the	DT	_	30	det
29	curve	curve	NN	_	30	compound
30	)	)	NN	_	19	nmod
31	of	of	IN	_	34	case
32	these	these	DT	_	34	det
33	two	two	CD	_	34	nummod
34	regimens	regimen	NNS	_	30	nmod
35	.	.	.	_	16	punct

1	Furthermore	furthermore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	difference	difference	NN	_	21	nsubjpass
6	in	in	IN	_	10	case
7	pharmacodynamic	pharmacodynamic	JJ	_	10	amod
8	effect	effect	NN	_	10	compound
9	(	(	NN	_	10	compound
10	reduction	reduction	NN	_	5	nmod
11	in	in	IN	_	18	case
12	low	low	JJ	_	18	amod
13	-	-	:	_	18	punct
14	density	density	NN	_	17	compound
15	lipoprotein	lipoprotein	NN	_	17	compound
16	cholesterol	cholesterol	NN	_	17	compound
17	levels	level	NNS	_	18	nsubj
18	)	)	VBP	_	10	nmod
19	could	could	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	ascertained	ascertain	VBN	_	0	ROOT
22	between	between	IN	_	24	case
23	mealtime	mealtime	NN	_	24	compound
24	dosing	dosing	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	bedtime	bedtime	NN	_	27	compound
27	dosing	dosing	NN	_	24	conj
28	.	.	.	_	21	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	8	nsubjpass
3	of	of	IN	_	4	case
4	fluvastatin	fluvastatin	NN	_	2	nmod
5	have	have	VBP	_	8	aux
6	also	also	RB	_	8	advmod
7	been	be	VBN	_	8	auxpass
8	assessed	assess	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	various	various	JJ	_	12	amod
11	demographic	demographic	JJ	_	12	amod
12	groups	group	NNS	_	8	nmod
13	.	.	.	_	8	punct

1	Relative	relative	JJ	_	13	ccomp
2	to	to	TO	_	5	case
3	the	the	DT	_	5	det
4	general	general	JJ	_	5	amod
5	population	population	NN	_	1	nmod
6	,	,	,	_	13	punct
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	13	nsubj
9	of	of	IN	_	10	case
10	fluvastatin	fluvastatin	NN	_	8	nmod
11	do	do	VBP	_	13	aux
12	not	not	RB	_	13	neg
13	vary	vary	VB	_	0	ROOT
14	as	as	IN	_	16	case
15	a	a	DT	_	16	det
16	function	function	NN	_	13	nmod
17	of	of	IN	_	19	case
18	either	either	CC	_	19	cc:preconj
19	age	age	NN	_	16	nmod
20	or	or	CC	_	19	cc
21	gender	gender	NN	_	19	conj
22	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	12	nmod
3	,	,	,	_	12	punct
4	administration	administration	NN	_	12	nsubj
5	to	to	TO	_	8	case
6	a	a	DT	_	8	det
7	patient	patient	NN	_	8	compound
8	population	population	NN	_	4	nmod
9	with	with	IN	_	11	case
10	hepatic	hepatic	JJ	_	11	amod
11	insufficiency	insufficiency	NN	_	8	nmod
12	resulted	result	VBD	_	0	ROOT
13	in	in	IN	_	18	case
14	a	a	DT	_	18	det
15	2.5	2.5	CD	_	18	nummod
16	-	-	:	_	18	punct
17	fold	fold	JJ	_	18	amod
18	increase	increase	NN	_	12	nmod
19	in	in	IN	_	22	case
20	both	both	CC	_	22	cc:preconj
21	the	the	DT	_	22	det
22	rate	rate	NN	_	18	nmod
23	and	and	CC	_	22	cc
24	extent	extent	NN	_	22	conj
25	of	of	IN	_	26	case
26	bioavailability	bioavailability	NN	_	22	nmod
27	relative	relative	JJ	_	26	amod
28	to	to	TO	_	29	case
29	controls	control	NNS	_	27	nmod
30	.	.	.	_	12	punct

1	Also	also	RB	_	34	advmod
2	,	,	,	_	34	punct
3	although	although	IN	_	15	mark
4	minimal	minimal	JJ	_	5	amod
5	alterations	alteration	NNS	_	15	nsubjpass
6	of	of	IN	_	8	case
7	fluvastatin	fluvastatin	NN	_	8	compound
8	clearance	clearance	NN	_	5	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	with	with	IN	_	13	case
12	renal	renal	JJ	_	13	amod
13	insufficiency	insufficiency	NN	_	10	nmod
14	are	be	VBP	_	15	auxpass
15	anticipated	anticipate	VBN	_	34	advcl
16	due	due	JJ	_	20	case
17	to	to	TO	_	16	mwe
18	limited	limited	JJ	_	20	amod
19	renal	renal	JJ	_	20	amod
20	excretion	excretion	NN	_	34	nmod
21	(	(	CD	_	22	compound
22	5	5	CD	_	23	nummod
23	%	%	NN	_	34	nsubj
24	)	)	CD	_	23	nummod
25	,	,	,	_	23	punct
26	a	a	DT	_	27	det
27	study	study	NN	_	23	appos
28	in	in	IN	_	31	case
29	this	this	DT	_	31	det
30	patient	patient	NN	_	31	compound
31	group	group	NN	_	27	nmod
32	is	be	VBZ	_	34	cop
33	currently	currently	RB	_	34	advmod
34	underway	underway	NN	_	0	ROOT
35	to	to	TO	_	36	mark
36	examine	examine	VB	_	34	xcomp
37	this	this	DT	_	36	dobj
38	further	further	RBR	_	37	advmod
39	.	.	.	_	34	punct

1	Interaction	interaction	NN	_	2	compound
2	studies	study	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	performed	perform	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	fluvastatin	fluvastatin	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	several	several	JJ	_	10	amod
10	drugs	drug	NNS	_	7	conj
11	with	with	IN	_	12	case
12	which	which	WDT	_	16	nmod
13	it	it	PRP	_	16	nsubjpass
14	might	might	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	coadministered	coadminister	VBN	_	7	acl:relcl
17	.	.	.	_	5	punct

1	Cholestyramine	Cholestyramine	NNP	_	9	nsubj
2	,	,	,	_	1	punct
3	an	a	DT	_	7	det
4	anionic	anionic	JJ	_	7	amod
5	-	-	:	_	7	punct
6	binding	bind	VBG	_	7	amod
7	resin	resin	NN	_	1	appos
8	,	,	,	_	1	punct
9	has	have	VBZ	_	0	ROOT
10	a	a	DT	_	12	det
11	considerable	considerable	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	in	in	IN	_	14	mark
14	lowering	lower	VBG	_	9	advcl
15	the	the	DT	_	16	det
16	rate	rate	NN	_	14	dobj
17	and	and	CC	_	16	cc
18	extent	extent	NN	_	16	conj
19	of	of	IN	_	21	case
20	fluvastatin	fluvastatin	NN	_	21	compound
21	bioavailability	bioavailability	NN	_	16	nmod
22	.	.	.	_	9	punct

1	Although	although	IN	_	5	mark
2	this	this	DT	_	3	det
3	effect	effect	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	noted	note	VBN	_	21	advcl
6	even	even	RB	_	7	advmod
7	when	when	WRB	_	10	advmod
8	cholestyramine	cholestyramine	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	5	advcl
11	4	4	CD	_	12	nummod
12	hours	hour	NNS	_	10	dobj
13	prior	prior	RB	_	12	advmod
14	to	to	TO	_	15	case
15	fluvastatin	fluvastatin	NN	_	13	nmod
16	,	,	,	_	21	punct
17	this	this	DT	_	18	det
18	regimen	regimen	NN	_	21	nsubj
19	did	do	VBD	_	21	aux
20	not	not	RB	_	21	neg
21	result	result	VB	_	0	ROOT
22	in	in	IN	_	24	case
23	diminished	diminish	VBN	_	24	amod
24	efficacy	efficacy	NN	_	21	nmod
25	.	.	.	_	21	punct

1	Further	further	RB	_	13	advmod
2	,	,	,	_	13	punct
3	no	no	DT	_	4	neg
4	effects	effect	NNS	_	13	nsubjpass
5	on	on	IN	_	8	case
6	either	either	CC	_	8	cc:preconj
7	warfarin	warfarin	NN	_	8	compound
8	levels	level	NNS	_	4	nmod
9	or	or	CC	_	8	cc
10	prothrombin	prothrombin	NN	_	11	compound
11	times	time	NNS	_	8	conj
12	were	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	in	in	IN	_	16	case
15	a	a	DT	_	16	det
16	study	study	NN	_	13	nmod
17	involving	involve	VBG	_	16	acl
18	concomitant	concomitant	JJ	_	19	amod
19	administration	administration	NN	_	17	dobj
20	of	of	IN	_	21	case
21	warfarin	warfarin	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	fluvastatin	fluvastatin	NN	_	21	conj
24	.	.	.	_	13	punct

1	Moreover	moreover	RB	_	12	advmod
2	,	,	,	_	12	punct
3	additional	additional	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	12	nsubj
6	with	with	IN	_	7	case
7	niacin	niacin	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	propranolol	propranolol	NN	_	7	conj
10	have	have	VBP	_	12	aux
11	not	not	RB	_	12	neg
12	demonstrated	demonstrate	VBN	_	0	ROOT
13	any	any	DT	_	14	det
14	effect	effect	NN	_	12	dobj
15	on	on	IN	_	18	case
16	fluvastatin	fluvastatin	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	,	,	,	_	12	punct
20	and	and	CC	_	12	cc
21	administration	administration	NN	_	29	nsubj
22	to	to	TO	_	25	case
23	a	a	DT	_	25	det
24	patient	patient	NN	_	25	compound
25	population	population	NN	_	21	nmod
26	chronically	chronically	RB	_	27	advmod
27	receiving	receive	VBG	_	25	acl
28	digoxin	digoxin	NN	_	27	dobj
29	resulted	result	VBD	_	12	conj
30	in	in	IN	_	32	case
31	no	no	DT	_	32	neg
32	difference	difference	NN	_	29	nmod
33	in	in	IN	_	35	case
34	the	the	DT	_	35	det
35	extent	extent	NN	_	32	nmod
36	of	of	IN	_	37	case
37	bioavailability	bioavailability	NN	_	35	nmod
38	of	of	IN	_	39	case
39	digoxin	digoxin	NN	_	37	nmod
40	relative	relative	JJ	_	32	amod
41	to	to	TO	_	42	mark
42	control	control	VB	_	40	xcomp
43	data	datum	NNS	_	42	dobj
44	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	generated	generate	VBD	_	0	ROOT
4	to	to	TO	_	5	case
5	date	date	NN	_	3	nmod
6	in	in	IN	_	9	case
7	clinical	clinical	JJ	_	9	amod
8	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
9	studies	study	NNS	_	3	nmod
10	with	with	IN	_	11	case
11	fluvastatin	fluvastatin	NN	_	9	nmod
12	thus	thus	RB	_	13	advmod
13	support	support	VBP	_	3	dep
14	its	its	PRP$	_	15	nmod:poss
15	use	use	NN	_	13	dobj
16	in	in	IN	_	19	case
17	a	a	DT	_	19	det
18	broad	broad	JJ	_	19	amod
19	population	population	NN	_	13	nmod
20	of	of	IN	_	22	case
21	hypercholesterolaemic	hypercholesterolaemic	JJ	_	22	amod
22	patients	patient	NNS	_	19	nmod
23	.	.	.	_	3	punct

1	Molecular	molecular	JJ	_	2	amod
2	basis	basis	NN	_	0	ROOT
3	for	for	IN	_	6	case
4	the	the	DT	_	6	det
5	selective	selective	JJ	_	6	amod
6	toxicity	toxicity	NN	_	2	nmod
7	of	of	IN	_	9	case
8	amphotericin	amphotericin	NN	_	9	compound
9	B	b	NN	_	6	nmod
10	for	for	IN	_	11	case
11	yeast	yeast	NN	_	6	nmod
12	and	and	CC	_	11	cc
13	filipin	filipin	NN	_	11	conj
14	for	for	IN	_	16	case
15	animal	animal	NN	_	16	compound
16	cells	cell	NNS	_	6	nmod
17	.	.	.	_	2	punct

1	Among	among	IN	_	4	case
2	the	the	DT	_	4	det
3	polyene	polyene	NN	_	4	compound
4	antibiotics	antibiotic	NNS	_	13	nmod
5	,	,	,	_	13	punct
6	many	many	JJ	_	13	nsubjpass
7	,	,	,	_	13	punct
8	like	like	IN	_	9	case
9	filipin	filipin	NN	_	13	nmod
10	,	,	,	_	13	punct
11	cannot	cannot	NN	_	13	nsubjpass
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	0	ROOT
14	clinically	clinically	RB	_	13	advmod
15	because	because	IN	_	18	mark
16	they	they	PRP	_	18	nsubj
17	are	be	VBP	_	18	cop
18	toxic	toxic	JJ	_	13	advcl
19	;	;	:	_	13	punct

1	amphotericin	amphotericin	NN	_	2	compound
2	B	b	NN	_	7	nsubj
3	,	,	,	_	7	punct
4	however	however	RB	_	7	advmod
5	,	,	,	_	7	punct
6	is	be	VBZ	_	7	cop
7	useful	useful	JJ	_	0	ROOT
8	in	in	IN	_	9	case
9	therapy	therapy	NN	_	7	nmod
10	of	of	IN	_	13	case
11	human	human	JJ	_	13	amod
12	fungal	fungal	JJ	_	13	amod
13	infections	infection	NNS	_	9	nmod
14	because	because	IN	_	18	mark
15	it	it	PRP	_	18	nsubj
16	is	be	VBZ	_	18	cop
17	less	less	RBR	_	18	advmod
18	toxic	toxic	JJ	_	7	advcl
19	.	.	.	_	7	punct

1	Both	both	CC	_	3	cc:preconj
2	the	the	DT	_	3	det
3	toxicity	toxicity	NN	_	15	nsubjpass
4	of	of	IN	_	5	case
5	filipin	filipin	NN	_	3	nmod
6	and	and	CC	_	3	cc
7	the	the	DT	_	9	det
8	therapeutic	therapeutic	JJ	_	9	amod
9	value	value	NN	_	3	conj
10	of	of	IN	_	12	case
11	amphotericin	amphotericin	NN	_	12	compound
12	B	b	NN	_	9	nmod
13	can	can	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	rationalized	rationalize	VBN	_	0	ROOT
16	at	at	IN	_	21	case
17	the	the	DT	_	21	det
18	cellular	cellular	JJ	_	21	amod
19	and	and	CC	_	18	cc
20	molecular	molecular	JJ	_	18	conj
21	level	level	NN	_	15	nmod
22	by	by	IN	_	25	case
23	the	the	DT	_	25	det
24	following	follow	VBG	_	25	amod
25	observations	observation	NNS	_	15	nmod
26	:	:	:	_	15	punct
27	(	(	CD	_	29	compound
28	i	i	FW	_	29	compound
29	)	)	FW	_	33	advmod
30	these	these	DT	_	32	det
31	polyene	polyene	NN	_	32	compound
32	antibiotics	antibiotic	NNS	_	33	nsubj
33	showed	show	VBD	_	15	parataxis
34	differential	differential	JJ	_	35	amod
35	effects	effect	NNS	_	33	dobj
36	on	on	IN	_	37	case
37	cells	cell	NNS	_	35	nmod
38	;	;	:	_	15	punct

1	filipin	filipin	NN	_	4	nsubj
2	was	be	VBD	_	4	cop
3	more	more	RBR	_	4	advmod
4	potent	potent	JJ	_	0	ROOT
5	in	in	IN	_	6	mark
6	lysing	lyse	VBG	_	4	advcl
7	human	human	JJ	_	10	amod
8	red	red	JJ	_	10	amod
9	blood	blood	NN	_	10	compound
10	cells	cell	NNS	_	6	dobj
11	,	,	,	_	4	punct
12	whereas	whereas	IN	_	4	dep
13	amphotericin	amphotericin	NN	_	14	compound
14	B	b	NN	_	17	nsubj
15	was	be	VBD	_	17	cop
16	more	more	RBR	_	17	advmod
17	potent	potent	JJ	_	4	parataxis
18	in	in	IN	_	19	mark
19	inhibiting	inhibit	VBG	_	17	advcl
20	yeast	yeast	NN	_	22	compound
21	cell	cell	NN	_	22	compound
22	growth	growth	NN	_	19	dobj
23	;	;	:	_	4	punct

1	and	and	CC	_	0	ROOT
2	(	(	CD	_	1	dep
3	ii	ii	LS	_	2	dep
4	)	)	IN	_	12	mark
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	12	nsubjpass
7	of	of	IN	_	8	case
8	filipin	filipin	NN	_	6	nmod
9	were	be	VBD	_	12	auxpass
10	more	more	RBR	_	11	advmod
11	efficiently	efficiently	RB	_	12	advmod
12	inhibited	inhibit	VBN	_	3	advcl
13	by	by	IN	_	15	case
14	added	add	VBN	_	15	amod
15	cholesterol	cholesterol	NN	_	12	nmod
16	,	,	,	_	12	punct
17	the	the	DT	_	20	det
18	major	major	JJ	_	20	amod
19	membrane	membrane	NN	_	20	compound
20	sterol	sterol	NN	_	16	root
21	in	in	IN	_	23	case
22	human	human	JJ	_	23	amod
23	cells	cell	NNS	_	20	nmod
24	,	,	,	_	20	punct
25	whereas	whereas	IN	_	34	mark
26	the	the	DT	_	27	det
27	effects	effect	NNS	_	34	nsubjpass
28	of	of	IN	_	30	case
29	amphotericin	amphotericin	NN	_	30	compound
30	B	b	NN	_	27	nmod
31	were	be	VBD	_	34	auxpass
32	more	more	RBR	_	33	advmod
33	efficiently	efficiently	RB	_	34	advmod
34	inhibited	inhibit	VBN	_	24	root
35	by	by	IN	_	36	case
36	ergosterol	ergosterol	NN	_	34	nmod
37	,	,	,	_	34	punct
38	the	the	DT	_	41	det
39	major	major	JJ	_	41	amod
40	membrane	membrane	NN	_	41	compound
41	sterol	sterol	NN	_	37	root
42	in	in	IN	_	43	case
43	yeast	yeast	NN	_	41	nmod
44	.	.	.	_	41	punct

1	The	the	DT	_	3	det
2	simplest	simplest	JJS	_	3	amod
3	inference	inference	NN	_	4	nsubj
4	is	be	VBZ	_	0	ROOT
5	that	that	IN	_	13	mark
6	the	the	DT	_	7	det
7	toxicity	toxicity	NN	_	13	nsubjpass
8	and	and	CC	_	7	cc
9	effectiveness	effectiveness	NN	_	7	conj
10	of	of	IN	_	11	case
11	polyenes	polyene	NNS	_	7	nmod
12	are	be	VBP	_	13	auxpass
13	determined	determine	VBN	_	4	ccomp
14	by	by	IN	_	17	case
15	their	they	PRP$	_	17	nmod:poss
16	relative	relative	JJ	_	17	amod
17	avidities	avidity	NNS	_	13	nmod
18	for	for	IN	_	21	case
19	the	the	DT	_	21	det
20	predominant	predominant	JJ	_	21	amod
21	sterol	sterol	NN	_	17	nmod
22	in	in	IN	_	24	case
23	cell	cell	NN	_	24	compound
24	membranes	membrane	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	[	[	RB	_	2	advmod
2	Hippocampus	hippocampus	NN	_	10	nsubj
3	as	as	IN	_	5	case
4	interaction	interaction	NN	_	5	compound
5	sites	site	NNS	_	2	nmod
6	between	between	IN	_	9	case
7	cerebral	cerebral	JJ	_	9	amod
8	memory	memory	NN	_	9	compound
9	systems	system	NNS	_	5	nmod
10	]	]	VBD	_	0	ROOT
11	Most	most	JJS	_	16	nsubj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	current	current	JJ	_	15	amod
15	theories	theory	NNS	_	11	nmod
16	assume	assume	VBP	_	10	dep
17	that	that	IN	_	19	mark
18	there	there	EX	_	19	expl
19	are	be	VBP	_	16	ccomp
20	multiple	multiple	JJ	_	21	amod
21	forms	form	NNS	_	19	nsubj
22	of	of	IN	_	23	case
23	memory	memory	NN	_	21	nmod
24	that	that	WDT	_	26	nsubjpass
25	are	be	VBP	_	26	auxpass
26	supported	support	VBN	_	21	acl:relcl
27	by	by	IN	_	30	case
28	separate	separate	JJ	_	30	amod
29	brain	brain	NN	_	30	compound
30	systems	system	NNS	_	26	nmod
31	and	and	CC	_	16	cc
32	have	have	VBP	_	16	conj
33	different	different	JJ	_	34	amod
34	characteristics	characteristic	NNS	_	32	dobj
35	.	.	.	_	10	punct

1	Animals	animal	NNS	_	2	compound
2	studies	study	NNS	_	12	nsubjpass
3	on	on	IN	_	9	case
4	the	the	DT	_	9	det
5	various	various	JJ	_	9	amod
6	dual	dual	JJ	_	9	amod
7	-	-	:	_	9	punct
8	memory	memory	NN	_	9	compound
9	theories	theory	NNS	_	2	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	carried	carry	VBN	_	0	ROOT
13	out	out	RP	_	12	compound:prt
14	mainly	mainly	RB	_	12	advmod
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	basis	basis	NN	_	12	nmod
18	of	of	IN	_	21	case
19	hippocampal	hippocampal	JJ	_	21	amod
20	system	system	NN	_	21	compound
21	function	function	NN	_	17	nmod
22	.	.	.	_	12	punct

1	Specifically	specifically	RB	_	5	advmod
2	,	,	,	_	5	punct
3	they	they	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	focused	focus	VBN	_	0	ROOT
6	on	on	IN	_	7	case
7	aspects	aspect	NNS	_	5	nmod
8	of	of	IN	_	9	case
9	learning	learning	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	memory	memory	NN	_	9	conj
12	that	that	WDT	_	14	nsubj
13	are	be	VBP	_	14	aux
14	impaired	impaired	JJ	_	7	acl:relcl
15	(	(	NN	_	14	dobj
16	vs	vs	CC	_	14	cc
17	.	.	.	_	5	punct
18	spared	spare	VBD	_	5	dep
19	)	)	CD	_	18	dobj
20	by	by	IN	_	21	case
21	lesions	lesion	NNS	_	18	nmod
22	of	of	IN	_	25	case
23	the	the	DT	_	25	det
24	hippocampal	hippocampal	JJ	_	25	amod
25	formation	formation	NN	_	21	nmod
26	.	.	.	_	5	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	are	be	VBP	_	0	ROOT
5	several	several	JJ	_	6	amod
6	instances	instance	NNS	_	4	nsubj
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	animal	animal	NN	_	10	compound
10	literature	literature	NN	_	6	nmod
11	showing	show	VBG	_	6	acl
12	that	that	IN	_	16	mark
13	hippocampal	hippocampal	JJ	_	14	amod
14	lesions	lesion	NNS	_	16	nsubj
15	actually	actually	RB	_	16	advmod
16	produced	produce	VBD	_	11	ccomp
17	enhanced	enhance	VBN	_	18	amod
18	learning	learning	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	memory	memory	NN	_	21	compound
21	function	function	NN	_	18	conj
22	.	.	.	_	4	punct

1	Moreover	moreover	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	acquisition	acquisition	NN	_	2	root
5	of	of	IN	_	6	case
6	tasks	task	NNS	_	4	nmod
7	that	that	WDT	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	facilitated	facilitate	VBN	_	6	acl:relcl
10	by	by	IN	_	12	case
11	hippocampal	hippocampal	JJ	_	12	amod
12	lesions	lesion	NNS	_	9	nmod
13	(	(	CD	_	16	nummod
14	or	or	CC	_	13	cc
15	dysfunction	dysfunction	NN	_	13	conj
16	)	)	NN	_	19	nsubjpass
17	is	be	VBZ	_	19	auxpass
18	nevertheless	nevertheless	RB	_	19	advmod
19	associated	associate	VBN	_	12	acl:relcl
20	,	,	,	_	4	punct
21	in	in	IN	_	23	case
22	intact	intact	JJ	_	23	amod
23	subjects	subject	NNS	_	4	nmod
24	,	,	,	_	4	punct
25	with	with	IN	_	28	case
26	specific	specific	JJ	_	28	amod
27	neurobiological	neurobiological	JJ	_	28	amod
28	alterations	alteration	NNS	_	4	nmod
29	in	in	IN	_	31	case
30	the	the	DT	_	31	det
31	hippocampus	hippocampus	NN	_	28	nmod
32	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	problem	problem	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	analysed	analyse	VBN	_	0	ROOT
6	using	use	VBG	_	5	xcomp
7	two	two	CD	_	9	nummod
8	different	different	JJ	_	9	amod
9	tasks	task	NNS	_	6	dobj
10	in	in	IN	_	11	case
11	mice	mouse	NNS	_	9	nmod
12	:	:	:	_	5	punct
13	a	a	DT	_	17	det
14	bar	bar	NN	_	17	compound
15	-	-	:	_	17	punct
16	press	press	NN	_	17	compound
17	conditioning	conditioning	NN	_	5	dep
18	and	and	CC	_	17	cc
19	a	a	DT	_	22	det
20	spatial	spatial	JJ	_	22	amod
21	discrimination	discrimination	NN	_	22	compound
22	task	task	NN	_	17	conj
23	.	.	.	_	5	punct

1	Results	result	NNS	_	2	nsubj
2	showed	show	VBD	_	0	ROOT
3	that	that	IN	_	15	mark
4	,	,	,	_	15	punct
5	depending	depend	VBG	_	8	case
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	task	task	NN	_	15	advcl
9	considered	consider	VBN	_	8	acl
10	,	,	,	_	15	punct
11	the	the	DT	_	14	det
12	same	same	JJ	_	14	amod
13	pharmacological	pharmacological	JJ	_	14	amod
14	treatment	treatment	NN	_	15	nsubj
15	produced	produce	VBD	_	2	ccomp
16	either	either	CC	_	18	cc:preconj
17	a	a	DT	_	18	det
18	facilitation	facilitation	NN	_	15	dobj
19	or	or	CC	_	18	cc
20	an	a	DT	_	21	det
21	impairment	impairment	NN	_	18	conj
22	of	of	IN	_	23	case
23	acquisition	acquisition	NN	_	21	nmod
24	.	.	.	_	2	punct

1	Moreover	moreover	RB	_	5	advmod
2	,	,	,	_	5	punct
3	each	each	DT	_	4	det
4	task	task	NN	_	5	nsubj
5	induced	induce	VBD	_	0	ROOT
6	significant	significant	JJ	_	7	amod
7	alterations	alteration	NNS	_	5	dobj
8	in	in	IN	_	12	case
9	hippocampal	hippocampal	JJ	_	12	amod
10	adenylate	adenylate	NN	_	12	compound
11	cyclase	cyclase	NN	_	12	compound
12	activity	activity	NN	_	7	nmod
13	but	but	CC	_	12	cc
14	in	in	IN	_	16	case
15	opposite	opposite	JJ	_	16	amod
16	directions	direction	NNS	_	12	conj
17	.	.	.	_	5	punct

1	Together	together	RB	_	8	advmod
2	with	with	IN	_	4	case
3	previous	previous	JJ	_	4	amod
4	findings	finding	NNS	_	1	nmod
5	,	,	,	_	8	punct
6	these	these	DT	_	7	det
7	results	result	NNS	_	8	nsubj
8	suggest	suggest	VBP	_	0	ROOT
9	that	that	IN	_	13	mark
10	the	the	DT	_	11	det
11	hippocampus	hippocampus	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	involved	involve	VBN	_	8	ccomp
14	in	in	IN	_	13	advmod
15	both	both	CC	_	14	dep
16	the	the	DT	_	15	dep
17	so	so	RB	_	19	advmod
18	-	-	:	_	19	punct
19	called	call	VBN	_	16	acl
20	&quot	&quot	NN	_	19	xcomp
21	;	;	:	_	20	punct
22	hippocampal	hippocampal	NN	_	24	compound
23	-	-	:	_	24	punct
24	dependent&quot	dependent&quot	NN	_	20	dep
25	;	;	:	_	8	punct

1	&quot	&quot	NN	_	0	ROOT
2	;	;	:	_	1	punct
3	hippocampal	hippocampal	NN	_	5	compound
4	-	-	:	_	5	punct
5	independent&quot	independent&quot	NN	_	1	dep
6	;	;	:	_	1	punct

1	forms	form	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	memory	memory	NN	_	1	nmod
4	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	postulated	postulate	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	some	some	DT	_	13	nsubj
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	observed	observe	VBN	_	9	amod
9	training	training	NN	_	5	nmod
10	-	-	:	_	13	punct
11	induced	induce	VBN	_	13	amod
12	neurobiological	neurobiological	JJ	_	13	amod
13	alterations	alteration	NNS	_	3	ccomp
14	might	might	MD	_	15	aux
15	reflect	reflect	VB	_	13	ccomp
16	the	the	DT	_	17	det
17	interaction	interaction	NN	_	15	dobj
18	between	between	IN	_	20	case
19	two	two	CD	_	20	nummod
20	(	(	CD	_	17	nmod
21	or	or	CC	_	20	cc
22	more	more	JJR	_	20	conj
23	)	)	NN	_	26	compound
24	competing	compete	VBG	_	26	amod
25	memory	memory	NN	_	26	compound
26	systems	system	NNS	_	20	dep
27	at	at	IN	_	30	case
28	the	the	DT	_	30	det
29	hippocampal	hippocampal	JJ	_	30	amod
30	level	level	NN	_	17	nmod
31	.	.	.	_	3	punct

1	Thus	thus	RB	_	11	advmod
2	,	,	,	_	11	punct
3	in	in	IN	_	4	case
4	addition	addition	NN	_	11	nmod
5	to	to	TO	_	10	case
6	its	its	PRP$	_	10	nmod:poss
7	proposed	propose	VBN	_	10	amod
8	specific	specific	JJ	_	10	amod
9	information	information	NN	_	10	compound
10	processing	processing	NN	_	4	nmod
11	functions	function	VBZ	_	0	ROOT
12	(	(	CD	_	24	nsubj
13	i	i	LS	_	24	dep
14	.	.	.	_	13	punct
15	e	e	LS	_	24	dep
16	.	.	.	_	15	punct
17	,	,	,	_	15	punct
18	relational	relational	JJ	_	19	amod
19	)	)	NN	_	24	nsubj
20	,	,	,	_	19	punct
21	the	the	DT	_	22	det
22	hippocampus	hippocampus	NN	_	19	appos
23	would	would	MD	_	24	aux
24	play	play	VB	_	11	ccomp
25	a	a	DT	_	26	det
26	role	role	NN	_	24	dobj
27	in	in	IN	_	28	mark
28	addressing	address	VBG	_	24	advcl
29	information	information	NN	_	28	dobj
30	to	to	TO	_	34	case
31	the	the	DT	_	34	det
32	brain	brain	NN	_	34	compound
33	memory	memory	NN	_	34	compound
34	system	system	NN	_	28	nmod
35	that	that	WDT	_	42	nsubj
36	,	,	,	_	42	punct
37	in	in	IN	_	40	case
38	a	a	DT	_	40	det
39	given	give	VBN	_	40	amod
40	situation	situation	NN	_	42	nmod
41	,	,	,	_	42	punct
42	has	have	VBZ	_	34	acl:relcl
43	the	the	DT	_	46	det
44	best	best	JJS	_	46	amod
45	adaptive	adaptive	JJ	_	46	amod
46	value	value	NN	_	42	dobj
47	.	.	.	_	11	punct
48	(	(	CD	_	49	nummod
49	ABSTRACT	abstract	NN	_	50	nsubj
50	TRUNCATED	truncate	VBD	_	11	parataxis
51	AT	at	IN	_	53	case
52	250	250	CD	_	53	nummod
53	WORDS	word	NNS	_	50	nmod
54	)	)	IN	_	11	punct

1	Behavioral	behavioral	JJ	_	2	amod
2	mechanisms	mechanism	NNS	_	0	ROOT
3	underlying	underlie	VBG	_	2	acl
4	the	the	DT	_	5	det
5	link	link	NN	_	3	dobj
6	between	between	IN	_	7	case
7	smoking	smoking	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drinking	drinking	NN	_	7	conj
10	.	.	.	_	2	punct

1	Many	many	JJ	_	2	amod
2	people	people	NNS	_	3	nsubj
3	use	use	VBP	_	0	ROOT
4	both	both	CC	_	5	cc:preconj
5	alcohol	alcohol	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	nicotine	nicotine	NN	_	9	compound
8	(	(	NN	_	9	compound
9	i	i	FW	_	5	conj
10	.	.	.	_	3	punct
11	e	e	LS	_	3	parataxis
12	.	.	.	_	11	punct
13	,	,	,	_	11	punct
14	cigarettes	cigarette	NNS	_	11	appos
15	and	and	CC	_	14	cc
16	other	other	JJ	_	18	amod
17	tobacco	tobacco	NN	_	18	compound
18	products	product	NNS	_	14	conj
19	)	)	CD	_	14	dep
20	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	behavioral	behavioral	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	of	of	IN	_	7	case
5	these	these	DT	_	7	det
6	two	two	CD	_	7	nummod
7	drugs	drug	NNS	_	3	nmod
8	differ	differ	VBP	_	0	ROOT
9	,	,	,	_	8	punct
10	and	and	CC	_	8	cc
11	they	they	PRP	_	14	nsubj
12	do	do	VBP	_	14	aux
13	not	not	RB	_	14	neg
14	act	act	VB	_	8	conj
15	on	on	IN	_	19	case
16	the	the	DT	_	19	det
17	same	same	JJ	_	19	amod
18	target	target	NN	_	19	compound
19	sites	site	NNS	_	14	nmod
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	brain	brain	NN	_	19	nmod
23	,	,	,	_	8	punct
24	although	although	IN	_	27	mark
25	they	they	PRP	_	27	nsubj
26	may	may	MD	_	27	aux
27	share	share	VB	_	8	advcl
28	,	,	,	_	27	punct
29	or	or	CC	_	27	cc
30	partly	partly	RB	_	31	advmod
31	share	share	NN	_	27	conj
32	,	,	,	_	27	punct
33	certain	certain	JJ	_	34	amod
34	properties	property	NNS	_	27	dobj
35	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	initiation	initiation	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	alcohol	alcohol	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	nicotine	nicotine	NN	_	7	compound
7	use	use	NN	_	4	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	precipitated	precipitate	VBN	_	0	ROOT
11	by	by	IN	_	14	case
12	similar	similar	JJ	_	14	amod
13	personality	personality	NN	_	14	compound
14	characteristics	characteristic	NNS	_	10	nmod
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	user	user	NN	_	14	nmod
18	,	,	,	_	14	punct
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	impulsivity	impulsivity	NN	_	14	nmod
22	and	and	CC	_	21	cc
23	sensation	sensation	NN	_	21	conj
24	seeking	seek	VBG	_	21	acl
25	.	.	.	_	10	punct

1	Moreover	moreover	RB	_	12	advmod
2	,	,	,	_	12	punct
3	the	the	DT	_	4	det
4	mechanisms	mechanism	NNS	_	12	nsubj
5	underlying	underlie	VBG	_	4	acl
6	the	the	DT	_	7	det
7	development	development	NN	_	5	dobj
8	of	of	IN	_	9	case
9	dependence	dependence	NN	_	7	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	similar	similar	JJ	_	0	ROOT
13	for	for	IN	_	14	case
14	alcohol	alcohol	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	nicotine	nicotine	NN	_	14	conj
17	.	.	.	_	12	punct

1	Thus	thus	RB	_	22	advmod
2	,	,	,	_	22	punct
3	certain	certain	JJ	_	4	amod
4	factors	factor	NNS	_	22	nsubj
5	,	,	,	_	4	punct
6	such	such	JJ	_	8	mark
7	as	as	IN	_	6	mwe
8	reinforcing	reinforce	VBG	_	4	acl
9	drug	drug	NN	_	10	compound
10	effects	effect	NNS	_	8	dobj
11	,	,	,	_	4	punct
12	conditioning	conditioning	NN	_	13	compound
13	processes	process	NNS	_	4	conj
14	,	,	,	_	4	punct
15	automatic	automatic	JJ	_	16	amod
16	behavior	behavior	NN	_	4	conj
17	,	,	,	_	4	punct
18	and	and	CC	_	4	cc
19	stress	stress	NN	_	4	conj
20	,	,	,	_	22	punct
21	may	may	MD	_	22	aux
22	influence	influence	VB	_	0	ROOT
23	the	the	DT	_	24	det
24	development	development	NN	_	22	dobj
25	of	of	IN	_	26	case
26	dependence	dependence	NN	_	24	nmod
27	on	on	IN	_	29	case
28	both	both	DT	_	29	det
29	drugs	drug	NNS	_	24	nmod
30	.	.	.	_	22	punct

1	Other	other	JJ	_	2	amod
2	factors	factor	NNS	_	23	nsubj
3	,	,	,	_	2	punct
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	tolerance	tolerance	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	sensitization	sensitization	NN	_	6	conj
9	to	to	TO	_	13	case
10	the	the	DT	_	11	det
11	drugs	drug	NNS	_	13	nmod:poss
12	'	'	POS	_	11	case
13	actions	action	NNS	_	8	nmod
14	and	and	CC	_	6	cc
15	the	the	DT	_	16	det
16	development	development	NN	_	6	conj
17	of	of	IN	_	19	case
18	withdrawal	withdrawal	NN	_	19	compound
19	symptoms	symptom	NNS	_	16	nmod
20	,	,	,	_	2	punct
21	may	may	MD	_	23	aux
22	also	also	RB	_	23	advmod
23	contribute	contribute	VB	_	0	ROOT
24	to	to	TO	_	25	case
25	dependence	dependence	NN	_	23	nmod
26	.	.	.	_	23	punct

1	This	this	DT	_	2	det
2	review	review	NN	_	3	nsubj
3	discusses	discuss	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	actions	action	NNS	_	15	nsubj
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	two	two	CD	_	9	nummod
9	drugs	drug	NNS	_	5	nmod
10	on	on	IN	_	13	case
11	certain	certain	JJ	_	13	amod
12	brain	brain	NN	_	13	compound
13	chemical	chemical	NN	_	5	nmod
14	(	(	CD	_	13	nummod
15	i	i	LS	_	3	dep
16	.	.	.	_	15	punct
17	e	e	LS	_	15	dep
18	.	.	.	_	17	punct
19	,	,	,	_	17	punct
20	neurotransmitter	neurotransmitter	NN	_	22	compound
21	)	)	CD	_	22	nummod
22	systems	system	NNS	_	17	dep
23	and	and	CC	_	22	cc
24	the	the	DT	_	25	det
25	extent	extent	NN	_	22	conj
26	to	to	TO	_	27	case
27	which	which	WDT	_	35	nmod
28	the	the	DT	_	29	det
29	effects	effect	NNS	_	35	nsubj
30	of	of	IN	_	33	case
31	the	the	DT	_	33	det
32	two	two	CD	_	33	nummod
33	drugs	drug	NNS	_	29	nmod
34	may	may	MD	_	35	aux
35	interact	interact	VB	_	25	acl:relcl
36	.	.	.	_	3	punct

1	Vancomycin	Vancomycin	NNP	_	3	compound
2	resistance	resistance	NN	_	3	compound
3	reversal	reversal	NN	_	0	ROOT
4	in	in	IN	_	5	case
5	enterococci	enterococci	NN	_	3	nmod
6	by	by	IN	_	7	case
7	flavonoids	flavonoid	NNS	_	5	nmod
8	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	development	development	NN	_	17	nsubj
3	of	of	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	vancomycin	vancomycin	NN	_	2	nmod
6	-	-	:	_	5	punct
7	resistant	resistant	JJ	_	8	amod
8	strains	strain	NNS	_	5	dep
9	of	of	IN	_	13	case
10	enterococci	enterococci	NN	_	13	compound
11	(	(	CD	_	13	nummod
12	VRE	vre	NN	_	13	compound
13	)	)	NN	_	8	nmod
14	is	be	VBZ	_	17	cop
15	a	a	DT	_	17	det
16	major	major	JJ	_	17	amod
17	cause	cause	NN	_	0	ROOT
18	for	for	IN	_	19	case
19	concern	concern	NN	_	17	nmod
20	.	.	.	_	17	punct

1	Here	here	RB	_	3	advmod
2	we	we	PRP	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	17	mark
5	a	a	DT	_	6	det
6	combination	combination	NN	_	17	nsubjpass
7	of	of	IN	_	8	case
8	galangin	galangin	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	3,7	3,7	CD	_	8	conj
11	-	-	:	_	8	punct
12	dihydroxyflavone	dihydroxyflavone	NN	_	8	dep
13	with	with	IN	_	14	case
14	vancomycin	vancomycin	NN	_	12	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	used	use	VBN	_	3	ccomp
18	to	to	TO	_	19	mark
19	sensitize	sensitize	VB	_	17	xcomp
20	resistant	resistant	JJ	_	21	amod
21	strains	strain	NNS	_	19	dobj
22	of	of	IN	_	24	case
23	Enterococcus	enterococcus	NN	_	24	compound
24	faecalis	faecalis	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	Enterococcus	enterococcus	NN	_	27	compound
27	faecium	faecium	NN	_	24	conj
28	to	to	TO	_	30	case
29	the	the	DT	_	30	det
30	level	level	NN	_	19	nmod
31	of	of	IN	_	32	case
32	vancomycin	vancomycin	NN	_	30	nmod
33	-	-	:	_	32	punct
34	sensitive	sensitive	JJ	_	35	amod
35	strains	strain	NNS	_	32	dep
36	.	.	.	_	3	punct

1	Minimum	Minimum	NNP	_	3	compound
2	inhibitory	inhibitory	JJ	_	3	amod
3	concentrations	concentration	NNS	_	11	nsubjpass
4	(	(	CD	_	5	nummod
5	MICs	mic	NNS	_	3	dep
6	)	)	CD	_	5	nummod
7	and	and	CC	_	5	cc
8	viable	viable	JJ	_	9	amod
9	counts	count	NNS	_	5	conj
10	were	be	VBD	_	11	auxpass
11	determined	determine	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	Iso	Iso	NNP	_	11	nmod
14	-	-	:	_	13	punct
15	sensitest	sensitest	NN	_	16	compound
16	broth	broth	NN	_	13	dep
17	using	use	VBG	_	16	acl
18	a	a	DT	_	20	det
19	microtitre	microtitre	NN	_	20	compound
20	method	method	NN	_	17	dobj
21	.	.	.	_	11	punct

1	MICs	mic	NNS	_	18	nsubjpass
2	of	of	IN	_	3	case
3	vancomycin	vancomycin	NN	_	1	nmod
4	against	against	IN	_	6	case
5	67	67	CD	_	6	nummod
6	%	%	NN	_	1	nmod
7	of	of	IN	_	10	case
8	resistant	resistant	JJ	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	isolates	isolate	NNS	_	6	nmod
11	and	and	CC	_	6	cc
12	a	a	DT	_	14	det
13	type	type	NN	_	14	compound
14	strain	strain	NN	_	6	conj
15	of	of	IN	_	16	case
16	enterococci	enterococcus	NNS	_	14	nmod
17	were	be	VBD	_	18	auxpass
18	lowered	lower	VBN	_	0	ROOT
19	from	from	IN	_	23	case
20	>	>	JJR	_	21	advmod
21	250	250	CD	_	23	nummod
22	microg	microg	NN	_	23	compound
23	mL	ml	NN	_	18	nmod
24	(	(	SYM	_	23	dep
25	-	-	:	_	24	punct
26	1	1	CD	_	27	compound
27	)	)	CD	_	25	root
28	to	to	TO	_	27	dep
29	1	1	CD	_	27	dep

1	4	4	CD	_	3	nummod
2	microg	microg	NN	_	3	compound
3	mL	ml	NN	_	34	dep
4	(	(	SYM	_	7	dep
5	-	-	:	_	7	punct
6	1	1	CD	_	7	nummod
7	)	)	NN	_	34	dep
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	presence	presence	NN	_	7	nmod
11	of	of	IN	_	12	case
12	galangin	galangin	NN	_	10	nmod
13	(	(	CD	_	14	compound
14	12.5	12.5	CD	_	12	nummod
15	microg	microg	NN	_	16	compound
16	mL	ml	NN	_	12	dep
17	(	(	SYM	_	12	dep
18	-	-	:	_	7	punct
19	1	1	CD	_	20	compound
20	)	)	CD	_	21	nummod
21	)	)	CD	_	7	dep
22	or	or	CC	_	21	cc
23	3,7	3,7	CD	_	21	conj
24	-	-	:	_	7	punct
25	dihydroxyflavone	dihydroxyflavone	NN	_	29	compound
26	(	(	NN	_	29	compound
27	6.25	6.25	CD	_	29	nummod
28	microg	microg	NN	_	29	compound
29	mL	ml	NN	_	7	dep
30	(	(	SYM	_	34	dep
31	-	-	:	_	34	punct
32	1	1	CD	_	33	compound
33	)	)	CD	_	34	nummod
34	)	)	NN	_	0	ROOT
35	.	.	.	_	34	punct

1	Viable	viable	JJ	_	2	amod
2	counts	count	NNS	_	0	ROOT
3	for	for	IN	_	6	case
4	type	type	NN	_	6	compound
5	culture	culture	NN	_	6	compound
6	E	e	NN	_	2	nmod
7	.	.	.	_	2	punct

1	faecalis	faecalis	NN	_	2	compound
2	ATCC	atcc	NN	_	4	nsubj
3	51299	51299	CD	_	2	nummod
4	showed	show	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	flavonoids	flavonoid	NNS	_	9	nsubj
7	alone	alone	RB	_	6	advmod
8	significantly	significantly	RB	_	9	advmod
9	lowered	lower	VBD	_	4	ccomp
10	numbers	number	NNS	_	15	nsubj
11	of	of	IN	_	14	case
12	colony	colony	NN	_	14	compound
13	forming	form	VBG	_	14	amod
14	units	unit	NNS	_	10	nmod
15	(	(	VBP	_	9	ccomp
16	CFUs	cfus	NNS	_	15	dobj
17	)	)	CD	_	16	nummod
18	.	.	.	_	4	punct

1	CFUs	cfus	NNS	_	3	nsubjpass
2	were	be	VBD	_	3	auxpass
3	maintained	maintain	VBN	_	0	ROOT
4	at	at	IN	_	6	case
5	low	low	JJ	_	6	amod
6	levels	level	NNS	_	7	nmod
7	(	(	VBP	_	3	dep
8	10	10	CD	_	11	compound
9	(	(	CD	_	11	compound
10	3	3	CD	_	11	compound
11	)	)	CD	_	13	nummod
12	CFU	CFU	NNP	_	13	compound
13	mL	ml	NN	_	7	dobj
14	(	(	SYM	_	18	dep
15	-	-	:	_	18	punct
16	1	1	CD	_	17	compound
17	)	)	CD	_	18	nummod
18	)	)	NN	_	13	dep
19	for	for	IN	_	21	case
20	24	24	CD	_	21	nummod
21	h	h	NN	_	18	nmod
22	by	by	IN	_	23	case
23	vancomycin	vancomycin	NN	_	18	nmod
24	/	/	:	_	18	punct
25	flavone	flavone	NN	_	26	compound
26	combinations	combination	NNS	_	18	dep
27	.	.	.	_	3	punct

1	This	this	DT	_	3	det
2	combinational	combinational	JJ	_	3	amod
3	action	action	NN	_	10	nsubj
4	in	in	IN	_	5	mark
5	reversing	reverse	VBG	_	3	acl
6	vancomycin	vancomycin	NN	_	7	compound
7	resistance	resistance	NN	_	5	dobj
8	of	of	IN	_	9	case
9	enterococci	enterococci	NN	_	7	nmod
10	highlights	highlight	VBZ	_	0	ROOT
11	novel	novel	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	targets	target	NNS	_	10	dobj
14	and	and	CC	_	10	cc
15	has	have	VBZ	_	10	conj
16	importance	importance	NN	_	15	dobj
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	design	design	NN	_	16	nmod
20	of	of	IN	_	23	case
21	new	new	JJ	_	23	amod
22	therapeutic	therapeutic	JJ	_	23	amod
23	regimes	regime	NNS	_	19	nmod
24	against	against	IN	_	26	case
25	resistant	resistant	JJ	_	26	amod
26	pathogens	pathogen	NNS	_	23	nmod
27	.	.	.	_	10	punct

1	Lack	lack	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	interaction	interaction	NN	_	1	nmod
4	between	between	IN	_	5	case
5	levofloxacin	levofloxacin	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	oxycodone	oxycodone	NN	_	5	conj
8	:	:	:	_	1	punct
9	pharmacokinetics	pharmacokinetic	NNS	_	1	dep
10	and	and	CC	_	9	cc
11	drug	drug	NN	_	12	compound
12	disposition	disposition	NN	_	9	conj
13	.	.	.	_	1	punct

1	Previous	previous	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	a	a	DT	_	7	det
6	significant	significant	JJ	_	7	amod
7	reduction	reduction	NN	_	4	dobj
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	oral	oral	JJ	_	11	amod
11	bioavailability	bioavailability	NN	_	7	nmod
12	of	of	IN	_	13	case
13	trovafloxacin	trovafloxacin	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	ciprofloxacin	ciprofloxacin	NN	_	13	conj
16	when	when	WRB	_	17	advmod
17	administered	administer	VBN	_	4	advcl
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	22	case
20	an	a	DT	_	22	det
21	intravenous	intravenous	JJ	_	22	amod
22	opiate	opiate	NN	_	17	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	morphine	morphine	NN	_	22	nmod
26	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	decrease	decrease	NN	_	5	nsubj
3	in	in	IN	_	4	case
4	absorption	absorption	NN	_	2	nmod
5	results	result	VBZ	_	0	ROOT
6	in	in	IN	_	9	case
7	a	a	DT	_	9	det
8	36	36	CD	_	9	nummod
9	%	%	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	50	50	CD	_	12	nummod
12	%	%	NN	_	9	conj
13	lower	lower	JJR	_	14	amod
14	AUC	auc	NN	_	9	dep
15	for	for	IN	_	16	case
16	trovafloxacin	trovafloxacin	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	ciprofloxacin	ciprofloxacin	NN	_	16	conj
19	,	,	,	_	9	punct
20	respectively	respectively	RB	_	9	advmod
21	,	,	,	_	9	punct
22	which	which	WDT	_	24	nsubj
23	could	could	MD	_	24	aux
24	cause	cause	VB	_	9	acl:relcl
25	clinical	clinical	JJ	_	26	amod
26	failures	failure	NNS	_	24	dobj
27	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	3	nsubj
3	investigated	investigate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	possibility	possibility	NN	_	3	dobj
6	of	of	IN	_	9	case
7	a	a	DT	_	9	det
8	similar	similar	JJ	_	9	amod
9	interaction	interaction	NN	_	5	nmod
10	between	between	IN	_	11	case
11	oxycodone	oxycodone	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	levofloxacin	levofloxacin	NN	_	11	conj
14	.	.	.	_	3	punct

1	Eight	eight	CD	_	3	nummod
2	healthy	healthy	JJ	_	3	amod
3	volunteers	volunteer	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	randomized	randomize	VBN	_	0	ROOT
6	in	in	IN	_	10	case
7	an	a	DT	_	10	det
8	open	open	JJ	_	10	amod
9	-	-	:	_	10	punct
10	label	label	NN	_	5	nmod
11	,	,	,	_	5	punct
12	two	two	CD	_	16	nummod
13	-	-	:	_	16	punct
14	way	way	NN	_	16	compound
15	crossover	crossover	NN	_	16	compound
16	study	study	NN	_	5	dobj
17	to	to	TO	_	18	mark
18	receive	receive	VB	_	16	acl
19	oxycodone	oxycodone	NN	_	18	dobj
20	,	,	,	_	19	punct
21	5	5	CD	_	22	compound
22	mg	mg	NN	_	25	amod
23	p	p	NN	_	25	compound
24	.	.	.	_	25	punct
25	o	o	NN	_	19	appos
26	.	.	.	_	5	punct

1	Q4H	q4h	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	and	and	CC	_	1	cc
4	levofloxacin	levofloxacin	NN	_	1	conj
5	,	,	,	_	4	punct
6	500	500	CD	_	7	nummod
7	mg	mg	NN	_	4	appos
8	p	p	NN	_	10	compound
9	.	.	.	_	10	punct
10	o	o	NN	_	7	dep
11	.	.	.	_	1	punct

1	1	1	CD	_	2	nummod
2	hour	hour	NN	_	0	ROOT
3	after	after	IN	_	2	mark
4	starting	start	VBG	_	2	dep
5	the	the	DT	_	6	det
6	oxycodone	oxycodone	NN	_	4	dobj
7	or	or	CC	_	6	cc
8	levofloxacin	levofloxacin	NN	_	10	compound
9	500	500	CD	_	10	nummod
10	mg	mg	NN	_	6	conj
11	p	p	NN	_	6	dep
12	.	.	.	_	2	punct
13	o	o	NN	_	2	dep
14	.	.	.	_	2	punct

1	alone	alone	RB	_	0	ROOT
2	.	.	.	_	1	punct

1	Blood	blood	NN	_	2	compound
2	samples	sample	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	drawn	draw	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	0	0	CD	_	4	nmod
7	,	,	,	_	6	punct
8	0.5	0.5	CD	_	6	conj
9	,	,	,	_	6	punct
10	1	1	CD	_	6	conj
11	,	,	,	_	6	punct
12	1.5	1.5	CD	_	6	conj
13	,	,	,	_	6	punct
14	2	2	CD	_	6	conj
15	,	,	,	_	6	punct
16	3	3	CD	_	6	conj
17	,	,	,	_	6	punct
18	4	4	CD	_	6	conj
19	,	,	,	_	6	punct
20	6	6	CD	_	6	conj
21	,	,	,	_	6	punct
22	8	8	CD	_	6	conj
23	,	,	,	_	6	punct
24	12	12	CD	_	6	conj
25	,	,	,	_	6	punct
26	18	18	CD	_	6	conj
27	,	,	,	_	6	punct
28	and	and	CC	_	6	cc
29	24	24	CD	_	6	conj
30	hours	hour	NNS	_	6	dep
31	for	for	IN	_	32	case
32	Cmax	Cmax	NNP	_	4	nmod
33	,	,	,	_	32	punct
34	tmax	tmax	NN	_	32	conj
35	,	,	,	_	32	punct
36	and	and	CC	_	32	cc
37	AUC	auc	NN	_	38	compound
38	determinations	determination	NNS	_	32	conj
39	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	not	not	RB	_	2	neg
4	a	a	DT	_	8	det
5	significant	significant	JJ	_	8	amod
6	difference	difference	NN	_	8	compound
7	(	(	NN	_	8	compound
8	p	p	NN	_	2	nsubj
9	>	>	JJR	_	10	advmod
10	0.05	0.05	CD	_	11	nummod
11	)	)	NN	_	8	dep
12	in	in	IN	_	13	case
13	AUC	auc	NN	_	11	nmod
14	(	(	CD	_	15	nummod
15	48.59	48.59	CD	_	13	nummod
16	+	+	CC	_	13	cc
17	/	/	:	_	13	punct
18	-	-	:	_	13	punct
19	8.52	8.52	CD	_	22	compound
20	vs	vs	CC	_	22	dep
21	.	.	.	_	22	punct
22	49.9	49.9	CD	_	13	dep
23	+	+	CC	_	22	cc
24	/	/	:	_	22	punct
25	-	-	:	_	13	punct
26	9.93	9.93	CD	_	27	compound
27	)	)	CD	_	13	dep
28	,	,	,	_	13	punct
29	Cmax	Cmax	NNP	_	13	appos
30	(	(	CD	_	31	nummod
31	7.73	7.73	CD	_	29	nummod
32	+	+	CC	_	29	cc
33	/	/	:	_	29	punct
34	-	-	:	_	8	punct
35	2.6	2.6	CD	_	38	nummod
36	vs	vs	CC	_	38	dep
37	.	.	.	_	38	punct
38	6.6	6.6	CD	_	8	dep
39	+	+	CC	_	38	cc
40	/	/	:	_	38	punct
41	-	-	:	_	8	punct
42	2.0	2.0	CD	_	43	nummod
43	)	)	NN	_	8	dep
44	,	,	,	_	2	punct
45	and	and	CC	_	2	cc
46	tmax	tmax	NN	_	47	compound
47	(	(	NN	_	2	conj
48	1.1	1.1	CD	_	47	nummod
49	+	+	CC	_	47	cc
50	/	/	:	_	47	punct
51	-	-	:	_	47	punct
52	0.6	0.6	CD	_	55	compound
53	vs	vs	CC	_	55	dep
54	.	.	.	_	55	punct
55	1.6	1.6	CD	_	47	dep
56	+	+	CC	_	55	cc
57	/	/	:	_	55	punct
58	-	-	:	_	55	punct
59	1.1	1.1	CD	_	60	nummod
60	)	)	NN	_	67	dep
61	for	for	IN	_	62	case
62	levofloxacin	levofloxacin	NN	_	60	nmod
63	versus	versus	CC	_	62	cc
64	levofloxacin	levofloxacin	NN	_	62	conj
65	/	/	:	_	67	punct
66	oxycodone	oxycodone	NN	_	67	compound
67	regimens	regimen	NNS	_	55	dep
68	.	.	.	_	2	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	concluded	conclude	VBN	_	0	ROOT
4	that	that	IN	_	11	mark
5	oral	oral	JJ	_	6	amod
6	oxycodone	oxycodone	NN	_	11	nsubjpass
7	and	and	CC	_	6	cc
8	levofloxacin	levofloxacin	NN	_	6	conj
9	can	can	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	administered	administer	VBN	_	3	ccomp
12	concomitantly	concomitantly	RB	_	11	advmod
13	without	without	IN	_	16	case
14	a	a	DT	_	16	det
15	significant	significant	JJ	_	16	amod
16	decrease	decrease	NN	_	11	nmod
17	in	in	IN	_	18	case
18	AUC	auc	NN	_	16	nmod
19	,	,	,	_	18	punct
20	Cmax	cmax	NN	_	18	conj
21	,	,	,	_	18	punct
22	or	or	CC	_	18	cc
23	tmax	tmax	NN	_	18	conj
24	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	mode	mode	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	toxic	toxic	JJ	_	5	amod
5	action	action	NN	_	2	nmod
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	pesticide	pesticide	NN	_	9	compound
9	gliftor	gliftor	NN	_	5	nmod
10	:	:	:	_	2	punct
11	the	the	DT	_	12	det
12	metabolism	metabolism	NN	_	2	dep
13	of	of	IN	_	14	case
14	1,3	1,3	CD	_	12	nmod
15	-	-	:	_	12	punct
16	difluoroacetone	difluoroacetone	NN	_	12	dep
17	to	to	TO	_	22	case
18	(	(	SYM	_	22	dep
19	-	-	:	_	22	punct
20	)	)	SYM	_	22	dep
21	-	-	:	_	22	punct
22	erythro	erythro	NN	_	16	nmod
23	-	-	:	_	22	punct
24	fluorocitrate	fluorocitrate	NN	_	22	dep
25	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	biochemical	biochemical	JJ	_	3	amod
3	toxicology	toxicology	NN	_	31	nsubjpass
4	of	of	IN	_	5	case
5	1,3	1,3	CD	_	3	nmod
6	-	-	:	_	5	punct
7	difluoroacetone	difluoroacetone	NN	_	5	dep
8	,	,	,	_	5	punct
9	a	a	DT	_	11	det
10	known	known	JJ	_	11	amod
11	metabolite	metabolite	NN	_	5	appos
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	major	major	JJ	_	15	amod
15	ingredient	ingredient	NN	_	11	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	pesticide	pesticide	NN	_	19	compound
19	Gliftor	gliftor	NN	_	15	nmod
20	(	(	CD	_	21	nummod
21	1,3	1,3	CD	_	19	nummod
22	-	-	:	_	19	punct
23	difluoro	difluoro	NN	_	19	dep
24	-	-	:	_	19	punct
25	2	2	LS	_	28	dep
26	-	-	:	_	28	punct
27	propanol	propanol	NN	_	28	compound
28	)	)	NN	_	19	dep
29	,	,	,	_	3	punct
30	was	be	VBD	_	31	auxpass
31	investigated	investigate	VBN	_	0	ROOT
32	in	in	FW	_	33	compound
33	vivo	vivo	FW	_	34	advmod
34	and	and	CC	_	31	advmod
35	in	in	FW	_	36	compound
36	vitro	vitro	FW	_	34	advmod
37	.	.	.	_	31	punct

1	Rat	rat	NN	_	3	compound
2	kidney	kidney	NN	_	3	compound
3	homogenates	homogenate	NNS	_	0	ROOT
4	supplemented	supplement	VBN	_	3	acl
5	with	with	IN	_	7	case
6	coenzyme	coenzyme	NN	_	7	compound
7	A	a	NN	_	4	nmod
8	,	,	,	_	7	punct
9	ATP	atp	NN	_	7	conj
10	,	,	,	_	7	punct
11	oxaloacetate	oxaloacetate	NN	_	7	conj
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	Mg2	mg2	NN	_	7	conj
15	+	+	CC	_	3	cc
16	converted	convert	VBD	_	3	conj
17	1,3	1,3	CD	_	19	nummod
18	-	-	:	_	19	punct
19	difluoroacetone	difluoroacetone	NN	_	16	dobj
20	to	to	TO	_	25	case
21	(	(	SYM	_	25	dep
22	-	-	:	_	25	punct
23	)	)	SYM	_	25	dep
24	-	-	:	_	25	punct
25	erythro	erythro	NN	_	19	nmod
26	-	-	:	_	25	punct
27	fluorocitrate	fluorocitrate	NN	_	25	dep
28	in	in	FW	_	29	compound
29	vitro	vitro	FW	_	27	advmod
30	.	.	.	_	3	punct

1	Administration	administration	NN	_	21	nsubj
2	of	of	IN	_	9	case
3	1,3	1,3	CD	_	9	nummod
4	-	-	:	_	9	punct
5	difluoroacetone	difluoroacetone	NN	_	9	compound
6	(	(	NN	_	9	compound
7	100	100	CD	_	8	compound
8	mg	mg	NN	_	9	amod
9	kg	kg	NN	_	1	nmod
10	(	(	SYM	_	15	dep
11	-	-	:	_	15	punct
12	1	1	CD	_	13	compound
13	)	)	CD	_	15	nummod
14	body	body	NN	_	15	compound
15	weight	weight	NN	_	9	dep
16	)	)	CD	_	15	nummod
17	to	to	TO	_	18	case
18	rats	rat	NNS	_	15	nmod
19	in	in	FW	_	20	compound
20	vivo	vivo	FW	_	15	advmod
21	resulted	result	VBD	_	0	ROOT
22	in	in	IN	_	27	case
23	(	(	SYM	_	27	dep
24	-	-	:	_	27	punct
25	)	)	SYM	_	27	dep
26	-	-	:	_	27	punct
27	erythro	erythro	NN	_	21	nmod
28	-	-	:	_	27	punct
29	fluorocitrate	fluorocitrate	JJ	_	30	amod
30	synthesis	synthesis	NN	_	27	dep
31	in	in	IN	_	33	case
32	the	the	DT	_	33	det
33	kidney	kidney	NN	_	30	nmod
34	,	,	,	_	30	punct
35	which	which	WDT	_	37	nsubjpass
36	was	be	VBD	_	37	auxpass
37	preceded	precede	VBN	_	30	acl:relcl
38	by	by	IN	_	40	case
39	an	a	DT	_	40	det
40	elevation	elevation	NN	_	37	nmod
41	in	in	IN	_	43	case
42	fluoride	fluoride	NN	_	43	compound
43	levels	level	NNS	_	40	nmod
44	and	and	CC	_	37	cc
45	followed	follow	VBN	_	37	conj
46	by	by	IN	_	48	case
47	citrate	citrate	NN	_	48	compound
48	accumulation	accumulation	NN	_	45	nmod
49	.	.	.	_	21	punct

1	Animals	animal	NNS	_	0	ROOT
2	dosed	dose	VBN	_	1	acl
3	with	with	IN	_	4	case
4	1,3	1,3	CD	_	2	nmod
5	-	-	:	_	1	punct
6	difluoroacetone	difluoroacetone	NN	_	9	nsubj
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	display	display	VB	_	1	dep
10	the	the	DT	_	16	det
11	2	2	LS	_	16	dep
12	-	-	:	_	16	punct
13	3	3	CD	_	14	compound
14	hour	hour	NN	_	16	amod
15	lag	lag	NN	_	16	compound
16	phase	phase	NN	_	9	dobj
17	in	in	IN	_	23	case
18	either	either	CC	_	23	cc:preconj
19	(	(	SYM	_	23	dep
20	-	-	:	_	23	punct
21	)	)	SYM	_	23	dep
22	-	-	:	_	23	punct
23	erythro	erythro	NN	_	9	nmod
24	-	-	:	_	23	punct
25	fluorocitrate	fluorocitrate	JJ	_	26	amod
26	synthesis	synthesis	NN	_	23	conj
27	or	or	CC	_	23	cc
28	in	in	IN	_	29	case
29	citrate	citrate	NN	_	23	conj
30	and	and	CC	_	29	cc
31	fluoride	fluoride	NN	_	33	compound
32	accumulation	accumulation	NN	_	33	compound
33	characteristic	characteristic	NN	_	29	conj
34	of	of	IN	_	35	case
35	animals	animal	NNS	_	29	nmod
36	dosed	dose	VBN	_	35	acl
37	with	with	IN	_	38	case
38	1,3	1,3	CD	_	36	nmod
39	-	-	:	_	38	punct
40	difluoro	difluoro	NN	_	38	dep
41	-	-	:	_	38	punct
42	2	2	LS	_	44	dep
43	-	-	:	_	44	punct
44	propanol	propanol	NN	_	38	dep
45	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	demonstrate	demonstrate	VBP	_	0	ROOT
3	that	that	IN	_	27	mark
4	the	the	DT	_	5	det
5	conversion	conversion	NN	_	27	nsubj
6	of	of	IN	_	7	case
7	1,3	1,3	CD	_	5	nmod
8	-	-	:	_	7	punct
9	difluoro	difluoro	NN	_	7	dep
10	-	-	:	_	7	punct
11	2	2	LS	_	13	dep
12	-	-	:	_	13	punct
13	propanol	propanol	NN	_	7	dep
14	to	to	TO	_	15	case
15	1,3	1,3	CD	_	13	nmod
16	-	-	:	_	13	punct
17	difluoroacetone	difluoroacetone	NN	_	13	dep
18	by	by	IN	_	20	case
19	an	a	DT	_	20	det
20	NAD	NAD	NNP	_	17	nmod
21	+	+	CC	_	17	cc
22	-	-	:	_	24	punct
23	dependent	dependent	JJ	_	24	amod
24	oxidation	oxidation	NN	_	17	conj
25	is	be	VBZ	_	27	cop
26	the	the	DT	_	27	det
27	rate	rate	NN	_	2	ccomp
28	-	-	:	_	27	punct
29	limiting	limit	VBG	_	30	amod
30	step	step	NN	_	27	dep
31	in	in	IN	_	33	case
32	the	the	DT	_	33	det
33	synthesis	synthesis	NN	_	30	nmod
34	of	of	IN	_	37	case
35	the	the	DT	_	37	det
36	toxic	toxic	JJ	_	37	amod
37	product	product	NN	_	33	nmod
38	,	,	,	_	30	punct
39	(	(	SYM	_	43	dep
40	-	-	:	_	43	punct
41	)	)	SYM	_	43	dep
42	-	-	:	_	43	punct
43	erythro	erythro	NN	_	30	appos
44	-	-	:	_	43	punct
45	fluorocitrate	fluorocitrate	NN	_	43	dep
46	from	from	IN	_	47	case
47	1,3	1,3	CD	_	45	nmod
48	-	-	:	_	47	punct
49	difluoro	difluoro	NN	_	47	dep
50	-	-	:	_	47	punct
51	2	2	LS	_	53	dep
52	-	-	:	_	53	punct
53	propanol	propanol	NN	_	47	dep
54	.	.	.	_	2	punct

1	Prior	prior	RB	_	0	ROOT
2	administration	administration	NN	_	1	dep
3	of	of	IN	_	2	amod
4	4	4	LS	_	3	dep
5	-	-	:	_	4	punct
6	methylpyrazole	methylpyrazole	NN	_	10	compound
7	(	(	CD	_	9	compound
8	90	90	CD	_	9	compound
9	mg	mg	NN	_	10	amod
10	kg	kg	NN	_	4	dep
11	(	(	SYM	_	19	dep
12	-	-	:	_	19	punct
13	1	1	CD	_	14	compound
14	)	)	CD	_	17	nummod
15	body	body	NN	_	17	compound
16	weight	weight	NN	_	17	compound
17	)	)	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	shown	show	VBN	_	10	acl
20	to	to	TO	_	21	mark
21	prevent	prevent	VB	_	19	xcomp
22	the	the	DT	_	23	det
23	conversion	conversion	NN	_	21	dobj
24	of	of	IN	_	25	case
25	1,3	1,3	CD	_	23	nmod
26	-	-	:	_	25	punct
27	difluoro	difluoro	NN	_	25	dep
28	-	-	:	_	25	punct
29	2	2	LS	_	35	dep
30	-	-	:	_	35	punct
31	propanol	propanol	NN	_	35	compound
32	(	(	NN	_	35	compound
33	100	100	CD	_	34	compound
34	mg	mg	NN	_	35	amod
35	kg	kg	NN	_	25	dep
36	(	(	SYM	_	41	dep
37	-	-	:	_	41	punct
38	1	1	CD	_	39	compound
39	)	)	CD	_	41	nummod
40	body	body	NN	_	41	compound
41	weight	weight	NN	_	35	dep
42	)	)	CD	_	44	compound
43	to	to	TO	_	44	dep
44	(	(	CD	_	41	nummod
45	-	-	:	_	41	punct
46	)	)	SYM	_	41	dep
47	-	-	:	_	41	punct
48	erythro	erythro	NN	_	41	dep
49	-	-	:	_	41	punct
50	fluorocitrate	fluorocitrate	NN	_	41	dep
51	in	in	FW	_	52	compound
52	vivo	vivo	FW	_	50	advmod
53	and	and	CC	_	41	cc
54	to	to	TO	_	55	mark
55	eliminate	eliminate	VB	_	41	conj
56	the	the	DT	_	60	det
57	fluoride	fluoride	NN	_	60	compound
58	and	and	CC	_	57	cc
59	citrate	citrate	NN	_	57	conj
60	elevations	elevation	NNS	_	55	dobj
61	seen	see	VBN	_	60	acl
62	in	in	IN	_	63	case
63	1,3	1,3	CD	_	61	nmod
64	-	-	:	_	35	punct
65	difluoro	difluoro	NN	_	35	dep
66	-	-	:	_	35	punct
67	2	2	LS	_	72	dep
68	-	-	:	_	72	punct
69	propanol	propanol	NN	_	72	compound
70	-	-	:	_	72	punct
71	intoxicated	intoxicated	JJ	_	72	amod
72	animals	animal	NNS	_	35	dep
73	.	.	.	_	1	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	administration	administration	NN	_	2	root
4	of	of	IN	_	3	amod
5	4	4	LS	_	4	dep
6	-	-	:	_	5	punct
7	methylpyrazole	methylpyrazole	NN	_	11	compound
8	(	(	CD	_	10	compound
9	90	90	CD	_	10	compound
10	mg	mg	NN	_	11	amod
11	kg	kg	NN	_	5	dep
12	(	(	SYM	_	17	dep
13	-	-	:	_	17	punct
14	1	1	CD	_	15	compound
15	)	)	CD	_	17	nummod
16	body	body	NN	_	17	compound
17	weight	weight	NN	_	11	dep
18	)	)	CD	_	17	nummod
19	to	to	TO	_	20	case
20	rats	rat	NNS	_	17	nmod
21	2	2	CD	_	22	nummod
22	hours	hour	NNS	_	20	dep
23	prior	prior	RB	_	22	amod
24	to	to	TO	_	25	case
25	1,3	1,3	CD	_	23	nmod
26	-	-	:	_	17	punct
27	difluoroacetone	difluoroacetone	NN	_	31	compound
28	(	(	NN	_	31	compound
29	100	100	CD	_	30	compound
30	mg	mg	NN	_	31	amod
31	kg	kg	NN	_	40	dep
32	(	(	SYM	_	40	dep
33	-	-	:	_	40	punct
34	1	1	CD	_	35	compound
35	)	)	CD	_	38	nummod
36	body	body	NN	_	38	compound
37	weight	weight	NN	_	38	compound
38	)	)	NN	_	40	nsubj
39	was	be	VBD	_	40	cop
40	ineffective	ineffective	JJ	_	17	dep
41	in	in	IN	_	42	mark
42	preventing	prevent	VBG	_	40	advcl
43	(	(	SYM	_	47	dep
44	-	-	:	_	47	punct
45	)	)	SYM	_	47	dep
46	-	-	:	_	47	punct
47	erythro	erythro	NN	_	50	dep
48	-	-	:	_	47	punct
49	fluorocitrate	fluorocitrate	JJ	_	50	amod
50	synthesis	synthesis	NN	_	42	dobj
51	and	and	CC	_	40	cc
52	did	do	VBD	_	54	aux
53	not	not	RB	_	54	neg
54	diminish	diminish	VB	_	40	conj
55	fluoride	fluoride	NN	_	58	compound
56	or	or	CC	_	55	cc
57	citrate	citrate	NN	_	55	conj
58	accumulation	accumulation	NN	_	54	dobj
59	in	in	FW	_	60	compound
60	vivo	vivo	FW	_	54	advmod
61	.	.	.	_	3	punct

1	We	we	PRP	_	2	nsubj
2	conclude	conclude	VBP	_	0	ROOT
3	that	that	IN	_	2	dobj
4	the	the	DT	_	8	det
5	prophylactic	prophylactic	NN	_	8	amod
6	and	and	CC	_	5	cc
7	antidotal	antidotal	JJ	_	5	conj
8	properties	property	NNS	_	3	dobj
9	of	of	IN	_	8	acl
10	4	4	LS	_	9	root
11	-	-	:	_	10	punct
12	methylpyrazole	methylpyrazole	NN	_	11	root
13	seen	see	VBN	_	12	acl
14	in	in	IN	_	15	case
15	animals	animal	NNS	_	13	nmod
16	treated	treat	VBN	_	15	acl
17	with	with	IN	_	18	case
18	1,3	1,3	CD	_	16	nmod
19	-	-	:	_	18	punct
20	difluoro	difluoro	NN	_	18	dep
21	-	-	:	_	18	punct
22	2	2	LS	_	25	dep
23	-	-	:	_	25	punct
24	propanol	propanol	NN	_	25	nsubj
25	derive	derive	VBP	_	18	dep
26	from	from	IN	_	28	case
27	its	its	PRP$	_	28	nmod:poss
28	capacity	capacity	NN	_	25	nmod
29	to	to	TO	_	30	mark
30	inhibit	inhibit	VB	_	28	acl
31	the	the	DT	_	32	det
32	NAD	NAD	NNP	_	30	dobj
33	+	+	CC	_	32	cc
34	-	-	:	_	32	punct
35	dependent	dependent	JJ	_	36	amod
36	oxidation	oxidation	NN	_	32	dep
37	responsible	responsible	JJ	_	36	amod
38	for	for	IN	_	39	mark
39	converting	convert	VBG	_	37	advcl
40	1,3	1,3	CD	_	42	nummod
41	-	-	:	_	42	punct
42	difluoro	difluoro	NN	_	39	dobj
43	-	-	:	_	42	punct
44	2	2	LS	_	46	dep
45	-	-	:	_	46	punct
46	propanol	propanol	NN	_	42	dep
47	to	to	TO	_	48	case
48	1,3	1,3	CD	_	46	nmod
49	-	-	:	_	46	punct
50	difluoroacetone	difluoroacetone	NN	_	46	dep
51	in	in	IN	_	54	case
52	the	the	DT	_	54	det
53	committed	committed	JJ	_	54	amod
54	step	step	NN	_	50	nmod
55	of	of	IN	_	58	case
56	the	the	DT	_	58	det
57	toxic	toxic	JJ	_	58	amod
58	pathway	pathway	NN	_	54	nmod
59	.	.	.	_	12	punct

1	Cypermethrin	cypermethrin	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	induced	induce	VBN	_	5	amod
4	oxidative	oxidative	JJ	_	5	amod
5	stress	stress	NN	_	12	nsubjpass
6	in	in	IN	_	8	case
7	rat	rat	NN	_	8	compound
8	brain	brain	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	liver	liver	NN	_	8	conj
11	is	be	VBZ	_	12	auxpass
12	prevented	prevent	VBN	_	1	dep
13	by	by	IN	_	15	case
14	vitamin	vitamin	NN	_	15	compound
15	E	e	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	allopurinol	allopurinol	NN	_	15	conj
18	.	.	.	_	1	punct

1	Considering	consider	VBG	_	14	nsubjpass
2	that	that	IN	_	9	mark
3	the	the	DT	_	4	det
4	involvement	involvement	NN	_	9	nsubj
5	of	of	IN	_	8	case
6	reactive	reactive	JJ	_	8	amod
7	oxygen	oxygen	NN	_	8	compound
8	species	species	NNS	_	4	nmod
9	(	(	VBP	_	1	ccomp
10	ROS	ros	NN	_	11	compound
11	)	)	NN	_	9	dobj
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	implicated	implicate	VBN	_	25	advcl
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	toxicity	toxicity	NN	_	14	nmod
18	of	of	IN	_	20	case
19	various	various	JJ	_	20	amod
20	pesticides	pesticide	NNS	_	17	nmod
21	,	,	,	_	25	punct
22	this	this	DT	_	23	det
23	study	study	NN	_	25	nsubjpass
24	was	be	VBD	_	25	auxpass
25	designed	design	VBN	_	0	ROOT
26	to	to	TO	_	27	mark
27	investigate	investigate	VB	_	25	xcomp
28	the	the	DT	_	29	det
29	possibility	possibility	NN	_	27	dobj
30	of	of	IN	_	33	case
31	oxidative	oxidative	JJ	_	33	amod
32	stress	stress	NN	_	33	compound
33	induction	induction	NN	_	29	nmod
34	by	by	IN	_	35	case
35	cypermethrin	cypermethrin	NN	_	33	nmod
36	,	,	,	_	35	punct
37	a	a	DT	_	40	det
38	Type	type	NN	_	40	compound
39	II	ii	CD	_	40	nummod
40	pyrethroid	pyrethroid	NN	_	35	appos
41	.	.	.	_	25	punct

1	Either	either	CC	_	43	cc
2	single	single	JJ	_	5	amod
3	(	(	NN	_	5	compound
4	170	170	CD	_	5	nummod
5	mg	mg	NN	_	43	nsubj
6	/	/	:	_	5	punct
7	kg	kg	NN	_	8	compound
8	)	)	NN	_	5	dep
9	or	or	CC	_	8	cc
10	repeated	repeat	VBN	_	13	amod
11	(	(	NN	_	13	compound
12	75	75	CD	_	13	nummod
13	mg	mg	NN	_	8	conj
14	/	/	:	_	5	punct
15	kg	kg	NN	_	5	dep
16	per	per	IN	_	17	case
17	day	day	NN	_	15	nmod
18	for	for	IN	_	20	case
19	5	5	CD	_	20	nummod
20	days	day	NNS	_	15	nmod
21	)	)	RB	_	22	advmod
22	oral	oral	JJ	_	23	amod
23	administration	administration	NN	_	27	nsubjpass
24	of	of	IN	_	25	case
25	cypermethrin	cypermethrin	NN	_	23	nmod
26	was	be	VBD	_	27	auxpass
27	found	find	VBN	_	20	acl:relcl
28	to	to	TO	_	29	mark
29	produce	produce	VB	_	27	xcomp
30	significant	significant	JJ	_	32	amod
31	oxidative	oxidative	JJ	_	32	amod
32	stress	stress	NN	_	29	dobj
33	in	in	IN	_	37	case
34	cerebral	cerebral	JJ	_	37	amod
35	and	and	CC	_	34	cc
36	hepatic	hepatic	JJ	_	34	conj
37	tissues	tissue	NNS	_	29	nmod
38	of	of	IN	_	39	case
39	rats	rat	NNS	_	37	nmod
40	,	,	,	_	5	punct
41	as	as	RB	_	43	advmod
42	was	be	VBD	_	43	cop
43	evident	evident	JJ	_	0	ROOT
44	by	by	IN	_	46	case
45	the	the	DT	_	46	det
46	elevation	elevation	NN	_	43	nmod
47	of	of	IN	_	49	case
48	the	the	DT	_	49	det
49	level	level	NN	_	46	nmod
50	of	of	IN	_	54	case
51	thiobarbituric	thiobarbituric	JJ	_	54	amod
52	acid	acid	NN	_	54	compound
53	reactive	reactive	JJ	_	54	amod
54	substances	substance	NNS	_	49	nmod
55	(	(	VBP	_	43	dep
56	TBARS	tbar	NNS	_	55	dobj
57	)	)	CD	_	56	nummod
58	in	in	IN	_	60	case
59	both	both	CC	_	60	det
60	tissues	tissue	NNS	_	56	nmod
61	,	,	,	_	55	punct
62	either	either	CC	_	66	cc:preconj
63	4	4	CD	_	66	nummod
64	or	or	CC	_	63	cc
65	24	24	CD	_	63	conj
66	h	h	NN	_	55	dep
67	after	after	IN	_	68	case
68	treatment	treatment	NN	_	66	nmod
69	.	.	.	_	43	punct

1	Much	much	RB	_	2	advmod
2	higher	higher	JJR	_	3	amod
3	changes	change	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	liver	liver	NN	_	5	nmod
8	,	,	,	_	5	punct
9	increasing	increase	VBG	_	5	xcomp
10	from	from	IN	_	12	case
11	a	a	DT	_	12	det
12	level	level	NN	_	9	nmod
13	of	of	IN	_	15	case
14	60	60	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	at	at	IN	_	18	case
17	4	4	CD	_	18	nummod
18	h	h	NN	_	9	nmod
19	up	up	IN	_	23	advmod
20	to	to	TO	_	23	dep
21	nearly	nearly	RB	_	23	advmod
22	4	4	CD	_	23	compound
23	times	time	NNS	_	25	nummod
24	the	the	DT	_	25	det
25	control	control	NN	_	9	dobj
26	at	at	IN	_	28	case
27	24	24	CD	_	28	nummod
28	h	h	NN	_	25	nmod
29	for	for	IN	_	31	case
30	single	single	JJ	_	31	amod
31	dose	dose	NN	_	25	nmod
32	.	.	.	_	5	punct

1	Reduced	reduce	VBN	_	2	amod
2	levels	level	NNS	_	3	nsubj
3	(	(	VBP	_	0	ROOT
4	up	up	RP	_	6	dep
5	to	to	TO	_	4	mwe
6	20	20	CD	_	7	nummod
7	%	%	NN	_	3	dobj
8	)	)	CD	_	7	nummod
9	of	of	IN	_	15	case
10	total	total	JJ	_	15	amod
11	glutathione	glutathione	NN	_	15	compound
12	(	(	NN	_	15	compound
13	total	total	JJ	_	15	amod
14	GSH	gsh	NN	_	15	compound
15	)	)	NN	_	7	nmod
16	,	,	,	_	3	punct
17	and	and	CC	_	3	cc
18	elevation	elevation	NN	_	22	nsubj
19	of	of	IN	_	21	case
20	conjugated	conjugate	VBN	_	21	amod
21	dienes	diene	NNS	_	18	nmod
22	(	(	VBP	_	3	conj
23	approximately	approximately	RB	_	24	advmod
24	60	60	CD	_	25	nummod
25	%	%	NN	_	22	dobj
26	in	in	IN	_	27	case
27	liver	liver	NN	_	22	nmod
28	by	by	IN	_	30	case
29	single	single	JJ	_	30	amod
30	dose	dose	NN	_	22	nmod
31	at	at	IN	_	34	case
32	4	4	CD	_	34	nummod
33	h	h	NN	_	34	compound
34	)	)	NN	_	22	nmod
35	also	also	RB	_	36	advmod
36	indicated	indicate	VBD	_	22	dep
37	the	the	DT	_	38	det
38	presence	presence	NN	_	36	dobj
39	of	of	IN	_	42	case
40	an	a	DT	_	42	det
41	oxidative	oxidative	JJ	_	42	amod
42	insult	insult	NN	_	38	nmod
43	.	.	.	_	3	punct

1	Glutathione	glutathione	NN	_	15	nsubj
2	-	-	:	_	1	punct
3	S	s	NN	_	1	dep
4	-	-	:	_	1	punct
5	transferase	transferase	NN	_	9	compound
6	(	(	CD	_	9	nummod
7	GST	gst	NN	_	9	compound
8	)	)	NN	_	9	compound
9	activity	activity	NN	_	1	dep
10	,	,	,	_	1	punct
11	however	however	RB	_	15	advmod
12	,	,	,	_	15	punct
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	differ	differ	VB	_	0	ROOT
16	from	from	IN	_	18	case
17	control	control	NN	_	18	compound
18	values	value	NNS	_	15	nmod
19	for	for	IN	_	21	case
20	any	any	DT	_	21	det
21	dose	dose	NN	_	18	nmod
22	or	or	CC	_	21	cc
23	at	at	IN	_	26	case
24	any	any	DT	_	26	det
25	time	time	NN	_	26	compound
26	point	point	NN	_	21	conj
27	in	in	IN	_	31	case
28	cerebral	cerebral	JJ	_	31	amod
29	and	and	CC	_	28	cc
30	hepatic	hepatic	JJ	_	28	conj
31	tissues	tissue	NNS	_	26	nmod
32	.	.	.	_	15	punct

1	Pretreatment	pretreatment	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	rats	rat	NNS	_	1	nmod
4	with	with	IN	_	8	case
5	allopurinol	allopurinol	NN	_	8	compound
6	(	(	NN	_	8	compound
7	100	100	CD	_	8	nummod
8	mg	mg	NN	_	1	nmod
9	/	/	:	_	8	punct
10	kg	kg	NN	_	8	dep
11	,	,	,	_	8	punct
12	ip	ip	NN	_	13	compound
13	)	)	NN	_	8	conj
14	or	or	CC	_	8	cc
15	Vitamin	vitamin	NN	_	16	compound
16	E	e	NN	_	8	conj
17	(	(	CD	_	18	compound
18	100	100	CD	_	16	nummod
19	mg	mg	NN	_	16	dep
20	/	/	:	_	1	punct
21	kg	kg	NN	_	1	dep
22	per	per	IN	_	23	case
23	day	day	NN	_	21	nmod
24	,	,	,	_	23	punct
25	ig	ig	NN	_	23	appos
26	,	,	,	_	23	punct
27	for	for	IN	_	29	case
28	3	3	CD	_	29	nummod
29	days	day	NNS	_	21	nmod
30	and	and	CC	_	29	cc
31	a	a	DT	_	32	det
32	dose	dose	NN	_	29	conj
33	of	of	IN	_	35	case
34	40	40	CD	_	35	nummod
35	mg	mg	NN	_	32	nmod
36	/	/	:	_	37	punct
37	kg	kg	NN	_	43	nsubj
38	on	on	IN	_	41	case
39	the	the	DT	_	41	det
40	4th	4th	JJ	_	41	amod
41	day	day	NN	_	37	nmod
42	)	)	CD	_	41	nummod
43	provided	provide	VBD	_	21	acl:relcl
44	significant	significant	JJ	_	45	amod
45	protection	protection	NN	_	43	dobj
46	against	against	IN	_	48	case
47	the	the	DT	_	48	det
48	elevation	elevation	NN	_	45	nmod
49	of	of	IN	_	51	case
50	TBARS	tbar	NNS	_	51	compound
51	levels	level	NNS	_	48	nmod
52	in	in	IN	_	56	case
53	cerebral	cerebral	JJ	_	56	amod
54	and	and	CC	_	53	cc
55	hepatic	hepatic	JJ	_	53	conj
56	tissues	tissue	NNS	_	45	nmod
57	,	,	,	_	43	punct
58	induced	induce	VBN	_	43	advcl
59	by	by	IN	_	62	case
60	single	single	JJ	_	62	amod
61	high	high	JJ	_	62	amod
62	dose	dose	NN	_	58	nmod
63	of	of	IN	_	66	case
64	oral	oral	JJ	_	66	amod
65	cypermethrin	cypermethrin	NN	_	66	compound
66	administration	administration	NN	_	62	nmod
67	within	within	IN	_	69	case
68	4	4	CD	_	69	nummod
69	h	h	NN	_	58	nmod
70	.	.	.	_	1	punct

1	Thus	thus	RB	_	5	advmod
2	,	,	,	_	5	punct
3	the	the	DT	_	4	det
4	results	result	NNS	_	5	nsubj
5	suggest	suggest	VBP	_	0	ROOT
6	that	that	IN	_	11	mark
7	cypermethrin	cypermethrin	NN	_	8	compound
8	exposure	exposure	NN	_	11	nsubj
9	of	of	IN	_	10	case
10	rats	rat	NNS	_	8	nmod
11	results	result	VBZ	_	5	ccomp
12	in	in	IN	_	14	case
13	free	free	JJ	_	14	amod
14	radical	radical	NN	_	11	nmod
15	-	-	:	_	14	punct
16	mediated	mediate	VBN	_	18	amod
17	tissue	tissue	NN	_	18	compound
18	damage	damage	NN	_	14	dep
19	,	,	,	_	14	punct
20	as	as	IN	_	21	mark
21	indicated	indicate	VBN	_	14	dep
22	by	by	IN	_	24	case
23	elevated	elevated	JJ	_	24	amod
24	cerebral	cerebral	JJ	_	21	nmod
25	and	and	CC	_	24	cc
26	hepatic	hepatic	JJ	_	28	amod
27	lipid	lipid	NN	_	28	compound
28	peroxidation	peroxidation	NN	_	24	conj
29	,	,	,	_	24	punct
30	which	which	WDT	_	32	nsubjpass
31	was	be	VBD	_	32	auxpass
32	prevented	prevent	VBN	_	24	acl:relcl
33	by	by	IN	_	34	case
34	allopurinol	allopurinol	NN	_	32	nmod
35	and	and	CC	_	34	cc
36	Vitamin	vitamin	NN	_	37	compound
37	E	e	NN	_	34	conj
38	.	.	.	_	5	punct

1	Serum	serum	NN	_	3	compound
2	digoxin	digoxin	NN	_	3	compound
3	levels	level	NNS	_	0	ROOT
4	using	use	VBG	_	3	acl
5	an	a	DT	_	9	det
6	125I	125i	NN	_	9	compound
7	-	-	:	_	9	punct
8	labelled	label	VBN	_	9	amod
9	antigen	antigen	NN	_	4	dobj
10	:	:	:	_	3	punct
11	Validation	validation	NN	_	3	dep
12	of	of	IN	_	13	case
13	method	method	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	observations	observation	NNS	_	13	conj
16	on	on	IN	_	18	case
17	cardiac	cardiac	JJ	_	18	amod
18	patients	patient	NNS	_	11	nmod
19	.	.	.	_	3	punct

1	1	1	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Determinations	determination	NNS	_	0	ROOT
2	of	of	IN	_	5	case
3	serum	serum	NN	_	5	compound
4	digoxin	digoxin	NN	_	5	compound
5	levels	level	NNS	_	1	nmod
6	utilizing	utilize	VBG	_	1	acl
7	commercially	commercially	RB	_	8	advmod
8	available	available	JJ	_	9	amod
9	kits	kit	NNS	_	6	dobj
10	with	with	IN	_	12	case
11	an	a	DT	_	12	det
12	125I	125i	NN	_	9	nmod
13	-	-	:	_	1	punct
14	labelled	label	VBN	_	15	amod
15	antigen	antigen	NN	_	17	nsubj
16	were	be	VBD	_	17	cop
17	precise	precise	JJ	_	1	dep
18	and	and	CC	_	17	cc
19	not	not	RB	_	21	neg
20	materially	materially	RB	_	21	advmod
21	different	different	JJ	_	17	conj
22	from	from	IN	_	23	case
23	results	result	NNS	_	17	nmod
24	obtained	obtain	VBN	_	23	acl
25	with	with	IN	_	30	case
26	a	a	DT	_	30	det
27	3H	3h	NN	_	30	compound
28	-	-	:	_	30	punct
29	labelled	label	VBN	_	30	amod
30	antigen	antigen	NN	_	24	nmod
31	.	.	.	_	1	punct

1	2	2	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	dep
4	approximate	approximate	JJ	_	15	advcl
5	the	the	DT	_	8	det
6	steady	steady	JJ	_	8	amod
7	state	state	NN	_	8	compound
8	level	level	NN	_	4	dobj
9	,	,	,	_	15	punct
10	serum	serum	NN	_	12	compound
11	digoxin	digoxin	NN	_	12	compound
12	levels	level	NNS	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	drawn	draw	VBN	_	0	ROOT
16	either	either	CC	_	22	cc:preconj
17	before	before	IN	_	22	case
18	or	or	CC	_	22	cc
19	at	at	IN	_	20	case
20	least	least	JJS	_	21	nmod:npmod
21	six	six	CD	_	22	nummod
22	hours	hour	NNS	_	15	nmod
23	following	follow	VBG	_	25	case
24	the	the	DT	_	25	det
25	administration	administration	NN	_	22	nmod
26	of	of	IN	_	29	case
27	an	a	DT	_	29	det
28	oral	oral	JJ	_	29	amod
29	tablet	tablet	NN	_	25	nmod
30	.	.	.	_	15	punct

1	3	3	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Concomitantly	concomitantly	RB	_	2	advmod
2	given	give	VBN	_	4	amod
3	thiazide	thiazide	JJ	_	4	amod
4	diuretics	diuretic	NNS	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	interfere	interfere	VB	_	0	ROOT
8	with	with	IN	_	10	case
9	the	the	DT	_	10	det
10	absorption	absorption	NN	_	7	nmod
11	of	of	IN	_	13	case
12	a	a	DT	_	13	det
13	tablet	tablet	NN	_	10	nmod
14	of	of	IN	_	15	case
15	digoxin	digoxin	NN	_	13	nmod
16	.	.	.	_	7	punct

1	4	4	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	digitalized	digitalized	JJ	_	4	amod
4	patient	patient	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	slow	slow	JJ	_	7	amod
7	alterations	alteration	NNS	_	5	root
8	in	in	IN	_	10	case
9	serum	serum	NN	_	10	compound
10	levels	level	NNS	_	7	nmod
11	after	after	IN	_	14	mark
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	14	nsubj
14	appeared	appear	VBD	_	7	acl
15	well	well	RB	_	16	advmod
16	correlated	correlate	VBN	_	14	xcomp
17	with	with	IN	_	16	nmod
18	,	,	,	_	16	punct
19	at	at	IN	_	16	advmod
20	least	least	JJS	_	19	mwe
21	,	,	,	_	16	punct
22	the	the	DT	_	25	det
23	negative	negative	JJ	_	25	amod
24	chronotropic	chronotropic	JJ	_	25	amod
25	effects	effect	NNS	_	16	dobj
26	of	of	IN	_	28	case
27	the	the	DT	_	28	det
28	drug	drug	NN	_	25	nmod
29	.	.	.	_	7	punct

1	5	5	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Maximal	maximal	JJ	_	3	amod
2	exercise	exercise	NN	_	3	compound
3	testing	testing	NN	_	16	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	6	det
6	maneuver	maneuver	NN	_	8	nsubj
7	often	often	RB	_	8	advmod
8	applied	apply	VBD	_	3	acl:relcl
9	to	to	TO	_	11	case
10	cardiac	cardiac	JJ	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	,	,	,	_	3	punct
13	does	do	VBZ	_	16	aux
14	not	not	RB	_	16	neg
15	significantly	significantly	RB	_	16	advmod
16	alter	alter	VB	_	0	ROOT
17	the	the	DT	_	20	det
18	serum	serum	NN	_	20	compound
19	digoxin	digoxin	NN	_	20	compound
20	level	level	NN	_	16	dobj
21	.	.	.	_	16	punct

1	Analysis	analysis	NN	_	0	ROOT
2	of	of	IN	_	6	case
3	16,16	16,16	CD	_	6	nummod
4	-	-	:	_	6	punct
5	dimethylprostaglandin	dimethylprostaglandin	NN	_	6	compound
6	E2	e2	NN	_	1	nmod
7	-	-	:	_	6	punct
8	induced	induce	VBN	_	9	amod
9	diarrhea	diarrhea	NN	_	6	dep
10	in	in	IN	_	12	case
11	cecectomized	cecectomized	JJ	_	12	amod
12	rats	rat	NNS	_	9	nmod
13	.	.	.	_	1	punct

1	The	the	DT	_	7	det
2	16,16	16,16	CD	_	7	nummod
3	-	-	:	_	7	punct
4	dimethylprostaglandin	dimethylprostaglandin	NN	_	7	compound
5	E2	e2	NN	_	7	compound
6	(	(	CD	_	7	nummod
7	dmPGE2	dmpge2	NN	_	0	ROOT
8	)	)	SYM	_	13	dep
9	-	-	:	_	13	punct
10	induced	induce	VBN	_	11	amod
11	diarrhea	diarrhea	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	analyzed	analyze	VBN	_	7	acl
14	in	in	IN	_	16	case
15	cecectomized	cecectomized	JJ	_	16	amod
16	rats	rat	NNS	_	13	nmod
17	prepared	prepare	VBN	_	16	acl
18	by	by	IN	_	19	mark
19	resecting	resect	VBG	_	17	advcl
20	the	the	DT	_	21	det
21	cecum	cecum	NN	_	19	dobj
22	and	and	CC	_	21	cc
23	its	its	PRP$	_	24	nmod:poss
24	vasculature	vasculature	NN	_	21	conj
25	without	without	IN	_	26	mark
26	disturbing	disturb	VBG	_	19	advcl
27	the	the	DT	_	29	det
28	ileocecal	ileocecal	JJ	_	29	amod
29	junction	junction	NN	_	26	dobj
30	.	.	.	_	7	punct

1	dmPGE2	dmpge2	NN	_	12	dep
2	(	(	CD	_	3	compound
3	0.1	0.1	CD	_	1	nummod
4	-	-	:	_	1	punct
5	1.0	1.0	CD	_	6	nummod
6	mg	mg	NN	_	1	dep
7	/	/	:	_	6	punct
8	kg	kg	NN	_	6	dep
9	,	,	,	_	1	punct
10	p	p	NN	_	12	compound
11	.	.	.	_	12	punct
12	o	o	NN	_	0	ROOT
13	.	.	.	_	12	punct
14	)	)	SYM	_	12	dep

1	dose	dose	NN	_	4	nsubj
2	-	-	:	_	1	punct
3	dependently	dependently	RB	_	4	advmod
4	increased	increase	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	number	number	NN	_	4	dobj
7	of	of	IN	_	9	case
8	defecation	defecation	NN	_	9	compound
9	episodes	episode	NNS	_	6	nmod
10	and	and	CC	_	4	cc
11	induced	induce	VBD	_	4	conj
12	a	a	DT	_	16	det
13	soft	soft	JJ	_	16	amod
14	and	and	CC	_	13	cc
15	watery	watery	JJ	_	13	conj
16	stool	stool	NN	_	11	dobj
17	in	in	IN	_	19	case
18	cecectomized	cecectomized	JJ	_	19	amod
19	rats	rat	NNS	_	11	nmod
20	.	.	.	_	4	punct

1	At	at	IN	_	3	case
2	0.3	0.3	CD	_	3	nummod
3	mg	mg	NN	_	16	nmod
4	/	/	:	_	5	punct
5	kg	kg	NN	_	3	dep
6	,	,	,	_	5	punct
7	the	the	DT	_	8	det
8	diarrhea	diarrhea	NN	_	5	appos
9	-	-	:	_	5	punct
10	inducing	induce	VBG	_	3	acl
11	effects	effect	NNS	_	10	dobj
12	of	of	IN	_	13	case
13	dmPGE2	dmpge2	NN	_	11	nmod
14	were	be	VBD	_	16	cop
15	more	more	RBR	_	16	advmod
16	pronounced	pronounced	JJ	_	0	ROOT
17	in	in	IN	_	18	case
18	cecectomized	cecectomize	VBN	_	16	nmod
19	than	than	IN	_	22	case
20	in	in	IN	_	22	case
21	control	control	NN	_	22	compound
22	rats	rat	NNS	_	16	nmod
23	.	.	.	_	16	punct

1	When	when	WRB	_	2	advmod
2	given	give	VBN	_	0	ROOT
3	i	i	LS	_	2	dobj
4	.	.	.	_	3	punct
5	p	p	NN	_	3	dep
6	.	.	.	_	5	punct
7	,	,	,	_	5	punct
8	dmPGE2	dmpge2	NN	_	11	compound
9	(	(	CD	_	10	compound
10	0.3	0.3	CD	_	11	nummod
11	mg	mg	NN	_	5	appos
12	/	/	:	_	14	punct
13	kg	kg	NN	_	14	compound
14	)	)	NN	_	15	nsubj
15	induced	induce	VBD	_	11	acl:relcl
16	a	a	DT	_	18	det
17	watery	watery	JJ	_	18	amod
18	stool	stool	NN	_	15	dobj
19	in	in	IN	_	23	case
20	cecectomized	cecectomize	VBN	_	23	amod
21	and	and	CC	_	20	cc
22	control	control	JJ	_	20	conj
23	rats	rat	NNS	_	15	nmod
24	with	with	IN	_	27	case
25	the	the	DT	_	27	det
26	same	same	JJ	_	27	amod
27	efficacy	efficacy	NN	_	23	nmod
28	,	,	,	_	5	punct
29	although	although	IN	_	33	mark
30	these	these	DT	_	31	det
31	effects	effect	NNS	_	33	nsubj
32	were	be	VBD	_	33	cop
33	short	short	JJ	_	5	dep
34	-	-	:	_	33	punct
35	lasting	last	VBG	_	33	dep
36	as	as	IN	_	37	mark
37	compared	compare	VBN	_	35	advcl
38	to	to	TO	_	40	case
39	oral	oral	JJ	_	40	amod
40	administration	administration	NN	_	37	nmod
41	.	.	.	_	2	punct

1	Castor	Castor	NNP	_	5	compound
2	oil	oil	NN	_	5	compound
3	(	(	NN	_	5	compound
4	4	4	CD	_	5	nummod
5	ml	ml	NN	_	0	ROOT
6	/	/	:	_	5	punct
7	kg	kg	NN	_	5	dep
8	,	,	,	_	7	punct
9	p	p	NN	_	11	compound
10	.	.	.	_	11	punct
11	o	o	NN	_	7	appos
12	.	.	.	_	5	punct
13	)	)	SYM	_	5	dep

1	also	also	RB	_	2	advmod
2	induced	induce	VBN	_	0	ROOT
3	diarrhea	diarrhea	NN	_	2	dobj
4	,	,	,	_	2	punct
5	but	but	CC	_	2	cc
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	produce	produce	VB	_	2	conj
9	a	a	DT	_	11	det
10	watery	watery	JJ	_	11	amod
11	stool	stool	NN	_	8	dobj
12	in	in	IN	_	14	case
13	cecectomized	cecectomized	JJ	_	14	amod
14	rats	rat	NNS	_	11	nmod
15	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	differences	difference	NNS	_	2	nsubj
5	between	between	IN	_	9	case
6	cecectomized	cecectomized	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	control	control	JJ	_	6	conj
9	rats	rat	NNS	_	4	nmod
10	in	in	IN	_	14	case
11	basal	basal	JJ	_	14	amod
12	small	small	JJ	_	14	amod
13	intestinal	intestinal	JJ	_	14	amod
14	transits	transit	NNS	_	9	nmod
15	or	or	CC	_	14	cc
16	in	in	IN	_	17	case
17	dmPGE2	dmpge2	NN	_	14	conj
18	(	(	CD	_	19	compound
19	0.3	0.3	CD	_	17	nummod
20	mg	mg	NN	_	17	dep
21	/	/	:	_	2	punct
22	kg	kg	NN	_	31	dep
23	,	,	,	_	22	punct
24	p	p	NN	_	26	compound
25	.	.	.	_	26	punct
26	o	o	NN	_	31	dep
27	.	.	.	_	26	punct
28	)	)	SYM	_	31	dep
29	-	-	:	_	31	punct
30	induced	induce	VBN	_	31	amod
31	enhancements	enhancement	NNS	_	2	parataxis
32	.	.	.	_	2	punct

1	Moreover	moreover	RB	_	15	advmod
2	,	,	,	_	15	punct
3	the	the	DT	_	12	det
4	basal	basal	JJ	_	12	amod
5	and	and	CC	_	4	cc
6	dmPGE2	dmpge2	NN	_	4	conj
7	-	-	:	_	4	punct
8	induced	induce	VBN	_	12	amod
9	jejunal	jejunal	JJ	_	12	amod
10	net	net	JJ	_	12	amod
11	fluid	fluid	NN	_	12	compound
12	transfers	transfer	NNS	_	15	nsubj
13	were	be	VBD	_	15	cop
14	the	the	DT	_	15	det
15	same	same	JJ	_	0	ROOT
16	in	in	IN	_	21	case
17	cecectomized	cecectomize	VBN	_	21	amod
18	and	and	CC	_	17	cc
19	in	in	IN	_	17	conj
20	control	control	NN	_	21	compound
21	rats	rat	NNS	_	15	nmod
22	.	.	.	_	15	punct

1	On	on	IN	_	4	case
2	the	the	DT	_	4	det
3	other	other	JJ	_	4	amod
4	hand	hand	NN	_	20	nmod
5	,	,	,	_	20	punct
6	the	the	DT	_	8	det
7	enhanced	enhance	VBN	_	8	amod
8	secretion	secretion	NN	_	20	nsubj
9	of	of	IN	_	11	case
10	colonic	colonic	JJ	_	11	amod
11	fluid	fluid	NN	_	8	nmod
12	by	by	IN	_	13	case
13	dmPGE2	dmpge2	NN	_	8	nmod
14	,	,	,	_	8	punct
15	given	give	VBN	_	8	acl
16	intraluminally	intraluminally	RB	_	15	advmod
17	,	,	,	_	8	punct
18	was	be	VBD	_	20	cop
19	only	only	RB	_	20	advmod
20	half	half	NN	_	0	ROOT
21	of	of	IN	_	22	case
22	that	that	DT	_	20	nmod
23	in	in	IN	_	25	case
24	control	control	NN	_	25	compound
25	rats	rat	NNS	_	22	nmod
26	,	,	,	_	20	punct
27	whereas	whereas	IN	_	20	dep
28	the	the	DT	_	30	det
29	colonic	colonic	JJ	_	30	amod
30	transit	transit	NN	_	41	nsubj
31	-	-	:	_	30	punct
32	enhancing	enhance	VBG	_	33	amod
33	effect	effect	NN	_	30	dep
34	of	of	IN	_	35	case
35	dmPGE2	dmpge2	NN	_	33	nmod
36	in	in	IN	_	38	case
37	cecectomized	cecectomized	JJ	_	38	amod
38	rats	rat	NNS	_	33	nmod
39	was	be	VBD	_	41	cop
40	more	more	RBR	_	41	advmod
41	pronounced	pronounced	JJ	_	20	parataxis
42	than	than	IN	_	45	case
43	in	in	IN	_	45	case
44	control	control	NN	_	45	compound
45	rats	rat	NNS	_	41	nmod
46	at	at	IN	_	47	case
47	15	15	CD	_	41	nmod
48	but	but	CC	_	47	cc
49	not	not	RB	_	52	neg
50	at	at	IN	_	52	case
51	30	30	CD	_	52	nummod
52	min	min	NN	_	47	conj
53	after	after	IN	_	55	case
54	its	its	PRP$	_	55	nmod:poss
55	administration	administration	NN	_	52	nmod
56	.	.	.	_	20	punct

1	The	the	DT	_	5	det
2	basal	basal	JJ	_	5	amod
3	colonic	colonic	JJ	_	5	amod
4	fluid	fluid	NN	_	5	compound
5	contents	contents	NNS	_	10	nsubj
6	and	and	CC	_	5	cc
7	transits	transit	NNS	_	5	conj
8	were	be	VBD	_	10	cop
9	the	the	DT	_	10	det
10	same	same	JJ	_	0	ROOT
11	in	in	IN	_	16	case
12	cecectomized	cecectomize	VBN	_	16	amod
13	and	and	CC	_	12	cc
14	in	in	IN	_	12	conj
15	control	control	NN	_	16	compound
16	rats	rat	NNS	_	10	nmod
17	.	.	.	_	10	punct

1	Loperamide	loperamide	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	morphine	morphine	NN	_	1	conj
4	(	(	CD	_	5	compound
5	0.1	0.1	CD	_	3	nummod
6	and	and	CC	_	1	cc
7	1.0	1.0	CD	_	8	nummod
8	mg	mg	NN	_	1	conj
9	/	/	:	_	1	punct
10	kg	kg	NN	_	12	compound
11	,	,	,	_	12	punct
12	s	s	NNS	_	1	dep
13	.	.	.	_	12	punct
14	c	c	LS	_	12	root
15	.	.	.	_	14	punct
16	)	)	SYM	_	14	dep

1	Loperamide	loperamide	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	morphine	morphine	NN	_	1	conj
4	(	(	CD	_	5	compound
5	0.1	0.1	CD	_	3	nummod
6	and	and	CC	_	1	cc
7	1.0	1.0	CD	_	8	nummod
8	mg	mg	NN	_	1	conj
9	/	/	:	_	1	punct
10	kg	kg	NN	_	12	compound
11	,	,	,	_	12	punct
12	s	s	NNS	_	1	dep
13	.	.	.	_	12	punct
14	c	c	LS	_	17	dep
15	.	.	.	_	14	punct
16	)	)	NN	_	17	nsubj
17	inhibited	inhibit	VBD	_	12	dep
18	the	the	DT	_	22	det
19	dmPGE2	dmpge2	NN	_	22	compound
20	(	(	NN	_	22	compound
21	0.3	0.3	CD	_	22	nummod
22	mg	mg	NN	_	17	dobj
23	/	/	:	_	22	punct
24	kg	kg	NN	_	22	dep
25	,	,	,	_	22	punct
26	p	p	NN	_	28	compound
27	.	.	.	_	28	punct
28	o	o	NN	_	22	appos
29	.	.	.	_	28	punct
30	)	)	SYM	_	33	dep
31	-	-	:	_	33	punct
32	induced	induce	VBN	_	33	amod
33	diarrhea	diarrhea	NN	_	28	dep
34	in	in	IN	_	36	case
35	cecectomized	cecectomized	JJ	_	36	amod
36	rats	rat	NNS	_	33	nmod
37	.	.	.	_	1	punct

1	N	n	NN	_	6	compound
2	-	-	:	_	6	punct
3	methyllevallorphan	methyllevallorphan	NN	_	6	compound
4	(	(	CD	_	5	compound
5	5	5	CD	_	6	nummod
6	mg	mg	NN	_	0	ROOT
7	/	/	:	_	6	punct
8	kg	kg	NN	_	10	compound
9	,	,	,	_	10	punct
10	s	s	NNS	_	6	dep
11	.	.	.	_	6	punct
12	c	c	LS	_	6	dep
13	.	.	.	_	12	punct
14	)	)	SYM	_	6	dep

1	N	n	NN	_	6	compound
2	-	-	:	_	6	punct
3	methyllevallorphan	methyllevallorphan	NN	_	6	compound
4	(	(	CD	_	5	compound
5	5	5	CD	_	6	nummod
6	mg	mg	NN	_	0	ROOT
7	/	/	:	_	6	punct
8	kg	kg	NN	_	10	compound
9	,	,	,	_	10	punct
10	s	s	NNS	_	6	dep
11	.	.	.	_	6	punct
12	c	c	LS	_	16	dep
13	.	.	.	_	12	punct
14	)	)	NN	_	16	nsubj
15	completely	completely	RB	_	16	advmod
16	antagonized	antagonize	VBD	_	6	dep
17	the	the	DT	_	19	det
18	inhibitory	inhibitory	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	of	of	IN	_	21	case
21	loperamide	loperamide	NN	_	19	nmod
22	and	and	CC	_	16	cc
23	partly	partly	RB	_	24	advmod
24	antagonized	antagonize	VBD	_	16	conj
25	the	the	DT	_	26	det
26	effect	effect	NN	_	24	dobj
27	of	of	IN	_	28	case
28	morphine	morphine	NN	_	26	nmod
29	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	oral	oral	JJ	_	6	amod
6	administration	administration	NN	_	9	nsubj
7	of	of	IN	_	8	case
8	dmPGE2	dmpge2	NN	_	6	nmod
9	induces	induce	VBZ	_	3	ccomp
10	a	a	DT	_	14	det
11	more	more	RBR	_	12	advmod
12	pronounced	pronounced	JJ	_	14	amod
13	secretory	secretory	JJ	_	14	amod
14	diarrhea	diarrhea	NN	_	9	dobj
15	in	in	IN	_	16	case
16	cecectomized	cecectomize	VBN	_	9	nmod
17	than	than	IN	_	20	case
18	in	in	IN	_	20	case
19	control	control	NN	_	20	compound
20	rats	rat	NNS	_	16	nmod
21	,	,	,	_	16	punct
22	probably	probably	RB	_	26	advmod
23	due	due	JJ	_	26	case
24	to	to	TO	_	23	mwe
25	the	the	DT	_	26	det
26	lack	lack	NN	_	16	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	reservoir	reservoir	NN	_	30	compound
30	function	function	NN	_	26	nmod
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	cecum	cecum	NN	_	30	nmod
34	in	in	IN	_	37	case
35	the	the	DT	_	37	det
36	operated	operate	VBN	_	37	amod
37	animals	animal	NNS	_	30	nmod
38	.	.	.	_	3	punct

1	This	this	DT	_	4	det
2	secretory	secretory	JJ	_	4	amod
3	diarrhea	diarrhea	NN	_	4	compound
4	model	model	NN	_	6	nsubj
5	is	be	VBZ	_	6	cop
6	suitable	suitable	JJ	_	0	ROOT
7	for	for	IN	_	8	mark
8	evaluating	evaluate	VBG	_	6	advcl
9	the	the	DT	_	11	det
10	antidiarrheal	antidiarrheal	JJ	_	11	amod
11	activity	activity	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	.	.	.	_	6	punct

1	Green	Green	NNP	_	3	compound
2	tea	tea	NN	_	3	compound
3	polyphenols	polyphenol	NNS	_	0	ROOT
4	as	as	IN	_	6	case
5	potent	potent	JJ	_	6	amod
6	enhancers	enhancer	NNS	_	3	nmod
7	of	of	IN	_	8	case
8	glucocorticoid	glucocorticoid	NN	_	6	nmod
9	-	-	:	_	3	punct
10	induced	induce	VBN	_	16	amod
11	mouse	mouse	NN	_	16	compound
12	mammary	mammary	JJ	_	16	amod
13	tumor	tumor	NN	_	16	compound
14	virus	virus	NN	_	16	compound
15	gene	gene	NN	_	16	compound
16	expression	expression	NN	_	3	dep
17	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	16	nsubjpass
3	of	of	IN	_	8	case
4	natural	natural	JJ	_	8	amod
5	and	and	CC	_	4	cc
6	synthetic	synthetic	JJ	_	4	conj
7	galloyl	galloyl	NN	_	8	compound
8	esters	ester	NNS	_	2	nmod
9	on	on	IN	_	10	case
10	glucocorticoid	glucocorticoid	NN	_	2	nmod
11	-	-	:	_	10	punct
12	induced	induce	VBN	_	14	amod
13	gene	gene	NN	_	14	compound
14	expression	expression	NN	_	10	dep
15	was	be	VBD	_	16	auxpass
16	evaluated	evaluate	VBN	_	0	ROOT
17	by	by	IN	_	18	mark
18	using	use	VBG	_	16	advcl
19	rat	rat	NN	_	22	compound
20	fibroblast	fibroblast	NN	_	22	compound
21	3Y1	3y1	NN	_	22	compound
22	cells	cell	NNS	_	18	dobj
23	stably	stably	RB	_	24	advmod
24	transfected	transfect	VBN	_	22	acl
25	with	with	IN	_	29	case
26	a	a	DT	_	29	det
27	luciferase	luciferase	NN	_	29	compound
28	reporter	reporter	NN	_	29	compound
29	gene	gene	NN	_	24	nmod
30	under	under	IN	_	33	case
31	the	the	DT	_	33	det
32	transcriptional	transcriptional	JJ	_	33	amod
33	regulation	regulation	NN	_	24	nmod
34	of	of	IN	_	40	case
35	the	the	DT	_	40	det
36	mouse	mouse	NN	_	40	compound
37	mammary	mammary	JJ	_	40	amod
38	tumor	tumor	NN	_	40	compound
39	virus	virus	NN	_	40	compound
40	promoter	promoter	NN	_	33	nmod
41	.	.	.	_	16	punct

1	The	the	DT	_	6	det
2	glucocorticoid	glucocorticoid	NN	_	6	compound
3	-	-	:	_	6	punct
4	induced	induce	VBN	_	6	amod
5	gene	gene	NN	_	6	compound
6	transcription	transcription	NN	_	9	nsubjpass
7	was	be	VBD	_	9	auxpass
8	strongly	strongly	RB	_	9	advmod
9	suppressed	suppress	VBN	_	0	ROOT
10	by	by	IN	_	13	case
11	synthetic	synthetic	JJ	_	13	amod
12	alkyl	alkyl	NN	_	13	compound
13	esters	ester	NNS	_	9	nmod
14	;	;	:	_	9	punct

1	n	n	NN	_	4	compound
2	-	-	:	_	4	punct
3	dodecyl	dodecyl	NN	_	4	compound
4	gallate	gallate	NN	_	5	nsubj
5	showed	show	VBD	_	0	ROOT
6	the	the	DT	_	13	det
7	most	most	RBS	_	8	advmod
8	potent	potent	JJ	_	13	amod
9	inhibition	inhibition	NN	_	13	compound
10	(	(	NN	_	13	compound
11	66	66	CD	_	12	compound
12	%	%	NN	_	13	amod
13	inhibition	inhibition	NN	_	5	dobj
14	at	at	IN	_	17	case
15	10	10	CD	_	16	compound
16	microM	microm	NN	_	17	amod
17	)	)	NN	_	13	nmod
18	,	,	,	_	17	punct
19	which	which	WDT	_	23	nsubj
20	was	be	VBD	_	23	cop
21	far	far	RB	_	23	advmod
22	more	more	RBR	_	23	advmod
23	potent	potent	JJ	_	17	acl:relcl
24	than	than	IN	_	25	case
25	that	that	DT	_	23	nmod
26	of	of	IN	_	29	case
27	crude	crude	JJ	_	29	amod
28	tannic	tannic	JJ	_	29	amod
29	acid	acid	NN	_	25	nmod
30	.	.	.	_	5	punct

1	n	n	NN	_	10	nsubj
2	-	-	:	_	1	punct
3	Octyl	octyl	NN	_	1	dep
4	and	and	CC	_	3	cc
5	n	n	NN	_	3	conj
6	-	-	:	_	1	punct
7	cetyl	cetyl	NN	_	8	compound
8	gallate	gallate	NN	_	1	dep
9	also	also	RB	_	10	advmod
10	showed	show	VBD	_	0	ROOT
11	good	good	JJ	_	12	amod
12	inhibition	inhibition	NN	_	10	dobj
13	,	,	,	_	10	punct
14	while	while	IN	_	21	mark
15	gallic	gallic	JJ	_	16	amod
16	acid	acid	NN	_	21	nsubj
17	itself	itself	PRP	_	16	nmod:npmod
18	was	be	VBD	_	21	cop
19	not	not	RB	_	21	neg
20	so	so	RB	_	21	advmod
21	active	active	JJ	_	10	advcl
22	,	,	,	_	10	punct
23	suggesting	suggest	VBG	_	10	advcl
24	that	that	IN	_	32	mark
25	the	the	DT	_	26	det
26	presence	presence	NN	_	32	nsubj
27	of	of	IN	_	30	case
28	hydrophobic	hydrophobic	JJ	_	30	amod
29	side	side	NN	_	30	compound
30	chain	chain	NN	_	26	nmod
31	is	be	VBZ	_	32	cop
32	important	important	JJ	_	23	ccomp
33	for	for	IN	_	36	case
34	the	the	DT	_	36	det
35	suppressive	suppressive	JJ	_	36	amod
36	effect	effect	NN	_	32	nmod
37	.	.	.	_	10	punct

1	On	on	IN	_	4	case
2	the	the	DT	_	4	det
3	other	other	JJ	_	4	amod
4	hand	hand	NN	_	28	nmod
5	,	,	,	_	28	punct
6	surprisingly	surprisingly	RB	_	28	advmod
7	,	,	,	_	28	punct
8	green	green	JJ	_	10	amod
9	tea	tea	NN	_	10	compound
10	gallocatechins	gallocatechin	NNS	_	28	nsubj
11	,	,	,	_	10	punct
12	(	(	SYM	_	16	dep
13	-	-	:	_	16	punct
14	)	)	SYM	_	16	dep
15	-	-	:	_	16	punct
16	epigallocatechin	epigallocatechin	NN	_	10	appos
17	-	-	:	_	16	punct
18	3	3	LS	_	22	dep
19	-	-	:	_	22	punct
20	O	o	SYM	_	22	dep
21	-	-	:	_	22	punct
22	gallate	gallate	NN	_	16	dep
23	and	and	CC	_	22	cc
24	theasinensin	theasinensin	NN	_	25	compound
25	A	a	NN	_	22	conj
26	,	,	,	_	10	punct
27	potently	potently	RB	_	28	advmod
28	enhanced	enhance	VBD	_	0	ROOT
29	the	the	DT	_	31	det
30	promoter	promoter	NN	_	31	compound
31	activity	activity	NN	_	28	dobj
32	(	(	CD	_	33	nummod
33	182	182	CD	_	31	dep
34	and	and	CC	_	33	cc
35	247	247	CD	_	36	compound
36	%	%	NN	_	33	conj
37	activity	activity	NN	_	33	dep
38	at	at	IN	_	40	case
39	1	1	CD	_	40	nummod
40	microM	microm	NN	_	33	nmod
41	,	,	,	_	33	punct
42	respectively	respectively	RB	_	43	advmod
43	)	)	CD	_	33	appos
44	.	.	.	_	28	punct

1	The	the	DT	_	2	det
2	regulation	regulation	NN	_	20	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	level	level	NN	_	2	nmod
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	glucocorticoid	glucocorticoid	NN	_	5	nmod
9	-	-	:	_	20	punct
10	induced	induce	VBN	_	12	amod
11	gene	gene	NN	_	12	compound
12	expression	expression	NN	_	20	nsubj
13	by	by	IN	_	16	case
14	the	the	DT	_	16	det
15	antioxidative	antioxidative	JJ	_	16	amod
16	gallates	gallate	NNS	_	12	nmod
17	is	be	VBZ	_	20	cop
18	of	of	IN	_	20	case
19	great	great	JJ	_	20	amod
20	interest	interest	NN	_	0	ROOT
21	from	from	IN	_	24	case
22	a	a	DT	_	24	det
23	therapeutic	therapeutic	JJ	_	24	amod
24	point	point	NN	_	20	nmod
25	of	of	IN	_	26	case
26	view	view	NN	_	24	nmod
27	.	.	.	_	20	punct

1	High	high	JJ	_	4	amod
2	-	-	:	_	4	punct
3	dose	dose	NN	_	4	compound
4	cisplatin	cisplatin	NN	_	0	ROOT
5	with	with	IN	_	8	case
6	sodium	sodium	NN	_	8	compound
7	thiosulfate	thiosulfate	NN	_	8	compound
8	protection	protection	NN	_	4	nmod
9	.	.	.	_	4	punct

1	Nephrotoxicity	nephrotoxicity	NN	_	3	nsubj
2	frequently	frequently	RB	_	3	advmod
3	limits	limit	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	dose	dose	NN	_	3	dobj
6	of	of	IN	_	7	case
7	cisplatin	cisplatin	NN	_	5	nmod
8	to	to	TO	_	12	case
9	less	less	JJR	_	11	advmod
10	than	than	IN	_	9	mwe
11	120	120	CD	_	12	nummod
12	mg	mg	NN	_	3	nmod
13	/	/	:	_	12	punct
14	m2	m2	NN	_	12	dep
15	per	per	IN	_	16	case
16	injection	injection	NN	_	14	nmod
17	.	.	.	_	3	punct

1	Sodium	sodium	NN	_	2	compound
2	thiosulfate	thiosulfate	NN	_	6	nsubj
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	neutralizing	neutralize	VBG	_	6	amod
6	agent	agent	NN	_	0	ROOT
7	for	for	IN	_	8	case
8	cisplatin	cisplatin	NN	_	6	nmod
9	that	that	WDT	_	10	nsubj
10	protects	protect	VBZ	_	8	acl:relcl
11	against	against	IN	_	13	case
12	renal	renal	JJ	_	13	amod
13	damage	damage	NN	_	10	nmod
14	.	.	.	_	6	punct

1	To	to	TO	_	2	mark
2	determine	determine	VB	_	28	advcl
3	whether	whether	IN	_	8	mark
4	injection	injection	NN	_	8	nsubj
5	of	of	IN	_	6	case
6	thiosulfate	thiosulfate	NN	_	4	nmod
7	would	would	MD	_	8	aux
8	permit	permit	VB	_	2	ccomp
9	larger	larger	JJR	_	10	amod
10	doses	dose	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	cisplatin	cisplatin	NN	_	10	nmod
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	administered	administer	VBN	_	8	xcomp
16	,	,	,	_	28	punct
17	a	a	DT	_	21	det
18	fixed	fixed	JJ	_	21	amod
19	9.9	9.9	CD	_	21	nummod
20	-	-	:	_	21	punct
21	g	g	NN	_	28	nsubjpass
22	/	/	:	_	21	punct
23	m2	m2	NN	_	24	compound
24	dose	dose	NN	_	21	dep
25	of	of	IN	_	26	case
26	thiosulfate	thiosulfate	NN	_	24	nmod
27	was	be	VBD	_	28	auxpass
28	given	give	VBN	_	0	ROOT
29	intravenously	intravenously	RB	_	28	advmod
30	over	over	IN	_	32	case
31	three	three	CD	_	32	nummod
32	hours	hour	NNS	_	28	nmod
33	concurrently	concurrently	RB	_	32	advmod
34	with	with	IN	_	36	case
35	escalating	escalate	VBG	_	36	amod
36	doses	dose	NNS	_	28	nmod
37	of	of	IN	_	38	case
38	cisplatin	cisplatin	NN	_	36	nmod
39	.	.	.	_	28	punct

1	Cisplatin	Cisplatin	NNP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	0	ROOT
4	over	over	IN	_	8	case
5	the	the	DT	_	8	det
6	last	last	JJ	_	8	amod
7	two	two	CD	_	8	nummod
8	hours	hour	NNS	_	3	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	thiosulfate	thiosulfate	NN	_	12	compound
12	infusion	infusion	NN	_	8	nmod
13	.	.	.	_	3	punct

1	Using	use	VBG	_	7	advcl
2	this	this	DT	_	3	det
3	technique	technique	NN	_	1	dobj
4	,	,	,	_	7	punct
5	it	it	PRP	_	7	nsubj
6	was	be	VBD	_	7	cop
7	possible	possible	JJ	_	0	ROOT
8	to	to	TO	_	9	mark
9	escalate	escalate	VB	_	7	xcomp
10	the	the	DT	_	12	det
11	cisplatin	cisplatin	NN	_	12	compound
12	dose	dose	NN	_	9	dobj
13	to	to	TO	_	15	case
14	225	225	CD	_	15	nummod
15	mg	mg	NN	_	9	nmod
16	/	/	:	_	15	punct
17	m2	m2	NN	_	15	dep
18	before	before	IN	_	19	case
19	dose	dose	NN	_	17	nmod
20	-	-	:	_	15	punct
21	limiting	limit	VBG	_	24	csubjpass
22	toxicities	toxicity	NNS	_	21	dobj
23	were	be	VBD	_	24	auxpass
24	encountered	encounter	VBN	_	15	dep
25	.	.	.	_	7	punct

1	Comparison	comparison	NN	_	27	dep
2	of	of	IN	_	4	case
3	cisplatin	cisplatin	NN	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	treated	treat	VBN	_	6	acl
8	with	with	IN	_	10	case
9	202.5	202.5	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	/	/	:	_	10	punct
12	m2	m2	NN	_	10	dep
13	plus	plus	CC	_	12	cc
14	thiosulfate	thiosulfate	NN	_	12	conj
15	to	to	TO	_	16	case
16	those	those	DT	_	10	nmod
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	treated	treat	VBN	_	18	acl
20	with	with	IN	_	22	case
21	100	100	CD	_	22	nummod
22	mg	mg	NN	_	19	nmod
23	/	/	:	_	24	punct
24	m2	m2	NN	_	27	nsubj
25	without	without	IN	_	26	case
26	thiosulfate	thiosulfate	NN	_	24	nmod
27	indicated	indicate	VBD	_	0	ROOT
28	that	that	IN	_	30	mark
29	there	there	EX	_	30	expl
30	were	be	VBD	_	27	ccomp
31	no	no	DT	_	32	neg
32	changes	change	NNS	_	30	nsubj
33	in	in	IN	_	39	case
34	the	the	DT	_	39	det
35	elimination	elimination	NN	_	37	nmod:npmod
36	rate	rate	NN	_	37	nmod:npmod
37	constant	constant	JJ	_	39	amod
38	,	,	,	_	37	punct
39	volume	volume	NN	_	32	nmod
40	of	of	IN	_	41	case
41	distribution	distribution	NN	_	39	nmod
42	,	,	,	_	39	punct
43	or	or	CC	_	39	cc
44	total	total	JJ	_	46	amod
45	body	body	NN	_	46	compound
46	clearance	clearance	NN	_	39	conj
47	of	of	IN	_	48	case
48	cisplatin	cisplatin	NN	_	46	nmod
49	.	.	.	_	27	punct

1	The	the	DT	_	4	det
2	total	total	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	exposure	exposure	NN	_	15	nsubj
5	for	for	IN	_	7	case
6	the	the	DT	_	7	det
7	plasma	plasma	NN	_	4	nmod
8	was	be	VBD	_	15	cop
9	approximately	approximately	RB	_	10	advmod
10	twofold	twofold	RB	_	15	advmod
11	at	at	IN	_	15	case
12	the	the	DT	_	15	det
13	higher	higher	JJR	_	15	amod
14	cisplatin	cisplatin	NN	_	15	compound
15	dose	dose	NN	_	0	ROOT
16	.	.	.	_	15	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	demonstrates	demonstrate	VBZ	_	0	ROOT
4	that	that	IN	_	9	mark
5	concurrent	concurrent	JJ	_	6	amod
6	administration	administration	NN	_	9	nsubj
7	of	of	IN	_	8	case
8	thiosulfate	thiosulfate	NN	_	6	nmod
9	permits	permit	VBZ	_	3	ccomp
10	at	at	IN	_	11	case
11	least	least	JJS	_	14	advmod
12	a	a	DT	_	14	det
13	twofold	twofold	JJ	_	14	amod
14	increase	increase	NN	_	9	dobj
15	in	in	IN	_	16	case
16	dose	dose	NN	_	14	nmod
17	and	and	CC	_	14	cc
18	total	total	JJ	_	19	amod
19	exposure	exposure	NN	_	14	conj
20	to	to	TO	_	21	case
21	cisplatin	cisplatin	NN	_	19	nmod
22	.	.	.	_	3	punct

1	Interaction	interaction	NN	_	0	ROOT
2	on	on	IN	_	5	case
3	the	the	DT	_	5	det
4	antinociceptive	antinociceptive	JJ	_	5	amod
5	effect	effect	NN	_	1	nmod
6	between	between	IN	_	7	case
7	neurotensin	neurotensin	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	enkephalins	enkephalin	NNS	_	7	conj
10	or	or	CC	_	9	cc
11	tuftsin	tuftsin	NN	_	9	conj
12	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	paper	paper	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	study	study	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	interaction	interaction	NN	_	8	dobj
11	between	between	IN	_	12	case
12	neurotensin	neurotensin	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	both	both	DT	_	15	cc:preconj
15	enkephalins	enkephalin	NNS	_	12	conj
16	or	or	CC	_	15	cc
17	its	its	PRP$	_	20	nmod:poss
18	synthetic	synthetic	JJ	_	20	amod
19	analogue	analogue	NN	_	20	compound
20	D	d	NN	_	15	conj
21	-	-	:	_	12	punct
22	Ala2	ala2	NN	_	24	compound
23	-	-	:	_	24	punct
24	metenkephalinamide	metenkephalinamide	NN	_	12	dep
25	,	,	,	_	24	punct
26	or	or	CC	_	24	cc
27	tuftsin	tuftsin	NN	_	24	conj
28	,	,	,	_	12	punct
29	on	on	IN	_	32	case
30	the	the	DT	_	32	det
31	antinonciceptive	antinonciceptive	JJ	_	32	amod
32	effect	effect	NN	_	10	nmod
33	of	of	IN	_	35	case
34	these	these	DT	_	35	det
35	peptides	peptide	NNS	_	32	nmod
36	in	in	IN	_	37	case
37	mice	mouse	NNS	_	32	nmod
38	after	after	IN	_	40	case
39	intracisternal	intracisternal	JJ	_	40	amod
40	injection	injection	NN	_	10	nmod
41	.	.	.	_	6	punct

1	Antinociception	antinociception	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	measured	measure	VBN	_	0	ROOT
4	by	by	IN	_	9	case
5	the	the	DT	_	9	det
6	hot	hot	JJ	_	9	amod
7	-	-	:	_	9	punct
8	plate	plate	NN	_	9	compound
9	method	method	NN	_	3	nmod
10	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	shown	show	VBN	_	0	ROOT
4	that	that	IN	_	6	mark
5	neurotensin	neurotensin	NN	_	6	nsubj
6	antagonized	antagonize	VBD	_	3	ccomp
7	evidently	evidently	RB	_	6	advmod
8	the	the	DT	_	10	det
9	antinociceptive	antinociceptive	JJ	_	10	amod
10	effect	effect	NN	_	6	dobj
11	of	of	IN	_	12	case
12	enkephalins	enkephalin	NNS	_	10	nmod
13	and	and	CC	_	12	cc
14	their	they	PRP$	_	15	nmod:poss
15	analogue	analogue	NN	_	12	conj
16	.	.	.	_	3	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	contrary	contrary	NN	_	9	nmod
4	,	,	,	_	9	punct
5	neurotensin	neurotensin	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	tuftsin	tuftsin	NN	_	5	conj
8	were	be	VBD	_	9	cop
9	agonists	agonist	NNS	_	0	ROOT
10	in	in	IN	_	11	case
11	induction	induction	NN	_	9	nmod
12	of	of	IN	_	13	case
13	analgesia	analgesia	NN	_	11	nmod
14	.	.	.	_	9	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	concluded	conclude	VBN	_	0	ROOT
4	that	that	IN	_	6	mark
5	neurotensin	neurotensin	NN	_	6	nsubj
6	modulates	modulate	VBZ	_	3	ccomp
7	in	in	IN	_	10	case
8	an	a	DT	_	10	det
9	opposite	opposite	JJ	_	10	amod
10	way	way	NN	_	6	nmod
11	the	the	DT	_	12	det
12	function	function	NN	_	10	dep
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	enkephalinergic	enkephalinergic	JJ	_	16	amod
16	neurons	neuron	NNS	_	12	nmod
17	and	and	CC	_	12	cc
18	the	the	DT	_	20	det
19	central	central	JJ	_	20	amod
20	action	action	NN	_	12	conj
21	of	of	IN	_	22	case
22	tuftsin	tuftsin	NN	_	20	nmod
23	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	emerging	emerge	VBG	_	3	amod
3	roles	role	NNS	_	0	ROOT
4	of	of	IN	_	10	case
5	non	non	JJ	_	10	amod
6	-	-	:	_	10	punct
7	nucleoside	nucleoside	NN	_	10	compound
8	reverse	reverse	JJ	_	10	amod
9	transcriptase	transcriptase	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	3	nmod
11	in	in	IN	_	13	case
12	antiretroviral	antiretroviral	JJ	_	13	amod
13	therapy	therapy	NN	_	3	nmod
14	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	availability	availability	NN	_	0	ROOT
3	of	of	IN	_	12	case
4	potent	potent	JJ	_	12	amod
5	non	non	JJ	_	12	amod
6	-	-	:	_	12	punct
7	nucleoside	nucleoside	NN	_	12	compound
8	reverse	reverse	JJ	_	12	amod
9	transcriptase	transcriptase	NN	_	12	compound
10	inhibitor	inhibitor	NN	_	12	compound
11	(	(	NN	_	12	compound
12	NNRTI	nnrti	NN	_	2	nmod
13	)	)	SYM	_	12	dep
14	-	-	:	_	12	punct
15	based	base	VBN	_	16	amod
16	regimens	regimen	NNS	_	12	dep
17	for	for	IN	_	19	case
18	antiretroviral	antiretroviral	JJ	_	19	amod
19	therapy	therapy	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	concerns	concern	NNS	_	19	conj
22	regarding	regard	VBG	_	21	acl
23	protease	protease	NN	_	26	compound
24	inhibitor	inhibitor	NN	_	26	compound
25	(	(	NN	_	26	compound
26	PI	pi	NN	_	22	dobj
27	)	)	SYM	_	26	dep
28	-	-	:	_	26	punct
29	related	related	JJ	_	31	amod
30	metabolic	metabolic	JJ	_	31	amod
31	disturbances	disturbance	NNS	_	33	nsubj
32	have	have	VBP	_	33	aux
33	led	lead	VBN	_	26	acl:relcl
34	to	to	TO	_	36	case
35	significant	significant	JJ	_	36	amod
36	shifts	shift	NNS	_	33	nmod
37	in	in	IN	_	39	case
38	treatment	treatment	NN	_	39	compound
39	practices	practice	NNS	_	36	nmod
40	in	in	IN	_	42	case
41	HIV	hiv	NN	_	42	compound
42	infection	infection	NN	_	39	nmod
43	.	.	.	_	2	punct

1	NNRTI	nnrti	SYM	_	6	dep
2	-	-	:	_	6	punct
3	based	base	VBN	_	4	amod
4	regimens	regimen	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	several	several	JJ	_	8	amod
8	advantages	advantage	NNS	_	6	dobj
9	over	over	IN	_	10	case
10	PI	pi	NN	_	8	nmod
11	-	-	:	_	8	punct
12	based	base	VBN	_	13	amod
13	therapy	therapy	NN	_	8	dep
14	for	for	IN	_	18	case
15	initial	initial	JJ	_	18	amod
16	or	or	CC	_	15	cc
17	prolonged	prolonged	JJ	_	15	conj
18	therapy	therapy	NN	_	13	nmod
19	,	,	,	_	13	punct
20	including	include	VBG	_	24	case
21	more	more	RBR	_	22	advmod
22	convenient	convenient	JJ	_	24	amod
23	administration	administration	NN	_	24	compound
24	regimens	regimen	NNS	_	13	nmod
25	,	,	,	_	24	punct
26	lower	lower	JJR	_	28	amod
27	tablet	tablet	NN	_	28	compound
28	volume	volume	NN	_	24	conj
29	,	,	,	_	24	punct
30	fewer	fewer	JJR	_	32	amod
31	drug	drug	NN	_	32	compound
32	interactions	interaction	NNS	_	24	conj
33	,	,	,	_	24	punct
34	and	and	CC	_	24	cc
35	central	central	JJ	_	38	amod
36	nervous	nervous	JJ	_	38	amod
37	system	system	NN	_	38	compound
38	penetration	penetration	NN	_	24	conj
39	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	8	nsubj
3	from	from	IN	_	6	case
4	prospective	prospective	JJ	_	6	amod
5	clinical	clinical	JJ	_	6	amod
6	trials	trial	NNS	_	2	nmod
7	currently	currently	RB	_	8	advmod
8	exist	exist	VBP	_	0	ROOT
9	comparing	compare	VBG	_	8	xcomp
10	the	the	DT	_	11	det
11	3	3	CD	_	9	dobj
12	approved	approve	VBD	_	8	dep
13	agents	agent	NNS	_	15	compound
14	(	(	CD	_	15	nummod
15	efavirenz	efavirenz	NN	_	12	dobj
16	,	,	,	_	15	punct
17	nevirapine	nevirapine	NN	_	15	conj
18	or	or	CC	_	15	cc
19	delavirdine	delavirdine	NN	_	20	compound
20	)	)	NN	_	15	conj
21	.	.	.	_	8	punct

1	Both	both	DT	_	2	cc:preconj
2	efavirenz	efavirenz	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	nevirapine	nevirapine	NN	_	2	conj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	compared	compare	VBN	_	0	ROOT
8	to	to	TO	_	10	case
9	triple	triple	JJ	_	10	amod
10	therapy	therapy	NN	_	7	nmod
11	with	with	IN	_	14	case
12	the	the	DT	_	14	det
13	PI	pi	NN	_	14	compound
14	indinavir	indinavir	NN	_	10	nmod
15	over	over	IN	_	17	case
16	48	48	CD	_	17	nummod
17	weeks	week	NNS	_	10	nmod
18	as	as	IN	_	20	case
19	initial	initial	JJ	_	20	amod
20	therapy	therapy	NN	_	7	nmod
21	,	,	,	_	20	punct
22	with	with	IN	_	24	case
23	similar	similar	JJ	_	24	amod
24	responses	response	NNS	_	20	nmod
25	being	be	VBG	_	26	auxpass
26	observed	observe	VBN	_	24	acl
27	with	with	IN	_	29	case
28	nevirapine	nevirapine	NN	_	29	compound
29	regimens	regimen	NNS	_	26	nmod
30	and	and	CC	_	29	cc
31	superiority	superiority	NN	_	29	conj
32	observed	observe	VBN	_	29	acl
33	with	with	IN	_	34	case
34	efavirenz	efavirenz	NN	_	32	nmod
35	.	.	.	_	7	punct

1	A	a	DT	_	6	det
2	smaller	smaller	JJR	_	6	amod
3	24	24	CD	_	6	nummod
4	-	-	:	_	6	punct
5	week	week	NN	_	6	compound
6	study	study	NN	_	8	nsubj
7	has	have	VBZ	_	8	aux
8	suggested	suggest	VBN	_	0	ROOT
9	nevirapine	nevirapine	NN	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	superior	superior	JJ	_	8	ccomp
13	to	to	TO	_	16	case
14	the	the	DT	_	16	det
15	PI	pi	NN	_	16	compound
16	nelfinavir	nelfinavir	NN	_	12	nmod
17	.	.	.	_	8	punct

1	Limited	limited	JJ	_	3	amod
2	comparative	comparative	JJ	_	3	amod
3	data	datum	NNS	_	0	ROOT
4	in	in	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	with	with	IN	_	9	case
7	high	high	JJ	_	9	amod
8	viral	viral	JJ	_	9	amod
9	loads	load	NNS	_	5	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	nevirapine	nevirapine	NN	_	10	nmod
13	-	-	:	_	12	punct
14	or	or	CC	_	12	cc
15	delavirdine	delavirdine	NN	_	12	conj
16	-	-	:	_	3	punct
17	based	base	VBN	_	18	amod
18	regimens	regimen	NNS	_	20	nsubj
19	currently	currently	RB	_	20	advmod
20	exist	exist	VBP	_	3	dep
21	.	.	.	_	3	punct

1	However	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	cohort	cohort	NN	_	4	compound
4	data	datum	NNS	_	12	nsubj
5	and	and	CC	_	4	cc
6	selected	select	VBN	_	8	amod
7	patient	patient	NN	_	8	compound
8	data	datum	NNS	_	4	conj
9	from	from	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	trials	trial	NNS	_	8	nmod
12	suggest	suggest	VBP	_	0	ROOT
13	comparable	comparable	JJ	_	14	amod
14	activity	activity	NN	_	12	dobj
15	to	to	TO	_	16	case
16	PI	pi	NN	_	14	nmod
17	-	-	:	_	14	punct
18	based	base	VBN	_	19	amod
19	regimens	regimen	NNS	_	14	dep
20	in	in	IN	_	22	case
21	these	these	DT	_	22	det
22	patients	patient	NNS	_	19	nmod
23	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	superiority	superiority	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	efavirenz	efavirenz	NN	_	2	nmod
5	over	over	IN	_	6	case
6	indinavir	indinavir	NN	_	2	nmod
7	-	-	:	_	2	punct
8	based	base	VBN	_	9	amod
9	regimens	regimen	NNS	_	12	nsubjpass
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	observed	observe	VBN	_	2	dep
13	in	in	IN	_	15	case
14	comparative	comparative	JJ	_	15	amod
15	data	datum	NNS	_	12	nmod
16	in	in	IN	_	18	case
17	a	a	DT	_	18	det
18	subset	subset	NN	_	15	nmod
19	of	of	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	with	with	IN	_	24	case
22	high	high	JJ	_	24	amod
23	viral	viral	JJ	_	24	amod
24	loads	load	NNS	_	20	nmod
25	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	treatment	treatment	NN	_	10	nmod
3	-	-	:	_	5	punct
4	experienced	experienced	JJ	_	5	amod
5	patients	patient	NNS	_	10	nsubj
6	,	,	,	_	5	punct
7	available	available	JJ	_	9	amod
8	uncontrolled	uncontrolled	JJ	_	9	amod
9	data	datum	NNS	_	5	appos
10	suggest	suggest	VBP	_	0	ROOT
11	these	these	DT	_	12	det
12	agents	agent	NNS	_	13	nsubj
13	contribute	contribute	VBP	_	10	ccomp
14	to	to	TO	_	16	case
15	regimen	regimen	NNS	_	16	compound
16	efficacy	efficacy	NN	_	13	nmod
17	in	in	IN	_	18	case
18	NNRTI	NNRTI	NNP	_	16	nmod
19	-	-	:	_	13	punct
20	na	na	TO	_	21	mark
21	ve	have	VB	_	13	xcomp
22	,	,	,	_	21	punct
23	treatment	treatment	NN	_	21	dobj
24	-	-	:	_	23	punct
25	experienced	experienced	JJ	_	26	amod
26	patients	patient	NNS	_	23	dep
27	.	.	.	_	10	punct

1	Efavirenz	Efavirenz	NNP	_	3	nsubj
2	has	have	VBZ	_	3	aux
3	demonstrated	demonstrate	VBN	_	0	ROOT
4	superiority	superiority	NN	_	3	dobj
5	over	over	IN	_	6	case
6	nelfinavir	nelfinavir	NN	_	4	nmod
7	in	in	IN	_	8	case
8	nucleoside	nucleoside	NN	_	4	nmod
9	-	-	:	_	4	punct
10	experienced	experienced	JJ	_	11	amod
11	patients	patient	NNS	_	4	dep
12	,	,	,	_	3	punct
13	although	although	IN	_	14	mark
14	combining	combine	VBG	_	19	csubj
15	these	these	DT	_	17	det
16	2	2	CD	_	17	nummod
17	agents	agent	NNS	_	14	dobj
18	may	may	MD	_	19	aux
19	represent	represent	VB	_	3	parataxis
20	the	the	DT	_	22	det
21	best	best	JJS	_	22	amod
22	approach	approach	NN	_	19	dobj
23	in	in	IN	_	25	case
24	these	these	DT	_	25	det
25	circumstances	circumstance	NNS	_	22	nmod
26	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	tolerability	tolerability	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	NNRTIs	nnrti	NNS	_	2	nmod
5	appears	appear	VBZ	_	0	ROOT
6	generally	generally	RB	_	7	advmod
7	good	good	JJ	_	5	xcomp
8	with	with	IN	_	11	mark
9	few	few	JJ	_	10	amod
10	individuals	individual	NNS	_	11	nsubj
11	discontinuing	discontinue	VBG	_	7	advcl
12	in	in	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	studies	study	NNS	_	11	nmod
15	as	as	IN	_	17	case
16	a	a	DT	_	17	det
17	result	result	NN	_	11	nmod
18	of	of	IN	_	21	case
19	adverse	adverse	JJ	_	21	amod
20	drug	drug	NN	_	21	compound
21	events	event	NNS	_	17	nmod
22	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	majority	majority	NN	_	8	nsubj
3	of	of	IN	_	5	case
4	adverse	adverse	JJ	_	5	amod
5	events	event	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	NNRTIs	nnrti	NNS	_	5	nmod
8	occur	occur	VBP	_	0	ROOT
9	within	within	IN	_	12	case
10	the	the	DT	_	12	det
11	first	first	JJ	_	12	amod
12	month	month	NN	_	8	nmod
13	,	,	,	_	8	punct
14	and	and	CC	_	8	cc
15	are	be	VBP	_	16	cop
16	predictable	predictable	JJ	_	8	conj
17	and	and	CC	_	16	cc
18	manageable	manageable	JJ	_	16	conj
19	without	without	IN	_	21	case
20	therapy	therapy	NN	_	21	compound
21	interruption	interruption	NN	_	16	nmod
22	.	.	.	_	8	punct

1	Suppression	suppression	NN	_	0	ROOT
2	by	by	IN	_	3	case
3	verapamil	verapamil	NN	_	1	nmod
4	of	of	IN	_	5	case
5	bombesin	bombesin	NN	_	3	nmod
6	-	-	:	_	1	punct
7	enhanced	enhance	VBN	_	9	amod
8	peritoneal	peritoneal	JJ	_	9	amod
9	metastasis	metastasis	NN	_	1	dep
10	of	of	IN	_	12	case
11	intestinal	intestinal	JJ	_	12	amod
12	adenocarcinomas	adenocarcinoma	NNS	_	9	nmod
13	induced	induce	VBN	_	12	acl
14	by	by	IN	_	15	case
15	azoxymethane	azoxymethane	NN	_	13	nmod
16	in	in	IN	_	18	case
17	wistar	wistar	JJ	_	18	amod
18	rats	rat	NNS	_	13	nmod
19	.	.	.	_	1	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	45	nsubjpass
5	of	of	IN	_	7	case
6	combined	combined	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	bombesin	bombesin	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	verapamil	verapamil	NN	_	15	compound
12	hydrochloride	hydrochloride	NN	_	15	compound
13	(	(	CD	_	15	nummod
14	verapamil	verapamil	NN	_	15	compound
15	)	)	NN	_	9	conj
16	,	,	,	_	9	punct
17	a	a	DT	_	20	det
18	calcium	calcium	NN	_	20	compound
19	channel	channel	NN	_	20	compound
20	blocker	blocker	NN	_	9	appos
21	,	,	,	_	9	punct
22	on	on	IN	_	24	case
23	the	the	DT	_	24	det
24	incidence	incidence	NN	_	4	nmod
25	of	of	IN	_	27	case
26	peritoneal	peritoneal	JJ	_	27	amod
27	metastasis	metastasis	NN	_	24	nmod
28	of	of	IN	_	30	case
29	intestinal	intestinal	JJ	_	30	amod
30	adenocarcinomas	adenocarcinoma	NNS	_	27	nmod
31	induced	induce	VBN	_	30	acl
32	by	by	IN	_	35	case
33	azoxymethane	azoxymethane	NN	_	35	compound
34	(	(	CD	_	35	nummod
35	AOM	AOM	NNP	_	31	nmod
36	)	)	CD	_	35	nummod
37	and	and	CC	_	35	cc
38	the	the	DT	_	40	det
39	labeling	labeling	NN	_	40	compound
40	index	index	NN	_	35	conj
41	of	of	IN	_	43	case
42	intestinal	intestinal	JJ	_	43	amod
43	cancers	cancer	NNS	_	40	nmod
44	were	be	VBD	_	45	auxpass
45	investigated	investigate	VBN	_	1	appos
46	in	in	IN	_	49	case
47	male	male	JJ	_	49	amod
48	Wistar	Wistar	NNP	_	49	compound
49	rats	rat	NNS	_	45	nmod
50	.	.	.	_	1	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	From	from	IN	_	5	case
4	the	the	DT	_	5	det
5	beginning	beginning	NN	_	12	nmod
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	experiment	experiment	NN	_	5	nmod
9	,	,	,	_	12	punct
10	rats	rat	NNS	_	12	nsubjpass
11	were	be	VBD	_	12	auxpass
12	given	give	VBN	_	1	dep
13	10	10	CD	_	16	nummod
14	weekly	weekly	JJ	_	16	amod
15	subcutaneous	subcutaneous	JJ	_	16	amod
16	injections	injection	NNS	_	12	dobj
17	of	of	IN	_	18	case
18	AOM	AOM	NNP	_	16	nmod
19	(	(	CD	_	20	compound
20	7.4	7.4	CD	_	18	nummod
21	mg	mg	NN	_	18	dep
22	/	/	:	_	16	punct
23	kg	kg	NN	_	26	compound
24	body	body	NN	_	26	compound
25	weight	weight	NN	_	26	compound
26	)	)	NN	_	16	dep
27	and	and	CC	_	26	cc
28	subcutaneous	subcutaneous	JJ	_	29	amod
29	injections	injection	NNS	_	26	conj
30	of	of	IN	_	31	case
31	bombesin	bombesin	NN	_	29	nmod
32	(	(	CD	_	33	compound
33	40	40	CD	_	31	nummod
34	microg	microg	NN	_	31	dep
35	/	/	:	_	16	punct
36	kg	kg	NN	_	38	compound
37	body	body	NN	_	38	compound
38	weight	weight	NN	_	16	conj
39	)	)	CD	_	38	nummod
40	every	every	DT	_	42	det
41	other	other	JJ	_	42	amod
42	day	day	NN	_	38	nmod:tmod
43	,	,	,	_	16	punct
44	and	and	CC	_	16	cc
45	from	from	IN	_	46	case
46	week	week	NN	_	16	conj
47	16	16	CD	_	46	nummod
48	,	,	,	_	46	punct
49	intraperitoneal	intraperitoneal	JJ	_	50	amod
50	injections	injection	NNS	_	46	appos
51	of	of	IN	_	52	case
52	verapamil	verapamil	NN	_	50	nmod
53	(	(	CD	_	54	nummod
54	10	10	CD	_	57	nummod
55	or	or	CC	_	54	cc
56	20	20	CD	_	54	conj
57	mg	mg	NN	_	52	dep
58	/	/	:	_	46	punct
59	kg	kg	NN	_	61	compound
60	body	body	NN	_	61	compound
61	weight	weight	NN	_	46	dep
62	)	)	CD	_	61	nummod
63	every	every	DT	_	65	det
64	other	other	JJ	_	65	amod
65	day	day	NN	_	61	nmod:tmod
66	until	until	IN	_	68	case
67	the	the	DT	_	68	det
68	end	end	NN	_	61	nmod
69	fo	fo	NN	_	71	compound
70	the	the	DT	_	71	det
71	experiment	experiment	NN	_	68	dep
72	in	in	IN	_	73	case
73	week	week	NN	_	71	nmod
74	45	45	CD	_	73	nummod
75	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Bombesin	bombesin	NN	_	5	nsubj
4	significantly	significantly	RB	_	5	advmod
5	increased	increase	VBD	_	1	dep
6	the	the	DT	_	7	det
7	incidence	incidence	NN	_	5	dobj
8	of	of	IN	_	10	case
9	intestinal	intestinal	JJ	_	10	amod
10	tumors	tumor	NNS	_	7	nmod
11	and	and	CC	_	10	cc
12	cancer	cancer	NN	_	13	compound
13	metastasis	metastasis	NN	_	10	conj
14	to	to	TO	_	16	case
15	the	the	DT	_	16	det
16	peritoneum	peritoneum	NN	_	5	nmod
17	.	.	.	_	1	punct

1	Although	although	IN	_	3	mark
2	verapamil	verapamil	NN	_	3	nsubj
3	administered	administer	VBN	_	0	ROOT
4	at	at	IN	_	6	case
5	either	either	CC	_	6	det
6	dose	dose	NN	_	3	nmod
7	had	have	VBD	_	3	dep
8	little	little	JJ	_	7	dobj
9	or	or	CC	_	8	cc
10	no	no	DT	_	8	conj
11	effect	effect	NN	_	8	dep
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	enhancement	enhancement	NN	_	7	nmod
15	of	of	IN	_	17	case
16	intestinal	intestinal	JJ	_	17	amod
17	carcinogenesis	carcinogenesis	NN	_	14	nmod
18	by	by	IN	_	19	case
19	bombesin	bombesin	NN	_	14	nmod
20	or	or	CC	_	19	cc
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	location	location	NN	_	19	conj
24	,	,	,	_	14	punct
25	histologic	histologic	JJ	_	26	amod
26	type	type	NN	_	14	conj
27	,	,	,	_	26	punct
28	depth	depth	NN	_	26	appos
29	of	of	IN	_	30	case
30	involvement	involvement	NN	_	28	nmod
31	,	,	,	_	26	punct
32	labeling	label	VBG	_	33	compound
33	index	index	NN	_	26	appos
34	,	,	,	_	26	punct
35	apoptotic	apoptotic	JJ	_	36	amod
36	index	index	NN	_	26	conj
37	or	or	CC	_	26	cc
38	tumor	tumor	NN	_	39	compound
39	vascularity	vascularity	NN	_	26	conj
40	of	of	IN	_	42	case
41	intestinal	intestinal	JJ	_	42	amod
42	cancers	cancer	NNS	_	26	nmod
43	,	,	,	_	14	punct
44	it	it	PRP	_	46	nsubj
45	significantly	significantly	RB	_	46	advmod
46	decreased	decrease	VBD	_	14	acl:relcl
47	the	the	DT	_	48	det
48	incidence	incidence	NN	_	46	dobj
49	of	of	IN	_	51	case
50	cancer	cancer	NN	_	51	compound
51	metastasis	metastasis	NN	_	48	nmod
52	.	.	.	_	3	punct

1	Verapamil	Verapamil	NNP	_	4	nsubj
2	also	also	RB	_	4	advmod
3	significantly	significantly	RB	_	4	advmod
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	incidence	incidence	NN	_	4	dobj
7	of	of	IN	_	9	case
8	lymphatic	lymphatic	JJ	_	9	amod
9	invasion	invasion	NN	_	6	nmod
10	of	of	IN	_	11	case
11	adenocarcinomas	adenocarcinoma	NNS	_	9	nmod
12	,	,	,	_	9	punct
13	which	which	WDT	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	enhanced	enhance	VBN	_	9	acl:relcl
16	by	by	IN	_	17	case
17	bombesin	bombesin	NN	_	15	nmod
18	.	.	.	_	4	punct

1	CONCLUSION	conclusion	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	These	these	DT	_	4	det
4	findings	finding	NNS	_	5	nsubj
5	indicate	indicate	VBP	_	1	appos
6	that	that	IN	_	8	mark
7	verapamil	verapamil	NN	_	8	nsubj
8	inhibits	inhibit	VBZ	_	5	ccomp
9	cancer	cancer	NN	_	10	compound
10	metastasis	metastasis	NN	_	8	dobj
11	through	through	IN	_	12	case
12	actions	action	NNS	_	8	nmod
13	that	that	WDT	_	16	nsubj
14	do	do	VBP	_	16	aux
15	not	not	RB	_	16	neg
16	affect	affect	VB	_	12	acl:relcl
17	the	the	DT	_	18	det
18	growth	growth	NN	_	16	dobj
19	of	of	IN	_	21	case
20	intestinal	intestinal	JJ	_	21	amod
21	cancers	cancer	NNS	_	18	nmod
22	.	.	.	_	1	punct

1	[	[	NN	_	2	compound
2	Dose	dose	NN	_	51	nsubjpass
3	-	-	:	_	2	punct
4	time	time	NN	_	5	compound
5	effects	effect	NNS	_	2	dep
6	of	of	IN	_	8	case
7	competitive	competitive	JJ	_	8	amod
8	displacement	displacement	NN	_	5	nmod
9	of	of	IN	_	10	case
10	radiopertechnetate	radiopertechnetate	NN	_	8	nmod
11	by	by	IN	_	13	case
12	sodium	sodium	NN	_	13	compound
13	perchlorate	perchlorate	NN	_	5	nmod
14	following	follow	VBG	_	18	case
15	oral	oral	JJ	_	18	amod
16	and	and	CC	_	15	cc
17	intravenous	intravenous	JJ	_	15	conj
18	administration	administration	NN	_	5	nmod
19	]	]	CD	_	21	nummod
20	The	the	DT	_	21	det
21	effect	effect	NN	_	18	dep
22	of	of	IN	_	24	case
23	various	various	JJ	_	24	amod
24	doses	dose	NNS	_	21	nmod
25	of	of	IN	_	27	case
26	sodium	sodium	NN	_	27	compound
27	perchlorate	perchlorate	NN	_	24	nmod
28	in	in	IN	_	31	case
29	several	several	JJ	_	31	amod
30	dose	dose	NN	_	31	compound
31	fractions	fraction	NNS	_	21	nmod
32	on	on	IN	_	34	case
33	the	the	DT	_	34	det
34	extent	extent	NN	_	21	nmod
35	and	and	CC	_	21	cc
36	the	the	DT	_	38	det
37	time	time	NN	_	38	compound
38	scale	scale	NN	_	21	conj
39	of	of	IN	_	40	case
40	displacement	displacement	NN	_	38	nmod
41	of	of	IN	_	42	case
42	radiopertechnetate	radiopertechnetate	NN	_	40	nmod
43	,	,	,	_	2	punct
44	in	in	IN	_	45	case
45	dependence	dependence	NN	_	2	nmod
46	on	on	IN	_	48	case
47	application	application	NN	_	48	compound
48	mode	mode	NN	_	45	nmod
49	,	,	,	_	2	punct
50	was	be	VBD	_	51	auxpass
51	studied	study	VBN	_	0	ROOT
52	.	.	.	_	51	punct

1	An	a	DT	_	3	det
2	intravenous	intravenous	JJ	_	3	amod
3	dose	dose	NN	_	10	nsubj
4	of	of	IN	_	7	case
5	50	50	CD	_	7	nummod
6	mg	mg	NN	_	7	compound
7	perchlorate	perchlorate	NN	_	3	nmod
8	was	be	VBD	_	10	cop
9	in	in	IN	_	10	case
10	respect	respect	NN	_	0	ROOT
11	of	of	IN	_	13	case
12	competitive	competitive	JJ	_	13	amod
13	suppression	suppression	NN	_	10	nmod
14	of	of	IN	_	15	case
15	organs	organ	NNS	_	13	nmod
16	actively	actively	RB	_	17	advmod
17	concentrating	concentrate	VBG	_	10	acl
18	pertechnetate	pertechnetate	NN	_	17	dobj
19	as	as	IN	_	20	advmod
20	effective	effective	JJ	_	17	dep
21	as	as	IN	_	25	case
22	intravenous	intravenous	JJ	_	25	amod
23	1000	1000	CD	_	25	nummod
24	mg	mg	NN	_	25	compound
25	ClO	clo	NN	_	20	nmod
26	-	-	:	_	17	punct
27	4	4	LS	_	17	dep
28	-	-	:	_	27	punct
29	simultaneously	simultaneously	RB	_	32	advmod
30	or	or	CC	_	29	cc
31	1000	1000	CD	_	29	conj
32	mg	mg	NN	_	27	dep
33	orally	orally	RB	_	34	advmod
34	30	30	CD	_	35	nummod
35	min	min	NN	_	32	dep
36	before	before	IN	_	38	case
37	the	the	DT	_	38	det
38	injection	injection	NN	_	32	nmod
39	of	of	IN	_	40	case
40	radiopertechnetate	radiopertechnetate	NN	_	38	nmod
41	.	.	.	_	10	punct

1	An	a	DT	_	3	det
2	intravenous	intravenous	JJ	_	3	amod
3	injection	injection	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	perchlorate	perchlorate	NN	_	3	nmod
6	given	give	VBN	_	9	mark
7	later	later	RB	_	9	advmod
8	also	also	RB	_	9	advmod
9	produces	produce	VBZ	_	0	ROOT
10	a	a	DT	_	15	det
11	complete	complete	JJ	_	15	amod
12	and	and	CC	_	11	cc
13	immediately	immediately	RB	_	14	advmod
14	beginning	begin	VBG	_	11	conj
15	depletion	depletion	NN	_	9	dobj
16	of	of	IN	_	17	case
17	pertechnetate	pertechnetate	NN	_	15	nmod
18	already	already	RB	_	19	advmod
19	accumulated	accumulate	VBN	_	15	acl
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	thyroid	thyroid	NN	_	19	nmod
23	,	,	,	_	9	punct
24	within	within	IN	_	26	case
25	a	a	DT	_	26	det
26	period	period	NN	_	9	nmod
27	of	of	IN	_	29	case
28	195	195	CD	_	29	nummod
29	min	min	NN	_	26	nmod
30	after	after	IN	_	31	case
31	99m	99m	CD	_	26	nmod
32	-	-	:	_	26	punct
33	TcO	tco	SYM	_	35	dep
34	-	-	:	_	35	punct
35	4	4	LS	_	26	dep
36	-	-	:	_	35	punct
37	injection	injection	NN	_	35	dep
38	with	with	IN	_	41	case
39	a	a	DT	_	41	det
40	corresponding	corresponding	JJ	_	41	amod
41	increase	increase	NN	_	37	nmod
42	in	in	IN	_	44	case
43	blood	blood	NN	_	44	compound
44	levels	level	NNS	_	41	nmod
45	.	.	.	_	9	punct

1	20	20	CD	_	2	compound
2	mg	mg	NN	_	3	amod
3	result	result	NN	_	0	ROOT
4	in	in	IN	_	6	case
5	incomplete	incomplete	JJ	_	6	amod
6	depletion	depletion	NN	_	3	nmod
7	which	which	WDT	_	8	nsubj
8	becomes	become	VBZ	_	6	acl:relcl
9	complete	complete	JJ	_	8	xcomp
10	after	after	IN	_	14	case
11	a	a	DT	_	14	det
12	second	second	JJ	_	14	amod
13	additional	additional	JJ	_	14	amod
14	dose	dose	NN	_	8	nmod
15	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	intravenous	intravenous	JJ	_	3	amod
3	application	application	NN	_	6	nsubj
4	of	of	IN	_	5	case
5	perchlorate	perchlorate	NN	_	3	nmod
6	offers	offer	VBZ	_	0	ROOT
7	advantages	advantage	NNS	_	6	dobj
8	in	in	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	use	use	NN	_	6	nmod
11	.	.	.	_	6	punct

1	Combinations	combination	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	clozapine	clozapine	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	phencyclidine	phencyclidine	NN	_	3	conj
6	:	:	:	_	1	punct
7	effects	effect	NNS	_	1	dep
8	on	on	IN	_	10	case
9	drug	drug	NN	_	10	compound
10	discrimination	discrimination	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	behavioral	behavioral	JJ	_	13	amod
13	inhibition	inhibition	NN	_	10	conj
14	in	in	IN	_	15	case
15	rats	rat	NNS	_	10	nmod
16	.	.	.	_	1	punct

1	Phencyclidine	phencyclidine	NN	_	4	compound
2	(	(	CD	_	4	nummod
3	PCP	pcp	NN	_	4	compound
4	)	)	NN	_	5	nsubj
5	produces	produce	VBZ	_	0	ROOT
6	psychotomimetic	psychotomimetic	JJ	_	7	amod
7	effects	effect	NNS	_	5	dobj
8	in	in	IN	_	9	case
9	humans	human	NNS	_	5	nmod
10	that	that	WDT	_	11	nsubj
11	resemble	resemble	VBP	_	9	acl:relcl
12	schizophrenia	schizophrenia	NN	_	13	compound
13	symptoms	symptom	NNS	_	11	dobj
14	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	an	a	DT	_	3	det
3	effort	effort	NN	_	14	nmod
4	to	to	TO	_	5	mark
5	screen	screen	NN	_	3	acl
6	compounds	compound	NNS	_	5	dobj
7	for	for	IN	_	9	case
8	antipsychotic	antipsychotic	JJ	_	9	amod
9	activity	activity	NN	_	5	nmod
10	,	,	,	_	14	punct
11	preclinical	preclinical	JJ	_	12	amod
12	researchers	researcher	NNS	_	14	nsubj
13	have	have	VBP	_	14	aux
14	investigated	investigate	VBN	_	0	ROOT
15	whether	whether	IN	_	18	mark
16	these	these	DT	_	17	det
17	compounds	compound	NNS	_	18	nsubj
18	block	block	VBP	_	14	ccomp
19	PCP	pcp	NN	_	22	compound
20	-	-	:	_	22	punct
21	induced	induce	VBN	_	22	amod
22	behaviors	behavior	NNS	_	18	dobj
23	in	in	IN	_	24	case
24	animals	animal	NNS	_	22	nmod
25	.	.	.	_	14	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	11	nmod
5	,	,	,	_	11	punct
6	the	the	DT	_	9	det
7	atypical	atypical	JJ	_	9	amod
8	antipsychotic	antipsychotic	JJ	_	9	amod
9	clozapine	clozapine	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	tested	test	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	combination	combination	NN	_	11	nmod
14	with	with	IN	_	17	case
15	an	a	DT	_	17	det
16	active	active	JJ	_	17	amod
17	dose	dose	NN	_	13	nmod
18	of	of	IN	_	19	case
19	PCP	pcp	NN	_	17	nmod
20	in	in	IN	_	25	case
21	two	two	CD	_	25	nummod
22	-	-	:	_	25	punct
23	lever	lever	NN	_	25	compound
24	drug	drug	NN	_	25	compound
25	discrimination	discrimination	NN	_	17	nmod
26	and	and	CC	_	25	cc
27	mixed	mixed	JJ	_	33	amod
28	signalled	signal	VBN	_	33	amod
29	-	-	:	_	33	punct
30	unsignalled	unsignalled	JJ	_	33	amod
31	differential	differential	JJ	_	33	amod
32	-	-	:	_	33	punct
33	reinforcement	reinforcement	NN	_	25	conj
34	-	-	:	_	25	punct
35	of	of	IN	_	40	case
36	-	-	:	_	40	punct
37	low	low	JJ	_	40	dep
38	-	-	:	_	40	punct
39	rates	rate	NNS	_	40	nsubj
40	(	(	VBP	_	25	acl
41	DRL	drl	NN	_	43	compound
42	)	)	CD	_	43	nummod
43	procedures	procedure	NNS	_	40	dobj
44	.	.	.	_	11	punct

1	PCP	pcp	NN	_	2	nsubj
2	produced	produce	VBD	_	0	ROOT
3	distinctive	distinctive	JJ	_	4	amod
4	effects	effect	NNS	_	2	dobj
5	in	in	IN	_	7	case
6	each	each	DT	_	7	det
7	task	task	NN	_	2	nmod
8	:	:	:	_	2	punct
9	it	it	PRP	_	10	nsubj
10	substituted	substitute	VBD	_	2	parataxis
11	for	for	IN	_	14	case
12	the	the	DT	_	14	det
13	training	training	NN	_	14	compound
14	dose	dose	NN	_	10	nmod
15	in	in	IN	_	17	case
16	PCP	pcp	NN	_	17	compound
17	discrimination	discrimination	NN	_	10	nmod
18	and	and	CC	_	10	cc
19	it	it	PRP	_	20	nsubj
20	increased	increase	VBD	_	10	conj
21	the	the	DT	_	22	det
22	number	number	NN	_	20	dobj
23	of	of	IN	_	24	case
24	responses	response	NNS	_	22	nmod
25	with	with	IN	_	28	case
26	short	short	JJ	_	28	amod
27	(	(	NN	_	28	compound
28	&lt	&lt	NN	_	24	nmod
29	;	;	:	_	10	punct
30	3	3	CD	_	31	nummod
31	s	s	NNS	_	32	nsubj
32	)	)	VBP	_	10	parataxis
33	interresponse	interresponse	JJ	_	34	amod
34	times	time	NNS	_	32	dobj
35	as	as	RB	_	34	cc
36	well	well	RB	_	35	mwe
37	as	as	IN	_	35	mwe
38	increasing	increase	VBG	_	41	amod
39	overall	overall	JJ	_	41	amod
40	response	response	NN	_	41	compound
41	rates	rate	NNS	_	34	conj
42	in	in	IN	_	45	case
43	the	the	DT	_	45	det
44	DRL	DRL	NNP	_	45	compound
45	schedule	schedule	NN	_	32	nmod
46	.	.	.	_	2	punct

1	Acute	acute	JJ	_	2	amod
2	dosing	dosing	NN	_	5	nsubj
3	with	with	IN	_	4	case
4	clozapine	clozapine	NN	_	2	nmod
5	failed	fail	VBD	_	0	ROOT
6	to	to	TO	_	7	mark
7	alter	alter	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	behavioral	behavioral	JJ	_	10	amod
10	effects	effect	NNS	_	7	dobj
11	of	of	IN	_	12	case
12	PCP	pcp	NN	_	10	nmod
13	in	in	IN	_	15	case
14	either	either	CC	_	15	det
15	procedure	procedure	NN	_	10	nmod
16	even	even	RB	_	17	advmod
17	when	when	WRB	_	18	advmod
18	tested	test	VBN	_	7	advcl
19	up	up	IN	_	21	case
20	to	to	TO	_	21	case
21	doses	dose	NNS	_	18	nmod
22	that	that	WDT	_	23	nsubj
23	produced	produce	VBD	_	21	acl:relcl
24	pharmacological	pharmacological	JJ	_	25	amod
25	effects	effect	NNS	_	23	dobj
26	alone	alone	RB	_	23	advmod
27	.	.	.	_	5	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	acute	acute	JJ	_	6	amod
6	dosing	dosing	NN	_	11	nsubj
7	with	with	IN	_	8	case
8	clozapine	clozapine	NN	_	6	nmod
9	would	would	MD	_	11	aux
10	not	not	RB	_	11	neg
11	affect	affect	VB	_	3	ccomp
12	behaviors	behavior	NNS	_	11	dobj
13	most	most	RBS	_	14	advmod
14	closely	closely	RB	_	15	advmod
15	associated	associate	VBN	_	11	dep
16	with	with	IN	_	18	case
17	PCP	pcp	NN	_	18	compound
18	intoxication	intoxication	NN	_	15	nmod
19	.	.	.	_	3	punct

1	Further	further	RB	_	4	advmod
2	,	,	,	_	4	punct
3	they	they	PRP	_	4	nsubj
4	bring	bring	VBP	_	0	ROOT
5	into	into	IN	_	6	case
6	question	question	NN	_	4	nmod
7	the	the	DT	_	8	det
8	utility	utility	NN	_	4	dobj
9	of	of	IN	_	10	mark
10	using	use	VBG	_	8	acl
11	PCP	pcp	NN	_	13	compound
12	combination	combination	NN	_	13	compound
13	procedures	procedure	NNS	_	10	dobj
14	in	in	IN	_	15	case
15	animals	animal	NNS	_	10	nmod
16	to	to	TO	_	17	mark
17	screen	screen	VB	_	10	advcl
18	for	for	IN	_	20	case
19	antipsychotic	antipsychotic	JJ	_	20	amod
20	potential	potential	NN	_	17	nmod
21	.	.	.	_	4	punct

1	Since	since	IN	_	5	mark
2	chronic	chronic	JJ	_	3	amod
3	dosing	dosing	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	0	ROOT
6	for	for	IN	_	8	case
7	therapeutic	therapeutic	JJ	_	8	amod
8	efficacy	efficacy	NN	_	5	nmod
9	of	of	IN	_	10	case
10	antipsychotics	antipsychotic	NNS	_	8	nmod
11	,	,	,	_	10	punct
12	future	future	JJ	_	13	amod
13	studies	study	NNS	_	15	nsubj
14	should	should	MD	_	15	aux
15	focus	focus	VB	_	10	acl:relcl
16	on	on	IN	_	17	case
17	investigation	investigation	NN	_	15	nmod
18	of	of	IN	_	21	case
19	chronic	chronic	JJ	_	21	amod
20	dosing	dosing	NN	_	21	compound
21	effects	effect	NNS	_	17	nmod
22	of	of	IN	_	24	case
23	these	these	DT	_	24	det
24	drugs	drug	NNS	_	21	nmod
25	in	in	IN	_	26	case
26	combination	combination	NN	_	21	nmod
27	with	with	IN	_	28	case
28	PCP	pcp	NN	_	26	nmod
29	.	.	.	_	5	punct

1	[	[	NN	_	4	compound
2	Multiple	multiple	JJ	_	4	amod
3	occupational	occupational	JJ	_	4	amod
4	exposure	exposure	NN	_	0	ROOT
5	to	to	TO	_	6	case
6	solvents	solvent	NNS	_	4	nmod
7	]	]	CD	_	6	nummod
8	This	this	DT	_	11	det
9	article	article	NN	_	11	compound
10	review	review	NN	_	11	compound
11	papers	papers	NNS	_	4	dep
12	published	publish	VBN	_	11	acl
13	over	over	IN	_	17	case
14	the	the	DT	_	17	det
15	last	last	JJ	_	17	amod
16	20	20	CD	_	17	nummod
17	years	year	NNS	_	12	nmod
18	on	on	IN	_	21	case
19	multiple	multiple	JJ	_	21	amod
20	occupational	occupational	JJ	_	21	amod
21	exposure	exposure	NN	_	12	nmod
22	to	to	TO	_	23	case
23	solvents	solvent	NNS	_	21	nmod
24	.	.	.	_	4	punct

1	At	at	IN	_	2	case
2	low	low	JJ	_	4	dep
3	-	-	:	_	4	punct
4	levels	level	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	exposure	exposure	NN	_	4	nmod
7	the	the	DT	_	9	det
8	toxicokinetic	toxicokinetic	JJ	_	9	amod
9	interferences	interference	NNS	_	16	nsubjpass
10	between	between	IN	_	11	case
11	solvents	solvent	NNS	_	9	nmod
12	have	have	VBP	_	16	aux
13	generally	generally	RB	_	16	advmod
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	observed	observe	VBN	_	6	acl:relcl
17	in	in	IN	_	18	case
18	man	man	NN	_	16	nmod
19	and	and	CC	_	4	cc
20	presumably	presumably	RB	_	23	advmod
21	a	a	DT	_	23	det
22	threshold	threshold	NN	_	23	compound
23	limit	limit	NN	_	24	nsubj
24	exists	exist	VBZ	_	4	conj
25	.	.	.	_	4	punct

1	Conversely	conversely	RB	_	12	advmod
2	,	,	,	_	12	punct
3	at	at	IN	_	5	case
4	exposure	exposure	NN	_	5	compound
5	levels	level	NNS	_	12	nmod
6	close	close	RB	_	5	advmod
7	to	to	TO	_	9	case
8	the	the	DT	_	9	det
9	&quot	&quot	NN	_	6	nmod
10	;	;	:	_	12	punct
11	limit	limit	NN	_	12	compound
12	values&quot	values&quot	NN	_	0	ROOT
13	;	;	:	_	12	punct

1	metabolic	metabolic	JJ	_	2	amod
2	interference	interference	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	sometimes	sometimes	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	the	the	DT	_	9	det
9	behaviour	behaviour	NN	_	14	nsubj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	biological	biological	JJ	_	13	amod
13	indicators	indicator	NNS	_	9	nmod
14	differs	differ	VBZ	_	6	conj
15	from	from	IN	_	19	mark
16	what	what	WP	_	19	nsubjpass
17	would	would	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	expected	expect	VBN	_	14	advcl
20	.	.	.	_	6	punct

1	Toxicodynamic	toxicodynamic	JJ	_	2	amod
2	interference	interference	NN	_	6	nsubj
3	between	between	IN	_	4	case
4	solvents	solvent	NNS	_	2	nmod
5	can	can	MD	_	6	aux
6	give	give	VB	_	0	ROOT
7	rise	rise	VB	_	6	dobj
8	to	to	TO	_	9	case
9	additive	additive	JJ	_	7	nmod
10	,	,	,	_	9	punct
11	potentiation	potentiation	NN	_	9	conj
12	,	,	,	_	9	punct
13	synergistic	synergistic	JJ	_	9	conj
14	,	,	,	_	9	punct
15	antagonistic	antagonistic	JJ	_	16	amod
16	effects	effect	NNS	_	9	conj
17	.	.	.	_	6	punct

1	For	for	IN	_	3	case
2	the	the	DT	_	3	det
3	identification	identification	NN	_	15	nmod
4	of	of	IN	_	5	case
5	&quot	&quot	NN	_	3	nmod
6	;	;	:	_	3	punct
7	limit	limit	NN	_	8	compound
8	values&quot	values&quot	NN	_	3	dep
9	;	;	:	_	3	punct
10	,	,	,	_	15	punct
11	it	it	PRP	_	15	nsubjpass
12	has	have	VBZ	_	15	aux
13	generally	generally	RB	_	15	advmod
14	been	be	VBN	_	15	auxpass
15	suggested	suggest	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	literature	literature	NN	_	15	nmod
19	that	that	IN	_	28	mark
20	the	the	DT	_	22	det
21	possible	possible	JJ	_	22	amod
22	effects	effect	NNS	_	28	nsubjpass
23	deriving	derive	VBG	_	22	acl
24	from	from	IN	_	26	case
25	multiple	multiple	JJ	_	26	amod
26	exposure	exposure	NN	_	23	nmod
27	be	be	VB	_	28	auxpass
28	considered	consider	VBN	_	15	ccomp
29	as	as	IN	_	30	case
30	additive	additive	JJ	_	28	advcl
31	.	.	.	_	15	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	numerous	numerous	JJ	_	5	amod
4	potentiation	potentiation	NN	_	5	compound
5	effects	effect	NNS	_	9	nsubjpass
6	have	have	VBP	_	9	aux
7	frequently	frequently	RB	_	9	advmod
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	for	for	IN	_	12	case
11	combined	combined	JJ	_	12	amod
12	exposure	exposure	NN	_	9	nmod
13	to	to	TO	_	14	case
14	substances	substance	NNS	_	12	nmod
15	of	of	IN	_	17	case
16	widespread	widespread	JJ	_	17	amod
17	use	use	NN	_	14	nmod
18	.	.	.	_	9	punct

1	In	in	IN	_	4	case
2	this	this	DT	_	4	det
3	paper	paper	NN	_	4	compound
4	lists	list	NNS	_	0	ROOT
5	of	of	IN	_	7	case
6	multiple	multiple	JJ	_	7	amod
7	exposure	exposure	NN	_	4	nmod
8	in	in	IN	_	9	case
9	which	which	WDT	_	29	nmod
10	the	the	DT	_	11	det
11	doses	dose	NNS	_	29	nsubjpass
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	substances	substance	NNS	_	11	nmod
15	,	,	,	_	11	punct
16	the	the	DT	_	17	det
17	types	type	NNS	_	11	conj
18	of	of	IN	_	19	case
19	interferences	interference	NNS	_	17	nmod
20	and	and	CC	_	11	cc
21	the	the	DT	_	22	det
22	behaviour	behaviour	NN	_	11	conj
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	biological	biological	JJ	_	26	amod
26	levels	level	NNS	_	22	nmod
27	have	have	VBP	_	29	aux
28	been	be	VBN	_	29	auxpass
29	drawn	draw	VBN	_	7	acl:relcl
30	up	up	RP	_	29	compound:prt
31	and	and	CC	_	29	cc
32	proposed	propose	VBN	_	29	conj
33	as	as	IN	_	35	case
34	a	a	DT	_	35	det
35	tool	tool	NN	_	32	nmod
36	for	for	IN	_	38	case
37	easy	easy	JJ	_	38	amod
38	consultation	consultation	NN	_	35	nmod
39	.	.	.	_	4	punct

1	Glucose	glucose	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	insulin	insulin	NN	_	1	conj
4	exert	exert	VBP	_	0	ROOT
5	additive	additive	JJ	_	10	amod
6	ocular	ocular	JJ	_	10	amod
7	and	and	CC	_	6	cc
8	renal	renal	JJ	_	6	conj
9	vasodilator	vasodilator	NN	_	10	compound
10	effects	effect	NNS	_	4	dobj
11	on	on	IN	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	humans	human	NNS	_	4	nmod
14	.	.	.	_	4	punct

1	AIMS	aim	NNS	_	3	compound
2	/	/	:	_	3	punct
3	HYPOTHESIS	hypothesis	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	There	there	EX	_	6	expl
6	is	be	VBZ	_	3	parataxis
7	evidence	evidence	NN	_	6	nsubj
8	that	that	IN	_	12	mark
9	insulin	insulin	NN	_	12	nsubj
10	and	and	CC	_	9	cc
11	glucose	glucose	NN	_	9	conj
12	cause	cause	VBP	_	7	ccomp
13	renal	renal	JJ	_	16	amod
14	and	and	CC	_	13	cc
15	ocular	ocular	JJ	_	13	conj
16	vasodilation	vasodilation	NN	_	12	dobj
17	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	,	,	,	_	2	punct
4	however	however	RB	_	2	advmod
5	,	,	,	_	2	punct
6	currently	currently	RB	_	2	advmod
7	no	no	DT	_	8	neg
8	data	datum	NNS	_	2	nsubj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	effect	effect	NN	_	8	nmod
12	of	of	IN	_	14	case
13	combined	combined	JJ	_	14	amod
14	hyperglycaemia	hyperglycaemia	NN	_	11	nmod
15	and	and	CC	_	14	cc
16	hyperinsulinaemia	hyperinsulinaemia	NN	_	14	conj
17	on	on	IN	_	23	case
18	the	the	DT	_	23	det
19	renal	renal	JJ	_	23	amod
20	and	and	CC	_	19	cc
21	ocular	ocular	JJ	_	19	conj
22	blood	blood	NN	_	23	compound
23	flow	flow	NN	_	11	nmod
24	seen	see	VBN	_	23	acl
25	in	in	IN	_	27	case
26	diabetic	diabetic	JJ	_	27	amod
27	patients	patient	NNS	_	24	nmod
28	on	on	IN	_	30	case
29	insulin	insulin	NN	_	30	compound
30	therapy	therapy	NN	_	27	nmod
31	.	.	.	_	2	punct

1	METHODS	method	NNS	_	4	nsubj
2	:	:	:	_	4	punct
3	We	we	PRP	_	4	nsubj
4	carried	carry	VBD	_	0	ROOT
5	out	out	RP	_	4	compound:prt
6	two	two	CD	_	16	nsubj
7	different	different	JJ	_	16	dep
8	3	3	LS	_	16	dep
9	-	-	:	_	8	punct
10	way	way	NN	_	12	compound
11	crossover	crossover	NN	_	12	compound
12	studies	study	NNS	_	16	nsubj
13	in	in	IN	_	15	case
14	healthy	healthy	JJ	_	15	amod
15	subjects	subject	NNS	_	12	nmod
16	(	(	VBP	_	4	xcomp
17	each	each	DT	_	20	dep
18	,	,	,	_	20	punct
19	n	n	NN	_	20	nsubj
20	=	=	JJ	_	16	dep
21	9	9	CD	_	22	nummod
22	)	)	NN	_	20	dobj
23	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	study	study	NN	_	0	ROOT
3	one	one	CD	_	2	nummod
4	,	,	,	_	2	punct
5	hyperglycaemic	hyperglycaemic	JJ	_	6	amod
6	clamps	clamp	NNS	_	4	root
7	(	(	RB	_	9	advmod
8	5.6	5.6	CD	_	9	nummod
9	mmol	mmol	NN	_	6	dep
10	/	/	:	_	9	punct
11	l	l	NN	_	9	dep
12	,	,	,	_	11	punct
13	11.1	11.1	CD	_	14	nummod
14	mmol	mmol	NN	_	11	appos
15	/	/	:	_	11	punct
16	1	1	CD	_	22	nummod
17	,	,	,	_	22	punct
18	16.7	16.7	CD	_	19	nummod
19	mmol	mmol	NN	_	22	dep
20	/	/	:	_	22	punct
21	l	l	NN	_	22	compound
22	)	)	NN	_	24	nsubjpass
23	were	be	VBD	_	24	auxpass
24	carried	carry	VBN	_	11	dep
25	out	out	RP	_	24	compound:prt
26	during	during	IN	_	27	case
27	placebo	placebo	NN	_	24	nmod
28	or	or	CC	_	27	cc
29	insulin	insulin	NN	_	31	compound
30	(	(	NN	_	31	compound
31	dose	dose	NN	_	27	conj
32	1	1	CD	_	31	nummod
33	:	:	:	_	24	punct
34	1	1	CD	_	35	nummod
35	mU	mu	NN	_	24	dep
36	/	/	:	_	35	punct
37	kg	kg	NN	_	39	compound
38	/	/	:	_	39	punct
39	min	min	NN	_	35	dep
40	;	;	:	_	35	punct
41	dose	dose	NN	_	35	dep
42	2	2	CD	_	41	nummod
43	:	:	:	_	41	punct
44	2	2	CD	_	45	nummod
45	mU	mu	NN	_	41	dep
46	/	/	:	_	35	punct
47	kg	kg	NN	_	49	compound
48	/	/	:	_	49	punct
49	min	min	NN	_	35	dep
50	)	)	CD	_	51	nummod
51	infusion	infusion	NN	_	49	dep
52	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	second	second	JJ	_	3	amod
3	study	study	NN	_	5	nsubj
4	was	be	VBD	_	5	cop
5	identical	identical	JJ	_	0	ROOT
6	but	but	CC	_	5	cc
7	endogenous	endogenous	JJ	_	9	amod
8	insulin	insulin	NN	_	9	compound
9	secretion	secretion	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	blocked	block	VBN	_	5	conj
12	with	with	IN	_	13	case
13	somatostatin	somatostatin	NN	_	11	nmod
14	.	.	.	_	5	punct

1	The	the	DT	_	4	det
2	renal	renal	JJ	_	4	amod
3	plasma	plasma	NN	_	4	compound
4	flow	flow	NN	_	15	nsubjpass
5	,	,	,	_	4	punct
6	glomerular	glomerular	JJ	_	8	amod
7	filtration	filtration	NN	_	8	compound
8	rate	rate	NN	_	4	conj
9	and	and	CC	_	4	cc
10	pulsatile	pulsatile	JJ	_	13	amod
11	choroidal	choroidal	JJ	_	13	amod
12	blood	blood	NN	_	13	compound
13	flow	flow	NN	_	4	conj
14	were	be	VBD	_	15	auxpass
15	measured	measure	VBN	_	0	ROOT
16	using	use	VBG	_	15	xcomp
17	the	the	DT	_	19	det
18	paraaminohippurate	paraaminohippurate	NN	_	19	compound
19	method	method	NN	_	16	dobj
20	,	,	,	_	15	punct
21	the	the	DT	_	23	det
22	inulin	inulin	NN	_	23	compound
23	method	method	NN	_	20	root
24	and	and	CC	_	23	cc
25	a	a	DT	_	28	det
26	laser	laser	NN	_	28	compound
27	interferometric	interferometric	JJ	_	28	amod
28	measurement	measurement	NN	_	23	conj
29	of	of	IN	_	32	case
30	fundus	fundus	NN	_	32	compound
31	pulsation	pulsation	NN	_	32	compound
32	amplitude	amplitude	NN	_	28	nmod
33	,	,	,	_	23	punct
34	respectively	respectively	RB	_	23	advmod
35	.	.	.	_	23	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Insulin	insulin	NN	_	4	nsubj
4	increased	increase	VBD	_	1	appos
5	renal	renal	JJ	_	7	amod
6	plasma	plasma	NN	_	7	compound
7	flow	flow	NN	_	4	dobj
8	and	and	CC	_	7	cc
9	fundus	fundus	NN	_	11	compound
10	pulsation	pulsation	NN	_	11	compound
11	amplitude	amplitude	NN	_	7	conj
12	but	but	CC	_	13	cc
13	not	not	RB	_	7	cc
14	the	the	DT	_	17	det
15	glomerular	glomerular	JJ	_	17	amod
16	filtration	filtration	NN	_	17	compound
17	rate	rate	NN	_	7	conj
18	.	.	.	_	1	punct

1	Hyperglycaemia	hyperglycaemia	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	all	all	PDT	_	8	det:predet
4	the	the	DT	_	8	det
5	renal	renal	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	ocular	ocular	JJ	_	5	conj
8	parameters	parameter	NNS	_	2	dobj
9	studied	study	VBN	_	8	acl
10	.	.	.	_	2	punct

1	Haemodynamic	haemodynamic	JJ	_	2	amod
2	effects	effect	NNS	_	8	nsubj
3	of	of	IN	_	4	case
4	glucose	glucose	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	insulin	insulin	NN	_	4	conj
7	were	be	VBD	_	8	cop
8	additive	additive	JJ	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	somatostatin	somatostatin	NN	_	12	nsubj
11	was	be	VBD	_	12	cop
12	co	co	SYM	_	8	advcl
13	-	-	:	_	12	punct
14	administered	administer	VBN	_	12	dep
15	but	but	CC	_	14	cc
16	not	not	RB	_	19	neg
17	under	under	IN	_	19	case
18	basal	basal	JJ	_	19	amod
19	conditions	condition	NNS	_	14	conj
20	.	.	.	_	8	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	/	/	:	_	3	punct
3	INTERPRETATION	INTERPRETATION	NNP	_	1	dep
4	:	:	:	_	3	punct
5	Glucose	glucose	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	insulin	insulin	NN	_	5	conj
8	can	can	MD	_	9	aux
9	exert	exert	VB	_	3	dep
10	additive	additive	JJ	_	12	amod
11	vasodilator	vasodilator	NN	_	12	compound
12	properties	property	NNS	_	9	dobj
13	on	on	IN	_	17	case
14	renal	renal	JJ	_	17	amod
15	and	and	CC	_	14	cc
16	ocular	ocular	JJ	_	14	conj
17	circulation	circulation	NN	_	9	nmod
18	.	.	.	_	1	punct

1	To	to	TO	_	2	mark
2	find	find	VB	_	0	ROOT
3	out	out	RP	_	2	compound:prt
4	whether	whether	IN	_	8	mark
5	this	this	DT	_	6	det
6	observation	observation	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	related	relate	VBN	_	2	ccomp
9	to	to	TO	_	13	case
10	the	the	DT	_	13	det
11	increased	increase	VBN	_	13	amod
12	regional	regional	JJ	_	13	amod
13	perfusion	perfusion	NN	_	8	nmod
14	in	in	IN	_	17	case
15	diabetes	diabetes	NN	_	17	compound
16	longitudinal	longitudinal	JJ	_	17	amod
17	studies	study	NNS	_	13	nmod
18	on	on	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	with	with	IN	_	21	case
21	Type	type	NN	_	19	nmod
22	I	i	CD	_	23	compound
23	(	(	CD	_	21	nummod
24	insulin	insulin	NN	_	21	dep
25	-	-	:	_	2	punct
26	dependent	dependent	JJ	_	29	amod
27	)	)	NN	_	29	compound
28	diabetes	diabetes	NN	_	29	compound
29	mellitus	mellitus	NN	_	31	nsubjpass
30	are	be	VBP	_	31	auxpass
31	needed	need	VBN	_	2	parataxis
32	.	.	.	_	2	punct

1	Interaction	interaction	NN	_	0	ROOT
2	between	between	IN	_	3	case
3	oxytocin	oxytocin	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	antidiuretic	antidiuretic	JJ	_	6	amod
6	hormone	hormone	NN	_	3	conj
7	and	and	CC	_	3	cc
8	its	its	PRP$	_	9	nmod:poss
9	effect	effect	NN	_	3	conj
10	on	on	IN	_	13	case
11	the	the	DT	_	13	det
12	milk	milk	NN	_	13	compound
13	secretion	secretion	NN	_	9	nmod
14	by	by	IN	_	15	case
15	alveoli	alveolus	NNS	_	1	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	mammary	mammary	JJ	_	19	amod
19	gland	gland	NN	_	15	nmod
20	of	of	IN	_	22	case
21	lactating	lactating	JJ	_	22	amod
22	rats	rat	NNS	_	19	nmod
23	.	.	.	_	1	punct

1	Interaction	interaction	NN	_	10	nsubjpass
2	between	between	IN	_	6	case
3	exogenous	exogenous	JJ	_	6	amod
4	and	and	CC	_	3	cc
5	endogenous	endogenous	JJ	_	3	conj
6	oxytocin	oxytocin	NN	_	1	nmod
7	and	and	CC	_	6	cc
8	vasopressin	vasopressin	NN	_	6	conj
9	was	be	VBD	_	10	auxpass
10	found	find	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	affect	affect	VB	_	10	xcomp
13	the	the	DT	_	14	det
14	mechanism	mechanism	NN	_	12	dobj
15	of	of	IN	_	17	case
16	milk	milk	NN	_	17	compound
17	ejection	ejection	NN	_	14	nmod
18	by	by	IN	_	20	case
19	the	the	DT	_	20	det
20	alveoli	alveolus	NNS	_	14	nmod
21	of	of	IN	_	24	case
22	the	the	DT	_	24	det
23	mammary	mammary	JJ	_	24	amod
24	gland	gland	NN	_	20	nmod
25	in	in	IN	_	27	case
26	lactating	lactating	JJ	_	27	amod
27	rats	rat	NNS	_	24	nmod
28	.	.	.	_	10	punct

1	Inhibition	inhibition	NN	_	15	nsubjpass
2	and	and	CC	_	1	cc
3	stimulation	stimulation	NN	_	1	conj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	effect	effect	NN	_	1	nmod
7	of	of	IN	_	8	case
8	oxytocin	oxytocin	NN	_	6	nmod
9	on	on	IN	_	11	case
10	milk	milk	NN	_	11	compound
11	ejection	ejection	NN	_	6	nmod
12	by	by	IN	_	13	case
13	vasopressin	vasopressin	NN	_	1	nmod
14	was	be	VBD	_	15	auxpass
15	demonstrated	demonstrate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	7	nmod
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	principles	principle	NNS	_	3	nmod
7	observed	observe	VBD	_	0	ROOT
8	the	the	DT	_	9	det
9	concentrations	concentration	NNS	_	10	nsubj
10	fo	fo	VBP	_	7	ccomp
11	these	these	DT	_	12	det
12	hormones	hormone	NNS	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	investigated	investigate	VBN	_	10	ccomp
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	plasma	plasma	NN	_	14	nmod
18	of	of	IN	_	19	case
19	dogs	dog	NNS	_	17	nmod
20	deprived	deprive	VBN	_	19	acl
21	of	of	IN	_	22	case
22	water	water	NN	_	20	nmod
23	for	for	IN	_	25	case
24	3	3	CD	_	25	nummod
25	days	day	NNS	_	20	nmod
26	and	and	CC	_	14	cc
27	then	then	RB	_	28	advmod
28	allowed	allow	VBD	_	14	conj
29	to	to	TO	_	30	mark
30	drink	drink	VB	_	28	xcomp
31	.	.	.	_	7	punct

1	[	[	RB	_	2	advmod
2	Quantitative	quantitative	JJ	_	3	amod
3	approach	approach	NN	_	0	ROOT
4	to	to	TO	_	5	case
5	treatment	treatment	NN	_	3	nmod
6	with	with	IN	_	8	case
7	incisive	incisive	JJ	_	8	amod
8	neuroleptics	neuroleptic	NNS	_	5	nmod
9	by	by	IN	_	12	case
10	therapeutic	therapeutic	JJ	_	12	amod
11	monitoring	monitoring	NN	_	12	compound
12	]	]	NN	_	5	nmod
13	;	;	:	_	3	punct
14	The	the	DT	_	15	det
15	problems	problem	NNS	_	27	nsubjpass
16	encountered	encounter	VBN	_	15	acl
17	during	during	IN	_	20	case
18	the	the	DT	_	20	det
19	longterm	longterm	JJ	_	20	amod
20	treatment	treatment	NN	_	16	nmod
21	of	of	IN	_	23	case
22	psychotic	psychotic	JJ	_	23	amod
23	patients	patient	NNS	_	20	nmod
24	with	with	IN	_	25	case
25	neuroleptics	neuroleptic	NNS	_	23	nmod
26	are	be	VBP	_	27	auxpass
27	illustrated	illustrate	VBN	_	3	parataxis
28	by	by	IN	_	32	case
29	six	six	CD	_	32	nummod
30	typical	typical	JJ	_	32	amod
31	case	case	NN	_	32	compound
32	reports	report	NNS	_	27	nmod
33	.	.	.	_	27	punct

1	A	a	DT	_	2	det
2	group	group	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	who	who	WP	_	7	nsubj
6	had	have	VBD	_	7	aux
7	had	have	VBN	_	4	acl:relcl
8	a	a	DT	_	11	det
9	new	new	JJ	_	11	amod
10	acute	acute	JJ	_	11	amod
11	episode	episode	NN	_	7	dobj
12	despite	despite	IN	_	15	case
13	seemingly	seemingly	RB	_	14	advmod
14	adequate	adequate	JJ	_	15	amod
15	treatment	treatment	NN	_	7	nmod
16	were	be	VBD	_	17	auxpass
17	selected	select	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	In	in	IN	_	4	case
2	these	these	DT	_	4	det
3	six	six	CD	_	4	nummod
4	cases	case	NNS	_	7	nmod
5	it	it	PRP	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	demonstrated	demonstrate	VBN	_	0	ROOT
8	that	that	IN	_	13	mark
9	the	the	DT	_	11	det
10	neuroleptics	neuroleptic	NNS	_	11	compound
11	dosage	dosage	NN	_	13	nsubj
12	was	be	VBD	_	13	cop
13	inappropriate	inappropriate	JJ	_	7	ccomp
14	,	,	,	_	13	punct
15	being	be	VBG	_	18	cop
16	either	either	CC	_	18	cc:preconj
17	too	too	RB	_	18	advmod
18	high	high	JJ	_	13	xcomp
19	or	or	CC	_	18	cc
20	too	too	RB	_	21	advmod
21	low	low	JJ	_	18	conj
22	as	as	IN	_	23	mark
23	judged	judge	VBN	_	18	dep
24	from	from	IN	_	27	case
25	the	the	DT	_	27	det
26	plasma	plasma	NN	_	27	compound
27	concentrations	concentration	NNS	_	23	nmod
28	.	.	.	_	7	punct

1	Ways	Ways	NNP	_	15	nsubjpass
2	of	of	IN	_	3	mark
3	improving	improve	VBG	_	1	acl
4	the	the	DT	_	5	det
5	adequacy	adequacy	NN	_	3	dobj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	treatment	treatment	NN	_	5	nmod
9	of	of	IN	_	11	case
10	psychotic	psychotic	JJ	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	with	with	IN	_	13	case
13	neuroleptics	neuroleptic	NNS	_	11	nmod
14	are	be	VBP	_	15	auxpass
15	discussed	discuss	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Longitudinal	longitudinal	JJ	_	2	amod
2	assessment	assessment	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	everolimus	everolimus	NN	_	2	nmod
5	in	in	IN	_	10	case
6	de	de	FW	_	10	amod
7	novo	novo	FW	_	6	dep
8	renal	renal	JJ	_	10	amod
9	transplant	transplant	NN	_	10	compound
10	recipients	recipient	NNS	_	2	nmod
11	over	over	IN	_	14	case
12	the	the	DT	_	14	det
13	first	first	JJ	_	14	amod
14	post	post	NN	_	2	nmod
15	-	-	:	_	2	punct
16	transplant	transplant	NN	_	17	compound
17	year	year	NN	_	2	dep
18	:	:	:	_	2	punct
19	pharmacokinetics	pharmacokinetic	NNS	_	2	dep
20	,	,	,	_	19	punct
21	exposure	exposure	NN	_	19	conj
22	-	-	:	_	19	punct
23	response	response	NN	_	24	compound
24	relationships	relationship	NNS	_	19	conj
25	,	,	,	_	19	punct
26	and	and	CC	_	19	cc
27	influence	influence	NN	_	19	conj
28	on	on	IN	_	29	case
29	cyclosporine	cyclosporine	NN	_	27	nmod
30	.	.	.	_	2	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Our	we	PRP$	_	4	nmod:poss
4	objective	objective	NN	_	5	nsubj
5	was	be	VBD	_	1	dep
6	to	to	TO	_	7	mark
7	characterize	characterize	VB	_	5	xcomp
8	the	the	DT	_	12	det
9	steady	steady	JJ	_	12	amod
10	-	-	:	_	12	punct
11	state	state	NN	_	12	compound
12	pharmacokinetics	pharmacokinetic	NNS	_	7	dobj
13	of	of	IN	_	14	case
14	everolimus	everolimus	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	cyclosporine	cyclosporine	NN	_	18	compound
17	(	(	CD	_	18	nummod
18	INN	INN	NNP	_	14	conj
19	,	,	,	_	12	punct
20	ciclosporin	ciclosporin	NN	_	21	compound
21	)	)	NN	_	12	appos
22	when	when	WRB	_	23	advmod
23	coadministered	coadminister	VBN	_	21	acl:relcl
24	in	in	IN	_	29	case
25	de	de	FW	_	29	amod
26	novo	novo	FW	_	25	dep
27	kidney	kidney	NN	_	29	compound
28	allograft	allograft	NN	_	29	compound
29	recipients	recipient	NNS	_	23	nmod
30	during	during	IN	_	33	case
31	the	the	DT	_	33	det
32	first	first	JJ	_	33	amod
33	year	year	NN	_	23	nmod
34	after	after	IN	_	35	case
35	transplantation	transplantation	NN	_	33	nmod
36	.	.	.	_	1	punct

1	METHOD	method	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	This	this	DT	_	4	det
4	study	study	NN	_	12	nsubj
5	was	be	VBD	_	12	cop
6	a	a	DT	_	12	det
7	multicenter	multicenter	JJ	_	12	amod
8	randomized	randomize	VBN	_	12	amod
9	double	double	JJ	_	12	amod
10	-	-	:	_	12	punct
11	blind	blind	JJ	_	12	amod
12	study	study	NN	_	1	parataxis
13	of	of	IN	_	15	case
14	101	101	CD	_	15	nummod
15	patients	patient	NNS	_	12	nmod
16	who	who	WP	_	19	nsubjpass
17	were	be	VBD	_	19	auxpass
18	randomly	randomly	RB	_	19	advmod
19	assigned	assign	VBN	_	15	acl:relcl
20	1	1	CD	_	19	dobj
21	:	:	:	_	12	punct
22	1	1	CD	_	12	dep
23	:	:	:	_	22	punct
24	1	1	CD	_	22	dep
25	to	to	TO	_	26	mark
26	receive	receive	VB	_	24	acl
27	everolimus	everolimus	NN	_	28	compound
28	tablets	tablet	NNS	_	26	dobj
29	at	at	IN	_	30	case
30	doses	dose	NNS	_	26	nmod
31	of	of	IN	_	33	case
32	0.5	0.5	CD	_	33	nummod
33	mg	mg	NN	_	30	nmod
34	,	,	,	_	33	punct
35	1	1	CD	_	36	nummod
36	mg	mg	NN	_	33	conj
37	,	,	,	_	33	punct
38	or	or	CC	_	33	cc
39	2	2	CD	_	40	nummod
40	mg	mg	NN	_	33	conj
41	twice	twice	RB	_	42	advmod
42	daily	daily	RB	_	40	advmod
43	with	with	IN	_	44	case
44	cyclosporine	cyclosporine	NN	_	40	nmod
45	and	and	CC	_	44	cc
46	prednisone	prednisone	NN	_	44	conj
47	.	.	.	_	1	punct

1	Blood	blood	NN	_	2	compound
2	sampling	sampling	NN	_	11	nsubjpass
3	for	for	IN	_	5	case
4	the	the	DT	_	5	det
5	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	everolimus	everolimus	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	cyclosporine	cyclosporine	NN	_	7	conj
10	was	be	VBD	_	11	auxpass
11	performed	perform	VBN	_	0	ROOT
12	on	on	IN	_	13	case
13	day	day	NN	_	11	nmod
14	1	1	CD	_	13	nummod
15	,	,	,	_	11	punct
16	on	on	IN	_	17	case
17	weeks	week	NNS	_	11	nmod
18	1	1	CD	_	17	nummod
19	,	,	,	_	17	punct
20	2	2	CD	_	17	nummod
21	,	,	,	_	17	punct
22	3	3	CD	_	17	nummod
23	,	,	,	_	17	punct
24	and	and	CC	_	17	cc
25	4	4	CD	_	17	conj
26	,	,	,	_	11	punct
27	and	and	CC	_	11	cc
28	on	on	IN	_	29	case
29	months	month	NNS	_	11	conj
30	2	2	CD	_	29	nummod
31	,	,	,	_	29	punct
32	3	3	CD	_	29	nummod
33	,	,	,	_	29	punct
34	6	6	CD	_	29	nummod
35	,	,	,	_	29	punct
36	9	9	CD	_	29	nummod
37	,	,	,	_	29	punct
38	and	and	CC	_	29	cc
39	12	12	CD	_	29	conj
40	.	.	.	_	11	punct

1	Everolimus	Everolimus	NNP	_	2	compound
2	dose	dose	NN	_	10	nsubjpass
3	-	-	:	_	2	punct
4	proportionality	proportionality	NN	_	2	dep
5	and	and	CC	_	4	cc
6	stability	stability	NN	_	4	conj
7	over	over	IN	_	8	case
8	time	time	NN	_	2	nmod
9	were	be	VBD	_	10	auxpass
10	assessed	assess	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	context	context	NN	_	10	nmod
14	of	of	IN	_	16	case
15	linear	linear	JJ	_	16	amod
16	regression	regression	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	ANOVA	ANOVA	NNP	_	19	compound
19	models	model	NNS	_	16	conj
20	.	.	.	_	10	punct

1	Everolimus	everolimus	NN	_	2	compound
2	exposure	exposure	NN	_	28	nsubjpass
3	-	-	:	_	2	punct
4	response	response	NN	_	5	compound
5	relationships	relationship	NNS	_	2	dep
6	between	between	IN	_	7	case
7	area	area	NN	_	5	nmod
8	under	under	IN	_	11	case
9	the	the	DT	_	11	det
10	blood	blood	NN	_	11	compound
11	concentration	concentration	NN	_	5	nmod
12	-	-	:	_	2	punct
13	time	time	NN	_	17	compound
14	curve	curve	NN	_	17	compound
15	(	(	CD	_	17	nummod
16	AUC	auc	NN	_	17	compound
17	)	)	NN	_	2	dep
18	and	and	CC	_	17	cc
19	changes	change	NNS	_	17	conj
20	in	in	IN	_	21	case
21	platelets	platelet	NNS	_	17	nmod
22	,	,	,	_	21	punct
23	leukocytes	leukocyte	NNS	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	lipids	lipid	NNS	_	21	conj
27	were	be	VBD	_	28	auxpass
28	explored	explore	VBN	_	0	ROOT
29	with	with	IN	_	34	case
30	the	the	DT	_	34	det
31	median	median	NN	_	34	compound
32	-	-	:	_	34	punct
33	effect	effect	NN	_	34	compound
34	model	model	NN	_	28	nmod
35	.	.	.	_	28	punct

1	Potential	potential	JJ	_	2	amod
2	differences	difference	NNS	_	15	nsubjpass
3	in	in	IN	_	5	case
4	cyclosporine	cyclosporine	NN	_	5	compound
5	dosing	dosing	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	pharmacokinetics	pharmacokinetic	NNS	_	5	conj
8	at	at	IN	_	10	case
9	different	different	JJ	_	10	amod
10	levels	level	NNS	_	2	nmod
11	of	of	IN	_	13	case
12	everolimus	everolimus	NN	_	13	compound
13	exposure	exposure	NN	_	10	nmod
14	were	be	VBD	_	15	auxpass
15	assessed	assess	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	context	context	NN	_	15	nmod
19	of	of	IN	_	20	case
20	ANOVA	ANOVA	NNP	_	18	nmod
21	.	.	.	_	15	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Everolimus	everolimus	NN	_	5	compound
4	steady	steady	JJ	_	5	amod
5	state	state	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	reached	reach	VBN	_	1	dep
8	on	on	IN	_	11	case
9	or	or	CC	_	8	cc
10	before	before	IN	_	8	conj
11	day	day	NN	_	7	nmod
12	7	7	CD	_	11	nummod
13	,	,	,	_	7	punct
14	with	with	IN	_	20	case
15	a	a	DT	_	20	det
16	median	median	JJ	_	20	amod
17	3	3	LS	_	20	dep
18	-	-	:	_	20	punct
19	fold	fold	JJ	_	20	amod
20	accumulation	accumulation	NN	_	7	nmod
21	of	of	IN	_	23	case
22	drug	drug	NN	_	23	compound
23	exposure	exposure	NN	_	20	nmod
24	compared	compare	VBN	_	26	case
25	with	with	IN	_	26	case
26	that	that	DT	_	20	nmod
27	after	after	IN	_	31	case
28	the	the	DT	_	31	det
29	first	first	JJ	_	31	amod
30	postoperative	postoperative	JJ	_	31	amod
31	dose	dose	NN	_	26	nmod
32	.	.	.	_	1	punct

1	Both	both	DT	_	6	cc:preconj
2	steady	steady	JJ	_	6	amod
3	-	-	:	_	6	punct
4	state	state	NN	_	6	compound
5	maximum	maximum	NN	_	6	compound
6	concentration	concentration	NN	_	11	nsubj
7	and	and	CC	_	6	cc
8	AUC	auc	NN	_	6	conj
9	were	be	VBD	_	11	cop
10	dose	dose	NN	_	11	nmod:npmod
11	proportional	proportional	JJ	_	0	ROOT
12	over	over	IN	_	16	case
13	the	the	DT	_	16	det
14	full	full	JJ	_	16	amod
15	dose	dose	NN	_	16	compound
16	range	range	NN	_	11	nmod
17	when	when	WRB	_	18	advmod
18	assessed	assess	VBN	_	11	advcl
19	on	on	IN	_	20	case
20	day	day	NN	_	18	nmod
21	1	1	CD	_	20	nummod
22	,	,	,	_	11	punct
23	as	as	RB	_	11	cc
24	well	well	RB	_	23	mwe
25	as	as	IN	_	23	mwe
26	for	for	IN	_	29	case
27	the	the	DT	_	29	det
28	full	full	JJ	_	29	amod
29	duration	duration	NN	_	11	conj
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	study	study	NN	_	29	nmod
33	at	at	IN	_	35	case
34	steady	steady	JJ	_	35	amod
35	state	state	NN	_	32	nmod
36	.	.	.	_	11	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	evidence	evidence	NN	_	2	nsubj
4	for	for	IN	_	6	case
5	longitudinal	longitudinal	JJ	_	6	amod
6	stability	stability	NN	_	3	nmod
7	in	in	IN	_	8	case
8	AUC	auc	NN	_	6	nmod
9	of	of	IN	_	10	case
10	everolimus	everolimus	NN	_	8	nmod
11	during	during	IN	_	13	case
12	the	the	DT	_	13	det
13	course	course	NN	_	6	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	study	study	NN	_	13	nmod
17	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	interindividual	interindividual	JJ	_	4	amod
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	variability	variability	NN	_	9	nsubj
5	for	for	IN	_	6	case
6	AUC	auc	NN	_	4	nmod
7	was	be	VBD	_	9	cop
8	85.4	85.4	CD	_	9	nummod
9	%	%	NN	_	0	ROOT
10	and	and	CC	_	9	cc
11	intraindividual	intraindividual	JJ	_	9	conj
12	,	,	,	_	9	punct
13	interoccasion	interoccasion	NN	_	14	compound
14	variability	variability	NN	_	17	nsubj
15	was	be	VBD	_	17	cop
16	40.8	40.8	CD	_	17	nummod
17	%	%	NN	_	9	parataxis
18	.	.	.	_	9	punct

1	Age	Age	NNP	_	3	compound
2	(	(	CD	_	3	nummod
3	range	range	NN	_	0	ROOT
4	,	,	,	_	3	punct
5	17	17	CD	_	33	nummod
6	-	-	:	_	33	punct
7	69	69	CD	_	8	nummod
8	years	year	NNS	_	9	nmod:npmod
9	)	)	RB	_	33	advmod
10	,	,	,	_	33	punct
11	weight	weight	NN	_	13	compound
12	(	(	NN	_	13	compound
13	range	range	NN	_	33	nsubj
14	,	,	,	_	13	punct
15	49	49	CD	_	19	nummod
16	-	-	:	_	19	punct
17	106	106	CD	_	19	nummod
18	kg	kg	NN	_	19	compound
19	)	)	NN	_	13	conj
20	,	,	,	_	13	punct
21	and	and	CC	_	13	cc
22	sex	sex	NN	_	23	compound
23	(	(	NN	_	13	conj
24	65	65	CD	_	25	nummod
25	men	man	NNS	_	23	dep
26	and	and	CC	_	25	cc
27	36	36	CD	_	28	nummod
28	women	woman	NNS	_	25	conj
29	)	)	CD	_	28	nummod
30	were	be	VBD	_	33	cop
31	not	not	RB	_	33	neg
32	significant	significant	JJ	_	33	amod
33	contributors	contributor	NNS	_	3	appos
34	to	to	TO	_	35	case
35	variability	variability	NN	_	33	nmod
36	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	an	a	DT	_	5	det
4	increasing	increase	VBG	_	5	amod
5	incidence	incidence	NN	_	2	nsubj
6	of	of	IN	_	9	case
7	transient	transient	JJ	_	9	amod
8	thrombocytopenia	thrombocytopenia	NN	_	9	compound
9	(	(	NN	_	5	nmod
10	or	or	CC	_	9	cc
11	=	=	JJ	_	9	conj
12	100	100	CD	_	17	nummod
13	x	x	CC	_	12	cc
14	10	10	CD	_	16	compound
15	(	(	CD	_	16	compound
16	9	9	CD	_	12	conj
17	)	)	NN	_	11	dep
18	/	/	:	_	9	punct
19	L	l	NN	_	20	compound
20	)	)	NN	_	9	dep
21	with	with	IN	_	26	case
22	increasing	increase	VBG	_	26	amod
23	everolimus	everolimus	NN	_	26	compound
24	AUC	auc	NN	_	26	compound
25	(	(	CD	_	26	nummod
26	P	p	NN	_	20	nmod
27	=	=	JJ	_	26	amod
28	.	.	.	_	2	punct
29	03	03	CD	_	30	nummod
30	)	)	NN	_	2	dep
31	.	.	.	_	2	punct

1	Cyclosporine	cyclosporine	NN	_	2	compound
2	doses	dose	NNS	_	9	nsubj
3	,	,	,	_	2	punct
4	trough	trough	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	conj
6	,	,	,	_	2	punct
7	and	and	CC	_	2	cc
8	AUC	auc	NN	_	2	conj
9	exhibited	exhibit	VBD	_	0	ROOT
10	similar	similar	JJ	_	12	amod
11	temporal	temporal	JJ	_	12	amod
12	patterns	pattern	NNS	_	9	dobj
13	during	during	IN	_	15	case
14	the	the	DT	_	15	det
15	course	course	NN	_	9	nmod
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	study	study	NN	_	15	nmod
19	regardless	regardless	RB	_	9	advmod
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	co	co	NN	_	19	nmod
23	-	-	:	_	9	punct
24	administered	administer	VBN	_	27	amod
25	everolimus	everolimus	NN	_	27	compound
26	dose	dose	NN	_	27	compound
27	level	level	NN	_	9	dep
28	(	(	CD	_	29	nummod
29	P	p	NN	_	27	dep
30	=	=	JJ	_	29	amod
31	.	.	.	_	9	punct
32	13	13	CD	_	9	dep
33	,	,	,	_	32	punct
34	.	.	.	_	32	punct
35	82	82	CD	_	32	conj
36	,	,	,	_	32	punct
37	and	and	CC	_	32	cc
38	.	.	.	_	32	punct
39	76	76	CD	_	32	conj
40	,	,	,	_	32	punct
41	respectively	respectively	RB	_	42	advmod
42	)	)	CD	_	32	appos
43	.	.	.	_	9	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Everolimus	everolimus	NN	_	4	nsubj
4	exhibited	exhibit	VBD	_	1	appos
5	dose	dose	NN	_	4	dobj
6	-	-	:	_	5	punct
7	proportional	proportional	JJ	_	10	amod
8	,	,	,	_	10	punct
9	stable	stable	JJ	_	10	amod
10	exposure	exposure	NN	_	5	dep
11	during	during	IN	_	14	case
12	the	the	DT	_	14	det
13	first	first	JJ	_	14	amod
14	post	post	NN	_	10	nmod
15	-	-	:	_	10	punct
16	transplant	transplant	NN	_	17	compound
17	year	year	NN	_	10	dep
18	.	.	.	_	1	punct

1	For	for	IN	_	6	case
2	a	a	DT	_	6	det
3	4	4	LS	_	6	dep
4	-	-	:	_	6	punct
5	fold	fold	JJ	_	6	amod
6	range	range	NN	_	11	nmod
7	of	of	IN	_	9	case
8	everolimus	everolimus	NN	_	9	compound
9	doses	dose	NNS	_	6	nmod
10	there	there	EX	_	11	expl
11	were	be	VBD	_	0	ROOT
12	no	no	DT	_	14	neg
13	differential	differential	JJ	_	14	amod
14	effects	effect	NNS	_	11	nsubj
15	on	on	IN	_	17	case
16	cyclosporine	cyclosporine	NN	_	17	compound
17	dosing	dosing	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	pharmacokinetics	pharmacokinetic	NNS	_	17	conj
20	.	.	.	_	11	punct

1	Toxicity	toxicity	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	cadmium	cadmium	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	zinc	zinc	NN	_	3	conj
6	to	to	TO	_	7	case
7	encystment	encystment	NN	_	1	nmod
8	and	and	CC	_	7	cc
9	in	in	FW	_	11	amod
10	vitro	vitro	FW	_	9	dep
11	excystment	excystment	NN	_	7	conj
12	of	of	IN	_	16	case
13	Parorchis	Parorchis	NNP	_	16	compound
14	acanthus	acanthus	NN	_	16	compound
15	(	(	CD	_	16	nummod
16	Digenea	Digenea	NNP	_	7	nmod
17	:	:	:	_	1	punct
18	Philophthalmidae	Philophthalmidae	NNP	_	1	dep
19	)	)	CD	_	18	nummod
20	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	toxicity	toxicity	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	cadmium	cadmium	NN	_	2	nmod
5	,	,	,	_	4	punct
6	zinc	zinc	NN	_	4	conj
7	and	and	CC	_	4	cc
8	cadmium	cadmium	NN	_	4	conj
9	/	/	:	_	2	punct
10	zinc	zinc	NN	_	11	compound
11	mixtures	mixture	NNS	_	2	dep
12	at	at	IN	_	13	case
13	concentrations	concentration	NNS	_	11	nmod
14	ranging	range	VBG	_	13	acl
15	from	from	IN	_	16	case
16	1000	1000	CD	_	23	nmod
17	to	to	TO	_	18	dep
18	50000	50000	CD	_	21	nummod
19	microg	microg	NN	_	21	compound
20	/	/	:	_	21	punct
21	l	l	NN	_	23	nsubjpass
22	were	be	VBD	_	23	auxpass
23	investigated	investigate	VBN	_	14	ccomp
24	against	against	IN	_	25	case
25	cercariae	cercaria	NNS	_	23	nmod
26	and	and	CC	_	25	cc
27	metacercariae	metacercaria	NNS	_	25	conj
28	of	of	IN	_	30	case
29	Parorchis	Parorchis	NNP	_	30	compound
30	acanthus	acanthus	NN	_	25	nmod
31	obtained	obtain	VBN	_	30	acl
32	from	from	IN	_	37	case
33	the	the	DT	_	37	det
34	dog	dog	NN	_	37	compound
35	whelk	whelk	NN	_	37	compound
36	Nucella	nucella	NN	_	37	compound
37	lapillus	lapillus	NN	_	31	nmod
38	.	.	.	_	2	punct

1	Cercarial	cercarial	JJ	_	2	amod
2	encystment	encystment	NN	_	14	nsubj
3	at	at	IN	_	4	case
4	concentrations	concentration	NNS	_	2	nmod
5	of	of	IN	_	7	case
6	25000	25000	CD	_	7	nummod
7	microg	microg	NN	_	4	nmod
8	/	/	:	_	7	punct
9	l	l	NN	_	7	dep
10	or	or	CC	_	7	cc
11	higher	higher	JJR	_	7	conj
12	was	be	VBD	_	14	aux
13	significantly	significantly	RB	_	14	advmod
14	impaired	impaired	JJ	_	0	ROOT
15	by	by	IN	_	18	case
16	all	all	DT	_	18	det
17	test	test	NN	_	18	compound
18	metals	metal	NNS	_	14	nmod
19	;	;	:	_	14	punct

1	however	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	at	at	IN	_	5	case
4	lower	lower	JJR	_	5	amod
5	concentrations	concentration	NNS	_	8	nmod
6	only	only	RB	_	7	advmod
7	zinc	zinc	NN	_	8	nsubj
8	demonstrated	demonstrate	VBD	_	0	ROOT
9	toxicity	toxicity	NN	_	8	dobj
10	.	.	.	_	8	punct

1	Mixtures	mixture	NNS	_	6	nsubj
2	of	of	IN	_	3	case
3	cadmium	cadmium	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	zinc	zinc	NN	_	3	conj
6	had	have	VBD	_	0	ROOT
7	a	a	DT	_	9	det
8	synergistic	synergistic	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	compared	compare	VBN	_	14	case
11	with	with	IN	_	14	case
12	single	single	JJ	_	14	amod
13	metal	metal	NN	_	14	compound
14	toxicity	toxicity	NN	_	9	nmod
15	but	but	CC	_	14	cc
16	only	only	RB	_	19	advmod
17	at	at	IN	_	19	case
18	50000	50000	CD	_	19	nummod
19	microg	microg	NN	_	21	dep
20	/	/	:	_	21	punct
21	l	l	NN	_	14	conj
22	.	.	.	_	6	punct

1	Excystment	Excystment	NNP	_	7	nsubjpass
2	in	in	FW	_	3	compound
3	vitro	vitro	FW	_	1	advmod
4	was	be	VBD	_	7	auxpass
5	only	only	RB	_	6	advmod
6	significantly	significantly	RB	_	7	advmod
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	cercariae	cercariae	NN	_	7	nmod
10	exposed	expose	VBN	_	9	acl
11	to	to	TO	_	12	case
12	cadmium	cadmium	NN	_	10	nmod
13	/	/	:	_	9	punct
14	zinc	zinc	NN	_	15	compound
15	mixtures	mixture	NNS	_	9	dep
16	whilst	whilst	IN	_	17	case
17	encysting	encysting	NN	_	15	nmod
18	.	.	.	_	7	punct

1	Twenty	twenty	CD	_	10	nsubj
2	-	-	:	_	10	punct
3	four	four	CD	_	5	nummod
4	h	h	NN	_	5	compound
5	exposures	exposure	NNS	_	10	nsubj
6	of	of	IN	_	9	case
7	fully	fully	RB	_	8	advmod
8	formed	form	VBN	_	9	amod
9	cysts	cyst	NNS	_	5	nmod
10	had	have	VBD	_	0	ROOT
11	no	no	DT	_	12	neg
12	effect	effect	NN	_	10	dobj
13	on	on	IN	_	14	case
14	excystment	excystment	NN	_	12	nmod
15	in	in	FW	_	16	compound
16	vitro	vitro	FW	_	10	advmod
17	.	.	.	_	10	punct

1	Effects	effect	NNS	_	12	nsubj
2	on	on	IN	_	6	case
3	in	in	FW	_	6	amod
4	vitro	vitro	FW	_	3	dep
5	excystment	excystment	NN	_	6	compound
6	rates	rate	NNS	_	1	nmod
7	over	over	IN	_	11	case
8	a	a	DT	_	11	det
9	2	2	CD	_	11	nummod
10	h	h	NN	_	11	compound
11	period	period	NN	_	1	nmod
12	demonstrated	demonstrate	VBD	_	0	ROOT
13	widespread	widespread	JJ	_	14	amod
14	effects	effect	NNS	_	12	dobj
15	for	for	IN	_	16	case
16	cercariae	cercariae	NN	_	14	nmod
17	-	-	:	_	16	punct
18	exposed	expose	VBN	_	19	amod
19	P	p	NN	_	16	dep
20	.	.	.	_	12	punct

1	acanthus	acanthus	NN	_	0	ROOT
2	.	.	.	_	1	punct

1	No	no	DT	_	2	neg
2	effects	effect	NNS	_	4	nsubj
3	were	be	VBD	_	4	cop
4	evident	evident	JJ	_	0	ROOT
5	on	on	IN	_	7	case
6	excystment	excystment	NN	_	7	compound
7	rates	rate	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	cyst	cyst	NN	_	7	nmod
10	-	-	:	_	4	punct
11	exposed	expose	VBN	_	12	amod
12	parasites	parasite	NNS	_	4	dep
13	.	.	.	_	4	punct

